Drug ID	Drug Name	CAS Number	Chemical Name	New Molecular Entity	Drug Interactions	Comparative Efficacy	Highest Development Phase	Indication	Molecular Formula	Mechanism Of Action	Organisation	Pharmacodynamic Characteristics	Route Of Administration	Route Of Elimination	Pharmacokinetic Characteristics	Adverse Events	Therapeutic Class (EphMRA)	Therapeutic Class (WHO)	Synonyms/Brand Names	Antimicrobial Activity	Immunogenicity	Last Significant Update Date	Therapeutic Area	Orphan Designation	License Availability	Brands	On Fastrack	Fastrack country	On PRIME	PRIME country	Biomarkers-Inclusion	Biomarkers-Exclusion	Biomarkers-Outcome Measure	Biomarkers-Safety	Biomarkers-not specified	URL
800004287	Ganaxolone - Marinus Pharmaceuticals	38398-32-2	"3_-Hydroxy,3_-methyl-5_-pregnan-20-one"	Yes			Phase III	"Early infantile epileptic encephalopathy 2, Status epilepticus, Fragile X syndrome, Tuberous sclerosis, Epilepsy, Lennox-Gastaut syndrome, Postnatal depression, Major depressive disorder, Post-traumatic stress disorders, Angelman syndrome, Partial epilepsies, Infantile spasms, Migraine, Neuropathic pain"	C22 H36 O2	GABA A receptor agonists	"Purdue Pharma (Originator), Purdue Pharma (Owner), Marinus Pharmaceuticals (Licensee), NovaMedica (Sub-licensee), CyDex Pharmaceuticals (Technology Provider), Ligand Pharmaceuticals (Technology Provider), Biomedical Advanced Research and Development Authority (Funder), Duke University Medical Center (Collaborator), Massachusetts General Hospital (Collaborator), PCDH19 Alliance (Collaborator), The Cute Syndrome Foundation (Collaborator), UC Davis MIND Institute (Collaborator), University of Adelaide (Collaborator)"		"PO, IV, unspecified"		"T<sub>max</sub> (h) (1 - 3 (Adult)), Vd (L/kg) (18.1 - 70 (Adult))"	"Constipation, Diarrhoea, Dizziness, Fatigue, Headache, Malaise, Movement disorders, Nasal congestion, Nasopharyngitis, Nausea, Seizures, Somnolence, Vomiting"	"N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), N03A-X (Other antiepileptics), N05B-X (Other anxiolytics), N06 (Psychoanaleptics), N07X (Other Nervous System Drugs)"	"CCD1042, GanaxaloneIV, gnx"			28/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain"	"Status epilepticus (USA), Infantile spasms (USA), Fragile X syndrome (USA), Epilepsy (USA), Epilepsy (European Union)"	Marinus Pharmaceuticals |  | Unspecified |  | 08 Aug 2019		no		no							https://adis.springer.com/drugs/800004287?userId=52029392&bpIds=3004037004&checksum=c61daad6da6c31c74e31f0a58bfcf8134474d2be-1617045530373-68d29149b7b9ab8f76420796269ffa62badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051342	VX 128			Yes			No development reported (I)	Pain		Nav1.8 voltage-gated sodium channel inhibitors	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	VX128			28/03/2021	Pain				no		no							https://adis.springer.com/drugs/800051342?userId=52029392&bpIds=3004037004&checksum=83f82efadabecc6540ad930b7e1e80a29442c729-1617045530374-699677480f1aba5d81951a0b9ba75d03badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048603	Research programme: Non narcotic analgesics - Vapogenix			No			No development reported (Preclinical)	"Pain, Inflammatory pain"		Undefined mechanism	"University of Texas M. D. Anderson Cancer Center (Originator), Vapogenix (Originator), University of Texas M. D. Anderson Cancer Center (Owner), Vapogenix (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)				28/03/2021	Pain				no		no							https://adis.springer.com/drugs/800048603?userId=52029392&bpIds=3004037004&checksum=ef3c6994d4820059c6993786517b1c31a632a2ed-1617045530375-d7b135f714daefd7264756452ef72951badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026736	Research programme: vesicular monoamine transporter inhibitors - Neurocrine Biosciences			Yes			No development reported (Research)	"Schizophrenia, Movement disorders, Bipolar disorders, Epilepsy, Neuropathic pain, Essential tremor"		"Vesicular monoamine transporter 2 inhibitors, GABA uptake inhibitors"	"Neurocrine Biosciences (Originator), Neurocrine Biosciences (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs)"	"N02 (Analgesics), N03A-G (Fatty acid derivatives), N05A (Antipsychotics), N07 (Other Nervous System Drugs)"	VMAT2 inhibitors Neurocrine Biosciences			28/03/2021	"Affective Disorders, Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800026736?userId=52029392&bpIds=3004037004&checksum=9fcd3f6fc44ff06eaf6bc3282387d1fe7f8dc0d7-1617045530451-e87ddd037ab04dc656ec7799fc85dcd3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051306	STR 324			Yes			Phase I	"Postoperative pain, Pain"		Neprilysin inhibitors	"Institut Pasteur (Originator), Institut Pasteur (Owner), Stragen Pharma SA (Licensee)"		IV				N2 (Analgesics)	N02 (Analgesics)	STR324			28/03/2021	Pain				no		no							https://adis.springer.com/drugs/800051306?userId=52029392&bpIds=3004037004&checksum=a9f8de2302fd31cb232a338ed5f6b37c385454b6-1617045530452-9b7da34ed585897a1d2f6917e004ec1abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039110	Research programme: purinoceptor P2X3 antagonists - Bellus Health			Yes			Preclinical	"Pain, Visceral pain, Cough, Interstitial cystitis"		Purinergic P2X3 receptor antagonists	"AstraZeneca (Originator), BELLUS Health (Owner), Pfizer (Funder)"		PO				"G4 (Urologicals), N2 (Analgesics), R3 (Anti-Asthma and COPD Products), R5 (Cough and Cold Preparations)"	"G04B (Urologicals), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases), R05 (Cough and Cold Preparations)"	"NEO5024, P2X3 receptor antagonists Bellus Health"			28/03/2021	"Genitourinary Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800039110?userId=52029392&bpIds=3004037004&checksum=c7381760fa9073bd6f6099cb41cac880270803f7-1617045530454-e0b3aa388138d9018ff8717cdbf1409abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045567	Nicotinamide riboside - ChromaDex	1341-23-7	"1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide"	No			Phase III	"COVID 2019 infections, Retinal disorders, Alzheimer's disease, Ataxia telangiectasia, Heart failure, Mitochondrial myopathies, Cockayne syndrome, Pain"	C11 H15 N2 O5	Nicotinamide adenine dinucleotide modulators	"Cornell University (Originator), Dartmouth College (Originator), Washington University (Originator), Cornell University (Owner), Dartmouth College (Owner), Washington University (Owner), ChromaDex (Licensee), Ecole Polytechnique Federale de Lausanne. (Collaborator), Emory University (Collaborator), National Institutes of Health (USA) (Collaborator), Oregon Health & Science University (Collaborator), ScandiBio Therapeutics (Collaborator), University of Cambridge (Collaborator), University of Iowa (Collaborator), University of Kansas (Collaborator), University of Paris-Sud (Collaborator)"		"PO, unspecified"				"J5 (Antivirals for Systemic Use), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"J05 (Antivirals for Systemic Use), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"	"NIAGEN, Nicotinamidebetariboside, Nicotinamideribonucleoside, Nicotinamideribose, SRT647"			28/03/2021	"Alzheimer's Disease and Cognition Disorders, Eye Disorders, Heart Failure, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Skin Disorders, Vascular Disorders, Viral Infections"			NIAGEN	no		no							https://adis.springer.com/drugs/800045567?userId=52029392&bpIds=3004037004&checksum=544a9faee9591cb3f3b6493d9dcae1745abb2a4b-1617045530456-efb37df17d39cc3378d6f97660aa6d19badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019286	AMG 0101			Yes			Phase III	"Atopic dermatitis, Back pain, Vascular restenosis, Musculoskeletal disorders, Psoriasis, Respiratory tract disorders, Spondylosis, Periodontal disorders, Inflammatory bowel diseases, Pain, Intervertebral disc degeneration"		"Genetic transcription modulators, NF-kappa B inhibitors"	"AnGes MG (Originator), Osaka University (Originator), AnGes (Owner), Nippon Zoki (Licensee), Shionogi (Licensee), MEDRx (Technology Provider), Morishita Jintan (Technology Provider), Rush University (Technology Provider), Aichi Gakuin University (Collaborator), Hosokawa Micron Corporation (Collaborator), MedGel (Collaborator), Osaka University (Collaborator)"		"Topical, Intra-articular, Intra-arterial, Inhalation, unspecified, PO, Parenteral"				"A1A (Stomatologicals), A7E (Intestinal Anti-Inflammatory Agents), C6A (Other Cardiovascular Products), D11A (Other Dermatological Preparations), D5 (Nonsteroidal Products for Inflammatory Skin Disorders), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M1A (Anti-Rheumatics, Non-Steroidal), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"A01A (Stomatological Preparations), A07E (Intestinal Antiinflammatory Agents), C (Cardiovascular System), C01E-B (Other cardiac preparations), D05 (Antipsoriatics), D11A (Other Dermatological Preparations), M01 (Antiinflammatory and Antirheumatic Products), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), M09A (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"AMG0101, AMG0102, AMG0103, AMS001, MP 40, MP 41, MP 42, NDON, NFkappaB decoy, NFkappaB decoy oligo, NFkappaB decoy oligonucleotide, NFkappaBDecoyAnGesMG, NFkappaBtranscriptionfactorDecoyAnGes, NFkB decoy oligo, NFkDtranscriptionfactorDecoyAnGes, NuclearfactorkappaBDecoyAnGes, S414114, SI3104"			28/03/2021	"Drug Delivery Systems, Inflammatory Bowel Disorders, Mouth Disorders, Musculoskeletal Disorders, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Rheumatic Disease, Skin Disorders, Vascular Disorders"				no		no				NFkB			https://adis.springer.com/drugs/800019286?userId=52029392&bpIds=3004037004&checksum=6011ac66793d570722f91e9dd46828baed079399-1617045530459-2f9655c0deca255675f4c3093b7668bfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048963	Research programme: cannabinoid-based therapeutics - Revive Therapeutics			Yes			Preclinical	"Neuropathic pain, Wounds, Acne, Autoimmune hepatitis, Non-alcoholic steatohepatitis, Psoriasis, Dermatitis, Liver disorders, Kidney disorders"		Cannabinoid receptor modulators	"Revive Therapeutics (Originator), Revive Therapeutics (Owner), Chemi Pharmaceutical (Collaborator), InMed Pharmaceuticals (Collaborator), University of Wisconsin-Madison (Collaborator), WeedMD (Collaborator)"		"Topical, unspecified"				"A5 (Cholagogues and Hepatic Protectors), D11A (Other Dermatological Preparations), G4 (Urologicals), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A05 (Bile and Liver Therapy), D11A (Other Dermatological Preparations), G04 (Urologicals), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"REV 100, REV 101, REV 200, REV 201"			28/03/2021	"Genitourinary Disorders, Liver Disorders, Pain, Skin Disorders"	"Autoimmune hepatitis (USA), Reperfusion injury (USA), Ischaemia (USA)"			no		no							https://adis.springer.com/drugs/800048963?userId=52029392&bpIds=3004037004&checksum=0d1580450dcfe35de69b65e6a91b5add05c9da8e-1617045530461-bb1813ae750fbf2419d0d0455856c459badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047450	KAND 567		"(2R)-2-[[2-amino-5-[(1S)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol"	Yes			Phase II	"SARS-CoV-2 acute respiratory disease, Myocardial infarction, Cardiovascular disorders, Spinal cord injuries, Cancer, Autoimmune disorders, Cancer pain, Breast cancer, Ovarian cancer, Multiple myeloma"	C19 H25 N5 O S2	Chemokine CXCL13 inhibitors	"AstraZeneca (Originator), Acturum Life Sciences (Owner), Kancera (Collaborator), Karolinska Institute (Collaborator), Recipharm (Collaborator), SciLifeLab (Collaborator), Uppsala University (Collaborator)"		"PO, IV, unspecified"				"C1 (Cardiac Therapy), J5B9 (Antivirals, others), L1 (Antineoplastics), N2 (Analgesics), N7X (All other CNS drugs)"	"C01 (Cardiac Therapy), J05A-X (Other antivirals), L01 (Antineoplastic Agents), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"AZD8797, KAN0440567, KAND567"			28/03/2021	"Cancer, Immunological Disorders, Ischaemic Heart Disease, Neurological Disorders, Pain, Vascular Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800047450?userId=52029392&bpIds=3004037004&checksum=0dbe37f867d557d7cf87736fb67e546279ac35e5-1617045530463-45292ec2f74a996c867be7d094e62f94badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048631	Research programme: cannabinoid therapeutics - GB Sciences			No			Preclinical	"Parkinson's disease, Neuropathic pain, Cardiovascular disorders, Inflammation, Heart failure"		"TRPV1 receptor antagonists, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Catalent Pharma Solutions (Originator), University of Hawaii (Originator), Catalent Pharma Solutions (Owner), University of Hawaii (Owner), Makai Biotechnology (Licensee), GB Sciences (Sub-licensee), CIBERSAM (Technology Provider), Universidad de Sevilla (Technology Provider), University of Cadiz (Technology Provider), Hawaii Community Foundation (Funder), National Institutes of Health (Funder), Chaminade University (Collaborator), Michigan State University (Collaborator), University of California at Los Angeles (Collaborator)"		"unspecified, PO"				"C1 (Cardiac Therapy), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N4A (Anti-Parkinson Drugs)"	"C01 (Cardiac Therapy), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N04 (Anti-Parkinson Drugs)"	"BCTC Makai Biotechnology, Cannabisbased neuroprotective compounds GB Sciences, GBS101, GBS102, GBS103, TRPV1 inhibitors"			28/03/2021	"Heart Failure, Inflammation, Ischaemic Heart Disease, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease, Vascular Disorders"		Makai Biotechnology |  | Unspecified |  | 02 Aug 2018		no		no							https://adis.springer.com/drugs/800048631?userId=52029392&bpIds=3004037004&checksum=736484befcd7016c96949d3e5509d4dfa457c610-1617045530464-016499febfd45e1d6b9b0eb5b09f8f2abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029997	AAT 008			Yes			Preclinical	"Cancer, Autoimmune disorders, Osteoarthritis, Inflammatory pain, Hypersensitivity, Psoriasis, Inflammatory bowel diseases, Acute pain, Contact dermatitis, Inflammation"		Prostaglandin E EP4 receptor antagonists	"Pfizer (Originator), Pfizer (Owner), AskAt (Licensee), Ikena Oncology (Sub-licensee), Ningbo NewBay Medical Technology (Sub-licensee)"		PO				"A7E (Intestinal Anti-Inflammatory Agents), D11A (Other Dermatological Preparations), D5B (Systemic Antipsoriasis Products), L1 (Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), D05B (Antipsoriatics for Systemic Use), D11A-X (Other dermatologicals), L01 (Antineoplastic Agents), L04 (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"AAT008, RQ00000008"			28/03/2021	"Cancer, Immunological Disorders, Inflammation, Inflammatory Bowel Disorders, Pain, Rheumatic Disease, Skin Disorders"		AskAt |  | Unspecified |  | 04 Mar 2021		no		no							https://adis.springer.com/drugs/800029997?userId=52029392&bpIds=3004037004&checksum=c5faf028ef781a3b6c39aef5300e89579c3c2cd4-1617045530466-44a830a540c97a60dea3440d23762b2cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050874	Paracetamol - Neumentum	103-90-2	N-(4-Hydroxyphenyl)acetanilide	No			Preclinical	Pain	C8 H9 N O2	"Cyclo-oxygenase 2 inhibitors, Cytochrome P 450 enzyme system inhibitors, Prostaglandin receptor antagonists"	"Neumentum (Originator), Neumentum (Owner)"		"IV, PO"				"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02 (Analgesics), N02B-E01 (Paracetamol)"	"APAP analogues Neumentum, NTM 004, NTM 005"			26/03/2021	Pain				no		no							https://adis.springer.com/drugs/800050874?userId=52029392&bpIds=3004037004&checksum=a91cefcd4c4581ca067196e46e5f308608551c0d-1617045530467-9c78f384dcabcf1cbef98ec7f0136393badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056279	NTM 006			Yes			Phase II	"Postoperative pain, Pain, Neuropathic pain"		Adenosine A3 receptor modulators	"Janssen (Originator), Janssen (Owner), Neumentum (Licensee), McNeil Consumer Pharmaceuticals (Collaborator)"		PO				"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02 (Analgesics), N02B (Other Analgesics and Antipyretics)"	"JNJ 10450232, JNJ232, NTM006"			26/03/2021	Pain				no		no							https://adis.springer.com/drugs/800056279?userId=52029392&bpIds=3004037004&checksum=ec48dcde9de6393be190e25f7f4621c9f42a531c-1617045530468-5dcdc9a096690e9d4a360d3832e1e74cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062204	Ketamine microneedle patch - PharmaTher	6740-88-1	2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone	No			Phase I/II	"Parkinson's disease, Amyotrophic lateral sclerosis, Pain"	C13 H16 Cl N O	"AMPA receptor agonists, NMDA receptor antagonists"	"National Health Research Institutes (Originator), PharmaTher (Owner), Queens University Belfast (Technology Provider), University of Kansas (Technology Provider), University of Arizona (Collaborator)"		unspecified				"N2 (Analgesics), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"N01A-X03 (Ketamine), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"				26/03/2021	"Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800062204?userId=52029392&bpIds=3004037004&checksum=abea1f94b228ce5e9aab2f066c6a274bcf683e81-1617045530470-9a52c7a6a866593993a7b01f3225b3d1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035830	Centanafadine - Otsuka Pharmaceutical	924012-43-1	"3-Azabicyclo[3.1.0]hexane, 1-(2-naphthalenyl)-, (1R,5S)-"	Yes			Phase III	"Attention-deficit hyperactivity disorder, Major depressive disorder, Neuropathic pain"	C15 H15 N	"Adrenergic uptake inhibitors, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"Euthymics Bioscience (Originator), Otsuka Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	"Centanafadine SR, CTN SR, EB1020, EB1020 SR"			26/03/2021	"Affective Disorders, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800035830?userId=52029392&bpIds=3004037004&checksum=c01611e79d2d43d1531eb3b9c75c371de2c9984e-1617045530471-640ee034cd6bee39a53a87746c60d40dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053941	DFN 10			Yes			No development reported (II)	Migraine		Undefined mechanism	"Promius Pharma (Originator), Promius Pharma (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	DFN10			25/03/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800053941?userId=52029392&bpIds=3004037004&checksum=105068699fe59e84d5e49c6a336974ae6e6ea97f-1617045530472-dd171caa28ad6d2900405dc868d0fb08badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034984	Rimegepant - Biohaven Pharmaceuticals	1374024-48-2	" (5S,6S,9R)-5-amino-6-(2,3_ difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1Himidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate sesquihydrate"	Yes			Marketed	"Migraine, Plaque psoriasis, Trigeminal neuralgia"	C28 H28 F2 N6 O3 . 0.5(H2 S O4) . 1.5(H2 O)	Calcitonin gene-related peptide receptor antagonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Genpharm Services (Market Licensee), Medison Pharma (Market Licensee), Biohaven Pharmaceuticals (Licensee), BioShin (Sub-licensee), Catalent (Technology Provider), Biohaven Pharmaceutical Holding Company (Collaborator), Weill Cornell Medicine (Collaborator)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"BHV3000, BMS927711, NURTEC ODT, Rimegepant orally disintegrating tablet Biohaven Pharmaceuticals, Rimegepant sulfate Biohaven Pharmaceuticals, Rimegepant Zydis ODT Biohaven Pharmaceuticals, Rimegepant Zydis oral fastdissolve tablet Biohaven Pharmaceuticals"			25/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain, Skin Disorders"			NURTEC ODT	no		no							https://adis.springer.com/drugs/800034984?userId=52029392&bpIds=3004037004&checksum=25747884193543f5093030e18861d68e7694c84b-1617045530476-e35b53f90432dbc64e8a01cce744ac5bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036477	Tramadol/type-5 cyclic nucleotide phosphodiesterase inhibitor - Aytu BioPharma			No			No development reported (Preclinical)	"Premature ejaculation, Erectile dysfunction"		"Opioid mu receptor agonists, Serotonin uptake inhibitors, Type 5 cyclic nucleotide phosphodiesterase inhibitors"	"Ampio Pharmaceuticals (Originator), Aytu BioPharma (Owner), Daewoong Pharmaceutical (Licensee)"		PO				"G4E (Erectile Dysfunction Products), G4X (All Other Urological Products), N2A (Narcotics)"	"G04B-E (Drugs used in erectile dysfunction), G04B-X (Other urologicals), N02A-X02 (Tramadol)"	"PDE5 inhibitor/tramadol Aytu BioPharma, Tramadol/PDE5 inhibitor Aytu BioPharma, Type5 cyclic nucleotide phosphodiesterase inhibitor/tramadol Aytu BioPharma, Zertane/PDE5 inhibitor, ZertaneED"			24/03/2021	Men's Health		Ampio Pharmaceuticals |  | Unspecified |  | 17 Jan 2012		no		no							https://adis.springer.com/drugs/800036477?userId=52029392&bpIds=3004037004&checksum=4b0db79c17aaff8e7eb084af5b7622eb3e26e2d7-1617045530478-bb6f7e50af8b4dafc7bb60b108f64cbbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053235	Gabapentin/trazodone hydrochloride - Angelini		"2-[1-(aminomethyl)cyclohexyl]acetic acid / 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-[1,2,4]triazolo[4,3-a]pyridin-3-one;hydrochloride"	No			Phase II	Diabetic neuropathies	C9 H17 N O2 . C19 H23 Cl2 N 5O	"Alpha adrenergic receptor agonists, CACNA2D1 protein modulators, GABA receptor agonists, Serotonin 2A receptor antagonists, Serotonin 2C receptor antagonists, Serotonin uptake inhibitors"	"Angelini Group (Originator), Angelini Group (Owner)"		PO				N2B1 (Prescription-bound non-narcotics and anti-pyretics)	"N02B-G (Other analgesics and antipyretics), N03A-X12 (Gabapentin), N06A-X05 (Trazodone)"	"Gabapentin/trazodone Angelini, Trazodone hydrochloride/gabapentin FDC Angelini, Trazodone/gabapentin FDC Angelini"			24/03/2021	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800053235?userId=52029392&bpIds=3004037004&checksum=efda31bc7adab9bb70e1a2127a1168cc180f6cb7-1617045530479-4d016a8f7571a82437c2db87a494c39bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042233	Zolmitriptan transdermal - Zosano Pharma	139264-17-8	S-4[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]- 2-oxazolidinone	No			Preregistration	"Migraine, Cluster headache"	C16 H21 N3 O2	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Zosano Pharma (Originator), Zosano Pharma (Owner), EVERSANA Life Science (Market Licensee)"		Transdermal				N2C1 (Antimigraine triptans)	N02C-C03 (Zolmitriptan)	"ADAMZolmitriptan, C213 Zosano Pharma, M 207, Qtrypta, Triptan microneedle patch Zosano Pharma, Triptan patch Zosano Pharma, Triptan transdermal Zosano Pharma, Zolmitriptan Intracutaneous Microneedle System, ZP triptan Zosano Pharma, ZPZolmitriptan, ZPZolmitriptan Intracutaneous Microneedle System"			24/03/2021	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"		Zosano Pharma |  | Unspecified |  | 14 Mar 2019	Qtrypta	no		no							https://adis.springer.com/drugs/800042233?userId=52029392&bpIds=3004037004&checksum=ce30a6ded989b79fea677edbe5c61250068dc22c-1617045530482-9253dbc1c444de984a16d11b5ab4afebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018956	Tramadol - Aytu BioPharma	27203-92-5	(±)-cis-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol	No			Discontinued (Preregistration)	Premature ejaculation	C16 H25 N O2	"Adrenergic receptor antagonists, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Enhance Lifesciences (Originator), Aytu BioPharma (Owner), Daewoong Pharmaceutical (Market Licensee), Endo International (Market Licensee), FBM Industria Farmaceutica (Market Licensee)"		PO			"Anxiety, Erectile dysfunction"	N2A (Narcotics)	N02A-X02 (Tramadol)	"BIO301, DMI7958, LI301, LIF301, Zertane"			24/03/2021	Men's Health				no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800018956?userId=52029392&bpIds=3004037004&checksum=f2f619c1f5d472b4c6b8f92326b234b55ebef908-1617045530484-a4cd8f2b07645b9951d16454c191fcecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020791	Loxoprofen - Daiichi Sankyo Company	68767-14-6	(+-)-p-((2-Oxocyclopentyl)methyl)hydratropic acid	No			Marketed	Pain	C15 H18 O3	Cyclooxygenase inhibitors	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner), Cardinal Health (Collaborator), Daiichi Sankyo Brasil (Collaborator), Lead Chemical (Collaborator)"		"PO, Transdermal"				"M1A (Anti-Rheumatics, Non-Steroidal)"	"M01A-E (Propionic acid derivatives), N02 (Analgesics)"	"CS600G, Loxonin, Loxonin Pap, Loxonin Tape, Loxoprofen gel, Loxoprofen poultice, Loxoprofen sodium, Loxoprofen tape, LXA, LXP"			24/03/2021	Pain			"Loxonin, Loxonin Pap, Loxonin Tape"	no		no		CRP		"CD4, CRP, IL17"			https://adis.springer.com/drugs/800020791?userId=52029392&bpIds=3004037004&checksum=1714dddbf570ed2aa4c2077713b633f636b9768d-1617045530488-bf5963de9926e1cb49abf737d43cc480badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052671	Oxycodone/promethazine - Charleston Laboratories		"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine"	No			Phase III	"Acute pain, Nausea and vomiting"	C18 H21 N O4 . C17 H20 N2 S	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Histamine H1 receptor antagonists, Muscarinic receptor antagonists, Serotonin receptor antagonists"	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		PO				"N2A (Narcotics), R6 (Systemic Antihistamines)"	"N02A-A05 (Oxycodone), R06A-D52 (Promethazine, combinations)"	"CLOX315, Promethazine/oxycodone"			23/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain"		Charleston Laboratories |  | Unspecified | World | 07 Aug 2018		no		no							https://adis.springer.com/drugs/800052671?userId=52029392&bpIds=3004037004&checksum=7069c0a76db1ad25479d59ef522434b9cf76a228-1617045530489-83e6db7dec6512bf9d306191c102f89cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050404	Rizatriptan intranasal - Benuvia Therapeutics	144034-80-0	"N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine"	No			Phase I	Migraine	C15 H19 N5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"INSYS Therapeutics, Inc (Originator), Benuvia Therapeutics (Owner)"		Intranasal				N2C1 (Antimigraine triptans)	N02C-C04 (Rizatriptan)	"Rizatriptan intranasal spray INSYS Therapeutics, Rizatriptan nasal spray"			23/03/2021	Advances in the Treatment of Nausea and Migraine		Benuvia Therapeutics |  | Unspecified |  | 23 Mar 2021		no		no							https://adis.springer.com/drugs/800050404?userId=52029392&bpIds=3004037004&checksum=a8cf10c5a47b68307bb1686cd1d9b3171c0d31f3-1617045530491-64d2af4db027a56e1055f2aaa887db5dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042145	Buprenorphine sublingual - Benuvia Therapeutics	52485-79-7	"(2S)-2-[(5R,6R,7R,14S)-9_-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol"	No			Preregistration	Postoperative pain	C29H41NO4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"INSYS Pharma (Originator), Benuvia Therapeutics (Owner)"		Sublingual				N2A (Narcotics)	N02A-E01 (Buprenorphine)	Buprenorphine sublingual spray INSYS Therapeutics			23/03/2021	Pain				no		no							https://adis.springer.com/drugs/800042145?userId=52029392&bpIds=3004037004&checksum=b4b52cfa01a924c0e0dd2b0f4fe7cb36f92a7b15-1617045530492-ac530a72449679176d49b4da4671a8efbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041942	Buprenorphine/naloxone sublingual - Benuvia Therapeutics	352020-56-5	"21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine / (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one"	No			Phase II	Opioid-related disorders	C29 H41 N O4 . C19 H21 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists, Opioid mu receptor antagonists"	"INSYS Therapeutics, Inc (Originator), Benuvia Therapeutics (Owner)"		Sublingual				"N7F (Drugs Used In Opioid Dependence), V3E (Antidotes)"	"N02A-E01 (Buprenorphine), N07B-C (Drugs used in opioid dependence), V03A-B15 (Naloxone)"	"Buprenorphine + naloxone Benuvia Therapeutics, Buprenorphine/naloxone Benuvia Therapeutics, Buprenorphine/naloxone sublingual spray INSYS Therapeutics"			23/03/2021	Drug Withdrawal		Benuvia Therapeutics |  | Unspecified |  | 23 Mar 2021		no		no							https://adis.springer.com/drugs/800041942?userId=52029392&bpIds=3004037004&checksum=72feeb8154da3a3a6fe317ad37be3548264b98ff-1617045530493-cbffbd803c37e7ecf4371bbb143f30a6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053122	Oxycodone hydrochloride - SpecGx	124-90-3	"(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride"	No			No development reported (Preregistration)	Pain	C18 H22 Cl N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"SpecGx (Originator), SpecGx (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"Abuse deterrent oxycodone Mallinckrodt, MNK812"			23/03/2021	Pain				no		no							https://adis.springer.com/drugs/800053122?userId=52029392&bpIds=3004037004&checksum=cfc5491c6a237db0df3900be0b0c949b2bd0d588-1617045530495-2ad584ec608bb46646f6d98c2b847ddbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062993	Diclofenac - Benuvia Therapeutics	15307-86-5	"Acetic acid, (o-(2,6-dichloroanilino)phenyl)-"	No			Phase II	Pain	C14 H11 Cl2 N O2	Cyclooxygenase inhibitors	"INSYS Therapeutics, Inc (Originator), Benuvia Therapeutics (Owner)"		Sublingual				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-B05 (Diclofenac), N02B (Other Analgesics and Antipyretics)"	Diclofenac sublingual Benuvia Therapeutics			23/03/2021	Pain		Benuvia Therapeutics |  | Unspecified |  | 23 Mar 2021		no		no							https://adis.springer.com/drugs/800062993?userId=52029392&bpIds=3004037004&checksum=962f4b62b3e8e919358691e550f55317c961636b-1617045530496-16a354dfcf072241c97a99249b8bb151badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025843	Research programme: cannabinoid receptor agonists - Cara			Yes			No development reported (Preclinical)	"Neuropathic pain, Inflammatory pain"		Cannabinoid receptor agonists	"Cara Therapeutics (Originator), Cara Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"CR08, CR701, CR859"			23/03/2021	Pain				no		no							https://adis.springer.com/drugs/800025843?userId=52029392&bpIds=3004037004&checksum=2b1a26bc9d2163f429d41a24b6db601b3914e4f6-1617045530497-e3048ca936aa5642fe152fb0c1bfa6e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052665	pUDK HGF			No			Preclinical	"Postoperative pain, Neuropathic pain, Peripheral arterial disorders"		"Gene transference, Hepatocyte growth factor expression modulators"	"Humanwell Healthcare (Originator), Humanwell Healthcare (Owner), XuanWu Hospital Capital Medical University (Collaborator)"		"IM, Intrathecal"				"C4A (Cerebral and Peripheral Vasotherapeutics), N2 (Analgesics)"	"C04A-X (Other peripheral vasodilators), N02 (Analgesics)"	pUDKHGF			23/03/2021	"Ischaemic Heart Disease, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800052665?userId=52029392&bpIds=3004037004&checksum=bbea9f4d6c4b302e91ff80d84b4ca387042f9709-1617045530499-c86ff90fedf901b4350756575e25dfdabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039982	Bupivacaine/meloxicam - Heron Therapeutics		"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide / 4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide"	No			Registered	Postoperative pain	C18 H28 N2 O . C14 H13 N3 O4 S2	"Cyclo-oxygenase 2 inhibitors, Sodium channel antagonists"	"Heron Therapeutics (Originator), Heron Therapeutics (Owner)"		"Topical, Instillation, Intralesional, Infiltration"				"M1C (Specific Anti-Rheumatic Agents), N1B1 (Anaesthetics local, medical injectables), N2 (Analgesics)"	"M01A-C06 (Meloxicam), N01B-B01 (Bupivacaine), N02 (Analgesics)"	"Bupivacaine/meloxicam extended release, HTX002/HTX009, HTX009/HTX002, HTX011, HTX011A, HTX011B, Meloxicam/bupivacaine, Meloxicam/bupivacaine extended release, ZYNRELEF"			23/03/2021	Pain			ZYNRELEF	yes	USA	no							https://adis.springer.com/drugs/800039982?userId=52029392&bpIds=3004037004&checksum=fb581710464204d83c29fcbcc587ce85f636aea0-1617045530501-6b51787e702e5ca7d8ef8d043b3ce69ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031053	SAF 312	871814-52-7	4-(7-Hydroxy-2-isopropyl-4-oxo-4<EM>H</EM>-quinazolin-3-yl)-benzonitrile	Yes			Phase II	"Postoperative pain, Neurogenic bladder"	C18 H15 N3 O2	TRPV cation channel antagonists	"Novartis (Originator), Novartis (Owner)"		"Ophthalmic, PO"				"G4X (All Other Urological Products), N2B (Non-Narcotics and Anti-Pyretics)"	"G04B-X (Other urologicals), N02B-G (Other analgesics and antipyretics)"	SAF312			22/03/2021	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031053?userId=52029392&bpIds=3004037004&checksum=d22e2ac7afec75650b46320d15c5482cc6c54fff-1617045530503-c858260e589499efd36a8dc581adb923badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023893	Nalbuphine extended release - Trevi Therapeutics	20594-83-6	"Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-,(5_,6_)-"	No			Phase II/III	"Prurigo nodularis, Pruritus, Cough, Drug-induced dyskinesia, Pain"	C21 H27 N O4	"Opioid kappa receptor agonists, Opioid mu receptor antagonists"	"Penwest Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner), Trevi Therapeutics (Owner), MentiNova (Collaborator), Rutgers (Collaborator)"		PO				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2A (Narcotics), N4A (Anti-Parkinson Drugs), R5 (Cough and Cold Preparations)"	"D04A-X (Other antipruritics), N02A-F (Morphinan derivatives), N04 (Anti-Parkinson Drugs), R05X (Other Cold Preparations)"	"Haduvio, Nalbuphine ER, Nalbuphine extendedrelease, PW4142, T 111"			22/03/2021	"Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Skin Disorders"			"Haduvio, Nalbuphine ER"	no		no							https://adis.springer.com/drugs/800023893?userId=52029392&bpIds=3004037004&checksum=88b72cad352605dfeb465fe00daf35270c29c8a3-1617045530506-89dc72638f3a07b775ad37b7acfc69bebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044787	Ibuprofen/paracetamol - AFT Pharmaceuticals	462631-86-3		No			Marketed	"Pain, Fever, Postoperative pain"	C13-H18-O2.C8-H9-N-O2	Cyclooxygenase inhibitors	"AFT Pharmaceuticals (Originator), AFT Pharmaceuticals (Owner), Aguettant (Market Licensee), Karo Pharma AB (Market Licensee), Medochemie (Market Licensee), New Zealand Trade and Enterprise (Funder), Hyloris Pharmaceuticals (Collaborator)"		"IV, PO"				N2B (Non-Narcotics and Anti-Pyretics)	"M01A-E01 (Ibuprofen), N02B-E01 (Paracetamol)"	"Acetaminophen/ibuprofen AFT Pharmaceuticals, Acetaminophen/ibuprofen intravenous AFT Pharmaceuticals, Acetaminophen/ibuprofen IV AFT Pharmaceuticals, Dolerin, Maxigesic IV, Paracetamol/ibuprofen intravenous AFT Pharmaceuticals"			19/03/2021	"Metabolic Disorders, Pain"			"Dolerin, Dolerin, Dolerin, Dolerin, Dolerin"	no		no							https://adis.springer.com/drugs/800044787?userId=52029392&bpIds=3004037004&checksum=1ba9a25430722c4d385a8ff1f9b4f6edb82b64fe-1617045530512-16986126bec637b4d2a0aee29735fe43badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058233	LY 03014			Yes			Phase I	"Cancer pain, Postoperative pain"		Opioid mu receptor agonists	"Luye Pharma Group (Originator), Luye Pharma Group (Owner)"		IV-infusion				N2 (Analgesics)	N02 (Analgesics)	"LPM3480392, LY03014"			19/03/2021	Pain				no		no							https://adis.springer.com/drugs/800058233?userId=52029392&bpIds=3004037004&checksum=d389c8d479420253b6b7b3995c0d394021e3af0c-1617045530513-deceda4f0b5a8e44d5649458643fde60badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052896	Gonyautoxin - Algenis	77462-64-7		No			Phase I/II	"Back pain, Fissure in ano"		Sodium channel antagonists	"Algenis (Originator), Algenis (Owner)"		"IM, Rectal, unspecified"				"C5 (Antivaricosis/Antihaemorrhoidal Preparations), N2 (Analgesics)"	"C05A (Agents for treatment of hemorrhoids and anal fissures for topical use), N02 (Analgesics)"	"Gonyautoxina, GTX2 / 3, NAVX010"			19/03/2021	"Digestive System Disorders, Musculoskeletal Disorders, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800052896?userId=52029392&bpIds=3004037004&checksum=43f6be4fe71e24bec0480005444b8c347a8c6bfd-1617045530515-28b07f7c42cba7932e4ee4469238c721badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021683	NE 3107	1001100-69-1	"(3<EM>S</EM>,7<EM>R</EM>,8<EM>R</EM>,9<EM>S</EM>,10<EM>R</EM>,13<EM>S</EM>,14<EM>S</EM>,17<EM>R</EM>)-17-Ethynyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1<EM>H</EM>-cyclopenta[<EM>a</EM>]phenanthrene-3,7,17-triol"	Yes			Phase I	"Parkinson's disease, Alzheimer's disease, Prostate cancer, Multiple myeloma, Drug-induced dyskinesia, Type 2 diabetes mellitus, Ulcerative colitis, Rheumatoid arthritis, Cognition disorders, Migraine, Myositis, Type 1 diabetes mellitus, Epilepsy, Amyotrophic lateral sclerosis, Cystic fibrosis, Uveitis, Glaucoma, Huntington's disease, Optic neuritis"	C21 H30 O3	"NF-kappa B inhibitors, Tumour necrosis factor inhibitors, Mitogen activated protein kinase 3 inhibitors, Mitogen-activated protein kinase 1 inhibitors, Interleukin 23 inhibitors, Interleukin 6 inhibitors"	"Hollis-Eden Pharmaceuticals (Originator), NeurMedix (Owner), The Michael J. Fox Foundation for Parkinson's Research (Funder), National Institutes of Health (USA) (Collaborator)"		"PO, unspecified"				"A10X (Other Drugs Used in Diabetes), A16 (Other Alimentary Tract and Metabolism Products), A7E (Intestinal Anti-Inflammatory Agents), A8A (Antiobesity Preparations, Excluding Dietetics), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N7 (Other CNS Drugs), N7X (All other CNS drugs), R7 (Other Respiratory System Products), S1 (Ophthalmologicals), S1E (Miotics and Antiglaucoma Preparations)"	"A07 (Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents), A07E (Intestinal Antiinflammatory Agents), A08 (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), A16 (Other Alimentary Tract and Metabolism Products), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02C (Antimigraine Preparations), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N06 (Psychoanaleptics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs), R07 (Other Respiratory System Products), S01 (Ophthalmologicals), S01E (Antiglaucoma Preparations and Miotics)"	"17aethynyl5androstene3717triol, 17alfaethynyl5androstene3717triol, 17alphaethynyl5androstene3beta7beta17betatriol, 17ethynyl5androstene3717triol, 17ethynyl5androstene3b7b17btriol, HE 3286, NE3107, Triolex"			18/03/2021	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Cancer, Diabetes, Epilepsy and Seizure Disorders, Eye Disorders, Inflammation, Inflammatory Bowel Disorders, Neurological Disorders, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Rheumatic Disease"		Harbor Therapeutics | Cystic fibrosis | Unspecified |  | 31 Dec 2010	Triolex	no		no		"A1C, Insulin"		"A1C, Insulin"			https://adis.springer.com/drugs/800021683?userId=52029392&bpIds=3004037004&checksum=548f2cc244b9096de63f3ff85b18b7eb9d74acdf-1617045530520-eee65797efa3837263d2fff556d839cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042985	MEDI 7352			Yes			Phase II	Pain		"Nerve growth factor modulators, Tumour necrosis factor modulators"	"AstraZeneca (Originator), AstraZeneca (Owner)"		"IV, Parenteral, SC"				N2 (Analgesics)	N02 (Analgesics)	MEDI7352			18/03/2021	Pain				no		no							https://adis.springer.com/drugs/800042985?userId=52029392&bpIds=3004037004&checksum=b769acee2548b30fbdfb821872997f575f55fc4d-1617045530522-798cb692277a84f781f16bad5d1e2b9abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051770	Clonidine extended release - Sollis Therapeutics	4205-90-7	"N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine"	No			Phase III	Sciatica	C9 H9 Cl2 N3	"Alpha 2 adrenergic receptor agonists, Imidazoline receptor agonists"	"Sollis Therapeutics (Originator), Sollis Therapeutics (Owner), West Virginia University (Collaborator)"		Epidural				N2 (Analgesics)	N02 (Analgesics)	"Clonidine micropellets Sollis Therapeutics, STX015"			18/03/2021	Pain				no		no							https://adis.springer.com/drugs/800051770?userId=52029392&bpIds=3004037004&checksum=8edc8c98b7ce3bd9d8203a9fd16c484f55305a55-1617045530524-50e9dbb76a2ef32e3d4e3f9469807f8abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040842	Research programme: SNA based therapeutics - Exicure			Yes			Preclinical	"CNS disorders, Amyotrophic lateral sclerosis, Eye disorders, Inflammatory bowel diseases, Spinal muscular atrophy, Respiration disorders, Friedreich's ataxia, Angelman syndrome, Huntington's disease, Neuropathic pain, Neuronal ceroid lipofuscinosis, Congenital ichthyosiform erythroderma, Atopic dermatitis, Fibrosis, Lymphoma, Brain cancer, Transplant rejection, Epidermolysis bullosa"		"HD protein inhibitors, Gene modulators, Survival of motor neuron 2 protein expression stimulants, Immunomodulators, Nav1.7 voltage-gated sodium channel modulators, CLN3 protein expression modulators, Interleukin 4 receptor modulators, Immunosuppressants, Interleukin 1 beta modulators"	"AuraSense Therapeutics (Originator), Exicure (Owner), Dermelix Biotherapeutics (Licensee), Defense Advanced Research Projects Agency (Funder), Friedreichs Ataxia Research Alliance (Collaborator)"		"Intrathecal, unspecified, Intraocular, Inhalation"				"A7E (Intestinal Anti-Inflammatory Agents), D (Dermatologicals), D11 (Other Dermatological Preparations), D11A (Other Dermatological Preparations), D5A (Topical Antipsoriasis Products), L1 (Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs), N7X (All other CNS drugs), R (Respiratory System), S1 (Ophthalmologicals)"	"A07E (Intestinal Antiinflammatory Agents), D (Dermatologicals), D05A-X (Other antipsoriatics for topical use), D11 (Other Dermatological Preparations), D11A (Other Dermatological Preparations), D11A-X (Other dermatologicals), L01 (Antineoplastic Agents), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs), R (Respiratory System), S01 (Ophthalmologicals)"	"SNA constructs Exicure, SNA targeting IL17RA Exicure, SNA targeting IL4RA Exicure, Spherical nucleic acid constructs Exicure, XCUR FXN"			18/03/2021	"Cancer, Eye Disorders, Inflammation, Inflammatory Bowel Disorders, Metabolic Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Skin Disorders, Transplant Rejection"				no		no							https://adis.springer.com/drugs/800040842?userId=52029392&bpIds=3004037004&checksum=2547b0aad75f0b3465d752c948f1d641997f2c02-1617045530528-2ca6311de6c6da79cb0b7628c876e66dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062877	ST 2427			Yes			Phase I	Postoperative pain		Nav1.7 voltage-gated sodium channel inhibitors	"Stanford University (Originator), Stanford University (Owner), SiteOne Therapeutics (Licensee), National Institute of Drug Abuse (Funder), National Institutes of Health (USA) (Funder)"		IV				N2 (Analgesics)	N02 (Analgesics)	ST2427			17/03/2021	Pain				no		no							https://adis.springer.com/drugs/800062877?userId=52029392&bpIds=3004037004&checksum=55d8577712d10b7c10e6805d75f4a8db4a329131-1617045530529-d8baa2e2425238079e8f27e9860ed6f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058108	Tempol - Matrix Biomed	2226-96-2	"4-hydroxy-1-oxyl-2,2,6,6-tetramethylpiperidine"	No			Phase III	"Radiodermatitis, Chemotherapy-induced damage, Prostate cancer, Neuropathic pain, Glioblastoma, Glaucoma, COVID 2019 infections"	C9 H18 N O2	"Antioxidants, Blood coagulation factor inhibitors, Inflammation mediator inhibitors"	"Matrix Biomed (Originator), Matrix Biomed (Owner), Adamis Pharmaceuticals Corporation (Market Licensee), Galveston National Laboratory (Collaborator), Stanford University (Collaborator), University of Maryland, College Park (Collaborator), University of Texas Medical Branch (Collaborator)"		"Topical, PO, Ophthalmic"				"D (Dermatologicals), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), N2 (Analgesics), S1 (Ophthalmologicals), V3 (All Other Therapeutic Products)"	"D (Dermatologicals), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), N02 (Analgesics), S01 (Ophthalmologicals), V03A (All Other Therapeutic Products)"	"MBM 02, MBM01, MTS01, MTS02, MTS10"			17/03/2021	"Cancer, Drug Withdrawal, Eye Disorders, Pain, Skin Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800058108?userId=52029392&bpIds=3004037004&checksum=42e65644bab2852911d6655d4fbf0343ae368189-1617045530531-7e1c06d1efc3a258de9dbef6fec39284badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008810	Onabotulinum toxin A - AbbVie	93384-43-1		No			Marketed	"Blepharospasm, Hyperhidrosis, Glabellar lines, Neurogenic bladder, Strabismus, Muscle spasticity, Migraine, Torticollis, Dysphonia, Overactive bladder, Facial wrinkles, Equinus foot deformity, Raynaud's disease, Muscle pain, Premature ejaculation, Carpal tunnel syndrome, Hypertrophy, Herpes labialis, Musculoskeletal pain, Major depressive disorder, Neuropathic pain, Pain, Gastrointestinal disorders, Pruritus, Benign prostatic hyperplasia, Prostatitis, Diabetic gastroparesis, Gilles de la Tourette's syndrome"		"Acetylcholine inhibitors, Glutamate antagonists, Membrane transport protein modulators, Neuromuscular blocking agents"	"Allergan (Originator), AbbVie (Owner), GlaxoSmithKline (Licensee), American Medical Systems (Collaborator), Centre hospitalier de l'Universite de Montreal (Collaborator), Johns Hopkins University (Collaborator), Queens University (Collaborator), Temple University (Collaborator), University of Illinois at Chicago (Collaborator), Wake Forest University School of Medicine (Collaborator)"		"IM, Intradermal, SC, unspecified, Parenteral, Intra-articular, PO, Rectal, Intraprostatic"			"Blepharoptosis, Deglutition disorders, Diaphoresis, Dysarthria, Dysgeusia, Hair disorders, Infections, Injection site reactions, Urinary tract infections"	"A10X (Other Drugs Used in Diabetes), A3 (Functional Gastro-Intestinal Disorder Drugs), C4A (Cerebral and Peripheral Vasotherapeutics), D11A (Other Dermatological Preparations), G4 (Urologicals), G4C (BPH (Benign Prostatic Hypertrophy) Products), G4X (All Other Urological Products), J5 (Antivirals for Systemic Use), M3A (Muscle Relaxants, Peripherally Acting), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs), R7X (All Other Respiratory System Products), S1X (Other Ophthalmologicals), V3 (All Other Therapeutic Products)"	"A03 (Drugs for Functional Gastrointestinal Disorders), A10X (Other Drugs Used in Diabetes), C04A-X (Other peripheral vasodilators), D11A (Other Dermatological Preparations), G04 (Urologicals), G04B-X (Other urologicals), G04C (Drugs Used In Benign Prostatic Hypertrophy), J05 (Antivirals for Systemic Use), M03A-X01 (Botulinum toxin), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), N06A (Antidepressants), N07X (Other Nervous System Drugs), R07A-X (Other respiratory system products), S01X-A (Other ophthalmologicals), V03A-Z (Nerve depressants)"	"AGN151586, BoNTA, Botox, Botulinum toxin A injectableAbbVie, GSK 1358820, Vistabel, Vistabex"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Bacterial Infections, Diabetes, Digestive System Disorders, Eye Disorders, Genitourinary Disorders, Men's Health, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Peptic Ulcer Disease, Respiratory Tract Disorders, Skin Disorders, Vascular Disorders, Viral Infections"	"Muscle spasticity (USA), Torticollis (USA)"		"Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Botox, Vistabel, Vistabex"	no		no		Bilirubin		"absent in melanoma 2, Bilirubin, C-X-C motif chemokine ligand 11, CCL5, CD40L, chromosome 7 open reading frame 49, CXCL10, D-Urobilinogen, G-CSF, ICAM-1, IFN-gamma, IL1 alpha, MIF, NGF, period circadian clock 3 pseudogene, PSA, Uric acid"		"bax, Creatinine, E-cadherin, IL1 beta, IL6, IL8, Ki67, purinergic receptor P2X 3, RAGE, TGF-beta, TJP1, TNF-alpha, TRP-V1, Tryptases"	https://adis.springer.com/drugs/800008810?userId=52029392&bpIds=3004037004&checksum=1231a4f764ca40efa020bc20b32ce165f37cf0a2-1617045530550-d12cb0f8df8c15f2f2d878d5141ce2cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024805	Hydrocodone/paracetamol controlled release			No			Discontinued (Preregistration)	"Osteoarthritis, Back pain, Postoperative pain"		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO			"Constipation, Diarrhoea, Headache, Nausea"	"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A (Opioids), N02B (Other Analgesics and Antipyretics)"	"ABT712, Acetaminophen/hydrocodone controlled release, Hydrocodone bitartrate/acetaminophen (HC/APAP) extended release Abbott, Hydrocodone/acetaminophen controlled release, Paracetamol/hydrocodone controlled release, Vicodin CR"			14/03/2021	"Pain, Rheumatic Disease"			"Vicodin CR, Vicodin CR, Vicodin CR"	no		no							https://adis.springer.com/drugs/800024805?userId=52029392&bpIds=3004037004&checksum=729494861aef7efcfe8d25a97e79f817e0053f4b-1617045530552-0c7b53d6b2731fa98914d1a079fb03cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029490	Promethazine/hydrocodone/paracetamol - Charleston Laboratories		"N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine/(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one/N-(4-hydroxyphenyl)acetamide"	No			Preregistration	"Nausea and vomiting, Acute pain"	C17 H20 N2 S . C18 H21 N O3 . C8 H9 N O2	"Histamine H1 receptor antagonists, Muscarinic receptor antagonists, Opioid receptor agonists, Prostaglandin receptor antagonists, Serotonin receptor antagonists"	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		PO				"A4A (Antiemetics and Antinauseants), N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"A04A (Antiemetics and Antinauseants), N02A (Opioids), N02B-E01 (Paracetamol), R05D-A03 (Hydrocodone), R06A-D52 (Promethazine, combinations)"	"CL108, HYDEXOR, Hydrocodone/paracetamol/promethazine, Paracetamol/promethazine/hydrocodone"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain"			"HYDEXOR, HYDEXOR"	no		no							https://adis.springer.com/drugs/800029490?userId=52029392&bpIds=3004037004&checksum=8f0e3ae28e1ad7287372d028e886f2a6376dab2c-1617045530553-2255ce153e5e7fba6a6a49dae2b7b563badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031738	Filorexant	1088991-73-4	"[(2<EM>R</EM>,5<EM>R</EM>)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone"	Yes			No development reported (II)	"Insomnia, Diabetic neuropathies, Migraine, Major depressive disorder"	C24 H25 F N4 O2	"Orexin receptor type 1 antagonists, Orexin receptor type 2 antagonists"	"Merck & Co (Originator), Merck & Co (Owner)"		PO				"N2 (Analgesics), N2C9 (All other anti-migraine preparations), N5B (Hypnotics/Sedatives), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N02C-X (Other antimigraine preparations), N05C (Hypnotics and Sedatives), N06A-X (Other antidepressants)"	MK6096			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800031738?userId=52029392&bpIds=3004037004&checksum=72319ce36d4748f5b600fadae5a63608e233d1e5-1617045530554-0cdfe53b7d06a91d786e5970a5f16ea1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013810	Nabiximols - GW Pharmaceuticals	56575-23-6	"(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol "	No			Marketed	"Muscle spasticity, Neuropathic pain, Cancer pain, Glioblastoma, Post-traumatic stress disorders, Bladder dysfunction, Stomatitis"	C42 H60 O4	"Cannabinoid receptor agonists, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Antioxidants"	"GW Pharmaceuticals (Originator), GW Pharmaceuticals (Owner), Al-Mojil (Market Licensee), Bayer HealthCare (Market Licensee), Emerge Health (Market Licensee), IDS Medical (Market Licensee), Ipsen (Market Licensee), Neopharm Ltd (Market Licensee), Almirall S.A. (Licensee), Novartis (Licensee)"		Buccal			"Dizziness, Nausea, Somnolence, Vomiting"	"A1 (Stomatologicals, Mouth Preparations, Medicinal Dentifrices etc), G4 (Urologicals), L1 (Antineoplastics), M1A (Anti-Rheumatics, Non-Steroidal), M3B (Muscle Relaxants, Centrally Acting), N2 (Analgesics)"	"A01A-D (Other agents for local oral treatment), G04 (Urologicals), L01 (Antineoplastic Agents), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), M03B-X (Other centrally acting agents), N02 (Analgesics), N02B-G10 (Cannabinoids, including nabiximols)"	"Cannabidiol/tetrahydrocannabinol, CBD/THC, CBDTHC, Delta9tetrahydrocannabinol/cannabidiol, Delta9THC/cannabidiol, Dronabinol/cannabidiol, GW 1000, GW100002, Medicinal cannabis GW Pharmaceuticals, Nabidiolex/Tetranabinex, Sativex, Tetrahydrocannabinol/cannabidiol, THC/CBD, THCCBD"			14/03/2021	"Anxiety Disorders, Cancer, Genitourinary Disorders, Mouth Disorders, Musculoskeletal Disorders, Pain"	"Glioma (USA), Glioma (European Union)"		"Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex, Sativex"	yes	USA	no							https://adis.springer.com/drugs/800013810?userId=52029392&bpIds=3004037004&checksum=ce697e48a9be2360a29557c4a24c14cd0a4aeec2-1617045530566-b89a111dfe2047d839c607d2b47f5df7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009249	Zonisamide - Eisai Co Ltd	68291-97-4	"1-(1,2-Benzoxazol-3-yl)methanesulphonamide"	Yes			Marketed	"Epilepsy, Parkinson's disease, Lewy body disease, Obesity, Manic episodes, Migraine, Neuropathic pain, Cerebral ischaemia"	C8 H8 N2 O3 S	"Antioxidants, Calcium channel antagonists, Sodium channel antagonists"	"Dainippon Sumitomo Pharma (Originator), Sumitomo Dainippon Pharma (Owner), Concordia Pharmaceuticals (Market Licensee), Ewopharma (Market Licensee), Eisai Co Ltd (Licensee)"		PO	hepatic	"Dose Modification in Hepatic Dysfunction (marked), Dose Modification in Renal Dysfunction (minimal), Linear Kinetics (yes), Route of Elimination (hepatic), Cl (L/h) (1.05 - 1.34 (Adult)), T<sub>_beta</sub> (h) (50 - 130 (Adult)), T<sub>max</sub> (h) (2.4 - 5.3 (Adult)), Vd (L/kg) (1.2 - 1.8 (Adult))"	"Appetite disorders, Ataxia, CNS disorders, Diarrhoea, Dizziness, Drowsiness, Fatigue, Fever, Gastrointestinal disorders, Headache, Renal calculi, Skin eruptions, Somnolence, Vomiting, Weight loss"	"A8A (Antiobesity Preparations, Excluding Dietetics), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N5A (Antipsychotics), N7 (Other CNS Drugs)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02B (Other Analgesics and Antipyretics), N02C (Antimigraine Preparations), N03A-X15 (Zonisamide), N04 (Anti-Parkinson Drugs), N05A-X (Other antipsychotics), N07X (Other Nervous System Drugs)"	"AD810, AD810N, CI912, Excegran, Kinaplase, PD110843, Tremode, Trerief, Zonegran"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Obesity, Pain, Parkinson's Disease and Movement Disorders"			"Excegran, Kinaplase, Tremode, Trerief, Trerief, Zonegran, Zonegran"	no		no				"A1C, CRP, EH domain containing 4, Urea, Valproic acid glucuronide"	A1C		https://adis.springer.com/drugs/800009249?userId=52029392&bpIds=3004037004&checksum=836527d70f8c74bd6246c6ec30fbcb918f6d30d1-1617045530572-0bd9add7d07f02b17ce4136c116c62abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011364	Lacosamide - UCB	175481-36-4	2(<EM>R</EM>)-Acetamido-<EM>N</EM>-benzyl-3-methoxypropionamide	Yes			Marketed	"Partial epilepsies, Tonic-clonic epilepsy, Generalised seizures, Epilepsy, Seizures, Fibromyalgia, Osteoarthritis, Sleep disorders, Essential tremor, Pain, Neuropathic pain, Migraine"	C13 H18 N2 O3	"CRMP2 protein modulators, Sodium channel antagonists, Glycine gated NMDA receptor antagonists"	"University of Houston (Originator), University of Houston (Owner), UCB (Licensee), Daiichi Sankyo Company (Sub-licensee), Duke University (Collaborator)"		"PO, IV"		"protein binding (%) (1 (Adult)), T<sub>_beta</sub> (h) (12 (Adult))"	"Arthralgia, Ataxia, Diarrhoea, Diplopia, Dizziness, Fatigue, Headache, Heart disorders, Nasopharyngitis, Nausea, Pathologic nystagmus, Respiratory tract infections, Sinusitis, Somnolence, Tremor, Vertigo, Vision disorders, Vomiting"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), N2C9 (All other anti-migraine preparations), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), N03 (Antiepileptics), N03A-X18 (Lacosamide), N05C-M (Other hypnotics and sedatives)"	"ADD 234037, Erlosamide, Harkoseride, SPM 927, SPM 929, VIMPAT, Vimpat"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease"			"VIMPAT, VIMPAT, Vimpat"	no		no				EH domain containing 4			https://adis.springer.com/drugs/800011364?userId=52029392&bpIds=3004037004&checksum=40c61756c0d03559c0cd41fbedec8b3e3612b765-1617045530600-0535a092883ea2fdee9d548675ae301bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015670	Perampanel - Eisai	380917-97-5	"Benzonitrile, 2-[1',6'-dihydro-6'-oxo-1'-phenyl(2,3'-bipyridin)-5'-yl]-"	Yes			Marketed	"Partial epilepsies, Tonic-clonic epilepsy, Seizures, Epilepsy, Parkinson's disease, Neuropathic pain, Migraine, Multiple sclerosis"	C23 H15 N3 O	AMPA receptor antagonists	"Eisai Co Ltd (Originator), Eisai Co Ltd (Owner), Biotoscana (Market Licensee), Hikma Pharmaceuticals (Market Licensee), ESTEVE (Collaborator)"		"PO, IV"			"Aggression, Anger, Ataxia, Behavioural disorders, Dizziness, Fatigue, Gait disturbances, Headache, Irritability, Mood disorders, Nausea, Psychiatric disorders, Somnolence, Suicidal ideation, Vertigo, Weight gain"	"N2 (Analgesics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"N02 (Analgesics), N02C (Antimigraine Preparations), N03A-X22 (Perampanel), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"	"E2007, ER15505590, Fycompa"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"			"Fycompa, Fycompa, Fycompa, Fycompa"	no		no			A1C	"A1C, Bilirubin, IGF1, L-Aspartic acid, period circadian clock 3 pseudogene, Thyroid stimulating hormone, beta, Thyroxine, Triiodothyronine"		Valproic acid glucuronide	https://adis.springer.com/drugs/800015670?userId=52029392&bpIds=3004037004&checksum=69392788b17d25673e72eb4cb0d4523181ee5413-1617045530613-6fd84075cc20cbcbd874606865de28f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024814	ADL 5859	850173-95-4	"<EM>N</EM>,<EM>N</EM>-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide hydrochloride"				Discontinued (II)	"Inflammatory pain, Neuropathic pain, Dental pain"	C24 H29 CL1 N2 O3	Opioid delta receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner), Pfizer (Licensee)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	"ADL5859, PF04856880, PF4856880"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800024814?userId=52029392&bpIds=3004037004&checksum=32e1829e9eb4affd7533dc55f570433a178b06cb-1617045530614-d3349ddf479b4744b36970c299297392badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014733	PTI 555			No			Discontinued (II)	Pain		"Opioid mu receptor agonists, Opioid receptor antagonists"	"Albert Einstein College of Medicine (Originator), Albert Einstein College of Medicine (Owner), Cassava Sciences (Licensee)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"morphinenaltrexone, MorViva"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800014733?userId=52029392&bpIds=3004037004&checksum=c7d55f3efd440766abdaaff65e4e1f8d125f38a4-1617045530615-590bd593562f34b11f60ead8efcb47e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038927	Dextromethadone - Cornell University/Relmada Therapeutics	5653-80-5	"3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-, (S)"	No			Phase III	"Major depressive disorder, Mitochondrial disorders, Rett syndrome, Eye disorders, Neuropathic pain"	C21 H27 N O	NMDA receptor antagonists	"Cornell University (Originator), Cornell University (Owner), Relmada Therapeutics (Licensee)"		PO				N2 (Analgesics)	N02A-C (Diphenylpropylamine derivatives)	"+Methadone Relmada Therapeutics, 6SMethadone Relmada Therapeutics, d Methadone Relmada Therapeutics, REL 1017, S(+)methadone, SMethadone Relmada Therapeutics"			14/03/2021	"Affective Disorders, Eye Disorders, Metabolic Disorders, Neurological Disorders, Pain"	Postherpetic neuralgia (USA)			yes	USA	no				spermine synthase			https://adis.springer.com/drugs/800038927?userId=52029392&bpIds=3004037004&checksum=eb8c8e3219802e87be517aea71d70b5ef97fb650-1617045530616-0db2a1911366509c47043935e47da4cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015120	Dextromethorphan/quinidine - Avanir Pharmaceuticals		"(1S,9S,10S)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.0^1,10.0^2,7]heptadeca-2(7),3,5-triene / (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol"	No			Marketed	"Emotional lability, Diabetic neuropathies, Neuropathic pain, Migraine, Agitation, Drug-induced dyskinesia"	C18 H25 N O . C20 H24 N2 O2	"Cytochrome P 450 enzyme system inhibitors, NMDA receptor antagonists, Norepinephrine plasma membrane transport protein inhibitors, Serotonin plasma membrane transport protein inhibitors, Sigma-1 receptor agonists, Sodium channel antagonists"	"Center for Neurologic Study (Originator), Center for Neurologic Study (Owner), Avanir Pharmaceuticals (Licensee), State University of New York (Collaborator)"		PO			"Cardiovascular disorders, Constipation, Diarrhoea, Dizziness, Fatigue, Gastrointestinal disorders, Headache, Insomnia, Nausea, Respiratory tract infections, Somnolence, Urinary tract infections, Vomiting"	"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics), N4A (Anti-Parkinson Drugs), N5A (Antipsychotics), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N02B (Other Analgesics and Antipyretics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N07 (Other Nervous System Drugs), N07X-X59 (Dextromethorphan, combinations)"	"AVP923, Dextromethorphan HBr/quinidine sulfate, Dextromethorphan hydrobromide/quinidine sulfate, Neurodex, Nuedexta, Quinidine/dextromethorphan, Zenvia"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Diabetes, Pain, Parkinson's Disease and Movement Disorders"			"Neurodex, Nuedexta, Nuedexta, Nuedexta, Nuedexta, Nuedexta, Zenvia"	no		no		PGR		PGR		CYP2D6	https://adis.springer.com/drugs/800015120?userId=52029392&bpIds=3004037004&checksum=289e3ec177dcd3a3d8fa8cfe872dcfb3a0b746f7-1617045530619-bc1607a4bb9b62a023a8a2b57043a1efbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018148	Gabapentin enacarbil - Arbor Pharmaceuticals	478296-72-9	"Cyclohexaneacetic acid,1-[[[[1-(2-methyl-1-oxopropoxy)ethoxy]carbonyl]amino]methyl]-"	Yes			Marketed	"Restless legs syndrome, Postherpetic neuralgia, Alcoholism, Migraine, Diabetic neuropathies"	C16 H27 N O6	"CACNA2D1 protein modulators, GABA receptor agonists"	"XenoPort (Originator), Arbor Pharmaceuticals (Owner), Astellas Pharma (Licensee), National Institute on Alcohol Abuse and Alcoholism (Collaborator)"		PO			"Dizziness, Somnolence"	"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics), N4A (Anti-Parkinson Drugs), N7E (Drugs Used In Alcohol Dependence)"	"N02 (Analgesics), N02B (Other Analgesics and Antipyretics), N04 (Anti-Parkinson Drugs), N07B-B (Drugs used in alcohol dependence)"	"1838262, ASP8825, GabapentinXP, GSK 1838262, Horizant, Regnite, Solzira, XP13512"			14/03/2021	"Drug Delivery Systems, Drug Withdrawal, Pain, Parkinson's Disease and Movement Disorders"		"Arbor Pharmaceuticals | Restless legs syndrome | Unspecified |  (Excluding Japan, USA) | 22 Apr 2014"	"Horizant, Horizant, Regnite, Solzira, Solzira"	no		no				"chymase 1, doublecortin like kinase 3, FGFR1OP N-terminal like, Huntingtin, Kell blood group, metallo-endopeptidase"			https://adis.springer.com/drugs/800018148?userId=52029392&bpIds=3004037004&checksum=de6741e6a84682c1354bc33cb4c170fa36faf681-1617045530622-df4eba707840f354ce5d541605ec73d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030018	Tramadol controlled release - e-Therapeutics	27203-92-5	"Cyclohexanol, 2-((dimethylamino)-1-(3-methoxyphenyl)-,cis-(+-)-"	No			Phase II	Major depressive disorder	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"e-Therapeutics (Originator), e-Therapeutics (Owner), Khandelwal Laboratories (Licensee)"		PO				"N2A (Narcotics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02A-X02 (Tramadol), N06 (Psychoanaleptics)"	"ETS6103, ETX6103, Tramadol extended release eTherapeutics, Tramadol hydrochloride, Tramadol sustained release eTherapeutics, Viotra"			14/03/2021	Affective Disorders		e-Therapeutics |  | Unspecified |  | 07 Jan 2016	Viotra	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800030018?userId=52029392&bpIds=3004037004&checksum=9737e4d261c1c69fcb81844b1a027f7e62d7cbbb-1617045530624-7a29300f7723b515c2005452cee277e0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041303	Tramadol orodispersible - Ethypharm	27203-92-5	"(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			Marketed	Pain	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Ethypharm (Originator), Ethypharm (Owner), Biovail Pharmaceuticals USA (Market Licensee), Meda (Market Licensee), sanofi-aventis-LEK (Market Licensee), Sun Pharmaceutical Industries (Market Licensee)"		PO				N2 (Analgesics)	N02A-X02 (Tramadol)	"Contramal, Topalgic, Tradonal Odis, Travex, Zamadol"			14/03/2021	Pain			"Contramal, Contramal, Contramal, Contramal, Contramal, Contramal, Topalgic, Travex, Zamadol, Zamadol"	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800041303?userId=52029392&bpIds=3004037004&checksum=0121d65099ba0ba3149aa8246fc6dbfff5b89221-1617045530626-23bde929ad9f818afb8e3bcbf522b23bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022464	Research programme: migraine therapy - Orexo						Discontinued (Preclinical)	Migraine		Undefined mechanism	"PharmaKodex (Originator), Orexo (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"OX 40, OX641"			14/03/2021	Advances in the Treatment of Nausea and Migraine		Orexo | Migraine | Preclinical |  | 21 Jul 2009		no		no							https://adis.springer.com/drugs/800022464?userId=52029392&bpIds=3004037004&checksum=5a8edcb6f9454c9183bcc455c3b1631c885c49fd-1617045530627-9da391caaca9623ce13641a2392790bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023165	Fentanyl transdermal	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Marketed	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Nycomed (Originator), Takeda (Owner), betapharm (Market Licensee), Daewoong Pharmaceutical (Market Licensee)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	Matrifen			14/03/2021	Pain			Matrifen	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800023165?userId=52029392&bpIds=3004037004&checksum=2cb29baa00c3a59d63dcac8e5430fbba6755c1e2-1617045530628-682363391b3e284ad4725086e3bcdbf8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014120	Neublastin			Yes			Discontinued (II)	"Radiculopathy, Sciatica, Neuropathic pain"		Neuron stimulants	"NsGene (Originator), NsGene (Owner), Biogen (Licensee)"		"IV, SC"				"N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"N02B-G (Other analgesics and antipyretics), N07 (Other Nervous System Drugs), N07X-X (Other nervous system drugs)"	"Artemin, ARTN, BG00010, Enovin"			14/03/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800014120?userId=52029392&bpIds=3004037004&checksum=a4ba445c203bb0063a939763b41dfb4bb4d03e30-1617045530630-affe3a4923a7c9ae713cca8b0c57224cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004254	Eletriptan	143322-58-1	5-[2-(Benzenesulfonyl)ethyl]-3-[1-methylpyrrolidin-2(<EM>R</EM>)-ylmethyl]-1<EM>H</EM>-indole	Yes			Marketed	"Migraine, Menstrual migraine"	C22 H26 N2 O2 S	Serotonin 1D receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		PO		"Linear Kinetics (yes), bioavailability oral (%) (50 (Adult)), T<sub>_beta</sub> (h) (4 - 5 (Adult)), T<sub>max</sub> (h) (1 (Adult))"	"Asthenia, Chest pain, Dizziness, Nausea, Paraesthesia, Somnolence, Xerostomia"	N2C1 (Antimigraine triptans)	N02C-C06 (Eletriptan)	"Relert, Relpax, UK 116044"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Women's Health"			"Relert, Relpax"	no		no							https://adis.springer.com/drugs/800004254?userId=52029392&bpIds=3004037004&checksum=2b37ac1b663d7f3d38edb968715c6b5bb615e447-1617045530633-b6b9135a265ced2a6bb9cab19ae553a7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002912	Rizatriptan	144034-80-0	"3-[2-(Dimethylamino)ethyl]-5-(1,2,4-triazol-1-ylmethyl)-indole benzoate"	Yes			Marketed	"Migraine, Motion sickness"	C15 H19 N5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Merck & Co (Originator), Merck & Co (Owner), Eisai Co Ltd (Market Licensee), University of Pittsburgh (Collaborator)"		PO		"Linear Kinetics (yes), bioavailability oral (%) (45 (Adult)), T<sub>_beta</sub> (h) (1.8 (Adult)), T<sub>max</sub> (h) (1.3 (Adult))"	"Dizziness, Drowsiness, Fatigue, Headache, Nausea, Pain, Paraesthesia, Syncope, Xerostomia"	"N2C (Anti-Migraine Preparations), N2C1 (Antimigraine triptans)"	N02C-C04 (Rizatriptan)	"L 705126, Maxalt, MaxaltMLT, MK 0462, MK 462, Rizatriptan benzoate"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Digestive System Disorders"			"Maxalt, MaxaltMLT"	no		no							https://adis.springer.com/drugs/800002912?userId=52029392&bpIds=3004037004&checksum=4e1852c46d95fddf53d47939a7d9e074320c2340-1617045530635-c40c209c1345a542d40d5df080efd0dfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034098	Galcanezumab - Eli Lilly and Company	1578199-75-3	"Immunoglobulin G4, anti-(human calcitonin gene-related peptide) (human-Mus musculus clone III heavy chain), disulfide with human-Mus musculus clone III kappa-chain, dimer"	Yes			Marketed	"Migraine, Cluster headache, Unspecified, Musculoskeletal pain"	C6392 H9854 N1686 O2018 S46	Calcitonin gene-related peptide antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		SC				"N2C (Anti-Migraine Preparations), V (Various)"	"N02C-D02 (Galcanezumab), V (Various)"	"Emgality, Galcanezumabgnlm, LY2951742"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain"			"Emgality, Emgality, Emgality, Emgality"	no		no							https://adis.springer.com/drugs/800034098?userId=52029392&bpIds=3004037004&checksum=4a7fde2aa1652c8a26ea29a51ecbba3689716567-1617045530640-72059d84643ec7fd4cac8b9721daa9e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009405	Hydromorphone controlled release - ALZA Corporation	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"	Yes			Marketed	"Pain, Cancer pain"	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Therapeutic Discovery Corporation (Originator), ALZA Corporation (Owner), Johnson & Johnson (Owner), Fresenius Kabi (Market Licensee), Janssen-Cilag (Market Licensee), Mallinckrodt Inc. (Licensee)"		"PO, Parenteral"			"Arthralgia, Constipation, Headache, Insomnia, Nausea, Vomiting"	N2A (Narcotics)	N02A-A03 (Hydromorphone)	"AP 77, Dilaudid, Dilaudid Oros, Exalgo, Hydromorphone extended release, Hydromorphone HCl, Hydromorphone hydrochloride, Jurnista, NMED1077, OROS Hydromorphone"			14/03/2021	Pain			"Dilaudid, Exalgo, Jurnista, Jurnista, Jurnista, Jurnista"	no		no				"Norepinephrine, serotonin"			https://adis.springer.com/drugs/800009405?userId=52029392&bpIds=3004037004&checksum=5b792b3374ea690117429b243ab47b3f4f24ddd0-1617045530643-f080af712165d6ae020c94c558ca556dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037098	Erenumab - Amgen/Novartis	1582205-90-0		Yes			Marketed	"Migraine, Headache, Rosacea, Trigeminal neuralgia, Hot flashes"	C6472 H9964 N1728 O2018 S50	Calcitonin gene-related peptide receptor antagonists	"Amgen (Originator), Amgen (Owner), Amgen (Market Licensee), Novartis (Market Licensee), Novartis (Licensee), Amgen Astellas BioPharma (Collaborator), Rigshospitalet (Collaborator)"		"SC, unspecified, IV"			"Abdominal pain, Arthralgia, Back pain, Constipation, Dental caries, Fatigue, Gastroenteritis, Influenza virus infections, Injection site pain, Nasopharyngitis, Pharyngitis, Respiratory tract infections, Sinusitis"	"C1X (All Other Cardiac Preparations), D11A (Other Dermatological Preparations), G2X9 (Other gynaecologicals), N2C (Anti-Migraine Preparations)"	"C01E-B (Other cardiac preparations), D11A (Other Dermatological Preparations), G02C (Other Gynecologicals), N02C-X07 (Erenumab)"	"Aimovig, AMG334, Erenumabaooe"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain, Skin Disorders, Women's Health"			"Aimovig, Aimovig, Aimovig"	no		no							https://adis.springer.com/drugs/800037098?userId=52029392&bpIds=3004037004&checksum=7dec25e503758b917ed199e6749a0ef8ed4594e2-1617045530649-e6b3b9757de7fd93a9a004aa9639a61fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045485	Oxycodone controlled release - Teikoku Seiyaku	76-42-6	"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Discontinued (III)	Cancer pain	C18 H21 N O4	Opioid mu receptor agonists	"Teikoku Seiyaku (Originator), Teikoku Seiyaku (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"Oxycodone, TK 641"			14/03/2021	Pain				no		no		"A1C, beta-hCG, CA-19-9, CD8a, CRP, dsDNA Auto-antibodies, EGFR, Ferritin, Fumaric acid, glycoprotein nmb, Uric acid"	"Bilirubin, CRP, EGFR, PD-L1, Uric acid"	"8-oxo-7-hydrodeoxyguanosine, A1C, beta-hCG, bFGF, Bilirubin, BNP, C-peptide, CA-125, CA-19-9, Carbonic anyhdrase 9, CD163, CD40L, CD63, CD8a, chromodomain helicase DNA binding protein 7, chymotrypsin like, Citrulline, CKB, CKM, complement component (3b/4b) receptor 1 (Knops blood group), connective tissue growth factor, CRP, Cyclin D1, D-Urobilinogen, dsDNA Auto-antibodies, dual specificity phosphatase 6, E-cadherin, ECP, Eotaxin, Ferritin, FGF23, Flt-3, Fumaric acid, G protein-coupled receptor 83, gamma-glutamyltransferase light chain 1, GLP-1, glutamic-oxaloacetic transaminase 2, glycoprotein nmb, IFN-gamma, IL1 beta, IL10, IL6, IL8, immunoglobulin heavy constant epsilon, immunoglobulin kappa variable 1-5, immunoglobulin kappa variable 1D-39, Ki67, KIM-1, L-FABP, lactate dehydrogenase A, Leukotriene E4, LTB4, mastermind like domain containing 1, meningioma expressed antigen 5 (hyaluronidase), pescadillo ribosomal biogenesis factor 1, PSA, PTH, sodium channel, voltage gated, type X alpha subunit, T cell receptor gamma variable 9, Tau protein, Testosterone, Thyroxine, Tissue factor, tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor), TNF-alpha, TNFRSF1A, Uric acid, VEGF-A"	"Carbonic anyhdrase 9, CD8a, IL1 beta, IL10, IL6, IL8, TNF-alpha, VEGF-A"	"cholinergic receptor, nicotinic, alpha 4 (neuronal), COMT, CYP2C19, CYP2D6, CYP3A4, ER alpha, Estradiol-17beta 3-sulfate, hypertrichosis 2 (generalized, congenital), Noroxycodone, OPRM1, Progesterone, SRC proto-oncogene, non-receptor tyrosine kinase, VPS52, GARP complex subunit"	https://adis.springer.com/drugs/800045485?userId=52029392&bpIds=3004037004&checksum=07180a7927ed0a48ef4af17020878b521fbcdefe-1617045530650-d324277fe742a4457aaa542f3f960c87badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014966	JNJ 38488502	228546-92-7	(<EM>R</EM>)-2-((<EM>R</EM>)-2-((<EM>R</EM>)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-<EM>N</EM>-((<EM>R</EM>)-5-guanidino-1-oxo-1-((pyridin-4-ylmethyl)amino)pentan-2-yl)hexanamide	Yes			No development reported (II)	Postoperative pain	C36 H49 N9 O4	Opioid kappa receptor agonists	"Ferring Pharmaceuticals (Originator), Freie Universitat Berlin (Originator), Ferring Pharmaceuticals (Owner), Freie Universitat Berlin (Owner), Cara Therapeutics (Licensee), ALZA Corporation (Sub-licensee)"		IV				N2A (Narcotics)	N02A (Opioids)	"CR665, FE 200665"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800014966?userId=52029392&bpIds=3004037004&checksum=f513272bbeb13645b1aca07491908b3d7416ffae-1617045530651-23e4e0a980424f38bb8c6010c8d914aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015068	Naproxen sodium/sumatriptan - Old API Wind-down	811794-26-0	"2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, sodium salt, (S)-/3-(2-(Dimethylamino)ethyl)-N-methylindole-5-methanesulfonamide succinate (1:1)"	No			Marketed	Migraine	C14 H13 Na O3 . C18 H27 N3 O6 S	"Cyclooxygenase inhibitors, Serotonin 1 receptor agonists"	"GlaxoSmithKline (Originator), POZEN (Originator), Old API Wind-down Ltd (Owner), Currax Pharmaceuticals (Market Licensee), Miravo Healthcare (Market Licensee), Orion (Market Licensee), Cilag GmbH International (Licensee), Desitin Pharmaceuticals GmbH (Licensee), Deerfield (Funder)"		PO			Dizziness	"M1A1 (Anti-rheumatics, non-steroidal plain), N2C1 (Antimigraine triptans)"	"M01A-E02 (Naproxen), N02C-C01 (Sumatriptan)"	"MT400, Naproxen sodium/sumatriptan succinate, SumaRT/Nap, Sumatriptan/naproxen sodium, Suvexx, Trexima, Treximet"			14/03/2021	Advances in the Treatment of Nausea and Migraine			"Suvexx, Trexima, Treximet"	no		no		Estradiol-17beta 3-sulfate	"ACE, Estradiol-17beta 3-sulfate"	"ACE, ACTH, Adiponectin, Estradiol-17beta 3-sulfate, Hydrocortisone, Leptin, PGE2, Prostacyclin, Resistin, VIP"		"CRP, Luteinizing hormone"	https://adis.springer.com/drugs/800015068?userId=52029392&bpIds=3004037004&checksum=c52e9583359d2f7544a02777928f0721ad0210f9-1617045530653-9d08913adbb4f2b90b19ae8b0aa4f22abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026256	Morphine extended-release/naltrexone	850636-73-6					Market Withdrawal	Pain		"Opioid mu receptor agonists, Opioid receptor antagonists"	"Alpharma (Originator), Pfizer (Owner)"		PO		T<sub>max</sub> (h) (8.1 (Adult))	"Constipation, Drowsiness, Euphoria, Headache, Nausea, Pruritus, Somnolence, Vomiting"	"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-A01 (Morphine), N07B-B04 (Naltrexone)"	"ALO01, Embeda, KADIAN NT, Morphine ER/naltrexone, Naltrexone/morphine ER"			14/03/2021	Pain			Embeda	no		no							https://adis.springer.com/drugs/800026256?userId=52029392&bpIds=3004037004&checksum=8db2b34e76cff9ba030c64e265883e4575ff5815-1617045530654-d491a7f1aa6fbaf9319b53a2f1133dd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015471	GW 468816						No development reported (II)	"Smoking withdrawal, Migraine"		Glycine antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), National Institute on Drug Abuse (Collaborator)"		PO				"N2C (Anti-Migraine Preparations), N7B (Antismoking Products)"	"N02C-X (Other antimigraine preparations), N07B-A (Drugs used in nicotine dependence)"	"468816, GW468816"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Drug Withdrawal"				no		no							https://adis.springer.com/drugs/800015471?userId=52029392&bpIds=3004037004&checksum=5cd5a0e6170664b50aecb81f6ef179a68c651cdc-1617045530655-fa0e80a1993d25bfbd46fee1c18ae0f4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002033	Lomerizine	101477-55-8	"1-[bis(4-Fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-piperazine dihydrochloride"	Yes			Marketed	"Migraine, Glaucoma, Cerebral infarction"	C27 H30 F2 N2 O8 . 2H Cl	Calcium channel antagonists	"Nippon Organon (Originator), Pfizer (Originator), Merck & Co (Owner), Santen Pharmaceutical (Licensee)"		PO				"N2C (Anti-Migraine Preparations), N7X (All other CNS drugs), S1E (Miotics and Antiglaucoma Preparations)"	"N02C (Antimigraine Preparations), N07X (Other Nervous System Drugs), S01E (Antiglaucoma Preparations and Miotics)"	"DE090, KB 2796, Lomerizine hydrochloride, Migsis"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Eye Disorders, Neurological Disorders"			Migsis	no		no							https://adis.springer.com/drugs/800002033?userId=52029392&bpIds=3004037004&checksum=30574bb42188a49c4c7fbad6dc0ffd62c1f04548-1617045530656-75364a3b202474b28a68f7fca28ad154badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028519	Lasmiditan - Eli Lilly and Company	439239-90-4	"2,4,6-Trifluoro-<EM>N</EM>-[6-[(1-methylpiperidine-4-yl)carbonyl]pyridin- 2-yl]benzamide"	Yes			Marketed	Migraine	C19 H18 F3 N3 O2	Serotonin 1F receptor agonists	"Eli Lilly and Company (Originator), Lundbeck A/S (Originator), Eli Lilly and Company (Owner), Lundbeck A/S (Owner), Ildong Pharmaceutical (Licensee)"		"PO, IV"			"Dizziness, Fatigue"	N2C9 (All other anti-migraine preparations)	N02C-C (Selective serotonin (5HT1) agonists)	"COL144, LY573144, REYVOW"			14/03/2021	Advances in the Treatment of Nausea and Migraine			REYVOW	no		no				"doublecortin like kinase 3, spermine synthase"			https://adis.springer.com/drugs/800028519?userId=52029392&bpIds=3004037004&checksum=91b2c58c66e263d0863f70fe4fa3ad4c30baa1db-1617045530660-e6b67d61d575c6cde7be945822c0b033badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005783	Almotriptan	154323-57-6	1-[[[3-[2-(dimethylamino)ethyl]indol-5-yl]methyl]sulfonyl]pyrrolidine	Yes			Marketed	Migraine	C17 H25 N3 O2 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Almirall-Prodesfarma (Originator), Almirall S.A. (Owner), Angelini Group (Market Licensee), Bayer (Market Licensee), Janssen Inc (Market Licensee), Meda (Market Licensee), Solvay (Market Licensee), Sumitomo Dainippon Pharma (Market Licensee), Teva Pharmachemie (Market Licensee), Yuhan (Market Licensee)"		PO		Linear Kinetics (yes)	"Diarrhoea, Dyspepsia, Dyspnoea, Flushing, Headache, Nausea, Pain, Paraesthesia, Somnolence, Vomiting, Xerostomia"	N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)	"Almogran, Axert, LAS 31416"			14/03/2021	Advances in the Treatment of Nausea and Migraine			"Almogran, Axert, Axert"	no		no							https://adis.springer.com/drugs/800005783?userId=52029392&bpIds=3004037004&checksum=ce71cec9ee6f39093cebffd585267c0ac47acf9e-1617045530661-252ff1a5a85b72f1eb152e7853bdf0b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002010	Naratriptan	121679-13-8	N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5- ethanesulphonamide	Yes			Marketed	Migraine	C17 H25 N3 O2 S	Serotonin 1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), AbbVie (Market Licensee), Sumitomo Dainippon Pharma (Market Licensee), UCB (Collaborator)"		PO		"Linear Kinetics (yes), T<sub>_beta</sub> (h) (6 (Adult)), T<sub>max</sub> (h) (1.5 - 2 (Adult))"	"Angina pectoris, Dizziness, Drowsiness, Fatigue, Nausea"	N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)	"Amerge, GR 85548, GR 85548A, Naramig, Naratriptan hydrochloride, SMP 948"			14/03/2021	Advances in the Treatment of Nausea and Migraine			"Amerge, Naramig, Naramig"	no		no				serotonin	serotonin		https://adis.springer.com/drugs/800002010?userId=52029392&bpIds=3004037004&checksum=338b5440f5161bbc7cd5004beaef9dcb5c6b639e-1617045530663-a009ce7f8090caf2cff1de9689cb57d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020120	Fentanyl buccal - Teva	990-73-8	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate	No			Marketed	"Cancer pain, Dyspnoea, Pain, Neuropathic pain"	C22 H28 N2 O . C6 H8 O7	Opioid mu receptor agonists	"CIMA LABS (Originator), Teva Pharmaceutical Industries (Owner), Lundbeck A/S (Market Licensee), BMP Sunstone Corporation (Licensee), Taiho Pharmaceutical (Licensee), Teikoku Seiyaku (Sub-licensee), M. D. Anderson Cancer Center (Collaborator)"		Buccal		Linear Kinetics (yes)	"Application site reactions, Dizziness, Headache, Nausea"	"N2 (Analgesics), R7A (Respiratory Stimulants)"	"N02A-B03 (Fentanyl), R07A-B (Respiratory stimulants)"	"Efen buccal tablets, Effentora, Fentanyl buccal Cephalon, Fentanyl citrate Teva, Fentora, OraVescent fentanyl, OVF"			14/03/2021	"Drug Delivery Systems, Obstructive Airways Disease, Pain"			"Efen buccal tablets, Effentora, Fentora"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800020120?userId=52029392&bpIds=3004037004&checksum=d79d9cf0d8529516a9cef44e427789e04d9784f8-1617045530666-24ee5ac753c3bb69cf75cae7c5c62f81badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020215	Fentanyl intranasal spray - Kyowa Kirin International	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Marketed	"Cancer pain, Anaesthesia"	C22 H28 N2 O	Opioid mu receptor agonists	"West Pharmaceutical Services (Originator), Kyowa Kirin International (Owner), AstraZeneca (Market Licensee), Slan Medicinal Holdings (Licensee), The Lundquist Institute (Collaborator)"		Intranasal				N2 (Analgesics)	N02A-B03 (Fentanyl)	"Fentanyl, Fentanyl pectin, Fentanyl pectin nasal spray, FPNS, Lazanda, Nasalfent, PecFent"			14/03/2021	"Drug Delivery Systems, Pain"		"Archimedes Pharma |  | Unspecified | World (Excluding North America, Western Europe) | 15 Dec 2010"	"Lazanda, Lazanda, PecFent"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800020215?userId=52029392&bpIds=3004037004&checksum=ce0a3b14426a2398751f61f2189905f97d9172e6-1617045530670-6c209e156d4846da82176589c93b16b6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018044	Fentanyl sublingual - Orexo	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Marketed	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Orexo (Originator), Orexo (Owner), Kyowa Kirin (Market Licensee), Kyowa Kirin International (Licensee), Sentynl Therapeutics (Licensee), Er-Kim Ilac (Sub-licensee), Fannin (Sub-licensee), Gedeon Richter (Sub-licensee), Hisamitsu Pharmaceutical (Sub-licensee), Paladin Labs (Sub-licensee), PharmaSwiss (Sub-licensee)"		Sublingual				N2 (Analgesics)	N02A-B03 (Fentanyl)	"Abstral, EN3267, Fentanyl citrate sublingual tablets, Fentanyl transmucosal Orexo, KW2246, OX20, Rapinyl"			14/03/2021	Pain			"Abstral, Abstral, Abstral, Abstral, Rapinyl"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800018044?userId=52029392&bpIds=3004037004&checksum=b470803695067d6bd392bdc68416e360e87c245a-1617045530674-90b8bdcb63d9bf83364031aded1ee286badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019962	Oxycodone controlled release - Cassava Sciences	124-90-3	"4,5a-Epoxy-14b-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride"	No			Discontinued (Preregistration)	Pain	C18 H21 N O4 . H Cl	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"DURECT Corporation (Originator), DURECT Corporation (Owner)"		PO			"Dizziness, Drowsiness, Nausea, Pruritus, Somnolence, Vomiting"	N2A (Narcotics)	N02A-A05 (Oxycodone)	"Extendedrelease oxycodone capsules CII, ORADURoxycodone, Oxycodone CII, Oxycodone extended release, PF00345439, PTI821, Remoxy, REMOXY ER"			14/03/2021	"Drug Delivery Systems, Pain"		Cassava Sciences | Pain | Clinical Phase Unknown |  | 04 Nov 2014	Remoxy	no		no							https://adis.springer.com/drugs/800019962?userId=52029392&bpIds=3004037004&checksum=15798601b58e7bccf8f55d958895f0371cb991f7-1617045530675-f3011bd035581e7abf477ec3b9952e74badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011477	Oxycodone controlled release - Purdue Pharma	124-90-3	"4,5_-Epoxy-14_-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride"	No			Marketed	"Pain, Postoperative pain, Cancer pain"	C18 H21 N O4 . H Cl	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Purdue Pharma (Originator), Purdue Pharma (Owner), Mundipharma International (Market Licensee), Napp Pharmaceutical Group (Market Licensee), Shionogi (Sub-licensee)"		PO	renal	"Active Metabolites (yes), Activity vs parent (²), Dose Modification in Hepatic Dysfunction (moderate), Dose Modification in Renal Dysfunction (moderate), Linear Kinetics (yes), Route of Elimination (renal), bioavailability oral (%) (60 - 87 (Adult)), Cl (L/h) (4.8 (Adult)), protein binding (%) (45 (Adult)), T<sub>_beta</sub> (h) (.6 - 6.9 (Adult)), T<sub>max</sub> (h) (2.7 - 3.2 (Adult)), Vd (L/kg) (2.6 (Adult))"	"Apnoea, Asthenia, Constipation, Dizziness, Headache, Hyperhidrosis, Hypotension, Nausea, Pruritus, Respiratory insufficiency, Shock, Somnolence, Vomiting"	N2A (Narcotics)	N02A-A05 (Oxycodone)	"OxiContin, Oxycodone controlled release Purdue, Oxycodone extended release Purdue, Oxycodone hydrochloride controlledrelease, OxyContin, OxyContin Neo, OxyContinTR, OxyNeo"			14/03/2021	Pain			"OxiContin, OxyContin, OxyContin, OxyContin, OxyContin Neo, OxyContinTR, OxyNeo"	no		no							https://adis.springer.com/drugs/800011477?userId=52029392&bpIds=3004037004&checksum=68bc63bcc48c24a52f513b27ad61478c34e695cd-1617045530682-9013b2fa9bf1b52bf694304b76148b66badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025748	Droxidopa - Lundbeck A/S	23651-95-8	"(-)-(2<EM>S</EM>,3<EM>R</EM>)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid"	No			Marketed	"Orthostatic hypotension, Dizziness, Intradialytic hypotension, Amyloid polyneuropathy, Fibromyalgia, Chronic fatigue syndrome, Attention-deficit hyperactivity disorder"	C9 H11 N O5	Adrenergic receptor agonists	"Dainippon Sumitomo Pharma (Originator), Sumitomo Dainippon Pharma (Owner), Lundbeck A/S (Licensee), St Josephs Hospital and Medical Center (Collaborator)"		PO			"Dizziness, Headache, Hypertension"	"C1C2 (Cardiac dopaminergic agents), N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"C01C-A (Adrenergic and dopaminergic agents), N02B-G (Other analgesics and antipyretics), N06B (Psychostimulants, agents used for ADHD and nootropics), N07X (Other Nervous System Drugs)"	"34Dihydroxyphenylserine, 34threoDOPS, Dops, LDOPS, Lthreodihydroxyphenylserine, Lthreodops, Northera, Threodopaserine, ThreoDOPS"			14/03/2021	"Affective Disorders, Neurological Disorders, Pain, Vascular Disorders"	"Orthostatic hypotension (USA), Orthostatic hypotension (European Union)"	"Lundbeck A/S |  | Unspecified | World (Excluding China, Japan, South Korea, Taiwan, USA) | 31 Dec 2009"	"Dops, Northera, Northera"	no		no			Norepinephrine	Norepinephrine			https://adis.springer.com/drugs/800025748?userId=52029392&bpIds=3004037004&checksum=6894701db6547837cbcba3da6766443d4684ee71-1617045530684-e3452ebaddbc65779307aa8bddf73ccabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024342	Fulranumab	902141-80-4	"Immunoglobulin G2, anti-(human nerve growth factor) (human monoclonal 4D4 heavy chain), disulfide with human monoclonal 4D4 light chain, dimer"	Yes			No development reported (I)	"Pain, Musculoskeletal pain, Neuropathic pain, Cancer pain, Back pain"	C6446 H9930 N1718 O2018 S50	Nerve growth factor inhibitors	"Amgen (Originator), Amgen (Owner)"		SC				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	"AMG403, JNJ42160443"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800024342?userId=52029392&bpIds=3004037004&checksum=e9742909b8b171f4f75ab946c55e909102affef6-1617045530688-f6ced26b07475a59c401465804bd25e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042363	ODM 108			Yes			Discontinued (I)	Neuropathic pain		TRPA1 protein inhibitors	"Orion (Originator), Orion (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	ODM108			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800042363?userId=52029392&bpIds=3004037004&checksum=1a1f257897b02b4267e4b39fdf4d9390630e0dc3-1617045530689-13304c0682817ab4974257c4c8bafed5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018291	SAB 378			Yes			Discontinued (II)	"Postherpetic neuralgia, Pain"		Cannabinoid receptor CB1 agonists	"Novartis (Originator), Novartis (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				14/03/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800018291?userId=52029392&bpIds=3004037004&checksum=8abfe1ba9d9dc29110e93d5ac53767a1d076730c-1617045530690-87963a6b07562e18048e5e8cad08ce41badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033783	PH 797904			Yes			Discontinued (II)	Pain		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PH797904			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800033783?userId=52029392&bpIds=3004037004&checksum=d9a1c063dd6f8f54bafa9da8ef128d51fb7920c9-1617045530690-c71953e0bfb00a86572c23749e8f71cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035393	ASP 6973						Discontinued (I)	"Osteoarthritis, Back pain"		Undefined mechanism	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	ASP6973			14/03/2021	"Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800035393?userId=52029392&bpIds=3004037004&checksum=054d9c270f8fae30ee5bf733e6840813e50a6937-1617045530691-a61a721f7c7b90f9f31aae95c46904cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033182	KHK 6188			Yes			Discontinued (II)	Neuropathic pain		Cannabinoid receptor CB2 agonists	"Kyowa Hakko Kirin (Originator), Kyowa Kirin (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	KHK6188			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800033182?userId=52029392&bpIds=3004037004&checksum=e90f81ea4237de14f3b844285bec8cccb5d7e11f-1617045530692-5ae8deac65b894820defb13f5189469bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024913	TAK 583						Discontinued (II)	"Diabetic neuropathies, Postherpetic neuralgia"		Undefined mechanism	"Takeda (Originator), Takeda (Owner)"		PO				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics)"	TAK583			14/03/2021	"Diabetes, Pain"				no		no				C-peptide			https://adis.springer.com/drugs/800024913?userId=52029392&bpIds=3004037004&checksum=8bf96224ad7a470349de9929c6871e9b3c210110-1617045530693-1b191facb7a582afc6f91c97ad869e69badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035276	ASP 9226			Yes			Discontinued (I)	Neuropathic pain		Undefined mechanism	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	ASP9226			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800035276?userId=52029392&bpIds=3004037004&checksum=432b3bd0b68eb9edb97d126e6b001b31f7006237-1617045530693-7f3d7044ac5a1b6959815e058129ffa1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025530	PF 4480682						Discontinued (II)	Neuropathic pain		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PF4480682			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800025530?userId=52029392&bpIds=3004037004&checksum=9177bc1dbdfbf10930d508dfca65e1f0683f1788-1617045530694-ef7dce9d975f6d459d639a90baaf9903badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035704	Deudextromethorphan - Avanir Pharmaceuticals	1079043-55-2	3-[(<SUP>2</SUP>H<SUB>3</SUB>)methoxy]-17-[(<SUP>2</SUP>H<SUB>3</SUB>)methyl]-ent-morphinan	No			Phase III	"Agitation, Schizophrenia, Neurodegenerative disorders, Impulse control disorders, Brain injuries, Major depressive disorder, Neuropathic pain, Psychiatric disorders"	C18 H19 D6 N O	"Cytochrome P 450 enzyme system inhibitors, KATP channel inhibitors, NMDA receptor antagonists, Norepinephrine plasma membrane transport protein inhibitors, Serotonin plasma membrane transport protein inhibitors, Sigma-1 receptor agonists, Sodium channel antagonists"	"Concert Pharmaceuticals (Originator), Concert Pharmaceuticals (Owner), Avanir Pharmaceuticals (Licensee)"		PO				"N2A (Narcotics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs)"	"N02A (Opioids), N05A-X (Other antipsychotics), N06A-X (Other antidepressants), N07 (Other Nervous System Drugs)"	"AVP786, CTP786, dDM, Deudextromethorphan Hydrobromide d6DM/Quinidine Sulfate Q, Deuterated dextromethorphan plus ultra low dose quinidine, Deuterated DM plus ultra low dose quinidine, Deuterateddextromethorphan, DeuteratedDM"			14/03/2021	"Affective Disorders, Anxiety Disorders, Neurological Disorders, Pain, Psychotic Disorders"				yes	USA	no				C3			https://adis.springer.com/drugs/800035704?userId=52029392&bpIds=3004037004&checksum=30f9dcdce79595f5fe2d1d265c98aa61c61dd621-1617045530697-8bd9ee33c1614e67031827aaad9224b9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005880	Asimadoline - Tioga Pharmaceuticals	153205-46-0	"Benzeneacetamide, N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]- N-methyl-_-phenyl-, [S-(R*,R*)]-"	Yes			Phase II	"Pruritus, Irritable bowel syndrome, Pain, Postoperative ileus"	C27 H30 N2 O2	Opioid kappa receptor agonists	"Merck KGaA (Originator), Merck KGaA (Owner), Tioga Pharmaceuticals (Licensee), Ono Pharmaceutical (Sub-licensee)"		PO				"A3 (Functional Gastro-Intestinal Disorder Drugs), D11A (Other Dermatological Preparations), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N1B (Anaesthetics, Local), N2A (Narcotics)"	"A03 (Drugs for Functional Gastrointestinal Disorders), D11A-X (Other dermatologicals), M01 (Antiinflammatory and Antirheumatic Products), N01B-B (Amides), N02A (Opioids)"	"EMD61753, EMR 63 320, ONO3951"			14/03/2021	"Digestive System Disorders, Pain, Rheumatic Disease, Skin Disorders"				yes	USA	no							https://adis.springer.com/drugs/800005880?userId=52029392&bpIds=3004037004&checksum=9bfae01af408897c8b780c62337cb9e166d6e4ac-1617045530699-d88c042ca9d2944981cce15edb7f82f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020059	Efipladib	381683-94-9	"Benzoic acid, 4-[3-[5-chloro-2-[2-[[[(3,4-dichlorophenyl)methyl]sulfonyl]amino]ethyl]-1-(diphenylmethyl)-1<EM>H</EM>-indol-3-yl]propyl]-"				Discontinued (II)	"Osteoarthritis, Rheumatoid arthritis, Pain, Asthma"	C40 H35 Cl3 N2 O4 S	Phospholipase A2 inhibitors	"Wyeth (Originator), Pfizer (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), R3 (Anti-Asthma and COPD Products)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), R03 (Drugs for Obstructive Airway Diseases)"	PLA902			14/03/2021	"Obstructive Airways Disease, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800020059?userId=52029392&bpIds=3004037004&checksum=fd99742803f7d5fb7f9f74d92fa423bd0ce9e91c-1617045530700-d1d7bac731687b83860297fae41c9b02badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044114	VX 150			Yes			Phase II	Pain		Nav1.8 voltage-gated sodium channel inhibitors	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	VX150			14/03/2021	"Drug Delivery Systems, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800044114?userId=52029392&bpIds=3004037004&checksum=313665ea92838f5a4ba684aca57d6af08f972545-1617045530701-49165d38b5b29a81ec672aa3e180cc4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035775	LY 3016859			Yes			Phase II	"Pain, Neuropathic pain, Back pain, Diabetic nephropathies"		"Epidermal growth factor inhibitors, Transforming growth factor alpha inhibitors"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		"IV, SC"				"A10 (Drugs Used in Diabetes), G4X (All Other Urological Products), N2B (Non-Narcotics and Anti-Pyretics)"	"A10 (Drugs Used in Diabetes), G04 (Urologicals), N02B (Other Analgesics and Antipyretics)"	"LY3016859, TGFalpha/epiregulin monoclonal antibody"			14/03/2021	"Diabetes, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800035775?userId=52029392&bpIds=3004037004&checksum=b472c9e3c4621a6df66e20ec846319263c3bf842-1617045530702-7eef5209b88a4ffe3160be5149bc622abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009946	Perzinfotel	144912-63-0	"[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethy]phosphonic acid"				Discontinued (II)	"Pain, Neuropathic pain, Stroke"	C9 H13 N2 O5 P	NMDA receptor antagonists	"Wyeth (Originator), Pfizer (Owner)"		IV				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	"EAA090, WAY126090"			14/03/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009946?userId=52029392&bpIds=3004037004&checksum=932befc6650323dd8de88df3be3802932cde60b1-1617045530703-1442062f6791746f3e43de6f5f981323badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035929	Eptinezumab - Lundbeck Seattle BioPharmaceuticals	1644539-04-7	"Immunoglobulin G1, anti-(calcitonin gene-related peptide) (human-oryctolagus cuniculus monoclonal ALD403 heavy chain), disulfide with human-oryctolagus cuniculus monoclonal ALD403 kappa-chain, dimer"	Yes			Marketed	"Migraine, Cluster headache"	C6352 H9838 N1694 O1992 S46	Calcitonin gene-related peptide antagonists	"Alder Biopharmaceuticals (Originator), Lundbeck Seattle BioPharmaceuticals Inc. (Owner), Teva Pharmaceuticals USA (Collaborator)"		"IV, IM, SC"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"ALD403, Eptinezumabjjmr, VYEPTI"			14/03/2021	Advances in the Treatment of Nausea and Migraine			VYEPTI	no		no							https://adis.springer.com/drugs/800035929?userId=52029392&bpIds=3004037004&checksum=6c0173ce8626f1f5b9d507a829fd34483830a85c-1617045530706-255f2640583c772a245c1fe7e9f01c40badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002911	Zolmitriptan - AstraZeneca/Burroughs Wellcome	139264-17-8	S-4[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]- 2-oxazolidinone	Yes			Marketed	"Migraine, Cluster headache, Menstrual migraine"	C16 H21 N3 O2	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Burroughs Wellcome (Originator), Burroughs Wellcome (Owner), Amneal Pharmaceuticals (Market Licensee), Grunenthal (Market Licensee), Sawai (Market Licensee), AstraZeneca (Licensee)"		"PO, Intranasal"	renal	"Active Metabolites (yes), Activity vs parent (²), Linear Kinetics (yes), Route of Elimination (renal), bioavailability oral (%) (40 - 46 (Adult)), Cl (L/h) (123 - 131 (Adult)), protein binding (%) (14 - 21 (Adult)), T<sub>_beta</sub> (h) (2.5 - 3 (Adult)), T<sub>max</sub> (h) (2 - 4 (Adult)), Vd (L/kg) (5.7 - 7.1 (Adult))"	"Asthenia, Chest pain, Dizziness, Drowsiness, Dysgeusia, Nausea, Pain, Paraesthesia, Somnolence"	N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"311C, 311C90, AscoTop, BW311C90, Zomig, Zomigon, ZomigZMT"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Women's Health"			"AscoTop, Zomig, Zomig, Zomig, ZomigZMT, Zomigon, Zomigon"	no		no							https://adis.springer.com/drugs/800002911?userId=52029392&bpIds=3004037004&checksum=39c0a26cc9768c43f2ba97fc1d45cba35877bd2c-1617045530711-2d59a940d885ff9a116d1ad249fdee8abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002881	Vigabatrin - sanofi-aventis	60643-86-9	4-amino-5-hexenoic acid	Yes			Marketed	"Epilepsy, Infantile spasms, Complex partial epilepsy, Cocaine-related disorders, Substance-related disorders"	C6 H11 N O2	4-aminobutyrate transaminase inhibitors	"sanofi-aventis (Originator), sanofi-aventis (Owner), Alfresa Pharma Corporation (Licensee), AstraZeneca (Licensee), Lundbeck Inc (Licensee), National Institute of Drug Abuse (Collaborator)"		PO	renal	"Dose Modification in Renal Dysfunction (moderate), Route of Elimination (renal), Cl (L/h) (5.5 (Adult)), T<sub>_beta</sub> (h) (7 (Adult)), T<sub>max</sub> (h) (1 (Adult)), Vd (L/kg) (.8 (Adult))"	"Aggression, Agitation, Ataxia, CNS disorders, Confusion, Depression, Diplopia, Dizziness, Drowsiness, Fatigue, Headache, Insomnia, Irritability, Vision disorders, Weight gain"	"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02C-X (Other antimigraine preparations), N03A-G04 (Vigabatrin), N07B (Drugs Used In Addictive Disorders)"	"GammavinylGABA, GVG, gvinylGABA, M071754, MDL 71754, RMI 71754, Sabril, Sabrilex, vinylGABA"			14/03/2021	"Drug Withdrawal, Epilepsy and Seizure Disorders"	"Infantile spasms (USA), Epilepsy (Japan)"		"Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabril, Sabrilex, Sabrilex"	yes	USA	no				"Benzoyl ecgonine, Taurine"			https://adis.springer.com/drugs/800002881?userId=52029392&bpIds=3004037004&checksum=01108effc8362e27aa12729ddbf6ec938f072345-1617045530716-dc6db68b18b0e6654deafa7f55036f0bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002416	Topiramate - Janssen	97240-79-4	"2,3:4,5-bis-O-(1-Methylethylidene)-_- D-fructopyranose 1-sulfamic acid ester"	Yes			Marketed	"Epilepsy, Migraine, Lennox-Gastaut syndrome, Obesity, Post-traumatic stress disorders, Diabetic neuropathies, Bipolar disorders"	C12 H21 N O8 S	"AMPA receptor antagonists, Carbonic anhydrase inhibitors, GABA-A receptor antagonists, Kainic acid receptor antagonists, Sodium channel antagonists, GABA A receptor agonists"	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner), Janssen-Cilag (Market Licensee), m8 Pharmaceuticals (Market Licensee), Ortho-McNeil (Market Licensee), Xian-Janssen (Market Licensee), Janssen Inc (Licensee), Kyowa Kirin (Licensee)"		PO	renal	"Route of Elimination (renal), Cl (L/h) (1.32 - 2.16 (Adult)), T<sub>_beta</sub> (h) (19 - 23 (Adult)), T<sub>max</sub> (h) (1.8 - 4.3 (Adult)), Vd (L/kg) (.6 - .8 (Adult))"	"Anorexia, Anxiety, Appetite disorders, Cognition disorders, Confusion, Diarrhoea, Dizziness, Fatigue, Headache, Irritability, Liver disorders, Memory disorders, Nausea, Paraesthesia, Renal calculi, Respiratory tract infections, Sleep disorders, Somnolence, Taste disorders, Tremor, Weight loss"	"A10X (Other Drugs Used in Diabetes), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7E (Drugs Used In Alcohol Dependence)"	"A10X (Other Drugs Used in Diabetes), N02C-X (Other antimigraine preparations), N03A-X11 (Topiramate), N05B-X (Other anxiolytics), N06A (Antidepressants), N07B-B (Drugs used in alcohol dependence)"	"Epitomax, KW6485, KW6485P, MCN 4853, RWJ 17021, Topamax, Topamax Migraine, Topimax, Topina, Topina fine granules"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Diabetes, Epilepsy and Seizure Disorders, Obesity"			"Epitomax, Topamax, Topamax, Topamax Migraine, Topimax, Topina, Topina fine granules"	no		no		"A1C, citrate lyase beta like"	"A1C, citrate lyase beta like, ER alpha"	"24,25-Dihydroxyvitamin D, A1C, Alkaline phosphatase, Benzoyl ecgonine, centrin 1, citrate lyase beta like, CRP, CTx, Cytokeratin 5, Deoxyadenosine monophosphate, dopamine receptor D2, EH domain containing 4, IGF1, Insulin, iodothyronine deiodinase 3, Leptin, MDR1, OPRM1, Osteocalcin, peptidylprolyl isomerase G, period circadian clock 2, PGE2, PTH, S100B, sodium channel, voltage gated, type I alpha subunit, spermine synthase, Valproic acid glucuronide"	Leptin	"ATP-binding cassette, sub-family B (MDR/TAP), member 7, GAST, Ghrelin, Orotic acid, TPMT, Urea, Uric acid"	https://adis.springer.com/drugs/800002416?userId=52029392&bpIds=3004037004&checksum=222727abd8bf2c76ef824c2c596936ae7c28f0a2-1617045530724-aa7e1408380c0a11c174ca81a61c05d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024645	Telcagepant	781649-09-0	"<EM>N</EM>-[(3<EM>R</EM>,6<EM>S</EM>)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1<EM>H</EM>-azepin-3-yl]-4-(2-oxo-2,3-dihydro-1<EM>H</EM>-imidazo[4,5-<EM>b</EM>]pyridin-1-yl)piperidine-1-carboxamide"				Discontinued (III)	"Migraine, Endocrine disorders"	C26 H27 F5 N6 O3	Calcitonin gene-related peptide receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				"N2C9 (All other anti-migraine preparations), V3 (All Other Therapeutic Products)"	"N02C-X (Other antimigraine preparations), V03 (All Other Therapeutic Products)"	"Caprolactamazabenzimidazolone Merck, MK0974, Telcagepant potassium"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Endocrine Disorders"				no		no				Calreticulin			https://adis.springer.com/drugs/800024645?userId=52029392&bpIds=3004037004&checksum=6b0f38cdbd185f5d8b6d6c87ae1c3df034d94efc-1617045530726-f6562225a44a85326d0de955b0211dafbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036373	Ubrogepant - AbbVie	1374248-77-7	"(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide"	Yes			Marketed	Migraine	C29 H26 F3 N5 O3	Calcitonin gene-related peptide receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner), AbbVie (Licensee)"		PO			"Diarrhoea, Headache, Nasopharyngitis, Nausea"	N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"MK1602, UBRELVY"			14/03/2021	Advances in the Treatment of Nausea and Migraine			UBRELVY	no		no							https://adis.springer.com/drugs/800036373?userId=52029392&bpIds=3004037004&checksum=1a578b4d4e4039eb1adf2e86d4e7cb2d2825da12-1617045530727-f1d52e078caac0ac0ac4af92bd8aba44badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010940	Carisbamate - SK biopharmaceuticals	194085-75-1	(<EM>S</EM>)-2-(2-Chlorophenyl)-2-hydroxyethyl carbamate	Yes			Phase II	"Lennox-Gastaut syndrome, Epilepsy, Diabetic neuropathies, Essential tremor, Migraine, Postherpetic neuralgia"	C9 H10 Cl N O3	Neurotransmitter modulators	"SK biopharmaceuticals (Originator), SK biopharmaceuticals (Owner), Ortho-McNeil Pharmaceutical (Licensee), Janssen Research & Development (Collaborator)"		PO		Linear Kinetics (yes)	"Dizziness, Somnolence"	"A10X (Other Drugs Used in Diabetes), N2C9 (All other anti-migraine preparations), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"A10X (Other Drugs Used in Diabetes), N02C-X (Other antimigraine preparations), N03A (Antiepileptics), N07X (Other Nervous System Drugs)"	"Comfyde, JNJ10234094, RWJ333369, YKP509"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Diabetes, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"	Infantile spasms (USA)		Comfyde	no		no							https://adis.springer.com/drugs/800010940?userId=52029392&bpIds=3004037004&checksum=0fea429e63677d9f26e8334cd687fa2cb5dcf6d3-1617045530729-96936a67fdced3a5769f398b2d9285bdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013390	Valproate semisodium - Abbott Laboratories	1069-66-5	"Pentanoic acid, 2-propyl-, sodium salt"	Yes			Marketed	"Bipolar disorders, Epilepsy, Migraine, Dementia"	C8 H15 Na O2	"GABA modulators, Enzyme inhibitors, GABA agents, Voltage-gated sodium channel modulators"	"Abbott Laboratories (Originator), AbbVie (Owner), Sanofi (Market Licensee)"		PO		"Cl (L/h) (.57 - .58), T<sub>_beta</sub> (h) (15.2 - 15.3), Vd (L/kg) (.17)"	"Rhinitis, Somnolence, Vomiting, Weight gain"	"N2C9 (All other anti-migraine preparations), N3A (Anti-Epileptics)"	"N02C (Antimigraine Preparations), N03A-G01 (Valproic acid)"	"14CSodium Valproate, Depakote, Depakote ER, Divalproex, Divalproex sodium, Divalproex sodium DR 500mg tablets Abbott Laboratories, Epival, Epival ER, LA40220"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Alzheimer's Disease and Cognition Disorders, Epilepsy and Seizure Disorders"			"Depakote, Depakote ER, Epival, Epival ER"	no		no		"chymase 1, ER alpha, Valproic acid glucuronide"	"All-trans-retinoic acid, ER alpha, Valproic acid glucuronide"	"All-trans-retinoic acid, chymase 1, ER alpha, FSH, gamma-aminobutyric acid type B receptor subunit 1, IGF1, Insulin, limb and CNS expressed 1, Testosterone, Thyroid stimulating hormone, beta, Thyroxine, tumor necrosis factor superfamily member 14, Valproic acid glucuronide"		"Adiponectin, BDNF, CRP, Gamma-Aminobutyric acid, Ghrelin, LAMA2, Leptin, Luteinizing hormone, NELL2, RELA, tenascin C"	https://adis.springer.com/drugs/800013390?userId=52029392&bpIds=3004037004&checksum=11b79e9b4adf0d56917b8486058166d1a477197c-1617045530731-0da31b961a6a2f65d4f940f88ca74c0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047515	Atogepant - AbbVie	1374248-81-3	"3'S)-1',2',5,7-Tetrahydro-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-3-piperidinyl)-2'-oxospiro(6H-cyclopenta(b)pyridine-6,3'-(3H)pyrrolo(2,3-b)pyridine)-3-carboxamide"	Yes			Phase III	Migraine	C29 H23 F6 N5 O3	Calcitonin gene-related peptide receptor antagonists	"Merck AG (Originator), Merck AG (Owner), AbbVie (Licensee)"		PO			"Constipation, Fatigue, Nasopharyngitis, Nausea, Urinary tract infections"	N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"AGN 241689, MK 8031"			14/03/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800047515?userId=52029392&bpIds=3004037004&checksum=18fcacc99718223523305cf0dae1a0f7c66a0692-1617045530733-7dda9bf854e6a56cde6679436f074f14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040986	Felbinac tape	5728-52-9	"(1,1'-Biphenyl)-4-acetic acid"	No			Marketed	"Inflammation, Pain"	C14 H12 O2	Cyclooxygenase inhibitors	"Pfizer Japan (Originator), Teikoku Seiyaku (Originator), Pfizer Japan (Owner), Teikoku Seiyaku (Owner)"		Transdermal				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-B (Acetic acid derivatives and related substances), N02 (Analgesics)"	"Felbinac transdermal, SELTOUCH, SELTOUCH TAPE 70"			14/03/2021	"Drug Delivery Systems, Inflammation, Pain"			"SELTOUCH, SELTOUCH, SELTOUCH, SELTOUCH"	no		no							https://adis.springer.com/drugs/800040986?userId=52029392&bpIds=3004037004&checksum=61e2800ac4d7ebf3d5c6b7be9447563363daa540-1617045530735-4fb32a76d6e97a69b3fb2d88793844e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029648	AZD 2516						Discontinued (II)	"Gastro-oesophageal reflux, Neuropathic pain"		Metabotropic glutamate receptor 5 antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"A2B (Antiulcerants), N2 (Analgesics)"	"A02B (Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (GORD)), N02 (Analgesics)"	AZD2516			14/03/2021	"Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800029648?userId=52029392&bpIds=3004037004&checksum=f319655a0903bfb2f78d1fc2a9e94f8ac3389b34-1617045530736-09c5a47e1f7438532ff95e2e59408232badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035078	ABT 639			Yes			Discontinued (II)	Diabetic neuropathies		T type calcium channel antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	ABT639			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800035078?userId=52029392&bpIds=3004037004&checksum=cc32a41811a9a44799f00c51ef1f53500b43d7c7-1617045530737-6535ba6de553b747bfd74ae3e78e4208badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024886	GRC 6211			No			No development reported (I)	"Pain, Urinary incontinence, Dental pain, Neuropathic pain, Osteoarthritis"		TRPV1 receptor antagonists	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner)"		PO				"G4 (Urologicals), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"G04 (Urologicals), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GRC6211			14/03/2021	"Genitourinary Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800024886?userId=52029392&bpIds=3004037004&checksum=c5ab0d446f77b81f788fb27b6c1a4666721628d6-1617045530738-6104cafefeb446c31dadb1583335c9d7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036041	DSP 2230			Yes			Phase I	Neuropathic pain		"Nav1.7 voltage-gated sodium channel inhibitors, Nav1.8 voltage-gated sodium channel inhibitors"	"Dainippon Sumitomo Pharma (Originator), Sumitomo Dainippon Pharma (Owner), AlphaNavi Pharma (Licensee), Sunovion Pharmaceuticals (Collaborator)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02 (Analgesics)	"ANP230, DSP2230"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800036041?userId=52029392&bpIds=3004037004&checksum=03cff615bf4e8cf31939b346ea162274ce1327c6-1617045530739-8e92af2e8537a958dbe1454e94c3a3fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036434	LY 3023703			Yes			Discontinued (II)	"Musculoskeletal pain, Dental pain, Acute pain"		Prostaglandin-E synthase inhibitors	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"14CLY3023703, LY3023703"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800036434?userId=52029392&bpIds=3004037004&checksum=ceea574b8d3a1b4fdad5e109729dceecb724367c-1617045530740-9fef72668ab8a757a3822999d7e1f2eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032043	GRC 15300			Yes			Discontinued (II)	"Neuropathic pain, Musculoskeletal pain, Skin disorders, Urinary incontinence"		TRPV3 protein inhibitors	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), Sanofi (Licensee)"		"PO, unspecified"				"D (Dermatologicals), N2 (Analgesics)"	"D (Dermatologicals), N02 (Analgesics)"	"GRC 17173, GRC15300, SAR 292833"			14/03/2021	"Genitourinary Disorders, Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800032043?userId=52029392&bpIds=3004037004&checksum=06895ebabc09689fd218f857c2ca8694a9440a77-1617045530741-8524ff5564c4a394925974b61aa1d8e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027923	PF 4191834						Discontinued (II)	"Pain, Asthma"			"Pfizer (Originator), Pfizer (Owner)"		"unspecified, PO"				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"PF04191834, PF4191834"			14/03/2021	"Obstructive Airways Disease, Pain"				no		no				"arachidonate 5-lipoxygenase, Arachidonic acid, Leukotriene E4"			https://adis.springer.com/drugs/800027923?userId=52029392&bpIds=3004037004&checksum=9696c3bc7a13fb54653790113ad1d243260faedc-1617045530742-b32c8e32c3401f1a82730923b10e373cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034227	Evodenoson	844873-47-8	Methyl 4-{3-[6-amino-9-(<EM>N</EM>-cyclopropyl-_-D-ribofuranosyluronamide)-9<EM>H</EM>-purin-2-yl]prop-2-ynyl}piperidine-1-carboxylate	Yes			Discontinued (I/II)	"Ocular hypertension, Glaucoma, Haematological malignancies, Multiple sclerosis, Neuropathic pain"	C23 H29 N7 O6	Adenosine A2A receptor agonists	"Adenosine Therapeutics (Originator), AbbVie (Owner), Santen Pharmaceutical (Licensee)"		"Ophthalmic, unspecified, Intrathecal"				"L1 (Antineoplastics), N2 (Analgesics), N7 (Other CNS Drugs), S1 (Ophthalmologicals), S1E1 (Miotics and antiglaucoma preparations, systemic)"	"L01 (Antineoplastic Agents), N02 (Analgesics), N07 (Other Nervous System Drugs), S01 (Ophthalmologicals), S01E-A (Sympathomimetics in glaucoma therapy)"	"ATL313, DE112"			14/03/2021	"Cancer, Eye Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800034227?userId=52029392&bpIds=3004037004&checksum=c294eecf3e8b1c5c9e58daf58475a6825f1ceb4d-1617045530744-b37b843f587c46bda62ae3a7c7181446badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027605	AZD 2066						Discontinued (II)	"Depressive disorders, Neuropathic pain, Gastro-oesophageal reflux"		Metabotropic glutamate receptor 5 antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"A2 (Antiacids, Antiflatulents and Anti-Ulcerants), N2 (Analgesics), N6A9 (Antidepressants, all others)"	"A02B-X (Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)), N02 (Analgesics), N06A-X (Other antidepressants)"	AZD2066			14/03/2021	"Affective Disorders, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800027605?userId=52029392&bpIds=3004037004&checksum=978c99af652df16c1ad6d98b393fbdac46c2cbdf-1617045530745-84aedd1c44bfcd466510d02304aad7fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035863	S 117957			Yes			Phase II	"Insomnia, Overactive bladder, Fibromyalgia, Dental pain, Neuropathic pain"		Nociceptin receptor agonists	"Purdue Pharma (Originator), Shionogi (Originator), Purdue Pharma (Owner), Shionogi (Owner), Imbrium Therapeutics (Collaborator)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N05C (Hypnotics and Sedatives)"	"IMB115, IT1315, S117957, V117957"			14/03/2021	"Anxiety Disorders, Genitourinary Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800035863?userId=52029392&bpIds=3004037004&checksum=2c9e559b0fea5693652f29f8f632752a9f833238-1617045530746-8af820babe493d89ec236b8be5e23f09badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026843	PF 4136309			Yes			Discontinued (II)	"Hepatic fibrosis, Pain, Pancreatic cancer"		CCR2 receptor antagonists	"Pfizer (Originator), Pfizer (Owner)"		PO				"A5 (Cholagogues and Hepatic Protectors), L1X9 (All other antineoplastics), N2 (Analgesics)"	"A05 (Bile and Liver Therapy), L01X-X (Other antineoplastic agents), N02 (Analgesics)"	"INCB 8761, PF04136309, PF4136309"			14/03/2021	"Cancer, Liver Disorders, Pain"	Pancreatic cancer (USA)			no		no				PGR			https://adis.springer.com/drugs/800026843?userId=52029392&bpIds=3004037004&checksum=b82dad7812d746d44a80354b6e772c4838f09bbd-1617045530747-0dc59a5be1aeec2ac61d481887767244badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028846	PLX 5568						No development reported (I)	"Pain, Polycystic kidney disease"		Raf kinase inhibitors	"Plexxikon (Originator), Plexxikon (Owner), Roche (Licensee)"		PO				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	"PLX5568, R 7376, RG7376"			14/03/2021	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800028846?userId=52029392&bpIds=3004037004&checksum=5cf75c354477835b60b1a8cee10eb64bd1c16586-1617045530748-e9645e63f36d6f2a2f35bff177c0d9ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023646	ADL 5747			Yes			Discontinued (II)	Pain		Opioid delta receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner), Pfizer (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"ADL5747, PF04856881, PF4856881, PF4856881 Adolor"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800023646?userId=52029392&bpIds=3004037004&checksum=1cc9a17d7657bd35f3e9368484dc92a793183a83-1617045530749-b315a056454791f689bfabf6a2e90800badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032171	AZD 5213	1476077-02-7		Yes			Discontinued (II)	"Alzheimer's disease, Diabetic neuropathies, Gilles de la Tourette's syndrome, Mild cognitive impairment, Attention-deficit hyperactivity disorder"		Histamine H3 receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"A10X9 (Other drugs used in diabetes), N2 (Analgesics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N6D (Nootropics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N06B (Psychostimulants, agents used for ADHD and nootropics), N06D (Anti-Dementia Drugs)"	AZD5213			14/03/2021	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Diabetes, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800032171?userId=52029392&bpIds=3004037004&checksum=fe62a4647d8a9ae6fbd61e34800f84100c639323-1617045530751-d9e1bb874d98865b35123261312fd9ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028715	SEP 228432						No development reported (I)	"Major depressive disorder, Neuropathic pain, Attention-deficit hyperactivity disorder"		"Adrenergic uptake inhibitors, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"Sepracor (Originator), Sunovion Pharmaceuticals (Owner)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics)"	SEP225432			14/03/2021	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800028715?userId=52029392&bpIds=3004037004&checksum=d841b7465a139a37f91b522687110915c69d48b4-1617045530752-92523aaaaab1a1561322ed2051c288c8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014027	Ataciguat	254877-67-3	5-Chloro-2-[(5-chloro-2-thienyl)sulfonylamino]-<EM>N</EM>-[4-(morpholin-4-ylsulfonyl)phenyl]benzamide	Yes			Phase II	"Aortic valve stenosis, Neuropathic pain, Peripheral arterial occlusive disorders, Heart failure"	C21 H19 Cl2 N3 O6 S3	Guanylate cyclase stimulants	"sanofi-aventis (Originator), Sanofi (Owner), Mayo Clinic (Collaborator), National Center for Advancing Translational Sciences (Collaborator)"		PO				"C1X (All Other Cardiac Preparations), C4 (Cerebral and Peripheral Vasotherapeutics), N2 (Analgesics)"	"C01D (Vasodilators Used in Cardiac Diseases), C04 (Peripheral Vasodilators), N02 (Analgesics)"	"1766, HMR 1766"			14/03/2021	"Heart Failure, Ischaemic Heart Disease, Pain, Thromboses"				no		no				"IL6, TNF-alpha"			https://adis.springer.com/drugs/800014027?userId=52029392&bpIds=3004037004&checksum=60013ed8e6977073755c12a9429c3b2223ca799e-1617045530754-9332e1f6a278d7e85aa8a0f8f1dde495badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033597	ASP 8477			Yes			Discontinued (II)	Neuropathic pain		Central nervous system modulators	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	ASP8477			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800033597?userId=52029392&bpIds=3004037004&checksum=b6bde3363c1da37df512a0a44c3ddeacf5572557-1617045530755-866652825055dda79c4f18ce84440731badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025667	SSR 411298						Phase Unknown	"Cancer pain, Anxiety disorders, Depressive disorders"		Fatty acid amide hydrolase inhibitors	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N05B (Anxiolytics), N06A-X (Other antidepressants)"	SSR411298			14/03/2021	"Affective Disorders, Anxiety Disorders, Pain"				no		no		sphingolipid transporter 1 (putative)		sphingolipid transporter 1 (putative)			https://adis.springer.com/drugs/800025667?userId=52029392&bpIds=3004037004&checksum=df584d02fb06728230fde003ca31a2163b1fa268-1617045530757-06f992fef3ef1b9ab6bf3c3bc27dbb97badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027672	AZD 1386						Discontinued (II)	"Pain, Musculoskeletal pain, Gastro-oesophageal reflux"		TRPV cation channel antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"A2 (Antiacids, Antiflatulents and Anti-Ulcerants), N2 (Analgesics)"	"A02 (Drugs for Acid Related Disorders), N02 (Analgesics)"	AZD1386			14/03/2021	"Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800027672?userId=52029392&bpIds=3004037004&checksum=53bc91db826b31bdb4acbaaac637b768e636e8b8-1617045530758-9c17d0ca0fb06a482e807d51a1168d6bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032225	ABT 652			Yes			Discontinued (II)	"Musculoskeletal pain, Diabetic neuropathies, Sleep disorders"		Histamine H3 receptor modulators	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	ABT652			14/03/2021	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800032225?userId=52029392&bpIds=3004037004&checksum=2c2affcd81927d4c19af1abccd38d5b47cf95d56-1617045530759-b2f914b5236f535f9c227e2a641ec888badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019097	Dilmapimod	444606-18-2	"Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-"	Yes			Discontinued (II)	"Neuropathic pain, Adult respiratory distress syndrome, Rheumatoid arthritis, Atherosclerosis, Chronic obstructive pulmonary disease, Acute lung injury"	C23 H19 F3 N4 O3	P38 mitogen-activated protein kinase inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		"unspecified, IV, PO"				"C6A (Other Cardiovascular Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3X2 (All other anti-asthma and COPD products, systemic), R7 (Other Respiratory System Products)"	"C (Cardiovascular System), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03D-X (Other systemic drugs for obstructive airway diseases), R07 (Other Respiratory System Products)"	"681323, GSK 681323, SB 681323"			14/03/2021	"Ischaemic Heart Disease, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800019097?userId=52029392&bpIds=3004037004&checksum=1174d63251784f9fb5fa9c597bb8aa5a18e72786-1617045530761-690c95bc07a7d94b7a247dc2da934182badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012295	Nitroglycerin topical - Kyowa Kirin International	55-63-0	"1,2,3-Propanetriol, trinitrate"	No			Marketed	"Fissure in ano, Haemorrhoids, Pain, Dyspareunia, Vulvodynia"	C3 H5 N3 O9	Nitric oxide donors	"Neptune Pharmaceuticals (Originator), Neptune Pharmaceuticals (Owner), Damon Pharm (Market Licensee), Epsilon Pharmaceuticals (Market Licensee), New Harbor Corporation (Market Licensee), PharmaSwiss (Market Licensee), Adare Pharmaceuticals (Licensee), Endo International (Licensee), Kyowa Kirin International (Licensee)"		Topical			"Dizziness, Headache, Vomiting"	"A2B9 (All other antiulcerants), C5A (Topical Anti-Haemorrhoidals), N2 (Analgesics)"	"A02X (Other Drugs for Acid Related Disorders), C05A-X (Other agents for treatment of hemorrhoids and anal fissures for topical use), N02B (Other Analgesics and Antipyretics)"	"Anogesic, Cellegesic, Rectiv, Rectogesic"			14/03/2021	"Digestive System Disorders, Pain, Vascular Disorders, Women's Health"		"Kyowa Kirin International |  | Unspecified | Asia, Japan, Latin America | 20 Jan 2011"	"Anogesic, Anogesic, Cellegesic, Rectiv, Rectogesic, Rectogesic"	no		no		"Luteinizing hormone, PSA"		"8-isoprostane, Ascorbic acid, BNP, CKB, CKM, CRP, Cystatin C, Glycerol, IL6, NTx, Troponin T, cardiac, VEGF-A"		"AMH, FGF23, HIF, PAI-1, PD-L1, PTH, TGF-beta, ULBP2, uPAR"	https://adis.springer.com/drugs/800012295?userId=52029392&bpIds=3004037004&checksum=007d19496866c639d49998129189fccb0df01f78-1617045530766-046e6ca80d9c5f02e4e8ad303cf75f8abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000652	Oxcarbazepine - Novartis	28721-07-5	"10,11-Dihydro-10-oxo-5<EM>H</EM>-dibenz(b,f)azepine-5-carboxamide"	Yes		= Carbamazepine	Marketed	"Epilepsy, Multiple sclerosis, Diabetic neuropathies, Bipolar disorders, Neurological disorders"	C15 H12 N2 O2	Sodium channel antagonists	"Novartis (Originator), Novartis (Owner), Nobelpharma (Licensee), Queen Mary University of London (Collaborator)"		PO			"Ataxia, Diarrhoea, Diplopia, Dizziness, Drowsiness, Eye disorders, Fatigue, Fever, Headache, Hyponatraemia, Irritability, Nasal congestion, Nausea, Respiratory tract infections, Somnolence, Vomiting"	"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N03A-F02 (Oxcarbazepine), N05A (Antipsychotics), N06A (Antidepressants), N07X (Other Nervous System Drugs)"	"GP 47680, KIN493, NPC 04, Oxacarbazepine, TRI 476, Trileptal"			14/03/2021	"Affective Disorders, Diabetes, Epilepsy and Seizure Disorders, Neurological Disorders, Pain"			"Trileptal, Trileptal"	no		no		GM-CSF		"BDNF, CPT2, dematin actin binding protein, FBN1, GM-CSF, NEFL, NSE, nystagmus 3, congenital autosomal dominant, Prolactin, S100B, Spermine, spermine synthase, T cell receptor gamma variable 9, Urea"	Prolactin	"HLA-B, Valproic acid glucuronide"	https://adis.springer.com/drugs/800000652?userId=52029392&bpIds=3004037004&checksum=950883a8af1a5ddc5c77fef8334ecac514bb77aa-1617045530770-8ace52ec735ada3008f17160e24dca14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001601	Xaliproden	90494-79-4	"Pyridine, 1 2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, monohydrochloride"				Discontinued (Preregistration)	"Amyotrophic lateral sclerosis, Cancer pain, Alzheimer's disease, Multiple sclerosis"	C24 H22 F3 N . H Cl	"Nerve growth factor stimulants, Serotonin 1A receptor agonists"	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		PO			"Anxiety, Diarrhoea, Dizziness, Insomnia, Tinnitus, Vertigo"	"N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N07X-X03 (Xaliproden)"	"SR 57746, SR 57746A, Xaliproden hydrochloride, xaliprodene, Xaprila"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain"	"Amyotrophic lateral sclerosis (Japan), Amyotrophic lateral sclerosis (European Union)"		Xaprila	no		no				NTx			https://adis.springer.com/drugs/800001601?userId=52029392&bpIds=3004037004&checksum=7bb0c0af551d360c87191ef4c4620a4171e885ce-1617045530773-2a3ace8b6d6989ef8852dfeb4d86bb11badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016991	Capsaicin dermal patch - Grunenthal	404-86-4	"6-Nonenamide, (<EM>E</EM>)-<EM>N</EM>-[(4-hydroxy-3-methoxy-phenyl)-methyl]-8-methyl"	No			Marketed	"Neuropathic pain, Postherpetic neuralgia, Diabetic neuropathies, Postoperative pain"	C18 H27 N O3	"GABA A receptor modulators, Melatonin receptor modulators, Substance P inhibitors, TRPV1 receptor agonists"	"NeurogesX (Originator), Grunenthal (Owner), Averitas Pharma (Market Licensee), Astellas Pharma Europe Ltd (Licensee)"		Transdermal			Application site reactions	"A10X (Other Drugs Used in Diabetes), D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N1B3 (Anaesthetics local, topical), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), D04A-X (Other antipruritics), N01B-X04 (Capsaicin), N02B (Other Analgesics and Antipyretics)"	"8 capsaicin patch NeurogesX, Capsaicin, NGX4010, Qutenza, Transacin, Transdolor Pain Treatment System"			14/03/2021	"Drug Delivery Systems, Pain"	"Neuropathic pain (USA), Postherpetic neuralgia (USA)"	"Grunenthal |  | Unspecified | Asia, Australia | 05 Nov 2018;
NeurogesX |  | Unspecified | Asia | 07 May 2009"	"Qutenza, Qutenza, Qutenza, Qutenza, Qutenza, Transacin"	no		no				"A1C, carnitine palmitoyltransferase 1A (liver), IL1 beta, IL6, IL8, TNF-alpha"		peroxiredoxin 2	https://adis.springer.com/drugs/800016991?userId=52029392&bpIds=3004037004&checksum=185b7cda5ec3b5cbbd3b92db315c47c66d7b6d12-1617045530781-e1c654616b74eb091eff6bb528156becbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002231	Rufinamide - Novartis	106308-44-5	"1-(2,6-Difluorobenzyl)-1<EM>H</EM>-1,2,3-triazole-4-carboxamide"	No			Marketed	"Lennox-Gastaut syndrome, Epilepsy, Generalised anxiety disorder, Neuropathic pain"	C10 H8 F2 N4 O	Sodium channel antagonists	"Novartis (Originator), Novartis (Owner), Biotoscana (Market Licensee), Eisai Co Ltd (Licensee)"		PO		"T<sub>_beta</sub> (h) (8.82 - 9.12 (Adult)), T<sub>max</sub> (h) (6.56 - 7.22 (Adult))"	"Diarrhoea, Diplopia, Dizziness, Fatigue, Fever, Headache, Nausea, Somnolence, Tremor, Viral infections, Vision disorders, Vomiting"	"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives)"	"N02B (Other Analgesics and Antipyretics), N03A-F03 (Rufinamide), N05B (Anxiolytics)"	"Banzel, CGP 33101, E 2080, Inovelon, RUF 331, SYN 111"			14/03/2021	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"	"Lennox-Gastaut syndrome (USA), Lennox-Gastaut syndrome (Japan), Lennox-Gastaut syndrome (European Union)"		"Banzel, Banzel, Banzel, Inovelon, Inovelon, Inovelon, Inovelon, Inovelon, Inovelon, Inovelon"	no		no							https://adis.springer.com/drugs/800002231?userId=52029392&bpIds=3004037004&checksum=3a2e416e6efb423044ddb483272b170193b0c032-1617045530788-4db9d5cf6db926d3b1a85a04fcb2b86fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014916	Talmapimod	309913-83-5	"2-[6-Chloro-5-[4-(4-fluorobenzyl)-2(<EM>R</EM>),5(<EM>S</EM>)-dimethylpiperazin-1-ylcarbonyl]-1-methyl-1<EM>H</EM>-indol-3-yl]-<EM>N,N</EM>-dimethyl-2-oxoacetamide"	Yes			No development reported (Preclinical)	"Skin disorders, Rheumatoid arthritis, Multiple myeloma, Dental pain, Myelodysplastic syndromes"	C27 H30 Cl F N4 O3	P38 mitogen-activated protein kinase inhibitors	"Scios (Originator), Scios (Owner)"		"Topical, PO"		"Linear Kinetics (yes), T<sub>_beta</sub> (h) (6 (Adult))"	"Dermatitis, Elevated liver enzymes"	"D5 (Nonsteroidal Products for Inflammatory Skin Disorders), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"D05A (Antipsoriatics for Topical Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	SCIO469			14/03/2021	"Cancer, Pain, Rheumatic Disease, Skin Disorders"				no		no						VEGF-A	https://adis.springer.com/drugs/800014916?userId=52029392&bpIds=3004037004&checksum=c7875a2ccfc72f935fc07576ca785fc2b70b05d1-1617045530789-ee03174533a40e6c38e3eb1e50ef8974badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020745	Radiprodil - Algernon Pharmaceuticals	496054-87-6	"2-{4-[(4-fluorophenyl)methyl]piperidin-1-yl}-2-oxo-N-(2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)acetamide"	Yes			Preclinical	"Idiopathic pulmonary fibrosis, Infantile spasms, Neuropathic pain, Pain, Epilepsy, Parkinson's disease"	C21 H20 FN3 O4	"NR2B N-Methyl-D-Aspartate antagonists, NMDA receptor antagonists"	"Gedeon Richter (Originator), Algernon Pharmaceuticals (Owner), UCB (Licensee), PRA Health Sciences (Collaborator)"		PO			"Dizziness, Fatigue, Insomnia"	"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics), N04A (Anticholinergic Agents)"	"NP 121, RGH896, UCB3491"			14/03/2021	"Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800020745?userId=52029392&bpIds=3004037004&checksum=70471f7a4c7375cda5d92c445430f53730262502-1617045530791-0c27868589a2bd50d46bb58ccf87fda8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005758	Pregabalin - Pfizer	148553-50-8	(+)-4-Amino-3(<EM>S</EM>)-isobutylbutyric acid	Yes			Marketed	"Neuropathic pain, Partial epilepsies, Generalised anxiety disorder, Fibromyalgia, Postherpetic neuralgia, Tonic-clonic epilepsy, Pain, Restless legs syndrome, Postoperative pain"	C8 H17 N O2	CACNA2D1 protein modulators	"Northwestern University (Originator), Northwestern University (Owner), Pfizer (Licensee), Eisai Co Ltd (Sub-licensee), Johns Hopkins University (Collaborator)"		PO	renal	"Active Metabolites (no), Dose Modification in Hepatic Dysfunction (minimal), Dose Modification in Renal Dysfunction (moderate), Linear Kinetics (yes), Route of Elimination (renal), bioavailability oral (%) (90 - ), Cl (L/h) (4.02 - 4.854), protein binding (%) (), T<sub>_beta</sub> (h) (4.6 - 6.8), Vd (L/kg) (.5)"	"Angioedema, Blurred vision, Constipation, Dizziness, Drowsiness, Euphoria, Fatigue, Hunger, Hypersensitivity, Insomnia, Myoclonic epilepsies, Nausea, Somnolence, Suicidal ideation, Vertigo, Weight gain, Xerostomia"	"A3 (Functional Gastro-Intestinal Disorder Drugs), N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N7X (All other CNS drugs)"	"A03A (Drugs for Functional Bowel Disorders), N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin), N05B-X (Other anxiolytics), N07X (Other Nervous System Drugs)"	"CI 1008, Isobutylgaba, Lyrica, PD 144723"			14/03/2021	"Anxiety Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease"			"Lyrica, Lyrica, Lyrica, Lyrica, Lyrica, Lyrica, Lyrica, Lyrica, Lyrica, Lyrica"	no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800005758?userId=52029392&bpIds=3004037004&checksum=2041405ec335241bcaab0382f62f795223f39962-1617045530878-df8fef5300ebded018c4ffe8b0c7357dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006923	Memantine - Children's Medical Center Corporation/Merz Pharma	41100-52-1	"3, 5-Dimethyl-1-adamantanamine hydrochloride"	Yes			Marketed	"Alzheimer's disease, Dementia, Cognition disorders, Vascular dementia, Glaucoma, Diabetic neuropathies, Neuropathic pain, Asperger syndrome, Autistic disorder, Fragile X syndrome"	C12 H21 N . H Cl	"Nicotinic receptor antagonists, NMDA receptor antagonists, Serotonin 3 receptor antagonists"	"Childrens Medical Center Corporation (Originator), Childrens Medical Center Corporation (Owner), Grunenthal (Market Licensee), Laboratorios Phoenix (Market Licensee), Merz Pharma (Licensee), AbbVie (Sub-licensee), Asubio Pharma (Sub-licensee), Daiichi Sankyo Company (Sub-licensee), Lundbeck A/S (Sub-licensee), Adamas Pharmaceuticals (Technology Provider), American Academy of Neurology (Collaborator), University of California, Davis (Collaborator)"		"PO, Ophthalmic"			"Constipation, Diarrhoea, Dizziness, Headache, Nausea, Psychomotor agitation, Sleep disorders, Urinary tract infections, Weight gain, Weight loss"	"N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs), S1E (Miotics and Antiglaucoma Preparations)"	"N02B (Other Analgesics and Antipyretics), N06D-X01 (Memantine), N07B (Drugs Used In Addictive Disorders), N07X (Other Nervous System Drugs), S01E (Antiglaucoma Preparations and Miotics)"	"Akatinol, Axura, D145, Ebixa, Extendedrelease memantine capsules AbbVie, Memantine hydrochloride, Memary, Namenda, Namenda XR, SUN Y7017, SUNY 017"			14/03/2021	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Diabetes, Eye Disorders, Neurological Disorders, Pain"			"Akatinol, Axura, Axura, Ebixa, Ebixa, Ebixa, Memary, Namenda, Namenda XR"	no		no		"Alpha-Tocopherol, Huntingtin, interferon, beta 1, fibroblast, tryptase gamma 1"	"Alpha-Tocopherol, Huntingtin"	"alcohol dehydrogenase 1B (class I), beta polypeptide, aldehyde dehydrogenase 2 family (mitochondrial), BOC cell adhesion associated, oncogene regulated, C3, C4, COMT, dopamine receptor D2, DRD3, Ferritin, Huntingtin, IL10, IL6, IL8, immunoglobulin kappa variable 4-1, interferon, beta 1, fibroblast, Kynurenic acid, Kynurenine, Myoinositol, N-Acetyl-L-aspartic acid, N-Acetylaspartylglutamic acid, NFH, Picolinic acid, PTH, replication protein A1, Tau protein, tryptase gamma 1, xenotropic and polytropic retrovirus receptor 1"		"A1C, ACTH, Alkaline phosphatase, ApoE, BDNF, Chromosome 21, Creatine, defensin beta 1, Hydrocortisone, opioid related nociceptin receptor 1, T cell receptor gamma variable 9, Thyroid stimulating hormone, beta, Thyroxine"	https://adis.springer.com/drugs/800006923?userId=52029392&bpIds=3004037004&checksum=dd01c0f9d1805afb723f5577f2375ebafef982d0-1617045530889-2e8de46b723d00a64ca0e3a8eebab0c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045782	Eliapixant - Bayer	1948229-21-7	"3-(5-methyl-1,3-thiazol-2-yl)-5-{[(3R)-oxolan-3-yl]oxy}-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5- yl]ethyl}benzamide"	Yes			Phase II	"Cough, Endometriosis, Diabetic neuropathies, Overactive bladder"	C22 H21 F3 N4 O3 S	Purinergic P2X3 receptor antagonists	"Bayer (Originator), Bayer (Owner), Evotec (Collaborator)"		"PO, IV"				"G2 (Other Gynaecologicals), G4D4 (Urinary incontinence products), N2B (Non-Narcotics and Anti-Pyretics), R5 (Cough and Cold Preparations)"	"G02 (Other Gynecologicals), G04B-D (Drugs for urinary frequency and incontinence), N02B (Other Analgesics and Antipyretics), R05 (Cough and Cold Preparations)"	"BAY181708, BAY1817080"			14/03/2021	"Diabetes, Genitourinary Disorders, Respiratory Tract Disorders, Women's Health"				no		no							https://adis.springer.com/drugs/800045782?userId=52029392&bpIds=3004037004&checksum=29a34e10642b32a0d6036bc03fa80d3115c537a6-1617045530892-9fa331c265e97b744316633ce17b6dc8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009837	Pamidronic acid	57248-88-1	"3-Amino-1-hydroxypropylidene-1,1-diphosphonate disodium salt"	Yes		"&gt; Clodronic acid, &gt; Etidronic acid, &gt; Plicamycin"	Marketed	"Postmenopausal osteoporosis, Malignant hypercalcaemia, Osteogenesis imperfecta, Osteitis deformans, Osteoporosis, Cancer metastases, Cancer pain, Bone cancer"	C3 H9 N Na2 O7 P2	Bone resorption factor inhibitors	"Gador (Originator), Henkel (Originator), Gador (Owner), Henkel (Owner), Andromaco (Market Licensee), Drogueria Marco-Med (Market Licensee), Gador (Market Licensee), Gador Paraguay (Market Licensee), Hanlim Pharmaceutical (Market Licensee), Leti (Market Licensee), MAC Laboratories (Market Licensee), Nippon Kayaku (Market Licensee), Novartis (Market Licensee), Raices (Market Licensee), Seignior Pharma (Market Licensee), Sued Farmaceutica (Market Licensee)"		"PO, IV-infusion, IV, Injection"	renal	"Active Metabolites (no), Route of Elimination (renal)"	"Anaemia, Arthralgia, Dyspnoea, Eye disorders, Fatigue, Fever, Flu-like symptoms, Hypocalcaemia, Injection site reactions, Leucopenia, Lymphopenia, Muscle pain, Neutropenia, Paraesthesia, Renal failure, Thrombocytopenia, Thrombophlebitis, Vomiting"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5B (Bone Calcium Regulators), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), M05B-A (Bisphosphonates), M05B-A03 (Pamidronic acid), N02B (Other Analgesics and Antipyretics)"	"AHPrBP, Amino hydroxypropylidene diphosphonic acid, Aminomux, APD, Aredia, CGP 23339A, CGP 23339AE, Disodium aminohydroxypropylidenediphosphonate, Disodium pamidronate, IG 7913, Pamidronate sodium, Panorin"			14/03/2021	"Cancer, Musculoskeletal Disorders, Pain"			"Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aminomux, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Aredia, Panorin"	no		no				"CTx, Deoxypyridinoline, DPYD, IL6, IL7, OPG, Osteocalcin, PINP, RANKL, TNF-alpha"		"CD34, EGFR"	https://adis.springer.com/drugs/800009837?userId=52029392&bpIds=3004037004&checksum=a8e954550cc9b856e7c8b7a21557141c76a14e12-1617045530899-0d6c54a0d29379d7fc9b2047859bf09cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006795	Celecoxib - Astellas Pharma/Pfizer	169590-42-5	"Benzenesulfonamide, 4-[1,1,1-trifluoromethyl- 5-(4-methylphenyl) pyrazol-1-yl]-"	Yes		"= Aspirin, = Diclofenac, ³ Ketoprofen, = Naproxen"	Marketed	"Acute pain, Familial adenomatous polyposis, Back pain, Rheumatoid arthritis, Pain, Osteoarthritis, Dysmenorrhoea, Juvenile rheumatoid arthritis, Cervicobrachial syndrome, Periarthritis, Tenosynovitis, Ankylosing spondylitis, Tendinitis, Dental pain, Postoperative pain, Rheumatic disorders, Breast cancer, Non-small cell lung cancer, Stomatitis, Small cell lung cancer, Gouty arthritis, Bladder cancer, Alzheimer's disease, Prostate cancer"	C17 H14 F3 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"Pfizer (Originator), Pfizer (Owner), Roemmers (Market Licensee), Astellas Pharma (Licensee), Dana-Farber Cancer Institute (Collaborator), Department of Veterans Affairs (Collaborator), Imperial College of Science, Technology and Medicine (Collaborator), Linkoping University Hospital (Collaborator), Swedish Lung Cancer Study Group (Collaborator), University Clinic Golnik (Collaborator), University of Connecticut (Collaborator), Vanderbilt University (Collaborator), Zydus Cadila (Collaborator)"		PO		"Linear Kinetics (yes), Cl (L/h) (32.5 - 36.3 (Adult)), Cl (L/h) (.6 - 1.4 (Children)), T<sub>_beta</sub> (h) (9.1 - 10.5 (Adult)), T<sub>_beta</sub> (h) (3 - 10.1 (Children)), T<sub>max</sub> (h) (1.75 - 2.08 (Adult)), T<sub>max</sub> (h) (2 - 5.8 (Children)), Vd (L/kg) (3.1 - 20.2 (Children))"	"Abdominal pain, Cardiovascular disorders, Diarrhoea, Dizziness, Dyspepsia, Gastrointestinal disorders, Headache, Heart disorders, Hypertension, Insomnia, Nausea, Oedema, Pruritus, Respiratory tract infections"	"A16A (Other Alimentary Tract and Metabolism Products), L1 (Antineoplastics), L1X9 (All other antineoplastics), M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"A16A (Other Alimentary Tract and Metabolism Products), L01 (Antineoplastic Agents), L01X-X33 (Celecoxib), M01A-H01 (Celecoxib), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	"Celebra, Celebrex, Celecox, Niflam, Onsenal, SC58635, YM177"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Bacterial Infections, Cancer, Mouth Disorders, Musculoskeletal Disorders, Pain, Rheumatic Disease"	"Familial adenomatous polyposis (European Union), Familial adenomatous polyposis (Australia)"		"Celebra, Celebra, Celebrex, Celebrex, Celebrex, Celebrex, Celebrex, Celebrex, Celecox, Celecox, Celecox, Celecox, Niflam, Niflam, Onsenal"	no		no		"Aromatase, CA-19-9, CEA, EGFR, PGE2, PSA, pyridoxal phosphatase, survival of motor neuron 1, telomeric"	"Chondroitin sulfate, COX2, EGFR, PGE2, PSA, survival of motor neuron 1, telomeric"	"24,25-Dihydroxyvitamin D, ACE, adhesion regulating molecule 1, AKT, Androgen receptor, angiopoietin like 2, arachidonate 15-lipoxygenase, Arachidonic acid, Aromatase, baculoviral IAP repeat containing 2, Bcl-2, Beta-catenin, bFGF, CA-19-9, Calprotectin, carbonic anhydrase II, caspase 6, CD163, CD31, CD4, CD68, CEA, Chondroitin sulfate, Collagen type 2, COMP, COX2, CRP, CYP2C19, CYP2C9, CYP3A5, cytochrome P450 family 2 subfamily B member 6, Cytokeratin 14, E-cadherin, EGFR, Elafin, ephrin A5, ER alpha, Estradiol-17beta 3-sulfate, Fibulin 3 peptides, Folinic acid, FOXP3, GATA binding protein 6, GUSB, hematological and neurological expressed 1, HER2, Histone H3, hyaluronan synthase 3, IFN-gamma, IGF1, IGFBP3, IL10, IL6, IL8, integrin subunit alpha V, Ki67, KRAS, L-Serine, MAPK1, mitogen-activated protein kinase 4, MMP-13, MMP-2, MMP9, NGF, opioid related nociceptin receptor 1, Osteocalcin, p53, PAGE family member 2, PAGE family member 3, PAI-1, PDGFA, PDGFB, PGE2, pleckstrin homology domain containing, family M (with RUN domain) member 1, PSA, pyridoxal phosphatase, serine/threonine kinase 36, SET binding protein 1, sex hormone-binding globulin, survival of motor neuron 1, telomeric, Syndecan-1, Thrombospondin-1, Thromboxane, TIMP-1, TNF-alpha, transforming growth factor, alpha, translocator protein, VEGF-A, VEGF-C, VEGFR, VEGFR1, Vimentin"	"AKT, Calprotectin, CD4, CRP, E-cadherin, Osteocalcin, PGE2, VEGF-A"	"13-cis-Retinoic acid, 25-Hydroxyvitamin D2, Aldosterone, Amphiregulin, Amyloid beta, ApoE, bax, BRCA2, C-C motif chemokine ligand 22, C-C motif chemokine receptor 4, C-X-C motif chemokine ligand 11, C-X-C motif chemokine receptor 3, CA-125, Caspase 3, CCR5, CD34, CD8a, CDKN1A, chemokine (C-C motif) receptor 6, Creatinine, CXCL10, CXCL12, CXCL9, CXCR4, CYP24A1, CYP3A4, Deoxyuridine triphosphate, DNA (cytosine-5-)-methyltransferase 1, DNA nucleotidylexotransferase, F2-isoprostanes, Fas cell surface death receptor, frizzled-related protein, Glutathione, GSTT1, HPGD, IL2, L-Threonine, Lewis X trisaccharide, MAPK3, NFkB, ornithine decarboxylase 1, p16, PCNA, PDZ and LIM domain 7, peroxisome proliferator activated receptor alpha, peroxisome proliferator-activated receptor gamma, PGR, phosphate cytidylyltransferase 1, choline, alpha, prostaglandin E synthase, prostaglandin-endoperoxide synthase 1, proteasome subunit beta 9, Renin, sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein), TGF-beta, Thymidine, tyrosine kinase, non-receptor, 2, UGT1A1, Uridine 5'-diphosphate"	https://adis.springer.com/drugs/800006795?userId=52029392&bpIds=3004037004&checksum=86cc3896f816ff6deaf52de01ed3c50e5560f9bc-1617045530907-1961a0237b2e8fca1bd32b7071a8ea84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027679	Vixotrigine - Biogen	934240-30-9	"(2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide"	Yes			Phase III	"Trigeminal neuralgia, Neuropathic pain, Erythromelalgia, Sciatica, Bipolar disorders"	C18-H19-F-N2-O2	Nav1.7 voltage-gated sodium channel inhibitors	"GlaxoSmithKline (Originator), Biogen (Owner)"		PO				"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02B (Other Analgesics and Antipyretics), N05A (Antipsychotics), N05C (Hypnotics and Sedatives)"	"1014802, BIIB 074, CNV 1014802, CNV 1014802 A, GSK 1014802 A, GSK1014802, Raxatrigine"			14/03/2021	"Affective Disorders, Neurological Disorders, Pain"	Trigeminal neuralgia (USA)	"Biogen | Neuropathic pain, Trigeminal neuralgia | Unspecified |  | 31 May 2007"		no		no				"D-Urobilinogen, Uric acid"			https://adis.springer.com/drugs/800027679?userId=52029392&bpIds=3004037004&checksum=7a7785cb809dfe68720c5a73230d58bf11d4458a-1617045530913-d3e260a091914ff8ddcdffd51f0c1858badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019466	Tanezumab - Eli Lilly and Company/Pfizer	880266-57-9	"Immunoglobulin G2, anti-(human nerve growth factor) (human- mouse monoclonal RN624 heavy chain), disulfide with human- mouse monoclonal RN624 light chain, dimer"	Yes			Preregistration	"Musculoskeletal pain, Back pain, Cancer pain, Diabetic neuropathies, Postherpetic neuralgia"	C6464 H9942 N1706 O2026 S46	Nerve growth factor inhibitors	"Rinat Neuroscience (Originator), Pfizer (Owner), Eli Lilly and Company (Licensee)"		"SC, IV"			"Arthralgia, Headache, Oedema, Osteonecrosis, Pain, Paraesthesia, Respiratory tract infections, Urinary tract infections"	N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"PF04383119, PF4383119, RI624, RN624"			14/03/2021	"Diabetes, Pain"				yes	USA	no				ER alpha			https://adis.springer.com/drugs/800019466?userId=52029392&bpIds=3004037004&checksum=f8e8b25694e25d2a0757e7904dc101b9b8dc4087-1617045530920-334ea40198dea4ab2f15ec8a6829fe0bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003707	Botulinum toxin B - Supernus Pharmaceuticals	75603-31-5		Yes			Marketed	"Torticollis, Sialorrhoea, Muscle spasticity"		"Neuromuscular blocking agents, Acetylcholine inhibitors"	"Solstice Neurosciences (Originator), Supernus Pharmaceuticals (Owner), Alvogen Korea (Licensee), Eisai Co Ltd (Licensee), Sloan Pharma (Licensee)"		"IM, Intraglandular, Parenteral"			"Blepharoptosis, Deglutition disorders, Dyspepsia, Injection site pain, Xerostomia"	"M3A (Muscle Relaxants, Peripherally Acting), N2B (Non-Narcotics and Anti-Pyretics)"	"D11A (Other Dermatological Preparations), M03A-X (Other muscle relaxants, peripherally acting agents), M03A-X01 (Botulinum toxin), N02B (Other Analgesics and Antipyretics)"	"AN 072, BoNT/B, BotB, Botulinum toxin type B, E 2014, Myobloc, NerBloc, Neurobloc, RimabotulinumtoxinB"			14/03/2021	"Mouth Disorders, Musculoskeletal Disorders, Neurological Disorders"			"Myobloc, Myobloc, NerBloc, Neurobloc"	no		no							https://adis.springer.com/drugs/800003707?userId=52029392&bpIds=3004037004&checksum=90d0a69f19d1d4e7a169600e8f783ea0953cee6e-1617045530923-b3bfd91733f830adceb6d1be9e9a89ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011606	Valdecoxib - Pfizer	181695-72-7	4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	Yes		"= Diclofenac, = Naproxen"	Market Withdrawal	"Rheumatoid arthritis, Dysmenorrhoea, Pain, Osteoarthritis, Migraine"	C16 H14 N2 O3 S	Cyclo-oxygenase 2 inhibitors	"Pfizer (Originator), Pfizer (Owner), Astellas Pharma (Licensee)"		PO	hepatic	"Active Metabolites (yes), Activity vs parent (&lt;), Dose Modification in Hepatic Dysfunction (marked), Dose Modification in Renal Dysfunction (nil), Linear Kinetics (yes), Route of Elimination (hepatic), bioavailability oral (%) (83 (Adult)), Cl (L/h) (6 (Adult)), T<sub>_beta</sub> (h) (8 - 11 (Adult)), T<sub>max</sub> (h) (2.25 (Adult))"	Cardiovascular disorders	"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	"Bextra, Kudeq, SC 65872, Vah, Valdyn, Valus, Vorth, YM 974"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Pain, Rheumatic Disease, Women's Health"			"Bextra, Bextra, Bextra, Bextra, Vah, Valus, Vorth"	no		no				"CRP, Valdecoxib"		COX2	https://adis.springer.com/drugs/800011606?userId=52029392&bpIds=3004037004&checksum=d23f65f9799bdd40eb71b0e39b175b41fe88e530-1617045530927-2066e1593a24dd7abcd6c418004779d3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017685	Saracatinib - AstraZeneca	379231-04-6	"<EM>N</EM>-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(methylpiperazin-1-yl)ethoxy]-5-[(tetrahydro-2<EM>H</EM>-pyran-4-yl)oxy]-quinazolin-4-amine bis[(2<EM>E</EM>)-but-2-enedioate]"	Yes			Phase II	"Fibrodysplasia ossificans progressiva, Alzheimer's disease, Cancer pain, Lymphangioleiomyomatosis, Idiopathic pulmonary fibrosis, Parkinson's disease, Alcoholism, Ovarian cancer, Bone cancer, Breast cancer, Prostate cancer, Solid tumours"	C27 H32 C I N5 O5 . 2 C4 H4 O4	Src-Family kinase inhibitors	"AstraZeneca (Originator), AstraZeneca (Owner), Baylor College of Medicine (Collaborator), Brigham and Women's Hospital (Collaborator), Icahn School of Medicine at Mount Sinai (Collaborator), Innovative Medicines Initiative (Collaborator), Loyola University Chicago (Collaborator), National Center for Advancing Translational Sciences (Collaborator), National Institute on Alcohol Abuse and Alcoholism (Collaborator), National Jewish Health (Collaborator), NHS National Services Scotland (Collaborator), Royal National Orthopaedic Hospital (Collaborator), Sheffield Teaching Hospitals NHS Foundation Trust (Collaborator), Stanford University (Collaborator), University of Cincinnati (Collaborator), University of Miami (Collaborator), University of Oxford (Collaborator), University of South Florida (Collaborator), VU University Medical Center (Collaborator), Yale University (Collaborator)"		PO		"T<sub>_beta</sub> (h) (36 - 40 (Adult)), T<sub>max</sub> (h) (4 - 6 (Adult))"	"Diarrhoea, Hoarseness, Hypertension, Hypocalcaemia, Hyponatraemia, Hypophosphataemia, Leucopenia, Nausea"	"L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics), N4 (Anti-Parkinson Drugs), N7D9 (All other anti-Alzheimer products), N7E (Drugs Used In Alcohol Dependence), R7X (All Other Respiratory System Products)"	"L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics), N04 (Anti-Parkinson Drugs), N06D-X (Other anti-dementia drugs), N07B-B (Drugs used in alcohol dependence), R07A-X (Other respiratory system products)"	"AZD 0530, Saracatinib difumarate"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Cancer, Drug Withdrawal, Haematological Disorders, Immunological Disorders, Musculoskeletal Disorders, Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Women's Health"	Idiopathic pulmonary fibrosis (USA)	AstraZeneca |  | Unspecified |  | 05 Aug 2014		no		no		"CA-125, ER alpha, HER2, PSA, SRC proto-oncogene, non-receptor tyrosine kinase"	ER alpha	"AKT, Alkaline phosphatase, CA-125, collagen, type I, alpha 2, Deoxypyridinoline, EGFR, ER alpha, HER2, Ki67, MAPK1, NTx, single-strand-selective monofunctional uracil-DNA glycosylase 1, SRC proto-oncogene, non-receptor tyrosine kinase, Tau protein"		"ApoE, c-src tyrosine kinase, CTx, FAK, HCY, IL8, MDR1, paxillin, STAT3, Thyroid stimulating hormone, beta, Thyroxine, Triiodothyronine, VEGF-A"	https://adis.springer.com/drugs/800017685?userId=52029392&bpIds=3004037004&checksum=5498b5bd12c99bb5e8a182f4a167273531f63697-1617045530931-b62f14dd99ddf0d5bd60aa1755485e26badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014634	Lumiracoxib	220991-20-8	2-[(2-Chloro-6-fluorophenyl)amino]-5-methylphenylacetic acid				Marketed	"Osteoarthritis, Acute pain, Dysmenorrhoea, Gout, Rheumatoid arthritis, Postoperative pain, Dental pain"	C15 H13 Cl F N O2	Cyclo-oxygenase 2 inhibitors	"Novartis (Originator), Novartis (Owner)"		PO		T<sub>_beta</sub> (h) (3 - 6 (Adult))		"M1A3 (Coxibs, plain), M4A (Anti-Gout Preparations), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), M04A (Antigout Preparations), N02B (Other Analgesics and Antipyretics)"	"COX 189, Joicela, Prexige"			14/03/2021	"Pain, Rheumatic Disease, Women's Health"			"Joicela, Prexige, Prexige, Prexige"	no		no				CRP			https://adis.springer.com/drugs/800014634?userId=52029392&bpIds=3004037004&checksum=e99200f6ad4aaa0c2f760c9c65f1c529763842bb-1617045530937-cf673fde8ab9c556478227919d739b64badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007328	Rofecoxib - Merck & Co.	162011-90-7	4-[4-(Methylsulfonyl)phenyl]-3-phenylfuran-2(5<EM>H</EM>)-one	No		"= Diclofenac, = Ibuprofen, = Nabumetone, = Naproxen"	Market Withdrawal	"Musculoskeletal disorders, Rheumatoid arthritis, Pain, Osteoarthritis, Dental pain, Dysmenorrhoea, Juvenile rheumatoid arthritis, Migraine, Preterm labour, Colorectal cancer, Periarthritis, Alzheimer's disease, Sporadic adenomas, Familial adenomatous polyposis"	C17 H14 O4 S	Cyclo-oxygenase 2 inhibitors	"Merck & Co (Originator), Merck & Co (Owner), Laboratorios Phoenix (Market Licensee), Banyu (Collaborator), CollaGenex Pharmaceuticals (Collaborator), Merck Canada (Collaborator)"		"PO, Topical, unspecified"	hepatic	"Linear Kinetics (yes), Route of Elimination (hepatic), bioavailability oral (%) (93 (Adult)), Cl (L/h) (7.2 - 8.46 (Adult)), protein binding (%) (87 (Adult)), T<sub>_beta</sub> (h) (17 (Adult)), T<sub>max</sub> (h) (2 - 3 (Adult))"	"Diarrhoea, Headache, Infections, Insomnia, Oedema"	"G2E (Labour Inhibitors), M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"G02C-A (Sympathomimetics, labour repressants), M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	"Ceoxx, MK 966, Vioxx, Vioxx Acute"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Cancer, Pain, Rheumatic Disease, Women's Health"			"Vioxx, Vioxx, Vioxx, Vioxx Acute, Vioxx Acute"	no		no				"PCNA, PGE2"		HLA-DR	https://adis.springer.com/drugs/800007328?userId=52029392&bpIds=3004037004&checksum=47165f7fa6e882c10db6383262cd31544a9858c5-1617045530945-dc5c1c9b5407f24e04fef77b441f5b00badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002737	Ibandronic acid - Roche	114084-78-5	1-Hydroxy-3-(methylpentylamino)propylidene-bisphosphonic acid	Yes			Marketed	"Malignant hypercalcaemia, Postmenopausal osteoporosis, Cancer metastases, Osteoporosis, Cancer pain"	C9 H23 N O7 P2	"Dimethylallyltranstransferase inhibitors, Bone resorption factor inhibitors"	"Roche (Originator), Roche (Owner), Chugai Pharmaceutical (Development Licensee), Taisho Pharmaceutical (Development Licensee), GlaxoSmithKline (Market Licensee), FAES Farma (Licensee), Takeda Pharmaceuticals International GmbH (Licensee)"		"IV, PO"	renal	"Dose Modification in Renal Dysfunction (nil), Linear Kinetics (yes), Route of Elimination (renal), protein binding (%) (99 (Adult)), T<sub>_beta</sub> (h) (10 - 16 (Adult))"	"Chills, Dyspepsia, Fever, Flu-like symptoms, Gastrointestinal disorders, Hypocalcaemia, Hypophosphataemia, Muscle pain, Musculoskeletal pain, Nausea, Vomiting"	"M5B (Bone Calcium Regulators), N2B (Non-Narcotics and Anti-Pyretics)"	"M05B-A06 (Ibandronic acid), N02B (Other Analgesics and Antipyretics)"	"BM 210955, Bondronat, Boniva, Bonviva, CT064, Ibandronate, Ibandronate sodium hydrate, Methylpentylaminopropylidene, R 484, RG484, RO 2005450, Ro2005450, Ro2005450iv, Ro2005450po, RPR 102289A"			14/03/2021	"Cancer, Musculoskeletal Disorders, Pain, Women's Health"			"Bondronat, Bondronat, Boniva, Boniva, Bonviva, Bonviva"	no		no				"Alendronic acid, Alkaline phosphatase, ATPase inhibitory factor 1, Cathepsin K, Collagen type 1, CTx, Fc fragment of IgG receptor and transporter, NTx, OPG, Osteocalcin, PINP, PTH, Pyridinoline, WAS/WASL interacting protein family, member 1"		"Deoxypyridinoline, ER alpha, PGR, PTHLH"	https://adis.springer.com/drugs/800002737?userId=52029392&bpIds=3004037004&checksum=2916817548b40af4351fc399c5c633dda70ab0ce-1617045530955-f93b88f52dda63b23546f4534098b389badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040151	Esreboxetine - Axsome Therapeutics	98819-76-2	(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine	Yes			Phase III	"Fibromyalgia, Diabetic neuropathies, Postherpetic neuralgia, Stress incontinence, Major depressive disorder"	C19 H23 N O3	Adrenergic uptake inhibitors	"Pfizer (Originator), Pfizer (Owner), Axsome Therapeutics (Licensee)"		PO				"G4D (Urinary Incontinence Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants)"	"G04B-D (Drugs for urinary frequency and incontinence), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics)"	"AXS14, PNU165442G, SSReboxetine"			14/03/2021	"Affective Disorders, Genitourinary Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800040151?userId=52029392&bpIds=3004037004&checksum=376d5859ff3f6f137d033922256e9ce269a4877d-1617045530959-c7bf6b7992a185f93cafb357e6c6c021badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017658	Brivaracetam - UCB Pharma	357336-20-0	(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide	Yes			Marketed	"Epilepsy, Myoclonic epilepsies, Postherpetic neuralgia"	C11 H20 N2 O2	"Sodium channel antagonists, SV2A protein modulators"	"UCB (Originator), UCB (Owner), Dr Reddys Laboratories (Market Licensee)"		"PO, IV"				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics), N03A-X23 (Brivaracetam), N07X (Other Nervous System Drugs)"	"BRIVIACT, BRIVIACT CV, BRIVLERA, RIKELTA, UCB34714"			14/03/2021	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"	"Myoclonic epilepsies (USA), Myoclonic epilepsies (European Union)"		"BRIVIACT, BRIVIACT, BRIVIACT CV, BRIVLERA, RIKELTA"	no		no				"Nibrin, period circadian clock 3 pseudogene, RRAD and GEM like GTPase 1, synaptic vesicle glycoprotein 2A"		CYP2C19	https://adis.springer.com/drugs/800017658?userId=52029392&bpIds=3004037004&checksum=124b615b97561414932f7b2eb0de0be27116b3f4-1617045530972-b5fac45a249a31669033454ddb815ed1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023088	Valnivudine - Hepion Pharmaceuticals	956483-02-6	"L-Valine 3(S)-hydroxy-5(R)-[2-oxo-6(4-pentylphenyl)-2-3-dihydrofuro[2,3-d]pyrimidin-3-yl]tetrahydrofuran-2(R)-ylmethyl ester hydrochloride"	Yes			Phase III	"Herpes zoster, Postherpetic neuralgia"	C27 H35 N3 O6 . HCl	Virus replication inhibitors	"Cardiff University (Originator), FermaVir Pharmaceuticals (Originator), Rega Institute for Medical Research (Originator), Hepion Pharmaceuticals (Owner)"		PO			"Headache, Nausea"	"J5 (Antivirals for Systemic Use), N2 (Analgesics)"	"J05 (Antivirals for Systemic Use), N02B (Other Analgesics and Antipyretics)"	"FV100, Valnivudine"			14/03/2021	"Neurological Disorders, Pain, Viral Infections"			Valnivudine	no		no							https://adis.springer.com/drugs/800023088?userId=52029392&bpIds=3004037004&checksum=5d90fed3c56c7242e21cd2a8a5bc87fa9ec8902b-1617045530974-f821bd17b7b4c3c725fa5847a7d58a11badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039958	Research programme: gene therapies - Voyager Therapeutics			No			Preclinical	"Alzheimer's disease, Huntington's disease, Dementia, Pain, Amyotrophic lateral sclerosis, Friedreich's ataxia, Spinal muscular atrophy"		"Gene transference, Tau protein inhibitors, Nav1.7 voltage-gated sodium channel inhibitors"	"Voyager Therapeutics (Originator), Voyager Therapeutics (Owner), California Institute of Technology/CalTech (Technology Provider), REGENXBIO (Technology Provider), Stanford University (Technology Provider), University of California at San Francisco (Technology Provider), University of Massachusetts Medical School (Technology Provider), CHDI (Collaborator), Neurocrine Biosciences (Collaborator), Sanofi Genzyme (Collaborator)"		"unspecified, Intrastriatal, Intralumbar, Parenteral, Intrathecal"				"M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2B (Non-Narcotics and Anti-Pyretics), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"M09A (Other Drugs for Disorders of the Musculo-Skeletal System), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs), N07X-X (Other nervous system drugs)"	"AAV Frataxin, AAVdelivered gene therapies for CNS disorders Voyager Therapeutics, AAVrh.10vectored PHF1, ALS SOD1, Amyotrophic lateral sclerosis gene therapy Voyager Therapeutics, AntiTau Antibody, Friedreich##8217##s ataxia gene therapy Voyager Therapeutics, Friedreichs ataxia gene therapy Voyager Therapeutics, Huntingtons disease gene therapy Voyager Therapeutics, VY FXN01, VY HTT01, VY SMN101, VY SOD101, VY SOD102, VYAADC, VYNAV01, VYTAU01"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"	Huntington's disease (USA)	Voyager Therapeutics | Amyotrophic lateral sclerosis | Clinical Phase Unknown |  | 17 Jun 2019		no		no							https://adis.springer.com/drugs/800039958?userId=52029392&bpIds=3004037004&checksum=f133f212f44cb75839df52f7a541198d9874c048-1617045530977-d11e75d28c46340f80c48589e2457cdebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007737	Rimonabant	168273-06-1	"<EM>N</EM>-Piperidino-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide"	Yes			Marketed	"Obesity, Type 2 diabetes mellitus, Smoking withdrawal, Liver disorders, Cardiovascular disorders, Atherosclerosis, Cognition disorders, Hyperlipidaemia, Schizophrenia, Neuropathic pain"	C22 H21 Cl3 N4 O	Cannabinoid receptor CB1 antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner), National Institutes of Health (USA) (Collaborator)"		PO			"Anxiety, Arthralgia, Back pain, Diarrhoea, Dizziness, Fatigue, Gastroenteritis, Headache, Hypoglycaemia, Influenza virus infections, Nasopharyngitis, Nausea, Paraesthesia, Respiratory tract infections, Vomiting"	"A10X (Other Drugs Used in Diabetes), A5B (Hepatic Protectors, Lipotropics), A8A (Antiobesity Preparations, Excluding Dietetics), C10 (Lipid-Regulating/Anti-Atheroma Preparations), C10A (Cholesterol and Triglyceride Regulating Preparations), N2 (Analgesics), N5A (Antipsychotics), N7 (Other CNS Drugs), N7B (Antismoking Products)"	"A05B-A (Liver therapy), A08A (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), C10 (Lipid Modifying Agents), C10A (Lipid Modifying Agents, Plain), N02 (Analgesics), N05A-X (Other antipsychotics), N07B (Drugs Used In Addictive Disorders), N07B-A (Drugs used in nicotine dependence), N07B-B (Drugs used in alcohol dependence), N07X (Other Nervous System Drugs)"	"Acomplia, SR 141716, SR 141716A, Zimulti"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Diabetes, Drug Withdrawal, Hyperlipidaemia, Ischaemic Heart Disease, Liver Disorders, Obesity, Pain, Psychotic Disorders, Vascular Disorders"			"Acomplia, Acomplia, Zimulti"	no		no		A1C	"A1C, C-peptide"	"A1C, Adiponectin, Apo A-1, Apo B, Apo C-III, apolipoprotein A-II, C-peptide, C3, CRP, G protein-coupled receptor 162, Hydrocortisone, ICAM-1, Leptin, lipase C, hepatic type, Norepinephrine, PGR, RFC4, TNF-alpha"		"Thyroid stimulating hormone, beta"	https://adis.springer.com/drugs/800007737?userId=52029392&bpIds=3004037004&checksum=7f2193dcc777170ea1aa6cd1026423e7f09df6ae-1617045530980-4014b0d5f05353de1d425c452e5230cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033181	Mirogabalin - Daiichi Sankyo Company	1138245-13-2	"2-[(1R,5S,6S)-6-(aminomethyl)-3-ethyl-6-bicyclo[3.2.0]hept-3-enyl]acetic acid"	Yes			Marketed	"Postherpetic neuralgia, Neuropathic pain, Pain"	C12 H19 N O2	"CACNA2D1 protein modulators, GABA receptor agonists"	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner)"		PO			"Dizziness, Headache, Somnolence"	N2 (Analgesics)	N02 (Analgesics)	"DS 5565, mirogabalin besylate, Tarlige"			14/03/2021	Pain			"Tarlige, Tarlige"	no		no				hyaluronan synthase 2			https://adis.springer.com/drugs/800033181?userId=52029392&bpIds=3004037004&checksum=f809f83cdd65ae1e5c29cca0f954984e7bedf778-1617045530986-78c84387e5abf197dff2e3dfcef8c253badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026875	PF 5089771			Yes			No development reported (II)	"Pain, Neuropathic pain, Dental pain"		Nav1.7 voltage-gated sodium channel inhibitors	"Icagen (Originator), Icagen, Inc. (Owner), Yale University (Collaborator)"		"PO, IV"				N2 (Analgesics)	N02 (Analgesics)	"PF05089771, PF5089771"			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800026875?userId=52029392&bpIds=3004037004&checksum=b9d47bd290124a6b9227f2ed3d50ed2637ffc377-1617045530987-b53617e0b90e0889cefdcd83914133f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012911	Eslicarbazepine acetate - Bial	236395-14-5	"(<EM>S</EM>)-(_)-10-Acetoxy-10,11-dihydro-5<EM>H</EM>-dibenzo[<EM>b,f</EM>]azepine-5-carboxamide"	Yes			Marketed	"Partial epilepsies, Migraine, Epilepsy, Postherpetic neuralgia, Neuropathic pain, Fibromyalgia, Bipolar disorders"	C17 H16 N2 O3	"T type calcium channel antagonists, Voltage-gated sodium channel inhibitors"	"Bial (Originator), Bial (Owner), m8 Pharmaceuticals (Market Licensee), Whanin Pharmaceutical (Market Licensee), Sunovion Pharmaceuticals (Licensee)"		PO			"Diplopia, Dizziness, Headache, Hyponatraemia, Nausea, Somnolence"	"N2 (Analgesics), N3A (Anti-Epileptics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N03A-F04 (Eslicarbazepine), N06B-X (Other psychostimulants and nootropics)"	"Aptiom, BIA 2093, ESL, Eslicarbazepine, Exalief, SEP0002093, SEP2093, Stedesa, Zebinix"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain"			"Aptiom, Aptiom, Exalief, Zebinix, Zebinix, Zebinix"	no		no				"period circadian clock 3 pseudogene, Thyroid stimulating hormone, beta, Thyroxine"		"Thyroxine-Binding Proteins, TPO Auto-antibodies, Triiodothyronine"	https://adis.springer.com/drugs/800012911?userId=52029392&bpIds=3004037004&checksum=60d34461042543578bdd9100cfd9e869f4ec657c-1617045530998-4835a2278028f3d01c1e2b3745b0a144badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026023	SAR 407899			Yes			Discontinued (II)	"Diabetic neuropathies, Syndrome X, Erectile dysfunction, Kidney disorders, Diabetic nephropathies, Hypertension, Pulmonary hypertension"		Rho-associated kinase inhibitors	"sanofi-aventis (Originator), Sanofi (Owner)"		PO				"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), C1 (Cardiac Therapy), C2 (Antihypertensives), G4 (Urologicals), G4E (Erectile Dysfunction Products), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), C01 (Cardiac Therapy), C02 (Antihypertensives), G04B (Urologicals), G04B-E (Drugs used in erectile dysfunction), N02 (Analgesics)"	"SAR407899, SAR407899A"			14/03/2021	"Diabetes, Genitourinary Disorders, Hypertension, Ischaemic Heart Disease, Men's Health, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800026023?userId=52029392&bpIds=3004037004&checksum=b862660d5a9dd7a438f018d950fc546f864534ea-1617045531000-43ed43aa1710d6ba3ee5d1b01b57197dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000550	Desvenlafaxine - Pfizer	386750-22-7	4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate monohydrate	No			Marketed	"Major depressive disorder, Vasomotor symptoms, Neuropathic pain, Fibromyalgia"	C16 H25 N O2 . C4 H6 O4 . H2O	"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Wyeth (Originator), Pfizer (Owner), Mochida Pharmaceutical (Development Licensee), Almirall S.A. (Market Licensee), Amneal Pharmaceuticals (Market Licensee), Jiangsu Hansoh Pharmaceutical (Collaborator)"		PO		"T<sub>_beta</sub> (h) ( - 11 (Adult)), T<sub>max</sub> (h) (5 - 8 (Adult))"	"Abdominal pain, Anorexia, Anxiety, Asthenia, Constipation, Diaphoresis, Dizziness, Ejaculation disorders, Hypertension, Insomnia, Nausea, Orthostatic hypotension, Somnolence, Tremor, Vertigo, Vomiting"	"G2X (Other Gynaecological products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N6A5 (SNRI antidepressants), V3 (All Other Therapeutic Products)"	"G02C (Other Gynecologicals), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06A-X23 (Desvenlafaxine), V03A (All Other Therapeutic Products)"	"Desvenlafaxine hydrochloride, Desvenlafaxine SR, Desvenlafaxine succinate, Desvenlafaxine succinate sustained release, Desvenlafaxine sustainedrelease, Desvenlaflaxine extended release, DVS233, DVS233 SR, DVSSR, MD120, Odesmethylvenlafaxine, Pristiq, WY45233"			14/03/2021	"Affective Disorders, Pain, Rheumatic Disease, Women's Health"			"Pristiq, Pristiq, Pristiq"	no		no				"AMH, chromodomain helicase DNA binding protein 7, EH domain containing 2, ER alpha, GATA3, serotonin, solute carrier family 6 (neurotransmitter transporter), member 4, Testosterone"			https://adis.springer.com/drugs/800000550?userId=52029392&bpIds=3004037004&checksum=56627a15c6680d955a87493b1db5cdf3e83d93d5-1617045531004-dbdbf1527e71a293eac92746c70f187dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015253	Tovetumab	1243266-04-7	"Immunoglobulin G2, anti-(human platelet-derived growth factor receptor _) (human monoclonal MEDI-575 heavy chain), disulfide with human monoclonal MEDI-575 _-chain, dimer"	Yes			Discontinued (II)	"Glioblastoma, Solid tumours, Non-small cell lung cancer"	C6400 H9906 N1726 O2002 S54	Platelet-derived growth factor alpha receptor modulators	"Cambridge Antibody Technology (Originator), MedImmune (Owner), Dyax (Technology Provider)"		IV			"Anaemia, Fatigue, Hypokalaemia, Muscle spasticity, Nausea"	"L1G (Monoclonal Antibody Antineoplastics), N2 (Analgesics), N7X (All other CNS drugs)"	"L01X-C (Monoclonal antibodies), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"AntiPDGFRa MAb MedImmune, MEDI575"			14/03/2021	Cancer				no		no				"Bilirubin, PDGFA, PDGFB, PDGFRA, Uric acid"			https://adis.springer.com/drugs/800015253?userId=52029392&bpIds=3004037004&checksum=20753d0687f6452fa34dfe060b829bd75a4f1873-1617045531005-b1da66632d8374e4077d596730a0bb5bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019505	PF 07265803	1083381-82-1	"5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide"	Yes			Phase III	"Dilated cardiomyopathy, Dental pain, Musculoskeletal pain, Ankylosing spondylitis, Cancer, Rheumatoid arthritis"	C22 H26 F2 N4 O2	P38 mitogen-activated protein kinase inhibitors	"Array BioPharma (Originator), Pfizer (Owner), Yarra Therapeutics (Collaborator)"		PO				"C1 (Cardiac Therapy), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"C01 (Cardiac Therapy), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"ARRY371797, ARRY797, PF07265803"			14/03/2021	"Cancer, Heart Failure, Pain, Rheumatic Disease"				no		no				"BNP, NTx"			https://adis.springer.com/drugs/800019505?userId=52029392&bpIds=3004037004&checksum=fa8a8a9ed92e0d670fc74ee090a0e3c68325ef98-1617045531007-e722aa6a5fe6c2479c9ffc784152ae5bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001785	Duloxetine - Eli Lilly and Company	116539-59-4	(+)-(S)-N-Methyl-_-(1-naphthyloxy)-2- thiophene- propylamine hydrochloride	Yes			Marketed	"Generalised anxiety disorder, Major depressive disorder, Stress incontinence, Fibromyalgia, Diabetic neuropathies, Neuropathic pain, Musculoskeletal pain, Back pain, Depressive disorders, Chronic fatigue syndrome"	C18 H19 N O S . H Cl	"Adrenergic uptake inhibitors, Serotonin plasma membrane transport protein inhibitors, Serotonin uptake inhibitors"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner), Shionogi (Licensee), Shiga University of Medical Science (Collaborator), Takeda (Collaborator)"		PO		"T<sub>_beta</sub> (h) (14 (Adult)), T<sub>max</sub> (h) (6 (Adult))"	"Agitation, Anorexia, Asthenia, Constipation, Decreased libido, Diarrhoea, Dizziness, Drowsiness, Erectile dysfunction, Fatigue, Flu-like symptoms, Headache, Hyperhidrosis, Insomnia, Nausea, Sleep disorders, Somnolence, Tremor, Vomiting, Weight gain, Xerostomia"	"G4D4 (Urinary incontinence products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"G04B-X (Other urologicals), M01B-X (Other antiinflammatory/antirheumatic agents in combination with other drugs), N02 (Analgesics), N05B (Anxiolytics), N06A-X21 (Duloxetine), N07X (Other Nervous System Drugs)"	"Ariclaim, Cymbalta, LY227942, LY248686, Xeristar, Yentreve"			14/03/2021	"Affective Disorders, Anxiety Disorders, Diabetes, Genitourinary Disorders, Neurological Disorders, Pain, Rheumatic Disease, Women's Health"			"Ariclaim, Ariclaim, Cymbalta, Cymbalta, Cymbalta, Cymbalta, Cymbalta, Cymbalta, Cymbalta, Cymbalta, Xeristar, Xeristar, Xeristar, Yentreve"	no		no			A1C	"5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 4, 8-oxo-7-hydrodeoxyguanosine, A1C, BDNF, Bilirubin, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD8a, chromodomain helicase DNA binding protein 7, COMT, CRP, CYP2C19, CYP2D6, DBH antisense RNA 1, Diethylphosphate, DRD3, DRD4, EH domain containing 2, Escitalopram, FK506 binding protein 5, Gamma-Aminobutyric acid, GDP-mannose 4,6-dehydratase, glutamate receptor, ionotropic, N-methyl D-aspartate 2B, HTR2A, Hydrocortisone, IL6, intestinal cell (MAK-like) kinase, L-Glutamic acid, monoamine oxidase A, monocyte to macrophage differentiation associated, myelin oligodendrocyte glycoprotein, Norepinephrine, NTx, Prolactin, serotonin, solute carrier family 1 member 1, solute carrier family 6 (neurotransmitter transporter), member 4, spindle and kinetochore associated complex subunit 2, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, syntaxin 2, Testosterone, TNF-alpha, Uric acid"	"IL6, TNF-alpha"	"5-hydroxytryptamine receptor 3A, Aromatase, Creatinine, CYP1A2, DSP, ER alpha, MMP-1, opioid related nociceptin receptor 1, solute carrier family 6 (neurotransmitter transporter), member 2"	https://adis.springer.com/drugs/800001785?userId=52029392&bpIds=3004037004&checksum=91b925381fa1c965897332f7a6939ece3e7744af-1617045531022-916cc7216ee16d95f30fb0de52020354badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023191	Losmapimod - Fulcrum Therapeutics	585543-15-3	"6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3- carboxamide"	Yes			Phase III	"Acute coronary syndromes, COVID 2019 infections, Facioscapulohumeral muscular dystrophy, Focal segmental glomerulosclerosis, Chronic obstructive pulmonary disease, Inflammation, Atherosclerosis, Neuropathic pain, Major depressive disorder, Rheumatoid arthritis, Dyslipidaemias"	C22 H26 F N3 O2	"P38 mitogen-activated protein kinase inhibitors, DUX4 protein inhibitors"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), Fulcrum Therapeutics (Licensee), Brigham and Womens Hospital (Collaborator)"		"PO, IV"				"C1 (Cardiac Therapy), C10 (Lipid-Regulating/Anti-Atheroma Preparations), G4X (All Other Urological Products), J5 (Antivirals for Systemic Use), L4X (Other Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), R3X2 (All other anti-asthma and COPD products, systemic)"	"C01 (Cardiac Therapy), C10 (Lipid Modifying Agents), G04B (Urologicals), J05 (Antivirals for Systemic Use), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N06A (Antidepressants), R03D (Other Systemic Drugs for Obstructive Airway Diseases)"	"856553, FTX1821, GS856553, GSK 856553, GW 856553, GW856553X"			14/03/2021	"Affective Disorders, Genitourinary Disorders, Hyperlipidaemia, Immunological Disorders, Inflammation, Ischaemic Heart Disease, Musculoskeletal Disorders, Neurological Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease, Viral Infections"	"Facioscapulohumeral muscular dystrophy (USA), Facioscapulohumeral muscular dystrophy (European Union)"			no		no		"Fibrinogen, Pulmonary disease, chronic obstructive, severe early-onset, troponin I, cardiac"	"Pulmonary disease, chronic obstructive, severe early-onset"	"BNP, CCL18, CD25, CKB, CKM, CRP, Fibrinogen, gamma-glutamyltransferase light chain 1, heat shock 27kDa protein 1, IL1 beta, IL10, IL2, IL6, IL8, MMP9, MPO, period circadian clock 1, Pulmonary disease, chronic obstructive, severe early-onset, Sorbitol, Surfactant protein D, TNF-alpha, troponin I, cardiac, Uric acid"		"A1AT, FSH"	https://adis.springer.com/drugs/800023191?userId=52029392&bpIds=3004037004&checksum=b418386ded15f8e62491e17af838ec687ae02330-1617045531031-4775b0bcc7404a34fec8f64c27bdfa9bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023875	Olesoxime - Roche	22033-87-0	"(1<EM>R</EM>,3a<EM>S</EM>,3b<EM>S</EM>,9a<EM>R</EM>,9b<EM>S</EM>,11a<EM>R</EM>,<EM>E</EM>)-10,13-Dimethyl-17-[(<EM>S</EM>)-6-methylheptan-2-yl]-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1<EM>H</EM>-cyclopenta[a]phenanthren-3(2<EM>H</EM>)-one oxime"	Yes			Discontinued (II/III)	"Spinal muscular atrophy, Amyotrophic lateral sclerosis, Neuropathic pain, Multiple sclerosis, Diabetic neuropathies, Non-alcoholic steatohepatitis, Huntington's disease"	C27 H45 N O	Mitochondrial permeability transition pore modulators	"Trophos (Originator), Roche (Owner), Association Francaise contre les Myopathies (Collaborator)"		PO				"A5B (Hepatic Protectors, Lipotropics), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N7 (Other CNS Drugs)"	"A05B-A (Liver therapy), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"Cholest4en3oneoxime, Cholest4en3ylidenehydroxylamine, RG6083, TRO19622"			14/03/2021	"Liver Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"	"Amyotrophic lateral sclerosis (USA), Spinal muscular atrophy (European Union)"			no		no		"survival of motor neuron 1, telomeric"	"survival of motor neuron 1, telomeric"	iodothyronine deiodinase 2			https://adis.springer.com/drugs/800023875?userId=52029392&bpIds=3004037004&checksum=ec7d827c9183434016fbe79f259beac03903f6e9-1617045531033-42552e326e0824e235b1153b4bd108dfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001086	Meloxicam - Boehringer Ingelheim	71125-38-7	"2<EM>H</EM>-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-<EM>N</EM>-(5-methyl- 2-thiazolyl)-, 1,1-dioxide"	Yes		"= Diclofenac, = Naproxen, = Piroxicam"	Marketed	"Rheumatoid arthritis, Ankylosing spondylitis, Osteoarthritis, Back pain, Periarthritis, Neuropathic pain, Gout, Juvenile rheumatoid arthritis, Preterm labour"	C14 H13 N3 O4 S2	Cyclo-oxygenase 2 inhibitors	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner), Almirall S.A. (Market Licensee), Bristol-Myers Squibb (Market Licensee), Daiichi Sankyo Company (Market Licensee), Roemmers (Market Licensee)"		"PO, unspecified, Rectal"	renal	"Activity vs parent (&lt;), Dose Modification in Hepatic Dysfunction (nil), Dose Modification in Renal Dysfunction (minimal), Route of Elimination (renal), bioavailability oral (%) (89 (Adult)), Cl (L/h) (.42 - .48 (Adult)), protein binding (%) (99 (Adult)), T<sub>_beta</sub> (h) (15.3 - 22 (Adult)), T<sub>max</sub> (h) (5 - 6 (Adult))"	"Gastrointestinal disorders, Pain"	"G2E (Labour Inhibitors), M1A (Anti-Rheumatics, Non-Steroidal), M1C (Specific Anti-Rheumatic Agents), N2 (Analgesics)"	"G02C-A (Sympathomimetics, labour repressants), M01A-C06 (Meloxicam), N02 (Analgesics)"	"Amelotex, Mobec, Mobic, Mobicox, Movalis, Movatec, Parocin, Tenaron, UH AC 62, UH AC 62 XX, UH AE 62 XX, Uticox"			14/03/2021	"Pain, Rheumatic Disease, Women's Health"			"Amelotex, Mobec, Mobec, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobic, Mobicox, Movalis, Movatec, Parocin, Parocin, Tenaron, Tenaron, Tenaron, Tenaron, Uticox, Uticox"	no		no							https://adis.springer.com/drugs/800001086?userId=52029392&bpIds=3004037004&checksum=d4609dc29720d033692c3800b65cea7f59bb9496-1617045531040-90f92df30b373aa307878760a808c3c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040983	Soticlestat - Ovid Therapeutics/Takeda	1429505-03-2	(4-benzyl-4-hydroxypiperidin-1-yl)-(2-pyridin-4-ylpyridin-3-yl)methanone	Yes			Phase II	"Complex regional pain syndromes, Tuberous sclerosis, Epilepsy, Lennox-Gastaut syndrome, Dravet syndrome, Myoclonic epilepsies"	C23 H23 N3 O2	"Cholesterol 24-hydroxylase inhibitors, NMDA receptor modulators"	"Takeda (Originator), Takeda (Owner), Ovid Therapeutics (Licensee)"		PO			"Headache, Nausea"	"N2 (Analgesics), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N03 (Antiepileptics), N07 (Other Nervous System Drugs)"	"OV935, TAK 935"			14/03/2021	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"	"Lennox-Gastaut syndrome (USA), Dravet syndrome (USA)"			no		no							https://adis.springer.com/drugs/800040983?userId=52029392&bpIds=3004037004&checksum=f9d2b83ddc6fa5f3d501b9c2c8c2b5fdbd1408b8-1617045531043-53561938bdcd2c3179f155a3aeb22635badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029032	JZP 150		<EM>N</EM>-(Pyridazin-3-yl)-4-[3-[5-(trifluoromethyl)pyridin-2-yloxy]benzylidene]piperidine-1-carboxamide	Yes			Preclinical	"Post-traumatic stress disorders, Pain, Alcoholism"	C23 H20 F3 N5 O2	Fatty acid amide hydrolase inhibitors	"Pfizer (Originator), Pfizer (Owner), SpringWorks Therapeutics (Licensee), Jazz Pharmaceuticals plc (Sub-licensee), Linkoping University (Collaborator), Stockholm Centre for Dependency Disorders (Collaborator)"		PO				"N (Nervous System), N2 (Analgesics), N7 (Other CNS Drugs), N7E (Drugs Used In Alcohol Dependence)"	"N (Nervous System), N02 (Analgesics), N07 (Other Nervous System Drugs), N07B-B (Drugs used in alcohol dependence)"	"JZP150, PF##8217##845, PF04457845, PF4457845, PF845"			14/03/2021	"Anxiety Disorders, Drug Withdrawal, Pain"				no		no				Niacinamide			https://adis.springer.com/drugs/800029032?userId=52029392&bpIds=3004037004&checksum=b79a02bac225976bcf84cb0132c66fe2f41c3e25-1617045531044-6052a368734b15b24e9e5798c493bc83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025495	PF 489791	853003-48-2		Yes			Discontinued (II)	"Diabetic nephropathies, Pulmonary hypertension, Raynaud's disease, Hypertension, Postherpetic neuralgia, Renal failure, Chronic obstructive pulmonary disease"		Type 5 cyclic nucleotide phosphodiesterase inhibitors	"Pfizer (Originator), Pfizer (Owner)"		PO				"A10X (Other Drugs Used in Diabetes), C2 (Antihypertensives), C4A (Cerebral and Peripheral Vasotherapeutics), C6A (Other Cardiovascular Products), G4 (Urologicals), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), C02 (Antihypertensives), C04A (Peripheral Vasodilators), G04 (Urologicals), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"PF00489791, PF0489791, PF489791"			14/03/2021	"Diabetes, Genitourinary Disorders, Hypertension, Pain, Respiratory Tract Disorders, Vascular Disorders"				no		no			A1C	"A1C, CRP, Cystatin C, TGF-beta"			https://adis.springer.com/drugs/800025495?userId=52029392&bpIds=3004037004&checksum=f30ba61d70593fdc01634017c1e2b81cc765fc38-1617045531048-4b59a74b468f69c9cb594ab11d4d47cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000714	Mirtazapine	85650-52-8	"1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a) pyrido(2,3-c)-(2) benzazepine"	Yes			Marketed	"Major depressive disorder, Fibromyalgia"	C17 H19 N3	"Alpha 2 adrenergic receptor antagonists, Serotonin 2 receptor antagonists, Serotonin 3 receptor antagonists"	"Organon (Originator), Merck & Co (Owner), Meiji Seika Pharma (Licensee)"		PO		"Active Metabolites (no), Linear Kinetics (yes), bioavailability oral (%) (56 (Adult))"	"Agitation, Appetite disorders, Blurred vision, Cardiovascular disorders, Constipation, Dizziness, Drowsiness, Fatigue, Haematological disorders, Headache, Insomnia, Liver disorders, Nausea, Sexual function disorders, Somnolence, Tremor, Vertigo, Weight gain, Weight loss, Xerostomia"	"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A-X11 (Mirtazepine)"	"Avanza, Azamianserin, ME2040, Mepirzapin, Norset, ORG3770, Promyrtil, Reflex, REFLEX Org3770, Remergil, Remergon, Remeron, RemeronSolTab, Rexer, Zispin"			14/03/2021	"Affective Disorders, Rheumatic Disease"			"Avanza, Promyrtil, Reflex, Reflex, Remergil, Remeron, Remeron, Remeron, RemeronSolTab, Rexer, Zispin, Zispin"	no		no		Benzoyl ecgonine	Folic acid	"BDNF, Benzoyl ecgonine, Folic acid, HCY, IL6, TNF-alpha"	"IL6, TNF-alpha"	"BCAR1, Cas family scaffolding protein, Dimethylsulfide"	https://adis.springer.com/drugs/800000714?userId=52029392&bpIds=3004037004&checksum=14e751e426a9ee10bff6ca8da6e3cf10c3f08570-1617045531050-23fde948c6016145450fd82596f42c65badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000181	Beraprost	88430-50-6	"1H-Cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b- tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-"	Yes			Marketed	"Peripheral vascular disorders, Pulmonary hypertension, Arterial occlusive disorders, Intermittent claudication, Diabetic neuropathies, Cancer"	C24 H30 O5	Epoprostenol agonists	"Toray (Originator), Toray (Owner), Sanofi (Licensee), United Therapeutics Corporation (Licensee), Kaken Pharmaceutical (Collaborator)"		PO			"Drowsiness, Flushing, Headache"	"A10X (Other Drugs Used in Diabetes), B1C (Platelet Aggregation Inhibitors), C4A (Cerebral and Peripheral Vasotherapeutics), L1 (Antineoplastics), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), B01A-C (Platelet aggregation inhibitors excl. heparin), C04A (Peripheral Vasodilators), L01 (Antineoplastic Agents), N02 (Analgesics)"	"Befraprost, Dorner, ML 129, ML1129, ML1229, Procyclin, RU55100, TRK100"			14/03/2021	"Cancer, Diabetes, Respiratory Tract Disorders, Thromboses, Vascular Disorders"			"Dorner, Dorner, Procyclin, Procyclin"	no		no							https://adis.springer.com/drugs/800000181?userId=52029392&bpIds=3004037004&checksum=d6656f69129feb63bb6949ffc36321db8a7df9c3-1617045531053-42cedf2faa6946e138b13bca10f82f2dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001839	Saredutant	142001-63-6	"Benzamide, (S)-N-[4-[4-(acetylamino)-4-phenyl- 1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]- N-methyl-,"				Discontinued (III)	"Major depressive disorder, Generalised anxiety disorder, Pain, Irritable bowel syndrome, Inflammatory bowel diseases, Asthma"	C31 H35 Cl2 N3 O2	Neurokinin 2 receptor antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		PO			Headache	"A3A (Plain Antispasmodics and Anticholinergics), A7E (Intestinal Anti-Inflammatory Agents), N2 (Analgesics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers), R3 (Anti-Asthma and COPD Products)"	"A03A (Drugs for Functional Bowel Disorders), A07E (Intestinal Antiinflammatory Agents), N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants), R03 (Drugs for Obstructive Airway Diseases)"	SR 48968			14/03/2021	"Affective Disorders, Anxiety Disorders, Digestive System Disorders, Inflammatory Bowel Disorders, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800001839?userId=52029392&bpIds=3004037004&checksum=9d11872b38e17789dda3642e5afd4e82faf53bd6-1617045531055-acd1aea9b06facaf8a9dc0923a134dedbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024875	Gefapixant - Merck & Co	1015787-98-0	"5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide"	Yes			Preregistration	"Cough, Musculoskeletal pain, Pelvic pain, Interstitial cystitis, Pain, Asthma, Sleep apnoea syndrome, Overactive bladder"	C14 H19 N5 O4 S	Purinergic P2X3 receptor antagonists	"Roche (Originator), Roche (Owner), Merck & Co (Licensee), Celerion (Collaborator)"		PO			Dysgeusia	"G4 (Urologicals), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N7 (Other CNS Drugs), R3 (Anti-Asthma and COPD Products), R5 (Cough and Cold Preparations)"	"G04 (Urologicals), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N07 (Other Nervous System Drugs), R03 (Drugs for Obstructive Airway Diseases), R05D-B (Other cough suppressants)"	"AF219, MK7264, R1646, RG1646, RO 4926219"			14/03/2021	"Genitourinary Disorders, Neurological Disorders, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no			Citric acid	Citric acid			https://adis.springer.com/drugs/800024875?userId=52029392&bpIds=3004037004&checksum=f3be0cf68a700e38621b7e238326449de37c0484-1617045531060-b78e336643fc1a30eec2fe04a13f0bd6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031896	Vibegron - Kyorin Pharmaceutical/Urovant Sciences	1190389-15-1	"(6S )-N -[4-({(2S ,5R )-5-[(R )-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a ]pyrimidine-6-carboxamide"	Yes			Marketed	"Overactive bladder, Pain, Endocrine disorders"	C26 H28 N4 O3	Beta 3 adrenergic receptor agonists	"Merck & Co (Originator), Merck & Co (Owner), Sunovion Pharmaceuticals (Market Licensee), Kyorin Pharmaceutical (Licensee), Urovant Sciences (Licensee), Jeil Pharmaceutical (Sub-licensee), Kissei Pharmaceutical (Sub-licensee), Codexis (Collaborator), Sinovant Sciences (Collaborator)"		PO				"G4D (Urinary Incontinence Products), N2 (Analgesics)"	"G04B-D (Drugs for urinary frequency and incontinence), N02 (Analgesics)"	"Beova, GEMTESA, KRP114V, MK4618, RVT 901, SNV004, URO 901"			14/03/2021	"Endocrine Disorders, Genitourinary Disorders, Pain"			"Beova, GEMTESA"	no		no				ER alpha			https://adis.springer.com/drugs/800031896?userId=52029392&bpIds=3004037004&checksum=ab41d1fd19bf0bd7e48e27f3ef47ba9b64c990b3-1617045531064-76d34aa7f85cd961c1900342fd945598badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004115	Galantamine - Janssen/Sanochemia Pharmazeutika	357-70-0	"(4a<EM>S</EM>,6<EM>R</EM>,8a<EM>S</EM>)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6<EM>H</EM>-benzofuro[3a,3,2-<EM>ef</EM>] [2]benzazepin-6-ol"	No			Marketed	"Alzheimer's disease, Down syndrome, Vascular dementia, Mild cognitive impairment, Delirium, Fibromyalgia, Chronic fatigue syndrome"	C17 H21 N O3	Acetylcholinesterase inhibitors	"Sanochemia Pharmazeutika (Originator), Synaptech (Owner), Janssen (Market Licensee), Janssen Inc (Market Licensee), Janssen-Cilag (Market Licensee), m8 Pharmaceuticals (Market Licensee), Ortho-McNeil (Market Licensee), Takeda (Market Licensee), Janssen Pharmaceutical KK (Licensee), Xian-Janssen (Licensee), Takeda (Sub-licensee)"		"PO, IM, unspecified"		"Linear Kinetics (yes), bioavailability oral (%) (90 - 100 (Adult)), Cl (L/h) (2.38 (Adult)), T<sub>_beta</sub> (h) (5.68 (Adult)), T<sub>max</sub> (h) (.75 (Adult)), Vd (L/kg) (2.64 (Adult))"	"Agitation, Arrhythmias, Bradycardia, Diarrhoea, Dizziness, Nausea, Sialorrhoea, Sleep disorders, Vomiting"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7D1 (Anti-Alzheimer products, cholinesterase inhibitors), N7X (All other CNS drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06D-A04 (Galantamine), N07X-X (Other nervous system drugs)"	"Galantamine Hydrobromide, Galanthamine, GP 37267, Nivalin, R113675, Razadyne, Razadyne ER, Reminyl, Reminyl ER"			14/03/2021	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain, Rheumatic Disease"			"Nivalin, Razadyne, Razadyne ER, Reminyl, Reminyl ER"	no		no		alkylglycerone phosphate synthase	"Folic acid, Prolactin"	"Adiponectin, alkylglycerone phosphate synthase, Allantoin, E1A binding protein p300, IL6, Insulin, Kynurenic acid, Kynurenine, Leptin, Picolinic acid, solute carrier family 27 member 5, Thrombin, TNF-alpha"		"C-C motif chemokine receptor 2, CD14, CD163, CD38, CD8a, Citicoline, COMT, CXCR1, CYP2D6, dopamine beta-hydroxylase, exostosin like glycosyltransferase 3, HLA-DR, MCP1, Tau protein, Thyroid stimulating hormone, beta"	https://adis.springer.com/drugs/800004115?userId=52029392&bpIds=3004037004&checksum=636d30aec713571aee04c3724d8fe65d6862e261-1617045531069-b48cf154b83307d100b9a9bf6ceb080cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039083	ART 2713	881413-29-2	"N-[2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]benzimidazol-5-yl]ethanesulfonamide"	Yes			Phase I/II	"Anorexia, Nausea and vomiting, Cancer pain, Cachexia, Pain, Neuropathic pain"	C20 H29 F2 N3 O2 S	"Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"AstraZeneca (Originator), NEOMED (Originator), Pfizer (Originator), adMare BioInnovations (Owner), Artelo Biosciences (Licensee), Aptus Clinical (Collaborator), Syngene (Collaborator), Trinity College Dublin (Collaborator)"		PO				"A4A9 (Other antiemetics and antinauseants), N2 (Analgesics)"	"A04A-D (Other antiemetics), N02 (Analgesics)"	"ART27.13, AZD1940, NEO1940"			14/03/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Cancer, Pain"				no		no							https://adis.springer.com/drugs/800039083?userId=52029392&bpIds=3004037004&checksum=427ee42cbbba45f4261f47204230578c68d191f7-1617045531071-11be4dc244e15fbcfeae9993a61896babadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039009	Darigabat - Cerevel Therapeutics	1614245-70-3	"7H-Imidazo(4,5-C)pyridazine, 7-ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxy(1,1'-biphenyl)-3-yl)-"	Yes			Phase II	"Seizures, Epilepsy, Panic disorder, Anxiety disorders, Back pain, Generalised anxiety disorder"	C22-H21-F-N4-O3-S	GABA A receptor agonists	"Pfizer (Originator), Cerevel Therapeutics (Owner)"		PO			Dizziness	"N2 (Analgesics), N3A (Anti-Epileptics), N5 (Psycholeptics)"	"N02 (Analgesics), N03A (Antiepileptics), N05B (Anxiolytics)"	"CVL865, PF06372865, PF6372865"			14/03/2021	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"				no		no				Uric acid			https://adis.springer.com/drugs/800039009?userId=52029392&bpIds=3004037004&checksum=ee06a2a42539b57b619f110f5ff49e97c466ef96-1617045531073-1a7ba61eb116ed3f99b70c18214d85e5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024954	Esomeprazole/naproxen - Old API Wind-down/AstraZeneca		"Magnesium, bis(5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl-kappaO)-1H-benzimidazolato-kappaN1)-, trihydrate, (T-4)-/+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid"	No			Marketed	"Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Juvenile rheumatoid arthritis"	C34 H42 Mg N6 O9 S2 . C14 H14 O3	"Cyclooxygenase inhibitors, Prostaglandin synthase inhibitors, Proton pump inhibitors"	"AstraZeneca (Originator), Cincinnati Children's Hospital Medical Center (Originator), POZEN (Originator), Old API Wind-down Ltd (Owner), Grunenthal (Market Licensee), Miravo Healthcare (Market Licensee), Deerfield (Funder), University of Illinois at Chicago (Collaborator)"		PO			"Abdominal pain, Diarrhoea, Duodenitis, Dyspepsia, Erosive oesophagitis, Gastritis, Headache, Ligament injuries, Respiratory tract infections, Sinusitis"	"A2B2 (Acid pump inhibitors), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"A02B-C05 (Esomeprazole), M01 (Antiinflammatory and Antirheumatic Products), M01A-E02 (Naproxen), N02 (Analgesics)"	"esomeprazole magnesium trihydrate/naproxen, Naproxen/esomeprazole, naproxen/esomeprazole magnesium trihydrate, PN400, Vimovo"			14/03/2021	Rheumatic Disease			"Vimovo, Vimovo, Vimovo, Vimovo, Vimovo, Vimovo, Vimovo, Vimovo, Vimovo"	no		no						ER alpha	https://adis.springer.com/drugs/800024954?userId=52029392&bpIds=3004037004&checksum=a22f78663f82bbf118f3a4f0c1b4012ee62c5ad0-1617045531080-e1d74f085676ed492e18fcbad26a12c9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001708	Icatibant - Takeda	130308-48-4	"D-arginyl-L-arginyl-L-propyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinoline carbonyl-L-(2_,3a_, 7a_)-octahydro-1H-indole-2-carbonyl-L-arginine"	Yes			Marketed	"Hereditary angioedema, Liver cirrhosis, Capillary leak syndrome, Angioedema, Pancreatitis, Rhinitis, Musculoskeletal pain, Myocardial infarction, Arrhythmias"	C59 H89 N19 O13 S	Bradykinin B2 receptor antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner), Jerini (Licensee), Takeda (Licensee), Technical University Munich (Collaborator)"		"SC, unspecified, Intranasal, Intra-articular"			"Fatigue, Gastrointestinal disorders, Xerostomia"	"A5B (Hepatic Protectors, Lipotropics), A7E (Intestinal Anti-Inflammatory Agents), B6C (Other Haematological Agents), C1 (Cardiac Therapy), C1B (Anti-Arrhythmics), C4 (Cerebral and Peripheral Vasotherapeutics), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"A05B-A (Liver therapy), A07E (Intestinal Antiinflammatory Agents), B06A-C02 (Icatibant), C01 (Cardiac Therapy), C05 (Vasoprotectives), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"Firazyr, HOE140, Icatibant, Icatibant acetate, JE049, SHP667, TAK667"			14/03/2021	"Arrhythmias, Digestive System Disorders, Ischaemic Heart Disease, Liver Disorders, Obstructive Airways Disease, Pain, Vascular Disorders"	"Capillary leak syndrome (USA), Hereditary angioedema (USA), Hereditary angioedema (European Union), Hereditary angioedema (Japan)"		Firazyr	no		no		tPA		"ACE, Adenosine triphosphate, BNP, C1 Inhibitor, D-dimer, F2-isoprostanes, GLP-1, IL6, Norepinephrine, PAI-1, tPA"		"C1QA, C4, Renin, TNF-alpha"	https://adis.springer.com/drugs/800001708?userId=52029392&bpIds=3004037004&checksum=8ffa2b3b4a4510cab91bb8c9dd7c363617c2b5b5-1617045531085-e4e2e97c829e2eea1ce5f0b0170ab8aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022957	Olodanrigan - Novartis	1316755-16-4	"(S)-5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid"	Yes			Discontinued (II)	"Postherpetic neuralgia, Diabetic neuropathies, Neuropathic pain"	C32 H29 N O5	Angiotensin type 2 receptor antagonists	"Spinifex Pharmaceuticals (Originator), Novartis (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	EMA401			14/03/2021	Pain				no		no							https://adis.springer.com/drugs/800022957?userId=52029392&bpIds=3004037004&checksum=b30b7a8db0a4c01ec42561aadba15fad9766d8c7-1617045531089-450a09d1523f6a05eabf796fe5f25928badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029842	Fasinumab - Mitsubishi Tanabe Pharma/Regeneron/Teva	1190239-42-9	"Immunoglobulin, anti-(human nerve growth factor)(human REGN475 heavy chain), disulfide with human REGN475 _ chain, dimer"	Yes			Phase III	"Pain, Back pain"	C6406 H9896 N1700 O2026 S46	Nerve growth factor inhibitors	"Regeneron Pharmaceuticals (Originator), sanofi-aventis (Originator), Regeneron Pharmaceuticals (Owner), Mitsubishi Tanabe Pharma Corporation (Licensee), Teva Pharmaceutical Industries (Licensee)"		"SC, IV"			"Arthralgia, Headache, Injection site reactions, Musculoskeletal pain, Numbness, Oedema, Paraesthesia, Respiratory tract infections"	N2 (Analgesics)	N02 (Analgesics)	"MT5547, REGN 475, SAR 164877"			14/03/2021	Pain				yes	USA	no							https://adis.springer.com/drugs/800029842?userId=52029392&bpIds=3004037004&checksum=bc8cc702eee3fb72f9ee6bf0371c039c0927fd67-1617045531093-488c529316cab377ed7507d415a4b409badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023880	EVT 101			Yes			Phase II	Major depressive disorder		NR2B N-Methyl-D-Aspartate antagonists	"Roche (Originator), Roche (Owner), Evotec SE (Licensee), Janssen Pharmaceuticals (Sub-licensee)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7D (Anti-Alzheimer Products)"	"N02 (Analgesics), N06A (Antidepressants), N06D (Anti-Dementia Drugs)"	"ENS 101, EVT101"			14/03/2021	Affective Disorders				no		no							https://adis.springer.com/drugs/800023880?userId=52029392&bpIds=3004037004&checksum=bc076d8ff9fe821709a30fd45cbb7c317d580d21-1617045531094-d13ea3fcdd4a21e31e7ee4ec1e1a0b9bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000563	Terguride	37686-84-3	"1,1-Diethyl-3-(6-methylergolin-8_-yl)urea"	Yes			Marketed	"Hyperprolactinaemia, Schizophrenia, Pulmonary arterial hypertension, Fibromyalgia, Parkinson's disease, Fibrosis"	C20 H28 N4 O	"Dopamine D2 receptor agonists, Serotonin 2 receptor agonists"	"Bayer HealthCare Pharmaceuticals (Originator), Bayer HealthCare Pharmaceuticals (Owner), Bayer Yakuhin (Market Licensee), ErgoNex Pharma (Licensee), IVAX Pharmaceuticals s.r.o. (Licensee), Novartis (Licensee), Pfizer (Sub-licensee)"		"PO, unspecified"	renal	"Route of Elimination (renal), bioavailability oral (%) (20 (Elderly)), Cl (L/h) (71.4 (Adult)), Cl (L/h) (71.4 (Elderly)), Vd (L/kg) (.7 (Adult)), Vd (L/kg) (.7 (Elderly))"		"C2 (Antihypertensives), G2 (Other Gynaecologicals), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N5A (Antipsychotics), R7 (Other Respiratory System Products)"	"C02 (Antihypertensives), G02C (Other Gynecologicals), M01 (Antiinflammatory and Antirheumatic Products), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N04B-C (Dopamine agonists), N05A-X (Other antipsychotics), R07 (Other Respiratory System Products)"	"Dironyl, Dironyl maleate, Mysalfon, SH 406, Teluron, Transdihydrolisuride, VUFB 6638, ZK 31224"			14/03/2021	"Connective Tissue Disorders, Endocrine Disorders, Parkinson's Disease and Movement Disorders, Psychotic Disorders, Respiratory Tract Disorders, Rheumatic Disease"	"Pulmonary hypertension (USA), Pulmonary hypertension (European Union)"		"Mysalfon, Teluron"	no		no							https://adis.springer.com/drugs/800000563?userId=52029392&bpIds=3004037004&checksum=9cda1a7ecfa90e673c315a67db1b4a30f7c52c7c-1617045531097-b7a247d1c86b0fd726fa8783533c2207badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012067	Rotigotine transdermal - UCB	99755-59-6	"(_)-(S)-6-[Propyl[2-(2-thienyl)ethyl]amino]-5,6,7,8-tetrahydro-1-naphthalenol"	Yes			Marketed	"Parkinson's disease, Restless legs syndrome, Fibromyalgia"	C19 H25 N O S	Dopamine D2 receptor agonists	"Aderis Pharmaceuticals (Originator), UCB (Owner), Abbott Laboratories (Market Licensee), Andromaco (Market Licensee), Otsuka Pharmaceutical (Licensee), Lohmann Therapie-Systeme (Technology Provider)"		"Transdermal, Intranasal"			"Application site reactions, Back pain, Dizziness, Dyskinesias, Fatigue, Flu-like symptoms, Headache, Lightheadedness, Nasopharyngitis, Nausea, Skin disorders, Tremor, Vomiting"	"N2B (Non-Narcotics and Anti-Pyretics), N4A (Anti-Parkinson Drugs)"	"N02 (Analgesics), N04B-C09 (Rotigotine)"	"Leganto, N0437, N0923, Neupro, Neupro Patch, Nubrenza, Rotigotine PR2.1.1, Rotigotine PR2.2.1, SPM962"			14/03/2021	"Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease"			"Leganto, Leganto, Neupro, Neupro, Neupro, Neupro, Neupro, Neupro, Neupro, Neupro, Neupro Patch, Neupro Patch, Nubrenza"	no		no		L-Dopa		"ATPase inhibitory factor 1, Bilirubin, HCY, Hydrocortisone, L-Cysteine, L-Dopa, prenyl (decaprenyl) diphosphate synthase, subunit 2, Uric acid, VPS52, GARP complex subunit"		solute carrier family 25 member 5	https://adis.springer.com/drugs/800012067?userId=52029392&bpIds=3004037004&checksum=e22844ef512413b6ec1766e84f501d7efd325841-1617045531103-b693b398235419a84648e821471c9fe1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000711	Dexmedetomidine - Hospira/Orion/Baudax Bio	113775-47-6	"4-[1-(2,3-Dimethylphenyl)ethyl]-1<EM>H</EM>-imidazole"	Yes			Marketed	"Sedation, Pain, Cancer pain, Subarachnoid haemorrhage, Delirium, Postoperative pain"	C13 H16 N2	Alpha 2 adrenergic receptor agonists	"Orion (Originator), Orion (Owner), Baudax Bio (Licensee), Hospira (Licensee), Maruishi Pharmaceutical (Collaborator), Turku University Hospital (Collaborator)"		"IV, Intranasal, Sublingual, Transdermal"	renal	"Route of Elimination (renal), Cl (L/h) (34.65 (Adult)), protein binding (%) (95 (Adult)), T<sub>_beta</sub> (h) (2 (Adult)), T<sub>max</sub> (h) (.25 - .33 (Adult)), Vd (L/kg) (1.33 (Adult))"	"Atrial fibrillation, Bradycardia, Dizziness, Drowsiness, Epistaxis, Hypertension, Hypotension, Hypoxia, Nasal congestion, Nausea, Vomiting"	"N1A (Anaesthetics, General), N2 (Analgesics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers)"	"N01A (Anesthetics, General), N02 (Analgesics), N05B-X (Other anxiolytics), N05C (Hypnotics and Sedatives)"	"DA 9501, Dexdor, DEXIN, Dexmedetomidine hydrochloride, DEXSL, DEXTD, MPV1440, Precedex, Primadex"			14/03/2021	"Neurological Disorders, Pain, Psychotic Disorders"		Baudax Bio |  | Unspecified |  | 21 Nov 2019	"Dexdor, Precedex, Precedex, Precedex"	no		no		"acireductone dioxygenase 1, ephrin A5, KRAS, NRAS"	"troponin I, cardiac"	"3-Hydroxybutyric acid, absent in melanoma 2, Acetylcholinesterase, Acid ceramidase, acireductone dioxygenase 1, ACTH, Adenosine, BNP, C-peptide, CD38, CD3d, CD3e, CD3g, CD4, CD8a, Creatinine, CRP, Cystatin C, cytochrome P450 family 4 subfamily F member 3, Endocan, Endothelin 1, ephrin A5, GFAP, Haptoglobin, HMGB1, Homovanillic acid, Hydrocortisone, IFN-gamma, IL1 alpha, IL1 beta, IL10, IL13, IL17, IL18, IL4, IL5, IL6, IL8, immunoglobulin kappa variable 1-5, Insulin, KRAS, L-Lactic acid, NGAL, Norepinephrine, NRAS, NSE, Prolactin, Renin, S100B, sphingolipid transporter 1 (putative), thoracoabdominal syndrome, TNF-alpha, TNFRSF1A, troponin I, cardiac, UDP glucuronosyltransferase family 1 member A4, Uridine 5'-diphosphate, VEGF-A"	"Hydrocortisone, IL1 beta, IL10, IL6, IL8, NSE, S100B, TNF-alpha, troponin I, cardiac"	"flap structure-specific endonuclease 1, interleukin 33, myelin basic protein, pyridoxal phosphatase, Soluble transferrin receptor"	https://adis.springer.com/drugs/800000711?userId=52029392&bpIds=3004037004&checksum=c3e30f5fe1cf49f0b604d649d811e074174217d2-1617045531110-e53563b0502c647e6a87af4b9cdf62ffbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030583	AZD 2423						Discontinued (II)	"Neuropathic pain, Chronic obstructive pulmonary disease"		Chemokine inhibitors	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	AZD2423			14/03/2021	"Pain, Respiratory Tract Disorders"				no		no				"C-C motif chemokine receptor 2, CCL5, CD3d, CD3e, CD3g, CD45, IL1 beta, IL6, IL8, MCP1, SAA, secretoglobin, family 1A, member 1, Surfactant protein D, TNF-alpha"			https://adis.springer.com/drugs/800030583?userId=52029392&bpIds=3004037004&checksum=2a105d6cbbf0281a23ff15fc711b31cf3af62976-1617045531112-555af08b76813666c9fe0d4d4c695244badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049491	TRV 250			Yes			Phase II	"Migraine, CNS disorders, Parkinson's disease, Neuropathic pain"		Opioid delta receptor agonists	"Trevena (Originator), Trevena (Owner)"		"SC, PO, unspecified"				"N2 (Analgesics), N2C (Anti-Migraine Preparations), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"N02 (Analgesics), N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"	TRV250			12/03/2021	"Advances in the Treatment of Nausea and Migraine, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800049491?userId=52029392&bpIds=3004037004&checksum=393bc86e3a5e8fa8f4696b5bc1c02fec6f00181e-1617045531114-e91250e49c08136021dba8c7f39d42d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047282	Pirenzepine topical - WinSanTor	28797-61-7	"11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one"	No			Phase II	"Diabetic neuropathies, Neuropathic pain"	C19 H21 N5 O2	Muscarinic M1 receptor antagonists	"University of California, San Diego (Originator), University of Manitoba (Originator), University of California, San Diego (Owner), University of Manitoba (Owner), WinSanTor (Licensee), Canadian Institutes of Health Research (Funder), JDRF (Funder), National Institutes of Health (USA) (Funder)"		"Topical, Transdermal"				"A10X (Other Drugs Used in Diabetes), A2B (Antiulcerants), N2 (Analgesics)"	"A02B-X (Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)), A10X (Other Drugs Used in Diabetes), N02 (Analgesics)"	"Topical pirenzepine WinSanTor, WST 057, WST01, WST1, WST1/analgesic, WST57"			12/03/2021	"Diabetes, Pain"		WinSanTor |  | Phase I |  | 10 Aug 2016		no		no							https://adis.springer.com/drugs/800047282?userId=52029392&bpIds=3004037004&checksum=c36be39676b44ce537b1946cde226f0879e95ad3-1617045531115-289c9074bcf0314dfd1d026413c4192fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050861	Psilocybin - COMPASS Pathways	520-52-5	[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate	Yes			Phase II	"Somatoform disorders, Depressive disorders, Major depressive disorder, Bipolar depression"	C12 H17 N2 O4 P	"ATP-binding cassette transporter modulators, Serotonin 2 receptor agonists"	"COMPASS Pathways (Originator), COMPASS Pathways (Owner), Kings College London (Collaborator)"		"PO, unspecified"				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N05B (Anxiolytics), N06A-X (Other antidepressants)"	"COMP360, Psilocybine"			12/03/2021	"Affective Disorders, Anxiety Disorders"		COMPASS Pathways |  | Unspecified |  | 09 Mar 2021		no		no							https://adis.springer.com/drugs/800050861?userId=52029392&bpIds=3004037004&checksum=a5d3439405440e50cf05f26a6b150d588f9f77f6-1617045531117-66bb924817bfc4e0f07b11c428978ccebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045618	Dronabinol/palmitoylethanolamide - SciSparc		"(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol/ N-(2-hydroxyethyl)hexadecanamide"	No			Phase II	"Gilles de la Tourette's syndrome, Sleep apnoea syndrome, Agitation, Back pain"	C21H30O2.C18H37NO2	"Cannabinoid receptor agonists, Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists, G-protein-coupled receptor 55 modulators, Peroxisome proliferator-activated receptor alpha agonists"	"Therapix Biosciences (Originator), SciSparc (Owner), Assuta Medical Center (Collaborator), Catalent Pharma Solutions (Collaborator), Yale University (Collaborator)"		PO				"N (Nervous System), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"N (Nervous System), N02 (Analgesics), N02B (Other Analgesics and Antipyretics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"	"SCI110, THX OSA01, THX RS01, THX110, THXTS01"			11/03/2021	"Anxiety Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800045618?userId=52029392&bpIds=3004037004&checksum=91bbe1a125edd70c6f92634a61c82d8cf8d1ee32-1617045531118-f57f9671daff7b40c7be688f2061da91badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043201	Zelminemab - Amgen/Novartis	2225850-33-7		Yes			Phase II	Migraine		Pituitary adenylate cyclase activating polypeptide type I receptor antagonists	"Amgen (Originator), Amgen (Owner), Novartis (Licensee)"		SC				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	AMG301			11/03/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800043201?userId=52029392&bpIds=3004037004&checksum=27d5e16373c8ec631f2c0e94384d9011ff445230-1617045531119-dd95054096afd4f5909649aab788f311badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035617	Oliceridine - Trevena	1401028-24-7	N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine	Yes			Marketed	Acute pain	C22 H30 N2 O2 S	"Opioid mu receptor agonists, Opioid receptor agonists"	"Trevena (Originator), Trevena (Owner), Jiangsu Nhwa Pharmaceutical (Licensee), Pharmbio Korea (Licensee)"		IV			"Dizziness, Flushing, Headache, Nausea, Pruritus, Somnolence, Vomiting"	N2 (Analgesics)	N02 (Analgesics)	"OLINVO, OLINVYK, TRV 130A, TRV130"			11/03/2021	Pain		Trevena |  | Unspecified |  (Excluding USA) | 31 Dec 2019	"OLINVO, OLINVYK"	no		no							https://adis.springer.com/drugs/800035617?userId=52029392&bpIds=3004037004&checksum=8ba730766c22c2d07ac43bc11621ea81f7c1ed44-1617045531121-b302e1391cb006254614f315ba892727badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003982	Ibudilast - MediciNova	50847-11-5	"1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-"	Yes			Marketed	"Allergic conjunctivitis, Cerebrovascular disorders, Asthma, Spinal cord disorders, Amyotrophic lateral sclerosis, Alcoholism, Multiple sclerosis, Substance-related disorders, Opioid-related disorders, SARS-CoV-2 acute respiratory disease, Glioblastoma, Chemotherapy-induced damage, Acute lung injury, Neuropathic pain, Headache, Brain injuries, Globoid cell leukodystrophy, Diabetic retinopathy, Diabetic neuropathies"	C14 H18 N2 O	"Leukotriene receptor antagonists, Phosphodiesterase 10A inhibitors, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Macrophage migration inhibitory factor inhibitors, Astrocyte inhibitors, Cytokine modulators, Glial cell modulators, Nitric oxide synthase inhibitors, Phosphodiesterase 11A inhibitors, Toll-like receptor 4 antagonists, Type 3 cyclic nucleotide phosphodiesterase inhibitors"	"Kyorin Pharmaceutical (Originator), Kyorin Pharmaceutical (Owner), Banyu (Market Licensee), Handok Inc (Market Licensee), Kuhnil Pharmaceutical Company (Market Licensee), Senju Pharmaceutical (Market Licensee), MediciNova (Licensee), Australasian Gastro-Intestinal Trials Group (Funder), Biomedical Advanced Research and Development Authority (Funder), Concord Cancer Centre (Funder), National Institute for Health Research (Funder), National Institute of Drug Abuse (Funder), National Institute on Alcohol Abuse and Alcoholism (Funder), University of Sydney (Funder), Cleveland Clinic (Collaborator), Department of Veterans Affairs (Collaborator), Harvard Medical School (Collaborator), Massachusetts General Hospital (Collaborator), National Institute of Neurological Disorders and Stroke (Collaborator), National Multiple Sclerosis Society (Collaborator), Oregon Health & Science University (Collaborator), Taisho Pharmaceutical (Collaborator), University of Adelaide (Collaborator), University of California (Collaborator), University of California at Los Angeles (Collaborator), University of Cambridge (Collaborator), University of Colorado at Boulder (Collaborator), University of New South Wales (Collaborator), University of Sydney (Collaborator)"		"Ophthalmic, PO, unspecified, Parenteral"			"Dizziness, Flushing, Heartburn, Nausea"	"A10X (Other Drugs Used in Diabetes), C4A (Cerebral and Peripheral Vasotherapeutics), J1 (Systemic Antibacterials), L1 (Antineoplastics), N2 (Analgesics), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs), R3H (PDE4 Inhibitors for Asthma/COPD), R3J2 (Antileukotriene anti-asthmatics, systemic), R7 (Other Respiratory System Products), S1 (Ophthalmologicals), S1X (Other Ophthalmologicals), V3 (All Other Therapeutic Products)"	"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), J01 (Antibacterials for Systemic Use), L01 (Antineoplastic Agents), N02 (Analgesics), N07B (Drugs Used In Addictive Disorders), N07B-C (Drugs used in opioid dependence), N07X (Other Nervous System Drugs), R03D-C04 (Ibudilast), R07A (Other Respiratory System Products), S01 (Ophthalmologicals), S03D (Other Ophthalmological and Otological Preparations), V03 (All Other Therapeutic Products)"	"AV411, Eyevinal, Ibinal, KC404, Ketas, MN166, Pinatos"			11/03/2021	"Advances in the Treatment of Nausea and Migraine, Cancer, Diabetes, Drug Withdrawal, Eye Disorders, Neurological Disorders, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Vascular Disorders, Viral Infections"	"Glioblastoma (USA), Amyotrophic lateral sclerosis (European Union), Amyotrophic lateral sclerosis (USA), Globoid cell leukodystrophy (USA)"	"MediciNova | Alcoholism, Neurological disorders, Opioid-related disorders, Substance-related disorders | Unspecified |  | 12 Feb 2018"	"Eyevinal, Ketas, Ketas, Ketas, Ketas, Pinatos"	yes	USA	no				"GFAP, IFN-gamma, IL10, IL6, TNF-alpha"			https://adis.springer.com/drugs/800003982?userId=52029392&bpIds=3004037004&checksum=acba26ef77488aebb50a37ef62d8fbcf4b2ddc9e-1617045531126-96e4a96d6031ed5548d882326849501abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035022	Tivanisiran - Sylentis			No			Phase III	"Dry eyes, Ocular pain"		"RNA interference, TRPV1 receptor antagonists"	"Sylentis (Originator), Sylentis (Owner)"		Ophthalmic				"N2 (Analgesics), S1X2 (Other Ophthalmologicals, Topical)"	"N02 (Analgesics), S01X-A (Other ophthalmologicals)"	"SYL1001, SYL1001 DP"			10/03/2021	Eye Disorders				no		no							https://adis.springer.com/drugs/800035022?userId=52029392&bpIds=3004037004&checksum=7574b3cbe20270fdb21a3b6c1632af15d8044dea-1617045531127-b280868065841bd14e618bdeaec4fd80badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042150	Zoledronic acid - Axsome Therapeutics	118072-93-8	"1-Hydroxy-2-(2-imidazolyl)ethyl-1,1-bis-phosphonic acid"	No			Phase II	"Back pain, Pain"	C5 H10 N2 O7 P2	"Bone resorption factor inhibitors, Geranyltranstransferase inhibitors, Osteoclast inhibitors"	"ANTECIP BIOVENTURES (Originator), ANTECIP BIOVENTURES (Owner), Axsome Therapeutics (Licensee), Department of Veterans Affairs (Collaborator), Stanford University School of Medicine (Collaborator)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	"M05B-A08 (Zoledronic acid), N02B-G (Other analgesics and antipyretics)"	"AXS 02, Disodium (1Hydroxy2(1HImidazol1yl)1 Phosphonoethyl)Phosphonic Acid Axsome Therapeutics, Disodium zoledronate tetrahydrate Axsome Therapeutics, Oral zoledronate"			09/03/2021	"Musculoskeletal Disorders, Pain, Rheumatic Disease"	"Pain (European Union), Pain (USA)"			yes	USA	no							https://adis.springer.com/drugs/800042150?userId=52029392&bpIds=3004037004&checksum=53eefb70489a5f6d03798dd1a073f8d64f0c77d0-1617045531128-eb76465508de4865fb2ccc29f1742e02badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042445	ONO 4474			Yes			Phase II	Pain		Tropomyosin-related kinase antagonists	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	ONO4474			09/03/2021	Pain				no		no						NGF	https://adis.springer.com/drugs/800042445?userId=52029392&bpIds=3004037004&checksum=f0f894efed96861228f239ea9d46848e946be481-1617045531129-3fec090b4c3c7162a8508a6e38195dcabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053197	Zavegepant - Biohaven Pharmaceuticals	1337918-83-8	N-[(2R)-3-(7-Methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-<EM>1H</EM>-quinolin-3-yl)piperidine-1-carboxamide	Yes			Phase III	"Migraine, COVID-19 respiratory infection"	C36 H46 N8 O3	Calcitonin gene-related peptide receptor antagonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Biohaven Pharmaceuticals (Licensee), BioShin (Sub-licensee), Biohaven Pharmaceutical Holding Company (Collaborator)"		"Intranasal, PO"				"J5 (Antivirals for Systemic Use), N2C (Anti-Migraine Preparations)"	"J05A-X (Other antivirals), N02C (Antimigraine Preparations)"	"BHV 3500, BMS742413, BMS74241303, Vazegepant, Zavegepant hydrochloride"			09/03/2021	"Advances in the Treatment of Nausea and Migraine, Viral Infections"				no		no							https://adis.springer.com/drugs/800053197?userId=52029392&bpIds=3004037004&checksum=81808afffb4999f22742593106e51af58b1de008-1617045531131-8754aa5f70b582e37d92ebaa6c956011badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042021	Ibuprofen arginine/tramadol - Farmalider		"(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-[4-(2-methylpropyl)phenyl]propanoic acid / (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			No development reported (III)	Pain	C19 H32 N4 O4 . C16 H25 N O2	"Cyclooxygenase inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Farmalider (Originator), Farmalider (Owner)"		"IV, PO"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	Tramadol/ibuprofen arginine			09/03/2021	Pain				no		no							https://adis.springer.com/drugs/800042021?userId=52029392&bpIds=3004037004&checksum=5aa766f9a6239ec17c87b212f42f563ea9042630-1617045531132-8e63c40eb68aa5d2f92974cee85e85ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026876	Levomilnacipran - AbbVie/Pierre Fabre	175131-60-9	"(1<EM>S</EM>,2<EM>R</EM>)-2-(Aminomethyl)-<EM>N,N</EM>-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride"	Yes			Marketed	"Major depressive disorder, Stroke, Pain"	C15 H22 N2 O . HCl	"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Pierre Fabre (Originator), Pierre Fabre (Owner), AbbVie (Licensee)"		PO			"Constipation, Dizziness, Headache, Hyperhidrosis, Nausea, Tachycardia, Xerostomia"	"N2 (Analgesics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs)"	"N02 (Analgesics), N05B (Anxiolytics), N06A-X (Other antidepressants), N07 (Other Nervous System Drugs)"	"1S 2Rmilnacipran, F 2695, F2695 SR, Fetzima, Levomilnacipran ER, Levomilnacipran SR"			09/03/2021	"Affective Disorders, Neurological Disorders, Pain"			Fetzima	no		no				NAD			https://adis.springer.com/drugs/800026876?userId=52029392&bpIds=3004037004&checksum=b31d37f45ae4e7b49c746cf4491b2e518b78817f-1617045531135-ef10b5fe59bd3b24bf829a96e0718091badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062675	EP 105			No			Preclinical	Postoperative pain		Undefined mechanism	"Eupraxia Pharmaceuticals (Originator), Eupraxia Pharmaceuticals (Owner)"		Topical				"N1 (Anaesthetics), N2 (Analgesics)"	"N01 (Anesthetics), N02 (Analgesics)"	EP105			08/03/2021	Pain		Eupraxia Pharmaceuticals | Perioperative pain | Unspecified |  | 05 Mar 2021		no		no							https://adis.springer.com/drugs/800062675?userId=52029392&bpIds=3004037004&checksum=78ab0c4a262571926f09469c8381b08b7c8f38af-1617045531136-b9acc421a45f98745500a89e4b13a20ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061671	ETX 018810			Yes			Phase II	"Sciatica, Neuropathic pain"		Undefined mechanism	"Eliem Therapeutics (Originator), Eliem Therapeutics (Owner)"		"PO, unspecified"				N2 (Analgesics)	N02 (Analgesics)	ETX018810			08/03/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800061671?userId=52029392&bpIds=3004037004&checksum=ba21c1795367e1018ab1d916079bb20241d3b6bf-1617045531136-00567fd2e43f530e12f8322456fa7efbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051550	Research programme: cannabinoid/naproxen conjugate - Claritas Pharmaceuticals			No			Research	Acute pain		"Cannabinoid receptor agonists, Dinoprostone antagonists"	"Beetlebung Pharma (Originator), Beetlebung Pharma (Owner), Claritas Pharmaceuticals (Licensee)"		PO				N2 (Analgesics)	"M01A-E02 (Naproxen), N02 (Analgesics)"				08/03/2021	Pain				no		no							https://adis.springer.com/drugs/800051550?userId=52029392&bpIds=3004037004&checksum=6f7db0627d0d80f508327dded787aae816200352-1617045531137-7c8cc5a260d7c87f37814df0e27760b6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034373	AAT 076			Yes			Phase I	"Neuropathic pain, Acute pain, Postoperative pain"		Cyclo-oxygenase 2 inhibitors	"RaQualia Pharma (Originator), AskAt (Owner), HaiHe Biopharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"AAT076, RMX 1001, RQ00317076"			08/03/2021	Pain		AskAt |  | Unspecified |  | 03 Mar 2021		no		no							https://adis.springer.com/drugs/800034373?userId=52029392&bpIds=3004037004&checksum=77fd0d50421e7f2c8a903ce69fe9a0070ba0f802-1617045531138-1bd998a7696eb75f32ff9fc34bf30763badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029996	Grapiprant - AskAt	415903-37-6	"N-{2-[4-(2-Ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}-N'-[(4-methylphenyl)sulfonyl]urea"	Yes			Phase III	"Cancer pain, Neuropathic pain, Pain, Non-small cell lung cancer, Colorectal cancer, Cancer, Hypersensitivity, Inflammation"	C26 H29 N5 O3 S	Prostaglandin E EP4 receptor antagonists	"Pfizer (Originator), Pfizer (Owner), AskAt (Licensee), HaiHe Biopharma (Sub-licensee), Ikena Oncology (Sub-licensee), Ningbo NewBay Medical Technology (Sub-licensee), Atlas Venture (Funder), OrbiMed (Funder), Merck Sharp & Dohme (Collaborator)"		PO				"L1 (Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"L01 (Antineoplastic Agents), L04 (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"423, AAT007, ARY 007, CJ023, CJ023423, CJ23423, IK 007, MR10A7, RMX1002, RQ00000007, RQ7"			08/03/2021	"Cancer, Immunological Disorders, Inflammation, Pain"		AskAt |  | Unspecified |  | 04 Mar 2021		no		no							https://adis.springer.com/drugs/800029996?userId=52029392&bpIds=3004037004&checksum=affa4d393337b5dea1192b3640590ca4e3bd31f2-1617045531140-a953f4db37330a38cd289babfc484ec0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026474	Ampreloxetine - Theravance Biopharma	1227056-84-9	"4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine"	Yes			Phase III	"Orthostatic hypotension, Fibromyalgia, Attention-deficit hyperactivity disorder"	C18 H18 F3 N O	"Adrenergic uptake inhibitors, Central nervous system stimulants, Serotonin uptake inhibitors"	"Theravance (Originator), Theravance Biopharma (Owner)"		PO			"Constipation, Dizziness, Headache, Insomnia, Nausea"	"C1C2 (Cardiac dopaminergic agents), N2 (Analgesics), N6D (Nootropics)"	"C01C-A (Adrenergic and dopaminergic agents), N02 (Analgesics), N06B (Psychostimulants, agents used for ADHD and nootropics)"	"Ampreloxetine, TD9855"			08/03/2021	"Affective Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800026474?userId=52029392&bpIds=3004037004&checksum=5569f9ecdd985abbdb27d2ec566e24eb729c23dd-1617045531141-85a5a6e500e1004262fa992b361804d6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041025	Desmetramadol - Syntrix Biosystems	73986-53-5	3-(2-((dimethylamino)methyl)-1-hydroxycyclohexyl)phenol	No			Phase II	Pain	C15 H23 N O2	"Adrenergic uptake inhibitors, Opioid mu receptor agonists"	"Syntrix Biosystems (Originator), Syntrix Biosystems (Owner), National Institute of Drug Abuse (Collaborator)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	"Odemethyltramadol, Odesmethyltramadol, ODMT, ODSMT, Omnitram"			05/03/2021	Pain				no		no							https://adis.springer.com/drugs/800041025?userId=52029392&bpIds=3004037004&checksum=fb1bfd3ce0139ea92bd11c9c720263d9229144f1-1617045531142-bffcf8f192593a7cf5a5668344757e16badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062530	SHR 8554			Yes			Phase II	Pain		Opioid mu receptor modulators	"Jiangsu Hengrui Medicine Co. (Originator), Jiangsu Hengrui Medicine Co. (Owner)"		IV				N2A (Narcotics)	N02A (Opioids)	SHR8554			05/03/2021	Pain				no		no							https://adis.springer.com/drugs/800062530?userId=52029392&bpIds=3004037004&checksum=bc9874130ee4f5b2dd51e410b2557dfd96376ef2-1617045531143-ffef7c01b5bce3a9b0708977331a3c6ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035166	CYT 1010			No			Phase II	"Acute pain, Pain"		Opioid mu receptor agonists	"Tulane University (Originator), Tulane University (Owner), Cytogel (Licensee)"		"IV, PO"				N2 (Analgesics)	N02A (Opioids)	Cyt1010			05/03/2021	Pain		Cytogel | Pain | Clinical Phase Unknown |  | 14 Nov 2014		no		no							https://adis.springer.com/drugs/800035166?userId=52029392&bpIds=3004037004&checksum=3cc401e1417ea6f107c733a49b9f9c032dbd7eb6-1617045531144-0eae18d25568ce21597381f7d8449ba4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062627	AAT 730			Yes			Preclinical	"Pain, Irritable bowel syndrome, Neuropathic pain"		Cannabinoid receptor CB2 agonists	"AskAt (Originator), AskAt (Owner), Oxford Cannabinoid Technologies (Collaborator)"		unspecified				"A16A (Other Alimentary Tract and Metabolism Products), N2 (Analgesics)"	"A16A-X (Various alimentary tract and metabolism products), N02 (Analgesics)"	AAT730			05/03/2021	"Digestive System Disorders, Pain"		AskAt |  | Unspecified | World (Excluding Japan) | 04 Mar 2021		no		no							https://adis.springer.com/drugs/800062627?userId=52029392&bpIds=3004037004&checksum=6efbdb1f9c3b8c9ba7eefe0e39a961d11b431741-1617045531144-c8d4705d8327ca673e7fcc9a1868ea22badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033861	V 158866			Yes			Preclinical	"CNS disorders, Neuropathic pain, Pain"		Fatty acid amide hydrolase inhibitors	"Vernalis (Originator), Vernalis (Owner), Neuritek Therapeutics (Licensee)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N5 (Psycholeptics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N05B-X (Other anxiolytics), N07X (Other Nervous System Drugs)"	V158866			05/03/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800033861?userId=52029392&bpIds=3004037004&checksum=52272516a3c37e9accdb8340300ae0c6be9fcade-1617045531145-f0846d1bea99c9aa854b100352352d2cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039164	Celecoxib/tramadol - ESTEVE		"4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide/(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	Yes			Preregistration	"Acute pain, Dental pain, Pain"	C17 H14 F3 N3 O2 S . C16 H25 N O2	"Adrenergic uptake inhibitors, Cyclo-oxygenase 2 inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"ESTEVE (Originator), ESTEVE (Owner), Mundipharma GmbH (Development Licensee), Purdue Pharma (Collaborator)"		PO			"Dizziness, Nausea, Vomiting"	"N2 (Analgesics), N2A (Narcotics)"	"M01A-H01 (Celecoxib), N02A-X52 (Tramadol, combinations), N02B (Other Analgesics and Antipyretics)"	"E58425, MR308, Tramadol/Celecoxib"			04/03/2021	Pain				no		no							https://adis.springer.com/drugs/800039164?userId=52029392&bpIds=3004037004&checksum=0f735f78e97237afcb40e67c579ef0d280b01907-1617045531147-4f904d3f294314666f095c4c72659737badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039582	Nabilone controlled release - AOP Orphan Pharmaceuticals	51022-71-0	"9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimtheylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-,(6aR,10aR)-rel-"	No			Phase III	"Parkinson's disease, Pain"	C24 H36 O3	Cannabinoid receptor agonists	"AOP Orphan Pharmaceuticals AG (Originator), AOP Orphan Pharmaceuticals AG (Owner), Innsbruck Medical University (Collaborator), Orthopadisches Spital Speising (Collaborator)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N4A (Anti-Parkinson Drugs)"	"N02B-G (Other analgesics and antipyretics), N04 (Anti-Parkinson Drugs)"	Nabilone FDT			04/03/2021	"Drug Delivery Systems, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800039582?userId=52029392&bpIds=3004037004&checksum=e6189028b4aa000c2623dcad3d1fc0992d5c4ed6-1617045531148-1bd8917da12e846eed36268a82053d05badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037508	Research programme: pain therapeutics - Interprotein Corporation/RaQualia Pharma			Yes			Research	Pain		Protein-protein interaction inhibitors	"Interprotein Corporation (Originator), RaQualia Pharma (Originator), Interprotein Corporation (Owner), RaQualia Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"PPI inhibitors Interprotein/RaQualia Pharma, Proteinprotein interaction inhibitors Interprotein/RaQualia Pharma"			04/03/2021	Pain				no		no							https://adis.springer.com/drugs/800037508?userId=52029392&bpIds=3004037004&checksum=68f4b7e091bb07edc80c051948fe28b8971c894d-1617045531149-993d5c726f676851141e7341c6bac5b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062100	AK 1780			Yes			Phase I	Neuropathic pain		Purinergic P2X7 receptor antagonists	"Asahi Kasei Pharma Corp (Originator), RaQualia Pharma (Originator), Asahi Kasei Pharma Corp (Owner), RaQualia Pharma (Owner), Eli Lilly and Company (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"AK1780, AKP23494954, RQ00466479"			04/03/2021	Pain				no		no							https://adis.springer.com/drugs/800062100?userId=52029392&bpIds=3004037004&checksum=a331db4d74e5009d54e7bc782c6ee9bc9ce96706-1617045531150-75f35a75f5e414b82c058f40fe3da757badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062670	Research programme: psychedelic microneedle patch - PharmaTher			No			Preclinical	"Neuromuscular disorders, Psychiatric disorders, Neurological disorders, Pain"		Undefined mechanism	"PharmaTher (Originator), PharmaTher (Owner), University of California at Los Angeles (Technology Provider)"		Transdermal				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02 (Analgesics)"				04/03/2021	"Affective Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800062670?userId=52029392&bpIds=3004037004&checksum=1bc1c99ca0a08746d0f631e3f4152eaffa034e5c-1617045531151-9c3b756f3b4ed48304ec9889323851e2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050633	Vocacapsaicin - Concentric Analgesics	1931116-86-7	"1-Piperidinecarboxylic acid, 2-((methylamino)methyl)-,2-methoxy-4-((((6E)-8-methyl-1-oxo-6-nonen-1-yl)amino)methyl)phenyl ester"	Yes			Phase II	Postoperative pain	C26 H41 N3 O4	TRPV1 receptor agonists	"Concentric Analgesics (Originator), Concentric Analgesics (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	CA008			04/03/2021	Pain				yes	USA	no							https://adis.springer.com/drugs/800050633?userId=52029392&bpIds=3004037004&checksum=b7af73d221733024a906f137d84ac80e8f1ea2c5-1617045531152-4ff24b4cd0cfcd90b3b579d42844b86bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039670	Olorinab - Arena Pharmaceuticals	1268881-20-4	"1H-Cyclopropa(4,5)cyclopenta(1,2-c)pyrazole-3-carboxamide, 4,4a,5,5a-tetrahydro-N-((1S)-1-(hydroxymethyl)-2,2-dimethylpropyl)-1-(4-oxido-2-pyrazinyl)-, (4aS,5aS)-"	Yes			Phase II	Irritable bowel syndrome	C18 H23 N5 O3	Cannabinoid receptor CB2 agonists	"Arena Pharmaceuticals (Originator), Arena Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	APD371			04/03/2021	Digestive System Disorders				no		no				"Calprotectin, CRP"			https://adis.springer.com/drugs/800039670?userId=52029392&bpIds=3004037004&checksum=642a7e1b13bdb88be69962e88aa1c73cfbdb1d04-1617045531152-c0f4edf451537352625dd4c7a7cd5f0dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038956	Dihydroergotamine mesilate intranasal - Satsuma Pharmaceuticals	6190-39-2	"Ergotamine, 9,10-dihydro-, monomethanesulfonate"	No			Phase III	Migraine	C33 H37 N5 O5.C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Shin Nippon Biomedical Laboratories (Originator), Satsuma Pharmaceuticals (Owner), Shin Nippon Biomedical Laboratories (Technology Provider)"		Intranasal	biliary	Route of Elimination (biliary)		N2C9 (All other anti-migraine preparations)	N02C-A01 (Dihydroergotamine)	"Dihydroergotamine mesilate Satsuma Pharmaceuticals, Dihydroergotamine mesylate Satsuma Pharmaceuticals, STS101, TO2070"			03/03/2021	Drug Delivery Systems				no		no							https://adis.springer.com/drugs/800038956?userId=52029392&bpIds=3004037004&checksum=77b2c25c1ca7d6781567714a38dbbbab06fdb619-1617045531153-15401ef2d20d87ba712b0eecfef41ee3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051571	Liquid filled aspirin capsule - PLx Pharma	50-78-2	Acetylsalicylic acid	No			Marketed	"Cardiovascular disorders, Pain"	C9 H8 O4	"Cyclooxygenase inhibitors, Nitric oxide stimulants, Platelet aggregation inhibitors"	"PLx Pharma (Originator), PLx Pharma (Owner), Park West Asset Management (Funder)"		PO				"B1C (Platelet Aggregation Inhibitors), N2B (Non-Narcotics and Anti-Pyretics)"	"B01A-C06 (Acetylsalicylic acid), N02B (Other Analgesics and Antipyretics)"	"Aspertec, Aspertec 325 mg, PL2200 Aspirin 325 mg, PLASA 325mg, PLASA 650mg, VAZALORE, Vazalore 325mg, Vazalore 81mg"			03/03/2021	"Pain, Vascular Disorders"		PLx Pharma |  | Unspecified |  | 20 Aug 2020	"Aspertec, VAZALORE"	no		no							https://adis.springer.com/drugs/800051571?userId=52029392&bpIds=3004037004&checksum=ba71fe2de72f0d3b3ea721a5779147050f4e6dcd-1617045531155-57e4dcbd81a3a86cabce4060325b4a04badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025125	Funapide - Flexion Therapeutics	1259933-16-8	"(3'S)-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}-2H,6H-spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one"	Yes			Phase II	"Postherpetic neuralgia, Neuropathic pain, Postoperative pain, Musculoskeletal pain, Erythromelalgia, Dental pain, Pain"	C22 H14 F3 N O5	Nav1.7 voltage-gated sodium channel inhibitors	"Xenon Pharmaceuticals (Originator), Flexion Therapeutics (Owner)"		"Topical, Parenteral, PO"			"Arthralgia, Nasopharyngitis, Respiratory tract infections, Urinary tract infections"	N2 (Analgesics)	N02 (Analgesics)	"FX301, TV45070, XEN 402, XPF 001, XPF002"			03/03/2021	"Pain, Rheumatic Disease"	Erythromelalgia (USA)			yes	USA	no							https://adis.springer.com/drugs/800025125?userId=52029392&bpIds=3004037004&checksum=2fb317abb337c3995c0ee5b76e10b5432668d989-1617045531156-58fa4bc5bbd3d65257493329d048b453badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056508	LY 3556050			Yes			Phase II	Pain		Somatostatin receptor subtype 4 agonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	LY3556050			02/03/2021	Pain				no		no							https://adis.springer.com/drugs/800056508?userId=52029392&bpIds=3004037004&checksum=71fae223ed0d2a81d10e30dda52abd5824ba19aa-1617045531157-4a1c974c5d10c7d38c2caef8bcc5e05dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028218	Difelikefalin - Cara Therapeutics	1024828-77-0	4-amino-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid	Yes			Preregistration	"Pruritus, Postoperative pain, Pain, Renal failure"	C36 H53 N7 O6	Opioid kappa receptor agonists	"Ferring Pharmaceuticals (Originator), Ferring Pharmaceuticals (Owner), Vifor Pharma (Market Licensee), Cara Therapeutics (Licensee), Chong Kun Dang (Sub-licensee), Maruishi Pharmaceutical (Sub-licensee), Vifor Fresenius Medical Care Renal Pharma (Sub-licensee), Enteris BioPharma (Technology Provider), Kissei Pharmaceutical (Collaborator)"		"IV, PO"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), G4 (Urologicals), N2A (Narcotics)"	"D04A-X (Other antipruritics), G04 (Urologicals), N02A (Opioids)"	"CKD943, CR 845, FE 202845, KORSUVA, MR13A9"			02/03/2021	"Genitourinary Disorders, Pain, Skin Disorders"		"Cara Therapeutics | Pain, Postoperative pain | Unspecified |  | 15 Mar 2018"	KORSUVA	no		no							https://adis.springer.com/drugs/800028218?userId=52029392&bpIds=3004037004&checksum=c5f6481b15e38b2711e643df8d6a981704197b1a-1617045531160-4751b1ffa0b7e370f536659ee243f743badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035384	GRT 6010			Yes			Discontinued (II)	"Neuropathic pain, Pain"		Nociceptin receptor agonists	"Grunenthal (Originator), Grunenthal (Owner)"		"PO, Intravesicular"				"G2 (Other Gynaecologicals), N2 (Analgesics)"	"G02 (Other Gynecologicals), N02 (Analgesics)"	GRT6010			02/03/2021	Pain				no		no				flap structure-specific endonuclease 1			https://adis.springer.com/drugs/800035384?userId=52029392&bpIds=3004037004&checksum=a096e2837f9892a7fe42794be3ac4e68df3ad649-1617045531161-763bf12fea9928d0134fa0170c0d9994badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062545	IW 3300			Yes			Preclinical	"Interstitial cystitis, Endometriosis"		Guanylate cyclase C agonists	"Ironwood Pharmaceuticals (Originator), Ironwood Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IW3300			01/03/2021	"Genitourinary Disorders, Women's Health"				no		no							https://adis.springer.com/drugs/800062545?userId=52029392&bpIds=3004037004&checksum=71f678e4c855278163add6e49fbe4575b4abf999-1617045531162-1674a9dc52271726a326ab2414f12aefbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024111	Research programme: allosteric modulators - Addex Therapeutics			Yes			Preclinical	"Neurodegenerative disorders, Parkinson's disease, Substance-related disorders, Charcot-Marie-Tooth disease, Post-traumatic stress disorders, Cognition disorders, Major depressive disorder, Polycystic ovary syndrome, Amyotrophic lateral sclerosis, Urinary incontinence, Alzheimer's disease, Fragile X syndrome, Pain, Endometriosis, Autistic disorder, Visceral pain, Anxiety disorders, Huntington's disease, Prostate cancer, Osteoporosis, Pregnancy, Gastro-oesophageal reflux, Sleep disorders, Psoriasis, Rheumatoid arthritis, Osteoarthritis, Inflammatory bowel diseases, Gout"		"GABA B receptor agonists, TrkB receptor agonists, Metabotropic glutamate receptor 7 modulators, Metabotropic glutamate receptor modulators, TrkB receptor modulators, Chorionic gonadotropin modulators, Follicle stimulating hormone modulators, Luteinising hormone modulators, Metabotropic glutamate receptor 2 modulators, Tumour necrosis factor receptor modulators, Ovarian follicle modulators, Orexin receptor type 2 modulators, Adenosine A2 receptor modulators, Interleukin 2 receptor modulators"	"Addex Pharmaceuticals (Originator), Addex Therapeutics (Owner), Indivior (Licensee), Enamine (Technology Provider), Swiss Commission for Technology and Innovation (Funder), The Michael J. Fox Foundation for Parkinson's Research (Funder), Centre Hospitalier Universitaire Vaudois (Collaborator), Charcot-Marie-Tooth Association (Collaborator), Ecole Polytechnique Federale de Lausanne. (Collaborator), Indivior (Collaborator), National Institute of Diabetes and Digestive and Kidney Diseases (Collaborator), National Institute of Drug Abuse (Collaborator), National Institute of Neurological Disorders and Stroke (Collaborator), National Institute on Alcohol Abuse and Alcoholism (Collaborator), University of Geneva (Collaborator), University of Lausanne (Collaborator), Viva Biotech (Collaborator)"		"PO, unspecified"				"A10 (Drugs Used in Diabetes), A3F (Gastroprokinetics), A7E (Intestinal Anti-Inflammatory Agents), D5B (Systemic Antipsoriasis Products), G2X9 (Other gynaecologicals), G3A (Hormonal Contraceptives, Systemic), G3G (Gonadotrophins, Including Other Ovulation Stimulants), G4D4 (Urinary incontinence products), L1X9 (All other antineoplastics), M1A (Anti-Rheumatics, Non-Steroidal), M3B (Muscle Relaxants, Centrally Acting), M4A (Anti-Gout Preparations), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7D9 (All other anti-Alzheimer products), N7E (Drugs Used In Alcohol Dependence), N7X (All other CNS drugs)"	"A03A (Drugs for Functional Bowel Disorders), A03F (Propulsives), A10A (Insulins and Analogues), D05B (Antipsoriatics for Systemic Use), G02C-X (Other gynecologicals), G03A (Hormonal Contraceptives for Systemic Use), G03G (Gonadotrophins and Other Ovulation Stimulants), G04 (Urologicals), L01X-X (Other antineoplastic agents), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), M03B (Muscle Relaxants, Centrally Acting Agents), M04A-X (Other antigout preparations), M05 (Drugs for Treatment of Bone Diseases), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05B (Anxiolytics), N05B-X (Other anxiolytics), N05C-M (Other hypnotics and sedatives), N06A-X (Other antidepressants), N06D-X (Other anti-dementia drugs), N07 (Other Nervous System Drugs), N07B-B (Drugs used in alcohol dependence), N07X (Other Nervous System Drugs)"	"A2A PAM, ADX 68692, ADX71743, ADX71943, ADX92639, Cpd 23, FSH NAM, FSHR/LHR NAM for sex hormone dependent tumours and reproductive system disorders Addex Therapeutics, GABABPAMs, GABABR PAM for overactive bladder Addex, IL1R1 NAM (CD121a), mGlu2 NAM, mGlu3 PAM, mGlu4 PAM, mGlu7 NAM, mGluR2 NAM, mGluR3 NAM, mGluR3 PAM, mGluR7 NAM, Orexin 2R NAM, TNFR1 NAM (CD120a), TNFR1 NAM (TNF receptor superfamily), TrkB PAM (RTK superfamily) Addex Therapeutics, TrkB receptor agonists Addex, TrkB receptor modulators Addex, TrkBPAM"			01/03/2021	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Cancer, Drug Withdrawal, Genitourinary Disorders, Inflammatory Bowel Disorders, Men's Health, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Peptic Ulcer Disease, Rheumatic Disease, Skin Disorders, Women's Health"		Addex Therapeutics |  | Research |  | 08 Jul 2011		no		no							https://adis.springer.com/drugs/800024111?userId=52029392&bpIds=3004037004&checksum=ddf764d83b404ab0107284de0e0b8328cb164e63-1617045531168-4a75fe58529fefa5144b495be915ac25badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043126	Trospium chloride/xanomeline - Karuna Therapeutics		"[(1R,5S)-Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride / 3-hexoxy-4-(1-methyl-3,6-dihydro-<EM>2H</EM>-pyridin-5-yl)-1,2,5-thiadiazole "	Yes			Phase III	"Schizophrenia, Alzheimer's disease, Dementia, Pain"	C25 H30 Cl NO3 . C14 H23 N3 OS	"Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Muscarinic receptor antagonists"	"Karuna Pharmaceuticals (Originator), Karuna Therapeutics (Owner), PureTech Health (Funder), The Wellcome Trust (Funder)"		PO				"N2 (Analgesics), N5A1 (Atypical antipsychotics), N7D (Anti-Alzheimer Products), N7D9 (All other anti-Alzheimer products)"	"N02 (Analgesics), N05A-X (Other antipsychotics), N06D (Anti-Dementia Drugs)"	"KarunaXanomelineTrospium, KarXT, Trospium chloride/LY 246708, Trospium chloride/xanomeline tartrate, Xanomeline/trospium chloride Karuna Therapeutics"			01/03/2021	"Alzheimer's Disease and Cognition Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800043126?userId=52029392&bpIds=3004037004&checksum=9688b6eb35fea17095c83efb5769b8eb5f48bb58-1617045531169-c5689d765daa4c97f210efe38a4cd325badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042284	CMX 020			Yes			No development reported (II)	Pain		"Adenosine A3 receptor modulators, Cannabinoid receptor CB1 modulators, Cannabinoid receptor CB2 modulators, Melatonin MT1 receptor modulators, Opioid delta receptor modulators, Opioid kappa receptor modulators, TRPV1 receptor modulators"	"Cmxtwenty (Originator), Cmxtwenty (Owner)"		"PO, IV"				N2A (Narcotics)	N02A-X (Other opioids)	CMX020			28/02/2021	Pain				no		no							https://adis.springer.com/drugs/800042284?userId=52029392&bpIds=3004037004&checksum=590055a008fbc51b8eb0af31dffe83a6ffd23609-1617045531170-cf929602a9b748c03a0f744f272c46a7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049659	ORP 101	1820753-68-1	"(2S)-2-[(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-11-[2-[[(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-yl]oxy]ethoxy]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-16-yl]-3,3-dimethylbutan-2-ol"	Yes			Phase II	Irritable bowel syndrome	C60H84N2O8	"Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"OrphoMed (Originator), OrphoMed (Owner)"		"PO, IV"				"A3 (Functional Gastro-Intestinal Disorder Drugs), N2 (Analgesics), N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"A03A (Drugs for Functional Bowel Disorders), N02A (Opioids), N07B-C (Drugs used in opioid dependence)"	"Buprenorphine dimer OrphoMed, ORP101"			28/02/2021	Digestive System Disorders				yes	USA	no							https://adis.springer.com/drugs/800049659?userId=52029392&bpIds=3004037004&checksum=b85d02ad8acc8901ba35b8d9416c88fdd09eab13-1617045531171-0ad0d06aaa0df2c4b97c4e46783d3b03badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051503	Flunarizine - Xenon Pharmaceuticals	52468-60-7	1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine	Yes			Phase II	"Absence epilepsy, Migraine"	C15H14FN3O3	"Calcium channel antagonists, Dopamine receptor antagonists, Histamine H1 receptor antagonists, Serotonin receptor antagonists"	"Xenon Pharmaceuticals (Originator), Xenon Pharmaceuticals (Owner)"		unspecified				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02C (Antimigraine Preparations), N03A (Antiepileptics)"	XEN 007			28/02/2021	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders"	"Migraine (USA), Hemiplegia (USA)"	Xenon Pharmaceuticals |  | Unspecified |  | 30 May 2018		no		no				period circadian clock 2			https://adis.springer.com/drugs/800051503?userId=52029392&bpIds=3004037004&checksum=a77b68d11c27ff63bb779e54c3b4a64ef7a4ee85-1617045531172-82013385ac3b99b017399cffde328015badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037614	Research programme: transcription factor inhibitors - Adynxx			Yes			No development reported (Preclinical)	"Back pain, Neuropathic pain, Inflammatory pain"		Kruppel-like transcription factor inhibitors	"Adynxx (Originator), Adynxx (Owner), National Institute of Neurological Disorders and Stroke (Funder)"		Parenteral				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	AYX 2			28/02/2021	Pain				no		no							https://adis.springer.com/drugs/800037614?userId=52029392&bpIds=3004037004&checksum=599ac88baece9b50985ceda14dce45bae1e28a5b-1617045531173-4393107cff03360cf0ad980669bf0367badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048658	Research programme: cancer and pain therapeutics - leon nanodrugs			No			No development reported (Preclinical)	"Pain, Cancer"		Undefined mechanism	"leon-nanodrugs (Originator), leon-nanodrugs (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	"In 006, In 011, In 012"			28/02/2021	"Cancer, Pain"		leon-nanodrugs |  | Unspecified |  | 12 Jan 2017		no		no							https://adis.springer.com/drugs/800048658?userId=52029392&bpIds=3004037004&checksum=3bac0e9ead1c2b956b8265dfc2200e4a48e9eafc-1617045531173-6a1f900a8435ceff9cabc23adaf70208badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043692	Research programme: non-opioid analgesics - PixarBio			No			No development reported (Preclinical)	"Postoperative pain, Epilepsy, Spinal cord injuries, Trigeminal neuralgia"		Sodium channel antagonists	"PixarBio Corporation (Originator), PixarBio Corporation (Owner)"		Parenteral				"N2 (Analgesics), N3 (Anti-Epileptics)"	"N02 (Analgesics), N03 (Antiepileptics)"	"Carbamazepine extended release PixarBio Corporation, Carbamazepine PixarBio Corporation, Extendedrelease liposomal carbamazepine PixarBio Corporation, NeuroRelease, NeuroRelease SCI, NR14, NRSCI, NRTN"			28/02/2021	"Drug Delivery Systems, Epilepsy and Seizure Disorders, Pain"			NeuroRelease	no		no							https://adis.springer.com/drugs/800043692?userId=52029392&bpIds=3004037004&checksum=768d7999a5341767e08696e31252754c3a1880bc-1617045531175-c700e929dcb0317510c2c1b9b3126683badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048898	BHV 5000			Yes			Phase I	"Complex regional pain syndromes, Neurological disorders, Rett syndrome"		NMDA receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner), Biohaven Pharmaceuticals (Licensee), Biohaven Pharmaceutical Holding Company (Collaborator)"		PO				"N (Nervous System), N2 (Analgesics), N5 (Psycholeptics), N6A (Anti-Depressants and Mood Stabilisers)"	"N (Nervous System), N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants)"	BHV5000			28/02/2021	"Neurological Disorders, Pain"	Rett syndrome (USA)			no		no							https://adis.springer.com/drugs/800048898?userId=52029392&bpIds=3004037004&checksum=69c4c9378694e6d8d9dfe72aae9a0936209fdbbc-1617045531176-7c50e17d89d6f746d057bfb3299566b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055007	NFX 81			Yes			Preclinical	"Neuropathic pain, Paralysis, Spinal cord injuries"		Undefined mechanism	"Lipopharma (Originator), National Hospital for Paraplegics (Originator), Laminar Pharmaceuticals (Owner), Neurofix Pharma (Licensee), University of the Balearic Islands (Technology Provider)"		unspecified				"M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N7X (All other CNS drugs)"	"M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"LP181A1, LPA181, NFX81"			28/02/2021	"Musculoskeletal Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800055007?userId=52029392&bpIds=3004037004&checksum=975028268878030dc7b4fab63ba9b38d148a2e7a-1617045531177-a064b71fd4c98b5a1b1755724d5b120abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045339	Research programme: small molecule therapeutics - Elorac			Yes			No development reported (Preclinical)	"Cancer, Psoriasis, Inflammation, Mycoses, Pain"		"Tetrahydrofolate dehydrogenase inhibitors, Retinoic acid receptor agonists, Cyclo-oxygenase 2 inhibitors, 14-alpha demethylase inhibitors"	"Gideon Pharmaceuticals (Originator), Elorac (Owner)"		unspecified				"D5B (Systemic Antipsoriasis Products), J2A (Systemic Agents for Fungal Infections), L1B (Antimetabolites), N2 (Analgesics)"	"D05B-B02 (Acitretin), J02A-C02 (Itraconazole), L01B-A01 (Methotrexate), N02 (Analgesics)"	Small molecules Heprotect			28/02/2021	"Cancer, Inflammation, Mycoses, Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800045339?userId=52029392&bpIds=3004037004&checksum=0b5a09479e2b399bafe40fe1e22d3f9621aa7a79-1617045531178-6d5775cebb338d4e26438f757b07fd02badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034039	Research programme: synthetic macrocycles - Ensemble Therapeutics			Yes			No development reported (Preclinical)	"Rheumatoid arthritis, Cancer, Inflammation, Reperfusion injury, Parkinson's disease, Cardiovascular disorders, Hepatitis B, Amyotrophic lateral sclerosis, Pain, Diabetes mellitus"		"Interleukin 17 receptor antagonists, Indoleamine-pyrrole 2,3-dioxygenase inhibitors, Inhibitor of apoptosis protein inhibitors, Tryptophan oxygenase inhibitors, USP28 protein inhibitors, Usp30 protein inhibitors, USP9X protein inhibitors, Cyclophilin D inhibitors, Ubiquitin thiolesterase modulators, PCSK9 protein inhibitors, Cyclophilin inhibitors, Checkpoint kinase inhibitors"	"Ensemble Discovery (Originator), Ensemble Therapeutics (Owner), Novartis (Licensee)"		PO				"A10X (Other Drugs Used in Diabetes), C1 (Cardiac Therapy), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N7X (All other CNS drugs)"	"A10B-X (Other oral blood glucose lowering drugs, excl. insulins), C01 (Cardiac Therapy), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs)"	"E36041, IDO checkpoint inhibitors, ubiquitin proteasome inhibitors"			28/02/2021	"Cancer, Diabetes, Inflammation, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease, Vascular Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800034039?userId=52029392&bpIds=3004037004&checksum=94c0c4b6872e50b784bbec482a7e0cc7fe2923cf-1617045531180-56cf4da3c98ecae9df4db2023de29fe8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055680	Research programme: bovine adrenal medulla 8 analogues - OKYO Pharma/Tufts Medical Center			Yes			Preclinical	"Ocular pain, Neuropathic pain"		G protein-coupled receptor agonists	"OKYO Pharma (Originator), OKYO Pharma (Owner), Tufts Medical Center (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Bam8 analogues, Bam822 analogues"			26/02/2021	"Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800055680?userId=52029392&bpIds=3004037004&checksum=52cd098b699eaee0c8bea9ff20d8f7b25e99f280-1617045531181-0a521e6cc125be766b9f7b497c499282badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055670	OKYO 0201			Yes			Preclinical	"Ocular pain, Neuropathic pain"		G protein-coupled receptor agonists	"Tufts University (Originator), Tufts University (Owner), OKYO Pharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"BAM8, BAM822, OK201, OKYO0201"			26/02/2021	"Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800055670?userId=52029392&bpIds=3004037004&checksum=1cac6d8b6e06fd364f8f4f464b039ff9d2b45e06-1617045531181-0b19e41b7f0bafeb74896ba0fb84a489badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035713	PRX 167700			Yes			Discontinued (II)	Inflammatory pain		AOC3 protein inhibitors	"Cambridge Biotechnology (Originator), Proximagen (Owner), Roche (Licensee)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"PRO VAP1 inh, PRX 167700H, PRX167700"			26/02/2021	"Inflammation, Pain"				no		no				CRP			https://adis.springer.com/drugs/800035713?userId=52029392&bpIds=3004037004&checksum=212b91b66374c6dc9373e94c470ab7830726eee9-1617045531182-28675924bb2c3ffee8da4c2004e6ba04badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033565	Dronabinol - Echo Pharmaceuticals	1972-08-3	"(6a<EM>R</EM>,10a<EM>R</EM>)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6<EM>H</EM>-benzo[<EM>c</EM>]chromen-1-ol"	No			Phase II	"Pain, Anorexia, Multiple sclerosis, Alzheimer's disease"	C21 H30 O2	"Cannabinoid receptor agonists, Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"Echo Pharmaceuticals (Originator), Echo Pharmaceuticals (Owner), University Medical Centre of Nijmegen (Collaborator), VU University Medical Center (Collaborator)"		"Sublingual, unspecified"				"A15 (Appetite Stimulants), A4A9 (Other antiemetics and antinauseants), N2 (Analgesics), N7 (Other CNS Drugs), N7D9 (All other anti-Alzheimer products)"	"A04A-D10 (Dronabinol), A15 (Appetite Stimulants), N02 (Analgesics), N06D-X (Other anti-dementia drugs), N07 (Other Nervous System Drugs)"	"Delta(9)tetrahydrocannabinol Echo Pharmaceutical, Delta(9)THC Echo Pharmaceutical, ECP022A (delta9THC), Namisol"			25/02/2021	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain"			"Namisol, Namisol"	no		no				"Calprotectin, CPM, CYP2C19, CYP2C9, IL1 beta, IL10, IL23, IL6, Leptin, MMP-2, MMP9, nystagmus 3, congenital autosomal dominant, TIMP-1, TNF-alpha"		"COMT, fatty acid amide hydrolase, monoglyceride lipase"	https://adis.springer.com/drugs/800033565?userId=52029392&bpIds=3004037004&checksum=32986ef2f65c5a4b65ef99a627dd76714dd9c14f-1617045531184-da3228d116b483b956e6311bd8b1d6c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014538	Botulinum toxin A - Merz Pharma	93384-43-1		No			Marketed	"Blepharospasm, Dystonia, Torticollis, Muscle spasticity, Glabellar lines, Sialorrhoea, Atrial fibrillation, Essential tremor, Trigeminal neuralgia, Pain, Cancer pain"		"Neuromuscular blocking agents, Acetylcholine inhibitors, Glutamate antagonists, Membrane transport protein modulators"	"BIOTECON Therapeutics (Originator), BIOTECON Therapeutics (Owner), Merz Pharma (Licensee), Merz Pharmaceuticals GmbH (Licensee), Teijin (Licensee), Beth Israel Deaconess Medical Center (Collaborator), Biolab Industrias Farmaceuticas (Collaborator), Thomas Jefferson University (Collaborator), Yale University (Collaborator)"		"IM, Parenteral"			"Arthralgia, Asthenia, Back pain, Blepharoptosis, Blurred vision, Constipation, Deglutition disorders, Diarrhoea, Diplopia, Dysarthria, Dysphonia, Fatigue, Headache, Infections, Muscle weakness, Musculoskeletal disorders, Musculoskeletal pain, Sinusitis, Urinary incontinence, Vision disorders, Xerophthalmia"	"C1 (Cardiac Therapy), M3A (Muscle Relaxants, Peripherally Acting), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"C01 (Cardiac Therapy), M03A-X01 (Botulinum toxin), N02 (Analgesics), S01X-A (Other ophthalmologicals)"	"Incobotulinum toxin A, NT201, Xeomin, Zeomaine"			25/02/2021	"Arrhythmias, Mouth Disorders, Musculoskeletal Disorders, Pain, Parkinson's Disease and Movement Disorders, Skin Disorders"			"Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Xeomin, Zeomaine"	no		no		Bilirubin		"absent in melanoma 2, Bilirubin, C-X-C motif chemokine ligand 11, CCL5, CD40L, chromosome 7 open reading frame 49, CXCL10, D-Urobilinogen, G-CSF, ICAM-1, IFN-gamma, IL1 alpha, MIF, NGF, period circadian clock 3 pseudogene, PSA, Uric acid"		"bax, Creatinine, E-cadherin, IL1 beta, IL6, IL8, Ki67, purinergic receptor P2X 3, RAGE, TGF-beta, TJP1, TNF-alpha, TRP-V1, Tryptases"	https://adis.springer.com/drugs/800014538?userId=52029392&bpIds=3004037004&checksum=3af204fe7f32c9edbb7cae3db0d0ab861efd1535-1617045531194-5dcee0168245386187213f2905203b56badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015882	Ketamine racemic intranasal - Seelos Therapeutics	6740-88-1	2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone	No			Phase II	"Suicidal ideation, Acute pain, Cancer pain"	C13 H16 Cl N O	"AMPA receptor agonists, NMDA receptor antagonists"	"Unknown (Originator), Unknown (Owner), Seelos Therapeutics (Licensee)"		Intranasal				"N1A (Anaesthetics, General), N2 (Analgesics), N5A (Antipsychotics)"	"N01A-X (Other general anesthetics), N02 (Analgesics), N05A (Antipsychotics)"	"Ereska, IN Ketamine, Intranasal ketamine, Intranasal raceamic ketamine, PMI100, PMI150, SLS002, TUR002"			24/02/2021	"Affective Disorders, Anxiety Disorders, Drug Delivery Systems, Pain, Psychotic Disorders"			Ereska	yes	USA	no				"OPRM1, potassium channel, two pore domain subfamily K, member 3"		"BDNF, glial cell derived neurotrophic factor, IGF1, IL6, IL8, PSA, superoxide dismutase 2, mitochondrial, synaptosomal-associated protein, 25kDa, TGF-beta, TNF-alpha, transforming growth factor, alpha"	https://adis.springer.com/drugs/800015882?userId=52029392&bpIds=3004037004&checksum=d7fd1b76a2d3d360da8ed8c4c2341237e09690a3-1617045531195-08e8d7bdfbb5e5e2d6c6fa3a7720693bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031615	Oxytocin - Tonix Pharmaceuticals	50-56-6	L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide	No			Phase II	"Migraine, Pain, Trigeminal neuralgia, Obesity, Glucose intolerance, Prader-Willi syndrome, Insulin resistance, Diabetes mellitus, Headache"	C43 H66 N12 O12 S2	"Calcitonin gene-related peptide antagonists, Oxytocin receptor agonists"	"Trigemina (Originator), Tonix Pharmaceuticals Holding Corp (Owner), INSERM (Technology Provider), University of Geneva (Technology Provider), Katana Pharmaceuticals (Technology Transfer)"		Intranasal				"A10 (Drugs Used in Diabetes), A8 (Antiobesity Preparations, Excluding Dietetics), A8A (Antiobesity Preparations, Excluding Dietetics), H1 (Pituitary and Hypothalamic Hormones), N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"A08 (Antiobesity Preparations, Excl. Diet Products), A08A (Antiobesity Preparations, Excl. Diet Products), A10 (Drugs Used in Diabetes), H01B-B02 (Oxytocin), N02 (Analgesics), N02C (Antimigraine Preparations)"	"Intranasal potentiated oxytocin Tonix Pharmaceuticals, Oxytocin intranasal Tonix Pharmaceuticals, TI001, TI114, TNX1900, TNX2900"			23/02/2021	"Advances in the Treatment of Nausea and Migraine, Diabetes, Metabolic Disorders, Obesity, Pain"				no		no		"arylsulfatase D, Estradiol-17beta 3-sulfate, Oxytocin, Testosterone"	"arylsulfatase D, Estradiol-17beta 3-sulfate, Oxytocin, sex hormone-binding globulin, Testosterone, Thyroid stimulating hormone, beta"	"ACTH, Adiponectin, arylsulfatase D, BCAR1, Cas family scaffolding protein, BCL2 related protein A1, Bilirubin, cholecystokinin, CRP, defensin beta 1, enolase 1, (alpha), Estradiol-17beta 3-sulfate, F7, fibroblast growth factor 9, Ghrelin, GLP-1, Hydrocortisone, IL6, Leptin, MCP1, Norepinephrine, Oxytocin, oxytocin receptor, PGE2, potassium channel, two pore domain subfamily K, member 3, PPY, Prolactin, PYY, SH3 domain containing GRB2 like 1, endophilin A2, spermine synthase, Testosterone, TNF-alpha, troponin I, cardiac, Vasopressin"		"BNP, CXCL10, ER alpha, IL4, Insulin, MIP-1 alpha, Procalcitonin, Progesterone, STAM binding protein, Thyroxine, TNFRSF1A, TNFRSF1B, Troponin T, cardiac, U2AF homology motif kinase 1, VEGF-A"	https://adis.springer.com/drugs/800031615?userId=52029392&bpIds=3004037004&checksum=f77ae4704f777996fb96f94220f4763e139ad988-1617045531198-3b901f49ee3bd4696c035f206c45a9d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037447	Promethazine/sumatriptan - Charleston Laboratories		"<EM>N,N</EM>-Dimethyl-1-phenothiazin-10-ylpropan-2-amine / 1-[3-[2-(Dimethylamino)ethyl]-<EM>1H</EM>-indol-5-yl]-<EM>N</EM>-methylmethanesulfonamide"	No			Phase III	"Nausea and vomiting, Migraine"	C17 H20 N2 S . C14 H21 N3 O2 S	"Histamine H1 receptor antagonists, Muscarinic receptor antagonists, Serotonin 1D receptor agonists"	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		PO				"A4A (Antiemetics and Antinauseants), N2C1 (Antimigraine triptans)"	"A04A (Antiemetics and Antinauseants), N02C-C01 (Sumatriptan)"	"CLH1T, sumatriptan succinate/promethazine HCl Charleston Laboratories"			23/02/2021	Advances in the Treatment of Nausea and Migraine		Charleston Laboratories |  | Unspecified | World | 12 Jan 2013		no		no							https://adis.springer.com/drugs/800037447?userId=52029392&bpIds=3004037004&checksum=fefeff57dae6a18d8cbe3ab01226c0bb9a93ff7a-1617045531199-8fb549e091d9a73a596060224a519d11badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030045	Cebranopadol - Grunenthal GmbH	863513-91-1	"<EM>Trans</EM>-6'-fluoro-<EM>N</EM>,<EM>N</EM>-dimethyl-4-phenyl-4',9'-dihydro-3'<EM>H</EM>-spiro[cyclohexane-1,1'-pyrano[3,4-<EM>b</EM>]indol]-4-amine"	Yes			Phase Unknown	"Neuropathic pain, Cancer pain, Diabetic neuropathies, Back pain, Musculoskeletal pain, Postoperative pain"	C24 H27 F N2 O	"Nociceptin receptor agonists, Opioid mu receptor agonists"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	GRT6005			23/02/2021	"Diabetes, Pain"				no		no				"EH domain containing 2, hyaluronan synthase 3, LIM homeobox transcription factor 1, beta, spermine synthase, symplekin"			https://adis.springer.com/drugs/800030045?userId=52029392&bpIds=3004037004&checksum=3c253bb2c3a999632e16cd90574b6b500d189653-1617045531204-a7f9ff21e1ac3650539bafc4bbf1accbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052600	CT 38			Yes			Phase I/II	"Encephalomyelitis, Chronic fatigue syndrome, Lyme disease, Fibromyalgia"		CRF receptor type 2 modulators	"Cortene (Originator), Cortene (Owner), Bateman Horne Center (Collaborator)"		"SC, unspecified"				"J1 (Systemic Antibacterials), N2 (Analgesics), N7 (Other CNS Drugs)"	"J01 (Antibacterials for Systemic Use), N02 (Analgesics), N07 (Other Nervous System Drugs)"	CT38			22/02/2021	"Bacterial Infections, Neurological Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800052600?userId=52029392&bpIds=3004037004&checksum=efe840e8e47dae6ed7da6db97aa2eba428e721d8-1617045531205-28ee12cdca584a505f9607fbb942f592badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024759	Ibuprofen - PLx Pharma	15687-27-1	2-[4-(2-methylpropyl)phenyl]propanoic acid	No			Discontinued (II)	"Inflammation, Pain"	C13 H18 O2	Cyclooxygenase inhibitors	"PLx Pharma (Originator), PLx Pharma (Owner)"		PO				"M1A2 (Anti-rheumatics, non-steroidal combination), N2 (Analgesics)"	"M01A-E01 (Ibuprofen), N02B (Other Analgesics and Antipyretics)"	"IBUPC, IbuprofenPC, Ibuprofenphosphatidylcholine, PL 1100, Zavryl"			22/02/2021	"Inflammation, Pain, Rheumatic Disease"		PLx Pharma |  | Unspecified | World | 16 Mar 2007	Zavryl	no		no							https://adis.springer.com/drugs/800024759?userId=52029392&bpIds=3004037004&checksum=0ba0b125f2c882cb1b163cd78ccc70d7ecb538d4-1617045531206-4a0e358365bac67ba65b4ba52edceb4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025057	Esflurbiprofen transdermal - Taisho Pharmaceutical	51543-39-6	"(S)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid"	No			Marketed	"Inflammation, Pain, Muscle pain, Periarthritis"	C15 H13 F O2	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Tokuhon Corporation (Originator), Tokuhon Corporation (Owner), Taisho Toyama Pharmaceutical (Market Licensee), Teijin Pharma (Market Licensee), GC-Rise Pharmaceutical (Licensee), Taisho Pharmaceutical (Licensee), Hirosaki University Graduate School of Medicine (Collaborator)"		Transdermal				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"Esflurbiprofen plaster, LOQOA Tape, SFlurbiprofen, SFPP, TT063"			22/02/2021	"Pain, Rheumatic Disease"			LOQOA Tape	no		no							https://adis.springer.com/drugs/800025057?userId=52029392&bpIds=3004037004&checksum=f6348550d7bfccffbf7caef8f6b6d75dfabde67f-1617045531207-961a5cffd11ddc75a8344d0d9df7ae7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062334	ZTL 103			No			Phase I	Pain		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Zelira Therapeutics (Originator), Zelira Therapeutics (Owner)"		Sublingual				N2B (Non-Narcotics and Anti-Pyretics)	"N02B (Other Analgesics and Antipyretics), N02B-G10 (Cannabinoids, including nabiximols)"	ZTL103			19/02/2021	Pain				no		no							https://adis.springer.com/drugs/800062334?userId=52029392&bpIds=3004037004&checksum=6690dbf261c439825ff59356a1895f5fb2ba2e6e-1617045531208-d78775f696890d9f83a91c731496b515badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045903	Cannabidiol - ANANDA Scientific	13956-29-1	"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-"	No			Phase I	"Neuropathic pain, COVID 2019 infections, Post-traumatic stress disorders, Psoriasis, Diabetes mellitus"	C21 H30 O2	"Antioxidants, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators, Cannabinoid receptor CB1 antagonists"	"ISA Scientific (Originator), ANANDA Scientific (Owner), Hebrew University of Jerusalem (Technology Provider), BGN Technologies (Technology Transfer), National Institute of Drug Abuse (Funder), Ben Gurion University (Collaborator), Hadassah Medical Organization (Collaborator), NYU Grossman School of Medicine (Collaborator)"		"PO, Topical"				"A10X9 (Other drugs used in diabetes), J5 (Antivirals for Systemic Use), N2 (Analgesics), N2B1 (Prescription-bound non-narcotics and anti-pyretics), N5B (Hypnotics/Sedatives), N7F (Drugs Used In Opioid Dependence)"	"A10B-X (Other oral blood glucose lowering drugs, excl. insulins), J05 (Antivirals for Systemic Use), N02 (Analgesics), N02B-G (Other analgesics and antipyretics), N05B (Anxiolytics), N07B (Drugs Used In Addictive Disorders)"	"Cannabidiol ANANDA Scientific, Liquid Structure Cannabidiol, Liquid Structure CBD"			19/02/2021	"Anxiety Disorders, Diabetes, Pain, Skin Disorders, Viral Infections"		ANANDA Scientific |  | Unspecified |  | 01 Feb 2021		no		no			"opsin 1 (cone pigments), medium-wave-sensitive, TNF-alpha"	"2-Arachidonylglycerol, Alpha-D-Glucose, Anandamide, Apo A-1, Apo B, BDNF, Bilirubin, C-peptide, Calprotectin, CRP, DBH antisense RNA 1, Erythropoietin, Hydrocortisone, IFN-gamma, IGF1, IL1 alpha, IL10, IL15, IL2, IL23, IL6, Insulin, Myoinositol, opsin 1 (cone pigments), medium-wave-sensitive, Prolactin, PSA, spermine synthase, TNF-alpha"	"Erythropoietin, Prolactin"	"A1C, COMT, IL1 beta, IL13, IL17, IL4, IL5"	https://adis.springer.com/drugs/800045903?userId=52029392&bpIds=3004037004&checksum=416ddb6d80ac379d08a53079a01eb0f01069a026-1617045531210-a611ef42c010e078bbf85a28db65617abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062215	HYR PB21			Yes			Phase I	Postoperative pain		Undefined mechanism	"Hefei Cosource Pharmaceutical (Originator), Hefei Cosource Pharmaceutical (Owner)"		SC				N2 (Analgesics)	N02 (Analgesics)	HYRPB21			19/02/2021	Pain				no		no							https://adis.springer.com/drugs/800062215?userId=52029392&bpIds=3004037004&checksum=3cfb346d13735f6c924ad1391d9a2b5b75907e86-1617045531210-2ffa0e490e961c73b7b4d8f01b30411dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062272	Research programme: serotonin 2A/C receptor agonists - Bright Minds Biosciences			Yes			Preclinical	Pain		"Serotonin 2A receptor agonists, Serotonin 2C receptor agonists"	"Bright Minds Biosciences (Originator), Bright Minds Biosciences (Owner), Medical College of Wisconsin (Collaborator), National Institutes of Health (USA) (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	5HT2A/C agonists receptor agonists Bright Minds Biosciences			19/02/2021	Pain				no		no							https://adis.springer.com/drugs/800062272?userId=52029392&bpIds=3004037004&checksum=d96642f692f10c76a3d5cc7d64f375075b35b929-1617045531211-23800c22d3c82bfa35d8b5c740dd373ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062292	Research programme: Nav1.8 voltage-gated sodium channel inhibitors - SiteOne Therapeutics			Yes			Research	"Pain, Cough"		Nav1.8 voltage-gated sodium channel inhibitors	"SiteOne Therapeutics (Originator), SiteOne Therapeutics (Owner)"		unspecified				"N2 (Analgesics), R5F (Other Cough and Cold Preparations)"	"N02 (Analgesics), R05 (Cough and Cold Preparations)"	NaV1.8 inhibitors SiteOne Therapeutics			18/02/2021	"Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800062292?userId=52029392&bpIds=3004037004&checksum=fe4b8d09165a01105496b65a716e725bac8ed934-1617045531212-d9ee812a1c0272da090a430b871cd94cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059775	PRAX 562			Yes			Phase I	"Epilepsy, Headache"		Nav1.6 voltage-gated sodium channel inhibitors	"Praxis Precision Medicines (Originator), Praxis Precision Medicines (Owner)"		"unspecified, PO"				N3A (Anti-Epileptics)	"N02 (Analgesics), N03A-X (Other antiepileptics)"	PRAX562			18/02/2021	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800059775?userId=52029392&bpIds=3004037004&checksum=71cf9855b08a0c600850d9646845cf4d1237b12c-1617045531213-9362374b88cbfe1a1ab1d44f3d662496badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045602	Cannabidiol/delta 9 tetrahydrocannabinol - Tetra Bio-Pharma		"2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol / (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol"	No			Phase III	Cancer pain	C21 H30 O2 . C21 H30 O2	Cannabinoid receptor agonists	"PhytoPain Pharma (Originator), PhytoPain Pharma (Owner), Alternavida S.A (Market Licensee), Azevedos Group (Market Licensee), Algorithme Pharma (Collaborator), Canopy Growth (Collaborator), Sante Cannabis (Collaborator), Storz & Bickel (Collaborator), Tetra Bio Pharma (Collaborator)"		Inhalation				N2 (Analgesics)	N02 (Analgesics)	"PPP001, PPP011, QIXLEEF, Smokable marijuana, Synthetic THC/CBD"			18/02/2021	Pain	Complex regional pain syndromes (USA)			no		no							https://adis.springer.com/drugs/800045602?userId=52029392&bpIds=3004037004&checksum=e7e9c7d98720c0946dc9fc96c166469cd3a29b3a-1617045531214-ca66f66cd9dbe576bffab9fea30f9f92badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006587	Liatermin - MedGenesis Therapeutix	188630-14-0	Glial-cell-line-derived neurotrophic factor	Yes			Preclinical	"Inborn genetic disorders, Peripheral nerve injuries, Parkinson's disease, Amyotrophic lateral sclerosis, Pain, Sensorineural hearing loss, Deafness, Epilepsy"	C1290 H2210 N420 O394 S18	Neuron stimulants	"Amgen (Originator), Amgen (Owner), MedGenesis Therapeutix (Licensee), North Bristol NHS Trust (Collaborator)"		"Parenteral, Intracerebral"				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs), N07X-X (Other nervous system drugs)"	"BVF014, GDNF, Glialderived neutrotrophic factor, rmetHuGDNF"			17/02/2021	"Ear, Nose and Throat Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no				glial cell derived neurotrophic factor			https://adis.springer.com/drugs/800006587?userId=52029392&bpIds=3004037004&checksum=4cbb10c7adb94f9ab23f3ff2f25cb8819de043cc-1617045531216-f34e8a307df4b05302d1a1cf9b45d4b8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028509	Fentanyl sublingual - INSYS Therapeutics	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Marketed	"Cancer pain, Dyspnoea, Postoperative pain"	C22 H28 N2 O	Opioid mu receptor agonists	"INSYS Therapeutics, Inc (Originator), INSYS Therapeutics, Inc (Owner), Lunatus (Market Licensee), M. D. Anderson Cancer Center (Collaborator)"		Sublingual				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Fentanyl SL spray INSYS Therapeutics, Fentanyl sublingual spray INSYS Therapeutics, FSS, Subsys"			16/02/2021	"Obstructive Airways Disease, Pain"			Subsys	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800028509?userId=52029392&bpIds=3004037004&checksum=82bd0815a28cf166d2a5e4b380dfea7ab4f17893-1617045531217-b9c2a66f5d3e008a67954a9f55897779badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019948	AV 101	75802-84-5	(2S)-2-Amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid	Yes			Phase II	"Major depressive disorder, Suicidal ideation, Psychiatric disorders, Parkinson's disease, Epilepsy, Neuropathic pain, Huntington's disease"	C10 H11 Cl N2 O3	"Kynurenine modulators, NMDA receptor modulators"	"Artemis Neuroscience (Originator), VistaGen Therapeutics (Owner), National Institute of Mental Health (Funder), Baylor College of Medicine (Collaborator), National Institute of Mental Health (Collaborator), National Institutes of Health (USA) (Collaborator), Nuformix Ltd (Collaborator)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N4 (Anti-Parkinson Drugs), N5A (Antipsychotics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N07X (Other Nervous System Drugs)"	"4Chlorokynurenine VistaGen, 4CLKYN, 7CLKYNA, AV101, L4chlorokynurenine, L4CLKYN"			15/02/2021	"Affective Disorders, Anxiety Disorders, Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				yes	USA	no							https://adis.springer.com/drugs/800019948?userId=52029392&bpIds=3004037004&checksum=9666e07f2aaf8aae71973930f66005adabf56843-1617045531219-75e8ae2c659d1118753748254c8e4611badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024333	Fremanezumab - Teva Pharmaceutical Industries	1655501-53-3	"Immunoglobulin G2, anti-(human alpha-calcitonin gene-related peptide/beta-calcitonin gene-related peptide) (human-mus musculus monoclonal TEV-48125 heavy chain), disulfide with human-mus musculus monoclonal TEV-48125 light chain, dimer"	Yes			Marketed	"Migraine, Fibromyalgia, Headache, Interstitial cystitis, Cluster headache"		Calcitonin gene-related peptide antagonists	"Rinat Neuroscience (Originator), Teva Pharmaceutical Industries (Owner), Otsuka Pharmaceutical (Licensee)"		"SC, IV"			"Erythema, Injection site pain, Injection site reactions, Pruritus"	N2C (Anti-Migraine Preparations)	N02C-D03 (Fremanezumab)	"AJOVY, Anticalcitonin generelated peptide monoclonal antibody, AntiCGRP monoclonal antibody, fremanezumabvfrm, LBR101, PF04427429, PF4427429, RN307, TEV48125"			11/02/2021	"Advances in the Treatment of Nausea and Migraine, Genitourinary Disorders, Pain, Rheumatic Disease"			"AJOVY, AJOVY, AJOVY, AJOVY"	yes	USA	no							https://adis.springer.com/drugs/800024333?userId=52029392&bpIds=3004037004&checksum=ca634692e32836e5e094522607e08db73d1ee473-1617045531226-b934a03fdd50bbf10f0cbc752cfb2c7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040845	Otenaproxesul - Antibe Therapeutics	1226895-20-0	"2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, 4-(aminothioxomethyl)phenyl ester"	Yes			Phase II	"Musculoskeletal pain, Malignant melanoma, Periodontal disorders, Intestinal cancer"	C21 H19 N O3 S	"Apoptosis stimulants, Cyclo-oxygenase 2 inhibitors"	"Antibe Therapeutics (Originator), Antibe Therapeutics (Owner), Knight Therapeutics (Market Licensee), Laboratoire Acbel (Market Licensee), Nuance Biotech (Market Licensee), Kwang Dong Pharmaceutical (Licensee), Imperial College of Science, Technology and Medicine (Collaborator), McMaster University (Collaborator), Universita di Napoli Federico II (Collaborator), University of Calgary (Collaborator), William Harvey Research Institute (Collaborator)"		PO				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	ATB346			11/02/2021	"Cancer, Mouth Disorders, Pain"		Antibe Therapeutics | Familial adenomatous polyposis | Unspecified |  | 05 Aug 2020		no		no							https://adis.springer.com/drugs/800040845?userId=52029392&bpIds=3004037004&checksum=045186f1daf613df2dbd42b42e942ca01aadff06-1617045531228-5945d7c47f881da363ba531a70a808a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041937	Research programme: cannabinoid based therapeutics - SciSparc			No			Preclinical	"Opioid-related disorders, Gilles de la Tourette's syndrome, Inflammation"		Cannabinoid receptor modulators	"Dekel Pharmaceuticals (Originator), SciSparc (Owner), Belvit Pharma (Technology Provider), Yissum Research Development Company (Technology Provider), Dalhousie University (Collaborator), The Tel Aviv Sourasky Medical Center (Collaborator), Weizmann Institute of Science (Collaborator)"		"unspecified, PO"				"J1 (Systemic Antibacterials), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N4 (Anti-Parkinson Drugs)"	"J01 (Antibacterials for Systemic Use), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B-G (Other analgesics and antipyretics), N04 (Anti-Parkinson Drugs)"	"Dronabinol/palmitoylethanolamide combination therapies SciSparc, Palmitoylethanolamide, Palmitoylethanolamide combination therapies SciSparc, THX 120, THXULD01"			10/02/2021	"Drug Delivery Systems, Inflammation, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800041937?userId=52029392&bpIds=3004037004&checksum=b29677a006baa4c27d65ce1295fbc099eb4303de-1617045531229-deb43f5f935ed8dc88c359a91441ec34badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054429	Topiramate oral - Eton Pharmaceuticals	97240-79-4	"[(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0<SUP>2,6</SUP>]dodecan-6-yl]methyl sulfamate"	No			Preregistration	"Lennox-Gastaut syndrome, Migraine, Tonic-clonic epilepsy, Epilepsy"	C12 H21 N O8 S	"AMPA receptor antagonists, Carbonic anhydrase inhibitors, GABA A receptor agonists, Kainic acid receptor antagonists, Sodium channel antagonists"	"Eton Pharmaceuticals (Originator), Azurity Pharmaceuticals (Owner)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02C-X (Other antimigraine preparations), N03A-X11 (Topiramate)"	ET101 Eton Pharmaceuticals			10/02/2021	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800054429?userId=52029392&bpIds=3004037004&checksum=e05d7b13e4b95929569dcad0bdef3986f9043da3-1617045531230-9d5603b195f7e72c9f851b914d634e54badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051781	Nepafenac punctal plug - Mati Therapeutics	78281-72-8	2-Amino-3-benzoylbenzeneacetamide	No			Phase II	"Pain, Inflammation"	C15 H14 N2 O2	Cyclooxygenase inhibitors	"Mati Therapeutics (Originator), Mati Therapeutics (Owner)"		Ophthalmic				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B (Other Analgesics and Antipyretics)"	NPPDS			10/02/2021	"Drug Delivery Systems, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800051781?userId=52029392&bpIds=3004037004&checksum=4b55e1f6210ff4cda734593e0e1dfc05ab867209-1617045531232-cac84c0ca6cc4929ed06de3f7b34a863badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057465	SCI 160			Yes			Preclinical	Pain		Cannabinoid receptor CB2 agonists	"Hebrew University of Jerusalem (Originator), SciSparc (Owner), Yissum Research Development Company (Technology Transfer), University of Calgary (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"SCI160, THX160"			10/02/2021	Pain				no		no							https://adis.springer.com/drugs/800057465?userId=52029392&bpIds=3004037004&checksum=99700b736da39ca7e548a568d6ce486e2daaeeb5-1617045531233-9e01ad8a101f8caeb05e5b7e4ddc6f89badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062225	AKE 1018			Yes			Preclinical	Neuropathic pain		Hyperpolarisation activated cation channel antagonists	"Columbia University (Originator), Weill Cornell Medicine (Originator), Columbia University (Owner), Weill Cornell Medicine (Owner), Akelos (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AKE1018			10/02/2021	Pain				no		no							https://adis.springer.com/drugs/800062225?userId=52029392&bpIds=3004037004&checksum=d0c3be8ffddd05a2f63091244c08fd1a822db6ba-1617045531234-2172d86842c6710caea54f48702b5b4fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023388	Cenobamate - SK biopharmaceuticals	913088-80-9	(1R)-1-(2-Chlorophenyl)-2-(2H-tetrazol-2-yl)ethylcarbamate	Yes			Marketed	"Partial epilepsies, Tonic-clonic epilepsy, Anxiety disorders, Neuropathic pain, Bipolar disorders"	C10 H10 Cl N5 O2	"GABA A receptor modulators, Sodium channel antagonists"	"SK biopharmaceuticals (Originator), SK biopharmaceuticals (Owner), Arvelle Therapeutics (Licensee), Ono Pharmaceutical (Licensee), SK Life Science (Collaborator)"		PO			"Dizziness, Somnolence"	"N2 (Analgesics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N03A (Antiepileptics), N05B (Anxiolytics), N06A (Antidepressants)"	"ONTOZRY, XCopri, XCOPRI, YKP3089"			10/02/2021	"Affective Disorders, Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"			"ONTOZRY, XCopri, XCOPRI"	no		no							https://adis.springer.com/drugs/800023388?userId=52029392&bpIds=3004037004&checksum=142efb6fbdbc03e4dbd9be7d1b4bf50a82d46373-1617045531239-1f0a240c9b4d3e360285f3d84ef5c7b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031188	RQ 00434739			Yes			Preclinical	"Neuropathic pain, Pain, Inflammation"		TRPM8 protein inhibitors	"RaQualia Pharma (Originator), RaQualia Pharma (Owner)"		"PO, unspecified"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"CMR1 anatgonist RaQualia Pharma, RQ00434739"			09/02/2021	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800031188?userId=52029392&bpIds=3004037004&checksum=f60d8848a8ab76dbc34a777e5e64f96f7570d0a3-1617045531240-e550af5844b7d83c51110442a22f70f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062198	Votucalis - Akari Therapeutics	872525-61-6		Yes			Preclinical	"Neuropathic pain, Pruritus"	C858-H1259-N221-O289-S10	"Histamine H1 receptor antagonists, Histamine H2 receptor antagonists, Histamine H3 receptor antagonists, Histamine H4 receptor antagonists"	"Akari Therapeutics (Originator), Akari Therapeutics (Owner)"		unspecified				"D11A (Other Dermatological Preparations), N2 (Analgesics)"	"D11A-X (Other dermatologicals), N02 (Analgesics)"	Votucalis			08/02/2021	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800062198?userId=52029392&bpIds=3004037004&checksum=791d944daf9774334c9099952b10929704197978-1617045531241-05b46c9415803165927447f76c54107abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032595	RPI 78			Yes			Phase I	"Rheumatoid arthritis, Pain"		Nicotinic receptor antagonists	"ReceptoPharm (Originator), ReceptoPharm (Owner), Nutra Pharma Corporation (Collaborator)"		Parenteral				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	RPI78			08/02/2021	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800032595?userId=52029392&bpIds=3004037004&checksum=8ed2710188290323f24cc170bdffa70d5d535227-1617045531242-9b5061064f04d91921e703f4665106c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060766	HRS 4800			Yes			Phase I	Pain		Undefined mechanism	"Atridia (Originator), Atridia (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	HRS4800			08/02/2021	Pain				no		no							https://adis.springer.com/drugs/800060766?userId=52029392&bpIds=3004037004&checksum=eacc7b44dca3928aa4c38d4a3863b9456b8b6bdc-1617045531243-022ea66600c3c4f890ddb456043be138badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061357	HSK 16149			Yes			Phase I	Neuropathic pain		Undefined mechanism	"Haisco Pharmaceutical Group (Originator), Haisco Pharmaceutical Group (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	HSK16149			05/02/2021	Pain				no		no							https://adis.springer.com/drugs/800061357?userId=52029392&bpIds=3004037004&checksum=e4cc1b194e61d1344a8c8a63116f214168ca6c46-1617045531244-93847fe6b7324c20fee29fb824997b1dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061048	RLVT 14-02			Yes			Preclinical	Neuropathic pain		Immunomodulators	"Duke University (Originator), Duke University (Owner), Releviate Therapeutics (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	RLVT1402			05/02/2021	Pain				no		no							https://adis.springer.com/drugs/800061048?userId=52029392&bpIds=3004037004&checksum=ce6119d849ac5afc319b17c5852b1ed68dfbf3f0-1617045531245-4ab392564cac19b2510dadc3dd04b88dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053206	GRF 6021			Yes			Phase II	"Postoperative pain, Parkinson's disease"		Neurogenesis stimulants	"Alkahest (Originator), Grifols (Originator), Alkahest (Owner), Grifols (Owner), The Michael J. Fox Foundation for Parkinson's Research (Funder)"		IV				"N2 (Analgesics), N4A (Anti-Parkinson Drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs)"	"AKST6021, GRF6021"			05/02/2021	"Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800053206?userId=52029392&bpIds=3004037004&checksum=2a2673d1c80f5487806dcfc16a7ef4222eeb4a34-1617045531246-79ac3d4321a819a85be747dced12159bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060776	Research programme: synthetic cannabinoid therapeutics - 180 Life Sciences/Hebrew University of Jerusalem/University of Oxford			No			Preclinical	"Pain, Arthritis"		Undefined mechanism	"CannbioRex Pharmaceuticals (Originator), Hebrew University of Jerusalem (Originator), University of Oxford (Originator), 180 Life Sciences (Owner), Yissum Research Development Company (Technology Transfer)"		PO				N2 (Analgesics)	N02 (Analgesics)				05/02/2021	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800060776?userId=52029392&bpIds=3004037004&checksum=3b2f638b39972916f3e550bbe07f2a15c16040e6-1617045531247-2a1ffdbc5255eacf00a1f3438d97dbf0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035971	Hydrocodone/paracetamol - Acura Pharmaceuticals		"(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid/N-(4-hydroxyphenyl)acetamide"	No			Phase II	Pain	C22 H27 N O9 . C8 H9 N O2	"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner), Abuse Deterrent Pharmaceuticals (Market Licensee)"		PO				N2 (Analgesics)	"N02 (Analgesics), N02B-E01 (Paracetamol)"	"Acetaminophen/hydrocodone, Acetaminophen/hydrocodone bitartrate, Aversion HA, Hydrocodone bitartrate/acetaminophen, Hydrocodone bitartrate/paracetamol, Hydrocodone/acetaminophen, LTX 03, Paracetamol/hydrocodone, Paracetamol/hydrocodone bitartrate, Vycavert Tablets"			04/02/2021	Pain			Vycavert Tablets	no		no							https://adis.springer.com/drugs/800035971?userId=52029392&bpIds=3004037004&checksum=77c844684f82e3dd6c30889230f53a23a73535ff-1617045531248-d0069049e51453671517567a4dfe0559badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054119	Research programme: GABAA receptor modulators - Engrail Therapeutics			Yes			Research	Pain		GABA A receptor modulators	"NeuroCycle Therapeutics (Originator), Engrail Therapeutics (Owner), National Institutes of Health (USA) (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/02/2021	Pain				no		no							https://adis.springer.com/drugs/800054119?userId=52029392&bpIds=3004037004&checksum=b77a370d5209389a913bb5f080dcacaee74135fd-1617045531249-4745c698931cee4e1b9e0072b285b75fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032880	Research programme: siRNA CNS disorder therapeutics - Quark Pharmaceuticals			Yes			Research	"CNS disorders, Neuropathic pain, Neurodegenerative disorders, Spinal cord injuries"		RNA interference	"Quark Pharmaceuticals (Originator), Quark Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	QP NR1			04/02/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800032880?userId=52029392&bpIds=3004037004&checksum=e4abb0f10971617cc7a4d27c5ac13c6bf1d2a7fa-1617045531250-a8f30eac01d7dadcbc45ea9adce66e1dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048569	Research programme: pain therapeutics - AnaBios Corporation			Yes			No development reported (Preclinical)	Pain		"Ion channel modulators, TRPA1 protein modulators, TRPV1 protein modulators"	"AnaBios Corporation (Originator), AnaBios Corporation (Owner), National Center for Advancing Translational Sciences (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Periheral neuropathy AnaBios Corporation, TRPA1/TRPV1 modulation AnaBios Corporation"			04/02/2021	Pain				no		no							https://adis.springer.com/drugs/800048569?userId=52029392&bpIds=3004037004&checksum=ac4d92944870a5b5b2ebd8d50360b31e86acb7cf-1617045531251-27bc65dc6f4e6ee8c4ea5d11f9e31b74badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061290	SUPERA 1R			Yes			Preclinical	"Seizures, Anxiety disorders, Epilepsy, Pain"		"Monoamine oxidase A inhibitors, Monoamine oxidase B inhibitors"	"MyMD Pharmaceuticals (Originator), MyMD Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N3 (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N03 (Antiepileptics), N07 (Other Nervous System Drugs)"	SUPERA1R			04/02/2021	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800061290?userId=52029392&bpIds=3004037004&checksum=23f0a924c3f6b9a6fee14165db3091435a4077ca-1617045531252-77f36d203e2e568ec689049774a8b07bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061756	HR 021618			Yes			Phase II	Postoperative pain		Undefined mechanism	"Jiangsu Hengrui Medicine Co. (Originator), Jiangsu Hengrui Medicine Co. (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	HR021618			04/02/2021	Pain				no		no							https://adis.springer.com/drugs/800061756?userId=52029392&bpIds=3004037004&checksum=9dd0db03f84089c7235ecb795196a47775a6c97c-1617045531252-8d3a3825a7adfce4bda36709bde3d6f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061946	DCR-LLY 10			Yes			Research	"Neurodegenerative disorders, Cardiovascular disorders, Pain, Metabolic disorders"		RNA interference	"Dicerna Pharmaceuticals (Originator), Dicerna Pharmaceuticals (Owner), Eli Lilly and Company (Licensee)"		Parenteral				"A16A (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"A16A (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), N02B (Other Analgesics and Antipyretics), N07X-X (Other nervous system drugs)"	DCRLLY10			04/02/2021	"Metabolic Disorders, Neurological Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800061946?userId=52029392&bpIds=3004037004&checksum=b74bf2ef93076281ac223bc54575cc419580fe56-1617045531254-89cf9a99ed69f63b28956d03d7904f60badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049478	PL 265	1206514-62-6	(2<EM>S</EM>)-2-[[(2<EM>S</EM>)-2-[[hydroxy-[(1<EM>R</EM>)-1-(2-methylpropanoyloxymethoxycarbonylamino)ethyl]phosphoryl]methyl]-3-(4-phenylphenyl)propanoyl]amino]propanoic acid	Yes			Preclinical	"Inflammatory pain, Cancer pain, Ocular pain, Dry eyes, Neuropathic pain"	C27 H35 N2 O9 P	"Aminopeptidase inhibitors, Neprilysin inhibitors"	"Pharmaleads (Originator), Pharmaleads (Owner), IACTA Pharmaceuticals (Licensee), Institut de la Vision (Collaborator)"		"PO, Intrathecal, Ophthalmic"				N2 (Analgesics)	N02 (Analgesics)	"IC805, PL265"			04/02/2021	"Eye Disorders, Pain"		Pharmaleads |  | Preclinical |  | 12 May 2017		no		no							https://adis.springer.com/drugs/800049478?userId=52029392&bpIds=3004037004&checksum=22b6cf7a21f22977eb77ee5450fb4b7857de80f2-1617045531255-38f4a81902daa95e50e4d5ae982ab53ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050839	S 600918			Yes			Phase II	"Neuropathic pain, Cough"		Purinergic P2X3 receptor antagonists	"Shionogi (Originator), Shionogi (Owner)"		PO				"N2 (Analgesics), R5 (Cough and Cold Preparations)"	"N02 (Analgesics), R05 (Cough and Cold Preparations)"	S600918			04/02/2021	"Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800050839?userId=52029392&bpIds=3004037004&checksum=350d1002bb5cdf3ac5ce5cb78053a132bdf28109-1617045531256-5d5abe2a3c991b95eb161a69ce5084cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039721	Synthetic cannabidiol - Benuvia Therapeutics/Radius Health	13956-29-1	"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-"	No			Preclinical	"Endocrine disorders, Prader-Willi syndrome, Lennox-Gastaut syndrome, Substance-related disorders, Dravet syndrome, Infantile spasms, Epilepsy, Pain, Peripheral nervous system diseases, Glioblastoma"	C21 H30 O2	"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"INSYS Therapeutics, Inc (Originator), Benuvia Therapeutics (Owner), Radius Health Inc. (Owner), California Pacific Medical Center (Technology Provider), Canadian Institutes of Health Research (Collaborator), Center for Medicinal Cannabis Research (Collaborator), National Institute of Drug Abuse (Collaborator), The University of Montreal Hospital Research Center (Collaborator), University of Chicago (Collaborator)"		"PO, unspecified"			"Anaemia, Diarrhoea, Respiratory tract infections, Seizures, Somnolence"	"A8 (Antiobesity Preparations, Excluding Dietetics), L1 (Antineoplastics), N2 (Analgesics), N3 (Anti-Epileptics), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"A08 (Antiobesity Preparations, Excl. Diet Products), L01 (Antineoplastic Agents), N02 (Analgesics), N03 (Antiepileptics), N03A (Antiepileptics), N07 (Other Nervous System Drugs), N07B (Drugs Used In Addictive Disorders)"	"Pharmaceutical cannabidiol (CBD) Benuvia Therapeutics/Radius Health, RAD011"			04/02/2021	"Cancer, Drug Withdrawal, Endocrine Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Obesity, Pain"	"Glioma (USA), Dravet syndrome (USA), Lennox-Gastaut syndrome (USA), Infantile spasms (USA), Glioblastoma (USA), Prader-Willi syndrome (USA), Schizophrenia (USA)"			yes	USA	no			"opsin 1 (cone pigments), medium-wave-sensitive, TNF-alpha"	"2-Arachidonylglycerol, Alpha-D-Glucose, Anandamide, Apo A-1, Apo B, BDNF, Bilirubin, C-peptide, Calprotectin, CRP, DBH antisense RNA 1, Erythropoietin, Hydrocortisone, IFN-gamma, IGF1, IL1 alpha, IL10, IL15, IL2, IL23, IL6, Insulin, Myoinositol, opsin 1 (cone pigments), medium-wave-sensitive, Prolactin, PSA, spermine synthase, TNF-alpha"	"Erythropoietin, Prolactin"	"A1C, COMT, IL1 beta, IL13, IL17, IL4, IL5"	https://adis.springer.com/drugs/800039721?userId=52029392&bpIds=3004037004&checksum=631756c2d100b7a932aa5aedbdde332656e157a0-1617045531261-476716c1d1925d79df196e4d9abaa2d3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028891	PL 37		"(9<EM>S</EM>)-9-Benzyl-1-hydroxy-3-methyl-1,5,8-trioxo-2,4-dioxa-11,12,17-trithiaoctadecan-14-aminium chloride"	Yes			Phase II	"Neuropathic pain, Pain, Cancer pain, Postoperative pain"	C21 H32 Cl N O6 S3	"Aminopeptidase inhibitors, Neprilysin inhibitors"	"Pharmaleads (Originator), Pharmaleads (Owner), IACTA Pharmaceuticals (Licensee)"		"PO, IV"				N2 (Analgesics)	N02 (Analgesics)	"Debio 0827, IC800, PL37"			04/02/2021	Pain				no		no							https://adis.springer.com/drugs/800028891?userId=52029392&bpIds=3004037004&checksum=426093ecd0bb204e164736cb6b34ecbd94141e54-1617045531263-a566f488073cb203dbefd5af456431ffbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032606	Ricolinostat - Regenacy Pharmaceuticals	1316214-52-4	2-(Diphenylamino)-<EM>N</EM>-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide	Yes			Phase II	"Diabetic neuropathies, Multiple myeloma, Lymphoma, Peritoneal cancer, Ovarian cancer, Fallopian tube cancer, Chronic lymphocytic leukaemia, Breast cancer, Charcot-Marie-Tooth disease, Peripheral nervous system diseases, Malignant melanoma"	C24 H27 N5 O3	HDAC6 protein inhibitors	"Dana-Farber Cancer Institute (Originator), Harvard University (Originator), Dana-Farber Cancer Institute (Owner), Harvard University (Owner), Celgene Corporation (Licensee), 3E-Regenacy Pharmaceuticals (BC Regenacy) (Sub-licensee), Regenacy Pharmaceuticals (Sub-licensee), Columbia University (Collaborator), Massachusetts General Hospital (Collaborator), The George Washington University (Collaborator), The Leukemia & Lymphoma Society (Collaborator), University of Texas M. D. Anderson Cancer Center (Collaborator)"		PO				"L (Antineoplastic and Immunomodulating Agents), L1 (Antineoplastics), N (Nervous System), N2 (Analgesics), N7 (Other CNS Drugs)"	"L (Antineoplastic and Immunomodulating Agents), L01 (Antineoplastic Agents), N (Nervous System), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"ACY1215, ACY63, Rocilinostat"			04/02/2021	"Cancer, Neurological Disorders, Pain"				no		no				"Tubulin alpha, stable"		"BIM, HIF, histone deacetylase 9, LC3, ras homolog family member B, SRC proto-oncogene, non-receptor tyrosine kinase"	https://adis.springer.com/drugs/800032606?userId=52029392&bpIds=3004037004&checksum=6cd5c3925bd280f0bfbf419ac4704d813d830fe6-1617045531266-d3d44749f399a98d8c77439c74aad83dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061866	Research programme: intra-neuronal antibody - CytoDel			Yes			Research	"Pain, Neurological disorders"		Undefined mechanism	"CytoDel (Originator), NYU Grossman School of Medicine (Originator), CytoDel (Owner), NYU Grossman School of Medicine (Owner)"		Parenteral				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02 (Analgesics)"				03/02/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800061866?userId=52029392&bpIds=3004037004&checksum=82163c5f350e6b5e73bdaf239a04d8ce9a51210f-1617045531267-fe5467ae7b0638f000fec03713a038e5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057093	ACD 440			Yes			Phase I	Neuropathic pain		TRPV1 receptor antagonists	"AstraZeneca (Originator), Acturum Life Sciences (Owner), AlzeCure (Licensee)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"ACD440, TRPV1 receptor antagonist AlzeCure, VR1 antagonist AlzeCure, VR1/ACD440"			02/02/2021	Pain				no		no							https://adis.springer.com/drugs/800057093?userId=52029392&bpIds=3004037004&checksum=620048006252d7be3342ff5a13fb8b9f90e34838-1617045531268-e55476c4250abcb71402683a53515d0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028257	Relugolix - Myovant/Takeda	737789-87-6	"1-[4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-<EM>d</EM>]pyrimidin-6-yl]phenyl)-3-methoxyurea"	Yes			Marketed	"Prostate cancer, Uterine leiomyoma, Endometriosis, Pain, Solid tumours"	C29 H27 F2 N7 O5 S	LHRH receptor antagonists	"Takeda (Originator), Takeda (Owner), ASKA Pharmaceutical (Licensee), Myovant Sciences (Licensee), NovaQuest Capital Management (Funder), Pfizer (Collaborator), Roivant Sciences (Collaborator), Sunovion Pharmaceuticals (Collaborator), Takeda Oncology (Collaborator)"		PO			"Diarrhoea, Fatigue, Hot flashes, Hyperhidrosis, Menorrhagia, Metrorrhagia"	"G2X (Other Gynaecological products), H1C3 (Antigonadotrophin-releasing hormones), L2 (Cytostatic Hormone Therapy), N2 (Analgesics)"	"G02 (Other Gynecologicals), H01C-C (Anti-gonadotropin-releasing hormones), L02 (Endocrine Therapy), N02B (Other Analgesics and Antipyretics)"	"ORGOVYX, Relumina, RVT 601, TAK385"			01/02/2021	"Cancer, Men's Health, Pain, Women's Health"			"ORGOVYX, Relumina"	no		no		"PSA, Testosterone"		"NTx, PSA, sex hormone-binding globulin, Testosterone"	PSA		https://adis.springer.com/drugs/800028257?userId=52029392&bpIds=3004037004&checksum=2880911c52492600687a50d2de428c7cb1255093-1617045531272-3e4244588802ddc3b21991f3bb5af6ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008839	Nalfurafine - Toray	152658-17-8	"2-Propenamide, N-((5alpha,6beta)-17-(cyclopropylmethyl)-4,5- epoxy-3,14-dihydroxymorphinan-6-yl)-3-(3-furanyl)-N-methyl- , monohydrochloride, (2E)-"	Yes			Marketed	"Pruritus, Cancer pain, Atopic dermatitis, Neuropathic pain"	C28 H32 N2 O5 . HCl	Opioid kappa receptor agonists	"Toray (Originator), Toray (Owner), Fresenius Medical Care (Market Licensee), Torii Pharmaceutical (Market Licensee), Meiji Seika Pharma (Licensee), Sansheng Pharmaceutical (Licensee), Japan Tobacco (Collaborator), Shenyang Sunshine Pharmaceutical (Collaborator), SK Chemicals (Collaborator), Sumitomo Dainippon Pharma (Collaborator)"		"PO, IV, unspecified"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A (Antipruritics, Incl. Antihistamines, Anesthetics, Etc.), N02 (Analgesics)"	"AC820, MT9938, Nalfurafine hydrochloride, Nopicor, REMITCH, SSS33, TRK820, Winfuran"			01/02/2021	"Pain, Skin Disorders"	Pruritus (European Union)		"Nopicor, REMITCH, Winfuran"	no		no							https://adis.springer.com/drugs/800008839?userId=52029392&bpIds=3004037004&checksum=ff139edff9023eff023731cb07a4a86e9f249bd3-1617045531275-4004c441f501967a49092a16aa4eca6ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061862	Research programme: cannabidiol-combination therapies - Enveric Biosciences			No			Preclinical	"Glioblastoma, Radiodermatitis, Peripheral nervous system diseases"		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Jay Pharma (Originator), Tikun Olam (Originator), Enveric Biosciences (Owner)"		"unspecified, Topical"				"D11A (Other Dermatological Preparations), L1X (All Other Antineoplastics), N2 (Analgesics), N7X (All other CNS drugs)"	"D11A-X (Other dermatologicals), L01X-X (Other antineoplastic agents), N02B-G10 (Cannabinoids, including nabiximols), N07X (Other Nervous System Drugs), N07X-X (Other nervous system drugs)"				29/01/2021	"Cancer, Neurological Disorders, Skin Disorders"				no		no							https://adis.springer.com/drugs/800061862?userId=52029392&bpIds=3004037004&checksum=69a5b6373cc015a69d13cd66b4158fcc55dbfff3-1617045531276-ab491dc74e4327dbbc0ef4426deaf16bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048532	MicroCor zolmitriptan - Corium International	139264-17-8	S-4[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]- 2-oxazolidinone	No			No development reported (Preclinical)	Migraine	C16 H21 N3 O2	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Corium International (Originator), Corium International (Owner)"		Transdermal				N2C1 (Antimigraine triptans)	N02C-C03 (Zolmitriptan)				28/01/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800048532?userId=52029392&bpIds=3004037004&checksum=5cb8e8220edf6fad11c5dbd16643d1ec1ed3ee90-1617045531277-435dc2f96f873e481047c8f7d8ccfab3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047945	Captisol-enabled paracetamol - Seelos Therapeutics	103-90-2		No			Preclinical	Pain	C8-H9-N-O2	Prostaglandin receptor antagonists	"Ligand Pharmaceuticals (Originator), Ligand Pharmaceuticals (Owner), Seelos Therapeutics (Licensee)"		IV				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	"Captisolenabled acetaminophen, CEacetaminophen, SLS012"			28/01/2021	Pain				no		no							https://adis.springer.com/drugs/800047945?userId=52029392&bpIds=3004037004&checksum=bb5490b6e22d982c28d18d8347661ae6c8e03b38-1617045531277-a8ddeb4b0f307429170275942e91de14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021218	Buprenorphine - Relmada Therapeutics	52485-79-7	"(2S)-2-[(-)-(5R,6R,7R,14S)- 9_-cyclopropylmethyl-4,5-epoxy- 6,14-ethanomorphinan-7-yl]-3-hydroxy- 6-methoxy-3,3-dimethylbutan-2-ol"	No			No development reported (I)	"Pain, Opioid-related disorders"	C29 H41 NO4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"TheraQuest Biosciences LLC (Originator), Relmada Therapeutics (Owner), Wonpung Mulsan (Licensee)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	"Buprenorphine ER Relmada Therapeutics, Buprenorphine extended release Relmada Therapeutics, BuTab ER, REL1028, TQ1028"			28/01/2021	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800021218?userId=52029392&bpIds=3004037004&checksum=86b2fb9f270b4aa14a75900e3c9208dbe38fefd7-1617045531278-a0fe44573c3dda9bd7084bdd2d1d6247badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043432	Dihydroergotamine - Impel NeuroPharma	6190-39-2	"Ergotamine 9,10-dihydro-, monomethanesulfonate (salt)"	No			Preregistration	Migraine	C33 H37 N5 O5 . C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Impel NeuroPharma (Originator), Impel NeuroPharma (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C-A01 (Dihydroergotamine)	"DHE, Dihydroergotamine Mesylate, INP104, PODDHE, TRUDHESA"			28/01/2021	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			TRUDHESA	no		no							https://adis.springer.com/drugs/800043432?userId=52029392&bpIds=3004037004&checksum=08f744204797f2eb9cca0d96519b6ad03ff84de6-1617045531279-78e32b140e4e840c2a7333f3a31d78c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037107	Oxymorphone transdermal - Avecho Biotechnology	76-41-5	"Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-"	No			Phase I/II	Pain	C17 H19 N O4	Opioid mu receptor agonists	"Phosphagenics (Originator), Avecho Biotechnology (Owner), Terumo (Collaborator), tesa Labtec (Collaborator)"		Transdermal				N2A (Narcotics)	N02A-X (Other opioids)	"Oxymorphone patch Avecho Biotechnology, Oxymorphone TPM Patch, TPM/oxymorphone"			28/01/2021	"Drug Delivery Systems, Pain"		Avecho Biotechnology | Pain | Phase III |  | 01 Aug 2013		no		no							https://adis.springer.com/drugs/800037107?userId=52029392&bpIds=3004037004&checksum=33ee84b7ee650160a993e446f49781c5604d97c2-1617045531280-218e79ac84d42b7a841f301afeee0f62badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035435	Research programme: pain therapeutics and companion diagnostics - Genentech/Xenon Pharmaceuticals			Yes			No development reported (Preclinical)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Xenon Pharmaceuticals (Originator), Xenon Pharmaceuticals (Owner), Genentech (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	XEN907			28/01/2021	Pain				no		no							https://adis.springer.com/drugs/800035435?userId=52029392&bpIds=3004037004&checksum=9abfac3123d3d8812487b9a6ea724a5b943094f3-1617045531281-b3bf6cc67d5cf2265b6440be098239d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033119	RNS 60			Yes			Phase II	"Multiple sclerosis, Asthma, Amyotrophic lateral sclerosis, Myocardial infarction, Parkinson's disease, Alzheimer's disease"		"G protein-coupled receptor modulators, Ion channel modulators, HSP90 heat-shock protein modulators"	"Revalesio (Originator), Revalesio (Owner), ALS Finding a Cure Foundation (Funder), Northeast ALS Consortium (Funder), Massachusetts General Hospital (Collaborator), Rush University (Collaborator)"		"IV, Inhalation, unspecified"				"C1 (Cardiac Therapy), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs), R3 (Anti-Asthma and COPD Products)"	"C01 (Cardiac Therapy), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs), N07X-X (Other nervous system drugs), R03D (Other Systemic Drugs for Obstructive Airway Diseases)"	"Oxygenated saline, RNS60"			28/01/2021	"Alzheimer's Disease and Cognition Disorders, Ischaemic Heart Disease, Neurological Disorders, Obstructive Airways Disease, Parkinson's Disease and Movement Disorders"	Amyotrophic lateral sclerosis (USA)	Revalesio |  | Unspecified |  | 18 Jan 2011		yes	USA	no				"FOXP3, IL17, MCP1"		peptidylprolyl isomerase G	https://adis.springer.com/drugs/800033119?userId=52029392&bpIds=3004037004&checksum=efe338a99fb8b57d89670439e5383576166033ec-1617045531283-e09a8dba8cfa30096abb986df2f11126badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058712	Oxycodone/naloxone sustained release - Shandong Luye Pharmaceutical			No			Marketed	Pain		"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Shandong Luye Pharmaceutical (Originator), Shandong Luye Pharmaceutical (Owner)"		PO				N2A (Narcotics)	"N02A-A55 (Oxycodone, combinations)"	LY021702			27/01/2021	Pain				no		no							https://adis.springer.com/drugs/800058712?userId=52029392&bpIds=3004037004&checksum=3214f43cfe8e333698a2871c78618944e5e52225-1617045531284-62b32a763b4ed41a8ed697ca792b63fabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800062010	ID 11046			Yes			Research	Pain		Undefined mechanism	"Ildong Pharmaceutical (Originator), Ildong Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ID11046			25/01/2021	Pain		Ildong Pharmaceutical |  | Unspecified |  | 25 Jan 2021		no		no							https://adis.springer.com/drugs/800062010?userId=52029392&bpIds=3004037004&checksum=d7ee7965812a660cbed3586bdcfeee260e6c8d19-1617045531284-2a1febd057c669b9ba6f049e31309f01badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051618	XT 150			No			Phase II	"Musculoskeletal pain, Neuropathic pain, Amyotrophic lateral sclerosis, Multiple sclerosis"		"Gene transference, Interleukin-10 replacements"	"Xalud Therapeutics (Originator), Xalud Therapeutics (Owner), University of Colorado at Boulder (Technology Provider)"		"Intra-articular, Intrathecal, Parenteral"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02 (Analgesics)"	"IL10 transgene plasmid DNA, XT 101, XT101R, XT150"			25/01/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800051618?userId=52029392&bpIds=3004037004&checksum=9a368c7326092608967a922aed34f99086b1a54f-1617045531285-73ddb6853fa4ec419ada7696ed96789abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026870	Evenamide - Newron Pharmaceuticals	1092977-61-1	"2-((2-(3-Butoxyphenyl)ethyl)amino)-<EM>N</EM>,<EM>N</EM>-dimethylacetamide"	Yes			Phase II	Schizophrenia	C16 H26 N2 O2	"Dopamine D2 receptor antagonists, Nav1.3 voltage-gated sodium channel inhibitors, Nav1.7 voltage-gated sodium channel inhibitors, Nav1.8 voltage-gated sodium channel inhibitors, Serotonin 2 receptor antagonists"	"Newron Pharmaceuticals (Originator), Newron Pharmaceuticals (Owner)"		PO				"N2 (Analgesics), N3 (Anti-Epileptics), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02 (Analgesics), N03A (Antiepileptics), N05A (Antipsychotics), N05B (Anxiolytics), N07X (Other Nervous System Drugs)"	"NW3509, NW3509A"			25/01/2021	Psychotic Disorders		Newron Pharmaceuticals |  | Unspecified |  | 11 Aug 2020		no		no							https://adis.springer.com/drugs/800026870?userId=52029392&bpIds=3004037004&checksum=34a7440a4970c5b78937297094c67a7c8087c971-1617045531287-a8a1aac6d39016b5f94215b7e39d2017badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024284	Fentanyl - Alexza Pharmaceuticals/Lee's Pharmaceutical	437-38-7	N-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Phase I	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Alexza Pharmaceuticals (Originator), Alexza Pharmaceuticals (Owner), Lee's Pharmaceutical (Licensee)"		Inhalation				N2A (Narcotics)	N02A-B03 (Fentanyl)	"AZ003, EN 3294, Inhaled fentanyl aerosol Alexza Pharmaceuticals, Staccato fentanyl"			22/01/2021	Pain		Alexza Pharmaceuticals |  | Unspecified |  | 26 Mar 2012	Staccato fentanyl	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024284?userId=52029392&bpIds=3004037004&checksum=2d3c90660126058f0d3dd42ed2d71d4e95dbdee6-1617045531288-5ede94de970d46a0110b7ded8cb0a32abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058011	Lysergic acid diethylamide - MindMed/The University Hospital of Basel	50-37-3	"(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide"	Yes			Phase II	"Major depressive disorder, Anxiety disorders, Cluster headache"	C20 H25 N3O	Serotonin 2A receptor agonists	"The University Hospital of Basel (Originator), The University Hospital of Basel (Owner), Mindmed (Licensee), Maastricht University (Collaborator)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N6D (Nootropics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N05B-X (Other anxiolytics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics)"	LSD MindMed/The University Hospital of Basel			22/01/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders"				no		no							https://adis.springer.com/drugs/800058011?userId=52029392&bpIds=3004037004&checksum=83e82006469369fbd88b1601b472dfcc30822a74-1617045531289-b4733d939a18bbff798099ea911cc50cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041793	Research programme: cannabis-based therapeutics - Skye Bioscience			No			Preclinical	"Open-angle glaucoma, Pain, Peripheral nervous system diseases, Chemotherapy-induced nausea and vomiting, Methicillin-resistant Staphylococcus aureus infections, Macular degeneration, Uveitis, Diabetic retinopathy, Dry eyes, Muscle spasticity, Anxiety disorders, Epilepsy"		Cannabinoid receptor agonists	"NEMUS Bioscience (Originator), University of Mississippi (Originator), Skye Bioscience (Owner), Nanomerics (Technology Provider), Teewinot Life Sciences Corporation (Technology Provider), University of Mississippi (Technology Provider), Emerald Health Sciences (Funder), Albany Molecular Research Inc (Collaborator), Glauconix Biosciences (Collaborator), Noramco (Collaborator)"		"Ophthalmic, unspecified"				"A4A (Antiemetics and Antinauseants), J1X9 (All other antibacterials), M3 (Muscle Relaxants), N2 (Analgesics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N7 (Other CNS Drugs), S1E2 (Miotics and antiglaucoma preparations, topical), S1X (Other Ophthalmologicals)"	"A04A (Antiemetics and Antinauseants), J01X-X (Other antibacterials), M03 (Muscle Relaxants), N02B-G (Other analgesics and antipyretics), N03A (Antiepileptics), N05B (Anxiolytics), N07 (Other Nervous System Drugs), S01E-X (Other antiglaucoma preparations), S01X (Other Ophthalmologicals)"	"cannabidiol ##173##valine hemisuccinate, Cannabidiol derivatives Skye Bioscience, cannabidiol valine hemisuccinate, Cannabidiol Valine Hemisuccinate, Cannabionoid therapeutics Skye Bioscience, CBD derivatives Skye Bioscience, CBDVHS, CBGAQ, CBGAQNa Salt, CBGAquinone, NB 1222, NB 2111, NB 2221, NB 2222, NB 23R1, NB 3111, NB 31R1, NB 51R1, NB3000 series, THCvalinehemisuccinate, UM 5070"			19/01/2021	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Bacterial Infections, Epilepsy and Seizure Disorders, Eye Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain"		Skye Bioscience |  | Unspecified |  | 03 Mar 2017		no		no							https://adis.springer.com/drugs/800041793?userId=52029392&bpIds=3004037004&checksum=ddb28963506509a96b4d7b74d4a080a1158eb43f-1617045531292-6b048758997aa76a6ab75ca159a58530badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060760	MR 107A 01			Yes			Phase II	Postoperative pain		Undefined mechanism	"Mylan (Originator), Viatris Inc (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	MR107A01			18/01/2021	Pain				no		no							https://adis.springer.com/drugs/800060760?userId=52029392&bpIds=3004037004&checksum=0aef3ad62afe4e6e29f9517f2c959b5799af40fe-1617045531293-b106b2d4678069c2faf0741604ad9997badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050388	LX 9211			Yes			Phase II	"Neuropathic pain, Postherpetic neuralgia"		Adaptor-associated kinase 1 inhibitors	"Bristol-Myers Squibb (Originator), Lexicon Pharmaceuticals (Originator), Bristol-Myers Squibb (Owner), Lexicon Pharmaceuticals (Owner), Lexicon Pharmaceuticals (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	LX9211			14/01/2021	Pain				yes	USA	no							https://adis.springer.com/drugs/800050388?userId=52029392&bpIds=3004037004&checksum=afc8b5bc721abef395869b6042f5a6877c628168-1617045531294-ee83680a54f4545350a938d1bd53eb58badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026957	Diclofenac epolamine transdermal patch - Institut Biochemique SA	119623-66-4	"Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1)"	No			Marketed	Pain	C14 H11 C12 N O2	Cyclooxygenase inhibitors	"IBSA (Originator), IBSA (Owner)"		Topical				"M2 (Topical Anti-Rheumatics), N2 (Analgesics)"	"M02A-A (Antiinflammatory preparations, non-steroids for topical use), N02 (Analgesics)"	"Effigel, Flector EP Tissugel, Flector Patch, Flector Tissugel"			14/01/2021	Pain			"Effigel, Flector EP Tissugel, Flector EP Tissugel, Flector Patch, Flector Tissugel"	no		no							https://adis.springer.com/drugs/800026957?userId=52029392&bpIds=3004037004&checksum=32f81bdc6484b91f95a4ffc3d8aff29a556172e3-1617045531295-e6f092d3b8096815be1467fd41cc0126badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029765	Research programme: GPCR modulators - Sosei Heptares			Yes			Preclinical	"Atopic dermatitis, Migraine, Substance-related disorders, Anxiety disorders, Obsessive-compulsive disorders, Psychotic disorders, Cognition disorders, Parkinson's disease, Sleep disorders, Autistic disorder, Depressive disorders, CNS disorders, Cocaine-related disorders, Unspecified"		"Histamine H4 receptor antagonists, Calcitonin gene-related peptide antagonists, G protein-coupled receptor modulators, Metabotropic glutamate receptor 5 antagonists, Orexin receptor type 1 antagonists, Metabotropic glutamate receptor 5 modulators, Muscarinic M1 receptor agonists, Muscarinic M4 receptor agonists, Adenosine A2A receptor antagonists, Orexin receptor type 2 antagonists, Adenosine A2 receptor antagonists"	"Heptares Therapeutics (Originator), Sosei Heptares (Owner), Takeda (Licensee), Tempero Bio (Licensee), National Institute of Drug Abuse (Funder), Emerald BioStructures (Collaborator), Medical Research Council (Collaborator), University of Cambridge (Collaborator)"		"unspecified, PO"				"A (Alimentary Tract and Metabolism), C (Cardiovascular System), D11 (Other Dermatological Preparations), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2C (Anti-Migraine Preparations), N4 (Anti-Parkinson Drugs), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7B (Antismoking Products), N7E (Drugs Used In Alcohol Dependence), N7F (Drugs Used In Opioid Dependence)"	"A (Alimentary Tract and Metabolism), C (Cardiovascular System), D11A-X (Other dermatologicals), M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N05B (Anxiolytics), N06A (Antidepressants), N07 (Other Nervous System Drugs), N07B (Drugs Used In Addictive Disorders), N07B-C (Drugs used in opioid dependence)"	"allosteric modulators of metabotropic glutamate receptor (5mGluR5) Sosei Heptares, calcitonin generelated peptide (CGRP) modulators Sosei Heptares, CNS disorder therapeutics Sosei Heptares, H4 receptor antagonist Sosei Heptares, M1/M4 agonist Sosei Heptares, mGlus NAM Sosei Heptares, muscarinic M1 agonists Sosei Heptares, Orexin OX1 receptor antagonist Sosei Heptares, Orexin OX1/OX2 dual receptor agonists, Orexin OX2 agonists Sosei Heptares, OX1 antagonist Sosei Heptares"			13/01/2021	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Drug Withdrawal, Neurological Disorders, Parkinson's Disease and Movement Disorders, Psychotic Disorders, Skin Disorders"				no		no							https://adis.springer.com/drugs/800029765?userId=52029392&bpIds=3004037004&checksum=856d41c055cd5159932d2b68390f93fa042eab8a-1617045531298-2818cc8c497ac2e1d4480c244e36b336badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053729	HTX 034			Yes			Phase I/II	Postoperative pain		"Cyclo-oxygenase 2 inhibitors, Sodium channel antagonists"	"Heron Therapeutics (Originator), Heron Therapeutics (Owner)"		Topical				"M1A (Anti-Rheumatics, Non-Steroidal), N1B3 (Anaesthetics local, topical), N2 (Analgesics)"	"M01A-C06 (Meloxicam), N01B-B01 (Bupivacaine), N02 (Analgesics)"	HTX034			13/01/2021	Pain				no		no							https://adis.springer.com/drugs/800053729?userId=52029392&bpIds=3004037004&checksum=58479b7737bf48316f60e8070c36dffc1ece2c29-1617045531299-1bd055c0236ef48563c25686805651e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042016	Cannabinol Topical - InMed Pharmaceuticals	521-35-7	"6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol"	No			Phase I	Epidermolysis bullosa	C21 H26 O2	"Apoptosis inhibitors, Cannabinoid receptor agonists"	"InMed Pharmaceuticals (Originator), InMed Pharmaceuticals (Owner), Natural Sciences and Engineering Research Council of Canada (Funder), ATERA (Collaborator), Centre for Human Drug Research (Collaborator), PharmaSeed (Collaborator), University of British Columbia (Collaborator)"		Topical			"Burning sensation, Erythema"	"D3 (Wound Healing Agents), D3A1 (Skin/dermal/epidermal/equivalents)"	"D03 (Preparations for Treatment of Wounds and Ulcers), N02B-G10 (Cannabinoids, including nabiximols)"	"INM 755, INM750"			12/01/2021	Skin Disorders				no		no							https://adis.springer.com/drugs/800042016?userId=52029392&bpIds=3004037004&checksum=21f5a247053f80e7cd00b3cbfe3b56e074b5a4c8-1617045531300-e7e9a837916932d3fcda87b33b8c3fecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034449	Oxycodone prodrug extended release - Ensysce Biosciences	76-42-6	"(5a)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Phase I	Pain	C18 H21 N O4	"Opioid mu receptor agonists, Opioid receptor agonists"	"PharmacoFore (Originator), Ensysce Biosciences (Owner), National Institute of Drug Abuse (Funder)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"BIOMD PF614, ER Oxycodone BioMD System, ER Oxycodone Ensysce Biosciences, PF 614, PF614 MPAR, PRF 06014, PRF06104"			11/01/2021	Pain		Ensysce Biosciences |  | Unspecified |  | 16 Dec 2016		yes	USA	no							https://adis.springer.com/drugs/800034449?userId=52029392&bpIds=3004037004&checksum=6363662f2151bfcdf23539b7e44706ec5220ca8d-1617045531301-a7c83e4f0cfdb80cde8ce08a4353b7b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050812	Meloxicam/rizatriptan - Axsome Therapeutics		"4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide/1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-"	No			Phase III	Migraine	C14 H13 N3 O4 S2 . C15 H19 N5	"Cyclo-oxygenase 2 inhibitors, Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Axsome Therapeutics (Originator), Axsome Therapeutics (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N2C1 (Antimigraine triptans)"	"M01A-C06 (Meloxicam), N02C-C04 (Rizatriptan)"	"AXS 07, MoSEIC meloxicam and rizatriptan, MoSEIC meloxicam/rizatriptan"			08/01/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800050812?userId=52029392&bpIds=3004037004&checksum=b6d6cfbae09b290922730cb1a1930159cdfc4022-1617045531302-56419bee4e1d280745b0c55be31973c4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041158	Research programme: PDZ domain inhibitors - Avilex Pharma			Yes			Research	"Subarachnoid haemorrhage, Stroke, Neuropathic pain"		PDZ domain inhibitors	"Avilex Pharma (Originator), Avilex Pharma (Owner)"		Parenteral				"B1 (Antithrombotic Agents), N2 (Analgesics)"	"B01A (Antithrombotic Agents), N02 (Analgesics)"				08/01/2021	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800041158?userId=52029392&bpIds=3004037004&checksum=f8219b2558041d4a28fdcc6cee9aac7daa7d26b2-1617045531302-2ab0ecf44825092e42f334b36bd25804badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053522	OLP 1002			Yes			Phase I	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"OliPass (Originator), OliPass (Owner)"		SC				N2 (Analgesics)	N02 (Analgesics)	OLP1002			08/01/2021	Pain		OliPass |  | Unspecified |  | 11 Dec 2018		no		no							https://adis.springer.com/drugs/800053522?userId=52029392&bpIds=3004037004&checksum=5a3de77021e2a375cfa3e3a959a0a1f5e2e69389-1617045531303-17b4f05f6236c08017d02a278fd8831bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044731	Goflikicept - TRPHARM	2416984-26-2		Yes			Phase II/III	"SARS-CoV-2 acute respiratory disease, Pericarditis, Pain, Inflammation"		Interleukin 1 beta inhibitors	"TRPHARM (Originator), TRPHARM (Owner), MonitorCRO (Collaborator), R-Pharm (Collaborator)"		SC				"C1 (Cardiac Therapy), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R7X (All Other Respiratory System Products)"	"C01E (Other Cardiac Preparations), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R07A-X (Other respiratory system products)"	RPH104			08/01/2021	"Heart Failure, Inflammation, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800044731?userId=52029392&bpIds=3004037004&checksum=91f5d7a32566308a4c3efebc5b4d3fa569ef250e-1617045531304-685f52875f6139f909d441589e6539abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061709	GA 801			Yes			Clinical Phase Unknown	Migraine		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	GA801			06/01/2021	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800061709?userId=52029392&bpIds=3004037004&checksum=84a4c18a17f836f7fb74e0b6c67821346246fb2f-1617045531305-3c8247a477a08a8544860d6050eafa68badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061702	GA 501			Yes			Clinical Phase Unknown	Musculoskeletal pain		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GA501			06/01/2021	Pain				no		no							https://adis.springer.com/drugs/800061702?userId=52029392&bpIds=3004037004&checksum=92a919f67c10be75b7b8cd752abe55940b9b4dbb-1617045531306-2b019277ad602b96b1790c686e305f8abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061706	GA 602			Yes			Clinical Phase Unknown	Musculoskeletal pain		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GA602			06/01/2021	Pain				no		no							https://adis.springer.com/drugs/800061706?userId=52029392&bpIds=3004037004&checksum=18470a21a7e35f307afe4089846f4b14805adf2b-1617045531306-5cf137160f01b335322a04d36ac1e9d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061701	GA 401			Yes			Clinical Phase Unknown	"Pain, Inflammation"		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GA401			06/01/2021	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800061701?userId=52029392&bpIds=3004037004&checksum=1d9d09d67a60af5f581d778c2b1bd6d4f3ee416b-1617045531307-9b443567d43c1ac87bb5a255a4958808badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061703	GA 502			Yes			Clinical Phase Unknown	"Pain, Inflammation"		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GA502			06/01/2021	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800061703?userId=52029392&bpIds=3004037004&checksum=605b78675bbadee696e0824320c677ec7522879f-1617045531308-2b1ec07755e5a2ba6e8f9eda308f5ae6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061705	GA 601			Yes			Clinical Phase Unknown	Musculoskeletal pain		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GA601			06/01/2021	Pain				no		no							https://adis.springer.com/drugs/800061705?userId=52029392&bpIds=3004037004&checksum=3599d6405c2939dd7a277c5c3e677e3ec05d316b-1617045531309-d6c927e70245636daa10117e1a07ece4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061700	GA 301 - Galt Pharmaceuticals			Yes			Clinical Phase Unknown	"Inflammation, Pain"		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"GA301, GA301 Galt Pharmaceuticals"			06/01/2021	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800061700?userId=52029392&bpIds=3004037004&checksum=beb0a97b31f65acd6ed3ae84769b1d1efe87dd29-1617045531310-7b4d4c8a6e990ba80afc65935f060aa8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061578	Nociceptin/orphanin FQ peptide receptor agonist therapeutic - Grunenthal			Yes			Phase I	Neuropathic pain		Nociceptin receptor agonists	"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				06/01/2021	Pain		Grunenthal |  | Unspecified |  | 16 Dec 2020		no		no							https://adis.springer.com/drugs/800061578?userId=52029392&bpIds=3004037004&checksum=fdec541f9cdfa0f3f3d3004d5de083a98c4ecce4-1617045531310-d20d04eb70aec7b3c91c0038d8317b88badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061698	GA 201 - Galt Pharmaceuticals			Yes			Clinical Phase Unknown	"Inflammation, Pain"		Undefined mechanism	"Galt Pharmaceuticals (Originator), Galt Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GA201 Galt Pharmaceuticals			06/01/2021	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800061698?userId=52029392&bpIds=3004037004&checksum=860629c0741f3087d1d6eb27e3c2938973133095-1617045531311-a0d1d1a70fedd3049ad733bf4d993928badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046512	NYX 2925			Yes			Phase II	"Diabetic neuropathies, Fibromyalgia, Neurological disorders"		NMDA receptor modulators	"Aptinyx (Originator), Aptinyx (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	NYX2925			06/01/2021	"Diabetes, Neurological Disorders, Pain"				yes	USA	no							https://adis.springer.com/drugs/800046512?userId=52029392&bpIds=3004037004&checksum=48b1c632ff16f77b6951d1f41bee65900b9e3d0f-1617045531312-bec63c259cd0ac2c152aecd39087a0fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061292	Research programme: adenosine analogues - Purnovate			Yes			Research	"Diabetes mellitus, Pain, Inflammation, Cocaine-related disorders, Cancer, Infections, Asthma"		Undefined mechanism	"Purnovate (Originator), Purnovate (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7F (Drugs Used In Opioid Dependence), R3X (All Other Anti-Asthma and COPD Products)"	"A10X (Other Drugs Used in Diabetes), J (Anti-infectives For Systemic Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), N07B (Drugs Used In Addictive Disorders), R03B-X (Other drugs for obstructive airways diseases, inhalants)"				04/01/2021	"Bacterial Infections, Cancer, Diabetes, Drug Withdrawal, Inflammation, Obstructive Airways Disease, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800061292?userId=52029392&bpIds=3004037004&checksum=3529df38a79ef68159527f8763b2b91d3d529450-1617045531313-3122708a833d8b9be23b09d644d8d67ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061658	Ketorolac ophthalmic implant - Layerbio	74103-06-3	"5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid"	No			Phase I	"Postoperative pain, Postoperative inflammation"	C15 H13 NO3	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Layerbio (Originator), Layerbio (Owner), Department of defence (Funder)"		Intraocular				"N2 (Analgesics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"N02 (Analgesics), S01B-C05 (Ketorolac)"	OcuRingK			04/01/2021	"Eye Disorders, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800061658?userId=52029392&bpIds=3004037004&checksum=f1a958ee7d86c2b96049add6a1d2f125124495bf-1617045531314-04c83d4858c32e857d39ffff0f57d2aebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058029	HU 308	1220887-84-2	"[(1R,4R,5R)-4-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methanol"	Yes			Phase I	"Uveitis, Dry eyes, Sepsis, Proliferative vitreoretinopathy, SARS-CoV-2 acute respiratory disease, Cytokine release syndrome, Renal failure"	C27 H42 O3	"Cannabinoid receptor CB2 agonists, Interleukin 1 beta inhibitors, Interleukin 6 inhibitors, Tumour necrosis factor alpha inhibitors"	"Panag Pharma (Originator), Panag Pharma (Owner), Tetra Bio Pharma (Licensee)"		"Ophthalmic, unspecified, IV"				"D11A (Other Dermatological Preparations), G4X (All Other Urological Products), L4 (Immunosuppressants), L4X (Other Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R7 (Other Respiratory System Products), S1X (Other Ophthalmologicals)"	"D11A (Other Dermatological Preparations), G04B (Urologicals), L04 (Immunosuppressants), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R07A-X (Other respiratory system products), S01B (Antiinflammatory Agents)"	"ARDS003, HU308, PPP003, PPP003 Covid product Tetra BioPharma"			04/01/2021	"Bacterial Infections, Eye Disorders, Genitourinary Disorders, Immunological Disorders, Viral Infections"	Proliferative vitreoretinopathy (USA)			no		no							https://adis.springer.com/drugs/800058029?userId=52029392&bpIds=3004037004&checksum=48220b147965e3e3f1a3fa510901211a4a6355c7-1617045531316-2e2a356fe2fbf079647c833dc318e29fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044788	Diclofenac sodium transdermal patch - Hisamitsu Pharmaceuticals	15307-79-6	"sodium;2-[2-(2,6-dichloroanilino)phenyl]acetate"	No			Phase III	"Cervicobrachial syndrome, Tenosynovitis, Cancer pain, Periarthritis, Back pain, Pain"	C14 H10 Cl2 N Na O2	Cyclooxygenase inhibitors	"Hisamitsu Pharmaceutical (Originator), Hisamitsu Pharmaceutical (Owner), Noven Pharmaceuticals (Collaborator)"		Transdermal				"M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2B (Non-Narcotics and Anti-Pyretics)"	"M05 (Drugs for Treatment of Bone Diseases), N02B (Other Analgesics and Antipyretics)"	"Diclofenac sodium transdermal patch, HP3150, HP5000, HSP3150"			01/01/2021	"Drug Delivery Systems, Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800044788?userId=52029392&bpIds=3004037004&checksum=57db30a82d3329df424c8474504c4e086231bac4-1617045531317-401ccbe7022771480dd7334d97d0b4aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059932	ITI 333			Yes			Phase I	"Substance-related disorders, Depressive disorders, Pain, Anxiety disorders, Mood disorders"		"Dopamine D1 receptor antagonists, Opioid receptor agonists, Serotonin 2A receptor antagonists"	"Intra-Cellular Therapies (Originator), Intra-Cellular Therapies (Owner), National Institute of Drug Abuse (Funder), National Institutes of Health (Funder)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N6A9 (Antidepressants, all others), N7X (All other CNS drugs)"	"N02 (Analgesics), N05B (Anxiolytics), N06A-X (Other antidepressants), N07B (Drugs Used In Addictive Disorders)"	ITI333			31/12/2020	"Affective Disorders, Anxiety Disorders, Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800059932?userId=52029392&bpIds=3004037004&checksum=56fc96528fe65aa102e444f760f5a8c81bc2d33e-1617045531318-9b19304d7bbd9b179a1680fd582c7cabbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016130	Enflicoxib - Esteve	251442-94-1	"4-(5-(2,4-difluorophenyl)-3-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide"	Yes			No development reported (I)	"Osteoarthritis, Pain"	C16 H12 F5 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"Esteve (Originator), Esteve (Owner)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"	E6087			30/12/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800016130?userId=52029392&bpIds=3004037004&checksum=9f2bd78ad28daafbbaf07d77e0aa2025ebfeb182-1617045531319-dbcf77fc1308dd3f911c3b97a4a332b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061247	Research programme: neuroprotective therapeutics - Neuropathix			Yes			Research	"Epilepsy, Neuropathic pain"		Undefined mechanism	"Advanced Neural Dynamics (Originator), Fox Chase Chemical Diversity Center (Originator), Neuropathix (Owner), National Institutes of Health (USA) (Funder)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A-X (Other antiepileptics)"	Sulphamide containing neuroprotective compounds Neuropathix			30/12/2020	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800061247?userId=52029392&bpIds=3004037004&checksum=66f55cb27c0fc3181e764f74dc83ead7a0a3b178-1617045531320-99581833396c452adb0d3a8cf60e42b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023017	Morphine transdermal - Avecho Biotechnology	57-27-2	"Morphinana-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-"	No			Discontinued (II)	Pain	C12 H19 N O3	Opioid mu receptor agonists	"Phosphagenics (Originator), Avecho Biotechnology (Owner)"		Transdermal				N2A (Narcotics)	N02A-A01 (Morphine)	"TPM 01/M, TPM 01/Morphine"			29/12/2020	"Drug Delivery Systems, Pain"				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800023017?userId=52029392&bpIds=3004037004&checksum=6c804c339d5cabbf68b8fca9495b2cbda8a1cd7c-1617045531321-b6cb099f29130fcf472eb17dd00c8138badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027073	Oxycodone transdermal - Avecho Biotechnology	76-42-6	"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Phase II	"Postherpetic neuralgia, Pain, Neuropathic pain"	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Phosphagenics (Originator), Avecho Biotechnology (Owner), tesa Labtec (Collaborator)"		"Transdermal, Topical"				N2A (Narcotics)	N02A-A05 (Oxycodone)	"Sustainedrelease oxycodone patch Avecho Biotechnology, TPM/O patch, TPM/Oxycodone patch, TPM/oxycodone patch Avecho Biotechnology"			29/12/2020	"Drug Delivery Systems, Pain"		Avecho Biotechnology | Pain | Unspecified |  | 01 Aug 2013		no		no							https://adis.springer.com/drugs/800027073?userId=52029392&bpIds=3004037004&checksum=4eaea6e41b83fb6b563cf74ee8a2e2a2a95f37c8-1617045531322-03b1e90701cc0c072e5377ae6a93e3c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047374	Research programme: TPM-based pain therapeutics - Avecho Biotechnology/Terumo			No			No development reported (Research)	Pain		Undefined mechanism	"Phosphagenics (Originator), Avecho Biotechnology (Owner), Terumo (Collaborator)"		unspecified				"M (Musculo-Skeletal System), N2 (Analgesics)"	"M (Musculo-Skeletal System), N02 (Analgesics)"				29/12/2020	Pain				no		no							https://adis.springer.com/drugs/800047374?userId=52029392&bpIds=3004037004&checksum=a2f9286345470312072d70a178cd4b0f5bb8443a-1617045531323-800983c41afe43186de38525e9d84486badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052337	LY 03012			Yes			Phase I	Pain		"Dopamine plasma membrane transport protein antagonists, Norepinephrine plasma membrane transport protein inhibitors, Serotonin plasma membrane transport protein inhibitors"	"Luye Pharma Group (Originator), Luye Pharma Group (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	LY03012			29/12/2020	Pain				no		no							https://adis.springer.com/drugs/800052337?userId=52029392&bpIds=3004037004&checksum=40ff8a3b9e0abf69fbe440d557d36eec3a57e77e-1617045531324-67803043a0888bed9cfd39e59137d664badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061652	PPL 138			Yes			Preclinical	Pain		"Nociceptin receptor agonists, Opioid mu receptor agonists"	"University of Bath (Originator), Phoenix PharmaLabs (Owner)"		"Parenteral, Intrathecal, Sublingual"				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07B (Drugs Used In Addictive Disorders)"	"BU10038, PPL138"			29/12/2020	Pain				no		no							https://adis.springer.com/drugs/800061652?userId=52029392&bpIds=3004037004&checksum=48d4ab9117d88f82d58a08c3d5f83c564dfc4b53-1617045531325-78bb8023e1ab41c562f4fee022987680badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048327	OREX 1019			No			No development reported (Preclinical)	Cocaine-related disorders		"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"University of Bath (Originator), University of Bath (Owner), Orexigen Therapeutics (Licensee)"		unspecified				"N2A (Narcotics), N7X (All other CNS drugs)"	"N02A (Opioids), N07B-C (Drugs used in opioid dependence)"	OREX1019			28/12/2020	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800048327?userId=52029392&bpIds=3004037004&checksum=c80db9ee5bfac9c906991d85f604d07c462f45c0-1617045531326-2265557a55aa9fbb6feba2c22c466396badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045331	Asalhydromorphone - KemPharm	1431529-94-0	"17-methyl-4,5_-epoxy-6,7-didehydromorphinan-3,6-diyl bis[2-(acetyloxy)benzoate]"	Yes			No development reported (I)	Acute pain	C35 H31 N O9	Opioid receptor agonists	"KemPharm (Originator), KemPharm (Owner)"		PO				N2A (Narcotics)	N02A-A03 (Hydromorphone)	"AsalHM, Hydromorphone extended release KemPharm, Hydromorphone immediate release KemPharm, KP 511/ER, KP 511/IR, KP511 API"			28/12/2020	Pain				yes	USA	no							https://adis.springer.com/drugs/800045331?userId=52029392&bpIds=3004037004&checksum=edeb07894155bea9a1da5d391e978949b5e1e342-1617045531327-4ee4ccc09bbae316fff184d5667f8968badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026615	Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical	76-42-6	"Morphinan-6-one,4,5-_-epoxy-14-hydroxy-3-methoxy-17-methyl-"	No			Marketed	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Collegium Pharmaceutical (Originator), Collegium Pharmaceutical (Owner)"		"PO, Intranasal, IV"				N2A (Narcotics)	N02A-A05 (Oxycodone)	"COL003, Oxycodone abuse resistant Collegium Pharmaceutical, Oxycodone DETERx, Oxycodone DETERxER, Oxycodone DETERxextendedrelease, Oxycodone extended release Collegium pharmaceutical, XTAMPZA ER"			28/12/2020	"Drug Delivery Systems, Pain"			XTAMPZA ER	no		no							https://adis.springer.com/drugs/800026615?userId=52029392&bpIds=3004037004&checksum=49a93593d7d008b7f1ae88a6c63e9d66a189095e-1617045531328-c8409c44e282b1c0711b5a78dc4bc644badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048268	Research programme: oral therapeutics - Bionex Pharmaceuticals			No			No development reported (Research)	"Mycoses, Pain"		Undefined mechanism	"Bionex Pharmaceuticals (Originator), Bionex Pharmaceuticals (Owner)"		PO				"J2A (Systemic Agents for Fungal Infections), N2 (Analgesics)"	"J02A (Antimycotics for Systemic Use), N02 (Analgesics)"				28/12/2020	"Mycoses, Pain"				no		no							https://adis.springer.com/drugs/800048268?userId=52029392&bpIds=3004037004&checksum=28a18115015fee8eb8974847bb80a56c315d5889-1617045531329-b9b5babfe28f2cd928cd4018577450c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050734	TRK 750			Yes			Phase II	"Peripheral nervous system diseases, Neuropathic pain"		Undefined mechanism	"Toray (Originator), Toray (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	TRK750			28/12/2020	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800050734?userId=52029392&bpIds=3004037004&checksum=da9156e0ae9f5644bbc57633dc2c22b6b546c6de-1617045531330-e1a725e6c4832dc70a374ce777887723badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016667	Oxymorphone - Endo Pharmaceuticals	76-41-5	"Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-"	No			Marketed	"Cancer pain, Musculoskeletal pain, Postoperative pain"	C17 H19 N O4	Opioid mu receptor agonists	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner), Bausch Health Companies (Market Licensee), Grunenthal (Technology Provider)"		"PO, Parenteral"			"CNS disorders, Constipation, Dizziness, Nausea, Somnolence, Vomiting"	N2A (Narcotics)	N02A (Opioids)	"EN 3202, EN 3203, Opana, Opana ER, oxymorphone HCl"			28/12/2020	"Drug Delivery Systems, Pain"			"Opana, Opana ER"	no		no				ER alpha			https://adis.springer.com/drugs/800016667?userId=52029392&bpIds=3004037004&checksum=f280bbd85171071ec93e4739e6d0b2f3723f6ed2-1617045531331-c4f9a5126e7de667909744c7e3febad2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048600	Research programme: protein therapeutics - Synthorx			Yes			Preclinical	"Cancer, Inflammation, Infections, Metabolic disorders, Pain"		"Immunomodulators, Interleukin 15 modulators"	"Synthorx (Originator), Synthorx (Owner), The Scripps Research Institute (Technology Provider)"		unspecified				"A16A (Other Alimentary Tract and Metabolism Products), J (General Anti-Infectives Systemic), L1X9 (All other antineoplastics), L3 (Immunostimulating Agents), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"A16A (Other Alimentary Tract and Metabolism Products), A16A-A (Amino acids and derivatives), J (Anti-infectives For Systemic Use), L01X-X (Other antineoplastic agents), L03 (Immunostimulants), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"IL10 synthorin, IL15 synthorin, Synthorin cytokines"			28/12/2020	"Bacterial Infections, Cancer, Haematological Disorders, Inflammation, Metabolic Disorders, Mycoses, Pain, Rheumatic Disease, Viral Infections"				no		no							https://adis.springer.com/drugs/800048600?userId=52029392&bpIds=3004037004&checksum=2bcdb02c690a6d559f59f4fdc87c77f1cceecfd4-1617045531333-d98de135513ad24bc2a43e0775e805e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047064	Research programme: cannabinoid prodrugs - Vitality Biopharma			No			Preclinical	"Ulcerative colitis, Schizophrenia, Guillain-Barre syndrome, Inflammatory bowel diseases, Huntington's disease, Pain, Epilepsy"		Cannabinoid receptor agonists	"Vitality Biopharma (Originator), Vitality Biopharma (Owner)"		"unspecified, IV"				"A7E (Intestinal Anti-Inflammatory Agents), N (Nervous System), N2 (Analgesics), N3A (Anti-Epileptics), N4 (Anti-Parkinson Drugs), N5A (Antipsychotics)"	"A07E (Intestinal Antiinflammatory Agents), N (Nervous System), N02 (Analgesics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics)"	"Cannabinoid glycosides Vitality Biopharma, Cannabinosides Vitality Biopharma"			28/12/2020	"Epilepsy and Seizure Disorders, Inflammatory Bowel Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800047064?userId=52029392&bpIds=3004037004&checksum=f44e967ab9060c25ee680c3f91e3d84160e41960-1617045531334-5130f01112d6b83797f383e95c56beb4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048216	Research programme: CNS therapeutics - Amorsa Therapeutics			Yes			No development reported (Research)	"Depressive disorders, Pain"		NMDA receptor antagonists	"Amorsa Therapeutics (Originator), Amorsa Therapeutics (Owner), Janssen Pharmaceuticals (Collaborator)"		unspecified				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	"Amorsa KER, KAER12, KAFA, KER12"			28/12/2020	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800048216?userId=52029392&bpIds=3004037004&checksum=2fbe28a029bcea82326c89e94648370495e475c3-1617045531335-d1e92f27cbc95e88d93909a0ed3674aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046940	ASP 8062			Yes			Phase I	"Substance-related disorders, Opioid-related disorders, Fibromyalgia"		GABA B receptor modulators	"Astellas Pharma (Originator), Astellas Pharma (Owner), National Institute of Drug Abuse (Funder)"		PO				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs)"	"N02 (Analgesics), N07B (Drugs Used In Addictive Disorders), N07B-C (Drugs used in opioid dependence)"	ASP8062			28/12/2020	"Drug Withdrawal, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800046940?userId=52029392&bpIds=3004037004&checksum=45e0460f39e4aa0870729c70a554ca1d1c376c13-1617045531336-a3b8671f7293234b28b46bdd8cf8128fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031716	Research programme: cannabis extract therapeutics - Cannabis Science			Yes			Preclinical	"Sickle cell anaemia, Wounds, Dyskinesias, Lung cancer, Skin disorders, Neurological disorders, Anxiety disorders, Rheumatic disorders, Pancreatic cancer, Prostatitis, Arthritis, Sleep disorders, Obsessive-compulsive disorders, Anaemia, Skin cancer, HIV infections, Kaposi's sarcoma, Adult respiratory distress syndrome, Pain, Cancer, Post-traumatic stress disorders, Respiratory tract disorders, Fibromyalgia, Attention-deficit hyperactivity disorder, Autistic disorder, Neuropathic pain"		"Cannabinoid receptor modulators, Human immunodeficiency virus tat gene product inhibitors"	"Cannabis Science (Originator), Cannabis Science (Owner), Apothecary Genetics Investments (Development Licensee), RockBrook (Licensee), Dana-Farber Cancer Institute (Collaborator), ImmunoClin Corporation (Collaborator), Italian Institute for Health and Science on Ageing (Collaborator), University of California at Irvine (Collaborator)"		"unspecified, Topical, PO, Inhalation, Transdermal"				"C2 (Antihypertensives), J5C (HIV antivirals), L (Antineoplastic and Immunomodulating Agents), L1 (Antineoplastics), N2 (Analgesics), N5 (Psycholeptics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), R7X (All Other Respiratory System Products)"	"C02K (Other Antihypertensives), J05A-X (Other antivirals), L01 (Antineoplastic Agents), N02 (Analgesics), N05 (Psycholeptics), N05B (Anxiolytics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics), N07 (Other Nervous System Drugs), R07A-X (Other respiratory system products)"	"CBIS GAP001, CBIS LC001, CBIS OBLD001, CBIS OCD001, CBIS PC001, CBIS PPC001, CBIS PS001, CBIS SD001, CBIS SSA001, CBISOS001, CBISPTSD001, CS NEURO 1, CSS/BCC1, CSTATI1, Phytocannabinoidbased pharmaceutical products Cannabis Science"			28/12/2020	"Affective Disorders, Anxiety Disorders, Bacterial Infections, Cancer, Haematological Disorders, Men's Health, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Rheumatic Disease, Skin Disorders, Viral Infections"		Cannabis Science |  | Preclinical |  | 02 May 2013		no		no							https://adis.springer.com/drugs/800031716?userId=52029392&bpIds=3004037004&checksum=59a2be2ff65d5c0bf1864be770fd51cefead227a-1617045531340-beb4261b11d1af6585180f81d84d0ef1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042506	Dinalbuphine sebacate - Lumosa Therapeutics	311768-81-7	"bis[(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-4a,7-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl] decanedioate"	Yes			Marketed	Pain	C52 H68 N2 O10	Opioid kappa receptor agonists	"Lumosa Therapeutics (Originator), Lumosa Therapeutics (Owner), InteRx Biomedical (Market Licensee), Syntano Technology Venture (Licensee), Camargo Pharmaceutical Services (Collaborator)"		IM				N2A (Narcotics)	N02A-F (Morphinan derivatives)	"LT 1001, Naldebain, Naldebain ER injection, SDE, Sebocoyl dinalbuphine ester"			24/12/2020	Pain		Lumosa Therapeutics |  | Unspecified |  | 03 Aug 2017	Naldebain	no		no							https://adis.springer.com/drugs/800042506?userId=52029392&bpIds=3004037004&checksum=dde7e5f16966dc5a87fe810495902ee8fe6127a3-1617045531341-e5d036cdcbbca0dae67f77e669aba95dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042081	Tramadol intravenous - Revogenex/Avenue Therapeutics	27203-92-5	"Cyclohexanol, 2-((dimethylamino)methyl)-1-(3-methoxyphenyl)-, cis-(+-)-"	No			Preregistration	Postoperative pain	C16 H25 N O2	"Adrenergic receptor antagonists, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Revogenex (Originator), Revogenex (Owner), Avenue Therapeutics (Licensee)"		IV			"Dizziness, Somnolence, Vomiting"	N2A (Narcotics)	N02A-X02 (Tramadol)	"AVE901, IV tramadol Revogenex/Avenue Therapeutics, RVX 109, Tramadol hydrochloride Revogenex/Avenue Therapeutics"			24/12/2020	Pain				no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800042081?userId=52029392&bpIds=3004037004&checksum=0683d13c6e3e7178bfd198b8421591005ebb6c5c-1617045531342-13aa2e08d27d46f114e1774413b8ff34badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051643	GSK 3858279			Yes			Phase I	Pain		Chemokine CCL17 inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		"IV, SC"				N2 (Analgesics)	N02 (Analgesics)	GSK3858279			24/12/2020	Pain				no		no							https://adis.springer.com/drugs/800051643?userId=52029392&bpIds=3004037004&checksum=62ad5d6798d730bb2677396d7cbaa685b06e0150-1617045531343-555bf47c3f19745c48b6f23f86691ad4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032240	PPL 103			Yes			Preclinical	"Pain, Substance-related disorders"		"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Phoenix PharmaLabs (Originator), Phoenix PharmaLabs (Owner), Aoxing Pharmaceutical Company (Licensee), National Institute of Drug Abuse (Funder), United States Department of Defense (Funder), National Institute of Drug Abuse (Collaborator), Peking University (Collaborator), SRI International (Collaborator), Torrey Pines Institute for Molecular Studies (Collaborator), University of Michigan (Collaborator), Virginia Commonwealth University (Collaborator), Wake Forest University Health Sciences (Collaborator)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02A (Opioids), N07B (Drugs Used In Addictive Disorders)"	"Opioid derivatives Phoenix PharmaLabs, PPL103"			23/12/2020	"Drug Withdrawal, Pain"		Phoenix PharmaLabs |  | Unspecified |  | 28 Apr 2015		no		no							https://adis.springer.com/drugs/800032240?userId=52029392&bpIds=3004037004&checksum=b8c249d29ef2d24e8b389b2ce1bfee6248105e38-1617045531344-eb976bc28484a05006c1907566ac9845badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041985	NRD 135S E1			Yes			Phase II	Neuropathic pain		Lyn protein-tyrosine kinase modulators	"Novaremed (Originator), Novaremed (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"E1, NRD.E1, NRD135S, NRD135SE1"			23/12/2020	Pain				no		no							https://adis.springer.com/drugs/800041985?userId=52029392&bpIds=3004037004&checksum=68afcd2dd62e401140ffc8afde668e0067a483eb-1617045531345-ba27447178b9b8fefc2d958ceb473f23badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024656	Diclofenac oral solution - Assertio Therapeutics/Novartis	15307-81-0	"Potassium [o-(2,6-dichloroanilino)phenyl]acetate"	No			Marketed	Migraine	C14 H10 Cl2 K N O2	Cyclooxygenase inhibitors	"Applied Pharma Research (Originator), Applied Pharma Research (Owner), CSC Pharmaceuticals Bulgaria (Market Licensee), Renhe Group (Market Licensee), Assertio Therapeutics (Licensee), Novartis (Licensee), Miravo Healthcare (Sub-licensee), Deerfield (Funder)"		PO				N2 (Analgesics)	"M01A-B05 (Diclofenac), N02 (Analgesics)"	"Cambia, Catafast, Dialrapid, Potassium diclofenac for oral solution, PRO513, Voltfast"			23/12/2020	Advances in the Treatment of Nausea and Migraine			"Cambia, Cambia, Catafast, Catafast, Dialrapid, Voltfast, Voltfast, Voltfast, Voltfast, Voltfast"	no		no							https://adis.springer.com/drugs/800024656?userId=52029392&bpIds=3004037004&checksum=55850b9a0a8f5c0b02850396d5fff022b410933c-1617045531348-7c2c75728a12856189007c2471d3be46badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057418	Cannabidiol/tetrahydrocannabinol - Zelira Therapeutics		"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-/ 1-trans-delta9-Tetrahydrocannabinol"	No			Marketed	Insomnia	C21-H30-O2.C21-H30-O2	"Cannabinoid receptor agonists, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Zelira Therapeutics (Originator), Zelira Therapeutics (Owner), Aunt Zelda (Collaborator), The University of Western Australia (Collaborator)"		Sublingual				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N02B-G10 (Cannabinoids, including nabiximols), N05C (Hypnotics and Sedatives)"	"CDB/THC, medicinal cannabis, Tetrahydrocannabinol/cannabidiol Zelira Therapeutics, Zenivol, ZTL 101"			22/12/2020	"Anxiety Disorders, Neurological Disorders"			Zenivol	no		no							https://adis.springer.com/drugs/800057418?userId=52029392&bpIds=3004037004&checksum=92f9f6baf20a611b94e251608c324d74075a12e5-1617045531349-5a013949ff3549b2879af1390443cbe2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055392	DWP 17061			Yes			Phase I	Musculoskeletal pain		Nav1.7 voltage-gated sodium channel inhibitors	"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	DWP17061			21/12/2020	Pain				no		no							https://adis.springer.com/drugs/800055392?userId=52029392&bpIds=3004037004&checksum=604ed7a36a29ecc0e379618579d11631b3e47e92-1617045531350-9ab09f74ba9dd6a32e0bda1bc5331549badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059947	KCP 506			Yes			Phase I	Neuropathic pain		Nicotinic receptor antagonists	"Kineta (Originator), Kineta (Owner), Genentech (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"alpha9/alpha10 nicotinic acetylcholine receptor antagonist Kineta, KCP506, nAChR antagonist Kineta"			21/12/2020	Pain				no		no							https://adis.springer.com/drugs/800059947?userId=52029392&bpIds=3004037004&checksum=430ed58e9aef44345550ce157d0de1860cb88bec-1617045531351-27ce9e37f05809ba395aaa0d70754ac5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032789	ISC 17536	1649479-05-9		Yes			Phase II	"Neuropathic pain, Cough, Allergic asthma"		TRPA1 protein inhibitors	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), Ichnos Sciences (Collaborator)"		"PO, Inhalation"				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products), R5D (Antitussives)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases), R05D (Cough Suppressants, Excl. Combinations with Expectorants)"	"GRC 17536 potassium powder for inhalation Glenmark Pharmaceuticals, GRC17536, ISC17536"			21/12/2020	"Obstructive Airways Disease, Pain, Respiratory Tract Disorders"		Glenmark Pharmaceuticals Ltd |  | Clinical Phase Unknown |  | 15 Oct 2013		no		no							https://adis.springer.com/drugs/800032789?userId=52029392&bpIds=3004037004&checksum=dd8fc6c640ad9f4bf0537af2cd65f17e33b2c2e3-1617045531352-8eaca0bda0b21ed14543ffb2a83b612fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058990	Amitriptyline topical - AlgoTherapeutix	50-48-6	"N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine"	No			Preclinical	Neuropathic pain	C20 H23 N		"AlgoTherapeutix (Originator), AlgoTherapeutix (Owner)"		Topical				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	"Amitriptyline gel, ATX01"			17/12/2020	Pain	Erythromelalgia (USA)			no		no							https://adis.springer.com/drugs/800058990?userId=52029392&bpIds=3004037004&checksum=55277592d396123c3a382bc528ef4bfaab17ae8c-1617045531353-c28dc8e9734289ed4c2a03e03a579580badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051732	Meloxicam - Viatris	71125-38-7	"2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl- 2-thiazolyl)-, 1,1-dioxide"	No			Preclinical	Acute pain	C14 H13 N3 O4 S2	"Cyclo-oxygenase 2 inhibitors, Cyclooxygenase inhibitors"	"Prayog Labs (Originator), Prayog Labs (Owner), Viatris Inc (Licensee)"		unspecified				N2 (Analgesics)	"M01A-C06 (Meloxicam), N02 (Analgesics)"				17/12/2020	Pain				no		no							https://adis.springer.com/drugs/800051732?userId=52029392&bpIds=3004037004&checksum=4fbd9eeacf22bacf226a9f4e58c4ffcd1fcf4474-1617045531354-e8a40382aef05223249165abf9787dd1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053962	Fentanyl transdermal - Nutriband/4P Therapeutics	437-38-7	N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Preclinical	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"4P Therapeutics (Originator), Nutriband (Owner)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"AVERSA, Defent fentanyl transdermal system"			15/12/2020	Pain				no		no							https://adis.springer.com/drugs/800053962?userId=52029392&bpIds=3004037004&checksum=892ffa44ce8d294cd00d52dd0d1d56ca5ea719de-1617045531355-a8f2462f95239513564558a3b7eb5262badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060378	Tramadol - Athena Bioscience	36282-47-0	 (±)cis-2- [(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride	No			Registered	Pain	C16 H25 N O2 . H CL	"Adrenergic uptake inhibitors, Opioid mu receptor agonists"	"Athena Bioscience (Originator), Athena Bioscience (Owner)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"QDOLO, Tramadol hydrochloride Athena Bioscienc"			14/12/2020	Pain			QDOLO	no		no							https://adis.springer.com/drugs/800060378?userId=52029392&bpIds=3004037004&checksum=efe61134e34cf2a41506cbd19848e9bbf2cf3b9f-1617045531355-58772349e8f320de656b7c744501b8d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061344	HTL 0022562			Yes			Preclinical	Migraine		Calcitonin gene-related peptide antagonists	"Sosei Heptares (Originator), Sosei Heptares (Owner), Biohaven Pharmaceuticals (Licensee), Biohaven Pharmaceutical Holding Company (Collaborator)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	HTL0022562			11/12/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800061344?userId=52029392&bpIds=3004037004&checksum=44c99ac1434af2cb8aac9ff0f049392c9e980d1d-1617045531356-1024b86dddfcdb6f339c213cf4cc5b7ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040833	Cannabinol ophthalmic - InMed Pharmaceuticals	521-35-7	"6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol"	No			Preclinical	"Glaucoma, Hypersensitivity"	C21 H26 O2	"Apoptosis inhibitors, Cannabinoid receptor agonists"	"Cannabis Technologies (Originator), InMed Pharmaceuticals (Owner), Mitacs (Funder), University of British Columbia (Collaborator), University of Debrecen (Collaborator)"		"Ophthalmic, unspecified"				"S1E2 (Miotics and antiglaucoma preparations, topical)"	"N02B-G10 (Cannabinoids, including nabiximols), S01E-X (Other antiglaucoma preparations)"	"CTI085, INM 085, INM088"			08/12/2020	"Eye Disorders, Immunological Disorders"				no		no							https://adis.springer.com/drugs/800040833?userId=52029392&bpIds=3004037004&checksum=bad004305b5abbd839759a484e6c04ef631f8e13-1617045531357-5fa316ef2f0f87bbc31957c7e229a0d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041270	Methoxyflurane inhalation - Medical Developments International	76-38-0	"Ethane, 2,2-dichloro-1,1-difluoro-1-methoxy-"	No			Marketed	Pain	C3 H4 Cl2 F2 O	"GABA receptor modulators, Gap junction modulators, Glutamate receptor modulators"	"Medical Developments International (Originator), Medical Developments International (Owner), LINK Healthcare (Market Licensee), Mundipharma International (Market Licensee), Nikkan Pharma (Market Licensee), Purdue Pharma (Market Licensee), Daiichi Sankyo Company (Licensee), Galen Limited (Licensee), Mundipharma International (Licensee), Singapore General Hospital (Collaborator)"		Inhalation				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G09 (Methoxyflurane)	"Anecotan, Green whistle, MEMEOTH, Methofane, Methoflurane, Methofluranum, Methoxane, Methoxyfluran, Metofane, Metoxifluran, NSC110432, Penthrane, Penthrop, Penthrox, PENTHROX, Penthrox3, Pentran, Pentrane"			07/12/2020	"Drug Delivery Systems, Pain"			"PENTHROX, Penthrop, Penthrox, Penthrox, Penthrox, Penthrox, Penthrox, Penthrox, Penthrox"	no		no							https://adis.springer.com/drugs/800041270?userId=52029392&bpIds=3004037004&checksum=39f2e90308b072c25eadd78f33ce730ecf680ddf-1617045531364-782ab6e7fdbb353256690f3315a45435badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046945	LEVI 04			Yes			Phase I	Pain		Nerve growth factor receptor modulators	"Pfizer (Originator), Levicept (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	"LEVI04, p75NTRFc"			07/12/2020	Pain				no		no				NGF			https://adis.springer.com/drugs/800046945?userId=52029392&bpIds=3004037004&checksum=958cb5a0df20b4fea3b9f27c6974a10fb8c5df36-1617045531365-709911304530a6198e08edb2cdff4037badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061086	JT 09			Yes			Preclinical	"Pruritus, Pain"		Opioid kappa receptor agonists	"JT Pharmaceuticals (Originator), Titan Pharmaceuticals (Owner), Medical University of South Carolina (Collaborator)"		"SC, PO"				"D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04 (Antipruritics, Incl. Antihistamines, Anesthetics, etc.), N02 (Analgesics)"	"JT09, JT09 Implant, JT09 ProNeura implants"			07/12/2020	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800061086?userId=52029392&bpIds=3004037004&checksum=9d740b3f88cc3d283082896e0cd4912092439619-1617045531366-5c99c8e0a750332031741b05d682d20bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051738	Cannabidiol/dronabinol- Beckley Canopy Therapeutics			Yes			Phase I/II	"Cancer pain, Unspecified"		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists"	"Beckley Canopy Therapeutics (Originator), Beckley Canopy Therapeutics (Owner)"		PO				"N7X (All other CNS drugs), V (Various)"	"N02B-G10 (Cannabinoids, including nabiximols), V (Various)"	BCT521			04/12/2020	Pain				no		no							https://adis.springer.com/drugs/800051738?userId=52029392&bpIds=3004037004&checksum=e098f861b5242712d6a7feff836828cee3a770c3-1617045531366-4b8d4da0abfd525f909aa7e3964d1129badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054894	NTRX 07		"(1-[(3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl)carbonyl]piperidine)"	Yes			Phase I	"Alzheimer's disease, Neuropathic pain"	C22 H25 N O2	Cannabinoid receptor CB2 agonists	"University of Texas M. D. Anderson Cancer Center (Originator), University of Texas System (Owner), NeuroTherapia (Licensee), Alzheimers Drug Discovery Foundation (Funder), Cleveland Clinic (Collaborator)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"MDA7, NTRX07"			04/12/2020	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800054894?userId=52029392&bpIds=3004037004&checksum=4fa3cb401a6019f1551af425968715de72ff7f6f-1617045531367-19f5358a2e2bcc481c30382cec44b0c6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019600	Befiradol - Neurolixis	208110-64-9	(3-chloro-4-fluorophenyl)-[4-fluoro-4-[[(5-methypyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone	Yes			Phase II	"Diabetic neuropathies, Drug-induced dyskinesia, Neuropathic pain, Cancer pain"	C20 H22 Cl F2 N3 O	Serotonin 1A receptor agonists	"Pierre Fabre (Originator), Pierre Fabre (Owner), Neurolixis (Licensee), Parkinson's UK (Funder), The Michael J. Fox Foundation for Parkinson's Research (Funder), Gala Laboratories (Collaborator), Jagiellonian University (Collaborator)"		PO				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics), N4 (Anti-Parkinson Drugs)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N02C-C (Selective serotonin (5HT1) agonists), N04 (Anti-Parkinson Drugs)"	"F13640, NLX 112"			01/12/2020	"Diabetes, Pain, Parkinson's Disease and Movement Disorders"		Neurolixis | Drug-induced dyskinesia | Unspecified | World | 06 Feb 2015		no		no							https://adis.springer.com/drugs/800019600?userId=52029392&bpIds=3004037004&checksum=354d6efb2a2b5da625a16727e60446246839eba4-1617045531370-30bde727e09af0d0da3fce1f6d37d41dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053087	LY 3451838			Yes			Phase II	Migraine		Pituitary adenylate cyclase-activating polypeptide receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		"IV, SC"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	LY3451838			01/12/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800053087?userId=52029392&bpIds=3004037004&checksum=a65915d748f84af356154c9d67a3dd5ef1ebe06c-1617045531371-bfdac5a4330ce46bc7281f2382517a5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049435	Parentide - DiverDrugs			Yes			Discontinued (II)	"Neuropathic pain, Cancer pain"		TRPV1 receptor antagonists	"DiverDrugs (Originator), DiverDrugs (Owner), BCN Peptides (Collaborator)"		"SC, unspecified"				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	DD 04107			01/12/2020	Pain				no		no							https://adis.springer.com/drugs/800049435?userId=52029392&bpIds=3004037004&checksum=27b6ecdc01ff427e69e19a1ee261a7139bb2ac9c-1617045531372-be783417bc9e6a759c7b741abb4d91c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044856	Pregabalin controlled release - Alvogen Korea	148553-50-8	(<EM>S</EM>)-3-(Aminomethyl)-5-methylhexanoic acid	No			No development reported (I)	Neuropathic pain	C8 H17 N O2	CACNA2D1 protein modulators	"KunWha Pharmaceutical (Originator), Alvogen Korea (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	KW21052			30/11/2020	Pain				no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800044856?userId=52029392&bpIds=3004037004&checksum=257c5856ba8f0d0e884ceb1f00eabbf24f1e0876-1617045531373-eb77e4460da41f9daa13351f7c35c3b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046495	RBM 007			Yes			Phase II	"Wet age-related macular degeneration, Achondroplasia, Bone disorders, Cancer pain, Age-related macular degeneration, Fibrosis"		Fibroblast growth factor inhibitors	"Ribomic (Originator), Ribomic (Owner), AJU Pharm (Licensee), Japan Agency for Medical Research and Development (Funder)"		"Intravitreous, SC, unspecified"				"L4 (Immunosuppressants), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"L04 (Immunosuppressants), M05 (Drugs for Treatment of Bone Diseases), N02 (Analgesics), S01X-A (Other ophthalmologicals)"	RBM007			30/11/2020	"Eye Disorders, Inflammation, Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800046495?userId=52029392&bpIds=3004037004&checksum=64a17f57161f4b904e07af59bb4badb650827e2e-1617045531375-b3ec486de7aec4396f7cf930ca2d9cb6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048170	Lohocla 201			Yes			No development reported (Preclinical)	"Anxiety disorders, Pain"		"Nav1.7 voltage-gated sodium channel modulators, Nav1.8 voltage-gated sodium channel modulators, NMDA receptor modulators, Opioid delta receptor agonists"	"Lohocla Research (Originator), Lohocla Research (Owner), National Institutes of Health (USA) (Funder)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	"Kindolor, Lohocla201"			28/11/2020	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800048170?userId=52029392&bpIds=3004037004&checksum=ecba9b9be5c2d718358adaf84a734ffce74e35a2-1617045531376-a0999df721af2324a578345b7726c421badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048155	Research programme: Src-ND2 inhibitors - NoNO			Yes			No development reported (Preclinical)	"Neuropathic pain, Inflammation"		Protein-protein interaction inhibitors	"NoNO (Originator), NoNO (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				28/11/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800048155?userId=52029392&bpIds=3004037004&checksum=98d49415bcfc4f0dcde8698b895345ac203bf651-1617045531376-d43f027faffe0e8e464fb2adbc61026abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050326	Naproxen/pregabalin conjugate - Xgene Pharmaceutical		(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid/ (+)-4-Amino-3(S)-isobutylbutyric acid	No			Phase II	"Acute pain, Postoperative pain, Neuropathic pain, Back pain, Diabetic neuropathies, Pain"	C14 H14 O3/ C8 H17 N O2	"CACNA2D1 protein modulators, Cyclooxygenase inhibitors"	"Xgene Pharmaceutical (Originator), Xgene Pharmaceutical (Owner)"		"PO, Topical"				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E (Propionic acid derivatives), M01A-E02 (Naproxen), N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	"XG 005, XG004 03, XG005 01, XG005 02, XG005 03"			28/11/2020	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800050326?userId=52029392&bpIds=3004037004&checksum=057edb734948a641976e1d62f93f45ef415ce082-1617045531378-e823765556bcad2575a0519d9763a4a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057295	PNB 001		"4-chloro-5-hydroxy-1-phenylethyl-5-phenyl-1,5-dihydro-pyrrol-2-one"	Yes			Phase II	"COVID 2019 infections, Dysmenorrhoea, Pain, Ulcerative colitis, Inflammatory bowel diseases"	C18 H16 N O2 Cl	"Cholecystokinin A receptor antagonists, Cholecystokinin B receptor antagonists"	"PNB Vesper Life Science (Originator), PNB Vesper Life Science (Owner)"		"PO, Intraperitoneal, SC"				"J5 (Antivirals for Systemic Use), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"J05 (Antivirals for Systemic Use), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N02B (Other Analgesics and Antipyretics)"	PNB001			27/11/2020	"Inflammatory Bowel Disorders, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800057295?userId=52029392&bpIds=3004037004&checksum=297adda687efc27b7fb3edac5821001b8375ca66-1617045531379-6ab9e7808c646366f6e5f97a4ad4e522badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051808	ART 2612			Yes			Research	"Pain, Inflammation, Cancer"		FABP5 protein inhibitors	"The Research Foundation of State University of New York (Originator), Artelo Biosciences (Owner), Mitacs (Funder)"		unspecified				"L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	ART26.12			27/11/2020	"Cancer, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800051808?userId=52029392&bpIds=3004037004&checksum=5475ce5182caf7cdf13efbd569f76783614471f5-1617045531380-b3ac3d61b7dca48b88c813958510dbaabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046803	EC 5026	1809885-32-2	(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea	Yes			Phase I	"Neuropathic pain, Pain, Diabetic neuropathies"	C18 H23 F4 N3 O3	Epoxide hydrolase inhibitors	"EicOsis (Originator), EicOsis (Owner), University of California, Davis (Technology Provider), National Cancer Institute (USA) (Funder), National Institute of Drug Abuse (Funder), NIH Blueprint Neurotherapeutics Network (Funder)"		PO				N2 (Analgesics)	N02 (Analgesics)	"BPN19186, EC5026"			25/11/2020	Pain				yes	USA	no							https://adis.springer.com/drugs/800046803?userId=52029392&bpIds=3004037004&checksum=cccde68fa564e0bcde2c628999be2af2edcf74fd-1617045531381-31eb5bd89a9c68a085f05456a6c1cecbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061168	TVT 004			Yes			Preclinical	"Pain, Neuropathic pain"		Undefined mechanism	"Travecta Therapeutics (Originator), Travecta Therapeutics (Owner), Duke-NUS Graduate Medical School Singapore (Technology Provider)"		PO				N2 (Analgesics)	N02 (Analgesics)	TVT004			24/11/2020	Pain				no		no							https://adis.springer.com/drugs/800061168?userId=52029392&bpIds=3004037004&checksum=0f6b81dd4b602412ac40c88714040a22c0b80bb3-1617045531382-3d63bf4330b9cf6ccdc7919d3183ef85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045527	Sodium metaarsenite - Komipharm International	7784-46-5	sodium;oxoarsinite	No			Phase II	"Liver cancer, Prostate cancer, Cancer pain, Non-Hodgkin's lymphoma, Cholangiocarcinoma, Glioblastoma, Lymphoma, Biliary cancer, Brain cancer, Solid tumours, Lung cancer, Non-small cell lung cancer"	Na As O2	"Gene expression modulators, Signal transduction pathway modulators, Telomerase inhibitors"	"Komipharm International (Originator), Komipharm International (Owner), University of Maryland Greenbaum Cancer Center (Collaborator)"		PO				"L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics)"	"KML 001, KOMINOX, PANAPHIX, PAX1"			24/11/2020	"Cancer, Pain"			"KOMINOX, PANAPHIX"	no		no							https://adis.springer.com/drugs/800045527?userId=52029392&bpIds=3004037004&checksum=97a2a45beb882fde14f2bf77c4e046b4465635c8-1617045531384-2b5ff1f08cfc9f99269e3e5b9cf2d55fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043276	Ropivacaine extended release - PainReform	84057-95-4	"(-)-1-Propyl-2',6'-pipecoloxylidide"	No			Phase II	Postoperative pain	C17 H26 N2 O	"Potassium channel antagonists, Sodium channel antagonists"	"PainReform (Originator), PainReform (Owner)"		"Instillation, Parenteral"				"N1B (Anaesthetics, Local), N2 (Analgesics)"	"N01B (Anesthetics, Local), N02 (Analgesics)"	"PRF 110, PRF110oily solution"			24/11/2020	Pain				no		no				"bFGF, BNP, CCL5, CD38, CKB, CKM, CRP, CXCL10, D-dimer, Eotaxin, G-CSF, Hydrocortisone, IFN-gamma, IGFBP7, IL1 beta, IL10, IL13, IL15, IL17, IL2, IL4, IL5, IL6, IL7, IL8, IL9, interleukin 1 receptor type 1, KRAS, MCP1, MIP-1 alpha, NGAL, Norepinephrine, NRAS, PDGFB, Prolactin, proteasome 26S subunit, non-ATPase 1, RAGE, serotonin, TIMP-2, TNF-alpha, troponin I, cardiac, VEGF-A, VEGF-C"	"bFGF, CCL5, CRP, CXCL10, D-dimer, Eotaxin, G-CSF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL15, IL17, IL2, IL4, IL5, IL6, IL7, IL8, IL9, MCP1, MIP-1 alpha, PDGFB, TNF-alpha, troponin I, cardiac, VEGF-A"	"CCL4, exo/endonuclease G, GM-CSF, HIF, IL12A, IL12B, IL1RA, PGE2"	https://adis.springer.com/drugs/800043276?userId=52029392&bpIds=3004037004&checksum=20ba2543096ba757623eb69031969efe52753b9e-1617045531385-d4c895c9fc2d26c493d510dfdff201febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059035	Cannabidiol transdermal patch - Greene Street Pharmaceuticals	13956-29-1	"2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol"	No			Research	Pain	C21 H30 O2	"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Green Street Pharmaceuticals (Originator), Green Street Pharmaceuticals (Owner), VerdePharmHealth (Collaborator)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)	CBDCubed Greene Street Pharmaceuticals			24/11/2020	Pain				no		no							https://adis.springer.com/drugs/800059035?userId=52029392&bpIds=3004037004&checksum=1cf0b89d6181cf5df6695282e5d8a4682c6d2ed0-1617045531386-d433e2415d42eb31ba38be416628a472badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061047	RLVT 9-01			Yes			Preclinical	Neuropathic pain		Immunomodulators	"University of California, Riverside (Originator), University of California, Riverside (Owner), Releviate Therapeutics (Licensee)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	RLVT901			23/11/2020	Pain				no		no							https://adis.springer.com/drugs/800061047?userId=52029392&bpIds=3004037004&checksum=7e40b16febe2a12e7a08d11fe7965341c9f3c24d-1617045531387-9dff7b2b99a3ad9ca362bfaf89de2c99badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050863	VPX 638			No			Phase II	Pain		Undefined mechanism	"University of Texas M. D. Anderson Cancer Center (Originator), Vapogenix (Originator), University of Texas M. D. Anderson Cancer Center (Owner), Vapogenix (Owner), National Institute of Arthritis and Musculoskeletal and Skin Diseases (Funder)"		Topical				"N1 (Anaesthetics), N2 (Analgesics)"	"N01 (Anesthetics), N02 (Analgesics)"	VPX638			22/11/2020	Pain		Vapogenix | Pain | Unspecified |  | 07 Jan 2020		no		no							https://adis.springer.com/drugs/800050863?userId=52029392&bpIds=3004037004&checksum=f6b491ab180baf5d0b22ed26dace45e3db532722-1617045531388-e7e85c95fe81a99e8ca90946f0b20398badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058530	Tramadol - Addpharma	27203-92-5	"Cyclohexanol, 2-((dimethylamino)-1-(3-methoxyphenyl)-, cis-(+-)-"	No			Phase I	Pain	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Addpharma (Originator), Addpharma (Owner)"		Parenteral				N2A (Narcotics)	N02A-X02 (Tramadol)	AD 2112			20/11/2020	Pain				no		no							https://adis.springer.com/drugs/800058530?userId=52029392&bpIds=3004037004&checksum=f7a23623f8ed29c6eef469949178954cf43468f9-1617045531388-09bbbbe8ae54895e38bb54b9c4d735b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800061070	Diclofenac epolamine - IBSA	119623-66-4	"2-[2-(2,6-dichloroanilino)phenyl]acetic acid;2-pyrrolidin-1-ylethanol"	No			Marketed	Acute pain	C20 H24 Cl2 N2 O3	Cyclooxygenase inhibitors	"IBSA (Originator), IBSA (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"Diclofenac epolamine topical system 1.3 IBSA, Licart"			19/11/2020	Pain			Licart	no		no							https://adis.springer.com/drugs/800061070?userId=52029392&bpIds=3004037004&checksum=b1cb3f68972ec3738bcfe8da21e6f8000f9c64c7-1617045531389-2b65ad4a6c23bf4309a7163b7b804a51badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040910	Ketamine sublingual - iX Biopharma	6740-88-1	2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone	No			Phase II	"Pain, Dental pain, Acute pain, Depressive disorders"	C13 H16 Cl N O	NMDA receptor antagonists	"iX Biopharma (Originator), iX Biopharma (Owner)"		Sublingual				N2B1 (Prescription-bound non-narcotics and anti-pyretics)	N02B (Other Analgesics and Antipyretics)	"Ketamine wafer iX Biopharma, Wafermine"			18/11/2020	"Affective Disorders, Pain"		iX Biopharma |  | Unspecified |  | 11 Dec 2019	Wafermine	no		no				"OPRM1, potassium channel, two pore domain subfamily K, member 3"		"BDNF, glial cell derived neurotrophic factor, IGF1, IL6, IL8, PSA, superoxide dismutase 2, mitochondrial, synaptosomal-associated protein, 25kDa, TGF-beta, TNF-alpha, transforming growth factor, alpha"	https://adis.springer.com/drugs/800040910?userId=52029392&bpIds=3004037004&checksum=98271d3d5c1b46c2b554c926e85d361737dce190-1617045531390-3432b00ff5da538e56f0d8c830d7391fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022481	Research programme: CNS disorders therapeutics - Ocuphire Pharma			No			No development reported (Preclinical)	"Major depressive disorder, Neuropathic pain, Cognition disorders, Anxiety disorders, Neurological disorders"		Undefined mechanism	"Revaax Pharmaceuticals (Originator), Revaax Pharmaceuticals (Owner), Ocuphire Pharma (Licensee)"		unspecified				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs)"	"N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants), N07 (Other Nervous System Drugs)"	RX10000			13/11/2020	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800022481?userId=52029392&bpIds=3004037004&checksum=535bc6ada71a4030e4113fa9fc9c1593a6057c67-1617045531391-5a8a04abf6a97f9bdcc10b4464ade3e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058634	Naproxen/rizatriptan - Eurofarma		"sodium;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate/N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine"	No			Preclinical	Migraine	C14 H14 O3.C15 H19 N5	"Cyclooxygenase inhibitors, Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Eurofarma (Originator), Eurofarma (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	Rizatriptan/naproxen			12/11/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800058634?userId=52029392&bpIds=3004037004&checksum=62f6c96abe2a83e83db39c2c577c944202c0e363-1617045531392-fb89c613858b2a2f7289a8fdc32b8de2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056188	HSK 21542			Yes			Phase II	"Pruritus, Postoperative pain"		Opioid kappa receptor agonists	"Sichuan Haisco Pharmaceutical (Originator), Sichuan Haisco Pharmaceutical (Owner)"		"Parenteral, Injection"				"D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2A (Narcotics)"	"D04A-X (Other antipruritics), N02A (Opioids)"	HSK21542			11/11/2020	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800056188?userId=52029392&bpIds=3004037004&checksum=ea0b2f7585bd164251b3aaa2350e2cbb3d5f6370-1617045531399-84b0810d498408704542292c6b5a75dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045062	CNTX 6970			Yes			Phase II	Inflammatory pain		CCR2 receptor antagonists	"Boehringer Ingelheim (Originator), Centrexion Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	CNTX6970			11/11/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800045062?userId=52029392&bpIds=3004037004&checksum=b6560caa3a2ea5f749a6a8bc47f5a6bcb3f291d4-1617045531400-dbaabc5df3c54b7a880b321318abd637badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024574	Tapentadol immediate release - Grunenthal	175591-23-8	"(-)-[(1R,2R)-3-(3-Dimethylamino)-1-ethyl-2-methyl-propyl)]phenol"	Yes			Marketed	"Pain, Postoperative pain"	C14 H23 N O	Opioid mu receptor agonists	"Grunenthal (Originator), Grunenthal (Owner), Janssen Pharmaceutical KK (Development Licensee), Collegium Pharmaceutical (Licensee), Janssen Research & Development (Licensee), Ortho-McNeil (Licensee)"		"PO, IV"			"Constipation, Dizziness, Nausea, Somnolence, Vomiting"	"N2 (Analgesics), N2A (Narcotics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N02A-X06 (Tapentadol), N07 (Other Nervous System Drugs)"	"BN200, CG5503, Nucynta, Palexia, R331333, Tapentadol HCl immediate release, Tapentadol hydrochloride, Tapentadol IR, Tapentadol OS"			10/11/2020	Pain			"Nucynta, Nucynta, Palexia"	no		no				"Bilirubin, CKB, CKM, EH domain containing 3, ER alpha, lipase C, hepatic type, Testosterone, Uric acid, WAS/WASL interacting protein family, member 1"			https://adis.springer.com/drugs/800024574?userId=52029392&bpIds=3004037004&checksum=5e3994f031574452834c16e8c0c092b4250eb96c-1617045531404-43308d584c2f68a1e807e667ecffb603badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029500	Sufentanil/triazolam sublingual - AcelRx			No			No development reported (II)	"Sedation, Procedural pain"		"GABA A receptor agonists, Opioid mu receptor agonists"	"AcelRx Pharmaceuticals (Originator), AcelRx Pharmaceuticals (Owner)"		Sublingual				"N2 (Analgesics), N5B2 (Non-barbiturates, combinations)"	"N02 (Analgesics), N05C-X (Hypnotics and sedatives in combination, excl. barbiturates)"	"ARX03, ARXF03, sublingual sufentanil/triazolam NanoTab, triazolam/sufentanil"			10/11/2020	Pain		"AcelRx Pharmaceuticals | Pain, Sedation | Unspecified |  | 30 Jun 2011"		no		no				"KRAS, NRAS"			https://adis.springer.com/drugs/800029500?userId=52029392&bpIds=3004037004&checksum=37be4998132a9b80147ece3eb57f69823fd8df25-1617045531405-9b202a82321de634e4ce598b1303a1a3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049862	Buprenorphine oral - Orexo	52485-79-7	"17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol"	No			Suspended (I)	"Opioid-related disorders, Pain"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Orexo (Originator), Orexo (Owner)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	OX382			06/11/2020	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800049862?userId=52029392&bpIds=3004037004&checksum=d2cb147dfbcf12a2617b4bca61dea7bfabd22a00-1617045531406-9debefe63b551d7b5f0696033e163d1abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045116	Esflurbiprofen transdermal - Teikoku Seiyaku			No			Phase I	Acute pain		"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Teikoku Seiyaku (Originator), Teikoku Seiyaku (Owner), SocraTec R&D (Collaborator)"		"Transdermal, Topical"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				06/11/2020	Pain				no		no							https://adis.springer.com/drugs/800045116?userId=52029392&bpIds=3004037004&checksum=9486918c8d7012c8f7129c9e53b341f6c8ea2453-1617045531407-56a05399ae392fef657f30391452da63badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045065	CNTX 6016			Yes			Phase I/II	Neuropathic pain		Cannabinoid receptor CB2 agonists	"Boehringer Ingelheim (Originator), Centrexion Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	CNTX6016			06/11/2020	Pain				no		no							https://adis.springer.com/drugs/800045065?userId=52029392&bpIds=3004037004&checksum=d5acfac07bb639dbbb27da78458774c05fa445c0-1617045531408-433080bfa6cdc834a179f1124a3ed231badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027281	Research programme: NOX inhibitors - GenKyoTex			Yes			Preclinical	"Pain, Inflammation, Cardiovascular disorders, Hearing loss, Parkinson's disease, Cancer, Idiopathic pulmonary fibrosis, Diabetic nephropathies"		"NOX1 protein inhibitors, NOX4 protein inhibitors"	"GenKyoTex (Originator), GenKyoTex (Owner), University of Southampton (Collaborator)"		unspecified				"A10 (Drugs Used in Diabetes), A10X (Other Drugs Used in Diabetes), A5B (Hepatic Protectors, Lipotropics), C (Cardiovascular System), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs), R (Respiratory System), S2D (Other Otologicals)"	"A05B (Liver Therapy, Lipotropics), A10 (Drugs Used in Diabetes), A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs), R (Respiratory System), S02D (Other Otologicals)"	"GKT03, GKT136901, GKT771, GKT901, HTS programme, NOX inhibitors GenKyoTex"			06/11/2020	"Cancer, Diabetes, Ear, Nose and Throat Disorders, Inflammation, Ischaemic Heart Disease, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Respiratory Tract Disorders, Vascular Disorders"	"Idiopathic pulmonary fibrosis (European Union), Idiopathic pulmonary fibrosis (USA)"			no		no							https://adis.springer.com/drugs/800027281?userId=52029392&bpIds=3004037004&checksum=8b800fa548ad50be8779197d7b058c922ca32e3d-1617045531409-8eaef19b46952e1f5ae2b36d0b918c53badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060819	Research programme: lasso peptide based therapeutics - Lassogen			Yes			Research	"Inflammation, Metabolic disorders, Autoimmune disorders, Pain, Infections"		Undefined mechanism	"Lassogen (Originator), Lassogen (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), J (General Anti-Infectives Systemic), L1X (All Other Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A16 (Other Alimentary Tract and Metabolism Products), J (Anti-infectives For Systemic Use), L01X (Other Antineoplastic Agents), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				05/11/2020	"Bacterial Infections, Immunological Disorders, Inflammation, Metabolic Disorders, Pain"		Lassogen |  | Unspecified |  | 16 Oct 2020		no		no							https://adis.springer.com/drugs/800060819?userId=52029392&bpIds=3004037004&checksum=c679d1504c90807c4e0000b860aaa383173366a4-1617045531411-9a07d559ec30a1fef289cc612ba6e101badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048744	JZP 385			Yes			Phase II	"Essential tremor, Epilepsy, Neuropathic pain"		T-type calcium channel modulators	"Cavion (Originator), Jazz Pharmaceuticals plc (Owner)"		unspecified				"N2 (Analgesics), N3 (Anti-Epileptics), N4 (Anti-Parkinson Drugs)"	"N02 (Analgesics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs)"	"CX8998, JZP385"			05/11/2020	"Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800048744?userId=52029392&bpIds=3004037004&checksum=17f332858c224afb31f4641c1f7cc04e2b00449b-1617045531412-5340c5ed4333996af09a831112fb694bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060845	CFTX 1554			Yes			Preclinical	Neuropathic pain		Angiotensin type 2 receptor antagonists	"Confo Therapeutics (Originator), Confo Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CFTX1554			04/11/2020	Pain				no		no							https://adis.springer.com/drugs/800060845?userId=52029392&bpIds=3004037004&checksum=2d5acc8a7929d5dbae03f18d6a8bf263df304d54-1617045531412-4552afdf86d80bbfb0fe59f4ee996c45badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049903	CNTX 0290			Yes			Phase II	"Musculoskeletal pain, Inflammatory pain, Neuropathic pain"		Somatostatin receptor subtype 4 agonists	"Boehringer Ingelheim (Originator), Centrexion Therapeutics (Owner), Eli Lilly and Company (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	CNTX0290			04/11/2020	Pain				no		no							https://adis.springer.com/drugs/800049903?userId=52029392&bpIds=3004037004&checksum=8781f841d40672eb0897dce9d7b9ba7a2662d332-1617045531413-239d9a175f875a87a5f887dcd592ef59badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036513	Sepranolone - Asarina Pharma	516-55-2	3_-hydroxy-5_-pregnan-20-one	Yes			Phase II	"Premenstrual dysphoric disorder, Menstrual migraine"	C21 H34 O2	GABA-A receptor antagonists	"Umecrine Mood (Originator), Asarina Pharma (Owner), Scandinavian CRO (Collaborator)"		SC				"N2C (Anti-Migraine Preparations), N6A (Anti-Depressants and Mood Stabilisers)"	"N02C (Antimigraine Preparations), N06A (Antidepressants)"	"Isoallopregnanolone, UC1010"			02/11/2020	"Affective Disorders, Women's Health"				no		no							https://adis.springer.com/drugs/800036513?userId=52029392&bpIds=3004037004&checksum=83c57050634790c367afbf43ce99c55ce87f9ed9-1617045531414-a4a35149cfcc1f68351f57a51b27fb84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050504	MEB 1170			Yes			Preclinical	Pain		Opioid mu receptor agonists	"MEBIAS Discovery (Originator), MEBIAS Discovery (Owner), National Institute of Drug Abuse (Funder)"		SC				N2 (Analgesics)	N02 (Analgesics)	MEB1170			02/11/2020	Pain		MEBIAS Discovery |  | Clinical Phase Unknown |  | 19 Oct 2017		no		no							https://adis.springer.com/drugs/800050504?userId=52029392&bpIds=3004037004&checksum=24afea325232e92ed5ae97b9e443f96863c7c9d5-1617045531415-7fa77a723b622726f29455d742c6be0bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025886	Bupivacaine implant - Innocoll	14252-80-3	"1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide monohydrochloride monohydrate"	No			Marketed	"Postoperative pain, Pain"	C18 H28 N2 O . H Cl . H2 O	Sodium channel antagonists	"Innocoll (Originator), Innocoll (Owner)"		unspecified				N2 (Analgesics)	"N01B-B01 (Bupivacaine), N02 (Analgesics)"	"BImplant, Bupivacaine HCl collagenmatrix implants Innocoll, Bupivacainecollagen bioresorbable implant Innocoll, CollaRx Bupivacaine implant, INL001, INNLD01, XaraColl"			02/11/2020	"Drug Delivery Systems, Pain"			XaraColl	no		no							https://adis.springer.com/drugs/800025886?userId=52029392&bpIds=3004037004&checksum=10f7cc8795d598836b704e8c31dab3ae887eaee8-1617045531416-83f5b88f0ef12645f7521aebca14bcbbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051479	BIIB 095			Yes			Phase I	Neuropathic pain		Nav1.7 voltage-gated sodium channel inhibitors	"Biogen (Originator), Biogen (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	BIIB095			29/10/2020	Pain				no		no							https://adis.springer.com/drugs/800051479?userId=52029392&bpIds=3004037004&checksum=16bea7feabcd2ca10612091e9d7a53c6da657baf-1617045531417-e2330c093b1440fab880113254704a6dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047701	Research programme: oxycodone abuse-resistant - Acura Pharmaceuticals		"Morphinan-6-one,4,5-_-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride"	No			No development reported (Research)	Pain	C18 H22 Cl N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"LTX01, LTX02, Oxycodone abuseresistant Acura Pharmaceuticals"			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800047701?userId=52029392&bpIds=3004037004&checksum=84938abea61b0779bffd549d5003e9e85360c63b-1617045531418-ea97f6dcd885985fff0b61134b4ffca9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047891	Research programme: oral therapeutics - Thar Pharmaceuticals			No			No development reported (Preclinical)	"Pain, Migraine, Anxiety disorders, Erectile dysfunction"		Undefined mechanism	"Thar Pharmaceuticals (Originator), Thar Pharmaceuticals (Owner)"		PO				"G4E (Erectile Dysfunction Products), N1 (Anaesthetics), N2C (Anti-Migraine Preparations), N5B (Hypnotics/Sedatives)"	"G04B-E (Drugs used in erectile dysfunction), N01 (Anesthetics), N02C (Antimigraine Preparations), N05B-X (Other anxiolytics)"	T 109			28/10/2020	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Men's Health, Pain"				no		no							https://adis.springer.com/drugs/800047891?userId=52029392&bpIds=3004037004&checksum=e08020627fac4302d52d3e30d15435c0fd092375-1617045531418-c65b3fa59557a1bcc298573fba4514fabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047849	Research programme: pain therapeutics - Domain Therapeutics/ Conectus			Yes			No development reported (Research)	Pain		Neuropeptide modulators	"Domain Therapeutics (Originator), Domain Therapeutics (Owner), Conectus Alsace (Collaborator)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"Neuropeptide FF Domain Therapeutics/Conectus, THIAPO 2"			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800047849?userId=52029392&bpIds=3004037004&checksum=b00ed4abc6bd24878cbcd9e7392bdee531950d4a-1617045531419-fbedef4560ac764d793c638d76e9f8e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047732	SP 15001			No			No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"Spherium Biomed (Originator), Spherium Biomed (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	SP15001			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800047732?userId=52029392&bpIds=3004037004&checksum=b8ea6b19c8197872bd960e80b51ee0817d228504-1617045531420-00e1997c79d44c9cd341286375f350b9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048318	RQ 00432979			Yes			No development reported (Preclinical)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Eli Lilly and Company (Originator), RaQualia Pharma (Originator), Eli Lilly and Company (Owner), RaQualia Pharma (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02 (Analgesics)	RQ00432979			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800048318?userId=52029392&bpIds=3004037004&checksum=0ebfcb0d1a90cb1acc6f4da5e37ddada46d83bcd-1617045531421-d1cca7b0f98dcb3e30d9d3835fc23d5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047916	S-Etifoxine			Yes			No development reported (Preclinical)	Neuropathic pain	C17 H17 Cl N2O	TSPO protein stimulants	"Anvyl (Originator), Anvyl (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	(S)Etifoxine			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800047916?userId=52029392&bpIds=3004037004&checksum=22dd15316dd257adde0a2141499ac19cc2850cc9-1617045531421-35e1bdf47d6a0cf984c7bd453ee9cdd2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020493	Research programme: G protein-coupled receptor modulators - Ogeda			Yes			No development reported (Preclinical)	"Brain injuries, Alzheimer's disease, Amyotrophic lateral sclerosis, Parkinson's disease, Multiple sclerosis, Ulcerative colitis, Obesity, Rheumatoid arthritis, Type 2 diabetes mellitus, Inflammation"		"G protein-coupled receptor modulators, G-protein coupled receptor 43 modulators"	"Euroscreen (Originator), Ogeda (Owner), EMD Serono (Funder), National Multiple Sclerosis Society (Funder)"		unspecified				"A10 (Drugs Used in Diabetes), A16 (Other Alimentary Tract and Metabolism Products), A7 (Antidiarrhoeals, Oral Electrolyte Replacers and Intestinal Anti-inflammatories), A8 (Antiobesity Preparations, Excluding Dietetics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"A07 (Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents), A08 (Antiobesity Preparations, Excl. Diet Products), A10 (Drugs Used in Diabetes), A16 (Other Alimentary Tract and Metabolism Products), M01 (Antiinflammatory and Antirheumatic Products), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	"ESN401, ESN502, ESN601, ESN603, ESN700"			28/10/2020	"Alzheimer's Disease and Cognition Disorders, Diabetes, Inflammation, Inflammatory Bowel Disorders, Neurological Disorders, Obesity, Parkinson's Disease and Movement Disorders, Rheumatic Disease"		Ogeda |  | Unspecified |  | 17 Jun 2013		no		no							https://adis.springer.com/drugs/800020493?userId=52029392&bpIds=3004037004&checksum=39c49e87903ff2a73a249d604f0e9fecd3d08569-1617045531423-59569ee9c130f2535308ff5c99504d6dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043573	GDC 0310			Yes			No development reported (I)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Xenon Pharmaceuticals (Originator), Xenon Pharmaceuticals (Owner), Genentech (Licensee)"		PO				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	"GDC0310, RG 6029"			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800043573?userId=52029392&bpIds=3004037004&checksum=c7d5893ff60efc0e8f35522a92974b5d763d69cc-1617045531424-9a122a5bb2d33769e6a19deab264ac09badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047770	Research programme: antibody-based therapeutics - NB Health Laboratory			Yes			No development reported (Research)	"Inflammation, Pain, Immunological disorders, Respiration disorders"		"Beta-arrestin stimulants, G protein-coupled receptor antagonists, Beta arrestin inhibitors, Cyclic AMP receptor modulators, Interleukin 17 receptor modulators, Prostaglandin E EP4 receptor antagonists"	"NB Health Laboratory (Originator), NB Health Laboratory (Owner)"		Parenteral				"L4 (Immunosuppressants), N2B (Non-Narcotics and Anti-Pyretics), R7 (Other Respiratory System Products)"	"L04A (Immunosuppressants), N02B (Other Analgesics and Antipyretics), R07A (Other Respiratory System Products)"	"Anti EP4 receptor antibody NB Health Laboratory, P 001 NB Health Laboratory, P 007, P 013, Respiratory diseases and inflammation therapeutic NB Health Laboratory"			28/10/2020	"Immunological Disorders, Inflammation, Pain, Respiratory Tract Disorders"		NB Health Laboratory |  | Clinical Phase Unknown | Japan | 13 Sep 2016		no		no							https://adis.springer.com/drugs/800047770?userId=52029392&bpIds=3004037004&checksum=05c68181844848b22fc4fb13439b689b2851c86d-1617045531425-a76ae8fa853109258dbbaddc14d7bc93badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030044	ABT 102			Yes			No development reported (I)	Pain		TRPV1 receptor antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	ABT102			28/10/2020	Pain				no		no							https://adis.springer.com/drugs/800030044?userId=52029392&bpIds=3004037004&checksum=70cd98e17c63e2f847fcc87ecb6a00b1fa8e1d06-1617045531426-3fa197884a79be04dcb56278e44bab32badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054228	ASN 008			Yes			Phase I	"Atopic dermatitis, Pruritus, Pain"		Sodium channel antagonists	"Asana BioSciences (Originator), Asana BioSciences (Owner)"		"Topical, SC"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc)"	"D04A-X (Other antipruritics), N02 (Analgesics)"	ASN008			28/10/2020	"Pain, Skin Disorders"		Asana BioSciences |  | Unspecified |  | 07 Sep 2020		no		no							https://adis.springer.com/drugs/800054228?userId=52029392&bpIds=3004037004&checksum=59ca5b3dec85011235bd5adb2e043341cc9ce105-1617045531427-200b526a534fa1c41f2b6141aab43714badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047488	Dexamethasone sodium phosphate injectable gel - Scilex Holding	2392-39-4	"[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate disodium"	No			Phase III	Sciatica	C22 H28 F Na2 O8 P	"Glucocorticoid receptor agonists, Immunosuppressants"	"Semnur Pharmaceuticals (Originator), Scilex Holding (Owner)"		Epidural				N2 (Analgesics)	N02 (Analgesics)	"SEMDEXA, SP 102"			28/10/2020	Pain			SEMDEXA	yes	USA	no							https://adis.springer.com/drugs/800047488?userId=52029392&bpIds=3004037004&checksum=ab8abc8f89aafb7573cf5a67496e2e7e0d24bef3-1617045531428-35348a9510b84a1403973f3ca7a3f1c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029389	RX 10045			Yes			Phase II	"Postoperative pain, Postoperative inflammation, Dry eyes, Allergic conjunctivitis, Retinal disorders, Diabetic macular oedema, Age-related macular degeneration"		"Inflammation mediator inhibitors, Lipid modulators"	"Resolvyx Pharmaceuticals (Originator), Resolvyx Pharmaceuticals (Owner), Auven Therapeutics (Licensee)"		Ophthalmic				"N2 (Analgesics), S1G (Ocular Anti-Allergics, Decongestants, Antiseptics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"N02 (Analgesics), S01B-C (Antiinflammatory agents, non-steroidals), S01G-X (Other antiallergics)"	"RvE1 synthetic analogue, RX10045"			28/10/2020	"Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800029389?userId=52029392&bpIds=3004037004&checksum=59ddd483fb41b895903ccfd931162a3a27da66e5-1617045531429-2410c200584e630fd9e73d4c92404fbabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024919	Research programme: cancer and CNS disorder therapeutics - Angiochem			No			No development reported (Preclinical)	"Pain, Brain metastases, Cancer, Obesity, Brain cancer, Diabetes mellitus, Parkinson's disease, Neurological disorders"		"Neurotensin receptor modulators, ERBB 2 receptor antagonists, Immunomodulators, Leptin receptor modulators, DNA intercalators, Type II DNA topoisomerase inhibitors, Glucagon like peptide 1 receptor agonists, Brain derived neurotrophic factor modulators"	"AngioChem (Originator), AngioChem (Owner)"		"unspecified, IV, Parenteral"				"A10X (Other Drugs Used in Diabetes), A8 (Antiobesity Preparations, Excluding Dietetics), L1 (Antineoplastics), L1X (All Other Antineoplastics), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs)"	"A08 (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), L01 (Antineoplastic Agents), L01X (Other Antineoplastic Agents), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs)"	"ANG 3201, ANG1007, ANG1009, ANG1011, ANG2002, ANG2004, ANG2008, ANG3101, ANG3202, ANG4043, Angiopepantibodydrug conjugate Angiochem"			28/10/2020	"Cancer, Diabetes, Drug Delivery Systems, Neurological Disorders, Obesity, Pain, Parkinson's Disease and Movement Disorders"		AngioChem |  | Preclinical | World | 06 Dec 2010		no		no							https://adis.springer.com/drugs/800024919?userId=52029392&bpIds=3004037004&checksum=5ac14d32725a7ca5bd110a9469762db0a932547c-1617045531431-8a45f9c6243b6482f1a12d4f0d19d97abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031669	E 52862	878141-96-9		Yes			Phase II	"Neuropathic pain, Diabetic neuropathies, Postoperative pain, Postherpetic neuralgia, Osteoarthritis"		Sigma-1 receptor antagonists	"Esteve (Originator), Esteve (Owner), Mundipharma GmbH (Licensee), Purdue Pharma (Licensee)"		PO			"Dizziness, Headache, Nausea"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"E52862, E52862.HCl, MR309, S1A, S1RA"			28/10/2020	"Diabetes, Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800031669?userId=52029392&bpIds=3004037004&checksum=ef8be05a15f91ebf06f1f4ca5b52f03e527bfd45-1617045531433-f64454e990f29bee51d951b1bd74c453badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045573	Pentosan polysulfate - Paradigm Biopharma			No			Phase II	"Seasonal allergic rhinitis, Pain, Ross River virus infections, Oedema, Mucopolysaccharidosis I, Allergic rhinitis, Allergic asthma, Chikungunya virus infections, Chronic obstructive pulmonary disease"		"Cell membrane permeability inhibitors, Enzyme inhibitors, Non-nucleoside reverse transcriptase inhibitors"	"Glycan Biosciences (Originator), Griffith University (Originator), Glycan Biosciences (Owner), Griffith University (Owner), Paradigm Biopharma (Licensee)"		"Intranasal, SC, IM, unspecified"				"A16 (Other Alimentary Tract and Metabolism Products), J5 (Antivirals for Systemic Use), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R1A9 (Other topical nasal preparations)"	"A16 (Other Alimentary Tract and Metabolism Products), J05 (Antivirals for Systemic Use), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics), R01A-X (Other nasal preparations)"	"Pentosan polysulfate sodium Paradigm Biopharma, PPS Paradigm Biopharma, Rhinosul, ZILOSUL"			28/10/2020	"Immunological Disorders, Metabolic Disorders, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Vascular Disorders, Viral Infections"			"Rhinosul, ZILOSUL"	no		no							https://adis.springer.com/drugs/800045573?userId=52029392&bpIds=3004037004&checksum=a3892a5396433beb76b51671b206f3c8d1b0ba16-1617045531435-1811c8e74ae830560ca904c3beef45febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044916	Capsaicin/Diclofenac - Boehringer Ingelheim		"(E)- (8CI)8-methyl-N-vanillyl-6-nonenamide / (o-(2,6-dichloroanilino)phenyl)-acetic acid"	No			No development reported (III)	Acute pain	C18 H27 N O3 . C14 H11 Cl2 N O2	"Cyclooxygenase inhibitors, Substance P inhibitors, TRPV1 receptor agonists"	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		Topical				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	Diclofenac/capsaicin			27/10/2020	Pain				no		no							https://adis.springer.com/drugs/800044916?userId=52029392&bpIds=3004037004&checksum=092193a84f649de7fd18241001c0a49018976ce7-1617045531435-4f1eac6c4b671a3d6898a247ddab20acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060963	Research programme: cannabinoid therapeutics - Renew Biopharma			No			Research	"Pain, Inflammation"		Cannabinoid receptor modulators	"Renew Biopharma (Originator), Renew Biopharma (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				27/10/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800060963?userId=52029392&bpIds=3004037004&checksum=e7a60c3d7f03ad3b489546654acd7db94518b4e5-1617045531436-38f565f32dce9e1291ce11ec33ec63c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007180	Lenabasum - Corbus Pharmaceuticals	137945-48-3	"6<EM>H</EM>-Dibenzo[<EM>b,d</EM>]pyran-9-carboxylic acid, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6a<EM>R</EM>,10a<EM>R</EM>)"	Yes			Phase III	"Systemic scleroderma, Dermatomyositis, Cystic fibrosis, Systemic lupus erythematosus, Rheumatoid arthritis, Pulmonary fibrosis, Neuropathic pain, Pain, Inflammation, Muscle spasticity, Interstitial cystitis, Poisoning"	C25 H36 O4	Cannabinoid receptor CB2 agonists	"University of Massachusetts Medical School (Originator), Corbus Pharmaceuticals (Owner), Kaken Pharmaceutical (Licensee), Cystic Fibrosis Foundation Therapeutics (Funder), National Institutes of Health (Funder), Case Western Reserve University (Collaborator), Cystic Fibrosis Therapeutics Development Network (Collaborator), European Cystic Fibrosis Society Clinical Trials Network (Collaborator), National Institute of Arthritis and Musculoskeletal and Skin Diseases (Collaborator), University of Erlangen-Nuremberg (Collaborator), University of Pennsylvania (Collaborator), University of Siena (Collaborator)"		PO			"Amnesia, Anorexia, Blurred vision, Confusion, Dermatomyositis, Dizziness, Euphoria, Fatigue, Headache, Herpes zoster, Hypotension, Nasopharyngitis, Nausea, Respiratory tract infections, Somnolence, Syncope, Tremor, Urinary tract infections, Vomiting, Xerostomia"	"G4 (Urologicals), L3 (Immunostimulating Agents), M1A (Anti-Rheumatics, Non-Steroidal), M3 (Muscle Relaxants), N2B (Non-Narcotics and Anti-Pyretics), R7X (All Other Respiratory System Products)"	"G04 (Urologicals), L03A (Immunostimulants), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), M03 (Muscle Relaxants), N02B (Other Analgesics and Antipyretics), R07A-X (Other respiratory system products)"	"Ajulemic acid, Anabasum, CPL7075, CT3, DMH11C, HU239, IP751, JBT101, Resunab"			27/10/2020	"Drug Withdrawal, Genitourinary Disorders, Immunological Disorders, Inflammation, Musculoskeletal Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease, Skin Disorders"	"Cystic fibrosis (USA), Dermatomyositis (USA), Systemic scleroderma (European Union), Cystic fibrosis (European Union), Systemic scleroderma (USA), Systemic scleroderma (Japan), Dermatomyositis (European Union)"		"Resunab, Resunab, Resunab"	yes	USA	no			TNF-alpha	"CRP, IFN-gamma, IL1 beta, IL6, Lipoxin A4, Mental retardation, X-linked, with short stature, TNF-alpha"			https://adis.springer.com/drugs/800007180?userId=52029392&bpIds=3004037004&checksum=671dcc2dd1e06ff2c904f8b95b7f9b0468592ce9-1617045531444-9af0e7b7caf714a5a342f63a73da8ef4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054367	TrkA NAM - AlzeCure Pharma			Yes			Research	Pain		TrkA receptor modulators	"AlzeCure (Originator), AlzeCure (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"TrkANAM AlzeCure pharma, TrkAnegative allosteric modulator AlzeCure Pharma"			25/10/2020	Pain		AlzeCure |  | Unspecified |  | 09 Oct 2020		no		no							https://adis.springer.com/drugs/800054367?userId=52029392&bpIds=3004037004&checksum=b65969160a621129ee4f9372e0fc5bc75a63a3e4-1617045531445-0093635ea161b285a20029c055367d75badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059428	Research programme: fatty acid binding protein 5 inhibitors - Artelo Biosciences/State University of New York			Yes			Preclinical	"Anxiety disorders, Post-traumatic stress disorders, Pain, Cancer, Inflammation"		FABP5 protein inhibitors	"State University of New York at Stony Brook (Originator), State University of New York at Stony Brook (Owner), Artelo Biosciences (Licensee), National Cancer Institute (USA) (Funder)"		unspecified				"L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs)"	"L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs)"				23/10/2020	"Anxiety Disorders, Cancer, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800059428?userId=52029392&bpIds=3004037004&checksum=d2dcd4fc0327aef1b98ba56b1bcb1f70c1bef529-1617045531446-2d824717b9f13d2b16f7d95f987be7b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027102	Dronabinol buccal - IntelGenx	1972-08-3	delta 9-Tetrahydrocannabinol	No			Marketed	"Cancer pain, Chemotherapy-induced nausea and vomiting, Neuropathic pain"	C21 H30 O2	"Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"Cannasat Therapeutics (Originator), Sunovion Pharmaceuticals (Owner), IntelGenx Corp. (Licensee), Tetra Bio Pharma (Sub-licensee)"		Buccal				"A4 (Antiemetics and Antinauseants), N2 (Analgesics)"	"A04A-D10 (Dronabinol), N02 (Analgesics)"	"CAT 310, Dronabinol AdVersa Mucoadhesive tablet, Dronabinol buccal IntelGenx/Tetra Bio Pharma, Dronabinol buccal IntelGenx/Tetra Bio Pharma##8203##, Dronabinol XL, INT 0010, INT 0010/2006, INT0028, INT0028/2011, PPP 002, Relivar"			23/10/2020	"Advances in the Treatment of Nausea and Migraine, Pain"		"IntelGenx Corp. |  | Unspecified |  (Excluding Canada, USA) | 24 May 2014"		no		no				"Calprotectin, CPM, CYP2C19, CYP2C9, IL1 beta, IL10, IL23, IL6, Leptin, MMP-2, MMP9, nystagmus 3, congenital autosomal dominant, TIMP-1, TNF-alpha"		"COMT, fatty acid amide hydrolase, monoglyceride lipase"	https://adis.springer.com/drugs/800027102?userId=52029392&bpIds=3004037004&checksum=dfdb866401c6fefb82c9f39f6db7ca82314da9ea-1617045531448-5489deeb3031c089debfccfc5b19ef88badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015772	Buprenorphine implant - Molteni/Titan Pharmaceuticals	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"	No			Marketed	"Opioid-related disorders, Pain"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Titan Pharmaceuticals (Originator), Molteni Farmaceutici (Owner), Molteni Farmaceutici (Market Licensee), Knight Therapeutics (Sub-licensee), National Institute of Drug Abuse (Collaborator)"		SC			"Constipation, Haematoma, Headache, Insomnia, Nasopharyngitis, Nausea, Pain, Pruritus, Respiratory tract infections, Vomiting"	"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	"Buprenorphine implant, Probuphine, Sixmo"			21/10/2020	"Drug Delivery Systems, Drug Withdrawal, Pain"		Titan Pharmaceuticals |  | Unspecified |  | 20 Aug 2020	"Probuphine, Probuphine, Sixmo"	no		no							https://adis.springer.com/drugs/800015772?userId=52029392&bpIds=3004037004&checksum=c4f98ab2bf6d7cda92c61faa4fe11d1ee7d9d758-1617045531449-46ff329868c2116c4d9a6fd64a6e85debadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060895	TBP 301			No			Preclinical	"Pain, Opioid-related disorders"		Cell replacements	"FibroGenesis (Originator), FibroGenesis (Owner)"		unspecified				"N2 (Analgesics), V3 (All Other Therapeutic Products)"	"N02 (Analgesics), V03 (All Other Therapeutic Products)"	TBP301			21/10/2020	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800060895?userId=52029392&bpIds=3004037004&checksum=197c281a98018afa7093897e0fa1c8d95c664b2a-1617045531450-62d2c75ddc10baa00663dc28655f2ca2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053782	AMT 143			No			Preclinical	Postoperative pain		Undefined mechanism	"AmacaThera (Originator), AmacaThera (Owner), University of Toronto (Technology Provider)"		Parenteral				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	AMT143			21/10/2020	Pain		AmacaThera |  | Unspecified |  | 20 Oct 2020		no		no							https://adis.springer.com/drugs/800053782?userId=52029392&bpIds=3004037004&checksum=bc12fde0bc307fcc21a2dba9b1c0e807d637aeeb-1617045531451-2b5c41bf2f2e8aea39f918f1dbcfd23dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060656	PUR 3100			Yes			Research	Migraine		Undefined mechanism	"Pulmatrix (Originator), Pulmatrix (Owner)"		Inhalation				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	PUR3100			16/10/2020	Advances in the Treatment of Nausea and Migraine		Pulmatrix |  | Unspecified |  | 29 Sep 2020		no		no							https://adis.springer.com/drugs/800060656?userId=52029392&bpIds=3004037004&checksum=1464a49dd5b44c7e7ae4a92cc15a04136aa18691-1617045531452-b78b0c79fceedea0483773ea9c12e309badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018012	Dihydroergotamine mesilate intranasal - Britannia	511-12-6	"Ergotoman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'_)-,"	No			No development reported (I)	Migraine	C33 H37 N5 O5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Britannia Pharmaceuticals (Originator), Britannia Pharmaceuticals (Owner), Novartis (Collaborator)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C-A01 (Dihydroergotamine)	Dihydroergotamine nasal powder Britannia			15/10/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800018012?userId=52029392&bpIds=3004037004&checksum=870f7c6b98967a39d99f7918cc9543b98b7c555e-1617045531453-d479abbcbfecca0de92e2a2d209c2a92badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028548	IMT 504			Yes			Preclinical	"Diabetes mellitus, Rabies, Hepatitis B, Chronic lymphocytic leukaemia, Osteoporosis, Influenza virus infections, Neuropathic pain, Sepsis, Breast cancer"		"B cell stimulants, Immunostimulants"	"Immunotech SA (Originator), Mid-Atlantic BioTherapeutics (Originator), Immunotech SA (Owner), Mid-Atlantic BioTherapeutics (Owner)"		Parenteral				"A10X (Other Drugs Used in Diabetes), J1X (Other Antibacterials), J5B (Antivirals, excluding anti-HIV products), J5B3 (Herpes antivirals), J5B4 (Influenza antivirals), L3A (Immunostimulating Agents Excluding Interferons), M5B (Bone Calcium Regulators), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), J01X (Other Antibacterials), J05A-X (Other antivirals), L03A (Immunostimulants), M05B (Drugs Affecting Bone Structure and Mineralization), N02B (Other Analgesics and Antipyretics)"	IMT504			14/10/2020	"Bacterial Infections, Cancer, Diabetes, Musculoskeletal Disorders, Pain, Vaccines, Viral Infections"	Rabies (USA)	Immunotech SA |  | Unspecified |  | 10 Jul 2008		no		no							https://adis.springer.com/drugs/800028548?userId=52029392&bpIds=3004037004&checksum=a0fd43292d616b38284afbdb9bfacf45dc31365c-1617045531454-8ff730c0d1118e80c5b3bb61621812f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009782	Resiniferatoxin - Sorrento Therapeutics	57444-62-9	"Benzeneacetic acid, 4-hydroxy-3-methoxy-, ((2<EM>S</EM>,3a<EM>R</EM>,3b<EM>S</EM>,6a<EM>R</EM>,9aR,9b<EM>R</EM>,10<EM>R</EM>,11a<EM>R</EM>)-3a,3b,6,6a,9a,10,11,11a-octahydro-6a-hydroxy-8,10-dimethyl-11a-(1-methylethenyl)-7- oxo-2-(phenylmethyl)-7<EM>H</EM>-2,9b-epoxyazuleno(5,4-e)-1,3-benzodioxol-5-yl)methyl ester"	Yes			Phase I/II	"Cancer pain, Pain, Overactive bladder, Interstitial cystitis, Rhinitis"	C37 H40 O9	TRPV1 receptor agonists	"National Institutes of Health (USA) (Originator), National Institutes of Health (USA) (Owner), Sorrento Therapeutics (Licensee), National Institute of Neurological Disorders and Stroke (Collaborator)"		"Intrathecal, Intra-articular, Epidural, Intravesicular, Intracavernous, unspecified"			"Constipation, Cystitis, Diaphoresis, Mucosal disorders, Pain"	"G4D4 (Urinary incontinence products), N2B (Non-Narcotics and Anti-Pyretics), R3 (Anti-Asthma and COPD Products)"	"G04B-D (Drugs for urinary frequency and incontinence), N02B (Other Analgesics and Antipyretics), R03 (Drugs for Obstructive Airway Diseases)"	"MCP101, RTX"			13/10/2020	"Genitourinary Disorders, Obstructive Airways Disease, Pain"	Cancer pain (USA)			no		no						"proteasome 26S subunit, non-ATPase 1"	https://adis.springer.com/drugs/800009782?userId=52029392&bpIds=3004037004&checksum=4cb8847ddc8b7e25afd6d8e226b72a31db5a70f1-1617045531456-ebcdc8e35eff48521330fe202154d9acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042033	Palmitoylethanolamide - Prismic Pharmaceuticals	544-31-0	N-(2-Hydroxyethyl)hexadecanamide	No			Phase II	"COVID 2019 infections, Inflammation, Pain, Fibromyalgia, Irritable bowel syndrome, Neurological disorders"	C18 H37 N O2	"Cannabinoid receptor agonists, G-protein-coupled receptor 55 modulators, Peroxisome proliferator-activated receptor alpha agonists"	"Epitech Group (Originator), Epitech Group (Owner), Prismic Pharmaceuticals (Licensee)"		"PO, unspecified"				"J5 (Antivirals for Systemic Use), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"J05 (Antivirals for Systemic Use), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"FSD 201, FSD 201 microPEA, micro PEA plus pregabalin, micropalmitoylethanolamide, micropalmitoylethanolamide (microPEA) plus pregabalin, microPEA, PP 101, PP 101 microPEA, Ultra MicroPalmitolylethanolamide, ultramicronized PEA"			13/10/2020	"Digestive System Disorders, Inflammation, Neurological Disorders, Pain, Rheumatic Disease, Viral Infections"		Prismic Pharmaceuticals |  | Unspecified | World | 13 Aug 2013		no		no				Acetylcholine receptor			https://adis.springer.com/drugs/800042033?userId=52029392&bpIds=3004037004&checksum=c425a2dc528cd7b2973ffc1b9f9da74d13af0f82-1617045531458-2e8ca698886f6579562709d1093e42d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055349	SR 419			Yes			Phase I	Neuropathic pain		Ion channel modulators	"SIMR Biotech (Originator), SIMR Biotech (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	SR419			09/10/2020	Pain				no		no							https://adis.springer.com/drugs/800055349?userId=52029392&bpIds=3004037004&checksum=203ae0e420b9e0a18578cca3e551845d21c57cf8-1617045531459-90b657ea997660475f1847e82b0131aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060765	Pain therapeutic - Xgene Pharmaceutical			Yes			Phase Unknown	Pain		Undefined mechanism	"Xgene Pharmaceutical (Originator), Xgene Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				08/10/2020	Pain				no		no							https://adis.springer.com/drugs/800060765?userId=52029392&bpIds=3004037004&checksum=7ef11a969a8c4569c04dc3659ed8960480ce518c-1617045531459-ff68840e1c6f7156b668572c2845e163badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039045	NEO 6860			Yes			Phase II	"Musculoskeletal pain, Visceral pain, Neuropathic pain"		TRPV1 receptor antagonists	"AstraZeneca Canada (Originator), adMare BioInnovations (Owner), Pfizer Canada (Funder)"		PO				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	"NEO6860, TRPV1 antagonist adMare BioInnovations, Vanilloid receptor 1 ion channel antagonist adMare BioInnovations"			07/10/2020	Pain		"adMare BioInnovations | Musculoskeletal pain, Neuropathic pain, Visceral pain | Preclinical | Canada | 30 Apr 2013"		no		no							https://adis.springer.com/drugs/800039045?userId=52029392&bpIds=3004037004&checksum=e99c064cbdd6a1aec0ff79911118e52ba5d23242-1617045531461-344afa1d555e856d3c904b3361d7cd33badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059488	Research programme: acetamide analgesics - South Rampart Pharma			Yes			Preclinical	"Diabetic neuropathies, Fever, Neuropathic pain, Acute pain"		"Cyclo-oxygenase 2 inhibitors, Cytochrome P 450 enzyme system inhibitors, Prostaglandin receptor antagonists"	"Louisiana State University (Originator), South Rampart Pharma (Owner), National Institutes of Health (USA) (Funder), University of Alcala (Collaborator)"		"PO, IV"				N2 (Analgesics)	N02 (Analgesics)	Acetaminophen analogues South Rampart Pharma			07/10/2020	"Diabetes, Metabolic Disorders, Pain"		South Rampart Pharma |  | Unspecified |  | 14 Jul 2020		no		no							https://adis.springer.com/drugs/800059488?userId=52029392&bpIds=3004037004&checksum=a14b02215e066ccf310fc17c776150e59cfb08e2-1617045531462-ccbc20e5a47832e27e1adb9f7431c4b1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047324	Fentanyl sublingual - iX Biopharma	437-38-7	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide	No			Phase I	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"iX Biopharma (Originator), iX Biopharma (Owner)"		Sublingual				N2A (Narcotics)	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	WafernylTM			06/10/2020	Pain				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800047324?userId=52029392&bpIds=3004037004&checksum=43dcd22d6f48e36dd12ca5ee9242e9972651a976-1617045531463-d352f59a4f62994bf8ed7283e1bb7299badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060585	XW 10508			Yes			Preclinical	"Major depressive disorder, Acute pain"		"AMPA receptor agonists, NMDA receptor antagonists"	"XW labs (Originator), XWPharma (Owner)"		PO				"N2 (Analgesics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N06A (Antidepressants)"	XW 10508			06/10/2020	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800060585?userId=52029392&bpIds=3004037004&checksum=0009794c2af4a50d4852a9c6ac2b9e5d2d3b6300-1617045531464-45369ddadee6eff2c24a86592af47840badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060548	CA 051			Yes			Preclinical	"Cancer pain, Postoperative pain"		TRPV1 receptor agonists	"Concentric Analgesics (Originator), Concentric Analgesics (Owner)"		Epidural				N2 (Analgesics)	N02 (Analgesics)	CA051			06/10/2020	Pain				no		no							https://adis.springer.com/drugs/800060548?userId=52029392&bpIds=3004037004&checksum=ea211218013837177906390c39e1b6ac31f68f27-1617045531465-117532c97a5b1559c9db014dbaa2fb80badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048758	Lactic acid - Stayble Therapeutics	50-21-5	2-hydroxypropanoic acid	No			Phase II	Back pain	C3 H6 O3	Inflammation mediator modulators	"Stayble Therapeutics (Originator), Stayble Therapeutics (Owner)"		Intraspinal				N2 (Analgesics)	N02 (Analgesics)	STA 363			06/10/2020	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800048758?userId=52029392&bpIds=3004037004&checksum=8400c3c71d41d9d5a131f9182699500b94f5643c-1617045531465-a579c6da63d7bef71cc0fd6e2eeca7f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020529	Fibroblast growth factor 1 - Venturis Therapeutics			Yes			Phase II	"Coronary artery disease, Diabetic foot ulcer, Wounds, Peripheral arterial disorders, Erectile dysfunction, Stroke, Intervertebral disc degeneration, Parkinson's disease, Back pain, Osteoporosis, Diabetes mellitus, Ischaemia"		"Angiogenesis inducing agents, Fibroblast growth factor stimulants"	"CardioVascular BioTherapeutics Inc (Originator), Venturis Therapeutics (Owner), Cordis Corporation (Technology Provider), Merck & Co (Technology Provider), Cardio Derma Clinical Partners (Collaborator)"		"Intracoronary, Topical, IM, unspecified"				"A10 (Drugs Used in Diabetes), C1X (All Other Cardiac Preparations), C4A (Cerebral and Peripheral Vasotherapeutics), D3A (Wound Healing Agents), D3A9 (All other wound healing agents), G4E (Erectile Dysfunction Products), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs), V3 (All Other Therapeutic Products)"	"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), C01E-B (Other cardiac preparations), D03 (Preparations for Treatment of Wounds and Ulcers), G04B-E (Drugs used in erectile dysfunction), M05B-X (Other drugs affecting bone structure and mineralization), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X-X (Other nervous system drugs), V03 (All Other Therapeutic Products)"	"Acidic FGF, Cardio VascuGrow, CVBT 141P, CVBT 141S, CVBT141A, CVBT141B, CVBT141C, CVBT141D, CVBT141E, CVBT141ED, CVBT141F, CVBT141G, CVBT141H, FGF1(141)"			05/10/2020	"Diabetes, Ischaemic Heart Disease, Men's Health, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Skin Disorders, Vascular Disorders"			Cardio VascuGrow	no		no							https://adis.springer.com/drugs/800020529?userId=52029392&bpIds=3004037004&checksum=eba3db713b58ae71db3fa908af622fe7c7d7d35d-1617045531468-1a2faf7fceb3cb693d25fa67a06f47c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060703	TS 1903			Yes			Preclinical	Migraine		Calcitonin gene-related peptide antagonists	"Shandong Boan Biotechnology (Originator), Luye Pharma Group (Owner)"		Parenteral				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	TS1903			30/09/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800060703?userId=52029392&bpIds=3004037004&checksum=6015810ad592b09e3a909dfc26de5d6b20f919df-1617045531469-c37a25b327bf57b4d8a78d3432c72906badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060704	TS 1502			Yes			Preclinical	"Musculoskeletal pain, Cancer pain, Back pain"		Nerve growth factor receptor antagonists	"Shandong Boan Biotechnology (Originator), Luye Pharma Group (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	TS1502			30/09/2020	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800060704?userId=52029392&bpIds=3004037004&checksum=f18ecc346a36da790e3ade8e1e74007c7bcf2e52-1617045531469-00a47091a5d7f5490b12565206699425badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040927	ISC 27864			Yes			Phase II	"Pain, Inflammation"		Prostaglandin-E synthase inhibitors	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), AbbVie (Collaborator), Ichnos Sciences (Collaborator)"		PO				"L4X (Other Immunosuppressants), N2 (Analgesics)"	"L04A-A (Selective immunosupressants), N02 (Analgesics)"	"GRC27864, ISC27864"			29/09/2020	"Inflammation, Pain, Rheumatic Disease"		Glenmark Pharmaceuticals Ltd |  | Phase II |  | 01 May 2017		no		no							https://adis.springer.com/drugs/800040927?userId=52029392&bpIds=3004037004&checksum=05b621b7045c2a2e3e0c3ca44e3db311fe06a832-1617045531471-2c165bb3aca82b72ea487fe2900b6ac7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060229	MT 1005mu			Yes			Research	Pain		Undefined mechanism	"Shaanxi Micot Technology Co (Originator), Shaanxi Micot Technology Co (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	"MT1005, MT1005micro, MT1005mu"			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800060229?userId=52029392&bpIds=3004037004&checksum=e78322f580e2636c17f7cc49d1de195cf1371f81-1617045531472-50489caa707421ff980439c752cdbbb9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047061	PAT N02			Yes			No development reported (Research)	Postherpetic neuralgia		Undefined mechanism	"Patagonia Pharmaceuticals (Originator), Patagonia Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PATN02			28/09/2020	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800047061?userId=52029392&bpIds=3004037004&checksum=03a9542d6b556d7985a7bf383f4c4da5fabb71a7-1617045531472-6ebc797a4c1a92dc32fc3c18ef91fec9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060234	MT 1005k			Yes			Research	Pain		Undefined mechanism	"Shaanxi Micot Technology Co (Originator), Shaanxi Micot Technology Co (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	"MT1005, MT1005kappa"			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800060234?userId=52029392&bpIds=3004037004&checksum=301d096076790b8053913258f9a1c452d63bbdc8-1617045531473-dceecc54ec4f83d8ddbbcc5df5abb22fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060236	MT 1005aa			Yes			Research	Pain		Undefined mechanism	"Shaanxi Micot Technology Co (Originator), Shaanxi Micot Technology Co (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	"MT1005, MT1005aa, MT1005alfaalfa, MT1005alphaalpha"			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800060236?userId=52029392&bpIds=3004037004&checksum=ad84ed28cadc72f6cb07105bf0095c5bde1ebd10-1617045531474-dd8918854f78fad8dcdc3c5bae052162badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047287	Research programme: peripheral neuropathy therapeutics - WinSanTor			Yes			No development reported (Research)	Neuropathic pain			"WinSanTor (Originator), WinSanTor (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	WST B1			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800047287?userId=52029392&bpIds=3004037004&checksum=339d0d39df2dc4e13b2388c929f610ea1e77ee1b-1617045531474-6b8e0e3a51d5bf8719cd74664cef2c7ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039904	Ketoprofen topical - Achelios Therapeutics	22071-15-4	"Benzeneacetic acid, 3-benzoyl-alpha-methyl-"	No			Phase II	"Migraine, Osteoarthritis, Sprains"	C16 H14 O3	Lipoxygenase-cyclooxygenase inhibitors	"Achelios Therapeutics (Originator), Achelios Therapeutics (Owner)"		Topical				"M2A (Topical Anti-rheumatics and Analgesics), N2C (Anti-Migraine Preparations)"	"M02A-A10 (Ketoprofen), N02C (Antimigraine Preparations)"	"ELS M11, Ketoprofen 2 gel Achelios Therapeutics, Ketoprofen 5 gel Achelios Therapeutics, Ketoprofen liquid spray Achelios Therapeutics, Topofen"			28/09/2020	"Advances in the Treatment of Nausea and Migraine, Musculoskeletal Disorders"		Achelios Therapeutics |  | Unspecified |  | 17 Jun 2014		no		no							https://adis.springer.com/drugs/800039904?userId=52029392&bpIds=3004037004&checksum=a566ccf83eb8d9e8214e727e50bc5435cc0afefe-1617045531476-71c591e36dab9d0d40e2858a794440f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046924	Indometacin - Ceridia	53-86-1	"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-"	No			No development reported (Preclinical)	Pain	C19 H16 Cl N O4	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Ceridia (Originator), Ceridia (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B01 (Indometacin), N02B (Other Analgesics and Antipyretics)"				28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800046924?userId=52029392&bpIds=3004037004&checksum=a31d3057d08f5a7571499a0bd00552aa186a18d5-1617045531476-2a89fd98b334ad67079c5c0f6b4fd11bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040139	Oxycodone hydrochloride - Acura Pharmaceuticals	124-90-3	"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride"	No			Marketed	Pain	C18 H22 Cl N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner), Assertio Therapeutics (Market Licensee)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"OXAYDO, Oxecta, Oxycodone HCl abuseresistant Pfizer, Oxycodone HCl Acura Pharmaceuticals"			28/09/2020	Pain			"OXAYDO, Oxecta"	no		no							https://adis.springer.com/drugs/800040139?userId=52029392&bpIds=3004037004&checksum=d9e9a24a24214cb84bc617ebb7d6b1d51bead47b-1617045531478-7273053b7a11f3ee2f0e10802a962625badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060281	Research programme: opioid mu receptor agonists - Mebias Disovery			Yes			Preclinical	Pain		Opioid mu receptor agonists	"MEBIAS Discovery (Originator), MEBIAS Discovery (Owner), National Institute of Drug Abuse (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MEB1051			28/09/2020	Pain		MEBIAS Discovery |  | Unspecified |  | 08 Sep 2020		no		no							https://adis.springer.com/drugs/800060281?userId=52029392&bpIds=3004037004&checksum=370b779de62384b9336883353e95e0e92151fbaf-1617045531478-bd28ceea3f4de45d487b7f78fe0f122cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047087	Research programme: nociceptin ORL-1 modulators - UniQuest			Yes			No development reported (Preclinical)	Pain		Nociceptin receptor modulators	"University of Queensland (Originator), University of Queensland (Owner), UniQuest (Technology Transfer)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/09/2020	Pain		UniQuest |  | Unspecified |  | 04 Aug 2016		no		no							https://adis.springer.com/drugs/800047087?userId=52029392&bpIds=3004037004&checksum=85f73f3a6d2a69bfb1058e9ca966c04a79b09183-1617045531479-0867463611c0d992066a25a5437bbd5bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046968	Research programme: pain therapeutics - Algynomics			Yes			No development reported (Research)	Pain			"Algynomics (Originator), Algynomics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/09/2020	Pain		Algynomics | Pain | Unspecified |  | 02 Aug 2016		no		no							https://adis.springer.com/drugs/800046968?userId=52029392&bpIds=3004037004&checksum=f8f675e46add4738acfbb72fe51ce658d541c5c5-1617045531480-9b73d0f4a57714d563cf7d396961a689badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047652	Research programme: vanilloid prodrugs - Vitality Biopharma			No			No development reported (Research)	Pain		TRPV1 receptor modulators	"Vitality Biopharma (Originator), Vitality Biopharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800047652?userId=52029392&bpIds=3004037004&checksum=bc18cd2e76430219656299660a4f0157c2b25333-1617045531480-3be7f4a8f2ccffa23b50709447a9484bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047090	IMB 007			Yes			No development reported (Preclinical)	Neuropathic pain		"GABA B receptor modulators, N type calcium channel antagonists"	"University of Queensland (Originator), University of Queensland (Owner), UniQuest (Technology Transfer)"		PO				N2 (Analgesics)	N02 (Analgesics)	IMB007			28/09/2020	Pain		UniQuest |  | Unspecified |  | 04 Aug 2016		no		no							https://adis.springer.com/drugs/800047090?userId=52029392&bpIds=3004037004&checksum=180670431e54a150ae006168441dca674d52660d-1617045531481-fa0cead1063dd319eec83d7ff758b778badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047049	Research programme: oxytocin analogues - UniQuest			Yes			No development reported (Preclinical)	Pain		Oxytocin receptor agonists	"University of Queensland (Originator), University of Queensland (Owner), UniQuest (Technology Transfer)"		PO				"N2 (Analgesics), N5C (Tranquillisers)"	"N02 (Analgesics), N05B-X (Other anxiolytics)"				28/09/2020	Pain		UniQuest |  | Unspecified |  | 03 Aug 2016		no		no							https://adis.springer.com/drugs/800047049?userId=52029392&bpIds=3004037004&checksum=ee552a33c24528984f2c839e54b39eb125648d00-1617045531482-f1789a8a00b1d14aae39f9dbf22be38fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047338	Research programme: pain therapeutics - Ampika			Yes			No development reported (Research)	Pain		Undefined mechanism	"Ampika (Originator), Ampika (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/09/2020	Pain		Ampika |  | Unspecified |  | 11 Aug 2016		no		no							https://adis.springer.com/drugs/800047338?userId=52029392&bpIds=3004037004&checksum=cb7c9a9cae7e905ddd7d816beb8e718b191d5ea2-1617045531483-76320b19231d681733e7da2e1b9ac4d3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047063	VB 210			No			No development reported (Preclinical)	"Fibromyalgia, Muscle spasticity, Irritable bowel syndrome, Neuropathic pain"		Cannabinoid receptor agonists	"Vitality Biopharma (Originator), Vitality Biopharma (Owner)"		"IV, PO"				"A3 (Functional Gastro-Intestinal Disorder Drugs), M3 (Muscle Relaxants), N2 (Analgesics)"	"A03 (Drugs for Functional Gastrointestinal Disorders), M03 (Muscle Relaxants), N02 (Analgesics)"	"VB210, VITA210"			28/09/2020	"Digestive System Disorders, Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800047063?userId=52029392&bpIds=3004037004&checksum=18256628e6f090f8d41fcaeccab5f0324900a53b-1617045531484-4e6621438dbd90121d0632050d1809cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047389	KB CN 001			Yes			No development reported (Preclinical)	Neuropathic pain		Sodium channel antagonists	"Krisani Biosciences (Originator), Krisani Biosciences (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	KBCN001			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800047389?userId=52029392&bpIds=3004037004&checksum=8a07b745d689429d1c437a3b9cdd0c74fc51144a-1617045531484-0fd88557f4e367e5d7b5bc77043502b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046922	Celecoxib - Ceridia	169590-42-5	"Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-"	No			No development reported (Preclinical)	Pain	C17 H14 F3 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"Ceridia (Originator), Ceridia (Owner)"		PO				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H01 (Celecoxib), N02B (Other Analgesics and Antipyretics)"				28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800046922?userId=52029392&bpIds=3004037004&checksum=01e4bd0563318db7a1532e9d0deb5472baa6d40a-1617045531485-5bd9df613f4ad911f81d0f721ead2368badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053193	Indometacin/l-menthol - Kowa Research Institute		"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-/Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-"	No			Phase II	Acute pain	C19 H16 Cl N O4 . C10 H20 O	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Kowa Research Institute (Originator), Kowa Research Institute (Owner)"		Topical				N2 (Analgesics)	"M01A-B01 (Indometacin), N02 (Analgesics)"	"K285, lmenthol/indometacin Kowa"			28/09/2020	Pain				no		no							https://adis.springer.com/drugs/800053193?userId=52029392&bpIds=3004037004&checksum=943f4e1034e04338b3b200bb77b7aea11e2a1932-1617045531486-79fafd148d146873d0f69d41f127d1c3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046951	Research programme: therapeutics - Re-Pharm			No			No development reported (Preclinical)	"Eye disorders, Respiration disorders, Inflammatory bowel diseases, Sexual function disorders, Neuropathic pain"		Undefined mechanism	"Re-Pharm (Originator), Re-Pharm (Owner)"		"Topical, unspecified"				"A7E (Intestinal Anti-Inflammatory Agents), N2 (Analgesics), R (Respiratory System), S1 (Ophthalmologicals)"	"A07E (Intestinal Antiinflammatory Agents), N02 (Analgesics), R (Respiratory System), S01 (Ophthalmologicals)"	RP 0217			28/09/2020	"Eye Disorders, Inflammatory Bowel Disorders, Men's Health, Pain, Respiratory Tract Disorders, Women's Health"		Re-Pharm |  | Unspecified |  | 02 Aug 2016		no		no							https://adis.springer.com/drugs/800046951?userId=52029392&bpIds=3004037004&checksum=84c0c66a574f692f2373d65ebb47f123de64a05d-1617045531487-679ffbd05aae3dc27cfac3b062ee0b00badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039486	Research programme: small molecule therapeutics - Algiax Pharmaceuticals			Yes			Preclinical	"Type 2 diabetes mellitus, Cognition disorders, Neuropathic pain, Type 1 diabetes mellitus"		"GABA A receptor modulators, Type 4 cyclic nucleotide phosphodiesterase modulators"	"Algiax Pharmaceuticals (Originator), Algiax Pharmaceuticals (Owner), JDRF (Funder), University of California at Los Angeles (Collaborator)"		"unspecified, PO"				"A10 (Drugs Used in Diabetes), N2 (Analgesics), N7 (Other CNS Drugs)"	"A10B (Blood Glucose Lowering Drugs, Excl. Insulins), N02 (Analgesics), N06D-X (Other anti-dementia drugs)"	"AP19, AP2, AP3, AP4, AP61, AP778, AP8, ThAc derivatives, Thioacrylamide derivatives"			28/09/2020	"Alzheimer's Disease and Cognition Disorders, Diabetes, Pain"		Algiax Pharmaceuticals |  | Unspecified |  | 10 Aug 2017		no		no							https://adis.springer.com/drugs/800039486?userId=52029392&bpIds=3004037004&checksum=f7d34eb2e7f3b724d73d9a8e13c904760b2632f7-1617045531488-b1c4a2b49aadd703b28382e102cb5715badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048787	Fentanyl inhalation - Boehringer Ingelheim Canada	437-38-7	N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Phase III	Dyspnoea	C22 H28 N2 O	Opioid mu receptor agonists	"Boehringer Ingelheim (Canada) (Originator), Boehringer Ingelheim (Canada) (Owner), Queens University (Collaborator)"		Inhalation				"N1A2 (Injectable general anaesthetics), N2A (Narcotics)"	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	"Inhaled fentanyl Boehringer Ingelheim Canada, Nebulized Fentanyl Boehringer Ingelheim Canada, Nebulized fentanyl citrate Boehringer Ingelheim Canada"			25/09/2020	Obstructive Airways Disease				no		no							https://adis.springer.com/drugs/800048787?userId=52029392&bpIds=3004037004&checksum=a8d908e4f137edf5574b8d088ae690e9f59efc68-1617045531489-f263fe264b2000c4ae30063d7d048b5abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036726	CR 4056		2-phenyl-6-(1H-imidazol-1yl)quinazoline	Yes			Phase II	"Pain, Acute pain, Cancer pain, Neuropathic pain"	C17 H12 N4	Imidazoline I2 receptor agonists	"Rottapharm Madaus (Originator), Rottapharm Biotech (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	CR4056			24/09/2020	Pain				no		no							https://adis.springer.com/drugs/800036726?userId=52029392&bpIds=3004037004&checksum=bb883b92b4b3ca02afe26f000ff8c6a587dec7c9-1617045531491-f944d9ba356b1be04e961ab55e5e1365badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050003	AP 325			Yes			Phase II	"Neuropathic pain, Spinal cord injuries"		"Dihydroorotate dehydrogenase inhibitors, GABA A receptor modulators"	"Algiax Pharmaceuticals (Originator), Algiax Pharmaceuticals (Owner)"		"PO, Injection"				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	AP325			22/09/2020	"Neurological Disorders, Pain"	Spinal cord injuries (European Union)	Algiax Pharmaceuticals |  | Unspecified |  | 07 Nov 2016		no		no							https://adis.springer.com/drugs/800050003?userId=52029392&bpIds=3004037004&checksum=46d77ed4ce5183a48347af77eefa3c68b6ef4ddf-1617045531492-dbbe3aa570493a787962f4ccb3442294badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003462	Tezampanel - Proniras	154652-83-2	"(_)-(3<EM>S</EM>,4a<EM>R</EM>,6<EM>R</EM>,8a<EM>R</EM>)-6-[2-(1<EM>H</EM>-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid"	Yes			Preclinical	"Opioid-related disorders, Seizures, Migraine, Neuromuscular disorders, Thrombosis"	C13 H21 N5 O2	"AMPA receptor antagonists, Kainic acid receptor antagonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner), Proniras Corporation (Licensee), Biomedical Advanced Research and Development Authority (Funder), National Institute of Drug Abuse (Funder), Indiana University School of Medicine (Collaborator)"		"Parenteral, SC, IV"			"Dizziness, Injection site pain, Injection site reactions, Somnolence, Xerostomia"	"B1 (Antithrombotic Agents), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N7F (Drugs Used In Opioid Dependence)"	"B01A (Antithrombotic Agents), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N02C (Antimigraine Preparations), N03A (Antiepileptics), N03A-X (Other antiepileptics), N05B (Anxiolytics), N07B-C (Drugs used in opioid dependence)"	"LY 293558, NGX 424"			21/09/2020	"Advances in the Treatment of Nausea and Migraine, Drug Withdrawal, Epilepsy and Seizure Disorders, Musculoskeletal Disorders, Neurological Disorders, Thromboses"				no		no							https://adis.springer.com/drugs/800003462?userId=52029392&bpIds=3004037004&checksum=e318f948e66bd9a2ef938f55d554c7d2890987cd-1617045531494-acae536a104323a6777a692ab86d1db8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036277	Oxycodone extended release - Assertio Therapeutics	76-42-6	"Morphinan-6-one,4,5-_-epoxy-14-hydroxy-3-methoxy-17-methyl-"	No			Discontinued (III)	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Egalet (Originator), Assertio Therapeutics (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"AD ER oxycodone, Egalet002, EGP114, Opioid 2"			21/09/2020	Pain		Zyla Life Sciences |  | Unspecified |  | 31 Dec 2018		no		no							https://adis.springer.com/drugs/800036277?userId=52029392&bpIds=3004037004&checksum=94397e041a7a36b2d99c3aed86833bc683c5c554-1617045531495-bec08db11ee634fc4a4a206aae3e7c90badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024335	Fentanyl transdermal - Hisamitsu	990-73-8	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate	No			Marketed	"Cancer pain, Pain"	C22 H28 N2 O . C6 H8 O7	Opioid mu receptor agonists	"Hisamitsu Pharmaceutical (Originator), Hisamitsu Pharmaceutical (Owner), Kyowa Kirin (Market Licensee)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Fentanyl citrate patch Hisamitsu, Fentanyl citrate transdermal Hisamitsu, FENTOS, FENTOS TAPE, HFT290"			18/09/2020	Pain			"FENTOS, FENTOS, FENTOS TAPE, FENTOS TAPE"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024335?userId=52029392&bpIds=3004037004&checksum=ca692976643b06cef172cf18b37aaa150e67d49a-1617045531497-0cee0c7ff374a65d57414d2f350ef14dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028242	Sumatriptan intranasal - OptiNose	103628-46-2	3-[2-(dimethyl-amino)ethyl]-N-methylindole-5-methanesulfonamide	No			Marketed	Migraine	C14 H21 N3 O2 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"OptiNose AS (Originator), OptiNose AS (Owner), Currax Pharmaceuticals (Market Licensee), Avanir Pharmaceuticals (Licensee), OptiNose UK (Collaborator)"		Intranasal			"Application site reactions, Rhinitis, Taste disorders"	N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"AVP825, ONZETRA Xsail, OptiNose sumatriptan"			15/09/2020	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			ONZETRA Xsail	no		no							https://adis.springer.com/drugs/800028242?userId=52029392&bpIds=3004037004&checksum=a7b4574b30d44693a39ca4e7e554cda80acca156-1617045531498-3d8aa531dd935f69162d573c33f6c7b9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060423	IKD 01400			Yes			Preclinical	Pain		Protein kinase G inhibitors	"InterK Peptide Therapeutics (Originator), InterK Peptide Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	IKD01400			15/09/2020	Pain		InterK Peptide Therapeutics |  | Unspecified |  | 15 Sep 2020		no		no							https://adis.springer.com/drugs/800060423?userId=52029392&bpIds=3004037004&checksum=8072d1bd747a678b62698aec556df9ad2de45570-1617045531499-39c46f62eda92cbed8255ec91e7f5b77badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060403	IK 01400			Yes			Preclinical	"Pain, Neuropathic pain"		Protein kinase G inhibitors	"InterK Peptide Therapeutics (Originator), InterK Peptide Therapeutics (Owner)"		"Intraperitoneal, Intrathecal, IV, PO"				N2 (Analgesics)	N02 (Analgesics)	IK01400			15/09/2020	Pain		InterK Peptide Therapeutics |  | Unspecified |  | 15 Sep 2020		no		no							https://adis.springer.com/drugs/800060403?userId=52029392&bpIds=3004037004&checksum=6030a2e9e01c90fea0c46596b1b73ad836d8642b-1617045531500-f787d215de2b9b19a8becea02242dd76badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037883	Benzhydrocodone/paracetamol - KemPharm		"6,7-didehydro-4,5_-epoxy-3-methoxy-17-methylmorphinan-6-yl benzoate / N-(4-hydroxyphenyl)acetamide"	No			Marketed	Acute pain	C25 H25 N O4 . C8 H9 N O2	"Opioid receptor agonists, Prostaglandin receptor antagonists"	"KemPharm (Originator), KemPharm (Owner), KVK Tech (Market Licensee), Acura Pharmaceuticals (Technology Provider)"		PO				"N2A (Narcotics), N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)"	"N02A (Opioids), N02B-E01 (Paracetamol)"	"Acetaminophen/benzhydrocodone, Acetaminophen/KP201, AGAPADAZ, Apadaz, APAP/KP201, Benzhydrocodone and acetaminophen, Benzhydrocodone/acetaminophen, KP201/acetaminophen, KP201/APAP, KP201/IR, Paracetamol/benzhydrocodone, Paracetamol/KP201"			14/09/2020	Pain			Apadaz	no		no							https://adis.springer.com/drugs/800037883?userId=52029392&bpIds=3004037004&checksum=4bd41e4f3e229d6d53fa8f516f35936b72608cc5-1617045531501-cf35aebf7883b97d0cfab7e0e3e09f61badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050761	Research programme: cannabidiol/tetrahydrocannabinol based therapeutics - BetterLife Pharma			No			Research	"Dysmenorrhoea, Eye disorders, Decreased libido, Skin disorders"		Cannabinoid receptor agonists	"Pivot Pharmaceuticals (Originator), BetterLife Pharma (Owner), S.T.U. (Market Licensee), Altum Pharmaceuticals (Technology Provider)"		Topical				"D11A (Other Dermatological Preparations), G2X (Other Gynaecological products), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"D11A-X (Other dermatologicals), G02C-X (Other gynecologicals), N02B-G10 (Cannabinoids, including nabiximols), S01X (Other Ophthalmologicals)"	"PVT011, PVT012, PVT013, PVT014"			11/09/2020	"Eye Disorders, Skin Disorders, Women's Health"				no		no							https://adis.springer.com/drugs/800050761?userId=52029392&bpIds=3004037004&checksum=6f7902c0acb24743092ffc66672033ec4099cf36-1617045531502-7025d8b4591bc4826b610325683d218abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039874	TRV 734			Yes			Phase I	"Opioid-related disorders, Pain"		"Beta arrestin inhibitors, Opioid mu receptor agonists"	"Trevena (Originator), Trevena (Owner), National Institute of Drug Abuse (Funder)"		PO			"Dizziness, Headache, Nausea, Somnolence, Vomiting"	"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02A (Opioids), N07B-C (Drugs used in opioid dependence)"	TRV734			11/09/2020	"Drug Withdrawal, Pain"		Trevena |  | Unspecified |  | 07 Feb 2014		no		no							https://adis.springer.com/drugs/800039874?userId=52029392&bpIds=3004037004&checksum=dc19c256442c3e76c29bec391f76995284d6e76c-1617045531503-b43bcc90574b3ec56d8137d6fb5b215fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042217	Research programme: cannabis based therapeutics - One World Cannabis			No			Clinical Phase Unknown	"Multiple myeloma, Pain, Fibromyalgia, Post-traumatic stress disorders"		Cannabinoid receptor agonists	"One World Cannabis (Originator), One World Cannabis (Owner), MedMar (Licensee), G.C. Group (Collaborator), The Chaim Sheba Medical Center at Tel Hashomer (Collaborator)"		"Sublingual, Intranasal"				"D (Dermatologicals), D5A (Topical Antipsoriasis Products), L (Antineoplastic and Immunomodulating Agents), N2 (Analgesics), N2C (Anti-Migraine Preparations), N5 (Psycholeptics)"	"D (Dermatologicals), D05A (Antipsoriatics for Topical Use), L01 (Antineoplastic Agents), N02 (Analgesics), N05B (Anxiolytics)"	"Cannabidiol One World Cannabis, cannabinoidenriched sublingual disintegrating tablet, Medical cannabis One World Cannabis, OWC1808, Tethahydrocannabidiol One World Cannabis"			09/09/2020	"Anxiety Disorders, Cancer, Pain"				no		no							https://adis.springer.com/drugs/800042217?userId=52029392&bpIds=3004037004&checksum=298a3b3098dcbdafb42f6569b9b9942ae1307b58-1617045531505-765b542f9446e9e6df9a5373a873a030badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043910	ASN 009			Yes			Preclinical	"Genitourinary disorders, Pain, Pruritus, Cough"		Purinergic P2X3 receptor antagonists	"Asana BioSciences (Originator), Asana BioSciences (Owner)"		PO				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics), R5 (Cough and Cold Preparations)"	"D04A-X (Other antipruritics), N02 (Analgesics), R05 (Cough and Cold Preparations)"	ASN009			08/09/2020	"Drug Delivery Systems, Genitourinary Disorders, Pain, Respiratory Tract Disorders, Skin Disorders"		Asana BioSciences |  | Unspecified |  | 08 Sep 2020		no		no							https://adis.springer.com/drugs/800043910?userId=52029392&bpIds=3004037004&checksum=fe0c6d6c57a91c07a9b0f11fe0f3d275e1d4bfd3-1617045531506-2d6a27a351962130b7dcad0ebb1c6e1dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056269	ALD 1910			Yes			Phase I	Migraine		Pituitary adenylate cyclase-activating polypeptide receptor antagonists	"Alder Biopharmaceuticals (Originator), Lundbeck Seattle BioPharmaceuticals Inc. (Owner)"		"IV, SC"				N2C9 (All other anti-migraine preparations)	N02C-X (Other antimigraine preparations)	"ALD1910, AntiPACAP38antibody Lundbeck Seattle BioPharmaceuticals Inc, LU AG09222, PACAP Lundeback"			07/09/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800056269?userId=52029392&bpIds=3004037004&checksum=d92fddbb6d7ab40a7da570c132d69a98150e8c3f-1617045531506-09866b1ac66be5b0296e9393dd8a2220badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060268	NEU P12			Yes			Phase I	"Pruritus, Neuropathic pain"		"Nav1.7 voltage-gated sodium channel inhibitors, TRPV1 receptor antagonists"	"Neurim Pharmaceuticals (Originator), Neurim Pharmaceuticals (Owner)"		unspecified				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A-X (Other antipruritics), N02 (Analgesics)"	NEUP12			07/09/2020	"Pain, Skin Disorders"		Neurim Pharmaceuticals |  | Unspecified |  | 07 Sep 2020		no		no							https://adis.springer.com/drugs/800060268?userId=52029392&bpIds=3004037004&checksum=9b241a3de2629f537a6ee02c266307a5f79170b6-1617045531507-5245a8f063d7c8591ab749f9f0f5cf2dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039069	IONIS PKKRx			Yes			Phase II	"Migraine, Hereditary angioedema"		Kallikrein inhibitors	"Isis Pharmaceuticals (Originator), Ionis Pharmaceuticals (Owner)"		"SC, unspecified"				"B6C (Other Haematological Agents), N2C9 (All other anti-migraine preparations)"	"B06A-C (Drugs used in hereditary angioedema), N02C (Antimigraine Preparations)"	"IONISPKKRx, ISIS 546254, ISISPKKRx"			04/09/2020	"Advances in the Treatment of Nausea and Migraine, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800039069?userId=52029392&bpIds=3004037004&checksum=678a86028020eacadca7ec6014834abba2701fea-1617045531508-1af3852338a0d96a70d810845f839e5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015178	Research programme: neuropeptide FF receptor antagonists - Juvantia Pharma			Yes			Discontinued (Preclinical)	Pain		Neuropeptide FF receptor antagonists	"Juvantia Pharma (Originator), Santhera Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Neuropeptide FF receptor antagonists research programme Juvantia Pharma			04/09/2020	Pain				no		no							https://adis.springer.com/drugs/800015178?userId=52029392&bpIds=3004037004&checksum=4265c4d0e49eb385d36b26dfa5d2af83b62d05b7-1617045531509-7bbcfe5786eda2b30084a1612ec35181badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054635	Research programme: small molecule therapeutics - Nocion Therapeutics			Yes			Preclinical	"Cough, Pain, Pruritus, Inflammation"		Sodium channel antagonists	"Boston Childrens Hospital (Originator), Harvard University (Originator), Boston Childrens Hospital (Owner), Harvard University (Owner), Nocion Therapeutics (Licensee), Pulmatrix (Technology Provider)"		"Inhalation, unspecified"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R5F (Other Cough and Cold Preparations)"	"D04A-X (Other antipruritics), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R05 (Cough and Cold Preparations)"				04/09/2020	"Inflammation, Pain, Respiratory Tract Disorders, Skin Disorders"				no		no							https://adis.springer.com/drugs/800054635?userId=52029392&bpIds=3004037004&checksum=ac486b8181cec236f35e0d77cb820235d080dee5-1617045531510-70efb392e7d45e9e5743db5e947147babadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058362	Psilocybin topical - Revive Therapeutics	520-52-5	[3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate	Yes			Preclinical	"Opioid-related disorders, Substance-related disorders"	C12 H17 N2 O4 P	Serotonin 2 receptor agonists	"Psilocin Pharma Corp (Originator), Revive Therapeutics (Owner), North Carolina State University (Technology Provider), University of Wisconsin-Madison (Collaborator)"		unspecified				"N2 (Analgesics), N6A9 (Antidepressants, all others), N7X (All other CNS drugs)"	"N02 (Analgesics), N06A-X (Other antidepressants), N07B (Drugs Used In Addictive Disorders)"				04/09/2020	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800058362?userId=52029392&bpIds=3004037004&checksum=57d52a2463911a5958854d0b1f18f841b9f730e7-1617045531511-4ac3ffa4774bc7e6d815b3f73218268dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032393	Research programme: G protein-coupled receptor modulating small molecules - Omeros Corporation			Yes			No development reported (Preclinical)	"Cancer, Pain, Multiple sclerosis, Metabolic disorders, Cognition disorders, Osteoporosis, Demyelinating disorders, Eating disorders, Epstein-Barr virus infections, Psychotic disorders, Autistic disorder, Rheumatoid arthritis, Sleep disorders, Inflammation, Gastrointestinal disorders, Obesity"		"G protein-coupled receptor modulators, Neuromedin U receptor modulators"	"Omeros Corporation (Originator), Omeros Corporation (Owner)"		unspecified				"A (Alimentary Tract and Metabolism), A16 (Other Alimentary Tract and Metabolism Products), A8 (Antiobesity Preparations, Excluding Dietetics), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N5 (Psycholeptics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"A (Alimentary Tract and Metabolism), A08 (Antiobesity Preparations, Excl. Diet Products), A16 (Other Alimentary Tract and Metabolism Products), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), M05 (Drugs for Treatment of Bone Diseases), N02 (Analgesics), N05 (Psycholeptics), N06 (Psychoanaleptics), N06A (Antidepressants), N06D-X (Other anti-dementia drugs), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"				04/09/2020	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Cancer, Digestive System Disorders, Inflammation, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Obesity, Pain, Psychotic Disorders, Rheumatic Disease, Viral Infections"				no		no							https://adis.springer.com/drugs/800032393?userId=52029392&bpIds=3004037004&checksum=0c5a2501454717b0d7fd64b38ae31b6ae2731d1c-1617045531514-6c97e5f0111e0b389bee23b21625bc54badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800060091	TRN 152			Yes			Clinical Phase Unknown	Pain		Undefined mechanism	"Tris Pharma (Originator), Tris Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TRN152			03/09/2020	Pain				no		no							https://adis.springer.com/drugs/800060091?userId=52029392&bpIds=3004037004&checksum=bd6e128df6e9d08c13c36e82f30646d61e1142fc-1617045531515-6c45a424b14ffa9894d0a4d7122aeed3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049507	DRGT 110			Yes			Preclinical	Pain		Undefined mechanism	"Druggability Technologies (Originator), Tavanta Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DRGT110			03/09/2020	Pain				no		no							https://adis.springer.com/drugs/800049507?userId=52029392&bpIds=3004037004&checksum=867efc8fb29d92e670cb0efe05907d4976479801-1617045531516-2de58d5b5f907edcf16c598205f33be3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049508	DRGT 111			Yes			Preclinical	Pain		Undefined mechanism	"Druggability Technologies (Originator), Tavanta Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DRGT111			03/09/2020	Pain				no		no							https://adis.springer.com/drugs/800049508?userId=52029392&bpIds=3004037004&checksum=e9eaa171563213f9705341ca4f07371cc7ffaade-1617045531517-3fa3b8e8e7268924c569a6423df05a15badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045440	Felbinac intravenous - Guangdong Zhongke Drug Research & Development/Shijiazhuang Yiling Pharmaceutical	5728-52-9	"(1,1'-Biphenyl)-4-acetic acid"	No			Phase III	"Postoperative pain, Inflammation"	C14 H12 O2	Cyclooxygenase inhibitors	"Shijiazhuang Yiling Pharmaceutical (Originator), Shijiazhuang Yiling Pharmaceutical (Owner), Guangdong Zhongke Drug Research & Development (Collaborator)"		IV				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-B (Acetic acid derivatives and related substances), N02 (Analgesics)"	Felbinac trometamol			02/09/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800045440?userId=52029392&bpIds=3004037004&checksum=ea7525ca54ace064bfb4aa45160032ee56d935ba-1617045531518-c346005e35aac77989d1d1f5477ba30dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059914	ND 340			No			Phase I	Postoperative pain		Undefined mechanism	"Nang Kuang Pharmaceutical (Originator), Nang Kuang Pharmaceutical (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	ND340			01/09/2020	Pain				no		no							https://adis.springer.com/drugs/800059914?userId=52029392&bpIds=3004037004&checksum=c0168e7c84835197777967698cbe055ba01473c1-1617045531519-24b6fa0f26f48b3d3ebfec441cd24a07badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030545	Rizatriptan oral film - IntelGenx	144034-80-0	"3-[2-(Dimethylamino)ethyl]-5-(1,2,4-triazol-1-ylmethyl)-indole benzoate"	No			Registered	Migraine	C15 H19 N5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"IntelGenx Corp. (Originator), IntelGenx Corp. (Owner), Exeltis (Market Licensee), Gensco Laboratories (Market Licensee), Orivas (Market Licensee), Pharmatronic (Market Licensee), Aquestive Therapeutics (Technology Provider)"		PO				N2C1 (Antimigraine triptans)	N02C-C04 (Rizatriptan)	"INT 0008/2007, INT 0008/2008, INT0008, RHB103, Rizaport, RIZAPORT VersaFilm"			31/08/2020	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"		"IntelGenx Corp. | Migraine | Unspecified | Europe, Latin America, USA | 05 Jul 2016"	"Rizaport, Rizaport"	no		no							https://adis.springer.com/drugs/800030545?userId=52029392&bpIds=3004037004&checksum=8dd62707b51ece4969a6e12594d7d4fb4a2b7b13-1617045531522-e2d91b2fd3fc7a74e6af04d5df86a2fcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046691	Nefopam - Beijing CoSci Med Tech	13669-70-0	"1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- (8CI,9CI)"	No			No development reported (Preclinical)	Pain	C17 H19 N O	"Adrenergic receptor agonists, Muscarinic receptor antagonists"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G06 (Nefopam)				28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046691?userId=52029392&bpIds=3004037004&checksum=4ab84398d747c73e0cc565f5ac27c9858d12eab6-1617045531523-ef0c63ca78dc152ea3118ad73b68a49dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046858	Tramadol extended release - Altus Formulation	27203-92-5	(±-cis-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol	No			No development reported (Research)	Pain	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	TramaFlex ER			28/08/2020	Pain		Altus Formulation Inc |  | Unspecified |  | 29 Jul 2016	TramaFlex ER	no		no							https://adis.springer.com/drugs/800046858?userId=52029392&bpIds=3004037004&checksum=5ecbd35ef351b76ea5d401841edba24710c49cd4-1617045531524-86034dfe6f0d828d43a572dd3cc9bd87badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046219	Research programme: triptans - Angelini Pharmaceuticals			Yes			No development reported (Preclinical)	Migraine		Serotonin 1 receptor agonists	"Angelini Pharmaceuticals (Originator), Angelini Pharmaceuticals (Owner)"		unspecified				N2C1 (Antimigraine triptans)	N02C-C (Selective serotonin (5HT1) agonists)	Triptans new formulations Angelini			28/08/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800046219?userId=52029392&bpIds=3004037004&checksum=724b44f73117319ccb80bef03b3a42d7ccee89af-1617045531525-5450444724caeaa4d89a3c105e748893badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046846	AFI 003			No			No development reported (Preclinical)	Pain		Opioid receptor agonists	"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner), Unknown (Development Licensee)"		PO				N2A (Narcotics)	N02A (Opioids)	AFI003			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046846?userId=52029392&bpIds=3004037004&checksum=cc4072280da8e5db5273f80409a081e326ef319d-1617045531526-ac606c0b5c551cd3f21f5aad57cf2a95badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046848	AFI 004			No			No development reported (Research)	Pain		Opioid receptor agonists	"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner), Unknown (Development Licensee)"		PO				N2A (Narcotics)	N02A (Opioids)	AFI004			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046848?userId=52029392&bpIds=3004037004&checksum=8c104022edb76de12206c7f670b3f549ca14d2f8-1617045531527-64806e4f71c53b41a3629ab0ad041282badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046849	AFI 005			No			No development reported (Research)	Pain		Opioid receptor agonists	"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	AFI005			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046849?userId=52029392&bpIds=3004037004&checksum=9211778c42ea5a0b9e14cc9e959965922c31ac1c-1617045531528-cc9498bc94f3ed310d228fd00933519bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046198	Valpentin			Yes			No development reported (Preclinical)	Pain			"CEAMED (Originator), CEAMED (Owner), University of Las Palmas de Gran Canaria (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046198?userId=52029392&bpIds=3004037004&checksum=9f1a51f560248ffcf805ee97aed1d042e65c67ce-1617045531529-b8c9751e8a5b131cc1abf2b0ce0b43d2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046317	Research programme: cannabinoid receptor 2 agonists - Dompe			Yes			No development reported (Research)	Pain		Cannabinoid receptor CB2 agonists	"Dompe SpA (Originator), Dompe SpA (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CNR2 agonists Dompe			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046317?userId=52029392&bpIds=3004037004&checksum=99d3c830c8181c8298d18714e72b066ebe5e71d8-1617045531530-28ad61f06f965a9d2bb9171801458a5dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046321	Research programme: pain therapeutics - Nippon Chemiphar			Yes			No development reported (Research)	Pain			"Nippon Chemiphar (Originator), Nippon Chemiphar (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain		Nippon Chemiphar | Pain | Unspecified |  | 19 Jul 2016		no		no							https://adis.springer.com/drugs/800046321?userId=52029392&bpIds=3004037004&checksum=c2c461674da0a068ecbf72d9b15179bb3b74ff08-1617045531531-dc5ea849666f8e9c0e1867842d564813badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046406	KLS 2020			No			No development reported (Preclinical)	Pain			"Kolon Life Science (Originator), Kolon Life Science (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	KLS2020			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046406?userId=52029392&bpIds=3004037004&checksum=9184cbd80515343fe2857b6dc9d0a357a23f5e70-1617045531531-90d46bc91870a51b92da5c6d915729f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046263	Research programme: cystathionine gamma-lyase inhibitors - Sova Pharmaceuticals			Yes			No development reported (Preclinical)	"Neuropathic pain, Inflammatory pain"		Cystathionine gamma-lyase inhibitors	"Sova Pharmaceuticals (Originator), Sova Pharmaceuticals (Owner)"		unspecified				N2B1 (Prescription-bound non-narcotics and anti-pyretics)	N02B (Other Analgesics and Antipyretics)				28/08/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800046263?userId=52029392&bpIds=3004037004&checksum=ad8130ca54f007890029cd536621f53b4922190b-1617045531533-21d52713a3f6e5860af5d3541aebcdf1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046062	Research programme: oligonucleotide therapeutics for pain - OliPass			Yes			No development reported (Preclinical)	Neuropathic pain		Nav1.7 voltage-gated sodium channel inhibitors	"OliPass (Originator), OliPass (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046062?userId=52029392&bpIds=3004037004&checksum=d4c2d7cbfa2311b8524c1887f3d42a4a5a0fce52-1617045531533-badc99bea326578b9a805d16e7664a52badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045899	TF 0066			Yes			No development reported (Preclinical)	"Depressive disorders, Neuropathic pain"		Undefined mechanism	"Techfields Pharma (Originator), Techfields Pharma (Owner)"		unspecified				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N05B (Anxiolytics)"	TF 0066			28/08/2020	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800045899?userId=52029392&bpIds=3004037004&checksum=1a9380a9bdb7f93fef8c58ca5a0c1e76055e5a1d-1617045531535-2804d0e845c92a3e4ac087e2e52768a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046534	Research programme: central nervous system analgesics - AfaSci			Yes			No development reported (Preclinical)	"Peripheral nervous system diseases, Diabetic neuropathies, Epilepsy, Neuropathic pain"		Ion channel antagonists	"AfaSci (Originator), AfaSci (Owner)"		unspecified				"A10 (Drugs Used in Diabetes), N2 (Analgesics), N3 (Anti-Epileptics), N7 (Other CNS Drugs)"	"A10 (Drugs Used in Diabetes), N02 (Analgesics), N03 (Antiepileptics), N07 (Other Nervous System Drugs)"				28/08/2020	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"		"AfaSci | Diabetic neuropathies, Epilepsy, Neuropathic pain, Peripheral nervous system diseases | Unspecified |  | 22 Jul 2016"		no		no							https://adis.springer.com/drugs/800046534?userId=52029392&bpIds=3004037004&checksum=6cbb371348216d03cad1a4642eec9047ac1a20bb-1617045531536-8102e1a038a8725089d5707fca9c428ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046860	PPI 001			No			No development reported (Preclinical)	Postoperative pain			"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	PPI001			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046860?userId=52029392&bpIds=3004037004&checksum=9c88f46926074ccac037758f02dc1d18d56d2c03-1617045531537-a29c3228908d7bb92df00f16c7f6fcd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046644	Research programme: pain theraputics - Colby Pharmaceuticals			Yes			No development reported (Preclinical)	Pain		Undefined mechanism	"Colby Pharmaceuticals (Originator), Colby Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"CPC 111, CPC 123"			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046644?userId=52029392&bpIds=3004037004&checksum=f094e0eb39aef943311a8bfe1478d498817754d6-1617045531538-0ca7f38fd2ec60e47fefbc3329e5b163badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046536	Research programme: peripheral analgesics - AfaSci			Yes			No development reported (Preclinical)	"Neuropathic pain, Inflammatory pain, Postoperative pain"		G protein-coupled receptor antagonists	"AfaSci (Originator), AfaSci (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain		"AfaSci | Inflammatory pain, Neuropathic pain, Postoperative pain | Unspecified |  | 22 Jul 2016"		no		no							https://adis.springer.com/drugs/800046536?userId=52029392&bpIds=3004037004&checksum=174f926454da5a41c5308cc69f79bec59c946715-1617045531539-b3e65c644b689c3bf3661d6cff998847badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045772	Research programme: cannabinoid receptor CB2 modulatorsagonists - C4T SCarl			Yes			No development reported (Preclinical)	Neuropathic pain		Cannabinoid receptor CB2 modulators	"C4T SCarl (Originator), C4T SCarl (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain		C4T SCarl |  | Unspecified |  | 05 Jul 2016		no		no							https://adis.springer.com/drugs/800045772?userId=52029392&bpIds=3004037004&checksum=0b0eba751476b582ab8bba56de5b8297050faf06-1617045531540-71cc31265d462cc112481e75f1cac980badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046292	Research programme: neuropathic pain therapeutics - NanoAxis			No			No development reported (Preclinical)	Neuropathic pain		Gene transference	"NanoAxis (Originator), NanoAxis (Owner)"		Parenteral				N2A (Narcotics)	N02 (Analgesics)				28/08/2020	Pain		NanoAxis |  | Unspecified |  | 18 Jul 2016		no		no							https://adis.springer.com/drugs/800046292?userId=52029392&bpIds=3004037004&checksum=fc26f5f0f00e7778c9b5f4772f552b45f9aedb67-1617045531541-e200af8adeaaf105ed8018089bc6d018badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030580	Research programme: TRPV1 receptor antagonists - Grunenthal/Medifron			Yes			No development reported (Preclinical)	"Postherpetic neuralgia, Diabetic neuropathies"		TRPV1 receptor antagonists	"Medifron DBT (Originator), Medifron DBT (Owner), Grunenthal (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MDR16523			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800030580?userId=52029392&bpIds=3004037004&checksum=c29e2e8d073e868a644c0dcc7f16a82ae3764a37-1617045531542-ac5e1cdfe73d247f2b28f72463168f89badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046485	RBM 004			Yes			No development reported (Preclinical)	Pain		Nerve growth factor inhibitors	"Ribomic (Originator), Ribomic (Owner), Fujimoto Pharmaceutical (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	RBM004			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046485?userId=52029392&bpIds=3004037004&checksum=1a08114d23cedf716ee1b35cd0df49a4ba35f072-1617045531543-bf0768973bee32c964e3da913e8592b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046523	A 100			Yes			No development reported (Preclinical)	Inflammatory pain		G protein-coupled receptor antagonists	"AfaSci (Originator), AfaSci (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	A100			28/08/2020	Pain		AfaSci | Inflammatory pain | Unspecified |  | 22 Jul 2016		no		no							https://adis.springer.com/drugs/800046523?userId=52029392&bpIds=3004037004&checksum=6ec17aaa8614b27f4f31cfe9e31988c3bac47bfc-1617045531544-6b528a2a708eb96c456deb09db8e71a3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046525	A 200 - AfaSci			Yes			No development reported (Preclinical)	Neuropathic pain		Ion channel modulators	"AfaSci (Originator), AfaSci (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	A200			28/08/2020	Pain		AfaSci | Neuropathic pain | Unspecified |  | 22 Jul 2016		no		no							https://adis.springer.com/drugs/800046525?userId=52029392&bpIds=3004037004&checksum=7fe5bda4f0e3b33d1cd612cfa39855ab21e16f31-1617045531545-89944b5f457f65b92499290882bedfccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046389	VAS 047			Yes			No development reported (Preclinical)	Headache			"Vastrata (Originator), Vastrata (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	VAS047			28/08/2020	Advances in the Treatment of Nausea and Migraine		Vastrata | Headache | Unspecified |  | 20 Jul 2016		no		no							https://adis.springer.com/drugs/800046389?userId=52029392&bpIds=3004037004&checksum=1c5ffbf74623878682b11406bfab8d9d2b7d3fb7-1617045531546-48e92528a9db6326a5813d2c2f0bc32fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045732	YD 307			Yes			No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"YD Global Life Science (Originator), YD Global Life Science (Owner), Hanrim University (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"FY307, YD307"			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800045732?userId=52029392&bpIds=3004037004&checksum=57ed1c052ae7f093d97e9d1a18d36ebb493375fe-1617045531547-46be68a50f5102295c732909b3a72a7abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046358	DX 0332			Yes			No development reported (Research)	Neuropathic pain		Undefined mechanism	"DermaXon (Originator), DermaXon (Owner), National Institutes of Health (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DX0332			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046358?userId=52029392&bpIds=3004037004&checksum=df8810d90776b342ccaaab1334b69c2917ebf555-1617045531548-2ff4095481c64f56ac3b2ec8044af34cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045740	PA 300			Yes			No development reported (Preclinical)	"Musculoskeletal pain, Multiple sclerosis"		Adenosylmethionine decarboxylase inhibitors	"Pathologica (Originator), Pathologica (Owner)"		PO				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	PA300			28/08/2020	"Neurological Disorders, Pain"		Pathologica |  | Unspecified |  | 08 Jul 2016		no		no							https://adis.springer.com/drugs/800045740?userId=52029392&bpIds=3004037004&checksum=500356133c61ab0d764ed36ebb0e1c7511fa334d-1617045531549-e2d90c2063b50465bdfcf0769e01d5c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046217	Research programme: non-steroidal anti-inflammatory drugs - Angelini Pharmaceuticals			Yes			No development reported (Preclinical)	"Inflammation, Pain"		Cyclooxygenase inhibitors	"Angelini Pharmaceuticals (Originator), Angelini Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	Nsaids new formulations Angelini			28/08/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800046217?userId=52029392&bpIds=3004037004&checksum=0130e5a84b9fbc6cc2b3b90946702a77bde11b57-1617045531550-5b5e393eeaf3d7b6f1d3a61b1ff496c8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045883	Research programme: cancer pain therapeutics - GlobalAcorn			Yes			No development reported (Preclinical)	Cancer pain		Purinergic P2X3 receptor antagonists	"GlobalAcorn (Originator), GlobalAcorn (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"				28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800045883?userId=52029392&bpIds=3004037004&checksum=6ece42f4003c0543baa5111a5feb91355f4432b0-1617045531551-37e21b588e2104fb56bb461099db278ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046113	Research programme: neuropathic pain antibodies - Expression Drug Designs			Yes			No development reported (Research)	Neuropathic pain		G protein-coupled receptor antagonists	"Expression Drug Designs (Originator), Expression Drug Designs (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046113?userId=52029392&bpIds=3004037004&checksum=12bca2c9738cf68dcddf51c05854bb6bb79e9fd0-1617045531551-22ecaa643dc1552e2c7afc64bf0c28d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030581	Research programme: TRPV1 receptor agonists - Medifron			Yes			No development reported (Preclinical)	"Postherpetic neuralgia, Diabetic neuropathies"		TRPV1 receptor agonists	"Digital Biotech (Originator), Medifron DBT (Owner)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)	MDR652			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800030581?userId=52029392&bpIds=3004037004&checksum=a17d1bf48436d1b9307cf2aa2249e47110cd0fce-1617045531552-1b6ab5b89294e18b1977ad9a227035ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046341	OSX 300 series			Yes			No development reported (Preclinical)	Neuropathic pain		Purinergic P2X3 receptor antagonists	"Ossianix (Originator), Ossianix (Owner), Lundbeck A/S (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	OSX300			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800046341?userId=52029392&bpIds=3004037004&checksum=0b21ff0bab653eb4a3772e889a30a7897b06514f-1617045531553-c36413001a3ed0fdac251ed519f90a3abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044303	Esomeprazole/meloxicam - Axsome Therapeutics		"1H-Benzimidazole, 5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)- /4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide"	No			No development reported (I)	Pain	C17 H19 N3 O3 S . C14 H13 N3 O4 S2	"Cyclo-oxygenase 2 inhibitors, Proton pump inhibitors"	"Axsome Therapeutics (Originator), Axsome Therapeutics (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	"A02B-C05 (Esomeprazole), M01A-C06 (Meloxicam), N02B (Other Analgesics and Antipyretics)"	AXS 06			28/08/2020	Pain				no		no							https://adis.springer.com/drugs/800044303?userId=52029392&bpIds=3004037004&checksum=b71dbb84b13693e1c7e1822ce463aada24a16f45-1617045531554-2e61ed6f9f92b6f552f02820e2fe6b5bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055642	CT 044 analogues - CERSCI Therapeutics			Yes			Preclinical	"Migraine, Diabetic neuropathies, Neurodegenerative disorders, Opioid-related disorders, Pain, Neuropathic pain"		Reactive oxygen species inhibitors	"CERSCI Therapeutics (Originator), CERSCI Therapeutics (Owner), National Institute of Neurological Disorders and Stroke (Funder), The National Institute of General Medical Sciences (Funder)"		"PO, unspecified"				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics), N2C (Anti-Migraine Preparations), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N02C-X (Other antimigraine preparations), N07B-C (Drugs used in opioid dependence), N07X-X (Other nervous system drugs)"	"CST10 452, CST10 452 and analogues, CST40 017, CST40 017 and analogues, CST40 035, CST40 035 and analogues"			27/08/2020	"Advances in the Treatment of Nausea and Migraine, Diabetes, Drug Withdrawal, Neurological Disorders, Pain"		CERSCI Therapeutics |  | Unspecified |  | 24 Mar 2020		no		no							https://adis.springer.com/drugs/800055642?userId=52029392&bpIds=3004037004&checksum=b732c1f01f12c712b41c181ce71374d6a8a5e342-1617045531556-f7fc910b864aa7bbb7b4587f55879cf6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049132	Research programme: non-opioid therapeutics - CerSci Therapeutics			Yes			Discontinued (Preclinical)	"Postoperative pain, Neuropathic pain"		AMP activated protein kinase stimulants	"CERSCI Therapeutics (Originator), CERSCI Therapeutics (Owner), The National Institute of General Medical Sciences (Funder)"		PO				N2 (Analgesics)	N02 (Analgesics)	"CT 2 series, CT 3 series, CT2, CT3"			27/08/2020	Pain				no		no							https://adis.springer.com/drugs/800049132?userId=52029392&bpIds=3004037004&checksum=560cb5cb1e851a74c2046fc50327227c62bf7134-1617045531558-0032591f010849fb81ef718cfa1a678cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055639	ACP 044			Yes			Phase I	"Postoperative pain, Neuropathic pain, Pain"		Reactive oxygen species inhibitors	"CERSCI Therapeutics (Originator), CERSCI Therapeutics (Owner), National Institute of Drug Abuse (Funder), National Institutes of Health (USA) (Funder), The National Institute of General Medical Sciences (Funder), Lotus Clinical Research (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	"ACP044, CT044"			27/08/2020	Pain				no		no							https://adis.springer.com/drugs/800055639?userId=52029392&bpIds=3004037004&checksum=49d557030d3c8d842b628cdee8dff0deb8cc7e4a-1617045531559-98f33b8056dca255609ff753ad645b11badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020736	Research programme: therapeutics - Newron			No			Research	"CNS disorders, Peripheral nervous system diseases, Pain, Neuropathic pain"		"Calcium channel antagonists, Sodium channel antagonists"	"Newron Pharmaceuticals (Originator), Newron Pharmaceuticals (Owner)"		"unspecified, PO"				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				18/08/2020	"Neurological Disorders, Pain"		Newron Pharmaceuticals |  | Unspecified |  | 11 Aug 2020		no		no							https://adis.springer.com/drugs/800020736?userId=52029392&bpIds=3004037004&checksum=ed072a18e1a6f998a72c08c12d74f4a1f6d58fbb-1617045531561-6be8d22ee96d4598308048b0682e7ea9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057756	Research programme: alpha GABA receptor neuromodulators - RespireRx Pharmaceuticals/University of Wisonsin Milwoukee			Yes			Preclinical	"Anxiety disorders, Epilepsy, Migraine, Trigeminal neuralgia"		GABA A receptor modulators	"University of Wisconsin at Milwaukee (Originator), University of Wisconsin at Milwaukee (Owner), RespireRx Pharmaceuticals (Licensee)"		unspecified				"N2 (Analgesics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02 (Analgesics), N02C (Antimigraine Preparations), N03A (Antiepileptics), N05B (Anxiolytics)"	GABA(A) receptor allosteric neuromodulators University of Wisconsin Milwaukee			10/08/2020	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800057756?userId=52029392&bpIds=3004037004&checksum=8d280833f285141f98b417a3aaea34a305b41edc-1617045531562-5608c5eece8ea6982105862699a731f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057620	ATB 352			Yes			Preclinical	Postoperative pain		"Lipoxygenase-cyclooxygenase inhibitors, Prostaglandin inhibitors"	"Antibe Therapeutics (Originator), Antibe Therapeutics (Owner), Knight Therapeutics (Market Licensee)"		"IV, PO"				N2 (Analgesics)	N02 (Analgesics)	ATB352			07/08/2020	Pain				no		no							https://adis.springer.com/drugs/800057620?userId=52029392&bpIds=3004037004&checksum=09d11bfc7337affb2377155489d405624c04e4e6-1617045531564-d0044f478aeb7a9a3df87ba8434a06fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059629	WIF 1806			Yes			Research	Pain		Undefined mechanism	"Whanin Pharmaceutical (Originator), Whanin Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	WIF1806			29/07/2020	Pain		Whanin Pharmaceutical |  | Unspecified |  | 24 Jul 2020		no		no							https://adis.springer.com/drugs/800059629?userId=52029392&bpIds=3004037004&checksum=90df18f9d93458aeed8c8ddb7b9f009db1957222-1617045531565-ae6018dad20c59904b6b91846157cfbcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047576	Dexamethasone opthalmic - Oculis Pharma	50-02-2	"(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one"	No			Phase II	"Diabetic macular oedema, Uveitis, Postoperative inflammation, Postoperative pain"	C22 H29 F O5	"Glucocorticoid receptor agonists, Immunosuppressants"	"Oculis Pharma (Originator), Oculis Pharma (Owner), Tel Aviv University (Collaborator)"		Ophthalmic				S3B (Eye/Ear Corticosteroids)	"N02 (Analgesics), S01B-A01 (Dexamethasone), S03B-A (Corticosteroids)"	"dexamethasone cyclodextrin nanoparticle eye drops, dexamethasone/CD nanoparticle, dexamethasone/gCD nanoparticle, DexNP, OC118, OCS01"			29/07/2020	"Eye Disorders, Pain"				no		no		"A1C, ABL1, acireductone dioxygenase 1, adhesion regulating molecule 1, AKT, amelogenin, X-linked, Androstenedione, Ascorbic acid, BCR, Bilirubin, CD28 molecule, CD38, CD86 molecule, CEA, Creatinine, Creatinine clearance QTL, CRP, dual specificity phosphatase 3, esterase D, FGFR3, GM-CSF, hematological and neurological expressed 1, Inosine triphosphate, MLL, mTOR, mucin 5AC, oligomeric mucus/gel-forming, p16, p53, PGR, Ph chromosome, promyelocytic leukemia, PSA, ras homolog family member J, retinoic acid receptor, alpha, solute carrier family 35 member B2, Testosterone, Thyroxine, VEGF-A, VEGFR1"	"17-Hydroxyprogesterone, A1C, ACTH, amelogenin, X-linked, BCR, BNP, CD34, CD38, CEA, COMT, Dihydroxyacetone phosphate, esterase D, FGFR3, hematological and neurological expressed 1, Hydrocortisone, metaxin 1, MLL, mTOR, mucin 5AC, oligomeric mucus/gel-forming, p53, PD-L1, Ph chromosome, PSA, Testosterone, Valproic acid glucuronide, VEGF-A"	"17-Hydroxyprogesterone, 24,25-Dihydroxyvitamin D, 25-Hydroxyvitamin D2, 5-Methyltetrahydrofolic acid, A1C, ACTH, adhesion regulating molecule 1, AKT, AKT1 substrate 1 (proline-rich), Aldosterone, Alkaline phosphatase, amelogenin, X-linked, amino-terminal enhancer of split, Androgen receptor, Androstenedione, Angiogenin, Angiopoietin 1, angiotensin II receptor, type 2, ANKRD1, apolipoprotein B mRNA editing enzyme catalytic subunit 3G, Ascorbic acid, asparaginase, asparaginase like 1, B2M, BAFF, Bcl-2, BCR, bFGF, Bilirubin, BNP, BTK, C-Kit, c-Myc, C3, C4, CA 15-3, CA-125, Calcitriol, carboxylesterase 2, CASP1, Caspase 3, caspase recruitment domain family, member 11, CBFB-MYH11 fusion, CD19, CD1d molecule, CD2, CD28 molecule, CD34, CD38, CD3d, CD3e, CD3g, CD4, CD45, CD56, CD79b molecule, immunoglobulin-associated beta, CD86 molecule, CD8a, CEA, cereblon, CFH, Chromosome 17, Collagen type 1, complement component (3b/4b) receptor 1 (Knops blood group), complement factor D (adipsin), Copeptin, Cortexolone, Corticosterone, Creatinine, Creatinine clearance QTL, CRP, CTx, CXCL12, Cyclin D1, Cystatin C, Cytidine, Cytidine deaminase, cytokine inducible SH2-containing protein, D-dimer, Deoxycorticosterone, derlin 3, DEXD/H-box helicase 58, Dihydroxyacetone phosphate, DKK1, dual specificity phosphatase 1, dual specificity phosphatase 3, embryonal Fyn-associated substrate, endoplasmic reticulum aminopeptidase 1, ER alpha, ERCC1, esterase D, Estradiol-17beta 3-sulfate, Fc gamma RIIIa, Ferritin, Flt-3, folate receptor, G-CSF, Galectin-3, GFAP, GLP-1, glycosylphosphatidylinositol specific phospholipase D1, GM-CSF, GR, HCY, hematological and neurological expressed 1, histidine decarboxylase, HLA-DR, huntingtin interacting protein 1, hyaluronan synthase 3, Hydrocortisone, IGF1, IGFBP1, IKAROS family zinc finger 1 (Ikaros), IL1 beta, IL10, IL18, IL2, IL4, IL6, IL8, Immunoglobulin heavy locus, Inhibin A, interleukin 3, Ki67, KRAS, Kynurenine, L-Asparagine, macrophage erythroblast attacher, major histocompatibility complex, class I, G, MAPK1, MCP1, metaxin 1, microtubule affinity regulating kinase 3, MIP-1 alpha, MLL, MR-proADM, mTOR, mucin 5AC, oligomeric mucus/gel-forming, MYD88, NFkB, NLR family, pyrin domain containing 3, Notch 1, NRAS, NTx, OPG, opioid related nociceptin receptor 1, Osteocalcin, Osteopontin, P-selectin, p53, PD-L1, PGR, Ph chromosome, phosphate cytidylyltransferase 1, choline, alpha, PICP, Procalcitonin, Progesterone, progesterone receptor membrane component 1, proline rich protein BstNI subfamily 3, PSA, PTEN, RANKL, RBP4, retinoblastoma 1, Rh family C glycoprotein, runt-related transcription factor 1; translocated to, 1 (cyclin D-related), RUNX1, serum amyloid A1, solute carrier family 17 (acidic sugar transporter), member 5, solute carrier family 25 member 10, spleen associated tyrosine kinase, STAT3, Syndecan-1, T cell receptor gamma variable 9, t(11;14) translocation, Tau protein, tensin 1, Testosterone, Thrombomodulin, Thyroid stimulating hormone, beta, TNF-alpha, TRAP-5, troponin I, cardiac, Tubulin alpha, stable, tumor protein p53 inducible nuclear protein 2, Uric acid, Valproic acid glucuronide, VEGF-A, VEGF-C, VEGFR1, Vitamin A, Vitamin D receptor"	"B2M, CD4, CRP, G-CSF, GR, IGF1, IL18, IL6, IL8, Ph chromosome, PSA, Syndecan-1, Thrombomodulin, VEGF-A"	"24-dehydrocholesterol reductase, AFF1, allantoicase, ALT, anthrax toxin receptor 2, bax, Bcl-XL, BRCA1, BRCA2, C-peptide, Carbonic anyhdrase 9, CD1a molecule, CD20, CD22, CD25, CD5, CD52 molecule, CD7, CD99 molecule, CDK2, Chromosome 1, Chromosome 13, cyclin L2, CYP24A1, cytoglobin, DNA nucleotidylexotransferase, DPYD, EGFR, ETV6-RUNX1 fusion, FIGF, FLT4, FOXP3, GLUT1, Glutathione, glycerol-3-phosphate acyltransferase 3, Gonadotropin releasing hormone, Guanine, heparanase, HER2, hes family bHLH transcription factor 1, hes family bHLH transcription factor 5, HGPRT, HIF, Hypoxanthine, Insulin, interleukin 6 receptor, iodothyronine deiodinase 3, jagged 1, jagged 2, killer cell lectin like receptor D1, Lactate dehydrogenase, leukotriene A4 hydrolase, Luteinizing hormone, MCL1, MDR1, megalencephalic leukoencephalopathy with subcortical cysts 1, melanoma cell adhesion molecule, MPO, Notch 2, nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100), PBX1-TCF3 fusion, PCNA, PLGF, pre-B-cell leukemia homeobox 1, pS6K, runt-related transcription factor 2, sCS1, SLC2A3, SRC proto-oncogene, non-receptor tyrosine kinase, Thymidylate synthetase, TOP2A, Topoisomerase 1, transcription factor 20, transcription factor 3, Tyrosine aminotransferase, Urea, VEGF-B, VEGFR"	https://adis.springer.com/drugs/800047576?userId=52029392&bpIds=3004037004&checksum=7a87a1651f18e6c0b88c36a010be6f33ef7540c9-1617045531573-38421d0f4aed2f22d1451cd3d2aa93abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045656	Research programme: neuroprotective therapeutics - Astrocyte Pharmaceuticals/University of Texas Health Science Center at San Antonio			Yes			No development reported (Preclinical)	"Stroke, Brain injuries, Neurodegenerative disorders, Migraine"		Purinoceptor P2U agonists	"Astrocyte Pharmaceuticals (Originator), University of Texas Health Science Center at San Antonio (Originator), Astrocyte Pharmaceuticals (Owner), University of Texas Health Science Center at San Antonio (Owner)"		"unspecified, PO, Sublingual"				"N (Nervous System), N2C9 (All other anti-migraine preparations), N7X (All other CNS drugs)"	"N (Nervous System), N02C-X (Other antimigraine preparations), N07X (Other Nervous System Drugs)"	"AST 002, AST 003, AST 004"			28/07/2020	"Advances in the Treatment of Nausea and Migraine, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800045656?userId=52029392&bpIds=3004037004&checksum=f0212785d6a8a61e9bd88b48ff67e65d4c9c9a51-1617045531574-ddcecfa8bf3a6d5019546915246b114fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045525	PAX 1 001			Yes			Phase II	"Cancer pain, Pain"		Undefined mechanism	"Komipharm International (Originator), Komipharm International (Owner)"		"PO, unspecified"				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"PANAPHIX, PAX1001"			28/07/2020	Pain			PANAPHIX	no		no							https://adis.springer.com/drugs/800045525?userId=52029392&bpIds=3004037004&checksum=0a293daf5143cf37c2d272807e6f718ffb9b3013-1617045531575-69907ff5134af7b2c20236c3fd839b52badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045513	Research programme: neuropathic pain therapeutics - QUE Oncology			Yes			No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"QUE Oncology (Originator), QUE Oncology (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Q 201			28/07/2020	Pain				no		no							https://adis.springer.com/drugs/800045513?userId=52029392&bpIds=3004037004&checksum=23d788e10e80ab0e39ec1a238d0ea08fee5e125b-1617045531576-55ee17c302b047beb8c60b6c36563a63badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046581	Research programme: pain therapeutics - Asahi Kasei/Orion			Yes			No development reported (Research)	Pain		Undefined mechanism	"Asahi Kasei (Originator), Orion (Originator), Asahi Kasei (Owner), Orion (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/07/2020	Pain				no		no							https://adis.springer.com/drugs/800046581?userId=52029392&bpIds=3004037004&checksum=ba1eec47c7ac9b6eaf0a31d97e39e592a718c9d2-1617045531577-ac16afb1421528f044aa8ba0f6e59c9ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045500	Research programme: inflammatory pain therapeutics - Arissa Pharma			No			No development reported (Preclinical)	Inflammatory pain		Undefined mechanism	"Arissa Pharma (Originator), Arissa Pharma (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"AP 2300, AP 2500, AP 2900"			28/07/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800045500?userId=52029392&bpIds=3004037004&checksum=8ae8927ca25e09b3b34533080e6a1d2ceb5383b0-1617045531578-7f7f4724d3314fca41ac5b001a5dff5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059430	TA A003			No			Preclinical	Postoperative pain		Cyclo-oxygenase 2 inhibitors	"TALLC Corporation (Originator), TALLC Corporation (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	TAA003			27/07/2020	Pain				no		no							https://adis.springer.com/drugs/800059430?userId=52029392&bpIds=3004037004&checksum=1b4c12ff5f132c577e9e951a30300ee322d12c09-1617045531578-5dbcf1a4ff51ae724d85666e20a28f45badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038462	Opiranserin - Vivozon	1441000-45-8	"4-Butoxy-N-((4-(dimethylamino)oxan-4-yl)methyl)- 3,5-dimethoxybenzamide"	Yes			Phase III	"Postoperative pain, Pain, Pruritus, Neuropathic pain"	C21 H34 N2 O5	"Glycine plasma membrane transport protein inhibitors, Serotonin 2A receptor antagonists"	"Vivozon (Originator), Vivozon (Owner)"		"IV, PO, Topical"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2B (Non-Narcotics and Anti-Pyretics)"	"D04A-X (Other antipruritics), N02B (Other Analgesics and Antipyretics)"	"VVZ000149, VVZ149"			27/07/2020	"Pain, Skin Disorders"				yes	USA	no							https://adis.springer.com/drugs/800038462?userId=52029392&bpIds=3004037004&checksum=eddcf5f2e8fe3758704a5353ee6982d8fb21c185-1617045531580-c6e0734845f347e5c10f5475d1d8b468badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059619	IGC 511			Yes			Phase Unknown	Pain		Cannabinoid receptor modulators	"India Globalization Capital (Originator), India Globalization Capital (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IGC511			24/07/2020	Pain				no		no							https://adis.springer.com/drugs/800059619?userId=52029392&bpIds=3004037004&checksum=668ae61ecb6f213b693b9eb9fba8e98d5d14c9d9-1617045531580-a415b1b6426699ac0edad98126b81c3cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051736	SHR 0410			Yes			Phase I	"Pruritus, Acute pain"		Opioid kappa receptor agonists	"Atridia (Originator), Atridia (Owner)"		IV				"D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A-X (Other antipruritics), N02 (Analgesics)"	SHR0410			23/07/2020	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800051736?userId=52029392&bpIds=3004037004&checksum=312f573a6b6d841d74fe4d63ee684e082a48a203-1617045531581-31a667b6ff6073dd0b9ce028d341cdd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035038	Cibinetide - Araim Pharmaceuticals	1208243-50-8	L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-ieucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine	Yes			Phase II	"Diabetic neuropathies, Neuropathic pain, Diabetic macular oedema, Cardiovascular disorders, Rheumatoid arthritis, Diabetic nephropathies, Non-alcoholic steatohepatitis, Wounds, Systemic lupus erythematosus, Inflammatory bowel diseases, Transplant rejection, Radiation injuries, Retinal disorders, Depressive disorders, Type 2 diabetes mellitus"	C51 H84 N16 O21	Erythropoietin receptor agonists	"Araim Pharmaceuticals (Originator), Araim Pharmaceuticals (Owner), Biomedical Advanced Research and Development Authority (Funder), Karolinska Institute (Collaborator), Leiden University (Collaborator), National Institute on Aging (Collaborator), Queens University Belfast (Collaborator), University of Messina (Collaborator), Vault Bioventures (Collaborator)"		"IV, SC, unspecified, Topical, Parenteral"				"A10 (Drugs Used in Diabetes), A10X (Other Drugs Used in Diabetes), A5B (Hepatic Protectors, Lipotropics), A7E (Intestinal Anti-Inflammatory Agents), C1 (Cardiac Therapy), D3 (Wound Healing Agents), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), V3 (All Other Therapeutic Products)"	"A05B-A (Liver therapy), A07E (Intestinal Antiinflammatory Agents), A10 (Drugs Used in Diabetes), A10X (Other Drugs Used in Diabetes), C01 (Cardiac Therapy), D03 (Preparations for Treatment of Wounds and Ulcers), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06 (Psychoanaleptics), V03 (All Other Therapeutic Products)"	ARA 290			22/07/2020	"Affective Disorders, Diabetes, Eye Disorders, Haematological Disorders, Immunological Disorders, Inflammatory Bowel Disorders, Ischaemic Heart Disease, Liver Disorders, Pain, Rheumatic Disease, Skin Disorders, Transplant Rejection, Vascular Disorders"	"Neuropathic pain (USA), Transplant rejection (USA), Transplant rejection (European Union), Sarcoidosis (European Union), Sarcoidosis (USA)"			yes	USA	no				"A1C, Insulin"		GLP-1	https://adis.springer.com/drugs/800035038?userId=52029392&bpIds=3004037004&checksum=6d40c04e9630f8ca3ea22ee70f4865bf2519fbac-1617045531584-378f694bcc36becfa7c3fbaab3273e92badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042256	Centhaquine - Midwestern University/Pharmazz	57961-90-7	2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline	No			Registered	"Haemorrhagic shock, Heart arrest, Postoperative pain"	C22H25N3	"Alpha 1 adrenergic receptor antagonists, Alpha 2 adrenergic receptor agonists"	"Midwestern University (Originator), Pharmazz (Originator), Midwestern University (Owner), Pharmazz (Owner)"		IV				"C1 (Cardiac Therapy), C2A1 (Antihypertensives plain, mainly centrally acting), N2 (Analgesics)"	"C01 (Cardiac Therapy), C02A (Antiadrenergic Agents, Centrally Acting), N02 (Analgesics)"	"Centhaquin Midwestern University/Pharmazz, Lyfaquin, PMZ 2010"			22/07/2020	"Arrhythmias, Haematological Disorders, Pain, Vascular Disorders"			Lyfaquin	no		no							https://adis.springer.com/drugs/800042256?userId=52029392&bpIds=3004037004&checksum=c7986fbfe0a9833fbf4e583125525dee5a4ef875-1617045531585-bd57103962e5979391bef9c1f4c77ebbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036725	Brivoligide - Adynxx	1803075-42-4	"DNA, d(C-T-A-C-G-C-C-C-A-C-C-G-C-C-C-A-C-G-C-A-T-A-C), complex with DNA d(G-T-A-T-GC- G-T-G-G-G-C-G-G-T-G-G-G-C-G-T-A-G) (1:1)"	Yes			Phase II	"Postoperative pain, Pain"	C444 H561 N177 O272 P44	Early growth response protein 1 inhibitors	"Adynxx (Originator), Adynxx (Owner), National Institute of Drug Abuse (Funder)"		Intrathecal				N2 (Analgesics)	N02 (Analgesics)	"AYX1, Brivoligidesodium"			20/07/2020	Pain				yes	USA	no							https://adis.springer.com/drugs/800036725?userId=52029392&bpIds=3004037004&checksum=e9da37267e72953faff10c268da82bf14929e68a-1617045531586-e9fde6f9ebf15458bf5ae643cdd73413badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058974	Research programme: acid-sensing ion channels inhibitors - Neurasic Therapeutics			Yes			Research	Pain		ASIC channel antagonists	"McGill University (Originator), Neurasic Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2020	Pain				no		no							https://adis.springer.com/drugs/800058974?userId=52029392&bpIds=3004037004&checksum=477784aeb8d625a47d0fab285206ec76bbac1557-1617045531587-9502b20faa337b2a68a642b58ad4d816badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800059418	TA A001			Yes			Preclinical	Postoperative pain		Cannabinoid receptor CB2 agonists	"TALLC Corporation (Originator), TALLC Corporation (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	TAA001			16/07/2020	Pain				no		no							https://adis.springer.com/drugs/800059418?userId=52029392&bpIds=3004037004&checksum=01c08d45a103f3354aa2ba737954f26e387a588f-1617045531587-fdf7aaa901a198d6602256581fdba215badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058364	Psilocybin transdermal - Revive Therapeutics	520-52-5	[3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate	Yes			Research	Unspecified	C12 H17 N2 O4 P	Serotonin 2 receptor agonists	"Psilocin Pharma Corp (Originator), Revive Therapeutics (Owner), University of Wisconsin-Madison (Collaborator)"		Transdermal				"N2 (Analgesics), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N06A-X (Other antidepressants)"				14/07/2020					no		no							https://adis.springer.com/drugs/800058364?userId=52029392&bpIds=3004037004&checksum=dad7aafc428c68ed1bdab7dd3372e22c24882146-1617045531588-a852f2a3a7625f530bb69d02401f7e06badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028005	Oxycodone controlled-release - Intellipharmaceutics	76-42-6	"Morphinan-6-one,4,5-_-epoxy-14-hydroxy-3-methoxy-17-methyl-"	No			Preregistration	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Intellipharmaceutics International (Originator), Intellipharmaceutics International (Owner), Undisclosed Company (Market Licensee)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"Abuse deterrent oxycodone hydrochloride extended release tablets Intellipharmaceutics, Abuseresistant oxycodone Intellipharmaceutics, Aximris XR, Oxycodone CR Intellipharmaceutics, Oxycodone ER Intellipharmaceutics, Oxycodone hydrochloride extendedrelease tablets Intellipharmaceutics, Rexista oxycodone"			07/07/2020	"Drug Delivery Systems, Pain"			"Aximris XR, Rexista oxycodone"	yes	USA	no							https://adis.springer.com/drugs/800028005?userId=52029392&bpIds=3004037004&checksum=2c130d12e8e253a47c9b4668dfa2262bdda57e8f-1617045531590-273a3c0c82ae5955e6490f4e61e83c48badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047543	Cannabidiol/tetrahydrocannabinol oral spray - Aphria/Medlab			No			Phase I	Cancer pain		"Cannabinoid receptor agonists, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Aphria (Originator), Medlab (Originator), Aphria (Owner), Medlab (Owner)"		Buccal				N2 (Analgesics)	N02 (Analgesics)	"MDCNB01, NanaBis, Nanocelle CBD, NanoCelle d9THC CBD"			04/07/2020	Pain			NanaBis	no		no							https://adis.springer.com/drugs/800047543?userId=52029392&bpIds=3004037004&checksum=df2bf164dac4d99b299ce317cae209e2f6f7a7bc-1617045531591-8296d47c9d6db05fed77af8a807890eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049445	Hydrocodone/paracetamol - Grunenthal			No			No development reported (I)	Pain		"Opioid mu receptor agonists, Prostaglandin receptor antagonists"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A (Opioids), N02B (Other Analgesics and Antipyretics)"	"Acetaminophen/hydrocodone Grunenthal, APAP/hydrocodone Grunenthal, GRT7014, Hydrocodone/acetaminophen Grunenthal, Hydrocodone/APAP Grunenthal, Paracetamol/hydrocodone Grunenthal"			28/06/2020	Pain				no		no							https://adis.springer.com/drugs/800049445?userId=52029392&bpIds=3004037004&checksum=541fac3004fb4d8334bafa5c15841328e0e5c1f1-1617045531592-dbfc7798b0e7a6a23c5f9c133c1b1d8cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037455	Research programme: non-opioid analgesics - Kineta			Yes			No development reported (Preclinical)	Pain		Nicotinic receptor antagonists	"University of Utah (Originator), University of Utah (Owner), Kineta (Licensee), KPI Therapeutics (Funder), Genentech (Collaborator), Universita degli Studi di Firenze (Collaborator), University of Washington (Collaborator), US Army Institute of Surgical Research (Collaborator)"		SC				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	"Conopeptide, CSP 4, CSP conopeptide, KCP 400"			28/06/2020	Pain				no		no							https://adis.springer.com/drugs/800037455?userId=52029392&bpIds=3004037004&checksum=a3cc26da68d11282e701bc4fba87bf7fc6b682dd-1617045531593-2c6e4fa8cdec42833dfb3db9c7a4516bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030205	Research programme: TrkA/B receptor antagonists - Array BioPharma/Asahi Kasei Pharma			Yes			No development reported (Preclinical)	"Pain, Inflammation"		"TrkA receptor antagonists, TrkB receptor antagonists, TrkC receptor antagonists"	"Array BioPharma (Originator), Array BioPharma (Owner), Asahi Kasei Pharma Corp (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"AR470, AR772, AR786, ARRY954"			28/06/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800030205?userId=52029392&bpIds=3004037004&checksum=4cb21847e5977d4599164837176d50e59d4f810b-1617045531595-eab270d3ef9963b228d5e4e1a2c411febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035109	Research programme: CNS disorders therapeutics - Sage Therapeutics			Yes			No development reported (Preclinical)	"Dravet syndrome, Depressive disorders, Rett syndrome, Seizures, Schizophrenia, Psychotic disorders, Brain injuries, Dementia, Pain, Fragile X syndrome, Autistic disorder, Post-traumatic stress disorders, Multiple sclerosis"		"GABA A receptor modulators, NMDA receptor modulators"	"Sage Therapeutics (Originator), Sage Therapeutics (Owner), Ligand Pharmaceuticals (Technology Provider), Washington University (Technology Provider), Charles River Laboratories (Collaborator)"		"IV, unspecified, PO, IM"				"N (Nervous System), N1 (Anaesthetics), N2 (Analgesics), N3A (Anti-Epileptics), N5 (Psycholeptics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N (Nervous System), N01 (Anesthetics), N02 (Analgesics), N03A (Antiepileptics), N03A-X (Other antiepileptics), N05A (Antipsychotics), N05B-X (Other anxiolytics), N06A (Antidepressants), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	"Fragile X syndrome (FXS) therapy Sage Therapeutics, PANAM platform Sage Therapeutics, SAGE 105, SGE202, SGE301, SGE516"			28/06/2020	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Psychotic Disorders"		SAGE Therapeutics |  | Unspecified |  | 13 Dec 2014		no		no							https://adis.springer.com/drugs/800035109?userId=52029392&bpIds=3004037004&checksum=6de6794858c498cfc8671b0e02c55a1a184aa531-1617045531599-32f498abe3469553cff4136ae5e8b742badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055439	Cannabidiol - Stero Biotechs	13956-29-1	"2-[(6R)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl]-5-pentylbenzene-1,3-diol"	No			Phase II	"Urticaria, Crohn's disease, Autoimmune hepatitis, Graft-versus-host disease"	C21 H30 O2	"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Immunosuppressants, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"STERO Biotechs (Originator), STERO Biotechs (Owner)"		"unspecified, PO"				"A7E (Intestinal Anti-Inflammatory Agents), D11A (Other Dermatological Preparations)"	"A07E (Intestinal Antiinflammatory Agents), D11A (Other Dermatological Preparations), N02B-G10 (Cannabinoids, including nabiximols)"	"ST101, STAH01, STSDCD01"			24/06/2020	"Immunological Disorders, Inflammatory Bowel Disorders, Liver Disorders, Skin Disorders"				no		no							https://adis.springer.com/drugs/800055439?userId=52029392&bpIds=3004037004&checksum=562bc19d6344433068df42bab7856b82cd12f6db-1617045531600-18ba086202ec2eb9622ab17dc3cb8dacbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053318	ZYKR 1			Yes			Phase I	"Visceral pain, Postoperative pain"		Opioid kappa receptor agonists	"Cadila Healthcare (Originator), Cadila Healthcare (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	ZYKR1			23/06/2020	Pain				no		no							https://adis.springer.com/drugs/800053318?userId=52029392&bpIds=3004037004&checksum=78d52b0386ffe38189d445bd8bcb77adda0769c6-1617045531602-67d906f043093de26f47e67bb9787d37badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004055	Suramin sodium - Bayer	129-46-4	"8,8'-[Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt"	Yes			Phase II	"Non-small cell lung cancer, Pervasive child development disorders, Enterovirus A infections, Cancer pain, Prostate cancer, HIV infections, Breast cancer, Bladder cancer, Vascular restenosis, Atherosclerosis"	C51 H34 N6 Na6 O23 S6	"DNA-directed DNA polymerase inhibitors, Intercellular signalling peptide and protein inhibitors"	"Bayer (Originator), Bayer (Owner), Pfizer (Market Licensee), Austrian Academy of Sciences (Collaborator), National Cancer Institute (USA) (Collaborator), Optimum Therapeutics (Collaborator), The First Affiliated Hospital of Zhengzhou University (Collaborator), University of California, San Diego (Collaborator), University of Wisconsin-Madison (Collaborator)"		"IV, unspecified"		"Cl (L/h) (.011 (Adult)), T<sub>_beta</sub> (h) (720 - 1200 (Adult))"	"Alopecia, Anaemia, Anorexia, Blood coagulation disorders, Chills, Fatigue, Fever, Haemorrhage, Hyperglycaemia, Infections, Kidney disorders, Lethargy, Leucopenia, Malaise, Neurological disorders, Neutropenia, Pain, Paraesthesia, Renal failure, Skin disorders, Skin eruptions, Thrombocytopenia, Vision disorders, Vomiting"	"C10 (Lipid-Regulating/Anti-Atheroma Preparations), C6A (Other Cardiovascular Products), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"C (Cardiovascular System), J05A (Direct acting antivirals), L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"	"Antrypol, Bayer 205, CI 1003, Germanin, Metaret, Moranyl, Suramin, Suramin hexasodium"			23/06/2020	"Cancer, Hyperlipidaemia, Men's Health, Pain, Psychotic Disorders, Vascular Disorders, Viral Infections, Women's Health"			Metaret	no		no				"bFGF, immunoglobulin kappa variable 1-5, PSA"		"ATP-binding cassette, sub-family C (CFTR/MRP), member 8, IL6"	https://adis.springer.com/drugs/800004055?userId=52029392&bpIds=3004037004&checksum=2aaf2deddb0ca2b99cdc54f1f5032b8f47d73abe-1617045531606-4ba36cb0f1734edfb9bb4cd4056046ccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058905	ASD 002			No			Preclinical	Migraine		"Cyclooxygenase inhibitors, Ion pump modulators"	"ASDERA (Originator), ASDERA (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	"M01A-G (Fenamates), N02C (Antimigraine Preparations)"	"ASD002, ASD002 ASDERA, Esterprodrug of mefenamic acid ASDERA, Mefenamic acid prodrug ASDERA"			19/06/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800058905?userId=52029392&bpIds=3004037004&checksum=7cc15843c3651307c0cd7976514bb3affcedf3cd-1617045531608-0c8697955cb4b793c2334a71466f319cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056749	CPL 01			Yes			Phase II	Postoperative pain		Undefined mechanism	"Cali Pharmaceuticals (Originator), Cali Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CPL01			19/06/2020	Pain				no		no							https://adis.springer.com/drugs/800056749?userId=52029392&bpIds=3004037004&checksum=e194b78e6e91938ec3ac8a0a1de3c4feffd51594-1617045531609-00724d6e96ff554146a29c5b8d5e84c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058943	Capsaicin - Propella Therapeutics	404-86-4	"6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-"	No			Phase II	Pain	C18 H27 N O3	"GABA A receptor modulators, Melatonin receptor modulators, Substance P inhibitors, TRPV1 receptor agonists"	"Propella Therapeutics (Originator), Propella Therapeutics (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	CGS2005			17/06/2020	"Pain, Rheumatic Disease"		Propella Therapeutics | Pain | Unspecified |  | 17 Jun 2020		no		no							https://adis.springer.com/drugs/800058943?userId=52029392&bpIds=3004037004&checksum=b2a03281fd69ef865daf52380e2913aedb3aee7f-1617045531610-43cbbaa2cc48d3ca424b6711cc47e4ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055061	Celecoxib long-acting injectable - Arthritis Innovation Corporation	169590-42-5	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	No			Phase II	"Postoperative pain, Inflammation"	C17 H14 F3 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"MedinCell S.A. (Originator), MedinCell S.A. (Owner), Arthritis Innovation Corporation (Licensee)"		Intra-articular				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"F14, mdcCWM"			09/06/2020	"Inflammation, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800055061?userId=52029392&bpIds=3004037004&checksum=c6928974b1a6a24a841368b4a5e775c9995f1e76-1617045531612-bfcaed512c53b84f813b1f5191525659badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043365	Salubrin HF - Pherin Pharmaceuticals			Yes			Phase II	"Hot flashes, Migraine"		Neurotransmitter receptor modulators	"Pherin Pharmaceuticals (Originator), Pherin Pharmaceuticals (Owner)"		"Intranasal, unspecified"				"N2C (Anti-Migraine Preparations), N7X (All other CNS drugs)"	"N02C (Antimigraine Preparations), N07X (Other Nervous System Drugs)"	"PH80 Pherin Pharmaceuticals, PH80HF, PH80HF NS, Salubrin HF"			08/06/2020	"Advances in the Treatment of Nausea and Migraine, Women's Health"				no		no							https://adis.springer.com/drugs/800043365?userId=52029392&bpIds=3004037004&checksum=8b38ba13bb650911b5d316781ec004f814ed3eea-1617045531613-891b44ad2ce04bb9583723630a693ef1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058834	Research programme: Nav1.7-targeting monoclonal antibodies - YUMAB			Yes			Research	Pain		Nav1.7 voltage-gated sodium channel modulators	"YUMAB (Originator), YUMAB (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)				02/06/2020	Pain		YUMAB |  | Unspecified |  | 02 Jun 2020		no		no							https://adis.springer.com/drugs/800058834?userId=52029392&bpIds=3004037004&checksum=cfab04748339ccb17ffbcbfba119d73ff2b20c6b-1617045531614-243df89e23938ca22240d4ca54e5064fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045178	Research programme: centrally acting opioid analgesics - ChironWell			Yes			No development reported (Preclinical)	Pain		Opioid receptor modulators	"ChironWells (Originator), ChironWells (Owner)"		Parenteral				N2A (Narcotics)	N02A (Opioids)	HS198			28/05/2020	Pain				no		no							https://adis.springer.com/drugs/800045178?userId=52029392&bpIds=3004037004&checksum=17d5375e3b6f87fc7b315865d8bf7eac125068f3-1617045531614-52e14cfc128925d08ef346c1162fb5c1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036279	Research programme: abuse-deterrent oral hydrocodone controlled-release - Assertio Therapeutics/Shionogi	125-29-1	"Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl"	No			No development reported (Preclinical)	Pain	C18 H21 N O3	Opioid receptor agonists	"Egalet (Originator), Assertio Therapeutics (Owner), Shionogi (Licensee)"		PO				N2A (Narcotics)	N02A-F (Morphinan derivatives)	"AD Combination hydrocodone, AD ER hydrocodone, Hydrocodone controlled release Assertio Therapeutics/Shionogi"			28/05/2020	Pain		Zyla Life Sciences | Pain | Unspecified |  | 20 Dec 2017		no		no							https://adis.springer.com/drugs/800036279?userId=52029392&bpIds=3004037004&checksum=1a2109aa8cb3fb9097d5bfcca9d38ca88085cefb-1617045531615-42bf4c106c21b9e9d8b9b9e58216e063badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036281	Egalet 003			No			Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Egalet (Originator), Assertio Therapeutics (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"AD opioid, Egalet003, Opioid 3"			28/05/2020	Pain		Zyla Life Sciences |  | Unspecified |  | 31 Dec 2018		no		no							https://adis.springer.com/drugs/800036281?userId=52029392&bpIds=3004037004&checksum=481c20e1d085edc946c632ba61545d0d58cc8a58-1617045531616-52beaf1c4095a468c4edadffe5e23040badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043209	Hydrocodone extended release - Assertio Therapeutics	125-29-1	"(4<EM>R</EM>,4a<EM>R</EM>,7a<EM>R</EM>,12b<EM>S</EM>)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one"	No			Discontinued (I)	Pain	C18 H21 N O3	Opioid receptor agonists	"Egalet (Originator), Assertio Therapeutics (Owner)"		PO				N2A (Narcotics)	"N02A (Opioids), R05D-A03 (Hydrocodone)"	"Abusedeterrent extendedrelease hydrocodone Assertio Therapeutics, AD ER hydrocodone Assertio Therapeutics, Egalet004, S 718632"			28/05/2020	Pain		Zyla Life Sciences |  | Unspecified |  | 31 Dec 2018		no		no							https://adis.springer.com/drugs/800043209?userId=52029392&bpIds=3004037004&checksum=4cc438ccc36a3285165f00060867a2a69c465b7c-1617045531617-946515a16ea928112d94d46216858769badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028043	APR 102			Yes			No development reported (I)	Pain		"Protein synthesis inhibitors, Ribosomal protein inhibitors"	"Advanced Pain Therapeutics LLC (Originator), Advanced Pain Remedies (Owner), University of Texas Southwestern Medical Center (Collaborator)"		Intrathecal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"SPSAP, Substance PSaporin"			28/05/2020	Pain				no		no							https://adis.springer.com/drugs/800028043?userId=52029392&bpIds=3004037004&checksum=21d6fceb48b9b0381d1596049cf94c59436171f9-1617045531618-514e075e98b226e79c2d7249aac8cabfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033032	Indometacin - Iroko Pharmaceuticals	53-86-1	"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-"	No			Marketed	"Acute pain, Postoperative pain"	C19 H16 Cl N O4	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"iCeutica (Originator), Assertio Therapeutics (Owner), Iroko Pharmaceuticals (Licensee)"		PO				"M1A1 (Anti-rheumatics, non-steroidal plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B01 (Indometacin), N02B (Other Analgesics and Antipyretics)"	"INDOCIN, Indomethacin, Indomethacin nanoformulation Iroko Pharmaceuticals, IP940, Lowerdose submicron indomethacin Iroko Pharmaceuticals, Submicron indomethacin Iroko Pharmaceuticals, Tiforbex, Tivorbex"			28/05/2020	Pain			"INDOCIN, Tivorbex"	no		no		"HER2, IFN-gamma, PGR, PSA, pyridoxal phosphatase"	iroquois homeobox 2	"c-Myc, Caspase 3, CRP, Cystatin C, Ferritin, ICAM-1, IFN-gamma, IL6, iroquois homeobox 2, PSA, PTEN, serine/threonine kinase 36, submaxillary gland androgen regulated protein 3B"	"Cystatin C, IFN-gamma"	"Aldosterone, Creatinine, F2-isoprostanes, IL2, PAI-1, PGE2, Renin"	https://adis.springer.com/drugs/800033032?userId=52029392&bpIds=3004037004&checksum=02e3dbe49b2ec7424754fe122c2d80a202d17d2d-1617045531620-0e025ea961ee81d25e0f8b39892b37acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058688	5 HT7 agonist - Celon Pharma			Yes			Research	Neuropathic pain		Serotonin 7 receptor antagonists	"Celon Pharma (Originator), Celon Pharma (Owner), The National Centre for Research and Development (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				23/05/2020	Pain				no		no							https://adis.springer.com/drugs/800058688?userId=52029392&bpIds=3004037004&checksum=6b2d5939e5f4285e080e5a7157eb8c3db2ea2b4f-1617045531621-95693bb7542e812998057de98939ec96badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038847	Cannabidivarin - GW Pharmaceuticals	24274-48-4	"2-[(1<EM>S</EM>,6<EM>S</EM>)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl]-5-propylbenzene-1,3 diol"	Yes			Phase II	"Partial epilepsies, Prader-Willi syndrome, Neuropathic pain, Rett syndrome, Autistic disorder, Pervasive child development disorders, Epilepsy"	C19 H26 O2	Cannabinoid receptor modulators	"GW Pharmaceuticals (Originator), GW Pharmaceuticals (Owner), Otsuka Pharmaceutical (Owner), Charite - Universitatsmedizin Berlin (Collaborator), Montefiore Medical Center (Collaborator), University of Reading (Collaborator)"		"PO, unspecified, IV"				"A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"A08A-X (Other antiobesity drugs), N02 (Analgesics), N03A-X (Other antiepileptics), N07X (Other Nervous System Drugs)"	"CBDV, CBDV GW Pharmaceuticals, GWP42006"			22/05/2020	"Affective Disorders, Anxiety Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Obesity, Pain, Psychotic Disorders"	Rett syndrome (USA)			no		no							https://adis.springer.com/drugs/800038847?userId=52029392&bpIds=3004037004&checksum=1b9d2823025e4346976e7ebe9777b0d2b824d49a-1617045531623-1bf97c049e04cf25e7ab753b82625ea7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052334	NP 10679			Yes			Phase I	"Pain, Subarachnoid haemorrhage, Epilepsy"		NR2B N-Methyl-D-Aspartate antagonists	"NeurOp (Originator), NeurOp (Owner), National Institute of Neurological Disorders and Stroke (Collaborator)"		IV				"N2 (Analgesics), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N03A (Antiepileptics), N07X (Other Nervous System Drugs)"	NP10679			20/05/2020	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800052334?userId=52029392&bpIds=3004037004&checksum=1e55226980f167f293e8a12b70534f68b51ccca4-1617045531624-5cef0e45e503edfa2d475123dab9af62badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017495	Dihydroergotamine mesilate inhalation - AbbVie	6190-39-2	"Ergotamine 9,10-dihydro-, monomethanesulfonate (salt)"	No			No development reported (Preregistration)	Migraine	C33 H37 N5 O5 . C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"MAP Pharmaceuticals (Originator), AbbVie (Owner)"		Inhalation			Nausea	N2C (Anti-Migraine Preparations)	N02C-A01 (Dihydroergotamine)	"DHEinhalation MAP, Levadex, MAP 0004, SEMPRANA"			19/05/2020	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"		"MAP Pharmaceuticals | Migraine | Unspecified | World (Excluding Canada, USA) | 25 May 2012"	SEMPRANA	no		no							https://adis.springer.com/drugs/800017495?userId=52029392&bpIds=3004037004&checksum=dcbf0aee6d793253262c8a65799ffa995244dfb2-1617045531625-4782b47e3a05499ec44e887f3f08262cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025948	Rezatomidine	847829-38-3	"4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1,3-dihydro-2H-Imidazole-2-thione"	Yes			No development reported (II)	"Fibromyalgia, Pain, Diabetic neuropathies"	C13 H16 N2 S	Alpha adrenergic receptor agonists	"ACADIA Pharmaceuticals (Originator), Allergan (Originator), AbbVie (Owner)"		PO				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	"AGN203818, AGNXX/YY"			19/05/2020	"Diabetes, Pain"		Allergan |  | Phase II |  | 09 Mar 2010		no		no							https://adis.springer.com/drugs/800025948?userId=52029392&bpIds=3004037004&checksum=53b4ee315588da54a8a6d6c43da4a0c1128903c8-1617045531626-f5641ffbe83ff4127dad5c69300e72fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009609	Neramexane - Merz Pharma	219810-59-0	"Cyclohexanamine, 1,3,3,5,5-pentamethyl"	Yes			Discontinued (III)	"Tinnitus, Alzheimer's disease, Pathologic nystagmus, Alcoholism, Pain"	C11 H23 N	"Nicotinic receptor antagonists, NMDA receptor antagonists"	"Merz Pharma (Originator), Merz Pharma (Owner), AbbVie (Licensee), Kyorin Pharmaceutical (Licensee)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N7D (Anti-Alzheimer Products), N7E (Drugs Used In Alcohol Dependence), S2D (Other Otologicals)"	"N02B-G (Other analgesics and antipyretics), N06D (Anti-Dementia Drugs), N07B-B (Drugs used in alcohol dependence), S02D (Other Otologicals)"	"KRP209, MRZ 2/579, Neramexane mesylate"			19/05/2020	"Alzheimer's Disease and Cognition Disorders, Drug Withdrawal, Ear, Nose and Throat Disorders, Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009609?userId=52029392&bpIds=3004037004&checksum=c1dda067cb0d16265ddc1f508c57758ec393bbf7-1617045531629-0f97c0b4af58711c208e6cd19b1460ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011153	NC 164			No			Discontinued (Preclinical)	Pain		Neurotransmitter inhibitors	"Health Protection Agency Porton Down (Originator), Health Protection Agency Porton Down (Owner), AbbVie (Market Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				19/05/2020	Pain				no		no							https://adis.springer.com/drugs/800011153?userId=52029392&bpIds=3004037004&checksum=86bbab15d9b5e75eb60c1d683ae2a5a3291bdce2-1617045531630-e77d721e1ca0d1d0a5a83757dc0ff52dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030055	Senrebotase - AbbVie/Ipsen	1290102-81-6	"L-methionylglycyl-L-seryl-des-(445-glycine,446-L-tyrosine)-[2-L-glutamic acid,432,442,444,447-tetra-L-aspartic acid]botulinum neurotoxin A precursor 27-L-alanine variant light chain (433-41')-disulfide with [14-L-arginine,15-L-lysine]human nociceptin fusion protein with L-alanyl-L-leucyl-L-alanyltris(tetraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-aspartic acid]botulinum neurotoxin A heavy chain-(1-419)-peptide"	Yes			Discontinued (II)	"Postherpetic neuralgia, Overactive bladder"	C4628 H7159 N1181 O1402 S21	SNARE protein antagonists	"Health Protection Agency Porton Down (Originator), Ipsen (Owner), AbbVie (Licensee), UroGen Pharma (Technology Provider)"		"Intradermal, Intravesicular"				"G4D4 (Urinary incontinence products), G4X (All Other Urological Products), N2 (Analgesics)"	"G04B (Urologicals), N02 (Analgesics)"	"AGN214868, SXN 100323, TEM"			19/05/2020	"Genitourinary Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800030055?userId=52029392&bpIds=3004037004&checksum=02dc5afa01a837aa2b79cd9058b713966d46d1bc-1617045531632-8602e3099dad47c04a4c44c4148688f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013947	Research programme: neurological disorders therapies - AbbVie/Syntaxin			Yes			No development reported (Preclinical)	Neurological disorders		SNARE protein antagonists	"Health Protection Agency (Originator), Ipsen (Owner), AbbVie (Market Licensee)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	SXN 113			19/05/2020	Neurological Disorders				no		no							https://adis.springer.com/drugs/800013947?userId=52029392&bpIds=3004037004&checksum=7465eca490c2713653beda698ad8d4789e83ff58-1617045531634-6c462975064d5803144314928a762275badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031281	Rapastinel - AbbVie	117928-94-6	L-threonyl-L-prolyl-L-prolyl-L-threoninamide	Yes			Discontinued (III)	"Major depressive disorder, Neuropathic pain, Bipolar depression"	C18 H31 N5 O6	NR2B N-Methyl-D-Aspartate receptor agonists	"Northwestern University (Originator), Northwestern University (Owner), AbbVie (Licensee), Takeda (Funder), Lundbeck Research USA (Collaborator)"		IV				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	"BV102, GLYX13, GLYX13peptide, GLYX13trifluoroacetate, TPPTamide, TPPTamidetrifluoroacetate"			19/05/2020	"Affective Disorders, Pain"				yes	USA	no				DBH antisense RNA 1			https://adis.springer.com/drugs/800031281?userId=52029392&bpIds=3004037004&checksum=17a1156a0f7c18cb0c95be0b97348d3fa852c8ee-1617045531638-dc0140b7c9b8ca23fc0a9e09c6694e9bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008331	AGN 190837	136527-40-7	<EM>trans</EM>-2-(2-Propylcyclohexylamino)-2-oxazoline	No			No development reported (Preclinical)	"Hypertension, Glaucoma, Pain, Migraine, Cognition disorders"	C12 H22 N2 O	Alpha 2 adrenergic receptor agonists	"Allergan (Originator), AbbVie (Owner)"		unspecified				"C2A2 (Antihypertensives plain, mainly peripherally acting), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations), N6D (Nootropics), S1E1 (Miotics and antiglaucoma preparations, systemic)"	"C02K (Other Antihypertensives), N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), N06B (Psychostimulants, agents used for ADHD and nootropics), S01E-A (Sympathomimetics in glaucoma therapy)"				18/05/2020	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Eye Disorders, Hypertension, Pain"				no		no							https://adis.springer.com/drugs/800008331?userId=52029392&bpIds=3004037004&checksum=e9cf49866d19eedf2de419bbdc951b5fd10c62ce-1617045531640-0c44cba7f1397dc10c3ee50a9e3cf3b6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010282	Oxycodone/ibuprofen		"4, 5a-Epoxy-14b-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride / (±)-_-Methyl-4-(2-methylpropyl)-benzeneacetic acid"	No			Marketed	Pain	C18 H21 N O4 . H Cl . C13 H18 O2	"Cyclooxygenase inhibitors, Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), AbbVie (Market Licensee)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-F (Morphinan derivatives), N02B (Other Analgesics and Antipyretics)"	Combunox			18/05/2020	Pain			Combunox	no		no							https://adis.springer.com/drugs/800010282?userId=52029392&bpIds=3004037004&checksum=a8247d5dd6956c7b68077c33155eb82af8dbe83c-1617045531641-06d58fbd1144c3e25561bdd0b3d963e7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012617	Morphine oral - AbbVie	57-27-2	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1)"	No			Marketed	"Cancer pain, Pain"	C17 H19 N O3 . 1/2 H2 S O4	Opioid mu receptor agonists	"Watson Pharmaceuticals (Originator), AbbVie (Owner), Mitsubishi Tanabe Pharma Corporation (Market Licensee)"		PO				"N2 (Analgesics), N2A (Narcotics)"	N02A-A01 (Morphine)	"PGuard, TA 2620"			18/05/2020	Pain			PGuard	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800012617?userId=52029392&bpIds=3004037004&checksum=2bc5023c48ecc8775e3c985031c37de7ab131536-1617045531643-4048c3bcad6c86ad219331d357617898badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026487	Morphine extended release			No			Marketed	Pain		Opioid receptor agonists	"Faulding Laboratories (Originator), AbbVie (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	KADIAN			18/05/2020	Pain			KADIAN	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800026487?userId=52029392&bpIds=3004037004&checksum=52c30208205318f35a95033ae94e7fc130594073-1617045531646-ae4e396ee1c6562437eba89038ff52f9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009562	Sumatriptan - GlaxoSmithKline	103628-48-4	3-[2-(dimethyl-amino)ethyl]-<EM>N</EM>-methylindole-5-methanesulfonamide succinate	No			Marketed	"Migraine, Menstrual migraine"	C14 H21 N3 O2 S . C6 H6 O4	Serotonin 1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), AbbVie (Market Licensee)"		"Intranasal, SC"				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"Imigran Nasal Spray, Imitrex Nasal Spray"			18/05/2020	"Advances in the Treatment of Nausea and Migraine, Women's Health"			"Imigran Nasal Spray, Imitrex Nasal Spray, Imitrex Nasal Spray, Imitrex Nasal Spray, Imitrex Nasal Spray, Imitrex Nasal Spray, Imitrex Nasal Spray"	no		no							https://adis.springer.com/drugs/800009562?userId=52029392&bpIds=3004037004&checksum=742692fbe291fe1b333332a985ab64149c8e5990-1617045531649-0eb930e8fb7c186c9839fad4b659d4a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028232	Research programme: calcitonin gene-related peptide receptor antagonists - Merck			Yes			No development reported (Preclinical)	Migraine		Calcitonin gene-related peptide receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner), AbbVie (Licensee)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"CGRP receptor antagonists Merck, Imidazoazepanes Merck, MK2918, MK8825"			18/05/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800028232?userId=52029392&bpIds=3004037004&checksum=57ef2f8b41b2bcc3044a5574204370e0927f6677-1617045531650-4e90088b76bb02d3e27e167fd42d6511badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029506	AGN 323			Yes			No development reported (I)	Pain			"Allergan (Originator), AbbVie (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AGN323			18/05/2020	Pain				no		no							https://adis.springer.com/drugs/800029506?userId=52029392&bpIds=3004037004&checksum=274bb7f0bf69c514c80e458e968dd8d17ca9e8e4-1617045531650-1782f2d99c05d3069d2d5670dfb0559dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040367	Research programme: microsomal prostaglandin E synthase-1 inhibitors - Glenmark Pharmaceuticals			Yes			No development reported (Preclinical)	"Pain, Inflammation"		Prostaglandin-E synthase inhibitors	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), AbbVie (Collaborator)"		PO				"L4X (Other Immunosuppressants), N2 (Analgesics)"	"L04A-A (Selective immunosupressants), N02 (Analgesics)"				18/05/2020	"Inflammation, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800040367?userId=52029392&bpIds=3004037004&checksum=d274c382d35b816065cd63a9d947faef297177dd-1617045531651-aa3e839a581d4de17a50b631fa7eed36badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015198	AGN 201781			Yes			Discontinued (II)	Neuropathic pain		Alpha adrenergic receptor agonists	"ACADIA Pharmaceuticals (Originator), Allergan (Originator), AbbVie (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	AGN201781			18/05/2020	Pain		ACADIA Pharmaceuticals |  | Unspecified |  | 26 Feb 2015		no		no							https://adis.springer.com/drugs/800015198?userId=52029392&bpIds=3004037004&checksum=12764627b50db0ab6da77c04f4b46b97bf39f1b9-1617045531652-8670cd700a81262dc8af8c4e745bd731badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022609	Research programme: pain therapies - ACADIA/AbbVie			Yes			No development reported (Preclinical)	Pain		Alpha adrenergic receptor agonists	"ACADIA Pharmaceuticals (Originator), ACADIA Pharmaceuticals (Owner), AbbVie (Licensee)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/05/2020	Pain		ACADIA Pharmaceuticals |  | Unspecified |  | 26 Feb 2015		no		no							https://adis.springer.com/drugs/800022609?userId=52029392&bpIds=3004037004&checksum=b288ddee2bc173ac69d36f6ec769960a28aabad3-1617045531653-1e2bba7741026052956f34e0c40533aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029462	AGN 209323			Yes			Discontinued (II)	Neuropathic pain		Undefined mechanism	"Allergan (Originator), ExonHit Therapeutics (Originator), AbbVie (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"AGN0001, AGN001, AGN209323, EHT/AGN0001, EHT0001, EHT001"			18/05/2020	Pain				no		no							https://adis.springer.com/drugs/800029462?userId=52029392&bpIds=3004037004&checksum=091107cf7b7b32981e338691e2d7f8678ade7f8c-1617045531654-dc1d7742cc2c97abb55097404c27d8ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021786	Research programme: drug discovery - AbbVie/ExonHit			Yes			No development reported (Preclinical)	"Eye disorders, Neurodegenerative disorders, Pain"		Undefined mechanism	"Allergan (Originator), ExonHit Therapeutics (Originator), AbbVie (Owner), Bristol-Myers Squibb (Licensee)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"	"AGN 002, EHT 002, EHT/AGN 0002, EHT/AGN 0003, EHT/AGN 002"			18/05/2020	"Eye Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800021786?userId=52029392&bpIds=3004037004&checksum=078d6127ec8341245ab84abc75595e9f70a1d5a5-1617045531656-bee0a48286d3458abb3aac041cf7fb7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031388	Research programme: NMDA receptor modulators - AbbVie			Yes			Preclinical	"Schizophrenia, Autistic disorder, Epilepsy, Major depressive disorder, Neuropathic pain, Alzheimer's disease, Brain injuries"		NMDA receptor modulators	"Naurex (Originator), AbbVie (Owner), National Cancer Institute (USA) (Funder), National Institute of Neurological Disorders and Stroke (Funder), National Institute on Aging (Funder), Aptinyx (Collaborator)"		"IV, PO, unspecified"				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"N02 (Analgesics), N06A (Antidepressants), N06D (Anti-Dementia Drugs), N07X-X (Other nervous system drugs)"	"NMDA receptor modulators Naurex, NRX1050, NRX1051, NRX1059, NRX105x, NRX1060, NRX2085, NRX20xx"			18/05/2020	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Psychotic Disorders"		Naurex |  | Unspecified |  | 13 Dec 2010		no		no							https://adis.springer.com/drugs/800031388?userId=52029392&bpIds=3004037004&checksum=f8249a07437d1bf853321646ed94df5c521b80a9-1617045531657-6dfee40e78dfb50e2a3e19e9f70b20a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017358	Research programme: adenosine A2A receptor agonists - Clinical Data			Yes			No development reported (Preclinical)	Inflammation		Adenosine A2 receptor agonists	"Adenosine Therapeutics LLC (Originator), AbbVie (Owner)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs), S1 (Ophthalmologicals), V3 (All Other Therapeutic Products)"	"A07E (Intestinal Antiinflammatory Agents), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs), S01 (Ophthalmologicals), V03A-X (Other therapeutic products)"	"ATL 1222, ATL908"			18/05/2020	"Inflammation, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800017358?userId=52029392&bpIds=3004037004&checksum=0b2212f8ec096a6775ec4e3ae72c35df3fa87b67-1617045531659-68282d64b17270b42d7ae0b5c5d7227ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008389	Ketorolac ophthalmic - AbbVie	74103-07-4	"(±)-5-Benzoyl-1,2-dihydro-3<EM>H</EM>-pyrrolo[1,2-<EM>a</EM>] pyrrole-1-carboxylic acid"	No			Marketed	"Postoperative inflammation, Allergic conjunctivitis, Postoperative pain"	C15 H13 N O3 . C4 H11 N O3	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Roche Palo Alto LLC (Originator), Roche (Owner), AbbVie (Market Licensee)"		Ophthalmic				"N2 (Analgesics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"N02 (Analgesics), S01B-C05 (Ketorolac)"	"ACULAR, ACULAR LS, ACULAR PF, ACUVAIL, Ketorolac tromethamine"			18/05/2020	"Eye Disorders, Pain"			"ACULAR, ACULAR LS, ACULAR PF, ACUVAIL"	no		no		"opsin 1 (cone pigments), long-wave-sensitive"		"CA-125, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, FasL, Hydrocortisone, IL10, IL17, MCP1, NGAL, PGE2, Prolactin, sodium voltage-gated channel alpha subunit 7, sphingolipid transporter 1 (putative), VEGF-A, VEGF-C"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"A1C, Calreticulin, delta like canonical Notch ligand 4, IGF1"	https://adis.springer.com/drugs/800008389?userId=52029392&bpIds=3004037004&checksum=6e1444f8ce20d4c8e13e2defc54556821a7a3ab2-1617045531662-a19f084ee0511b6a880836a1240df70bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038015	Dexketoprofen/tramadol - Menarini Ricerche		"(2S)-2-(3-benzoylphenyl)propanoic acid / (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			Marketed	Acute pain	C16 H14 O3 . C16 H25 N O2	"Adrenergic uptake inhibitors, Cyclooxygenase inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Menarini Ricerche (Originator), Menarini Ricerche (Owner)"		PO				"M1A2 (Anti-rheumatics, non-steroidal combination), N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E17 (Dexketoprofen), N02A-X02 (Tramadol), N02B-G (Other analgesics and antipyretics)"	"Dexketoprofen trometamol/tramadol, Dexketoprofen trometamol/tramadol hydrochloride, Dexketoprofen/tramadol hydrochloride, Dexketoprofene/tramadolo, DKP.TRIS/TRAM, DKP.TRIS/TRAM.HCL, DKP/TRAM, DKP/TRAM.HCL, Lenizak, Skudex, Skudexa, Skudexum, Skudo, TRAM.HCL/DKP, TRAM.HCL/DKP.TRIS, TRAM/DKP, TRAM/DKP.TRIS, Tramadol hydrochloride/dexketoprofen, Tramadol hydrochloride/dexketoprofen trometamol, Tramadol/dexketoprofen, Tramadol/dexketoprofen trometamol"			15/05/2020	Pain			"Lenizak, Skudex, Skudex, Skudex, Skudex, Skudex, Skudex, Skudex, Skudex, Skudexa, Skudexa, Skudexa, Skudexa, Skudexa, Skudexum, Skudo"	no		no							https://adis.springer.com/drugs/800038015?userId=52029392&bpIds=3004037004&checksum=4227a78212cd6961dd0e1e52062388477de35aa3-1617045531672-4adfb61ed37c2ce1d5a5d00428deb44fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047197	Cannabidiol/tetrahydrocannabinol - Intec Pharma			No			Phase I	"Fibromyalgia, Pain"		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Intec Pharma (Originator), Intec Pharma (Owner), Yissum Research Development Company (Technology Provider)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Accordion Pill Cannabidiol/tetrahydrocannabinol, APcannabinoids, APCBD/THC, Tetrahydrocannabinol/cannabidiol Intec Pharma"			14/05/2020	Pain				no		no							https://adis.springer.com/drugs/800047197?userId=52029392&bpIds=3004037004&checksum=a74223c1b4895160b8a8306ea0cd255f806d1253-1617045531674-db5da2b9662b12370ff706bb8955a6f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058283	Flusalazine - GNT Pharma			Yes			Phase I	"Diabetic nephropathies, Arthritis, Pancreatitis, Pain"		"Antioxidants, Prostaglandin-E synthase inhibitors"	"GNT Pharma (Originator), GNT Pharma (Owner)"		unspecified				"A (Alimentary Tract and Metabolism), A10X (Other Drugs Used in Diabetes), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"A (Alimentary Tract and Metabolism), A10X (Other Drugs Used in Diabetes), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"				11/05/2020	"Diabetes, Digestive System Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800058283?userId=52029392&bpIds=3004037004&checksum=8367f999ea094458c05ce671470c760f653fb5ca-1617045531676-fb0c5ec7ff82590a47ce05afd60e0332badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056297	Topical detomidine - Clexio Biosciences	76631-46-4	"5-[(2,3-dimethylphenyl)methyl]-1H-imidazole"	No			Phase I	Diabetic neuropathies	C12 . H14 . N2	Alpha adrenergic receptor agonists	"Clexio Biosciences (Originator), Clexio Biosciences (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	CLE400			11/05/2020	Pain				no		no							https://adis.springer.com/drugs/800056297?userId=52029392&bpIds=3004037004&checksum=ff69e8541f0142b872ae72ac27706b0c4663d6c1-1617045531677-995f88fe2fee6e39c074d8c6419a5fc8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054944	Tramadol extended release - Orbis Biosciences	27203-92-5	"(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			Preclinical	Pain	C16 H25 N O2	"Adrenergic receptor antagonists, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Orbis Biosciences (Originator), Orbis Biosciences (Owner)"		Parenteral				N2 (Analgesics)	N02A-X02 (Tramadol)	ORB201			09/05/2020	Pain		Orbis Biosciences |  | Unspecified |  | 28 May 2019		no		no							https://adis.springer.com/drugs/800054944?userId=52029392&bpIds=3004037004&checksum=76863e78396e08f12832e35693193e3a67fd9831-1617045531678-7e3d86d076451d505c7ee124f8541787badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052217	Ibuprofen delayed release - Orbis Biosciences	15687-27-1	2-[4-(2-methylpropyl)phenyl]propanoic acid	No			Preclinical	Pain	C13 H18 O2	Cyclooxygenase inhibitors	"Orbis Biosciences (Originator), Orbis Biosciences (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	"ORB 108, ORB113"			09/05/2020	Pain		Orbis Biosciences |  | Unspecified |  | 27 May 2019		no		no							https://adis.springer.com/drugs/800052217?userId=52029392&bpIds=3004037004&checksum=ded13a63be9d40860f5a4de1e19dc7ac9e78c41e-1617045531679-b7437688ee28f5441b164f15b7b58d3fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054943	Ibuprofen encapsulated - Orbis Biosciences	15687-27-1	2-(4-Isobutylphenyl)propanoic acid	No			Preclinical	Pain	C13 H18 O2	Cyclooxygenase inhibitors	"Orbis Biosciences (Originator), Orbis Biosciences (Owner)"		PO				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	ORB112			09/05/2020	Pain		Orbis Biosciences |  | Unspecified |  | 28 May 2019		no		no							https://adis.springer.com/drugs/800054943?userId=52029392&bpIds=3004037004&checksum=497cd76a4cd89c6f6b9297aa1fb69b792821be87-1617045531680-222987a3bacf8e69eb813ddfd3196c39badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058437	UI 032			No			Preclinical	Pain		Cyclooxygenase inhibitors	"Korea United Pharm Inc (Originator), Korea United Pharm Inc (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	UI032			08/05/2020	Pain		Korea United Pharm Inc |  | Unspecified |  | 30 Apr 2020		no		no							https://adis.springer.com/drugs/800058437?userId=52029392&bpIds=3004037004&checksum=e5b47368774e7fa7cc01347c3c890846e9796d09-1617045531681-3a0971692decbc55137724f4732fb9ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058429	UI 048			No			Research	"Diabetes mellitus, Pain"		Undefined mechanism	"Korea United Pharm Inc (Originator), Korea United Pharm Inc (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics)"	UI048			08/05/2020	"Diabetes, Pain"		Korea United Pharm Inc |  | Unspecified |  | 30 Apr 2020		no		no							https://adis.springer.com/drugs/800058429?userId=52029392&bpIds=3004037004&checksum=4f3c023a3f99017c8481572e5f6709a9df3c0ae2-1617045531683-b61a61d6d19a21c7202118997d53cee4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058424	UI 053			No			Research	Pain		Undefined mechanism	"Korea United Pharm Inc (Originator), Korea United Pharm Inc (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	UI053			08/05/2020	Pain		Korea United Pharm Inc |  | Unspecified |  | 30 Apr 2020		no		no							https://adis.springer.com/drugs/800058424?userId=52029392&bpIds=3004037004&checksum=c2b7e9fc312fd8e06e97255b0208948f53a1c936-1617045531684-88904dd47877307d4b1ab2e3ff8117a8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050322	Metenkefalin/tridecactide - Farmacija		(2S)-2-[(2S)-2-(2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}acetamido)-3-phenylpropanamido]-4-(methylsulfanyl)butanoic acid/L-seryl-L-tyrosyl-L-seryl-L-methionyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophyl-glycyl-L-lysyl-L-prolyl-L-valine	No			Marketed	"Multiple sclerosis, Asthma, COVID 2019 infections, Ulcerative colitis, Crohn's disease, Rheumatoid arthritis, Systemic lupus erythematosus, Psoriasis"	C27 H35 N5 O7 S . C75 H106 N20 O19 S	"Leukocyte stimulants, Opioid delta receptor agonists, Th1 cell modulators"	"Farmacija (Originator), Farmacija (Owner), Bosnalijek (Collaborator)"		SC				"J5 (Antivirals for Systemic Use), N2B (Non-Narcotics and Anti-Pyretics)"	"J05 (Antivirals for Systemic Use), N02B (Other Analgesics and Antipyretics)"	"EK12, Enkorten"			08/05/2020	"Immunological Disorders, Inflammatory Bowel Disorders, Neurological Disorders, Obstructive Airways Disease, Rheumatic Disease, Skin Disorders, Viral Infections"			Enkorten	no		no			"EPH receptor A6, interferon, beta 1, fibroblast"	"EPH receptor A6, interferon, beta 1, fibroblast"			https://adis.springer.com/drugs/800050322?userId=52029392&bpIds=3004037004&checksum=3a64045c460c1c3541086bdbc49128d319d66851-1617045531686-2313a6b1ed9ee02785839418a9b9ba6cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055159	TRV 045			Yes			Preclinical	"Pain, Neurological disorders, Epilepsy"		Sphingosine 1 phosphate receptor modulators	"Trevena (Originator), Trevena (Owner), National Institutes of Health (USA) (Collaborator)"		"PO, unspecified"				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	TRV045			08/05/2020	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"		Trevena |  | Unspecified |  | 20 Jun 2019		no		no							https://adis.springer.com/drugs/800055159?userId=52029392&bpIds=3004037004&checksum=3d21f8e192a82bf2160374d68ee57e840368015d-1617045531688-d6520fd77c119f14039933f6c157b50dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042697	Celecoxib - Promius Pharma	169590-42-5	4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide	No			Registered	"Migraine, Postoperative pain"	C17 H14 F3 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"Promius Pharma (Originator), Promius Pharma (Owner), Beth Israel Deaconess Medical Center (Collaborator), Dr Reddys Laboratories (Collaborator)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"L01X-X33 (Celecoxib), N02 (Analgesics)"	"DFN15, DFN15A, DFN15B, ELYXYB"			07/05/2020	"Advances in the Treatment of Nausea and Migraine, Pain"			ELYXYB	no		no		"Aromatase, CA-19-9, CEA, EGFR, PGE2, PSA, pyridoxal phosphatase, survival of motor neuron 1, telomeric"	"Chondroitin sulfate, COX2, EGFR, PGE2, PSA, survival of motor neuron 1, telomeric"	"24,25-Dihydroxyvitamin D, ACE, adhesion regulating molecule 1, AKT, Androgen receptor, angiopoietin like 2, arachidonate 15-lipoxygenase, Arachidonic acid, Aromatase, baculoviral IAP repeat containing 2, Bcl-2, Beta-catenin, bFGF, CA-19-9, Calprotectin, carbonic anhydrase II, caspase 6, CD163, CD31, CD4, CD68, CEA, Chondroitin sulfate, Collagen type 2, COMP, COX2, CRP, CYP2C19, CYP2C9, CYP3A5, cytochrome P450 family 2 subfamily B member 6, Cytokeratin 14, E-cadherin, EGFR, Elafin, ephrin A5, ER alpha, Estradiol-17beta 3-sulfate, Fibulin 3 peptides, Folinic acid, FOXP3, GATA binding protein 6, GUSB, hematological and neurological expressed 1, HER2, Histone H3, hyaluronan synthase 3, IFN-gamma, IGF1, IGFBP3, IL10, IL6, IL8, integrin subunit alpha V, Ki67, KRAS, L-Serine, MAPK1, mitogen-activated protein kinase 4, MMP-13, MMP-2, MMP9, NGF, opioid related nociceptin receptor 1, Osteocalcin, PAGE family member 2, PAGE family member 3, PAI-1, PDGFA, PDGFB, PGE2, pleckstrin homology domain containing, family M (with RUN domain) member 1, PSA, pyridoxal phosphatase, serine/threonine kinase 36, SET binding protein 1, sex hormone-binding globulin, survival of motor neuron 1, telomeric, Syndecan-1, Thrombospondin-1, Thromboxane, TIMP-1, TNF-alpha, transforming growth factor, alpha, translocator protein, VEGF-A, VEGF-C, VEGFR, VEGFR1, Vimentin"	"AKT, Calprotectin, CD4, CRP, E-cadherin, Osteocalcin, PGE2, VEGF-A"	"13-cis-Retinoic acid, 25-Hydroxyvitamin D2, Aldosterone, Amphiregulin, Amyloid beta, ApoE, bax, BRCA2, C-C motif chemokine ligand 22, C-C motif chemokine receptor 4, C-X-C motif chemokine ligand 11, C-X-C motif chemokine receptor 3, CA-125, Caspase 3, CCR5, CD34, CD8a, CDKN1A, chemokine (C-C motif) receptor 6, Creatinine, CXCL10, CXCL12, CXCL9, CXCR4, CYP3A4, Deoxyuridine triphosphate, DNA (cytosine-5-)-methyltransferase 1, DNA nucleotidylexotransferase, F2-isoprostanes, Fas cell surface death receptor, frizzled-related protein, Glutathione, GSTT1, HPGD, IL2, L-Threonine, Lewis X trisaccharide, MAPK3, NFkB, ornithine decarboxylase 1, p16, p53, PCNA, PDZ and LIM domain 7, peroxisome proliferator activated receptor alpha, peroxisome proliferator-activated receptor gamma, PGR, phosphate cytidylyltransferase 1, choline, alpha, prostaglandin E synthase, prostaglandin-endoperoxide synthase 1, proteasome subunit beta 9, Renin, sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein), TGF-beta, Thymidine, tyrosine kinase, non-receptor, 2, UGT1A1, Uridine 5'-diphosphate"	https://adis.springer.com/drugs/800042697?userId=52029392&bpIds=3004037004&checksum=d60aa472b1474aa6da9dc564cb3511d3c9bc7797-1617045531692-ed9f7d08d805eb6548c5e1c390702727badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058134	Cannabidiol/tetrahydrocannabinol - AusCann		"2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol/(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol"	No			Phase I	Pain	C21 H30 O2/C21 H30 O2	"Cannabinoid receptor agonists, Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"AusCann (Originator), AusCann (Owner)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N02B-G10 (Cannabinoids, including nabiximols), N05C (Hypnotics and Sedatives)"	"ACNV 201, ACNV 202, THCCBD AusCann"			28/04/2020	Pain				no		no							https://adis.springer.com/drugs/800058134?userId=52029392&bpIds=3004037004&checksum=267c476b19d33ed0a7b54cacdab8815f6fd29a42-1617045531693-f567f96a40a01fbac9fdeefff7481df3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044973	Research programme: neuropathic pain therpaeutic - Jeil Pharmaceuticals			Yes			No development reported (Research)	Neuropathic pain		Undefined mechanism	"Jeil Pharmaceutical (Originator), Jeil Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/04/2020	Pain				no		no							https://adis.springer.com/drugs/800044973?userId=52029392&bpIds=3004037004&checksum=53ae0a436c354493b2f534b457282ee69d1923e7-1617045531694-72880a15f831522d0c767aa0ed0eb8c1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037073	Research programme: monoclonal antibody therapeutics - Integral Molecular/Ligand Pharmaceuticals			Yes			Research	Pain		Immunomodulators	"Crystal Bioscience (Originator), Integral Molecular (Originator), Integral Molecular (Owner), Ligand Pharmaceuticals (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	MPS Discovery Engine Integral Molecular			28/04/2020	Pain				no		no							https://adis.springer.com/drugs/800037073?userId=52029392&bpIds=3004037004&checksum=1cc724e7b13aa4a3a43f1b4ce0216edf279cff65-1617045531696-2c31a02ba177b910ea6fd59dd320210bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035973	Research programme: extended-release therapeutics - Pacira BioSciences			No			No development reported (Preclinical)	Acute pain			"Pacira Pharmaceuticals (Originator), Pacira BioSciences (Owner)"		Injection				"B2A1 (Synthetic antifibrinolytics), N2 (Analgesics)"	"B02A-A02 (Tranexamic acid), N02 (Analgesics)"	"DepoMeloxicam, DepoMLX, DepoNSAID"			28/04/2020	Pain				no		no							https://adis.springer.com/drugs/800035973?userId=52029392&bpIds=3004037004&checksum=d01c3805dd04a39bcaa75b5bac285f338fe14762-1617045531697-93b4c08e5c1011d366157851fa5d66acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053315	Research programme: RNAi therapeutics - Dicerna Pharmaceuticals/Eli Lilly and Company			Yes			Preclinical	"Cardiovascular disorders, Metabolic disorders, Neurodegenerative disorders, Unspecified, Pain"		RNA interference	"Dicerna Pharmaceuticals (Originator), Dicerna Pharmaceuticals (Owner), Eli Lilly and Company (Licensee)"		"unspecified, Parenteral"				"A16A (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs), V (Various)"	"A16A (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), N02B (Other Analgesics and Antipyretics), N07X-X (Other nervous system drugs), V (Various)"	"DCRCM3, DCRCM4, DCRCM5, DCRLLY9, DCRNEURO1, DCRNEURO2, DCRPAIN1, DCRPAIN2"			24/04/2020	"Ischaemic Heart Disease, Metabolic Disorders, Neurological Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800053315?userId=52029392&bpIds=3004037004&checksum=4495c0daa8165a3accc5edb4ecd2f15e3986f44c-1617045531698-5e413168c240b4a2663b2af82fc36e4bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056063	Etifoxine - GABA Therapeutics			No			Phase I	"Anxiety disorders, Mood disorders"		GABA modulators	"GABA Therapeutics (Originator), GABA Therapeutics (Owner), ATAI Life Sciences (Collaborator)"		"PO, unspecified"				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N05B (Anxiolytics)"	GRX917			24/04/2020	"Affective Disorders, Anxiety Disorders"				no		no							https://adis.springer.com/drugs/800056063?userId=52029392&bpIds=3004037004&checksum=880a1a422ab82af4cfdb4b763fdab3204fa56a07-1617045531700-6a4398a2eaa197d947041b22007a9e15badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058255	BCI 1445			Yes			Preclinical	Pain		Undefined mechanism	"BCI Pharma (Originator), BCI Pharma (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	BCI1445			23/04/2020	Pain				no		no							https://adis.springer.com/drugs/800058255?userId=52029392&bpIds=3004037004&checksum=fbbcc6af9f7535fecbaa608af7649774b1064b75-1617045531700-fec649b31fb93c85e7088301fc3e1af2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058244	BCI 1446			Yes			Preclinical	"Psoriasis, Neuropathic pain"		Fms-like tyrosine kinase 3 inhibitors	"BCI Pharma (Originator), BCI Pharma (Owner)"		unspecified				"D5B (Systemic Antipsoriasis Products), N2B (Non-Narcotics and Anti-Pyretics)"	"D05 (Antipsoriatics), N02B (Other Analgesics and Antipyretics)"	BCI1446			23/04/2020	"Pain, Skin Disorders"		"BCI Pharma | Neuropathic pain, Psoriasis | Preclinical |  | 21 Apr 2020"		no		no							https://adis.springer.com/drugs/800058244?userId=52029392&bpIds=3004037004&checksum=e02a817f7ecfd39b8e5169662f3e798f1de0507b-1617045531701-1ed21023f96c4317783be18291d14c5fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800058251	BCI 1415			Yes			Research	"Cancer, Pain, Inflammation"		Macrophage colony stimulating factor receptor antagonists	"BCI Pharma (Originator), BCI Pharma (Owner)"		unspecified				"L1H (Protein Kinase Inhibitor Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"L01X-E (Protein kinase inhibitors), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	BCI1415			23/04/2020	"Cancer, Inflammation, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800058251?userId=52029392&bpIds=3004037004&checksum=b227129840ff7211d5520287a1fafcb7ef891bfd-1617045531702-3974ec40be0edd2120d361f82cbfdf83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047777	Celecoxib/lisinopril - Adhera Therapeutics			No			Preclinical	"Hypertension, Inflammation, Cancer, Pain, Arthritis"		"ACE inhibitors, Cyclo-oxygenase 2 inhibitors"	"IthenaPharma (Originator), Adhera Therapeutics (Owner), Autotelic (Technology Provider)"		unspecified				"C9A (ACE Inhibitors, Plain), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M1A3 (Coxibs, plain), N2 (Analgesics)"	"C09A (ACE Inhibitors, Plain), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), M01A-H (Coxibs), N02 (Analgesics)"	IT 102			22/04/2020	"Cancer, Hypertension, Inflammation, Rheumatic Disease"		Adhera Therapeutics |  (Excluding Hypertension) | Preclinical |  | 16 May 2019		no		no							https://adis.springer.com/drugs/800047777?userId=52029392&bpIds=3004037004&checksum=cc437f6a996eed1f8770bac3ac15ffb19befa837-1617045531703-fc4ec985c14c72183ffe2d13bd067ee8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047781	Celecoxib/olmesartan - Adhera Therapeutics			No			Preclinical	"Hypertension, Inflammation, Cancer, Pain, Arthritis"		"Angiotensin type 1 receptor antagonists, Cyclo-oxygenase 2 inhibitors"	"IthenaPharma (Originator), Adhera Therapeutics (Owner), Autotelic Bio (Licensee)"		PO				"C9A (ACE Inhibitors, Plain), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M1A3 (Coxibs, plain), N2 (Analgesics)"	"C09A (ACE Inhibitors, Plain), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), M01A-H (Coxibs), N02 (Analgesics)"	IT103			22/04/2020	"Cancer, Hypertension, Inflammation, Musculoskeletal Disorders, Pain"		Adhera Therapeutics |  (Excluding Hypertension) | Preclinical |  | 16 Apr 2019		no		no							https://adis.springer.com/drugs/800047781?userId=52029392&bpIds=3004037004&checksum=15d277ae6f30f35efa186268320adedb0b7e6c27-1617045531705-6d0a50242de1ad3691809ca66015c06ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032805	Crisdesalazine - GNT Pharma	927685-43-6	2-hydroxy-5-({2-[4- (trifluoromethyl)phenyl]ethyl}amino)benzoic acid	Yes			Phase I	"Amyotrophic lateral sclerosis, Alzheimer's disease, Depressive disorders, Parkinson's disease, Pain, Diabetes mellitus, Pancreatitis, Arthritis"	C16 H14 F3 N O3	"Amyloid beta-protein inhibitors, Antioxidants, Dinoprostone antagonists, Free radical scavengers, Prostaglandin-E synthase inhibitors"	"Neurotech Pharmaceuticals (Originator), GNT Pharma (Owner), Toyota Tsusho Corporation (Market Licensee)"		unspecified				"A (Alimentary Tract and Metabolism), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"A (Alimentary Tract and Metabolism), M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D-X (Other anti-dementia drugs), N07X (Other Nervous System Drugs)"	AAD2004			21/04/2020	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Diabetes, Digestive System Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease"		GNT Pharma |  | Unspecified |  | 21 Apr 2020		no		no							https://adis.springer.com/drugs/800032805?userId=52029392&bpIds=3004037004&checksum=f399c0e1064ac83ee88bee3ce308b837e84c8e37-1617045531706-441ad563360bd5c65603eb7c23566a36badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049120	Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma			No			Preclinical	"Complex regional pain syndromes, Ocular inflammation, Neuropathic pain, Uveitis, Epidermolysis bullosa, Ocular pain, Inflammation"		Cannabinoid receptor CB2 modulators	"Panag Pharma (Originator), Panag Pharma (Owner), Tetra Bio Pharma (Licensee)"		"unspecified, Ophthalmic, Topical"				"D11A (Other Dermatological Preparations), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"D11A (Other Dermatological Preparations), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), S01B (Antiinflammatory Agents)"	"PPP 004, PPP009"			20/04/2020	"Eye Disorders, Inflammation, Pain, Skin Disorders"	"Epidermolysis bullosa (USA), Complex regional pain syndromes (USA), Proliferative vitreoretinopathy (USA)"			no		no							https://adis.springer.com/drugs/800049120?userId=52029392&bpIds=3004037004&checksum=b2aa3fdd2afb3ee3c1d90b547b945df4611a5cc4-1617045531708-575ba28e3474f0124f80e6bf1a9fd378badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010875	GM 1485			Yes			Preclinical	"Wounds, Myocardial infarction, Cartilage disorders, Bone disorders, Erectile dysfunction, Parkinson's disease, Dementia, HIV-associated nephropathy"		Immunophilin modulators	"MGI GP (Originator), GliaMed (Owner)"		"Topical, unspecified, PO"				"C1 (Cardiac Therapy), D3 (Wound Healing Agents), G4D4 (Urinary incontinence products), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N6D (Nootropics)"	"C01 (Cardiac Therapy), D03 (Preparations for Treatment of Wounds and Ulcers), G04B-E (Drugs used in erectile dysfunction), M05 (Drugs for Treatment of Bone Diseases), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs)"	"GM1485, GPI1485, NILA"			20/04/2020	"Alzheimer's Disease and Cognition Disorders, Genitourinary Disorders, Ischaemic Heart Disease, Men's Health, Musculoskeletal Disorders, Parkinson's Disease and Movement Disorders, Skin Disorders, Thromboses, Viral Infections"				no		no							https://adis.springer.com/drugs/800010875?userId=52029392&bpIds=3004037004&checksum=12d3ec15f4445fa0dd28df043618587bfe2815da-1617045531709-9e2b33d4b660fc82771a26824b4f553fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051484	RMX 1002			Yes			Phase III	"Cancer pain, Neuropathic pain"		Prostaglandin E EP4 receptor antagonists	"RMX biopharma (Originator), HaiHe Biopharma - CSPC (JV) (Owner), Ningbo NewBay Medical Technology (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	RMX1002			17/04/2020	Pain				no		no							https://adis.springer.com/drugs/800051484?userId=52029392&bpIds=3004037004&checksum=292c6717aeb0be6f1938fa2cce1b24d42c07ea08-1617045531710-0b7ac9c06771d111a91177d7c28d62dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049691	Research programme: cannabinoid based therapeutics - Tetra Bio Pharma			No			Research	"Eye disorders, Cancer"		Hedgehog protein inhibitors	"Tetra Bio Pharma (Originator), Tetra Bio Pharma (Owner), Ovensa (Technology Provider), Unknown (Technology Provider), Constance Therapeutics (Collaborator), Undisclosed Company (Collaborator)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"				16/04/2020	"Cancer, Eye Disorders"				no		no							https://adis.springer.com/drugs/800049691?userId=52029392&bpIds=3004037004&checksum=0d3abec116e63664d08da1437d8279032a895804-1617045531711-d22aca67e6aa037123515f827cdea7e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042484	AB 001			Yes			Phase II	Back pain		Undefined mechanism	"ABsize (Originator), Frontier Biotechnologies (Owner)"		"Topical, PO"				N2 (Analgesics)	N02 (Analgesics)	AB001			08/04/2020	Pain				no		no							https://adis.springer.com/drugs/800042484?userId=52029392&bpIds=3004037004&checksum=74f76b1c33f93a9732e554c469ea9d2dec26d74f-1617045531712-b7a6699e0e544b46c5b8e1355ff0f978badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044257	FP 004			Yes			Research	"Pain, Opioid-related disorders"		Opioid receptor agonists	"Foresee Pharmaceuticals (Originator), Foresee Pharmaceuticals (Owner)"		SC				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N07B-C (Drugs used in opioid dependence)"	FP004			01/04/2020	"Drug Delivery Systems, Drug Withdrawal, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800044257?userId=52029392&bpIds=3004037004&checksum=78fb276dcc3fefe134bf7a2a60e6b249cc233ab9-1617045531713-e50414a05310467139dcc812e900719fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049193	Research programme: phytocannabinoid-based therapeutics - India Globalization Capital			Yes			Preclinical	"Cancer pain, Eating disorders, Post-traumatic stress disorders, Parkinson's disease, Cachexia, Neuropathic pain, Epilepsy"		"Cannabinoid receptor CB1 modulators, Cannabinoid receptor CB2 modulators, G protein-coupled receptor modulators"	"University of South Florida (Originator), University of South Florida (Owner), India Globalization Capital (Licensee), Parkinsons Institute and Clinical Center (Collaborator)"		"unspecified, Topical"				"A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N5 (Psycholeptics)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02 (Analgesics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N05B (Anxiolytics)"	"Hyalolex, IGC501, IGC503, IGC504, IGC506, Serosapse"			01/04/2020	"Affective Disorders, Anxiety Disorders, Cancer, Epilepsy and Seizure Disorders, Metabolic Disorders, Pain, Parkinson's Disease and Movement Disorders, Viral Infections"			Hyalolex	no		no							https://adis.springer.com/drugs/800049193?userId=52029392&bpIds=3004037004&checksum=5a4612f665eccb15206b1587edde015729791007-1617045531714-9f202e2c1306c62b0dd458872e03a102badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032615	Research programme: siRNA therapeutics - OliX Pharmaceuticals			Yes			Preclinical	"Age-related macular degeneration, Idiopathic pulmonary fibrosis, Atopic dermatitis, Neuropathic pain, Hepatic fibrosis, COVID 2019 infections, Herpes simplex virus infections, Cancer"		"Connective tissue growth factor inhibitors, RNA interference"	"BioMolecular Therapeutics (Originator), OliX Pharmaceuticals (Owner), Hugel (Licensee), Thea Open Innovation (Licensee), AM Chemicals (Technology Provider), A STAR (Funder), Korea Drug Development Fund (Funder), Korea Health Industry Development Institute (Funder), Small and Medium Business Administration (Funder), Korea Institute of Toxicology (Collaborator), Samyang Biopharmaceuticals Corporation (Collaborator), University of Virginia School of Medicine (Collaborator)"		"unspecified, Inhalation, Topical"				"A5B (Hepatic Protectors, Lipotropics), D11 (Other Dermatological Preparations), D3 (Wound Healing Agents), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), N2 (Analgesics), R7 (Other Respiratory System Products), S1 (Ophthalmologicals)"	"A05B-A (Liver therapy), D03A (Cicatrizants), D11 (Other Dermatological Preparations), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), N02 (Analgesics), R07 (Other Respiratory System Products), S01 (Ophthalmologicals)"	"asiRNA therapeutics OliX Pharmaceuticals, BMT 101, cpasiRNA therapeutics OliX Pharmaceuticals, OLX 10020, OLX 103, OLX 201, OLX 301, OLX 401, OLX 701"			30/03/2020	"Cancer, Eye Disorders, Liver Disorders, Pain, Respiratory Tract Disorders, Skin Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800032615?userId=52029392&bpIds=3004037004&checksum=e2abb23ab2ac19da163dd18c2db20d6f26c97c0d-1617045531717-063e6a0cd48055d6db469bd62adf0600badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034447	Research programme: extended release opioid analgesics - Ensysce Biosciences			No			No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"PharmacoFore (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	"N02A-A (Natural opium alkaloids), N02A-A01 (Morphine)"	"ER Morphine BioMD System, ER Morphine Ensysce Biosciences, ER Morphine PharmacoFore, ER Oxymorphone BioMD System, ER Oxymorphone Ensysce Biosciences, ER Oxymorphone PharmacoFore, PF03, PFR 03088, PFR 03325"			28/03/2020	Pain		Ensysce Biosciences |  | Unspecified |  | 03 Sep 2012		no		no							https://adis.springer.com/drugs/800034447?userId=52029392&bpIds=3004037004&checksum=b242b30c54d525ea6f81d541aaaf2f08ca045bb0-1617045531719-103e753125a22011e5ee42425dc53383badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044747	Hydromorphone immediate-release - Ensysce Biosciences			No			No development reported (Preclinical)	Pain		Opioid receptor agonists	"Ensysce Biosciences (Originator), Ensysce Biosciences (Owner)"		PO				N2 (Analgesics)	N02A-A03 (Hydromorphone)	PFR 03321			28/03/2020	Pain				no		no							https://adis.springer.com/drugs/800044747?userId=52029392&bpIds=3004037004&checksum=a97ce8454f2f811cce4aaa92c2319ebb846679b1-1617045531720-94621c51f510b745b8191d5d525c85adbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044754	Oxymorphone immediate-release - Ensysce Biosciences			No			No development reported (Research)	Pain		Opioid mu receptor agonists	"Ensysce Biosciences (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	PFR 03323			28/03/2020	Pain				no		no							https://adis.springer.com/drugs/800044754?userId=52029392&bpIds=3004037004&checksum=5d1b467a654c4dd2b4517f9a69c67fbfec3e311c-1617045531721-b0bfbed2ef25d1ac6b6a8b34dbfecb78badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044746	Hydrocodone extended release - Ensysce Biosciences			No			No development reported (Preclinical)	Pain		Opioid receptor agonists	"Ensysce Biosciences (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"PFR 06176, PFR 06177"			28/03/2020	Pain				no		no							https://adis.springer.com/drugs/800044746?userId=52029392&bpIds=3004037004&checksum=632523d21a68912d9aa173b14ff3a762415dfe46-1617045531722-f1a0513c4651ee66071abbd1bd733ee1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044753	Morphine immediate-release - Ensysce Biosciences			No			No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"Ensysce Biosciences (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	PFR 03318			28/03/2020	Pain				no		no							https://adis.springer.com/drugs/800044753?userId=52029392&bpIds=3004037004&checksum=3ba162cc027c50540a4d2ffbe322abbf6f52bddd-1617045531723-dbbc643b6d5145ac6e43166e7933cbaabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034450	Research programme: hydrocodone immediate release - Ensysce Biosciences	125-29-1	"morphinan-6-one,4,5-alpha-epoxy-3-methoxy-17-methyl"	No			No development reported (Preclinical)	Pain	C18 H21 N O3	Opioid receptor agonists	"PharmacoFore (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"IR Hydrocodone BioMD System, IR Hydrocodone Ensysce Biosciences, IR Hydrocodone PharmacoFore, PF 6129"			28/03/2020	Pain		Ensysce Biosciences |  | Unspecified |  | 03 Sep 2012		no		no							https://adis.springer.com/drugs/800034450?userId=52029392&bpIds=3004037004&checksum=55696839baacceb3b1fe6ee78bc389e02f55cec9-1617045531725-39eff727df820ea0ab20de9c46cb08efbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052670	Cannabidiol - Leaf Vertical	13956-29-1	"1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-"	No			Preclinical	"Multiple myeloma, Squamous cell cancer, Basal cell cancer, Glioblastoma, Cancer"	C21 H30 O2	"Antioxidants, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Leaf Vertical (Originator), Leaf Vertical (Owner)"		Sublingual				"L1 (Antineoplastics), M2A (Topical Anti-rheumatics and Analgesics), N2 (Analgesics), N3A (Anti-Epileptics), N5A (Antipsychotics), N7E (Drugs Used In Alcohol Dependence), N7X (All other CNS drugs)"	"L01 (Antineoplastic Agents), M02A-X (Other topical products for joint and muscular pain), N02B-G10 (Cannabinoids, including nabiximols), N03A (Antiepileptics), N05A (Antipsychotics), N07B (Drugs Used In Addictive Disorders), N07B-B (Drugs used in alcohol dependence)"	"bioRenovate CX, BRCX014"			28/03/2020	Cancer			bioRenovate CX	no		no							https://adis.springer.com/drugs/800052670?userId=52029392&bpIds=3004037004&checksum=7892496e73d3377a6920270ba44a20c440f9aa0a-1617045531727-553b82c6fbf38fa27f8c22fdba659af4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036716	Research programme: oxycodone immediate release - Ensysce Biosciences	76-42-6	"(5a)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			No development reported (Preclinical)	Pain	C18 H21 N O4	Opioid receptor agonists	"Signature Therapeutics (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"IR Oxycodone BioMD System, IR Oxycodone Ensysce Biosciences, IR Oxycodone PharmacoFore, PFR 06158"			28/03/2020	Pain		Ensysce Biosciences |  | Unspecified |  | 24 Feb 2016		no		no							https://adis.springer.com/drugs/800036716?userId=52029392&bpIds=3004037004&checksum=e8680c5d9152771aaebb03f00fe8ff8a649b4fe5-1617045531728-657f85aaffe76b728e60400dc536a631badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030882	Research programme: monoclonal antibody therapeutics - argenx/Bird Rock Bio			Yes			No development reported (Preclinical)	"Renal cancer, Cancer, Inflammation, Pain, Ovarian cancer, Autoimmune disorders"		"Interleukin 6 inhibitors, G protein-coupled receptor modulators, Nav1.7 voltage-gated sodium channel inhibitors"	"arGEN-X (Originator), argenx (Owner), Bird Rock Bio (Licensee), Genor Biopharma (Sub-licensee), AGC Biologics (Technology Provider), BioWa (Technology Provider), Lonza (Technology Provider), University of Texas Southwestern Medical Center (Technology Provider)"		"SC, Parenteral, unspecified"				"D11 (Other Dermatological Preparations), L1G (Monoclonal Antibody Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2 (Analgesics)"	"D11 (Other Dermatological Preparations), L01X-C (Monoclonal antibodies), L04 (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02 (Analgesics)"	"AntiNav1.7 monoclonal antibody, Monoclonal antibodies targeting GPCR receptors Bird Rock Bio"			28/03/2020	"Cancer, Immunological Disorders, Inflammation, Pain, Women's Health"		argenx |  | Research |  | 09 Feb 2012		no		no							https://adis.springer.com/drugs/800030882?userId=52029392&bpIds=3004037004&checksum=6a3c361157ef3f2bbff46cc6b72957d7df767822-1617045531730-5e9943a9bb0da7853e33f41ecd26297abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018328	Capsaicin - Centrexion Therapeutics	404-86-4	"6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-"	No			Phase III	"Pain, Neuropathic pain, Postoperative pain"	C18 H27 N O3	"GABA A receptor modulators, Melatonin receptor modulators, Substance P inhibitors, TRPV1 receptor agonists"	"Johns Hopkins University (Originator), Johns Hopkins University (Owner), Centrexion Therapeutics (Licensee)"		Intra-articular				N2 (Analgesics)	N02 (Analgesics)	"Adlea, ALGRX4975, CNTX4975, CNTX497505, transcapsaicin, VLNX4975"			26/03/2020	Pain	Neuropathic pain (USA)		Adlea	yes	USA	no				"A1C, carnitine palmitoyltransferase 1A (liver), IL1 beta, IL6, IL8, TNF-alpha"		peroxiredoxin 2	https://adis.springer.com/drugs/800018328?userId=52029392&bpIds=3004037004&checksum=ded41c313bcc61d4bde5e6c7122f0c4ceb9f87ec-1617045531731-3cb4f60c5bafc23462c3c2be75f17053badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034352	Buprenorphine transdermal - Grunenthal	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-a-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-a-methyl-,[5-a,7-a-(S)]-"	No			Marketed	"Pain, Cancer pain"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Grunenthal (Originator), Grunenthal (Owner), Taiwan Mundipharma Pharmaceuticals (Development Licensee), AWD.pharma (Market Licensee), Napp Pharmaceutical Group (Market Licensee), Norpharma (Market Licensee), Prodotti Formenti (Market Licensee)"		Transdermal				N2A (Narcotics)	N02A-E01 (Buprenorphine)	"Transdermal buprenorphine Grunenthal, Transtec, Transtec twiceweekly"			24/03/2020	Pain			"Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec, Transtec"	no		no							https://adis.springer.com/drugs/800034352?userId=52029392&bpIds=3004037004&checksum=9d1adc98443e5e0fb43562d2584eab8c69fb68fb-1617045531737-352350b90b73b28f6511618412c00325badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026473	Ibuprofen intravenous - Cumberland Pharmaceuticals	15687-27-1	2-[4-(2-Methylpropyl)phenyl]propanoic acid	No			Marketed	"Fever, Pain"	C13 H18 O2	Cyclooxygenase inhibitors	"Cumberland Pharmaceuticals (Originator), Cumberland Pharmaceuticals (Owner), Al-Nabil (Market Licensee), Alveda Pharma (Market Licensee), Cardinal Health (Market Licensee), DB Pharm Korea (Market Licensee), GerminMED (Market Licensee), Grifols (Market Licensee), Insanbakti (Market Licensee), Phebra (Market Licensee), Piramal Critical Care (Market Licensee), PT SOHO Industri Pharmasi (Market Licensee), PT. ETHICA Industri Farmasi (Market Licensee), Sandor Medicaids (Market Licensee), Seqirus (Market Licensee), Valmorca Laboratories (Market Licensee), Grifols (Licensee), Winhealth Pharma (Licensee)"		IV				"M1A1 (Anti-rheumatics, non-steroidal plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E01 (Ibuprofen), N02B (Other Analgesics and Antipyretics)"	"Amelior, Caldolor, Ibuprofen injection"			24/03/2020	"Metabolic Disorders, Pain"			"Caldolor, Caldolor, Caldolor, Caldolor, Caldolor, Caldolor"	no		no		"C-peptide, opsin 1 (cone pigments), long-wave-sensitive"	peroxisome proliferator-activated receptor gamma	"A1C, ACTH, adrenoceptor alpha 1D, Arachidonic acid, C-peptide, Calprotectin, CD34, CRP, CXCL10, Elastase, Endothelin 1, ER alpha, Estrone sulfate, Ferritin, IFN-gamma, IL1 beta, IL17, IL2, IL5, IL6, IL8, LTB4, Nitric Oxide, NOX2-dp, nuclear prelamin A recognition factor like, peroxisome proliferator-activated receptor gamma, PGE2, Prostacyclin, proteasome subunit alpha 7, Pulmonary disease, chronic obstructive, severe early-onset, RNA, Ro-associated Y1, secretoglobin, family 1A, member 1, sex hormone-binding globulin, Soluble transferrin receptor, submaxillary gland androgen regulated protein 3B, Surfactant protein D, Thromboxane, TNF-alpha"	"A1C, C-peptide, Calprotectin, IFN-gamma, IL1 beta, IL17, IL2, IL5, TNF-alpha"	"Aldosterone, Calreticulin, CD4, CD68, CD8a, Creatinine, CTx, CYP2C9, cytochrome P450 family 2 subfamily C member 8, delta like canonical Notch ligand 4, endothelin receptor type A, F2-isoprostanes, GAD Auto-antibodies, Hepcidin, IGF1, IL10, IL13, IL4, Lactate dehydrogenase, MCP1, miR-146a, OPRM1, PAI-1, PGD2, PGE1, PICP, PIIINP, PINP, Renin, Thromboxane B2, TNFRSF1A, TNFRSF1B, VEGF-A"	https://adis.springer.com/drugs/800026473?userId=52029392&bpIds=3004037004&checksum=9c736e1c4a765785f667063d6ea0bfc7a8ece100-1617045531746-6d7aee50c7c963c3666b3bcbb0212697badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057633	Naproxen/pregabalin topical - XGene Pharmaceutical		(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid / (3S)-3-(aminomethyl)-5-methylhexanoic acid	No			Phase I	Diabetic neuropathies	C14 H14 O3 . C8 H17 N O2	"CACNA2D1 protein modulators, Cyclooxygenase inhibitors"	"Xgene Pharmaceutical (Originator), Xgene Pharmaceutical (Owner)"		Topical				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E (Propionic acid derivatives), N02B (Other Analgesics and Antipyretics)"	"XG00503, XG005topical"			19/03/2020	Pain				no		no							https://adis.springer.com/drugs/800057633?userId=52029392&bpIds=3004037004&checksum=50d8083d9f060546387e531c7d50519ff5336bfa-1617045531747-4f6840ca3a4e2d3a07fc5c45d213b67bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007024	Tizanidine - Novartis	51322-75-9	"2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-"	No		"= Baclofen, = Diazepam"	Marketed	"Muscle spasticity, Migraine, Fibromyalgia"	C9 H8 Cl N5 S	Alpha 2 adrenergic receptor agonists	"Novartis (Originator), Novartis (Owner), Daiichi Sankyo Company (Market Licensee), Takeda (Market Licensee), Zeneus Pharma (Market Licensee), Acorda Therapeutics (Licensee), Endo International (Sub-licensee)"		"PO, unspecified"			"Asthenia, Dizziness, Drowsiness, Hallucinations, Hepatitis, Xerostomia"	"M3B (Muscle Relaxants, Centrally Acting), M5X (All Other Musculoskeletal Products), N2C (Anti-Migraine Preparations)"	"M03B (Muscle Relaxants, Centrally Acting Agents), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02C (Antimigraine Preparations)"	"AN 021A, AN021, DS 103282 CH, DS103282, Sirdalud, Ternelin, Tizanidine hydrochloride, Zanaflex"			17/03/2020	"Advances in the Treatment of Nausea and Migraine, Musculoskeletal Disorders, Rheumatic Disease"	"Muscle spasticity (USA), Muscle spasticity (Japan)"		"Sirdalud, Sirdalud, Ternelin, Zanaflex, Zanaflex, Zanaflex, Zanaflex"	no		no							https://adis.springer.com/drugs/800007024?userId=52029392&bpIds=3004037004&checksum=c095479fcecb7b126961e767197220caec562c55-1617045531753-c2680058d5be0121cc9f5c0e06196bcebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057757	Research programme: therapeutics - Gmax Biopharm			Yes			Research	"Pain, Metabolic disorders, Osteoporosis"		Undefined mechanism	"Gmax Biopharm (Originator), Gmax Biopharm (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), M5X (All Other Musculoskeletal Products), N2 (Analgesics)"	"A16 (Other Alimentary Tract and Metabolism Products), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics)"				13/03/2020	"Metabolic Disorders, Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800057757?userId=52029392&bpIds=3004037004&checksum=335d12a7ed2ebdd441b711bab4b975cb9df291b6-1617045531755-7420ecb168bf04c651819091e415b2cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057697	Research programme: cannabinoid receptor modulators - MakScientific/Tetra Bio Pharma			Yes			Research	"Inflammation, Cancer, Pain"		"Cannabinoid receptor CB1 modulators, Cannabinoid receptor CB2 modulators"	"University of Connecticut (Originator), University of Connecticut (Owner), MakScientific (Licensee), Tetra Bio Pharma (Sub-licensee)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"cannabinoid receptor agonists MakScientific/Tetra Bio Pharma, cannabinoid receptor antagonists MakScientific/Tetra Bio Pharma"			12/03/2020	"Cancer, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800057697?userId=52029392&bpIds=3004037004&checksum=431bfa9c8d370aa679338469f782febb4808da0c-1617045531757-9eac149777e5c27b5757a4243e5fd987badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054728	IMB 110			No			Phase I	Back pain		Undefined mechanism	"Imbrium Therapeutics (Originator), Imbrium Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"IMB110, IMB9011010"			09/03/2020	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800054728?userId=52029392&bpIds=3004037004&checksum=ebe093d4adb3ffe79ce62096190d3c9b01abc30c-1617045531758-96e77cde8bdb312b14615610332360c3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057710	Topical cannabidiol - Futura Medical/CBDerma Technology			No			Preclinical	Pain		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"CBDerma Technology (Originator), Futura Medical (Originator), CBDerma Technology (Owner), Futura Medical (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	CBD100			05/03/2020	Pain				no		no							https://adis.springer.com/drugs/800057710?userId=52029392&bpIds=3004037004&checksum=cdc4b95014bf785b8aad1718dc22d4be0277b58a-1617045531759-27d12214c7565523d2d15dc840f3992cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009596	Research programme: zinc finger DNA binding protein transcription factors - Sangamo Therapeutics			No			Preclinical	"Neurological disorders, Neuropathic pain, Cancer, Age-related macular degeneration"		"Genetic transcription modulators, Nav1.8 voltage-gated sodium channel inhibitors, TrkA receptor antagonists"	"Sangamo BioSciences (Originator), Sangamo Therapeutics (Owner), Biogen (Licensee)"		"unspecified, Parenteral"				"A10X (Other Drugs Used in Diabetes), L1X9 (All other antineoplastics), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"A10X (Other Drugs Used in Diabetes), L01X-X (Other antineoplastic agents), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X-X (Other nervous system drugs), S01X (Other Ophthalmologicals)"	"AAVZFPVEGF, AdVZFPVEGF, AdZFPVEGF, ZFP TF ATV, ZFP TF therapeutics Sangamo"			05/03/2020	"Cancer, Eye Disorders, Neurological Disorders, Pain"		"Sangamo Therapeutics | Age-related macular degeneration, Alzheimer's disease, Cancer, Neuropathic pain, Parkinson's disease | Unspecified |  | 16 Dec 2010"		no		no							https://adis.springer.com/drugs/800009596?userId=52029392&bpIds=3004037004&checksum=ab76008fb297de6e04a57663758d3b5bebaf58c1-1617045531761-b529e165f8e42224d92193581aff8ee6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057659	CLX NEU 161A11			Yes			Preclinical	Postoperative pain		Undefined mechanism	"Cellix Bio (Originator), Cellix Bio (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CLXNEU161A11			04/03/2020	Pain				no		no							https://adis.springer.com/drugs/800057659?userId=52029392&bpIds=3004037004&checksum=c083a3c7c61b98aa3690cf49e9e22736e6f6b572-1617045531762-19ff1a389005dda0d35621f048537f3dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054973	Bupivacaine hydrochloride monohydrate implant - Foundry Therapeutics 1	73360-54-0	"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride"	No			Phase I/II	Postoperative pain	C18 H31 Cl N2 O2	Sodium channel antagonists	"Foundry Therapeutics 1 (Originator), Foundry Therapeutics 1 (Owner)"		Implant				"N1B9 (Anaesthetics local, others), N2 (Analgesics)"	"N01B-B01 (Bupivacaine), N02 (Analgesics)"	"Bupivacaine HCl releasing bioresorbable implant system Foundry Therapeutics 1, Bupivacaine implant Foundry Therapeutics 1, TKAine, TKAine depot, Tkaine system"			04/03/2020	Pain				no		no							https://adis.springer.com/drugs/800054973?userId=52029392&bpIds=3004037004&checksum=05491c3bc4b34685cadacd71dfb5fceba0ff5456-1617045531763-db3d7a9dc002b94cdc4a70e33754abaebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023746	Buprenorphine buccal - BioDelivery Sciences International	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"	No			Marketed	Pain	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"BioDelivery Sciences International (Originator), BioDelivery Sciences International (Owner), Purdue Biopharma (Market Licensee)"		Buccal				N2A (Narcotics)	N02A-E01 (Buprenorphine)	"BELBUCA, BEMA Buprenorphine, BEMA LA, BEMA Long Acting, Buprenorphine long acting, Buprenorphine transmucosal, EN 3409"			03/03/2020	Pain		BioDelivery Sciences International |  | Unspecified |  (Excluding USA) | 08 Dec 2016	"BELBUCA, BELBUCA, BEMA Buprenorphine"	no		no							https://adis.springer.com/drugs/800023746?userId=52029392&bpIds=3004037004&checksum=c56466af61cd007142231538f4b4fd459bae586d-1617045531764-c198bfed0801ac075a4e6555bbfcf173badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033881	Oxycodegol - Nektar Therapeutics	1211231-76-3	"4,5alpha-Epoxy-6alpha-((2,5,8,11,14,17-hexaoxanonadecan-19-yl)oxy)-3-methoxy-17-methylmorphinan-14-ol"	Yes			Discontinued (Preregistration)	"Back pain, Pain, Musculoskeletal pain"	C31 H49 N O10	Opioid mu receptor agonists	"Nektar Therapeutics (Originator), Nektar Therapeutics (Owner)"		PO		T<sub>_beta</sub> (h) (12 (Adult))	"Constipation, Dizziness, Nausea, Somnolence"	N2 (Analgesics)	N02A (Opioids)	"Loxicodegol Nektar Therapeutics, NKTR181, NKTR181phosphate, Oxycodegol phosphate, Oxycodegol phosphate Nektar Therapeutics"			03/03/2020	Pain				yes	USA	no							https://adis.springer.com/drugs/800033881?userId=52029392&bpIds=3004037004&checksum=4811869ba92b3d32da2748e31289082961c899a6-1617045531765-42bb06c155bb75d3f59a3094cd43ab44badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057581	SAN 711			Yes			Preclinical	"Pruritus, Neuropathic pain"		GABA A alpha 3 receptor modulators	"Saniona (Originator), Saniona (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	SAN711			03/03/2020	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800057581?userId=52029392&bpIds=3004037004&checksum=d79b68c2f2fffedff2bff1a9ebf50ad3335a0bf0-1617045531766-daf1e5d76dbb85dbb71907d060f54cf2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017260	Research programme: ion channel and GABA A modulators - Saniona			Yes			Discontinued (Preclinical)	"Neuropathic pain, Schizophrenia, Inflammatory bowel diseases, Dyskinesias, CNS disorders, Alzheimer's disease"		"GABA A alpha 2 receptor modulators, GABA A alpha 3 receptor modulators, GABA modulators, Alpha4beta2 nicotinic receptor modulators, Alpha7 nicotinic acetylcholine receptor agonists, Ion channel modulators, Intermediate conductance calcium activated potassium channel modulators, Small conductance calcium activated potassium channel modulators, GABA A receptor modulators"	"GlaxoSmithKline (Originator), NeuroSearch (Originator), Saniona (Owner)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), A8 (Antiobesity Preparations, Excluding Dietetics), D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), G4D4 (Urinary incontinence products), L4X (Other Immunosuppressants), N2 (Analgesics), N3 (Anti-Epileptics), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants), N7 (Other CNS Drugs), N7E (Drugs Used In Alcohol Dependence), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs)"	"A07E (Intestinal Antiinflammatory Agents), A08 (Antiobesity Preparations, Excl. Diet Products), D04 (Antipruritics, Incl. Antihistamines, Anesthetics, etc.), G04 (Urologicals), L04A (Immunosuppressants), N02 (Analgesics), N03 (Antiepileptics), N05A (Antipsychotics), N05B (Anxiolytics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics), N06D (Anti-Dementia Drugs), N07 (Other Nervous System Drugs), N07B (Drugs Used In Addictive Disorders), N07X (Other Nervous System Drugs)"	"AN 346, AN 363, AN 470, AN 761, AN726, NS9283, NSD708, NSD761, NSD847, NSD867"			03/03/2020	"Alzheimer's Disease and Cognition Disorders, Inflammatory Bowel Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800017260?userId=52029392&bpIds=3004037004&checksum=35679c516659514377c44bf1f81b66463558074f-1617045531768-aa3d849d1abc8accabfeb264593e625bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044276	Nefopam topical cream - ScarX Therapeutics	13669-70-0		No			No development reported (I)	Hypertrophic scars		Beta catenin inhibitors	"ScarX Therapeutics (Originator), ScarX Therapeutics (Owner)"		Topical				D3A (Wound Healing Agents)	N02B-G06 (Nefopam)	SCX001			28/02/2020	Skin Disorders				no		no							https://adis.springer.com/drugs/800044276?userId=52029392&bpIds=3004037004&checksum=65109d5dffa7ea0506c5ad88ec41d113be5a9f03-1617045531769-2a9c657eb8cdd5fef50cec903e737b3dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044447	Research programme: FAAH inhibitors - Advinus Therapeutics			Yes			No development reported (Preclinical)	Neuropathic pain		Fatty acid amide hydrolase inhibitors	"Advinus Therapeutics (Originator), Advinus Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Fatty acid amide hydrolase inhibitors Advinus			28/02/2020	Pain		Advinus Therapeutics | Neuropathic pain | Preclinical |  | 21 Jan 2016		no		no							https://adis.springer.com/drugs/800044447?userId=52029392&bpIds=3004037004&checksum=2004dff805e75c666e38bebf38a4cb6b759c216d-1617045531769-423ad63256a2fed78e8e615e2dddea0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049441	Research programme: pain therapeutics - PhytoPain Pharma			No			No development reported (Research)	Neuropathic pain		Cannabinoid receptor agonists	"PhytoPain Pharma (Originator), PhytoPain Pharma (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"PhytoPain Topical Gel Relief, PPTGR"			28/02/2020	Pain				no		no							https://adis.springer.com/drugs/800049441?userId=52029392&bpIds=3004037004&checksum=464af5b8cd6eacfbf84cff776ccb91dd94892b5d-1617045531770-11c1cffe0b6c8e874afba70c1b668a5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034937	Research programme: pain and arthritis therapies - Sagene Pharmaceuticals			No			No development reported (Preclinical)	"Arthritis, Pain"		"Cyclooxygenase inhibitors, Monoamine oxidase B inhibitors"	"Sagene Pharmaceuticals (Originator), Sagene Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				28/02/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800034937?userId=52029392&bpIds=3004037004&checksum=6eb8c3601f663a1756dbc7d0331c30da2d1b2f0e-1617045531771-3a13653204a26224ca8d3616c1a96e3ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044407	Research programme: combination therapies - TRINITY Laboratories			No			No development reported (Preclinical)	"Fibromyalgia, Neuropathic pain, Dysmenorrhoea"		"NMDA receptor antagonists, Opioid mu receptor agonists, Serotonin uptake inhibitors, Sigma-1 receptor agonists"	"Trinity Laboratories (Originator), Trinity Laboratories (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Dextromethorphan/gabapentin/tramadol, Dextromethorphan/sildenafil/tramadol, TLI 0651, TLI 1026"			28/02/2020	Pain				no		no							https://adis.springer.com/drugs/800044407?userId=52029392&bpIds=3004037004&checksum=6b2fbc6cce9b22fb82034a4ff924249aaad5c7bc-1617045531772-5f8eda8843342ba051841eefcb93e21bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044375	Research programme: intranasal therapeutic agents - Cognition Life Science			No			No development reported (Research)	"Alzheimer's disease, Sleep disorders, Parkinson's disease, Pain"		"Cannabinoid receptor agonists, Immunomodulators"	"University of South Florida (Originator), University of South Florida (Owner), Cognition Life Science (Licensee)"		Intranasal				"N2 (Analgesics), N4A (Anti-Parkinson Drugs), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D-X (Other anti-dementia drugs), N07X-X (Other nervous system drugs)"				28/02/2020	"Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800044375?userId=52029392&bpIds=3004037004&checksum=21fdf0b60217a7d49ec5c090eba623d5495cb265-1617045531773-43fcbefaea82d33b2dda3e5148039706badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025732	Research programme: stem cell-based therapeutics - Pluristem Therapeutics			No			Preclinical	"Cancer, Preeclampsia, Neuropathic pain, Diastolic heart failure, Musculoskeletal disorders, Pulmonary fibrosis, Stroke, Parkinson's disease, Haematological malignancies, Inflammatory bowel diseases, Multiple sclerosis, Myocardial infarction, Pain, Pulmonary arterial hypertension, Diabetic foot"		"Cell replacements, Dopaminergic cell replacements"	"Pluristem Life Systems (Originator), Pluristem Therapeutics (Owner), United Therapeutics Corporation (Licensee), Israel Innovation Authority (Funder), Berlin-Brandenburg Center for Regenerative Therapies (Collaborator), Case Western Reserve University (Collaborator), Charite - Universitatsmedizin Berlin (Collaborator), Hadassah Medical School (Collaborator), Hebrew University of Jerusalem (Collaborator), National Institute of Allergy and Infectious Diseases (Collaborator), New York University School of Medicine (Collaborator), Texas A&M University (Collaborator)"		"IM, Parenteral, IV"				"A10X (Other Drugs Used in Diabetes), B6 (All Other Haematological Agents), C1 (Cardiac Therapy), C2 (Antihypertensives), C6A (Other Cardiovascular Products), L1 (Antineoplastics), L4X (Other Immunosuppressants), M (Musculo-Skeletal System), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs), V3 (All Other Therapeutic Products)"	"A10X (Other Drugs Used in Diabetes), B06A (Other Hematological Agents), C01 (Cardiac Therapy), C01E (Other Cardiac Preparations), C02 (Antihypertensives), C02K (Other Antihypertensives), L01 (Antineoplastic Agents), L04A (Immunosuppressants), M (Musculo-Skeletal System), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs), V03 (All Other Therapeutic Products)"	"Placenta expanded mesenchymal cells, Placentalderived mesenchymal stem cells, PLXBMP, PLXBMT, PLXI, PLXIBD, PLXImmune, PLXMS, PLXORTHO, PLXPAH, PLXSTROKE"			28/02/2020	"Cancer, Diabetes, Drug Delivery Systems, Heart Failure, Inflammatory Bowel Disorders, Ischaemic Heart Disease, Musculoskeletal Disorders, Neurological Disorders, Pain, Respiratory Tract Disorders, Vascular Disorders, Women's Health"		Pluristem Therapeutics |  | Unspecified | Japan | 16 Sep 2014		no		no							https://adis.springer.com/drugs/800025732?userId=52029392&bpIds=3004037004&checksum=7651c3ca1051e66ec13da2188f5024f907a6cba7-1617045531776-bceeb433876704450ae6b6bb0c40f339badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054423	Research programme:anti-hyperalgesic therapeutics - Akelos			Yes			Preclinical	Neuropathic pain		Hyperpolarisation activated cation channel antagonists	"Weill Cornell Medicine (Originator), Weill Cornell Medicine (Owner), Akelos (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Nonopioid antihyperalgesic drugs Akelos/Weill Cornell Medicine, Pain therapeutics Akelos/Weill Cornell Medicine"			25/02/2020	Pain				no		no							https://adis.springer.com/drugs/800054423?userId=52029392&bpIds=3004037004&checksum=e61b2f96422d18d4e46da53b61c8aa8fd3c83556-1617045531777-96f6e49b826da174567f165425682b6abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033333	Research programme: analgesic monoclonal antibody - Lundbeck Seattle BioPharmaceuticals Inc			No			Discontinued (Preclinical)	Pain		Undefined mechanism	"Alder Biopharmaceuticals (Originator), Lundbeck Seattle BioPharmaceuticals Inc. (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	ALD901			24/02/2020	Pain				no		no							https://adis.springer.com/drugs/800033333?userId=52029392&bpIds=3004037004&checksum=f4ca8d9c6bff53e46a3a6cfe1524c2379f523f80-1617045531778-0f273487647e4bd2a43fe306ae476deebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057475	Insulin-like growth factor-1 - Seurat Therapeutics	123618-03-1	(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-oxopentanoic acid	No			Research	Migraine	C71 H119 N17 O19 S	Insulin-like growth factor 1 replacements	"University of Chicago (Originator), University of Chicago (Owner), Seurat Therapeutics (Licensee), National Institute of Neurological Disorders and Stroke (Funder)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	Insulinlike Growth Factor1 nasal spray			21/02/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800057475?userId=52029392&bpIds=3004037004&checksum=dec9aafd32841659bc2377e1182c3ad853a638c4-1617045531780-005bc5139d9ab53b761e71dc58ed5236badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057396	Cannabidiol/tetrahydrocannabinol - Knop Laboratories		"2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol/(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol"	No			Clinical Phase Unknown	Fibromyalgia	C21 H30 O2/C21 H30 O2	Cannabinoid receptor agonists	"Knop Laboratories (Originator), Knop Laboratories (Owner)"		PO				N2 (Analgesics)	"N02 (Analgesics), N03A-X24 (Cannabidiol)"	KL 16012			21/02/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800057396?userId=52029392&bpIds=3004037004&checksum=809dbe1445bfd5e9c8befa65d24e863025f84ab6-1617045531781-adc1511280d824f9e47863661a8411c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025703	Tapentadol controlled-release - Grunenthal/Janssen Research & Development/Ortho-McNeil	175591-23-8	"(-)-((1<EM>R</EM>,2<EM>R</EM>)-3-(3-Dimethylamino)-1-ethyl-2-methyl-propyl))phenol"	No			Marketed	"Pain, Diabetic neuropathies, Cancer pain, Neuropathic pain"	C14 H23 N O	"Adrenergic uptake inhibitors, Opioid mu receptor agonists, Alpha 2 adrenergic receptor antagonists"	"Grunenthal (Originator), Grunenthal (Owner), Janssen Pharmaceutical KK (Development Licensee), Collegium Pharmaceutical (Licensee), Janssen Research & Development (Licensee), Ortho-McNeil (Licensee)"		PO			"Constipation, Dizziness, Fatigue, Headache, Nausea, Pruritus, Somnolence, Vomiting"	"A10X (Other Drugs Used in Diabetes), N2A (Narcotics), N7 (Other CNS Drugs)"	"A10X (Other Drugs Used in Diabetes), N02A-X06 (Tapentadol), N07 (Other Nervous System Drugs)"	"BN200 ER, BN200 PR, CG 5503 ER, CG 5503 PR, JNS024ER, Nucynta ER, Palexia Depot, Palexia Retard, Palexia RP, Palexia SR, Palexia XR, R331333 PR, Tapenta, Tapentadol CR tamperresistant formulation, Tapentadol CR TRF, Tapentadol ER PR2, Tapentadol ER prolongedrelease 2, Tapentadol ER tamperresistant formulation, Tapentadol ER TRF, Tapentadol extended release, Tapentadol PR, Tapentadol prolonged release, Tapentadol prolonged release granules, Yantil Retard"			18/02/2020	"Diabetes, Pain"			"Nucynta ER, Nucynta ER, Nucynta ER, Palexia Depot, Palexia Retard, Palexia SR, Tapenta, Yantil Retard"	no		no							https://adis.springer.com/drugs/800025703?userId=52029392&bpIds=3004037004&checksum=09cdbd3dd19cd1b0c00e433da4ab25df0b56cc0a-1617045531796-c269de5c76b41f06cd824b73684ba2b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057520	CB 003 - Zhimeng Biopharma			Yes			Preclinical	"Pain, Epilepsy"		"KCNQ2 potassium channel stimulants, KCNQ3 potassium channel stimulants"	"Zhimeng Biopharma (Originator), Zhimeng Biopharma (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	CB003 Zhimeng Biopharma			18/02/2020	"Epilepsy and Seizure Disorders, Pain"		Zhimeng Biopharma |  | Unspecified |  | 17 Feb 2020		no		no							https://adis.springer.com/drugs/800057520?userId=52029392&bpIds=3004037004&checksum=9d0a7d504e1122224bd6c9f52abd7b5a2a338f3d-1617045531797-ef132aa443cb2e2ed2bab147e0e467c8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054031	Research programme: biological therapeutics - Dianomi Therapeutics			Yes			Research	"Pain, Osteoarthritis"		Interleukin 1 receptor antagonists	"Dianomi Therapeutics (Originator), Dianomi Therapeutics (Owner), Wisconsin Alumni Research Foundation (Technology Provider), Ligand Pharmaceuticals (Collaborator)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				17/02/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800054031?userId=52029392&bpIds=3004037004&checksum=0442e72d4c4b650e16fc6a80f7abcaa459394f70-1617045531798-5c4b1a40ce9f7c769dc8326c7ecc4192badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029237	Research programme: estrogen receptor ligands - ENDECE			Yes			Discontinued (Preclinical)	"Inflammation, Pain, Cancer"		"Estrogen receptor modulators, Apoptosis stimulants, Estrogen receptor beta agonists"	"ENDECE (Originator), ENDECE (Owner), Myelin Repair Foundation (Collaborator)"		"unspecified, IV"				"L2A1 (Cytostatic oestrogens), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"L02A-A (Estrogens), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06D-X (Other anti-dementia drugs), N07X (Other Nervous System Drugs)"	"NDC 1022, NDC 1352, NDC 1407"			17/02/2020	"Cancer, Inflammation, Pain"		ENDECE | Multiple sclerosis | Unspecified |  | 10 Dec 2012		no		no							https://adis.springer.com/drugs/800029237?userId=52029392&bpIds=3004037004&checksum=13f549be013c518838e3bd97d9fc003264b530c4-1617045531800-67334a0944b90737572779b2bc38eb06badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056441	VX 961			Yes			Discontinued (I)	Pain		Nav1.8 voltage-gated sodium channel inhibitors	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	VX961			12/02/2020	Pain				yes	USA	no							https://adis.springer.com/drugs/800056441?userId=52029392&bpIds=3004037004&checksum=2ca89019ecaa25617b4508a637c551f6d03af2ee-1617045531801-ec1066425156a18721a92de017eff0f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031656	TC 6987			Yes			Discontinued (II)	"Type 2 diabetes mellitus, Asthma"		Alpha7 nicotinic acetylcholine receptor modulators	"Targacept (Originator), CODA Biotherapeutics (Owner)"		PO				"A10 (Drugs Used in Diabetes), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"A10 (Drugs Used in Diabetes), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	TC6987			11/02/2020	"Diabetes, Obstructive Airways Disease"				no		no							https://adis.springer.com/drugs/800031656?userId=52029392&bpIds=3004037004&checksum=54106830b4dac23ca772fcfb0a1dfa8e76ab97cc-1617045531802-039f8b699c244b362bff905807485f56badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044076	Meloxicam - Sedor Pharmaceuticals	71125-38-7	"2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl- 2-thiazolyl)-, 1,1-dioxide"	No			Preclinical	"Postoperative pain, Cancer pain"	C14 H13 N3 O4 S2	Cyclo-oxygenase 2 inhibitors	"Ligand Pharmaceuticals (Originator), Ligand Pharmaceuticals (Owner), Los Altos Pharmaceuticals (Licensee), Sedor Pharmaceuticals (Licensee)"		"IV, IM"				"G2E (Labour Inhibitors), M1A (Anti-Rheumatics, Non-Steroidal), M1C (Specific Anti-Rheumatic Agents), N2 (Analgesics)"	"G02C-A (Sympathomimetics, labour repressants), M01A-C06 (Meloxicam), N02 (Analgesics)"	CE Meloxicam			05/02/2020	Pain				no		no							https://adis.springer.com/drugs/800044076?userId=52029392&bpIds=3004037004&checksum=54629ab54881c988f21d0d714573c0fe0a675b8b-1617045531804-f332c4e28e622e6fad3a98aab53e86dfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052203	Ketorolac sublingual - Orexo	74103-06-3	"1H-Pyrrolizine-1-carboxylic acid, 2,3-dihydro-5-benzoyl-, (+-)-"	No			Phase I	Pain	C15 H13 N O3	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Orexo (Originator), Orexo (Owner)"		Sublingual				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	OX338			03/02/2020	Pain				no		no							https://adis.springer.com/drugs/800052203?userId=52029392&bpIds=3004037004&checksum=d0b16141d792c83a35f8b49fbc934cc7e6a48fa5-1617045531805-74fd661bd5c40a7b3696031bc9abc5fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057296	DW 6008			No			Phase I	Inflammatory pain		Undefined mechanism	"Dong Wha Pharmaceutical (Originator), Dong Wha Pharmaceutical (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	DW6008			03/02/2020	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800057296?userId=52029392&bpIds=3004037004&checksum=18320190f0ea5f351d2f7c5f0882c5522bb8f85e-1617045531807-b7a2f00bdc4e7e202975754f1711bd41badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045415	Tapentadol intranasal - Torrent Pharmaceuticals	175591-23-8	"Phenol, 3-((1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-"	No			Phase III	Postoperative pain	C14 H23 N O	"Adrenergic uptake inhibitors, Alpha 2 adrenergic receptor antagonists, Opioid mu receptor agonists"	"Torrent Pharmaceuticals (Originator), Torrent Pharmaceuticals (Owner)"		Intranasal				N2A (Narcotics)	N02A-X06 (Tapentadol)				31/01/2020	Pain				no		no							https://adis.springer.com/drugs/800045415?userId=52029392&bpIds=3004037004&checksum=9dd47ae0900846b3ca9876bec9c0b8ce8fa2844a-1617045531808-2bebe3989324ebce2d347a06ef13d659badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044160	Celecoxib/Tramadol - YooYoung Pharmaceuticals		"4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide/(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			No development reported (Preclinical)	Pain	C17 H14 F3 N3 O2 S . C16 H25 N O2	"Adrenergic uptake inhibitors, Cyclo-oxygenase 2 inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Yooyoung Pharmaceutical (Originator), Yooyoung Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N2A (Narcotics)"	"M01A-H01 (Celecoxib), N02A-X52 (Tramadol, combinations), N02B (Other Analgesics and Antipyretics)"	YYC301			28/01/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800044160?userId=52029392&bpIds=3004037004&checksum=d874cd505dd5c27b8cfef6f9699fc2b3e2b7eeda-1617045531809-62a9e5b16df0f442c8693483edfe4bbdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041491	Buprenorphine depot - BioDelivery Sciences International/Evonik	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(S)]-"	No			No development reported (Preclinical)	"Pain, Opioid-related disorders"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Evonik (Originator), Evonik (Owner), BioDelivery Sciences International (Licensee)"		SC				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	N02A-E01 (Buprenorphine)	"Buprenorphine long acting BioDelivery Sciences International/Evonik, Buprenorphine microparticle depot BioDelivery Sciences International/Evonik, Sustained release buprenorphine injection BioDelivery Sciences International"			28/01/2020	"Drug Delivery Systems, Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800041491?userId=52029392&bpIds=3004037004&checksum=17a9b105f103c5bbc03e1b26c358278b930e0bd2-1617045531810-6c8b877bcab16e8bb3003a8f8932f85dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044119	VX 241			Yes			No development reported (Preclinical)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	VX241			28/01/2020	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800044119?userId=52029392&bpIds=3004037004&checksum=b3f85b0ea0616653fb17d9e50c2217ff8add9641-1617045531811-aa6ef7298118f8df62fdfc4af73e4980badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039611	Research programme: controlled-release therapeutics - Camurus/undiclosed companies			Yes			No development reported (Preclinical)	"Cancer, Endocrine disorders, Pain, Metabolic disorders, Viral infections"		Undefined mechanism	"Camurus (Originator), Unknown (Originator), Camurus (Owner), Unknown (Owner)"		unspecified				"A (Alimentary Tract and Metabolism), J (General Anti-Infectives Systemic), L1 (Antineoplastics), N2 (Analgesics), V (Various)"	"A (Alimentary Tract and Metabolism), J (Anti-infectives For Systemic Use), L01 (Antineoplastic Agents), N02 (Analgesics), V (Various)"				28/01/2020	"Cancer, Endocrine Disorders, Metabolic Disorders, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800039611?userId=52029392&bpIds=3004037004&checksum=a3c635ca164a6b62431618874d3f4195cac56665-1617045531813-bdaaec05865db082244beb9bf458adf1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043302	Research programme: controlled-release therapeutics - Camurus			Yes			No development reported (Preclinical)	"Pain, Inflammation, Postoperative pain, Diabetes mellitus"		Undefined mechanism	"Camurus (Originator), Camurus (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"CAM 2041, CAM 2046"			28/01/2020	"Diabetes, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800043302?userId=52029392&bpIds=3004037004&checksum=4f0bcc34250654c140f0ca2fa2baf60449d329a3-1617045531815-d425d300ecffca6f607233f1b710905dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035203	Research programme: T-type calcium channel modulators - Jazz Pharmaceuticals plc			Yes			No development reported (Preclinical)	Cancer		T type calcium channel antagonists	"Tau Therapeutics (Originator), Cavion (Owner), University of Virginia (Collaborator)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	TTL1177			28/01/2020	Cancer				no		no							https://adis.springer.com/drugs/800035203?userId=52029392&bpIds=3004037004&checksum=cd4ea83362d0733d05f9386b57ba16dffc6b1e6b-1617045531816-b5019050d57998905c43e33e57045811badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048520	Bupivacaine - Liquidia Technologies	38396-39-3	"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide"	No			Phase I	Postoperative pain	C18 H28 N2 O	Sodium channel antagonists	"Liquidia Technologies (Originator), Liquidia Technologies (Owner)"		SC				N2 (Analgesics)	N02 (Analgesics)	"LIQ865, LIQ865A, LIQ865A bupivacaine formulation, LIQ865B, LIQ865B bupivacaine formulation"			28/01/2020	Pain				no		no							https://adis.springer.com/drugs/800048520?userId=52029392&bpIds=3004037004&checksum=1ebfab425861be33677850f1a25734ee4c6717c7-1617045531817-41f9a032f6a783c0ac20c6ce837a939abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027507	Research programme: sigma receptor modulators - Anavex Life Sciences			Yes			No development reported (Preclinical)	"Malignant melanoma, Acute pain, Ovarian cancer, Pancreatic cancer, Prostate cancer, Solid tumours, Neuropathic pain, Pain"		"Chloride channel modulators, Muscarinic M3 receptor antagonists, Sigma-1 receptor agonists, Sigma-2 receptor agonists, Sodium channel modulators, Sigma-1 receptor antagonists, Sigma-2 receptor antagonists"	"Anavex Life Sciences (Originator), Anavex Life Sciences (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	"ANAVEX 1005, ANAVEX 1007, ANAVEX 1066, ANAVEX 1067, ANAVEX 1079, ANAVEX 1519, ANAVEX 271041, ANAVEX 281078, ANAVEX 301022, ANAVEX 353016, ANAVEX 401042, ANAVEX 71037, ANAVEX 8142, Cancer therapeutics Anavex Life Sciences, SigmaceptorC programme"			28/01/2020	"Cancer, Men's Health, Pain"		Anavex Life Sciences |  | Preclinical |  | 13 Jul 2011		no		no							https://adis.springer.com/drugs/800027507?userId=52029392&bpIds=3004037004&checksum=5000cf4a80af7965a94060aa88eed9aec65c3cff-1617045531819-9550ced3e7df5232114b0f109b4e95c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004160	KRN 5500	151276-95-8	"6-[4-Deoxy-4-(2<EM>E</EM>,4<EM>E</EM>)-tetradecadienoylglycyl]amino-<EM>L</EM>-glycero-(_-<EM>L</EM>-mannoheptopyranosyl)amino-9<EM>H</EM>-purine"	Yes			Phase II	"Neuropathic pain, Multiple myeloma, Cancer"	C28 H43 N7 O7	Protein synthesis inhibitors	"Kirin Brewery (Originator), Massachusetts General Hospital (Originator), Kyowa Kirin (Owner), Fortovia Therapeutics (Licensee), National Cancer Institute (USA) (Collaborator)"		"IV, unspecified"		T<sub>_beta</sub> (h) (1.3 (Adult))	"Diarrhoea, Nausea, Vomiting"	"L1X9 (All other antineoplastics), N2B (Non-Narcotics and Anti-Pyretics)"	"L01X-X (Other antineoplastic agents), N02B (Other Analgesics and Antipyretics)"	"KRN5500, NSC650426, SPK241"			28/01/2020	"Cancer, Pain"	"Neuropathic pain (USA), Multiple myeloma (USA)"	Fortovia Therapeutics |  | Phase II |  | 02 Nov 2015		yes	USA	no							https://adis.springer.com/drugs/800004160?userId=52029392&bpIds=3004037004&checksum=c704b094dbc8e8275673ebcd3220c096884ebae8-1617045531820-8787dce6c136f52a23abe7e38e240a6dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019401	Research programme: ion channel modulators - Merck & Co			No			No development reported (Preclinical)	Neuropathic pain		Calcium channel antagonists	"ArQule (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Ion channel modulators research programme ArQule			20/01/2020	Pain				no		no							https://adis.springer.com/drugs/800019401?userId=52029392&bpIds=3004037004&checksum=9784c17f6e7fae6fed61d76ae65330e5a1c89d2e-1617045531821-b88d759a5d53aec2e6a7ec4b6391aa6fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057078	BIO 205			Yes			Preclinical	Pain		Adenosine A3 receptor agonists	"National Institutes of Health (USA) (Originator), Saint Louis University (Originator), National Institutes of Health (USA) (Owner), Saint Louis University (Owner), BioIntervene (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	BIO205			20/01/2020	Pain				no		no							https://adis.springer.com/drugs/800057078?userId=52029392&bpIds=3004037004&checksum=bc6fd6ae947896ba04b9d1f9481e01f5078958f1-1617045531822-024b54931c120a96b3b5c349bce1a5e5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005786	IS 159	133790-13-3	2-[3-(2-Aminoethyl)-1<EM>H</EM>-indol-5-yloxy]acetyl-<EM>L</EM>-tyrosyl-glycinamide	No			Discontinued (II)	Migraine	C23 H27 N5 O5	Serotonin 1D receptor agonists	"Immunotech (Originator), Immunotech (Owner), The Medicines Company (Market Licensee)"		Intranasal		T<sub>_beta</sub> (h) (2.5 (Adult))		N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				17/01/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800005786?userId=52029392&bpIds=3004037004&checksum=040de7190a7b9b7518a8edc27ac336015347a97a-1617045531823-9e2eb26473fbe16387ac828348eda4afbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015918	Fentanyl iontophoretic - ALZA Corporation	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Registered	Postoperative pain	C22 H28 N2 O	Opioid mu receptor agonists	"ALZA Corporation (Originator), ALZA Corporation (Owner), Janssen-Cilag (Market Licensee), Ortho-McNeil (Market Licensee), The Medicines Company (Licensee)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"ETRANS fentanyl, Fentanyl HCI, Fentanyl iontophoretic transdermal system, Fentanyl transdermal ALZA Corporation, IONSYS, SyB P 1501"			17/01/2020	"Drug Delivery Systems, Pain"			"IONSYS, IONSYS"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800015918?userId=52029392&bpIds=3004037004&checksum=b5918b17e983031436282ca76d95e87b741ace26-1617045531826-10e72378cdb12d82ca5e58f7a9a4506cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800057133	PH 81			Yes			Preclinical	Migraine		Undefined mechanism	"Pherin Pharmaceuticals (Originator), Pherin Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	PH81			16/01/2020	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800057133?userId=52029392&bpIds=3004037004&checksum=c663c3886786d162ec6114383f0cd6f32f7594ef-1617045531827-55f9eecafa3cebb49a2c217e7a01b42fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014979	Ralfinamide - Newron Pharmaceuticals	133865-88-0	(<EM>S</EM>)-(+)-2-[4-(2-Fluorobenzyloxy)benzylamino]propanamide	Yes			Phase III	"Neuropathic pain, Dental pain, Inflammatory pain"	C17 H19 F N2 O2	"N type calcium channel antagonists, Nav1.7 voltage-gated sodium channel inhibitors, NMDA receptor antagonists, Sodium channel antagonists"	"Newron Pharmaceuticals (Originator), Purdue Biopharma (Originator), Newron Pharmaceuticals (Owner), Purdue Biopharma (Owner)"		PO			"Abdominal pain, Dizziness, Dyspepsia, Headache, Nausea, Vertigo, Vomiting, Xerostomia"	"N2B (Non-Narcotics and Anti-Pyretics), N5 (Psycholeptics)"	"N02B (Other Analgesics and Antipyretics), N05 (Psycholeptics)"	"NW1029, Priralfinamide"			07/01/2020	Pain		"Newron Pharmaceuticals | Pain, Psychiatric disorders | Unspecified | World | 10 Sep 2010"		no		no							https://adis.springer.com/drugs/800014979?userId=52029392&bpIds=3004037004&checksum=ef010e05586120821ed39d006b288d23c8fcd210-1617045531829-66f744ac6e55b71e114bd945ae37e035badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016242	Tetrodotoxin - WEX Pharmaceuticals	4368-28-9	"5,9:7,10a-Dimethano-10aH-(1,3)dioxocino(6,5-d)pyrimidine-4,7,10,11,12-pentol, octahydro-12-(hydroxymethyl)-2-imino-"	Yes			Phase III	"Cancer pain, Neuropathic pain, Pain, Opioid-related disorders, Anaesthesia"	C11 H17 N3 O8	Sodium channel antagonists	"Beijing Medical University (Originator), WEX Pharmaceuticals (Originator), Beijing Medical University (Owner), WEX Pharmaceuticals (Owner), Nanning Maple Leaf Pharmaceutical (Market Licensee)"		"SC, Parenteral, IM"				"N1 (Anaesthetics), N2B (Non-Narcotics and Anti-Pyretics), N7F (Drugs Used In Opioid Dependence)"	"N01 (Anesthetics), N02B (Other Analgesics and Antipyretics), N07B-C (Drugs used in opioid dependence)"	"9401TTX, Halneuron, Tectin, Tetrodin, Tocudin"			06/01/2020	"Drug Withdrawal, Pain"			"Halneuron, Tectin, Tetrodin, Tocudin"	no		no							https://adis.springer.com/drugs/800016242?userId=52029392&bpIds=3004037004&checksum=481ba9c72d57a57d4073826bdcb01eaae6efd0b6-1617045531832-a9eb1bff69326b1da62be90668d6afeabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056294	Fentanyl transdermal patch - Clexio Biosciences			No			Discontinued (I)	Pain		Opioid mu receptor agonists	"Clexio Biosciences (Originator), Clexio Biosciences (Owner)"		Transdermal				N2 (Analgesics)	N02A-B03 (Fentanyl)	CLE200			03/01/2020	Pain				no		no							https://adis.springer.com/drugs/800056294?userId=52029392&bpIds=3004037004&checksum=112b02fdf7dce2895c765e4e19bf04ba7450b169-1617045531833-bc47fc29d77d8cc037b32c1810c71f37badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056296	CLE 300			Yes			Discontinued (Preclinical)	Diabetic neuropathies		Undefined mechanism	"Clexio Biosciences (Originator), Clexio Biosciences (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	CLE300			03/01/2020	Pain				no		no							https://adis.springer.com/drugs/800056296?userId=52029392&bpIds=3004037004&checksum=b5334406b59039574db323c8b9259de4134970ab-1617045531834-e0628cf9990967bd2afa2ead4b896a4abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056988	CX 6526			Yes			Phase I	Neuropathic pain		T-type calcium channel modulators	"Cavion (Originator), Jazz Pharmaceuticals plc (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CX6526			03/01/2020	Pain				no		no							https://adis.springer.com/drugs/800056988?userId=52029392&bpIds=3004037004&checksum=6387adbe099993492867a3528c56d17b29f23287-1617045531835-68644fe8e95f411126c8494639264356badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011315	Research programme: mirror-image oligonucleotides - NOXXON			Yes			Discontinued (Preclinical)	"Pain, Heart failure, Pneumonia, Diabetes mellitus, Cancer, Inflammation"		"Vasopressin receptor antagonists, Complement C5 inhibitors, HMGA1b protein inhibitors, Complement C5a inhibitors"	"NOXXON Pharma AG (Originator), NOXXON Pharma AG (Owner)"		"Parenteral, IV"				"A10X (Other Drugs Used in Diabetes), B3 (Anti-Anaemic Preparations), C3A7 (Vasopressin receptor antagonist diuretics), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), B03 (Antianemic Preparations), C03X-A (Vasopressin antagonists), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"NOXA50, NOXD14, NOXD19, NOXD20, NOXD21, NOXF37, NOXG15, NOXG16"			03/01/2020	"Cancer, Diabetes, Heart Failure, Inflammation, Pain"		NOXXON Pharma AG |  | Unspecified |  | 05 Nov 2014		no		no							https://adis.springer.com/drugs/800011315?userId=52029392&bpIds=3004037004&checksum=0d4e83442abd6baee6d3a71d86058b39263deaf6-1617045531837-b017e3538d16a6d4e2251d848030a244badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035511	Oxycodone/paracetamol controlled release - Mallinckrodt		"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / N-(4-Hydroxyphenyl)-acetanilide"	No			Marketed	Acute pain	C18 H21 N O4 . C8 H9 N O2	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Prostaglandin receptor antagonists"	"Mallinckrodt Inc. (Originator), Mallinckrodt Inc. (Owner), Assertio Therapeutics (Technology Provider)"		PO			"Constipation, Dizziness, Headache, Nausea, Pruritus, Somnolence, Vomiting"	"N2A (Narcotics), N2B1 (Prescription-bound non-narcotics and anti-pyretics)"	"N02A-A55 (Oxycodone, combinations), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Acetaminophen/oxycodone hydrochloride, COV795, MNK795, Oxycodone hydrochloride/acetaminophen, Xartemis XR"			28/12/2019	Pain			Xartemis XR	no		no							https://adis.springer.com/drugs/800035511?userId=52029392&bpIds=3004037004&checksum=c152843ae2185f3df5071d4c4e088e92d2becafa-1617045531839-5f80114482d55bbe8a2335676b0fd248badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048368	Fentanyl orally-dissolving film - NAL Pharma	437-38-7	N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide 	No			No development reported (Clinical)	Cancer pain	C22 H28 N 2O	Opioid mu receptor agonists	"NAL Pharma (Originator), NAL Pharma (Owner)"		Sublingual				N2 (Analgesics)	N02A-B03 (Fentanyl)	NAL 1239			28/12/2019	"Drug Delivery Systems, Pain"		NAL Pharma |  | Unspecified |  | 29 Nov 2016		no		no							https://adis.springer.com/drugs/800048368?userId=52029392&bpIds=3004037004&checksum=8622f017980d4b10de4b98cc6ba73695a4edc52c-1617045531840-3ad2b266c29c00f2e3fa90735888b1b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043962	Research programme: cannabinoid therapeutics - CannaPharmaRx			Yes			No development reported (Research)	"Infections, Pain, Eye disorders, Neurodegenerative disorders, Metabolic disorders, Inflammation, Cancer, Gastrointestinal disorders"		Cannabinoid receptor modulators	"CannaPharmaRx (Originator), CannaPharmaRx (Owner)"		unspecified				"A (Alimentary Tract and Metabolism), A16A (Other Alimentary Tract and Metabolism Products), J1X (Other Antibacterials), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs), S1X (Other Ophthalmologicals)"	"A (Alimentary Tract and Metabolism), A16A (Other Alimentary Tract and Metabolism Products), J01X (Other Antibacterials), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"				28/12/2019	"Bacterial Infections, Cancer, Digestive System Disorders, Eye Disorders, Haematological Disorders, Inflammation, Metabolic Disorders, Mycoses, Neurological Disorders, Pain, Peptic Ulcer Disease, Rheumatic Disease, Viral Infections"		CannaPharmaRx |  | Unspecified |  | 30 Nov 2015		no		no							https://adis.springer.com/drugs/800043962?userId=52029392&bpIds=3004037004&checksum=351003b469d2a85f6f3b981558e6a1119b1f7cdb-1617045531842-df891561538accaa25f24689374ccf5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044582	Cannabidiol/tetrahydrocannabinol - Axim Biotech			No			Preclinical	"Postherpetic neuralgia, Psychotic disorders, Restless legs syndrome, Pain, Dementia, Parkinson's disease"		Cannabinoid receptor agonists	"Axim Biotech (Originator), Axim Biotech (Owner), Syncom BV (Collaborator)"		Buccal				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"	"CanChew RL, CanChewRx, CBD/THC gum, MedChew 1401, MedChew 1502, MedChew 1503, MedChew 1504, MedChew GP, MedChew Rx, MedChewRL, Tetrahydrocannabinol/cannabidiol Axim Biotech"			28/12/2019	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"			MedChew Rx	no		no							https://adis.springer.com/drugs/800044582?userId=52029392&bpIds=3004037004&checksum=4b2bbb6315ce2bc3f133af4248cf7550801115e5-1617045531844-d38211c696e965b9910f3596f02446f9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020235	Trazodone - Angelini Group/Labopharm	19794-93-5	"1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3- chlorophenyl)-1-piperazinyl)propyl)-"	No			Marketed	"Major depressive disorder, Insomnia, Diabetic neuropathies"	C19 H22 Cl N5 O	"Serotonin 2A receptor antagonists, Serotonin 2C receptor antagonists, Serotonin uptake inhibitors"	"Angelini Group (Originator), Labopharm (Originator), Angelini Group (Owner), Labopharm (Owner), Angelini Group (Market Licensee), Lee's Pharmaceutical (Licensee), Altus Formulation Inc (Collaborator)"		PO			"Diarrhoea, Dizziness, Fatigue, Headache, Nausea, Somnolence, Xerostomia"	"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N05B (Anxiolytics), N06A-X05 (Trazodone)"	"AF1161, DDS04A, Oleptro, Trazodone Contramid OAD, Trazodone extended release, Trazodone HCl, Trazodone OAD, Triticum AC, Trittico"			26/12/2019	"Affective Disorders, Anxiety Disorders, Diabetes, Pain"			"Oleptro, Triticum AC, Trittico, Trittico, Trittico, Trittico, Trittico, Trittico"	no		no				"BDNF, IL6, TNF-alpha"	"IL6, TNF-alpha"		https://adis.springer.com/drugs/800020235?userId=52029392&bpIds=3004037004&checksum=8a7753eff7e8977ed05bfd6bef1971b1ca2c3c5b-1617045531849-bd6d8ff29a17d54d81bad2129d1bc72ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056882	MEDI 0618			Yes			Phase I	Pain		PAR 2 receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		"IV, SC"				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	MEDI0618			23/12/2019	Pain				no		no							https://adis.springer.com/drugs/800056882?userId=52029392&bpIds=3004037004&checksum=269b4918b6cc0c546ad9292263464f687dc30c89-1617045531850-401a7a56ccc400bd06acd74467213fd6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037612	Zoledronic acid oral - Thar Pharmaceuticals	118072-93-8	"1-Hydroxy-2-(2-imidazolyl)ethyl-1,1-bis-phosphonic acid"	No			No development reported (III)	Complex regional pain syndromes	C5 H10 N2 O7 P2	"Bone resorption factor inhibitors, Geranyltranstransferase inhibitors, Osteoclast inhibitors"	"Thar Pharmaceuticals (Originator), Thar Pharmaceuticals (Owner)"		PO				"M5B4 (Bisphosphonates for tumour-related calcium disorders), N2 (Analgesics)"	"M05B-A08 (Zoledronic acid), N02 (Analgesics)"	"T 121E01F, T121"			23/12/2019	Pain	Complex regional pain syndromes (USA)	Thar Pharmaceuticals |  | Unspecified |  | 26 Feb 2013		no		no							https://adis.springer.com/drugs/800037612?userId=52029392&bpIds=3004037004&checksum=6cb5b7d4419e27db3b8d47685242cf8219d8b1ae-1617045531851-df0dcd1d4425c0201859e3c154416136badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037072	V 116517			Yes			No development reported (II)	"Musculoskeletal pain, Postherpetic neuralgia, Pain"		Undefined mechanism	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	V116517			23/12/2019	Pain				no		no							https://adis.springer.com/drugs/800037072?userId=52029392&bpIds=3004037004&checksum=10e9a10bb0cb7aa63894b1f87e14da727b8f17b5-1617045531852-ceb655fa4865a5cd1be65c756c55e1c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056819	DX 416			Yes			Research	"Pruritus, Pain"		T type calcium channel antagonists	"DermaXon (Originator), DermaXon (Owner), National Institutes of Health (Funder), Montana Department of Commerce (Collaborator), National Institute of Arthritis and Musculoskeletal and Skin Diseases (Collaborator), National Institute of Neurological Disorders and Stroke (Collaborator), Syneos Health (Collaborator), VantAI (Collaborator)"		"Topical, unspecified"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A-X (Other antipruritics), N02 (Analgesics)"	DX416			19/12/2019	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800056819?userId=52029392&bpIds=3004037004&checksum=67ba03aace7220a7f3456518e36c55de11e037cb-1617045531853-4822ad034c4f790fc1ee96fc75424277badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044618	Neuropathic pain therapeutic - Sphaera Pharma/Synthia Dermatech			No			No development reported (I/II)	Neuropathic pain		Cyclooxygenase inhibitors	"Sphaera Pharma (Originator), Sphaera Pharma (Owner), Synthia Dermatech (Collaborator)"		Topical				"A10 (Drugs Used in Diabetes), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A10 (Drugs Used in Diabetes), M01A-B05 (Diclofenac), N02 (Analgesics)"	diclofenac sodium 1 + triclocarban			18/12/2019	Pain				no		no							https://adis.springer.com/drugs/800044618?userId=52029392&bpIds=3004037004&checksum=df7845f2216015d11f2bf96f457dd195b0cccad9-1617045531854-97f85d417fbe4d42a322de3a1ac33097badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043526	Research programme: pain therapeutics - Bionomics/Merck			Yes			Preclinical	Pain		"Nav1.7 voltage-gated sodium channel inhibitors, Nav1.8 voltage-gated sodium channel inhibitors"	"Bionomics (Originator), Merck & Co (Originator), Bionomics (Owner), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				17/12/2019	Pain				no		no							https://adis.springer.com/drugs/800043526?userId=52029392&bpIds=3004037004&checksum=bad904381e1f20de992fa592f7a62852015dae92-1617045531855-c394c7624962327ee56e04e61c503510badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034104	Research programme: pain therapeutics - BetterLife Pharma			No			No development reported (Research)	"Sciatica, Intervertebral disc displacement"		Interleukin 1 receptor antagonists	"Neurokine Pharmaceuticals (Originator), BetterLife Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	NK003			13/12/2019	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800034104?userId=52029392&bpIds=3004037004&checksum=7237f4e2884e8d9bf2157e3ad909b2ca2873f809-1617045531855-d7eb953eaac377dc6302068565476707badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013146	Research programme: neurological disorders therapeutics - Gloriana therapeutics			Yes			Preclinical	"Epilepsy, Neurodegenerative disorders, Neuropathic pain, Motor neuron disease, Corticobasal degeneration, Parkinson's disease"		Glial cell line-derived neurotrophic factor modulators	"NsGene USA (Originator), Gloriana Therapeutics (Owner), Neurotech SA (Technology Provider), CBD Solutions (Funder), AlzeCure (Collaborator), Sanofi Genzyme (Collaborator), Takeda (Collaborator)"		"Intracerebral, unspecified"				"N2 (Analgesics), N3A (Anti-Epileptics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs), V3X (All Other Therapeutic Products)"	"N02 (Analgesics), N03A (Antiepileptics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs), V03A-X (Other therapeutic products)"	"BrainRepair research project Gloriana Therapeutics, EC biodelivery programme Gloriana Therapeutics, ECBPD, ECTPD, Meteorin, Meteorinlike growth factors Gloriana Therapeutics, Ns G34, NsG 0301, NsG 33"			05/12/2019	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800013146?userId=52029392&bpIds=3004037004&checksum=a9a3a65b798ba992749d724bde36444c19b3316a-1617045531857-aedf7655e1a6075e038ca25199485a56badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026922	Research programme: monoclonal antibodies - Regeneron			Yes			Preclinical	"Cancer, Cardiovascular disorders, Musculoskeletal disorders, Immunological disorders, Pain, Eye disorders, Metabolic disorders, Inflammation"		Undefined mechanism	"Regeneron Pharmaceuticals (Originator), Regeneron Pharmaceuticals (Owner), Columbia University (Collaborator), University of Texas Southwestern Medical Center (Collaborator)"		Parenteral				"A16 (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), L1G (Monoclonal Antibody Antineoplastics), L3 (Immunostimulating Agents), L4 (Immunosuppressants), M (Musculo-Skeletal System), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"A16 (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), L01X-C (Monoclonal antibodies), L03 (Immunostimulants), L04 (Immunosuppressants), M (Musculo-Skeletal System), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), S01X (Other Ophthalmologicals)"	VelocImmune research programme Regeneron			03/12/2019	"Cancer, Eye Disorders, Immunological Disorders, Inflammation, Metabolic Disorders, Musculoskeletal Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800026922?userId=52029392&bpIds=3004037004&checksum=c04f646373ba9c231790c73c1f8c4e044da99a55-1617045531858-fc98afc4927525d0deb90c154d3a48a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042248	Research programme: deuterium stabilised enantiomers - Poxel			No			Preclinical	"Metabolic disorders, Cancer, Type 2 diabetes mellitus, CNS disorders, Acute coronary syndromes, Major depressive disorder, Sickle cell anaemia, Alzheimer's disease, Inflammation"		"AMP activated protein kinase stimulants, Mitochondrial protein inhibitors, Peroxisome proliferator-activated receptor gamma agonists, Platelet ADP receptor antagonists, Adrenergic receptor antagonists, Dopamine uptake inhibitors, Acetylcholinesterase inhibitors, Mitochondrial protein stimulants, Immunomodulators, Interleukin 1 beta inhibitors, Interleukin 10 stimulants, Tumour necrosis factor inhibitors"	"DeuteRx (Originator), Poxel (Owner), Celgene Corporation (Collaborator), Daiichi Sankyo Company (Collaborator), Metabolic Solutions Development Company (Collaborator)"		"unspecified, PO"				"A10K (Glitazone Antidiabetics), A16 (Other Alimentary Tract and Metabolism Products), A5 (Cholagogues and Hepatic Protectors), B1C2 (ADP (adenosine diphosphate) receptor antagonist platelet aggregation inhibitors), B3X (Other Anti-Anaemic Products, Including Folic Acid, Folinic Acid), L1 (Antineoplastics), L1X9 (All other antineoplastics), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7D1 (Anti-Alzheimer products, cholinesterase inhibitors)"	"A05B-A (Liver therapy), A10B-G03 (Pioglitazone), A16 (Other Alimentary Tract and Metabolism Products), B01A-C22 (Prasugrel), B03X (Other Antianemic Preparations), L01 (Antineoplastic Agents), L01X-X (Other antineoplastic agents), N02 (Analgesics), N06A-X12 (Bupropion), N06D (Anti-Dementia Drugs), N06D-A02 (Donepezil), N07 (Other Nervous System Drugs)"	"Deuterated bupropion, Deuterated CC11006, Deuterated inolitazone, Deuterated mitoglitazone, Deuterated MSDC 0160, Deuterium stabilised enantiomer bupropion, Deuterium stabilised enantiomer CC 11006, Deuterium stabilised enantiomer inolitazone, Deuterium stabilised enantiomer mitoglitazone, Deuterium stabilised enantiomer MSDC 0160, DRX 184, DRX 195, DRX164, DRX194"			03/12/2019	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Cancer, Diabetes, Haematological Disorders, Inflammation, Ischaemic Heart Disease, Metabolic Disorders, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800042248?userId=52029392&bpIds=3004037004&checksum=d280edc59438730b7a6d0681379221ded754de51-1617045531862-f400de5c172ef0b5857ac86733f28a12badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039635	Research programme: opioid therapeutics - Elite Pharmaceuticals			No			No development reported (Research)	Pain		Opioid receptor agonists	"Elite Pharmaceuticals (Originator), Elite Pharmaceuticals (Owner)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A (Opioids), N07B-C (Drugs used in opioid dependence)"	"ELI400, ELI500, ELI501, ELI600, ELI601, Opioid products Elite Pharmaceuticals"			28/11/2019	Pain				no		no							https://adis.springer.com/drugs/800039635?userId=52029392&bpIds=3004037004&checksum=31fadbeb4f8fee2a59033e912999fa657714f5ed-1617045531863-05daab2813aff273cb20cc60e989bb4fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048067	CC 8464			Yes			No development reported (I)	"Neuropathic pain, Sciatica, Osteoarthritis, Diabetic neuropathies"		Nav1.7 voltage-gated sodium channel inhibitors	"Chromocell Corporation (Originator), Chromocell Corporation (Owner), Astellas Pharma (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"ASP 1807, CC 8464"			28/11/2019	"Musculoskeletal Disorders, Pain, Rheumatic Disease"				yes	USA	no							https://adis.springer.com/drugs/800048067?userId=52029392&bpIds=3004037004&checksum=d855fb26c73992b962fcdeec2be7809f80beeb02-1617045531864-44c778beea1d0ce7b3f03ad83e9b4210badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056618	VIS NAV			Yes			Preclinical	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Visterra (Originator), Visterra (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	VISNAV			26/11/2019	Pain				no		no							https://adis.springer.com/drugs/800056618?userId=52029392&bpIds=3004037004&checksum=2272e380e8a92e24de2b82aa4c172264060455ce-1617045531865-4fa673802db83950f5c2687f8f8d8732badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008664	UP 23761		5-Chloro-3-(1-methylpiperidin-4-ylsulfanyl)-1<EM>H</EM>-indole	No			Discontinued (Preclinical)	Pain	C14 H17 Cl N2 S	Serotonin uptake inhibitors	"UPSA (Originator), UPSA (Owner)"		unspecified				N2A (Narcotics)	N02A-X (Other opioids)				18/11/2019	Pain				no		no							https://adis.springer.com/drugs/800008664?userId=52029392&bpIds=3004037004&checksum=6f834467049eae2d7b61eb7fd2df37f6236f20de-1617045531866-70763c897bf5c8278a1bf1733be4b2cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056556	Sumatriptan dry powder inhalation - MannKind Corporation			No			Preclinical	Migraine		"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"MannKind Corporation (Originator), MannKind Corporation (Owner)"		Inhalation				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	Sumatriptan Technosphere MannKind			18/11/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800056556?userId=52029392&bpIds=3004037004&checksum=3e14633cfd0ef77ad826d134fe8d10de7a4198d4-1617045531868-ff5fa3323836508f86cbc638a12478b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003159	UP 20232		N<SUP>6</SUP>-[2-(1-Cyclopentylindol-3-yl)ethyl]-5'- (cyclopropylamino)-5'-deoxy-5'-oxoadenosine	No			Discontinued (Preclinical)	Pain	C28 H33 N7 O4	Purinergic P1 receptor agonists	"UPSA (Originator), UPSA (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				18/11/2019	Pain				no		no							https://adis.springer.com/drugs/800003159?userId=52029392&bpIds=3004037004&checksum=6e50c70ead3816ae8de304235a96884a74b1ca0c-1617045531869-765dd83c0a45f4df41e71ac898065634badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007946	UP 20256	163838-06-0	"_-D-Ribofuranuronamide, <EM>N</EM>-cyclopropyl-1-deoxy-1- [(6-[([(2-[(1-[((2,5-dimethylphenyl)methyl)]-2-methyl- 1<EM>H</EM>-indol-3-yl)]ethyl)]amino)]-9<EM>H</EM>-purin-9-yl)]-"	No			Discontinued (Preclinical)	Pain	C33 H37 N7 O4	Adenosine A1 receptor agonists	"UPSA (Originator), UPSA (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/11/2019	Pain				no		no							https://adis.springer.com/drugs/800007946?userId=52029392&bpIds=3004037004&checksum=c12f6362149013a72c3490f7baa112dc99b7fa03-1617045531870-49569486de7871708b35e6993c56fe2ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003282	Ruzadolane	115762-17-9	"1,2,4-Triazolo[(4,3-a)]pyridine, 3-[([(2-[(4-(2,4-difluorophenyl)- 1-piperazinyl)]ethyl)]thio)]-"	No			Discontinued (II)	"Pain, Anxiety disorders"	C18 H19 F2 N5 S	Serotonin receptor antagonists	"UPSA (Originator), UPSA (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N5C (Tranquillisers)"	"N02B (Other Analgesics and Antipyretics), N05B-X (Other anxiolytics)"	UP 2691			18/11/2019	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800003282?userId=52029392&bpIds=3004037004&checksum=c8add2d9d66b08237e0cc92fc2d13c9277d3cff2-1617045531871-8bfce0ead861021c9faf2014fbc4d7dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034517	SNA 125			Yes			Phase II	"Atopic dermatitis, Psoriasis, Pruritus, Inflammatory bowel diseases, Neuropathic pain, Arthritis, Scars, Pain"		"Janus kinase 3 inhibitors, TrkA receptor antagonists"	"Creabilis SA (Originator), Sienna Biopharmaceuticals (Owner)"		"Topical, unspecified"			"Pain, Pruritus"	"A7E (Intestinal Anti-Inflammatory Agents), D3A (Wound Healing Agents), D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), D5A (Topical Antipsoriasis Products), D5X (Other Nonsteroidal Products for Inflammatory Skin Disorders), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), D03 (Preparations for Treatment of Wounds and Ulcers), D04A-X (Other antipruritics), D05A-X (Other antipsoriatics for topical use), D11A-H (Agents for atopic dermatitis, excluding corticosteroids), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"CT 340, SNA 125"			18/11/2019	"Inflammatory Bowel Disorders, Pain, Rheumatic Disease, Skin Disorders"				no		no							https://adis.springer.com/drugs/800034517?userId=52029392&bpIds=3004037004&checksum=b5ce1a1c9013533d29f2da59cd4744f5cd2b913a-1617045531873-e92b1f750181aaad5f5e9455bf415e00badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056324	Duloxetine delayed-release capsules - Sun Pharma Global FZE	116539-59-4	3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine	No			Marketed	"Anxiety disorders, Major depressive disorder, Neuropathic pain, Pain, Musculoskeletal pain"	C18 H19 N O S	"Adrenergic uptake inhibitors, Serotonin plasma membrane transport protein inhibitors, Serotonin uptake inhibitors"	"Sun Pharma Global FZE (Originator), Sun Pharma Global FZE (Owner)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02 (Analgesics), N06A-X21 (Duloxetine), N07X (Other Nervous System Drugs)"	"Drizalma Sprinkle, Neuralserotoninuptakeinhibitors Sun Pharma Global FZE"			18/11/2019	"Affective Disorders, Anxiety Disorders, Pain"			Drizalma Sprinkle	no		no							https://adis.springer.com/drugs/800056324?userId=52029392&bpIds=3004037004&checksum=4d560c36d2f2c009ba58885eb07f791b38808029-1617045531875-2751b83d2cf94b6c1129cc1c386077f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043069	HX 100			Yes			Phase I	"Neuropathic pain, Allergic asthma"		TRPA1 protein inhibitors	"Hydra Biosciences (Originator), Eli Lilly and Company (India) Pvt. Ltd (Owner)"		PO				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"HX100, TRPA1 Antagonist Eli Lilly and Company"			15/11/2019	"Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800043069?userId=52029392&bpIds=3004037004&checksum=604ac5fdf80b81a43dcbd84f1067d83a75e91bfb-1617045531876-38d7f19520ac110b9aba9dfab8833790badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055964	BOL DP o 04			No			Phase II	"Diabetic neuropathies, Pain"		Cannabinoid receptor modulators	"BOL Pharma (Originator), BOL Pharma (Owner)"		Sublingual				"A10 (Drugs Used in Diabetes), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N02B-G10 (Cannabinoids, including nabiximols)"	BOLDPo 04			11/11/2019	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800055964?userId=52029392&bpIds=3004037004&checksum=f5d17740c15455cf835312ff8430ed275d507724-1617045531877-be0154df172892d6e90fc0190b892605badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047648	Research programme: small molecules - Zosano Pharma			No			No development reported (Preclinical)	"Anaphylaxis, Pain, Chemotherapy-induced nausea and vomiting, Migraine, Thrombosis, Interstitial cystitis"		"Adrenergic receptor agonists, Opioid mu receptor agonists, Serotonin 3 receptor antagonists, Serotonin 1 receptor agonists, Serotonin 1B receptor agonists, Serotonin 1D receptor agonists, Cell membrane structure inhibitors"	"Zosano Pharma (Originator), Zosano Pharma (Owner)"		Transdermal				"A4A1 (Serotonin antagonist antiemetics/antinauseants), N2A (Narcotics), N2C1 (Antimigraine triptans), R3A (B2-Stimulants)"	"A04A (Antiemetics and Antinauseants), N02A-B03 (Fentanyl), N02C-C (Selective serotonin (5HT1) agonists), N02C-C01 (Sumatriptan), N02C-C03 (Zolmitriptan), R03A-A01 (Epinephrine)"	"Epinephrine transdermal Zosano Pharma, Fentanyl Zosano Pharma, Granisetron Zosano Pharma, Naratriptan Zosano Pharma, Pentosan polysulfate Zosano Pharma, Sumatriptan Zosano Pharma, Zolmitriptan Zosano Pharma"			28/10/2019	"Advances in the Treatment of Nausea and Migraine, Genitourinary Disorders, Immunological Disorders, Pain, Thromboses"				no		no							https://adis.springer.com/drugs/800047648?userId=52029392&bpIds=3004037004&checksum=1947be9049745c21881bc4b05588f3d7fb2e2ad3-1617045531879-d02079d40e38ea115c7f41b2e52a651cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047771	Rizatriptan oral film - MonoSol Rx/Dr Reddy's Laboratories	144034-80-0	"3-[2-(Dimethylamino)ethyl]-5-(1,2,4-triazol-1-ylmethyl)-indole benzoate"	No			No development reported (Clinical)	Migraine	C15 H19 N5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"MonoSol Rx (Originator), Aquestive Therapeutics (Owner), Dr Reddys Laboratories (Collaborator)"		PO				N2C1 (Antimigraine triptans)	N02C-C04 (Rizatriptan)	Rizatriptan Aquestive Therapeutics/Dr Reddys Laboratories			28/10/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800047771?userId=52029392&bpIds=3004037004&checksum=596bfbe96813065d2c9c152fc169880c226b1c25-1617045531880-48322e7628195744372442ea8ae665d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047259	3 VM 1001 topical cream - CDA Research Group			Yes			Phase I/II	"Pain, Osteoarthritis"		Undefined mechanism	"CDA Research Group (Originator), CDA Research Group (Owner)"		Topical				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"3VM1001, 3VM1001 cream CDA Research Group"			28/10/2019	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800047259?userId=52029392&bpIds=3004037004&checksum=ecbdd8c9435ed6d0112a47283927302e5ee0def4-1617045531880-d3329648ed8f267b0792a107b54a5f0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043245	Research programme: pain and inflammation therapeutics - Angelini			Yes			No development reported (Research)	"Pain, Inflammation"		Nicotinamide phosphoribosyltransferase inhibitors	"Angelini Group (Originator), Angelini Group (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				28/10/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800043245?userId=52029392&bpIds=3004037004&checksum=91dad88c3fd60377b38268eaba9b4146d5bb5091-1617045531881-45a4057a0b5a62d2d65f7fe954281e24badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043442	Research programme: sodium ion channel modulators - Purdue Pharma			Yes			No development reported (Research)	Pain		Nav1.7 voltage-gated sodium channel modulators	"Purdue Pharma (Originator), Purdue Pharma (Owner), AnaBios Corporation (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	NaV1.7 ion channel modulators Purdue Pharma			28/10/2019	Pain				no		no							https://adis.springer.com/drugs/800043442?userId=52029392&bpIds=3004037004&checksum=81c6174411f73e3502d7d0729441c3bb3881752b-1617045531883-d97f4cef6d8c956c30e2ad7cdaf98abcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043198	Research programme: voltage gated sodium channel antagonists - Chromocell Corporation/Astellas Pharma			Yes			No development reported (Preclinical)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Chromocell Corporation (Originator), Chromocell Corporation (Owner), Astellas Pharma (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)				28/10/2019	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800043198?userId=52029392&bpIds=3004037004&checksum=97c460a8b59ad149c29ea5f0712ebbdfd8feb9e6-1617045531884-1d8513327945555fc02bfc9224f9109cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046916	Ibuprofen - Ceridia	15687-27-1	"Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-"	No			No development reported (I)	Pain	C13 H18 O2	Cyclooxygenase inhibitors	"Ceridia (Originator), Ceridia (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-E01 (Ibuprofen), N02 (Analgesics)"				28/10/2019	Pain				no		no		"C-peptide, opsin 1 (cone pigments), long-wave-sensitive"	peroxisome proliferator-activated receptor gamma	"A1C, ACTH, adrenoceptor alpha 1D, Arachidonic acid, C-peptide, Calprotectin, CD34, CRP, CXCL10, Elastase, Endothelin 1, ER alpha, Estrone sulfate, Ferritin, IFN-gamma, IL1 beta, IL17, IL2, IL5, IL6, IL8, LTB4, Nitric Oxide, NOX2-dp, nuclear prelamin A recognition factor like, peroxisome proliferator-activated receptor gamma, PGE2, Prostacyclin, proteasome subunit alpha 7, Pulmonary disease, chronic obstructive, severe early-onset, RNA, Ro-associated Y1, secretoglobin, family 1A, member 1, sex hormone-binding globulin, Soluble transferrin receptor, submaxillary gland androgen regulated protein 3B, Surfactant protein D, Thromboxane, TNF-alpha"	"A1C, C-peptide, Calprotectin, IFN-gamma, IL1 beta, IL17, IL2, IL5, TNF-alpha"	"Aldosterone, Calreticulin, CD4, CD68, CD8a, Creatinine, CTx, CYP2C9, cytochrome P450 family 2 subfamily C member 8, delta like canonical Notch ligand 4, endothelin receptor type A, F2-isoprostanes, GAD Auto-antibodies, Hepcidin, IGF1, IL10, IL13, IL4, Lactate dehydrogenase, MCP1, miR-146a, OPRM1, PAI-1, PGD2, PGE1, PICP, PIIINP, PINP, Renin, Thromboxane B2, TNFRSF1A, TNFRSF1B, VEGF-A"	https://adis.springer.com/drugs/800046916?userId=52029392&bpIds=3004037004&checksum=e51b2d1c36b431b3786e627f9f9f1717f1b5291a-1617045531886-945eb0d2227f05ec03ddd45d8a44b6b1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056301	Research programme: sphingosine 1 phosphate receptor agonists - MEBIAS Discovery			Yes			Research	"Pain, Inflammation"		Sphingosine 1 phosphate receptor agonists	"MEBIAS Discovery (Originator), MEBIAS Discovery (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				22/10/2019	"Inflammation, Pain"		MEBIAS Discovery |  | Clinical Phase Unknown |  | 18 Oct 2019		no		no							https://adis.springer.com/drugs/800056301?userId=52029392&bpIds=3004037004&checksum=1a9df17332991335447e6aba544d03d58740b953-1617045531888-2cf64b8620ab5217fed95940391702d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056225	Research programme: somatostatin receptor subtype 4 agonists - Peptide Logic			Yes			Research	Pain		Somatostatin receptor subtype 4 agonists	"Peptide Logic (Originator), Peptide Logic (Owner), Pfizer (Technology Provider), National Institutes of Health (USA) (Funder)"		Parenteral				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	LASSTR4 agonists Peptide Logic			18/10/2019	Pain				no		no							https://adis.springer.com/drugs/800056225?userId=52029392&bpIds=3004037004&checksum=d26491227a676c1f3fd0aa380f571bda0a3fd825-1617045531889-ccf47629eecea9a677d33011007e7498badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056298	CLE 500			Yes			Preclinical	Cluster headache		Undefined mechanism	"Clexio Biosciences (Originator), Clexio Biosciences (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CLE500			17/10/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800056298?userId=52029392&bpIds=3004037004&checksum=c776638f581e5fb60dac392e559ff5a395435b0a-1617045531890-6d6237bc13a4c711c129eed8450ef136badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041593	Sumatriptan intranasal - Upsher-Smith	103628-46-2	3-[2-(dimethyl-amino)ethyl]-N-methylindole-5-methanesulfonamide	No			Marketed	Migraine	C14 H21 N3 O2 S	Serotonin 1D receptor agonists	"Dr Reddys Laboratories (Originator), Upsher-Smith (Owner), Neurelis (Technology Provider), Promius Pharma (Collaborator)"		Intranasal				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"DFN02, DFP 02, TOSYMRA"			14/10/2019	Advances in the Treatment of Nausea and Migraine			TOSYMRA	no		no				"Adenosine monophosphate, cytokine inducible SH2-containing protein, PGE2, Prostacyclin, Valproic acid glucuronide"		CRP	https://adis.springer.com/drugs/800041593?userId=52029392&bpIds=3004037004&checksum=bb60d431c4b56ba69d08d25f58d3eecb6be90357-1617045531891-5a2f2857b947c1961527bd8ff8cc5b2ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051258	XC 101			Yes			Phase I	Migraine		"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists, Serotonin 1F receptor agonists, Serotonin 2A receptor antagonists, Serotonin 2B receptor antagonists, Serotonin 2C receptor antagonists, Serotonin 7 receptor agonists"	"Xoc Pharmaceuticals (Originator), Xoc Pharmaceuticals (Owner)"		PO				N2C9 (All other anti-migraine preparations)	N02C (Antimigraine Preparations)	"XC101, XC101D13H"			11/10/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800051258?userId=52029392&bpIds=3004037004&checksum=31967bbdf0822c3526fc9a0ca90a9bb16a182ed1-1617045531893-50982c0fb6e2a1d952ef250e6a44db1cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040333	Research programme: pain therapeutics - Biogen/Evotec SE			Yes			No development reported (Research)	Pain		G protein-coupled receptor modulators	"Convergence Pharmaceuticals (Originator), Evotec AG (Originator), Biogen (Owner), Evotec SE (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				07/10/2019	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800040333?userId=52029392&bpIds=3004037004&checksum=93c7c5f15761e272c9a009ae204db502428fd82d-1617045531894-104ade68f448c9bc9b91635eb37bd715badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800056086	Ketamine hydrochloride intranasal - CCH Pharmaceuticals	1867-66-9	2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one;hydrochloride	No			Phase II	Cluster headache	C13 H17 Cl2 NO	"AMPA receptor agonists, NMDA receptor antagonists"	"CCH Pharmaceutical (Originator), CCH Pharmaceutical (Owner)"		Intranasal				N2 (Analgesics)	N02 (Analgesics)	Ketamine hydrochloride intranasal spray CCH Pharmaceuticals			04/10/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800056086?userId=52029392&bpIds=3004037004&checksum=c73d8b0d9014c3b634d6217297ee9423dde25a74-1617045531895-dcfd5c1637f9164faf0f90db87f1d86abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044984	Olpadronic acid	63132-39-8	"[3-(Dimethylamino)-1-hydroxypropane-1,1-diyl]bis(phosphonic acid)"	No			Discontinued (II)	Back pain	C5 H15 NO7 P2	"Bone resorption factor inhibitors, HMG-CoA reductase inhibitors"	"Gador (Originator), Gador (Owner)"		IV				"M5B (Bone Calcium Regulators), N2 (Analgesics)"	"M05B-A (Bisphosphonates), N02 (Analgesics)"	"IG8801, Monosodium olpadronate"			04/10/2019	Pain				no		no							https://adis.springer.com/drugs/800044984?userId=52029392&bpIds=3004037004&checksum=cd72f8856854d522e9366087f849c76f80b79332-1617045531896-3254a930f69c77cce8eaf8c71e6ee661badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036580	Pregabalin controlled release - GL PharmTech	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid	No			Registered	Neuropathic pain	C8 H17 N O2	CACNA2D1 protein modulators	"GL PharmTech (Originator), GL PharmTech (Owner), Daewon Pharmaceutical (Collaborator)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin), N07X (Other Nervous System Drugs)"	"GLA5PR, GLA5PR GLARS, GLA5PR GLARSNF1, GLA5PR GLARSNF3, Pregabalin GLARS, Pregabalin QD"			03/10/2019	Pain				no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800036580?userId=52029392&bpIds=3004037004&checksum=b7c25b36b4334d70d387aab35db9dd14778cf964-1617045531898-0c638c48a5a16ceccd4121a280b859eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045340	COL 195			No			Phase I/II	Pain		Opioid receptor agonists	"Collegium Pharmaceutical (Originator), Collegium Pharmaceutical (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"COL195, Hydrocodone DETERx Collegium Pharmaceutical"			01/10/2019	Pain				no		no							https://adis.springer.com/drugs/800045340?userId=52029392&bpIds=3004037004&checksum=91265aedb1b4c09b1b8c1c2b0f7a809ec9a3074d-1617045531899-181a467aa4b56173bfa16e0fdfe44e84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045460	Methadone - Teikoku Seiyaku	1095-90-5	"6-(dimethylamino)-4,4-diphenylheptan-3-one;hydrochloride"	No			Discontinued (III)	Cancer pain	C21 H28 Cl N O	Opioid mu receptor agonists	"Teikoku Seiyaku (Originator), Teikoku Seiyaku (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	TK642			30/09/2019	Pain				no		no							https://adis.springer.com/drugs/800045460?userId=52029392&bpIds=3004037004&checksum=1a2e793ed24a823ab2cddb7dabc5982c5f98ac1b-1617045531900-9fe4244ac4d2c546b1cd1ef75991b156badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053283	Research programme: ketamine derivatives - Shenox Pharmaceuticals			No			Preclinical	"Neuropathic pain, Major depressive disorder"		NMDA receptor antagonists	"Shenox Pharmaceuticals (Originator), Shenox Pharmaceuticals (Owner)"		Buccal				"N2 (Analgesics), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N06 (Psychoanaleptics)"	"SHX004, SHX004/005/006/007/011, SHX005, SHX006, SHX007, SHX011"			30/09/2019	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800053283?userId=52029392&bpIds=3004037004&checksum=5b037f1e0e19f105396c781147be95b662a78758-1617045531901-953df630e1a9f827b64c85cd81af8447badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014464	Research programme: NR2B NMDA receptor antagonists - Evotec SE			Yes			Discontinued (Preclinical)	"Postoperative pain, Alzheimer's disease, Neuropathic pain"		NR2B N-Methyl-D-Aspartate antagonists	"Roche (Originator), Roche (Owner), Evotec SE (Licensee)"		"IV, PO"				"N2 (Analgesics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations), N7D (Anti-Alzheimer Products)"	"N02B (Other Analgesics and Antipyretics), N06 (Psychoanaleptics), N06D (Anti-Dementia Drugs)"	"ENS 102, EVT 100 series, EVT 102, NR2Bselective NMDA receptor antagonists, RO631908"			27/09/2019	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800014464?userId=52029392&bpIds=3004037004&checksum=9cf2f411c968b5f0c34da9a5ad8423a8eab6f5fb-1617045531902-4cba345c30e5a8b5f30eca7e800697f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027716	Research programme: histamine H3 receptor antagonists - Evotec SE			No			No development reported (Preclinical)	"Cognition disorders, Narcolepsy, Pain"		Histamine H3 receptor antagonists	"Evotec AG (Originator), Evotec SE (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	EVT501			27/09/2019	"Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027716?userId=52029392&bpIds=3004037004&checksum=89c5588828e022d52fc589b4dd36ac89d666a190-1617045531903-bdda3a3e38af02b40ccaeb681f16a34fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045489	Oxetacaine - Amato Pharmaceutical	126-27-2	2-[2-hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide	No			Discontinued (II)	Pain	C28 H41 N3 O3	Undefined mechanism	"AMATO PHARMACEUTICAL PRODUCTS (Originator), AMATO PHARMACEUTICAL PRODUCTS (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"AM4, Oxetacaine ointment"			26/09/2019	Pain				no		no							https://adis.springer.com/drugs/800045489?userId=52029392&bpIds=3004037004&checksum=11e71830fef0d4985c9769dcbd17005cdf2ff739-1617045531904-2f2c9581b9397f3af426a2612cc033bdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036890	K 103 IP			Yes			Discontinued (III)	"Inflammation, Acute pain"		Cyclooxygenase inhibitors	"Kowa Pharmaceutical (Originator), Kowa Pharmaceutical (Owner)"		Topical				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"K103IP, K103PA"			26/09/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800036890?userId=52029392&bpIds=3004037004&checksum=171415f35af15eed07b83a2aa8657c950b836d71-1617045531905-65b7a7e9ef22c2816355c014fa9e89b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026234	Research programme: fatty acid amide hydrolase modulators - Evotec SE			No			No development reported (Preclinical)	Pain		Fatty acid amide hydrolase modulators	"Renovis (Originator), Evotec SE (Owner)"		unspecified				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5B (Hypnotics/Sedatives), N5C (Tranquillisers)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05B (Anxiolytics)"	"RNA, RNB"			26/09/2019	Pain				no		no							https://adis.springer.com/drugs/800026234?userId=52029392&bpIds=3004037004&checksum=190028bdaeb3857f75b52c2679c6ccd0a9bce522-1617045531906-78a6e7e2e738a16ec81ad30cfd826b0fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032162	Neuropathic pain therapeutic - Boehringer Ingelheim			No			No development reported (I)	Neuropathic pain		Undefined mechanism	"Boehringer Ingelheim (Originator), Evotec AG (Originator), Boehringer Ingelheim (Owner), Evotec SE (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				25/09/2019	Pain				no		no							https://adis.springer.com/drugs/800032162?userId=52029392&bpIds=3004037004&checksum=db9d7a48116d8497635ccd81e52fb76674b2a969-1617045531907-2f09a35ce57d3a0de69c2bbed21b999dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036876	Research programme: small molecule therapeutics - Evotec SE/Novartis			Yes			Preclinical	"Pain, CNS disorders"		Undefined mechanism	"Evotec AG (Originator), Novartis (Originator), Evotec SE (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				25/09/2019	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800036876?userId=52029392&bpIds=3004037004&checksum=f8b8c247dfcdd466208a82115ca297bd4082ba54-1617045531908-4815b189c2228f03bce21897b6643001badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027717	Research programme: bradykinin B1 receptor antagonists - Evotec SE			No			No development reported (Preclinical)	"Pain, Inflammation"		Bradykinin B1 receptor antagonists	"Evotec AG (Originator), Evotec SE (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				25/09/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800027717?userId=52029392&bpIds=3004037004&checksum=aae00a1145d93a38a45e3e65c851cc95953f0727-1617045531909-15864378e1dccf0d1bf39659b7722e0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055985	CRB 0089			Yes			Research	Pain		TrkA receptor antagonists	"Rottapharm Biotech (Originator), Rottapharm Biotech (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	CRB0089			25/09/2019	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800055985?userId=52029392&bpIds=3004037004&checksum=aeedce635d4d9fb8ab8b85d695b46f3ce90e8a1a-1617045531909-7f65c71da4b0bd5c692147d1336539e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031696	CRB 0022			Yes			Discontinued (Research)	Pain		TrkA receptor antagonists	"Rottapharm Madaus (Originator), Rottapharm Biotech (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	CRB0022			25/09/2019	Pain				no		no							https://adis.springer.com/drugs/800031696?userId=52029392&bpIds=3004037004&checksum=46a4877642aad4f777d7260d75cdeffdc555a6a1-1617045531910-ce700b38f78270d8c3144a87b96ea28ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020483	Research programme: TRPV1 receptor antagonists - Renovis/Pfizer			Yes			No development reported (Preclinical)	"Urinary incontinence, Pain"		TRPV1 receptor antagonists	"Pfizer (Originator), Renovis (Originator), Evotec SE (Owner)"		PO				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	"TRPV1 antagonists Renovis/Pfizer, Vanilloid receptor antagonists Renovis/Pfizer"			25/09/2019	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020483?userId=52029392&bpIds=3004037004&checksum=f1505181754f5f1f0d54705d263928ec31b89b1b-1617045531911-8474979efa8a546df1eacc0612a6a35bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025660	Research programme: purinergic receptor antagonists - Evotec SE			Yes			No development reported (Preclinical)	"Urinary incontinence, Pain"		"Purinergic P2 receptor antagonists, Purinergic P2X3 receptor antagonists"	"Renovis (Originator), Evotec SE (Owner)"		unspecified				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	"P2X2/3 antagonists, P2X2/3 antagonists Evotec SE, P2X3 antagonists, P2X3 antagonists Evotec SE, P2X7 receptor antagonists Evotec SE"			25/09/2019	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800025660?userId=52029392&bpIds=3004037004&checksum=5b53b78c7b7bc104ada8c83dc2dee2dd926b882d-1617045531912-17762c6aec1aa68d82eef0d556f4f935badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034202	TRPV1 receptor antagonist - Renovis/Pfizer			Yes			Discontinued (I)	"Pain, Urinary incontinence"		TRPV1 receptor antagonists	"Pfizer (Originator), Renovis (Originator), Evotec SE (Owner), Pfizer (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)				25/09/2019	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800034202?userId=52029392&bpIds=3004037004&checksum=c52cbe1e51bcab29949ced275180b32814deb336-1617045531913-5521e594b417aa6a1e5b76679d058b6fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021465	Research programme: small molecule therapeutics - Boehringer Ingelheim/Evotec SE			Yes			Phase Unknown	"Metabolic disorders, Cardiovascular disorders, Immunological disorders, Respiratory tract disorders, Inflammation, Pain, Cancer, CNS disorders"		"G protein-coupled receptor modulators, Ion channel modulators"	"Boehringer Ingelheim (Originator), Evotec AG (Originator), Evotec SE (Owner), Evotec NeuroSciences (Collaborator)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), L1 (Antineoplastics), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs), R7 (Other Respiratory System Products)"	"A16 (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), L01 (Antineoplastic Agents), L04 (Immunosuppressants), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics), N07X-X (Other nervous system drugs), R07 (Other Respiratory System Products)"	"CB2 receptor agonists Boehringer Ingelheim/Evotec SE, Enzyme modulators Boehringer Ingelheim/Evotec SE, GPCR modulators Boehringer Ingelheim/Evotec SE, Ion channel modulators Boehringer Ingelheim/Evotec SE"			25/09/2019	"Cancer, Immunological Disorders, Inflammation, Ischaemic Heart Disease, Metabolic Disorders, Neurological Disorders, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800021465?userId=52029392&bpIds=3004037004&checksum=14a64c27f52975bd1dc9ec9642ca9dfe3cb7df9b-1617045531914-b95079a258732e6c322b8789ddb64e6fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041160	Hydromorphone abuse-resistant - Acura Pharmaceuticals	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"	No			Phase I	Pain	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner), National Institute of Drug Abuse (Funder)"		PO				N2A (Narcotics)	N02A-A03 (Hydromorphone)	"Limitx abuseresistant hydromorphone, LIMITX Hydromorphone, LTX04"			19/09/2019	Pain				yes	USA	no							https://adis.springer.com/drugs/800041160?userId=52029392&bpIds=3004037004&checksum=9b30e1d127cac5d728571011efebebcfd07c5aa2-1617045531915-c3fbb5556eb37d0a2dbe6a452b7f247cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039664	Research programme: potassium channel activators - Knopp Biosciences			Yes			Preclinical	"Neuropathic pain, Tinnitus"		KCNQ3 potassium channel stimulants	"Knopp Biosciences (Originator), Knopp Biosciences (Owner), National Institutes of Health (USA) (Funder), Baylor College of Medicine (Collaborator)"		"Topical, unspecified, PO"				"N2 (Analgesics), N3A (Anti-Epileptics), S2 (Otologicals)"	"N02 (Analgesics), N03A (Antiepileptics), S02 (Otologicals)"	"KCNQ2 potassium channel activators Knopp Biosciences, Kv7 channel activators, Kv7.2/7.3 channel activators"			19/09/2019	"Ear, Nose and Throat Disorders, Pain"				no		no							https://adis.springer.com/drugs/800039664?userId=52029392&bpIds=3004037004&checksum=4ed7c9b5d0c5b0518b47ef24c81492b68570cd56-1617045531916-1a975420ea0db72056abe7956b7f7369badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037435	BI 1026706			Yes			Phase II	"Diabetic macular oedema, Chronic obstructive pulmonary disease, Osteoarthritis, Postoperative pain"		Bradykinin B1 receptor antagonists	"Boehringer Ingelheim Pharmaceuticals (Originator), Boehringer Ingelheim Pharmaceuticals (Owner)"		PO				"A10X9 (Other drugs used in diabetes), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	BI1026706			19/09/2019	"Diabetes, Eye Disorders, Musculoskeletal Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800037435?userId=52029392&bpIds=3004037004&checksum=8a827c951f1edcd0875d61fcb7c78990fc041058-1617045531918-88119bde353687be2a7e6a101439b68dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029095	Oral nalbuphine - PhytoHealth	20594-83-6	"(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol"	No			No development reported (Preregistration)	Pain	C21 H27 N O4	Opioid receptor agonists	"PhytoHealth (Originator), PhytoHealth (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	PHN131			09/09/2019	Pain				no		no							https://adis.springer.com/drugs/800029095?userId=52029392&bpIds=3004037004&checksum=260b02935145ac4c7e41750099b3da0f8b1a82bc-1617045531919-19d780f34dd6b55da625ee336bd910e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055832	Research programme: non-opioid therapeutics - Grunenthal/UniQuest			Yes			Research	Neuropathic pain		Undefined mechanism	"The University of Queensland (Originator), UniQuest (Originator), The University of Queensland (Owner), UniQuest (Owner), Grunenthal (Collaborator), University of Wollongong (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				05/09/2019	Pain				no		no							https://adis.springer.com/drugs/800055832?userId=52029392&bpIds=3004037004&checksum=6f388913198d93fb0c03777917c5e94314d389a3-1617045531920-43b6afc5ba3c69985c426bb79d147a60badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049928	NVP 1603			Yes			Discontinued (Preclinical)	Pain		Undefined mechanism	"Navipharm (Originator), Navipharm (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"NVP1603, NVP16031, NVP16031and NVP16032, NVP16032"			04/09/2019	Pain				no		no							https://adis.springer.com/drugs/800049928?userId=52029392&bpIds=3004037004&checksum=4e191f1b8be95b1dd000b64540588dd96dcf9b11-1617045531921-6000b51a7c43a37c919e2acdf2b5ccf7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044545	Carbon dioxide intranasal - Soleno Therapeutics	124-38-9		No			Phase II	"Allergic rhinitis, Trigeminal neuralgia, Cluster headache"	C O2	Calcitonin gene-related peptide antagonists	"Capnia (Originator), Soleno Therapeutics (Owner), Clinvest (Collaborator)"		Intranasal				"N2 (Analgesics), R7 (Other Respiratory System Products), V3 (All Other Therapeutic Products)"	"N02 (Analgesics), R07 (Other Respiratory System Products), V03A-N (Medical gases)"	"Serenz, Serenz Allergy Relief"			29/08/2019	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems, Obstructive Airways Disease, Pain"	Trigeminal neuralgia (USA)		Serenz	no		no							https://adis.springer.com/drugs/800044545?userId=52029392&bpIds=3004037004&checksum=ea6165be6dd93bec6ee8c8192d0b70d9fdef4b23-1617045531922-cdb775ce4582a7b10c8999363dfd3722badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030801	Research programme: small molecule therapeutics - e-therapeutics			Yes			Preclinical	"Neurodegenerative disorders, Viral infections, Fibrosis, Cancer, Pain, Age-related macular degeneration"		"Protein modulators, Hedgehog cell-signalling pathway inhibitors, Telomerase inhibitors"	"e-Therapeutics (Originator), e-Therapeutics (Owner)"		unspecified				"C10 (Lipid-Regulating/Anti-Atheroma Preparations), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs), N7D (Anti-Alzheimer Products), S1X (Other Ophthalmologicals)"	"C10A (Lipid Modifying Agents, Plain), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06D (Anti-Dementia Drugs), N07 (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"	"ETS 2123, ETS 5200, ETS 6114, ETS 7211, ETS2300, ETS2400, ETS6200, ETX 6201, ETX 6765, ETXP009171, ETXP009181, ETXP009425"			29/08/2019	"Cancer, Connective Tissue Disorders, Eye Disorders, Neurological Disorders, Pain, Rheumatic Disease, Viral Infections"				no		no							https://adis.springer.com/drugs/800030801?userId=52029392&bpIds=3004037004&checksum=ebc3313370ef4974f40032f61ab40b1867b34a7c-1617045531924-c96f98fac0202ba30750cf007c8970febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031671	Fentanyl patch - Kyukyu Pharmaceutical/Maruishi Pharmaceutical	437-38-7	N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			No development reported (III)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Kyukyu Pharmaceutical (Originator), Kyukyu Pharmaceutical (Owner), Maruishi Pharmaceutical (Licensee)"		Transmucosal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Fentanyl film Nippon Kayaku, MRQ01, NKQ01"			28/08/2019	Pain				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800031671?userId=52029392&bpIds=3004037004&checksum=7eac7cc27c2d9a10b7269d711d43e1ddc80ef6fc-1617045531925-7688e7ab384be41a7f82d88109026075badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055741	Chronic pain therapeutic - SIMR Biotech			Yes			Preclinical	Pain		Ion channel modulators	"SIMR Biotech (Originator), SIMR Biotech (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				27/08/2019	Pain				no		no							https://adis.springer.com/drugs/800055741?userId=52029392&bpIds=3004037004&checksum=f454db158743aac3f4d744673f9305ff1c905ce7-1617045531926-4b1a9bce765e70309cde0e5717b6d3cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055738	Research programme: neuropathic pain therapeutics - SIMR Biotech			Yes			Preclinical	Neuropathic pain		Ion channel modulators	"SIMR Biotech (Originator), SIMR Biotech (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				27/08/2019	Pain				no		no							https://adis.springer.com/drugs/800055738?userId=52029392&bpIds=3004037004&checksum=6cd111d94a419a6b57a41a5780df95565be2a57f-1617045531927-d3fedf50574131e018b56f833730bac2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029507	DWP 05195			Yes			Discontinued (II)	Neuropathic pain		TRPV1 receptor antagonists	"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"DWP05195, TR1"			27/08/2019	Pain		Daewoong Pharmaceutical |  | Phase II |  | 07 Oct 2015		no		no							https://adis.springer.com/drugs/800029507?userId=52029392&bpIds=3004037004&checksum=6deb9d9feeac8fa7f59f94abb65855b9eb63acf8-1617045531928-938bd6ac14a48358417a29864c34f7b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028794	Amitriptyline/oxymetazoline/ketoprofen - Omeros Corporation		"10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene / 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol / 2-(3-benzoylphenyl)propanoic acid"	No			Discontinued (III)	Postoperative pain	C20 H23 N . C16 H24 N2 O . C16 H14 O3	"Alpha 1 adrenergic receptor agonists, Alpha 2 adrenergic receptor agonists, Lipoxygenase-cyclooxygenase inhibitors, Serotonin uptake inhibitors"	"Omeros Corporation (Originator), Omeros Corporation (Owner), Fagron (Licensee)"		Intra-articular				N2B (Non-Narcotics and Anti-Pyretics)	"M01A-E53 (Ketoprofen, combinations), N02B (Other Analgesics and Antipyretics), N06A-A09 (Amitriptyline), R01A-A05 (Oxymetazoline)"	"Ketoprofen/amitriptyline/oxymetazoline, Ketoprofen/oxymetazoline/amitriptyline, OMS 103, OMS103HP, Oxymetazoline/amitriptyline/ketoprofen"			27/08/2019	Pain				no		no							https://adis.springer.com/drugs/800028794?userId=52029392&bpIds=3004037004&checksum=8de0a492eacd8e18a616d42728d2add43a298a5b-1617045531930-04c69f02af073b9cf56d19ab4650af44badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010172	Morphine rectal - CeNeS Pharmaceuticals	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate"	Yes			Marketed	"Cancer pain, Postoperative pain"	C17 H19 N O3 . 1/2 H2 S O4 . 5/2 H2 O	Opioid mu receptor agonists	"University of Strathclyde (Originator), BTG (Owner), Gamida-MedEquip (Market Licensee), PAION (Licensee), Bausch Health Companies (Sub-licensee)"		Rectal				N2A (Narcotics)	N02A-A01 (Morphine)	Moraxen			21/08/2019	"Drug Delivery Systems, Pain"			Moraxen	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800010172?userId=52029392&bpIds=3004037004&checksum=9a8033f03483ff755d3674a2a090d02beda9ecc6-1617045531932-65c5509eeabbe47d1ef3f5edc3cfc653badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015448	AP 1531			Yes			Discontinued (I)	Migraine		Prostaglandin E4 antagonists	"Asterand plc (Originator), Asterand plc (Owner), BTG (Licensee), Ariel Pharmaceuticals (Sub-licensee)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"BGC201531, PGN1531"			21/08/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800015448?userId=52029392&bpIds=3004037004&checksum=5041f3ad8cc6b2fa1183e6b6bba4642e46f50106-1617045531933-481a73d33cd6182fde3f2872e4b13b81badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009427	CEE 04421			No			Discontinued (Preclinical)	"Postoperative pain, Neuropathic pain, Inflammation"		Undefined mechanism	"National Institute for Biological Standards and Controls (Originator), University of Sao Paulo (Originator), National Institute for Biological Standards and Controls (Owner), University of Sao Paulo (Owner), CeNeS Pharmaceuticals (Market Licensee), BTG (Collaborator)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	Analgesic tripeptide (CEE 04421) CeNeS			21/08/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800009427?userId=52029392&bpIds=3004037004&checksum=2f2176bc9431def2b7f63677774e5b8340b7cefe-1617045531934-a358589233ae4f40817737d572bd8f72badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011579	Research programme: GABA transport inhibitors - Novo Nordisk/BTG			No			No development reported (Preclinical)	"Epilepsy, Pain"		GABA uptake inhibitors	"Novo Nordisk (Originator), Novo Nordisk (Owner), BTG (Market Licensee)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	GABA transport inhibitors research programme Novo Nordisk/BTG			21/08/2019	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800011579?userId=52029392&bpIds=3004037004&checksum=e5b1cc8ba8c8031db3cc6621639706a6d1ad8bf6-1617045531935-d42fa812c1ecf0e41037a09bcd060796badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020360	Research programme: cannabinoid CB2 receptor agonists - BTG			No			Discontinued (Preclinical)	"Pain, Neuropathic pain, Multiple sclerosis"		Cannabinoid receptor CB2 agonists	"BTG (Originator), BTG (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				21/08/2019	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020360?userId=52029392&bpIds=3004037004&checksum=97b88b96701d84da6c3c7f9fc21fcc6c47bd6f53-1617045531936-ae9c5f9dbb2348162ba40339bb8f0d0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026450	Research programme: modafinil/opioid analgesic combinations: Victory Pharma			No			No development reported (Preclinical)	Pain		"Alpha 1 adrenergic receptor agonists, Opioid receptor agonists"	"BTG (Originator), BTG (Owner), Victory Pharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MGX002			21/08/2019	Pain				no		no							https://adis.springer.com/drugs/800026450?userId=52029392&bpIds=3004037004&checksum=e4998de1204d87755b4652d6d8b40630f58a6b45-1617045531937-d8cb514856da146b8e9aa01ce41e4082badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026452	Morphine/modafinil			No			Discontinued (II)	Pain		"Alpha 1 adrenergic receptor agonists, Opioid receptor agonists"	"BTG (Originator), BTG (Owner), Victory Pharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MGX001			21/08/2019	Pain				no		no							https://adis.springer.com/drugs/800026452?userId=52029392&bpIds=3004037004&checksum=97efb3e08bb2fb084d9a4d8515c2df91a5105500-1617045531937-d0589f17a78e4c417a5049c4cfc37106badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025813	Research programme: opioid agonists - BTG			Yes			Discontinued (Preclinical)	Postoperative pain		Opioid receptor agonists	"CLL PHARMA (Originator), CLL PHARMA (Owner), BTG (Market Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	BTG6001			21/08/2019	Pain				no		no							https://adis.springer.com/drugs/800025813?userId=52029392&bpIds=3004037004&checksum=ff13d85e2238de1536e54dfb5d4b4d41cad5cba9-1617045531938-1465e4947d7d66398e22c4b1f5ec00d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015717	Liposome encapsulated mitoxantrone	65271-80-9	"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione"	Yes			Discontinued (I/II)	"Multiple sclerosis, Solid tumours, Leukaemia"	C22 H28 N4 O6	"DNA inhibitors, DNA topoisomerase inhibitors, Immunosuppressants, Type II DNA topoisomerase inhibitors"	"NeoPharm Inc (Originator), INSYS Therapeutics, Inc (Owner)"		"unspecified, IV"			Neutropenia	"L1D (Antineoplastic Antibiotics), L4X (Other Immunosuppressants), N2 (Analgesics), N7X (All other CNS drugs)"	"L01D-B (Anthracyclines and related substances), L01D-B07 (Mitoxantrone), L04A-X (Other immunosuppressants), N02 (Analgesics)"	"LEM, LEM ETU, Liposomal mitoxantrone, Mitoxantrone liposomal"			21/08/2019	"Cancer, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800015717?userId=52029392&bpIds=3004037004&checksum=03f2c3bff949798d97d55a545fe6c4bbbb6c86b9-1617045531939-c4384c477382515cdbc511b054edbab1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023360	Raseglurant - Addex Therapeutics	757950-09-7	"2-[2-(3-fluorophenyl)ethynyl]-4,6-dimethylpyridin-3-amine"	Yes			Discontinued (II)	"Gastro-oesophageal reflux, Migraine, Anxiety disorders, Parkinson's disease, Drug-induced dyskinesia"	C15 H13 F N2	Metabotropic glutamate receptor 5 modulators	"Addex Pharmaceuticals (Originator), Addex Pharmaceuticals (Owner)"		PO				"A2C (Other Stomach Disorder Preparations), A7E (Intestinal Anti-Inflammatory Agents), N2 (Analgesics), N2C (Anti-Migraine Preparations), N4 (Anti-Parkinson Drugs), N5B (Hypnotics/Sedatives), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"A02B (Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (GORD)), N02 (Analgesics), N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N05B (Anxiolytics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	ADX10059			19/08/2019	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Parkinson's Disease and Movement Disorders, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800023360?userId=52029392&bpIds=3004037004&checksum=1cff8427041b1ed8830e376284334a722eac9289-1617045531941-daa3008c6b31fe3ff29e3b05d2872e6ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033741	Alfentanil sublingual - Orexo	69049-06-5	"N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4- (methoxymethyl)piperidin-4-yl)-N-phenylpropionamide hydrochloride"	No			Phase II/III	Acute pain	C21 H33 Cl N6 O3	Opioid mu receptor agonists	"Orexo (Originator), Orexo (Owner)"		Sublingual				"N2 (Analgesics), N2A (Narcotics)"	"N01A-H02 (Alfentanil), N02A (Opioids)"	OX51			19/08/2019	Pain		Orexo | Acute pain | Phase III |  | 22 Mar 2018		no		no				"CD59 molecule, complement regulatory protein"			https://adis.springer.com/drugs/800033741?userId=52029392&bpIds=3004037004&checksum=40c0d3c2813a0f0b12b7c93ea26e0502483063c4-1617045531942-ef612e8662ceee44b97983cdb109c490badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033407	Rosiptor - Neoleukin Therapeutics	782487-28-9	"(1S,3S,4R)-4-[(3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-3,3a,4,5,6,7-hexahydro-2H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol"	Yes			Discontinued (III)	"Interstitial cystitis, Chronic obstructive pulmonary disease, Allergic asthma, Prostatitis, Atopic dermatitis, Haematological disorders, Inflammation, Irritable bowel syndrome, Immunological disorders, Pulmonary fibrosis, Hypersensitivity"	C20 H35 N O2	"Inositol-1,4,5-trisphosphate 5-phosphatase stimulants"	"Aquinox Pharmaceuticals (Originator), Neoleukin Therapeutics (Owner), Astellas Pharma (Licensee), Orexo (Technology Provider)"		PO				"A3 (Functional Gastro-Intestinal Disorder Drugs), B6C (Other Haematological Agents), D11A (Other Dermatological Preparations), G4 (Urologicals), L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3 (Anti-Asthma and COPD Products), R7 (Other Respiratory System Products), R7X (All Other Respiratory System Products)"	"A03A (Drugs for Functional Bowel Disorders), B06A (Other Hematological Agents), D11A-H (Agents for atopic dermatitis, excluding corticosteroids), G04 (Urologicals), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases), R07 (Other Respiratory System Products), R07A-X (Other respiratory system products)"	"AQX 1125, Rosiptor acetate"			13/08/2019	"Connective Tissue Disorders, Digestive System Disorders, Genitourinary Disorders, Haematological Disorders, Immunological Disorders, Inflammation, Men's Health, Obstructive Airways Disease, Respiratory Tract Disorders, Skin Disorders"				no		no							https://adis.springer.com/drugs/800033407?userId=52029392&bpIds=3004037004&checksum=c4050fc19beded321baeaaa2ac4d9653e495dd8c-1617045531946-e8782299d467630b6d3e36037a83a5f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024012	Buprenorphine transdermal - Mundipharma	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"	No			Marketed	Pain	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Mundipharma International (Originator), Mundipharma International (Owner), Grunenthal (Market Licensee), Napp Pharmaceutical Group (Market Licensee), Norpharma (Market Licensee), Pharmaco (NZ) (Market Licensee), Purdue Pharma (Market Licensee), Hisamitsu Pharmaceutical (Licensee)"		Transdermal			"Application site reactions, Constipation, Dizziness, Erythema, Exanthema, Headache, Nausea, Pruritus, Somnolence, Vomiting, Xerostomia"	N2A (Narcotics)	N02A-E01 (Buprenorphine)	"BTDS, BuTrans, Butrans, Butrans Transdermal System CIII, Norspan, Norspan Tape, Restive, Sovenor"			08/08/2019	Pain			"BuTrans, BuTrans, Butrans, Butrans, Butrans, Butrans, Butrans Transdermal System CIII, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan, Norspan Tape, Restive, Sovenor, Sovenor"	no		no				"8-Hydroxy-14,16-hentriacontanedione, SH3 domain containing GRB2 like 1, endophilin A2, T cell receptor gamma variable 9, Valproic acid glucuronide"		defensin beta 1	https://adis.springer.com/drugs/800024012?userId=52029392&bpIds=3004037004&checksum=be442176123dfe943443bcf8659f97207a26836d-1617045531951-6217c39bd4b286cf84507770fc610109badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030687	Buprenorphine/naloxone - Ology Bioservices			No			Phase II	"Dental pain, Opioid-related disorders"	C29 H41 N O4 . C19 H21 N 04	Opioid receptor antagonists	"Nanotherapeutics (Originator), Ology Bioservices (Owner)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence), V3E (Antidotes)"	"N02A-E01 (Buprenorphine), N07B-C51 (Buprenorphine, combinations), V03A-B15 (Naloxone)"	"NanoBUP, NTC0510, NTC510"			07/08/2019	"Drug Withdrawal, Pain"			NanoBUP	no		no							https://adis.springer.com/drugs/800030687?userId=52029392&bpIds=3004037004&checksum=76d29bb0030ad42a9e11867f21650142eccc9365-1617045531952-728111582934c2644c8974a1e1844b73badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020308	Sumatriptan oral spray - SUDA	103628-46-2	"1<EM>H</EM>-Indole-5-methanesulfonamide,3-(2-(dimethylamino)ethyl)-<EM>N</EM>-methyl-"	No			Phase II	Migraine	C14 H21 N3 O2 S	Serotonin 1D receptor agonists	"NovaDel Pharma (Originator), SUDA (Owner), Strides Pharma Science (Licensee)"		Transmucosal				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"NVD201, SUDA001"			02/08/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800020308?userId=52029392&bpIds=3004037004&checksum=306ae56a0cb23add7251c8e4394367afe071db7a-1617045531953-d7e62de6ac67123a5dcb27f2a2e10700badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016703	Naloxone/oxycodone - Mundipharma	92522-88-8	"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 1-N-Allyl-7,8-dihydro-14-hydroxynormorphinone"	No			Marketed	"Restless legs syndrome, Constipation, Pain, Interstitial cystitis"	C18 H21 N O4 . C19 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Mundipharma GmbH (Originator), Mundipharma GmbH (Owner), Rafa Laboratories (Licensee), Shionogi (Licensee), Napp Pharmaceutical Group (Collaborator), Purdue Pharma (Collaborator)"		PO				"A3 (Functional Gastro-Intestinal Disorder Drugs), N2A (Narcotics), N7 (Other CNS Drugs), N7F (Drugs Used In Opioid Dependence)"	"A03A (Drugs for Functional Bowel Disorders), N02A-A55 (Oxycodone, combinations), N07 (Other Nervous System Drugs), N07B-C (Drugs used in opioid dependence)"	"OXN PR, Oxycodone hydrochloride/naloxone hydrochloride Mundipharma, Oxycodone/naloxone extended release Mundipharma, Oxycodone/naloxone prolonged release Mundipharma, Targin, Targinact, Targiniq, Targiniq ER"			02/08/2019	"Digestive System Disorders, Genitourinary Disorders, Pain, Parkinson's Disease and Movement Disorders"			"Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targin, Targinact, Targinact, Targinact, Targinact, Targinact, Targinact, Targinact, Targinact, Targinact, Targinact, Targiniq, Targiniq, Targiniq, Targiniq, Targiniq, Targiniq, Targiniq"	no		no				"EH domain containing 3, NTx"	NTx	"ER alpha, PGR"	https://adis.springer.com/drugs/800016703?userId=52029392&bpIds=3004037004&checksum=3bd193ba632954686a77114111e8c7d1d567f590-1617045531962-62a8126edbfede4f37f18222deb93b98badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038672	Research programme: therapeutics for pain and other indications - Array BioPharma			No			No development reported (Preclinical)	"Pain, Unspecified"		"TrkA receptor antagonists, TrkB receptor antagonists, TrkC receptor antagonists"	"Array BioPharma (Originator), Array BioPharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				02/08/2019	Pain				no		no							https://adis.springer.com/drugs/800038672?userId=52029392&bpIds=3004037004&checksum=176506e618176710d47f506b74a62a2e9e262a82-1617045531963-4b442b73e2b2e3798bcba40321e85582badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023278	Sumatriptan needle-free injection - Desitin Pharmaceuticals	103628-46-2	3-[2-(dimethyl-amino)ethyl]-<EM>N</EM>-methylindole-5-methanesulfonamide	No			Marketed	Migraine	C14 H21 N3 O2 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Zogenix (Originator), Endo International (Owner), Desitin Pharmaceuticals GmbH (Licensee), Aradigm Corporation (Technology Provider)"		SC				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"Needlefree subcutaneous sumatriptan, Sumatriptan DosePro, Sumatriptan Intraject, Sumavel DosePro"			31/07/2019	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			"Sumavel DosePro, Sumavel DosePro"	no		no							https://adis.springer.com/drugs/800023278?userId=52029392&bpIds=3004037004&checksum=2c3e2b1edb662e295f68fd8a7565a4bdd6233925-1617045531965-2f6f28a7d800853075b73871073940a2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055339	Research programme: pain therapeutics - Biogen/Inscopix			Yes			Research	Pain		Undefined mechanism	"Biogen (Originator), Inscopix (Originator), Biogen (Owner), Inscopix (Owner), Stanford University (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				29/07/2019	Pain				no		no							https://adis.springer.com/drugs/800055339?userId=52029392&bpIds=3004037004&checksum=20e45c66b06cb66432a1beed651758b8127a794c-1617045531965-146c1c5d871b7722f57923c4bc2e9f68badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036946	Research programme: peptide-based therapeutics - RAPID Pharmaceuticals			Yes			No development reported (Preclinical)	"Psoriasis, Hepatitis B, Neuropathic pain, Prostate cancer, Alzheimer's disease, Ovarian cancer"		"Chemokine receptor modulators, Immunostimulants, CCR2 receptor antagonists, CCR5 receptor antagonists, Stem cell inhibitors, Chemokine receptor antagonists, CCR3 receptor antagonists"	"RAPID Pharmaceuticals (Originator), RAPID Pharmaceuticals (Owner), McGill University (Collaborator), University of Duisburg-Essen (Collaborator), University of Michigan (Collaborator)"		PO				"D5B (Systemic Antipsoriasis Products), J5 (Antivirals for Systemic Use), L1 (Antineoplastics), L3 (Immunostimulating Agents), N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"D05B-X (Other antipsoriatics for systemic use), J05 (Antivirals for Systemic Use), L01 (Antineoplastic Agents), L03 (Immunostimulants), N02B-G (Other analgesics and antipyretics), N06D (Anti-Dementia Drugs)"	"RAP 160, RAP 163, RAP 164, RAP 310, RAP 701, RAP103"			28/07/2019	"Alzheimer's Disease and Cognition Disorders, Cancer, Pain, Skin Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800036946?userId=52029392&bpIds=3004037004&checksum=15e1975e1f92d85b30c86ec5758d211c7a93a9bd-1617045531967-24ea18b1a3838324ae30553b2c541847badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045697	AQU 005			Yes			No development reported (I)	Neuropathic pain		"Matrix metalloproteinase 2 inhibitors, Matrix metalloproteinase 9 inhibitors"	"Aquilus Pharmaceuticals (Originator), Aquilus Pharmaceuticals (Owner), NeuroMax (Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"AQU005, NMAQU005"			28/07/2019	Pain				no		no							https://adis.springer.com/drugs/800045697?userId=52029392&bpIds=3004037004&checksum=578924b0f874f14b9915521a1006689c937eff78-1617045531968-aa81d831b490f58d1b534f5fb75b124cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048101	Research programme: ophthalmic analgesic - D.Western Therapeutics Institute			Yes			No development reported (Preclinical)	Preoperative pain		Undefined mechanism	"Unknown (Originator), Unknown (Owner), D. Western Therapeutics Institute (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/07/2019	Pain				no		no							https://adis.springer.com/drugs/800048101?userId=52029392&bpIds=3004037004&checksum=e922da09e53e47f39d3f6468d62a509c9eeb7176-1617045531969-b84b5ec40758485bafde000f5b7ba095badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044892	AP 2200			No			No development reported (I)	Pain		Cyclo-oxygenase 2 inhibitors	"Arissa Pharma (Originator), Arissa Pharma (Owner)"		PO				"M1C (Specific Anti-Rheumatic Agents), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	AP2200			28/07/2019	Pain				no		no							https://adis.springer.com/drugs/800044892?userId=52029392&bpIds=3004037004&checksum=83cfacd3f02c1dbac3a9fba3ca17b0b9b097660e-1617045531970-c6c56f32964a5194d334e595e37e2b8abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024906	Hydromorphone controlled release - DURECT Corporation	466-99-9	"4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone"	No			No development reported (I)	Pain	C17 H19 N O3	Opioid receptor modulators	"DURECT Corporation (Originator), DURECT Corporation (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"ORADURHydromorphone, PTI 202"			28/07/2019	Pain				no		no							https://adis.springer.com/drugs/800024906?userId=52029392&bpIds=3004037004&checksum=32f1bd80fc84b002c2f03f4bf7c96dbf2774a6d2-1617045531970-44c1fa18271f31a0653d10bde9a0d458badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041477	Research programme: BH4 synthesis modulators - Quartet Medicine			Yes			No development reported (Preclinical)	"Inflammation, Pain"		"GTP cyclohydrolase modulators, Sepiapterin reductase modulators"	"Quartet Medicine (Originator), Quartet Medicine (Owner), Merck & Co (Funder)"		"unspecified, PO"				"L (Antineoplastic and Immunomodulating Agents), N2 (Analgesics)"	"L (Antineoplastic and Immunomodulating Agents), N02 (Analgesics)"	"QMED1, QMED2, Sepiapterin reductase inhibitors"			28/07/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800041477?userId=52029392&bpIds=3004037004&checksum=e6a469090725a612d72dd75a37331a13dbd33c10-1617045531972-2d17e2c15e1477eafbdfd5e9a7428208badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038339	NC 2600			Yes			No development reported (I)	Neuropathic pain		Purinoceptor P2X antagonists	"Kyushu University (Originator), Nippon Chemiphar (Originator), Kyushu University (Owner), Nippon Chemiphar (Owner), Japan Agency for Medical Research and Development (Funder)"		PO				N2 (Analgesics)	N02 (Analgesics)				28/07/2019	Pain				no		no							https://adis.springer.com/drugs/800038339?userId=52029392&bpIds=3004037004&checksum=43abe45bdf254c4aee42a12840386e2ae74fc792-1617045531972-802245d297a576e70f50041334a453b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045571	Buprenorphine - Chiesi Farmaceutici	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(S)]-"	No			Phase I/II	Substance-related disorders	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor antagonists"	"Chiesi (Originator), Chiesi (Owner), Thomas Jefferson University (Collaborator)"		Sublingual				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	Buprenorphine sublingual solution Chiesi Farmaceutici			24/07/2019	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800045571?userId=52029392&bpIds=3004037004&checksum=a6f227e34d88683b3b23efc0a9a87560e6316ec4-1617045531973-2f37398b38ed83e3fb993bfe6d67baa0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055403	MUMO 1			Yes			Phase I	Pain		Sigma-1 receptor antagonists	"ESTEVE (Originator), ESTEVE (Owner), Purdue Pharma (Development Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"MuMo 1, MUMO1"			24/07/2019	Pain				no		no							https://adis.springer.com/drugs/800055403?userId=52029392&bpIds=3004037004&checksum=c84c23d29ce039fb7a813feb9831a656eecb9e34-1617045531974-d46a67ac9555c39c606de24d07d13675badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041943	Research programme: sigma-1 receptor property enhancers - Esteve			Yes			Preclinical	Pain		Sigma-1 receptor modulators	"ESTEVE (Originator), ESTEVE (Owner), Purdue Pharma (Development Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				24/07/2019	Pain				no		no							https://adis.springer.com/drugs/800041943?userId=52029392&bpIds=3004037004&checksum=3c7fe7b5722257d1825f428fe2b98367e6ea028d-1617045531975-8555722adaac2812ab61888f3646cc2abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042245	Sumatriptan succinate - Promius Pharma	103628-46-2	1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide	No			Marketed	Migraine	C14 H21 N3 O2 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Promius Pharma (Originator), Promius Pharma (Owner), Upsher-Smith (Market Licensee)"		SC				N2C (Anti-Migraine Preparations)	N02C-C01 (Sumatriptan)	"DFN11, ZEMBRACESymTouch"			23/07/2019	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			ZEMBRACESymTouch	no		no							https://adis.springer.com/drugs/800042245?userId=52029392&bpIds=3004037004&checksum=128400bd2ea5cc91e5ccb8b03e2b20e964edac56-1617045531976-4c78380e1dab461df3ebc516f7726d73badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002067	Research programme: adenosine A2A receptor antagonists - Kyowa Kirin			Yes			Discontinued (Preclinical)	"Parkinson's disease, Sleep disorders, Migraine"		Adenosine A2 receptor antagonists	"Kyowa Hakko (Originator), Kyowa Hakko Kirin - Mitsui Knowledge (JV) (Originator), Kyowa Kirin (Owner), Lundbeck A/S (Development Licensee)"		unspecified				"N2C (Anti-Migraine Preparations), N4 (Anti-Parkinson Drugs), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants)"	"N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N06A-B (Selective serotonin reuptake inhibitors), N06A-X (Other antidepressants), N06B-A (Centrally acting sympathomimetics)"	K056			16/07/2019	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800002067?userId=52029392&bpIds=3004037004&checksum=cb8e322b6e4af6d568353685638664eb9fdd13af-1617045531977-a77252626521a37ff355b2859f071aeabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029396	Research programme: neuropathic pain therapeutics - Kyowa Kirin			Yes			No development reported (Preclinical)	Neuropathic pain		Chemokine receptor antagonists	"Kyowa Hakko Kirin (Originator), Kyowa Kirin (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CompoundA			16/07/2019	Pain				no		no							https://adis.springer.com/drugs/800029396?userId=52029392&bpIds=3004037004&checksum=03ee78b6aa46d017a02e65ed2af7596b991361e4-1617045531977-875782e9f001104c9c83fedd3cccf433badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037280	Hydrocodone/paracetamol controlled-release - Mallinckrodt		"(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one / N-(4-hydroxyphenyl)acetamide"	No			Preregistration	"Acute pain, Musculoskeletal pain, Back pain"	C18 H21 N O3 . C8 H9 N O2	"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Mallinckrodt Inc. (Originator), Mallinckrodt Inc. (Owner), Assertio Therapeutics (Technology Provider)"		PO			"Constipation, Dizziness, Headache, Nausea, Pruritus, Somnolence, Vomiting"	"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-F (Morphinan derivatives), N02B-E01 (Paracetamol)"	"Acetaminophen/hydrocodone controlled release Mallinckrodt, COV155, Hydrocodone bitartrate/acetaminophen extended release Mallinckrodt, Hydrocodone/acetaminophen controlled release Mallinckrodt, Hydrocodone/paracetamol controlled release Mallinckrodt, Hydrocodone/paracetamol CR Mallinckrodt, MNK155, Paracetamol/hydrocodone Mallinckrodt"			08/07/2019	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800037280?userId=52029392&bpIds=3004037004&checksum=f76b9c2058d08e56599ed4ab2f18199a4d00cabf-1617045531979-fda7e038742bafab2154d07d7190c9d5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015864	Fentanyl buccal - BioDelivery Sciences/TTY Biopharm	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Marketed	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"QLT USA (Originator), BioDelivery Sciences International (Owner), Collegium Pharmaceutical (Licensee), Meda (Licensee), TTY Biopharm (Licensee)"		Buccal		Linear Kinetics (yes)	"Dehydration, Dizziness, Dyspnoea, Nausea, Somnolence, Vomiting"	N2A (Narcotics)	N02A-B03 (Fentanyl)	"BEMAFentanyl, Breakyl, Fentanyl buccal soluble film, Fentanyl transmucosal BioDelivery Sciences, Onsolis, Painkyl"			08/07/2019	"Drug Delivery Systems, Pain"		"BioDelivery Sciences International |  | Unspecified | Canada, Mexico, USA | 27 Jan 2015"	"Breakyl, Onsolis, Onsolis, Painkyl"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800015864?userId=52029392&bpIds=3004037004&checksum=05a46bd1486044e8742ab8a4eb98fd9799da506d-1617045531981-5cbb836d9c79aedf72683ad5c51fa1eabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038509	ALLOD 2			No			Phase II/III	"Back pain, Migraine, Adjustment disorders"		"Cyclo-oxygenase 2 inhibitors, Cytokine inhibitors"	"Allodynic Therapeutics (Originator), Allodynic Therapeutics (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"ALLOD2, ALLOD2H, ATNC 05"			05/07/2019	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Pain"				no		no			AFP	Bilirubin			https://adis.springer.com/drugs/800038509?userId=52029392&bpIds=3004037004&checksum=a2c346b231db448610dfde2d965a11ac9eb4e5af-1617045531982-4e768455199eeecf67496d1f77a3684abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054982	Propofol hemisuccinate - Epalex			No			Preclinical	"Epilepsy, Migraine"		GABA A receptor agonists	"Epalex (Originator), Epalex (Owner), Epilepsy Foundation (Funder), National Institutes of Health (USA) (Funder), University of California, Davis (Funder), University of California, Davis (Collaborator)"		"Inhalation, PO"				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02C (Antimigraine Preparations), N03A (Antiepileptics)"	"EP102 Epalex, EP103 Epalex"			04/07/2019	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800054982?userId=52029392&bpIds=3004037004&checksum=012c8e456616e125c9519a81c3ca305378e9adec-1617045531983-b30f81fe845b33f1213d21927d1a19afbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021185	Pegcantratinib - Sienna Biopharmaceuticals	1233363-33-1	"(+)-9,12(<EM>R</EM>)-Epoxy-9(<EM>S</EM>)-methyl-10(<EM>R</EM>)-[<EM>N</EM>-[(PEG<SUB>2_</SUB>)methoxypolyethyleneglycol]carbamoyloxy]-1-oxo-2,3,9,10,11,12-hexahydro-1<EM>H</EM>-diindolo[1,2,3-<EM>fg</EM>:3',2',1'-<EM>kl</EM>]-pyrrolo[3,4-<EM>i</EM>][1,6]benzodiazocine-10-carboxylic acid methyl ester"	Yes			Phase II	"Atopic dermatitis, Plaque psoriasis, Pruritus, Neuropathic pain"	C30 H24 N4 O6(C2 H4 O)n	TrkA receptor antagonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner), Sienna Biopharmaceuticals (Licensee), Rockefeller University (Collaborator)"		Topical			"Dermatitis, Pruritus, Psoriasis"	"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), D5A (Topical Antipsoriasis Products), N2 (Analgesics)"	"D04A-X (Other antipruritics), D05A-X (Other antipsoriatics for topical use), N02 (Analgesics)"	"CT 301/P, CT 327, K252aPEG2K, Pegylated K252A, SNA120"			04/07/2019	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800021185?userId=52029392&bpIds=3004037004&checksum=df9c8e395c1f538783f49605681e4dd7c75df226-1617045531985-15a32ad52462351152b01e1a74ae8b4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027939	Hydrocodone/ibuprofen - Kowa Pharmaceuticals America		"(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one / 2-[4-(2-methylpropyl)phenyl]propanoic acid"	No			Marketed	Acute pain	C18 H21 N O3 . C13 H18 O2	"Cyclooxygenase inhibitors, Opioid receptor agonists"	"ProEthic Pharmaceuticals (Originator), Kowa Pharmaceuticals America (Owner)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"M02A-A13 (Ibuprofen), N02A-F (Morphinan derivatives)"				03/07/2019	Pain				no		no							https://adis.springer.com/drugs/800027939?userId=52029392&bpIds=3004037004&checksum=eda6d515351757ab5d269f7090d70982b4b87085-1617045531986-ca985b082f386fbcadd558b0d58620aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032350	Tilidine - Aoxing	20380-58-9	"3-Cyclohexene-1-carboxylic acid, 2-(dimethylamino)-1-phenyl-, ethyl ester, (1R,2S)-rel-"	Yes			Marketed	"Postoperative pain, Cancer pain"	C17 H23 N 02	Opioid receptor agonists	"Aoxing Pharmaceutical Company (Originator), Aoxing Pharmaceutical Company (Owner), American Oriental Bioengineering (Collaborator)"		PO				N2A (Narcotics)	N02A-X01 (Tilidine)	Tilidate Aoxing			02/07/2019	Pain		"Aoxing Pharmaceutical Company | Cancer pain, Postoperative pain | Phase III |  | 28 Apr 2010"		no		no							https://adis.springer.com/drugs/800032350?userId=52029392&bpIds=3004037004&checksum=7e759a065f3de1240e0230d38c5a62751cec94aa-1617045531987-16d2979c9428560875f8d386f9cd1d0fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049421	QBM 001			No			Preclinical	Pervasive child development disorders		Undefined mechanism	"Q BioMed (Originator), Q BioMed (Owner), Sphaera Pharma (Collaborator), SRI International (Collaborator)"		unspecified				"N2C (Anti-Migraine Preparations), N7 (Other CNS Drugs)"	"M01A-G (Fenamates), N02C (Antimigraine Preparations), N07 (Other Nervous System Drugs)"	QBM001			02/07/2019	"Affective Disorders, Psychotic Disorders"		Q BioMed |  | Phase I |  | 04 Jun 2019		no		no							https://adis.springer.com/drugs/800049421?userId=52029392&bpIds=3004037004&checksum=bc14dc5a5f6d9880abdedcacd3e1d5b68e618107-1617045531988-4c6869c0d7e2e93eb3cc062f3443cd24badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044527	Research programme: ASK1 inhibitors - Calchan			Yes			No development reported (Preclinical)	"Inflammation, Pain"		MAP kinase kinase kinase 5 inhibitors	"Calchan (Originator), Calchan (Owner)"		PO				"L (Antineoplastic and Immunomodulating Agents), N2 (Analgesics)"	"L (Antineoplastic and Immunomodulating Agents), N02 (Analgesics)"				28/06/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800044527?userId=52029392&bpIds=3004037004&checksum=2dc054416acf17f849fdfdb2184cb184c4e5e6cd-1617045531989-46f26fbee92771d6e0b89a90483651fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045272	Huwentoxin-I			Yes			No development reported (Clinical)	Pain		N type calcium channel antagonists	"Xiamen Bioway Biotech (Originator), Sinobioway Bio-medicine (Owner), Hunan Normal University (Collaborator)"		Intrathecal				N2 (Analgesics)	N02 (Analgesics)	"HWAPI, HWTXI"			28/06/2019	Pain				no		no							https://adis.springer.com/drugs/800045272?userId=52029392&bpIds=3004037004&checksum=68eddf35dc4a9a66cf2d553e2d8e99e5c323a1ac-1617045531989-78cec82a24020242191b5e18c70eb48abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038300	Research programme: melanotransferrin conjugated therapeutics - biOasis/MedImmune			Yes			No development reported (Preclinical)	Neuropathic pain		"Biological transport stimulants, Transferrin-binding protein modulators"	"MedImmune (Originator), MedImmune (Owner), biOasis Technologies (Technology Provider), biOasis Technologies (Collaborator)"		Parenteral				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02 (Analgesics)"				28/06/2019	Pain				no		no							https://adis.springer.com/drugs/800038300?userId=52029392&bpIds=3004037004&checksum=a3edf3925ec51f2cac22478b3e4906bc626cc5bf-1617045531990-f971e761d1955133d07e873d45e0e4abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045293	Ibuprofen topical - Crescita Therapeutics	15687-27-1	"Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-"	No			No development reported (I)	Acute pain	C13-H18-O2	Cyclooxygenase inhibitors	"Nuvo Research (Originator), Crescita Therapeutics (Owner)"		Topical				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-E01 (Ibuprofen), N02 (Analgesics)"	"Ibufoam, Topical ibuprofen foam Crescita Therapeutics"			28/06/2019	Pain		Crescita Therapeutics |  | Unspecified |  | 20 Aug 2015		no		no		"C-peptide, opsin 1 (cone pigments), long-wave-sensitive"	peroxisome proliferator-activated receptor gamma	"A1C, ACTH, adrenoceptor alpha 1D, Arachidonic acid, C-peptide, Calprotectin, CD34, CRP, CXCL10, Elastase, Endothelin 1, ER alpha, Estrone sulfate, Ferritin, IFN-gamma, IL1 beta, IL17, IL2, IL5, IL6, IL8, LTB4, Nitric Oxide, NOX2-dp, nuclear prelamin A recognition factor like, peroxisome proliferator-activated receptor gamma, PGE2, Prostacyclin, proteasome subunit alpha 7, Pulmonary disease, chronic obstructive, severe early-onset, RNA, Ro-associated Y1, secretoglobin, family 1A, member 1, sex hormone-binding globulin, Soluble transferrin receptor, submaxillary gland androgen regulated protein 3B, Surfactant protein D, Thromboxane, TNF-alpha"	"A1C, C-peptide, Calprotectin, IFN-gamma, IL1 beta, IL17, IL2, IL5, TNF-alpha"	"Aldosterone, Calreticulin, CD4, CD68, CD8a, Creatinine, CTx, CYP2C9, cytochrome P450 family 2 subfamily C member 8, delta like canonical Notch ligand 4, endothelin receptor type A, F2-isoprostanes, GAD Auto-antibodies, Hepcidin, IGF1, IL10, IL13, IL4, Lactate dehydrogenase, MCP1, miR-146a, OPRM1, PAI-1, PGD2, PGE1, PICP, PIIINP, PINP, Renin, Thromboxane B2, TNFRSF1A, TNFRSF1B, VEGF-A"	https://adis.springer.com/drugs/800045293?userId=52029392&bpIds=3004037004&checksum=2c033a0af2070697b414f26448aae8f343892750-1617045531992-417f86a122cd41cc237b8f9c7b968182badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055198	Research Programme: oral cannabinoid therapeutics - Receptor Life Sciences			No			Preclinical	Unspecified		Cannabinoid receptor modulators	"Receptor Life Sciences (Originator), Receptor Life Sciences (Owner)"		PO					"N02B-G10 (Cannabinoids, including nabiximols)"				27/06/2019					no		no							https://adis.springer.com/drugs/800055198?userId=52029392&bpIds=3004037004&checksum=c65eaf0e929cdddd1d49ceaa9ac748431ddf74d1-1617045531993-1b47e970187eb7e9be3f2a9d94f58feebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030360	Morphine extended release - Assertio Therapeutics			No			Market Withdrawal	Pain		Opioid mu receptor agonists	"Egalet (Originator), Zyla Life Sciences (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	"ARYMO, ARYMO ER, Egalet Morphine, Egalet001, EGP113, EGPO66 Morphine, Morphine sulfate Assertio Therapeutics"			25/06/2019	Pain			"ARYMO, ARYMO ER, Egalet Morphine"	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800030360?userId=52029392&bpIds=3004037004&checksum=ef723ab6f4a6eee74ad08871077b3b16f0da43d5-1617045531995-0f0ee9587606fc96103c3f374a747b16badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033035	Naproxen - Iroko Pharmaceuticals	22204-53-1	(+)-(S)-6-Methoxy-_-methyl-2-naphthaleneacetic acid	No			Discontinued (II)	"Musculoskeletal pain, Dental pain"	C14 H14 O3	Cyclooxygenase inhibitors	"iCeutica (Originator), Egalet (Owner), Iroko Pharmaceuticals (Licensee)"		PO				"M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"M01A-E02 (Naproxen), N02 (Analgesics)"	"IP 890, Nanoformulated naproxen Iroko Pharmaceuticals, SoluMatrix Naproxen"			25/06/2019	Pain		Zyla Life Sciences |  | Unspecified |  | 31 Dec 2018		no		no		"interferon, beta 1, fibroblast, metaxin 1, Uric acid"	"arachidonate 5-lipoxygenase, Estradiol-17beta 3-sulfate, interferon, beta 1, fibroblast, metaxin 1, NGF, proline rich protein BstNI subfamily 3"	"ApoE, arachidonate 5-lipoxygenase, Arachidonic acid, BNP, CD4, CRP, cytokine inducible SH2-containing protein, E-selectin, ER alpha, Estradiol-17beta 3-sulfate, Fibrinogen, ICAM-1, interferon, beta 1, fibroblast, Leukotriene E4, metaxin 1, MPO, NGF, Niacinamide, Paraoxonase 1, paraoxonase 2, pescadillo ribosomal biogenesis factor 1, PGE2, proline rich protein BstNI subfamily 3, TNF-alpha, Uric acid, Valproic acid glucuronide, VCAM-1, Von Willebrand factor"	CD4	"Ferritin, HLA-DR, Thromboxane B2"	https://adis.springer.com/drugs/800033035?userId=52029392&bpIds=3004037004&checksum=b18598a89d376cb19bde9ec268cd22b29841a94d-1617045531996-996f7c539040f961970ffe5ed32a2427badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024626	Research programme: pain therapies - ASINEX/Ingenium			No			No development reported (Preclinical)	Pain			"ASINEX (Originator), Ingenium Pharmaceuticals AG (Originator), ASINEX (Owner), Vivoryon Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				17/06/2019	Pain				no		no							https://adis.springer.com/drugs/800024626?userId=52029392&bpIds=3004037004&checksum=d2ded7bd4b2b8ded11d3283acfd8c8411e45975b-1617045531997-d9e9b0eb09692dd3d27c0d3067143b71badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800055003	NFX 88	56472-29-8	(Z)-2-hydroxyoctadec-9-enoic acid	Yes			Phase II	Neuropathic pain	C18 H34 O3	"G protein-coupled receptor modulators, Phospholipase A1 inhibitors, Phospholipase A2 inhibitors, Prostaglandin-E synthase inhibitors"	"Neurofix Pharma (Originator), Neurofix Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"2OHOA Neurofix Pharma, NFX88"			17/06/2019	Pain				no		no							https://adis.springer.com/drugs/800055003?userId=52029392&bpIds=3004037004&checksum=1483fbcbde2ba3da2588fe007e72b5a15b64df33-1617045531998-6fd6a540b1c7d6cb1c702ba85c9c320abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018573	Research programme: pain therapeutics - Elan/Ingenium			No			No development reported (Preclinical)	"Inflammation, Pain, Neuropathic pain"		Undefined mechanism	"Elan Corporation (Originator), Ingenium Pharmaceuticals AG (Originator), Elan Corporation (Owner), Vivoryon Therapeutics (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				17/06/2019	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800018573?userId=52029392&bpIds=3004037004&checksum=4294472f1e3e9f000eb38b22ad2f83004cfc68d4-1617045531999-5a43fe72e410e2aea6313b3445feecfabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045157	Rizatriptan orally-dissolving film - NAL Pharma	144034-80-0	"1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-"	No			No development reported (Clinical)	Migraine	C15 H19 N5	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"NAL Pharma (Originator), NAL Pharma (Owner)"		Sublingual				N2C1 (Antimigraine triptans)	N02C-C04 (Rizatriptan)	"NAL1606, Rizatriptan benzoate NAL Pharma, Rizatriptan ODF"			28/05/2019	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"		NAL Pharma | Migraine | Unspecified | World | 21 Apr 2016		no		no							https://adis.springer.com/drugs/800045157?userId=52029392&bpIds=3004037004&checksum=f45bf69841fc9c208c5335b9ac91bff1897c4443-1617045532000-7cf919ef8d261c8e83decf0b720134fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030817	Calcitonin intranasal - Neurelis	9007-12-9		No			No development reported (I)	Cancer pain		Calcitonin receptor agonists	"Aegis Therapeutics (Originator), Neurelis (Owner)"		Intranasal				N2 (Analgesics)	N02 (Analgesics)				28/05/2019	Pain				no		no							https://adis.springer.com/drugs/800030817?userId=52029392&bpIds=3004037004&checksum=efbd9ca2b7ab2aa8a2f6ce4951edc2caf30c7fc0-1617045532000-101d4471190204829e864d91bd57296abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033384	Research programme: positive allosteric modulators - Proximagen			Yes			Preclinical	"Parkinson's disease, Cognition disorders"		"Alpha7 nicotinic acetylcholine receptor modulators, Dopamine D1 receptor agonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), Proximagen (Licensee)"		unspecified				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N6D (Nootropics), N7D (Anti-Alzheimer Products)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs)"				28/05/2019	"Alzheimer's Disease and Cognition Disorders, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800033384?userId=52029392&bpIds=3004037004&checksum=06e2ce0f5efdf4436577241a2fa55087297164c0-1617045532001-376a1314cce91f3f86431696da67e870badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033444	Research programme: purinoceptor P2Z antagonists - Affectis/Merck Serono			Yes			No development reported (Preclinical)	"Multiple sclerosis, Neuropathic pain, Charcot-Marie-Tooth disease"		Purinergic P2X7 receptor antagonists	"Affectis Pharmaceuticals (Originator), Affectis Pharmaceuticals (Owner), Merck Serono (Licensee), Charcot-Marie-Tooth Association (Collaborator)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"AFC5128, AFC5261"			28/05/2019	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800033444?userId=52029392&bpIds=3004037004&checksum=0f0c85c2ce04fa52b16624029cc345dccfc9f7bd-1617045532002-71b57df5257bc17ab6e5e2e28824ecd0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027038	ICA 105665	1147856-25-4		Yes			No development reported (II)	"Epilepsy, Pain, Neurological disorders"		KCNQ potassium channel agonists	"Icagen (Originator), Icagen, Inc. (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3 (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N03 (Antiepileptics), N07 (Other Nervous System Drugs)"	ICA105665			28/05/2019	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027038?userId=52029392&bpIds=3004037004&checksum=5139bb25f0d8434a36c4ef65ac31c21c6f07089a-1617045532003-8fd4c3e646178f6049e2f38ce74062f6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053943	Dihydroergotamine mesilate - Promius Pharma		C33 H37 N5 O5 . C H4 O3 S	No			Phase II	Migraine	"Ergotamine 9,10-dihydro-, monomethanesulfonate (salt)"	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Promius Pharma (Originator), Promius Pharma (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C-A01 (Dihydroergotamine)	DFN19			23/05/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800053943?userId=52029392&bpIds=3004037004&checksum=fd03e2d5f41519a69dc97cd660afaf3921494af7-1617045532004-94f1ee46fa528c0ffb38a6d637e83319badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054729	Cannabidiol drug delivery system - Vivera Pharmaceuticals			No			Research	"Alcoholism, Opioid-related disorders, Pain"		"Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"Vivera Pharmaceuticals (Originator), Vivera Pharmaceuticals (Owner), Sentar Pharmaceuticals (Technology Provider)"		Sublingual				N2 (Analgesics)	"N02 (Analgesics), N02B-G10 (Cannabinoids, including nabiximols)"				22/05/2019	"Drug Delivery Systems, Drug Withdrawal"				no		no							https://adis.springer.com/drugs/800054729?userId=52029392&bpIds=3004037004&checksum=0a4ab3c90f7aac3516a10401486363365ded6735-1617045532005-abb35340e47128b1922706e2e829b34cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054730	IMB 150			No			Preclinical	Interstitial cystitis		Undefined mechanism	"Imbrium Therapeutics (Originator), Imbrium Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"IMB150, IMB9011500"			17/05/2019	Genitourinary Disorders				no		no							https://adis.springer.com/drugs/800054730?userId=52029392&bpIds=3004037004&checksum=c76a2dceb33a64cc621ab9c77e7dc8845457b88d-1617045532006-32e9ed74ba9128e916d82ff746aebdbcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054731	IMB 1021012			Yes			Preclinical	Neuropathic pain		Undefined mechanism	"Imbrium Therapeutics (Originator), Imbrium Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IMB1021012			17/05/2019	Pain				no		no							https://adis.springer.com/drugs/800054731?userId=52029392&bpIds=3004037004&checksum=fe411c18d7ad21d50fb8e48374548dc664c0343e-1617045532006-30747e203ad0ccd5271bc2a744d5c66ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054747	Research programme: cannabinoid based therapeutics - Altus Formulation - Tetra Bio-Pharma (JV)			No			Research	"Eye disorders, Cancer, Pain"		Cannabinoid receptor modulators	"Altus Formulation - Tetra Bio-Pharma (JV) (Originator), Altus Formulation - Tetra Bio-Pharma (JV) (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics), S1X (Other Ophthalmologicals)"	"L01 (Antineoplastic Agents), N02 (Analgesics), S01X-A (Other ophthalmologicals)"	"Cannabinoid derived therapeutics Altus Formulation Tetra BioPharma (JV), Cannabinoidreceptor targeted therapeutics Altus Formulation Tetra BioPharma (JV)"			17/05/2019	"Cancer, Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800054747?userId=52029392&bpIds=3004037004&checksum=8cbdac1b45317ae125f84f66e5f946dbd5cdeff6-1617045532007-fdffeb11962de11686d52a40aaa54aa6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054733	Research programme: neuropathic pain therapeutics - Imbrium Therapeutics			Yes			Preclinical	Neuropathic pain		Undefined mechanism	"Imbrium Therapeutics (Originator), Imbrium Therapeutics (Owner), Unknown (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"IMB 111, IMB2011010"			17/05/2019	Pain				no		no							https://adis.springer.com/drugs/800054733?userId=52029392&bpIds=3004037004&checksum=e636fea9ec563419000c2998887bd8b08a84d2a7-1617045532008-69c1337a43fcfb576843ff3c70df54a7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052700	Research programme: cannabis extract therapeutics - MMJ International			No			Preclinical	"Huntington's disease, Multiple sclerosis"		"Cannabinoid receptor modulators, Cannabinoid receptor CB1 inverse agonists, Cannabinoid receptor CB2 inverse agonists, Serotonin 1 receptor modulators, Transient receptor potential channel modulators"	"MMJ International Holdings (Originator), MMJ International Holdings (Owner)"		"unspecified, PO"				"D (Dermatologicals), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), R7X (All Other Respiratory System Products)"	"D (Dermatologicals), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05B (Anxiolytics), N06A (Antidepressants), N07 (Other Nervous System Drugs), R07A-X (Other respiratory system products)"	"Cannabidiolderived medicines MMJ International Holding, Medical marijuana products MMJ International Holdings, MMJ001, MMJ002"			17/05/2019	"Neurological Disorders, Parkinson's Disease and Movement Disorders"	Huntington's disease (USA)			no		no							https://adis.springer.com/drugs/800052700?userId=52029392&bpIds=3004037004&checksum=583578b7db35f2406fe542d4a7b2d60d7ad318f0-1617045532009-c13873fdd58a540c50cd61b4c1c7a603badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023744	Dasolampanel	503294-13-1	"(3<EM>S</EM>,4a<EM>S</EM>,6<EM>S</EM>,8a<EM>R</EM>)-6-[3-chloro-2-(1<EM>H</EM>-tetrazol-5-yl)phenoxy]-decahydroisoquinoline-3-carboxylic-acid"	No			Discontinued (I)	"Neuropathic pain, Migraine"	C17 H20 Cl N5 O3	"AMPA receptor antagonists, Kainic acid receptor antagonists"	"Eli Lilly and Company (Originator), Horizon Pharma (Originator), Horizon Therapeutics plc (Owner), Raptor Pharmaceutical Corp (Licensee)"		PO				"N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"N02 (Analgesics), N02C (Antimigraine Preparations)"	NGX426			16/05/2019	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800023744?userId=52029392&bpIds=3004037004&checksum=2892c394b8d2790812cf7743e0df6ca54bc53ad4-1617045532010-9e02aaae58022894139427694a4a9e2ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025490	Famotidine/ibuprofen - Horizon Therapeutics plc	1011231-26-7	"Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, mixt. with 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl) propanimidamide"	No			Marketed	"Rheumatoid arthritis, Musculoskeletal pain, Osteoarthritis, NSAID-induced ulcer, Ankylosing spondylitis"	C13 H18 O2.C8 H15 N7 O2 S3	"Cyclooxygenase inhibitors, Histamine H2 receptor antagonists"	"Horizon Therapeutics (Originator), Horizon Therapeutics plc (Owner), Grunenthal (Market Licensee)"		PO			"Abdominal pain, Constipation, Diarrhoea, Headache, Nausea"	"A2B1 (H2 antagonists), M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"A02B-A03 (Famotidine), M02A-A13 (Ibuprofen), N02 (Analgesics)"	"Duexa, Duexis, HZT501, Ibuprofen/famotidine"			16/05/2019	"Pain, Peptic Ulcer Disease, Rheumatic Disease"			"Duexis, Duexis, Duexis, Duexis, Duexis, Duexis, Duexis, Duexis"	no		no							https://adis.springer.com/drugs/800025490?userId=52029392&bpIds=3004037004&checksum=1cb1c51661cfd99b3f90afe54aa20a324b13a769-1617045532013-03805a4269f85e2b896d9eb31608181ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054666	Research programme: pain therapeutics - LifeArc/University of Kent			Yes			Research	Pain		Potassium channel modulators	"LifeArc (Originator), University of Kent (Originator), LifeArc (Owner), University of Kent (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				13/05/2019	Pain				no		no							https://adis.springer.com/drugs/800054666?userId=52029392&bpIds=3004037004&checksum=826785c645207d9e59a83cac2c2ed5e7f9a2b60d-1617045532014-5b142456693aaa9b473d9021d0b47358badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042895	Chlorpheniramine/hydrocodone/pseudoephedrine	956596-07-9	"3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-yl-propan-1-amine/4,5_-epoxy-3-methoxy-17-methylmorphinan-6-one/(S,S)-2-methylamino-1-phenylpropan-1-ol"	No			Marketed	"Nasal congestion, Cough, Common cold"	C16H19ClN2 . C18H21NO3 . C10H15NO	"Alpha adrenergic receptor agonists, Histamine H1 receptor antagonists, Opioid receptor agonists"	"Cypress Pharmaceutical (Originator), Currax Pharmaceuticals (Owner)"		PO				"R1B (Systemic Nasal Preparations), R5D (Antitussives), R6 (Systemic Antihistamines)"	"N02A-F (Morphinan derivatives), R01B-A02 (Pseudoephedrine), R05D-A03 (Hydrocodone), R06A-B04 (Chlorphenamine), R06A-B54 (Chlorphenamine, combinations)"	"Chlorpheniramine/hydrocodone/pseudoephedrine Currax Pharmaceuticals, Chlorpheniramine/pseudoephedrine/hydrocodone, Hydrocodone/chlorpheniramine/pseudoephedrine, Hydrocodone/pseudoephedrine/chlorpheniramine, Pseudoephedrine/chlorpheniramine/hydrocodone, Pseudoephedrine/hydrocodone/chlorpheniramine, ZUTRIPRO"			09/05/2019	Respiratory Tract Disorders			"ZUTRIPRO, ZUTRIPRO, ZUTRIPRO"	no		no							https://adis.springer.com/drugs/800042895?userId=52029392&bpIds=3004037004&checksum=fb0ffeb9dc2801159149fe3fb6d79c9d5a8efb9d-1617045532022-d00650c7ba2e3141e6dc3459394496a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042793	Hydrocodone/chlorpheniramine - Currax Pharmaceuticals		"(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one/ 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine"	No			Marketed	"Common cold, Cough"	C18 H21 NO3 C4H6O6 2.5H2O . C16 H19 ClN2 C4H4O4	"Histamine H1 receptor antagonists, Opioid receptor agonists"	"Cypress Pharmaceutical (Originator), Currax Pharmaceuticals (Owner)"		PO				"N2A (Narcotics), R5D2 (Antitussives in combinations), R6A (Systemic Antihistamines)"	"N02A-F (Morphinan derivatives), R05D-A03 (Hydrocodone), R06A (Antihistamines for Systemic Use), R06A-B54 (Chlorphenamine, combinations)"	"Chlorpheniramine/hydrocodone Currax Pharmaceuticals, Vituz"			09/05/2019	Respiratory Tract Disorders			"Vituz, Vituz"	no		no							https://adis.springer.com/drugs/800042793?userId=52029392&bpIds=3004037004&checksum=4ebf4e9ee34adb9023af415f95f7dbb60ccfcc3a-1617045532023-ec89b4ee8ecb8314a056edd5f50067c3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027542	Hydrocodone controlled-release - Currax Pharmaceuticals	125-29-1	"Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl-"	No			Marketed	Pain	C18 H21 N O3	Opioid receptor agonists	"Daravita (Originator), Perrigo (Owner), Currax Pharmaceuticals (Licensee), Endo International (Licensee), Altus Formulation Inc (Technology Provider)"		PO			"Abdominal pain, Back pain, Constipation, Dizziness, Fatigue, Headache, Muscle spasticity, Nausea, Oedema, Pruritus, Respiratory tract infections, Somnolence, Tremor, Urinary tract infections, Vomiting, Xerostomia"	N2A (Narcotics)	N02A-F (Morphinan derivatives)	"AFI001, Hydrocodone bitartrate, Hydrocodone ER, Hydrocodone extended release, Zohydro ER, ZX 007, ZX002"			09/05/2019	Pain		Altus Formulation Inc |  | Unspecified |  (Excluding USA) | 29 Jul 2016	Zohydro ER	no		no				"ER alpha, gamma-glutamyltransferase light chain 1, Uric acid"			https://adis.springer.com/drugs/800027542?userId=52029392&bpIds=3004037004&checksum=4625fb259b3dc25cac29bd869d0fa60700f028d2-1617045532024-f43a7937a0ae19bc31e9f3529ee7b5eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054625	Research programme: ion channel modulators - Daiichi Sankyo			Yes			Preclinical	Pain		Ion channel modulators	"LifeArc (Originator), Oxford University Nuffield Department of Clinical Neurosciences (Originator), LifeArc (Owner), Oxford University Nuffield Department of Clinical Neurosciences (Owner), Daiichi Sankyo Inc (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				09/05/2019	Pain				no		no							https://adis.springer.com/drugs/800054625?userId=52029392&bpIds=3004037004&checksum=f4782f050d5e84ef49ba9a6ccbe3a579c52b785d-1617045532025-0b99ac6f32f010287f68a77692a9daa4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048233	Sumatriptan transmucosal - Targia Pharmaceuticals			No			No development reported (I)	Migraine		Serotonin 1 receptor agonists	"Targia Pharmaceuticals (Originator), Targia Pharmaceuticals (Owner), SoluBest (Collaborator)"		Sublingual				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"Omexa, Omexa Sumatriptan"			28/04/2019	Advances in the Treatment of Nausea and Migraine			Omexa	no		no							https://adis.springer.com/drugs/800048233?userId=52029392&bpIds=3004037004&checksum=29a0a20844034323462206099336bfbb08f3c30f-1617045532026-084b2b349e8c5ffe9bc2ad4ee019a1f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033087	Botulinum toxin A topical - Revance Therapeutics	93384-43-1		No			Phase II	"Migraine, Neuropathic pain, Facial wrinkles, Hyperhidrosis"		"Acetylcholine inhibitors, Glutamate antagonists, Membrane transport protein modulators, Neuromuscular blocking agents"	"Revance Therapeutics (Originator), Revance Therapeutics (Owner)"		Topical				"D (Dermatologicals), M3A (Muscle Relaxants, Peripherally Acting), N2 (Analgesics), N2C (Anti-Migraine Preparations), R3 (Anti-Asthma and COPD Products)"	"D (Dermatologicals), M03A-X01 (Botulinum toxin), N02 (Analgesics), N02C-X (Other antimigraine preparations), R03 (Drugs for Obstructive Airway Diseases)"	"RT 001 Revance, RT001"			28/04/2019	"Advances in the Treatment of Nausea and Migraine, Pain, Skin Disorders"				no		no		Bilirubin		"absent in melanoma 2, Bilirubin, C-X-C motif chemokine ligand 11, CCL5, CD40L, chromosome 7 open reading frame 49, CXCL10, D-Urobilinogen, G-CSF, ICAM-1, IFN-gamma, IL1 alpha, MIF, NGF, period circadian clock 3 pseudogene, PSA, Uric acid"		"bax, Creatinine, E-cadherin, IL1 beta, IL6, IL8, Ki67, purinergic receptor P2X 3, RAGE, TGF-beta, TJP1, TNF-alpha, TRP-V1, Tryptases"	https://adis.springer.com/drugs/800033087?userId=52029392&bpIds=3004037004&checksum=cf2c2642b744dcc126e39d3f89383df4bf733eea-1617045532028-9be1448c8b5728a0b34d44ce360313b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045002	SWT 06101			No			No development reported (I)	Fibromyalgia			"SWITCH Biotech (CEASED) (Originator), SWITCH Biotech (CEASED) (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	SWT06101			28/04/2019	Pain				no		no							https://adis.springer.com/drugs/800045002?userId=52029392&bpIds=3004037004&checksum=962854bcfa76eb0465573191224fd106cffdd975-1617045532029-7fe4d66b597d8f24728309d477773376badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035461	Research programme: CNS therapeutics - Ossianix			Yes			No development reported (Research)	"CNS disorders, Pain"		Ion channel modulators	"Ossianix (Originator), Ossianix (Owner), Lundbeck A/S (Collaborator)"		unspecified				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02 (Analgesics)"	AntiCD20/TfR1 bispecific antibodies			28/04/2019	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800035461?userId=52029392&bpIds=3004037004&checksum=d13ac661a907f2946b4f7e4f55764721e89daf85-1617045532030-5f428987b43772a1dc38ae21d320d337badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040835	Research programme: cannabinoid-based therapeutics - InMed Pharmaceuticals			Yes			No development reported (Preclinical)	"Inflammation, Pain, Arthritis, Joint disorders, Musculoskeletal pain, Chronic obstructive pulmonary disease"		"Gene expression modulators, Interleukin 6 inhibitors, Immunomodulators"	"Cannabis Technologies (Originator), InMed Pharmaceuticals (Owner), Mitacs (Funder), National Research Council Canada (Funder), University of British Columbia (Collaborator)"		"unspecified, Topical, Transdermal"				"L4 (Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N7X (All other CNS drugs)"	"L04 (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"CTI091, Delta9tetrahydrocannabinol InMed Pharmaceuticals, Dronabinol InMed Pharmaceuticals, INM405"			28/04/2019	"Inflammation, Musculoskeletal Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800040835?userId=52029392&bpIds=3004037004&checksum=08e9b73bf321ddf45e5f25eb1354c99c17eb80e6-1617045532031-a313294880109243a33b4134c72293c6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054546	Buprenorphine controlled release - Lyndra Therapeutics	52485-79-7	"(2S)-2-[(-)-(5R,6R,7R,14S)- 9_-cyclopropylmethyl-4,5-epoxy- 6,14-ethanomorphinan-7-yl]-3-hydroxy- 6-methoxy-3,3-dimethylbutan-2-ol"	No			Preclinical	Opioid-related disorders	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Lyndra (Originator), Lyndra (Owner), Massachusetts Institute of Technology (Technology Provider), National Institute of Allergy and Infectious Diseases (Funder)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	"LYN013, Ultralongacting oral buprenorphine Lyndra Therapeutics"			26/04/2019	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800054546?userId=52029392&bpIds=3004037004&checksum=33f5b1ce921451c320045157843711b658aee9e5-1617045532032-899849ff75ba242e5e4e66f8baf368ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013776	Morphine intranasal - Adhera Therapeutics	57-27-2	"9<EM>H</EM> -9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, gluconate"	No			Discontinued (II)	"Cancer pain, Pain, Dental pain"	C17 H19 N O3 . C6 H12 O7	Opioid mu receptor agonists	"Nastech Pharmaceutical Company (Originator), Adhera Therapeutics (Owner)"		Intranasal				N2A (Narcotics)	N02A-A01 (Morphine)				17/04/2019	"Drug Delivery Systems, Pain"				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800013776?userId=52029392&bpIds=3004037004&checksum=1e0ac49d55a2cb991d4715796ceb803c6d153f5c-1617045532034-2212c8fcf11ffbd114f6404ce5d6cf15badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017262	Serotonin agonist-intranasal - Adhera Thearpeutics			No			Discontinued (I)	Migraine		Serotonin receptor agonists	"Nastech Pharmaceutical Company (Originator), Adhera Therapeutics (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"Intranasal serotonin agonist Nastech, Intranasal triptan Nastech, Triptanintranasal Nastech"			17/04/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800017262?userId=52029392&bpIds=3004037004&checksum=67e3071cab84f82d0f7853c3d9d0206bd978858f-1617045532034-f00cfd807646439e11ebe077756471e7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011743	Secretin - ChiRhoClin	108153-74-8	H-His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg- Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln- Gly-Leu-Val-NH2	No			Marketed	"Exocrine pancreatic insufficiency, Pancreatic cancer, Pancreatitis, Pain"		"Radionuclide imaging enhancers, Gastrointestinal hormone replacements"	"ChiRhoClin (Originator), ChiRhoClin (Owner)"		IV		"Cl (L/h) (34.85), T<sub>_beta</sub> (h) (.75), Vd (L/kg) (.04)"	"Abdominal pain, Anxiety, Diarrhoea, Flushing, Heat sensation, Hypotension, Nausea, Pancreatitis"	"N2 (Analgesics), T1D (Cholecystography and Cholangiography)"	"N02 (Analgesics), V04C-K (Tests for pancreatic function)"	"ChiRhoStim, Synthetic secretin diagnostics ChiRhoClin"			16/04/2019	"Cancer, Digestive System Disorders, Pain"	Pancreatitis (USA)		"ChiRhoStim, ChiRhoStim"	no		no				"C-peptide, chymotrypsin like elastase family member 3B, IAPP"		"A1C, CA-19-9, GLP-1"	https://adis.springer.com/drugs/800011743?userId=52029392&bpIds=3004037004&checksum=bdc3bd49b79d60fe0c5187f5f62c6eb5294319d3-1617045532036-f8a825b7da6b6877a63a0e82832ae92cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009266	Morphine liposomal	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate-(2:1) pentahydrate"	No			Marketed	Postoperative pain	C17 H19 N O3 . 1/2H2 S O4 . 5/2H2 O	Opioid mu receptor agonists	"SkyePharma Inc (Originator), Pacira BioSciences (Owner), Flynn Pharma (Licensee), Orphan Australia (Licensee)"		Intralumbar			"Nausea, Pruritus, Respiratory insufficiency, Vomiting"	N2A (Narcotics)	N02A-A01 (Morphine)	"C 0401, D 0401, DepoDur, DepoMorphine, Morphine DepoFoam, SKY 0401"			15/04/2019	"Drug Delivery Systems, Pain"			"DepoDur, DepoMorphine"	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800009266?userId=52029392&bpIds=3004037004&checksum=a833c423eeec8dd356756a7890383190722ec989-1617045532038-cab384a130fd9c1b8146f4db09b6d872badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034867	Pregabalin controlled release - Yuhan	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid	No			Phase III	"Neuropathic pain, Neurological disorders"	C8 H17 N O2	CACNA2D1 protein modulators	"Yuhan (Originator), Yuhan (Owner)"		PO				"N (Nervous System), N2 (Analgesics)"	"N02 (Analgesics), N03A-X16 (Pregabalin)"	"Pregabalin SR, YHD 1119"			04/04/2019	"Neurological Disorders, Pain"				no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800034867?userId=52029392&bpIds=3004037004&checksum=6396d408584a4bf76ec3a5c4996ad259439de87d-1617045532039-6cbc1d7d725838ea35d5465fcfcbe4b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037085	Pregabalin controlled release - Intellipharmaceutics	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid	No			Phase I	"Neuropathic pain, Fibromyalgia"	C8 H17 N O2	CACNA2D1 protein modulators	"Intellipharmaceutics International (Originator), Intellipharmaceutics International (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	"Pregabalin extendedrelease capsules, Pregabalin XR, Pregabalin XR Intellipharmaceutics, Regabatin XR"			04/04/2019	Pain		Intellipharmaceutics International |  | Unspecified |  | 14 Nov 2014	Regabatin XR	no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800037085?userId=52029392&bpIds=3004037004&checksum=86d9de61c53c24f1feec1ca7e4586a10b8736284-1617045532041-b1997f23b9733942fa38a13f49d18325badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039088	Pain therapeutic - Charleston Laboratories/Stanford University School of Medicine			Yes			Phase II	Pain		Undefined mechanism	"Charleston Laboratories (Originator), Stanford University School of Medicine (Originator), Charleston Laboratories (Owner), Stanford University School of Medicine (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				03/04/2019	Pain				no		no							https://adis.springer.com/drugs/800039088?userId=52029392&bpIds=3004037004&checksum=7172bd92853eb5364a6799f75707361c7a10bff9-1617045532041-0138514ee44c1f4f8176f01ff2852e6bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014737	PTI 701			No			Discontinued (II)	Pain		"Opioid receptor agonists, Opioid receptor antagonists"	"Albert Einstein College of Medicine (Originator), Pain Therapeutics (Originator), Cassava Sciences (Owner)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-A (Natural opium alkaloids), N02B-E (Anilides)"				01/04/2019	Pain				no		no							https://adis.springer.com/drugs/800014737?userId=52029392&bpIds=3004037004&checksum=c43e44533ff3bbfd7f1d9c5a4c15ebcdb926108c-1617045532042-6d3c447a3fc138c5e6d289b4f27bfbd0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014735	PTI 601			No			Discontinued (II)	Pain		"Opioid receptor agonists, Opioid receptor antagonists"	"Albert Einstein College of Medicine (Originator), Albert Einstein College of Medicine (Owner), Cassava Sciences (Market Licensee)"		PO				"N2A (Narcotics), N7X (All other CNS drugs)"	"N02A-X52 (Tramadol, combinations), N07B-B04 (Naltrexone)"				01/04/2019	Pain				no		no							https://adis.springer.com/drugs/800014735?userId=52029392&bpIds=3004037004&checksum=6b698dbddb4b8e65e5deb295b963ee15a830203a-1617045532043-e809ebe64edc3fb7a4e14526cbe25f00badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014734	PTI 501			No			Discontinued (II)	Pain		"Opioid mu receptor agonists, Opioid receptor antagonists"	"Albert Einstein College of Medicine (Originator), Albert Einstein College of Medicine (Owner), Cassava Sciences (Market Licensee)"		unspecified				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	morphinenaloxone			01/04/2019	Pain				no		no							https://adis.springer.com/drugs/800014734?userId=52029392&bpIds=3004037004&checksum=9ea11186818db8d5356df4dd17cbe146c57ab634-1617045532044-91928262c645edec4cb8b7f84c1fd983badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041336	Fentanyl transdermal - Cassava Sciences	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			No development reported (Preclinical)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Pain Therapeutics (Originator), Cassava Sciences (Owner), National Institute on Drug Abuse (Funder)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	Fenrock			01/04/2019	Pain			Fenrock	no		no							https://adis.springer.com/drugs/800041336?userId=52029392&bpIds=3004037004&checksum=019f42bf7265b20f8361dec191430e9df7380d1d-1617045532044-50c93a762e5da77f8439bc4e715f5db7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018130	PTI 901			No			Discontinued (III)	Irritable bowel syndrome		Opioid receptor antagonists	"Pain Therapeutics (Originator), Cassava Sciences (Owner)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	"Irritable bowel syndrome pain therapeutic Cassava Sciences, NaltrexoneHCl, PTI901"			01/04/2019	Digestive System Disorders				no		no		"A1C, CD4, dicarbonyl and L-xylulose reductase, NTx, OPRM1, PSA"	"A1C, CRP, dicarbonyl and L-xylulose reductase, Insulin, NTx"	"A1C, ACTH, BDNF, Benzoyl ecgonine, C-X-C motif chemokine ligand 5, Carbohydrate-deficient transferrin, CCL5, CCL7, CD4, CD40L, CRP, CXCL10, CXCL12, dicarbonyl and L-xylulose reductase, EGF, EH domain containing 3, Eotaxin, Ethyl glucuronide, FIGF, G-CSF, Ghrelin, GM-CSF, Hydrocortisone, ICAM-1, IFN-alpha 2, IFN-gamma, IGF1, IL1 alpha, IL1 beta, IL10, IL13, IL15, IL17, IL18, IL2, IL22, IL23, IL31, IL4, IL5, IL6, IL7, IL8, IL9, Insulin, interferon, beta 1, fibroblast, interleukin 17F, Leptin, MCP1, MIP-1 alpha, Norepinephrine, NTx, OPRM1, PAI-1, PDGFB, phosphatidylserine synthase 1, Resistin, reticulon 4 interacting protein 1, SH3 domain containing GRB2 like 1, endophilin A2, TGF-beta, TNF-alpha, TNF-beta, transforming growth factor, alpha, VCAM-1, VEGF-A"	CRP	"Calreticulin, COMT, Prolactin"	https://adis.springer.com/drugs/800018130?userId=52029392&bpIds=3004037004&checksum=7011d8867b8991c384e6fed95ac50b9c3640b8ef-1617045532046-77c6d1b2f7878b415e868c0d3a64b3e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033607	Research programme: analgesics - Cassava Sciences			Yes			No development reported (Preclinical)	"Arthritis, Pain"			"Pain Therapeutics (Originator), Cassava Sciences (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2A (Narcotics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02A (Opioids)"	PTI609			01/04/2019	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800033607?userId=52029392&bpIds=3004037004&checksum=35bafc1c00e0019c947ebec5f188354ac76eb231-1617045532047-edf6ad184ab23101e959f6c74c9ce0d6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015994	Oxycodone/naltrexone		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one"	No			Discontinued (III)	Pain	C18 H21 N O4 . C20 H23 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Opioid receptor antagonists"	"Albert Einstein College of Medicine (Originator), Albert Einstein College of Medicine (Owner), Cassava Sciences (Licensee), DURECT Corporation (Technology Provider)"		PO				"N2A (Narcotics), V3 (All Other Therapeutic Products)"	"N02A-A (Natural opium alkaloids), V03A (All Other Therapeutic Products)"	"Oxytrex, PTI801"			01/04/2019	"Drug Delivery Systems, Pain"			Oxytrex	no		no							https://adis.springer.com/drugs/800015994?userId=52029392&bpIds=3004037004&checksum=235a77ecbb87531377e558bab988905531eace2c-1617045532048-b73a9566b4be0361d043ef585937515bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053811	Research programme: analgesic therapeutic - Cassava Sciences/University of Texas at Austin			No			Research	Pain		Undefined mechanism	"Pain Therapeutics (Originator), Cassava Sciences (Owner), University of Texas at Austin (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				01/04/2019	Pain				no		no							https://adis.springer.com/drugs/800053811?userId=52029392&bpIds=3004037004&checksum=5ed59dd7e3a81415871f4a70072430c821273953-1617045532049-e1b46dd4fc3aaf73ae45a5b6c00a9a70badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054286	Research programme: HCN2 antagonists - Kings College London/Merck			Yes			Preclinical	Neuropathic pain		Hyperpolarisation activated cation channel antagonists	"Kings College London (Originator), Kings College London (Owner), Merck & Co (Licensee), Wellcome Trust (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Hyperpolarisation activated cation channel 2 antagonists Merck			01/04/2019	Pain				no		no							https://adis.springer.com/drugs/800054286?userId=52029392&bpIds=3004037004&checksum=64322edd815449a7aa8c36b6e20c53381ce38786-1617045532049-b6a41a268ea2c63d257eef1ad37593f6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000947	Pelubiprofen - Daewon Pharmaceutical	69956-77-0	"Benzeneacetic acid, _-methyl-4-(2-oxocyclohexylidenemethyl)-"	Yes			Marketed	"Osteoarthritis, Back pain, Acute pain, Fever, Rheumatoid arthritis, Musculoskeletal pain, Rheumatic disorders"	C16 H18 O3	Cyclooxygenase inhibitors	"Sankyo (Originator), Sankyo (Owner), Daewon Pharmaceutical (Licensee)"		PO	renal	"Route of Elimination (renal), protein binding (%) (90 (Adult)), T<sub>max</sub> (h) (.75 (Adult))"		"M1A (Anti-Rheumatics, Non-Steroidal), N2B1 (Prescription-bound non-narcotics and anti-pyretics)"	"M01A-E (Propionic acid derivatives), N02B-G (Other analgesics and antipyretics)"	"CS 670, DW330, DW330SR, DW9801, Pelubi, Pelubiprofen sustained release, RS 2131"			29/03/2019	"Metabolic Disorders, Pain, Rheumatic Disease"			"Pelubi, Pelubi"	no		no							https://adis.springer.com/drugs/800000947?userId=52029392&bpIds=3004037004&checksum=eeeda3831593d3b3a428089f3de190d5ee203a71-1617045532051-bd79de8c145244afce846e2822cb4ab9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024836	Research programme: serotonin 2 receptor antagonists - AnaMar			Yes			No development reported (Preclinical)	"Osteoarthritis, Rheumatoid arthritis, Inflammatory pain, Idiopathic pulmonary fibrosis"		"Serotonin 2 receptor antagonists, Serotonin 2B receptor antagonists"	"AnaMar Medical (Originator), AnaMar AB (Owner), AcurePharma (Collaborator)"		"PO, Topical, unspecified"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), D5X (Other Nonsteroidal Products for Inflammatory Skin Disorders), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5X (All Other Musculoskeletal Products), N2 (Analgesics)"	"D04A-X (Other antipruritics), D11A-H (Agents for atopic dermatitis, excluding corticosteroids), M01 (Antiinflammatory and Antirheumatic Products), M09A (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics)"	"AM260, Am260 TASS, AM260 TASS, AMAP 312, AMAP332"			28/03/2019	"Musculoskeletal Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease"		AnaMar AB |  | Unspecified |  | 03 Feb 2015		no		no							https://adis.springer.com/drugs/800024836?userId=52029392&bpIds=3004037004&checksum=4e7983b3bb318a43fcc135a53c07de02794d473b-1617045532052-0d44e03e1bc3c17a8693f96f38477c75badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054364	KP 1199			Yes			Phase I	Pain		Undefined mechanism	"Kalyra Pharmaceuticals (Originator), Kalyra Pharmaceuticals (Owner), United States Department of Defense (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	KP1199			27/03/2019	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800054364?userId=52029392&bpIds=3004037004&checksum=39aafe22cc97d26d1bc1dee62bee5cc67d4ff9ef-1617045532053-58e4484f21c8d545fae5e7f9cc370268badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049739	Copper amino acid chelate complex - RR MedSciences			No			Phase II	Neuropathic pain		Undefined mechanism	"RR MedSciences (Originator), RR MedSciences (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"Copper amino acid chelate complex, CopperXHA spray, RM 191A, RRMCIP01"			27/03/2019	Pain				no		no							https://adis.springer.com/drugs/800049739?userId=52029392&bpIds=3004037004&checksum=ffb863fc8cbd0315fcdc163867435d191dc471fa-1617045532054-56b8311be33c7a51b2ed59babef36f65badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054271	Research programme: liposomal therapeutics - 3SBio/Taiwan Liposome Company			Yes			Research	"Eye disorders, Osteoarthritis, Pain, Cancer, Infections"		Undefined mechanism	"3SBio (Originator), Taiwan Liposome Company (Originator), 3SBio (Owner), Taiwan Liposome Company (Owner)"		unspecified				"J (General Anti-Infectives Systemic), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), S1 (Ophthalmologicals)"	"J (Anti-infectives For Systemic Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), S01 (Ophthalmologicals)"				27/03/2019	"Bacterial Infections, Cancer, Eye Disorders, Haematological Disorders, Mycoses, Pain, Rheumatic Disease, Viral Infections"				no		no							https://adis.springer.com/drugs/800054271?userId=52029392&bpIds=3004037004&checksum=855974d827873529ead78af9d8b32c76aea33b02-1617045532056-f5e4641f6ee5c652bbef65505335061bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044737	C 013			Yes			Discontinued (II)	Tension type headache		Undefined mechanism	"Curatis (Originator), Curatis (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				20/03/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800044737?userId=52029392&bpIds=3004037004&checksum=e392054f4a2dbb38ec6c35b0ccf4b0faf48be7c3-1617045532056-5bb16206787f1efec6a70ca2d1bdb303badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053942	DFN 42			Yes			Discontinued (I)	Migraine		Undefined mechanism	"Promius Pharma (Originator), Promius Pharma (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	DFN42			15/03/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800053942?userId=52029392&bpIds=3004037004&checksum=d2898a85aa9861d50ffd80236a5086a1e073c016-1617045532057-cbdc53f9499e824188c7cc0d7cd7a57cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011957	Tarenflurbil	51543-40-9	"(1,1'-Biphenyl)-4-acetic acid,2-fluoro-alpha-methyl-,(_<EM>R</EM>)-"	Yes			Phase II	"Multiple sclerosis, Alzheimer's disease, Prostate cancer, Inflammation, Pain"	C15 H13 F O2	"NF-kappa B inhibitors, Amyloid precursor protein secretase modulators, Transcription factor AP-1 inhibitors"	"Loma Linda University Medical Center (Originator), Loma Linda University Medical Center (Owner), Lundbeck A/S (Market Licensee), Encore Pharmaceuticals (Licensee), PAZ GmbH (Licensee), Horizon Pharma AG (Sub-licensee), Fraunhofer Institute for Molecular Biology and Applied Ecology (Collaborator)"		PO		"Linear Kinetics (yes), T<sub>_beta</sub> (h) (4.5 - 6.6 (Adult))"		"L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06D-X (Other anti-dementia drugs), N07X (Other Nervous System Drugs)"	"E7869, Flurizan, MPC7869, RFlurbiprofen, TMP001, TruNoc"			11/03/2019	"Alzheimer's Disease and Cognition Disorders, Cancer, Inflammation, Neurological Disorders, Pain"			TruNoc	no		no				Purine		"CYP2C9, PSA"	https://adis.springer.com/drugs/800011957?userId=52029392&bpIds=3004037004&checksum=88bbd9ccee1e796b37a9a8ee4c88061a887c75d4-1617045532059-6f66a047d9852ad2d3f5c262d92b892cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054216	Research programme: monoclonal antibody pain therapeutics - Imbrium Therapeutics/TetraGenetics			Yes			Research	Pain		Ion channel modulators	"Imbrium Therapeutics (Originator), Tetragenetics (Originator), Imbrium Therapeutics (Owner), Tetragenetics (Owner), Tetragenetics (Technology Provider)"		Parenteral				N2 (Analgesics)	"L01X-C (Monoclonal antibodies), N02 (Analgesics)"	"IMB 112, IMB 2011200"			05/03/2019	Pain		Imbrium Therapeutics |  | Research |  | 04 Mar 2019		no		no							https://adis.springer.com/drugs/800054216?userId=52029392&bpIds=3004037004&checksum=8ceec272abfe7fa63b8a965d478d23ab024b2157-1617045532060-9d51f8ce95a4b9971eaf5da705a1f0b4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038187	CTP 354			Yes			Discontinued (I)	"Neuropathic pain, Muscle spasticity"		GABA A receptor modulators	"Concert Pharmaceuticals (Originator), Concert Pharmaceuticals (Owner), Cipla (Licensee), Fast Forward (Funder)"		PO				"M3B (Muscle Relaxants, Centrally Acting), N2B (Non-Narcotics and Anti-Pyretics)"	"M03B (Muscle Relaxants, Centrally Acting Agents), N02B (Other Analgesics and Antipyretics)"	"C21191, CTP354, DL838417"			05/03/2019	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800038187?userId=52029392&bpIds=3004037004&checksum=8e317b85235912afd51c7584e6fa60d4d141d64c-1617045532061-a505968caa7195805d00e21acd173f52badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041945	MK 8291			Yes			No development reported (I)	Postherpetic neuralgia		Undefined mechanism	"Merck Sharp & Dohme (Originator), Merck Sharp & Dohme (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				28/02/2019	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800041945?userId=52029392&bpIds=3004037004&checksum=cb4182119a0f1277a8b0b414150a21e7aebac537-1617045532062-ef5ac82dfddf3eaeeae7176b735441dbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044428	YNP 1707			No			No development reported (I)	Neuropathic pain		Undefined mechanism	"Yungjin Pharm Co (Originator), Yungjin Pharm Co (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	YNP1707			28/02/2019	Pain				no		no							https://adis.springer.com/drugs/800044428?userId=52029392&bpIds=3004037004&checksum=e3fa99347db524460e95d3531c9279e905cb68e4-1617045532062-25c89ea60f01db3fb6d33db3cabe53e2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040458	Research programme: macrocyclic compounds - Cyclenium Pharma			Yes			Research	"Cardiovascular disorders, Neurological disorders, Immunological disorders, Infections, Cancer"		Undefined mechanism	"Cyclenium Pharma (Originator), Cyclenium Pharma (Owner), Fundacion MEDINA (Collaborator), McGill University (Collaborator), SickKids (Collaborator), Southern Research Institute (Collaborator), University of Montreal (Collaborator)"		unspecified				"A (Alimentary Tract and Metabolism), A3 (Functional Gastro-Intestinal Disorder Drugs), C1X (All Other Cardiac Preparations), J (General Anti-Infectives Systemic), L (Antineoplastic and Immunomodulating Agents), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2 (Analgesics)"	"A (Alimentary Tract and Metabolism), A03 (Drugs for Functional Gastrointestinal Disorders), C01E (Other Cardiac Preparations), J (Anti-infectives For Systemic Use), L (Antineoplastic and Immunomodulating Agents), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02 (Analgesics)"	"Cancer therapeutics Cyclenium/Southern Research Institute, Cancer therapeutics Cyclenium/University of Montreal, Gastrointestinal and metabolic disorders therapeutics Cyclenium, Immunological disorder therapeutics Cyclenium/University of Montreal, Infectious diseases therapeutics Cyclenium/Fundacin MEDINA, Infectious diseases therapeutics Cyclenium/Fundacion MEDINA, Infectious diseases therapeutics Cyclenium/Southern Research Institute, Inflammation and pain therapeutics Cyclenium, Neurological disorder therapeutics Cyclenium/Southern Research Institute"			28/02/2019	"Bacterial Infections, Cancer, Immunological Disorders, Ischaemic Heart Disease, Mycoses, Neurological Disorders, Vascular Disorders"		"Cyclenium Pharma | Gastrointestinal disorders, Metabolic disorders | Unspecified |  | 21 Mar 2015"		no		no							https://adis.springer.com/drugs/800040458?userId=52029392&bpIds=3004037004&checksum=30b52dbf7f459afd7cbfa32e06137003af1691d1-1617045532065-65a494e6504236bc81ca5a89ec319898badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044653	C 012			Yes			Discontinued (II)	Migraine			"Curatis (Originator), Ygraine Therapeutics (Originator), Curatis (Owner), Ygraine Therapeutics (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	C012			27/02/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800044653?userId=52029392&bpIds=3004037004&checksum=cdbb1cdd0115de8dbae92a09d2ef137c1688f9c9-1617045532066-0eaf9a871b0d81a2b734fc00a6fd5376badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044654	MAL			No			Discontinued (II)	"Opioid-related disorders, Pain"		"Opioid kappa receptor agonists, Opioid mu receptor antagonists"	"D&A Pharma (Originator), D&A Pharma (Owner)"		"PO, Intranasal"				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N07B-C (Drugs used in opioid dependence)"				27/02/2019	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800044654?userId=52029392&bpIds=3004037004&checksum=dfacda265c629dd5b4f8123e7ea40cceb1261c98-1617045532067-90d6588b57f04f5f1db86aacfd78a116badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054121	Exulta 005			Yes			Preclinical	"Opioid-related disorders, Pain"		Undefined mechanism	"Sen Jam Pharmaceutical (Originator), Sen Jam Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N07B-C (Drugs used in opioid dependence)"	Exulta005			19/02/2019	"Drug Withdrawal, Pain"		Sen Jam Pharmaceutical |  | Unspecified |  | 19 Feb 2019		no		no							https://adis.springer.com/drugs/800054121?userId=52029392&bpIds=3004037004&checksum=26976e1091dd17bd45acc3f55af51a7d0d51084e-1617045532068-b2f48418324769881836fad5fb47553cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054052	Recombinant human cometin - Hoba Therapeutics			No			Preclinical	"Hearing disorders, Neuropathic pain"		Nerve growth factor stimulants	"Hoba Therapeutics (Originator), Hoba Therapeutics (Owner)"		"Otic, unspecified"				"N2 (Analgesics), S2 (Otologicals)"	"N02 (Analgesics), S02 (Otologicals)"	HB 097			19/02/2019	"Ear, Nose and Throat Disorders, Pain"				no		no							https://adis.springer.com/drugs/800054052?userId=52029392&bpIds=3004037004&checksum=34cd548f6f022247e3eb1879ca5cfc2d7486dc0b-1617045532069-ad34b3ecd234344a6d9e342ec3e4dca8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047167	BLNP 023			Yes			Clinical Phase Unknown	"Pain, Metabolic disorders"		Undefined mechanism	"BL-&-H (Originator), BL-&-H (Owner)"		"Inhalation, unspecified"				"A16 (Other Alimentary Tract and Metabolism Products), N2 (Analgesics)"	"A16 (Other Alimentary Tract and Metabolism Products), N02 (Analgesics)"	BLNP023			19/02/2019	"Metabolic Disorders, Pain"				no		no							https://adis.springer.com/drugs/800047167?userId=52029392&bpIds=3004037004&checksum=cd2ba2e51ef48180fb551a3ff363f5ae3acfafff-1617045532070-4e9400c2f188a4ae302d52c61c34ce25badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054090	PACAP 38 antibody - Eli Lilly and Company			Yes			Phase I	Pain		Pituitary adenylate cyclase-activating polypeptide receptor modulators	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	PACAP38 Antibody			15/02/2019	Pain				no		no							https://adis.springer.com/drugs/800054090?userId=52029392&bpIds=3004037004&checksum=5b77ee082b036a5175b8b5d6386f576661ae1e42-1617045532071-be1f8d734e145cbfecff82c8f73d9011badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054091	ADX 71441			Yes			Discontinued (Preclinical)	"Overactive bladder, Muscle spasticity, Alcoholism, Visceral pain, Charcot-Marie-Tooth disease, Substance-related disorders, Cocaine-related disorders"		GABA B receptor agonists	"Addex Therapeutics (Originator), Addex Therapeutics (Owner), Indivior (Licensee), National Institute on Alcohol Abuse and Alcoholism (Collaborator), National Institute on Drug Abuse (Collaborator)"		"PO, IM"				"G4 (Urologicals), M3 (Muscle Relaxants), M3B (Muscle Relaxants, Centrally Acting), N2 (Analgesics), N7 (Other CNS Drugs), N7E (Drugs Used In Alcohol Dependence)"	"G04 (Urologicals), M03B (Muscle Relaxants, Centrally Acting Agents), N02 (Analgesics), N07B (Drugs Used In Addictive Disorders), N07B-B (Drugs used in alcohol dependence)"	ADX71441			15/02/2019	"Drug Withdrawal, Genitourinary Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Vaccines"				no		no							https://adis.springer.com/drugs/800054091?userId=52029392&bpIds=3004037004&checksum=7854209bb10daa99b1a22e567869e2b7bc88787f-1617045532073-805645e29374a8058eec5be6b7722880badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014811	Tramadol/paracetamol	147630-09-9	"N-(4-hydroxyphenyl)-acetamide / (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			Marketed	Pain	C16 H25 N O2 . C8 H9 N O2	"Opioid receptor agonists, Prostaglandin synthase inhibitors"	"Ortho-McNeil (Originator), Ortho-McNeil (Owner), Mochida Pharmaceutical (Market Licensee), Xian-Janssen (Market Licensee), Janssen (Licensee), Janssen-Cilag (Licensee)"		PO			"Constipation, Nausea, Somnolence"	"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-X02 (Tramadol), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Acetaminophen mixture with tramadol OrthoMcNeil, Toramusetto, Tramacet, Tramadol/acetaminophen, Tramadol/APAP, Tramcet, Ultracet"			14/02/2019	Pain			"Tramacet, Tramacet, Tramcet, Ultracet, Ultracet"	no		no							https://adis.springer.com/drugs/800014811?userId=52029392&bpIds=3004037004&checksum=6ea30928d2f07e583cc327806f550938af26849d-1617045532076-fa8a704dd2c4d05d302f1a913f822e0bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032266	Zolmitriptan oral dispersible film	139264-17-8	S-4[[3-[2-(Dimethylamino)ethyl]-1<EM>H</EM>-indol-5-yl]methyl]-2-oxazolidinone	No			Marketed	Migraine	C16 H21 N3 O2	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"APR Applied Pharma Research (Originator), Labtec (Originator), APR Applied Pharma Research (Owner), Labtec (Owner), Aquestive Therapeutics (Technology Provider)"		PO				N2C1 (Antimigraine triptans)	N02C-C03 (Zolmitriptan)	"zolmitriptan ODF, Zolmitriptan PharmaFilm, Zolmitriptan RapidFilm, Zolmitriptan Renantos 2.5mg Schmelzfilm, Zolmitriptan Renantos 5mg Schmelzfilm"			13/02/2019	Advances in the Treatment of Nausea and Migraine		tesa Labtec |  | Unspecified |  | 14 Jun 2010	"Zolmitriptan PharmaFilm, Zolmitriptan RapidFilm, Zolmitriptan Renantos 2.5mg Schmelzfilm, Zolmitriptan Renantos 5mg Schmelzfilm"	no		no							https://adis.springer.com/drugs/800032266?userId=52029392&bpIds=3004037004&checksum=3d01d04f40d32f2d7d7d4505f8aa5dac4086a1aa-1617045532078-9e7c2a804a12b89feed796393b16210ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022758	Axomadol - Grunenthal	187219-99-4	"(1<EM>RS</EM>,3<EM>RS</EM>,6<EM>RS</EM>)-6-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexane-1,3-diol"	Yes			Discontinued (II)	"Postoperative pain, Pain, Neuropathic pain"	C16-H25-N-O3	"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Grunenthal (Originator), Grunenthal (Owner)"		"PO, unspecified"				N2 (Analgesics)	N02 (Analgesics)	"Axomadol hydrochloride, BN110, EN3324, GRT0151Y, GRT151"			13/02/2019	Pain				no		no							https://adis.springer.com/drugs/800022758?userId=52029392&bpIds=3004037004&checksum=ced74478af0f5a37a15704097ddebf16b0e22c2e-1617045532079-8614c4978d8162979124f6669b8cca04badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011434	Piroxicam betadex - Chiesi	96684-40-1	"4-Hydroxy-2-methyl-2<EM>H</EM>-1,2-benzothiazine-3-[<EM>N</EM>-(2-pyridyl)carboxamide]-1,1-dioxide, complex with beta-cyclodextrin (2:5)"	Yes		"&gt; Dipyrone, ³ Etodolac, = Ibuprofen arginine, = Nabumetone, = Piroxicam, = Tenoxicam"	Marketed	"Pain, Rheumatic disorders, Musculoskeletal disorders, Dysmenorrhoea, Ankylosing spondylitis, Gout, Osteoarthritis, Inflammation, Rheumatoid arthritis, Migraine, Tension type headache"	(C15 H13 N3 O4 S)2 . (C42 H70 O35)5	Cyclooxygenase inhibitors	"Chiesi (Originator), Chiesi (Owner), Ache Laboratories (Market Licensee), Andromaco (Market Licensee), Christiaens (Market Licensee), GE Healthcare (Market Licensee), Mer National Pharmaceuticals (Market Licensee), Microsules-Bernabo (Market Licensee), Pfizer (Market Licensee), Robapharm (Market Licensee), Trinity-Chiesi Pharmaceuticals (Market Licensee)"		PO			Gastrointestinal disorders	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"M01A-C (Oxicams), N02B (Other Analgesics and Antipyretics), N02C (Antimigraine Preparations)"	"Betacyclodextrin piroxicam, Brexecam, Brexidol, Brexin, Brexine, Brexinil, CHF 1194, Cicladol, Cycladol, Flogene, Piroxicam betacyclodextrin, Piroxicam betacyclodextrin complex, Solocalm Rapido"			12/02/2019	"Advances in the Treatment of Nausea and Migraine, Inflammation, Musculoskeletal Disorders, Pain, Rheumatic Disease"			"Brexecam, Brexecam, Brexecam, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexidol, Brexin, Brexin, Brexin, Brexin, Brexin, Brexin, Brexine, Brexine, Brexine, Brexine, Brexine, Brexine, Brexinil, Brexinil, Brexinil, Brexinil, Brexinil, Brexinil, Brexinil, Cicladol, Cicladol, Cicladol, Cycladol, Cycladol, Cycladol, Cycladol, Cycladol, Cycladol, Cycladol, Flogene, Solocalm Rapido"	no		no							https://adis.springer.com/drugs/800011434?userId=52029392&bpIds=3004037004&checksum=2a8b60aef089d2675e978fccce2ea116694148e4-1617045532087-c05fa45a719eca5f17649db8966cea37badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015173	Tramadol extended release - Cipher Pharmaceuticals	36282-47-0	(±)-<EM>cis</EM>-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride	No			Marketed	Pain	C16 H25 N O2 . H Cl	Opioid receptor agonists	"Cipher Pharmaceuticals (Originator), Cipher Pharmaceuticals (Owner), Old API Wind-down Ltd (Market Licensee), Tecnofarma International (Market Licensee), Vertical Pharmaceuticals (Market Licensee), Galephar Pharmaceutical Research (Technology Provider)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"CIPTramadol ER, Conzip, Durela, Extendedrelease tramadol"			12/02/2019	Pain		"Cipher Pharmaceuticals |  | Unspecified | World (Excluding Canada, Latin America, USA) | 25 Jul 2012"	"Conzip, Durela"	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800015173?userId=52029392&bpIds=3004037004&checksum=64aa54a6e3d52e703bab6b86547f231a6e4290b7-1617045532089-78f4bc74918fb646b63f88a9d78be9bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000876	Vapreotide	103222-11-3	"L-Tryptophanamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2_7)-disulfide"	No			Marketed	"Crohn's disease, Neuroendocrine tumours, Acromegaly, Diarrhoea, Oesophageal varices, Carcinoid tumour, Prostate cancer, Breast cancer, Liver cancer"	C57 H70 N12 O9 S2	Somatotropin receptor antagonists	"Tulane University (Originator), Tulane University (Owner), EMS Sigma Farma (Market Licensee), LG Chem (Market Licensee), Sun Pharmaceutical Industries (Market Licensee), Tzamal Pharma (Market Licensee), Debiovision (Licensee), Salix Pharmaceuticals (Licensee)"		"IV, SC"			"Abdominal pain, Anorexia, Constipation, Diarrhoea, Fatigue, Headache, Inflammation, Injection site reactions, Leucopenia, Neutropenia, Vomiting"	"A7 (Antidiarrhoeals, Oral Electrolyte Replacers and Intestinal Anti-inflammatories), A7E (Intestinal Anti-Inflammatory Agents), H1C2 (Antigrowth hormones), H4X (Other Hormones and Preparations with Similar Actions), L1 (Antineoplastics), N2 (Analgesics)"	"A07 (Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents), A07E (Intestinal Antiinflammatory Agents), H01C-B (Somatostatin and analogues), L01 (Antineoplastic Agents), N02 (Analgesics)"	"BMY41606, Debio 8609, Docrised, RC160, Sanvar, Sanvar IR, Sanvar SR"			12/02/2019	"Cancer, Digestive System Disorders, Endocrine Disorders, Inflammatory Bowel Disorders, Men's Health"	"Oesophageal varices (USA), Oesophageal varices (European Union)"		"Docrised, Docrised, Docrised, Docrised, Docrised, Sanvar, Sanvar IR, Sanvar SR"	no		no							https://adis.springer.com/drugs/800000876?userId=52029392&bpIds=3004037004&checksum=063b5a54180e52ca0f178f3289e20d7ca93e0baf-1617045532092-e21afe6c453834487d8cc48cb9993b29badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031437	Aspirin/clopidogrel - Sanofi		"2-acetyloxybenzoic acid / methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate"	No			Marketed	Acute coronary syndromes	C9 H8 O4 . C16 H16 Cl NO 2S	"Cyclooxygenase inhibitors, Platelet aggregation inhibitors, Purinergic P2 receptor antagonists"	"sanofi-aventis (Originator), Sanofi (Owner), Bristol-Myers Squibb (Licensee)"		PO				"B1C (Platelet Aggregation Inhibitors), C (Cardiovascular System)"	"B01A-C04 (Clopidogrel), C (Cardiovascular System), N02B-A01 (Acetylsalicylic acid)"	"Clopidogrel/aspirin Sanofi, ComPlavin, DuoCover, DuoPlavin"			11/02/2019	Ischaemic Heart Disease			"ComPlavin, DuoCover, DuoPlavin"	no		no							https://adis.springer.com/drugs/800031437?userId=52029392&bpIds=3004037004&checksum=74d5bf65267b633ae57e08a6cce752d3b6f75e67-1617045532096-273494b4c97ce8cf30197fea6e6afbdbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029867	Aspirin/omeprazole 650/20			No			No development reported (I)	Pain		Cyclooxygenase inhibitors	"POZEN (Originator), Old API Wind-down Ltd (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	"N02B-A51 (Acetylsalicylic acid, combinations excl. psycholeptics)"	"Aspirin/omeprazole 650mg/20mg, OA65020, Omeprazole/aspirin 20/650, PA65020"			08/02/2019	Pain		POZEN |  | Unspecified |  | 01 Oct 2012		no		no							https://adis.springer.com/drugs/800029867?userId=52029392&bpIds=3004037004&checksum=bee5b20cbc450a966a5829ec2dad77128bd0ebfc-1617045532097-4cc7bb1f2eac8ae4a3f951f8d1fcaf5abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000973	Lornoxicam	70374-39-9	"2<EM>H</EM>-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide"	Yes		"³ Diclofenac, = Diclofenac, = Indometacin"	Marketed	"Postoperative pain, Rheumatic disorders, Pain, Neuropathic pain, Osteoarthritis, Migraine"	C13 H10 Cl N3 O4 S2	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Roche (Originator), Roche (Owner), Andromaco (Market Licensee), Hikma Pharmaceuticals (Market Licensee), Hyundai Pharmaceutical (Market Licensee), Merckle (Market Licensee), Prodotti Formenti (Market Licensee), Taisho Pharmaceutical (Market Licensee), Old API Wind-down Ltd (Licensee), Takeda Pharmaceuticals International GmbH (Licensee), PAION (Collaborator)"		"PO, IV"	hepatic	"Active Metabolites (no), Activity vs parent (&lt;), Linear Kinetics (yes), Route of Elimination (hepatic), bioavailability IM (%) (87 (Adult)), Cl (L/h) (1.5 - 3.4 (Adult)), protein binding (%) (99 (Adult)), T<sub>_beta</sub> (h) (3 - 5 (Adult)), T<sub>_beta</sub> (h) (2.5 (Elderly)), T<sub>max</sub> (h) (2.5 (Adult)), T<sub>max</sub> (h) (2 (Elderly)), Vd (L/kg) (.2 (Adult))"	Gastrointestinal disorders	"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"M01A-C (Oxicams), M01A-C05 (Lornoxicam), N02 (Analgesics), N02C (Antimigraine Preparations)"	"Bosporon, Chlortenoxicam, HN 10000, RO 139297, Safem, TS 110, Xefo"			08/02/2019	"Advances in the Treatment of Nausea and Migraine, Pain, Rheumatic Disease"			"Bosporon, Xefo"	no		no				"PSA, sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein)"		"CRP, IL10, IL6"	https://adis.springer.com/drugs/800000973?userId=52029392&bpIds=3004037004&checksum=d71a3b8d1b4294b01fae5eb03125aa874a4c7b23-1617045532100-717ab117469fa319f8e35523b8cbec33badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800054030	Research programme: small molecule therapeutics - Dianomi Therapeutics			Yes			Research	"Osteoarthritis, Pain"		Undefined mechanism	"Dianomi Therapeutics (Originator), Dianomi Therapeutics (Owner), Wisconsin Alumni Research Foundation (Technology Provider), Ligand Pharmaceuticals (Collaborator)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				08/02/2019	"Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800054030?userId=52029392&bpIds=3004037004&checksum=dd929ae72fc94c2008d6e5c37cf084ea9ffe471d-1617045532101-6af114839b6a353c78ed5f670fcda39abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018773	Ethinylestradiol/levonorgestrel + ethinylestradiol - Teva Pharmaceuticals Industries/Theramex	39366-37-5	"(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6~{H}-cyclopenta[a]phenanthrene-3,17-diol / (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one "	No			Marketed	"Pregnancy, Menstrual migraine"	C21 H28 O2 . C20 H24 O2	"Estrogen receptor agonists, Progesterone receptor agonists"	"Duramed Pharmaceuticals Inc (Originator), Teva Pharmaceutical Industries (Owner), Theramex (Owner), Endo International (Market Licensee)"		PO				"G3A3 (Biphasic preparations), N2C9 (All other anti-migraine preparations)"	"G03A-A03 (Lynestrenol and ethinylestradiol), G03A-A07 (Levonorgestrel and ethinylestradiol), N02C-X (Other antimigraine preparations)"	"DP3, DR103, DR105, LoSeasonique, Seasonique"			05/02/2019	Women's Health			"LoSeasonique, Seasonique, Seasonique, Seasonique, Seasonique, Seasonique, Seasonique"	no		no							https://adis.springer.com/drugs/800018773?userId=52029392&bpIds=3004037004&checksum=bb81b459ac9bd29965eb812fd13234b916edf8c1-1617045532103-5a555370519f2e052751a2c4ca5affecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037246	Paracetamol/tramadol extended release - Janssen	147630-09-9	"N-(4-hydroxyphenyl)acetamide / (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol;hydrochloride"	No			Marketed	Pain	C8 H9 N O2 . C16 H26 N O2 Cl	"Opioid receptor agonists, Prostaglandin-E synthase inhibitors"	"Janssen (Originator), Janssen (Owner), Daewoong Pharmaceutical (Market Licensee)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-X02 (Tramadol), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Paracetamol/tramadol hydrochloride Janssen, Tramadol/paracetamol extended release Janssen, Ultracet ER TAB"			04/02/2019	Pain			"Ultracet ER TAB, Ultracet ER TAB"	no		no							https://adis.springer.com/drugs/800037246?userId=52029392&bpIds=3004037004&checksum=e2750f55f4bde8df1bb4ed47ba13ffa43cb40429-1617045532104-3932bcc1d37c8855029994fdf37959a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050475	Hydromorphone intranasal - Neurelis	466-99-9		No			Preclinical	Acute pain	C17 H19 NO3	Opioid receptor agonists	"Aegis Therapeutics (Originator), Neurelis (Owner)"		Intranasal				N2A (Narcotics)	N02A-A03 (Hydromorphone)				04/02/2019	Pain		Neurelis | Acute pain | Preclinical |  | 10 Oct 2017		no		no							https://adis.springer.com/drugs/800050475?userId=52029392&bpIds=3004037004&checksum=213f219ca7d9211d9d50b20123afe97516080ca0-1617045532105-fda94d5771ddf9cabdddd6d4fbce6eb4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031146	Research programme: ligand activated therapeutics - KemPharm			No			No development reported (Preclinical)	"Acute pain, Pain, CNS disorders, Cardiovascular disorders"		"Opioid receptor agonists, Adrenergic uptake inhibitors, Alpha 2 adrenergic receptor antagonists, Dopamine D2 receptor antagonists, Serotonin 1A receptor agonists, Serotonin 2A receptor antagonists"	"KemPharm (Originator), KemPharm (Owner)"		PO				"C (Cardiovascular System), N2A (Narcotics), N5A1 (Atypical antipsychotics), N6B (Psychostimulants)"	"C (Cardiovascular System), N02A (Opioids), N05A-H04 (Quetiapine), N06B-A (Centrally acting sympathomimetics)"	"KP 214, KP 515, KP 606, KP 612, KP 746, KP303, KP606/IR, KP7xx"			04/02/2019	"Neurological Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800031146?userId=52029392&bpIds=3004037004&checksum=3f8d3383a68f33d8c2d39bc85fb360f1ca672141-1617045532106-99e7c91f8e9fbdf4e5c1e2532a301476badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033733	Benzhydrocodone - KemPharm	1259440-61-3	"6,7-didehydro-4,5_-epoxy-3-methoxy-17-methylmorphinan-6-yl benzoate"	No			No development reported (I)	Acute pain	C25 H25 N O4	Opioid receptor agonists	"KemPharm (Originator), KemPharm (Owner), Acura Pharmaceuticals (Technology Provider)"		"Intranasal, PO"				N2A (Narcotics)	N02A (Opioids)	"KP201, KP201/IR (acetaminophenfree), KP201/IR (APAPfree)"			04/02/2019	Pain		KemPharm |  | Phase I |  | 27 May 2011		yes	USA	no							https://adis.springer.com/drugs/800033733?userId=52029392&bpIds=3004037004&checksum=f0bc5c52c84f1591bb9245fc7d5e15fcca6e7e6a-1617045532107-2ddc14d2db835ac0f49e3b4f7ba5d34cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009677	Tonabersat	175013-84-0	"(3<EM>S</EM>,4<EM>S</EM>)-<EM>cis</EM>-<EM>N</EM>-(6-Acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydro-2<EM>H</EM>-1-benzopyran-4-yl)-3-chloro-4-fluoro-benzamide"	Yes			No development reported (I)	"Epilepsy, Migraine, Neuropathic pain"	C20 H19 Cl F N O4	Gap junction inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), Proximagen (Licensee), Upsher-Smith (Sub-licensee)"		PO				"N2 (Analgesics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), N03A (Antiepileptics)"	"SB220453, USL260"			31/01/2019	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009677?userId=52029392&bpIds=3004037004&checksum=ebc71bdaad39eb3475d1c50a24d391a996543bfd-1617045532109-a5df6708068a0a8112b30005669b7f0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051596	GTX 201			Yes			Phase I	Trigeminal neuralgia		Undefined mechanism	"Grace Therapeutics (Originator), Grace Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GTX201			31/01/2019	Pain				no		no							https://adis.springer.com/drugs/800051596?userId=52029392&bpIds=3004037004&checksum=c79420a568c5bc5d9982a1bd87395bc8358c2003-1617045532110-d96d2afd33a276156f00661b263cd17fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022843	Research programme: Parkinson's disease therapeutics - Proximagen/Upsher-Smith			Yes			No development reported (Preclinical)	"Parkinson's disease, Neuropathic pain"		Nitric oxide synthase inhibitors	"Proximagen Neuroscience (Originator), Upsher-Smith (Owner), Boehringer Ingelheim (Collaborator)"		PO				"N2 (Analgesics), N4A (Anti-Parkinson Drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs)"	"PRX1, PRX1235, PRX2, PRX5"			31/01/2019	"Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800022843?userId=52029392&bpIds=3004037004&checksum=f5db682360481a6c8f110178926c14a196c16d2b-1617045532111-391a11c59674090914499c45f984e76bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043821	Zolmitriptan inhalation - Acorda Therapeutics			No			No development reported (I)	Migraine		"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Civitas Therapeutics (Originator), Acorda Therapeutics (Owner), Alkermes plc (Technology Provider)"		Inhalation				N2C1 (Antimigraine triptans)	N02C-C03 (Zolmitriptan)	"CVT 427, Zolmitriptan inhalation powder"			28/01/2019	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800043821?userId=52029392&bpIds=3004037004&checksum=78fbc712ede9de6d4cc8432395f58fdf78a08fe6-1617045532112-ba255bcb7ca87f64ceef309f4bd6e360badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040423	Research programme: Biochronomer extended release therapeutics - Heron Therapeutics			No			No development reported (Preclinical)	"Postoperative pain, Opioid-related disorders"		"Potassium channel antagonists, Sodium channel antagonists"	"Heron Therapeutics (Originator), Heron Therapeutics (Owner)"		"Injection, SC"				"N1B1 (Anaesthetics local, medical injectables), N7F (Drugs Used In Opioid Dependence)"	"N01B-B01 (Bupivacaine), N01B-B09 (Ropivacaine), N02A-E01 (Buprenorphine)"	"Buprenorphine extended release Heron Therapeutics, HTX 003, Ropivacaine extended release Heron Therapeutics"			28/01/2019	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800040423?userId=52029392&bpIds=3004037004&checksum=871091f71e5d18ea517d3932b513f8ec04d1d5af-1617045532113-57ea28abfc64df65ed2cc5961c9f7b45badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031128	VBY 129			Yes			No development reported (I)	"Crohn's disease, Neuropathic pain, Psoriasis, Alzheimer's disease"		Cathepsin S inhibitors	"Unknown (Originator), Unknown (Owner), Virobay (Licensee)"		PO				"D5B (Systemic Antipsoriasis Products), N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"D05B (Antipsoriatics for Systemic Use), N02B (Other Analgesics and Antipyretics), N06D-X (Other anti-dementia drugs)"	VBY129			28/01/2019	"Alzheimer's Disease and Cognition Disorders, Drug Delivery Systems, Inflammatory Bowel Disorders, Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800031128?userId=52029392&bpIds=3004037004&checksum=860fe231ebf5d35e5b9c1e3f4d55a7cc4893a7a9-1617045532115-1d18012c3ea93dc27b887460d9d02887badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048125	Pregabalin controlled release - Mapi Pharma	148553-50-8	(3S)-3-(aminomethyl)-5-methylhexanoic acid	No			Phase II	Neuropathic pain	C8 H17 N O2	CACNA2D1 protein modulators	"Mapi Pharma (Originator), Mapi Pharma (Owner), Jiangsu Nhwa Pharmaceutical (Licensee)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	"Pregabalin ER Mapi Pharma, Pregabalin extendedrelease Mapi Pharma"			28/01/2019	Pain				no		no							https://adis.springer.com/drugs/800048125?userId=52029392&bpIds=3004037004&checksum=6e611ea66162111d7c920c397014478c382284b4-1617045532116-7dcc2d51b1d2dfb489df8a43a5eb97a0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044040	AF 130			Yes			No development reported (I)	"Hypertension, Migraine"		Purinergic P2X3 receptor antagonists	"Roche (Originator), Roche (Owner), Merck & Co (Licensee)"		PO				"C2 (Antihypertensives), N2 (Analgesics)"	"C02 (Antihypertensives), N02 (Analgesics)"	AF130			28/01/2019	"Advances in the Treatment of Nausea and Migraine, Hypertension"				no		no							https://adis.springer.com/drugs/800044040?userId=52029392&bpIds=3004037004&checksum=c272a11ec769cd6ae34fef8bb19ab644332e4a32-1617045532117-38660321f37780a83b8ca6f0b1c8b599badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041759	Research programme: cyclo-oxygenase-2 selective inhibitors - Euclises Pharmaceuticals/Guangzhou Institutes of Biomedicine and Health			Yes			No development reported (Preclinical)	"Cancer, Pain, Inflammation"		Cyclo-oxygenase 2 inhibitors	"Guangzhou Institutes of Biomedicine and Health (Originator), Guangzhou Institutes of Biomedicine and Health (Owner), Euclises Pharmaceuticals (Collaborator)"		PO				"L1X (All Other Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"L01X-X (Other antineoplastic agents), M01A-H (Coxibs), N02 (Analgesics)"	"Compound 1014, ECP 1014, GIBH1014"			28/01/2019	"Cancer, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800041759?userId=52029392&bpIds=3004037004&checksum=e0bc97818cc42b7a29fa45e9f1044f751163da60-1617045532119-2f1044055ae8b616713d4be49add0cf0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042780	Morphine injection - BD Rx	6211-15-0	"7,8-Didehydro-4,5-epoxy-17-methyl-(5a,6a)-morphinan-3,6diolsulfate (2: 1) (salt), pentahydrate"	No			Marketed	Pain	(C17H19NO3)2 H2SO4 5H2O	Opioid mu receptor agonists	"BD Rx (Originator), BD Rx (Owner)"		"IM, IV"				N2A (Narcotics)	N02A-A01 (Morphine)	Morphine sulfate injection BD Rx			21/01/2019	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800042780?userId=52029392&bpIds=3004037004&checksum=349ecfdaa453b59c1b2c93ac20b29c854c91b692-1617045532121-f3a71d3b00735f73cd976ae25894410ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009062	Frakefamide		L-Tyrosyl-D-alanyl-(4-fluro-L-phenylalanyl)-L-phenylalaninamide	No			No development reported (II)	Pain	C30 H34 F N5 O5	Opioid mu receptor agonists	"Shire Pharmaceuticals Group (Originator), Takeda (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"BCH 3963, LEF, LEF 576, SPD 759"			16/01/2019	Pain				no		no							https://adis.springer.com/drugs/800009062?userId=52029392&bpIds=3004037004&checksum=a4ee8806c9b1a7011c84f009f0cd5158bbd2e3fe-1617045532122-06ce40050f30b57a7881dd0bc2170e09badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003724	BCH 150			No			Discontinued (Preclinical)	Pain		Opioid mu receptor agonists	"Shire Pharmaceuticals Group (Originator), Takeda (Owner), AstraZeneca (Market Licensee)"		PO				N2A (Narcotics)	N02A (Opioids)				16/01/2019	Pain				no		no							https://adis.springer.com/drugs/800003724?userId=52029392&bpIds=3004037004&checksum=370a0f5f7b5a3ffb89bdd2148fc8ff80f0a9678f-1617045532123-18e93b6cc430e43fee4bfbb35a0ecfdabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009073	BCH 2687	171807-58-2	<EM>l</EM>-Tyrosyl-<EM>d</EM>-arginyl-<EM>l</EM>-phenylalanyl- <EM>l</EM>-phenylalanylamide hydrochloride	No			Discontinued (Preclinical)	Pain	C33 H42 N8 O5 . H Cl	Opioid mu receptor agonists	"Shire Pharmaceuticals Group (Originator), Takeda (Owner), AstraZeneca (Market Licensee)"		SC				N2A (Narcotics)	N02A (Opioids)	LEF 553			16/01/2019	Pain				no		no							https://adis.springer.com/drugs/800009073?userId=52029392&bpIds=3004037004&checksum=e558facb544db178717af843c5b2efffb73059ee-1617045532124-5db8124816ff3210ca214e76a9111cecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003460	Propiram	15686-91-6	"Propanamide, N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)-, (E)-2-butenedioate (1:1)"	Yes			Discontinued (III)	"Postoperative pain, Musculoskeletal pain"	C16 H25 N3 O . C4 H4 O4	"Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Bayer (Originator), Bayer (Owner), Takeda (Market Licensee)"		PO	hepatic/renal	"Route of Elimination (hepatic/renal), bioavailability oral (%) (97 (Adult)), Cl (L/h) (26.6 (Adult)), T<sub>_beta</sub> (h) (5 - 7 (Adult)), T<sub>max</sub> (h) (.5 - 1.5 (Adult)), Vd (L/kg) (2.3 (Adult))"		N2A (Narcotics)	N02A (Opioids)	"Algeril, BAY 4503, Dirame, Propiram fumarate"			16/01/2019	Pain			"Algeril, Algeril"	no		no							https://adis.springer.com/drugs/800003460?userId=52029392&bpIds=3004037004&checksum=5674f9536d53f747cd8d2295b5ce7709efaad63e-1617045532125-f5b1d0c1b538163a3869bb60e8ba62e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020910	Research programme: chronic pain therapeutics - New River Pharmaceuticals			No			Discontinued (Preclinical)	Pain		Opioid receptor agonists	"New River Pharmaceuticals (Originator), Takeda (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"NRP 369, Oxycodone prodrugs New River Pharmaceuticals"			15/01/2019	Pain				no		no							https://adis.springer.com/drugs/800020910?userId=52029392&bpIds=3004037004&checksum=e3797ebf3181892949f5065eb8319bd05f70a0a9-1617045532126-ccf01afb9beaac122723b9a0b461e663badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053758	Research programme: non-opioid analgesics - Ocular Therapeutix/Purdue Pharma			Yes			Research	Pain		Undefined mechanism	"Purdue Pharma (Originator), Purdue Pharma (Owner), Ocular Therapeutix (Collaborator)"		Topical				N2 (Analgesics)	N02 (Analgesics)				15/01/2019	Pain				no		no							https://adis.springer.com/drugs/800053758?userId=52029392&bpIds=3004037004&checksum=5cbfe780a94074267d796d8fa4a02e224fe3208e-1617045532127-cf9f21716d83736bc63f13353ccf76eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020881	Research programme: acute pain therapeutics - New River Pharmaceuticals			No			Discontinued (Preclinical)	Acute pain		Opioid receptor agonists	"New River Pharmaceuticals (Originator), Takeda (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				15/01/2019	Pain				no		no							https://adis.springer.com/drugs/800020881?userId=52029392&bpIds=3004037004&checksum=0b2265df096b8b680b61689960babdf1129a1c1b-1617045532127-0e6ee8adc947f4995c683ed9d8f51fdabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025946	Research programme: analgesic transdermal - Takeda			No			Discontinued (Preclinical)	Pain		Undefined mechanism	"Shire plc (Originator), Takeda (Owner)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)	SPD 491			15/01/2019	Pain				no		no							https://adis.springer.com/drugs/800025946?userId=52029392&bpIds=3004037004&checksum=76f28f4661044be6dcdb1bc096bae9943c3b1a39-1617045532128-2dfebd75b630fb1f1745a24bce56aa78badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023801	NRP 290			No			Discontinued (I/II)	Pain		Opioid receptor agonists	"New River Pharmaceuticals (Originator), Takeda (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	NRP290			15/01/2019	Pain				no		no							https://adis.springer.com/drugs/800023801?userId=52029392&bpIds=3004037004&checksum=f3111c6a8ac433178edfab014a8a2f1aef55beee-1617045532129-48bc3fbd47000f1231a9ae3705004faabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049528	Buprenorphine/meloxicam sublingual - Bridge therapeutics		"17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol / 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide"	No			Research	Pain	C29 H41 N O4 . C14 H13 N3 O4 S2	"Cyclo-oxygenase 2 inhibitors, Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Bridge Therapeutics (Originator), Bridge Therapeutics (Owner)"		Sublingual				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-C06 (Meloxicam), N02 (Analgesics)"	BT 205			10/01/2019	Pain				no		no							https://adis.springer.com/drugs/800049528?userId=52029392&bpIds=3004037004&checksum=d4d8de8d3b7f5c3a740b4d3d5a47c661ecd60b01-1617045532129-fb6d5afca1cdc179417590b4002e3098badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051324	Bupivacaine - Cellix Bio	38396-39-3	"2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-"	Yes			Preclinical	"Mucositis, Postoperative pain"	C18 H28 N2 O	Sodium channel antagonists	"Cellix Bio (Originator), Cellix Bio (Owner), Spark Technology (Funder), University of Connecticut (Funder), Logic Biosciences (Collaborator), RVL (Collaborator)"		unspecified				"A7 (Antidiarrhoeals, Oral Electrolyte Replacers and Intestinal Anti-inflammatories), N2 (Analgesics)"	"A07 (Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents), N02 (Analgesics)"	"Bupivacaine PO6FA, CLX117, CLXONC17, LBS1011"			10/01/2019	"Inflammation, Mouth Disorders, Pain"				no		no							https://adis.springer.com/drugs/800051324?userId=52029392&bpIds=3004037004&checksum=dbc147b096bdb412541684fa650788cb59608a34-1617045532130-2f9495820205712ae88b8124b3fd2093badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026002	Apricoxib	197904-84-0	"Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)-4-methyl-1<EM>H</EM>-pyrrol-1-yl]-,"	Yes			Discontinued (II)	"Non-small cell lung cancer, Breast cancer, Inflammation, Pancreatic cancer, Inflammatory pain"	C19 H20 N2 O3 S	Cyclo-oxygenase 2 inhibitors	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner), Adastra Pharmaceuticals (Licensee)"		PO			"Diarrhoea, Nausea, Skin eruptions"	"L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"Capoxigem, CS706, Kymena, R109339, TG 01, TP1001 programme, TP2001 programme"			04/01/2019	"Cancer, Inflammation, Pain"			"Capoxigem, Capoxigem, Kymena"	no		no			EGFR	"CD4, FOXP3, IL10, Survivin"	CD4		https://adis.springer.com/drugs/800026002?userId=52029392&bpIds=3004037004&checksum=c266a080e11c05c3583a6cb74693e5a0bb897ca5-1617045532132-aa4d46463d36790b743fb9aad76d7d74badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047725	Ibuprofen/magnesium/ascorbic acid - Spherium Biomed			No			Discontinued (II)	Muscle pain		Cyclooxygenase inhibitors	"Spherium Biomed (Originator), Spherium Biomed (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-E01 (Ibuprofen), N02B (Other Analgesics and Antipyretics)"	"COMBOPROFEN, JAN12006, SP12006"			02/01/2019	Pain				no		no							https://adis.springer.com/drugs/800047725?userId=52029392&bpIds=3004037004&checksum=1e5a4a1319384b016d09bb0be1fee23729a2f2ea-1617045532132-d49789062462191888d0243fa1a682b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053608	Research programme: transient receptor potential cation channel subfamily A anatgonists - Hydra Biosciences			Yes			No development reported (Preclinical)	"Asthma, Pain"		TRPA1 protein inhibitors	"Hydra Biosciences (Originator), Eli Lilly and Company (Owner)"		unspecified				"N2 (Analgesics), R7 (Other Respiratory System Products)"	"N02 (Analgesics), R07A (Other Respiratory System Products)"	"HC030031, Reseach programme TRPA1 anatagonist Hydra Biosciences"			02/01/2019	"Obstructive Airways Disease, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800053608?userId=52029392&bpIds=3004037004&checksum=59054938dad5bf29730415ef2e2e55fcfcd386dd-1617045532133-b526ecb9c870009728f7afd06f61783abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032836	GRT 9906			Yes			Discontinued (II)	"Neuropathic pain, Fibromyalgia"		"Adrenergic uptake inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	"GRT 9906 PR, GRT9906"			31/12/2018	Pain				no		no							https://adis.springer.com/drugs/800032836?userId=52029392&bpIds=3004037004&checksum=f637b5cc3c1918f9c67259ad63bdd0dbfb99165a-1617045532134-f287c41e29236ac65b8367551e1a12babadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043768	Methadone sublingual - LondonPharma	76-99-3	"3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-"	No			No development reported (Clinical)	"Cancer pain, Opioid-related disorders"	C21 H27 N O	Opioid mu receptor agonists	"LondonPharma (Originator), LondonPharma (Owner)"		Sublingual				"L1 (Antineoplastics), N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"L01 (Antineoplastic Agents), N02A (Opioids), N07B-C (Drugs used in opioid dependence)"				28/12/2018	"Drug Withdrawal, Pain"				no		no				"2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, ACTH, CYP2D6, CYP3A4, Hydrocortisone, Morphine-3-glucuronide, MTOR associated protein, LST8 homolog, NTx, Prolactin"		"BNP, CD4, cytochrome P450 family 2 subfamily B member 6, DSP, Retinoyl b-glucuronide, troponin I, cardiac"	https://adis.springer.com/drugs/800043768?userId=52029392&bpIds=3004037004&checksum=6a292f97beecc3e1cf07530be4a1f297a468fb55-1617045532135-e24b33499e8ada318c918e9a62de712fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053625	Research programme: NaV1.8 inhibitor pain therapeutics - Vertex Pharmaceuticals			Yes			Preclinical	Pain		Nav1.8 voltage-gated sodium channel inhibitors	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				28/12/2018	Pain				no		no							https://adis.springer.com/drugs/800053625?userId=52029392&bpIds=3004037004&checksum=2798982d55e3264807fd985ba25ffc80c814d9b1-1617045532136-bd14a859a78780190c0e08566be06ea2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033399	Fentanyl transdermal - Janssen Pharmaceutical KK	437-38-7	N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide	No			Marketed	"Pain, Cancer pain"	C22 H28 N2 O	Opioid mu receptor agonists	"Janssen Pharmaceutical KK (Originator), Janssen Pharmaceutical KK (Owner), Janssen Research & Development (Collaborator)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Durotep, JNJ35685AAAG016, JNJ35685AAAG021, JNS020, JNS020QD"			28/12/2018	Pain			Durotep	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800033399?userId=52029392&bpIds=3004037004&checksum=8cd1be81be5f95ab1e8c3063b3fc188bbb6ff260-1617045532137-5482926e6e2eabf6c59210d0099e874ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043571	Research programme: ddRNAi-based therapeutics - Benitec/Circuit Therapeutics			Yes			No development reported (Research)	Pain		Sodium channel antagonists	"Benitec Biopharma (Originator), Benitec Biopharma (Owner), Circuit Therapeutics (Licensee)"		PO				"A5 (Cholagogues and Hepatic Protectors), L1 (Antineoplastics), N2 (Analgesics), S1 (Ophthalmologicals)"	"A05 (Bile and Liver Therapy), L01 (Antineoplastic Agents), N02 (Analgesics), S01 (Ophthalmologicals)"				28/12/2018	Pain				no		no							https://adis.springer.com/drugs/800043571?userId=52029392&bpIds=3004037004&checksum=32332481c191dd6c59b6757ec1002ca2d946a29c-1617045532138-cace70f2999957e5b915b14ab645a5b8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043820	CGS 125			No			No development reported (Clinical)	Osteoarthritis		TRPV1 receptor agonists	"CapGenesis Therapeutics (Originator), CapGenesis Therapeutics (Owner)"		Topical				"D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N1B3 (Anaesthetics local, topical)"	"N01B-X04 (Capsaicin), N02B (Other Analgesics and Antipyretics)"	"CGS125, transcapsaicin CapGenesis Therapeutics"			28/12/2018	"Musculoskeletal Disorders, Rheumatic Disease"				no		no				"A1C, carnitine palmitoyltransferase 1A (liver), IL1 beta, IL6, IL8, TNF-alpha"		peroxiredoxin 2	https://adis.springer.com/drugs/800043820?userId=52029392&bpIds=3004037004&checksum=749900834337cc8d2bb905e2fdb388b4645c7e09-1617045532139-924c60364e118ef0362d7e6aeae2b061badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038177	Research programme: disulfide rich peptides - Protagonist Therapeutics			Yes			No development reported (Preclinical)	"Inflammatory bowel diseases, Neuropathic pain"		"Interleukin-23 receptor antagonists, Nav1.7 voltage-gated sodium channel modulators"	"Protagonist Therapeutics (Originator), Protagonist Therapeutics (Owner), National Institute of Diabetes and Digestive and Kidney Diseases (Funder)"		"PO, Parenteral"				"A7E (Intestinal Anti-Inflammatory Agents), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), N02 (Analgesics)"	"Hepcidin agonists Protagonist Therapeutics, Interleukin23 receptor antagonist Protagonist Therapeutics, Nav1.7 voltage gated sodium channel modulators Protagonist Thearapeutics"			28/12/2018	"Inflammatory Bowel Disorders, Pain"				no		no							https://adis.springer.com/drugs/800038177?userId=52029392&bpIds=3004037004&checksum=2ca4f358b63d7631b290b9cadcbff34e07b34ee0-1617045532140-4bccf1228cf25f03b35969b62987e163badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046784	Leucine enkephalin	58822-25-6	(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid	Yes			No development reported (Preclinical)	Neuropathic pain	C28 H37 N5 O7	Opioid delta receptor agonists	"Nanomerics (Originator), Nanomerics (Owner), University College London (Technology Provider), University of Exeter (Collaborator)"		"IV, Intranasal, PO"				N2 (Analgesics)	N02 (Analgesics)	"METDoloron, Nanoenabled leucine5 enkephalin, NM 0127, NM 127"			28/12/2018	Pain				no		no							https://adis.springer.com/drugs/800046784?userId=52029392&bpIds=3004037004&checksum=8803b1af000f25618806d05f0783b64de243f98c-1617045532141-5eabf97d282f4dacad42e79f20deb7d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049910	Paracetamol combination - Sinew Pharma	103-90-2	"Acetamide, N-(4-hydroxyphenyl)-"	No			Preclinical	Pain	C8 H9 N O2	"Cyclo-oxygenase 2 inhibitors, Cytochrome P 450 enzyme system inhibitors, Prostaglandin receptor antagonists"	"Sinew Pharma (Originator), Sinew Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Hepatotoxicityfree acetaminophen prescription combination, SNP830 and SNP840, SNP830/SNP840"			27/12/2018	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800049910?userId=52029392&bpIds=3004037004&checksum=0693480d0021c002f056534a18eedba8ee1ef8f5-1617045532142-22220b2701b493db950e9381e95b7cadbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038370	Paracetamol/tramadol sustained-release - Yungjin Pharm	147630-09-9	"N-(4-Hydroxyphenyl)acetamide /(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			No development reported (Preregistration)	Pain	C16 H25 N O2.C8 H9 N O2	"Adrenergic receptor antagonists, Opioid mu receptor agonists, Prostaglandin receptor antagonists, Serotonin uptake inhibitors"	"Yungjin Pharm Co (Originator), Yungjin Pharm Co (Owner)"		PO				N2 (Analgesics)	"N02A-X52 (Tramadol, combinations), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Paracetamol/tramadol, YJAT sustained release tablet, YJATSR"			19/12/2018	Pain				no		no							https://adis.springer.com/drugs/800038370?userId=52029392&bpIds=3004037004&checksum=d7e1699ef0a84d58ed63c600dfe7250859f04fb0-1617045532142-a2e2fd5bd38f33ab255d57640f79f694badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053536	Diclofenac/tramadol - Grunenthal			No			Phase III	Acute pain		"Cyclooxygenase inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				M1 (Anti-Inflammatory and Anti-Rheumatic Products)	"M01A-B55 (Diclofenac, combinations), N02A-X52 (Tramadol, combinations)"	"Adorlan, Adorlan Forte"			13/12/2018	Pain			"Adorlan, Adorlan Forte"	no		no							https://adis.springer.com/drugs/800053536?userId=52029392&bpIds=3004037004&checksum=8bd0470a0d5c8124a7fe5a9b5856ea2f1c46067f-1617045532144-9e84dfa0781aeae59a16f4a14371841cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049093	Research programme: G protein-coupled modulators - Daiichi Sankyo/Sosei Heptares			Yes			Research	Pain		G protein-coupled receptor modulators	"Heptares Therapeutics (Originator), Sosei Heptares (Owner), Daiichi Sankyo Company (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				13/12/2018	Pain				no		no							https://adis.springer.com/drugs/800049093?userId=52029392&bpIds=3004037004&checksum=9093043a88df8f097e3203bd7940cfc3bf292d7d-1617045532145-f3696211effad2ecbd8546f3013a3a65badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022884	Research Programme: neuropathic pain therapy - NeuroSolutions/Sosei Heptares			Yes			Discontinued (Preclinical)	Neuropathic pain			"NeuroSolutions (Originator), Sosei (Originator), NeuroSolutions (Owner), Sosei Heptares (Owner)"		"PO, IV"				N2 (Analgesics)	N02 (Analgesics)	NSL036			13/12/2018	Pain				no		no							https://adis.springer.com/drugs/800022884?userId=52029392&bpIds=3004037004&checksum=019cdc0f2de64a2b9017bb1057b746758647e796-1617045532146-fe640de6e5f3cecea3b2af33bc9af03ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053527	Abuse resistant oxycodone immediate release - Grunenthal			No			Phase I	Substance-related disorders		"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)				12/12/2018	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800053527?userId=52029392&bpIds=3004037004&checksum=0650ebbc6d77325eda3c301e4884705c09659dad-1617045532147-2ae7595e3a849b81ec86620ba130f906badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040908	Analgecine - Vanway Pharmaceutical			Yes			Marketed	"Neuralgia, Back pain, Neuropathic pain"		"Bradykinin receptor antagonists, Serotonin receptor modulators"	"Vanway (Originator), Vanway (Owner)"		"IM, PO, Infusion"				N2 (Analgesics)	N02 (Analgesics)	"AGC, Analgecine"			10/12/2018	"Musculoskeletal Disorders, Pain"			"AGC, AGC, Analgecine, Analgecine"	no		no							https://adis.springer.com/drugs/800040908?userId=52029392&bpIds=3004037004&checksum=492e747d3d5618bb27392e3269c68361446e7296-1617045532149-ab7b6ac0f53c314d1cf9980fc5b49e2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041337	Research programme: submicron migraine therapeutics - iCeutica			No			No development reported (Preclinical)	Migraine		Serotonin receptor agonists	"iCeutica (Originator), iCeutica (Owner)"		"Intranasal, Sublingual"				"N2C (Anti-Migraine Preparations), N2C1 (Antimigraine triptans)"	"N02C (Antimigraine Preparations), N02C-C (Selective serotonin (5HT1) agonists)"	"ICE1209, ICE1210, ICE1211"			28/11/2018	Advances in the Treatment of Nausea and Migraine		iCeutica |  | Unspecified |  | 01 Oct 2014		no		no							https://adis.springer.com/drugs/800041337?userId=52029392&bpIds=3004037004&checksum=18fe8d461f0d298ca32c45e542b975c4b8b607d5-1617045532149-4a34862ea26d8065083556e191fa808dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041360	ZYN 001			No			No development reported (Preclinical)	"Cancer pain, Neuropathic pain, Fibromyalgia"		"Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"Zynerba Pharmaceuticals (Originator), Zynerba Pharmaceuticals (Owner), Lohmann Therapie-Systeme (Technology Provider)"		Transdermal				"M2A (Topical Anti-rheumatics and Analgesics), N2B1 (Prescription-bound non-narcotics and anti-pyretics)"	"M02A-X (Other topical products for joint and muscular pain), N02B-G (Other analgesics and antipyretics)"	"Dglyceric acid ester delta 9tetrahydrocannabinol, Tetrahydrocannabinol prodrug, Tetrahydrocannabinol prodrug transdermal patch, THC prodrug, THC prodrug transdermal patch, ZYN001"			28/11/2018	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800041360?userId=52029392&bpIds=3004037004&checksum=37905c919300566de60ac05acfc4384c2a46b43b-1617045532150-5f20b4467269edced019d4b5f321810bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041481	Research programme: osteoarthritis pain therapeutics - Calchan/Galapagos			Yes			No development reported (Research)	Musculoskeletal pain			"Calchan (Originator), Galapagos NV (Originator), Calchan (Owner), Galapagos NV (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/11/2018	Pain				no		no							https://adis.springer.com/drugs/800041481?userId=52029392&bpIds=3004037004&checksum=7f0611d671c44a706ec9527d24f25fb1f369ce31-1617045532151-e426ec5ad500aea8cc26bd299e9dbe49badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043418	HM 01 - Helsinn			Yes			No development reported (I)	Neuropathic pain		Ghrelin receptor agonists	"Helsinn (Originator), Helsinn (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	HM01			28/11/2018	Pain				no		no							https://adis.springer.com/drugs/800043418?userId=52029392&bpIds=3004037004&checksum=b484f95a8fbc047b252dad5caf564e6599c3fceb-1617045532152-c3324edc60f3973e6e831165921752dabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041524	Research programme: peptide therapeutics for pain - Johnson and Johnson Innovation/ University of Queensland			Yes			No development reported (Research)	Pain		Undefined mechanism	"Johnson & Johnson Innovation (Originator), University of Queensland (Originator), Johnson & Johnson Innovation (Owner), University of Queensland (Owner), Australian Research Council (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Peptides derived from spider venom			28/11/2018	Pain				no		no							https://adis.springer.com/drugs/800041524?userId=52029392&bpIds=3004037004&checksum=a8c150200290857bbf086dd741719308895f9206-1617045532153-01330604668afe3d7a791b2522960576badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041461	Research programme: analgesic and anti-inflammatory therapeutics - Cosmederm Bioscience						No development reported (Preclinical)	"Neuropathic pain, Allergic rhinitis, Pain"		"Cytokine inhibitors, Substance P inhibitors"	"Cosmederm Bioscience (Originator), Cosmederm Bioscience (Owner)"		Topical				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"C 525, C 737, C 757, C 787TE"			28/11/2018	"Immunological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800041461?userId=52029392&bpIds=3004037004&checksum=e52c36b35a67ef9bfd17d6c65c6c01cd5501f0d9-1617045532153-0a2aa98ac7b7c854df4954613cdc8f71badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041528	Research programme: topical therapeutics for pain and nasal congestion - China Pharmaceutical University/ Johnson and Johnson Innovation			Yes			No development reported (Research)	"Nasal congestion, Pain"		Undefined mechanism	"China Pharmaceutical University (Originator), Johnson & Johnson Innovation (Originator), China Pharmaceutical University (Owner), Johnson & Johnson Innovation (Owner)"		Topical				"N2 (Analgesics), R1A (Topical Nasal Preparations)"	"N02 (Analgesics), R01A (Decongestants and Other Nasal Preparations for Topical Use)"	"Nasal decongestants China Pharmaceutical University Johnson Johnson Innovation, Pain therapeutics China Pharmaceutical University Johnson Johnson Innovation"			28/11/2018	"Ear, Nose and Throat Disorders, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800041528?userId=52029392&bpIds=3004037004&checksum=13e9ec8f7971af3a28b553fd9cb770ba82fc8153-1617045532154-ce5467d79e5a46a2600daf41e2d1e5fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042160	Pelubiprofen/Eperisone			No			Phase II	Back pain		Cyclooxygenase inhibitors	"Daewon Pharmaceutical (Originator), Daewon Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"DW340, pelubiprofen/eperisone Daewon Pharmaceutical"			28/11/2018	Pain				no		no							https://adis.springer.com/drugs/800042160?userId=52029392&bpIds=3004037004&checksum=13678680aa08579959dbb7b3092d32daf8833187-1617045532155-0d32456389c9bc1d24974311beeb1320badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042898	Hydromorphone - Hospira	71-68-1	"6-Deoxy-7,8-dihydro-6-oxomorphine hydrochloride"	No			Marketed	Pain	C17 H19 NO3 HCl	Opioid receptor agonists	"Hospira (Originator), Hospira (Owner)"		"IV, SC, IM"				N2A (Narcotics)	N02A-A03 (Hydromorphone)	Hydromorphone hydrochloride Hospira			27/11/2018	Pain				no		no							https://adis.springer.com/drugs/800042898?userId=52029392&bpIds=3004037004&checksum=13ba124637cc350315573e54fd63b783731e1e71-1617045532156-e57da05c24febe715efc7aa330b1c66fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032775	DWJ 208			Yes			Phase I	"Neuropathic pain, Cancer pain"		Ion channel antagonists	"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DWJ208			23/11/2018	Pain				no		no							https://adis.springer.com/drugs/800032775?userId=52029392&bpIds=3004037004&checksum=c31a46c8d507e9a91b9289e940b9496e7f29c6d9-1617045532157-9e0b5d368124af4fdd4409b7c2a53574badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020962	CDS PM 101			No			Discontinued (I)	Postoperative pain			"pSivida Inc (Originator), EyePoint Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CDS PM101			20/11/2018	Pain				no		no							https://adis.springer.com/drugs/800020962?userId=52029392&bpIds=3004037004&checksum=8c2bbea15561a76d432068897c94ede48b50dc12-1617045532157-57065bf0f7b174c0091449dc1959e342badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043165	Paracetamol/tramadol - Athena Drug Delivery Solutions/Novartis	147630-09-9	"<EM>N</EM>-(4-hydroxyphenyl)acetamide/(1<EM>R</EM>,2<EM>R</EM>)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol"	No			Marketed	Pain	C16 H25 N O2 . C8 H9 N O2	"Opioid receptor agonists, Prostaglandin synthase inhibitors"	"Novartis (Originator), Novartis (Owner), Athena Drug Delivery Solutions (Technology Provider)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-X02 (Tramadol), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Palitex, Paracetamol/tramadol ODT, Paracetamol/tramadol oral dispersible tablet, Paracetamol/tramadol orodispersible tablet, Tramadol/paracetamol oral dispersible tablet"			19/11/2018	Pain			Palitex	no		no							https://adis.springer.com/drugs/800043165?userId=52029392&bpIds=3004037004&checksum=43f062fb18205431a44e2b48af926e44fff71ef6-1617045532158-886818b97137fd27bc2132ff4147382ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003652	Ziconotide - RIEMSER Arzeneimittel/TerSera Therapeutics	107452-89-1	"H-cys-lys-gly-lys-gly-ala-lys-cys-ser-arg-leu-met-tyr- asp-cys-cys-thr-gly-ser-cys-arg-ser-gly-lys-cys-NH2 cyclic(1-16),(8-20),(15-25)-tris(disulfide)"	Yes			Marketed	"Pain, Stroke, Craniocerebral trauma"	C102 H172 N36 O32 S7	Calcium channel antagonists	"Elan Pharmaceuticals (Originator), RIEMSER Arzneimittel (Owner), TerSera Therapeutics (Owner)"		Intrathecal			"Ataxia, Bradycardia, Confusion, Conjunctival disorders, Diarrhoea, Dizziness, Fever, Hallucinations, Nausea, Orthostatic hypotension, Somnolence, Syncope"	"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B-G08 (Ziconotide), N07 (Other Nervous System Drugs)"	"CI 1009, MVIIA, Prialt, SNX 111, SNX 194, Ziconotide acetate Jazz Pharmaceuticals/RIEMSER Arzeneimittel"			15/11/2018	"Neurological Disorders, Pain"	Pain (European Union)		"Prialt, Prialt, Prialt"	no		no							https://adis.springer.com/drugs/800003652?userId=52029392&bpIds=3004037004&checksum=ec15a593afc37b1e5e13375d3e31e42a5f81cc41-1617045532161-0cce5ef225ff7065cec601e1eecc5d48badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039857	S 010887			Yes			Phase I	Neuropathic pain		Undefined mechanism	"Shionogi (Originator), Shionogi (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	S010887			12/11/2018	Pain				no		no							https://adis.springer.com/drugs/800039857?userId=52029392&bpIds=3004037004&checksum=7367edb237907fd82a15443ea2c9c5c7097d3a16-1617045532162-bda9c956b752dae061976a5bd8967b7fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053280	SHX 002			Yes			Preclinical	Pain		Undefined mechanism	"Shenox Pharmaceuticals (Originator), Shenox Pharmaceuticals (Owner)"		Transdermal				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	SHX002			08/11/2018	Pain				no		no							https://adis.springer.com/drugs/800053280?userId=52029392&bpIds=3004037004&checksum=fdac25d7280854d17e01705fd6f4b9d70872ea6a-1617045532163-9422ca1a631c9c64a84925dc993adf4dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039104	Adefovir dipivoxil - Akron Molecules	142340-99-6	"Propanoic acid, 2,2-dimethyl-, [[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]phosphinylidene]bis(oxymethylene) ester"	No			Discontinued (II)	Musculoskeletal pain	C20 H32 N5 O8 P	"Enzyme inhibitors, Purinergic receptor modulators"	"Akron Molecules (Originator), Akron Molecules (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AKR202			08/11/2018	Pain				no		no							https://adis.springer.com/drugs/800039104?userId=52029392&bpIds=3004037004&checksum=b0a499b30c58970c5fd5d2af9825cf3fedf0c006-1617045532164-12ad56ae299e59a490ae1006aece2c4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013220	Fadolmidine	189353-32-0	"1<EM>H</EM>-inden-5-ol, 2,3-dihydro-3-(1<EM>H</EM>-imidazol-4-ylmethyl)-, monohydrochloride"	No			Phase II	"Postoperative pain, Neuropathic pain"	C13 H14 N2 O	Alpha 2 adrenergic receptor agonists	"Orion (Originator), Orion (Owner), Recro Pharma (Licensee)"		"Intrathecal, Topical"				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"Fado, MPV 2426, Radolmidine"			28/10/2018	Pain				no		no							https://adis.springer.com/drugs/800013220?userId=52029392&bpIds=3004037004&checksum=b608dbe24bff1eac8d7c128ee62bfaa72a50d37f-1617045532165-332bcac4da8f151ba71a179e3b4ba473badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041972	Research programme: anti-sense oligonucleotide therapeutics - nLife			No			No development reported (Preclinical)	"Depressive disorders, Neurogenic inflammation, Duchenne muscular dystrophy, Obesity"		"Antisense RNA modulators, Serotonin 1A receptor modulators, Protein tyrosine phosphatase modulators"	"nLife Therapeutics (Originator), nLife Therapeutics (Owner)"		"Intrathecal, Intranasal"				"A8A (Antiobesity Preparations, Excluding Dietetics), M5X (All Other Musculoskeletal Products), N2 (Analgesics), N6A9 (Antidepressants, all others)"	"A08 (Antiobesity Preparations, Excl. Diet Products), M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics), N06A (Antidepressants)"				28/10/2018	"Affective Disorders, Inflammation, Musculoskeletal Disorders, Obesity"				no		no							https://adis.springer.com/drugs/800041972?userId=52029392&bpIds=3004037004&checksum=7f35a65e50d51fa31f3e9f0e6fb7da87c0fed8ea-1617045532166-098d21cfbee64167e18e57ab4388c764badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028531	Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics			Yes			No development reported (Research)	"Anxiety disorders, Parkinson's disease, Pain, Schizophrenia"		"Metabotropic glutamate receptor 4 modulators, Metabotropic glutamate receptor 3 modulators, Metabotropic glutamate receptor 2 modulators"	"Faust Pharmaceuticals (Originator), Domain Therapeutics (Owner), Mavalon Therapeutics (Licensee), Prexton Therapeutics (Licensee), The Michael J. Fox Foundation for Parkinson's Research (Funder)"		"PO, unspecified"				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5 (Psycholeptics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N05B (Anxiolytics), N06A (Antidepressants)"	"DT 1687, DT 2208, DT2228, mGluR PAM Domain Therapeutics, mGluR2 PAM, mGluR3 PAM, mGluR4 PAMs"			28/10/2018	"Anxiety Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800028531?userId=52029392&bpIds=3004037004&checksum=e7a82cba051d44e79ac8f18bfa54bd12db8c64f1-1617045532168-937f0c9c4140309f475c14fc6f5eb012badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041299	Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics			Yes			Preclinical	"Postoperative pain, Pain, Muscle hypertonia, Pruritus, Cancer"		"Nav1.7 voltage-gated sodium channel inhibitors, Positron-emission tomography enhancers"	"Stanford University (Originator), Stanford University (Owner), SiteOne Therapeutics (Licensee), National Institutes of Health (USA) (Funder), Amgen (Collaborator)"		"IV, PO, SC"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), M3 (Muscle Relaxants), N2 (Analgesics), T1 (Diagnostic Imaging)"	"D04A (Antipruritics, Incl. Antihistamines, Anesthetics, Etc.), M03 (Muscle Relaxants), N02 (Analgesics), V04C-X (Other diagnostic agents)"	"GTX analogues SiteOne Therapeutics, Guanidinium toxin analogues SiteOne Therapeutics, NaV1.7 inhibitors SiteOne Therapeutics, Selective NaV1.7 channel blockers SiteOne Therapeutics, Sodium ion channel 1.7 inhibitors OneSite Therapeutics, ST Oral, ST SubQ, ST Topical, ST2578"			28/10/2018	"Cancer, Musculoskeletal Disorders, Pain, Rheumatic Disease, Skin Disorders"				no		no							https://adis.springer.com/drugs/800041299?userId=52029392&bpIds=3004037004&checksum=b094af29b27b30dd431c367d25a85f4b7b842899-1617045532170-91d803129dfc2b1ecb27613955d778f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024819	Lpathomab			Yes			No development reported (I)	"Neuropathic pain, Cancer, Spinal cord injuries, Fibrosis, Brain injuries, Diabetic neuropathies"		Lysophosphatidic acid receptor antagonists	"Lpath (Originator), Lpath (Owner), National Institute of Neurological Disorders and Stroke (Funder), National Institutes of Health (USA) (Funder), Monash University (Collaborator), University of California at Los Angeles (Collaborator), University of Kentucky (Collaborator), University of Melbourne (Collaborator), Walter Reed Army Institute of Research (Collaborator)"		Parenteral				"L1G (Monoclonal Antibody Antineoplastics), N2 (Analgesics), N7 (Other CNS Drugs), V3 (All Other Therapeutic Products)"	"L01X-C (Monoclonal antibodies), N02 (Analgesics), N07 (Other Nervous System Drugs), V03 (All Other Therapeutic Products)"	"AntiLPA MAbs Lpath, Lpathomab, mAb against lysophosphatidic acid (LPA) Lpath"			28/10/2018	"Cancer, Connective Tissue Disorders, Diabetes, Neurological Disorders, Pain"		Lpath |  | Unspecified |  | 27 Apr 2011	"Lpathomab, Lpathomab, Lpathomab, Lpathomab"	no		no							https://adis.springer.com/drugs/800024819?userId=52029392&bpIds=3004037004&checksum=8aa6a07c6fb2b76c481199fa40fe05c21a9d13fb-1617045532173-ac2047ebe107cc86fefacfa9a7955558badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010271	DFP		"Furan-3-one, 5, 5-dimethyl-2-propyloxy-4-methylsulfonylphenyl-,"	No			Discontinued (Clinical)	"Dental pain, Inflammation"	C16 H22 O5 S	Cyclo-oxygenase 2 inhibitors	"Merck & Co (Originator), Merck Frosst (Originator), Merck Canada (Owner)"		PO				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"				25/10/2018	"Inflammation, Pain"				no		no		Ferritin		Ferritin			https://adis.springer.com/drugs/800010271?userId=52029392&bpIds=3004037004&checksum=a935c307e59e101334b2386460181039eabdf22c-1617045532174-17593fea7794525c74f9a3bc55f4d735badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051132	Amitriptyline/Mefloquine - Theranexus		"10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene/alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol"	No			Preclinical	Neuropathic pain	C20 H23 N . C17 H16 F6 N2 O	Serotonin uptake inhibitors	"Theranexus (Originator), Theranexus (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	THN 101			24/10/2018	Pain				no		no							https://adis.springer.com/drugs/800051132?userId=52029392&bpIds=3004037004&checksum=5f6f49275a4dedf2a50d051a7a134fe3c289247d-1617045532175-a375e9b3da117bc2900a7060ac38faf0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053142	PRI 004			Yes			Preclinical	Neuropathic pain		Calcium channel antagonists	"Priavoid (Originator), Priavoid (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PRI004			23/10/2018	Pain				no		no							https://adis.springer.com/drugs/800053142?userId=52029392&bpIds=3004037004&checksum=658ebb9e55bca2a82cd21ecfd0a41d11a346a12b-1617045532176-57b1dedcd6fcaf8467d4c2c969c32b85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043259	Meloxicam orodispersible tablets - Athena Drug Delivery Solutions	71125-38-7	"2<EM>H</EM>-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-<EM>N</EM>-(5-methyl- 2-thiazolyl)-, 1,1-dioxide"	No			Preregistration	Pain	C14 H13 N3 O4 S2	Cyclo-oxygenase 2 inhibitors	"Athena Drug Delivery Solutions (Originator), Athena Drug Delivery Solutions (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-C06 (Meloxicam), N02 (Analgesics)"	Meloxicam ODT Athena Drug Delivery Solutions			18/10/2018	Pain				no		no							https://adis.springer.com/drugs/800043259?userId=52029392&bpIds=3004037004&checksum=8689bbb5ee4c2ea9451076268591eef1b3ca5d53-1617045532177-6bb69428ac955d04c4f0edad3e844558badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022267	Research programme: buprenorphine intranasal - Vernalis/Reckitt Benckiser	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"	No			No development reported (Preclinical)	"Pain, Substance-related disorders"	C29 H41 N O4	"Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Reckitt Benckiser (Originator), Vernalis (Originator), Reckitt Benckiser (Owner), Vernalis (Owner), Archimedes Pharma (Technology Provider)"		Intranasal				N2A (Narcotics)	N02A (Opioids)	"IX1004, IX1005, V 1004, V 1005"			17/10/2018	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800022267?userId=52029392&bpIds=3004037004&checksum=ecb330bedbfde9ac8137dd6c0167331930c30657-1617045532178-60d8e9c4587ae96df21323781066b658badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015844	Research programme: glutamate antagonists - Vernalis			No			Discontinued (Preclinical)	Neuropathic pain		Glutamate receptor antagonists	"Vernalis (Originator), Vernalis (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	glutamate antagonists research programme Vernalis			17/10/2018	Pain				no		no							https://adis.springer.com/drugs/800015844?userId=52029392&bpIds=3004037004&checksum=c88694b85316a5dcf5fdb20b81267fdb1c5d6a9e-1617045532179-487b33a1a17ab243dbe068b222a60309badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017872	Buprenorphine intranasal - Vernalis	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"	No			No development reported (II)	"Postoperative pain, Pain"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Vernalis (Originator), Vernalis (Owner), Archimedes Pharma (Technology Provider)"		Intranasal			"Dizziness, Nausea, Sleep disorders, Vomiting"	N2A (Narcotics)	N02A-E01 (Buprenorphine)	"IX1003, V1003"			16/10/2018	Pain				no		no							https://adis.springer.com/drugs/800017872?userId=52029392&bpIds=3004037004&checksum=3cb77602a782236ebe22251b36d737ae59e84544-1617045532181-9175a4b3a2384d9ba2e9f66dec343832badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003815	Frovatriptan	158930-17-7	"<EM>R</EM>-(+) 3-methylamino-6-carboxamido-l,2,3,4-tetrahydrocarbazole monosuccinate monohydrate"	Yes			Marketed	"Migraine, Menstrual migraine"	C14 H17 N3 O . C4 H6 O4 . H2 O	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), Menarini (Market Licensee), SK Chemicals (Market Licensee), Vernalis (Market Licensee), Endo Pharmaceuticals (Licensee), Recordati (Sub-licensee), Teva Neuroscience (Sub-licensee)"		PO		"bioavailability oral (%) (24 - 30 (Adult)), Cl (L/h) (7.92 - 12.96 (Adult)), T<sub>_beta</sub> (h) (25 - 26 (Adult)), Vd (L/kg) (3 - 4.2 (Adult))"	"Dizziness, Fatigue, Headache, Nausea, Paraesthesia, Respiratory tract infections, Somnolence"	N2C (Anti-Migraine Preparations)	N02C-C07 (Frovatriptan)	"Allegro, Auradol, EN 3266, Frova, Frovatriptan succinate, Isimig, Migard, Pitunal, Rilamig, SB 209509, SB 209509AX, VML 251"			16/10/2018	"Advances in the Treatment of Nausea and Migraine, Women's Health"			"Allegro, Auradol, Frova, Frova, Isimig, Migard, Pitunal, Rilamig"	no		no							https://adis.springer.com/drugs/800003815?userId=52029392&bpIds=3004037004&checksum=b32408b65dcbc91e55ec7db81a44c6989853fee1-1617045532186-dc19336293e40563e2bce49d73095bc0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013526	Research programme: sodium channel antagonists - Vernalis			No			No development reported (Preclinical)	"Stroke, Neuropathic pain, CNS disorders"		Sodium channel antagonists	"Vernalis (Originator), Vernalis (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"				16/10/2018	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800013526?userId=52029392&bpIds=3004037004&checksum=1de0f6ff4de74c60806d0e7998feff7d4df77f85-1617045532187-35ef9bce1492cdcbe1ba168a564742f9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016944	Research programme: analgesic therapeutics - Vernalis			Yes			Discontinued (Preclinical)	"Pain, Urinary incontinence"		"Sodium channel antagonists, Calcium channel antagonists"	"Vernalis (Originator), Vernalis (Owner)"		unspecified				"G4D4 (Urinary incontinence products), N2 (Analgesics)"	"G04B (Urologicals), N02 (Analgesics)"	"1X 2000, 1X 3000, Analgesic therapeutics research programme Vernalis, IX 4000"			16/10/2018	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800016944?userId=52029392&bpIds=3004037004&checksum=e35a9bf950a67c18f03116306ab9586a4d872b2a-1617045532187-465f43d0b6c98b2bff0a5b422c15b4b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028871	Research programme: fatty acid amide hydrolase inhibitors - Vernalis			No			No development reported (Preclinical)	Pain		Fatty acid amide hydrolase inhibitors	"Vernalis (Originator), Vernalis (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/10/2018	Pain				no		no							https://adis.springer.com/drugs/800028871?userId=52029392&bpIds=3004037004&checksum=7349af3c74d7d1a745c9571fb120cebf3fb16cca-1617045532188-34823155b900bd7e3bdd387314856bc5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017496	Research programme: analgesics - Vernalis/Xenome			Yes			Discontinued (Preclinical)	Pain		Sodium channel antagonists	"Vernalis (Originator), Xenome (Originator), Vernalis (Owner), Xenome (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Analgesics research programme Vernalis/Xenome			16/10/2018	Pain				no		no							https://adis.springer.com/drugs/800017496?userId=52029392&bpIds=3004037004&checksum=afc842c2830147d12527c9655489b6a87b717337-1617045532189-7eb2a4675ea6c07be5e5f4656a5169f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018081	Alfadolone	14107-37-0	"3_,21-Dihydroxy-5_-pregnane-11,20-dione"	No			Discontinued (I)	Cancer pain	C21 H32 O4	GABA A receptor agonists	"Monash University (Originator), Monash University (Owner), Vernalis (Market Licensee)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"Alphadolone, Alphadolone acetate, R 140, V140"			16/10/2018	Pain				no		no							https://adis.springer.com/drugs/800018081?userId=52029392&bpIds=3004037004&checksum=f81c2855423201090aa5dc3d5ecd1db4ea9cabc7-1617045532190-4140d831d4a37f34ff7877c7d7404c42badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011999	Indantadol	202844-10-8	"2-(2,3-Dihydro-1<EM>H</EM>-inden-3-ylamino)acetamide hydrochloride"	Yes			Discontinued (II)	"Neuropathic pain, Cough"	C11 H14 N2 O . H Cl	"Monoamine oxidase inhibitors, NMDA receptor antagonists"	"Chiesi Farmaceutici (Originator), Chiesi Farmaceutici (Owner), Vernalis (Licensee), University Hospital of South Manchester NHS Foundation Trust (Collaborator), University of Manchester (Collaborator)"		PO	hepatic/renal	"Route of Elimination (hepatic/renal), T<sub>_beta</sub> (h) (4 - 5 (Adult)), T<sub>max</sub> (h) (.5 - 2 (Adult))"	"Asthenia, Cognition disorders, Dizziness"	"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N7D9 (All other anti-Alzheimer products), R5D (Antitussives)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics), N06D-X (Other anti-dementia drugs), R05D (Cough Suppressants, Excl. Combinations with Expectorants)"	"CHF 3381, CMP 3381, CNP 3381, GT 3381, IL 0001, V 3881, V3381, V3381CC"			16/10/2018	"Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800011999?userId=52029392&bpIds=3004037004&checksum=095dc1470b5a53afb0e71dc608de20b169504510-1617045532191-7f1864c347c21c4fcddf29bb2bc6e8ccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043761	Methadone - Recordati	76-99-3	"3-Heptanone, 6-(dimethylamino)-4,4-diphenyl-"	No			Marketed	"Opioid-related disorders, Cancer pain"	C21 H27 N O	Opioid mu receptor agonists	"Recordati (Originator), Recordati (Owner)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A (Opioids), N07B-C02 (Methadone)"	Methadone chlorhydrate AP HP			15/10/2018	"Drug Withdrawal, Pain"				no		no				"2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, ACTH, CYP2D6, CYP3A4, Hydrocortisone, Morphine-3-glucuronide, MTOR associated protein, LST8 homolog, NTx, Prolactin"		"BNP, CD4, cytochrome P450 family 2 subfamily B member 6, DSP, Retinoyl b-glucuronide, troponin I, cardiac"	https://adis.springer.com/drugs/800043761?userId=52029392&bpIds=3004037004&checksum=1ce8f55f695648dfee7ddc04eafc90042b5c9a2c-1617045532192-398392c59525c55735ede80f38634f46badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053125	Research programme: antibodies - Oblique Therapeutics			Yes			Research	"Colorectal cancer, Pain"		"Immunomodulators, TRPV1 receptor antagonists"	"Oblique Therapeutics (Originator), Oblique Therapeutics (Owner)"		Parenteral				"L1D (Antineoplastic Antibiotics), N2 (Analgesics)"	"L01D-C (Other cytotoxic antibiotics), N02 (Analgesics)"	"aKRAS Oblique Therapeutics, aTRPA1 Oblique Therapeutics, aTRPV1 Oblique Therapeutics"			15/10/2018	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800053125?userId=52029392&bpIds=3004037004&checksum=30c5bc87177236b9fb7166d41e8a66c23620053c-1617045532193-3f074c60079fe7cd3a351e04d3cc37f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053118	Research programme: glycine transporter 2 inhibitors - Boehringer Ingelheim			Yes			Preclinical	Neuropathic pain		Glycine plasma membrane transport protein inhibitors	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner), University of Queensland (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)				12/10/2018	Pain				no		no							https://adis.springer.com/drugs/800053118?userId=52029392&bpIds=3004037004&checksum=6f059a754b3afa115bc97d99d208d2e031edb1b8-1617045532193-202d6bd314e98dd7181bf19a59527b69badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053113	RQ 00488738			Yes			Preclinical	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"RaQualia Pharma (Originator), RaQualia Pharma (Owner), XuanZhu Pharma (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	RQ00488738			11/10/2018	Pain				no		no							https://adis.springer.com/drugs/800053113?userId=52029392&bpIds=3004037004&checksum=1d0d6c3d39657e58c545416de47b4b64e68e5dd6-1617045532194-00ddd4a19d7733e79f70a12f7d9c9e83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044180	Research programme: pain therapeutics - RaQualia Pharma/XuanZhu Pharma			Yes			Preclinical	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"RaQualia Pharma (Originator), XuanZhu Pharma (Originator), RaQualia Pharma (Owner), XuanZhu Pharma (Owner), RaQualia Pharma (Licensee), XuanZhu Pharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				11/10/2018	Pain				no		no							https://adis.springer.com/drugs/800044180?userId=52029392&bpIds=3004037004&checksum=8b0e18e91c9ad99c794241d5d598770e53fe7471-1617045532195-58f5b8fd0a06fb820d4de4da1490b4e7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044910	TRK 700			Yes			Phase II	"Postherpetic neuralgia, Peripheral nervous system diseases"		Undefined mechanism	"Toray Industries (Originator), Toray Industries (Owner)"		PO				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	TRK700			11/10/2018	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800044910?userId=52029392&bpIds=3004037004&checksum=5cdc5da068cf188365efd39dbca91790223415fa-1617045532196-529f64911e683fecb7ed4f40050339dfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048568	Oxycodone hydrochloride hydrate controlled-release - Daiichi Sankyo	591229-40-2	"Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, hydrochloride, hydrate (1:1:3), (5alpha)-"	No			No development reported (I)	Pain	C18 H21 N O4 . H Cl . 3 H2 O	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"DS5058b, Oxycodone hydrochloride trihydrate"			28/09/2018	Pain				no		no							https://adis.springer.com/drugs/800048568?userId=52029392&bpIds=3004037004&checksum=b00421cfafc9e2987a2f50fe947b58fc8e318257-1617045532196-da7a3a302c23ccc9f13cc230eb59d2f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800053026	Recombinant human meteorin - Hoba Therapeutics			No			Preclinical	Neuropathic pain		"Glial cell modulators, Neuron stimulants"	"Hoba Therapeutics (Originator), Hoba Therapeutics (Owner), Selexis (Technology Provider), Innovation Fund Denmark (Funder)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"HB086, rhMeteorin"			28/09/2018	Pain				no		no							https://adis.springer.com/drugs/800053026?userId=52029392&bpIds=3004037004&checksum=0b24aa1c232e00c4e91ff74dc73f52b2f153208c-1617045532197-8391f35e55853fac087443198aa4cf51badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043093	Ketorolac PatchPump - SteadyMed Therapeutics	74103-06-3	"5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid"	No			No development reported (I)	Pain	C15 H13 N O3	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"SteadyMed Therapeutics (Originator), SteadyMed Therapeutics (Owner)"		SC				"M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"M01A-B15 (Ketorolac), N02 (Analgesics)"	SMT201			28/09/2018	"Drug Delivery Systems, Pain"		SteadyMed Therapeutics |  | Phase I |  | 18 Aug 2015		no		no							https://adis.springer.com/drugs/800043093?userId=52029392&bpIds=3004037004&checksum=1e9a54e56a73ca9c9db5fbbd15d3fb97b870a37b-1617045532198-015db0a6a7980f25578cd392745670c6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044486	Research programme: inhaled therapeutics - MannKind/Receptor Life Sciences	1972-08-3	"6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-dibenzo(b,d)pyran-1-ol"	No			Research	"Nausea and vomiting, Anorexia, Pain, Inflammation, Neurological disorders"	C21 H30 O2	Cannabinoid receptor agonists	"MannKind Corporation (Originator), Receptor Life Sciences (Originator), MannKind Corporation (Owner), Receptor Life Sciences (Owner)"		Inhalation				"A4A9 (Other antiemetics and antinauseants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs)"	"A04A-D10 (Dronabinol), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"9Tetrahydrocannabinol MannKind/Receptor Life Sciences, Dronabinol dry powder inhalation MannKind/Receptor Life Sciences, THC MannKind/Receptor Life Sciences"			17/09/2018	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Drug Delivery Systems, Inflammation, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800044486?userId=52029392&bpIds=3004037004&checksum=812781ad99e89b6c8816dc07960418600d5ff010-1617045532199-715b37d85240c90179f52591d1c2b33fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032007	Oxycodone/paracetamol controlled release		"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / N-(4-Hydroxyphenyl)-acetanilide"	No			No development reported (I)	Pain	C18 H21 N O4 . C8 H9 N O2	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Prostaglandin receptor antagonists"	"Labopharm (Originator), Endo International (Owner)"		PO				"N2A (Narcotics), N2B1 (Prescription-bound non-narcotics and anti-pyretics)"	"N02A-A55 (Oxycodone, combinations), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"DDS06B, DDS08B, oxycodone/acetaminophen Labopharm, Oxycodone/paracetamol INTELLITAB"			12/09/2018	Pain				no		no							https://adis.springer.com/drugs/800032007?userId=52029392&bpIds=3004037004&checksum=c5f39b94d9867f69db60acf859627b3c2f6f5d4b-1617045532200-dd83d529f3cccd8b52c58ec2c024f506badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020492	Morphine/oxycodone	1286202-52-5	"4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol / 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Discontinued (Preregistration)	"Pain, Postoperative pain"	C17 H19 N O3 . C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"QRxPharma (Originator), QRxPharma (Owner), Teva Pharmaceutical Industries (Market Licensee), Actavis Inc (Licensee), Aoxing Pharmaceutical Company (Licensee), Aspen Pharmacare Australia (Licensee), Endo International (Licensee), Supernus Pharmaceuticals (Technology Provider)"		"PO, IV"			"Dizziness, Emesis, Nausea, Skin eruptions, Somnolence"	N2A (Narcotics)	"N02A-A51 (Morphine, combinations), N02A-A55 (Oxycodone, combinations)"	"MoxDuo, MoxDuo CR, MoxDuo IV, Oxycodone/morphine, Q 8003, Q 8011, Q8012"			12/09/2018	Pain			MoxDuo	no		no							https://adis.springer.com/drugs/800020492?userId=52029392&bpIds=3004037004&checksum=a69facee785887d50b602bebb79f50b02f7d57cf-1617045532201-67b2059c9ab8a28276fa70c337a65f5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034233	Oxycodone/naltrexone - Pfizer		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one"	No			Marketed	Pain	C18 H21 N O4 . C20 H23 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Opioid receptor antagonists"	"Pfizer (Originator), Pfizer (Owner)"		"PO, Intranasal, IV"			"Diarrhoea, Nausea, Vomiting"	N2A (Narcotics)	"N02A-A55 (Oxycodone, combinations), N02A-X (Other opioids)"	"ALO02, Naltrexone/oxycodone Pfizer, Oxycodonenaltrexone core (King), TROXYCAER"			12/09/2018	Pain			TROXYCAER	no		no			"aldo-keto reductase family 1 member C1, Purine"	"aldo-keto reductase family 1 member C1, EH domain containing 4, nuclear receptor subfamily 0, group B, member 2, opioid related nociceptin receptor 1, Purine"		"SRC proto-oncogene, non-receptor tyrosine kinase"	https://adis.springer.com/drugs/800034233?userId=52029392&bpIds=3004037004&checksum=3382516d44c3da6db8e92939be0f52d4843da181-1617045532203-1170c216c0854e859fc370063b76d06cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017612	Oxycodone/paracetamol/dextromethorphan - Endo		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / N-(4-hydroxyphenyl)-acetamide / 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan"	No			Discontinued (II)	Pain	C18 H21 N O4 . C8 H9 N O2 . C18 H25 N O	"NMDA receptor antagonists, Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Prostaglandin receptor antagonists"	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner), Virginia Commonwealth University (Technology Provider)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"EN3227, PercoDex"			12/09/2018	Pain			PercoDex	no		no							https://adis.springer.com/drugs/800017612?userId=52029392&bpIds=3004037004&checksum=7dd8975d4064acba9f0f563ff639c84c6cc7dbfd-1617045532204-4c4dcddc567a79439381de55a85fa78cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017613	Oxycodone/dextromethorphan - Endo		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan"	No			Discontinued (II)	Pain	C18 H21 N O4 . C18 H25 N O	"NMDA receptor antagonists, Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner), Virginia Commonwealth University (Technology Provider)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"EN3229, OxycoDex"			12/09/2018	Pain			OxycoDex	no		no							https://adis.springer.com/drugs/800017613?userId=52029392&bpIds=3004037004&checksum=6f1ce988f15943119f605b41d8daf2663ccae105-1617045532205-2018209d1ca46956d3765399f873cdcbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019069	Oxycodone/naltrexone - Elite Pharmaceuticals		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one"	No			Preregistration	"Pain, Postoperative pain"	C18 H21 N O4 . C20 H23 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Opioid receptor antagonists"	"Elite Pharmaceuticals (Originator), Elite Pharmaceuticals (Owner)"		PO				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	"N02A-A55 (Oxycodone, combinations), N07B-B04 (Naltrexone), N07B-C (Drugs used in opioid dependence)"	"Abuse resistant oxycodone, ELI200, ELI201, ELI216, Naltrexone/oxycodone Elite Pharmaceuticals, Oxycodone hydrochloride/Naltrexone Elite Pharmaceuticals, OxyNal, SequestOx"			12/09/2018	Pain		Elite Pharmaceuticals | Pain | Phase III |  | 31 Mar 2010	"OxyNal, SequestOx"	no		no							https://adis.springer.com/drugs/800019069?userId=52029392&bpIds=3004037004&checksum=5d1d589a37d51be07a0b022d9555d1e5bb1af5fd-1617045532207-fc76c7028d200ee4e9ce67e0435c92c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029296	Research programme: endomorphin analogues - Cytogel Pharma			No			Preclinical	Pain		Opioid mu receptor agonists	"Tulane University (Originator), Tulane University (Owner), Cytogel (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"EM1, Endomorphin1"			11/09/2018	Pain		Cytogel |  | Clinical Phase Unknown |  | 07 Sep 2018		no		no							https://adis.springer.com/drugs/800029296?userId=52029392&bpIds=3004037004&checksum=d384dd20697b19eae87c0151655c7e29fb9d459c-1617045532209-d6f8041926f8e91bf28331671fdf2b9abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027387	Dimiracetam - Neurotune	126100-97-8	"Dihydro-1H-pyrrolo[1,2-<EM>a</EM>]imidazole-2,5(3<EM>H</EM>,6<EM>H</EM>)-dione"	Yes			No development reported (II)	"Neuropathic pain, Musculoskeletal pain"	C6 H8 N2 O2	NMDA receptor antagonists	"Brane Discovery (Originator), Neurotune (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"BND11624, NT11624"			11/09/2018	Pain				no		no		CD4		CD4	CD4		https://adis.springer.com/drugs/800027387?userId=52029392&bpIds=3004037004&checksum=541db1351e0d2146f6e26d69c588b5ad9f0dcdce-1617045532210-89df8cadaaffb637dea6862e8acf46b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052681	Research programme: abuse-deterrent therapeutics - Charleston Laboratories			No			Preclinical	Pain		Undefined mechanism	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				29/08/2018	Pain		Charleston Laboratories |  | Unspecified |  | 29 Aug 2018		no		no							https://adis.springer.com/drugs/800052681?userId=52029392&bpIds=3004037004&checksum=70fa633a09b036d4519649a5a62055fbbb353e2c-1617045532211-5c90b287c4e432fde546d6cb6dd1d4d3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046992	ELI 202			No			No development reported (I)	Pain		"Opioid delta receptor antagonists, Opioid receptor agonists"	"Elite Pharmaceuticals (Originator), Elite Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	ELI202 opioid			28/08/2018	Pain				no		no							https://adis.springer.com/drugs/800046992?userId=52029392&bpIds=3004037004&checksum=3a15d92ced1f117491e4ec0032fe84b4be4af100-1617045532212-da7d8bc87ba6f5b7e70c2cdc0faf7670badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052753	Research programme: kappa opioid receptor agonists - Peptide Logic			Yes			Research	"Pain, Pruritus"		Opioid kappa receptor agonists	"Peptide Logic (Originator), Peptide Logic (Owner), Pfizer (Technology Provider), National Institute of Drug Abuse (Funder), University of Arizona (Collaborator)"		unspecified				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A-X (Other antipruritics), N02B (Other Analgesics and Antipyretics)"				24/08/2018	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800052753?userId=52029392&bpIds=3004037004&checksum=18671dfd0d6822fca7fc3cbda5426b45fd63e053-1617045532214-5c40b4160e8f0d4035fa8f8729d3d927badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030489	Paracetamol/opioid analgesic controlled-release - Medtronic/Assertio Therapeutics			No			No development reported (I)	Pain		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Covidien (Originator), Depomed (Originator), Assertio Therapeutics (Owner), Medtronic (Owner)"		PO				"N2A (Narcotics), N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)"	"N02A (Opioids), N02B-E01 (Paracetamol)"	Acetaminophen/opioid analgesic controlledrelease Covidien/Depomed			20/08/2018	Pain				no		no							https://adis.springer.com/drugs/800030489?userId=52029392&bpIds=3004037004&checksum=cd9cd5fb07ff139af3d21d9e7612df66fcf98bb1-1617045532215-f6c169e2efc4d5de69999970ff20c70ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034083	Lexanopadol	1357348-09-4	"<EM>Trans </EM>-6Õ-fluoro-4Õ,9Õ-dihydro-N-methyl-4-phenyl-spiro[cyclohexane-1,1Õ(3ÕH)-pyrano[3,4-b]indol]-4-amine"	Yes			No development reported (I)	Pain	C23 H25 F N2 O	"Nociceptin receptor agonists, Opioid mu receptor agonists"	"Grunenthal (Originator), Grunenthal (Owner), Assertio Therapeutics (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"GRT13106G, GRT6006"			20/08/2018	Pain				no		no							https://adis.springer.com/drugs/800034083?userId=52029392&bpIds=3004037004&checksum=4703e0e1eefbb9ac1e417deb7fef0d110c97ec09-1617045532216-dbc6140275c1ebab853a8a41cbb7fcd5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016826	Diclofenac - Assertio Therapeutics	15307-81-0	"Potassium [<EM>o</EM>-(2,6-dichloroanilino)phenyl]acetate"	No			Marketed	Acute pain	C14 H10 Cl2 K N O2	"Cyclooxygenase inhibitors, Prostaglandin synthase inhibitors"	"AAIPharma (Originator), Alcami (Owner), Assertio Therapeutics (Owner), Ferring Pharmaceuticals (Market Licensee)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B05 (Diclofenac), N02B (Other Analgesics and Antipyretics)"	"Lynxorb, ProSorbD, XP 21L, Zipsor"			20/08/2018	Pain			Zipsor	no		no							https://adis.springer.com/drugs/800016826?userId=52029392&bpIds=3004037004&checksum=cc62f4c3deccb1dc5e004236b0046e0906377dfe-1617045532217-7fd19bc3caf97190acfa2e10541d4806badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005494	Retigabine - Bausch Health Companies/GlaxoSmithKline	150812-12-7	"Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester"	Yes			Market Withdrawal	"Partial epilepsies, Lennox-Gastaut syndrome, Amyotrophic lateral sclerosis, Postherpetic neuralgia"	C16 H18 F N3 O2	"GABA A receptor agonists, KCNQ potassium channel agonists"	"Meda (Originator), Meda (Owner), Bausch Health Companies (Licensee), GlaxoSmithKline (Sub-licensee), Harvard University (Collaborator), Louvain University Hospital of Mont-Godinne (Collaborator), Massachusetts General Hospital (Collaborator), The ALS Association (Collaborator)"		PO			"Ataxia, Blurred vision, Confusion, Dizziness, Dysarthria, Fatigue, Headache, Kidney disorders, Nausea, Somnolence, Tremor, Urinary retention, Urinary tract infections, Urination disorders"	"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A-X21 (Retigabine)"	"ADD230001, AW21360, D20443, D20443 dihydrochloride, D23129, Ezogabine, EzogabineXR, GKE 841, GW582892X, Potiga, RetigabineXR, Trobalt, WAY143841"			17/08/2018	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"			"Potiga, Trobalt"	no		no		cathepsin L	cathepsin L	"Bilirubin, cathepsin L, chromodomain helicase DNA binding protein 7, CKB, CKM, Uric acid"			https://adis.springer.com/drugs/800005494?userId=52029392&bpIds=3004037004&checksum=1c95dcee41651641dacc5aef0a4d679b05c4f85f-1617045532224-941e254e5ffa71775693afc2e8861c52badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052673	Hydromorphone/promethazine - Charleston Laboratories		"(4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one / N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine"	No			Phase I	"Nausea and vomiting, Pain"	C17 H19 N O3 . C17 H20 N2 S	"Histamine H1 receptor antagonists, Muscarinic M1 receptor antagonists, Serotonin receptor antagonists, Opioid receptor agonists"	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		PO				"N2A (Narcotics), R6 (Systemic Antihistamines)"	"N02A-A03 (Hydromorphone), R06A-D52 (Promethazine, combinations)"	"CLP517, Promethazine/hydromorphone"			07/08/2018	"Advances in the Treatment of Nausea and Migraine, Pain"		Charleston Laboratories |  | Unspecified | World | 07 Aug 2018		no		no							https://adis.springer.com/drugs/800052673?userId=52029392&bpIds=3004037004&checksum=22b18c807e0d9355424b80b06b08eac30acd83cc-1617045532225-5cc663c723d4d5546d4bd1625e20aab7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052672	Tramadol/promethazine - Charleston Laboratories		"(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol / N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine"	No			Phase I	"Pain, Nausea and vomiting"	C16 H25 N O2 . C17 H20 N2 S	"Opioid mu receptor agonists, Histamine H1 receptor antagonists, Muscarinic receptor antagonists, Serotonin receptor antagonists"	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		PO				"N2A (Narcotics), R6A (Systemic Antihistamines)"	"N02A-X52 (Tramadol, combinations), R06A-D52 (Promethazine, combinations)"	"CLP417, Promethazine/tramadol"			07/08/2018	"Advances in the Treatment of Nausea and Migraine, Pain"		Charleston Laboratories |  | Unspecified | World | 07 Aug 2018		no		no							https://adis.springer.com/drugs/800052672?userId=52029392&bpIds=3004037004&checksum=92cb98755af1cc3227268a036ee5e15df9e2a0a7-1617045532225-ab71a68d6cf5fea97630a63f0531734abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052674	CL H2T			No			Preclinical	"Nausea and vomiting, Migraine"		Undefined mechanism	"Charleston Laboratories (Originator), Charleston Laboratories (Owner)"		unspecified				"A4 (Antiemetics and Antinauseants), N2C (Anti-Migraine Preparations)"	"A04 (Antiemetics and Antinauseants), N02C (Antimigraine Preparations)"	CLH2T			07/08/2018	Advances in the Treatment of Nausea and Migraine		Charleston Laboratories |  | Unspecified | World | 07 Aug 2018		no		no							https://adis.springer.com/drugs/800052674?userId=52029392&bpIds=3004037004&checksum=25797abbd952bc38e46a4dc3de69fc26f89e3da0-1617045532226-dab263b38cb99379ca1845795c8ec693badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035874	NKTR 192			Yes			No development reported (Preclinical)	"Acute pain, Migraine"		Opioid mu receptor agonists	"Nektar Therapeutics (Originator), Nektar Therapeutics (Owner)"		"Parenteral, PO"				"N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"N02A (Opioids), N02C (Antimigraine Preparations)"	NKTR192			28/07/2018	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800035874?userId=52029392&bpIds=3004037004&checksum=6bfbb3efa60abdd64c7768275aad09c1650be9c8-1617045532227-434c0fe008161d6cc28ad0c2e0033baabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042778	Hydromorphone controlled-release - Avadel Pharmaceuticals	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"	No			No development reported (I)	Pain	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Flamel Technologies (Originator), Avadel Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A-A03 (Hydromorphone)	"FT 227, Hydromorphone extendedrelease Avadel, Trigger Lock hydromorphone"			28/07/2018	Pain		Avadel Pharmaceuticals | Pain | Unspecified |  | 28 Mar 2017		no		no							https://adis.springer.com/drugs/800042778?userId=52029392&bpIds=3004037004&checksum=7a23a3ec3dc4affdf5ccae72da0610d22051d1c7-1617045532228-1635eb11abca1e3997e595bc4d7debd7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034401	Hydromorphone extended release - Ensysce Biosciences	466-99-9	"Morphinan-6-one, 4,5-alpha-epoxy-3-hydroxy-17-methyl-"	No			No development reported (I)	Pain	C17 H19 N O3	Opioid receptor agonists	"PharmacoFore (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-A03 (Hydromorphone)	"ER hydromorphone Ensysce, PF0329, PF329"			28/07/2018	Pain		Ensysce Biosciences |  | Unspecified |  | 02 Sep 2012		no		no							https://adis.springer.com/drugs/800034401?userId=52029392&bpIds=3004037004&checksum=d669e86355cd4b46cba49fb38248c5902bde06ac-1617045532229-7c77d256727ebb01528e3403cf0ffff1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042071	MP 10X			No			No development reported (Clinical)	Pain		Cannabinoid receptor modulators	"Medipure Holdings (Originator), Medipure Holdings (Owner)"		Sublingual				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	MP10X			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800042071?userId=52029392&bpIds=3004037004&checksum=da47a6f74a5dafc3cf98e5653354617d9112a5a6-1617045529452-c2b632c1112a3a37aedc7d90770abd96badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040689	Opioid analgesic - Mundipharma			No			No development reported (I)	Pain		Opioid receptor modulators	"Mundipharma Research (Originator), Mundipharma Research (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"MR 1XXX, MR 2XXX, MR 902, MR XXX"			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800040689?userId=52029392&bpIds=3004037004&checksum=b88f201128057e3fa0eeebc244dd0ad2ef34a2bc-1617045529453-5a66c3938526563a9d88dc9b0a3d2a06badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041618	Paracetamol intravenous - Uni-Pharma			No			No development reported (Clinical)	Fever		Prostaglandin receptor antagonists	"Uni-Pharma SA (Originator), Uni-Pharma SA (Owner)"		IV				N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)	N02B-E01 (Paracetamol)	POTEL ax			28/07/2018	Metabolic Disorders			POTEL ax	no		no		"A1AT, A1C, PSA, WT1"	"CD3d, CD3e, CD3g"	"11-Dehydro-thromboxane B2, 7-Hydroxy-6-methyl-8-ribityl lumazine, A1AT, A1C, Acetaminophen glucuronide, Acetylcysteine, Acid ceramidase, Angiopoietin 2, Arachidonic acid, AT-III, C-peptide, C4, CD34, CD3d, CD3e, CD3g, Collagen type 2, CRP, cytochrome P450 family 2 subfamily E member 1, Cytokeratin 18, dsDNA Auto-antibodies, F2-isoprostanes, Fibulin 3 peptides, Glutathione, growth hormone 1, Heme, HMGB1, Hydrocortisone, IFN-gamma, IGFBP7, IL6, insulin receptor related receptor, L-Cysteine, L-Cystine, microRNA 122, MMP-2, NGAL, opioid related nociceptin receptor 1, Osteocalcin, peptidylprolyl isomerase G, peroxiredoxin 5, PHGDH, Prostacyclin, PSA, RAGE, Thromboxane A2, Thromboxane B2, TIMP-2, TNF-alpha, transcription factor 21, VEGF-A, VEGFR, VEGFR1, WT1"	"Acid ceramidase, AT-III, Cytokeratin 18, HMGB1, NGAL, Osteocalcin, PSA"	"ATP binding cassette subfamily G member 2 (Junior blood group), Calreticulin, CTx, CYP2D6, Fe3+, GIP"	https://adis.springer.com/drugs/800041618?userId=52029392&bpIds=3004037004&checksum=49804b70caf2616b127fad578565b70e2805ff4f-1617045529455-e2bac52ee3bad476b400321688a4fa47badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035158	Research programme: peptide therapeutics - Soricimed			Yes			No development reported (Preclinical)	"Pain, Prostate cancer, Breast cancer, Ovarian cancer"		"Sodium channel antagonists, Apoptosis stimulants, TRPV6 protein inhibitors"	"Soricimed Biopharma (Originator), Soricimed Biopharma (Owner), University Health Network (Technology Provider), Mount Allison University (Collaborator)"		"unspecified, IV"				"L1X9 (All other antineoplastics), N2B (Non-Narcotics and Anti-Pyretics)"	"L01X-X (Other antineoplastic agents), N02B-G (Other analgesics and antipyretics)"	"SORC27, Soricidinderived Cseries peptide therapeutics, Soricidinderived Nseries peptide therapeutics, SORN54"			28/07/2018	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800035158?userId=52029392&bpIds=3004037004&checksum=699e69fd41e3f4d30f93d3e71f8b7e6bee441d30-1617045529456-1b58a8f2b6467614536c4f459d8362a9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045834	EV 007156			Yes			No development reported (Preclinical)	"Sepsis, Neuropathic pain"		HMGB1 protein inhibitors	"Evec (Originator), Evec (Owner)"		Parenteral				"J1X (Other Antibacterials), N2B (Non-Narcotics and Anti-Pyretics)"	"J01X (Other Antibacterials), N02B (Other Analgesics and Antipyretics)"	EV007156			28/07/2018	"Bacterial Infections, Pain"		Evec |  | Unspecified |  | 06 Jul 2016		no		no							https://adis.springer.com/drugs/800045834?userId=52029392&bpIds=3004037004&checksum=d04e1aeb96b06ede016330242fc4ddc0096cf4a1-1617045529457-897a123e829ee127fc193fa188f7d0ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039638	NKTR 171			Yes			No development reported (I)	Neuropathic pain		Sodium channel antagonists	"Nektar Therapeutics (Originator), Nektar Therapeutics (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	NKTR171			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800039638?userId=52029392&bpIds=3004037004&checksum=b94924af0f1d35ee13f0153fab5ee035b45cac94-1617045529458-6a4abce6ead94b8b23aaea04464a140cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046349	Research programme: pain therapeutic - Oroxcell			Yes			No development reported (Preclinical)	Pain			"Oroxcell (Originator), Oroxcell (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/07/2018	Pain		Oroxcell | Pain | Unspecified |  | 19 Jul 2016		no		no							https://adis.springer.com/drugs/800046349?userId=52029392&bpIds=3004037004&checksum=5d4239afcadcbca457a61ffc4ae336d9128c377a-1617045529459-fb5bc7d5242d006db64a5c15f8694597badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045735	FY 304			Yes			No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"YD Global Life Science (Originator), YD Global Life Science (Owner), Hanrim University (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	FY304			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800045735?userId=52029392&bpIds=3004037004&checksum=65e71f9e8cf6a2dbfb80ea2f32079805d6da6b7f-1617045529459-f08da82380610ba4f05295e5b270b1f6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036080	Research programme: pain therapeutics - Dompe			Yes			No development reported (Research)	"Neuropathic pain, Pain"		"Bradykinin B1 receptor antagonists, Complement C5a receptor antagonists"	"Dompe Farmaceutici (Originator), Dompe Farmaceutici (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"BKB1r antagonists Dompe, c5ar antagonists Dompe"			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800036080?userId=52029392&bpIds=3004037004&checksum=4ab782d3b5c933889bd8f7b63a9335810d3c8b10-1617045529460-a31e7dd5d2495bb7d569864df741aac9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041460	C 746			Yes			No development reported (I)	Pain		"Cytokine inhibitors, Substance P inhibitors"	"Cosmederm Bioscience (Originator), Cosmederm Bioscience (Owner)"		Topical				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics)"	"D04A-X (Other antipruritics), N02 (Analgesics)"	C746			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800041460?userId=52029392&bpIds=3004037004&checksum=fb0cfddda90f290a26ee7c7d663675847d9ba4c9-1617045529461-46b94eedc38d8c71a3336067ff38bbdcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043535	IDN 5243			Yes			No development reported (I)	"Back pain, Pain"		"Inflammation mediator inhibitors, Muscle protein modulators"	"Indena (Originator), Indena (Owner), Nerviano Medical Sciences (Collaborator)"		"IM, Intraperitoneal"				N2 (Analgesics)	N02 (Analgesics)				28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800043535?userId=52029392&bpIds=3004037004&checksum=1e2a6bd5f085b355d3af6c996117528352ef00a5-1617045529462-fef52af130c6b1626ddb7b7a3dac814fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040588	Pregabalin controlled release - Ildong Pharmaceutical	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid	No			No development reported (I)	Neuropathic pain	C8 H17 N O2	CACNA2D1 protein modulators	"Ildong Pharmaceutical (Originator), Ildong Pharmaceutical (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	"Pregabalin CR Ildong Pharmaceutical, Pregabalin SR Ildong Pharmaceutical"			28/07/2018	Pain				no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800040588?userId=52029392&bpIds=3004037004&checksum=50ed0dd5f4821cb8995e41d4716f60258c596759-1617045529463-25a112bb8112666477e7b481a8992e5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040743	GBR 900			Yes			No development reported (I)	Pain		TrkA receptor antagonists	"Lay Line Genomics (Originator), Lay Line Genomics (Owner), Glenmark Pharmaceuticals S.A. (Licensee)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	"BXL1H5, GBR900, MNAC13"			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800040743?userId=52029392&bpIds=3004037004&checksum=1640d651dd11adf8bfb67c52a7d82c4021b2030c-1617045529463-ef1234dce2db170e519bcfac38003e26badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035366	Z 944		N-[[1-[2-(tert-butylamino)-2-oxoethyl]piperidin-4-yl]methyl]-3-chloro-5-fluorobenzamide	Yes			No development reported (I)	Pain	C19 H27 Cl F N3 O2	T type calcium channel antagonists	"Zalicus (Originator), Taro Pharmaceuticals USA (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	Z944			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800035366?userId=52029392&bpIds=3004037004&checksum=eab35e037faec46dd6b335e6b2cafc683ac7df32-1617045529464-b56951f94e3e1f54e1845fded489260dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024064	Research programme: cysteine endopeptidase inhibitors - Amura			Yes			No development reported (Preclinical)	"Osteoarthritis, Bone metastases, Neuropathic pain, Malaria, Rheumatoid arthritis, Osteoporosis"		"Cathepsin K inhibitors, Cathepsin S inhibitors, Cysteine endopeptidase inhibitors"	"Amura (Originator), Amura (Owner)"		unspecified				"C (Cardiovascular System), D5 (Nonsteroidal Products for Inflammatory Skin Disorders), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N7 (Other CNS Drugs), P1D (Anti-Malarials)"	"C (Cardiovascular System), D05 (Antipsoriatics), M01 (Antiinflammatory and Antirheumatic Products), M05 (Drugs for Treatment of Bone Diseases), N02 (Analgesics), N07 (Other Nervous System Drugs), P01B (Antimalarials)"	"AM3701, AM3840, AM3876"			28/07/2018	"Cancer, Musculoskeletal Disorders, Pain, Parasitic Infections, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800024064?userId=52029392&bpIds=3004037004&checksum=fa778d39d8250e732826d30fade9517c71763116-1617045529465-2475b117c94816ce55a2a8a6f442b0e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037196	Research programme: TLR4/MD-2 complex formation inhibitors - BiolineRx/University of Colorado-Boulder			Yes			No development reported (Preclinical)	"Neuropathic pain, Scleroderma"		"Membrane protein inhibitors, Toll-like receptor 4 antagonists"	"University of Colorado at Boulder (Originator), University of Colorado at Boulder (Owner), BioLineRx (Licensee)"		PO				"D11 (Other Dermatological Preparations), N2 (Analgesics)"	"D11 (Other Dermatological Preparations), N02 (Analgesics)"	"BL1110, EDP34"			28/07/2018	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800037196?userId=52029392&bpIds=3004037004&checksum=e9a1a6cafc892dc6cc181a5e86a1c91cf4e70fd2-1617045529466-8ca504b532c8566ccef7f3862dba8bf1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043593	JNJ 38893777		"[2-(1-piperidinyl)-N-[4-(trifluoromethyl) phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-aminesulfate]"	Yes			No development reported (I)	Pain		TRPV1 receptor antagonists	"Janssen Research & Development (Originator), Janssen Research & Development (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	JNJ38893777			28/07/2018	Pain				no		no							https://adis.springer.com/drugs/800043593?userId=52029392&bpIds=3004037004&checksum=ad0d31c6435b4200c342142209cadb8b56d17887-1617045529467-2b8ef563e9dc4fafebef408593df5d6abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040691	Research programme: antibody therapeutics - Eloxx Pharmaceuticals			Yes			No development reported (Preclinical)	"Autoimmune disorders, Cancer, Inflammation, Pain"		"Immunomodulators, Kv1.3 potassium channel inhibitors, Angiogenesis modulating agents, G protein-coupled receptor modulators, Ion channel antagonists"	"Fabrus (Originator), Eloxx Pharmaceuticals (Owner)"		Parenteral				"L1G (Monoclonal Antibody Antineoplastics), L4 (Immunosuppressants), N2 (Analgesics)"	"L01X-C (Monoclonal antibodies), L04 (Immunosuppressants), N02 (Analgesics)"	"FB 001, FB 002, FB 003, FB 004, G proteincoupled receptor modulators Eloxx Pharmaceuticals, Ion channel antagonists Eloxx Pharmaceuticals, SVN001, SVN002"			28/07/2018	"Cancer, Immunological Disorders, Inflammation, Pain, Rheumatic Disease"		Eloxx Pharmaceuticals |  | Unspecified |  | 27 May 2014		no		no							https://adis.springer.com/drugs/800040691?userId=52029392&bpIds=3004037004&checksum=873809a3cc48256c436fe39b30fd594c583dc5bc-1617045529469-3f5ea6865a3ad9d56423fa38597c5ea6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029993	Research programme: sodium channel blockers - RaQualia Pharma			Yes			No development reported (Research)	"Neuropathic pain, Inflammatory pain"		Nav1.3 voltage-gated sodium channel inhibitors	"Pfizer (Originator), Pfizer (Owner), RaQualia Pharma (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	RQ00203066			28/07/2018	Pain		RaQualia Pharma |  | Unspecified |  | 01 Oct 2014		no		no							https://adis.springer.com/drugs/800029993?userId=52029392&bpIds=3004037004&checksum=3f585870511ddadea523a786ff55887f2338be9a-1617045529470-c4588d822f3058c0bdd33c20d6a04e38badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040617	Research programme: monoclonal antibody therapeutics - Kymab			Yes			Preclinical	"Pulmonary hypertension, Cancer, Inflammatory bowel diseases, Systemic lupus erythematosus, Haematological disorders, Graft-versus-host disease, Dyslipidaemias, Pain, Cardiovascular disorders, Fibrosis, Infections"		"Inducible T-cell co-stimulator protein antagonists, Programmed cell death-1 ligand-1 modulators, Immunomodulators, Immunostimulants"	"Kymab (Originator), Kymab (Owner), Bill & Melinda Gates Foundation (Funder), The Wellcome Trust (Funder), Roche (Collaborator), University of Texas M. D. Anderson Cancer Center (Collaborator)"		Parenteral				"A7E (Intestinal Anti-Inflammatory Agents), B (Blood and Blood Forming Organs), C (Cardiovascular System), C10A (Cholesterol and Triglyceride Regulating Preparations), J (General Anti-Infectives Systemic), L (Antineoplastic and Immunomodulating Agents), L1G (Monoclonal Antibody Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), B (Blood and Blood Forming Organs), C (Cardiovascular System), C10 (Lipid Modifying Agents), J (Anti-infectives For Systemic Use), L (Antineoplastic and Immunomodulating Agents), L01X-C (Monoclonal antibodies), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"AntiOPG Antibody, KY 1003, KY 1006, KY 1007, KY 1009, KY 1015, KY 1016, KY 1017, KY 1020, KY 1021, KY 1031, KY 1034, KY 1040, KY 1041, KY 1047, KY 1050, KY 1055, KY 1081, KY 7001, KY 7002, KY 7003, KY 7004, KY 7005, KY 7006, Ky3"			28/07/2018	"Bacterial Infections, Cancer, Haematological Disorders, Hyperlipidaemia, Immunological Disorders, Inflammation, Inflammatory Bowel Disorders, Pain, Respiratory Tract Disorders, Vascular Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800040617?userId=52029392&bpIds=3004037004&checksum=41cfd029e0ed99174e170f101106532ae37b759c-1617045529472-bbc1b2dab4664f260725b7ce3abfa0dbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052564	Research programme: cannabinoid based therapeutics - Acerus Pharmaceuticals			No			Research	Unspecified		Cannabinoid receptor modulators	"Acerus Pharmaceuticals (Originator), Acerus Pharmaceuticals (Owner)"		Inhalation				N7 (Other CNS Drugs)	"N02B-G10 (Cannabinoids, including nabiximols)"	Cannabinoids Initiative Acerus Pharmaceuticals			26/07/2018			Acerus Pharmaceuticals |  | Unspecified |  | 28 Jun 2018		no		no							https://adis.springer.com/drugs/800052564?userId=52029392&bpIds=3004037004&checksum=7e37b9a8fe22b3c93780a50879998476580ce402-1617045529473-e8acb5e42fc13474bd9b23bdb2a69a26badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028852	Ketorolac/phenylephrine - Omeros Corporation		"5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid/3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol<!-- In case all the names should be broken, uncomment the line below and comment the line above --><!--%= getNameWithLineBreaks(cdbItem.getName(), 60)%--><!-- In case all the names should be broken, uncomment the line below and comment the line above --><!--%= getNameWithLineBreaks(cdbItem.getName(), 60)%-->"	No			Marketed	"Miosis, Postoperative pain"	C15 H13 N O3 . C9 H13 N O2	"Alpha 1 adrenergic receptor agonists, Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Omeros Corporation (Originator), Omeros Corporation (Owner), ITROM Trading Drug Store (Licensee)"		Intraocular			"Headache, Ocular hypertension, Ocular inflammation, Ocular pain"	"N2 (Analgesics), S1F (Mydriatics and Cycloplegics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"N02 (Analgesics), S01B-C05 (Ketorolac), S01F-B01 (Phenylephrine)"	"Omidria, OMS302, OMS302PE, Phenylephrine and ketorolac intraocular solution, Phenylephrine/ketorolac"			25/07/2018	"Eye Disorders, Pain"		"Omeros Corporation |  | Unspecified | European Union, Iceland, Liechtenstein, Norway | 22 May 2015"	"Omidria, Omidria, Omidria, Omidria, Omidria, Omidria, Omidria, Omidria, Omidria, Omidria"	no		no							https://adis.springer.com/drugs/800028852?userId=52029392&bpIds=3004037004&checksum=95b3749203c4c432ead169e25ed29b0867c88fde-1617045529476-8a3c477b029cac9b53081d08a810fbe0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029018	Flupirtine-based pain therapy	56995-20-1	Ethyl N-(2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl)carbamate	Yes			Discontinued (II/III)	"Neuropathic pain, Diabetic neuropathies"	C15 H17 F N4 O2	"KCNQ potassium channel agonists, NMDA receptor antagonists, Opioid receptor agonists"	"CNSBio (Originator), Relevare Pharmaceuticals (Owner)"		"PO, unspecified"				N2 (Analgesics)	"N02A (Opioids), N02A-A01 (Morphine), N02A-A51 (Morphine, combinations), N02B-G07 (Flupirtine)"	"CNSB001, CNSB015"			19/07/2018	Pain				no		no							https://adis.springer.com/drugs/800029018?userId=52029392&bpIds=3004037004&checksum=682bd506b7a95fc874a1786c875bf196d64e2aa1-1617045529477-8b2922461a3c4b517e38661ec0f7b28fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016565	Dihydroergotamine mesilate - POZEN	6190-39-2	"Ergotoman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'_)-, monomethanesulfonate (salt)"	No			Discontinued (Preregistration)	Migraine	C33 H37 N5 O5 . C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"POZEN (Originator), POZEN (Owner), Bausch Health Companies (Market Licensee)"		Parenteral			"Abdominal pain, Diarrhoea, Dizziness, Injection site reactions, Nausea"	N2C (Anti-Migraine Preparations)	N02C-A01 (Dihydroergotamine)	"Dihydroergotamine mesylate injection POZEN, MT300"			18/07/2018	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800016565?userId=52029392&bpIds=3004037004&checksum=afa9b92f6208edd3a10fbf95ba15f2c2602aa444-1617045529478-22b80ce291e0a42743127dc838288561badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009972	Dihydroergotamine mesylate intranasal - Novartis	6190-39-2	"Ergotamine 9,10-dihydro-, monomethanesulfonate (salt)"	No			Marketed	Migraine	C33 H37 N5 O5 . C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Novartis (Originator), Novartis (Owner), Bausch Health Companies (Market Licensee), SteriMax (Market Licensee), ASCEND Therapeutics (Sub-licensee), Zogenix (Sub-licensee)"		Intranasal		"bioavailability IM (%) (100 (Adult)), bioavailability nasal (%) (40 (Adult)), bioavailability oral (%) (1 (Adult))"	"Nasal congestion, Nausea, Oedema, Rhinitis, Taste disorders"	N2C9 (All other anti-migraine preparations)	N02C-A01 (Dihydroergotamine)	"Dihydroergotamine mesylate nasal spray Novartis, Dihydroergotaminemesylate, Migranal"			18/07/2018	Advances in the Treatment of Nausea and Migraine			"Migranal, Migranal, Migranal, Migranal"	no		no							https://adis.springer.com/drugs/800009972?userId=52029392&bpIds=3004037004&checksum=55e8ede95bfc157d2199bafd1fd41b8eaf49220b-1617045529480-3de5825fa54ed434630559e9e71650eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005259	Zucapsaicin	25775-90-0	"6-Nonenamide, <EM>N</EM>-((4-hydroxy-3-methoxyphenyl)methyl)-8- methyl-, (<EM>Z</EM>)-"	Yes			Marketed	"Pain, Keratoconjunctivitis sicca, Cluster headache, Postherpetic neuralgia, Crohn's disease, Rhinitis, Migraine"	C18 H27 N O3	TRPV1 receptor agonists	"Winston Laboratories (Originator), Winston Pharmaceuticals (Owner), Sanofi (Licensee), Bausch Health Companies (Sub-licensee)"		"Topical, Intranasal, PO"			Application site reactions	"A7E (Intestinal Anti-Inflammatory Agents), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations), R1A9 (Other topical nasal preparations), S1X (Other Ophthalmologicals)"	"A07E (Intestinal Antiinflammatory Agents), N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), R01A-X (Other nasal preparations), S01X (Other Ophthalmologicals)"	"cisCapsaicin, Civamide, Civamide 0.075 cream Winston Pharmaceuticals, Civanex, Civanex Nasal Solution, Dolorac Nasal Solution, Neuroderm Patch, Zuacta"			17/07/2018	"Advances in the Treatment of Nausea and Migraine, Eye Disorders, Inflammatory Bowel Disorders, Obstructive Airways Disease, Pain, Rheumatic Disease"	Postherpetic neuralgia (USA)		"Civanex, Civanex Nasal Solution, Dolorac Nasal Solution, Neuroderm Patch, Zuacta"	no		no							https://adis.springer.com/drugs/800005259?userId=52029392&bpIds=3004037004&checksum=bd0bdf57e618021d9ef22af1c74d2e068b88e489-1617045529482-1e22086eccb7b1bf433c402b8f578751badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014614	Tramadol - Bausch Health Companies \	36282-47-0	(±)-<EM>cis</EM>-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride	No			Marketed	"Pain, Premature ejaculation"	C16 H25 N O2 . H Cl	"Adrenergic receptor antagonists, Opioid receptor agonists, Serotonin uptake inhibitors"	"Biovail Corporation (Originator), Bausch Health Companies (Owner), Ortho-McNeil (Market Licensee), Massachusetts General Hospital (Collaborator)"		PO			"Constipation, Diarrhoea, Dizziness, Fatigue, Flushing, Headache, Insomnia, Nausea, Pruritus, Somnolence, Vomiting"	"G4X (All Other Urological Products), N2A (Narcotics)"	"G04B-X (Other urologicals), N02A-X02 (Tramadol)"	"BVF127, BVF324, Ralivia, RWJ26898002, Tramadol ER, Tramadol ODT, Tramadol RD, Ultram, Ultram ER"			17/07/2018	"Men's Health, Pain"			"Ralivia, Ultram, Ultram, Ultram ER"	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800014614?userId=52029392&bpIds=3004037004&checksum=1ae42464b18981e6385aef3fc79b0db6be10ccef-1617045529484-f0e63597a2698d899aaca5da20a68421badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025856	Nabilone	51022-71-0	"9H-Dibenzo(b,d)pyran-9-one, 3-(1,1-dimtheylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-,(6aR,10aR)-rel-"	Yes			Marketed	"Nausea and vomiting, Insomnia, Neuropathic pain, Muscle spasticity, Fibromyalgia"	C24 H36 O3	Cannabinoid receptor agonists	"Eli Lilly and Company (Originator), Bausch Health Companies (Owner)"		PO				"A4A (Antiemetics and Antinauseants), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"A04A (Antiemetics and Antinauseants), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N05C (Hypnotics and Sedatives)"	Cesamet			17/07/2018	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Musculoskeletal Disorders, Pain"			Cesamet	no		no				T cell receptor gamma variable 9			https://adis.springer.com/drugs/800025856?userId=52029392&bpIds=3004037004&checksum=27ca2774046774ecfe9df9ebadb952ba03819925-1617045529485-cdfd0c9cd5892a5b916a785ce0cb4542badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052433	DSP 3905			Yes			Phase I	Neuropathic pain		Nav1.7 voltage-gated sodium channel inhibitors	"Sunovion Pharmaceuticals (Originator), Sunovion Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02 (Analgesics)	DSP3905			11/07/2018	Pain				no		no							https://adis.springer.com/drugs/800052433?userId=52029392&bpIds=3004037004&checksum=f04c79f56da2a32ebc600583c75f6ee28c0f8050-1617045529486-3a2179decde5d672e48837090881517ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052407	TRN 132			No			Clinical Phase Unknown	Pain		Undefined mechanism	"Tris Pharma (Originator), Tris Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TRN132			06/07/2018	Pain				no		no							https://adis.springer.com/drugs/800052407?userId=52029392&bpIds=3004037004&checksum=44cf2048c2061c130090ee04f6b6f3d15d0e9444-1617045529487-228762d946c7c608394f1adea26b99eabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800052405	TRN 105			No			Clinical Phase Unknown	Pain		Undefined mechanism	"Tris Pharma (Originator), Tris Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TRN105			05/07/2018	Pain				no		no							https://adis.springer.com/drugs/800052405?userId=52029392&bpIds=3004037004&checksum=c8939a0f4d7af4c792ee6a12dd0a90f1842f901b-1617045529487-46eaea67f3aa11a86c1021960f022c7cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032020	Research programme: pain therapeutics - Nektar Therapeutics			Yes			No development reported (Preclinical)	"Acute pain, Visceral pain, Neuropathic pain"		"Opioid receptor agonists, Opioid kappa receptor agonists, NMDA receptor antagonists, Opioid mu receptor agonists, Sodium channel antagonists"	"Nektar Therapeutics (Originator), Nektar Therapeutics (Owner)"		PO				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids), N06A-X (Other antidepressants)"	"NKTR174, NKTR194, NKTR195, NKTR196, Sodium channel blockers Nektar Therapeutics"			28/06/2018	Pain				no		no							https://adis.springer.com/drugs/800032020?userId=52029392&bpIds=3004037004&checksum=a180efcf515510ac568f43a63713d4940b25faf8-1617045529488-57f0c50ebff31c26bd5a985b4b9a8842badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040585	Research programme: pain therapeutics - Jubilant Biosys/Orion Corporation			Yes			No development reported (Research)	Pain			"Jubilant Biosys (Originator), Orion (Originator), Jubilant Biosys (Owner), Orion (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/06/2018	Pain				no		no							https://adis.springer.com/drugs/800040585?userId=52029392&bpIds=3004037004&checksum=dce08c06c1495642e37e92db547563ea39d3a765-1617045529489-1b6e1742654256e250c91919ae114bbebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019555	Oxycodone immediate release - Purdue	76-42-6	"4,5a-Epoxy-14b-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Marketed	"Pain, Cancer pain, Back pain, Postoperative pain"	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Purdue Pharma (Originator), Purdue Pharma (Owner), Napp Pharmaceutical Group (Market Licensee), Mundipharma International (Licensee), Shionogi (Licensee)"		"IV, SC, PO"				N2A (Narcotics)	N02A-A05 (Oxycodone)	"OxiFast, OxiNorm, OxyFast, OxyGesic, OxyIR, OxylR, OxyNorm, S8116, S8117, S811717"			11/06/2018	Pain			"OxiFast, OxiNorm, OxyFast, OxyGesic, OxyIR, OxyNorm, OxyNorm, OxyNorm, OxyNorm, OxyNorm, OxylR"	no		no				"E-cadherin, pescadillo ribosomal biogenesis factor 1, T cell receptor gamma variable 9"		"COMT, CYP2C19, CYP2D6, CYP3A4, ER alpha, hypertrichosis 2 (generalized, congenital), Noroxycodone, OPRM1"	https://adis.springer.com/drugs/800019555?userId=52029392&bpIds=3004037004&checksum=4c6ae78748fd7e1add273b0c275c90b474b88e59-1617045529500-b4708eac9ab049ff5190d120413446c9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018753	S-Ethylisothiouronium diethylphosphate - TrioxBio		<EM>S</EM>-ethylisothiouronium diethylphosphate	Yes			Marketed	"Hypotension, Intradialytic hypotension, Migraine"	C3 H8 N2 S. C4 H 11 O4 P	Nitric oxide synthase inhibitors	"Meditor Pharmaceuticals (Originator), Meditor Pharmaceuticals (Owner), TrioxBio (Licensee)"		"IV, PO"				"C6A (Other Cardiovascular Products), N2C (Anti-Migraine Preparations)"	"C01 (Cardiac Therapy), N02C (Antimigraine Preparations)"	"Difetur, MTR 104, MTR105, MTR106, MTR107, MTR108, Nitric oxide synthase inhibitors TrioxBio, Raviclust, Ravimig, Raviten"			06/06/2018	"Advances in the Treatment of Nausea and Migraine, Vascular Disorders"	Intradialytic hypotension (USA)	Meditor Pharmaceuticals |  | Unspecified |  | 26 Sep 2006	"Difetur, Raviten"	no		no							https://adis.springer.com/drugs/800018753?userId=52029392&bpIds=3004037004&checksum=704b88ffcc798c79d06f8ad94c2e46415dc05b70-1617045529501-bd0f9c5ca53167dc1c307cc32db8be50badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051778	Paracetamol intravenous - Altan Pharma	103-90-2	N-(4-Hydroxyphenyl)acetanilide	No			Marketed	"Pain, Fever"	C8 H9 N O2	Prostaglandin receptor antagonists	"Altan Pharma (Originator), Altan Pharma (Owner)"		IV				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	Acetaminophen intravenous Altan pharma			04/06/2018	"Metabolic Disorders, Pain"				no		no							https://adis.springer.com/drugs/800051778?userId=52029392&bpIds=3004037004&checksum=1ea39848a35a7cb2080a7a56a99ee9421b279987-1617045529502-f9fe1a1532c7ac71692d0c59a09282dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041702	TV 46139			Yes			Discontinued (I)	Pain		Undefined mechanism	"Teva Pharmaceutical Industries (Originator), Teva Pharmaceutical Industries (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	TV46139			31/05/2018	Pain				no		no							https://adis.springer.com/drugs/800041702?userId=52029392&bpIds=3004037004&checksum=f646bb3af9be71ce3ca0af81272c8075fec642e6-1617045529503-47e33bd784bf110941a85dfe85d7cc7cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041704	Hydrocodone/paracetamol immediate release - Teva Pharmaceutical	330988-71-1		No			Discontinued (III)	Pain	C18 H21 N O3.C8 H9 N O2.C4 H6 O6	"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Teva Pharmaceutical Industries (Originator), Teva Pharmaceutical Industries (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"Acetaminophen/hydrocodone bitartarate Teva Pharmaceutical, TV46763"			31/05/2018	Pain				no		no							https://adis.springer.com/drugs/800041704?userId=52029392&bpIds=3004037004&checksum=5c7124bbaf8b3193cbdf740041eb63ad6fcc5411-1617045529504-2efde3c99e350ceb6aadd4214ad57942badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043257	Paracetamol - AYUMI Pharma	103-90-2	N-(4-Hydroxyphenyl)acetanilide	No			Marketed	"Pain, Fever"	C8 H9 N O2	Prostaglandin inhibitors	"Showa Yakuhin Kako (Originator), AYUMI Pharma (Owner)"		"PO, Rectal"				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	"Calonal, Calonal fine granules, Calonal powder, Calonal suppositories, Calonal syrup, Calonal tablet"			29/05/2018	"Metabolic Disorders, Pain, Rheumatic Disease"			"Calonal, Calonal"	no		no		"A1AT, A1C, PSA, WT1"	"CD3d, CD3e, CD3g"	"11-Dehydro-thromboxane B2, 7-Hydroxy-6-methyl-8-ribityl lumazine, A1AT, A1C, Acetaminophen glucuronide, Acetylcysteine, Acid ceramidase, Angiopoietin 2, Arachidonic acid, AT-III, C-peptide, C4, CD34, CD3d, CD3e, CD3g, Collagen type 2, CRP, cytochrome P450 family 2 subfamily E member 1, Cytokeratin 18, dsDNA Auto-antibodies, F2-isoprostanes, Fibulin 3 peptides, Glutathione, growth hormone 1, Heme, HMGB1, Hydrocortisone, IFN-gamma, IGFBP7, IL6, insulin receptor related receptor, L-Cysteine, L-Cystine, microRNA 122, MMP-2, NGAL, opioid related nociceptin receptor 1, Osteocalcin, peptidylprolyl isomerase G, peroxiredoxin 5, PHGDH, Prostacyclin, PSA, RAGE, Thromboxane A2, Thromboxane B2, TIMP-2, TNF-alpha, transcription factor 21, VEGF-A, VEGFR, VEGFR1, WT1"	"Acid ceramidase, AT-III, Cytokeratin 18, HMGB1, NGAL, Osteocalcin, PSA"	"ATP binding cassette subfamily G member 2 (Junior blood group), Calreticulin, CTx, CYP2D6, Fe3+, GIP"	https://adis.springer.com/drugs/800043257?userId=52029392&bpIds=3004037004&checksum=34ff268d27bf5685c4f67c60107c0d9196a27596-1617045529506-d063322b64b77cf86c368ab66eac16b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041429	Research programme: cannabinoid based therapeutics - Lara Pharmaceuticals			No			No development reported (Research)	Pain		"Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"LaraPharm (Originator), LaraPharm (Owner)"		Inhalation				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	LP306			28/05/2018	"Drug Delivery Systems, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800041429?userId=52029392&bpIds=3004037004&checksum=eb76dec5945196b5776e9f557ec75db6f2ff3696-1617045529507-02a7334607a2d53c71d25942f88bed0cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034601	Research programme: extended-release/abuse-resistant pain therapeutics - Collegium Pharmaceutical			No			Preclinical	Pain		"Opioid mu receptor agonists, Opioid receptor agonists"	"Collegium Pharmaceutical (Originator), Collegium Pharmaceutical (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	COL196			28/05/2018	Pain				no		no							https://adis.springer.com/drugs/800034601?userId=52029392&bpIds=3004037004&checksum=a92564b4b88594cd55c06d010d172e8d3f5bd47c-1617045529508-d21599e6f54af7ed3f368757a1a28dd1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020058	Oxymorphone extended-release/abuse-resistant - Collegium Pharmaceutical	76-41-5	"Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-"	No			Clinical Phase Unknown	Pain	C17 H19 N O4	Opioid mu receptor agonists	"Collegium Pharmaceutical (Originator), Collegium Pharmaceutical (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"COL172, Oxymorphone DETERx"			28/05/2018	Pain			Oxymorphone DETERx	yes	USA	no							https://adis.springer.com/drugs/800020058?userId=52029392&bpIds=3004037004&checksum=cbf22c9ed408a92b565ea2c5b8c6bb6daa314071-1617045529509-1d7cbf8aac900bff546f59aa189c3a43badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025147	HS 731		"2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid"	Yes			Preclinical	Pain		Opioid mu receptor agonists	"AlcaSynn Pharmaceuticals (Originator), ChironWells (Owner)"		"Parenteral, PO"				N2A (Narcotics)	N02A (Opioids)	"AS 006, HS731"			28/05/2018	Pain				no		no							https://adis.springer.com/drugs/800025147?userId=52029392&bpIds=3004037004&checksum=041d1a856f97710599962c4960c2c69754011bb6-1617045529509-ac23ef0e73d5b373bad2663b8d65596fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025860	BF 1			Yes			No development reported (I)	Migraine		Serotonin 2B receptor antagonists	"Biofrontera AG (Originator), Biofrontera AG (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	BF1			28/05/2018	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800025860?userId=52029392&bpIds=3004037004&checksum=73a7e9237d9c9149378d5de8d76d9b044e865bf5-1617045529510-0f85880b3f23279d19c59e5e050ac70dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051097	Research programme: small molecule therapeutics - Axxam/Proximagen			Yes			Research	"Neurological disorders, Inflammation, Pain"		Undefined mechanism	"Axxam (Originator), Proximagen (Originator), Axxam (Owner), Proximagen (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs)"				28/05/2018	"Inflammation, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800051097?userId=52029392&bpIds=3004037004&checksum=606c20c5c44073222df79d1f20e875bb5508a798-1617045529511-76f8cc7fcfd4d9f6436ea5f75f3c33babadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019168	Syn 1002			Yes			No development reported (I)	"Rheumatoid arthritis, Neuropathic pain, Pain, Crohn's disease"		Immunomodulators	"INSERM (Originator), INSERM (Owner), CLL PHARMA (Licensee)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"PAT, Peptide analogue of thymulin, SYN 1002, Syn1002"			28/05/2018	"Inflammatory Bowel Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800019168?userId=52029392&bpIds=3004037004&checksum=57a4fd1729b83d2a54d0d4763bad5ecd8bfc9213-1617045529512-d1db98b469eedf9351171b816d7c6814badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051936	Research programme: ion-channel modulators - Saniona			Yes			Preclinical	"Epilepsy, Urinary incontinence, Pain"		Kv channel-interacting protein modulators	"BenevolentAI (Originator), Saniona (Originator), Saniona (Owner), Danish Innovation Fund (Funder)"		unspecified				"G4D (Urinary Incontinence Products), N2 (Analgesics), N3 (Anti-Epileptics)"	"G04B-D (Drugs for urinary frequency and incontinence), N02 (Analgesics), N03 (Antiepileptics)"	KV7 programme			24/05/2018	"Epilepsy and Seizure Disorders, Genitourinary Disorders, Pain, Rheumatic Disease, Women's Health"				no		no							https://adis.springer.com/drugs/800051936?userId=52029392&bpIds=3004037004&checksum=8e8bd90d1af507671b921c18248a05817afe8da3-1617045529513-f6af7cd18da1cf3bfe94a37f14617189badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018527	Lidocaine transdermal patch - Immune Pharmaceuticals Inc	137-58-6	"Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-"	No			No development reported (II)	"Back pain, Postoperative pain, Headache, Tinnitus"	C14 H22 N2 O	Sodium channel antagonists	"EpiCept Corporation (Originator), Immune Pharmaceuticals Inc (Owner)"		Transdermal				"N1B (Anaesthetics, Local), N2 (Analgesics), N2C (Anti-Migraine Preparations), N7 (Other CNS Drugs), S2D (Other Otologicals)"	"N01B (Anesthetics, Local), N01B-B02 (Lidocaine), N02 (Analgesics), N02C-X (Other antimigraine preparations), N07C-A (Antivertigo preparations), S02D (Other Otologicals)"	"ADL 87223, LidoPAIN BP, LidoPAIN HM, LidoPAIN SP, LidoPAIN TV"			23/05/2018	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems, Ear, Nose and Throat Disorders, Pain"			"LidoPAIN BP, LidoPAIN HM, LidoPAIN HM, LidoPAIN SP, LidoPAIN TV, LidoPAIN TV"	no		no		A1AT	"COX2, small proline rich protein 2A"	"A1AT, ACADM, ACC, Adiponectin, AMPKa, Angiopoietin-like 4, BNP, CD38, cell death inducing DFFA like effector c, cell death-inducing DFFA-like effector a, CKB, CKM, COX2, CRP, cryptochrome circadian clock 1, CXCL10, fatty acid binding protein 4, fatty acid synthase, Ghrelin, hemoglobin subunit gamma 2, Hydrocortisone, IFN-gamma, IGF1R, IL10, IL6, IL8, Insulin, insulin receptor substrate 2, IRS-1, Leptin, lipase E, hormone sensitive type, lipoprotein lipase, MCP1, MIP-1 alpha, MLX interacting protein-like, neuronal PAS domain protein 2, opioid related nociceptin receptor 1, Osteocalcin, patatin-like phospholipase domain containing 2, patatin-like phospholipase domain containing 3, PGC-1 alpha, PIK3R1, Procalcitonin, pyruvate dehydrogenase kinase 4, PYY, RNA, Ro-associated Y1, SIRT3, small proline rich protein 2A, solute carrier family 2 member 4, sterol regulatory element binding transcription factor 1, Testosterone, TNF-alpha, TRAP-5, troponin I, cardiac, uncoupling protein 2 (mitochondrial, proton carrier), v-akt murine thymoma viral oncogene homolog 2, VEGF-A, VEGFR, VEGFR1"	"BNP, CRP, IL6"	"CD4, Cortisone, CXCL12, cytochrome b5 reductase 1, cytochrome b5 reductase 2, cytochrome b5 reductase 3, cytochrome b5 reductase 4, G6PD, HLA-DR, HMGB1, IL1 beta, IL12A, IL12B, IL1RA, Thyroxine"	https://adis.springer.com/drugs/800018527?userId=52029392&bpIds=3004037004&checksum=d045569a2b8cd44bc9787b09ec9076bfd7169f73-1617045529515-de1d7be7eb240f0391de54680a4da6a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036562	Hydromorphone - Daiichi Sankyo	71-68-1	"6-Deoxy-7,8-dihydro-6-oxomorphine hydrochloride"	No			Marketed	Cancer pain	C17 H19 NO3 HCl	Opioid receptor agonists	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner)"		"PO, IV, SC"				N2A (Narcotics)	N02A-A03 (Hydromorphone)	"DS7113, DS7113b, Hydromorphone HCl Daiichi Sankyo, Hydromorphone hydrochloride Daiichi Sankyo, Narurapid Tablets, Narusus Tablets, Naruvein Injection"			21/05/2018	Pain			"Narurapid Tablets, Narusus Tablets, Naruvein Injection"	no		no							https://adis.springer.com/drugs/800036562?userId=52029392&bpIds=3004037004&checksum=ced39171fdf8ab09cbefd0a65844e9f0ab48c558-1617045529517-064f30894c553d123841ffe4ba25cf04badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039030	IPX 232			Yes			No development reported (I)	Migraine			"Impax Pharmaceuticals (Originator), Amneal Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	IPX232			15/05/2018	Advances in the Treatment of Nausea and Migraine		Amneal Pharmaceuticals |  | Unspecified |  | 01 Aug 2014		no		no							https://adis.springer.com/drugs/800039030?userId=52029392&bpIds=3004037004&checksum=4e481b4992b07535315cb3cafa9736390e91f42b-1617045529518-323309efbf53490dbc0f59192d9199f4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051991	S 637880			Yes			Phase I	Neuropathic pain		Undefined mechanism	"Shionogi (Originator), Shionogi (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	S637880			15/05/2018	Pain				no		no							https://adis.springer.com/drugs/800051991?userId=52029392&bpIds=3004037004&checksum=c6ca7a2f54702ea2d4af5424cc3aba65376e431b-1617045529519-cc9012368edfc1cd3d9783d7f0d7ae33badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029665	Research programme: G-protein coupled receptor modulators - Trevena			Yes			Preclinical	"Pain, Peripheral nervous system diseases, Parkinson's disease, Major depressive disorder, Inflammation, Cachexia"		"Opioid delta receptor modulators, Opioid kappa receptor modulators, Opioid mu receptor modulators, Sphingosine 1 phosphate receptor modulators, G protein-coupled receptor modulators"	"Trevena (Originator), Trevena (Owner), Duke University Medical Center (Technology Provider), Ligand Pharmaceuticals (Collaborator), Merck & Co (Collaborator), SCYNEXIS (Collaborator)"		"PO, unspecified"				"A16 (Other Alimentary Tract and Metabolism Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N (Nervous System), N2 (Analgesics), N2C (Anti-Migraine Preparations), N4 (Anti-Parkinson Drugs), N6A9 (Antidepressants, all others)"	"A16 (Other Alimentary Tract and Metabolism Products), M01 (Antiinflammatory and Antirheumatic Products), N (Nervous System), N02 (Analgesics), N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N06A-X (Other antidepressants)"	TRV 0109101			14/05/2018	"Affective Disorders, Inflammation, Metabolic Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800029665?userId=52029392&bpIds=3004037004&checksum=00e0a43b080a28836d2cbe5494910956261d2ab4-1617045529520-835d467c256e9f7f7ca2f41fc7f444bfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030615	Paracetamol ODT - Adare Pharmaceuticals	103-90-2	N-(4-Hydroxyphenyl)acetanilide	No			Registered	"Pain, Fever"	C8 H9 N O2	Prostaglandin inhibitors	"Eurand (Originator), Adare Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	"Acetaminophen ODT, AdvaTab Paracetamol ODT, Orally disintegrating paracetamol, Orodispersible paracetamol"			14/05/2018	"Metabolic Disorders, Pain"		Adare Pharmaceuticals |  | Unspecified |  | 17 Jan 2011		no		no		"A1AT, A1C, PSA, WT1"	"CD3d, CD3e, CD3g"	"11-Dehydro-thromboxane B2, 7-Hydroxy-6-methyl-8-ribityl lumazine, A1AT, A1C, Acetaminophen glucuronide, Acetylcysteine, Acid ceramidase, Angiopoietin 2, Arachidonic acid, AT-III, C-peptide, C4, CD34, CD3d, CD3e, CD3g, Collagen type 2, CRP, cytochrome P450 family 2 subfamily E member 1, Cytokeratin 18, dsDNA Auto-antibodies, F2-isoprostanes, Fibulin 3 peptides, Glutathione, growth hormone 1, Heme, HMGB1, Hydrocortisone, IFN-gamma, IGFBP7, IL6, insulin receptor related receptor, L-Cysteine, L-Cystine, microRNA 122, MMP-2, NGAL, opioid related nociceptin receptor 1, Osteocalcin, peptidylprolyl isomerase G, peroxiredoxin 5, PHGDH, Prostacyclin, PSA, RAGE, Thromboxane A2, Thromboxane B2, TIMP-2, TNF-alpha, transcription factor 21, VEGF-A, VEGFR, VEGFR1, WT1"	"Acid ceramidase, AT-III, Cytokeratin 18, HMGB1, NGAL, Osteocalcin, PSA"	"ATP binding cassette subfamily G member 2 (Junior blood group), Calreticulin, CTx, CYP2D6, Fe3+, GIP"	https://adis.springer.com/drugs/800030615?userId=52029392&bpIds=3004037004&checksum=534f7b137fcac1967ad62d5457561dbd132fc24f-1617045529523-510bda6cd83f8dbc5aeea5ff4c03a967badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051616	Research programme: conjugated glucocorticoids - Manzanita Pharmaceuticals			No			Preclinical	Pain		Glucocorticoid receptor agonists	"Manzanita Pharmaceuticals (Originator), Manzanita Pharmaceuticals (Owner)"		SC				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				09/05/2018	Pain				no		no							https://adis.springer.com/drugs/800051616?userId=52029392&bpIds=3004037004&checksum=fa40b36e66caa56344687916e59ba5bf004f1ba7-1617045529523-1616cf8a404ecbfa35bca815cd14567abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040439	DS 1971			Yes			Discontinued (I)	Pain		Undefined mechanism	"Daiichi Sankyo Inc (Originator), Daiichi Sankyo Inc (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"DS1971, DS1971a"			04/05/2018	Pain				no		no							https://adis.springer.com/drugs/800040439?userId=52029392&bpIds=3004037004&checksum=d6ccb57fa07c23ada6e7b5c94cd6d5e324d27e5a-1617045529524-7347af9613305dbe59629847e80f0d2abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036964	S 120083			Yes			Phase II	Inflammatory pain		Undefined mechanism	"Purdue Pharma (Originator), Shionogi (Originator), Purdue Pharma (Owner), Shionogi (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"S120083, V 120083"			28/04/2018	Pain				no		no							https://adis.springer.com/drugs/800036964?userId=52029392&bpIds=3004037004&checksum=0674026acc0c36b6092a8a387be79793213080c1-1617045529525-84ce16d53f5a9f4d734e9d89528f8fd9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039399	Research programme: neuro-inflammatory therapeutics - Xalud Therapeutics			No			Research	"CNS disorders, Amyotrophic lateral sclerosis, Rheumatoid arthritis"		"Gene transference, Interleukin-10 replacements"	"Xalud Therapeutics (Originator), Xalud Therapeutics (Owner), University of Colorado at Boulder (Technology Provider)"		Parenteral				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs)"				28/04/2018	"Neurological Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800039399?userId=52029392&bpIds=3004037004&checksum=b6547a202973095d9e4d13d27b29430815a43255-1617045529527-db2d8e9a7007f89867e2a9d372a2dee6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045657	Research programme: nociceptin receptor agonists - Astraea Therapeutics			Yes			No development reported (Preclinical)	"Substance-related disorders, Alcoholism, Dyskinesias, Pain"		"Nociceptin receptor agonists, Opioid receptor agonists"	"Astraea Therapeutics (Originator), Astraea Therapeutics (Owner), National Institutes of Health (USA) (Funder), The Michael J. Fox Foundation for Parkinson's Research (Funder)"		unspecified				"N2 (Analgesics), N7E (Drugs Used In Alcohol Dependence), N7F (Drugs Used In Opioid Dependence)"	"N02B (Other Analgesics and Antipyretics), N07B (Drugs Used In Addictive Disorders)"	"AT127, AT200, AT326, AT403"			28/04/2018	"Drug Withdrawal, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800045657?userId=52029392&bpIds=3004037004&checksum=ae7f6ec1e374f3f279f2228ba7559e4d9b50e077-1617045529528-d8a97d4382e86068f89100bc74d35a74badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021020	ATx09 002	800397-99-3		Yes			No development reported (I)	"Back pain, Neuropathic pain, Type 2 diabetes mellitus"		Glycogen phosphorylase inhibitors	"Prosidion (Originator), Prosidion (Owner), Aestus Therapeutics (Licensee)"		PO				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics)"	"ATx09002, PSN357, PSN357AB"			28/04/2018	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800021020?userId=52029392&bpIds=3004037004&checksum=e669980a3db9198d3889c35f7994ca4aac9825d6-1617045529529-7b7c5560b8b8c58c751930210015ea02badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037104	Hydromorphone intrathecal - CNS Therapeutics	71-68-1	"6-Deoxy-7,8-dihydro-6-oxomorphine hydrochloride"	No			Phase III	Pain	C17 H19 NO3 . HCl	Opioid receptor agonists	"CNS Therapeutics (Originator), Piramal Enterprises (Owner)"		Intrathecal				N2A (Narcotics)	N02A-A03 (Hydromorphone)				27/04/2018	Pain				no		no							https://adis.springer.com/drugs/800037104?userId=52029392&bpIds=3004037004&checksum=d49f0dcc7a53d9bd6f24fbce6ffcd7bc72ceddc6-1617045529530-c4aeb041193dcaa9f6a274050150dd18badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037108	Research programme: pain therapeutics - Flexion Therapeutics			Yes			Discontinued (Preclinical)	"Musculoskeletal pain, Postoperative pain"		TrkA receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner), Flexion Therapeutics (Licensee)"		Intra-articular				"M (Musculo-Skeletal System), N2B (Non-Narcotics and Anti-Pyretics)"	"M (Musculo-Skeletal System), N02B (Other Analgesics and Antipyretics)"	FX 007			18/04/2018	Pain				no		no							https://adis.springer.com/drugs/800037108?userId=52029392&bpIds=3004037004&checksum=395df056600d00b0138df5fbb06fa3cd27329499-1617045529532-50b575f0a57935c90ffc3b3f0f9660cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051713	DB 0015			Yes			Research	Fever		Undefined mechanism	"DongKoo Bio&Pharma (Originator), DongKoo Bio&Pharma (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	DB0015			12/04/2018	Metabolic Disorders				no		no							https://adis.springer.com/drugs/800051713?userId=52029392&bpIds=3004037004&checksum=ef204ef17dff93226879a0d333b412c6c5838d36-1617045529532-862ae5bdb200c7288a6f073f0c225da5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051714	DB 0016			Yes			Research	"Inflammation, Pain"		Undefined mechanism	"DongKoo Bio&Pharma (Originator), DongKoo Bio&Pharma (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	DB0016			12/04/2018	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800051714?userId=52029392&bpIds=3004037004&checksum=1eebacd812f8c6b1bf03911910544026b4f65e59-1617045529533-3552768897654d3ae5383d611ec4c018badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051673	DB 0008			Yes			Research	"Pain, Inflammation"		Undefined mechanism	"DongKoo Bio&Pharma (Originator), DongKoo Bio&Pharma (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	DB0008			12/04/2018	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800051673?userId=52029392&bpIds=3004037004&checksum=b4f271381ac42e067ed6edd9ffcc2c1f6ea8cc6c-1617045529535-02e128ef37dc8876608105de36eb9025badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051675	DB 0010			Yes			Research	"Inflammation, Pain"		Undefined mechanism	"DongKoo Bio&Pharma (Originator), DongKoo Bio&Pharma (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	DB0010			12/04/2018	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800051675?userId=52029392&bpIds=3004037004&checksum=f000d9c68e59637d8b41c06b890a05cb5c857ca7-1617045529536-70d84e3549d35b45fa03dce3d0eed64ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051698	Research programme: non-opioid pain therapeutics - Grunenthal/Katholieke Universiteit Leuven			Yes			Research	Pain		Transient receptor potential channel modulators	"Grunenthal (Originator), Katholieke Universiteit Leuven (Originator), Grunenthal (Owner), Katholieke Universiteit Leuven (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Transient receptor potential channel modulators Grunenthal/Katholieke Universiteit Leuven, Transient receptor potential channel modulators Katholieke Universiteit Leuven/Grunenthal, TRP channel modulators Grunenthal/Katholieke Universiteit Leuven, TRP channel modulators Katholieke Universiteit Leuven/Grunenthal"			11/04/2018	Pain				no		no							https://adis.springer.com/drugs/800051698?userId=52029392&bpIds=3004037004&checksum=3a0b21d2512d98c0ae6ca56643b8bc69d6ccd61d-1617045529537-9f34cf0d4ad8b14d2169b29026babe2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000568	Venlafaxine - Pfizer	93413-69-5	"Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-,"	Yes		"³ Fluoxetine, &gt; Imipramine, ³ Trazodone"	Marketed	"Major depressive disorder, Social phobia, Panic disorder, Generalised anxiety disorder"	C17 H27 N O2	"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Wyeth (Originator), Pfizer (Owner), AbbVie (Market Licensee), Almirall S.A. (Market Licensee), Gador (Market Licensee), Teva Pharmaceutical Industries (Market Licensee), Erasmus MC (Collaborator), Sumitomo Dainippon Pharma (Collaborator)"		PO	renal	"Active Metabolites (yes), Dose Modification in Renal Dysfunction (moderate), Route of Elimination (renal), T<sub>_beta</sub> (h) (4 (Adult))"	"Abdominal pain, Aggression, Breast pain, Constipation, Dizziness, Drowsiness, Headache, Hyperhidrosis, Hypertension, Nausea, Seizures, Sexual function disorders, Sleep disorders, Tremor, Xerostomia"	"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N6A5 (SNRI antidepressants)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N05B (Anxiolytics), N06A-X16 (Venlafaxine)"	"Dobupal, Efexor XR, Effexor, Effexor XR, Elafax, WY 45030, WY 45651, WY 45655"			05/04/2018	"Affective Disorders, Anxiety Disorders"			"Dobupal, Efexor XR, Efexor XR, Effexor, Effexor XR, Effexor XR, Effexor XR, Effexor XR, Elafax"	no		no			"Hydrocortisone, serotonin"	"3-Hydroxybutyric acid, ApoE, BDNF, Citric acid, CRP, DBH antisense RNA 1, HCY, Hydrocortisone, IL6, L-Cysteine, L-Isoleucine, L-Lactic acid, L-Leucine, L-Threonine, L-Valine, N-Acetyl-L-methionine, NGF, serotonin, Stearic acid, Succinic acid, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, TNF-alpha"	"IL6, TNF-alpha"	"arrestin, beta 1, arrestin, beta 2, BCAR1, Cas family scaffolding protein, Creatinine, CYP2D6, MMP-1, neurotrophin 4, Norepinephrine, PTH, sulfotransferase family 1A member 1"	https://adis.springer.com/drugs/800000568?userId=52029392&bpIds=3004037004&checksum=44b2f47213bb1162c9a2687a0020f112010a9dfa-1617045529542-5c76c5e7682d9aa37a963d5a40bf68c8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039286	Research programme: P2X7 receptor antagonists - Asahi Kasei Pharma/RaQualia Pharma			Yes			Preclinical	Neuropathic pain		Purinergic P2X7 receptor antagonists	"Asahi Kasei Pharma Corp (Originator), RaQualia Pharma (Originator), Asahi Kasei Pharma Corp (Owner), RaQualia Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				29/03/2018	Pain				no		no							https://adis.springer.com/drugs/800039286?userId=52029392&bpIds=3004037004&checksum=16fee2de39ef689a995feb1ce26f6665522f853d-1617045529542-f586e73ec1a21e252ef0586fdaa8ba6dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027601	TC 6499			Yes			Phase II	"Haematological disorders, Irritable bowel syndrome, Diabetic gastroparesis, Neuropathic pain"		"Alpha4beta2 nicotinic receptor modulators, Alpha3beta4 nicotinic receptor agonists"	"Targacept (Originator), Catalyst Biosciences (Owner), Unknown (Owner)"		"unspecified, PO"				"A3 (Functional Gastro-Intestinal Disorder Drugs), B6 (All Other Haematological Agents), N2 (Analgesics)"	"A03A (Drugs for Functional Bowel Disorders), B06A (Other Hematological Agents), N02 (Analgesics)"	"TC6499, TC649912"			29/03/2018	"Diabetes, Digestive System Disorders, Haematological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027601?userId=52029392&bpIds=3004037004&checksum=adc3851f1a516ea628f45165c9d7168a6bfb76af-1617045529543-6786ddbe890b1352c7d6adafb3f3bcb5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030857	Zolmitriptan intranasal - Shin Nippon Biomedical Laboratories	139264-17-8	S-4[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]- 2-oxazolidinone	No			No development reported (I)	Migraine	C16 H21 N3 O2	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Shin Nippon Biomedical Laboratories (Originator), Shin Nippon Biomedical Laboratories (Owner)"		Intranasal				N2C1 (Antimigraine triptans)	N02C-C03 (Zolmitriptan)	TRZ			28/03/2018	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"		Shin Nippon Biomedical Laboratories |  | Phase I |  | 03 Sep 2009		no		no							https://adis.springer.com/drugs/800030857?userId=52029392&bpIds=3004037004&checksum=6393122dabb931f690813daabc168317b978543d-1617045529544-65fa11adda608fc5c97eef42aab1fa8ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017692	Fentanyl buccal - Generex Biotechnology	990-73-8	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate	No			No development reported (I)	Pain	C22 H28 N2 O . C6 H8 O7	Opioid mu receptor agonists	"Generex Biotechnology Corporation (Originator), Generex Biotechnology Corporation (Owner)"		Buccal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Fentanyl citrate buccal Generex, Fentanyl oral spray Generex"			28/03/2018	"Drug Delivery Systems, Pain"		Generex Biotechnology Corporation |  | Unspecified |  | 10 Jan 2013		no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800017692?userId=52029392&bpIds=3004037004&checksum=ec52583134d9c61b13b2dc9ac047490a92210c76-1617045529546-a3e9b8e2be5991b4c9600838fba3110abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034305	Research programme: small molecule therapeutics - Kareus Therapeutics						No development reported (Preclinical)	"Alzheimer's disease, Cancer, Multiple sclerosis, Neuropathic pain, Inflammatory pain"		"Cannabinoid receptor modulators, Enkephalin agonists"	"Kareus Therapeutics (Originator), Kareus Therapeutics (Owner)"		"unspecified, PO"				"L1 (Antineoplastics), N2 (Analgesics), N7D (Anti-Alzheimer Products), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"L01 (Antineoplastic Agents), N02 (Analgesics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs), N07X-X (Other nervous system drugs)"				28/03/2018	"Alzheimer's Disease and Cognition Disorders, Cancer, Neurological Disorders, Pain"		Kareus Therapeutics |  | Unspecified |  | 14 Feb 2014		no		no							https://adis.springer.com/drugs/800034305?userId=52029392&bpIds=3004037004&checksum=60f22bf1e5b87d0c19bcea80e88de5004eff9d97-1617045529547-f6cf6c9314e804e0132bd1c2e4b0dbafbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051527	AK 115			Yes			Preclinical	Pain		Undefined mechanism	"Akeso Biopharma (Originator), Akeso Biopharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AK115			21/03/2018	Pain		Akeso Biopharma |  | Unspecified |  | 21 Mar 2018		no		no							https://adis.springer.com/drugs/800051527?userId=52029392&bpIds=3004037004&checksum=108316710ee57db6619f8086c5cc7d2a35184d6f-1617045529548-2d774c3e43a507f8e659fcbe3bcaf1acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027403	Research programme: reuptake inhibitors - Neurovance			Yes			No development reported (Preclinical)	"Anxiety disorders, Cognition disorders, Substance-related disorders, Major depressive disorder, Pain, Premenstrual dysphoric disorder, Obesity"		"Adrenergic uptake inhibitors, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"DOV Pharmaceutical (Originator), Euthymics Bioscience (Owner), Neurovance (Owner)"		unspecified				"A8A (Antiobesity Preparations, Excluding Dietetics), N2B (Non-Narcotics and Anti-Pyretics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants), N7 (Other CNS Drugs), V3 (All Other Therapeutic Products)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02B (Other Analgesics and Antipyretics), N05B (Anxiolytics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics), N07 (Other Nervous System Drugs), V03 (All Other Therapeutic Products)"				21/03/2018	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Drug Withdrawal, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800027403?userId=52029392&bpIds=3004037004&checksum=615ad10f9c6a3e69bfe7853b30a4496d03d01c82-1617045529549-25a01cd54f3459a41e5e6d1ef0ab521cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021845	Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma			Yes			Research	"Vascular disorders, Rheumatoid arthritis, Fever, Pain, Osteoarthritis"		Prostaglandin-E synthase inhibitors	"Biolipox (Originator), Gesynta Pharma (Owner)"		"PO, unspecified"				"C (Cardiovascular System), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics)"	"C (Cardiovascular System), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N02B (Other Analgesics and Antipyretics)"	OXMPI programme			13/03/2018	"Metabolic Disorders, Pain, Rheumatic Disease, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800021845?userId=52029392&bpIds=3004037004&checksum=8633bd59f943b7a82126a312d89f0d45affd9cc4-1617045529550-075300534a55bf1c7665bc82d9c07644badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051432	Buprenorphine - Faran Shirin			No			Phase II	"Substance-related disorders, Pain, Opioid-related disorders"		"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Faran Shimi (Originator), Faran Shimi (Owner), Tehran University of Medical Sciences (Collaborator)"		Sublingual				"N2A (Narcotics), N7F (Drugs Used In Opioid Dependence)"	N02A-E01 (Buprenorphine)				07/03/2018	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800051432?userId=52029392&bpIds=3004037004&checksum=5c969e770cdce3479904e54dafd01b9f8d520873-1617045529551-bd0c5fa1c2c596cf3a4f192818ac800ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043353	DWJ 1341			Yes			No development reported (I)	Pain			"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DWJ1341			28/02/2018	Pain				no		no							https://adis.springer.com/drugs/800043353?userId=52029392&bpIds=3004037004&checksum=450f3c0fccfb67cd28c388af1a9de854739c81d5-1617045529551-8ef2c857b5de25bb78fcdc2b7dc2bae8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039716	Research programme: pain therapeutics - Aerial BioPharma			Yes			No development reported (Preclinical)	Pain			"Aerial BioPharma (Originator), Aerial BioPharma (Owner)"		Parenteral				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Prostatic acid phosphatase Aerial BioPharma			28/02/2018	Pain				no		no							https://adis.springer.com/drugs/800039716?userId=52029392&bpIds=3004037004&checksum=01aeade3eb6bcac6bb424d7ab6dba4133d7b869d-1617045529552-de2b56b55bd0f6cd647d64514e17db22badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039587	Research programme: pain therapeutics - Biogen			Yes			No development reported (Research)	Pain		"GPR84 protein modulators, MAP-kinase-activated kinase 5 modulators, P2RY14 protein modulators, Prostaglandin-E synthase modulators"	"Convergence Pharmaceuticals (Originator), Biogen (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"ASK1 modulators, GPR84 modulators, mPGES modulators, P2Y14 modulators"			28/02/2018	"Pain, Rheumatic Disease"		Convergence Pharmaceuticals |  | Unspecified |  | 01 Jan 2014		no		no							https://adis.springer.com/drugs/800039587?userId=52029392&bpIds=3004037004&checksum=34de7fc239329e7f4590f543b9015353d2f30201-1617045529553-1f12f6d97928a408eca12635ee60b9a7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030468	NXN 462			Yes			Phase II	"Postherpetic neuralgia, Migraine"		Nitric oxide synthase type I inhibitors	"NeurAxon (Originator), NeurAxon (Owner), Knight Therapeutics (Market Licensee)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	NXN462			28/02/2018	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800030468?userId=52029392&bpIds=3004037004&checksum=ac93591399b5750c821a2fad6a60abef9098db96-1617045529554-280972ffe7d0c133c8b10fa915dffa6fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036797	Research programme: prostaglandin E synthase inhibitors - Cadila Pharmaceuticals/NovaSAID			Yes			No development reported (Preclinical)	"Inflammation, Pain, Fever"		Prostaglandin-E synthase inhibitors	"NovaSAID (Originator), NovaSAID (Owner), Cadila Pharmaceuticals (Collaborator)"		"PO, unspecified"				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	Antiinflammatory therapeutics / analgesics Cadila Pharmaceuticals/NovaSAID			28/02/2018	"Inflammation, Metabolic Disorders, Pain"				no		no							https://adis.springer.com/drugs/800036797?userId=52029392&bpIds=3004037004&checksum=189739e64ae3ad2207b730c8984ebc78d082d7a1-1617045529555-94c82311d2109c30bbb2ab4b8c6e68d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048901	Research programme: calcitonin gene-related peptide receptor antagonists - Biohaven Pharmaceuticals			Yes			Research	Migraine		Calcitonin gene-related peptide receptor antagonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Biohaven Pharmaceuticals (Licensee), Catalent (Technology Provider), Biohaven Pharmaceutical Holding Company (Collaborator)"		unspecified				"N (Nervous System), N2C (Anti-Migraine Preparations)"	"N (Nervous System), N02C (Antimigraine Preparations)"				23/02/2018	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800048901?userId=52029392&bpIds=3004037004&checksum=a800173dba88e3ecf726e0ea4c24298e8896c17d-1617045529556-530425b9bb9dc91d02cd74328fb12bd2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051286	CY 19			Yes			Preclinical	Pain		Undefined mechanism	"Overseas Pharmaceuticals (Originator), Overseas Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CY19			22/02/2018	Pain				no		no							https://adis.springer.com/drugs/800051286?userId=52029392&bpIds=3004037004&checksum=6ae42960f9e9efde810a1ba33c762d27dfa5a550-1617045529557-d2a4581d05b4105d9ed79833c2ac4d2fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029391	SPI 017			Yes			Discontinued (II)	"Pain, Peripheral arterial disorders"		Chloride channel agonists	"Sucampo Pharmaceuticals (Originator), Mallinckrodt plc (Owner)"		IV				"C4A (Cerebral and Peripheral Vasotherapeutics), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N7 (Other CNS Drugs)"	"C04A (Peripheral Vasodilators), M05 (Drugs for Treatment of Bone Diseases), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"SPI017, SPL017"			21/02/2018	"Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800029391?userId=52029392&bpIds=3004037004&checksum=ea3d2adc1bcf50a9fc7c1ecc9240c0746e895cfb-1617045529557-9de6135b52ff99edb60fb1681cf2fbedbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026281	Cenplacel-L - Celularity			No			Phase II	"Crohn's disease, Rheumatoid arthritis, Multiple sclerosis, Haematological disorders, Ulcerative colitis, Graft-versus-host disease, Cancer, Neuropathic pain, Amyotrophic lateral sclerosis, Stroke, Pulmonary sarcoidosis"		Cell replacements	"Celgene Cellular Therapeutics (Originator), Celgene Cellular Therapeutics (Owner), Celularity (Licensee)"		IV				"A7E (Intestinal Anti-Inflammatory Agents), B (Blood and Blood Forming Organs), B6C (Other Haematological Agents), L1 (Antineoplastics), L4 (Immunosuppressants), L4X (Other Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs), V3 (All Other Therapeutic Products)"	"A07E (Intestinal Antiinflammatory Agents), B (Blood and Blood Forming Organs), B06A-B (Other Hem Products), L01 (Antineoplastic Agents), L04A (Immunosuppressants), L04A-X (Other immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs), V03A (All Other Therapeutic Products)"	"PDA001, PDAC cells Celgene Cellular Therapeutics, Placentalderived adherent cells intravenous"			21/02/2018	"Cancer, Haematological Disorders, Immunological Disorders, Inflammatory Bowel Disorders, Neurological Disorders, Pain, Rheumatic Disease, Transplant Rejection"				no		no							https://adis.springer.com/drugs/800026281?userId=52029392&bpIds=3004037004&checksum=3851445a6321ce150bfb5c523a20a254673b02f3-1617045529559-6ff52be9fe08bc6d14d8d6dacf0158e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800048479	Research programme: pain therapeutics - Impel Neuropharma			Yes			No development reported (Preclinical)	Pain		Undefined mechanism	"Impel NeuroPharma (Originator), Impel NeuroPharma (Owner)"		Intranasal				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	INP106			09/02/2018	Pain				no		no							https://adis.springer.com/drugs/800048479?userId=52029392&bpIds=3004037004&checksum=783ccdae17023dd18914972052b7c5b3eb4ec4ce-1617045529560-381a873372c01da14668940e97fdc5d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039269	ASP 7962			Yes			Discontinued (II)	Pain		TrkA receptor antagonists	"Astellas Pharma Europe Ltd (Originator), Astellas Pharma Europe Ltd (Owner)"		PO				"M (Musculo-Skeletal System), N2 (Analgesics)"	"M (Musculo-Skeletal System), N02 (Analgesics)"	ASP7962			07/02/2018	Pain				no		no			NGF	NGF			https://adis.springer.com/drugs/800039269?userId=52029392&bpIds=3004037004&checksum=7fd069409ad0ffabc367afcfb90699e6ce532055-1617045529561-c4a3e8f1a036faaa146df7cb1c0da8d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044034	MCS 18			Yes			Discontinued (II)	"Musculoskeletal pain, Atherosclerosis"		"TRPV1 receptor antagonists, Dendritic cell modulators"	"SiNatur (Originator), SiNatur (Owner)"		Parenteral				"C10B (Anti-Atheroma Preparations of Natural Origin), N2B1 (Prescription-bound non-narcotics and anti-pyretics)"	"C10A (Lipid Modifying Agents, Plain), N02B (Other Analgesics and Antipyretics)"	MCS18			06/02/2018	"Hyperlipidaemia, Ischaemic Heart Disease, Pain"				no		no							https://adis.springer.com/drugs/800044034?userId=52029392&bpIds=3004037004&checksum=99bc8bff56838afe9ae57659170774d860678188-1617045529562-14787bd80faa9eb44d9f57a1488eab9abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051177	Research programme: dimer therapeutics - OrphoMed			Yes			Preclinical	"Gastroparesis, Gastrointestinal disorders, Pain"		"Adrenergic receptor modulators, Serotonin 1 receptor modulators, Opioid mu receptor antagonists, Prostaglandin receptor antagonists"	"OrphoMed (Originator), OrphoMed (Owner)"		unspecified				"A3 (Functional Gastro-Intestinal Disorder Drugs), N2 (Analgesics)"	"A03A (Drugs for Functional Bowel Disorders), N02B-E01 (Paracetamol)"	"ORP102, ORP103, ORP105"			05/02/2018	"Digestive System Disorders, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800051177?userId=52029392&bpIds=3004037004&checksum=d8a10ea70e4954a0737dd2ee0e7b22c2f97f7d44-1617045529563-c236b5463282ee070ecb46162e4425a2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030851	AN 721			Yes			No development reported (I)	"Pain, Inflammatory pain, Neuropathic pain, Anxiety disorders"		"GABA A alpha 2 receptor modulators, GABA A alpha 3 receptor modulators"	"NeuroSearch (Originator), Saniona (Owner)"		unspecified				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N05B (Anxiolytics)"	"AN721, NSD721"			28/01/2018	"Anxiety Disorders, Pain"		Saniona |  | Unspecified |  | 04 Dec 2013		no		no							https://adis.springer.com/drugs/800030851?userId=52029392&bpIds=3004037004&checksum=8f3480f6c8b19aa1e0e3ab15fb249c77da7a1516-1617045529564-45f7744914c4ecda029ac030ca57891bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036761	Ondansetron/rizatriptan oral transmucosal film			No			No development reported (I)	"Nausea, Migraine"		"Serotonin 3 receptor antagonists, Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"MonoSol Rx (Originator), Aquestive Therapeutics (Owner)"		Transmucosal				"A4A1 (Serotonin antagonist antiemetics/antinauseants), N2C1 (Antimigraine triptans)"	"A04A-A01 (Ondansetron), N02C-C04 (Rizatriptan)"	"MSRX202, Rizatriptan/ondansetron"			22/01/2018	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800036761?userId=52029392&bpIds=3004037004&checksum=0a4e5e98a7e5af4d1783bfacbd0839c7704b6a59-1617045529565-0a7aae2c258df37fb914f6b69b41f8a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032172	Tramadol - Nippon Shinyaku/Janssen Pharmaceutica	27203-92-5	"(1<EM>R</EM>,2<EM>R</EM>)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol"	No			Marketed	"Cancer pain, Pain"	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Grunenthal (Originator), Grunenthal (Owner), Janssen Pharmaceutica (Licensee), Nippon Shinyaku (Licensee), Pfizer (Sub-licensee)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"NS315, Tramal, Tramal OD Tablet"			19/01/2018	Pain			"Tramal, Tramal, Tramal OD Tablet, Tramal OD Tablet"	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800032172?userId=52029392&bpIds=3004037004&checksum=f92abffa2dfd6faa85215fe3a8c5bcfc5d985cfc-1617045529566-f5a469ecad4709cbc79ea6fc7c4a0644badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800051093	Research programme: neurological disorder therapeutics - Aequus Pharmaceuticals/CannaRoyalty			Yes			Research	Neurological disorders		Cannabinoid receptor modulators	"Aequus Pharmaceuticals (Originator), Aequus Pharmaceuticals (Owner), CannaRoyalty (Collaborator)"		unspecified				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02A (Opioids)"	Cannabisbased therapies Aequus Pharmaceuticals/CannaRoyalty			15/01/2018	Neurological Disorders				no		no							https://adis.springer.com/drugs/800051093?userId=52029392&bpIds=3004037004&checksum=86cf1e6d4d6b09bbefa411ffeb9c9e383c081c4f-1617045529567-1bfb46f9c272288bc636bd10d8af8093badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049427	Abuse resistant oxycodone immediate release - Inspirion Delivery Sciences	124-90-3	"4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride"	No			Registered	Pain	C18 H21 N O4 . Cl H	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Inspirion Delivery Sciences (Originator), Inspirion Delivery Sciences (Owner), Daiichi Sankyo Company (Market Licensee)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"Oxycodone hydrochloride tablets, RoxyBond"			15/01/2018	Pain			RoxyBond	no		no							https://adis.springer.com/drugs/800049427?userId=52029392&bpIds=3004037004&checksum=1a492be0c1e944a49175c16a814b928eaf1e0d49-1617045529568-62eaa6c178ed1c356ee586c028afe700badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019882	Trabodenoson			Yes			Discontinued (III)	"Ocular hypertension, Glaucoma, Arrhythmias, Atrial fibrillation, Optic nerve disorders, Pain"		"Adenosine A1 receptor agonists, Gelatinase stimulants"	"Inotek Pharmaceuticals (Originator), Rocket Pharmaceuticals (Owner)"		"Ophthalmic, IV, unspecified"				"C1 (Cardiac Therapy), C1B (Anti-Arrhythmics), N2 (Analgesics), S1E2 (Miotics and antiglaucoma preparations, topical)"	"C01 (Cardiac Therapy), C01B (Antiarrhythmics, Class I and III), N02 (Analgesics), S01E-X (Other antiglaucoma preparations)"	"INO8875, PJ875"			09/01/2018	"Arrhythmias, Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800019882?userId=52029392&bpIds=3004037004&checksum=00cf667373c2a66b84bbb9d295c02624beba8994-1617045529569-125e7f7cd60203cd4c471dc8b21bdd0cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050808	QRX 001			Yes			Preclinical	Postoperative pain		NMDA receptor antagonists	"Quoin Pharmaceuticals (Originator), Quoin Pharmaceuticals (Owner)"		Transdermal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	QRX001			29/12/2017	Pain				no		no							https://adis.springer.com/drugs/800050808?userId=52029392&bpIds=3004037004&checksum=f62cf2a5ee062206dad7545e557dd527b7cf879c-1617045529570-2244e10a6e852bdd045dbb84f9521b1abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041211	Research programme: serotonin receptor-targeted therapeutics - Neurolixis			Yes			No development reported (Preclinical)	"Rett syndrome, Drug-induced dyskinesia"		Serotonin 1A receptor agonists	"Pierre Fabre (Originator), Pierre Fabre (Owner), Neurolixis (Licensee), The Michael J. Fox Foundation for Parkinson's Research (Funder)"		"PO, unspecified"				"N4 (Anti-Parkinson Drugs), N6A (Anti-Depressants and Mood Stabilisers), N6D (Nootropics), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs)"	"N02C-C (Selective serotonin (5HT1) agonists), N04 (Anti-Parkinson Drugs), N06A-X (Other antidepressants), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"	"F13640 Neurolixis, F15599 Neurolixis"			28/12/2017	"Neurological Disorders, Parkinson's Disease and Movement Disorders"	"Rett syndrome (European Union), Rett syndrome (USA)"			no		no							https://adis.springer.com/drugs/800041211?userId=52029392&bpIds=3004037004&checksum=9989f7ced19b17c88fa97df3143c321cec549fc3-1617045529571-9321b019395c4dd3b737227ab09a7f4fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020927	Research programme: dronabinol controlled-release - Aphios Corporation	1972-08-3	"(_)-(6aR,10aR)-6,6,9-trimethyl- 3-pentyl-6a,7,8,10a-tetrahydro- 6H-benzo[c]chromen-1-ol"	No			No development reported (Preclinical)	"Substance-related disorders, Cachexia, Cancer pain, Pain, Multiple sclerosis, Chemotherapy-induced nausea and vomiting"	C21 H30 O2	Cannabinoid receptor agonists	"Aphios Corporation (Originator), Aphios Corporation (Owner), National Institutes of Health (USA) (Funder)"		PO				"A16A (Other Alimentary Tract and Metabolism Products), A4A9 (Other antiemetics and antinauseants), N2 (Analgesics), N7X (All other CNS drugs)"	"A04A-D (Other antiemetics), A16A (Other Alimentary Tract and Metabolism Products), N02B-G (Other analgesics and antipyretics), N07B (Drugs Used In Addictive Disorders), N07X-X (Other nervous system drugs)"	"APH0802, Cannabinoid therapeutics Aphios Corporation, nanoTHC"			28/12/2017	"Advances in the Treatment of Nausea and Migraine, Cancer, Drug Delivery Systems, Drug Withdrawal, Metabolic Disorders, Neurological Disorders, Pain"		"Aphios Corporation | Cachexia, Cancer pain, Multiple sclerosis, Nausea and vomiting, Pain, Substance-related disorders | Preclinical |  | 14 Jun 2004"		no		no							https://adis.springer.com/drugs/800020927?userId=52029392&bpIds=3004037004&checksum=c12e00532a158823b93cbc82db1fd7d0f9c059d7-1617045529572-6d0db6a50f114b202904db52d30ea79dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008928	DP VPA			No			Phase II	"Epilepsy, Migraine, Bipolar disorders"		GABA uptake inhibitors	"D-Pharm (Originator), D-Pharm (Owner), Jiangsu Nhwa Pharmaceutical (Licensee)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02C (Antimigraine Preparations), N03A-G01 (Valproic acid), N06A (Antidepressants)"	"DPVPA, SPD 421"			28/12/2017	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800008928?userId=52029392&bpIds=3004037004&checksum=6ae14dee1a47fb5e8cab8082299f3b3c53fb9084-1617045529573-6c968032843df5e308b9ae9f89d8da68badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031629	Hydrocodone extended-release - Teva Pharmaceutical Industries	125-29-1	"Morphinan-6-one, 4,5alpha-epoxy-3-methoxy-17-methyl-"	No			Registered	Pain	C18 H21 N O3	Opioid receptor agonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner)"		PO		Linear Kinetics (yes)		N2A (Narcotics)	"N02A-A (Natural opium alkaloids), R05D-A03 (Hydrocodone)"	"CEP33237, Hydrocodone bitartrate extendedrelease Teva, Tamperdeterrent hydrocodone, Twicedaily hydrocodone Teva, VANTRELAER"			12/12/2017	Pain			VANTRELAER	no		no							https://adis.springer.com/drugs/800031629?userId=52029392&bpIds=3004037004&checksum=5af883b795f85d5aa22b375e931284e45076aea7-1617045529574-88d46d663ee6b674fe8e962bb5135922badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026631	Research programme: flavonoid anti-inflammatory molecules - Kazia Therapeutics			Yes			No development reported (Preclinical)	"Inflammation, Rheumatoid arthritis"		Signal transduction pathway modulators	"Novogen (Originator), Kazia Therapeutics (Owner)"		PO				"C (Cardiovascular System), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"C (Cardiovascular System), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				12/12/2017	"Inflammation, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800026631?userId=52029392&bpIds=3004037004&checksum=32017e495d407aba0fd76f7b80aca7e462ffd096-1617045529575-4691e31e07ff5223edf306bdb50cd337badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042883	Oxycodone - VistaPharm	76-42-6	"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Marketed	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"VistaPharm (Originator), VistaPharm (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	Oxycodone hydrochloride			11/12/2017	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800042883?userId=52029392&bpIds=3004037004&checksum=c540223435c26a231e29314567d6854668e508ec-1617045529576-858efff84cd8cfc930c21a568b62e93dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050503	MEB 1166			Yes			Preclinical	Pain		Opioid mu receptor agonists	"MEBIAS Discovery (Originator), MEBIAS Discovery (Owner)"		SC				N2 (Analgesics)	N02 (Analgesics)	MEB1166			11/12/2017	Pain		MEBIAS Discovery |  | Clinical Phase Unknown |  | 19 Oct 2017		no		no							https://adis.springer.com/drugs/800050503?userId=52029392&bpIds=3004037004&checksum=e1c9b7a2503fe62332ac5f59e6b25e9cd268c8de-1617045529576-40a6749abd61eb92f4834df378f728dabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041720	T4P 1001			Yes			Phase II	"Pain, Neuropathic pain"		Undefined mechanism	"Tools4Patient (Originator), Tools4Patient (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	T4P1001			08/12/2017	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800041720?userId=52029392&bpIds=3004037004&checksum=6d2b6a96721e2bfb63d9088d55f0e94333089b16-1617045529577-3f4c83855736f07337cb1a23d6e143ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032698	Etodolac injection - Ipca Laboratories	41340-25-4	"Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-"	No			Marketed	Postoperative pain	C17 H21 N O3	Cyclooxygenase inhibitors	"Ipca Laboratories (Originator), Ipca Laboratories (Owner)"		IM				N2 (Analgesics)	N02 (Analgesics)	"EtovaAQ, MACRE09"			04/12/2017	Pain			EtovaAQ	no		no		PSA		Hydrocortisone		"CRP, IFN-gamma, IL10, IL2, IL4, IL6, immunoglobulin kappa variable 1D-39, negative elongation factor complex member C/D, NTx, VEGF-A"	https://adis.springer.com/drugs/800032698?userId=52029392&bpIds=3004037004&checksum=6d7cf877d14227e8f3a8ad0327516e92b9d1e044-1617045529578-c6a7255cb2a76e82b75733cdbd5b1516badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043233	VM 902			Yes			Phase II	Pain		Tropomyosin-related kinase antagonists	"VM Discovery (Originator), Purdue Pharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	VM 902A			30/11/2017	Pain				no		no							https://adis.springer.com/drugs/800043233?userId=52029392&bpIds=3004037004&checksum=701198b5d8ae31dcdaa5cfc111ec89eefd2b508d-1617045529579-7b867d13c76c77aefc2dcb602ab6e0ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042041	Abuse resistant morphine extended release - Inspirion Delivery Technologies	6211-15-0	"9H-9,9c-Iminoethanophenanthro[4,5-bcd]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate"	No			Marketed	Pain	C17 H19 N O3 . 1/2 H2 S O4 . 5/2H2 O	Opioid mu receptor agonists	"Inspirion Delivery Technologies (Originator), Inspirion Delivery Technologies (Owner), Daiichi Sankyo Inc (Market Licensee)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	"Abuse deterrent morphine extended release Inspirion Delivery Technologies, MorphaBond ER"			28/11/2017	Pain		Inspirion Delivery Technologies |  | Unspecified |  | 09 Feb 2015	MorphaBond ER	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800042041?userId=52029392&bpIds=3004037004&checksum=e3e90a7bdcb462df3bc37264a864cef130bd3268-1617045529580-61e4372e80473da26421554f58af3127badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050759	Opioid analgesic - Sarfez			No			Preclinical	Migraine		Opioid mu receptor agonists	"Sarfez Pharmaceuticals (Originator), Sarfez Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)	Mureceptor agonist Sarfez pipeline November 2017			24/11/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800050759?userId=52029392&bpIds=3004037004&checksum=a6edc175e4118a5a2f660feda26667d9845d1d44-1617045529581-f4e40723df435a18de80ce383315fadbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050713	Research programme: kappa opioid receptor agonist implant - Titan Pharmaceuticals			Yes			Research	Pain		Opioid kappa receptor agonists	"Titan Pharmaceuticals (Originator), Titan Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02A (Opioids)				20/11/2017	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800050713?userId=52029392&bpIds=3004037004&checksum=f0ddc18ccffd407ba2ebb9f01f0643d5763a0e9c-1617045529582-c8591f99b84e3437aad2ebf8964cab7abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036396	Dextropropoxyphene/paracetamol - Xanodyne			No			No development reported (III)	Acute pain		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"AAIPharma (Originator), Alcami (Owner), Xanodyne Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	"N02A-C54 (Dextropropoxyphene, comb. excl. psycholeptics), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"Propoxyphene/acetaminophen Xanodyne, XP 20B"			16/11/2017	Pain				no		no							https://adis.springer.com/drugs/800036396?userId=52029392&bpIds=3004037004&checksum=6fa4692e46b786212fd4d52667861486d0299a26-1617045529583-63cdb6d9ef5ccd9f9636f8c22b399985badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015921	Research programme: pain therapeutics - DURECT Corporation	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"				No development reported (Preclinical)	"Pain, Cancer pain"	C17 H19 N O3 . H Cl	Opioid receptor agonists	"DURECT Corporation (Originator), DURECT Corporation (Owner)"		"unspecified, Intrathecal"				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	DUROS hydromorphone			04/11/2017	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800015921?userId=52029392&bpIds=3004037004&checksum=77e77fb236b56eb1b50db6231a2021394157d294-1617045529585-aec78b3fd4e774a58bd2a73e1e63c764badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022197	Research programme: pain and migraine therapy - OptiNose						No development reported (Preclinical)	"Pain, Migraine"		Undefined mechanism	"OptiNose AS (Originator), OptiNose AS (Owner)"		Intranasal				"N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"N02 (Analgesics), N02C (Antimigraine Preparations)"	OPT 1005			04/11/2017	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800022197?userId=52029392&bpIds=3004037004&checksum=234918629ad5b4ccc2b97f6d76373df4ee5671eb-1617045529586-be9f3926876d779781b60c2e8150fa5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025359	Hydrocodone/paracetamol - Mallinckrodt			No			No development reported (I)	Pain		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Questcor Pharmaceuticals (Originator), Mallinckrodt plc (Owner), Adare Pharmaceuticals (Technology Provider)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A (Opioids), N02B (Other Analgesics and Antipyretics)"	"hydrocodone/acetaminophen Mallinckrodt, QSC001"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800025359?userId=52029392&bpIds=3004037004&checksum=a1647acbb3339b6156c3b4b6fb49b73a9cc35ea0-1617045529586-8c1b0905479839ca3090c03038156133badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022365	Research programme: NMDA receptor antagonists - Sosei R&D						No development reported (Preclinical)	"Pain, Neuropathic pain"		NMDA receptor antagonists	"Sosei R&D (Originator), Sosei R&D (Owner)"		"unspecified, Transdermal"				"N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02 (Analgesics), N02B (Other Analgesics and Antipyretics)"	"AD529, ED1812, NMDA antagonists research programme Arakis"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800022365?userId=52029392&bpIds=3004037004&checksum=f6fc8408cba3733195fcc0d52dc87ddb0fdc83ae-1617045529588-b26d571ce294c6f64ddeb7f4b2e46cf4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026356	Research programme: abuse-resistant analgesics - Acura Pharmaceuticals			No			No development reported (Preclinical)	Pain		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner)"		PO				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	"acetaminophen/niacin/oxycodone, acetaminophen/oxycodone, acetaminophen/oxycodone/niacin, Acuracet, Acuracet with Niacin, niacin/acetaminophen/oxycodone, niacin/oxycodone/acetaminophen, niacin/oxycodone/paracetamol, niacin/paracetamol/oxycodone, oxycodone/acetaminophen, oxycodone/acetaminophen/niacin, oxycodone/niacin/acetaminophen, oxycodone/niacin/paracetamol, oxycodone/paracetamol, oxycodone/paracetamol/niacin, paracetamol/niacin/oxycodone, paracetamol/oxycodone, paracetamol/oxycodone/niacin"			04/11/2017	"Drug Delivery Systems, Pain"			"Acuracet, Acuracet with Niacin"	no		no							https://adis.springer.com/drugs/800026356?userId=52029392&bpIds=3004037004&checksum=99ab04e748c9aac9409e181e4b2a531f64477e14-1617045529589-6f5f3f6cdd79b25efec96e89d07bbe99badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026547	Research programme: broad spectrum anticonvulsants - Johnson & Johnson			Yes			No development reported (Preclinical)	"Metabolic disorders, CNS disorders, Obesity, Migraine, Diabetes mellitus, Major depressive disorder, Epilepsy, Neuropathic pain"		Undefined mechanism	"Johnson & Johnson (Originator), Johnson & Johnson (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), A16 (Other Alimentary Tract and Metabolism Products), A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), N2C (Anti-Migraine Preparations), N3 (Anti-Epileptics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"A08 (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), A16A-X (Various alimentary tract and metabolism products), N02 (Analgesics), N02C (Antimigraine Preparations), N03A (Antiepileptics), N06A (Antidepressants), N07X (Other Nervous System Drugs)"	JNJ26990990			04/11/2017	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Diabetes, Epilepsy and Seizure Disorders, Metabolic Disorders, Neurological Disorders, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800026547?userId=52029392&bpIds=3004037004&checksum=363d3d365ec0d549c9ba6febe8ddd7435c33a436-1617045529591-f36955fbe04c94e0fb86f63a816f1c8bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029401	Research programme: pain therapeutics - Axxam						No development reported (Research)	Pain		"Bradykinin B1 receptor antagonists, Cannabinoid receptor CB2 agonists, Nav1.7 voltage-gated sodium channel inhibitors, Purinergic P2X7 receptor antagonists, TRPM8 protein inhibitors"	"Axxam (Originator), Newron Pharmaceuticals (Originator), Primm srl (Originator), University of Milan Bicocca (Originator), Axxam (Owner), Newron Pharmaceuticals (Owner), Primm srl (Owner), University of Milan Bicocca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	"BKR1 antagonist Axxam, CB2 agonist Axxam, Nav 1.7 blocker Axxam, TRPM8 blocker Axxam"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800029401?userId=52029392&bpIds=3004037004&checksum=d76f346977c3c552d0fe80831d7053e9af551fa7-1617045529592-9169fa1d5cc2aaa2dfb4b9538f38bb1ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028915	Research programme: bradykinin B1 receptor antagonists - Gedeon Richter						No development reported (Research)	Pain		Bradykinin B1 receptor antagonists	"Gedeon Richter (Originator), Gedeon Richter (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800028915?userId=52029392&bpIds=3004037004&checksum=b50bef0e48b501f6b4cf162b68be791621c700d2-1617045529593-bd18fd2c96fba5fd1590d92579d869c9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030923	Research programme: naloxegol/opioid analgesic combination - AstraZeneca/Nektar			Yes			No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"Nektar Therapeutics (Originator), Nektar Therapeutics (Owner), AstraZeneca (Licensee)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	"Naloxegol/opioid, NKTR118/opioid Nektar Therapeutics/AstraZeneca, NKTR119"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800030923?userId=52029392&bpIds=3004037004&checksum=0548620165853c1558f78137cd7d3e515d1833f5-1617045529593-a1cfbc2f9944490309963990e7d256f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041909	Morphine transdermal - Teika Pharmaceutical			No			No development reported (Clinical)	Pain		Opioid mu receptor agonists	"Teika Pharmaceutical (Originator), Teika Pharmaceutical (Owner), National University Corporation Hamamatsu University School of Medicine, Japan (Collaborator)"		Transdermal				N2A (Narcotics)	N02A-A01 (Morphine)				04/11/2017	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800041909?userId=52029392&bpIds=3004037004&checksum=bf95f8a1fb54e56495c4ca0050339252998ef33e-1617045529595-9924b9af2d1f0c393bb2c774cb2eb8a2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041515	GIC 1002			Yes			No development reported (I)	Procedural pain		Opioid receptor agonists	"gIcare Pharma (Originator), Inversago Pharma (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"GIC1002, NonH2S releasing tosylate salt gIcare Pharma"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800041515?userId=52029392&bpIds=3004037004&checksum=c85dd2c121e53fb1b1b3700482171cc4a62e3d5f-1617045529595-c7c727e7bce6e263522eed23caf15868badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026941	Research programme: opioid prodrugs - NeurogesX						No development reported (Preclinical)	Pain		Opioid receptor agonists	"NeurogesX (Originator), NeurogesX (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	NGX6052			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800026941?userId=52029392&bpIds=3004037004&checksum=93f83fff2170d18bf21d0df6f19310584f795fd6-1617045529596-dcd38772dd47c6e425fd4fa5d163c2cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034147	Research programme: controlled-release pain therapeutics - Avadel Pharmaceuticals			No			No development reported (Preclinical)	Pain		Opioid receptor agonists	"Flamel Technologies (Originator), Avadel Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	Trigger Lock therapeutics Avadel Pharmaceuticals			04/11/2017	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800034147?userId=52029392&bpIds=3004037004&checksum=06cb50821ba3d655a66670f0cf7bbb23ea895ff3-1617045529597-e9640fe8663839a0994db88279201099badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029365	Research programme: buprenorphine depot - Encore Therapeutics	52485-79-7	"6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (5alpha,7alpha(S))-"				No development reported (Preclinical)	"Opioid-related disorders, Pain"	C29 H41 N O4	"Opioid delta receptor antagonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Encore Therapeutics (Originator), Encore Therapeutics (Owner)"		SC				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02A-E01 (Buprenorphine), N07B-C01 (Buprenorphine)"	ETI311			04/11/2017	"Drug Withdrawal, Pain"		Encore Therapeutics |  | Unspecified | World | 26 Sep 2011		no		no							https://adis.springer.com/drugs/800029365?userId=52029392&bpIds=3004037004&checksum=b88bd83f92b1854f04620deee8d3e3a32f125a02-1617045529598-d65bdf5e42cb0199c70c68af684c6db4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039038	AMG 333			Yes			No development reported (I)	Migraine			"Amgen (Originator), Amgen (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	AMG333			04/11/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800039038?userId=52029392&bpIds=3004037004&checksum=415273e60e19a42a4d995471daec157bfd3fc771-1617045529599-f8cb00730584b03f321c3dfa170eadd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024966	Sumatriptan transdermal - Teva	103628-46-2	3-(2-(Dimethylamino)ethyl)-<EM>N</EM>-methyl-1<EM>H</EM>-indole-5-methanesulfonamide	No			Marketed	Migraine	C14 H21 N3 O2 S	Serotonin 1D receptor agonists	"NuPathe (Originator), Teva Pharmaceutical Industries (Owner)"		Transdermal			Application site reactions	N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"NP 101, Sumatriptan iontophoretic transdermal patch, Sumatriptan iontophoretic transdermal system, Zecuity, Zelrix"			04/11/2017	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			Zecuity	no		no				"Adenosine monophosphate, cytokine inducible SH2-containing protein, PGE2, Prostacyclin, Valproic acid glucuronide"		CRP	https://adis.springer.com/drugs/800024966?userId=52029392&bpIds=3004037004&checksum=5cfe57eb12b08decad11637477f1feb20583cda4-1617045529600-6e4bfc7509c42bf73d27f469e12583f7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033774	Research programme: analgesics - Orion						No development reported (Research)	Neuropathic pain		Undefined mechanism	"Orion (Originator), Orion (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800033774?userId=52029392&bpIds=3004037004&checksum=1da3ee8f52f6a1a4207d150835b22b61427241a0-1617045529601-c9da96ed1727719b5cd0823c6bfc62f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026984	Research programme: calcitonin gene related peptide receptor antagonists - Bristol-Myers Squibb			Yes			No development reported (Preclinical)	Migraine		Calcitonin gene-related peptide receptor antagonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		"Intranasal, SC"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	BMS694153			04/11/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800026984?userId=52029392&bpIds=3004037004&checksum=33b299659f83a3612a298c7e54a4eb70bc557abb-1617045529602-720b07bfd91be8965ef15f429c4a8cd3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023507	Research programme: transported prodrugs - Arbor Pharmaceuticals			No			Suspended (Preclinical)	"Fragile X syndrome, Parkinson's disease, Migraine, Nausea and vomiting"		"GABA receptor agonists, GABA A receptor agonists"	"XenoPort (Originator), Arbor Pharmaceuticals (Owner)"		PO				"A4 (Antiemetics and Antinauseants), N1A (Anaesthetics, General), N2C (Anti-Migraine Preparations), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs)"	"A04 (Antiemetics and Antinauseants), N01A-X10 (Propofol), N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N07X-X (Other nervous system drugs)"	"Acamprosate prodrug, Propofol prodrug Arbor Pharmaceuticals, XP 20925"			04/11/2017	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems, Neurological Disorders, Parkinson's Disease and Movement Disorders"		Arbor Pharmaceuticals |  | Preclinical |  | 24 Jul 2010		no		no							https://adis.springer.com/drugs/800023507?userId=52029392&bpIds=3004037004&checksum=71807ed4ed37763bafdb1795c9c2fa9d242bfc26-1617045529603-1626ebbf83cbfb01d4033fdea01f50b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039864	Prostaglandin E EP4 receptor antagonist - Eli Lilly and Company			Yes			No development reported (I)	"Osteoarthritis, Musculoskeletal pain"		Prostaglandin E EP4 receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	EP4R Antagonist Eli Lilly and Company			04/11/2017	"Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800039864?userId=52029392&bpIds=3004037004&checksum=3c6413b6e64d1ea2b375e3a7d02b6e94dadbfafe-1617045529604-01d5e5da29d97153cfc55406bc8d4967badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022264	Research programme: serotonin reuptake inhibitors - Sosei R&D						No development reported (Preclinical)	"Pain, Back pain"		"Adrenergic receptor antagonists, Serotonin uptake inhibitors"	"Sosei R&D (Originator), Sosei R&D (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"ARAK0029, ARAK0051, SD 726"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800022264?userId=52029392&bpIds=3004037004&checksum=2bef1c3b1a2493817d094946cfdc0e1dff7ee1a0-1617045529605-28ace10923497acbce24bcf90b5313f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028122	Research programme: fatty acid amide hydrolase inhibitors - Johnson & Johnson		"4-(Phenyl-1,2,4-thiadiazol-5-yl)piperazine-1-carboxylic acid phenylamide"	Yes			No development reported (Preclinical)	Neuropathic pain	C19 H19 N5 O S	Fatty acid amide hydrolase inhibitors	"Johnson & Johnson (Originator), Johnson & Johnson (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"JNJ 28833155, JNJ1661010"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800028122?userId=52029392&bpIds=3004037004&checksum=0c6c8c10f7a2c915921878bc83d7999bd9388b9a-1617045529606-a3ed8770fbdb7c19ff8b6d72e1cae0e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025854	SAR 115740						No development reported (I)	"Inflammatory pain, Neuropathic pain"		TRPV cation channel antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	SAR115740			04/11/2017	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800025854?userId=52029392&bpIds=3004037004&checksum=58706ca2263d95fcd03b0c5ae07012b040c03c22-1617045529607-caa82f90a68eaae9f75f7a64d3ebb029badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040947	IP 114			Yes			No development reported (Clinical)	Pain			"InnoPharma Inc (Originator), InnoPharma Inc (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IP114			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800040947?userId=52029392&bpIds=3004037004&checksum=55b4a1176869a6fcf1db41d5a679c369f8199925-1617045529608-6e4b97d4fdfca87418973c0ef3f143f3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027751	Research programme: pain therapeutics - ImmuPharma			Yes			No development reported (Preclinical)	"Pain, Postoperative pain, Cancer pain"		Opioid receptor agonists	"ImmuPharma (Originator), ImmuPharma (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	IPP102199			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800027751?userId=52029392&bpIds=3004037004&checksum=89349902a18f419e2902da1609d613034e81a5ad-1617045529608-6f3124bab3a983cbb49c224e7faff6e2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023967	Research programme: pain therapeutics - Apeiron Biologics						No development reported (Preclinical)	Pain		Kv channel-interacting protein modulators	"Apeiron Biologics (Originator), Apeiron Biologics (Owner), Evotec SE (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	APN 601			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800023967?userId=52029392&bpIds=3004037004&checksum=852ff7e1bfab3366085ee7f9ab593a325ac9174e-1617045529609-882301430dead9518c34c6d22524d591badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026854	Research programme: analgesics - Labopharm						No development reported (Preclinical)	Pain		"Opioid receptor agonists, Prostaglandin receptor antagonists"	"Labopharm (Originator), Endo International (Owner)"		PO				N2A (Narcotics)	N02 (Analgesics)	DDS06A			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800026854?userId=52029392&bpIds=3004037004&checksum=1b7720c3069b2ea4188b25a4678644b8a92702ba-1617045529610-b450c18dabb87cd866af7f82bb690b2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028038	Research programme: microsomal prostaglandin E synthase-1 inhibitors - Angelini						No development reported (Preclinical)	"Inflammatory pain, Cancer"		Prostaglandin-E synthase inhibitors	"Angelini Group (Originator), Angelini Group (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	"AF3485, Eicosanoid inhibitors, Eicosanoid modulators"			04/11/2017	"Cancer, Inflammation"				no		no							https://adis.springer.com/drugs/800028038?userId=52029392&bpIds=3004037004&checksum=e617273842663240aa4aa6ef89f9b3a7f523c1cf-1617045529611-b1300dacd5694efa7b227866816009abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022756	Research programme: bradykinin-1 receptor inhibitors - Grunenthal						No development reported (Preclinical)	"Inflammation, Pain"		Bradykinin B1 receptor antagonists	"Grunenthal (Originator), Grunenthal (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				04/11/2017	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800022756?userId=52029392&bpIds=3004037004&checksum=e684c70fcab87e1b721e3286b19ec8a51d6ed96d-1617045529612-2e5d611ea6b9a6aa56af26e1d7169937badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023777	Research programme: pain therapeutics - Purdue Pharma/Shionogi						No development reported (Preclinical)	Pain		Undefined mechanism	"Purdue Pharma (Originator), Shionogi (Originator), Purdue Pharma (Owner), Shionogi (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800023777?userId=52029392&bpIds=3004037004&checksum=234f07b07f4d36ac46c070123927f71e3bef7278-1617045529612-0d6540316ff0037072915211a6bc40b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018011	MCP 201						No development reported (I)	Pain		"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Mount Cook Biosciences (Originator), Mt Cook Pharma (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	DPI125			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800018011?userId=52029392&bpIds=3004037004&checksum=8ee0c55a425563f3b5465661a9b2820640e5a29f-1617045529613-210c9f2f5110e5a9f7a17915020aa15dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036018	Research programme: pain therapeutics - Galleon Pharmaceuticals						No development reported (Preclinical)	Postoperative pain			"Galleon Pharmaceuticals (Originator), Galleon Pharmaceuticals (Owner)"		"PO, IV"				N2 (Analgesics)	N02 (Analgesics)	"GAL044, GAL044 IV, GAL044 oral (PO)"			04/11/2017	Pain		Galleon Pharmaceuticals | Pain | Preclinical |  | 09 May 2012		no		no							https://adis.springer.com/drugs/800036018?userId=52029392&bpIds=3004037004&checksum=98ba4374b052ec1aac93f2d930aec0a1284f2cbc-1617045529614-4fd851abca92bd7dcf2f10961fdf2280badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019360	Research programme: anti-TrkA monoclonal antibodies - Glenmark Pharmaceuticals			Yes			No development reported (Preclinical)	Pain		TrkA receptor antagonists	"Lay Line Genomics (Originator), Lay Line Genomics (Owner), Glenmark Pharmaceuticals S.A. (Licensee)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800019360?userId=52029392&bpIds=3004037004&checksum=ac2842b2fb4434168663b4df2d7f3d0c433e62a9-1617045529615-79b8af48580dc098bd25f90ea23be8bfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030206	Research programme: paracetamol prodrugs - NeurogesX						No development reported (Preclinical)	Pain		Prostaglandin receptor antagonists	"NeurogesX (Originator), NeurogesX (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"NGX1576, NGX5752, NGX9674"			04/11/2017	Pain		NeurogesX |  | Preclinical |  | 30 May 2011		no		no							https://adis.springer.com/drugs/800030206?userId=52029392&bpIds=3004037004&checksum=53dfb29e667275230fafcdf9e9fa0ec223f2dd0d-1617045529616-f17c9b54b881ebdb88f0d88abdd56a7ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028642	Research programme: pain therapeutics - Rottapharm			Yes			No development reported (Research)	Pain		Nav1.8 voltage-gated sodium channel inhibitors	"Rottapharm Madaus (Originator), Rottapharm Madaus (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CR 4892			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800028642?userId=52029392&bpIds=3004037004&checksum=d470855f413f5807638d161a4ed0f9c4a7edad93-1617045529617-5b11f2518ca796f963435063272c7ec2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023047	Research programme: alkaloid-conjugate analgesics - Chimeracom						No development reported (Preclinical)	Pain		"Neurokinin 1 receptor agonists, Opioid mu receptor agonists"	"Chimeracom LLC (Originator), Chimeracom LLC (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Chimeric hybrid molecules, Hybrid chimera"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800023047?userId=52029392&bpIds=3004037004&checksum=8cc1bd0b1aed805f76564819f9b012050a166d19-1617045529618-225706e76b2c34d2a59988cb45f027a8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024355	Research programme: pain therapeutics - NAEJA						No development reported (Preclinical)	Pain		Undefined mechanism	"NAEJA Pharmaceutical (Originator), NAEJA Pharmaceutical (Owner), AstraZeneca (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800024355?userId=52029392&bpIds=3004037004&checksum=83f969b410aeb53981fe5e781c6c65d7cea09408-1617045529618-a77de2a80aea26d31323385911ff5785badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026896	Research programme: NMDA receptor antagonists - Gedeon Richter						No development reported (Preclinical)	"Pain, Neuropathic pain"		NMDA receptor antagonists	"Gedeon Richter (Originator), Gedeon Richter (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	NmethylDaspartate receptor agonists Gedeon Richter			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800026896?userId=52029392&bpIds=3004037004&checksum=1e7428e35d31f334e33076fcff097d3566313460-1617045529619-a5ab91771f200e97f2fafa33ddc77eb6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028037	Research programme: serotonin 4 receptor antagonists - Angelini						No development reported (Preclinical)	Neuropathic pain		Serotonin 4 receptor antagonists	"Angelini Group (Originator), Angelini Group (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AF3473			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800028037?userId=52029392&bpIds=3004037004&checksum=d83342d8fa01743fdf79004188c300d493031b03-1617045529620-38dce89848d6dd5d401f3010c5f69520badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039102	Research programme: pain therapeutics - Akron Molecules			No			No development reported (Preclinical)	Pain		Undefined mechanism	"Akron Molecules (Originator), Akron Molecules (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AKR210			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800039102?userId=52029392&bpIds=3004037004&checksum=ede3c60b94d8a1e0b5f3d6df737401a2ab8aedf0-1617045529621-0035919b14ead01ccfe5584e822c6c9abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020467	Research programme: cysteine protease inhibitors - Biofrontera AG						No development reported (Preclinical)	Neuropathic pain		Cysteine endopeptidase inhibitors	"Biofrontera AG (Originator), Biofrontera AG (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800020467?userId=52029392&bpIds=3004037004&checksum=571ae7b1328f0b19f1c9a4849fd54ebaa6793dcc-1617045529621-31adbfb98aed8b754a23738bf8e28ebebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020469	Research programme: bradykinin B1/2 antagonists - Biofrontera AG						No development reported (Preclinical)	Pain		"Bradykinin B1 receptor antagonists, Bradykinin B2 receptor antagonists"	"Biofrontera AG (Originator), Biofrontera AG (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800020469?userId=52029392&bpIds=3004037004&checksum=fd5e320e94d7666e5411496f49f2b32bfdc7bc6d-1617045529622-8753cb2d7bfac469b1a9ad888b9cb293badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019002	Research programme: glutamate carboxypeptidase II inhibitors - Eisai			Yes			No development reported (Preclinical)	"Eye disorders, Pain, Neurological disorders"		Glutamate carboxypeptidase II inhibitors	"Johns Hopkins Brain Science Institute (Originator), MGI GP (Originator), Eisai Co Ltd (Owner), Santen Pharmaceutical (Licensee)"		unspecified				"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs), S1X (Other Ophthalmologicals)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"				04/11/2017	"Eye Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800019002?userId=52029392&bpIds=3004037004&checksum=86ec13ed90ff7924aaa147e54511946a425a0fa2-1617045529623-0d2ecec14f3254b4bb7ec2527a2fa689badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025082	Research programme: bradykinin B1 receptor antagonists - Amgen		"2-[(<EM>R</EM>)-3-Oxo-1-tosyl-1,2,3,4-tetrahydropyrazin-2-yl]-<EM>N</EM>-[(<EM>R</EM>)-6-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]acetamide"				No development reported (Preclinical)	"Pain, Inflammation"	C29 H36 N4 O4 S	Bradykinin B1 receptor antagonists	"Amgen (Originator), Amgen (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				04/11/2017	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800025082?userId=52029392&bpIds=3004037004&checksum=86a60cea17b8fad5386b7cf3fb767c3c7840f531-1617045529624-19ce3e8ee54308b61c1a047f0d43e272badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018279	Research programme: calcium channel antagonists - Ajinomoto		"4-(3-Chlorophenyl)-6-(dimethoxymethyl)-2-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid 5-[3-phenyl-2(<EM>E</EM>)-propenyl] monoester"				No development reported (Preclinical)	Neuropathic pain	C26 H26 Cl N O6	Calcium channel antagonists	"Ajinomoto (Originator), Ajinomoto (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"AGS 1164, APJ 2708, APJ 2929"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800018279?userId=52029392&bpIds=3004037004&checksum=b9f05fa42b4a49eee419301e0a77765504cafd74-1617045529625-124a08fac43cf4a6b90ad50079172467badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016392	Research programme: vanilloid receptor antagonists - Ligand/Merck		<EM>N</EM>-(4-(Trifluoromethyl)phenyl)-7-(3(trifluoromethyl)pyridin-2-yl)quinazolin-4-amine				No development reported (Preclinical)	"Pain, Urinary incontinence"	C21 H12 F6 N4	TRPV cation channel antagonists	"Merck & Co (Originator), Neurogen Corporation (Originator), Ligand Pharmaceuticals (Owner), Merck & Co (Owner)"		PO				"G4D4 (Urinary incontinence products), N2B (Non-Narcotics and Anti-Pyretics)"	"G04B (Urologicals), N02B (Other Analgesics and Antipyretics)"	"NGD 8695, NRGN16"			04/11/2017	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800016392?userId=52029392&bpIds=3004037004&checksum=57c56b0817fd722b7281824b52821cb2cc40ae20-1617045529626-72d5ee16abc8c6460e61f53e9e6d3596badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033002	Diclofenac injection - IBSA	15307-79-6	"2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid monosodium salt"	No			Marketed	"Back pain, Acute pain, Musculoskeletal pain, Postoperative pain, Inflammatory pain, Renal colic, Pain"	C14 H10 Cl2 N Na O2	Cyclooxygenase inhibitors	"IBSA (Originator), IBSA (Owner)"		"SC, IM, IV"				"M1A2 (Anti-rheumatics, non-steroidal combination), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B55 (Diclofenac, combinations), N02B (Other Analgesics and Antipyretics)"	"Akis, Diclofenac HPBCD, Dicloin"			04/11/2017	"Drug Delivery Systems, Genitourinary Disorders, Pain"			"Akis, Dicloin"	no		no							https://adis.springer.com/drugs/800033002?userId=52029392&bpIds=3004037004&checksum=51d276e5bc8c6ddf2f9949a48b9321cfd7d3b6bd-1617045529629-4a7c2d69ecec864bf615d7e4da016f35badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041740	GDC 0276			Yes			No development reported (I)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Xenon Pharmaceuticals (Originator), Xenon Pharmaceuticals (Owner), Genentech (Licensee)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"GDC0276, RG7893"			04/11/2017	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800041740?userId=52029392&bpIds=3004037004&checksum=7f50393a7b4199830a69966d002fce0f788adc6f-1617045529629-7591d3f09fe5b69e228438a092c735c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032410	Research programme: NSAIDs transdermal - Acrux						No development reported (Preclinical)	"Inflammation, Pain"		"Cyclooxygenase inhibitors, Lipoxygenase-cyclooxygenase inhibitors"	"Acrux (Originator), Acrux (Owner)"		Transdermal				"M2A (Topical Anti-rheumatics and Analgesics), N2 (Analgesics)"	"M02A-A10 (Ketoprofen), M02A-A13 (Ibuprofen), M02A-A15 (Diclofenac), N02 (Analgesics)"	"NSAID Metered Dose Transdermal System, NSAID transdermal system Acrux, NSAIDs Acrux, NSAIDs MDTS, Topical NSAIDs Acrux"			04/11/2017	"Drug Delivery Systems, Pain"		"Acrux | Inflammation, Pain | Preclinical |  | 12 Nov 2008"		no		no							https://adis.springer.com/drugs/800032410?userId=52029392&bpIds=3004037004&checksum=8de58b82c0944fe8b3e7c7027a02d92f174836e7-1617045529630-52a61afe326e018c9c67bc9890562e1bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035501	Nitric oxide topical - NOLabs	10102-43-9	Nitric oxide	No			No development reported (Clinical)	Diabetic neuropathies	N O	Nitric oxide stimulants	"NOLabs AB (Originator), NOLabs AB (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"Nitric oxidereleasing patch NOLabs, NitroSense PA6, NitroSense patch NOLabs"			04/11/2017	"Diabetes, Drug Delivery Systems"				no		no		"T-box 1, tumor protein, translationally-controlled 1"	"hemoglobin subunit gamma 2, Prostacyclin, tumor protein, translationally-controlled 1"	"8-oxo-7-hydrodeoxyguanosine, BNP, choroideremia (Rab escort protein 1), chromodomain helicase DNA binding protein 7, CKB, CKM, CRP, Endothelin 1, Haptoglobin, hemoglobin subunit gamma 2, Hemopexin, IFN-gamma, IL10, IL6, IL8, Inosine, Insulin, Nitric Oxide, PGE2, Prostacyclin, S100B, TNF-alpha, troponin I, cardiac, Troponin T, cardiac, tumor protein, translationally-controlled 1, VEGF-A, VEGF-C"		"Creatinine, IL12A, IL12B, IL2, Thrombin"	https://adis.springer.com/drugs/800035501?userId=52029392&bpIds=3004037004&checksum=0e482e12a5f9bcf6bff361ea3e050fe46b59fbea-1617045529632-4eebf5d4ea6aef83059880bf3b5a65f7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025889	Research programme: norepinephrine reuptake inhibitors - Pfizer		"7-Fluoro-1-[(1<EM>R</EM>,2<EM>S</EM>)-1-(3-fluorophenyl)-2-hydroxy-3-(methylamino)propyl]-3,3-dimethylindolin-2-one"				No development reported (Preclinical)	"Major depressive disorder, Anxiety disorders, Vasomotor symptoms, Attention-deficit hyperactivity disorder, Pain"	C20 H22 F2 N2 O2	Adrenergic receptor antagonists	"Wyeth (Originator), Pfizer (Owner)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants)"	"N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants), N06B (Psychostimulants, agents used for ADHD and nootropics)"	"NRI022, NRI193, WAY253203, WAY256805, WAY260022, WAY315193, WAY318068"			04/11/2017	"Affective Disorders, Anxiety Disorders, Pain, Women's Health"				no		no							https://adis.springer.com/drugs/800025889?userId=52029392&bpIds=3004037004&checksum=f69d389f247d10a122625475dfc9ef73583f9601-1617045529633-068e58927b6593a79381f0e7369b97cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029465	Research programme: CNS and neurological disorder therapeutics - ACADIA						No development reported (Preclinical)	"Neuropathic pain, Parkinson's disease, Multiple sclerosis"		"Estrogen receptor beta agonists, Dopamine modulators, Nuclear receptor subfamily 4 group A member 2 agonists, Retinoid X receptor agonists, Selective estrogen receptor beta agonists"	"ACADIA Pharmaceuticals (Originator), ACADIA Pharmaceuticals (Owner), University of California at Los Angeles (Collaborator)"		unspecified				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs)"	"AC131, AC186, ER programme ACADIA, ERb programme ACADIA, ERbeta programme ACADIA, Estrogen receptor beta agonists ACADIA, Nurr1 programme ACADIA, Nurr1retinoid X receptor agonists ACADIA, Nurr1RXR agonists ACADIA"			04/11/2017	"Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800029465?userId=52029392&bpIds=3004037004&checksum=3eda29257d2fb4b383cc8f3f8bac41470991147e-1617045529634-ec985cc6c34368b9c9bcb104df712509badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030161	Research programme: therapeutic agents - AstraZeneca/Jubilant Biosys						No development reported (Research)	"Cardiovascular disorders, Pain, Neurological disorders, Psychiatric disorders, Metabolic disorders, Cognition disorders"		Undefined mechanism	"Jubilant Biosys (Originator), AstraZeneca (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), C6A (Other Cardiovascular Products), N2 (Analgesics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N6D (Nootropics), N7X (All other CNS drugs)"	"A16A (Other Alimentary Tract and Metabolism Products), C (Cardiovascular System), N02 (Analgesics), N05A (Antipsychotics), N06A (Antidepressants), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"				04/11/2017	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Metabolic Disorders, Neurological Disorders, Pain, Psychotic Disorders, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800030161?userId=52029392&bpIds=3004037004&checksum=47c048f1dba67eb9ccf05bbf6b79a901ab2c0d71-1617045529635-1f1a0c4a76851d4e4f5566228ad10863badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016482	HF 0299						No development reported (I)	"Neuropathic pain, Osteoporosis"		Insulin-like growth factor I stimulants	"LTT Institute (Originator), LTT Institute (Owner), Newron Pharmaceuticals (Licensee)"		unspecified				"M5B (Bone Calcium Regulators), N2 (Analgesics)"	"M05B-X (Other drugs affecting bone structure and mineralization), N02 (Analgesics)"	HF0299			04/11/2017	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800016482?userId=52029392&bpIds=3004037004&checksum=7165e76e6f987b2bb2f96e50f66fbc833e6e6fb3-1617045529636-a1c1e1fea67e4025c5f94a293e5b1230badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026952	Research programme: nerve-targeted gene therapy - Periphagen			No			No development reported (Preclinical)	"Erectile dysfunction, Neuropathic pain, Glioma, Peripheral nervous system diseases"		"Nerve growth factor stimulants, GABA modulators, Glutamate decarboxylase stimulants, Opioid receptor agonists"	"Diamyd Medical (Originator), Periphagen Holdings (Owner), CNRS (Technology Provider), University of Pittsburgh (Technology Provider), University of Michigan (Collaborator)"		"Parenteral, Intradermal"				"G4E (Erectile Dysfunction Products), L1 (Antineoplastics), N2 (Analgesics), N7 (Other CNS Drugs)"	"G04B-E (Drugs used in erectile dysfunction), L01 (Antineoplastic Agents), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"NC 3, NE 2, NE2 Endomorphin, NG 2, NG2 GAD, NN1 Neurotrophin"			04/11/2017	"Cancer, Men's Health, Neurological Disorders, Pain"		Periphagen Holdings |  | Preclinical | World | 28 Oct 2010		no		no							https://adis.springer.com/drugs/800026952?userId=52029392&bpIds=3004037004&checksum=9cec2d597dc5b4efdde7c7401befd80ab3809ffe-1617045529637-d3f2a3d5c9ac9a916d67eb1a0bc73e4ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021292	Research programme: CCR2 receptor antagonists - EPIX						No development reported (Preclinical)	Pain		CCR2 receptor antagonists	"EPIX Pharmaceuticals (Originator), Unknown (Owner)"		PO				"A10 (Drugs Used in Diabetes), C (Cardiovascular System), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs)"	"A10 (Drugs Used in Diabetes), C (Cardiovascular System), M01 (Antiinflammatory and Antirheumatic Products), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics), N07X (Other Nervous System Drugs)"	EPX102216			04/11/2017	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800021292?userId=52029392&bpIds=3004037004&checksum=5dd80eac97c5c1a3bc566aed8ba4a5380fdf85a0-1617045529638-5c9b6f7b7594e787b5a18e48180f6819badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015324	Research programme: purinergic P2 receptor antagonists - Merck		"5-(5-Iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine"	Yes			No development reported (0)	"Pain, Overactive bladder"	C14 H17 I N4 O2	Purinergic P2X3 receptor antagonists	"Roche (Originator), Roche (Owner), Merck & Co (Licensee)"		PO				"G4D4 (Urinary incontinence products), N2 (Analgesics)"	"G04B (Urologicals), N02 (Analgesics)"	"AF220, AF221, AF742, RO4"			04/11/2017	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015324?userId=52029392&bpIds=3004037004&checksum=10fad3538a06f8ade4f865f635f64578ddd6a067-1617045529639-c9a8eb78b4257faeb0ac184f3e47e99abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024134	Research programme: pain therapeutics - AstraZeneca		"[5-(Ethylsulfonyl)-2-(tetrahydro-2<EM>H</EM>-pyran-4-yl)-2,3,4,5-tetrahydro-1<EM>H</EM>-pyrido[4,3-<EM>b</EM>]indol-8-yl](4-methylpiperidin-1-yl)methanone"				No development reported (Preclinical)	"Neuropathic pain, Inflammatory pain, Gastro-oesophageal reflux"	C25 H35 N3 O4 S	"Nav1.7 voltage-gated sodium channel inhibitors, TRPV1 receptor antagonists, Bradykinin B2 receptor antagonists, Cannabinoid receptor CB1 agonists, Sodium channel antagonists"	"AstraZeneca (Originator), AstraZeneca (Owner)"		"IV, unspecified"				"A2B (Antiulcerants), N2 (Analgesics)"	"A02B (Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (GORD)), N02 (Analgesics)"	"AZ 09, AZ 11760788, AZ 12048189, AZ 12099548, AZ 1297442, AZ 599, AZD 7903, AZD 9335"			04/11/2017	"Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800024134?userId=52029392&bpIds=3004037004&checksum=32b82fa141ab6c3c7fc46c1fff2d8cf46fda6872-1617045529640-e661273aa5c0eaae5b900b5442a571d7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014988	Research programme: metabotropic glutamate receptor modulators - AstraZeneca			Yes			No development reported (Preclinical)	"Pain, Schizophrenia, Anxiety disorders, Substance-related disorders, Stroke, Epilepsy, CNS disorders"		"Metabotropic glutamate receptor modulators, Metabotropic glutamate receptor 5 modulators"	"AstraZeneca (Originator), NPS Pharmaceuticals (Originator), AstraZeneca (Owner), National Institute on Drug Abuse (Collaborator)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics), N5A (Antipsychotics), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N03A (Antiepileptics), N05A (Antipsychotics), N07B (Drugs Used In Addictive Disorders), N07X (Other Nervous System Drugs)"	"CPPZ, NPS 2398, NPS2390"			04/11/2017	"Anxiety Disorders, Drug Withdrawal, Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800014988?userId=52029392&bpIds=3004037004&checksum=6d3743f9d561e8ded024036018634a6eb286fad9-1617045529641-f2f651bbf981c8c6460142d12d455e0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018922	Research programme: P2X receptor antagonists - Abbvie						No development reported (Preclinical)	"Pain, Inflammation, Mood disorders"		Purinergic P2X7 receptor antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N06A (Antidepressants)"	A740003			04/11/2017	"Affective Disorders, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800018922?userId=52029392&bpIds=3004037004&checksum=e26b3ddd1f1e9580f9f874d275b001d7c85eb141-1617045529642-bfc65114bb96681b8c0b1b86cb63b4e0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023258	Research programme: transient receptor potential vanilloid 1 cation channel antagonists - AbbVie Laboratories						No development reported (Preclinical)	Pain		TRPV cation channel antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"A 889425, A425619, A780150, A784168, ABT443"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800023258?userId=52029392&bpIds=3004037004&checksum=1f54395a2c5eac8b51d4c8308d60ed5eacbbe774-1617045529643-985b1ea1caa93b980178c1ac1c169e7fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011004	"Research programme: KCNQ potassium channel agonists - Icagen, Inc."		"<EM>N</EM>-(6-Chloropyridin-3-yl)-3,4-difluorobenzamide"	Yes			No development reported (Preclinical)	"Neuropathic pain, Epilepsy"	C12 H7 Cl F2 N2 O	KCNQ potassium channel agonists	"Icagen (Originator), Icagen, Inc. (Owner)"		PO				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	"ICA27243, ICA69673"			04/11/2017	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800011004?userId=52029392&bpIds=3004037004&checksum=34b3f582ea5aaa1be52098b89dda70bc92fb5949-1617045529644-1aa8eb8c7a88fdcd67b71959c3942ba9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014395	"Research programme: ion channel modulators - Icagen, Inc."			Yes			No development reported (Preclinical)	"Inflammation, Pain, Neuropathic pain"		"Nav1.8 voltage-gated sodium channel inhibitors, TRPA1 protein inhibitors"	"Icagen (Originator), University of California at Los Angeles (Originator), Icagen, Inc. (Owner), University of London (Collaborator)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				04/11/2017	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800014395?userId=52029392&bpIds=3004037004&checksum=a7e9b5960097151eafbe6bf6259f7f9bb20848e9-1617045529645-3f731d821954577271db0f9e49849cbbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027168	Research programme: ion channel modulators - Lectus Therapeutics						No development reported (Preclinical)	"Urinary incontinence, Angina pectoris, Neuropathic pain, Multiple sclerosis"		"Ion channel modulators, N-type calcium channel modulators, Potassium channel modulators"	"Lectus Therapeutics (Originator), Lectus Therapeutics (Owner)"		"unspecified, PO"				"C1 (Cardiac Therapy), G4D4 (Urinary incontinence products), N2 (Analgesics), N7X (All other CNS drugs)"	"C01 (Cardiac Therapy), G04 (Urologicals), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"Cav2.2 ion channel modulator Lectus, voltagegated potassium channel modulators Lectus"			04/11/2017	"Genitourinary Disorders, Ischaemic Heart Disease, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027168?userId=52029392&bpIds=3004037004&checksum=f193eee0137050387b13d1c238735f0477e4c1bc-1617045529646-97cc192221d7de786587f70746d7c789badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023885	Research programme: neuroprotectants - Trophos		"(3r,3aR,5aS,6R,9aS,9bS)-3-[1(R),5-Dimethylhexyl]-6-(3-hydroxypropyl)-3a,6-dimethylperhydrocyclopenta[a]-naphthalen-7-one oxime"	Yes			No development reported (Preclinical)	"Neurological disorders, Huntington's disease, Reperfusion injury, Parkinson's disease, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Multiple sclerosis, Pain, Neuropathic pain"	C26 H47 N O2	Mitochondrial permeability transition pore modulators	"Trophos (Originator), Roche (Owner)"		unspecified				"C1 (Cardiac Therapy), M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"C01 (Cardiac Therapy), M09 (Other Drugs for Disorders of the Musculo-Skeletal System), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"	"Cholesteroloxime compounds Roche, TRO11592, TRO17416, TRO20021, TRO51644, TRO6391"			04/11/2017	"Ischaemic Heart Disease, Musculoskeletal Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800023885?userId=52029392&bpIds=3004037004&checksum=eb42660e3d77190866abc3464a6acbbc0a98266d-1617045529647-c2e6e8d87b566610b0dfa334de72e2a8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025244	Research programme: cannabinoid CB2 receptor agonists - AbbVie		"[1-(2-Morpholinoethyl)-1<EM>H</EM>-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 4-methylbenzenesulfonate"				No development reported (Preclinical)	Pain	C22 H34 N2 O2 . C7 H8 O3 S	Cannabinoid receptor CB2 agonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	A796260			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800025244?userId=52029392&bpIds=3004037004&checksum=db123f4cc6b8003a775e17868589e407f0ff126d-1617045529648-35763eb58fb65775fa8ed9ab2ff4eb36badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017677	Research programme: P2 receptor modulators - Inspire Pharmaceuticals		5'-<EM>O</EM>-(Carboxy-5-methoxyphenyl)-N<SUP>6</SUP> -(N-ethylcarbamoyl)-2' 3'-<EM>O</EM>-[1(<EM>S</EM>)-(4-fluorophenyl)methylidene]-adenosine				No development reported (Preclinical)	"Pain, Thrombosis"	C28H27FN6O8	Purinergic P2 receptor modulators	"Inspire Pharmaceuticals (Originator), Inspire Pharmaceuticals (Owner)"		unspecified				"B1C (Platelet Aggregation Inhibitors), N2 (Analgesics)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), N02 (Analgesics)"	"INS 117284, INS 48506, INS 48821, INS 48824, NonP2Y2 receptor modulators Inspire, P2X3 receptor antagonists Inspire, P2Y12 receptor antagonists Inspire"			04/11/2017	"Pain, Thromboses"				no		no							https://adis.springer.com/drugs/800017677?userId=52029392&bpIds=3004037004&checksum=158408e26e764bc995ab65de77166bd85cd16edb-1617045529649-cbe496691283ccf0f2e7147bf64e2f53badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028127	Research programme: NR2B NMDA receptor antagonists - Merck & Co						No development reported (Preclinical)	"Neuropathic pain, Parkinson's disease"		NR2B N-Methyl-D-Aspartate antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				"N2 (Analgesics), N4 (Anti-Parkinson Drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs)"				04/11/2017	"Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800028127?userId=52029392&bpIds=3004037004&checksum=eba5c9ad3b9b2b400902063eb086a8485d01d217-1617045529650-140a9a343cfe6d62577f1025b645d369badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024127	Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics			Yes			No development reported (Preclinical)	"Inflammatory bowel diseases, Irritable bowel syndrome"		Immunomodulators	"Antibe Therapeutics (Originator), Antibe Therapeutics (Owner), Knight Therapeutics (Market Licensee)"		unspecified				"A3 (Functional Gastro-Intestinal Disorder Drugs), A7E (Intestinal Anti-Inflammatory Agents), B1C1 (Cyclo-oxygenase inhibitor platelet aggregation inhibitors), N2 (Analgesics)"	"A03 (Drugs for Functional Gastrointestinal Disorders), A07E (Intestinal Antiinflammatory Agents), B01A-C (Platelet aggregation inhibitors excl. heparin), N02 (Analgesics)"	"Aspirin derivative Antibe Therapeutics, ATB282, ATB284, ATB427, ATB428, ATB429"			04/11/2017	"Digestive System Disorders, Inflammatory Bowel Disorders"		Antibe Therapeutics |  | Unspecified |  | 20 Jul 2015		no		no							https://adis.springer.com/drugs/800024127?userId=52029392&bpIds=3004037004&checksum=85b5370bcc3e0b7d7d842458495c2c4bcea57715-1617045529651-dff16e908d6d50eef749508efd0d1714badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026096	Research programme: voltage-gated sodium channel inhibitors - Merck		"1-[2',5'-Bis(trifluoromethyl)biphenyl-3-yl]-1<EM>H</EM>-pyrazole-3,5-dicarboxamide"				No development reported (Preclinical)	Neuropathic pain	C19 12 F6 N4 O2	Sodium channel antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800026096?userId=52029392&bpIds=3004037004&checksum=8e2ba5ea9da003eafb8f39797a256a3bf15d4658-1617045529652-1ce71e810da451c6e19f0fc85dfb4d20badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037945	Research programme: sodium channel blockers - Biogen			Yes			No development reported (Preclinical)	"Pain, Epilepsy"		Nav1.7 voltage-gated sodium channel inhibitors	"GlaxoSmithKline (Originator), Biogen (Owner), Selcia (Technology Provider)"		PO				"N2 (Analgesics), N3 (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	"CNV 1061436, CNV3000164, CNV3000223, Nav 1.7 blockers Biogen"			04/11/2017	"Epilepsy and Seizure Disorders, Pain"		Convergence Pharmaceuticals |  | Unspecified |  | 13 Jan 2014		no		no							https://adis.springer.com/drugs/800037945?userId=52029392&bpIds=3004037004&checksum=5a96ca3aa77ebe8b087e544781e498ea2502b2eb-1617045529652-1d73d91f9d856d599e551f57221c4874badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027481	Research programme: CNS disease therapeutics - Bristol-Myers Squibb			Yes			No development reported (Preclinical)	"Pain, Major depressive disorder, Cerebral ischaemia"		"NR2B N-Methyl-D-Aspartate antagonists, NR2B N-Methyl D-Aspartate receptor modulators"	"NeurOp (Originator), Bristol-Myers Squibb (Owner), Emory University (Technology Provider)"		"Parenteral, unspecified"				"N2 (Analgesics), N6A9 (Antidepressants, all others), N7 (Other CNS Drugs)"	"N02 (Analgesics), N06A (Antidepressants), N07 (Other Nervous System Drugs)"	"Disease activated CNS therapeutics, pHactivated CNS therapeutics"			04/11/2017	"Affective Disorders, Neurological Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800027481?userId=52029392&bpIds=3004037004&checksum=edead9c752ed10d2f1e7aad1b63f95bf2a270dca-1617045529653-53a690dda492506439eed63021c34d50badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011117	SCP 1		"1, 2-Benzisothiazol-3(2<EM>H</EM>)-one, 1, 1-dioxide, 2-[<EM>N</EM>-(4-hydroxyphenyl)aminocarbonyl]methyl-,"				No development reported (I)	Pain	C15 H12 N2 O5 S	Undefined mechanism	"St. Charles Pharmaceuticals (Originator), St. Charles Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800011117?userId=52029392&bpIds=3004037004&checksum=63fedf5f918a370c41a0be71c474e558f46b0434-1617045529654-4ce08858b919de44e3dd70cd3493b18dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025235	Research programme: bradykinin B1 receptor antagonists - Elan		"7-Chloro-2-[4-[9-(pyridin-4-yl)-3,9-diazaspiro[5.5]undecane-3-carbonyl]phenyl]isoindolin-1-one"				No development reported (Preclinical)	Pain	C29 H29 Cl N4 O2	Bradykinin B1 receptor antagonists	"Elan Pharmaceuticals (Originator), Elan Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Benzamide B1 receptor antagonists Elan, ELN 441958"			04/11/2017	Pain				no		no							https://adis.springer.com/drugs/800025235?userId=52029392&bpIds=3004037004&checksum=497caa2af828ed78889460f410da5f2f424a98c6-1617045529655-43bfa9cbfc5594aac85265e3d1c01364badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021451	Research programme: transient receptor potential channel inhibitors - Johnson & Johnson		"<EM>N</EM>7-[3-Chloro-4-(trifluoromethyl)phenyl]-<EM>N</EM>2-(2,6-dichlorophenyl)thiazolo[5,4-<EM>d</EM>]pyrimidine-2,7-diamine"				No development reported (Preclinical)	"Cough, Pain"	C18 H9 Cl3 F3 N5 S	"TRPV1 receptor antagonists, TRPM8 protein inhibitors"	"Johnson & Johnson (Originator), Johnson & Johnson (Owner)"		"unspecified, PO"				"N2 (Analgesics), R5 (Cough and Cold Preparations)"	"N02 (Analgesics), R05 (Cough and Cold Preparations)"	"27diaminothiazolo54dpyrimidine derivatives Johnson Johnson, JNJ 17203212, TRPM8 antagonists Johnson Johnson, TRPV1 antagonists Johnson Johnson"			04/11/2017	"Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800021451?userId=52029392&bpIds=3004037004&checksum=d27f45896e11e97224dc4580feca73b417c037f5-1617045529656-01f09753f6935b38faee43ebb7f20a94badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021378	Research programme: transient receptor potential channel therapeutics - PharmEste						No development reported (Preclinical)	"Neuropathic pain, Overactive bladder, Respiratory tract disorders"		"TRPV1 receptor antagonists, TRPA1 protein inhibitors"	"PharmEste (Originator), PharmEste (Owner)"		unspecified				"G4D4 (Urinary incontinence products), N2 (Analgesics), R (Respiratory System)"	"G04B (Urologicals), N02 (Analgesics), R (Respiratory System)"	"PHE 575, TRPA1 antagonists, TRPV1 antagonists"			04/11/2017	"Genitourinary Disorders, Pain, Respiratory Tract Disorders"		PharmEste |  | Preclinical |  | 24 May 2011		no		no							https://adis.springer.com/drugs/800021378?userId=52029392&bpIds=3004037004&checksum=3fe8dc68db4d910dcbf30c02d2882925a11b8882-1617045529657-8669d082b58090b204770b06c1764edfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015056	Research programme: neuropeptide Y modulators - Lundbeck			Yes			No development reported (Preclinical)	"Pain, Substance-related disorders, Major depressive disorder"		"Neuropeptide Y receptor agonists, Neuropeptide Y receptor antagonists, Neuropeptide Y5 receptor antagonists"	"Lundbeck Research USA (Originator), Lundbeck Research USA (Owner)"		"unspecified, Parenteral, PO"				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N06A (Antidepressants), N07B-C (Drugs used in opioid dependence)"	Lu AA33810			04/11/2017	"Affective Disorders, Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800015056?userId=52029392&bpIds=3004037004&checksum=fc2a73d27a1801dacd23841b197c148fae8d2793-1617045529658-565db37431194222a0d8a0be68e1bb85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010715	Recombinant osteoprotegerin - Amgen						No development reported (Preclinical)	"Hyperparathyroidism, Postmenopausal osteoporosis, Bone disorders, Rheumatoid arthritis, Cancer pain"		Osteoclast inhibitors	"Amgen (Originator), Amgen (Owner)"		"unspecified, SC"		T<sub>max</sub> (h) (24 - 48 (Adult))		"M5 (Other Drugs for Disorders of the Musculo-Skeletal System), N2B (Non-Narcotics and Anti-Pyretics)"	"M05 (Drugs for Treatment of Bone Diseases), N02B (Other Analgesics and Antipyretics)"	"AMGN0007, OCIF Amgen, OPG Amgen, Osteoclastogenesis Inhibiting Factor Amgen"			04/11/2017	"Endocrine Disorders, Musculoskeletal Disorders, Pain, Rheumatic Disease, Women's Health"				no		no							https://adis.springer.com/drugs/800010715?userId=52029392&bpIds=3004037004&checksum=5222bda534a8a1dbd4c401035b89f897fcdc3b22-1617045529659-2211dd893777844fd5bb7b2745d4f1ffbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028387	Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals			Yes			No development reported (Preclinical)	"Kidney disorders, Inflammation, Methicillin-resistant Staphylococcus aureus infections, HIV infections, Cancer, Neuropathic pain, Pulmonary arterial hypertension, Epilepsy, Cardiovascular disorders, Hepatitis C"		"Type 4 cyclic nucleotide phosphodiesterase inhibitors, Protein 30S ribosomal subunit inhibitors, HIV protease inhibitors, Angiogenesis inhibitors, Immunomodulators, Interleukin 1 beta stimulants, Interleukin 10 stimulants, Tumour necrosis factor inhibitors, GABA A receptor modulators, Sigma-1 receptor agonists, Epoprostenol agonists, Partial fatty acid oxidation inhibitors, Platelet aggregation inhibitors, Pyruvate dehydrogenase stimulants, Type 3 cyclic nucleotide phosphodiesterase inhibitors, Hepatitis C protease inhibitors, Hepatitis C virus NS3 protein inhibitors"	"Concert Pharmaceuticals (Originator), Concert Pharmaceuticals (Owner), GlaxoSmithKline (Collaborator), National Institute of Neurological Disorders and Stroke (Collaborator), Walter Reed Army Institute of Research (Collaborator)"		"unspecified, PO"	renal	Route of Elimination (renal)		"A3A (Plain Antispasmodics and Anticholinergics), A5 (Cholagogues and Hepatic Protectors), B1C (Platelet Aggregation Inhibitors), B1C9 (Other platelet aggregation inhibitors), C1X (All Other Cardiac Preparations), G4 (Urologicals), G4C (BPH (Benign Prostatic Hypertrophy) Products), G4X (All Other Urological Products), H4 (Other hormones), J1X (Other Antibacterials), J5B (Antivirals, excluding anti-HIV products), J5C (HIV antivirals), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), M3B (Muscle Relaxants, Centrally Acting), N2 (Analgesics), N3A (Anti-Epileptics), N5A (Antipsychotics), N5B1 (Non-barbiturates, plain), N7X (All other CNS drugs), R7X (All Other Respiratory System Products)"	"A03A (Drugs for Functional Bowel Disorders), A05B-A (Liver therapy), B01A-C11 (Iloprost), B01A-C23 (Cilostazol), C01E-B18 (Ranolazine), G04 (Urologicals), G04B-X (Other urologicals), G04C (Drugs Used In Benign Prostatic Hypertrophy), H05 (Calcium Homeostasis), J01X-X08 (Linezolid), J05A-E10 (Darunavir), J05A-X (Other antivirals), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), M03B (Muscle Relaxants, Centrally Acting Agents), N02 (Analgesics), N03A (Antiepileptics), N05A (Antipsychotics), N05C-M (Other hypnotics and sedatives), N07X (Other Nervous System Drugs), R07A-X (Other respiratory system products)"	"C10068, C20081, C21246, C21359, CTP221, Dapremilast, Dboceprevir, Dcilostazol, Ddarunavir, Diloprost, Dlenalidomide, Dlinezolid, Dranolazine"			04/11/2017	"Bacterial Infections, Cancer, Epilepsy and Seizure Disorders, Genitourinary Disorders, Inflammation, Pain, Respiratory Tract Disorders, Vascular Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800028387?userId=52029392&bpIds=3004037004&checksum=8c583cbdea9925c15a069d8338cce1234c62d0c4-1617045529662-696f3521f059f5ed541deb807ba64a63badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019739	Research programme: glutamate receptor modulators - Eli Lilly and Company			No			No development reported (Preclinical)	"Major depressive disorder, Schizophrenia, Anxiety disorders, Mood disorders, Pain, Cognition disorders, Parkinson's disease"		"AMPA receptor agonists, Metabotropic glutamate receptor 2 modulators, Kainic acid receptor antagonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		"Parenteral, PO, unspecified"				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N06A (Antidepressants), N07X-X (Other nervous system drugs)"	"GluR5 kainate receptor antagonists Eli Lilly and Company, LY 503430, LY2607540, LY450108"			04/11/2017	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Pain, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800019739?userId=52029392&bpIds=3004037004&checksum=6dc2fd9699f118d8ed16cbe16b6571129283eab0-1617045529664-e047bf5b66123dac0582221bf07b2f62badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020139	Research programme: neuronal nicotinic receptor agonists - AbbVie		"(1<EM>R</EM>,5<EM>R</EM>)-5-[5-[(<EM>1R,5R</EM>)-6-Methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl]pyridin-2-yl]-1H-indole"	Yes			No development reported (Preclinical)	"Cognition disorders, Pain"	C19 H20 N4	"Alpha7 nicotinic acetylcholine receptor agonists, Nicotinic receptor agonists"	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"A366833, A582941, A844606, A85380, A859261, A867744, A870022, A880006, A988056"			04/11/2017	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020139?userId=52029392&bpIds=3004037004&checksum=ed63115aa82c389ae5e4aa0a038e25a1d2e45748-1617045529665-a532db21b7312d670725c0b176445995badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043429	Hydromorphone intranasal - Impel Neuropharma	466-99-9	"4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one"	Yes			Discontinued (Clinical)	Pain	C17 H19 N O3	Undefined mechanism	"Impel NeuroPharma (Originator), Impel NeuroPharma (Owner)"		Intranasal				N2 (Analgesics)	N02 (Analgesics)	INP101			03/11/2017	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800043429?userId=52029392&bpIds=3004037004&checksum=b6a4c0c1c25efa0c6c099412afe08f7ce6a1f184-1617045529666-2232e6f45fd2f5ea3a8cfa35fb7db26fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050549	AM 1710			Yes			Preclinical	Pain		Cannabinoid receptor CB2 agonists	"MakScientific (Originator), MakScientific (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AM1719			02/11/2017	Pain				no		no							https://adis.springer.com/drugs/800050549?userId=52029392&bpIds=3004037004&checksum=19de270c8826c395e506f2efe81532d1cf49a45b-1617045529667-98abc2d559154195a076e8890adb27b8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050589	Research programme: monoclonal antibody therapeutics - Gmax Biopharm			Yes			Preclinical	Type 2 diabetes mellitus		Undefined mechanism	"Gmax Biopharm (Originator), Gmax Biopharm (Owner)"		Parenteral				"A10 (Drugs Used in Diabetes), N2 (Analgesics)"	"A10 (Drugs Used in Diabetes), N02 (Analgesics)"	"GMA 103, GMA 104"			02/11/2017	Diabetes		Gmax Biopharm |  | Unspecified | World | 01 Nov 2017		no		no							https://adis.springer.com/drugs/800050589?userId=52029392&bpIds=3004037004&checksum=0e36e23a8e52a67cfe540eedd57d78a5dea70cd3-1617045529668-8d04e91c3a4082d5beef703ba16a8e5dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050512	Research programme: capsaicin prodrugs - Concentric Analgesics			No			Preclinical	"Pain, Acute pain"		"Substance P inhibitors, TRPV1 receptor agonists"	"Concentric Analgesics (Originator), Concentric Analgesics (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	"CA 011, CA016, CA01X, CA05X"			24/10/2017	Pain				no		no							https://adis.springer.com/drugs/800050512?userId=52029392&bpIds=3004037004&checksum=89e2a6879d6aee3df56f8d933b8e76b452369d88-1617045529669-1c5b7fb7f176e2109984adcef3324d89badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034344	Pregabalin controlled release - Pfizer	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid	No			Registered	"Neuropathic pain, Postherpetic neuralgia, Fibromyalgia, Epilepsy"	C8 H17 N O2	CACNA2D1 protein modulators	"Pfizer (Originator), Pfizer (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A-X16 (Pregabalin)"	"GRO 12 Pfizer, Lyrica CR, MR1 Pfizer, MR2 Pfizer, Pregabalin CR, Pregabalin ER"			23/10/2017	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"			"Lyrica CR, Lyrica CR"	no		no		Chymotrypsin	Citric acid	"A1C, BDNF, Bilirubin, CBFB-MYH11 fusion, CD28 molecule, CD3d, CD3e, CD3g, CD4, CD56, CD59 molecule, complement regulatory protein, CD8a, Citric acid, Dimethylarsinate, EH domain containing 2, EH domain containing 4, flap structure-specific endonuclease 1, Hydrocortisone, IL6, interferon alpha inducible protein 6, intestinal cell (MAK-like) kinase, L-Glutamic acid, opioid related nociceptin receptor 1, proteasome 26S subunit, non-ATPase 1, S100B, serotonin, sphingolipid transporter 1 (putative), STS, Thyroid stimulating hormone, beta, Thyroxine, TNF-alpha, TNFRSF1A, WAS/WASL interacting protein family, member 1"	IL6	"AXIN2, ER alpha, IL10"	https://adis.springer.com/drugs/800034344?userId=52029392&bpIds=3004037004&checksum=4b4dd9da77c00682ea3a9ea829121bcdf0bf7998-1617045529674-adcf22950fd38b3fe94020f59f4e8813badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050396	FGY 1153			Yes			Preclinical	Retinal disorders		Bradykinin B1 receptor antagonists	"Gedeon Richter (Originator), Gedeon Richter (Owner)"		unspecified				"N2 (Analgesics), S1X (Other Ophthalmologicals)"	"N02 (Analgesics), S01X (Other Ophthalmologicals)"	FGY1153			10/10/2017	Eye Disorders				no		no							https://adis.springer.com/drugs/800050396?userId=52029392&bpIds=3004037004&checksum=a6a3ad2b3dc4ed4b54910be4efd7d9a155f7ca35-1617045529674-b2137b0957a920af60985a0ea66575cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050273	KF 059			Yes			Research	Pain		Undefined mechanism	"Akeso Biopharma (Originator), Akeso Biopharma (Owner)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	KF059			18/09/2017	Pain		Akeso Biopharma |  | Unspecified |  | 14 Sep 2017		no		no							https://adis.springer.com/drugs/800050273?userId=52029392&bpIds=3004037004&checksum=ed81880f94c9167f0bb8a4df7e388d5b1c0b884d-1617045529675-99615faf454ff3ec2a2f93cdba9e1d79badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050039	Carbamazepine - GT Biopharma			No			Preclinical	Neuropathic pain		Sodium channel antagonists	"Accu-Break Pharmaceuticals (Originator), Accu-Break Pharmaceuticals (Owner), GT Biopharma (Licensee), Accu-Break Pharmaceuticals (Technology Provider)"		PO				N2 (Analgesics)	N02 (Analgesics)	PainBrake			18/09/2017	Pain			PainBrake	no		no							https://adis.springer.com/drugs/800050039?userId=52029392&bpIds=3004037004&checksum=c5aa709c2dbd90b5bb41e8f1b6351e7f532790d8-1617045529676-9539dc48d3d4b8d0e50f0cef37d40500badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040629	Lamotrigine/sertraline			No			Phase II	Back pain		"Serotonin uptake inhibitors, Sodium channel antagonists"	"Meditop Pharmaceutical (Originator), Meditop Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N3A (Anti-Epileptics), N6A4 (SSRI antidepressants)"	"N02 (Analgesics), N03A-X09 (Lamotrigine), N06A-B06 (Sertraline)"	"15/30SERLAM, 30/15LAM/SER, LAM/SER, SER/LAM, Sertraline/lamotrigine"			05/09/2017	Pain				no		no							https://adis.springer.com/drugs/800040629?userId=52029392&bpIds=3004037004&checksum=9554d0259e8d91fd6dbd2968fa43c58bd35b3f13-1617045529677-7a27bb067fdc5ad7168778e962355ed1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030122	Selurampanel	912574-69-7	"<EM>N</EM>-[6-(1-methyl-1<EM>H</EM>-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2<EM>H</EM>)-yl]methanesulfonamide"	Yes			No development reported (II)	"Partial epilepsies, Migraine, Tinnitus, Epilepsy"	C16 H19 N5 O4 S	"AMPA receptor antagonists, Kainic acid receptor antagonists"	"Novartis (Originator), Novartis (Owner)"		PO				"N2 (Analgesics), N3A (Anti-Epileptics), S2D (Other Otologicals)"	"N02 (Analgesics), N03A (Antiepileptics), S02D (Other Otologicals)"	"BGG492, BGG492A"			05/09/2017	"Advances in the Treatment of Nausea and Migraine, Ear, Nose and Throat Disorders, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800030122?userId=52029392&bpIds=3004037004&checksum=e71c1d841c68a0c607452e5ce1ee994a0b59066f-1617045529680-23ed9448c191fe326a16d611a66ad447badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800050052	Research programme: peptide therapeutics - PreveCeutical Medical/UniQuest			Yes			Research	Pain		Undefined mechanism	"PreveCeutical Medical (Originator), UniQuest (Originator), PreveCeutical Medical (Owner), UniQuest (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				09/08/2017	Pain				no		no							https://adis.springer.com/drugs/800050052?userId=52029392&bpIds=3004037004&checksum=f28536116c275f7fa3761532ef823d1e14d7435a-1617045529680-90f7522e5f66b52d4182e221b1ffbcc9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018544	Amitriptyline/ketamine - Immune Pharmaceuticals			No			Phase II	"Neuropathic pain, Postherpetic neuralgia, Diabetic neuropathies"	C20 H23 N . C13 H16 Cl N O	"Adrenergic uptake inhibitors, Alpha 1 adrenergic receptor antagonists, NMDA receptor antagonists, Serotonin uptake inhibitors"	"EpiCept Corporation (Originator), Immune Pharmaceuticals Inc (Owner), Hebrew University of Jerusalem (Technology Provider), Yissum Research Development Company (Technology Transfer), National Cancer Institute (USA) (Collaborator)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"AmiKet, Amiket Nano, EpiCept NP1, Ketamine/amitriptyline, NP1"			09/08/2017	"Diabetes, Pain"	Postherpetic neuralgia (USA)	Immune Pharmaceuticals Inc |  | Unspecified |  | 07 Aug 2017	AmiKet	yes	USA	no							https://adis.springer.com/drugs/800018544?userId=52029392&bpIds=3004037004&checksum=1cf3545d44b84ae1aee06c51fd20797ac2e7686d-1617045529682-b91fc6a16362a86ec6df47d3e428a848badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042730	Diclofenac - Novartis	15307-86-5		No			No development reported (III)	Dental pain	C14 H11 Cl2 N O2	Cyclooxygenase inhibitors	"Novartis (Originator), Novartis (Owner)"		PO				M1 (Anti-Inflammatory and Anti-Rheumatic Products)	"M01A-B05 (Diclofenac), N02B (Other Analgesics and Antipyretics)"	Diclofenac potassium softgelatin capsules Novartis			08/08/2017	Pain				no		no							https://adis.springer.com/drugs/800042730?userId=52029392&bpIds=3004037004&checksum=f8e9c64f43e06c6be2fabed7dbeea5ee649a8020-1617045529682-b4b449f2a8370f02b325f4b9df3fde8ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040639	ASP 3662			Yes			Discontinued (II)	"Diabetic neuropathies, Alzheimer's disease"		11-beta-hydroxysteroid dehydrogenase type 1 inhibitors	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				"N2 (Analgesics), N7D (Anti-Alzheimer Products)"	"N02 (Analgesics), N06D (Anti-Dementia Drugs)"	ASP3662			01/08/2017	"Alzheimer's Disease and Cognition Disorders, Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800040639?userId=52029392&bpIds=3004037004&checksum=edb499731c473baee23d64c678aedcbd6fd5f1cb-1617045529683-8f280e40d9e82422d8ae5d85799bfef1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049937	Research programme: Macrocyclic compounds - Cyclenium Pharma/University of Sherbrooke			Yes			Research	Pain		Opioid delta receptor agonists	"Cyclenium Pharma (Originator), University of Sherbrooke (Originator), Cyclenium Pharma (Owner), University of Sherbrooke (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				26/07/2017	Pain				no		no							https://adis.springer.com/drugs/800049937?userId=52029392&bpIds=3004037004&checksum=b1337a8f3eadc76a3fec54838be6c9f59b0ff27e-1617045529684-c0d37d1a6c56da33f9e44feb1ca2b9e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049943	Research programme: cannabinoids - PreveCeutical Medical/UniQuest			No			Research	"Inflammation, Neurological disorders, Seizures, Pain"		Undefined mechanism	"PreveCeutical Medical (Originator), UniQuest (Originator), PreveCeutical Medical (Owner), UniQuest (Owner)"		Intranasal				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs)"				26/07/2017	"Drug Delivery Systems, Epilepsy and Seizure Disorders, Inflammation, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800049943?userId=52029392&bpIds=3004037004&checksum=b0bdfdda9f64796646b589a9c36b88575204d88a-1617045529685-e477f301c3044aeb335d16bccb2ec16ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049874	Botulinum toxin - OBI Pharma			No			Preclinical	Migraine		"Acetylcholine inhibitors, Glutamate antagonists, Neuromuscular blocking agents"	"OBI Pharma (Originator), OBI Pharma (Owner)"		Parenteral				"M3A (Muscle Relaxants, Peripherally Acting), N2C9 (All other anti-migraine preparations)"	"M03A-X01 (Botulinum toxin), N02C-X (Other antimigraine preparations)"	OBI 858			14/07/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800049874?userId=52029392&bpIds=3004037004&checksum=8f6ac54a23e4934d8e81a46ba4ed32f96f2b1f04-1617045529686-5c811b906128370ddc5e43f0b717c6e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030302	Hydrocodone controlled release - DURECT Corporation	125-29-1	"Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl-"	No			Discontinued (I)	Pain	C18 H21 N O3	Opioid receptor agonists	"DURECT Corporation (Originator), DURECT Corporation (Owner)"		PO				N2 (Analgesics)	N02A (Opioids)	PTI 721			13/07/2017	Pain				no		no							https://adis.springer.com/drugs/800030302?userId=52029392&bpIds=3004037004&checksum=b8b9f5e5cf05d09181dd52158f7216f250826424-1617045529686-e9e0829dcedb1f103c07b25ffb5ae3f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028799	Research programme: abuse-resistant opioid analgesics - DURECT Corporation			No			Preclinical	Pain		"Opioid mu receptor agonists, Opioid receptor agonists"	"DURECT Corporation (Originator), DURECT Corporation (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"Abuseresistant oxymorphone, ORADUROxymorphone"			13/07/2017	Pain				no		no							https://adis.springer.com/drugs/800028799?userId=52029392&bpIds=3004037004&checksum=e9c60987b7b66a24d9769f79e47b15fe573b8ade-1617045529687-442e5fe0bfa0f5a56e483fbf02fd9565badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049832	GSK 589			Yes			Preclinical	Visceral pain		Proto oncogene protein c ret inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner), University of Oklahoma Health Sciences Center (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	GSK589			10/07/2017	Pain				no		no							https://adis.springer.com/drugs/800049832?userId=52029392&bpIds=3004037004&checksum=1b79c7398efb387fcd5c607c90489faa34b3c533-1617045529688-ba402b177ffc4451097c872cade681a3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049798	Ice 3682			Yes			Preclinical	Neuropathic pain		TRPM8 protein inhibitors	"Janssen Pharmaceuticals (Originator), Janssen Pharmaceuticals (Owner), Ice Therapeutics (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Ice3682, JNJ 42503682"			04/07/2017	Pain				no		no							https://adis.springer.com/drugs/800049798?userId=52029392&bpIds=3004037004&checksum=6672e3a00beda91853d7809d160ab8f467b87b59-1617045529689-a856e945f3641b29a167c481d6ed3e9ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031559	FX 005			Yes			Discontinued (I/II)	Musculoskeletal pain		P38 mitogen-activated protein kinase inhibitors	"AstraZeneca (Originator), AstraZeneca (Owner), Flexion Therapeutics (Licensee)"		Intra-articular				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	FX005			14/06/2017	Pain				no		no							https://adis.springer.com/drugs/800031559?userId=52029392&bpIds=3004037004&checksum=40a0da8dc141d6783a8e26238df99eca562950e5-1617045529690-f126b9a6ed3168f79a8a9bedbc892931badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027667	Clonidine topical gel - BioDelivery Sciences International	4205-90-7	"1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-"	No			Discontinued (III)	Diabetic neuropathies	C9 H9 Cl2 N3	"Adrenergic receptor antagonists, Alpha 2 adrenergic receptor agonists, Imidazoline receptor agonists"	"Arcion Therapeutics (Originator), Arcion Therapeutics (Owner)"		Topical				N2 (Analgesics)	N02C-X02 (Clonidine)	ARC4558			12/06/2017	Pain				yes	USA	no							https://adis.springer.com/drugs/800027667?userId=52029392&bpIds=3004037004&checksum=c664395aa47768febae1ccd94cc6e33e6929cfed-1617045529690-1e72d437fe92a3f44540fca4563ae9c6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025994	Paracetamol intravenous - Bristol-Myers Squibb/Mallinckrodt	103-90-2	N-Acetyl-p-aminophenol	No			Marketed	"Pain, Fever"	C8 H9 N O2	Prostaglandin receptor antagonists	"Pharmatop (Originator), Pharmatop (Owner), Bristol-Myers Squibb (Licensee), Mallinckrodt plc (Sub-licensee), Terumo (Sub-licensee)"		IV				"N2B (Non-Narcotics and Anti-Pyretics), N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)"	N02B-E01 (Paracetamol)	"Acelio, acetaminophen IV, Acetavance, IV APAP, Ofirmev, Perfalgan, TRM1106"			02/06/2017	"Metabolic Disorders, Pain"			"Acelio, Acetavance, Acetavance, Ofirmev, Ofirmev, Perfalgan, Perfalgan"	no		no		"A1AT, A1C, PSA, WT1"	"CD3d, CD3e, CD3g"	"11-Dehydro-thromboxane B2, 7-Hydroxy-6-methyl-8-ribityl lumazine, A1AT, A1C, Acetaminophen glucuronide, Acetylcysteine, Acid ceramidase, Angiopoietin 2, Arachidonic acid, AT-III, C-peptide, C4, CD34, CD3d, CD3e, CD3g, Collagen type 2, CRP, cytochrome P450 family 2 subfamily E member 1, Cytokeratin 18, dsDNA Auto-antibodies, F2-isoprostanes, Fibulin 3 peptides, Glutathione, growth hormone 1, Heme, HMGB1, Hydrocortisone, IFN-gamma, IGFBP7, IL6, insulin receptor related receptor, L-Cysteine, L-Cystine, microRNA 122, MMP-2, NGAL, opioid related nociceptin receptor 1, Osteocalcin, peptidylprolyl isomerase G, peroxiredoxin 5, PHGDH, Prostacyclin, PSA, RAGE, Thromboxane A2, Thromboxane B2, TIMP-2, TNF-alpha, transcription factor 21, VEGF-A, VEGFR, VEGFR1, WT1"	"Acid ceramidase, AT-III, Cytokeratin 18, HMGB1, NGAL, Osteocalcin, PSA"	"ATP binding cassette subfamily G member 2 (Junior blood group), Calreticulin, CTx, CYP2D6, Fe3+, GIP"	https://adis.springer.com/drugs/800025994?userId=52029392&bpIds=3004037004&checksum=032bef6fe56a38001231947f7fb125629027ffbe-1617045529694-23973ba4ba8da7458f2495104c1f8118badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030239	Tongjingshule			Yes			Discontinued (Preregistration)	Dysmenorrhoea		Prostaglandin inhibitors	"China Aoxing Pharmaceutical (Originator), Aoxing Pharmaceutical Company (Owner)"		PO				"G2X1 (Gynaecological antispasmodics), N2 (Analgesics)"	"G02C (Other Gynecologicals), N02 (Analgesics)"	TJSL			02/06/2017	"Pain, Women's Health"				no		no							https://adis.springer.com/drugs/800030239?userId=52029392&bpIds=3004037004&checksum=b4df030c14818ea40fe0a181cdf50f90ebbad788-1617045529695-e92ade0e2118b7af1784688dfdb276e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049537	Ropivacaine Transdermal - tesa Labtec			No			Preclinical	Pain		"Potassium channel antagonists, Sodium channel antagonists"	"tesa Labtec (Originator), tesa Labtec (Owner)"		Transdermal				"N1B (Anaesthetics, Local), N2 (Analgesics)"	"N01B (Anesthetics, Local), N02 (Analgesics)"	Ropivacaine Transdermal patch tesa Labtec			29/05/2017	Pain		tesa Labtec |  | Phase II |  | 09 May 2017		no		no							https://adis.springer.com/drugs/800049537?userId=52029392&bpIds=3004037004&checksum=057ae30c966eb24c1bd2a19c776081fe94978d47-1617045529696-9f72d65b6bfd5e94c7802bf8ed3cd737badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049399	VVZ 368			Yes			Research	Pain		"Glycine plasma membrane transport protein inhibitors, Serotonin 2A receptor antagonists"	"Vivozon (Originator), Vivozon (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	VVZ368			19/05/2017	Pain				no		no							https://adis.springer.com/drugs/800049399?userId=52029392&bpIds=3004037004&checksum=73e4f57aaca678dd8669c8387218a245586f0898-1617045529696-ee228b4d6c1140134a2d4b759c40c678badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024874	Research programme: G protein-coupled receptor modulators - Alchemia/Ogeda			Yes			Suspended (Preclinical)	"Obesity, Chronic obstructive pulmonary disease, Inflammation, Rheumatoid arthritis, Diabetes mellitus, Pain"		G protein-coupled receptor modulators	"Alchemia (Originator), Euroscreen (Originator), Ogeda (Owner)"		unspecified				"A10 (Drugs Used in Diabetes), A8 (Antiobesity Preparations, Excluding Dietetics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R7 (Other Respiratory System Products)"	"A08 (Antiobesity Preparations, Excl. Diet Products), A10 (Drugs Used in Diabetes), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R07 (Other Respiratory System Products)"				18/05/2017	"Diabetes, Inflammation, Obesity, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800024874?userId=52029392&bpIds=3004037004&checksum=718e9f0696ce2deeee84462c6dc6d1b00f12cee6-1617045529698-bef673daacef88b8d22d605d46352d13badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049431	Research programme: pain therapeutics - Nissan Chemical Industries/Shionogi			Yes			Research	Pain		Undefined mechanism	"Nissan Chemical Industries (Originator), Shionogi (Originator), Nissan Chemical Industries (Owner), Shionogi (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				09/05/2017	Pain				no		no							https://adis.springer.com/drugs/800049431?userId=52029392&bpIds=3004037004&checksum=5b845c156a9d1ff3ac7e6d1a13d6b18faffedbfd-1617045529698-74305ed65769e68842afa615784290d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039262	Hydrocodone controlled-release - Purdue Pharma	143-71-5	"Morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl-, (5_)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate"	No			Marketed	Pain	C18 H21 N O3 . C4 H6 O6	Opioid receptor agonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		PO				N2A (Narcotics)	"N02A-F (Morphinan derivatives), R05D-A03 (Hydrocodone)"	"HYD Purdue Pharma, hydrocodone bitartrate extendedrelease Purdue Pharma, Hydrocodone bitartrate oncedaily Purdue Pharma, Hysingla"			04/05/2017	Pain			Hysingla	no		no							https://adis.springer.com/drugs/800039262?userId=52029392&bpIds=3004037004&checksum=118831d683a5dd9b9e8e51acc8407a4e87cfe475-1617045529699-a3449ac68591fee86d3a467a2cd73b4bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013855	Tramadol controlled release - Labopharm	36282-47-0	(±)-<EM>cis</EM>-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride	No			Marketed	"Pain, Cancer pain"	C16 H25 N O2 . H Cl	"Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Labopharm (Originator), Endo International (Owner), Angelini Group (Market Licensee), CSC Pharmaceuticals Handels (Market Licensee), Dexcel-Pharma (Market Licensee), Endo International (Market Licensee), ESTEVE (Market Licensee), GlaxoSmithKline (Market Licensee), Grunenthal (Market Licensee), HEXAL (Market Licensee), iNova Pharmaceuticals (Market Licensee), Lavipharm S.A. (Market Licensee), Merck Sharp & Dohme (Market Licensee), Nycomed Canada (Market Licensee), Purdue Pharma (Market Licensee), Sanofi (Market Licensee), Whanin Pharmaceutical (Market Licensee), Nippon Shinyaku (Licensee), Pfizer (Sub-licensee)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"Contramal Uno, Dolpar, Durotram XR, Monoalgic L.P., Monotramal L.P., Noax Uno, NS24, Oncedaily tramadol, Oncedaily tramadol MP, Onetram, Ryzolt, Tradorec XL, TramaConti CR, Tramadol CR, Tramadol extended release, Tramadolor einmal teglich, Tridural, Unitrama"			24/04/2017	Pain			"Contramal Uno, Dolpar, Durotram XR, Monoalgic L.P., Monotramal L.P., Noax Uno, Onetram, Onetram, Ryzolt, Tradorec XL, TramaConti CR, Tramadolor einmal teglich, Tridural, Unitrama"	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800013855?userId=52029392&bpIds=3004037004&checksum=7705377216dfd310dc20dde3856c55f444489d06-1617045529703-f185f3a05f1a7ce907f9411ffd2f4d75badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028817	NP 2			No			Discontinued (II)	"Cancer pain, Neuropathic pain"		"Enkephalin modulators, Gene transference"	"Diamyd Medical (Originator), Periphagen Holdings (Owner), University of Pittsburgh (Technology Provider), University of Michigan (Collaborator)"		Intradermal				N2 (Analgesics)	N02 (Analgesics)	"NETENK, NP2, NP2 Enkephalin, NTDDS expressing enkephalin, PGN202"			12/04/2017	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800028817?userId=52029392&bpIds=3004037004&checksum=f339a9dc91649d7a8bc066d27950408b73d3a482-1617045529704-cf33624e46e53c0f7a9c309f176486b4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040936	Aspirin/sumatriptan			No			Suspended (II)	Headache		"Cyclooxygenase inhibitors, Serotonin 1 receptor agonists"	"Vivid Pharma Inc (Originator), Vivid Pharma Inc (Owner)"		PO				N2 (Analgesics)	"N02B-A01 (Acetylsalicylic acid), N02C-C01 (Sumatriptan)"	"Aspirin/sumatriptan 325/12.5, VVD 101"			11/04/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800040936?userId=52029392&bpIds=3004037004&checksum=61667ca028cc73f8b645f5b674bc1d4ee2e9ffd2-1617045529704-c04db3cc1b931b967c76e55053d1c39abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049178	Research programme: controlled release pain therapeutics - POLYPID			No			Research	Postoperative pain		Undefined mechanism	"POLYPID (Originator), POLYPID (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				01/04/2017	Pain		POLYPID | Pain | Unspecified |  | 29 Mar 2017		no		no							https://adis.springer.com/drugs/800049178?userId=52029392&bpIds=3004037004&checksum=b1dd94e40fb4a6210f9092720e87c8edd9866ed1-1617045529705-fde1d86a87dcad5837857002e1461d10badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040174	MDT 10013			Yes			No development reported (II)	Postoperative pain		Undefined mechanism	"Medtronic (Originator), Medtronic (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MDT10013			22/03/2017	Pain				no		no							https://adis.springer.com/drugs/800040174?userId=52029392&bpIds=3004037004&checksum=df821b6b70f8b84a52ff00beddb07cff4ee6515b-1617045529706-aa1d9eeead08d9af27bfcfc3011f4674badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800049079	AGM 251			Yes			Preclinical	Neuropathic pain		Undefined mechanism	"AnyGen (Originator), AnyGen (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AGM251			16/03/2017	Pain				no		no							https://adis.springer.com/drugs/800049079?userId=52029392&bpIds=3004037004&checksum=824d0930cdf0a8ca27660150bb9e45b606ab256b-1617045529707-e94141b7d3f685ca0265a908d4e552e0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025586	SYN 116			Yes			Discontinued (I)	Pain		Prostaglandin I2 antagonists	"Roche (Originator), Roche (Owner), Acorda Therapeutics (Licensee)"		PO				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)	SYN116			02/03/2017	Pain				no		no							https://adis.springer.com/drugs/800025586?userId=52029392&bpIds=3004037004&checksum=95cd09b56a1e95f3e3ea8a26fc439cac422daefc-1617045529707-3ddf08d9d0e40c1c7b965055caae9cbbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019339	Research programme: serotonin 1F receptor agonists - Eli Lilly and Company/Lundbeck			Yes			Discontinued (Preclinical)	Migraine		Serotonin 1F receptor agonists	"Eli Lilly and Company (Originator), Lundbeck Research USA (Originator), Eli Lilly and Company (Owner), Lundbeck Research USA (Owner), CoLucid Pharmaceuticals (Market Licensee)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	LY 418094			02/03/2017	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800019339?userId=52029392&bpIds=3004037004&checksum=909b29199b50732a63e877889ec175fc3b9debb3-1617045529708-5d94e68e89d091da04d3ebd8c26139f4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030829	Research programme: monoamine reuptake inhibitors/mu opioid receptor agonists - Merck			Yes			Discontinued (Research)	Pain		"Biogenic monoamine uptake inhibitors, Opioid mu receptor agonists"	"Adolor Corporation (Originator), Merck & Co (Owner)"		PO				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"				08/02/2017	Pain				no		no							https://adis.springer.com/drugs/800030829?userId=52029392&bpIds=3004037004&checksum=a0b085a8d9b46a19a1e4e1a001410096e684ddda-1617045529709-b3f97a6d5a5859a4a1b6ce10ddb0926dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030826	Research programme: imipramine derivatives - Merck			Yes			Discontinued (Research)	Pain		"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Adolor Corporation (Originator), Merck & Co (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	Imipramine derivatives			08/02/2017	Pain				no		no							https://adis.springer.com/drugs/800030826?userId=52029392&bpIds=3004037004&checksum=9c7746777962f0f5a25d3c28289cbb905489990a-1617045529710-55038896ae34a4aa0a40736da2a2d5d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017183	Research programme: cannabinoid receptor agonists - Merck			Yes			Discontinued (Preclinical)	"Cancer pain, Pain, Neuropathic pain"		"Cannabinoid receptor agonists, Cannabinoid receptor CB2 agonists"	"Adolor Corporation (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"ADC X, ADC Y, ADC Z"			08/02/2017	Pain				no		no							https://adis.springer.com/drugs/800017183?userId=52029392&bpIds=3004037004&checksum=e1e826cf8eae00ad56594abd8c59192e0cf9a624-1617045529710-be821b6d0aafc6b81a32b1baea0e7f21badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018036	Research programme: AAV/ZFP TF pain therapy - Avigen/Sangamo Therapeutics			Yes			Discontinued (Preclinical)	Neuropathic pain		Genetic transcription inhibitors	"Avigen (Originator), Sangamo BioSciences (Originator), Sangamo Therapeutics (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	AAV/ZFP TF			11/01/2017	Pain				no		no							https://adis.springer.com/drugs/800018036?userId=52029392&bpIds=3004037004&checksum=c9704731d4671e913a91c6f7f5a00c1eab3957f1-1617045529711-94dcc0bad3a0fe8f6ad6f32d417ec406badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042938	Morphine - Lannett Holdings	6211-15-0	"7,8-didehydro-4,5 alpha-epoxy-17 methyl-morphinan-3,6 alpha-diol sulfate (2:1) (salt) pentahydrate"	No			Marketed	Pain	C17-H19-N-O3.1/2H2-O4-S.5H2-O	Opioid mu receptor agonists	"Lannett (Originator), Lannett (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)				23/12/2016	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800042938?userId=52029392&bpIds=3004037004&checksum=5600175dc54d13b9d020a31fc3791f5488a69421-1617045529713-4ee0489b7cf594c8105392a56fa1be0fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007886	CereCRIB			Yes			Discontinued (II)	Pain		"Adrenergic receptor agonists, Opioid receptor agonists"	"StemCells (Originator), Microbot Medical (Owner)"		Intrathecal				N2A (Narcotics)	N02A (Opioids)	ACTID			13/12/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800007886?userId=52029392&bpIds=3004037004&checksum=31c05df61ff1bb61e618d107b4797ebfc98ce313-1617045529713-74559545afb4fa48dc877c607ce0283ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043918	Fentanyl transdermal - Luye Pharma	437-38-7	N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide	No			Marketed	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Acino (Originator), Luye Pharma Group (Owner)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	Fentavera			09/12/2016	Pain		Acino |  | Unspecified |  | 30 Jun 2013	Fentavera	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800043918?userId=52029392&bpIds=3004037004&checksum=4bd57baca2d88a42a96866e9099aef9017b76b0f-1617045529716-95b644552b10f71e177b7e629865a517badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046365	Loxoprofen sodium/methocarbamol		Sodium;2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoate/[2-hydroxy-3-(2-methoxyphenoxy)propyl] carbamate	No			Phase III	Pain	C15 H17 Na O3 . C11 H15 N O5	Cyclooxygenase inhibitors	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"IPTN, Loxoprofen/methocarbamol"			06/12/2016	Pain				no		no							https://adis.springer.com/drugs/800046365?userId=52029392&bpIds=3004037004&checksum=219ad5554ba96b427044fd3d2f158fa66db1f152-1617045529716-ea55b2d5b4449569255b261683627bf6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026412	Valproic acid oral - Banner Life Sciences	99-66-1	"Pentanoic acid, 2-propyl"	Yes			Marketed	"Migraine, Bipolar disorders, Epilepsy"	C8 H16 O2	"4-aminobutyrate transaminase inhibitors, Glutamate decarboxylase stimulants, Neurotransmitter modulators, Sodium channel modulators"	"Banner Pharmacaps (Originator), Banner Life Sciences (Owner), Noven Therapeutics (Licensee)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N6A3 (Mood stabilisers)"	"N02C (Antimigraine Preparations), N03A-G01 (Valproic acid), N06A (Antidepressants)"	"Stavzor, Stavzor ER, Valproic acid delayedrelease capsules (Stavzor), Valproic acid extendedrelease capsules (Stavzor ER)"			01/12/2016	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders"			"Stavzor, Stavzor, Stavzor, Stavzor ER, Stavzor ER, Stavzor ER"	no		no		"adhesion regulating molecule 1, CD4, chymase 1, Creatinine, GATA3, hematological and neurological expressed 1, immunoglobulin kappa variable 1-5, PDGFRA, phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha, sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase), solute carrier family 35 member B2, Thyroglobulin, Valproic acid glucuronide"	"All-trans-retinoic acid, Creatinine, ER alpha, hematological and neurological expressed 1, Valproic acid glucuronide"	"adhesion regulating molecule 1, Alkaline phosphatase, All-trans-retinoic acid, Bilirubin, CA-125, CD8a, centrin 1, chymase 1, CKB, CKM, Clusterin, CPT2, CRP, CTx, DNA (cytosine-5-)-methyltransferase 1, ER alpha, folate receptor, FSH, GR, hematological and neurological expressed 1, HSP90AA1, IGF1, immunoglobulin kappa variable 1-5, Insulin, interferon regulatory factor 4, iodothyronine deiodinase 3, Ki67, Lactate dehydrogenase, Nibrin, Osteocalcin, p16, p53, PDGFRA, Prolactin, PTH, REL proto-oncogene, NF-kB subunit, sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase), solute carrier family 5 member 5, synaptic vesicle glycoprotein 2A, Tau protein, Testosterone, Thrombospondin-1, Thyroglobulin, Thyroid stimulating hormone, beta, Thyroxine, TOP2A, Uric acid, Valproic acid glucuronide"	"CKB, Lactate dehydrogenase, Prolactin"	"Adiponectin, ARG1, ASL, ASS1, Bcl-2, CPS1, death associated protein kinase 1, E-cadherin, Ghrelin, growth differentiation factor 10, histone deacetylase 9, inhibitor of DNA binding 4, HLH protein, LAMA2, Leptin, Luteinizing hormone, mTOR, myogenic differentiation 1, NAGS, NELL2, OTC, PHGDH, POLG, PSA, Ras association (RalGDS/AF-6) domain family member 1, RELA, tenascin C, twist family bHLH transcription factor 2, VEGF-A, WT1"	https://adis.springer.com/drugs/800026412?userId=52029392&bpIds=3004037004&checksum=06ce1eaf0fdb04adc6b7f3ba480920e8a8f0a795-1617045529719-ce187b2d99078ba28fb00f02545e8229badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024140	Research programme: RetroMetabolic therapeutics - ARYx			Yes			Suspended (Research)	"Gastrointestinal disorders, Metabolic disorders"			"ARYx Therapeutics (Originator), ARYx Therapeutics (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), A3 (Functional Gastro-Intestinal Disorder Drugs), C10A (Cholesterol and Triglyceride Regulating Preparations), C8 (Calcium Antagonists), N1 (Anaesthetics), N2 (Analgesics), N3 (Anti-Epileptics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), R3A2 (B2-stimulants, systemic)"	"A03A (Drugs for Functional Bowel Disorders), A16 (Other Alimentary Tract and Metabolism Products), C08 (Calcium Channel Blockers), C10 (Lipid Modifying Agents), N01 (Anesthetics), N02A (Opioids), N03 (Antiepileptics), N05A (Antipsychotics), N06A (Antidepressants), R03C-C (Selective beta-2-adrenoceptor agonists)"	"ATI20000, ATI24000"			25/11/2016	"Digestive System Disorders, Metabolic Disorders"				no		no							https://adis.springer.com/drugs/800024140?userId=52029392&bpIds=3004037004&checksum=701fb23e160ce1fab6cacd3941e7e3fc717bc306-1617045529720-db3684bbb810626a032e2da1bf7b09c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004527	Levacecarnine	14992-62-2	3-acetyloxy-4-trimethylammonio-butanoate	No			Marketed	"Alzheimer's disease, Diabetic neuropathies, Dementia, Peripheral nervous system diseases, Diabetic complications, Fatigue"	C9 H17 N O4	Carnitine acetyltransferase stimulants	"sigma-tau SpA (Originator), sigma-tau SpA (Owner), Dong-A ST (Market Licensee), Duncan (Market Licensee), GlaxoSmithKline (Market Licensee), Mitsubishi Tanabe Pharma Corporation (Market Licensee), Roche (Market Licensee), Lee's Pharmaceutical (Licensee), GlaxoSmithKline (Collaborator)"		"PO, unspecified, IV"				"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics), N6D (Nootropics), N7 (Other CNS Drugs), N7D9 (All other anti-Alzheimer products)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	"AcetylLcarnitine, ALC, Alcar, Branigen, Lacetylcarnitine, Nicetile, RO 447190, ST 200, ST 211HCl, Zibren"			09/11/2016	"Alzheimer's Disease and Cognition Disorders, Diabetes, Neurological Disorders, Pain"			"Alcar, Alcar, Branigen, Branigen, Nicetile, Nicetile, Nicetile, Zibren"	no		no		"CA-125, PSA"	Insulin	"CA-125, Insulin, PSA"		"Adiponectin, ATP-binding cassette, sub-family A (ABC1), member 4, CD4, CD8a, CRP, Leptin, TNF-alpha"	https://adis.springer.com/drugs/800004527?userId=52029392&bpIds=3004037004&checksum=78af50c03db7522f9b942c4358552b4c88bde42f-1617045529723-05300e6b800dd16b0c8037d1b223af89badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025274	Research programme: cannabinoid receptor modulators - Sunovion Pharmaceuticals/IntelGenx			Yes			Suspended (Preclinical)	"Major depressive disorder, Anxiety disorders, Schizophrenia"		Cannabinoid receptor modulators	"Cannasat Therapeutics (Originator), Sunovion Pharmaceuticals (Owner), IntelGenx Corp. (Technology Provider)"		PO				"A4A (Antiemetics and Antinauseants), N2 (Analgesics), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers)"	"A04A (Antiemetics and Antinauseants), N02 (Analgesics), N05A (Antipsychotics), N05B (Anxiolytics), N06A (Antidepressants)"	"CAT 210, CAT 320, INT 0014/2008, Modulyn"			25/10/2016	"Affective Disorders, Anxiety Disorders, Drug Delivery Systems, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800025274?userId=52029392&bpIds=3004037004&checksum=cdc67a3182d43e724b1326aa41449de7ff1538d8-1617045529724-356e82c3aade0db83438014ff3226a3cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027219	LLL 2011			Yes			Discontinued (III)	Migraine		Undefined mechanism	"Lupin (Originator), Lupin (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"Amigra, LL2011, LLL2011"			08/09/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800027219?userId=52029392&bpIds=3004037004&checksum=26290d88eb6d29dd440a5c0c0e731469635d2155-1617045529725-78fa86bd2cf7aa89dded0d1ff9035c29badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024356	Research programme: neuropathic pain therapeutics - Cara Therapeutics						No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"Cara Therapeutics (Originator), Cara Therapeutics (Owner), Certara (Technology Provider)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				08/09/2016	Pain				no		no							https://adis.springer.com/drugs/800024356?userId=52029392&bpIds=3004037004&checksum=e574a6b48cfa16d71db2f74a235b0333e162fac0-1617045529725-6d551554cf4d363cd9fd06cdaaf63695badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800047415	Ketoprofen transdermal - NAL Pharma	22071-15-4	2-(3-benzoylphenyl)propanoic acid	No			Discontinued (Clinical)	Pain	C16 H14 O3	Lipoxygenase-cyclooxygenase inhibitors	"NAL Pharma (Originator), NAL Pharma (Owner)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)	NAL 1216			30/08/2016	"Drug Delivery Systems, Pain"		NAL Pharma |  | Unspecified |  | 12 Aug 2016		no		no							https://adis.springer.com/drugs/800047415?userId=52029392&bpIds=3004037004&checksum=d627e87ff51491b1d5ef74d7dc78f50e1f6a2377-1617045529726-84bcf1052f3c1a00cd52f18af401e155badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027930	Flupirtine - Synthetic Biologics	56995-20-1	Ethyl <EM>N</EM>-(2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl)carbamate	Yes			Suspended (II)	"Fibromyalgia, Retinitis pigmentosa"	C15 H17 FN4 O2	"KCNQ potassium channel agonists, NMDA receptor antagonists"	"ASTA Medica (Originator), McLean Hospital (Owner), Synthetic Biologics (Licensee), Meda (Sub-licensee), NNRI (Collaborator)"		PO				"A10X (Other Drugs Used in Diabetes), M3B (Muscle Relaxants, Centrally Acting), N2B (Non-Narcotics and Anti-Pyretics), S1E (Miotics and Antiglaucoma Preparations), S1X (Other Ophthalmologicals)"	"A10X (Other Drugs Used in Diabetes), M03B (Muscle Relaxants, Centrally Acting Agents), N02B-G07 (Flupirtine), S01E (Antiglaucoma Preparations and Miotics), S01X (Other Ophthalmologicals)"	Effirma			19/08/2016	"Eye Disorders, Pain, Rheumatic Disease"			Effirma	no		no							https://adis.springer.com/drugs/800027930?userId=52029392&bpIds=3004037004&checksum=fc3da49bf3d91986954a07dee0cbbfdf805df4a1-1617045529727-2ac53aa6fba72f75f23697f843762b64badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026318	Ketoprofen/omeprazole						Marketed	"Inflammation, Pain"		"Lipoxygenase-cyclooxygenase inhibitors, Proton pump inhibitors"	"Ethypharm (Originator), Ethypharm (Owner), Meda (Market Licensee)"		PO				"M1A2 (Anti-rheumatics, non-steroidal combination), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"Axorid, Keithon, Multicaps, Omeprazole/ketoprofen"			19/08/2016	"Inflammation, Pain"			"Axorid, Axorid, Keithon, Keithon"	no		no							https://adis.springer.com/drugs/800026318?userId=52029392&bpIds=3004037004&checksum=3c83e73c8fa6115d48208e8029d282b7e9afc9d4-1617045529728-56f644a0687e61a15a7f6bebee9907a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022807	Nortriptyline/prednisolone			No			Discontinued (II)	"Allergic asthma, Pain"		"Catecholamine receptor modulators, Steroid receptor agonists, Glucocorticoid receptor agonists"	"CombinatoRx (Originator), Zalicus (Owner)"		PO				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	"CRx170, Prednisolone/nortriptyline CombinatoRx"			01/08/2016	"Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800022807?userId=52029392&bpIds=3004037004&checksum=af8d814aec402071ecc7d8f3b214f8b6ff20be5d-1617045529730-62955e953d78a07941bac490f82c49a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016526	Research programme: calcium channel and sodium channel antagonists - Anabios Corporation			Yes			Discontinued (Preclinical)	Pain		"N type calcium channel antagonists, Sodium channel antagonists"	"Neuromed Pharmaceuticals (Originator), EPIRUS Biopharmaceuticals (Owner), AnaBios Corporation (Licensee), Hydra Biosciences (Collaborator)"		PO				"C (Cardiovascular System), N2 (Analgesics), N3A (Anti-Epileptics)"	"C (Cardiovascular System), N02 (Analgesics), N03A (Antiepileptics)"	"N/TType CCB, NPA, Ntype CCB, Ttype CCB, Z212"			01/08/2016	Pain				no		no							https://adis.springer.com/drugs/800016526?userId=52029392&bpIds=3004037004&checksum=a9a2d0b91471dd5c0b0b57f9f4d02bf5cc3b781e-1617045529731-a5ff89dca3514960cfbbf64b6f829147badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046852	Paracetamol extended release - Altus Formulation	103-90-2	"Acetamide, N-(4-hydroxyphenyl)-"	No			Phase II	Pain	C8 H9 N O2	Prostaglandin receptor antagonists	"Altus Formulation Inc (Originator), Altus Formulation Inc (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	AcetaFlex ER			29/07/2016	Pain		Altus Formulation Inc |  | Phase II |  | 29 Jul 2016	AcetaFlex ER	no		no		"A1AT, A1C, PSA, WT1"	"CD3d, CD3e, CD3g"	"11-Dehydro-thromboxane B2, 7-Hydroxy-6-methyl-8-ribityl lumazine, A1AT, A1C, Acetaminophen glucuronide, Acetylcysteine, Acid ceramidase, Angiopoietin 2, Arachidonic acid, AT-III, C-peptide, C4, CD34, CD3d, CD3e, CD3g, Collagen type 2, CRP, cytochrome P450 family 2 subfamily E member 1, Cytokeratin 18, dsDNA Auto-antibodies, F2-isoprostanes, Fibulin 3 peptides, Glutathione, growth hormone 1, Heme, HMGB1, Hydrocortisone, IFN-gamma, IGFBP7, IL6, insulin receptor related receptor, L-Cysteine, L-Cystine, microRNA 122, MMP-2, NGAL, opioid related nociceptin receptor 1, Osteocalcin, peptidylprolyl isomerase G, peroxiredoxin 5, PHGDH, Prostacyclin, PSA, RAGE, Thromboxane A2, Thromboxane B2, TIMP-2, TNF-alpha, transcription factor 21, VEGF-A, VEGFR, VEGFR1, WT1"	"Acid ceramidase, AT-III, Cytokeratin 18, HMGB1, NGAL, Osteocalcin, PSA"	"ATP binding cassette subfamily G member 2 (Junior blood group), Calreticulin, CTx, CYP2D6, Fe3+, GIP"	https://adis.springer.com/drugs/800046852?userId=52029392&bpIds=3004037004&checksum=6ac0212a471c52e4fbbf43882ed4b7b45cb09c8f-1617045529733-b5fd1e4958ae62a6baa6b4d6172453d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046674	Sodium valproate extended release - Beijing CoSci Med Tech	1069-66-5	"Pentanoic acid, 2-propyl-, sodium salt"	No			Phase Unknown	"Manic episodes, Migraine, Epilepsy"	C8 H15 Na O2	"GABA modulators, Sodium channel modulators"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N5A (Antipsychotics)"	"N02C (Antimigraine Preparations), N03A (Antiepileptics), N05A (Antipsychotics)"				29/07/2016	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800046674?userId=52029392&bpIds=3004037004&checksum=55edc8c3e0c853d324a006319cdd10d457e32db2-1617045529734-0cb1a5726354e67696375da373fb10edbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046684	Valproate semisodium extended release - Beijing CoSci Med Tech	76584-70-8	Sodium;2-propylpentanoate;2-propylpentanoic acid	No			Phase Unknown	"Manic episodes, Migraine, Epilepsy"	C16 H31 Na O4	"GABA modulators, Sodium channel modulators"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics), N5A (Antipsychotics)"	"N02C (Antimigraine Preparations), N03A (Antiepileptics), N05A (Antipsychotics)"				29/07/2016	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders"				no		no							https://adis.springer.com/drugs/800046684?userId=52029392&bpIds=3004037004&checksum=655033fe9c20ce46ee3ac6bdc5e6c26b6fad332a-1617045529735-1e5360c4e1bda88f25bbe3474ada3be6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046640	Naproxen extended release - Beijing CoSci Med Tech	22204-53-1	(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid	No			Phase Unknown	"Musculoskeletal disorders, Dysmenorrhoea"	C14 H14 O3	Cyclooxygenase inhibitors	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-E02 (Naproxen), N02 (Analgesics)"				29/07/2016	"Musculoskeletal Disorders, Women's Health"				no		no							https://adis.springer.com/drugs/800046640?userId=52029392&bpIds=3004037004&checksum=e16d3363f987d8964c0b6a8f73e0cf4e60d3a999-1617045529736-3b3e6ff4ec84148a48d3a6d86de1fa85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046642	Diclofenac extended release - Beijing CoSci Med Tech	15307-86-5	"Acetic acid, (o-(2,6-dichloroanilino)phenyl)-"	No			Phase Unknown	"Musculoskeletal disorders, Pain"	C14 H11 Cl2 N O2	Cyclooxygenase inhibitors	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"M01A-B05 (Diclofenac), N02 (Analgesics)"				29/07/2016	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800046642?userId=52029392&bpIds=3004037004&checksum=527b5e3bdf71db1ae3ae6219fbc9b7d29c21d56d-1617045529737-88bae7ebadfd6f9eabc6ed64f997414fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046637	Indometacin extended release - Beijing CoSci Med Tech	53-86-1	"1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-"	No			Phase Unknown	"Pain, Musculoskeletal disorders"	C19 H16 Cl N O4	"Cyclo-oxygenase 1 inhibitors, Cyclo-oxygenase 2 inhibitors"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-B01 (Indometacin), N02 (Analgesics)"				29/07/2016	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800046637?userId=52029392&bpIds=3004037004&checksum=a10657d37d73da58e253225a2719a6a7cb920270-1617045529738-6aaba9c95cb4e4bf5fa365b61cfe5bd2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046645	Acemetacin extended release - Beijing CoSci Med Tech	53164-05-9	1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid ester with glycolic acid	No			Phase Unknown	"Pain, Arthritis"	C21 H18 Cl N O6	Cyclooxygenase inhibitors	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"M01A-B (Acetic acid derivatives and related substances), N02 (Analgesics)"				29/07/2016	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800046645?userId=52029392&bpIds=3004037004&checksum=207473e2060db6a0353d87f084bd1e0041a3cb34-1617045529739-235256ff11264bfe6b331d1d4e02bc85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046636	Ibuprofen/codeine - Beijing CoSci Med Tech			No			Phase Unknown	Pain		"Cyclooxygenase inhibitors, Opioid mu receptor agonists"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2A (Narcotics)"	"M01A-E01 (Ibuprofen), N02A-A59 (Codeine, combinations excl. psycholeptics)"	Codeine/ibuprofen			25/07/2016	Pain				no		no							https://adis.springer.com/drugs/800046636?userId=52029392&bpIds=3004037004&checksum=871cc3f7404624644bcf1943db8842521317179e-1617045529739-129f2b9538b471537548f4f0fbd20589badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046508	Ibuprofen - Beijing CoSci Med Tech	15687-27-1	"Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-"	No			Phase Unknown	Pain	C13 H18 O2	Cyclooxygenase inhibitors	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				25/07/2016	Pain				no		no							https://adis.springer.com/drugs/800046508?userId=52029392&bpIds=3004037004&checksum=de1d27501fa40cabbfd789cd81c3342dc78cb51f-1617045529740-bd87c70939aa457d0e43a60c5a06a391badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046630	Naproxen/pseudoephedrine - Beijing CoSci Med Tech			No			Phase Unknown	Common cold		"Alpha adrenergic receptor agonists, Cyclooxygenase inhibitors"	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				"N2 (Analgesics), R1B (Systemic Nasal Preparations)"	"M01A-E02 (Naproxen), N02 (Analgesics), R01B-A52 (Pseudoephedrine, combinations)"	Pseudoephedrine/naproxen			25/07/2016	Respiratory Tract Disorders				no		no							https://adis.springer.com/drugs/800046630?userId=52029392&bpIds=3004037004&checksum=58186cafca442b3a1b3421f554bf814d59a1b43d-1617045529741-4c1e903dd93834039c68557c2079d92fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046506	Paracetamol - Beijing CoSci Med Tech	103-90-2	"Acetamide, N-(4-hydroxyphenyl)-"	No			Phase Unknown	"Fever, Pain"	C8 H9 N O2	Prostaglandin receptor antagonists	"Beijing CoSci Med-Tech (Originator), Beijing CoSci Med-Tech (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E01 (Paracetamol)	"Acetaminophen Beijing CoSci Med Tech, Acetaminophen chewable tablet Beijing CoSci Med Tech"			22/07/2016	"Metabolic Disorders, Pain"				no		no							https://adis.springer.com/drugs/800046506?userId=52029392&bpIds=3004037004&checksum=b934569cc6b5fd51b7f5f1237f47b06d6c34c441-1617045529742-9a66417a5d576b88f02fe42856c91727badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046552	BBI 11008			Yes			No development reported (Preclinical)	Inflammatory pain		Opioid delta receptor agonists	"Biousian Biosystems (Originator), Biousian Biosystems (Owner), US Department of Health and Human Services (Funder)"		PO				N2 (Analgesics)	N02A (Opioids)	BBI11008			22/07/2016	Pain				no		no							https://adis.springer.com/drugs/800046552?userId=52029392&bpIds=3004037004&checksum=9bea523084e8df5ebea6f9c8142744bcd40c2bd2-1617045529743-a6d2c3f909b45edda393c64ec2d12684badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046319	Research programme: TRPV4 ligands - Dompe			Yes			Discontinued (Research)	Pain		TRPV4 protein modulators	"Dompe SpA (Originator), Dompe SpA (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				19/07/2016	Pain				no		no							https://adis.springer.com/drugs/800046319?userId=52029392&bpIds=3004037004&checksum=fb5b776e78c3239451f52b9b0705e4554be94555-1617045529743-8cfc1ad8273e079df891b2808f81edc4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046316	Gabapentin - Dompe	60142-96-3	1-(Aminomethyl)-cyclohexaneacetic acid	No			Phase III	Cancer pain	C9 H17 N O2	"CACNA2D1 protein modulators, GABA receptor agonists"	"Dompe SpA (Originator), Dompe SpA (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				19/07/2016	Pain				no		no		Gad65 Auto-antibodies	OCT2	"A1C, chymase 1, EH domain containing 4, FGFR1OP N-terminal like, Gad65 Auto-antibodies, nuclear prelamin A recognition factor like, OCT2, period circadian clock 3 pseudogene, pregnancy specific beta-1-glycoprotein 5, solute carrier family 22 (organic cation/zwitterion transporter), member 4, solute carrier family 25 member 5"	Gad65 Auto-antibodies	"Carbohydrate-deficient transferrin, Creatinine, CYP2D6, endothelin receptor type A, solute carrier family 22 (organic cation/carnitine transporter), member 5, sulfotransferase family 1A member 1"	https://adis.springer.com/drugs/800046316?userId=52029392&bpIds=3004037004&checksum=3999b831d1b46aebfb5c3b67d345dbfd598d5102-1617045529744-e070efbb722e5a0ca2398d920c051c4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032044	Research programme: gabapentin/pregabalin/tapentadol/tramadol - Grunenthal						No development reported (Research)	Pain		"Adrenergic uptake inhibitors, Alpha 2 adrenergic receptor antagonists, CACNA2D1 protein modulators, GABA receptor agonists, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"ProTect Pharmaceuticals (Originator), Grunenthal (Owner)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-X06 (Tapentadol), N02A-X52 (Tramadol, combinations), N02B (Other Analgesics and Antipyretics), N03A-X12 (Gabapentin), N03A-X16 (Pregabalin)"	"NPRx300, PRTT100"			16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800032044?userId=52029392&bpIds=3004037004&checksum=9b64abc56202ad32fa06de5cc897f9ce51c336f0-1617045529745-a09dfbe39766a30662a1b3e566b3ec18badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033479	Research programme: inhaled therapeutics - Acorda Therapeutics			No			No development reported (Research)	"Pain, Lung disorders, Hypersensitivity"		Undefined mechanism	"Civitas Therapeutics (Originator), Acorda Therapeutics (Owner), Alkermes plc (Technology Provider), Bill & Melinda Gates Foundation (Funder), Massachusetts Institute of Technology (Collaborator)"		Inhalation				"N2 (Analgesics), N2C1 (Antimigraine triptans), N4A (Anti-Parkinson Drugs), R4 (Chest Rubs and Other Inhalants), V1A (Allergens)"	"N02 (Analgesics), N02C-C (Selective serotonin (5HT1) agonists), N02C-C03 (Zolmitriptan), N04 (Anti-Parkinson Drugs), R07 (Other Respiratory System Products), V01A (Allergens)"	Inhaled zolmitriptan Acorda Therapeutics			16/07/2016	"Drug Delivery Systems, Immunological Disorders, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800033479?userId=52029392&bpIds=3004037004&checksum=fb7ebeede03decf8d6ef47f92ad61ca6df9a396f-1617045529746-cd3550dd2f04c8867660228ea9dad491badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026859	Research programme: migraine and pain therapeutics - NeurAxon			Yes			No development reported (Preclinical)	"Neuropathic pain, Inflammatory pain, Migraine, Pain"		"Adrenergic receptor modulators, Nitric oxide synthase type I inhibitors, Nitric oxide synthase type II inhibitors, Opioid receptor agonists"	"NeurAxon (Originator), NeurAxon (Owner), Knight Therapeutics (Market Licensee)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"N02A (Opioids), N02B (Other Analgesics and Antipyretics), N02C (Antimigraine Preparations)"	"nNOS inhibitors NeurAxon, nNOS/iNOS NeurAxon, nNOS/NET NeurAxon, nNOS/Opiate NeurAxon"			16/07/2016	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800026859?userId=52029392&bpIds=3004037004&checksum=7ee947d27ebadac0cf7376ea0ed02cbe3772a8bc-1617045529747-c86c427b47a1ce7d5e4f2abd9f23e02cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025299	Research programme: serotonin 7 receptor agonists - Esteve						No development reported (Preclinical)	"Major depressive disorder, Insomnia, Urinary incontinence, Pain, Psychiatric disorders, Migraine, Anxiety disorders"		Serotonin 7 receptor agonists	"Esteve (Originator), Esteve (Owner)"		PO				"G4 (Urologicals), N2 (Analgesics), N2C (Anti-Migraine Preparations), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N6A3 (Mood stabilisers)"	"G04 (Urologicals), N02 (Analgesics), N02C (Antimigraine Preparations), N05A (Antipsychotics), N05B-X (Other anxiolytics), N06A (Antidepressants)"	5HT7 ligands Esteve			16/07/2016	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800025299?userId=52029392&bpIds=3004037004&checksum=0d0273b0c9640d41e6e6997931c5d722405c94fa-1617045529748-5f9856cbf26853a2a6855e81446be675badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030524	Mavatrep	956274-94-5	"Benzenemethanol, _,_-dimethyl-2-[2-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1H-benzimidazol-6-yl]-"	Yes			No development reported (I)	"Musculoskeletal pain, Pain"	C25 H21 F3 N2 O	TRPV1 receptor antagonists	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Janssen Research & Development (Owner)"		PO				N2 (Analgesics)	"N02B (Other Analgesics and Antipyretics), N02B-G (Other analgesics and antipyretics)"	JNJ39439335			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800030524?userId=52029392&bpIds=3004037004&checksum=cd52122c41d0435757b68b2ba073530bda09c1e3-1617045529749-87446572f7a5f7a20222cb793ecb48d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025966	Research programme: opioid receptor agonists - Johnson and Johnson		"<EM>N</EM>,<EM>N</EM>-Diethyl-4-(1-phenyl-1-((1<EM>R</EM>,5<EM>S</EM>)-8-(2-phenylethyl)-8-azabicyclo(3.2.1)oct-3-ylidene)methyl)benzamide"				No development reported (Preclinical)	"Pain, Inflammatory pain"	C33 H38 N2 O	"Opioid delta receptor agonists, Opioid mu receptor agonists"	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		"unspecified, PO"				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	"JNJ20788560, RWJ394674, RWJ413216"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800025966?userId=52029392&bpIds=3004037004&checksum=fc142b4cf2c4b2e9d45995b190e1ac9c380e1b02-1617045529750-daa081836f4736a9f0f4c0c68d1c7b6ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035114	Clopidogrel/aspirin - Hanmi Pharmaceutical						No development reported (I)	Acute coronary syndromes		"Cyclooxygenase inhibitors, Platelet aggregation inhibitors, Purinergic P2 receptor antagonists"	"Hanmi Pharmaceutical (Originator), Hanmi Pharmaceutical (Owner)"		PO				"B1C5 (Platelet aggregation inhibitors, combinations), C (Cardiovascular System)"	"B01A-C04 (Clopidogrel), B01A-C30 (Combinations), C (Cardiovascular System), N02B-A01 (Acetylsalicylic acid)"	aspirin/clopidogrel Hanmi Pharmaceutical			16/07/2016	Ischaemic Heart Disease				no		no							https://adis.springer.com/drugs/800035114?userId=52029392&bpIds=3004037004&checksum=9933833cb39465ac3e187fd12cd538260f4e9522-1617045529751-d350d2b78e3b23556ecc31622f926df6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019167	Syn 1001						No development reported (I)	Pain		Opioid mu receptor agonists	"Synt:em (Originator), Synt:em (Owner)"		IV				N2 (Analgesics)	N02A-F (Morphinan derivatives)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800019167?userId=52029392&bpIds=3004037004&checksum=6c108b6262a1c5b73b53ed726c68afbb48f49a85-1617045529751-802b2e6dcb47d77bbc31d3c48ae82eadbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038342	Research programme: opioid delta receptor agonists - Nippon Chemiphar			Yes			No development reported (Research)	Pain		Opioid delta receptor agonists	"Nippon Chemiphar (Originator), Nippon Chemiphar (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800038342?userId=52029392&bpIds=3004037004&checksum=d03303b0ab3451bb586c6020e51e2e4a02eaafe9-1617045529752-a65eeb906e955c4b624d7acdeed6c396badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036586	Oxycodone controlled-release - GL PharmTech	76-42-6	"Morphinan-6-one,4,5-_-epoxy-14-hydroxy-3-methoxy-17-methyl-"	No			No development reported (I)	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"GL PharmTech (Originator), GL PharmTech (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"GL2907, GL2907 XL, Oxycodone QD, Oxycodone XL"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800036586?userId=52029392&bpIds=3004037004&checksum=c6400f2d513a02834a0dd1a11052e5893bda1688-1617045529753-a1d338691d8046747841ca66ed68a940badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034351	P 3914						No development reported (I)	Dental pain		Cyclooxygenase inhibitors	"Piramal Life Sciences (Originator), Piramal Enterprises (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-E02 (Naproxen), N02B-G (Other analgesics and antipyretics)"	P3914			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034351?userId=52029392&bpIds=3004037004&checksum=005dc0342810a88476e3fa00c1e6cf88f6a8e280-1617045529754-91dd63a1d7184881169fb90da2951793badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032048	PRTT 300						No development reported (Research)	Pain		Opioid receptor agonists	"ProTect Pharmaceuticals (Originator), ProTect Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)				16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800032048?userId=52029392&bpIds=3004037004&checksum=7cdbfeea407c0921b3510d08e4ce49a52e32fa8a-1617045529755-d9b10e86c3b5a70ad9f80cfe4170b97cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032060	Research programme: opioid receptor agonists - Alchemia						No development reported (Research)	Pain		"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Alchemia (Originator), Alchemia (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800032060?userId=52029392&bpIds=3004037004&checksum=46dfcb3e767d37a9358754ba5d4d18f0e59ca750-1617045529756-48bd5a08163a967fd2cf2b6f1cc97094badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036721	Research programme: opioid analgesics - Relmada Therapeutics						No development reported (Preclinical)	Pain		Opioid receptor agonists	"Relmada Therapeutics (Originator), Relmada Therapeutics (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	REL1041			16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800036721?userId=52029392&bpIds=3004037004&checksum=6a9f9e93b1e51e7206195baf036cdb2663bf36ff-1617045529757-e1df81e5d4186988f80ea927865618fcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030942	Research programme: abuse resistant therapeutics - Inspirion Delivery Technologies			No			No development reported (Preclinical)	"Attention-deficit hyperactivity disorder, Pain"		"Adrenergic receptor agonists, Dopamine receptor agonists, Opioid receptor agonists"	"Inspirion Delivery Technologies (Originator), Inspirion Delivery Technologies (Owner)"		PO				"N2A (Narcotics), N6B (Psychostimulants)"	"N02A (Opioids), N06A-B (Selective serotonin reuptake inhibitors)"	"Oxycodone ER, Research programme abuse deterrent therapeutics Inspirion"			16/07/2016	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800030942?userId=52029392&bpIds=3004037004&checksum=e4aba5a1e4f581d6faf632f16c4f4e8ddaf82bf4-1617045529757-cee4154ca22b8628a4ff026a729eb4fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038520	Research programme: abuse-resistant opioid analgesics - Atlantic Pharmaceuticals			No			No development reported (Preclinical)	Pain		Opioid receptor agonists	"Atlantic Pharmaceuticals (Originator), Atlantic Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"ATLP02, ATLP03"			16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800038520?userId=52029392&bpIds=3004037004&checksum=0205ea08f505aacb769478ea5885a11b49017b7a-1617045529758-f3b0b06c3053fb7def0e6ee951fbf766badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033864	Research programme: extended release opioid therapeutics - Acura Pharmaceuticals						No development reported (Research)	Pain		Opioid receptor agonists	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"ER opioids Acura, Extended release opioids Acura, Extendedrelease oxycodone, Oxycodone extendedrelease"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800033864?userId=52029392&bpIds=3004037004&checksum=0a0fe611cef34bcc58efc53b985f44fb356dda8f-1617045529759-9a7ed411e2e3d8e7627564b3dae2f7a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035297	Research programme: oral opioid pain therapeutics - Orexo/Uppsala						No development reported (Research)	Pain		Undefined mechanism	"Orexo (Originator), Uppsala University (Originator), Orexo (Owner), Uppsala University (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800035297?userId=52029392&bpIds=3004037004&checksum=01ec8da6a675843384282d25ee65732e842e177d-1617045529760-c798f3d53cdfe353852abf53a2d6064ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037908	Research programme: abuse-resistant opioid analgesics - Neura Therapeutik						No development reported (Research)	Pain		Opioid receptor agonists	"Neura Therapeutik (Originator), Neura Therapeutik (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"NL001, NL002"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800037908?userId=52029392&bpIds=3004037004&checksum=9e27fbd208982f60b41aa9ecc87f742bb9367686-1617045529760-c9ea1be48021a5935931c60151ac925abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031626	Hydromorphone extended release - Teva Pharmaceutical Industries	71-68-1	"Morphinan-6-one, 4, 5a-epoxy-3-hydroxy-17-methyl-, hydrochloride"	No			No development reported (I)	Pain	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	CEP33236			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031626?userId=52029392&bpIds=3004037004&checksum=1f078826149731afc3265d4995ea492d3deca4df-1617045529761-52af030142e5be3aa6b977a19a5f19d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030154	Tramadol PM	27203-92-5	"(1<EM>R</EM>,2<EM>R</EM>)-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol"	No			No development reported (I)	Pain	C16 H25 N O2	"Opioid mu receptor agonists, Serotonin receptor agonists"	"Circ Pharma (Originator), Circ Pharma (Owner), Perrigo (Development Licensee)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)				16/07/2016	Pain				no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800030154?userId=52029392&bpIds=3004037004&checksum=23bc6fdaa968a3c1f185ca2754ef6645c0f94906-1617045529762-ded5034dae715b4509b2fd4828161e70badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028417	Research programme: migraine therapeutics - Eli Lilly and Company/NOXXON Pharma			Yes			No development reported (Preclinical)	Migraine		Calcitonin gene-related peptide antagonists	"NOXXON Pharma AG (Originator), NOXXON Pharma AG (Owner), Eli Lilly and Company (Licensee)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"NOXC89, NOXL41, Spiegelmer migraine therapeutics Eli Lilly and Company/NOXXON Pharma"			16/07/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800028417?userId=52029392&bpIds=3004037004&checksum=6a2ff0d8cb612389c8de229bb6bdeabed742860f-1617045529763-7523e1f140848b980356bd6dafc8fc29badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019916	Research programme: tension-type headache therapeutics - NsExplorer						No development reported (Preclinical)	Tension type headache		Undefined mechanism	"NsExplorer (Originator), NsExplorer (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				16/07/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800019916?userId=52029392&bpIds=3004037004&checksum=e56d7a714beaf9be8fba1ec9c63ac467faf08dde-1617045529764-c005b0f85154fd44444e383b47a812f9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012002	Donitriptan mesilate		"Indole, 3-aminoethyl-5-[1-(4-cyanophenyl)piperazin-4-yl]carbonylmethoxy-, methanesulphonate"				No development reported (Preclinical)	Migraine	C23 H25 N5 O2 . C H4 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Pierre Fabre (Originator), Pierre Fabre (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	F 12640			16/07/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800012002?userId=52029392&bpIds=3004037004&checksum=6a4cf917ea425c67fc46d0d96fe5e06604071e57-1617045529765-01e353cfa56f81506f06a60f6b7435d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035013	Research programme: EP4 receptor modulators - Ariel Pharmaceuticals						No development reported (Research)	"Migraine, Inflammation"		"Prostaglandin E EP4 receptor antagonists, Prostaglandin E EP4 receptor modulators"	"Ariel Pharmaceuticals (Originator), Ariel Pharmaceuticals (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2C9 (All other anti-migraine preparations)"	"M01 (Antiinflammatory and Antirheumatic Products), N02C-X (Other antimigraine preparations)"	"EP4 receptor agonists Ariel Pharmaceuticals, EP4 receptor antagonists Ariel Pharmaceuticals, Prostanoid EP4 receptor ligands Ariel Pharmaceuticals"			16/07/2016	"Advances in the Treatment of Nausea and Migraine, Inflammation"				no		no							https://adis.springer.com/drugs/800035013?userId=52029392&bpIds=3004037004&checksum=dba5df0f2f3b29bf9c78bd61f14e9beeb89ebb39-1617045529766-ab626f338f13bd5b2b551ad7772a0f30badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022926	Research programme: migraine therapy - GEMACBIO						No development reported (Preclinical)	Migraine		Undefined mechanism	"GEMACBIO (Originator), GEMACBIO (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	GEM MIG			16/07/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800022926?userId=52029392&bpIds=3004037004&checksum=10b6321f4668c845b6837bfc1b4c233dde84fc79-1617045529766-7a9b14c9e4a6d78c3176eb81632ffe66badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036728	Research programme: calcitonin gene-related peptide antagonists - Amgen						No development reported (Preclinical)	Migraine		Calcitonin gene-related peptide receptor antagonists	"Amgen (Originator), Amgen (Owner)"		IV				N2C9 (All other anti-migraine preparations)	N02C-X (Other antimigraine preparations)	AA95			16/07/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800036728?userId=52029392&bpIds=3004037004&checksum=639ae1f9769aadb52657eb654a720cc1e49161f0-1617045529767-c9e3265b45b86099f24481aad460351dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030592	Fentanyl transmucosal - Endo	437-38-7	N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide	No			No development reported (I)	Acute pain	C22 H28 N2 O	Opioid mu receptor agonists	"Auxilium Pharmaceuticals (Originator), Endo International (Owner)"		Transmucosal				N2A (Narcotics)	N02A-B03 (Fentanyl)				16/07/2016	Pain		Auxilium Pharmaceuticals | Pain | Unspecified | World | 01 Feb 2011		no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800030592?userId=52029392&bpIds=3004037004&checksum=5626d18de783f81bd4c8a24a7dfe45ec29188b62-1617045529769-5f5decd70f672367e38e9f2a949527bebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022485	Research programme: pain therapy - WEX Pharmaceuticals						No development reported (Preclinical)	Pain		Undefined mechanism	"WEX Pharmaceuticals (Originator), WEX Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"0302, 0303, 0404, 0405, 0406"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800022485?userId=52029392&bpIds=3004037004&checksum=c6233ca41caf7cecb374bd2cc89f99bb99ec0276-1617045529770-f441cb0e96f9965a1fd7f2764c030a5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032355	Levorphanol - Relmada Therapeutics	77-07-6	17-methylmorphinan-3-ol	No			Phase I/II	Pain	C17 H23 NO	"Adrenergic uptake inhibitors, NMDA receptor antagonists, Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"TheraQuest Biosciences (Originator), Relmada Therapeutics (Owner), Memorial Sloan-Kettering Cancer Center (Collaborator)"		PO				N2A (Narcotics)	N02A (Opioids)	"LevoCap, LevoCap ER, REL 1015, TQ1020"			16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800032355?userId=52029392&bpIds=3004037004&checksum=6dd686a7e9b01a1953d180eb9f2eacd37becc559-1617045529771-6c1759d40ace07de6792d8a6d646bd07badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018005	Research programme: opioid delta receptor agonists - Mt Cook Pharma						No development reported (Preclinical)	"Urination disorders, Major depressive disorder, Parkinson's disease, Neuropathic pain, Ischaemic heart disorders"		Opioid delta receptor agonists	"Enhance Biotech (Originator), Mt Cook Pharma (Owner)"		"unspecified, PO, IV"				"C1X (All Other Cardiac Preparations), G4X (All Other Urological Products), N2A (Narcotics), N4 (Anti-Parkinson Drugs), N6A (Anti-Depressants and Mood Stabilisers)"	"C01E-B (Other cardiac preparations), G04B-X (Other urologicals), N02A (Opioids), N04 (Anti-Parkinson Drugs), N06A (Antidepressants)"	"ARD353, BIO247, BIO305, DPI289, DPI290, MCP203, MCP204, MCP205"			16/07/2016	"Affective Disorders, Genitourinary Disorders, Ischaemic Heart Disease, Pain, Parkinson's Disease and Movement Disorders"		Mt Cook Pharma |  (Excluding Urination disorders) | Clinical Phase Unknown |  | 04 Feb 2011		no		no							https://adis.springer.com/drugs/800018005?userId=52029392&bpIds=3004037004&checksum=f594de3ef187add1c647d7db2905ea3aae7305fb-1617045529773-d73f2a93a19cb6618c89458050305903badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031863	Research programme: abuse resistant therapeutics - Pisgah						No development reported (Preclinical)	"Pain, Attention-deficit hyperactivity disorder, Depressive disorders"		"Opioid receptor agonists, Adrenergic receptor agonists, Adrenergic uptake inhibitors, Central nervous system stimulants, Serotonin uptake inhibitors"	"Pisgah Labs (Originator), Pisgah Labs (Owner)"		"Intranasal, PO, unspecified"				"N2A (Narcotics), N6A (Anti-Depressants and Mood Stabilisers), N6B (Psychostimulants)"	"N02A (Opioids), N06A-A (Non-selective monoamine reuptake inhibitors), N06B (Psychostimulants, agents used for ADHD and nootropics)"	"ephedrine (abusedeterrent) Pisgah, hydrocodone/paracetamol (abusedeterrent) Pisgah, pseudoephedrine (abusedeterrent) Pisgah"			16/07/2016	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031863?userId=52029392&bpIds=3004037004&checksum=a3364e9d9c29532612c25057b90944d396a2c88f-1617045529774-67378ee990657bc9e0bf3f2f2d5368bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032773	Research programme: neuropathic pain therapeutic - Daewoong Pharmaceutical						No development reported (Research)	Neuropathic pain		Undefined mechanism	"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DWJ207			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800032773?userId=52029392&bpIds=3004037004&checksum=bad0903d03fa27c3c932aed99fb59732b79a1944-1617045529775-426d3c09538cb3999178632a84a5c7cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035036	Research programme: neuropathic pain therapeutics - SK biopharmaceuticals						No development reported (Preclinical)	Neuropathic pain		Undefined mechanism	"SK biopharmaceuticals (Originator), SK biopharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800035036?userId=52029392&bpIds=3004037004&checksum=92d2d4fee6afbc432e3f37e6ed612e0686ae15d2-1617045529776-d2828d2b54e44de9ea7599e56cb9a5cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017254	NT 13			Yes			No development reported (Preclinical)	"Stroke, Neuropathic pain, CNS disorders"		NMDA receptor modulators	"Nyxis Neurotherapies (Originator), Nyxis Neurotherapies (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"				16/07/2016	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800017254?userId=52029392&bpIds=3004037004&checksum=95c113b20898291cc458a9d0bdfe22f636e47976-1617045529777-c529a7b848eabdbfec09cc8261bdead6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027226	Research programme: non-narcotic analgesics - Alte Biosciences						No development reported (Preclinical)	Pain		Undefined mechanism	"Alte Biosciences (Originator), Alte Biosciences (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Oraleze products			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800027226?userId=52029392&bpIds=3004037004&checksum=1ca63dd155fe28c9ed38939946a2418c027ced1c-1617045529778-d1579d2ac83d04f034656fc706f7551cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034897	BL 7050						No development reported (Preclinical)	"Inflammatory pain, Neuropathic pain"		Potassium channel modulators	"Ramot at Tel Aviv University (Originator), Ramot at Tel Aviv University (Owner), BioLineRx (Licensee)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	BL7050			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034897?userId=52029392&bpIds=3004037004&checksum=84e733ccaf054a25325b18023423e5c8984879c0-1617045529779-e2a74331979754c3a06eae2a7caa8b0ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027136	Research programme: analgesics and neurodegenerative disorders therapies - Biogen/BSi			Yes			No development reported (Research)	"Multiple sclerosis, Pain, Neurodegenerative disorders, Alzheimer's disease"		Undefined mechanism	"Biogen Idec (Originator), Johns Hopkins Brain Science Institute (Originator), Biogen (Owner), Johns Hopkins Brain Science Institute (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"	BSiBiogen Idec Research Program			16/07/2016	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027136?userId=52029392&bpIds=3004037004&checksum=a376df9c35646a56dcd0dac7647de3e255ec7f58-1617045529781-a071f0c6b518b3e35c968a059298ff51badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023169	Research programme: neuropathic pain therapies - Neurosciences Victoria						No development reported (Preclinical)	Neuropathic pain		Sodium channel antagonists	"Neurosciences Victoria (Originator), Neurosciences Victoria (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800023169?userId=52029392&bpIds=3004037004&checksum=9f80aff2149f8c3c7e42acda8b73597905543995-1617045529782-af64f72dcdb5a5f9897297f8d3929b4fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037932	Research programme: calcium channel modulators - Grunenthal						No development reported (Research)	Pain		Calcium channel modulators	"Grunenthal (Originator), Grunenthal (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Cav2.2 modulators Grunenthal, Pain Cav2.2 Grunenthal"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800037932?userId=52029392&bpIds=3004037004&checksum=277dc102dce7540fc79548905004dd3b06ba1d3b-1617045529783-8a6ba6ebab5e9e51a360b7b4b273008ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032803	Research programme: ENT-1 inhibitors - Johnson and Johnson						No development reported (Preclinical)	"Pain, Inflammation"		Equilibrative nucleoside transporter 1 inhibitors	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		unspecified				"L (Antineoplastic and Immunomodulating Agents), N2 (Analgesics)"	"L (Antineoplastic and Immunomodulating Agents), N02 (Analgesics)"				16/07/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800032803?userId=52029392&bpIds=3004037004&checksum=65636247e81bdcd72ae27a70b06a7d3bd3aedd16-1617045529784-0f86745ae95d274774269b27cb7d841bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033323	Research programme: metabotropic glutamate receptor modulators - Sunovion						No development reported (Preclinical)	"Anxiety disorders, Autistic disorder, Pain"		Metabotropic glutamate receptor 5 modulators	"Sunovion Pharmaceuticals (Originator), Sunovion Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N7 (Other CNS Drugs)"	"N02 (Analgesics), N05B (Anxiolytics), N07 (Other Nervous System Drugs)"				16/07/2016	"Affective Disorders, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800033323?userId=52029392&bpIds=3004037004&checksum=6851a56af989e768b4dc5ed9cd599161753d7f3b-1617045529785-019f215cd091dd81dbc55adf0449da55badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032304	Research programme: pain therapeutics - Essen BioScience/Nycomed						No development reported (Research)	Pain		Ion channel modulators	"Essen BioScience (Originator), Nycomed (Originator), Essen BioScience (Owner), Takeda (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800032304?userId=52029392&bpIds=3004037004&checksum=99a7049fe3e0774bbd5121817f4837660dd2ad44-1617045529827-fe522ac5409581a6ecfa0e69f9ff9a90badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038167	BNV 220			Yes			No development reported (Preclinical)	"Pain, Cancer"		Undefined mechanism	"Bionevia Pharmaceuticals (Originator), Bionevia Pharmaceuticals (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	BNV220			16/07/2016	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800038167?userId=52029392&bpIds=3004037004&checksum=35587276a0982ce01c3787161bd55036cad776f5-1617045529828-2aeee8bb5c7e31ca5ba48201e57ab21cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031756	Research programme: pain therapeutics - MedImmune/Xenome						No development reported (Research)	Pain			"MedImmune (Originator), Xenome (Originator), MedImmune (Owner), Xenome (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Venom peptide therapeutics Xenome/MedImmune			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031756?userId=52029392&bpIds=3004037004&checksum=d89528f8e8264efbc946e0a739e8966e104466aa-1617045529829-d68b4cbe87350880ce00f373ddaf00e0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030992	Research programme: neuropathic pain therapeutics - Indigene Pharma						No development reported (Research)	Neuropathic pain			"Indigene Pharmaceuticals (Originator), Indigene Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IGCN023			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800030992?userId=52029392&bpIds=3004037004&checksum=4e263059d1db5ecb175184c6a34122d1d3476330-1617045529829-96308bac0d3a37f2ef2a2c02f7131fc9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025756	Research programme: NMDA receptor agonists - Tikvah	68-41-7	"3-Isoxazolidinone, 4-amino-, (+)- (8Cl)"	Yes			No development reported (Preclinical)	"Anxiety disorders, Pain"	C3 H6 N2 O2	NMDA receptor agonists	"Apkarian Technologies LLC (Originator), Therapade Technologies LLC (Originator), Apkarian Technologies LLC (Owner), Therapade Technologies LLC (Owner), Tikvah Therapeutics (Licensee)"		"PO, unspecified"				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers)"	"N02 (Analgesics), N05B (Anxiolytics)"				16/07/2016	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800025756?userId=52029392&bpIds=3004037004&checksum=48b3a10ff089233de7dbe6525cc84b28d9230820-1617045529830-6be16a4d8f270de94fa233a3f1ca8eb3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037225	Research programme: protein inhibitors - ProMining Therapeutics						No development reported (Research)	"Cardiovascular disorders, Cancer, Inflammatory pain, Inflammation"		Protein inhibitors	"ProMining Therapeutics (Originator), ProMining Therapeutics (Owner)"		PO				"C1 (Cardiac Therapy), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"C01 (Cardiac Therapy), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				16/07/2016	"Cancer, Inflammation, Ischaemic Heart Disease"		ProMining Therapeutics |  | Unspecified |  | 20 Dec 2012		no		no							https://adis.springer.com/drugs/800037225?userId=52029392&bpIds=3004037004&checksum=4080918bec57afa6095731531c97686d5c8c46ce-1617045529831-ec36499bca961d382d6f5a5e5c7db28dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036099	Research programme: pain therapeutics - Reviva Pharmaceuticals						No development reported (Research)	Pain		Undefined mechanism	"Reviva Pharmaceuticals (Originator), Reviva Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	RP8000 Reviva Pharmaceuticals			16/07/2016	Pain		Reviva Pharmaceuticals |  | Unspecified |  | 27 Jun 2012		no		no							https://adis.springer.com/drugs/800036099?userId=52029392&bpIds=3004037004&checksum=334d68255786ab6ab013d409f9b473b8ef0cb9ee-1617045529832-cc71d7a124611fc3b2fa534bbc0eedeabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026923	URG 301						No development reported (I)	"Pain, Overactive bladder"		Undefined mechanism	"Urigen Pharmaceuticals (Originator), Urigen Pharmaceuticals (Owner)"		Transurethral				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	URG301			16/07/2016	"Drug Delivery Systems, Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800026923?userId=52029392&bpIds=3004037004&checksum=36b5eae2c3d9fbcf1354eb96d2f602acec1320f9-1617045529833-14f41cb9654a466017042f7f4104fae9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028924	Research programme: TRPV1 receptor antagonists - Traxion Therapeutics						No development reported (Preclinical)	Pain		TRPV1 receptor antagonists	"Traxion Therapeutics (Originator), Traxion Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TXT0400			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800028924?userId=52029392&bpIds=3004037004&checksum=97b991fc8243894c8c5f262e8a64b61ec00718ce-1617045529833-9574fba370246fcb3ffbd6fb6c3e4278badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030745	MR 1817						No development reported (I)	Pain		TRPV1 receptor antagonists	"Mochida Pharmaceutical (Originator), Mochida Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"MR1817, VRA175"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800030745?userId=52029392&bpIds=3004037004&checksum=fb7c79e9ae1bf9c7ecaa184f5b08a46e86393caa-1617045529834-d57c18148d1962d4da9906dee9598a28badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025800	Research programme: PKCe-targeted therapeutics - VM Discovery						No development reported (Preclinical)	"Pain, Alcoholism, Cancer"		Protein kinase modulators	"VM Discovery (Originator), VM Discovery (Owner)"		unspecified				"L1 (Antineoplastics), N2 (Analgesics), N7E (Drugs Used In Alcohol Dependence)"	"L01 (Antineoplastic Agents), N02 (Analgesics), N07B (Drugs Used In Addictive Disorders)"	VMDC620			16/07/2016	"Cancer, Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800025800?userId=52029392&bpIds=3004037004&checksum=fcfc6b4d79c92e1f4624efe683d202455533504c-1617045529835-74908f870d28061e1ccbd55b6f3a7389badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030283	Research programme: pain therapeutics - Zambon						No development reported (Research)	Pain			"Yissum Research Development Company (Originator), Yissum Research Development Company (Owner), Zambon Company SpA (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800030283?userId=52029392&bpIds=3004037004&checksum=5f39dd96e94f3df3fe5313a7eec895d8def24274-1617045529836-11fd0b5521fc4fc6f1d22c66d8cdab8ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031157	Research programme: cannabinoid 2 receptor agonists - Pfizer						No development reported (Preclinical)	Inflammation		Cannabinoid receptor CB2 agonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"CB2 receptor agonists Pfizer, GW 405833"			16/07/2016	Inflammation				no		no							https://adis.springer.com/drugs/800031157?userId=52029392&bpIds=3004037004&checksum=dccbe49dad3587770223a2114c281c51f6447741-1617045529836-3b6c8d55826b82ce24aba2c2f9d474ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034682	Research programme: cytokine synthesis inhibitors - Angelini						No development reported (Preclinical)	"Prostate cancer, Inflammatory pain, Neuropathic pain, Uveitis, Inflammatory bowel diseases, Breast cancer"		"Chemokine CCL2 inhibitors, Cytokine inhibitors"	"Angelini Group (Originator), Angelini Group (Owner)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), L1 (Antineoplastics), N2 (Analgesics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"A07E (Intestinal Antiinflammatory Agents), L01 (Antineoplastic Agents), N02 (Analgesics), S01B-C (Antiinflammatory agents, non-steroidals)"				16/07/2016	"Cancer, Eye Disorders, Inflammatory Bowel Disorders, Pain"				no		no							https://adis.springer.com/drugs/800034682?userId=52029392&bpIds=3004037004&checksum=0a2b0a2701d5d527c0cdd3b4ea2019467c641201-1617045529837-cc6d023317a992fb78ef300d32923003badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029951	Research programme: TRPV1 antagonists - Merck						No development reported (Preclinical)	Pain		TRPV1 receptor antagonists	"Schering-Plough (Originator), Merck & Co (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800029951?userId=52029392&bpIds=3004037004&checksum=bb0d13c35246753efa1d810da6425e16dccc46ec-1617045529838-0aa00e113dd163a7b9f42b0fa08f58cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029342	Research programme: glycine receptor agonists - AstraZeneca						No development reported (Preclinical)	Pain		Glycine agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800029342?userId=52029392&bpIds=3004037004&checksum=b911d55e8094c3d6e5641857323ddc0ede894899-1617045529839-e863b6cfdc2a669464ca0358f5085cb3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023657	Research programme: pain therapeutics - St. Charles Pharmaceuticals						No development reported (Preclinical)	Pain		Undefined mechanism	"St. Charles Pharmaceuticals (Originator), St. Charles Pharmaceuticals (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	SCP123			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800023657?userId=52029392&bpIds=3004037004&checksum=f261b475f5225a8f033b5e57381596102e3c9ebe-1617045529840-748d96ac9501098239577c6fb69cbba7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025228	Research programme: pain therapeutics - SRI International						No development reported (Preclinical)	Pain		"Nociceptin receptor agonists, Nociceptin receptor antagonists"	"SRI International (Originator), SRI International (Owner)"		Injection				N2 (Analgesics)	N02 (Analgesics)	"Nociceptin agonists SRI International, Nociceptin antagonists SRI International, NOP agonists SRI International, NOP antagonists SRI International, SR 14148, SR 14150, SR 16430, SR 16435, SR 165606"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800025228?userId=52029392&bpIds=3004037004&checksum=81c21a4ea9ae0c43b5acc8816bc45598aba8a97f-1617045529841-f6c20364308a69a4adc5c02ab98eb529badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034179	Research programme: cancer pain therapeutics - Benitec						No development reported (Preclinical)	Cancer pain		"D amino acid oxidase inhibitors, Gene silencing, Protein kinase C gamma inhibitors, RNA interference"	"Benitec Ltd (Originator), Benitec Ltd (Owner)"		Intrathecal				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034179?userId=52029392&bpIds=3004037004&checksum=2e84feb217048f2285f679b1bfd6cf2c12b19186-1617045529841-d95c652a1f6ad9e9d6ff743f68259218badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034755	Research programme: therapeutic agents - HUYA Bioscience/Shanghai Jiao Tong University						No development reported (Research)	Pain		Undefined mechanism	"Shanghai Jiao Tong University (Originator), Shanghai Jiao Tong University (Owner), HUYA Bioscience International (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034755?userId=52029392&bpIds=3004037004&checksum=b542d2823d4daf7825cdcc7ee9e8e86a5bbc1620-1617045529842-510c2f0013b21bf2e3fe6163b7742034badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035132	ABT 272						No development reported (I)	Pain		Alpha7 nicotinic acetylcholine receptor agonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ABT272			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800035132?userId=52029392&bpIds=3004037004&checksum=8a2f406a5428e8f1ba3094cc8d5829f499d3a0a8-1617045529843-29e3bf2cf27f96550b5cd9c37b604e9fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026897	Research programme: NMDA receptor antagonists - AstraZeneca						No development reported (Preclinical)	"Pain, Neuropathic pain"		NMDA receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	NmethylDaspartate receptor antagonists AstraZeneca			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800026897?userId=52029392&bpIds=3004037004&checksum=aff97f007da62c9ad97b45cd46dccb25b1503583-1617045529844-2bd72e024d43d86b7c599c25ff5e57febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028973	Research programme: chloride channel modulators - Chlorion Pharma			Yes			No development reported (Preclinical)	"Neurological disorders, Partial epilepsies, Neuropathic pain"		Chloride channel modulators	"Chlorion Pharma (Originator), Chlorion Pharma (Owner)"		unspecified				"N (Nervous System), N2 (Analgesics), N3A (Anti-Epileptics)"	"N (Nervous System), N02 (Analgesics), N03A (Antiepileptics)"	"CL301, CLP290"			16/07/2016	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800028973?userId=52029392&bpIds=3004037004&checksum=c3dba902aa46cb5860c01da680351585ed3d1425-1617045529845-50e3f20fc9026d63637770f8fcc2910fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032544	Research programme: diabetic neuropathic pain therapeutics - Galapagos/University of Bristol						No development reported (Research)	Neuropathic pain		Undefined mechanism	"Galapagos NV (Originator), Galapagos NV (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800032544?userId=52029392&bpIds=3004037004&checksum=070cb92c04a54dda7c3eca2c9638ce7bf4482d03-1617045529845-aba7bc20dca87ef935d4f9216d83082cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032941	Research programme: cannabinoid receptor CB2 agonists - Merck						No development reported (Preclinical)	Pain		Cannabinoid receptor CB2 agonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics)"				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800032941?userId=52029392&bpIds=3004037004&checksum=ba83860379f3321b6a77b68d42986dee0fe562e0-1617045529846-d4d8bb0aab0feafbee2c78cee31978c9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031242	Research programme: CNS disorders therapeutics - NeuroTherapeutics Pharma			Yes			No development reported (Preclinical)	"Pain, Epilepsy"		Symporter inhibitors	"NeuroTherapeutics Pharma (Originator), NeuroTherapeutics Pharma (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	NTP2014			16/07/2016	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031242?userId=52029392&bpIds=3004037004&checksum=b160d31d7cd140bf23054b9535ad984cd2222cc1-1617045529847-10dbb0df1d453a5d9fccf807daaf0ef4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025242	Research programme: siRNA neuropathic pain therapeutics - Alnylam Pharmaceuticals			Yes			No development reported (Preclinical)	Neuropathic pain		"Neuropeptide Y receptor antagonists, RNA interference, Sodium channel antagonists"	"Alnylam Pharmaceuticals (Originator), Alnylam Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800025242?userId=52029392&bpIds=3004037004&checksum=b0aebef95d3c957019347c109f7258f8138b33d8-1617045529848-517bb3379f16b32510f33c72534e4daebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026403	Research programme: pain therapeutics - Cameleon/NeuroSolutions						No development reported (Preclinical)	"Neuropathic pain, Pain"		Undefined mechanism	"Cameleon (Originator), NeuroSolutions (Originator), Cameleon (Owner), NeuroSolutions (Owner), Gentronix (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	NSL105			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800026403?userId=52029392&bpIds=3004037004&checksum=1b2e19cf4eba1f59ee4c98012a4857a1cc9a6308-1617045529848-c6d704b73abb5a009d53a4de3db31ccdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036623	Research programme: cannabinoid and kappa-opioid receptor modulators - Nectid						No development reported (Research)	"Cancer pain, Pain, Neuropathic pain, Diabetes mellitus"		"Opioid kappa receptor agonists, Cannabinoid receptor modulators"	"Nectid (Originator), Nectid (Owner)"		unspecified				"A10 (Drugs Used in Diabetes), N2 (Analgesics)"	"A10 (Drugs Used in Diabetes), N02 (Analgesics)"	"NRT11, NRT12, NRT20"			16/07/2016	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800036623?userId=52029392&bpIds=3004037004&checksum=845c7d32cd46b32f5b5c14908111fd5c2dc3a2c0-1617045529850-5632a022820d68d97d7b029906b065ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034374	Research programme: pain therapeutics - Maruho			Yes			Preclinical	"Neuropathic pain, Inflammatory pain"		"Sodium channel antagonists, T type calcium channel antagonists"	"RaQualia Pharma (Originator), RaQualia Pharma (Owner), Maruho (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Ttype calcium channel/voltagegated sodium channel blocker Maruho			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034374?userId=52029392&bpIds=3004037004&checksum=92c00af008cadcc199296e0e991afda00fe989ad-1617045529850-7b99edbc2b1e70562a84dab4bd3db34cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033642	Research programme: pain therapeutics - BIOALVO						No development reported (Preclinical)	Pain		Cyclo-oxygenase 2 inhibitors	"BIOALVO (Originator), BIOALVO (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"BLV0704, BLV200704, PAIN programme BIOALVO"			16/07/2016	Pain		BIOALVO | Pain | Preclinical | World | 15 Feb 2011		no		no							https://adis.springer.com/drugs/800033642?userId=52029392&bpIds=3004037004&checksum=a729b2b12eaa7dbf651ab17653da7846f67f5dad-1617045529851-b9a6c0a085806a3bc5d43198138c200abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033033	Research programme: calcium channel modulators - Biogen			Yes			No development reported (Preclinical)	Pain		Calcium channel modulators	"Calchan (Originator), GlaxoSmithKline (Originator), Calchan (Owner), GlaxoSmithKline (Owner), Selcia (Technology Provider), Biogen (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Cav2.2 Biogen, Cav2.2 modulators Biogen"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800033033?userId=52029392&bpIds=3004037004&checksum=b666b0d11b6cd79397ffff4c2cfee2bc232ea4b0-1617045529852-db2607e41f5cde1e180fa1ad9d484c7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024798	Research programme: suprofenac - CIS Pharma						No development reported (Preclinical)	"Pain, Ocular inflammation"		Cyclooxygenase inhibitors	"CIS Pharma (Originator), CIS Pharma (Owner)"		"Transdermal, Ophthalmic"				"M2 (Topical Anti-Rheumatics), N2 (Analgesics)"	"M02A-A (Antiinflammatory preparations, non-steroids for topical use), N02 (Analgesics)"	"diclofenacprodrug, suprofenac"			16/07/2016	"Eye Disorders, Pain"				no		no							https://adis.springer.com/drugs/800024798?userId=52029392&bpIds=3004037004&checksum=2af66f053cc9a787642cce440e4d9a8ef65e3ac0-1617045529853-b3751dc32b282c3429b7ab072d25b60abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034091	Research programme: TRPV1 agonists - Sumitomo Dainippon Pharma/Maruho						No development reported (Preclinical)	Neuropathic pain		TRPV1 receptor agonists	"Dainippon Sumitomo Pharma (Originator), Sumitomo Dainippon Pharma (Owner), Maruho (Licensee)"		Topical				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034091?userId=52029392&bpIds=3004037004&checksum=0d5c45c2e0da5e3b433845a7e68652464f572b94-1617045529853-763ce116c82757ef49cf9ac648854ed9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026373	Research programme: neurostabilising therapeutics - Cambria Pharmaceuticals			Yes			No development reported (Preclinical)	"Pain, Epilepsy"		Undefined mechanism	"Cambria Biosciences LLC (Originator), Cambria Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N3 (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	"CMB00208, CMB00294, CMB00792, CMB44349"			16/07/2016	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800026373?userId=52029392&bpIds=3004037004&checksum=b64e20060d6ff22cb167074f2f9192158b994cfd-1617045529854-bd1947bc581260c764097116113267f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029786	GSK 1482160						No development reported (I)	Inflammatory pain		Purinergic P2X7 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"1482160, GSK1482160"			16/07/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800029786?userId=52029392&bpIds=3004037004&checksum=994809dc2d484ca72cf25864f1a69ff56da46527-1617045529855-f103b3bdf9959ca71fb27362d5457c2dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031753	Research programme: transmucosal therapeutics - Endo			No			No development reported (Preclinical)	"Pain, Bladder dysfunction"			"Auxilium Pharmaceuticals (Originator), Endo International (Owner)"		Transmucosal				"G4 (Urologicals), N2 (Analgesics)"	"G04B (Urologicals), N02 (Analgesics)"				16/07/2016	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031753?userId=52029392&bpIds=3004037004&checksum=c3c918552cd310ddddde8b1548d1e33fba80ceae-1617045529856-d675ff49adc73856a81c8efdbf7eb666badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034915	Research programme: ion channel modulators - Grunenthal/Xention						No development reported (Research)	Pain		Ion channel modulators	"Grunenthal (Originator), Xention (Originator), Grunenthal (Owner), Xention (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034915?userId=52029392&bpIds=3004037004&checksum=cb688d5300db75779ca82735a44c4c65eca65412-1617045529856-4628fc2d140e829e679cc1268f4e2168badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027754	Research programme: TRPV1 cation channel inhibitors - Mochida						No development reported (Research)	Pain		TRPV1 receptor antagonists	"Mochida Pharmaceutical (Originator), Mochida Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	M 68008			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800027754?userId=52029392&bpIds=3004037004&checksum=e22a1d8df277293c1980c5c3bf05d9e64fc11ea3-1617045529857-314d628172365968bdec7004405eb20dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031075	Research programme: neurodegenerative disorders/pain therapeutics - Mimetogen Pharmaceuticals						No development reported (Research)	"Neurodegenerative disorders, Pain"		Neuron stimulants	"Mimetogen Pharmaceuticals (Originator), Mimetogen Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				16/07/2016	"Neurological Disorders, Pain"		Mimetogen Pharmaceuticals |  | Preclinical |  | 08 Oct 2009		no		no							https://adis.springer.com/drugs/800031075?userId=52029392&bpIds=3004037004&checksum=a6382073a59bf5e15eb7c340adb360d69eee66f4-1617045529858-a00b7b24d3a506e77ac667ee237de6ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027216	Research programme: endothelin receptor antagonists - Chicago Labs						No development reported (Preclinical)	"Alzheimer's disease, Stroke, Pain"		Endothelin receptor antagonists	"Chicago Labs (Originator), Chicago Labs (Owner)"		unspecified				"N2 (Analgesics), N7D (Anti-Alzheimer Products), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				16/07/2016	"Alzheimer's Disease and Cognition Disorders, Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800027216?userId=52029392&bpIds=3004037004&checksum=6b1445bc56882aa2469e8a093785189552418cc9-1617045529859-a5ae987465d6b8cc3741a1b6eeef3290badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022092	Research programme: neurokinin-2 receptor antagonists - Menarini						No development reported (Preclinical)	"Pain, Asthma"		Neurokinin 2 receptor antagonists	"Menarini (Originator), Menarini (Owner)"		unspecified				"N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	Tachykinin NK2 receptor antagonists Menarini			16/07/2016	"Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800022092?userId=52029392&bpIds=3004037004&checksum=1f1a8c9de72264dd640c1ef2980dc2066bc23b3c-1617045529859-288a6c2bb54009a5d6ccac2af4238e17badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031755	Research programme: analgesics - Xenome						No development reported (Preclinical)	Pain		Opioid kappa receptor agonists	"Xenome (Originator), Xenome (Owner)"		Parenteral				N2 (Analgesics)	N02 (Analgesics)	XenKappa			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031755?userId=52029392&bpIds=3004037004&checksum=ff9b653f49daf21b3cabed08ab242f86aa4de930-1617045529860-339836996e4e817d7f185630350c7826badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024952	Research programme: mu opioid agonists - Xsira Pharmaceuticals						No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"Xsira Pharmaceuticals (Originator), Xsira Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800024952?userId=52029392&bpIds=3004037004&checksum=3a6e961a8a8bd779ea00b7cf46aab0eb9e52e790-1617045529861-b840e2b1bcd8b8e43b035c51b40abe7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033648	Research programme: potassium channel agonists - Grunenthal						No development reported (Preclinical)	Pain		"KCNQ potassium channel agonists, TSPO protein modulators"	"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	Kv7.2/3 agonist			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800033648?userId=52029392&bpIds=3004037004&checksum=0915881df8874a95e66b0c7386208098eb290e1c-1617045529861-838e3566b4e29b204de1f30c0de26f63badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022560	Research programme: sigma receptor-targeting therapeutics - Esteve			Yes			No development reported (Preclinical)	"Psychotic disorders, Pain"		Sigma receptor antagonists	"Esteve (Originator), Esteve (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics)"	"N02 (Analgesics), N05A (Antipsychotics)"	Sigma therapeutics Esteve			16/07/2016	"Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800022560?userId=52029392&bpIds=3004037004&checksum=51ed34c8107c51acd5360f180dd38c388d5bac8e-1617045529862-0a8240baa2eac6780b03a5a0a6e16386badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024453	LPCN 1029						No development reported (I)	Pain		Undefined mechanism	"Lipocine (Originator), Lipocine (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800024453?userId=52029392&bpIds=3004037004&checksum=c25ebc65587e95eb27db8a19d57779c834eae621-1617045529863-6f1e344bbd0869e35c440f27a636a74ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031757	Research programme: G protein-coupled receptor modulators - Axxam/Xenome						No development reported (Research)	"Eye disorders, Obesity, Pain, Metabolic disorders"		"G protein-coupled receptor modulators, GPR120 protein stimulants"	"Axxam (Originator), Xenome (Originator), Axxam (Owner), Xenome (Owner)"		unspecified				"A8A (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), S1X (Other Ophthalmologicals), V3 (All Other Therapeutic Products)"	"A08A (Antiobesity Preparations, Excl. Diet Products), N02 (Analgesics), S01X (Other Ophthalmologicals), V03A (All Other Therapeutic Products)"	GPR120 agonist Axxam			16/07/2016	"Eye Disorders, Metabolic Disorders, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800031757?userId=52029392&bpIds=3004037004&checksum=de13bfadd8e53bcdcd9d83145c7d9520c78ae2b4-1617045529864-cedbcd513edb446009423d64ed6466b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027615	Research programme: encapsulated anaesthetics - Capsulated Systems						No development reported (Preclinical)	"Postoperative pain, Pain"		Undefined mechanism	"Capsulated Systems (Originator), Capsulated Systems (Owner)"		Parenteral				"N1 (Anaesthetics), N2 (Analgesics)"	"N01 (Anesthetics), N02 (Analgesics)"				16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800027615?userId=52029392&bpIds=3004037004&checksum=b4036e1d925d92e2c9152372337708440f47cd70-1617045529865-c1076231ca68c6cb9653bd6d4f2e6372badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031724	Research programme: pain therapeutics - Almirall/Esteve/Palau Pharma/Proteomika						No development reported (Preclinical)	Musculoskeletal pain			"Almirall S.A. (Originator), Esteve (Originator), Palau Pharma (Originator), Proteomika (Originator), Almirall S.A. (Owner), Esteve (Owner), Palau Pharma (Owner), Proteomika (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Neogenius Pharma project			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031724?userId=52029392&bpIds=3004037004&checksum=8c9ad18a33c69e7229bfa29dc93c0816039146d0-1617045529865-61d1bbd099051c0f6d19562f2a52ebccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028923	Research programme: N-type calcium channel antagonists - Traxion Therapeutics						No development reported (Preclinical)	Neuropathic pain		N type calcium channel antagonists	"Traxion Therapeutics (Originator), Traxion Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TXT0200			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800028923?userId=52029392&bpIds=3004037004&checksum=72770ee02b024cc0a6ede3aea4e6eeea77dee23b-1617045529866-99e1bb5dd188808f0336f5a8b1ca2278badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031616	Research programme: intranasal analgesics - Trigemina			No			No development reported (Preclinical)	Pain			"Trigemina (Originator), Trigemina (Owner)"		Intranasal				N2 (Analgesics)	N02 (Analgesics)	"TI 002, TRI 002"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031616?userId=52029392&bpIds=3004037004&checksum=2df1e744aff39589e12c9f56567dbb0868a0decf-1617045529867-82b2326604952270ba3907dbf4393093badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034532	Research programme: 5-lipoxygenase inhibitors - Panmira Pharmaceuticals						No development reported (Preclinical)	"Cardiovascular disorders, Pain"		5-lipoxygenase inhibitors	"Amira Pharmaceuticals (Originator), Panmira Pharmaceuticals (Owner)"		unspecified				"C6A (Other Cardiovascular Products), N2 (Analgesics)"	"C (Cardiovascular System), N02 (Analgesics)"				16/07/2016	"Pain, Vascular Disorders"				no		no							https://adis.springer.com/drugs/800034532?userId=52029392&bpIds=3004037004&checksum=8691e8b2d3210a4bc48cbc73b466cd8ab5e4d74b-1617045529868-7e3bd38e246b31721a2a652c4dad6e33badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031944	Research programme: ion channel modulators - Axxam/Polyphor						No development reported (Research)	"Metabolic disorders, Pain, Inflammation"		Ion channel modulators	"Axxam (Originator), Polyphor (Originator), Axxam (Owner), Polyphor (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A16 (Other Alimentary Tract and Metabolism Products), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				16/07/2016	"Inflammation, Metabolic Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031944?userId=52029392&bpIds=3004037004&checksum=51d731346470366afa929e193d38cf00dc75a1a4-1617045529869-5ae8cd03c54ca9eb685908fef7aedd86badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028463	Research programme: pain therapeutics - Celtic Pharma						No development reported (Preclinical)	Postherpetic neuralgia		Undefined mechanism	"IDEA (Originator), IDEA (Owner), Celtic Pharma (Licensee)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"IDEA077, TDT077"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800028463?userId=52029392&bpIds=3004037004&checksum=ffe68185522edd0ec12def28ff9b8f5a6909e27a-1617045529870-5ed31affe9bae2a5041146e83351d0cfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029341	Research programme: aryl-amide therapeutics - Cascade Therapeutics			Yes			No development reported (Preclinical)	"Anxiety disorders, Neuropathic pain, Epilepsy"			"Cascade Therapeutics (Originator), Cascade Therapeutics (Owner)"		PO				"N2 (Analgesics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N03A (Antiepileptics), N05B (Anxiolytics)"	"CSC 700008, CSC series"			16/07/2016	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800029341?userId=52029392&bpIds=3004037004&checksum=d0b8603f1929c17dbc979e268caac3206584187c-1617045529871-b82c88c77293190456df827001fd7b76badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025771	Research programme: gastrointestinal disease and pain therapies - AstraZeneca						No development reported (Preclinical)	"Pain, Gastrointestinal disorders"		Undefined mechanism	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				A3 (Functional Gastro-Intestinal Disorder Drugs)	"A03 (Drugs for Functional Gastrointestinal Disorders), N02 (Analgesics)"	AZD 5329			16/07/2016	"Digestive System Disorders, Pain"				no		no							https://adis.springer.com/drugs/800025771?userId=52029392&bpIds=3004037004&checksum=9e7fc0157e85f7a81bc45dfe97bdd1b9dab656bf-1617045529871-ab4384c11e95c6380ed7eea33eac7ba5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800040114	Research programme: cancer-associated pain therapeutics - Benitec/Stanford University			Yes			No development reported (Preclinical)	Cancer pain		"Gene silencing, Protein kinase C gamma inhibitors, RNA interference"	"Benitec Biopharma (Originator), Benitec Biopharma (Owner), Stanford University (Collaborator)"		Intrathecal				N2 (Analgesics)	N02 (Analgesics)	"BLTPKC34, BLTPKC4"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800040114?userId=52029392&bpIds=3004037004&checksum=8895a7d3ce9210d95a75a685efa04131061afb10-1617045529872-314ada7b25163348e0a62dc8d3fb288cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025844	Research programme: G protein-coupled receptor modulators - Cara Therapeutics						No development reported (Preclinical)	"Inflammation, Pain"		G protein-coupled receptor modulators	"Cara Therapeutics (Originator), Cara Therapeutics (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GPCR modulators Cara Therapeutics			16/07/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800025844?userId=52029392&bpIds=3004037004&checksum=5baf3daa290b5f44ab02f35be4ece43a00142301-1617045529873-d6d2d6ea7c2466af038d589a6202592cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037460	Research programme: small-molecule therapeutics - Endo Pharmaceuticals/GVK Biosciences						No development reported (Research)	"Inflammation, Pain"			"Endo Pharmaceuticals (Originator), GVK BIO (Originator), Endo Pharmaceuticals (Owner), GVK BIO (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	Pain and inflammation smallmolecule therapeutics GVK Biosciences/Endo Pharmaceuticals			16/07/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800037460?userId=52029392&bpIds=3004037004&checksum=c929123d8a3f6a8a05614f6527523187d07ddf0f-1617045529874-6108ee08aa415eeabc9124777c4e9292badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031133	Research programme: transient receptor potential A1 antagonists - AbbVie						No development reported (Preclinical)	Pain		TRPA1 protein inhibitors	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	A967079			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031133?userId=52029392&bpIds=3004037004&checksum=e0fe76ec99e7c80333dcfd9b6518ce02716c6e42-1617045529874-ff9a4eb679b803533e1eea287ae8b658badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035137	ABT 521						No development reported (I)	Pain		Cannabinoid receptor CB2 agonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ABT521			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800035137?userId=52029392&bpIds=3004037004&checksum=8dee6e5f04d9c973e687e91c7cf7ceb28e64e710-1617045529875-fd341f7af3f37c860ac37cdaa1cdadd7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037138	Naproxen/esomeprazole SR - Hanmi						No development reported (I)	Rheumatoid arthritis		"Cyclooxygenase inhibitors, Prostaglandin synthase inhibitors, Proton pump inhibitors"	"Hanmi Pharmaceutical (Originator), Hanmi Pharmaceutical (Owner)"		PO				"A2B2 (Acid pump inhibitors), M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics)"	"A02B-C05 (Esomeprazole), M01A-E02 (Naproxen), N02 (Analgesics)"	HCP 1004			16/07/2016	Rheumatic Disease				no		no							https://adis.springer.com/drugs/800037138?userId=52029392&bpIds=3004037004&checksum=2fc08f44ea2c7afa9a0479ef9fecbe914869885c-1617045529876-343d2fc17e36eeaf0fcc9a8e8702e29bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021308	Research programme: topical diclofenac - NanoCyte						No development reported (Preclinical)	Pain		"Arachidonic acid inhibitors, Cyclooxygenase inhibitors"	"NanoCyte (Originator), NanoCyte (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"IR diclofenac, Topical diclofenac research programme NanoCyte Inc."			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800021308?userId=52029392&bpIds=3004037004&checksum=e0c4b0a478d80b372b24ac5412f369054b4509b6-1617045529877-ea0bd29d1f98ebac5e1f4050f71bd035badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022545	Ganshao - Jilin Natural Pharmatech						No development reported (I)	Dysmenorrhoea		Undefined mechanism	"Jilin Natural Pharmatech (Originator), Jilin Natural Pharmatech (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Dysmenorrhea therapy Jilin Natural Pharmatech, Ganshao capsule, TCM therapies, Traditional Chinese Medicine Jilin Natural Pharmatech"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800022545?userId=52029392&bpIds=3004037004&checksum=3c87f5b3e40d22be66f9749be038e2bf442c1881-1617045529878-a3ff1bcdc5f2bef15658edd53995e778badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037431	"Research programme: topical wound, inflammation and pain therapies - BioChemics"			No			No development reported (Research)	"Wounds, Inflammation, Skin ulcer, Diabetic neuropathies"		"Antioxidants, Mitochondrial protein stimulants, Nitric oxide donors, Transketolase stimulants"	"BioChemics (Originator), BioChemics (Owner)"		Topical				"A11 (Vitamins), D3 (Wound Healing Agents), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A11 (Vitamins), D03 (Preparations for Treatment of Wounds and Ulcers), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"BCDN01 topical, Benfotiamine topical BioChemics"			16/07/2016	"Diabetes, Inflammation, Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800037431?userId=52029392&bpIds=3004037004&checksum=2e02ab2f93c02ebb1970427901c7a8721b79d6d8-1617045529880-f0a2fc229294f10223087a2a538e3b5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037761	VBY 891			Yes			No development reported (I)	"Psoriasis, Neuropathic pain"		Cathepsin S inhibitors	"Virobay (Originator), Virobay (Owner), LEO Pharma (Licensee)"		PO				"D5B (Systemic Antipsoriasis Products), N2B (Non-Narcotics and Anti-Pyretics)"	"D05B-X (Other antipsoriatics for systemic use), N02B (Other Analgesics and Antipyretics)"	VBY891			16/07/2016	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800037761?userId=52029392&bpIds=3004037004&checksum=708df2eb5442e6c77d90aad9f2f6c2ecfb50033d-1617045529881-9891d98b470922096d21cf046b624d87badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024570	Research programme: pain therapeutics - Mochida		2-(4-Hydroxybenzoyl)amino-2-methylpropionic acid				No development reported (Preclinical)	"Pain, Neuropathic pain"	C11 H13 N O4	Undefined mechanism	"Mochida Pharmaceutical (Originator), Mochida Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"	"M43068, M58373, M58996"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800024570?userId=52029392&bpIds=3004037004&checksum=a9db1a05430ba20aa9b53984d9e2fad8ac217d35-1617045529882-a6ef34f0aad7e41d0eac6469dc9999f1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031130	Research programme: protease inhibitors - Virobay						No development reported (0)	"Neuropathic pain, Autoimmune disorders, Bone cancer, Alzheimer's disease, Hepatitis C, Cancer pain"		"Cathepsin S inhibitors, Cathepsin B inhibitors, Cathepsin inhibitors, Hepatitis C protease inhibitors"	"Virobay (Originator), Virobay (Owner)"		"PO, unspecified"				"A5 (Cholagogues and Hepatic Protectors), D5B (Systemic Antipsoriasis Products), J5B (Antivirals, excluding anti-HIV products), L1 (Antineoplastics), L4X (Other Immunosuppressants), N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"A05 (Bile and Liver Therapy), D05B-X (Other antipsoriatics for systemic use), J05A-E (Protease inhibitors), L01 (Antineoplastic Agents), L04A (Immunosuppressants), N02B (Other Analgesics and Antipyretics), N06D-X (Other anti-dementia drugs)"	"VBY106, VBY285, VBY825"			16/07/2016	"Alzheimer's Disease and Cognition Disorders, Cancer, Immunological Disorders, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800031130?userId=52029392&bpIds=3004037004&checksum=6ff0e9cec2ed04e26d68b7dce7bf4c3a366fda91-1617045529883-e7f010d19d1a100c058e18273e4594fabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009951	FR 140423		3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole				No development reported (Preclinical)	"Pain, Inflammation"	C18 H16 N2 F2 O2 S	Cyclo-oxygenase 2 inhibitors	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"				16/07/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800009951?userId=52029392&bpIds=3004037004&checksum=ccc4287e2a5c4597b7a0844d4e420d5507339303-1617045529884-35c0a940f6893674f1e523eeccc63fa3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033760	Research programme: inflammation and pain therapeutic - UMeWorld			No			No development reported (Preclinical)	"Ocular inflammation, Postoperative pain, Gout"		Cyclooxygenase inhibitors	"AlphaRx (Originator), UMeWorld (Owner), Gaia BioPharma (Licensee)"		"Ophthalmic, Parenteral, PO"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), M4A (Anti-Gout Preparations), N2B (Non-Narcotics and Anti-Pyretics), S1X2 (Other Ophthalmologicals, Topical)"	"M01 (Antiinflammatory and Antirheumatic Products), M04A (Antigout Preparations), N02B (Other Analgesics and Antipyretics), S01B (Antiinflammatory Agents)"	ARX8203			16/07/2016	"Eye Disorders, Pain, Rheumatic Disease"		UMeWorld |  | Unspecified |  | 22 Feb 2013		no		no							https://adis.springer.com/drugs/800033760?userId=52029392&bpIds=3004037004&checksum=5062a4f9b87f703735757c7cd6a26e793b8d7750-1617045529885-0534922a5556fdb7d8fc6473a53531d2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020524	Research programme: TRPV1 antagonists - DiverDrugs			Yes			No development reported (Preclinical)	"Pain, Inflammation, Cancer pain"		TRPV1 receptor antagonists	"DiverDrugs (Originator), DiverDrugs (Owner), BCN Peptides (Collaborator)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	DD 01127			16/07/2016	"Inflammation, Pain"		DiverDrugs |  | Unspecified |  | 31 Oct 2010		no		no							https://adis.springer.com/drugs/800020524?userId=52029392&bpIds=3004037004&checksum=70d2fa55835418f3b98368a29a56c6e0072aab0c-1617045529886-a038e265a41ac3b99d7a801f1c5190c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038145	VBY 036			Yes			No development reported (I)	"Neuropathic pain, Alzheimer's disease"		Cathepsin S inhibitors	"Virobay (Originator), Virobay (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"N02B (Other Analgesics and Antipyretics), N06D-X (Other anti-dementia drugs)"	VBY036			16/07/2016	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800038145?userId=52029392&bpIds=3004037004&checksum=64aef34155ad0b49b86af7e5cdb1381bdc51828c-1617045529886-e83a07596dc1ef1421290b13b3f252dabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032046	Research programme: pregabalin gastric-retentive - ProTect	148553-50-8	(+)-4-Amino-3(S)-isobutylbutyric acid				No development reported (Research)	"Diabetic neuropathies, Fibromyalgia"	C8 H17 N O2	CACNA2D1 protein modulators	"ProTect Pharmaceuticals (Originator), ProTect Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"NPRx1000, PRTT200"			16/07/2016	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800032046?userId=52029392&bpIds=3004037004&checksum=a21145840090bf7d31e4977d7f7af713673cfe24-1617045529887-569a4f198109b64eee5a69252246cf20badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015422	Research programme: galantamine derivatives - Sanochemia Pharmazeutika						No development reported (Preclinical)	"Neurological disorders, Neuropathic pain, Alzheimer's disease, Dementia"		Acetylcholinesterase inhibitors	"Sanochemia Pharmazeutika (Originator), Sanochemia Pharmazeutika (Owner)"		unspecified				"N2 (Analgesics), N7D1 (Anti-Alzheimer products, cholinesterase inhibitors), N7X (All other CNS drugs)"	"N02 (Analgesics), N06D (Anti-Dementia Drugs), N06D-A (Anticholinesterases)"	"SPH1285, SPH1286, SPH1371, SPH1373, SPH1375"			16/07/2016	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015422?userId=52029392&bpIds=3004037004&checksum=def1a7afc0e7e6df600c4f695033b0beba1bd0c9-1617045529888-c8a016964006b5b5de010b2506816490badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024479	Research programme: glutamate receptor antagonists - Astellas Pharma		"<EM>N</EM>-(2,2-Dimethylpropyl)-5-fluoro-<EM>N</EM>-methyl-6-(oxetan-3-ylaminomethyl)thiazolo(3,2-<EM>a</EM>)benzimidazole-2-carboxamide fumarate"				No development reported (Preclinical)	Pain	C24 H29 F N4 O6 S	Glutamate receptor antagonists	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"AS1529122FM, AS1655619FM, YM 230888, YM 298198"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800024479?userId=52029392&bpIds=3004037004&checksum=4c781034287475353ad6de2e878f4ed749c7e8a1-1617045529889-c5ff0ba3d595b8ab5e77c6d6ed5036e7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025143	Research programme: opioid receptor modulators - Alkermes			Yes			No development reported (Preclinical)	"Pain, Constipation, CNS disorders, Substance-related disorders"		"Opioid receptor agonists, Opioid receptor antagonists, Opioid receptor modulators, Opioid delta receptor antagonists, Opioid kappa receptor agonists, Opioid mu receptor antagonists"	"Rensselaer Polytechnic Institute (Originator), Rensselaer Polytechnic Institute (Owner), Alkermes plc (Licensee)"		"PO, SC, IM"				"A3A (Plain Antispasmodics and Anticholinergics), N2 (Analgesics), N5B (Hypnotics/Sedatives), N7 (Other CNS Drugs), N7F (Drugs Used In Opioid Dependence), N7X (All other CNS drugs)"	"A03A (Drugs for Functional Bowel Disorders), N02 (Analgesics), N05B (Anxiolytics), N07B (Drugs Used In Addictive Disorders), N07X (Other Nervous System Drugs)"	"ALKS 36, RDC5768"			16/07/2016	"Digestive System Disorders, Drug Withdrawal, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800025143?userId=52029392&bpIds=3004037004&checksum=c215f23ecdc2b04e2c097d97652deaa090eaf464-1617045529891-035601b67d2fdfe48bbd05e334bd35b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021361	Research programme: inflammation and pain therapeutics - Kalypsys						No development reported (Preclinical)	"Neuropathic pain, Inflammation, Asthma"		"Nitric oxide synthase type II inhibitors, P38 mitogen-activated protein kinase inhibitors"	"Kalypsys (Originator), Kalypsys (Owner)"		"Topical, PO, unspecified"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3X (All Other Anti-Asthma and COPD Products)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03D-X (Other systemic drugs for obstructive airway diseases)"				16/07/2016	"Inflammation, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800021361?userId=52029392&bpIds=3004037004&checksum=0c9383b452593cf4abd9ba103014e738a78a35ca-1617045529892-29c5431139cc79b3fddd75ae287934d7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024918	Tedalinab		"(4<EM>S</EM>,7<EM>R</EM>)-<EM>N</EM>-<EM>tert</EM>-butyl-1-(2,4-difluorophenyl)-4,5,6,7-tetrahydro-1<EM>H</EM>-4,7-methanoindazole-3-carboxamide"				No development reported (I)	"Osteoarthritis, Neuropathic pain, Inflammatory pain"	C19 H21 F2 N3 O	Cannabinoid receptor CB2 agonists	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner)"		"unspecified, PO"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	GRC10693			16/07/2016	"Inflammation, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800024918?userId=52029392&bpIds=3004037004&checksum=e02f59d3f9ad92cf6c944589ec8850f39928e3b2-1617045529892-b15244dbac138c003000440aeb1f8c0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010094	Research programme: T-type calcium channel antagonists - Merck			Yes			No development reported (Preclinical)	"Smoking withdrawal, Epilepsy, Sleep disorders, Pain, Stroke"		T type calcium channel antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				"C8 (Calcium Antagonists), C8A (Calcium Antagonists, Plain), N2 (Analgesics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N7B (Antismoking Products), N7X (All other CNS drugs)"	"C08 (Calcium Channel Blockers), N02 (Analgesics), N03A (Antiepileptics), N05B (Anxiolytics), N07B-A (Drugs used in nicotine dependence), N07X (Other Nervous System Drugs)"	"TTA1, TTA2, TTA3, TTAA2, TTAP2"			16/07/2016	"Anxiety Disorders, Drug Withdrawal, Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800010094?userId=52029392&bpIds=3004037004&checksum=b3cd10e5a5cf7fc5d739e9740a8e5b851af3c4b8-1617045529894-696ed495935693b8b8f5d70e8a61187ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025340	BL 1021						No development reported (I)	Neuropathic pain		Adrenergic receptor antagonists	"Bar-Ilan-Research-&-Development-Company (Originator), Ramot at Tel Aviv University (Originator), Bar-Ilan-Research-&-Development-Company (Owner), Ramot at Tel Aviv University (Owner), BioLineRx (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	BL1021			16/07/2016	Pain		BioLineRx |  | Unspecified |  | 22 Mar 2012		no		no							https://adis.springer.com/drugs/800025340?userId=52029392&bpIds=3004037004&checksum=795ca0b6562bb378c3953a6d8bc3d05915ac788d-1617045529894-58ed154ebaa581619afc042ad2f5bf7abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031126	Research programme: monoamine oxidase inhibitors - Sunovion						No development reported (Preclinical)	"Pain, Major depressive disorder, Mood disorders"		Monoamine oxidase inhibitors	"Sepracor (Originator), Sunovion Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics), N6A (Anti-Depressants and Mood Stabilisers), N6A9 (Antidepressants, all others)"	"N02 (Analgesics), N05A (Antipsychotics), N06A (Antidepressants), N06A-F (Monoamine oxidase inhibitors, non-selective)"	SEP 230864			16/07/2016	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800031126?userId=52029392&bpIds=3004037004&checksum=0dcdf7497af7bb373834fbb5289aee22a199127d-1617045529895-01ab2d386fc127879c36ebba19d817d1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033740	Sufentanil - Orexo	56030-54-7	<EM>N</EM>-[4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide	No			No development reported (I)	Cancer pain	C22 H30 N2 O2 S	Undefined mechanism	"Orexo (Originator), Orexo (Owner)"		Sublingual				N2 (Analgesics)	N02 (Analgesics)	OX27			16/07/2016	Pain				no		no				"BNP, CKB, CKM, Hydrocortisone, IGFBP7, IL6, NGAL, Norepinephrine, Prolactin, Pyruvic acid, RAGE, TIMP-2, troponin I, cardiac, Troponin T, cardiac"		Creatine	https://adis.springer.com/drugs/800033740?userId=52029392&bpIds=3004037004&checksum=d3b71f37eb99f6d2c7456c2243ccd60801dcfc43-1617045529896-1b4d81d02f47e9ec0e57819b7bbac18bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026396	Nuclomedone - Beijing Tide Pharmaceutical	75963-52-9	"6-(4-chlorobenzyl)- 5<EM>H</EM>-2,3,6,7-tetrahydro-5,7-dioxothiazolo[3,2-a]pyrimidine"				No development reported (I)	"Neuropathic pain, Rheumatic disorders"	C13 H11 O2 Cl N2 S	Immunomodulators	"Teijin (Originator), Beijing Tide Pharmaceutical (Owner)"		PO			"Numbness, Paraesthesia"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"DRP043, NSL 043, SD118, TEI 3096, TI 31"			16/07/2016	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800026396?userId=52029392&bpIds=3004037004&checksum=9eb82308489d4d3ba8ece7814a044fed7e66573c-1617045529897-0b18a879b4c3afa925addcb373ff0795badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021554	Research programme: protein kinase C modulators - KAI Pharmaceuticals						No development reported (Preclinical)	"Cancer, Cardiovascular disorders, Eye disorders, Diabetic retinopathy, Transplant rejection, Autoimmune disorders, Neuropathic pain"		"Protein kinase C modulators, Protein kinase C delta inhibitors, Protein kinase C beta inhibitors, Protein kinase C epsilon modulators, Protein kinase C theta inhibitors, Protein kinase C gamma inhibitors"	"KAI Pharmaceuticals (Originator), Amgen (Owner)"		"unspecified, Ophthalmic, Parenteral"				"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), L (Antineoplastic and Immunomodulating Agents), L4X (Other Immunosuppressants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), S1 (Ophthalmologicals)"	"A10X (Other Drugs Used in Diabetes), C (Cardiovascular System), L (Antineoplastic and Immunomodulating Agents), L04A (Immunosuppressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), S01 (Ophthalmologicals)"	"KAI9706, KP2018"			16/07/2016	"Cancer, Diabetes, Eye Disorders, Immunological Disorders, Pain, Transplant Rejection, Vascular Disorders"		KAI Pharmaceuticals |  | Preclinical |  | 26 Feb 2007		no		no							https://adis.springer.com/drugs/800021554?userId=52029392&bpIds=3004037004&checksum=54b3dd90aec69144f1a271a28a7146335e25bdfc-1617045529898-8b5844f10644cdab9e45c863803f230dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034079	CNV 2197944			Yes			Phase II	"Diabetic neuropathies, Postherpetic neuralgia, Pain"		N type calcium channel antagonists	"GlaxoSmithKline (Originator), Calchan (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	CNV2197944			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800034079?userId=52029392&bpIds=3004037004&checksum=edf288619b973afdf18da27a991c284d651454b9-1617045529900-bc2c854e7d0502e3f105039957315b2dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022184	Research programme: NMDA receptor antagonists - Neurotune			Yes			No development reported (Preclinical)	"Neuropathic pain, Diabetic neuropathies"		NMDA receptor antagonists	"NiKem Research (Originator), Neurotune (Owner)"		"PO, unspecified"				N2 (Analgesics)	N02 (Analgesics)	"BND003, BND13317, BND3, NiK 003, Nik003, NiK13317, NT13317, NT24336"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800022184?userId=52029392&bpIds=3004037004&checksum=a49fe903a7436183a0f1ed98e678fe5e0990926d-1617045529901-2f736dd3051f406c99d45ed402341b8bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026656	Research programme: peptide therapeutics - SynVax		<EM>N</EM><SUP>2</SUP>-Acetyl-L-arginyl-3-chloro-L-tyrosyl-L-tyrosyl-l-arginyl-L-tryptophyl-L-arginamide				No development reported (Preclinical)	"Pain, Oedema, Heart failure, Bacterial infections, Major depressive disorder, Viral infections, Anxiety disorders, Mycoses"	C49 H68 Cl N17 O19	"Opioid receptor agonists, Diuretics"	"SynVax Pharmaceuticals (Originator), SynVax Pharmaceuticals (Owner), SRI International (Collaborator)"		unspecified				"C3A (Diuretics), J1 (Systemic Antibacterials), J2A (Systemic Agents for Fungal Infections), J5B (Antivirals, excluding anti-HIV products), N2 (Analgesics), N5 (Psycholeptics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations)"	"C03 (Diuretics), J (Anti-infectives For Systemic Use), J01 (Antibacterials for Systemic Use), J02A (Antimycotics for Systemic Use), J05A (Direct acting antivirals), N02 (Analgesics), N05 (Psycholeptics), N06A (Antidepressants)"	"NOP receptor agonists SynVax, Syn 1020"			16/07/2016	"Affective Disorders, Anxiety Disorders, Bacterial Infections, Heart Failure, Mycoses, Pain, Vascular Disorders, Viral Infections"				no		no							https://adis.springer.com/drugs/800026656?userId=52029392&bpIds=3004037004&checksum=933584076aa1b2926d7df3e7523dd54af0c9d8f7-1617045529902-283776a30115cd796cb0917ed149c510badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029969	Research programme: fatty acid amide hydrolase inhibitors - Amgen		"(<EM>S</EM>)-3-[1-[2-Amino-4-(4-fluorophenyl)pyrimidin-5-yl]piperidin-3-yl]-1-ethyl-1<EM>H</EM>-imidazo[4,5-<EM>b</EM>]pyridin-2(3<EM>H</EM>)-one"				No development reported (Research)	"Inflammation, Pain, CNS disorders"	C23 H24 F N7 O	Fatty acid amide hydrolase inhibitors	"Amgen (Originator), Amgen (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07 (Other Nervous System Drugs)"				16/07/2016	"Inflammation, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800029969?userId=52029392&bpIds=3004037004&checksum=96e201f2758fdb4b66baa4f05cf1bbeff1fc1dc1-1617045529903-544616602dd01d6452c48c915b64275fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025796	Research programme: TrkA receptor antagonists - VM Discovery			Yes			No development reported (Preclinical)	"Inflammation, Psoriasis, Vascular restenosis, Pancreatic cancer, Prostate cancer, Neuropathic pain"		TrkA receptor antagonists	"VM Discovery (Originator), Purdue Pharma (Owner)"		unspecified				"C6A (Other Cardiovascular Products), D5 (Nonsteroidal Products for Inflammatory Skin Disorders), L (Antineoplastic and Immunomodulating Agents), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"C (Cardiovascular System), D05 (Antipsoriatics), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	VMD902			16/07/2016	"Cancer, Inflammation, Pain, Skin Disorders, Vascular Disorders"		VM Discovery |  | Preclinical |  | 21 Feb 2007		no		no							https://adis.springer.com/drugs/800025796?userId=52029392&bpIds=3004037004&checksum=06fe5bbe29f5a38627a757d17a451fa2f2323a7a-1617045529904-c6437fbda22ad927cb769c5babed4e76badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026706	Research programme: transient receptor potential channel inhibitors - Hydra/Pfizer						No development reported (Preclinical)	Pain		TRPV3 protein inhibitors	"Hydra Biosciences (Originator), Hydra Biosciences (Owner), Pfizer (Licensee), Pfizer (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"HC001403, TRPV3 antagonists Hydra/Pfizer"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800026706?userId=52029392&bpIds=3004037004&checksum=5611b0e5aeff7b501835bda04d06d3b958f8c8a9-1617045529905-f23880e444b0bf4061a21daed06c1327badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011755	YM 598		(<EM>E)</EM>-<EM>N</EM>-[6-Methoxy-5-(2-methoxyphenoxy)- 2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethenesulfonamide potassium salt				No development reported (Preclinical)	"Pulmonary hypertension, Prostate cancer, Pain, Hypertension"	C24 H20 N5 K O5 S	Endothelin A receptor antagonists	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		PO				"C2 (Antihypertensives), C2A (Antihypertensives (of Non-Herbal Origin) Plain), L1 (Antineoplastics), N2 (Analgesics)"	"C02 (Antihypertensives), C02K (Other Antihypertensives), L01 (Antineoplastic Agents), N02 (Analgesics)"				16/07/2016	"Cancer, Hypertension, Men's Health, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800011755?userId=52029392&bpIds=3004037004&checksum=176c1e4336b192aedba7f707be8a6b27fcd614c5-1617045529906-1ca1b521620c4138cca7eadd3d1266c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025626	CE 245677						No development reported (Preclinical)	"Inflammatory pain, Cancer"		"TIE 2 receptor antagonists, TrkA receptor antagonists, TrkB receptor antagonists, TrkC receptor antagonists"	"Pfizer (Originator), Pfizer (Owner)"		PO				"L1 (Antineoplastics), N2 (Analgesics)"	"L01 (Antineoplastic Agents), N02 (Analgesics)"	CE245677			16/07/2016	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800025626?userId=52029392&bpIds=3004037004&checksum=4938083a6bfef60fcdc6df4c4449ca82635480e0-1617045529907-d639075009edd6424499e8c441961f3ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039848	Research programme: small molecule therapeutics - Snowdon			Yes			No development reported (Preclinical)	"Tuberculosis, Neurological disorders, Neuropathic pain, Toxoplasmosis"		"Glutamate release inhibitors, Glutamate receptor modulators"	"Snowdon (Originator), Snowdon (Owner), Defense Threat Reduction Agency (Funder), National Institute of Neurological Disorders and Stroke (Funder), National Institutes of Health (USA) (Funder), New Jersey Commission on Science and Technology (Funder), University of Chicago Pritzker School of Medicine (Collaborator), University of Medicine & Dentistry of New Jersey (Collaborator)"		"unspecified, PO"				"J4A (Antitubercular products), N2 (Analgesics), N7X (All other CNS drugs), P1G (Other Anti-Parasitic Agents)"	"J04A (Drugs for Treatment of Tuberculosis), N02 (Analgesics), N07X (Other Nervous System Drugs), P01A (Agents Against Amoebiasis and Other Protozoal Diseases)"	"SND121, SND159, SND226"			16/07/2016	"Bacterial Infections, Neurological Disorders, Pain, Parasitic Infections"				no		no							https://adis.springer.com/drugs/800039848?userId=52029392&bpIds=3004037004&checksum=d9600c2350cb0067e7baf9a391cabfa0b15146c7-1617045529908-87a3acf4a0cf89043fa76d9b9700c814badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029245	IPI 940			Yes			No development reported (I)	"Neuropathic pain, Inflammatory pain"		Fatty acid amide hydrolase inhibitors	"Infinity Pharmaceuticals (Originator), Infinity Pharmaceuticals (Owner), FAAH Pharma (Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"FAAH inhibitor Infinity, IPI940"			16/07/2016	Pain				no		no							https://adis.springer.com/drugs/800029245?userId=52029392&bpIds=3004037004&checksum=66e641d3b8596af57603c947c950582a22939b6d-1617045529909-d7372407c38844719403905e43ed37abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029154	Celecoxib intravenous - Teva	169590-42-5	4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide	No			No development reported (I)	Postoperative pain	C17 H14 F3 N3 O2 S	Cyclo-oxygenase 2 inhibitors	"Acusphere (Originator), Acusphere (Owner), Teva Pharmaceutical Industries (Licensee)"		IV				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H01 (Celecoxib), N02B (Other Analgesics and Antipyretics)"	"AI525, CEP33222"			16/07/2016	Pain				no		no		"Aromatase, CA-19-9, CEA, EGFR, PGE2, PSA, pyridoxal phosphatase, survival of motor neuron 1, telomeric"	"Chondroitin sulfate, COX2, EGFR, PGE2, PSA, survival of motor neuron 1, telomeric"	"24,25-Dihydroxyvitamin D, ACE, adhesion regulating molecule 1, AKT, Androgen receptor, angiopoietin like 2, arachidonate 15-lipoxygenase, Arachidonic acid, Aromatase, baculoviral IAP repeat containing 2, Bcl-2, Beta-catenin, bFGF, CA-19-9, Calprotectin, carbonic anhydrase II, caspase 6, CD163, CD31, CD4, CD68, CEA, Chondroitin sulfate, Collagen type 2, COMP, COX2, CRP, CYP2C19, CYP2C9, CYP3A5, cytochrome P450 family 2 subfamily B member 6, Cytokeratin 14, E-cadherin, EGFR, Elafin, ephrin A5, ER alpha, Estradiol-17beta 3-sulfate, Fibulin 3 peptides, Folinic acid, FOXP3, GATA binding protein 6, GUSB, hematological and neurological expressed 1, HER2, Histone H3, hyaluronan synthase 3, IFN-gamma, IGF1, IGFBP3, IL10, IL6, IL8, integrin subunit alpha V, Ki67, KRAS, L-Serine, MAPK1, mitogen-activated protein kinase 4, MMP-13, MMP-2, MMP9, NGF, opioid related nociceptin receptor 1, Osteocalcin, p53, PAGE family member 2, PAGE family member 3, PAI-1, PDGFA, PDGFB, PGE2, pleckstrin homology domain containing, family M (with RUN domain) member 1, PSA, pyridoxal phosphatase, serine/threonine kinase 36, SET binding protein 1, sex hormone-binding globulin, survival of motor neuron 1, telomeric, Syndecan-1, Thrombospondin-1, Thromboxane, TIMP-1, TNF-alpha, transforming growth factor, alpha, translocator protein, VEGF-A, VEGF-C, VEGFR, VEGFR1, Vimentin"	"AKT, Calprotectin, CD4, CRP, E-cadherin, Osteocalcin, PGE2, VEGF-A"	"13-cis-Retinoic acid, 25-Hydroxyvitamin D2, Aldosterone, Amphiregulin, Amyloid beta, ApoE, bax, BRCA2, C-C motif chemokine ligand 22, C-C motif chemokine receptor 4, C-X-C motif chemokine ligand 11, C-X-C motif chemokine receptor 3, CA-125, Caspase 3, CCR5, CD34, CD8a, CDKN1A, chemokine (C-C motif) receptor 6, Creatinine, CXCL10, CXCL12, CXCL9, CXCR4, CYP24A1, CYP3A4, Deoxyuridine triphosphate, DNA (cytosine-5-)-methyltransferase 1, DNA nucleotidylexotransferase, F2-isoprostanes, Fas cell surface death receptor, frizzled-related protein, Glutathione, GSTT1, HPGD, IL2, L-Threonine, Lewis X trisaccharide, MAPK3, NFkB, ornithine decarboxylase 1, p16, PCNA, PDZ and LIM domain 7, peroxisome proliferator activated receptor alpha, peroxisome proliferator-activated receptor gamma, PGR, phosphate cytidylyltransferase 1, choline, alpha, prostaglandin E synthase, prostaglandin-endoperoxide synthase 1, proteasome subunit beta 9, Renin, sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein), TGF-beta, Thymidine, tyrosine kinase, non-receptor, 2, UGT1A1, Uridine 5'-diphosphate"	https://adis.springer.com/drugs/800029154?userId=52029392&bpIds=3004037004&checksum=163063d1e3d801832472fa53c60ea50d058b9bd2-1617045529911-dda76af3de77743d606793bbecc76886badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800046223	Research programme: neuropathic pain therapeutics - Medisyn Technologies			Yes			Phase Unknown	Neuropathic pain		"GABA B receptor agonists, GABA receptor agonists"	"Medisyn Technologies (Originator), Medisyn Technologies (Owner), MD Biosciences (Collaborator)"		unspecified				N2A (Narcotics)	N02A (Opioids)				15/07/2016	Pain				no		no							https://adis.springer.com/drugs/800046223?userId=52029392&bpIds=3004037004&checksum=b9c1639e1800482cc10cd62b9001390a0e92b936-1617045529912-cd6ed9ec17f33a26b1b59bbd5ca60e45badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031494	Research programme: pain therapeutics - Neorphys			Yes			Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Neorphys (Originator), Neorphys (Owner)"		unspecified				N2 (Analgesics)	N02A (Opioids)	"Neo1507, Neo1509, Neo1528, Neo15xx"			12/07/2016	Pain				no		no							https://adis.springer.com/drugs/800031494?userId=52029392&bpIds=3004037004&checksum=044131ed0f03f254285e475c4a1ad5d82caee8dc-1617045529913-39d304f34b45ea29eec90bdeba64a5c4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020787	ACV 1			No			Discontinued (II)	"Neuropathic pain, Postherpetic neuralgia"		Cholinergic receptor antagonists	"University of Melbourne (Originator), University of Melbourne (Owner), Calzada (Licensee)"		SC				N2 (Analgesics)	N02 (Analgesics)	"ACV1, AVC 6.8, Vc1.1"			17/06/2016	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020787?userId=52029392&bpIds=3004037004&checksum=f70c71ce94c1ab921b418dfef9ca9a47bdd8e452-1617045529913-8f0fb2aee83ea4dfc2e6f7a333bdc8a3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016097	Placulumab	945781-29-3	"Des-(light chain)-immunoglobulin G1, anti-(human tumour necrosis factor (cachectin, TNF-alpha, tumour necrosis factor ligand superfamily member 2)); des-(CH1)-human monoclonal _1 heavy chain dimer (120-120'':123-123'')-bisdisulfide"	Yes			No development reported (II)	"Rheumatoid arthritis, Psoriasis, Inflammation, Sciatica"	C3404 H5262 N902 O1036 S22	Tumour necrosis factor alpha inhibitors	"Domantis (Originator), Peptech (Originator), Teva Pharmaceutical Industries (Owner)"		"SC, IV, Epidural"				"A7E (Intestinal Anti-Inflammatory Agents), D5B (Systemic Antipsoriasis Products), L4B (Anti-TNF Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"A07E (Intestinal Antiinflammatory Agents), D05 (Antipsoriatics), L04A-A (Selective immunosupressants), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"AntiTNF alpha antibody, Antitumour necrosis factor alpha antibody, ART621, CEP37247, PN0621"			15/06/2016	"Inflammation, Pain, Rheumatic Disease, Skin Disorders"				no		no							https://adis.springer.com/drugs/800016097?userId=52029392&bpIds=3004037004&checksum=f9499729c2712aade1dac789127749a2c38e75c4-1617045529915-d0e13ff2127e4d78a2109fb4a0f70c5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045533	K 133W			Yes			Discontinued (III)	Dysmenorrhoea		Undefined mechanism	"Kowa (Originator), Kowa (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	K133W			09/06/2016	Pain				no		no							https://adis.springer.com/drugs/800045533?userId=52029392&bpIds=3004037004&checksum=51dd8d429137d68a66c35c9814d6478aa152014a-1617045529916-59d61aac90e57c1c2120d3555312ba14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045483	M 519101			Yes			Discontinued (III)	Pain		Undefined mechanism	"Maruho (Originator), Maruho (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	M519101			03/06/2016	Pain				no		no							https://adis.springer.com/drugs/800045483?userId=52029392&bpIds=3004037004&checksum=3e3d2da393a23cb783ba426546c8ee4bb1a17bd1-1617045529917-92ccec53e9dbfb4291479498990a347dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031105	MK 4409		2-(5-(5-((5-chloropyridin-2-yl)thio)-2-(4-fluorophenyl)oxazol-4-yl)pyridin-2-yl)propan-2-ol	Yes			No development reported (I)	Pain	C22 H17 Cl F N3 O2 S	Fatty acid amide hydrolase inhibitors	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				27/05/2016	Pain				no		no							https://adis.springer.com/drugs/800031105?userId=52029392&bpIds=3004037004&checksum=72920a69cfc41cc65f4521388348b5b6ee133fd0-1617045529917-22374c6183e7a719322f84fb774a0d93badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020859	Fentanyl transmucosal - Teva Pharmaceutical Industries	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Marketed	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner), Mitsubishi Tanabe Pharma Corporation (Licensee)"		Transmucosal			"Dizziness, Nausea, Somnolence, Vomiting"	N2A (Narcotics)	N02A-B03 (Fentanyl)	"Actiq, TA8317"			20/05/2016	"Drug Delivery Systems, Pain"			"Actiq, Actiq"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800020859?userId=52029392&bpIds=3004037004&checksum=f5309fe1f37a3889706661cb159911630857cb09-1617045529920-67a8539b8e98a609f36d28212e68aa65badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039478	LY 2969822			Yes			Discontinued (I)	Pain		"Metabotropic glutamate receptor 2 agonists, Metabotropic glutamate receptor 3 agonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	LY2969822			19/05/2016	Pain				no		no							https://adis.springer.com/drugs/800039478?userId=52029392&bpIds=3004037004&checksum=82282c749fd7afc866f33dc1c936317e0b60c22f-1617045529921-82d5108a4a05978b9d5b155af59b580bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045371	GRT 6012			Yes			No development reported (I)	Pain			"Grunenthal (Originator), Grunenthal (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GRT6012			18/05/2016	Pain		"Grunenthal | Pain | Unspecified | Europe, Latin America, USA | 31 Dec 2010"		no		no							https://adis.springer.com/drugs/800045371?userId=52029392&bpIds=3004037004&checksum=329dfd6b84f9439b680526f70d19e320fa88aa84-1617045529922-28726cfcc26b316e187cc631fef91deabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800045370	GRT 6011			Yes			No development reported (I)	"Hypersensitivity, Neuropathic pain"			"Grunenthal (Originator), Grunenthal (Owner)"		PO				"L (Antineoplastic and Immunomodulating Agents), N2 (Analgesics)"	"L (Antineoplastic and Immunomodulating Agents), N02 (Analgesics)"	GRT6011			18/05/2016	"Immunological Disorders, Pain"		"Grunenthal | Hypersensitivity, Neuropathic pain | Unspecified | Europe, Latin America, USA | 31 Dec 2010"		no		no							https://adis.springer.com/drugs/800045370?userId=52029392&bpIds=3004037004&checksum=683cc476face26a100e3c1495628063551639e28-1617045529923-dbc2585af7ffbd82feda6cba955d5b28badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028382	Lidocaine topical - Crescita Therapeutics	137-58-6	"2',6'-Acetoxylidide, 2-(diethylamino)-"	No			Discontinued (I)	Pain	C14 H22 N2 O	Undefined mechanism	"Nuvo Research (Originator), Crescita Therapeutics (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"Lidocaine topical spray Crescita Therapeutics, NRIANA"			18/05/2016	"Drug Delivery Systems, Pain"		Nuvo Research |  | Unspecified |  | 20 Aug 2015		no		no		A1AT	"COX2, small proline rich protein 2A"	"A1AT, ACADM, ACC, Adiponectin, AMPKa, Angiopoietin-like 4, BNP, CD38, cell death inducing DFFA like effector c, cell death-inducing DFFA-like effector a, CKB, CKM, COX2, CRP, cryptochrome circadian clock 1, CXCL10, fatty acid binding protein 4, fatty acid synthase, Ghrelin, hemoglobin subunit gamma 2, Hydrocortisone, IFN-gamma, IGF1R, IL10, IL6, IL8, Insulin, insulin receptor substrate 2, IRS-1, Leptin, lipase E, hormone sensitive type, lipoprotein lipase, MCP1, MIP-1 alpha, MLX interacting protein-like, neuronal PAS domain protein 2, opioid related nociceptin receptor 1, Osteocalcin, patatin-like phospholipase domain containing 2, patatin-like phospholipase domain containing 3, PGC-1 alpha, PIK3R1, Procalcitonin, pyruvate dehydrogenase kinase 4, PYY, RNA, Ro-associated Y1, SIRT3, small proline rich protein 2A, solute carrier family 2 member 4, sterol regulatory element binding transcription factor 1, Testosterone, TNF-alpha, TRAP-5, troponin I, cardiac, uncoupling protein 2 (mitochondrial, proton carrier), v-akt murine thymoma viral oncogene homolog 2, VEGF-A, VEGFR, VEGFR1"	"BNP, CRP, IL6"	"CD4, Cortisone, CXCL12, cytochrome b5 reductase 1, cytochrome b5 reductase 2, cytochrome b5 reductase 3, cytochrome b5 reductase 4, G6PD, HLA-DR, HMGB1, IL1 beta, IL12A, IL12B, IL1RA, Thyroxine"	https://adis.springer.com/drugs/800028382?userId=52029392&bpIds=3004037004&checksum=27b0c246eac489eebdd50ec3bf1ab1c395e2dc1e-1617045529924-9433403075db9748410ba6c5e11eb162badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037660	Fentanyl sublingual - Ethypharm	437-38-7	N-(1-(2-phenethyl)-4-piperidinyl-N-phenyl-propanamide	No			Marketed	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Ethypharm (Originator), Ethypharm (Owner), Grunenthal (Market Licensee)"		Sublingual				N2A (Narcotics)	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	"Fentanyl citrate sublingual tablets Ethypharm, Fentanyl Ethypharm, Fentanyl sublingual tablets Ethypharm, Recivit"			06/05/2016	Pain			"Recivit, Recivit, Recivit, Recivit"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800037660?userId=52029392&bpIds=3004037004&checksum=68cb4858d849c359f4c1ce739d4e5d3cf896388c-1617045529926-4558da2d88bbf8e636e7d245b58a7a4bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031726	Fentanyl needle-free injectable - Glide/Endo	437-38-7	N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide	No			No development reported (I)	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Glide Pharma (Originator), Glide Technologies (Owner), Endo International (Licensee)"		SC				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Fentanyl SDI, Glide fentanyl, GP03"			03/05/2016	"Drug Delivery Systems, Pain"				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800031726?userId=52029392&bpIds=3004037004&checksum=adfee01dc5abb064dc1fac38a26518382c23998c-1617045529928-97143fdd7820158700e5a40ebe794487badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031537	CB 189625			Yes			No development reported (I)	Postoperative pain		TRPA1 protein inhibitors	"Cubist Pharmaceuticals (Originator), Hydra Biosciences (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"CB189625, CB625"			03/05/2016	Pain				no		no							https://adis.springer.com/drugs/800031537?userId=52029392&bpIds=3004037004&checksum=9483354c4093093d8f1805c947612f501db3d8c3-1617045529929-aaf916c4b728b5deb794702277f3775abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034628	Research programme: cannabinoid receptor CB2 agonists - Arena Pharmaceuticals			Yes			Discontinued (Preclinical)	"Pain, Osteoarthritis"		Cannabinoid receptor CB2 agonists	"Arena Pharmaceuticals (Originator), Arena Pharmaceuticals (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	ARXYZ			03/05/2016	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800034628?userId=52029392&bpIds=3004037004&checksum=0bfc933927e87b0d0693e5baf4113c830beada4e-1617045529929-0b373d96b59574a3fb3a1599dff79218badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044406	Tarenflurbil spraygel - MIKA Pharma	51543-40-9	"(1,1'-Biphenyl)-4-acetic acid,2-fluoro-alpha-methyl-,(_R)-"	No			Phase Unknown	"Pain, Skin disorders, Inflammation"	C15 H13 F O2	"Amyloid precursor protein secretase modulators, NF-kappa B inhibitors, Transcription factor AP-1 inhibitors"	"PAZ GmbH (Originator), PAZ GmbH (Owner), MIKA Pharma GmbH (Licensee), Galen Pharma (Sub-licensee)"		Transdermal				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"MIKAtarenflurbilspraygel, MK50"			02/05/2016	"Inflammation, Pain, Rheumatic Disease, Skin Disorders"				no		no							https://adis.springer.com/drugs/800044406?userId=52029392&bpIds=3004037004&checksum=b610c8182c438f6e0fd614dd2824deb2f8f0f6c5-1617045529930-0d249150f135269a58400d4e7a307d57badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024996	Fentanyl patch - ZARS	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Discontinued (III)	"Cancer pain, Osteoarthritis"	C22 H28 N2 O	Opioid mu receptor agonists	"ZARS (Originator), Crescita Therapeutics (Owner)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Titragesia, ZR0201"			29/04/2016	"Pain, Rheumatic Disease"			"Titragesia, Titragesia"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024996?userId=52029392&bpIds=3004037004&checksum=242aa1190eb6143c2bd85f6dc53724011bd06b85-1617045529932-2d6dcc5e12d02b225cc4feb51e506fa8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024998	Ketoprofen patch - ZARS	22071-15-4	2-(3-benzoylphenyl)-propionic acid	No			Discontinued (III)	Osteoarthritis	C16 H14 O3	"Arachidonic acid inhibitors, Lipoxygenase-cyclooxygenase inhibitors"	"ZARS (Originator), Crescita Therapeutics (Owner)"		Transdermal				"M2A (Topical Anti-rheumatics and Analgesics), N2 (Analgesics)"	"M02A-A (Antiinflammatory preparations, non-steroids for topical use), N02 (Analgesics)"	ThermoProfen			29/04/2016	"Drug Delivery Systems, Rheumatic Disease"			ThermoProfen	no		no							https://adis.springer.com/drugs/800024998?userId=52029392&bpIds=3004037004&checksum=e1a1c2add898a5f85248703bf1d2d7d7e9ce6fdb-1617045529933-46ac9b99b8d3f7d7a596edf7b4f542d6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033244	AZD 3161	1369501-46-1	"3-Pyridinecarboxamide, N-((3S)-3,4-dihydro-5-(5-methoxy-2-pyrazinyl)-2H-1-benzopyran-3-yl)-6-((2,2,2-trifluoroethoxy)methyl)-"	Yes			Discontinued (I)	"Pain, Neuropathic pain"	C23 H21 F3 N4 O4	Nav1.7 voltage-gated sodium channel inhibitors	"AstraZeneca (Originator), AstraZeneca (Owner)"		Intradermal				N2 (Analgesics)	N02 (Analgesics)	AZD3161			28/04/2016	Pain				no		no							https://adis.springer.com/drugs/800033244?userId=52029392&bpIds=3004037004&checksum=27d9bc25144fae23cd9f2b6cd4706c745d65ac28-1617045529933-cce6efb3833c0f9b5919e7e9c6cb3b6abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031648	PHE 377			Yes			Discontinued (I)	Neuropathic pain		TRPV1 receptor antagonists	"PharmEste (Originator), PharmEste (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"PHE377, V377"			22/04/2016	Pain		PharmEste |  | Clinical Phase Unknown |  | 18 Jul 2009		no		no							https://adis.springer.com/drugs/800031648?userId=52029392&bpIds=3004037004&checksum=d2e53a9aaaadb6fecbb36b590cea1f5437e25a03-1617045529934-175426599783d4a76c618d3d72af3ff5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036210	Dexsiometheptene mucate - Tonix Pharmaceuticals	7492-31-1	"6-Methylamino-2-methylheptene, tetrahydroxyadipic acid (2:1) (salt)"	No			Discontinued (II)	Tension type headache	(C9 H19 N)2 . C6 H10 O8	Adrenergic receptor agonists	"Tonix Pharmaceuticals Inc (Originator), Tonix Pharmaceuticals Holding Corp (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"Dexisometheptene mucate Tonix Pharmaceuticals, TNX 201"			19/04/2016	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800036210?userId=52029392&bpIds=3004037004&checksum=4477b829d7f0ce67741ed59c462dad2ab049d93f-1617045529935-86e82e62c4dbe8f7ff3488c2c9c81220badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037760	Verapamil - Calosyn Pharma	52-53-9	"Benzeneacetonitrile, alpha-(3-((2-(3,4- dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy- alpha-(1-methylethyl)-"	No			No development reported (I/II)	Musculoskeletal pain	C27 H38 N2 O4	Calcium channel antagonists	"Calosyn Pharma (Originator), Calosyn Pharma (Owner)"		Intra-articular				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				18/04/2016	Pain				no		no							https://adis.springer.com/drugs/800037760?userId=52029392&bpIds=3004037004&checksum=00d672b60e74fcc2926b75f4d1ffabc094e5a382-1617045529936-9cd63b1c43302e0dab1147d2ed9043c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042774	Codeine - Hikma Pharmaceuticals	6854-40-6	"Morphinan-6-ol,7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-,(5_, 6_)-, sulfate (2:1) (salt), trihydrate"	No			Marketed	Pain	(C18H21NO3)2 H2SO4 3H2O	Opioid mu receptor agonists	"Roxane Laboratories (Originator), Hikma Pharmaceuticals (Owner), TAGI Pharma (Market Licensee)"		PO				N2 (Analgesics)	"N02A (Opioids), R05D-A04 (Codeine)"	Codeine sulfate Hikma Pharmaceuticals			13/04/2016	Pain				no		no			CYP2D6	CYP2D6			https://adis.springer.com/drugs/800042774?userId=52029392&bpIds=3004037004&checksum=6c17562c14a91e383c5788f969e4b8bf455c01f2-1617045529937-99011acc547aaa580c47e52fc4599b81badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039105	AKR 203			No			No development reported (I)	Pain		"Enzyme inhibitors, Purinergic receptor modulators"	"Akron Molecules (Originator), Akron Molecules (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AKR203			13/04/2016	Pain				no		no							https://adis.springer.com/drugs/800039105?userId=52029392&bpIds=3004037004&checksum=bd852785d884f765d090962ce2ff022393b0dff6-1617045529937-982bde6b0b4f44ce123d8e63c4e7f51cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044029	BIA 102474		3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide	Yes			Suspended (I)	"Psychiatric disorders, Neurological disorders, Pain"	C16 H20 N4 O2	Fatty acid amide hydrolase inhibitors	"BIAL (Originator), BIAL (Owner)"		PO				"N (Nervous System), N2 (Analgesics)"	"N (Nervous System), N02 (Analgesics)"	"BIA 10, BIA 10 2474"			05/04/2016	"Affective Disorders, Anxiety Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800044029?userId=52029392&bpIds=3004037004&checksum=c5c762125d0d8a4a70bba3b042c6d65bccd0bf8f-1617045529938-f8f099d1873c5037578c81e053f5fcaabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031167	TRL 382			Yes			Discontinued (Preclinical)	Neuropathic pain		Cyclo-oxygenase 1 inhibitors	"Toray (Originator), Toray (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TRL382			24/03/2016	Pain				no		no							https://adis.springer.com/drugs/800031167?userId=52029392&bpIds=3004037004&checksum=f2f69312d86c2c197adc7b681a26f6469488cd14-1617045529939-a939a595d4280e6d3f51552ba049bc8dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028883	PPC 5650			Yes			Discontinued (I)	Pain		ASIC1a channel antagonists	"Aros Pharma (Originator), PainCeptor Pharma Corporation (Originator), Aros Pharma (Owner)"		Rectal				N2 (Analgesics)	N02 (Analgesics)	PPC5650			24/03/2016	Pain				no		no							https://adis.springer.com/drugs/800028883?userId=52029392&bpIds=3004037004&checksum=65cb2aec594a54535826b58e9d2238f99c960dc9-1617045529940-d13783c9efd8fda1b84ab28ef0f31884badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034674	PF 5105679			Yes			No development reported (I)	Pain		TRPM8 protein inhibitors	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PF05105679			16/03/2016	Pain				no		no							https://adis.springer.com/drugs/800034674?userId=52029392&bpIds=3004037004&checksum=9f3957263e5fc7563e51d42446a2c016db6fd9b7-1617045529941-e0aee9b7bd7405f40969f9d517e111a6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800041812	TPW 196			Yes			Discontinued (I)	Pain		Undefined mechanism	"Teikoku Pharma USA (Originator), Teikoku Pharma USA (Owner)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)	TPW196			07/03/2016	Pain				no		no							https://adis.springer.com/drugs/800041812?userId=52029392&bpIds=3004037004&checksum=9ecedd3cad24593b29a29a4ac4e345b0776e64d4-1617045529942-a28d3523126507c5c3ae20066fd1603ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037557	Research programme: pain therapeutic - BioMed Valley Discoveries			Yes			Discontinued (Preclinical)	Pain		Undefined mechanism	"BioMed Valley Discoveries (Originator), BioMed Valley Discoveries (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	BVDMOR			26/02/2016	Pain				no		no							https://adis.springer.com/drugs/800037557?userId=52029392&bpIds=3004037004&checksum=38535bfb2c97381fb9ad92fa0c3c6d96044c520f-1617045529943-b959174bb80e1dadf755b5e8adda2fa5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039741	PRC 062			Yes			No development reported (III)	Pain		Undefined mechanism	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				25/02/2016	Pain				no		no							https://adis.springer.com/drugs/800039741?userId=52029392&bpIds=3004037004&checksum=716ecaf311cff384e9ec502a00aae946af4849a6-1617045529943-f79e55e99175c47d80531438f66ac446badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034454	Research programme: pain therapeutics - Ensysce Biosciences			No			Discontinued (Research)	Inflammatory pain		Opioid receptor modulators	"PharmacoFore (Originator), Ensysce Biosciences (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	PF14			24/02/2016	Pain				no		no							https://adis.springer.com/drugs/800034454?userId=52029392&bpIds=3004037004&checksum=81df8c3c6abc34cb16a60231e1a77099695a0915-1617045529944-25d8e1a209711f6f66c1b6aeda2fe78cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034453	Research programme: tapentadol - Ensysce Biosciences	175591-23-8	3-(3-Dimethylamino-1-ethyl-2-methylpropyl)phenol	No			Discontinued (Research)	Pain	C14 H23 N O	"Alpha 2 adrenergic receptor antagonists, Opioid mu receptor agonists"	"PharmacoFore (Originator), Ensysce Biosciences (Owner)"		PO				N2A (Narcotics)	N02A-X06 (Tapentadol)	"PF 16, Tapentadol BioMD System"			24/02/2016	Pain		Ensysce Biosciences |  | Unspecified |  | 03 Sep 2012		no		no							https://adis.springer.com/drugs/800034453?userId=52029392&bpIds=3004037004&checksum=fb54af77b57c0c331c0ae195f4808b17ddbc697a-1617045529946-9ac50ed07eb96333060e0d8f64c37094badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044735	Morphine oral - Purdue Pharma	57-27-2	"Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-"	No			Discontinued (I/II)	Neuropathic pain	C17 H19 N O3	Opioid mu receptor agonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	V113741			23/02/2016	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800044735?userId=52029392&bpIds=3004037004&checksum=439aaa6fe332adc9bf84719c69311e9f831ebc5e-1617045529947-060f4adaced37b73249d290b2d8e42b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037420	Trimebutine 3-thiocarbamoylbenzenesulfonate		"2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate 3-carbamothioylbenzenesulfonate"	Yes			No development reported (II)	"Procedural pain, Irritable bowel syndrome"	C22 H29 N O5 . C7 H7 N O3 S2	"Muscarinic receptor antagonists, Neurotransmitter modulators, Opioid kappa receptor agonists, Opioid mu receptor agonists, Oxygen radical scavengers"	"Antibe Therapeutics (Originator), Antibe Therapeutics (Owner), gIcare Pharma (Licensee)"		PO				"A3A (Plain Antispasmodics and Anticholinergics), N2A (Narcotics)"	"A03A-A (Synthetic anticholinergics, esters with tertiary amino group), N02A (Opioids)"	"GIC1001, TB90502"			17/02/2016	"Digestive System Disorders, Pain"				no		no							https://adis.springer.com/drugs/800037420?userId=52029392&bpIds=3004037004&checksum=ebd9e8838066f7060eae05c8fb4308900d5e1435-1617045529949-f0191ec15f1276fddffdebec0c6b1d95badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800044423	MK 49			Yes			Phase Unknown	Pain		Undefined mechanism	"MIKA Pharma GmbH (Originator), MIKA Pharma GmbH (Owner)"		"Transmucosal, Buccal"				N2 (Analgesics)	N02 (Analgesics)	MK49			21/01/2016	Pain				no		no							https://adis.springer.com/drugs/800044423?userId=52029392&bpIds=3004037004&checksum=77721b62b43ce3439ce0314c62f40c1da6eb5b88-1617045529950-35e55e149a995ed25b415342c040a1aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031796	Research programme: pain and inflammation therapeutics - Xel			Yes			Discontinued (Preclinical)	"Inflammation, Pain"		"Serotonin modulators, Sodium channel modulators"	"Xel Pharmaceuticals (Originator), Xel Pharmaceuticals (Owner)"		"Parenteral, Transdermal, Topical"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"XEL 002BG, XEL 002BI, XEL 002BP, XEL 002LG, XEL 004FP"			07/01/2016	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800031796?userId=52029392&bpIds=3004037004&checksum=bd06379e5b9749f053cd68b203f484d101c73a49-1617045529951-78549b1d5642a76bac74e4d68cd51694badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025698	Ropivacaine extended release - Encore/PainReform	84057-95-4	"(-)-1-Propyl-2',6'-pipecoloxylidide"	No			No development reported (I/II)	Postoperative pain	C17 H26 N2 O	"Potassium channel antagonists, Sodium channel antagonists"	"Encore Therapeutics (Originator), Encore Therapeutics (Owner), PainReform (Licensee)"		SC				"N1B (Anaesthetics, Local), N2 (Analgesics)"	"N01B (Anesthetics, Local), N02 (Analgesics)"	"ETI211 Encore, F93, LNPoily solution, LNPoily solution (Ropivacaine), PRF108"			06/01/2016	Pain		Encore Therapeutics |  | Unspecified | World (Excluding North America) | 26 Sep 2011		no		no				"bFGF, BNP, CCL5, CD38, CKB, CKM, CRP, CXCL10, D-dimer, Eotaxin, G-CSF, Hydrocortisone, IFN-gamma, IGFBP7, IL1 beta, IL10, IL13, IL15, IL17, IL2, IL4, IL5, IL6, IL7, IL8, IL9, interleukin 1 receptor type 1, KRAS, MCP1, MIP-1 alpha, NGAL, Norepinephrine, NRAS, PDGFB, Prolactin, proteasome 26S subunit, non-ATPase 1, RAGE, serotonin, TIMP-2, TNF-alpha, troponin I, cardiac, VEGF-A, VEGF-C"	"bFGF, CCL5, CRP, CXCL10, D-dimer, Eotaxin, G-CSF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL15, IL17, IL2, IL4, IL5, IL6, IL7, IL8, IL9, MCP1, MIP-1 alpha, PDGFB, TNF-alpha, troponin I, cardiac, VEGF-A"	"CCL4, exo/endonuclease G, GM-CSF, HIF, IL12A, IL12B, IL1RA, PGE2"	https://adis.springer.com/drugs/800025698?userId=52029392&bpIds=3004037004&checksum=9c555cff2f7d7b332fb468170385478e0546c09d-1617045529954-ea76cf859cff85549960816afd458d29badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032693	Analgesics - Pfizer			Yes			Discontinued (I)	Pain			"Pfizer (Originator), Pfizer (Owner)"		"IV, PO"				N2 (Analgesics)	N02 (Analgesics)	"PF 5141328, PF 5150122, PF 5186462, PF05141328, PF05150122, PF05186462"			09/12/2015	Pain				no		no							https://adis.springer.com/drugs/800032693?userId=52029392&bpIds=3004037004&checksum=6ebf5a204d04e471340cecf277e95dbae111f7ea-1617045529955-b553b51b5052bb1ba7f6a42d140efaf9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043882	IMD 3 - Yuhan			No			Discontinued (III)	Pain			"Yuhan (Originator), Yuhan (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	IMD3 Yuhan			01/12/2015	Pain				no		no							https://adis.springer.com/drugs/800043882?userId=52029392&bpIds=3004037004&checksum=84e9963aa7cfdd416d0b415e7cfaa5774a008fe1-1617045529956-4f9c8008937160dbe2fbb2f1b4221149badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032594	Hydrocodone/chlorphenamine extended-release - Covidien	13219-97-1	"4,5-alpha-epoxy-3-methoxy-17-methylmorphinan-6-one á 3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine"	No			Marketed	Cough	C18 H21 N O3 . C16 H19 Cl N2	"Histamine H1 receptor antagonists, Opioid receptor agonists"	"Mallinckrodt Inc. (Originator), Mallinckrodt Inc. (Owner), Akorn (Market Licensee)"		PO				"N2A (Narcotics), R5D2 (Antitussives in combinations), R6A (Systemic Antihistamines)"	"N02A-F (Morphinan derivatives), R05D (Cough Suppressants, Excl. Combinations with Expectorants), R06A (Antihistamines for Systemic Use)"	"Chlorphenamine/hydrocodone, Chlorpheniramine/hydrocodone, Hydrocodone/chlorpheniramine, TussiCaps"			17/11/2015	Respiratory Tract Disorders			TussiCaps	no		no							https://adis.springer.com/drugs/800032594?userId=52029392&bpIds=3004037004&checksum=0ec31bfe2ffd2675ac926bf4c36b609644b93dd2-1617045529957-29c7f01820d35cdef9750bdec5c4d488badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800039859	Metabotropic glutamate 2/3 receptor agonist - Eli Lilly and Company			Yes			Discontinued (I)	Pain		"Metabotropic glutamate receptor 2 agonists, Metabotropic glutamate receptor 3 agonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	mGlu2/3 Agonist Eli Lilly and Company			28/10/2015	Pain				no		no							https://adis.springer.com/drugs/800039859?userId=52029392&bpIds=3004037004&checksum=8d73087e9223eaf4c32cf6321d9c6c3630836802-1617045529958-7e98fdda865858dd6392bcf546e9a322badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032761	DWJ 204			Yes			Discontinued (I)	Neuropathic pain		Undefined mechanism	"Daewoong Pharmaceutical (Originator), Daewoong Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DWJ204			07/10/2015	Pain				no		no							https://adis.springer.com/drugs/800032761?userId=52029392&bpIds=3004037004&checksum=3e6145f74e82fef65849056f5edaa22221a0ee16-1617045529958-e2417efafc859996e986e395e26e1749badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800042880	Morphine - Hospira	6211-15-0	"Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-,(5_,6_)-, sul-fate(2:1)(salt), pentahydrate"	No			Marketed	Pain	C17-H19-N-O3.1/2H2-O4-S.5H2-O	Opioid mu receptor agonists	"Hospira (Originator), Hospira (Owner)"		IV				N2A (Narcotics)	N02A-A01 (Morphine)	Morphine sulfate Hospira			30/09/2015	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800042880?userId=52029392&bpIds=3004037004&checksum=5dc1fc1d738e5f7830b745d0ff69d3189ca8bcdd-1617045529960-57e12efff9b7d04b6bdc13033dc76c6fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024603	Morphine/phenylephrine/sorbitol			No			No development reported (I/II)	Pain		Undefined mechanism	"Gevys Pharmaceuticals (Originator), Gevys Pharmaceuticals (Owner), BioLineRx (Market Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	BL3010			29/09/2015	Pain				no		no							https://adis.springer.com/drugs/800024603?userId=52029392&bpIds=3004037004&checksum=8cf04dd843cf395e637f2974636c09b3274aa3e7-1617045529961-6432ea5074e508e8b22bb054a5fdb586badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800043258	Tramadol orally disintegrating tablets - Athena Drug Delivery Solutions	27203-92-5	(±)-<EM>cis</EM>-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol	No			Marketed	Pain	C16 H25 N O2	Opioid receptor agonists	"Athena Drug Delivery Solutions (Originator), Athena Drug Delivery Solutions (Owner)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"Dispan, Tramadol ODT Athena Drug Delivery Solutions"			21/09/2015	Pain			Dispan	no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800043258?userId=52029392&bpIds=3004037004&checksum=8b21816b9159951d3520461b4f1a8c8cf6ed2929-1617045529962-84fc65d909523983c91b08e27a813046badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016051	Research programme: neuronal nicotinic receptor modulators - Targacept			Yes			Discontinued (Preclinical)	"Cognition disorders, Parkinson's disease, Drug-induced dyskinesia, Schizophrenia"		"Alpha7 nicotinic acetylcholine receptor agonists, Nicotinic receptor modulators"	"Targacept (Originator), Targacept (Owner)"		unspecified				"A8 (Antiobesity Preparations, Excluding Dietetics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"A08 (Antiobesity Preparations, Excl. Diet Products), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N05A (Antipsychotics), N05B (Anxiolytics), N05C (Hypnotics and Sedatives), N06A-X (Other antidepressants), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	"TC2429, TC7020, TC8831"			14/09/2015	"Alzheimer's Disease and Cognition Disorders, Parkinson's Disease and Movement Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800016051?userId=52029392&bpIds=3004037004&checksum=68a3b97fd8935d434ed2dfef180d7de28d32a83d-1617045529963-fe7d503c15626c0d8e4e8aa758ec023ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023819	ZY I1			Yes			Discontinued (II)	Pain			"Zydus-Cadila (Originator), Zydus-Cadila (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	ZYI1			11/09/2015	Pain				no		no							https://adis.springer.com/drugs/800023819?userId=52029392&bpIds=3004037004&checksum=7a314b7a23f50187c33d50ad81e4fe9213abd2c6-1617045529964-6e0eb465e4af04805b478e4bf59d9c43badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009224	Zonampanel		"[2,3-Dioxo-7-(1<EM>H</EM>-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl]-acetic acid monohydrate"	Yes			Discontinued (II)	"Stroke, Brain injuries, Pain"	C13 H9 N5 O4	AMPA receptor antagonists	"Astellas Pharma (Originator), Astellas Pharma (Owner)"		"IV, unspecified, Intrathecal"				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	YM872			10/09/2015	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009224?userId=52029392&bpIds=3004037004&checksum=48bed440d4369abb6bc25dbe374294c24c573927-1617045529966-ccad8f8843bb40a29b801b325857af50badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031397	LY 545694			Yes			No development reported (II)	"Neuropathic pain, Musculoskeletal pain"		Kainic acid receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				08/09/2015	Pain				no		no							https://adis.springer.com/drugs/800031397?userId=52029392&bpIds=3004037004&checksum=f44fe47b2ba742de2c384b2c2a894e25aae3e511-1617045529968-18bc1715840b7dbf12cf336226c362b1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021315	XEN 2174			Yes			Discontinued (II)	"Postoperative pain, Cancer pain"		"Adrenergic uptake inhibitors, Catecholamine plasma membrane transport protein inhibitors"	"Xenome (Originator), Xenome (Owner)"		"Intrathecal, IV"				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	XEN2174			08/09/2015	Pain				no		no							https://adis.springer.com/drugs/800021315?userId=52029392&bpIds=3004037004&checksum=b69556e3b44dac0824f2f97bd10126d738f6b27e-1617045529969-57eeadca25621f24761840fa083a0bcdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025957	Galantamine liposomal	357-70-0	"(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef] [2]benzazepin-6-ol"	No			Discontinued (II)	Neuropathic pain	C17 H21 N O3	Acetylcholinesterase inhibitors	"Sanochemia Pharmazeutika (Originator), Sanochemia Pharmazeutika (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	Topical galantamine			08/09/2015	Pain		Sanochemia Pharmazeutika |  | Phase II |  | 30 Nov 2009		no		no		alkylglycerone phosphate synthase	"Folic acid, Prolactin"	"Adiponectin, alkylglycerone phosphate synthase, Allantoin, E1A binding protein p300, IL6, Insulin, Kynurenic acid, Kynurenine, Leptin, Picolinic acid, solute carrier family 27 member 5, Thrombin, TNF-alpha"		"C-C motif chemokine receptor 2, CD14, CD163, CD38, CD8a, Citicoline, COMT, CXCR1, CYP2D6, dopamine beta-hydroxylase, exostosin like glycosyltransferase 3, HLA-DR, MCP1, Tau protein, Thyroid stimulating hormone, beta"	https://adis.springer.com/drugs/800025957?userId=52029392&bpIds=3004037004&checksum=68eb1fafba3157e58ba297db0e10d271a2fa07d7-1617045529971-49a72c05d0ec8ee6a6af0bb99ce3eb73badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029022	Research programme: inflammatory pain therapeutic - Relevare			No			Discontinued (Preclinical)	Inflammatory pain			"CNSBio (Originator), Relevare Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	CNSB 006			01/09/2015	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800029022?userId=52029392&bpIds=3004037004&checksum=e262a8263347d2d199719d4e28ecc7f9815389d0-1617045529971-57a803e5a1142bb003fb02f92646f55dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029021	Research programme: severe pain therapeutic - Relevare			Yes			Discontinued (Preclinical)	Pain		N-type calcium channel modulators	"CNSBio (Originator), Relevare Pharmaceuticals (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	"CNSB 004, Leconotide Relevare"			01/09/2015	Pain				no		no							https://adis.springer.com/drugs/800029021?userId=52029392&bpIds=3004037004&checksum=e37023e42a5a8ca6bb14ea0514cf41fda8e73ae8-1617045529972-c00c153d9d8d05bda8e4f9292250df6dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033305	Buprenorphine/naloxone - Aoxing Pharmaceutical Company			No			Phase II	Opioid-related disorders		"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Aoxing Pharmaceutical Company (Originator), Aoxing Pharmaceutical Company (Owner), Beijing Medical University (Development Licensee)"		Sublingual				"N7F (Drugs Used In Opioid Dependence), V3E (Antidotes)"	"N02A-E01 (Buprenorphine), V03A-B15 (Naloxone)"	Naloxone/buprenorphine Aoxing Pharmaceutical Company			31/08/2015	Drug Withdrawal				no		no							https://adis.springer.com/drugs/800033305?userId=52029392&bpIds=3004037004&checksum=d8723f6e9abe2d5c3b80b52f5a04eddd566fd44a-1617045529974-c2adbacc32b37ba98edd811c39b049d2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034017	BMS 954561			Yes			Discontinued (II)	"Diabetic neuropathies, Postherpetic neuralgia"		"GABA receptor modulators, Nicotinic receptor modulators"	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	BMS954561			28/08/2015	Pain				no		no							https://adis.springer.com/drugs/800034017?userId=52029392&bpIds=3004037004&checksum=3edc9510babb6e687c3bf9ccacc10e0f8beb67b7-1617045529975-468f6d1a31e946700f5101e9b536c512badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028777	VA 111913			Yes			No development reported (II)	Dysmenorrhoea		Vasopressin 1a receptor antagonists	"Vantia Therapeutics (Originator), Vantia Therapeutics (Owner)"		PO				"G2X1 (Gynaecological antispasmodics), N2 (Analgesics)"	N02 (Analgesics)	"VA 111913 TS, VA 913, VA111913"			25/08/2015	Women's Health				no		no							https://adis.springer.com/drugs/800028777?userId=52029392&bpIds=3004037004&checksum=63153812216b298e6dadb36f4ea495144cc9f6e2-1617045529976-d0d74e4f9460555b3a7f39aa63d5596bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020448	Ketoprofen topical - Celtic Pharma	22071-15-4	"Benzeneacetic acid, 3-benzoyl-alpha-methyl-"	No			Discontinued (II)	"Skin disorders, Photodamage"	C16 H14 O3	"Cyclooxygenase inhibitors, Lipoxygenase inhibitors"	"IDEA (Originator), IDEA (Owner), Celtic Pharma (Licensee)"		Topical				"D11A (Other Dermatological Preparations), M2A (Topical Anti-rheumatics and Analgesics), N2 (Analgesics)"	"D11A (Other Dermatological Preparations), M02A-A (Antiinflammatory preparations, non-steroids for topical use), N02 (Analgesics)"	TDT070			20/08/2015	"Drug Delivery Systems, Skin Disorders"				no		no							https://adis.springer.com/drugs/800020448?userId=52029392&bpIds=3004037004&checksum=e4e264db8d004b0efb7930f302f8553dcae3d508-1617045529977-3629c11fec8a38596f21ef61b6ed4c15badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028356	KAI 1678	1253964-58-7		Yes			Discontinued (II)	"Neuropathic pain, Postoperative pain"		Protein kinase C epsilon inhibitors	"KAI Pharmaceuticals (Originator), Amgen (Owner)"		SC				N2 (Analgesics)	N02 (Analgesics)	KAI1678			19/08/2015	Pain				no		no							https://adis.springer.com/drugs/800028356?userId=52029392&bpIds=3004037004&checksum=2b71d9bd574b1550ac34df8d247d185f8ffe3926-1617045529978-68ab14b78f47a6912f524d4d649bd144badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032097	IW 6118			Yes			Discontinued (II)	"Pain, Inflammation"		Fatty acid amide hydrolase inhibitors	"Ironwood Pharmaceuticals (Originator), Ironwood Pharmaceuticals (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	IW6118			17/08/2015	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800032097?userId=52029392&bpIds=3004037004&checksum=5f1470be91927a5dd96358744c4949f956622c4e-1617045529979-d31957ae100427a4dba19f4f833193a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013571	ATx08 001	193012-35-0	"1-(2,4-Dichlorobenzyl)-2-methyl-<EM>N</EM>-(pentylsulfonyl)-1<EM>H</EM>-benzimidazole-6-carboxamide"	Yes			No development reported (II)	"Postherpetic neuralgia, Type 2 diabetes mellitus"	C21 H23 Cl2 N3 O3 S	Peroxisome proliferator-activated receptor gamma agonists	"Astellas Pharma (Originator), Astellas Pharma (Owner), Aestus Therapeutics (Licensee)"		PO				"A10 (Drugs Used in Diabetes), N2 (Analgesics)"	"A10B (Blood Glucose Lowering Drugs, Excl. Insulins), N02 (Analgesics)"	"ATx08001, FK 614"			13/08/2015	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800013571?userId=52029392&bpIds=3004037004&checksum=a0d05123a7cc3877493ba3cb58bd793005d13207-1617045529981-a969ad41ce479eb6369403edb2bc350abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033233	Doxepin intranasal - Winston Pharmaceuticals	1668-19-5	"1-Propanamine, 3-dibenz(b,e)oxepin-11(6H)-ylidene-N,N- dimethyl-"	No			Phase II	Headache	C19 H21 N O	"Histamine H1 receptor antagonists, Serotonin uptake inhibitors"	"Winston Pharmaceuticals (Originator), Winston Pharmaceuticals (Owner)"		Intranasal			Drowsiness	N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	Dolorac			08/08/2015	Advances in the Treatment of Nausea and Migraine			Dolorac	no		no						CYP2D6	https://adis.springer.com/drugs/800033233?userId=52029392&bpIds=3004037004&checksum=c18771a3b4ec9843b9c7283dd7a8f1493ce73d5a-1617045529981-d3cc692c27a7bad9d71687936f2eda88badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036394	Diclofenac - Xanodyne	15307-81-0	"Potassium [o-(2,6-dichloroanilino)phenyl]acetate"	No			Discontinued (II)	Acute pain	C14 H10 Cl2 K N O2	"Cyclooxygenase inhibitors, Prostaglandin synthase inhibitors"	"Xanodyne Pharmaceuticals (Originator), Xanodyne Pharmaceuticals (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B05 (Diclofenac), N02B (Other Analgesics and Antipyretics)"	XP 21B			03/08/2015	Pain				no		no							https://adis.springer.com/drugs/800036394?userId=52029392&bpIds=3004037004&checksum=fec01a000813aaf441ad8120e28d6e209a11c632-1617045529982-50f7f8d7df8f810dd067b3cd467b7bc1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036619	Agomelatine - Nectid	138112-76-2	N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide	No			No development reported (II)	"Autistic disorder, Neuropathic pain, Fibromyalgia, Multiple sclerosis"	C15 H17 N O2	"Melatonin MT1 receptor agonists, Melatonin MT2 receptor agonists, Serotonin 2C receptor antagonists"	"Nectid (Originator), Nectid (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"NRT31, NRT34, NRT36"			30/07/2015	"Affective Disorders, Neurological Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800036619?userId=52029392&bpIds=3004037004&checksum=6311bb0e137c290177ab968ae69a0a114c52a2f3-1617045529983-5cb4792cb241450cc4ad92964ec1878fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024584	Adenosine - Xsira	58-61-7		No			Discontinued (II)	Postoperative pain	C10 H13 N5 O4	Adenosine A1 receptor agonists	"Harbor-UCLA Research and Education Institute (Originator), Harbor-UCLA Research and Education Institute (Owner), Xsira Pharmaceuticals (Market Licensee)"		IV				N2 (Analgesics)	N02 (Analgesics)	"Adenogesic, IVadenosine"			29/07/2015	Pain			Adenogesic	no		no							https://adis.springer.com/drugs/800024584?userId=52029392&bpIds=3004037004&checksum=8f40078ced3722b2d85293e1055947f10400b08e-1617045529984-27bdbca3f230669e98c0ace976b364a6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022514	AD 337			Yes			Discontinued (II)	Fibromyalgia		"Adrenergic receptor antagonists, Serotonin uptake inhibitors"	"Sosei R&D (Originator), Sosei R&D (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AD337			29/07/2015	Rheumatic Disease				no		no							https://adis.springer.com/drugs/800022514?userId=52029392&bpIds=3004037004&checksum=c9712d0adfd6c225380413117fff3706e276bba7-1617045529985-ffdce6280db3899371243c49d92d0b97badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033877	Sumatriptan needle-free injectable - Glide/Endo	103628-46-2	3-[2-(Dimethyl-amino)ethyl]-N-methylindole-5-methanesulfonamide	Yes			Discontinued (II)	Migraine	C14 H21 N3 O2 S	Serotonin 1D receptor agonists	"Glide Pharma (Originator), Glide Technologies (Owner), Endo International (Licensee)"		SC				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	"Glide sumatriptan, GP01, Sumatriptan SDI"			27/07/2015	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"				no		no							https://adis.springer.com/drugs/800033877?userId=52029392&bpIds=3004037004&checksum=0b45a2986833851e596afa59eee7679b4726ef43-1617045529985-0ee2c8aee03bf402980f13e425548263badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020258	Danazol transdermal	17230-88-5	"17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol"	No			Phase II	Breast pain	C22 H27 N O2	"Estrogen receptor antagonists, Testosterone congener stimulants"	"FemmePharma (Originator), FemmePharma (Owner)"		Transdermal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	FP1198			27/07/2015	"Pain, Women's Health"				no		no		Inosine triphosphate		"FAS antisense RNA 1, Inosine triphosphate, Nitric Oxide"		"D-dimer, Fibrinogen"	https://adis.springer.com/drugs/800020258?userId=52029392&bpIds=3004037004&checksum=faa6d2f790c3ce406852ee54cd42f4b547c731ba-1617045529986-c05172aacb12e3b8a373db4f5467c94dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022354	GSK 705498	501951-42-4	(<EM>R</EM>)-1-(2-Bromophenyl)-3-[1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea	Yes			Discontinued (II)	"Rhinitis, Allergic rhinitis, Pain, Migraine, Cough, Dental pain, Atopic dermatitis, Pruritus"	C17 H16 Br F3 N4 O	TRPV1 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		"Intranasal, PO, Topical"				"D11A (Other Dermatological Preparations), D4 (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2 (Analgesics), N2C (Anti-Migraine Preparations), R1 (Nasal Preparations), R5 (Cough and Cold Preparations)"	"D04 (Antipruritics, Incl. Antihistamines, Anesthetics, etc.), D11A (Other Dermatological Preparations), N02 (Analgesics), N02C-X (Other antimigraine preparations), R01 (Nasal Preparations), R05 (Cough and Cold Preparations)"	"705498, GSK705498, SB705498"			21/07/2015	"Advances in the Treatment of Nausea and Migraine, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Skin Disorders"				no		no				"Uric acid, WAS/WASL interacting protein family, member 1"			https://adis.springer.com/drugs/800022354?userId=52029392&bpIds=3004037004&checksum=c7dadc82cff0ebc9ca1a12db8db1c46c98fd4b53-1617045529988-fee6ff6e1d0aac88245b81947b707eccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800035148	RGH 478			Yes			Discontinued (II)	"Osteoarthritis, Musculoskeletal pain"		Bradykinin B1 receptor antagonists	"Gedeon Richter (Originator), Gedeon Richter (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	RGH478			20/07/2015	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800035148?userId=52029392&bpIds=3004037004&checksum=718f6855535f22cdc96239c2e1628ec073a5345f-1617045529988-8102727d068f8825f4645512fc4b546bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022976	SKL NP			Yes			Discontinued (II)	Diabetic neuropathies		"12-lipoxygenase inhibitors, 15-lipoxygenase inhibitors, Calcium channel modulators, Hyperpolarisation-activated cation channel modulators"	"SK biopharmaceuticals (Originator), SK Life Science (Originator), SK biopharmaceuticals (Owner), SK Life Science (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"SKL11197, SKLNP"			20/07/2015	Pain				no		no							https://adis.springer.com/drugs/800022976?userId=52029392&bpIds=3004037004&checksum=eddc929f5cc59b3d3e731d36f14e5d4058e7a56b-1617045529989-c3923dc98865a8ad2585246965a35c49badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010013	Research programme: cathepsin S inhibitors - Medivir AB			Yes			Discontinued (Preclinical)	"Rheumatoid arthritis, Asthma, Multiple sclerosis, Hypersensitivity, Neuropathic pain, Autoimmune disorders"		Cathepsin S inhibitors	"Medivir AB (Originator), Medivir AB (Owner)"		PO				"L4X (Other Immunosuppressants), N2 (Analgesics), N7 (Other CNS Drugs), R3 (Anti-Asthma and COPD Products)"	"L04A-A (Selective immunosupressants), N02 (Analgesics), N07 (Other Nervous System Drugs), R03 (Drugs for Obstructive Airway Diseases)"	"CD1, MIV247, MV57471"			14/07/2015	"Immunological Disorders, Neurological Disorders, Obstructive Airways Disease, Pain, Rheumatic Disease"		Medivir AB |  | Unspecified |  | 21 Aug 2014		no		no							https://adis.springer.com/drugs/800010013?userId=52029392&bpIds=3004037004&checksum=a2f6ee13506d80bf3a4e06232c08563d4ab4362b-1617045529990-8e8a1ffc5b5523b243b6e5341073b0aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026624	Research programme: pain therapeutics - Solace Pharmaceuticals			Yes			Discontinued (Preclinical)	Pain		GTP cyclohydrolase inhibitors	"Solace Pharmaceuticals (Originator), Solace Pharmaceuticals (Owner), Massachusetts General Hospital (Technology Provider)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GCH1 inhibitors Solace			29/06/2015	Pain				no		no							https://adis.springer.com/drugs/800026624?userId=52029392&bpIds=3004037004&checksum=727d59592594bf873df70a366d4565ac45e9cbfa-1617045529991-9e3e8e0f0441fafede222bfbbbc72c3ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026626	SLC 022			Yes			Discontinued (II)	Postherpetic neuralgia		Glial cell modulators	"Solace Pharmaceuticals (Originator), Solace Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Glial cell modulator Solace Pharmaceuticals, SLC022"			29/06/2015	Pain				no		no							https://adis.springer.com/drugs/800026626?userId=52029392&bpIds=3004037004&checksum=3a521326590819130893e43949f7fc670fe3b6a4-1617045529992-062b7571989d4c012071a3472262fe14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029191	Research programme: TRPV3 antagonists - Glenmark Pharmaceuticals			Yes			Discontinued (Preclinical)	Pain		TRPV3 protein inhibitors	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), Sanofi (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				25/06/2015	Pain				no		no							https://adis.springer.com/drugs/800029191?userId=52029392&bpIds=3004037004&checksum=bfc7a67df99f60859207737df9b03c41805dd7f7-1617045529993-595b9301f73cc2692f8b83e58321c377badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031624	GRT 3983Y			Yes			Discontinued (II)	Pain			"Grunenthal (Originator), Grunenthal (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	GRT3983Y			25/06/2015	Pain				no		no							https://adis.springer.com/drugs/800031624?userId=52029392&bpIds=3004037004&checksum=34814dafeaa321e2036d7611e80a8f0b6e586af0-1617045529993-452f23df29420b4681e81c7c61f58658badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018045	CJ 15161	204970-97-8	4-(((S)-2-((S)-3-hydroxypyrrolidin-1-yl)-1-phenylethyl)(methyl)amino)-N-propylbenzamide	Yes			Discontinued (II)	"Back pain, Cancer pain"	C23 H31 N3 O2	Opioid kappa receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	CJ15161			24/06/2015	Pain				no		no							https://adis.springer.com/drugs/800018045?userId=52029392&bpIds=3004037004&checksum=ea86c80ee313ce465bf7307c4823b39a3b014dc9-1617045529994-cae536fd00e3fa5206f06ce00b29f91ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026861	NXN 188			Yes			Phase II	Migraine		"Calcitonin gene-related peptide antagonists, Nitric oxide synthase inhibitors, Serotonin receptor agonists"	"NeurAxon (Originator), NeurAxon (Owner), Knight Therapeutics (Licensee)"		"PO, IV"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	NXN188			24/06/2015	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800026861?userId=52029392&bpIds=3004037004&checksum=cef163ecc82f19797f24c8143a007e6a1f7c56b6-1617045529995-27bdfea5e08391d3682d5a3d4e408721badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003782	Cizolirtine	142155-43-9	(±)-5-[alpha-[2-(Dimethylamino)ethoxy]benzyl]-1-methylpyrazole	Yes			Discontinued (II)	"Overactive bladder, Pain, Stress incontinence, Urinary incontinence"	C15 H21 N3 O	"Calcitonin gene-related peptide antagonists, Substance P release inhibitors"	"Esteve (Originator), Esteve (Owner)"		"PO, unspecified"				"G4 (Urologicals), G4D4 (Urinary incontinence products), N2 (Analgesics)"	"G04 (Urologicals), G04B (Urologicals), N02 (Analgesics)"	"E 4960, E 4961, E4018"			24/06/2015	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800003782?userId=52029392&bpIds=3004037004&checksum=27239a2959833382d2fe2900a8b60b4326b15869-1617045529997-6a4e696939654b8e607daf1c1e23788cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034770	PP 4001			Yes			Discontinued (II)	Dysuria		Undefined mechanism	"Pinnacle Pharmaceuticals (Originator), Pinnacle Pharmaceuticals (Owner)"		PO				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	PP4001			23/06/2015	Genitourinary Disorders				no		no							https://adis.springer.com/drugs/800034770?userId=52029392&bpIds=3004037004&checksum=3d88057b119623590491af371b336bb4684484ea-1617045529998-a6adf536d874a60964e2991b4147cc2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017128	Morphine hydrochloride sustained release - Takeda	52-26-6	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, hydrochloride"	No			No development reported (Registered)	Cancer pain	C17 H19 O3 . H Cl	Opioid mu receptor agonists	"Takeda (Originator), Takeda (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	"TAK 453 SR, TAK453"			11/06/2015	Pain				no		no							https://adis.springer.com/drugs/800017128?userId=52029392&bpIds=3004037004&checksum=e7b962e792a4d0bd24e49074e94d082d6bf0bc00-1617045529999-606816973f7de30259dc3f31dab316d2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024489	Oxycodone controlled release - Elite Pharmaceuticals	76-42-6	"4,5_-Epoxy-14_-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Discontinued (II)	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Elite Pharmaceuticals (Originator), Elite Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A-A05 (Oxycodone)	"ELI154, onceaday oxycodone Elite Pharmaceuticals, oxycodone CR Elite Pharmaceuticals, OxyQD"			10/06/2015	Pain		Elite Pharmaceuticals | Pain | Phase III | Europe | 19 Feb 2009		no		no							https://adis.springer.com/drugs/800024489?userId=52029392&bpIds=3004037004&checksum=76ccdb51d1cdf0ace0e1d5a1dac8b40d6c39f703-1617045530000-77ab9b2c645653c6815d23fceb4d3778badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009277	Morphine-6-glucuronide - PAION	70001-26-2	"(5_, 6_) - 4, 5-Epoxy-3 hydroxy-17-methylmorphinan-6-yl _-D-glucopyranosiduronic acid"	No			Phase Unknown	Postoperative pain	C23 H29 N O9	Opioid mu receptor agonists	"CeNeS Pharmaceuticals (Originator), PAION (Owner), Yichang Humanwell Pharmaceutical (Licensee)"		IV	renal	"Dose Modification in Renal Dysfunction (marked), Route of Elimination (renal), bioavailability oral (%) (10 (Adult)), Cl (L/h) (9.7 - 10 (Adult)), T<sub>_beta</sub> (h) (1.3 - 1.7 (Adult)), Vd (L/kg) (.3 - .4 (Adult))"	"Dysphoria, Nausea, Somnolence"	N2A (Narcotics)	"N02A-A (Natural opium alkaloids), N02A-F (Morphinan derivatives)"	"CEE 04410, M6G"			01/06/2015	"Drug Delivery Systems, Pain"		PAION |  | Phase III |  | 28 Mar 2007		no		no							https://adis.springer.com/drugs/800009277?userId=52029392&bpIds=3004037004&checksum=4852e229e6152b43ce0b802866451123c19daaa7-1617045530002-54a94bead3183b43287b33c98deadc9ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021596	Fentanyl inhalation - Akela Pharma	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide	No			Discontinued (III)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"LAB International (Originator), Akela Pharma (Owner), Janssen Pharmaceutica (Licensee), SK Chemicals (Licensee)"		Inhalation		bioavailability inhaled (%) ( - 80)	Somnolence	"N1A1 (Inhalation general anaesthetics), N2A (Narcotics)"	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	Fentanyl TAIFUN			26/05/2015	Pain			Fentanyl TAIFUN	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800021596?userId=52029392&bpIds=3004037004&checksum=508d5a04ed75d3f45ad38ebd6f499e0225c3f48e-1617045530005-41a07ccb516510ca11eb550501503733badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033679	Diclofenac/tramadol - AbbVie			No			No development reported (III)	Pain		"Cyclooxygenase inhibitors, Opioid mu receptor agonists, Serotonin uptake inhibitors"	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2A (Narcotics)"	"M01A-B55 (Diclofenac, combinations), N02A-X52 (Tramadol, combinations)"				21/04/2015	Pain				no		no							https://adis.springer.com/drugs/800033679?userId=52029392&bpIds=3004037004&checksum=73b99bec7e594e2b861f881c38e4a90df4733725-1617045530006-fbf3d96b9d1926ce2f574f4b8b5b98d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034573	Diclofenac diethylamine	78213-16-8	"N-Ethylethanamine 2-[(2,6-dichlorophenyl)amino]benzeneacetate; 2-[(2,6-Dichlorophenyl)amino]-benzeneacetic acid compd.with N-ethylethanamine(1:1)"	No			No development reported (III)	"Acute pain, Musculoskeletal pain"	C14H11Cl2NO2 . C4H11N	Cyclooxygenase inhibitors	"Zambon SpA (Originator), Zambon SpA (Owner)"		Topical				"M2A (Topical Anti-rheumatics and Analgesics), N2 (Analgesics)"	"M02A-A15 (Diclofenac), N02 (Analgesics)"	Z7202			21/04/2015	Pain				no		no							https://adis.springer.com/drugs/800034573?userId=52029392&bpIds=3004037004&checksum=b604a85d68d0f5df45171e77a4d50f3b2a18c89c-1617045530007-2c07fba672d208ad6c6608c2de4f85f6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025602	Dronabinol - GW Pharmaceuticals	1972-08-3	"6<EM>H</EM>-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6a<EM>R</EM>-trans)-"	No			Discontinued (III)	"Neuropathic pain, Postoperative pain, Pain"	C21 H30 O2	Cannabinoid receptor agonists	"GW Pharmaceuticals (Originator), GW Pharmaceuticals (Owner)"		Buccal				N2 (Analgesics)	N02 (Analgesics)	"GW200002, Tetrahydrocannabinol GW Pharmaceuticals, THC GW Pharmaceuticals"			21/04/2015	Pain				no		no				"Calprotectin, CPM, CYP2C19, CYP2C9, IL1 beta, IL10, IL23, IL6, Leptin, MMP-2, MMP9, nystagmus 3, congenital autosomal dominant, TIMP-1, TNF-alpha"		"COMT, fatty acid amide hydrolase, monoglyceride lipase"	https://adis.springer.com/drugs/800025602?userId=52029392&bpIds=3004037004&checksum=9f0c9ef760fde9ded5192293ae5e1862c0d07096-1617045530009-67adb28b8889c857de0d44a904f1bf2abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006826	Dexibuprofen	51146-56-6	"Benzeneacetic acid, (<EM>S</EM>)-_-methyl-4-(2-methylpropyl)-"	No			Marketed	"Pain, Osteoarthritis, Headache, Dysmenorrhoea, Rheumatic disorders, Back pain, Inflammation, Postoperative pain, Musculoskeletal pain"	C13 H18 O2	Cyclooxygenase inhibitors	"Gebro Pharma GmbH (Originator), Gebro Pharma GmbH (Owner), Bago (Market Licensee), Binex (Market Licensee), Madaus (Market Licensee), Sanofi (Market Licensee), Spirig Pharma (Market Licensee), Hanmi Pharmaceutical (Collaborator)"		PO			Vertigo	"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"M01A-E (Propionic acid derivatives), M01A-E14 (Dexibuprofen), N02 (Analgesics), N02C (Antimigraine Preparations)"	"Daxfen, DexOptifen, Movone, S(+)Ibuprofen, Seractil, Ultraprofen"			20/04/2015	"Advances in the Treatment of Nausea and Migraine, Pain, Rheumatic Disease"			"Daxfen, DexOptifen, DexOptifen, Seractil, Ultraprofen"	no		no							https://adis.springer.com/drugs/800006826?userId=52029392&bpIds=3004037004&checksum=7d674c232df7a80325481d66f91f1353fb641f20-1617045530013-a44578caa102994dabb29cb3e30480bcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034542	Ketoprofen topical spray	22071-15-4	(+-)-3-Benzoyl-alpha-methylbenzeneacetic acid	No			Marketed	"Acute pain, Inflammation"	C16 H14 O3	Lipoxygenase-cyclooxygenase inhibitors	"Cyathus Exquirere (Originator), Cyathus Exquirere (Owner), MegaPharm Ltd (Market Licensee)"		Topical				"M2A (Topical Anti-rheumatics and Analgesics), N2B (Non-Narcotics and Anti-Pyretics)"	"M02A-A10 (Ketoprofen), N02B (Other Analgesics and Antipyretics)"	"KetoSpray, ProntoFlex, Yerasel"			18/04/2015	"Inflammation, Pain"			"KetoSpray, KetoSpray, KetoSpray, KetoSpray, KetoSpray, KetoSpray, ProntoFlex, ProntoFlex, Yerasel, Yerasel"	no		no							https://adis.springer.com/drugs/800034542?userId=52029392&bpIds=3004037004&checksum=3be69ef5c0587328505f2e9e8c0cd4a8885972a1-1617045530020-570a4d58a8281f09ab233d5af5a77c38badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002129	Sarpogrelate	125926-17-2	(±)-2-(Dimethylamino)-1-[[<EM>o</EM>-(<EM>m</EM>-methoxyphenethyl)phenoxy]methyl]ethyl hydrogen succinate	Yes			Marketed	"Arterial occlusive disorders, Cerebral infarction, Stroke, Pain, Raynaud's disease, Respiratory tract disorders, Myocardial infarction"	C24 H31 N O6	Serotonin 2A receptor antagonists	"Mitsubishi Chemical (Originator), Mitsubishi Tanabe Pharma Corporation (Owner)"		PO		"Activity vs parent (&gt;), protein binding (%) (95 (Adult)), T<sub>_beta</sub> (h) (.6 - .8 (Adult))"	"Blood dyscrasias, Flushing, Gastrointestinal disorders, Gastrointestinal haemorrhage, Headache, Nausea"	"B1C (Platelet Aggregation Inhibitors), C6A (Other Cardiovascular Products), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs), R7 (Other Respiratory System Products)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), C (Cardiovascular System), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs), R07 (Other Respiratory System Products)"	"Anplag, MCI9042"			17/04/2015	"Ischaemic Heart Disease, Neurological Disorders, Pain, Respiratory Tract Disorders, Thromboses, Vascular Disorders"			Anplag	no		no				pyridoxal phosphatase		"A1C, complement component (3b/4b) receptor 1 (Knops blood group)"	https://adis.springer.com/drugs/800002129?userId=52029392&bpIds=3004037004&checksum=25de9bedda068edbd55106ee276d775e2712c007-1617045530023-e6cd0652311a59fbd09691141337550cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800038405	ALKS 7106			Yes			Discontinued (I)	Pain		Opioid receptor modulators	"Alkermes plc (Originator), Alkermes plc (Owner)"		PO				N2A (Narcotics)	N02A-X (Other opioids)	ALKS7106			09/04/2015	Pain				no		no							https://adis.springer.com/drugs/800038405?userId=52029392&bpIds=3004037004&checksum=8f92862b88c3e99b4a576061ae5c3048d89b7030-1617045530024-b74e1b336ee82fc1ebbf1bc3e6251fa3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026856	Tramadol/paracetamol controlled-release	147630-09-9	"Acetamide, N-(4-hydroxyphenyl)-, mixt. with rel-(1R,2R)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol"	No			No development reported (Registered)	Pain	C16 H25 N O2.C8 H9 N O2	"Opioid mu receptor agonists, Prostaglandin receptor antagonists, Serotonin uptake inhibitors"	"Labopharm (Originator), Endo International (Owner)"		PO				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A-X52 (Tramadol, combinations), N02B-E51 (Paracetamol, combinations excl. psycholeptics)"	"DDS06C, Paracetamol/tramadol controlledrelease, Tramadol/acetaminophen CR Labopharm"			30/03/2015	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800026856?userId=52029392&bpIds=3004037004&checksum=6ee58f66f933be152123110b7b2bbf0bb52d699d-1617045530026-9c4d9158e608e124fa89d2ca8f13da98badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018894	Ketoprofen transdermal - IDEA AG	22071-15-4	(+-)-3-Benzoyl-alpha-methylbenzeneacetic acid	No			Discontinued (Registered)	"Musculoskeletal pain, Pain"	C16 H14 O3	Lipoxygenase-cyclooxygenase inhibitors	"IDEA (Originator), IDEA (Owner), Pfizer (Licensee)"		Transdermal				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E (Propionic acid derivatives), N02B (Other Analgesics and Antipyretics)"	"Diractin, IDEA033"			26/03/2015	"Pain, Rheumatic Disease"			Diractin	no		no							https://adis.springer.com/drugs/800018894?userId=52029392&bpIds=3004037004&checksum=f09b05f6bfea6154b79f9af1cdec8c6208d3bce9-1617045530028-e9055aaec0fce079eea14f732b575b8fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024115	Fentanyl transdermal patch - Lavipharm	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Marketed	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Lavipharm S.A. (Originator), Lavipharm S.A. (Owner), Pfizer (Licensee)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	"Durfenta, Fentadur, Fentanilo Parke Davis, Fentanyl Pfizer, Lafene, Opiodur, Recorfen"			13/03/2015	Pain			"Durfenta, Fentadur, Fentadur, Fentanilo Parke Davis, Fentanyl Pfizer, Fentanyl Pfizer, Fentanyl Pfizer, Fentanyl Pfizer, Lafene, Lafene, Opiodur, Recorfen"	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024115?userId=52029392&bpIds=3004037004&checksum=16e50d0a3e117a0203c5671c98d71617e556bda7-1617045530032-1011a80de23815c9ec08b8b34d97f063badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024249	Fentanyl injection - Daiichi Sankyo Company	990-73-8	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate	No			Marketed	"Pain, Anaesthesia, Sedation"	C22 H28 N2 O . C6 H8 O7	Opioid mu receptor agonists	"Janssen L.P. (Originator), Janssen L.P. (Owner), Daiichi Sankyo Company (Licensee)"		Parenteral				"N1A2 (Injectable general anaesthetics), N2A (Narcotics)"	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	"CS1401E, Fentanyl citrate injection Daiichi Sankyo"			12/03/2015	Pain				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024249?userId=52029392&bpIds=3004037004&checksum=d1c9617e77832d5140e322fb7d6f24db6276df64-1617045530035-b0267b8b3cc08e27d83dfc6a2d83fe0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000939	Butibufen	55837-18-8	"Benzeneacetic acid, _-ethyl-4-(2-methylpropyl)-"	Yes		³ Indometacin	Marketed	Pain	C14 H20 O2	Cyclooxygenase inhibitors	"Juste (Originator), Juste (Owner), Merck KGaA (Market Licensee)"		"PO, Topical"			"Gastrointestinal disorders, Headache"	"M1A1 (Anti-rheumatics, non-steroidal plain), N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B-A (Salicyclic acid and derivatives)"	"Butilopan, FF 105, Mijal"			05/03/2015	"Pain, Rheumatic Disease"			"Butilopan, Mijal"	no		no							https://adis.springer.com/drugs/800000939?userId=52029392&bpIds=3004037004&checksum=4be29d826af44239cc0174dde5a6c6d8d8e3e780-1617045530037-c998b5aa772943d9b47ebe27fc11bb53badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026942	Capsaicin topical liquid - NeurogesX	404-86-4	"6-Nonenamide, (E)-N-[(4-hydroxy-3-methoxy-phenyl)-methyl]-8-methyl"	No			Discontinued (II)	Postherpetic neuralgia	C18 H27 N O3	"Substance P inhibitors, TRPV1 receptor agonists"	"NeurogesX (Originator), NeurogesX (Owner), Acorda Therapeutics (Licensee)"		Topical				"N1B3 (Anaesthetics local, topical), N2 (Analgesics)"	"N01B-X04 (Capsaicin), N02 (Analgesics)"	"NGX1998, NP1998"			18/02/2015	Pain		NeurogesX |  | Unspecified | Asia | 03 Aug 2012		no		no				"A1C, carnitine palmitoyltransferase 1A (liver), IL1 beta, IL6, IL8, TNF-alpha"		peroxiredoxin 2	https://adis.springer.com/drugs/800026942?userId=52029392&bpIds=3004037004&checksum=f3d3f1dcd577ed3384b32c8ac7769a0ee3243206-1617045530038-a327af0363150822eda33d299d7c9f14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014967	CR 666			Yes			Discontinued (Preclinical)	Pain		Opioid kappa receptor agonists	"Ferring Pharmaceuticals (Originator), Freie Universitat Berlin (Originator), Ferring Pharmaceuticals (Owner), Freie Universitat Berlin (Owner), Cara Therapeutics (Licensee), ALZA Corporation (Sub-licensee)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"CR666, FE 200666"			12/02/2015	Pain				no		no							https://adis.springer.com/drugs/800014967?userId=52029392&bpIds=3004037004&checksum=0a68c890e41d3ff23eb91329b2dd0e3178348906-1617045530040-96d6fc0d7317c98954c79839e12f5990badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036307	PF 6273340			Yes			Discontinued (I)	Pain		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"PF06273340, PF6273340"			11/02/2015	Pain				no		no							https://adis.springer.com/drugs/800036307?userId=52029392&bpIds=3004037004&checksum=bbb85f0e0258689638b332fc44f58be6e3b16a55-1617045530041-2ba0987144bc2c23b9294500b9dae697badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029164	SD 254			No			No development reported (I)	"Major depressive disorder, Neuropathic pain"		"Adrenergic receptor antagonists, Serotonin uptake inhibitors"	"Auspex Pharmaceuticals (Originator), Teva Pharmaceutical Industries (Owner)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A-X (Other antidepressants)"	"Deuterated venlafaxine, SD254, Venlafaxine deuteriumsubstituted"			15/01/2015	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800029164?userId=52029392&bpIds=3004037004&checksum=63621630684195b65326bedf14a4affe4e3b1a60-1617045530042-c5c34460a0838bfc281aff9ee6e0dc3ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023970	MK 2295			Yes			Discontinued (II)	Pain		TRPV cation channel antagonists	"Merck & Co (Originator), Neurogen Corporation (Originator), Merck & Co (Owner), Neurogen Corporation (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"MK2295, NGD8243"			30/12/2014	Pain				no		no							https://adis.springer.com/drugs/800023970?userId=52029392&bpIds=3004037004&checksum=487c4c5899ec420d37b966c06cc3d2d2c3200e97-1617045530043-a9345e6f748302af718269f79c2a8530badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017458	Sumatriptan transmucosal - BDSI			No			Discontinued (Preclinical)	Migraine		Serotonin 1 receptor agonists	"QLT USA (Originator), QLT USA (Owner), BioDelivery Sciences International (Licensee)"		PO				N2C1 (Antimigraine triptans)	N02C-C01 (Sumatriptan)	Transmucosal sumatriptan BDSI			26/11/2014	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"				no		no							https://adis.springer.com/drugs/800017458?userId=52029392&bpIds=3004037004&checksum=110c5f2fb5d0be9c2b130cbc91c49ec74e6ba549-1617045530044-71c9619ef3335cc63787d416e9462b94badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025500	Diclofenac rapid release - Nautilus Neurosciences	15307-81-0	"Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monopotassium salt"	No			Discontinued (I)	Pain	C14 H10 Cl2 K N O2	Cyclooxygenase inhibitors	"Applied Pharma Research (Originator), Applied Pharma Research (Owner), Kowa Pharmaceuticals America (Licensee), Nautilus Neurosciences (Sub-licensee)"		PO				N2 (Analgesics)	"M02A-A15 (Diclofenac), N02 (Analgesics)"	PRO571			24/11/2014	Pain				no		no							https://adis.springer.com/drugs/800025500?userId=52029392&bpIds=3004037004&checksum=3078d9f970fba40d764bdbffa01bcb5be699e923-1617045530045-1e9958c2c6369f2353040f76c55ec605badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012893	Crobenetine	221019-25-6	"(2<EM>R</EM>,6<EM>S</EM>)-3-[(2<EM>S</EM>)-2-(Benzyloxy)propyl]-1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-2,6-methano-3-benzazocin-10-ol"	Yes			Discontinued (II)	"Stroke, Pain"	C25 H33 N O2	Sodium channel antagonists	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		IV				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"	"BIII890, BIII890CL"			13/11/2014	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800012893?userId=52029392&bpIds=3004037004&checksum=957e38a2d23b06427104515b176d943a48210f3d-1617045530046-4e0cbd5f04cf799a9ce59988ce4cd6b4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028842	BI 44370			Yes			Discontinued (II)	Migraine		Calcitonin gene-related peptide receptor antagonists	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		"PO, IV"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"BI 44370 BS, BI 44370 TA, BI44370"			08/10/2014	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800028842?userId=52029392&bpIds=3004037004&checksum=7874aa713ce1d85a3398e25a6a67ab4bb4ed40ff-1617045530047-688dca2a5bb5c262556df1847f31c43cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005313	Dexketoprofen	22161-81-5	"Benzeneacetic acid, 3-benzoyl-alpha-methyl-, (S)-,"	Yes			Marketed	"Pain, Inflammation, Musculoskeletal pain"	C16 H14 O3	"Cyclooxygenase inhibitors, Prostaglandin synthase inhibitors"	"Menarini (Originator), Menarini (Owner), Juste (Licensee), Berlin Chemie (Collaborator), Celltech Group (Collaborator), Istituto Lusofarmaco (Collaborator), Malesci (Collaborator)"		"PO, Topical, IM"	renal	"Route of Elimination (renal), protein binding (%) (99.2 (Adult)), T<sub>_beta</sub> (h) (1 - 3 (Adult)), T<sub>max</sub> (h) (.5 (Adult))"	"Dizziness, Dyspepsia, Gastric ulcer, Headache, Photosensitivity"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-E (Propionic acid derivatives), M01A-E17 (Dexketoprofen), N02B (Other Analgesics and Antipyretics)"	"Arveles, D 1158, Desketo, Dexketoprofen trometamol, Dexketoprofen tromethamine, Dextroketoprofen, Enangel, Enantyum, Keral, Ketesse, LM 1158, Nosatel, Quiralam, Quirgel, Sketoprofen, Stadium, Sympal, Viaxal"			29/09/2014	"Pain, Rheumatic Disease"			"Arveles, Desketo, Enangel, Enantyum, Keral, Ketesse, Ketesse, Nosatel, Quiralam, Quiralam, Quirgel, Stadium, Sympal, Viaxal"	no		no							https://adis.springer.com/drugs/800005313?userId=52029392&bpIds=3004037004&checksum=4dc2ddd1a1b81c2df0150ec57486719114974ed7-1617045530052-3006ef07da22f86cbe4a5d00e55074dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034965	PF 5180999			Yes			Discontinued (I)	"Schizophrenia, Migraine"		Type 2 cyclic nucleotide phosphodiesterase inhibitors	"Pfizer (Originator), Pfizer (Owner)"		PO				"N2C (Anti-Migraine Preparations), N7X (All other CNS drugs)"	"N02C (Antimigraine Preparations), N07X (Other Nervous System Drugs)"	"modified release PF05180999, MR PF05180999, PF05180999, PF5180999, PF999"			04/09/2014	"Advances in the Treatment of Nausea and Migraine, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800034965?userId=52029392&bpIds=3004037004&checksum=8da03f6b934937ff38ce94be1fead2c9b131d9cb-1617045530054-3ce80418049a58dedeeb73a3f3b7e8bfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025845	Fentanyl controlled-release - Onxeo	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide	No			Discontinued (I/II)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"BioAlliance Pharma (Originator), Onxeo SA (Owner)"		Buccal		Linear Kinetics (yes)		N2A (Narcotics)	N02A-B03 (Fentanyl)	"BA041, Fentanyl Lauriad"			03/09/2014	"Drug Delivery Systems, Pain"		BioAlliance Pharma | Cancer pain | Phase I |  | 07 Oct 2010	Fentanyl Lauriad	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800025845?userId=52029392&bpIds=3004037004&checksum=f442a1744bd6bdb999f238db1551e7605c2670cc-1617045530056-faa55087e0f81c58fa6b1ecec703f082badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013643	Morphine intranasal - Hospira	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate (salt)"	Yes			No development reported (III)	Postoperative pain	C17 H19 N O3 . 1/2 H2 S O4 . 5/2 H2 O	Opioid mu receptor agonists	"Innovative Drug Delivery Systems (Originator), Hospira (Owner), Archimedes Pharma (Technology Provider), West Pharmaceutical Services (Technology Provider)"		Intranasal			"Dizziness, Drowsiness, Nasal congestion, Nausea, Sneezing, Taste disorders, Vomiting"	N2A (Narcotics)	N02A-A01 (Morphine)	"MNS075, Rylomine"			07/08/2014	"Drug Delivery Systems, Pain"			"Rylomine, Rylomine"	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800013643?userId=52029392&bpIds=3004037004&checksum=2ef66c78404a7731577acaea4152485a1d11032c-1617045530059-33ac406cd2feabf46f6c7f18f4ec3379badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008296	Felbinac ethyl	14062-23-8	"(1,1-Biphenyl)-4-acetic acid ethyl ester"	No			Marketed	"Inflammation, Pain"	C16 H16 O2	Cyclooxygenase inhibitors	"Wyeth (Originator), Pfizer (Owner)"		"IV, Rectal"				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-B (Acetic acid derivatives and related substances), N02 (Analgesics)"	"Daitac, Ethyl 4biphenylylacetate, LM 001"			25/07/2014	"Pain, Rheumatic Disease"			"Daitac, Daitac"	no		no							https://adis.springer.com/drugs/800008296?userId=52029392&bpIds=3004037004&checksum=5a59c57aac90d363ccfab127992d6b87a8956987-1617045530060-192cec20e75b705d0d45e5f896babbb4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024644	MK 0759			Yes			Discontinued (II)	Postherpetic neuralgia		Undefined mechanism	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MK0759			22/07/2014	Pain				no		no							https://adis.springer.com/drugs/800024644?userId=52029392&bpIds=3004037004&checksum=c61991fceb679cbcf045926d858343f8b003c4ff-1617045530060-892e6eea2c22384c5af57fd870a35febbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014677	MH 200	52-26-6	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl hydrochloride"	No			Marketed	Cancer pain	C17 H19 N O3 . H Cl	Opioid mu receptor agonists	"Daiichi Sankyo Company (Originator), Dainippon Sumitomo Pharma (Originator), Shionogi (Originator), Takeda (Originator), Tanabe Seiyaku (Originator), Sumitomo Dainippon Pharma (Owner)"		unspecified				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"ANPEC, MH200, Morphine hydrochloride"			15/07/2014	Pain			ANPEC	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800014677?userId=52029392&bpIds=3004037004&checksum=9de29044250ba62b90df29f8ab1c22680e9e1981-1617045530062-c3f6580b40658be7cb395638f37ed0a3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015106	AN 982	52-26-6	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, hydrochloride"	No			Marketed	Cancer pain	C17 H19 N O3 . H Cl	Opioid mu receptor agonists	"Dainippon Sumitomo Pharma (Originator), Sumitomo Dainippon Pharma (Owner)"		PO				N2 (Analgesics)	N02A-A01 (Morphine)	"Morphinehydrochloride, OPSO"			10/07/2014	Pain			OPSO	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800015106?userId=52029392&bpIds=3004037004&checksum=88e9b6c7f0443fc97a2563d6da885bb8cfe1a6a7-1617045530064-c6079d5f0dca6217a69a3c37961d1110badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800034391	Research programme: pain therapeutics - Eli Lilly and Company/RaQualia Pharma			Yes			Discontinued (Research)	Pain		Ion channel modulators	"Eli Lilly and Company (Originator), RaQualia Pharma (Originator), Eli Lilly and Company (Owner), RaQualia Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				02/07/2014	Pain				no		no							https://adis.springer.com/drugs/800034391?userId=52029392&bpIds=3004037004&checksum=c8114a0fda081e5b646c744ef7bb1629a9bc6e2b-1617045530065-c6d91ea772a85b6d20909ab45eb44d9cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026488	Loxapine low dose inhalation - Alexza Pharmaceuticals	1977-10-2	"2-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine"	No			Suspended (II)	Migraine	C18 H18 Cl N3 O	"Dopamine D2 receptor antagonists, Serotonin 2 receptor antagonists"	"Alexza Pharmaceuticals (Originator), Alexza Pharmaceuticals (Owner)"		Inhalation				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"AZ104, Staccato loxapine low dose"			30/06/2014	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"			Staccato loxapine low dose	no		no							https://adis.springer.com/drugs/800026488?userId=52029392&bpIds=3004037004&checksum=76fd53eaf9bcb6010190112c8b10381347a42e2e-1617045530066-746fc512eb676e6bc1c20f135a4685c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027459	PSD 509			No			Discontinued (I)	Pain		Sodium channel antagonists	"Metris Therapeutics (Originator), Metris Therapeutics (Owner), Plethora Solutions (Licensee)"		Vaginal				N2 (Analgesics)	N02 (Analgesics)	"M5004, PSD509"			28/05/2014	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800027459?userId=52029392&bpIds=3004037004&checksum=405d02ee6868a50b70060c4080303b158820bcdd-1617045530067-1d3f177b9ee800d19465dbe644435bbbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024201	Lidocaine intravesicular - Plethora Solutions	137-58-6	"Acetamide,2-(diethylamino)-<EM>N</EM>-(2,6-dimethylphenyl)-"	No			Discontinued (II)	"Interstitial cystitis, Perioperative pain"	C14 H22 N2 O	Sodium channel antagonists	"Queens University (Originator), Queens University (Owner), Plethora Solutions (Licensee), Maelor Pharmaceuticals (Technology Provider)"		Intravesicular				"G4 (Urologicals), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"	"Intravesical alkalized lidocaine (PSD597) Plethora Solutions, PSD 597"			28/05/2014	"Genitourinary Disorders, Pain"				no		no		A1AT	"COX2, small proline rich protein 2A"	"A1AT, ACADM, ACC, Adiponectin, AMPKa, Angiopoietin-like 4, BNP, CD38, cell death inducing DFFA like effector c, cell death-inducing DFFA-like effector a, CKB, CKM, COX2, CRP, cryptochrome circadian clock 1, CXCL10, fatty acid binding protein 4, fatty acid synthase, Ghrelin, hemoglobin subunit gamma 2, Hydrocortisone, IFN-gamma, IGF1R, IL10, IL6, IL8, Insulin, insulin receptor substrate 2, IRS-1, Leptin, lipase E, hormone sensitive type, lipoprotein lipase, MCP1, MIP-1 alpha, MLX interacting protein-like, neuronal PAS domain protein 2, opioid related nociceptin receptor 1, Osteocalcin, patatin-like phospholipase domain containing 2, patatin-like phospholipase domain containing 3, PGC-1 alpha, PIK3R1, Procalcitonin, pyruvate dehydrogenase kinase 4, PYY, RNA, Ro-associated Y1, SIRT3, small proline rich protein 2A, solute carrier family 2 member 4, sterol regulatory element binding transcription factor 1, Testosterone, TNF-alpha, TRAP-5, troponin I, cardiac, uncoupling protein 2 (mitochondrial, proton carrier), v-akt murine thymoma viral oncogene homolog 2, VEGF-A, VEGFR, VEGFR1"	"BNP, CRP, IL6"	"CD4, Cortisone, CXCL12, cytochrome b5 reductase 1, cytochrome b5 reductase 2, cytochrome b5 reductase 3, cytochrome b5 reductase 4, G6PD, HLA-DR, HMGB1, IL1 beta, IL12A, IL12B, IL1RA, Thyroxine"	https://adis.springer.com/drugs/800024201?userId=52029392&bpIds=3004037004&checksum=5823f57000aba7b33fc0132b216971af878ce808-1617045530070-5f73c0332530655786cd4d2efd1c4e8bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032229	XEN 403			Yes			No development reported (I)	Pain		Nav1.7 voltage-gated sodium channel inhibitors	"Xenon Pharmaceuticals (Originator), Xenon Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	XEN403			19/05/2014	Pain				no		no							https://adis.springer.com/drugs/800032229?userId=52029392&bpIds=3004037004&checksum=86197f27da05821d54bb3e2d5fd7b9910496d0bf-1617045530071-44ead686cfd9551a5d22884894281740badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022484	Hydroxocobalamin	13422-51-0	"Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl- 1H-benzimidazole-kappaN3)"	No			Discontinued (II)	"Migraine, Vitamin deficiency"	C62 H89 Co N13 O15 P	Vitamin B 12 replacements	"Ariston Pharmaceuticals (Originator), TG Therapeutics Inc (Owner)"		Intranasal				"B3X (Other Anti-Anaemic Products, Including Folic Acid, Folinic Acid), N2C (Anti-Migraine Preparations)"	"B03B-A03 (Hydroxocobalamin), N02C (Antimigraine Preparations)"	AST726			02/05/2014	"Advances in the Treatment of Nausea and Migraine, Nutritional Disorders"				no		no		carboxypeptidase B1	Norepinephrine	"carboxypeptidase B1, HCY, Methylmalonic acid, Norepinephrine"			https://adis.springer.com/drugs/800022484?userId=52029392&bpIds=3004037004&checksum=feba6cef0858b7c47838619cb69411230476314b-1617045530073-fac22f831c2ff19b3985875bc7d698febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017931	Milnacipran modified-release - Collegium Pharmaceutical			No			Discontinued	Fibromyalgia		"Adrenergic uptake inhibitors, Serotonin uptake inhibitors"	"Collegium Pharmaceutical (Originator), Cypress Bioscience (Originator), Collegium Pharmaceutical (Owner), Cypress Bioscience (Owner)"		PO				"M5X (All Other Musculoskeletal Products), N2B (Non-Narcotics and Anti-Pyretics), N6A (Anti-Depressants and Mood Stabilisers)"	"M09A-X (Other drugs for disorders of the musculo-skeletal system), N02B (Other Analgesics and Antipyretics), N06A-X (Other antidepressants)"	COL007			20/03/2014	Pain		Collegium Pharmaceutical |  | Unspecified |  | 01 Apr 2010		no		no							https://adis.springer.com/drugs/800017931?userId=52029392&bpIds=3004037004&checksum=d910874b92cff6d2f9243521ef67154954c152b8-1617045530074-a25bb66d35a943fb97ca4fa7be4cd06abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800037292	PF 6305591			Yes			Discontinued (I)	Pain			"Pfizer (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"PF06305591, PF6305591"			11/03/2014	Pain				no		no							https://adis.springer.com/drugs/800037292?userId=52029392&bpIds=3004037004&checksum=54b4222c29d252d213a9934fde362774cc74395f-1617045530075-aae12833b5024a3c13e42614c1e67fdebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026353	Oxycodone/niacin- Acura		"4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one / 3-Pyridinecarboxylic acid"	No			Discontinued (Preregistration)	Pain	C18 H21 N O4 . C6 H5 NO2	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Acura Pharmaceuticals (Originator), Acura Pharmaceuticals (Owner)"		PO			"Dizziness, Flushing, Nausea, Pruritus, Vomiting"	N2A (Narcotics)	N02A-A05 (Oxycodone)	"Acurox with Niacin, OxyADF, Oxycodone HCl/niacin, Oxycodone/niacin, Oxycodone/niacin IR Acura"			10/03/2014	Pain			Acurox with Niacin	no		no							https://adis.springer.com/drugs/800026353?userId=52029392&bpIds=3004037004&checksum=f8e357254030833ca85a0d4be01664511e6c0195-1617045530076-4730e4898faca53b24d8d532a9d492d5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026787	Research programme: opioid analgesics - Heron Therapeutics						Suspended (Preclinical)	"Postoperative pain, Cancer pain, Pain"		Opioid receptor agonists	"A.P. Pharma (Originator), Heron Therapeutics (Owner)"		Parenteral				N2A (Narcotics)	N02A (Opioids)	APF580			15/01/2014	Pain				no		no							https://adis.springer.com/drugs/800026787?userId=52029392&bpIds=3004037004&checksum=876900b504d8232ba429427c4b930b6a14102263-1617045530077-38c6d716680667c58e4d2c9371dd3c65badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009080	Morphine oral - Elan Corporation	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-bcd]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulphate (2:1) pentahydrate"	No			Marketed	Pain	C17 H19 N O3 . 1/2 H2 S O4 . 5/2 H2 O	Opioid mu receptor agonists	"Elan Corporation (Originator), Elan Corporation (Owner), Pfizer (Market Licensee)"		PO			"Constipation, Drowsiness, Headache, Nausea, Pruritus, Somnolence, Vomiting"	N2A (Narcotics)	N02A-A01 (Morphine)	Avinza			20/12/2013	Pain			Avinza	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800009080?userId=52029392&bpIds=3004037004&checksum=02862ab36fdb124d83bff95928b6a6109efd0e5f-1617045530079-d8d6c4e349347df19cf5840454ec6692badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015381	Research programme: GABA receptor modulators - NeuroSearch						Discontinued (Preclinical)	"Anxiety disorders, Neuropathic pain, CNS disorders"		"GABA modulators, GABA A receptor modulators"	"NeuroSearch (Originator), NeuroSearch (Owner)"		"unspecified, PO"				"N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"N02 (Analgesics), N05B (Anxiolytics)"	GABAA receptor positive modulators NeuroSearch			03/12/2013	"Anxiety Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015381?userId=52029392&bpIds=3004037004&checksum=489648bd605727af62c05365bf2ae6b1ff23fddb-1617045530081-db69591861bbca346c363a8a97e6959cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025529	PF 592379		"5-[(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine"	Yes			Discontinued (II)	"Erectile dysfunction, Pain"	C13 H21 N3 O	Dopamine D3 receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		PO				"G4E (Erectile Dysfunction Products), N2 (Analgesics)"	"G04B-E (Drugs used in erectile dysfunction), N02 (Analgesics)"	"PF000592379, PF592379"			18/11/2013	"Men's Health, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800025529?userId=52029392&bpIds=3004037004&checksum=aa788cfbb6ad41fa8a89ae64509f5de074379de1-1617045530082-3505cddfeeeea6a1b90b23c3945c2256badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016715	Z 160			Yes			Discontinued (II)	"Neuropathic pain, Postherpetic neuralgia, Pain, Stroke"		N type calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Zalicus (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"MK6721, NMED160, Z160"			15/11/2013	"Neurological Disorders, Pain"	Postherpetic neuralgia (USA)			no		no							https://adis.springer.com/drugs/800016715?userId=52029392&bpIds=3004037004&checksum=df223bb8725b749261de08b0ee4ec5dd0686ddc1-1617045530083-c1597d537998b6779e26c7c13c6c6271badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032194	Fentanyl oral spray - NovaDel	437-38-7	N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (Preclinical)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"NovaDel Pharma (Originator), SUDA (Owner)"		Transmucosal				N2A (Narcotics)	N02A-B03 (Fentanyl)	NVD501			22/08/2013	Pain				no		no							https://adis.springer.com/drugs/800032194?userId=52029392&bpIds=3004037004&checksum=fac00149826788fdfbf611a555b1c4cf13d25107-1617045530083-5dc9e758fa36bc65106759971f726a3bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025001	Research programme: gabapentin controlled release - SCOLR	60142-96-3	1-(aminomethyl)cyclohexaneacetic acid	No			Discontinued (Preclinical)	Neuropathic pain	C9 H17 N O2	GABA A receptor agonists	"SCOLR Pharma (Originator), SCOLR Pharma (Owner)"		PO				N2 (Analgesics)	"N02 (Analgesics), N03A-X12 (Gabapentin)"	CDT gabapentin SCOLR			07/08/2013	Pain		SCOLR Pharma |  | Unspecified |  | 31 Dec 2010		no		no							https://adis.springer.com/drugs/800025001?userId=52029392&bpIds=3004037004&checksum=423862f07a0bbdc6fadf17b47a0a291cacfe0e7e-1617045530084-29fc65c6705d68c6102ebb4e47536eabbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026404	Research programme: cannabinoid receptor modulators - CeNeRx BioPharma						Discontinued (Preclinical)	"Obesity, Pain, Muscle spasticity, Glaucoma"		"Cannabinoid receptor CB1 antagonists, Cannabinoid receptor CB1 agonists"	"PharmaNess Neuroscience (Originator), PharmaNess Neuroscience (Owner), CeNeRx BioPharma (Licensee)"		unspecified				"A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), S1E (Miotics and Antiglaucoma Preparations)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02 (Analgesics), S01E (Antiglaucoma Preparations and Miotics)"	"CXB 006, CXB 029, CXB 040, CXB070, NESS 006A, NESS040C5, NESS070C5"			28/06/2013	"Eye Disorders, Musculoskeletal Disorders, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800026404?userId=52029392&bpIds=3004037004&checksum=dd91fb580a3fbe52239f4cfc684fee2760dd0ce7-1617045530085-6beab2c4d86c3613709ce8fffcc374f8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015061	GW 406381	221148-46-5	"2-(4-Ethoxyphenyl)-3-[4-(methysulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine"				Discontinued (III)	"Rheumatoid arthritis, Dental pain, Osteoarthritis, Pain"	C21 H19 N3 O3 S	Cyclo-oxygenase 2 inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	"'381, 406381, GW 406381X"			04/04/2013	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800015061?userId=52029392&bpIds=3004037004&checksum=facf22d70f0e818695ea9c4a4000d5cdbe2c6cce-1617045530088-b45e71a47c0f1d349d34a4d23c8697bebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027904	Opioid analgesic controlled-release - Akela Pharma						Discontinued (I)	Pain		Opioid receptor agonists	"Akela Pharma (Originator), Akela Pharma (Owner)"		PO				N2 (Analgesics)	N02A (Opioids)	EDACSbased opioid analgesic			18/03/2013	Pain				no		no							https://adis.springer.com/drugs/800027904?userId=52029392&bpIds=3004037004&checksum=cbf58672a440345f90441968d9bc7fa8023bd4c9-1617045530089-83c93c45de68319d7683798f97186faabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011002	Research programme: ion channel modulators - Merck		"5-(4-Chlorophenyl)-<EM>N</EM>-(3,5-dimethoxyphenyl)furan-2-carboxamide"				No development reported (Preclinical)	"Inflammation, Pain, Neuropathic pain, Neurogenic bladder, Genitourinary disorders"	C19 H16 Cl N O4	"Ion channel modulators, Sodium channel antagonists"	"Abbott Laboratories (Originator), Icagen (Originator), Abbott Laboratories (Owner), Icagen (Owner), Merck & Co (Licensee)"		PO				"G4X (All Other Urological Products), N2 (Analgesics)"	"G04B-X (Other urologicals), N02 (Analgesics)"	"A 317567 analogues Merck, A1048400, A317567, A803467, Ion channel modulators Abbott/Icagen"			13/02/2013	"Genitourinary Disorders, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800011002?userId=52029392&bpIds=3004037004&checksum=6a6951ba2b4b82d5f6654a04480226aafb94a9f0-1617045530091-3c6f37c35a2e6e8c4eb2805ce9dec249badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017973	Fentanyl inhalation - YM BioSciences	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (II)	"Postoperative pain, Cancer pain"	C22 H28 N2 O	Opioid mu receptor agonists	"YM BioSciences (Originator), Gilead Sciences (Owner)"		Inhalation				N2A (Narcotics)	N02A-B03 (Fentanyl)	AeroLEF			12/02/2013	"Drug Delivery Systems, Pain"			AeroLEF	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800017973?userId=52029392&bpIds=3004037004&checksum=f23abea5c642e59145e686e0d11c9453f88be71e-1617045530093-8533bf3c81c3a90cb919db6a73a1b981badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010491	A 183827		1-(4-Chlorobenzoyl)-3-[4-(4-fluorophenyl)thiazol-2-ylmethyl]-5- methoxy-2-methylindole				Discontinued (Preclinical)	"Pain, Inflammation"	C27 H20 N2 Cl F O2 S	Cyclo-oxygenase 2 inhibitors	"Abbott Laboratories (Originator), Abbott Laboratories (Owner)"		unspecified				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02 (Analgesics)"				12/02/2013	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800010491?userId=52029392&bpIds=3004037004&checksum=c3cdca374e519a9704db74e82d86f5e3298dbe40-1617045530094-e385b70ebcf5b1a47bfe57a589de6131badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021385	ABT 110			Yes			Discontinued (II)	"Back pain, Pain"		Nerve growth factor inhibitors	"Lay Line Genomics (Originator), Lay Line Genomics (Owner), PanGenetics BV (Licensee), AbbVie (Sub-licensee)"		IV				N2 (Analgesics)	N02 (Analgesics)	"ABT110, HU aD11, HU alfaD11, HU alphaD11, HU D11, HualphaD11, HuAlphaD11, PG110"			05/02/2013	Pain				no		no							https://adis.springer.com/drugs/800021385?userId=52029392&bpIds=3004037004&checksum=754ca6c831e49624b610871133763c4d62370333-1617045530097-41addc77bae09a948b51b2ad8dcad58ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009632	Tebanicline	198283-73-7	(<EM>R</EM>)-5-(2-Azetidinylmethoxy)-2-chloropyridine				Discontinued (II)	"Neuropathic pain, Pain"	C9 H11 Cl N2 O	Cholinergic receptor agonists	"Abbott Laboratories (Originator), AbbVie (Owner), Merck & Co (Market Licensee), Novartis (Market Licensee)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	"ABT 594, ABT165594, ABT166594.47"			04/02/2013	Pain				no		no							https://adis.springer.com/drugs/800009632?userId=52029392&bpIds=3004037004&checksum=d330855518cd88b333dc17bd9c224a3d1e80bbd3-1617045530099-936171a4bcf19b05b378b096f34e1b56badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023956	Research programme: prostaglandin E2 antagonists - deCODE genetics						No development reported (Preclinical)	Pain		Dinoprostone receptor antagonists	"deCODE genetics (Originator), Amgen (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	DG 061			31/01/2013	Pain				no		no							https://adis.springer.com/drugs/800023956?userId=52029392&bpIds=3004037004&checksum=582a4a8117ddb6dcdf79b2e152c114c2add1af26-1617045530100-0de61b763e39ffaec90ab21f220c8c03badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016243	Research programme: histamine H3 receptor antagonists - Abbvie						No development reported (Preclinical)	"Cognition disorders, Pain, Attention-deficit hyperactivity disorder"		Histamine H3 receptor antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				"N2 (Analgesics), N6D (Nootropics), N7X (All other CNS drugs)"	"N02 (Analgesics), N06B (Psychostimulants, agents used for ADHD and nootropics), N07X (Other Nervous System Drugs)"	"A 320436, A 349821, A 431404"			30/01/2013	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800016243?userId=52029392&bpIds=3004037004&checksum=a1c22ad38db8535dae7fe3125afab7074b0261c1-1617045530101-a10307210003835d509a9569c5cbd439badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006253	Esflurbiprofen	51543-39-6	"[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (S)-"				Discontinued (II)	Pain		"Cyclooxygenase inhibitors, Platelet aggregation inhibitors, Prostaglandin synthase inhibitors"	"Abbott GmbH & Co. KG (Originator), AbbVie (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"BTS 24332, NI 505"			29/01/2013	Pain				no		no							https://adis.springer.com/drugs/800006253?userId=52029392&bpIds=3004037004&checksum=014740b19e5cc12307428c425bf6c1ee4e885ab7-1617045530103-fcd072beb7c19323f0feecc3be33809dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014976	ABT 702		"4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-<EM>d</EM>]pyrimidine"				Discontinued (Preclinical)	"Rheumatoid arthritis, Pain"	C22 H19 Br N6 O	Adenosine kinase inhibitors	"Abbott Laboratories (Originator), AbbVie (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				24/01/2013	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800014976?userId=52029392&bpIds=3004037004&checksum=1d1870b77a4529f2481036770537665548ab5a29-1617045530104-cb0bb9c54616c6e32cbb1330aaa64885badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015926	ABT 963						Discontinued (I)	"Pain, Osteoarthritis"		Cyclo-oxygenase 2 inhibitors	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"				23/01/2013	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800015926?userId=52029392&bpIds=3004037004&checksum=fe13313df526cfd26cd5623904d883f33db96dcd-1617045530105-9999d57332b0fa187601a20fa103d3a2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009094	A 134974		"7-Amino-3-(3-amino-1_,2_-dihydroxy-cyclopentyl)-1-iodopyrrolo[2,3-d]pyrimidine"	Yes			Discontinued (Preclinical)	"Neurological disorders, Pain, Seizures"	C11 H14 I N5 O2	Adenosine kinase inhibitors	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N03A-X (Other antiepileptics), N07X (Other Nervous System Drugs)"				23/01/2013	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009094?userId=52029392&bpIds=3004037004&checksum=9d882ffbdf8b5ad41145d8f9f065bcedfe6678fe-1617045530106-6c5d7046664c7cb58e80750a37b303edbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015975	ABT 202						Discontinued (I)	"Pain, Anxiety disorders"		Purinergic P2X3 receptor antagonists	"Abbott Laboratories (Originator), NeuroSearch (Originator), AbbVie (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N5B (Hypnotics/Sedatives)"	"N02B (Other Analgesics and Antipyretics), N05B (Anxiolytics)"	A317491			23/01/2013	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015975?userId=52029392&bpIds=3004037004&checksum=1d8ee494097a2654fe03f0aef04bc1780df8e312-1617045530108-616fd5016388c918bdf0f80bd555b9b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019709	Sofinicline	799279-80-4	"3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1<EM>S</EM>,5<EM>S</EM>)-"				No development reported (II)	"Attention-deficit hyperactivity disorder, Cognition disorders, Diabetic neuropathies"	C10 H11 Cl2 N3	"Alpha4beta2 nicotinic receptor modulators, Nicotinic receptor agonists"	"Abbott Laboratories (Originator), NeuroSearch (Originator), AbbVie (Owner), NeuroSearch (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	"A422894.0, ABT894"			23/01/2013	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Diabetes, Pain"		NeuroSearch |  | Unspecified |  | 27 Sep 2011		no		no							https://adis.springer.com/drugs/800019709?userId=52029392&bpIds=3004037004&checksum=92e6e0c00c2a689d6a875f1dd0cf6377fecc5e98-1617045530109-722596c83bfd6c9d8cf23211a1313055badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019702	ABT 239		4-[2-[2-[(2<EM>R</EM>)-2-Methylpyrrolidinyl]ethyl]-benzofuran-5-yl]benzonitrile				Discontinued (Preclinical)	"Neuropathic pain, Cognition disorders, Inflammatory pain"	C22 H22 N2 O	Histamine H3 receptor antagonists	"Abbott Laboratories (Originator), AbbVie (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	ABT239			23/01/2013	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800019702?userId=52029392&bpIds=3004037004&checksum=0a4e339fd3a1002393dab7bb94a6c1da8df3a3af-1617045530109-a746a70d052e581e4f9e0eacec053612badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001613	Tiagabine	145821-59-6	"3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, hydrochloride "	Yes			Marketed	"Epilepsy, Anxiety disorders, Insomnia, Neuropathic pain"	C20 H25 N O2 S2 . H Cl	GABA uptake inhibitors	"Novo Nordisk (Originator), Novo Nordisk (Owner), Gerolymatos Group (Market Licensee), AbbVie (Licensee), Teva Pharmaceutical Industries (Licensee)"		PO	hepatic	"Linear Kinetics (yes), Route of Elimination (hepatic), T<sub>_beta</sub> (h) (10.8 (Adult)), T<sub>max</sub> (h) (.5 - 2.6 (Adult))"	"Abdominal pain, Anxiety, Asthenia, Blurred vision, CNS disorders, Confusion, Dizziness, Headache, Insomnia, Memory disorders, Skin disorders, Somnolence, Tremor, Vomiting"	"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers)"	"N02B (Other Analgesics and Antipyretics), N03A-G06 (Tiagabine), N05B (Anxiolytics), N05C (Hypnotics and Sedatives)"	"A70569, CEP6671, Gabitril, NO050328, NO328, Tiagabine hydrochloride"			23/01/2013	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"			Gabitril	no		no				EH domain containing 4		Gamma-Aminobutyric acid	https://adis.springer.com/drugs/800001613?userId=52029392&bpIds=3004037004&checksum=b2501fb600ebec8ff460852a6a7b95786531eba8-1617045530112-d20e0cbd4fa945107e0c9278e9d7a460badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016843	Morphine buccal - Generex Biotechnology	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate"				No development reported (I)	Pain	C17 H19 N O3 . 1/2 H2 S O4 . 5/2 H2 O	Opioid mu receptor agonists	"Generex Biotechnology Corporation (Originator), Generex Biotechnology Corporation (Owner)"		Buccal				N2A (Narcotics)	N02A-A01 (Morphine)	Morphine oral spray Generex			10/01/2013	"Drug Delivery Systems, Pain"		Generex Biotechnology Corporation |  | Unspecified |  | 10 Jan 2013		no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800016843?userId=52029392&bpIds=3004037004&checksum=85a1bf869a3e50d142c658d40f6cd5744c853d59-1617045530113-201f788d16a7d4f0ab60daef32cea338badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026043	RPI 70			Yes			Discontinued (I)	Pain		Nicotinic receptor antagonists	"ReceptoPharm (Originator), ReceptoPharm (Owner), Bio Therapeutics (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)	RPI70			20/12/2012	Pain				no		no							https://adis.springer.com/drugs/800026043?userId=52029392&bpIds=3004037004&checksum=420faa6a83948c78124c652a124bb0057c118c5c-1617045530114-b7af03fbb72fe60c5498a775fac465e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025146	Research programme: nicotinic acetylcholine receptor antagonists - ReceptoPharm			No			Discontinued (Preclinical)	"Pain, Viral infections"		Nicotinic receptor antagonists	"ReceptoPharm (Originator), ReceptoPharm (Owner), Bio Therapeutics (Collaborator), Nutra Pharma Corporation (Collaborator)"		unspecified				"J5 (Antivirals for Systemic Use), N2 (Analgesics)"	"J05 (Antivirals for Systemic Use), N02 (Analgesics)"	Alphacobratoxin			20/12/2012	"Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800025146?userId=52029392&bpIds=3004037004&checksum=abf1fddbeac5a3e301712d0457a0681f0aafbb31-1617045530115-817a7386b19cc5f7249422590ba89cd5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024628	Fentanyl transdermal - Altea Therapeutics	990-73-8	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate				Discontinued (I)	Pain	C22 H28 N2 O . C6 H8 O7	Opioid mu receptor agonists	"Altea Therapeutics (Originator), Nitto Denko (Owner)"		Transdermal				"N1B3 (Anaesthetics local, topical), N2A (Narcotics)"	"N01A-H01 (Fentanyl), N02A-B03 (Fentanyl)"	"AT3022, Fentanyl citrate Altea Therapeutics"			15/11/2012	"Drug Delivery Systems, Pain"				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800024628?userId=52029392&bpIds=3004037004&checksum=848d374c86efba8d16faaa44807f814543a062f0-1617045530116-fe4bd38e806d6f2709a020962379f76bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019238	Hydromorphone transdermal - Altea Therapeutics	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"				Discontinued (II)	Pain	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Altea Therapeutics (Originator), Nitto Denko (Owner)"		Transdermal				N2A (Narcotics)	N02A (Opioids)	"AT1022, AT2022"			15/11/2012	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800019238?userId=52029392&bpIds=3004037004&checksum=681ebdd139f6039f1f0596e1a8efb63499aedc26-1617045530117-b1edf3af49f0070e28b73225d1eee559badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800036507	Osteoarthritis pain therapeutic - Eli Lilly and Company			No			Discontinued (I)	Musculoskeletal pain		Undefined mechanism	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				26/10/2012	Pain				no		no							https://adis.springer.com/drugs/800036507?userId=52029392&bpIds=3004037004&checksum=6f8b9b4ce817e198d6644f2daf52ba6214879457-1617045530118-41dfd4fa02427e421c0ab51cde6f930ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026755	Research programme: NNR modulators - GlaxoSmithKline/Targacept			Yes			Discontinued (Preclinical)	"Substance-related disorders, Parkinson's disease, Obesity, Smoking withdrawal, Pain"		Nicotinic receptor modulators	"Targacept (Originator), Targacept (Owner)"		PO				"A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs), N7B (Antismoking Products)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07B (Drugs Used In Addictive Disorders), N07B-A (Drugs used in nicotine dependence)"				23/10/2012	"Drug Withdrawal, Obesity, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800026755?userId=52029392&bpIds=3004037004&checksum=3c4e81c5fef73bc1c9dfdba7cbf76cd9109376e5-1617045530119-269ccacb973f4ebba0cfc2aebad0daa6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028118	Research programme: cannabinoid receptor CB2 agonists - Boehringer Ingelheim						No development reported (Preclinical)	"Pain, Inflammation"		Cannabinoid receptor CB2 agonists	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				16/10/2012	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800028118?userId=52029392&bpIds=3004037004&checksum=0ff68e0fc69899279e254e816b96ff64e883c4be-1617045530120-fd3942a1fb4306a65135d47c082113b2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024031	Research programme: small molecule therapeutics - Amphora						Discontinued (Preclinical)	"Metabolic disorders, CNS disorders, Pain"		"Glycogen synthase kinase 3 inhibitors, TRPV cation channel antagonists"	"Amphora Discovery Corporation (Originator), Amphora Discovery Corporation (Owner)"		unspecified				"A16 (Other Alimentary Tract and Metabolism Products), N2 (Analgesics), N6 (Psychoanaleptics Excluding Anti-Obesity Preparations)"	"A16 (Other Alimentary Tract and Metabolism Products), N02 (Analgesics), N06 (Psychoanaleptics)"	"GSK3, GSK3b, TRPV1"			24/09/2012	"Metabolic Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800024031?userId=52029392&bpIds=3004037004&checksum=808ca6dc4bf89b9cd8553456b246a2cc88f22ac1-1617045530121-0ec43639b356e9e2b541036b498c487fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026906	Research programme: sigma 1 receptor antagonists - Neurotech						No development reported (Preclinical)	"Neuropathic pain, Pain"		"Glutamate agonists, Sigma-1 receptor antagonists"	"Neurotech Pharmaceuticals (Originator), Neurotech Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"NP07, NP2007"			28/08/2012	Pain				no		no							https://adis.springer.com/drugs/800026906?userId=52029392&bpIds=3004037004&checksum=ae7dfd27def16fd24801c735e1064e963e339541-1617045530121-d320e015b8f8285f93927a836dfc1d2fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031033	PF 4531083						Discontinued (II)	"Postoperative pain, Pain"			"Pfizer (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	PF04531083			14/08/2012	Pain				no		no							https://adis.springer.com/drugs/800031033?userId=52029392&bpIds=3004037004&checksum=bacb148bb7724032074fa0f67e0af6acaa01f3a2-1617045530122-9eacec9f32e7fd57de7993041bb61df4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031731	MEDI 578						Discontinued (I)	Musculoskeletal pain		Nerve growth factor inhibitors	"MedImmune (Originator), MedImmune (Owner)"		IV				N2 (Analgesics)	N02 (Analgesics)	"AntiNGF monoclonal antibody (MEDI578), MEDI578"			09/08/2012	Pain				no		no							https://adis.springer.com/drugs/800031731?userId=52029392&bpIds=3004037004&checksum=d40f63c5b40074315c558a360d1e443d5bdd97f9-1617045530123-ab0fc999cdafa4a10fa1bc02ccb9ddcebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032738	LY 2300559			No			Discontinued (II)	Migraine		"Leukotriene D4 receptor antagonists, Metabotropic glutamate receptor 2 modulators"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"LY2300559, mGlu Pot/Cys Eli Lilly"			07/08/2012	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800032738?userId=52029392&bpIds=3004037004&checksum=f33107e1d542004326f2edd7741c70047d9d5361-1617045530124-2d0e6cd09fdec0c1e104d07410e8202fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014096	NCX 701		4-(Nitrooxy)butyric acid 4-acetamidophenyl ester				Discontinued (II)	Pain	C12 H16 N2 O6	Nitric oxide donors	"NicOx (Originator), NicOx (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B-E (Anilides)	"nitroparacetamol, NOparacetamol"			31/07/2012	Pain				no		no							https://adis.springer.com/drugs/800014096?userId=52029392&bpIds=3004037004&checksum=6cf60e8a53d37cfd7c7d8d076abb07048c73c75b-1617045530125-c6034e09ccebe7d93f76282acdd04e91badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015388	Research programme: nitric oxide-donating compounds - NicOx		"7-[(1<EM>S</EM>, 2<EM>S,</EM> 6<EM>S</EM>, 8<EM>S</EM>, 8a<EM>R</EM>)-6-Hydroxy-2-methyl-8-[2(<EM>S</EM>)-methylbutyryloxy]-1,2,6,7,8,8a-hexahydronapthaleb-1-yl]-3(<EM>R</EM>),5(<EM>R</EM>)-dihydroxyheptanoic acid 4-(nitrooxy)butylester"				Discontinued (Preclinical)	"Cancer, Inflammation, Viral infections, Hypertension, Bacterial infections, Pulmonary arterial hypertension, Pain, Metabolic disorders, Osteoarthritis, Diabetic retinopathy"	C27 H43 N O10	"Nitric oxide donors, Cyclooxygenase inhibitors, Endothelin receptor antagonists"	"NicOx (Originator), NicOx (Owner)"		unspecified				"A10 (Drugs Used in Diabetes), C1 (Cardiac Therapy), C2 (Antihypertensives), J (General Anti-Infectives Systemic), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), S1P (Ocular Antineovascularisation Products)"	"A10 (Drugs Used in Diabetes), C01 (Cardiac Therapy), C02 (Antihypertensives), C02K (Other Antihypertensives), J (Anti-infectives For Systemic Use), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), S01L-A (Antineovascularisation agents)"	"HCT 2037, NCX 1236, NCX 226, NCX 429, NCX 6550, NCX 8001, NCX 976"			31/07/2012	"Bacterial Infections, Cancer, Eye Disorders, Hypertension, Inflammation, Metabolic Disorders, Pain, Respiratory Tract Disorders, Rheumatic Disease, Viral Infections"		NicOx |  | Preclinical |  | 04 Aug 2010		no		no							https://adis.springer.com/drugs/800015388?userId=52029392&bpIds=3004037004&checksum=47f0c60c3410349984fb588f987301a9c6480175-1617045530127-49e088accd8d2608e9e033fea21024a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020292	Research programme: vanilloid 1 receptor antagonists - Amorepacific/Schwarz Pharma			Yes			Discontinued (Preclinical)	Pain		TRPV cation channel antagonists	"Amorepacific (Originator), Amorepacific (Owner), UCB (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"PAC 20030, SPM 95, SPM 955, Vanilloid 1 receptor antagonists Schwarz/Amorepacific"			26/06/2012	Pain				no		no							https://adis.springer.com/drugs/800020292?userId=52029392&bpIds=3004037004&checksum=5f56de02f75de2b6368c8486421a587558343bcc-1617045530128-b088003a2197b826e9478363ec4f8aecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023166	Fentanyl intranasal - Takeda	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Marketed	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Nycomed (Originator), Takeda (Owner)"		Intranasal				N2A (Narcotics)	N02A-B03 (Fentanyl)	Instanyl			29/05/2012	Pain			Instanyl	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800023166?userId=52029392&bpIds=3004037004&checksum=7bf23cedb4daee48cca246ea197236dade7275b7-1617045530131-caf6297a706c55c926e6b9d445898660badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027037	CRA 13		Napthalen-1-yl-(4-pentyloxynapthalen-1-yl)methanone				No development reported (I)	Pain		"Cannabinoid receptor CB1 agonists, Cannabinoid receptor CB2 agonists"	"Novartis (Originator), Novartis (Owner)"		PO		"Linear Kinetics (yes), T<sub>_beta</sub> (h) (21 - 41 (Adult)), T<sub>max</sub> (h) (1.5 - 2 (Adult))"		N2 (Analgesics)	N02 (Analgesics)	CRA13			21/05/2012	Pain				no		no							https://adis.springer.com/drugs/800027037?userId=52029392&bpIds=3004037004&checksum=a6736561981fcc46876020a3c21ca2b17b0d4dc1-1617045530132-0ab8fc1b3b564ed95457735b1312a76fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027439	2 PX						No development reported (III)	"Neuropathic pain, Musculoskeletal pain, Postherpetic neuralgia"		"Ion channel modulators, Phospholipase A2 inhibitors"	"SantoSolve (Originator), SantoSolve (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"2PX, Topical strontium chloride hexahydrate SantoSolve AS"			14/05/2012	Pain				no		no							https://adis.springer.com/drugs/800027439?userId=52029392&bpIds=3004037004&checksum=ffe3e81ae939e6046d60f61e9230fcf712059251-1617045530133-aa3c571bc76b95743e5c9e43e7fa9397badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033711	SAR 114137						Discontinued (I)	"Neuropathic pain, Pain"		"Cathepsin K inhibitors, Cathepsin S inhibitors"	"sanofi-aventis (Originator), Sanofi (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	SAR114137			02/05/2012	Pain				no		no							https://adis.springer.com/drugs/800033711?userId=52029392&bpIds=3004037004&checksum=1400aa4ec6e773fdc682b658e202cc4448bed559-1617045530134-7153c817682bf8e53de4fa6783cfa301badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033712	SAR 411298						Discontinued (I)	Cancer pain		Fatty acid amide hydrolase inhibitors	"sanofi-aventis (Originator), Sanofi (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	SAR411298			02/05/2012	Pain				no		no							https://adis.springer.com/drugs/800033712?userId=52029392&bpIds=3004037004&checksum=c8809156d5961217f3167ef3cc453042a1f144c0-1617045530135-f6e17640246b737702ecaac884be3120badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025491	Research programme: analgesic/famotidine fixed combinations - Horizon						Discontinued (Preclinical)	Pain		"Cyclooxygenase inhibitors, Histamine H2 receptor antagonists"	"Horizon Therapeutics (Originator), Horizon Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Aspirin/famotidine, HZN602, HZT602, HZT703, Immediaterelease naproxen/highdose famotidine (HZT602), Naproxen/famotidine"			26/04/2012	Pain				no		no							https://adis.springer.com/drugs/800025491?userId=52029392&bpIds=3004037004&checksum=83a738079a5e000e46326b066d5cc38bd4717b5d-1617045530137-f8dd752778215090a46fc790c414b4bcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800033999	LY 2828360			No			Discontinued (II)	Musculoskeletal pain		Cannabinoid receptor CB2 agonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B-G (Other analgesics and antipyretics)"	"Cannaboid receptor2 agonist Eli Lilly, LY2828360"			19/04/2012	Pain				no		no							https://adis.springer.com/drugs/800033999?userId=52029392&bpIds=3004037004&checksum=db3e22ec77ee4bed4e52b0b42d2e782acd377a82-1617045530138-d40712f1c6df7018b5bb894250b2a9b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021410	Research programme: pain therapeutic - Taisho						Discontinued (Preclinical)	Pain		"NMDA receptor antagonists, NR2B N-Methyl-D-Aspartate antagonists"	"Taisho Pharmaceutical (Originator), Taisho Pharmaceutical (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"NMDA receptor antagonists Taisho, NR2B receptor antagonist Taisho, Pain therapeutic research programme Taisho"			17/04/2012	Pain				no		no							https://adis.springer.com/drugs/800021410?userId=52029392&bpIds=3004037004&checksum=38d77a1dbd4d084e21e76ef38412da681df8bf09-1617045530139-122d2f9255ca01743f321a50ecb01f45badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029651	Research programme: pain therapeutics - Endo/Harvard University						No development reported (Research)	Pain		Undefined mechanism	"Harvard University (Originator), Massachusetts General Hospital (Originator), Harvard University (Owner), Massachusetts General Hospital (Owner), Endo Pharmaceuticals (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				26/03/2012	Pain				no		no							https://adis.springer.com/drugs/800029651?userId=52029392&bpIds=3004037004&checksum=28b7095baf77b5a4d3cb6874c00174afa68fc4a4-1617045530140-33e3440abe3ce7d2b358a2793f320a0abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032092	Aspirin/phosphatidylcholine			No			Discontinued (I)	"Fever, Pain, Stroke, Myocardial infarction"		"Cyclooxygenase inhibitors, Nitric oxide stimulants, Platelet aggregation inhibitors"	"University of Texas System (Originator), University of Texas System (Owner), PLx Pharma (Licensee)"		PO				"C1X (All Other Cardiac Preparations), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"C01E-X (Other cardiac combination products), N02B-A (Salicyclic acid and derivatives), N07X (Other Nervous System Drugs)"	"ASAPC, AspirinPC, PL2100"			14/03/2012	"Ischaemic Heart Disease, Metabolic Disorders, Pain, Thromboses"				no		no							https://adis.springer.com/drugs/800032092?userId=52029392&bpIds=3004037004&checksum=0bd4886bf27fb3779ec911807f4e2dd6829878e3-1617045530141-c8553a20cdaf0d5a8ff18baaee86fb1abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027164	Research programme: controlled release analgesics - Doxa/Orexo						Discontinued (Preclinical)	"Acute pain, Pain"		Opioid receptor agonists	"Orexo (Originator), Orexo (Owner), Doxa (Technology Provider), Doxa (Collaborator)"		"Sublingual, PO"				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	"OX 23, OX 30"			09/03/2012	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800027164?userId=52029392&bpIds=3004037004&checksum=e96d96e15318aaa4b5a6caca8f73e7f2cae06e48-1617045530142-b3dc2c34adaf39c730c7804ef41aa9e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021669	Research programme: NMDA receptor antagonists - Yaupon Therapeutics						Discontinued (Preclinical)	Neuropathic pain		NMDA receptor antagonists	"Yaupon Therapeutics (Originator), Yaupon Therapeutics (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Analgesics Yaupon Therapeutics, Norketamine, Snorketamine, YT 1006"			12/01/2012	Pain				no		no							https://adis.springer.com/drugs/800021669?userId=52029392&bpIds=3004037004&checksum=9430b54d9412fd4556dcb7fed0c47809203e8042-1617045530143-fc713edcec7c7df15a717279aeb4727cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001334	Beloxepin	135928-30-2	"1,3,4,13b-Tetrahydro-2,10-dimethyl-dibenz[2,3:6,7]oxepino[4,5-c]pyridin-4a(2H)-ol"	Yes			Discontinued (III)	"Major depressive disorder, Pain"	C19 H21 N O2	"Adrenergic uptake inhibitors, Serotonin 2 receptor antagonists"	"Organon (Originator), Organon (Owner), Merck & Co (Licensee)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A-X (Other antidepressants)"	"ADL 6906, ORG 4428"			15/12/2011	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800001334?userId=52029392&bpIds=3004037004&checksum=93528bd1b567e3c24440bcf9987da3bfd1d95621-1617045530145-0f9dbb97e6819b77a9b38a13d719f8acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025012	Hydrocodone/paracetamol/alvimopan						Suspended (II)	Pain		"Opioid mu receptor antagonists, Opioid receptor agonists, Prostaglandin receptor antagonists"	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				"A3F (Gastroprokinetics), N2A (Narcotics)"	"A03F-A (Propulsives), N02A (Opioids)"	"Alvimopan/hydrocodone/acetaminophen, Alvimopan/hydrocodone/paracetamol, Hydrocodone/acetaminophen/alvimopan"			14/12/2011	Pain				no		no							https://adis.springer.com/drugs/800025012?userId=52029392&bpIds=3004037004&checksum=129eeb96ee2cc9fe26ab9691da277456e862fde6-1617045530195-e094ee28f97a1f07775c3e10f2a738bcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028307	CEP 28190			Yes			Discontinued (I)	Pain		Opioid receptor agonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	CEP28190			26/10/2011	Pain				no		no							https://adis.springer.com/drugs/800028307?userId=52029392&bpIds=3004037004&checksum=de688539508ed3082c62ff9b8f0c019616cbad69-1617045530196-51e618097b98dbd10ba1e26e815a4ce0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014994	CEP 3800		"9(<EM>S</EM>),12(<EM>R</EM>)-Epoxy-10(<EM>S</EM>)-hydroxy-9,10-dimethyl-2,3,9,10,11,12-hexahydrodiindolo[1,2,3-fg:3',2',1'-<EM>kl</EM>]-pyrrolo[3,4-<EM>i</EM>][1,6]benzodiazocin-1-one"	Yes			Discontinued (Preclinical)	Pain	C26 H21 N3 O3	Protein tyrosine kinase inhibitors	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				26/10/2011	Pain				no		no							https://adis.springer.com/drugs/800014994?userId=52029392&bpIds=3004037004&checksum=4799509b62bdac89bd80148217264c6e45bff940-1617045530197-dcd04162118636342bd0c4db072b9770badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013902	Research programme: ASIC and NGF/p75 antagonists - PainCeptor						Discontinued (Preclinical)	Pain		"ASIC channel antagonists, Nerve growth factor inhibitors"	"PainCeptor Pharma Corporation (Originator), PainCeptor Pharma Corporation (Owner), NeuroSearch (Collaborator)"		unspecified				"A3 (Functional Gastro-Intestinal Disorder Drugs), G4 (Urologicals), N2B (Non-Narcotics and Anti-Pyretics)"	"A03 (Drugs for Functional Gastrointestinal Disorders), G04 (Urologicals), N02B (Other Analgesics and Antipyretics)"	"PPC1807, PPC5383, PPC5692, PPC778"			25/10/2011	Pain				no		no							https://adis.springer.com/drugs/800013902?userId=52029392&bpIds=3004037004&checksum=ae1d3a3ff2c415b04afb68f235ce4339fe5a4a7f-1617045530198-27f018c0add0b4cfe2fa9d208e9de97ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020750	Gabapentin controlled release - Labopharm			No			Discontinued (Preclinical)	"Neuralgia, Epilepsy"		"CACNA2D1 protein modulators, GABA receptor agonists"	"Labopharm (Originator), Paladin Labs (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"	"DDS 2003, Gabapentin sustained release Labopharm"			10/10/2011	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020750?userId=52029392&bpIds=3004037004&checksum=dc890488aa7ec60fef8d915df69d263e56a370fc-1617045530199-9f3a72c68ece7a58fd00b36d3a9353d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024473	Research programme: NMDA antagonists - Wyeth		"[[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphoryl]bis(oxy)bis(methylene) dibenzoate"				No development reported (Preclinical)	Pain	C25 H25 N2 O9 P	NMDA receptor antagonists	"Wyeth (Originator), Pfizer (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	"EAA 129, WAY 209129"			03/10/2011	Pain				no		no							https://adis.springer.com/drugs/800024473?userId=52029392&bpIds=3004037004&checksum=e9ff72db8ed255c3738e1ad7745c3e04d9e38b8e-1617045530199-57a106a58897229fd5b7eca3b3cd66a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004607	Gamolenic acid - Scotia Pharmaceuticals	506-26-3	"6,9,12-Octadecatrienoic acid, (Z,Z,Z)-"	No			Marketed	"Atopic dermatitis, Breast pain, Breast cancer, Rheumatoid arthritis"	C18 H30 O2	"Prostaglandin synthase stimulants, Thromboxane synthase stimulants, Cell adhesion molecule inhibitors, Immunomodulators"	"Scotia Holdings [CEASED] (Originator), Scotia Pharmaceuticals [CEASED] (Originator), Pfizer (Owner), Beiersdorf (Market Licensee), Cosmopharm (Market Licensee), Handok Inc (Market Licensee), Laboratorios LETI (Market Licensee), Norpharma (Market Licensee), Sidroga (Market Licensee), Strathmann GmbH & Co. KG (Market Licensee), Wyeth Consumer Healthcare (Market Licensee)"		PO				"D11A (Other Dermatological Preparations), L1 (Antineoplastics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"D11A-X (Other dermatologicals), L01 (Antineoplastic Agents), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"Efamast, Efarmol, Epogam, Epogam SnipOff capsules, Epostart, Gamma linolenic acid, Gamolenic acid/vitamin E, Primast, Primogam"			03/10/2011	"Cancer, Pain, Rheumatic Disease, Skin Disorders"			"Efamast, Epogam, Epogam, Epogam, Epogam, Epogam, Epogam, Epogam"	no		no				Linoleic acid			https://adis.springer.com/drugs/800004607?userId=52029392&bpIds=3004037004&checksum=7c31444b474666f4948790ca97dcf6ca9eeed9b2-1617045530203-88a486a032092a79a8b852dde83d31c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008327	YKP 10A	561069-23-6					No development reported (II)	"Major depressive disorder, CNS disorders, Narcolepsy, Neuropathic pain"		Undefined mechanism	"SK Bio-Pharmaceuticals (Originator), SK Corporation (Originator), SK Holdings (Owner), Janssen (Licensee)"		PO			"Agitation, Anxiety, Gastrointestinal disorders, Headache, Insomnia"	"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02 (Analgesics), N06A (Antidepressants), N07X (Other Nervous System Drugs)"	"R 228060, YKP10A"			29/09/2011	"Affective Disorders, Anxiety Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800008327?userId=52029392&bpIds=3004037004&checksum=ca73854c9a1c4bb643ed61b6c659250459d0c2e5-1617045530204-4029cf00baad0b1442ba1b0384d77ae4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026038	Ibuprofen-eluting beads - Biocompatibles	15687-27-1	(±)-_-Methyl-4-(2-methylpropyl)-benzeneacetic acid				Discontinued (Clinical)	Pain	C13 H18 O2	Cyclooxygenase inhibitors	"Biocompatibles International (Originator), Biocompatibles International (Owner)"		Intra-arterial				N2 (Analgesics)	N02 (Analgesics)	Ibuprofen bead			21/09/2011	"Drug Delivery Systems, Pain"				no		no		"C-peptide, opsin 1 (cone pigments), long-wave-sensitive"	peroxisome proliferator-activated receptor gamma	"A1C, ACTH, adrenoceptor alpha 1D, Arachidonic acid, C-peptide, Calprotectin, CD34, CRP, CXCL10, Elastase, Endothelin 1, ER alpha, Estrone sulfate, Ferritin, IFN-gamma, IL1 beta, IL17, IL2, IL5, IL6, IL8, LTB4, Nitric Oxide, NOX2-dp, nuclear prelamin A recognition factor like, peroxisome proliferator-activated receptor gamma, PGE2, Prostacyclin, proteasome subunit alpha 7, Pulmonary disease, chronic obstructive, severe early-onset, RNA, Ro-associated Y1, secretoglobin, family 1A, member 1, sex hormone-binding globulin, Soluble transferrin receptor, submaxillary gland androgen regulated protein 3B, Surfactant protein D, Thromboxane, TNF-alpha"	"A1C, C-peptide, Calprotectin, IFN-gamma, IL1 beta, IL17, IL2, IL5, TNF-alpha"	"Aldosterone, Calreticulin, CD4, CD68, CD8a, Creatinine, CTx, CYP2C9, cytochrome P450 family 2 subfamily C member 8, delta like canonical Notch ligand 4, endothelin receptor type A, F2-isoprostanes, GAD Auto-antibodies, Hepcidin, IGF1, IL10, IL13, IL4, Lactate dehydrogenase, MCP1, miR-146a, OPRM1, PAI-1, PGD2, PGE1, PICP, PIIINP, PINP, Renin, Thromboxane B2, TNFRSF1A, TNFRSF1B, VEGF-A"	https://adis.springer.com/drugs/800026038?userId=52029392&bpIds=3004037004&checksum=d55ab87b9cddc88b7b273e91ea4374a535295ebd-1617045530206-ddfa8c9cf59e3bb4e4b8a6d35acbdd12badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026398	Research programme: pain and neurological disorder therapeutics - CSIRO/NeuroDiscovery						No development reported (Preclinical)	"Pain, Neuralgia, Neurological disorders"		Gap junction modulators	"NeuroDiscovery (Originator), NeuroDiscovery (Owner), CSIRO (Collaborator), Xention (Collaborator)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				16/09/2011	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800026398?userId=52029392&bpIds=3004037004&checksum=7dd58ae781350a751a3c8b2c4de288182f111f9a-1617045530207-e18d10b7e11c62f8acf6859e1c621cdabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031041	NRI 470						No development reported (0)	Pain		Undefined mechanism	"Wyeth (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	NRI470			14/09/2011	Pain				no		no							https://adis.springer.com/drugs/800031041?userId=52029392&bpIds=3004037004&checksum=3c20fec6927b153aab663b3336fddfa0143e0eeb-1617045530208-3f54c9b4c60894218c55dcbfa39694cebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023937	VR 147						Discontinued (I)	Migraine			"Vectura (Originator), Vectura (Owner)"		Inhalation				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	VR147			09/09/2011	Advances in the Treatment of Nausea and Migraine		Vectura |  | Unspecified |  | 31 Mar 2010		no		no							https://adis.springer.com/drugs/800023937?userId=52029392&bpIds=3004037004&checksum=2597e8be34ba303d0abdd8734fc1c5337c89d320-1617045530208-4164bd14d5b20b046fa0db80a77c62e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013348	Research programme: pain therapy - Merck/Banyu			Yes			No development reported (Preclinical)	"Pain, Traumatic stress disorders"		"Nociceptin receptor antagonists, Opioid receptor antagonists"	"Banyu (Originator), Merck & Co (Originator), Banyu (Owner), Merck & Co (Owner)"		"SC, IV"				N2A (Narcotics)	N02A (Opioids)	"Comp B, J 113397"			29/08/2011	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800013348?userId=52029392&bpIds=3004037004&checksum=9fa1432e1d11e9af19c6176c7206c80467679c91-1617045530209-87feaf9ae92e36b58394cbfcbb2fc08bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021348	Hydromorphone intranasal	71-68-1	"Morphinan-6-one, 4, 5_-epoxy-3-hydroxy-17-methyl-, hydrochloride"				Discontinued (II)	Pain	C17 H19 N O3 . H Cl	Opioid receptor agonists	"Intranasal Therapeutics (Originator), Ikano Therapeutics (Owner)"		Intranasal				N2A (Narcotics)	N02A (Opioids)	Intranasal hydromorphone HCl			29/08/2011	Pain				no		no							https://adis.springer.com/drugs/800021348?userId=52029392&bpIds=3004037004&checksum=8fcbf83ab0b98ba4ef461f91e082638827f0424f-1617045530210-5720c60f806ea28aac3f07d918d02d68badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018667	Research programme: bradykinin B1 receptor antagonists - Merck		"(<EM>R</EM>)-Methyl 3-chloro-3'-fluoro-4'-[1-[1-(2,2,2-trifluoroacetamido)cyclopropanecarboxamido]ethyl]biphenyl-2-carboxylate"	Yes			No development reported (Preclinical)	"Inflammation, Pain"	C22 H19 Cl F4 N2 O4	Bradykinin B1 receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				26/08/2011	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800018667?userId=52029392&bpIds=3004037004&checksum=b8666a919ae9fdbf6cfbc0a491adc5fdc47ebe6d-1617045530211-34bb03d92fc56e4770752f733611efa1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026156	KD 7040						No development reported (II)	Neuropathic pain		Nitric oxide synthase type II inhibitors	"Kalypsys (Originator), Kalypsys (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	KD7040			18/08/2011	Pain				no		no							https://adis.springer.com/drugs/800026156?userId=52029392&bpIds=3004037004&checksum=e0cf0b464e2779ac5dcc6ce614d09d18c945bb6c-1617045530212-7d73bcd38a81c7a77fd0da75f331556abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028532	JTS 653						Discontinued (II)	"Overactive bladder, Pain"		TRPV1 receptor antagonists	"Japan Tobacco (Originator), Japan Tobacco (Owner)"		PO				"G4X (All Other Urological Products), N2 (Analgesics)"	"G04B (Urologicals), N02 (Analgesics)"	JTS653			11/08/2011	"Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800028532?userId=52029392&bpIds=3004037004&checksum=8bb043bbef9b6c975f00785270a0951e2ba23e79-1617045530212-6803b3cbafdc3fc85a3011c8c4a533fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018575	NMK 150			Yes			Discontinued (I)	Visceral pain		Pancrelipase replacements	"Axcan Pharma (Originator), Norax (Originator), Axcan Pharma (Owner), Norax (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	NMK150			11/08/2011	Pain				no		no							https://adis.springer.com/drugs/800018575?userId=52029392&bpIds=3004037004&checksum=4f5c13a1c9b5cbc4fa61825362e3bbf82283525f-1617045530213-38ba6233ab656a57253b2027d5c5e16ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020326	KDS 2000						Discontinued (II)	Postherpetic neuralgia		Cannabinoid receptor CB1 antagonists	"Kadmus Pharmaceuticals (Originator), Kadmus Pharmaceuticals (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	Anandamidetopical			09/08/2011	Pain				no		no							https://adis.springer.com/drugs/800020326?userId=52029392&bpIds=3004037004&checksum=62fb06d370b7706320a45e32ef49efcc9d2e73d9-1617045530214-535a0fc1df7fa2294887a72a0d31048ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022427	Capsaicin topical - Maruishi Pharmaceutical	404-86-4	"6-Noneamide, (<EM>E</EM>)-<EM>N</EM>-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-,"				No development reported (II)	Postherpetic neuralgia	C18 H27 N O3	"Nociceptin receptor antagonists, TRPV1 receptor agonists"	"Maruishi (Originator), Maruishi (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	MR3H3			09/08/2011	Pain				no		no				"A1C, carnitine palmitoyltransferase 1A (liver), IL1 beta, IL6, IL8, TNF-alpha"		peroxiredoxin 2	https://adis.springer.com/drugs/800022427?userId=52029392&bpIds=3004037004&checksum=e16ec153345951f0aae542bce7354ccf7853240b-1617045530215-17a7b0ed1ef8a85589f7b8d5ce3e1036badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001117	Amesergide	121588-75-8	8B-N-Cyclohexyl-6-methyl-1-(1-methylethyl) ergoline-8-carboxamide	No			Discontinued (II)	"Premature ejaculation, Erectile dysfunction, Schizophrenia, Major depressive disorder, Thrombosis, Anxiety disorders, Migraine"	C25 H35 N3 O	"Serotonin 1C receptor antagonists, Serotonin 2 receptor antagonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		"PO, unspecified"				"B1C (Platelet Aggregation Inhibitors), G4E (Erectile Dysfunction Products), N2C (Anti-Migraine Preparations), N5A (Antipsychotics), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), G04B-E (Drugs used in erectile dysfunction), N02C-X (Other antimigraine preparations), N05A-X (Other antipsychotics), N05B-X (Other anxiolytics), N06A-X (Other antidepressants)"	LY 237733			22/07/2011	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Men's Health, Psychotic Disorders, Thromboses"				no		no							https://adis.springer.com/drugs/800001117?userId=52029392&bpIds=3004037004&checksum=e400d0bd7b9443a237cc142b4ad76b6709046f3e-1617045530216-9536d0e0212307e92213f691b2f70351badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022886	Research programme: pain therapy - EQiTX						Discontinued (Preclinical)	Pain		TRPV1 receptor agonists	"EQiTX (Originator), EQiTX (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ZingoTX			13/07/2011	Pain				no		no							https://adis.springer.com/drugs/800022886?userId=52029392&bpIds=3004037004&checksum=5099a76b1f4e1b6b30db199f8da95c3023408699-1617045530217-379b97e2742d830c3ebe6cdd331a4d11badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018094	Research programme: JNK pathway inhibitors - Pharmascience			No			Discontinued (Preclinical)	"Peripheral nervous system diseases, Diabetic neuropathies, Neuropathic pain, Cancer"		JNK mitogen-activated protein kinase inhibitors	"Aegera Therapeutics (Originator), Pharmascience (Owner)"		PO				"A10 (Drugs Used in Diabetes), L1 (Antineoplastics), N2 (Analgesics), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"A10 (Drugs Used in Diabetes), L01 (Antineoplastic Agents), N02 (Analgesics), N07 (Other Nervous System Drugs), N07X (Other Nervous System Drugs)"	AEG 3482			02/06/2011	"Cancer, Diabetes, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800018094?userId=52029392&bpIds=3004037004&checksum=2f1f3cca821c3bba723d3a103b7f8a83532f2600-1617045530218-7823545fe526b9b1cffd746fa6c9cbaabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027961	AEG 33773			No			No development reported (II)	Diabetic neuropathies		JNK mitogen-activated protein kinase inhibitors	"Aegera Therapeutics (Originator), Pharmascience (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AEG33773			02/06/2011	Pain				no		no							https://adis.springer.com/drugs/800027961?userId=52029392&bpIds=3004037004&checksum=b69633aa0822c8131f54f07505a6a022382ceb05-1617045530219-7a762e4cc470056a4dfd6394403bb9d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021298	Propofol phosphate						Discontinued (Preclinical)	"Neurological disorders, Parkinson's disease, Migraine, Anaesthesia, Alzheimer's disease"		GABA receptor agonists	"Vyrex Corporation (Originator), Vyrex Corporation (Owner)"		unspecified				"N1A (Anaesthetics, General), N2C9 (All other anti-migraine preparations), N4A (Anti-Parkinson Drugs), N7D9 (All other anti-Alzheimer products), N7X (All other CNS drugs)"	"N01A-X (Other general anesthetics), N02C-X (Other antimigraine preparations), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"	"Neuprox, Propofol prodrug"			30/05/2011	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800021298?userId=52029392&bpIds=3004037004&checksum=8db4d2e30e8119bae51f831e8290e6c8152f2a8a-1617045530220-20d1c84d0fd35e956c2eaf1abbac1b2fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018546	Ketamine/butamben topical - EpiCept			No			Discontinued (I/II)	Neuropathic pain		"NMDA receptor antagonists, Sodium channel antagonists"	"EpiCept Corporation (Originator), EpiCept Corporation (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	"EpiCeptNP2, NP2"			13/05/2011	Pain				no		no							https://adis.springer.com/drugs/800018546?userId=52029392&bpIds=3004037004&checksum=856b354ca87473cabfae2bd2ea9d365e80d58612-1617045530221-d79a9f1b5c33939815d9f4b0b715c62fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004070	FR 122047	130717-51-0	"1-[4,5-Bis(4-methoxyphenyl)thiazol-2-ylcarbonyl]-4-methylpiperazine hydrochloride"				No development reported (Preclinical)	"Pain, Thrombosis, Rheumatoid arthritis"	C23 H25 N3 O3 S . H Cl	Cyclo-oxygenase 1 inhibitors	"Fujisawa (Originator), Fujisawa (Owner)"		PO				"B1C (Platelet Aggregation Inhibitors), M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B (Other Analgesics and Antipyretics)"	ASP 6537			26/04/2011	"Pain, Rheumatic Disease, Thromboses"				no		no							https://adis.springer.com/drugs/800004070?userId=52029392&bpIds=3004037004&checksum=ef64e258d786297ea474d0c1d4366ca3aaee75db-1617045530222-fc4fd66602af80c01cacc0b68c93d748badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026955	Research programme: histamine H3 receptor antagonists - GlaxoSmithKline						No development reported (Preclinical)	"Allergic rhinitis, Pain, Neuropathic pain, Dementia"		Histamine H3 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		"unspecified, PO"				"N2 (Analgesics), N7 (Other CNS Drugs), R6A (Systemic Antihistamines)"	"N02 (Analgesics), N06D (Anti-Dementia Drugs), R06A (Antihistamines for Systemic Use)"	"GSK 207040, GSK 334429"			19/04/2011	"Alzheimer's Disease and Cognition Disorders, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800026955?userId=52029392&bpIds=3004037004&checksum=a05c8f8ef3ae3e8437a2f4ba1feafb08626e0508-1617045530223-71c6cad184894c93626d57840b2da224badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026651	Research programme: prostanoid EP1 antagonists - GlaxoSmithKline		"6-[2-[5-Chloro-2-(2,4-difluorobenzyloxy)phenyl]-1-cyclopenten-1-yl]pyridine-2-carboxylic acid"				No development reported (Preclinical)	Inflammatory pain	C24 H18 Cl F2 N O3	Prostaglandin-E EP1 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	GW 848687X			18/04/2011	Pain				no		no							https://adis.springer.com/drugs/800026651?userId=52029392&bpIds=3004037004&checksum=21b8dbe02620b954d2f71a02d15c7e175e47ed4c-1617045530224-361f7f70df5f9a98e963f9f0d14595d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025252	Research programme: prostaglandin EP4 receptor agonists - GlaxoSmithKline						No development reported (Preclinical)	Pain		Dinoprostone agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	GSK 324202A			18/04/2011	Pain				no		no							https://adis.springer.com/drugs/800025252?userId=52029392&bpIds=3004037004&checksum=558096c0a8b42f8a7e05546448434e4ef5831e9f-1617045530224-63b06eaa1952db51dcc1756f575533a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024137	Research programme: drug discovery - GlaxoSmithKline/Ligand						Discontinued (Preclinical)	"Inflammatory pain, Respiratory tract disorders, Pain"			"GlaxoSmithKline (Originator), Pharmacopeia Drug Discovery (Originator), GlaxoSmithKline (Owner), Pharmacopeia Drug Discovery (Owner)"		unspecified				"N2 (Analgesics), R (Respiratory System)"	"N02 (Analgesics), R (Respiratory System)"				18/04/2011	"Inflammation, Pain, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800024137?userId=52029392&bpIds=3004037004&checksum=b371c2682400931ed9c7c3ace3f4511d28defc89-1617045530225-15a94cff827b1b1c4e9c0b0baaf6f1b3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028930	Research programme: cannabinoid receptor CB2 agonists - Amgen		"3-(2-Chloro-4-fluorophenyl)-5-[1-(6-chloroquinolin-3-yl)piperidin-4-yl]-1,2,4-oxadiazole"				No development reported (Preclinical)	Pain	C22 H17 Cl2 F N4 O	Cannabinoid receptor CB2 agonists	"Amgen (Originator), Amgen (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				06/04/2011	Pain				no		no							https://adis.springer.com/drugs/800028930?userId=52029392&bpIds=3004037004&checksum=92843bb49e9fa34f00c2e983288c2a345b654df5-1617045530226-dbfce478eb51fd0f6a009026b1113d53badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003921	Mirfentanil	117523-47-4	N-[1-(2-Phenylethyl)-4-piperidinyl]-N-(2-pyrazinyl)furan-2-carboxamide				Discontinued (II)	Pain	C22 H24 N4 O2	Opioid receptor agonists	"Baxter International (Originator), Baxter International (Owner)"		unspecified		"Cl (L/h) (4.9 - 6.1 (Adult)), T<sub>_beta</sub> (h) (.25 - .29 (Adult)), Vd (L/kg) (3.5 - 4.9 (Adult))"	"Nausea, Tachycardia"	N2 (Analgesics)	N02 (Analgesics)	"A3508, ANQ 3508"			01/04/2011	Pain				no		no							https://adis.springer.com/drugs/800003921?userId=52029392&bpIds=3004037004&checksum=c75fa2a0ab0b7ddf73a2c7d8cbed293c665c554d-1617045530227-a6623ef1b4c497b127f2ca702dd5755dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018957	Bezafibrate/diflunisal						Discontinued (II)	Type 2 diabetes mellitus		"Cyclooxygenase inhibitors, Peroxisome proliferator-activated receptor alpha agonists"	"CombinatoRx (Originator), Zalicus (Owner)"		PO			"Dizziness, Nausea"	"A10 (Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics)"	"A10B-D (Combinations of oral blood glucose lowering drugs), N02B-A (Salicyclic acid and derivatives)"	"bezafibrate SR + diflunisal IR, CRx401, Diflunisal/bezafibrate"			29/03/2011	Diabetes				no		no							https://adis.springer.com/drugs/800018957?userId=52029392&bpIds=3004037004&checksum=a0a3a66fc181beaf7c49a0e8af386d506719a354-1617045530228-3b8e2979b06e0ba2be9bb79594744ab8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016148	Oxycodone intranasal - CPEX/Auxilium	76-42-6	"4,5a-Epoxy-14b-hydroxy-3-methoxy-17-methylmorphinan-6-one"	No			Discontinued (Preclinical)	Pain	C18 H21 N O4	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Bentley Pharmaceuticals (Originator), CPEX Pharmaceuticals (Owner), Auxilium Pharmaceuticals (Licensee)"		Intranasal				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				14/03/2011	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800016148?userId=52029392&bpIds=3004037004&checksum=61b7a7c0d6f9c21afd03f71744caa3c31fd7f519-1617045530228-e912d4f30692b8dac76b51ffad485f4dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021026	Research programme: cannabinoid-2 receptor agonists - Pharmos						Discontinued (Preclinical)	"Inflammation, Multiple sclerosis, Rheumatoid arthritis, Autoimmune disorders, Pain, Psychiatric disorders, Neuropathic pain"		Cannabinoid receptor CB2 agonists	"Pharmos Corporation (Originator), Pharmos Corporation (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7 (Other CNS Drugs), N7X (All other CNS drugs), V3 (All Other Therapeutic Products)"	"M01 (Antiinflammatory and Antirheumatic Products), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics), N07 (Other Nervous System Drugs), N07X-X (Other nervous system drugs), V03A-X (Other therapeutic products)"	"HU308, PRS 211058, PRS639058"			04/03/2011	"Immunological Disorders, Inflammation, Neurological Disorders, Pain, Psychotic Disorders, Rheumatic Disease"		Pharmos Corporation |  | Preclinical |  | 31 Dec 2010		no		no							https://adis.springer.com/drugs/800021026?userId=52029392&bpIds=3004037004&checksum=06fd0ec4dc9180a28df907592dc557c2109eaab7-1617045530230-3b1cdd1606a54f101b1dc02e654ed1d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800032334	BI 660848						Suspended (I)	Neuropathic pain		Undefined mechanism	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				28/02/2011	Pain				no		no							https://adis.springer.com/drugs/800032334?userId=52029392&bpIds=3004037004&checksum=871a4821d654a5682e6f6b38594ec8b5e9900e8a-1617045530230-53ca5bc3905b590076d2779a8e5dff95badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026465	Research programme: ion channel antagonists - Neurocrine						No development reported (Preclinical)	"Pain, CNS disorders"		Ion channel antagonists	"Neurocrine Biosciences (Originator), Neurocrine Biosciences (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	"ion channel blockers Neurocrine, ion channel inhibitors Neurocrine"			24/02/2011	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800026465?userId=52029392&bpIds=3004037004&checksum=7a0356cdc953c70362b40677740c286d4625e77a-1617045530231-920e33be25d68a6580dad21ae19c228bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025270	Research programme: selective adrenergic reuptake inhibitors - Neurocrine						Discontinued (Preclinical)	"Pain, Psychiatric disorders"		Adrenergic uptake inhibitors	"Neurocrine Biosciences (Originator), Neurocrine Biosciences (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics), N5B (Hypnotics/Sedatives), N7X (All other CNS drugs)"	"N02 (Analgesics), N05A-X (Other antipsychotics), N05B (Anxiolytics), N07X (Other Nervous System Drugs)"	"Selective norepinephrine reuptake inhibitors Neurocrine, SNRI Neurocrine"			24/02/2011	"Affective Disorders, Anxiety Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800025270?userId=52029392&bpIds=3004037004&checksum=6f56d1ac7513b9b6c943a0ef8c630e16a79376b0-1617045530232-01016084dfa91d2cf489527c3b7d6fe4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013547	Research programme: melanocortin-4 receptor modulators - Neurocrine Biosciences		"(1<EM>S</EM>,2<EM>S</EM>)-Ethyl 2-[4-[(<EM>R</EM>)-2-[3-aminopropanamido]-3-(2,4-dichlorophenyl)propanoyl]piperazin-1-yl]cyclohexanecarboxylate"				Discontinued (Preclinical)	"Obesity, Cachexia, Anxiety disorders, Erectile dysfunction, Pain"	C25 H36 Cl2 N4 O4	"Melanocortin type 4 receptor agonists, Melanocortin type 4 receptor antagonists"	"Neurocrine Biosciences (Originator), Neurocrine Biosciences (Owner)"		PO				"A16 (Other Alimentary Tract and Metabolism Products), A8A (Antiobesity Preparations, Excluding Dietetics), G4E (Erectile Dysfunction Products), N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"A08A (Antiobesity Preparations, Excl. Diet Products), A16 (Other Alimentary Tract and Metabolism Products), G04B-E (Drugs used in erectile dysfunction), N02 (Analgesics), N05B (Anxiolytics)"				24/02/2011	"Anxiety Disorders, Men's Health, Metabolic Disorders, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800013547?userId=52029392&bpIds=3004037004&checksum=f73b10474ab959473f7c70d7463f4c0291104895-1617045530233-0c1032b7d9dfff0bd3c2f348ae6ff8fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019814	Research programme: neurological disorder therapies - NPS			Yes			Discontinued (Preclinical)	"Epilepsy, Schizophrenia, Neuropathic pain, CNS disorders"		Glycine gated NMDA receptor agonists	"NPS Pharmaceuticals (Originator), NPS Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics), N5A (Antipsychotics), N7X (All other CNS drugs)"	"N02 (Analgesics), N03A-X (Other antiepileptics), N05A-X (Other antipsychotics), N07X (Other Nervous System Drugs)"	"CSC 500, CSC 500204, NPS 156, NPS 1897, NPSP 156"			24/02/2011	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Psychotic Disorders"		NPS Pharmaceuticals |  | Unspecified |  | 31 Dec 2009		no		no							https://adis.springer.com/drugs/800019814?userId=52029392&bpIds=3004037004&checksum=acad43a7385097304f5fa837f70f0aa7cc1a062a-1617045530234-e20b4a74860e6513723a9d0f98502341badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015542	AZD 9272						Discontinued (I)	"Gastro-oesophageal reflux, Neuropathic pain, Neurological disorders"		"Metabotropic glutamate receptor antagonists, Glutamate agonists, Glutamate receptor antagonists, Metabotropic glutamate receptor agonists"	"AstraZeneca (Originator), NPS Pharmaceuticals (Originator), AstraZeneca (Owner), NPS Pharmaceuticals (Owner)"		unspecified				"A2B9 (All other antiulcerants), N2 (Analgesics), N7X (All other CNS drugs)"	"A02B-X (Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)), N02 (Analgesics), N07X (Other Nervous System Drugs)"	AZD 6538			23/02/2011	"Neurological Disorders, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800015542?userId=52029392&bpIds=3004037004&checksum=9c114f0bddcca9cd3c55d513367928fcb66072d9-1617045530235-3722177bf9134fc95107b120800c2c9bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000671	Anpirtoline	98330-05-3	2-Chloro-6-(4-piperidinylthio)-pyridine hydrochloride				Discontinued (I)	"Pain, Major depressive disorder"	C10 H13 Cl N2 S . H Cl	"Serotonin 1B receptor agonists, Serotonin 3 receptor antagonists"	"ASTA Medica [CEASED] (Originator), ASTA Medica [CEASED] (Owner)"		unspecified				"A4A (Antiemetics and Antinauseants), N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"A04A-A (Serotonin (5HT3) antagonists), N02B (Other Analgesics and Antipyretics), N06A-X (Other antidepressants)"	D 16949			08/02/2011	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800000671?userId=52029392&bpIds=3004037004&checksum=b88e2db667add5dd0a5876303b08cd8d9b267757-1617045530236-2a739deda53023c264fe7035dd607dd5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017907	QR 333						Discontinued (II)	Diabetic neuropathies		Antioxidants	"Quigley Pharma (Originator), Quigley Pharma (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	QR333			02/02/2011	Diabetes		Quigley Pharma |  | Phase II |  | 02 Feb 2011		no		no							https://adis.springer.com/drugs/800017907?userId=52029392&bpIds=3004037004&checksum=90edc35c137710f8a6991381da51bd44585f5060-1617045530237-a1204967b26a4877c1822050bd59ea74badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025798	Research programme: calcium channel antagonists - VM Discovery			Yes			No development reported (Preclinical)	"Cancer, Cardiovascular disorders, Hypertension, Epilepsy, Pain"		Calcium channel antagonists	"VM Discovery (Originator), VM Discovery (Owner)"		unspecified				"C (Cardiovascular System), C2 (Antihypertensives), L1 (Antineoplastics), N2 (Analgesics), N3 (Anti-Epileptics)"	"C (Cardiovascular System), C02 (Antihypertensives), L01 (Antineoplastic Agents), N02 (Analgesics), N03 (Antiepileptics)"	VMDC300 series			19/01/2011	"Cancer, Epilepsy and Seizure Disorders, Hypertension, Ischaemic Heart Disease, Pain"				no		no							https://adis.springer.com/drugs/800025798?userId=52029392&bpIds=3004037004&checksum=4433ca419a661981bedd78e9e7dc3962d4d8ef84-1617045530238-c4f7778e7ff1f942a6b7394d4dcb3249badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026515	SKP 1032						No development reported (I)	"Inflammation, Pain"			"SkyePharma AG (Originator), SkyePharma AG (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	SKP1032			18/01/2011	"Inflammation, Pain"		"SkyePharma AG | Inflammation, Pain | Phase I |  | 29 Jun 2007"		no		no							https://adis.springer.com/drugs/800026515?userId=52029392&bpIds=3004037004&checksum=a54ea5838dab9230f8cb021c61bce607e9ea4718-1617045530239-37da210558dfdec6d369140d229a4704badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009809	NS 1209	254751-28-5	"Butanoic acid, 2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3<EM>H</EM>-pyrrolo[3,2-<EM>h</EM>]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy-,"	Yes			Discontinued (II)	"Status epilepticus, Stroke, Neuropathic pain"	C24 H28 N4 O7 S	"AMPA receptor antagonists, Metabotropic glutamate receptor 5 modulators"	"NeuroSearch (Originator), NeuroSearch (Owner)"		IV				"N2 (Analgesics), N3A (Anti-Epileptics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N03A-X (Other antiepileptics), N07X (Other Nervous System Drugs)"	SPD 502			06/12/2010	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009809?userId=52029392&bpIds=3004037004&checksum=6b8280ba0dcb15fbc5eff49f32bfef2fdae93ad4-1617045530240-607cb5776add744b86da12dda8e66400badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023558	Buprenorphine transdermal - Samyang	52485-79-7	"6,14-Ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-_-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-_-methyl-,[5-_,7-_-(<EM>S</EM>)]-"				No development reported (I)	"Postoperative pain, Cancer pain"	C29 H41 N O4	"Nociceptin receptor agonists, Opioid delta receptor antagonists, Opioid kappa receptor antagonists, Opioid mu receptor agonists"	"Samyang Group (Originator), Samyang Group (Owner)"		Transdermal				N2 (Analgesics)	N02A-E01 (Buprenorphine)				01/12/2010	Pain				no		no							https://adis.springer.com/drugs/800023558?userId=52029392&bpIds=3004037004&checksum=14a7a3593401fae80b66451d9497a88ab3967bc3-1617045530241-9cd4b13c025e02ec77f164bc2a9614c7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800030153	SEP 227900						Discontinued (I)	"Cognition disorders, Neuropathic pain, Alzheimer's disease"		D amino acid oxidase inhibitors	"Sepracor (Originator), Sunovion Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	SEP227900			12/11/2010	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800030153?userId=52029392&bpIds=3004037004&checksum=817f2635a7cb017797949832b9dbc4cabfa52e82-1617045530242-d275c8db6c6af70c0714547830c38a0bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000928	Zaltoprofen	89482-00-8	"2-[10-Oxo-10,11-dihydrodibenzo[<EM>b,f</EM>]thiepin-2-yl]propanoic acid"				Marketed	"Rheumatic disorders, Inflammation, Musculoskeletal disorders, Pain, Respiratory tract disorders"	C17 H14 O3 S	Cyclooxygenase inhibitors	"Nippon Chemiphar (Originator), Nippon Chemiphar (Owner), Laboratorios Cryopharma (Market Licensee), Zeria (Licensee)"		PO	renal	"Route of Elimination (renal), Cl (L/h) (6.3 (Adult)), T<sub>_beta</sub> (h) (9.08 (Adult)), T<sub>max</sub> (h) (1.17 (Adult)), Vd (L/kg) (1.2 (Adult))"	"CNS disorders, Gastrointestinal disorders, Nausea, Oedema, Skin disorders"	"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics), R7 (Other Respiratory System Products)"	"M01A-E (Propionic acid derivatives), N02 (Analgesics), R07 (Other Respiratory System Products)"	"CN100, Peon, Pyranoprofen, Soleton, ZC102"			12/11/2010	"Inflammation, Pain, Respiratory Tract Disorders, Rheumatic Disease"			"Peon, Peon, Peon, Soleton, Soleton, Soleton, Soleton, Soleton, Soleton, Soleton"	no		no				Cystatin C			https://adis.springer.com/drugs/800000928?userId=52029392&bpIds=3004037004&checksum=922aefcb467d52367baefd33147fbe4994778b9c-1617045530244-64636f99de009a8de7a5eeabbac9a388badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026479	Research programme: D-amino acid oxidase inhibitors - Sepracor						Discontinued (Preclinical)	"Pain, Schizophrenia, Cognition disorders, Psychotic disorders"		D amino acid oxidase inhibitors	"Sepracor (Originator), Sepracor (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics), N7X (All other CNS drugs)"	"N02 (Analgesics), N05A (Antipsychotics), N07X (Other Nervous System Drugs)"	DAAO inhibitors Sepracor			28/10/2010	"Alzheimer's Disease and Cognition Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800026479?userId=52029392&bpIds=3004037004&checksum=7d556a23f065186bd8d2e7a3785e93796f073127-1617045530245-1e0055441ee94b25618be4a620c6d9a7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021028	Research programme: G protein-coupled receptor antagonists - TransTech Pharma						Discontinued (Preclinical)	Neuropathic pain		G protein-coupled receptor antagonists	"TransTech Pharma (Originator), TransTech Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"GPCR antagonists TransTech, Pain therapeutics TransTech"			21/09/2010	Pain				no		no							https://adis.springer.com/drugs/800021028?userId=52029392&bpIds=3004037004&checksum=ecaabf2ab998c8f4820ac0a08db7e81a4fbe6a9e-1617045530246-2a8e574098fd7936eb2fcfe2e02039aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013838	Tramadol controlled release - Toray	36282-47-0	(±)-<EM>cis</EM>-2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol hydrochloride				Discontinued (II)	Pain	C16 H25 N O2 . H Cl	"Opioid receptor agonists, Serotonin receptor agonists"	"Purdue Pharma (Originator), Purdue Pharma (Owner), Toray (Licensee)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"THCR, Tramadol hydrochloride controlledrelease, Tramadol hydrochloride slowrelease, Tramadol hydrochloride SR, TRK091"			21/07/2010	Pain				no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800013838?userId=52029392&bpIds=3004037004&checksum=3ea342ff6ceba462fec2d7e53153e213abb5b020-1617045530247-9d7d9de601cc26e8807906dc91128c1dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019655	Research programme: TRPV cation channel inhibitors - Purdue Pharma						Discontinued (Preclinical)	Pain		TRPV cation channel antagonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"BCTC, Research programme vanilloid receptor 1 antagonists Purdue Pharma"			21/07/2010	Pain				no		no							https://adis.springer.com/drugs/800019655?userId=52029392&bpIds=3004037004&checksum=bc122970944ebf018cd577ecd16912861b75729e-1617045530248-e8dd74017898c7abcc88145b8733bb75badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024636	Research programme: vanilloid receptor antagonists - Novartis						Discontinued (Preclinical)	Neuropathic pain		TRPV cation channel antagonists	"Novartis (Originator), Novartis (Owner)"		PO				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	"TRPV1 antagonists Novartis, TRVPV1 antagonists Novartis, VR1 antagonists Novartis"			16/07/2010	Pain				no		no							https://adis.springer.com/drugs/800024636?userId=52029392&bpIds=3004037004&checksum=4cf553970a937df48025b8185d1c280666a6d0a1-1617045530249-dd6c109a0b6cde7e5b9f786d636b9da1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010123	SDZ 249665		1-[4-(Aminomethoxy)-3-methoxybenzyl]-3-(4-<EM>tert</EM>-butylbenzyl)urea				Discontinued (Preclinical)	"Rhinitis, Pain"	C21 H29 N3 O3	TRPV cation channel agonists	"Novartis (Originator), Novartis (Owner)"		SC				"N2B (Non-Narcotics and Anti-Pyretics), R7 (Other Respiratory System Products)"	"N02B (Other Analgesics and Antipyretics), R07 (Other Respiratory System Products)"				16/07/2010	"Obstructive Airways Disease, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800010123?userId=52029392&bpIds=3004037004&checksum=9850186de163264b429a9329d20c681686e7a1f9-1617045530250-51e990ca601d283456a3cfa4d2f61d57badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025361	Research programme: opioid analgesics - Antares						Discontinued (Preclinical)	Pain		"Opioid receptor agonists, Opioid receptor antagonists"	"Antares Pharma (Originator), Antares Pharma (Owner)"		Transmucosal				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	AP159 Antares			06/07/2010	Pain				no		no							https://adis.springer.com/drugs/800025361?userId=52029392&bpIds=3004037004&checksum=d37b403fa284c485af4dcecd57e08ff863ee08b3-1617045530251-ecdb3c2f7fbb7ec08b33b702c2825eaebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024169	Tramadol - TheraQuest Biosciences	27203-92-5	"Cyclohexanol, 2-((dimethylamino)-1-(3-methoxyphenyl)-,cis-(+-)-"				Discontinued (I)	Neuropathic pain	C16 H25 N O2	Opioid receptor agonists	"TheraQuest Biosciences LLC (Originator), TheraQuest Biosciences LLC (Owner)"		PO				N2A (Narcotics)	N02A-X02 (Tramadol)	"Sustained release tramadol, TQ1017"			28/06/2010	Pain				no		no			CYP3A4	"CD3d, CD3e, CD3g, CD4, CD56, CD8a, CRP, CYP3A4, Dimethylarsinate, Hydrocortisone, IL6, Norepinephrine, nuclear prelamin A recognition factor like, Prolactin, serotonin, VEGF-A, VEGFR, VEGFR1"	"CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CYP2D6, cytochrome P450 family 2 subfamily B member 6, endothelin receptor type A, IL10, TNF-alpha"	https://adis.springer.com/drugs/800024169?userId=52029392&bpIds=3004037004&checksum=5070fd06656ac45908596dda951e66d37ea4a548-1617045530252-646dd13afe572cffb6487aa385ded093badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024162	TQ 1015						Discontinued (Preclinical)	Pain		Opioid receptor agonists	"TheraQuest Biosciences LLC (Originator), TheraQuest Biosciences LLC (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	TQ1015			28/06/2010	Pain				no		no							https://adis.springer.com/drugs/800024162?userId=52029392&bpIds=3004037004&checksum=7d3b3b7b243641ca5de98c58a865af1af58099a1-1617045530253-a2feed01c98305367355815bfa9355a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022070	Ketoprofen intravenous						Discontinued (II)	Postoperative pain		Lipoxygenase-cyclooxygenase inhibitors	"TheraQuest Biosciences LLC (Originator), TheraQuest Biosciences LLC (Owner)"		IV				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"NSAID analgesic TheraQuest Biosciences, TQ1011"			28/06/2010	Pain				no		no							https://adis.springer.com/drugs/800022070?userId=52029392&bpIds=3004037004&checksum=48b1e985d4d2cf2b1c45b41989dad8c7a6ae7255-1617045530254-a7deb4c52b519abaa2aa37078f8dff40badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010984	Isovaleramide	541-46-8	3-Methylbutanamide	No			Discontinued (II)	"Migraine, CNS disorders, Bipolar disorders, Epilepsy"	C5 H11 N O	Undefined mechanism	"NPS Pharmaceuticals (Originator), NPS Pharmaceuticals (Owner)"		PO				"N2C (Anti-Migraine Preparations), N3 (Anti-Epileptics), N5 (Psycholeptics), N7X (All other CNS drugs)"	"N02C (Antimigraine Preparations), N03 (Antiepileptics), N05 (Psycholeptics), N07X (Other Nervous System Drugs)"	NPS1776			25/06/2010	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Epilepsy and Seizure Disorders, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800010984?userId=52029392&bpIds=3004037004&checksum=c374884114f4682e748e788c46ccff4dbaed63e2-1617045530255-b75492856a47ef32746d1acaf3b673b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009052	Mitoxantrone	65271-80-9	"1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione"	Yes			Marketed	"Acute nonlymphocytic leukaemia, Acute promyelocytic leukaemia, Cancer pain, Ovarian cancer, Leukaemia, Cancer, Liver cancer, Breast cancer, Multiple sclerosis, Non-Hodgkin's lymphoma, Acute myeloid leukaemia"	C22 H28 N4 O6	"DNA inhibitors, DNA topoisomerase inhibitors, Type II DNA topoisomerase inhibitors, Immunosuppressants"	"Wyeth (Originator), Amgen (Owner), Pfizer (Owner), Baxter Oncology (Market Licensee), EMD Serono (Market Licensee), Inibsa (Market Licensee), OSI Pharmaceuticals (Market Licensee), Takeda (Market Licensee)"		IV	biliary	"Dose Modification in Hepatic Dysfunction (moderate), Dose Modification in Renal Dysfunction (nil), Route of Elimination (biliary), protein binding (%) (78 (Adult)), T<sub>_beta</sub> (h) (.3 - 3.1 (Adult)), Vd (L/kg) (14.3 - 57.1 (Adult))"	"Agranulocytosis, Alopecia, Amenorrhoea, Anaemia, Anorexia, Cardiovascular disorders, Constipation, Diarrhoea, Fatigue, Leucopenia, Leukaemia, Lymphopenia, Malaise, Menstruation disorders, Mucositis, Nail disorders, Nausea, Neutropenia, Oedema, Stomatitis, Thrombocytopenia, Urinary tract infections, Vomiting"	"L1D (Antineoplastic Antibiotics), L4X (Other Immunosuppressants), N2 (Analgesics), N7X (All other CNS drugs)"	"L01D-B (Anthracyclines and related substances), L01D-B07 (Mitoxantrone), L04A-X (Other immunosuppressants), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"CL 232315, DHAD, DHAQ, dihydroxyanthracenedione, mitozantrone, Novantron, Novantrone, NSC 279836, NSC 301739, Onkotrone, Pralifan"			11/06/2010	"Cancer, Neurological Disorders, Pain, Women's Health"			"Novantron, Novantrone, Novantrone, Novantrone, Novantrone, Onkotrone, Pralifan"	no		no		"ABL1, Bilirubin, CD30, Immunoglobulin heavy locus, MLL, opioid related nociceptin receptor 1, Ph chromosome, promyelocytic leukemia, PSA, retinoic acid receptor, alpha"	"C-C motif chemokine ligand 28, G-CSF, interferon, beta 1, fibroblast, mTOR, PDZ domain containing 2, PSA"	"2-Hydroxyglutarate, alanyl aminopeptidase, membrane, asparaginase, Bcl-2, Bilirubin, BNP, C-C motif chemokine ligand 28, carcinoembryonic antigen related cell adhesion molecule 6, CD19, CD1d molecule, CD30, CD33 molecule, CD34, CD38, CD3d, CD3e, CD3g, CD45, CD58 molecule, CD74 molecule, major histocompatibility complex, class II invariant chain, CKB, CKM, complement component (3b/4b) receptor 1 (Knops blood group), complement factor D (adipsin), CXCL12, DCK, EGFR, embryonal Fyn-associated substrate, exportin 1, Flt-3, G-CSF, GM-CSF, hyaluronan synthase 3, Immunoglobulin heavy locus, interferon, beta 1, fibroblast, interleukin 3 receptor, alpha (low affinity), MLL, mTOR, Neprilysin, nuclear receptor subfamily 3, group C, member 2, PDGFRA, phosphate cytidylyltransferase 1, choline, alpha, promyelocytic leukemia, PSA, RPS6, solute carrier family 25 member 10, solute carrier family 29 member 2, Thrombomodulin, TOP2A, troponin I, cardiac, tumor necrosis factor superfamily member 8"	"EGFR, Flt-3, GM-CSF, Thrombomodulin"	"13-cis-Retinoic acid, 9-cis-Retinoic acid, ATP binding cassette subfamily G member 2 (Junior blood group), BC1 (ubiquinol-cytochrome c reductase) synthesis-like, C-Kit, c-Myc, C2, CBFB-MYH11 fusion, CBL, CD20, CD4, CD56, CD8a, CEBPA, Chromosome 17, Chromosome 3, Chromosome 5, Chromosome 7, colony stimulating factor 1 receptor, CXCR4, Cytidine deaminase, dual specificity phosphatase 3, ER alpha, GATA binding protein 1 (globin transcription factor 1), IGHV, MDR1, MECOM, MLLT3, NMO Autoantibodies, Nucleophosmin, p53, PSMB5, RPN1, RUNX1, RUNX1-RUNX1T1 fusion, SRC proto-oncogene, non-receptor tyrosine kinase, T cell receptor gamma variable 9, t(9;11) translocation, TET2, Topoisomerase 1, transcription factor 20, WT1"	https://adis.springer.com/drugs/800009052?userId=52029392&bpIds=3004037004&checksum=15019153413da9953f56bbc49da6e0b1b3f48cab-1617045530261-214ec547962c10f3fa350a2f3c564658badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018244	GW 274150		<EM>S</EM>-[2-[(1-iminoethyl)-amino]ethyl]-L-homocysteine				Discontinued (II)	"Allergic rhinitis, Migraine, Asthma, Chronic obstructive pulmonary disease, Rheumatoid arthritis"	C8 H17 N3 O2 S	Nitric oxide synthase type II inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2C (Anti-Migraine Preparations), R1B (Systemic Nasal Preparations), R3X2 (All other anti-asthma and COPD products, systemic)"	"M01 (Antiinflammatory and Antirheumatic Products), N02C (Antimigraine Preparations), R01B (Nasal Decongestants for Systemic Use), R03D-X (Other systemic drugs for obstructive airway diseases)"	"274150, GSK 274150"			01/06/2010	"Advances in the Treatment of Nausea and Migraine, Obstructive Airways Disease, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800018244?userId=52029392&bpIds=3004037004&checksum=9e74482eb53f695ecae359a240f39ab0609d6238-1617045530262-de774107532f9665c1f9c39014c5384abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027457	Research programme: PICK1 PZD domain inhibitors - NeuroSearch						No development reported (Preclinical)	"Cocaine-related disorders, Neuropathic pain"		AMPA receptor modulators	"NeuroSearch (Originator), NeuroSearch (Owner)"		unspecified				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N07B (Drugs Used In Addictive Disorders)"	Compound 231			26/05/2010	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800027457?userId=52029392&bpIds=3004037004&checksum=e919357e00c198ccf27d33f3a560aa24835c177c-1617045530263-dcb6b389d2118dfe7b05dcf404ffd475badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014044	ONO 8711		"6-[(2<EM>S</EM>,3<EM>S</EM>)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)bicyclo[2.2.2]octan-2-yl]5<EM>Z</EM>-hexenoic acid"				Discontinued (I)	"Cancer, Pain"	C22 H30 Cl N O4 S	Prostaglandin E1 antagonists	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		PO				"L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics)"				26/05/2010	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800014044?userId=52029392&bpIds=3004037004&checksum=08ef9d260fe2d3b6cd6d596ecd6b534097a161ff-1617045530264-2e26a1c34f77447c4952bccddc056d79badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009030	CNS 5161		<EM>N</EM><SUP>3</SUP>-[2-Chloro-5-(methylsulfanyl)phenyl]- <EM>N</EM><SUP>1</SUP>-methyl-<EM>N</EM><SUP>1</SUP>- [3-(methylsulfanyl)phenyl]guanidine				Discontinued (II)	"Cancer pain, Neuropathic pain"	C16 H18 N3 Cl S2	Glutamate receptor antagonists	"CeNeS Pharmaceuticals (Originator), CeNeS Pharmaceuticals (Owner), Ergomed (Collaborator)"		"IV, Transdermal"		T<sub>_beta</sub> (h) (176 (Adult))		N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				26/05/2010	Pain				no		no							https://adis.springer.com/drugs/800009030?userId=52029392&bpIds=3004037004&checksum=05917d4f9c2d6976d27cd67e6cb544a1be1b268b-1617045530265-de958172302d79351e2b03ffd525d937badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003348	Flubichin methanesulfonate	139055-77-9	"4(3H)-Quinazolinone, 3-[2-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)oxy]ethyl]-, monomethanesulfonate"				Discontinued (Preclinical)	Pain	C22 H16 F2 N2 O2 . C H4 O8 S	Cyclooxygenase inhibitors	"VUFB (Originator), VUFB (Owner)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	VUFB 12950			14/04/2010	Pain				no		no							https://adis.springer.com/drugs/800003348?userId=52029392&bpIds=3004037004&checksum=f8f567c28b5417e8f7fc6199204fa8f38870d03f-1617045530266-c44a8135b96c9e8e1bf8717ea7f85043badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007941	S 18616		"(<EM>S</EM>)-8-Chloro-3,4-dihydro-1<EM>H</EM>,5'<EM>H</EM>-spiro[naphthalene-2,4'-oxazol]-2'-amine hydrochloride"				Discontinued (Preclinical)	Pain	C12 H13 Cl N2 O . HCl	Alpha adrenergic receptor agonists	"Servier (Originator), Servier (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	S18616			14/04/2010	Pain				no		no							https://adis.springer.com/drugs/800007941?userId=52029392&bpIds=3004037004&checksum=4ac3f62b65804a1e72047b3ac5258bf78914bea5-1617045530267-f1bfecbafe26cfe94e465b382446fe4ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026044	DD5			Yes			No development reported (I)	Pain		Opioid mu receptor agonists	"Cephalon (Originator), Teva Pharmaceutical Industries (Owner)"		Buccal				N2 (Analgesics)	N02A-B03 (Fentanyl)	Fentanyl patch Teva Pharmaceutical Industries			13/04/2010	Pain				no		no							https://adis.springer.com/drugs/800026044?userId=52029392&bpIds=3004037004&checksum=8fdf215c2420299d8447db091ae0a6d5cbb5a807-1617045530268-c1bd5cafe62b166d3b23e4ccd3362b08badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007513	OT 7100		"5-<EM>n</EM>-Butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine"				Discontinued (I)	Pain	C20 H24 N4 O4	Undefined mechanism	"Otsuka Pharmaceutical (Originator), Otsuka Pharmaceutical (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				31/03/2010	Pain				no		no							https://adis.springer.com/drugs/800007513?userId=52029392&bpIds=3004037004&checksum=59e726547c45e873a925308568f72f2d7ca3b0b8-1617045530268-ae1414b80e5073ffd441d78307f156abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024715	Research programme: bradykinin B2 receptor antagonists - Jerini						Discontinued (Preclinical)	"Pain, Inflammation"		Bradykinin B2 receptor antagonists	"Jerini (Originator), Jerini (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	JSM10292			24/03/2010	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800024715?userId=52029392&bpIds=3004037004&checksum=7c33a41a03d6d145863ddd623e9758fd432dc242-1617045530269-14647a9158545b15e19c79457e3cbb26badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027564	Research programme: bradykinin B1 receptor antagonists - Jerini						Discontinued (Research)	"Pain, Inflammation"		Bradykinin B1 receptor antagonists	"Jerini (Originator), Jerini (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"				24/03/2010	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800027564?userId=52029392&bpIds=3004037004&checksum=7c3a73e6ea8fca4a8499ea992e7ed973bd763946-1617045530270-1f004cbce37245b5c4ae99c7f75aa551badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025986	AMG 379						Discontinued (I)	Pain		Bradykinin B1 receptor antagonists	"Amgen (Originator), Amgen (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				23/03/2010	Pain				no		no							https://adis.springer.com/drugs/800025986?userId=52029392&bpIds=3004037004&checksum=216bc935ab8dd95521efcfe43582438c2de27702-1617045530271-fcd88b654858bf4858ab4663415ddd84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024642	MK 0686						Discontinued (II)	Postherpetic neuralgia		Undefined mechanism	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	MK0686			18/03/2010	Pain				no		no							https://adis.springer.com/drugs/800024642?userId=52029392&bpIds=3004037004&checksum=9313e6f5739cb8f0d46ebb3923ef5f6c5d1c829d-1617045530271-a3bf1d5cb065ed8f2646ed25a6e62aa5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022236	L 791515		(5<EM>S</EM>)-5-Ethyl-3-isopropoxy-5-methyl-4-[4-(methylsulfonyl)phenyl]furan-2(5<EM>H</EM>)-one			= Ibuprofen	Discontinued (II)	Pain	C17 H22 O5 S	Cyclo-oxygenase 2 inhibitors	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"	MK0703			18/03/2010	Pain				no		no							https://adis.springer.com/drugs/800022236?userId=52029392&bpIds=3004037004&checksum=a80b30cc67819d1ea8c5e4dd0c14cf646b3af6a3-1617045530272-f90d60daa834c426e01097f394b71af2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019805	T 62						Discontinued (II)	Postherpetic neuralgia		Adenosine A1 receptor agonists	"King Pharmaceuticals (Originator), King Pharmaceuticals (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	T62			10/03/2010	Pain				no		no							https://adis.springer.com/drugs/800019805?userId=52029392&bpIds=3004037004&checksum=e544911ad1e3abaf737356e7ce9aeaacbd7a1b9d-1617045530273-c0d12f7df124863a62ee220fe9b1441dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013593	E 5296						Discontinued (I)	Pain		"Opioid receptor agonists, Serotonin uptake stimulants"	"Esteve (Originator), Esteve (Owner), DevCo Pharmaceuticals (Market Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				26/02/2010	Pain				no		no							https://adis.springer.com/drugs/800013593?userId=52029392&bpIds=3004037004&checksum=4e68546283f0ea4e29825e879c4e537be8aaa973-1617045530273-d4f1fe560314a9adc3b0c5a2039f3883badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026032	Research programme: cytokine inhibitors - Rottapharm						No development reported (Preclinical)	Osteoarthritis		Cytokine inhibitors	"Rottapharm (Originator), Rottapharm (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	CR 3719			25/02/2010	Rheumatic Disease				no		no							https://adis.springer.com/drugs/800026032?userId=52029392&bpIds=3004037004&checksum=b1760d9c2d032354bec70ac29a61650d88a52cc3-1617045530274-dd03364e1a9a64db08f98d4efb2b4b7abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023039	BVT 115959						Discontinued (II)	"Neuropathic pain, Inflammatory pain"		Adenosine A2 receptor agonists	"Cambridge Biotechnology (Originator), Swedish Orphan Biovitrum (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"BVT.115959, CBT1008"			24/02/2010	Pain				no		no							https://adis.springer.com/drugs/800023039?userId=52029392&bpIds=3004037004&checksum=3121563698f56e24142dff048e740d68132cc6c9-1617045530275-00491c2adc5de6aefda5df1a8d5045c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019036	FHPC 01						Discontinued (I)	Migraine		Undefined mechanism	"Sciele Pharma (Originator), Sciele Pharma (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				17/02/2010	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800019036?userId=52029392&bpIds=3004037004&checksum=b08c5db2e2f4092bfc651a0bf9b9259ee16276b9-1617045530276-21eda9536c0d0155d4aec9873c581a37badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800031069	AZD 6088						Discontinued (I)	Neuropathic pain		Muscarinic M1 receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AZD6088			15/02/2010	Pain				no		no							https://adis.springer.com/drugs/800031069?userId=52029392&bpIds=3004037004&checksum=eea52b4f83c6bc84d1b6823fb84e69f90906e321-1617045530277-c037dc56febbfc145b8d7c71641d3bf1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026842	PF 3557156						Discontinued (I)	Pain		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PF3557156			28/01/2010	Pain				no		no							https://adis.springer.com/drugs/800026842?userId=52029392&bpIds=3004037004&checksum=856e5adb0b5bea1516e21b67b74530627a09ac50-1617045530277-69d50e13757e8df3f8909cbc9b201249badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025080	Research programme: cannabinoid CB1 receptor agonists - Organon		"[1-(Cyclohexylmethyl)-7-methoxy-1<EM>H</EM>-indol-3-yl][(3<EM>S</EM>,5<EM>R</EM>)-3,4,5-trimethylpiperazin-1-yl]methanone"				No development reported (Preclinical)	Pain	C24 H35 N3 O2	Cannabinoid receptor CB1 agonists	"Organon (Originator), Organon (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"ORG 207788, ORG 223782, ORG 28312"			27/01/2010	Pain				no		no							https://adis.springer.com/drugs/800025080?userId=52029392&bpIds=3004037004&checksum=97e056d1abebcfff66f20a6d074b1fbeb4902190-1617045530278-d249ab6ff5f704053855f491c10cf336badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021419	Research programme: pain therapeutics - Schering-Plough						No development reported (Preclinical)	"Pain, Sedation"		Nociceptin receptor agonists	"Organon (Originator), Organon (Owner)"		IV				"N2A (Narcotics), N5B (Hypnotics/Sedatives), N5C (Tranquillisers)"	"N02A (Opioids), N05C (Hypnotics and Sedatives)"	"opioid like receptor 1 agonists, ORG 26383, ORG 27899, ORL1 agonists"			26/01/2010	Pain				no		no							https://adis.springer.com/drugs/800021419?userId=52029392&bpIds=3004037004&checksum=3363a3a89c494f3f32c1c8d669fd5334d282a974-1617045530279-42f21cc4ce6009cac8199be1e01bf93abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026502	Research programme: neurotensin derivatives - Argolyn Bioscience						Discontinued (Preclinical)	"Schizophrenia, Pain"		Neurotensin type 2 receptor agonists	"Argolyn Bioscience (Originator), Argolyn Bioscience (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics)"	"N02 (Analgesics), N05A (Antipsychotics)"	"ABS 201, ABS 212"			30/12/2009	"Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800026502?userId=52029392&bpIds=3004037004&checksum=70bcc7daa996a3ffe681549f019c4af2a6600e90-1617045530280-e4afb64cd07e65da5677237f6855f2e2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026980	LY 466195		"(3<EM>S</EM>,4a<EM>R</EM>,6S,8a<EM>R</EM>)-6-[[(<EM>R</EM>)-2-Carboxy-4,4-difluoropyrrolidin-1-yl]methyl]decahydroisoquinoline-3-carboxylic acid"	No			No development reported (I)	Migraine	C16 H24 F2 N2 O4	Kainic acid receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		"PO, IV"				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				29/12/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800026980?userId=52029392&bpIds=3004037004&checksum=0e3075ce1633f95855c2ee749feaf3840f6b5f93-1617045530281-75f2a85516e0609ea06ab9c2670f493dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029345	LY 2590443			No			Discontinued (II)	Migraine			"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	LY2590443			29/12/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800029345?userId=52029392&bpIds=3004037004&checksum=78bace95cfbbdf49003838c4c302864d00a3669d-1617045530281-f53b52046a8f3a7ed03ac84e06f3de6cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027014	Research programme: metabotropic glutamate receptor antagonists - Schering-Plough						Discontinued (Preclinical)	Pain		Metabotropic glutamate receptor type 1 antagonists	"Schering-Plough (Originator), Schering-Plough (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				30/11/2009	Pain				no		no							https://adis.springer.com/drugs/800027014?userId=52029392&bpIds=3004037004&checksum=a3785ad129200a72ccecca1b3e8ee86d4d17c6e9-1617045530282-bd519f59372b38c051ae34f38f42197dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022923	Research programme: FAAH inhibitors - Organon			Yes			No development reported (Preclinical)	"Anxiety disorders, Major depressive disorder, Pain"		Fatty acid amide hydrolase inhibitors	"Kadmus Pharmaceuticals (Originator), University of California at Irvine (Originator), Kadmus Pharmaceuticals (Owner), University of California at Irvine (Owner)"		PO				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants)"	"KDS4103, ORG 231295, URB 597"			27/11/2009	"Affective Disorders, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800022923?userId=52029392&bpIds=3004037004&checksum=e9082891ca6b675198c2470ee69c4c5dada42a87-1617045530283-00c8efd451d70f9b53c1df5a3679c6ccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028792	Topiramate extended-release - Spherics	97240-79-4	"[(3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate"	No			No development reported (II)	"Migraine, Epilepsy"	C12 H21 N O8 S	"AMPA receptor antagonists, Carbonic anhydrase inhibitors, GABA A receptor agonists, Kainic acid receptor antagonists, Sodium channel antagonists"	"Spherics (Originator), Spherics (Owner)"		PO				"N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02C-X (Other antimigraine preparations), N03A-X11 (Topiramate)"	"SRx502, Topiramate XR Spherics"			23/11/2009	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders"				no		no		"A1C, citrate lyase beta like"	"A1C, citrate lyase beta like, ER alpha"	"24,25-Dihydroxyvitamin D, A1C, Alkaline phosphatase, Benzoyl ecgonine, centrin 1, citrate lyase beta like, CRP, CTx, Cytokeratin 5, Deoxyadenosine monophosphate, dopamine receptor D2, EH domain containing 4, IGF1, Insulin, iodothyronine deiodinase 3, Leptin, MDR1, OPRM1, Osteocalcin, peptidylprolyl isomerase G, period circadian clock 2, PGE2, PTH, S100B, sodium channel, voltage gated, type I alpha subunit, spermine synthase, Valproic acid glucuronide"	Leptin	"ATP-binding cassette, sub-family B (MDR/TAP), member 7, GAST, Ghrelin, Orotic acid, TPMT, Urea, Uric acid"	https://adis.springer.com/drugs/800028792?userId=52029392&bpIds=3004037004&checksum=65543faa41ed20ca4a9fa8b37f039c5f5e4dd10a-1617045530285-05fb5b0de81e1caabe15d14332aa493bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011055	Olcegepant	204697-65-4	"<EM>N</EM>-[(1<EM>R</EM>)-2-[[(1<EM>S</EM>)-5-Amino-1-[[4-(pyridin-4-yl)piperazin-1-yl]carbonyl]pentyl]amino]-1-(3,5-dibromo-4-hydroxybenzyl)-2-oxoethyl]-4-[2-oxo-1,4-dihydroquinazolin-3(2<EM>H</EM>)-yl]piperidine-1-carboxamide"				Discontinued (II)	Migraine	C38 H47 Br2 N9 O5	Calcitonin gene-related peptide antagonists	"Boehringer Ingelheim (Originator), Boehringer Ingelheim (Owner)"		IV		"Cl (L/h) (12), T<sub>_beta</sub> (h) (2.5)"		N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"BIBN 4096, BIBN 4096BS"			19/11/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800011055?userId=52029392&bpIds=3004037004&checksum=357f5f0364edbae71dbac38d4661e6988be075eb-1617045530285-fa0841cfe366deb224d8b7e6ffa51424badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017338	Morphine - Ethypharm		"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate"	No			Marketed	Pain	C17 H19 N O3 . 1/2H2 S O4	Opioid mu receptor agonists	"Ethypharm (Originator), Ethypharm (Owner), Xanodyne Pharmaceuticals (Market Licensee)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	"Morphine sulfate SR Multicaps, Morphine sulfate sustainedrelease Multicaps, Morphine sulphate SR Multicaps, Morphine sulphate sustainedrelease Multicaps, Morphine Xanodyne, Oramorph"			13/11/2009	Pain			Oramorph	no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800017338?userId=52029392&bpIds=3004037004&checksum=de8ed0287129a3b7d29f92780a20dd1735029fe0-1617045530287-526f0979b7e848ac0d434b8bc89140eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018832	Fentanyl sublingual - Sosei	437-38-7	<EM>N</EM>-(1-Phenethylpiperidin-4-yl)-<EM>N</EM>-phenylpropionamide				Suspended (III)	Cancer pain	C22 H28 N2 O	Opioid mu receptor agonists	"Sosei R&D (Originator), Sosei R&D (Owner), Pharmasol Ltd (Licensee)"		Sublingual				N2A (Narcotics)	N02A-B03 (Fentanyl)	"AD923, SGX2001, SRSS001"			08/10/2009	Pain				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800018832?userId=52029392&bpIds=3004037004&checksum=922edaaf91247b966e8d5223c9bffb81857a44db-1617045530289-c1a6d9d376a30a6f035bd6a78b2c4d7cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020442	Research programme: serotonin 2B receptor antagonists - Biofrontera AG						No development reported (Preclinical)	"Pulmonary hypertension, Migraine"		Serotonin 2B receptor antagonists	"Biofrontera AG (Originator), Biofrontera AG (Owner)"		unspecified				"C2 (Antihypertensives), N2C (Anti-Migraine Preparations)"	"C02 (Antihypertensives), N02C (Antimigraine Preparations)"				29/09/2009	"Advances in the Treatment of Nausea and Migraine, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800020442?userId=52029392&bpIds=3004037004&checksum=c27389600aed6889ef0827eb470e04e18cf00a54-1617045530290-167624dad5c51ab55cd64b56fcc8634bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028384	Research programme: transmucosal therapeutics - ULURU						Discontinued (Preclinical)	"Migraine, Pain"		Undefined mechanism	"ULURU (Originator), ULURU (Owner)"		Transmucosal				"N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"N02 (Analgesics), N02C (Antimigraine Preparations)"				25/09/2009	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800028384?userId=52029392&bpIds=3004037004&checksum=b1f49bedd66cc76bc287be7e4a921ef40567720b-1617045530291-5575ca852b767b103d4e7af94a25e591badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800029725	MK 3207						Discontinued (II)	Migraine		Calcitonin gene-related peptide antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	MK3207			14/09/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800029725?userId=52029392&bpIds=3004037004&checksum=ea1f3eaade8ca2a35985c30b0ebd9b5e8791a19e-1617045530292-c6873b1f51891f4feaeaf4474c54620ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021826	GW 842166		"2-(2,4-Dichlorophenylamino)-<EM>N</EM>-(tetrahydropyran-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide"	Yes			Discontinued (II)	"Dental pain, Musculoskeletal pain"	C18 H17 Cl2 F3 N4 O2	Cannabinoid receptor CB2 agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"842166, 842166X, GW 842166X, Noncannabinoid CB2 receptor agonist GlaxoSmithKline"			31/08/2009	Pain				no		no							https://adis.springer.com/drugs/800021826?userId=52029392&bpIds=3004037004&checksum=bcbabcadece3fca44d6a2d410943f079d0167e72-1617045530293-ead19089f8d373c09fb60fbb33411ec7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007239	NPC 17731	147267-10-5	"Bradykinin, <EM>N</EM>2-D-arginyl-3-(<EM>trans</EM>-4-hydroxy-L-proline)- 7-(<EM>trans</EM>-4-propoxy-D-proline)- 8-[L-(2_,3a_,7a_)-octahydro- 1<EM>H</EM>-indole-2-carboxylic acid]-"				Discontinued (Preclinical)	"Gram-negative infections, Sepsis, Asthma, Pain, Inflammation"	C59 H95 N19 O14	Bradykinin receptor antagonists	"Scios (Originator), Scios (Owner)"		"IV, Parenteral, unspecified"				"J1X (Other Antibacterials), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), R3 (Anti-Asthma and COPD Products), V3 (All Other Therapeutic Products)"	"J01X (Other Antibacterials), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), R03 (Drugs for Obstructive Airway Diseases), V03A-X (Other therapeutic products)"				27/08/2009	"Bacterial Infections, Inflammation, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800007239?userId=52029392&bpIds=3004037004&checksum=81553773af8483cfcc21059c2e0851fe8815bf48-1617045530294-e19cdb14b0352e017a05e7c89c97732ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018739	LAS 34475	485397-26-0	"Phenylsulfonamide, 4-(2-oxo-3-phenyl-1,3-oxazol-5yl)-,"			³ Naproxen	Discontinued (II/III)	"Osteoarthritis, Pain"	C15 H12 N2 O4 S	Cyclo-oxygenase 2 inhibitors	"Almirall-Prodesfarma (Originator), Almirall S.A. (Owner)"		"PO, unspecified"				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"				24/08/2009	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800018739?userId=52029392&bpIds=3004037004&checksum=8b96e77de64f4d53f25223010acbf044672be545-1617045530295-d506b004831e31ff9a9e6ad4fff01de7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024992	Research programme: adenosine A1 receptor allosteric enhancers - PGxHealth			Yes			Discontinued (Preclinical)	"Epilepsy, Pain"		Adenosine A1 receptor agonists	"Adenosine Therapeutics LLC (Originator), PGxHealth (Owner)"		unspecified				"N2A (Narcotics), N3A (Anti-Epileptics)"	"N02 (Analgesics), N03A (Antiepileptics)"				20/08/2009	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800024992?userId=52029392&bpIds=3004037004&checksum=0599824e53d44d372111e63963dad4394790dbdd-1617045530296-0bd1f18895b62c0679baef3af79b9e20badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023824	Research programme: analgesic therapeutics - Eurand						Discontinued (Preclinical)	Pain		Undefined mechanism	"University of Milan (Originator), University of Sassari (Originator), University of Milan (Owner), University of Sassari (Owner), Eurand (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				14/08/2009	Pain				no		no							https://adis.springer.com/drugs/800023824?userId=52029392&bpIds=3004037004&checksum=94e687d8c980a1ef7fdc07388d95897ea93c206d-1617045530296-c239ab1f4a39051ed7613c42d32c38a5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023672	Research programme: neuronal nitric oxide synthase inhibitors - Pfizer		6-[4-[(Dimethylamino)methyl]-5-ethyl-2-methoxyphenyl]pyridin-2-amine				No development reported (Preclinical)	"Craniocerebral trauma, Alzheimer's disease, Neurological disorders, Parkinson's disease, Stroke, Neuropathic pain"	C17 H23 N3 O	Nitric oxide synthase inhibitors	"Pfizer (Originator), Pfizer (Owner)"		IV				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7 (Other CNS Drugs), N7D (Anti-Alzheimer Products)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs), N07X (Other Nervous System Drugs)"	"CP 536404, CP 601073, CP 695516"			13/08/2009	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800023672?userId=52029392&bpIds=3004037004&checksum=ebfa62ce36bff54a5ff586cb52e4d1afdafd26f0-1617045530298-d14bf61a92cebb486709baa71423f7adbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022238	WAY 195725						Discontinued (I)	"Dysmenorrhoea, Osteoarthritis, Rheumatoid arthritis"		Phospholipase A2 inhibitors	"Wyeth (Originator), Pfizer (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	WAY195725			10/08/2009	"Pain, Rheumatic Disease, Women's Health"				no		no							https://adis.springer.com/drugs/800022238?userId=52029392&bpIds=3004037004&checksum=66d2fc003b7ac228254214eba1160be2fa886f8e-1617045530298-7f90484a75fda6b0c3fe6a9d4556a3d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013599	Besonprodil	253450-09-8	6-[3-[4-(4-Fluorobenzyl)piperidin-1-yl]propanoyl]benzo[<EM>d</EM>]oxazol-2(3<EM>H</EM>)-one				Discontinued (I)	"Neuropathic pain, Pain, Parkinson's disease"	C21 H23 F N2 O3 S	NR2B N-Methyl-D-Aspartate antagonists	"Pfizer (Originator), Pfizer (Owner)"		"unspecified, PO"				"N2 (Analgesics), N4A (Anti-Parkinson Drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs)"	"CI 1041, CO 200461, PD 196860"			06/08/2009	"Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800013599?userId=52029392&bpIds=3004037004&checksum=69e0f6c057585c6bb771af0e603f43e06ab51aa0-1617045530299-b7fead14b618ee94d3a6c3c18750bb52badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002331	CP 99994	136982-36-0	"(+)-(2<EM>S</EM>,3<EM>S</EM>)-3-(2-Methoxybenzylamino)-2-phenyl piperidine"				No development reported (Preclinical)	"Cough, Asthma, Rheumatic disorders, Arrhythmias, Allergic rhinitis, Nausea and vomiting, Pain"	C19 H24 N2 O	"Neurokinin 1 antagonists, Substance P inhibitors"	"Pfizer (Originator), Pfizer (Owner), Schering-Plough (Collaborator)"		IV				"A4A (Antiemetics and Antinauseants), C1B (Anti-Arrhythmics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3 (Anti-Asthma and COPD Products), R5D1 (Plain antitussives)"	"A04A (Antiemetics and Antinauseants), C01 (Cardiac Therapy), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases), R05D (Cough Suppressants, Excl. Combinations with Expectorants)"				04/08/2009	"Advances in the Treatment of Nausea and Migraine, Arrhythmias, Obstructive Airways Disease, Pain, Respiratory Tract Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800002331?userId=52029392&bpIds=3004037004&checksum=98028e3a2a9d4afebaf2ec02b4c7a08f5c4036b0-1617045530301-9ee371e8c987822e0863db2f20c7b883badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027804	Research programme: non-acetylated salicylates - Acorda Therapeutics						Discontinued (Preclinical)	"Inflammation, Neuropathic pain"		Prostaglandin synthase inhibitors	"Neurorecovery (Originator), Acorda Therapeutics (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B-A (Salicyclic acid and derivatives)	"CMS, CMSal"			30/07/2009	"Inflammation, Pain"			"CMSal, CMSal"	no		no							https://adis.springer.com/drugs/800027804?userId=52029392&bpIds=3004037004&checksum=3d263edab004ff894c53964929ee7285ab410015-1617045530302-a42c011ca8045522aa7a1869074355bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017065	PRS 211096						Discontinued (Preclinical)	"Pain, Neuropathic pain, Autoimmune disorders"		Cannabinoid receptor CB2 agonists	"Pharmos Corporation (Originator), Pharmos Corporation (Owner)"		unspecified				"L4X (Other Immunosuppressants), N2B (Non-Narcotics and Anti-Pyretics)"	"L04A (Immunosuppressants), N02B (Other Analgesics and Antipyretics)"	PRS211096			28/07/2009	"Immunological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800017065?userId=52029392&bpIds=3004037004&checksum=043624e58bca47923c502522d4d50cb1dbc7d90f-1617045530303-75749b262c54947598ed3d7de34c38d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023150	Cannabinor						Discontinued (II)	"Pain, Neuropathic pain"		Cannabinoid receptor CB2 agonists	"Pharmos Corporation (Originator), Pharmos Corporation (Owner)"		"IV, PO"				N2 (Analgesics)	N02 (Analgesics)	"PRS 375, PRS211375"			28/07/2009	Pain				no		no							https://adis.springer.com/drugs/800023150?userId=52029392&bpIds=3004037004&checksum=5b6beff433fe21176320a668bc75eeefff4bbf9b-1617045530304-402d6553156def2a488de0eab8ce978fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006668	VPI 013		"1-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-5-methoxy-1,2,3,4-tetrahydroquinolin-2-one monomethanesulfonate"				No development reported (II)	"Major depressive disorder, Neuropathic pain"	C23 H28 Cl N3 O2 . C H4 O3 S	"Serotonin 1A receptor agonists, Serotonin uptake inhibitors, Sigma-1 receptor agonists"	"Otsuka Pharmaceutical (Originator), Otsuka Pharmaceutical (Owner)"		PO				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	OPC14523			27/07/2009	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800006668?userId=52029392&bpIds=3004037004&checksum=7af2f49073a4772c06f2d337cac81581081b06d0-1617045530305-5099cd02e87100badf8661ccae2db065badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028718	SEP 228425						Discontinued (I)	"Major depressive disorder, Pain"		"Adrenergic receptor antagonists, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"Sepracor (Originator), Sepracor (Owner)"		unspecified				"N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N06A (Antidepressants)"	"SEP225425, SEP228425"			14/07/2009	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800028718?userId=52029392&bpIds=3004037004&checksum=75514cdade0a7a3d456c906d37070f3d932297e3-1617045530305-6d710941ae9e7d6390d7403d44aa4ecdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022988	Research programme: transdermal NSAIDs - SK Drug Development Center						Discontinued (Preclinical)	Pain		Undefined mechanism	"SK Bio-Pharmaceuticals (Originator), SK Drug Development Center (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	YKPPN			10/07/2009	Pain				no		no							https://adis.springer.com/drugs/800022988?userId=52029392&bpIds=3004037004&checksum=4ecbb3cf2c44cd0cfab5d9a2925faffb264293b9-1617045530306-d6241e7c1016c6fc4af28031a3292495badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025997	Research programme: N-type calcium channel antagonists - Neuromed/Merck						Discontinued (Preclinical)	Pain		N type calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Neuromed Pharmaceuticals (Owner), Merck & Co (Collaborator)"		PO				N2 (Analgesics)	N02 (Analgesics)				16/06/2009	Pain				no		no							https://adis.springer.com/drugs/800025997?userId=52029392&bpIds=3004037004&checksum=6406d3290b73d3f4d6d18ff370527e4ca1644bb1-1617045530307-e070f14e0ec3a110de3c0cbda65d1105badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021347	Butorphanol intranasal						Discontinued (III)	"Pain, Migraine"		Opioid receptor agonists	"Ikano Therapeutics (Originator), Ikano Therapeutics (Owner)"		Intranasal				"N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"N02A (Opioids), N02A-F (Morphinan derivatives)"	Intranasal butorphanol spray			22/05/2009	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800021347?userId=52029392&bpIds=3004037004&checksum=f890eff19781418e5bba4dafb3cb385be2905141-1617045530308-776ff9028b971f1c0e2018e5aa24ae6bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020074	Research programme: neuropathic pain gene therapy - Avigen						Discontinued (Preclinical)	Neuropathic pain		Immunostimulants	"University of Colorado at Boulder (Originator), University of Colorado at Boulder (Owner), Avigen (Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	AV333			22/05/2009	Pain				no		no							https://adis.springer.com/drugs/800020074?userId=52029392&bpIds=3004037004&checksum=af16528d2ca339107777ffeb6b165228e460e167-1617045530309-eb0c3ae2ce893de22b1da7108a019f29badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025405	Research programme: neuropathic pain and drug abuse therapies - Avigen						Discontinued (Preclinical)	"Neuropathic pain, Opioid-related disorders"		"Glial cell modulators, Immunomodulators, Phosphoric diester hydrolase inhibitors"	"Avigen (Originator), Avigen (Owner)"		unspecified				"N2 (Analgesics), N7F (Drugs Used In Opioid Dependence)"	"N02 (Analgesics), N07B-C (Drugs used in opioid dependence)"				22/05/2009	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800025405?userId=52029392&bpIds=3004037004&checksum=a1bb96722d251e22f902bd48028aa043a224cbdf-1617045530309-273c788ffd10fd9177517b96a3aa28fabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027649	LU AA 37096						Discontinued (I)	"Pain, Mood disorders"		Undefined mechanism	"Lundbeck A/S (Originator), Lundbeck A/S (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"Lu AA37096, LUAA37096"			18/05/2009	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027649?userId=52029392&bpIds=3004037004&checksum=58ed7b06899dd060559ff3cafb8b7b710b4c71ba-1617045530310-abd4d4b954b1bff9f9e4c985cfe6b51ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016253	SSR 180575		"7-chloro-<EM>N</EM>-<EM>N</EM>,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4<EM>H</EM>-pyridazino[4,5-<EM>b</EM>]indole-1-acetamide"	Yes			No development reported (I)	"Rheumatic disorders, Heart failure, CNS disorders, Diabetic neuropathies"	C21 H19 Cl N4 O2	TSPO protein inhibitors	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		"unspecified, PO"				"C6A (Other Cardiovascular Products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N7X (All other CNS drugs), T1X (Other imaging agents)"	"C01E (Other Cardiac Preparations), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N07X (Other Nervous System Drugs), V04C-X (Other diagnostic agents)"	SSR180575			05/05/2009	"Diabetes, Heart Failure, Neurological Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800016253?userId=52029392&bpIds=3004037004&checksum=f30fb65264753d107a3deaf4a5110e595306c86e-1617045530311-ec0d2acc156a9f3345d9391f90944390badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028910	PF 3864086						Discontinued (I)	Pain		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	"PF03864086, PF3864086"			28/04/2009	Pain				no		no							https://adis.springer.com/drugs/800028910?userId=52029392&bpIds=3004037004&checksum=651abaeba351f9d4f3c154af659bebfeeb0a1769-1617045530312-e6a4fe2b8e4aed85856050ad4ebfa023badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027949	PF 2393296						Discontinued (I)	Pain		"Calcium channel antagonists, GABA receptor agonists"	"Pfizer (Originator), Pfizer (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	PF2393296			28/04/2009	Pain				no		no							https://adis.springer.com/drugs/800027949?userId=52029392&bpIds=3004037004&checksum=d85aecbbad389b62d1831dd98a9314be7751dbc1-1617045530313-58e9c0fa421999a7432d325e19b1e8ddbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020224	Research programme: ion channel modulators - Vertex Pharmaceuticals						Discontinued (Preclinical)	Pain		Ion channel modulators	"Vertex Pharmaceuticals (Originator), Vertex Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	VX409			20/04/2009	Pain				no		no							https://adis.springer.com/drugs/800020224?userId=52029392&bpIds=3004037004&checksum=3d0809d19d30a746616f661925e377a111e1a96e-1617045530313-b810ac03eeaecb321271933a8859c89dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800026153	metabotropic glutamate receptor 3 antagonist			No			Discontinued (II)	Migraine		Metabotropic glutamate receptor 3 antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	mGluR3 antagonist			31/03/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800026153?userId=52029392&bpIds=3004037004&checksum=4fa512169b8c379d27ef96301c2fa402d94a82eb-1617045530314-299f22eb9000a7dda6f3b2fb31e8c6dabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019647	Research programme: G protein-coupled receptor antagonists - Novasite Pharmaceuticals			No			Discontinued (Preclinical)	"Psychotic disorders, Autoimmune disorders, Obesity, Cancer, Pain"		G protein-coupled receptor antagonists	"Novasite Pharmaceuticals (Originator), Novasite Pharmaceuticals (Owner)"		unspecified				"A8 (Antiobesity Preparations, Excluding Dietetics), L1 (Antineoplastics), L4 (Immunosuppressants), N2 (Analgesics), N5A (Antipsychotics)"	"A08 (Antiobesity Preparations, Excl. Diet Products), L01 (Antineoplastic Agents), L04 (Immunosuppressants), N02 (Analgesics), N05A (Antipsychotics)"				30/03/2009	"Cancer, Immunological Disorders, Obesity, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800019647?userId=52029392&bpIds=3004037004&checksum=0a036cc70d89ea63bd1f55d3064ecf32b0d99f8d-1617045530315-db40e59f3e134d2b57cf1e0199441a98badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015556	Research programme: excitatory amino acid receptor modulators - Eli Lilly and Company		"(3S, 4aR, 6S, 8aR)-6-[2-(1H-Tetrazol-5-yl)phenoxy]-perhydroisoquinoline-3-carboxylic acid isobutyl ester hydrochloride"	No			Discontinued (Preclinical)	"Neurological disorders, Pain"	C21 H30 Cl N5 O3	"Excitatory amino acid agonists, Excitatory amino acid antagonists"	"Eli Lilly and Company (Originator), NPS Pharmaceuticals (Originator), Eli Lilly and Company (Owner), NPS Pharmaceuticals (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	"LY457691, LY458545, LY467711, LY525327"			27/03/2009	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015556?userId=52029392&bpIds=3004037004&checksum=0d73621463239c7241298d88d647bbd4920e4ea5-1617045530316-938ba6786faa036e26c49c7fda5ee8febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027266	Research programme: TRPV1 antagonists - Eli Lilly and Company			Yes			No development reported (Preclinical)	"Inflammation, Urinary incontinence, Pain"		TRPV1 receptor antagonists	"Glenmark Pharmaceuticals Ltd (Originator), Glenmark Pharmaceuticals Ltd (Owner), Eli Lilly and Company (Licensee)"		unspecified				"G4 (Urologicals), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"G04 (Urologicals), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"Transient receptor potential vanilloid subtype1 antagonists Eli Lilly and Company, VR1 antagonists Eli Lilly and Company"			24/03/2009	"Genitourinary Disorders, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800027266?userId=52029392&bpIds=3004037004&checksum=06b9a12abb83e225f61be25ee71a872a738e3f9e-1617045530317-1a5ffd802d510366892768f8e7542c9ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017078	SSR 240612		"[(2<EM>R</EM>)-2-[(3<EM>R</EM>)-3-(1,3-Benzodioxol-5-yl)-3-[[(6-methoxy-2-napthyl)sulfonyl]amino]propanoyl)amino]]-2-[[4-[(2<EM>R</EM>,6<EM>S</EM>)-2,6-dimethylpiperidinyl]methyl]phenyl]-<EM>N</EM>-isopropyl-<EM>N</EM>-methylpropanoylamide hydrochloride"				No development reported (II)	"Pain, CNS disorders, Inflammation, Neuropathic pain"		Bradykinin B1 receptor antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		PO				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	SSR240612			23/03/2009	"Inflammation, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800017078?userId=52029392&bpIds=3004037004&checksum=7c847e94588f39559bfeb771b8a076b7da69945d-1617045530318-604da319ee66df6f5451414da65eb909badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018675	Research programme: dopamine D3 receptor antagonists - sanofi-aventis			Yes			No development reported (Preclinical)	"Anxiety disorders, Schizophrenia, Alzheimer's disease, Substance-related disorders, Migraine"		Dopamine D3 receptor antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		unspecified				"N2C (Anti-Migraine Preparations), N5A (Antipsychotics), N7 (Other CNS Drugs), N7D (Anti-Alzheimer Products)"	"N02C (Antimigraine Preparations), N05A (Antipsychotics), N06D (Anti-Dementia Drugs), N07B (Drugs Used In Addictive Disorders)"	"MDL 815541, MDL 815994"			17/03/2009	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Anxiety Disorders, Drug Withdrawal, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800018675?userId=52029392&bpIds=3004037004&checksum=692be4d8ed120a939a7247c0d228b4db8ec72315-1617045530319-0324a1f0867ed3a40df8e67154fc2ee1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019150	Research programme: FAAH inhibitors - sanofi-aventis						No development reported (Preclinical)	"Anxiety disorders, Major depressive disorder, Pain"		Fatty acid amide hydrolase inhibitors	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		unspecified				"N2 (Analgesics), N5B (Hypnotics/Sedatives), N6A (Anti-Depressants and Mood Stabilisers)"	"N02 (Analgesics), N05B (Anxiolytics), N06A (Antidepressants)"				17/03/2009	"Affective Disorders, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800019150?userId=52029392&bpIds=3004037004&checksum=3046bb98c117f8467ac53dc74f28f9f80c70d0de-1617045530320-686be1d5e6f67f84657f36614f56db5cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027496	Research programme: fatty acid amide hydrolase inhibitors - Adolor Corporation						No development reported (Preclinical)	Inflammatory pain		Fatty acid amide hydrolase inhibitors	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	OL135			11/03/2009	Pain				no		no							https://adis.springer.com/drugs/800027496?userId=52029392&bpIds=3004037004&checksum=8531ec24971ab05bfd9f099ca10c7b2f7c526f62-1617045530321-e4bb76c80e17598ab799773fd85e9789badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027018	Research programme: nitric oxide synthase type II inhibitors - Adolor Corporation						No development reported (Preclinical)	"Inflammation, Neuropathic pain, Autoimmune disorders"		"Immunosuppressants, Nitric oxide synthase type II inhibitors"	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				"L4 (Immunosuppressants), N2 (Analgesics)"	"L04 (Immunosuppressants), N02 (Analgesics)"	"BBS2, iNOS dimerisation inhibitors Adolor Corporation, iNOS inhibitors Adolor Corporation"			11/03/2009	"Immunological Disorders, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800027018?userId=52029392&bpIds=3004037004&checksum=828207fcbf311d91f4e1ae86e0d9e937476edd50-1617045530322-3f05e465ba2891b0a71b0cda864edd84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017354	Bicifadine	66504-75-4	"3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, hydrochloride, (±)-,"				Discontinued (III)	"Pain, Osteoarthritis, Diabetic neuropathies"	C12 H15 N . H Cl	"Adrenergic receptor antagonists, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"Wyeth (Originator), Pfizer (Owner), DOV Pharmaceutical (Licensee), DOV Pharmaceutical - Elan Corporation (JV) (Collaborator)"		PO			"Nausea, Vomiting"	"A10X (Other Drugs Used in Diabetes), G4D4 (Urinary incontinence products), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), G04B-D (Drugs for urinary frequency and incontinence), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"CL 220075, DOV 220075"			02/03/2009	"Diabetes, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800017354?userId=52029392&bpIds=3004037004&checksum=dca9c095f927f34bbeded46a9c1249373ebfff17-1617045530323-102179adce9e69227e1d575afd184157badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800028889	AZD 1704						Discontinued (I)	Pain		Cannabinoid receptor CB1 agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AZD1704			17/02/2009	Pain				no		no							https://adis.springer.com/drugs/800028889?userId=52029392&bpIds=3004037004&checksum=80864c1e8684ae7c432f3371e8864ae2b9613dac-1617045530324-52fec03d278d1f46eaa184c7a6877086badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020730	Research programme: opioid receptor like-1 antagonists - Brane Discovery						Discontinued (Preclinical)	"Neuropathic pain, Parkinson's disease, CNS disorders"		"Opioid receptor antagonists, Adenylate cyclase stimulants, Calcium channel agonists, G protein-coupled receptor antagonists"	"GlaxoSmithKline (Originator), Brane Discovery (Owner)"		PO				"N2 (Analgesics), N4 (Anti-Parkinson Drugs), N7X (All other CNS drugs)"	"N02 (Analgesics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs)"	"819555, 848814, BND001, BND1 programme, GSK 819555, GSK 848814, NiK001, ORL1 orphan receptor antagonists, ORL1 programme, SB 612111"			11/02/2009	"Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800020730?userId=52029392&bpIds=3004037004&checksum=9de739acbc6bf305be344bb4bd71ceefcfc76853-1617045530325-cbec97d7a81b135e62c1cb10cce9b2d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020988	Fentanyl transdermal - Acrux	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (I)	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Acrux (Originator), Acrux (Owner), CSL (Market Licensee), KV Pharmaceutical Company (Licensee)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	Fentanyl MDTS			03/02/2009	"Drug Delivery Systems, Pain"			Fentanyl MDTS	no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800020988?userId=52029392&bpIds=3004037004&checksum=de5d251e89fd872c47c5bf091de208f8407d47ec-1617045530327-1b2ae7a877aead6b97ea0b3101a665acbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800027571	NSD 644						Discontinued (I)	"CNS disorders, Neuropathic pain"		"Adrenergic receptor antagonists, Dopamine uptake inhibitors, Serotonin uptake inhibitors"	"NeuroSearch (Originator), NeuroSearch (Owner), GlaxoSmithKline (Collaborator)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	NSD644			02/02/2009	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800027571?userId=52029392&bpIds=3004037004&checksum=35a0716a9208e53660d5f4898d6f30b4ffad161e-1617045530328-37ef8a59c40feb0d18a333ff22d6b944badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008912	BW 2378W92		"3-[_(R)-[4-Allyl-2(S), 5(R)-dimethylpiperazin-1-yl]-3-hydroxybenzyl]-N, N-diethylbenzamide"				Discontinued (Preclinical)	Pain	C27 H37 N3 O2	"Opioid delta receptor agonists, Opioid mu receptor agonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				05/01/2009	Pain				no		no							https://adis.springer.com/drugs/800008912?userId=52029392&bpIds=3004037004&checksum=523488107697d5a6ea2a42d6dff79a849cb7d1dc-1617045530328-2354c36e90402881277d050314c9ff8cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013934	BRL 56905	146993-12-6	"1H-Carbazole-6-carboxamide, 3-amino-2,3,4,9-tetrahydro-, monohydrochloride"				Discontinued (Preclinical)	Migraine	C13 H15 N3 O.Cl H	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"3Amino6carboxamido1234tetrahydrocarbazole, BRL56905"			05/01/2009	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013934?userId=52029392&bpIds=3004037004&checksum=43c28bfd49c0e232cd72f9bd6a09bb205bbc944e-1617045530329-33093c846703c960d89c8284f00a5db1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020509	Research programme: TRPV1 cation channel antagonists - Amgen		"1-[5-Chloro-6-[(<EM>R</EM>)-3-methyl-4-[6-(trifluoromethyl)-4-(3,4,5-trifluorophenyl)-1<EM>H</EM>-benzo[<EM>d</EM>]imidazol-2-yl]piperazin-1-yl]pyridin-3-yl]ethane-1,2-diol"				Discontinued (Preclinical)	Pain	C26 H22 Cl F6 N5 O2	TRPV cation channel antagonists	"Amgen (Originator), Amgen (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"AMG 0347, AMG 2674, AMG 8163, AMG 9810, AMG8562, TRPV1 cation channel antagonists Amgen"			08/12/2008	Pain				no		no							https://adis.springer.com/drugs/800020509?userId=52029392&bpIds=3004037004&checksum=fee67ad2bcc0376e74f985ddd52f845500ca38bf-1617045530330-8e6cdc10efe5df4db0d3d5c6060c81cbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013813	Research programme: alpha-2C adrenoceptor agonists - AstraZeneca						Discontinued (Preclinical)	Pain		Alpha 2c adrenoceptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Alpha2C adrenoceptor agonists research programme AstraZeneca			20/10/2008	Pain				no		no							https://adis.springer.com/drugs/800013813?userId=52029392&bpIds=3004037004&checksum=fc94460a1e5bd603ce535a16e69d71183a8720a7-1617045530331-1cb4a894f56957a3e88c3442b630c08ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025505	PF 738502						Discontinued (I)	Fibromyalgia		Undefined mechanism	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PF738502			03/10/2008	Rheumatic Disease				no		no							https://adis.springer.com/drugs/800025505?userId=52029392&bpIds=3004037004&checksum=ab79a086a409b56c19c31f499301891c1f22deee-1617045530332-4e602c1fcf2057f07a459d2bdf9fb8b7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021882	PD 217014						Discontinued (II)	"Postherpetic neuralgia, Irritable bowel syndrome, Overactive bladder"		Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), G4D4 (Urinary incontinence products), N2 (Analgesics)"	"A03A (Drugs for Functional Bowel Disorders), G04B (Urologicals), N02 (Analgesics)"	PD217014			12/09/2008	"Digestive System Disorders, Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800021882?userId=52029392&bpIds=3004037004&checksum=af33673d36c60a1d756005b015b86d15fe208ad0-1617045530333-ff7a0b6c925850ce9e422cfaea3d9450badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020507	Research programme: nerve growth factor inhibitors - Amgen			Yes			Discontinued (Preclinical)	Pain		Nerve growth factor inhibitors	"Amgen (Originator), Amgen (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				09/09/2008	Pain				no		no							https://adis.springer.com/drugs/800020507?userId=52029392&bpIds=3004037004&checksum=9de751a97009f4d7266fc5810b2ff5161f0b23e6-1617045530333-0a4190201aa0660f270a597013eb4ba6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013927	PNU 142633F		"2-Isochromane 6-methylamide, 1(<EM>S</EM>)-[2-[4-(4-aminocarbonylphenyl)piperidin-1-yl]ethyl]-, succinate"				Discontinued (II)	"Migraine, Headache, Cluster headache"	C24 H30 N4 O2 . C4 H6 O4	Serotonin 1D receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		PO		T<sub>_beta</sub> (h) (8 - 12 (Adult))		N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	PNU 142633			12/08/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013927?userId=52029392&bpIds=3004037004&checksum=efdbad66ab0121e41428e28a70a70d51bb3420d0-1617045530334-e401ca5eee1f2218a03ac3fe4bf02347badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015067	Naproxen sodium/metoclopramide			No			Discontinued (Registered)	Migraine		"Cyclooxygenase inhibitors, Dopamine receptor antagonists"	"POZEN (Originator), POZEN (Owner), Nycomed ApS (Market Licensee)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"Metoclopramide/naproxensodium, MT 100, Naproxensodium/metoclopramide"			08/07/2008	Advances in the Treatment of Nausea and Migraine			MT 100	no		no							https://adis.springer.com/drugs/800015067?userId=52029392&bpIds=3004037004&checksum=860130ee28944eab8362c86fd44885052dc5d727-1617045530335-f33162d09dacaf351a707fe8e90801b4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018003	M 40419						Discontinued (I)	Pain		Superoxide dismutase stimulants	"MetaPhore Pharmaceuticals (Originator), ActivBiotics (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	M40419			27/05/2008	Pain				no		no							https://adis.springer.com/drugs/800018003?userId=52029392&bpIds=3004037004&checksum=c9dae9540f15fc3606f4638c8c6b56f96554773f-1617045530336-5f69b7ed0353ef8d974934b762ac1801badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013030	Imisopasem manganese	218791-21-0	"Manganese, dichloro ((4a<EM>R</EM>,13a<EM>R</EM>,17a<EM>R</EM>,21a<EM>R</EM>)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-7<EM>H</EM>-dibenzo(<EM>b,h</EM>)(1,4,7,10)tetraazacycloheptadecine-_<EM>N</EM><SUP>5</SUP>,_<EM>N</EM><SUP>13</SUP>,_<EM>N</EM><SUP>18</SUP>,_<EM>N</EM><SUP>21</SUP>,_<EM>N</EM><SUP>22</SUP>)-,(PB-7-11-2344'3')-"	Yes			Discontinued (II)	"Pain, Cancer pain, Postoperative pain, Stomatitis, Cancer"	C21 H35 Cl2 Mn N5	Superoxide dismutase stimulants	"MetaPhore Pharmaceuticals (Originator), MetaPhore Pharmaceuticals (Owner), ActivBiotics (Licensee)"		"IV, unspecified"				"A16 (Other Alimentary Tract and Metabolism Products), L1 (Antineoplastics), N2 (Analgesics)"	"A16 (Other Alimentary Tract and Metabolism Products), L01 (Antineoplastic Agents), N02 (Analgesics)"	"M 40403, Superoxide dismutase mimic MetaPhore"			27/05/2008	"Cancer, Mouth Disorders, Pain"	"Mucositis (European Union), Mucositis (USA)"			no		no							https://adis.springer.com/drugs/800013030?userId=52029392&bpIds=3004037004&checksum=6cec2ab66e4d102a8f5dd30f666da858fb0d418e-1617045530337-435b48afda136bd01f6a7689999e700fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013092	CS 502						Discontinued (II)	"Pain, Inflammation"		Cyclo-oxygenase 2 inhibitors	"Daiichi Sankyo Company (Originator), Daiichi Sankyo Company (Owner)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"	CS502			12/05/2008	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800013092?userId=52029392&bpIds=3004037004&checksum=0d62b65b7758e045e40a092c1458fbeafac22b30-1617045530338-80bb0223dbd4894e275d2659bc1f0fc3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016381	VANH 36						Discontinued (I)	Pain		Opioid receptor agonists	"Vita (Originator), Vita (Owner)"		"PO, IV"				N2A (Narcotics)	N02A-X (Other opioids)				08/05/2008	Pain				no		no							https://adis.springer.com/drugs/800016381?userId=52029392&bpIds=3004037004&checksum=8c7441c2fd11e0d8b0c8b879fc1d9af42f4d8347-1617045530339-90ad54a92b46a8f1893918826c192556badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012898	CGX 1160		Pyro-glutamate-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro-Tyr-Ile-Leu-OH				Discontinued (I)	Neuropathic pain	C88 H140 N20 O37	Neurotensin type 1 receptor agonists	"Cognetix (Originator), Cognetix (Owner), Salk Institute (Technology Provider), University of Utah (Technology Provider)"		Intrathecal				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)	ContulakinG			29/04/2008	Pain	Neuropathic pain (USA)			no		no							https://adis.springer.com/drugs/800012898?userId=52029392&bpIds=3004037004&checksum=3ce644f85987def6c5538ac37cdc47f214544986-1617045530340-7485a7716fe3d6c20ca350a2f35e7380badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015086	Research programme: conopeptide analgesics - Cognetix						Discontinued (Preclinical)	Pain			"University of Utah (Originator), University of Utah (Owner), Cognetix (Licensee)"		Parenteral				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Conopeptide analgesics research programme Cognetix			29/04/2008	Pain				no		no							https://adis.springer.com/drugs/800015086?userId=52029392&bpIds=3004037004&checksum=403dd9d896e0e8ff1d11f3c91c1207410e31d9a4-1617045530340-3d4496fe7de271efff8b5d49ae5a9f3fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013209	Research programme: nicotinic agonists - Cognetix						Discontinued (Preclinical)	Pain		Nicotinic receptor agonists	"Salk Institute (Originator), University of Utah (Originator), Salk Institute (Owner), University of Utah (Owner), Cognetix (Licensee)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"CGX 1204, Nicotinic agonists research programme Cognetix"			29/04/2008	Pain				no		no							https://adis.springer.com/drugs/800013209?userId=52029392&bpIds=3004037004&checksum=680b6ab0f0d2a44c9448f64844b23f1728b8c7b6-1617045530341-d72f7299c881a4b68e5868659a0c7541badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021012	TC 2696						Discontinued (II)	Pain		Nicotinic receptor agonists	"Targacept (Originator), Targacept (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	TC2696			21/04/2008	Pain				no		no							https://adis.springer.com/drugs/800021012?userId=52029392&bpIds=3004037004&checksum=d6d19a560147f0647e1a6776ec61651dadff6cdf-1617045530342-3b4dfa6873c01eaa570c8cf048a843fdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018292	MCI 225						Discontinued (Preclinical)	"Stress incontinence, Pain, Irritable bowel syndrome"		"Adrenergic receptor antagonists, Serotonin 3 receptor antagonists, Serotonin uptake inhibitors"	"Mitsubishi Chemical (Originator), Mitsubishi Tanabe Pharma Corporation (Owner), Arachnova (Licensee)"		unspecified				"A3 (Functional Gastro-Intestinal Disorder Drugs), G4 (Urologicals), N2 (Analgesics)"	"A03A (Drugs for Functional Bowel Disorders), G04 (Urologicals), N02 (Analgesics)"	"AA 10021, AA 10025, AA 10026"			02/04/2008	"Digestive System Disorders, Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800018292?userId=52029392&bpIds=3004037004&checksum=df22f46aaaf5b91cdf1417cb310874bd697264af-1617045530343-9d0fc3cfa9e5d3faa7f2a3152d08d706badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800024143	Research programme: cannabinoid receptor CB1 modulators - Predix Pharmaceuticals						Discontinued (Preclinical)	"Obesity, Pain"		"Cannabinoid receptor CB1 antagonists, Cannabinoid receptor CB1 agonists"	"EPIX Pharmaceuticals (Originator), EPIX Pharmaceuticals (Owner)"		unspecified				"A8 (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics)"	"A08 (Antiobesity Preparations, Excl. Diet Products), N02 (Analgesics)"				28/03/2008	"Obesity, Pain"				no		no							https://adis.springer.com/drugs/800024143?userId=52029392&bpIds=3004037004&checksum=1d50956bac03584c094522d24a132a0ba717e597-1617045530344-bf244614b56f17d66b992e3fd9d1b775badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010244	Prosaptide TX14 A			Yes			Discontinued (II)	"Diabetic neuropathies, Neuropathic pain"		Neuron stimulants	"Myelos Corporation (Originator), Myelos Corporation (Owner)"		SC				"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics)"	"Prosaposinderived peptide, Prosaptide"			26/03/2008	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800010244?userId=52029392&bpIds=3004037004&checksum=11281bceb8a4cff4f1e17790a6a6036daeee3a6e-1617045530344-b156184861e0ef60c4114615969926a6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016553	Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor						Discontinued (Preclinical)	"Schizophrenia, Neuropathic pain, Cognition disorders, Psychotic disorders, CNS disorders"		"Muscarinic M1 receptor agonists, Muscarinic receptor agonists, Muscarinic receptor antagonists"	"ACADIA Pharmaceuticals (Originator), Sepracor (Originator), ACADIA Pharmaceuticals (Owner), Sepracor (Owner), Sepracor (Licensee)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics), N6D (Nootropics), N7X (All other CNS drugs)"	"N02 (Analgesics), N05A (Antipsychotics), N06B (Psychostimulants, agents used for ADHD and nootropics), N07X (Other Nervous System Drugs)"	"108LM3936, AC 90987, AC260584"			26/03/2008	"Alzheimer's Disease and Cognition Disorders, Neurological Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800016553?userId=52029392&bpIds=3004037004&checksum=4228efad415cfd82de4f099b87e9c965c4fc744b-1617045530346-cb351901fc92855e65ac5d4e0dadca78badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015538	FYK 1258						Discontinued (Preclinical)	Pain		Opioid mu receptor agonists	"Daiichi Fine Chemical (Originator), Daiichi Fine Chemical (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				25/03/2008	Pain				no		no							https://adis.springer.com/drugs/800015538?userId=52029392&bpIds=3004037004&checksum=6fb1e6bbc49ed38e6fb551205e00b95ba8124ba6-1617045530346-ac58cbd6f63ec853d94eceb8953d5100badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016514	NMED 427						Discontinued (Preclinical)	Migraine		Calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Neuromed Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				25/03/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800016514?userId=52029392&bpIds=3004037004&checksum=6d3fd04e67b182362139c540cf8f535ed0b0ad77-1617045530347-ea5a7b49832aa9c59cd8c94f932c06e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016516	NMED 826						Discontinued (Preclinical)	Migraine		Calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Neuromed Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				25/03/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800016516?userId=52029392&bpIds=3004037004&checksum=b326dd12ce7a970921b07dcb4b6043fd2e7ee0d6-1617045530348-af9d73526a0e1af719964fb5558fb3e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016515	NMED 724						Discontinued (Preclinical)	Migraine		Calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Neuromed Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				25/03/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800016515?userId=52029392&bpIds=3004037004&checksum=eab0d1ad1db274dfde10f743eebc3a7027abfcaf-1617045530348-d4fae05e5c635b96ea28a5a3f9ebeb54badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016714	NMED 126			Yes			Discontinued (Preclinical)	"Epilepsy, Pain, Anxiety disorders"		Calcium channel antagonists	"Neuromed Pharmaceuticals (Originator), Neuromed Pharmaceuticals (Owner), Merck & Co (Market Licensee)"		unspecified				"N2 (Analgesics), N3 (Anti-Epileptics)"	"N02 (Analgesics), N03 (Antiepileptics)"				25/03/2008	"Anxiety Disorders, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800016714?userId=52029392&bpIds=3004037004&checksum=343f1d46cd67bb499e6d790fd8637c0a711fc15a-1617045530349-def86f98b42e404b1e5f419c980ca033badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018635	Research programme: cyclo-oxygenase-2 inhibitors - NitroMed						Discontinued (Preclinical)	"Pain, Inflammation"		Cyclo-oxygenase 2 inhibitors	"NitroMed (Originator), NitroMed (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"COX2 inhibitors research programme NitroMed, Cyclooxygenase2 inhibitors research programme NitroMed, Research programme COX2 inhibitors NitroMed"			19/03/2008	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800018635?userId=52029392&bpIds=3004037004&checksum=509bef02d9400aa57c7cbc94dd60b26e0831fc0c-1617045530350-c90fe58e1531197d9affbf14ffd5ff5dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020060	Research programme: nitric oxide-based COX-2 inhibitors and NSAIDs - NitroMed						Discontinued (Preclinical)	"Pain, Inflammation"		"Cyclo-oxygenase 2 inhibitors, Nitric oxide donors"	"NitroMed (Originator), NitroMed (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"NMI 150, NMI 153, NMI 159, NMI 161, NMI 172, NMI 377, NMI1182"			19/03/2008	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800020060?userId=52029392&bpIds=3004037004&checksum=1de5bfb9871bc69632572c0a6567bf7d0cf0eb48-1617045530351-b99b543dc8a8de12d61c0d231f8e45afbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006732	NCX 4016	175033-36-0	3-(Nitrooxymethyl)phenyl 2-acetoxybenzoate				Discontinued (II)	"Peripheral arterial occlusive disorders, Type 2 diabetes mellitus, Pain"	C16 H13 N O7	"Cyclooxygenase inhibitors, Nitric oxide donors, Nitric oxide stimulants, Platelet aggregation inhibitors"	"NicOx (Originator), NicOx (Owner)"		PO				"A10X (Other Drugs Used in Diabetes), B1C (Platelet Aggregation Inhibitors), C1X (All Other Cardiac Preparations), C6A (Other Cardiovascular Products), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), B01A-C (Platelet aggregation inhibitors excl. heparin), C (Cardiovascular System), C01E-B (Other cardiac preparations), N02B (Other Analgesics and Antipyretics)"	"NOASA, NOaspirin"			19/03/2008	"Diabetes, Pain, Thromboses, Vascular Disorders"				no		no		"T-box 1, tumor protein, translationally-controlled 1"	"hemoglobin subunit gamma 2, Prostacyclin, tumor protein, translationally-controlled 1"	"8-oxo-7-hydrodeoxyguanosine, BNP, choroideremia (Rab escort protein 1), chromodomain helicase DNA binding protein 7, CKB, CKM, CRP, Endothelin 1, Haptoglobin, hemoglobin subunit gamma 2, Hemopexin, IFN-gamma, IL10, IL6, IL8, Inosine, Insulin, Nitric Oxide, PGE2, Prostacyclin, S100B, TNF-alpha, troponin I, cardiac, Troponin T, cardiac, tumor protein, translationally-controlled 1, VEGF-A, VEGF-C"		"Creatinine, IL12A, IL12B, IL2, Thrombin"	https://adis.springer.com/drugs/800006732?userId=52029392&bpIds=3004037004&checksum=82b8ea77c1f35959f6f0a920d94818fe9f6d8803-1617045530353-58f033a052ef5d8b9f68d78f9831687ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015165	GPI 5693			Yes			Discontinued (I)	"Diabetic neuropathies, Neuropathic pain, Prostate cancer, Amyotrophic lateral sclerosis, Glaucoma, Cerebral ischaemia"		Glutamate carboxypeptidase II inhibitors	"MGI GP (Originator), MGI GP (Owner), Pfizer (Market Licensee)"		PO				"A10X (Other Drugs Used in Diabetes), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"				17/03/2008	"Cancer, Diabetes, Eye Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015165?userId=52029392&bpIds=3004037004&checksum=0723b83ea6113d73d941494dbb7f955cfd752689-1617045530354-3fdc32aceb657b6c43a910480d67bd2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015919	Oxycodone - ALZA Corporation	124-90-3	"4,5_-Epoxy-14_-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride"	No			Discontinued (Clinical)	Pain	C18 H21 N O4 . H Cl	"Opioid delta receptor agonists, Opioid kappa receptor agonists, Opioid mu receptor agonists"	"ALZA Corporation (Originator), ALZA Corporation (Owner)"		PO				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	OROS oxycodone			03/03/2008	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800015919?userId=52029392&bpIds=3004037004&checksum=1ac7753380fe7f502517e94bdbe4063017b57866-1617045530355-1b41d7eea23866c8df460ed3e079d38cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009622	MRZ 2/571			Yes			Discontinued (Preclinical)	"Pain, Stroke"		Glycine gated NMDA receptor antagonists	"Merz Pharma (Originator), Merz Pharma (Owner)"		unspecified				"N2A (Narcotics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				28/02/2008	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009622?userId=52029392&bpIds=3004037004&checksum=224f61611b62b1dfc3c11a5752b150f4a60052ca-1617045530356-5938fb623db5cc71c704f4f576493091badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025781	Selective adrenergic uptake inhibitor - Neurocrine						Discontinued (I)	"Psychiatric disorders, Neuropathic pain, Urinary incontinence"		Adrenergic uptake inhibitors	"Neurocrine Biosciences (Originator), Neurocrine Biosciences (Owner)"		unspecified				"G4 (Urologicals), N2 (Analgesics), N7X (All other CNS drugs)"	"G04 (Urologicals), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"Selective norepinephrine reuptake inhibitor Neurocrine, sNRI Neurocrine Biosciences"			28/02/2008	"Genitourinary Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800025781?userId=52029392&bpIds=3004037004&checksum=45585aee507ac0651a426bc8388c21bdef92dd4d-1617045530356-9ec5f18cf4582dadd9ec76df04f361eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009621	MRZ 2/576						Discontinued (Preclinical)	"Stroke, Pain"		NMDA receptor antagonists	"Merz Pharma (Originator), Merz Pharma (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				28/02/2008	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009621?userId=52029392&bpIds=3004037004&checksum=be552e607e0fb3ea5976e2eb2889b21cd6988d7d-1617045530357-635ae32889d91ba4033acfd263236a3ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009608	MRZ 2/570			Yes			Discontinued (Preclinical)	Pain		Glycine gated NMDA receptor antagonists	"Merz Pharma (Originator), Merz Pharma (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/02/2008	Pain				no		no							https://adis.springer.com/drugs/800009608?userId=52029392&bpIds=3004037004&checksum=d9240947ecc31f8f336f280f8f9f02e9fcc09b76-1617045530358-dd192ebdd850744631bd27bafc5f763fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021121	SRN 002						Discontinued (II)	Migraine		"Serotonin 1B receptor antagonists, Serotonin 1D receptor antagonists"	"KeyNeurotek AG (Originator), KeyNeurotek AG (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"Intranasal migraine therapeutic Sirenade, SRN002"			26/02/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800021121?userId=52029392&bpIds=3004037004&checksum=9093e0080fb182c608e78cb2e7087fe075ba7417-1617045530359-201d3908c2c6b527e5143a32ade7f2ccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021116	SRN 001						Discontinued (II)	"Parkinson's disease, Alzheimer's disease, Migraine"		Undefined mechanism	"KeyNeurotek AG (Originator), KeyNeurotek AG (Owner)"		unspecified				"N2C (Anti-Migraine Preparations), N4A (Anti-Parkinson Drugs), N6D (Nootropics)"	"N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs), N06D (Anti-Dementia Drugs)"	SRN001			26/02/2008	"Advances in the Treatment of Nausea and Migraine, Alzheimer's Disease and Cognition Disorders, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800021116?userId=52029392&bpIds=3004037004&checksum=7a3ee4c12b6ea04f2dd846e27519e958c6d81654-1617045530360-4c2c91dbf4630123c0458fd2fa8180e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000913	Devazepide	103420-77-5	"1H-Indole-2-carboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (S)-"				Discontinued (II)	"Neuropathic pain, Peptic ulcer, Anxiety disorders, Cancer"	C25 H20 N4 O2	Cholecystokinin A receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner), Panos Therapeutics (Market Licensee)"		"PO, unspecified"				"A2B9 (All other antiulcerants), L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics), N5B (Hypnotics/Sedatives)"	"A02X (Other Drugs for Acid Related Disorders), L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics), N05B (Anxiolytics)"	"Devacade, L 364718, MK 329"			22/02/2008	"Anxiety Disorders, Cancer, Pain, Peptic Ulcer Disease"			Devacade	no		no							https://adis.springer.com/drugs/800000913?userId=52029392&bpIds=3004037004&checksum=5677ccd7d63f2f0bf6ed420a40e2d32145c22107-1617045530361-c3e13cf633dd2f5304fb8965d54b1f30badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015991	Research programme: NAALADase inhibitors - MGI GP			Yes			Discontinued (Preclinical)	"Neuropathic pain, Substance-related disorders, Neurodegenerative disorders, Prostate cancer"		Glutamate carboxypeptidase II inhibitors	"MGI GP (Originator), MGI GP (Owner)"		unspecified				"L1 (Antineoplastics), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"L01 (Antineoplastic Agents), N02B (Other Analgesics and Antipyretics), N07B (Drugs Used In Addictive Disorders), N07X (Other Nervous System Drugs), S01X-A (Other ophthalmologicals)"	"2MPPA, GPI 16476, GPI 16477, Small molecule presynaptic glutamate inhibitors"			20/02/2008	"Cancer, Drug Withdrawal, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800015991?userId=52029392&bpIds=3004037004&checksum=d0824ec5f855649b918df903cb2d99d394d87763-1617045530362-229eecb5734d6c716d3531524813fd4abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022176	C 8928						Discontinued (I)	Pain		Undefined mechanism	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	C8928			18/02/2008	Pain				no		no							https://adis.springer.com/drugs/800022176?userId=52029392&bpIds=3004037004&checksum=c172539f7472560b83d81ea514c2dd1cd2728b00-1617045530363-c0985ca81f582a77b1c88e0bb3427832badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022178	C 6740						Discontinued (I)	Pain		Undefined mechanism	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	C6740			18/02/2008	Pain				no		no							https://adis.springer.com/drugs/800022178?userId=52029392&bpIds=3004037004&checksum=787c62603f1036988c982bdc52f8b3d20587f8d7-1617045530363-8a1a9b259b5ab997668e1d9d1514abf7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022180	C 1246						Discontinued (I)	Pain		Undefined mechanism	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	C1246			14/02/2008	Pain				no		no							https://adis.springer.com/drugs/800022180?userId=52029392&bpIds=3004037004&checksum=394e3a952a5c432256520c4306e0cd3b4f6a560b-1617045530364-4f92869f783de0acc163a58b78e4536ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022777	Research programme: G protein-coupled receptor modulators - Paradigm Therapeutics/Ortho-McNeil Pharmaceuticals						Discontinued (Preclinical)	"Urinary incontinence, Pain, Migraine"		G protein-coupled receptor modulators	"Ortho-McNeil (Originator), Paradigm Therapeutics (Originator), Ortho-McNeil (Owner), Paradigm Therapeutics (Owner)"		unspecified				"G4D4 (Urinary incontinence products), N2 (Analgesics)"	"G04 (Urologicals), N02 (Analgesics)"				12/02/2008	"Advances in the Treatment of Nausea and Migraine, Genitourinary Disorders, Pain"				no		no							https://adis.springer.com/drugs/800022777?userId=52029392&bpIds=3004037004&checksum=66a6de89bf6f954d063a2897ca6e3e837f16fe9e-1617045530365-8e7640ee350a7c02ec622556ded9541abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019624	Research programme: transdermal anti-emetic therapy - NexMed						Discontinued (Preclinical)	"Pain, Nausea and vomiting"		Undefined mechanism	"NexMed (Originator), NexMed (Owner)"		Topical				"A4A (Antiemetics and Antinauseants), N2 (Analgesics)"	"A04A (Antiemetics and Antinauseants), N02 (Analgesics)"	"Antiemetic patch NexMed, NM 10065, NM 10066"			11/02/2008	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800019624?userId=52029392&bpIds=3004037004&checksum=b29d8ec6a23e2a57d6d42df4d7b939ed798b455a-1617045530366-2ecb6c1091a1b06113b013381ee7b54cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003663	Xorphanol	77287-89-9	17-Cyclobutylmethyl-3-hydroxy-6- methylene-8_-methylmorphinan				Discontinued	Pain	C23 H31 N O	Opioid kappa receptor agonists	"HG Pars (Originator), HG Pars (Owner)"		PO			"Asthenia, Dizziness, Drowsiness, Flushing"	N2A (Narcotics)	N02A (Opioids)	"TR 5379, TR 5379M"			08/02/2008	Pain				no		no							https://adis.springer.com/drugs/800003663?userId=52029392&bpIds=3004037004&checksum=2b285abd98a9e87352f2777a1479af3edf309fb1-1617045530367-15851a57b60699fb002ff690b23499bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003300	Conorfone	72060-05-0	"17-Cyclopropylmethyl-4, 5_-epoxy-8_-ethyl-3-methoxymorphinan-6-one hydrochloride"				Discontinued	Pain	C23 H29 N O3 . H Cl	"Opioid receptor agonists, Opioid receptor antagonists"	"HG Pars (Originator), HG Pars (Owner)"		PO			"Asthenia, Dizziness, Drowsiness, Flushing"	N2A (Narcotics)	N02A (Opioids)	"Codorphone hydrochloride, HGP 10, TR 5109"			08/02/2008	Pain				no		no							https://adis.springer.com/drugs/800003300?userId=52029392&bpIds=3004037004&checksum=5ac8ea9b0027c3367c6261391bab23a572ebe128-1617045530368-6f3f966f03a1d258110c54f01da4cd79badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013111	ZM 325802						Discontinued (Preclinical)	Pain		Prostaglandin E1 antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				08/02/2008	Pain				no		no							https://adis.springer.com/drugs/800013111?userId=52029392&bpIds=3004037004&checksum=e317e40f582d29cae6e7185fefae621a82167dfa-1617045530368-2fc3d2b3f680679cd28ca0d1e3a704d1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003749	Nabitan	66556-74-9	"8-(1,2-Dimethylheptyl)-1,3,4,5-tetrahydro-5,5-dimethyl- 2-(2-propynyl)-2H-[1]benzopyrano[4,3-c]pyridin-10-yl ester 1-piperidinebutanoic acid monohydrochloride"				Discontinued	"Pain, Nausea and vomiting"		Undefined mechanism	"HG Pars (Originator), HG Pars (Owner)"		PO				"A4A (Antiemetics and Antinauseants), N2 (Analgesics)"	"A04A-D (Other antiemetics), N02 (Analgesics)"	"HGP 4, SP 106"			08/02/2008	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800003749?userId=52029392&bpIds=3004037004&checksum=4a3f5d9284de2efc43e494d4eeb485f6eade68c6-1617045530369-1c880099f884b9441c37d51c3355ce0cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020378	Research programme: cannabinoid receptor agonists - MakScientific/Endo Pharmaceuticals						Discontinued (Preclinical)	"CNS disorders, Pain"		Cannabinoid receptor CB2 agonists	"MakScientific (Originator), MakScientific (Owner), Endo Pharmaceuticals (Licensee)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				07/02/2008	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020378?userId=52029392&bpIds=3004037004&checksum=1d0cfa2f752efc112d42604606604a68e47a3704-1617045530370-6d4576c262239812afd121e2b2063db0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021835	Research programme: intranasal therapeutics - West Pharmaceuticals						Discontinued (Preclinical)	"Pain, Nausea and vomiting, Insomnia"		"Lipoxygenase-cyclooxygenase inhibitors, Serotonin receptor antagonists, GABA A receptor agonists"	"West Pharmaceutical Services (Originator), West Pharmaceutical Services (Owner)"		Intranasal				"A4A (Antiemetics and Antinauseants), N2 (Analgesics), N5B (Hypnotics/Sedatives)"	"A04A-A (Serotonin (5HT3) antagonists), N02 (Analgesics), N05C (Hypnotics and Sedatives)"	"Granisetron intranasal West Pharmaceuticals, Ketoprofen intranasal West Pharmaceuticals, Morphine6glucuronide intranasal West Pharmaceuticals, NSAID intranasal West Pharmaceuticals, Zolpidem intranasal West Pharmaceuticals"			04/02/2008	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800021835?userId=52029392&bpIds=3004037004&checksum=ed050b94c7bcb3dfcf4be5fdcd9cbfd4fa31def1-1617045530371-23ded969d18f2a7b2a4c0b67f18cbcfebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009725	Hydrocodone/paracetamol/dextromethorphan						Discontinued (II)	"Postoperative pain, Musculoskeletal pain"		"NMDA receptor antagonists, Opioid receptor agonists, Prostaglandin receptor antagonists"	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner)"		unspecified				"N2A (Narcotics), N2B (Non-Narcotics and Anti-Pyretics)"	"N02A (Opioids), N02B (Other Analgesics and Antipyretics)"	"EN3232, HydrocoDex SR"			30/01/2008	Pain			HydrocoDex SR	no		no							https://adis.springer.com/drugs/800009725?userId=52029392&bpIds=3004037004&checksum=6d995c63fe28af076de210ba10608531246efbff-1617045530372-beb77995b3eb9710323c70ae0e2661febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014370	Dextromethorphan/methadone - Endo						Discontinued (II)	Heroin-related disorders		"NMDA receptor antagonists, Opioid mu receptor agonists"	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner)"		unspecified				N2A (Narcotics)	N02A-C (Diphenylpropylamine derivatives)	"Methadex, Methadone/dextromethorphan"			30/01/2008	Drug Withdrawal			Methadex	no		no							https://adis.springer.com/drugs/800014370?userId=52029392&bpIds=3004037004&checksum=c47bff02c3b896ab318821301649e107d45cffd3-1617045530373-1db080e61442544469b1241e62d0e294badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011734	DUP 747	115904-76-2	"<EM>trans</EM>-3, 4-Dichloro-<EM>N</EM>-(5-methoxy-2-(pyrrolidin-1-yl)-1, 2, 3, 4-tetrahydronaphth-1-yl)-<EM>N</EM>-methylbenzeneacetamide methanesulfonate"				Discontinued (Preclinical)	"Postoperative pain, Cancer pain"	C24 H28 N2 Cl2 O2 . C H4 O3 S	Opioid kappa receptor agonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Endo Pharmaceuticals (Collaborator)"		unspecified				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				30/01/2008	Pain				no		no							https://adis.springer.com/drugs/800011734?userId=52029392&bpIds=3004037004&checksum=a3bdfb80ac82a7c3c7a41769313aebe12a0e7d82-1617045530373-7707d0357e2bc9641b7bef24d62acf0dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003768	DUP 631		"4-(2,3-Dihydrothiophen-3-yl)-4-(2-hydroperoxypropan-2-yl)-1-methylpiperidine"				Discontinued (Preclinical)	Pain	C13 H23 N O2 S	Serotonin uptake inhibitors	"Bristol-Myers Squibb (Originator), Endo Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				30/01/2008	Pain				no		no							https://adis.springer.com/drugs/800003768?userId=52029392&bpIds=3004037004&checksum=735b41425bbc1c278505a0c6c9a98d3ec44558a2-1617045530374-608731d68bbceb9db40603b9352704aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020071	MH 15E	52-26-6					No development reported (Registered)	Cancer pain	C17 H19 N O3. HCl	Opioid mu receptor agonists	"Daiichi Sankyo Company (Originator), Dainippon Sumitomo Pharma (Originator), Shionogi (Originator), Takeda (Originator), Tanabe Seiyaku (Originator), Daiichi Sankyo Company (Owner), Dainippon Sumitomo Pharma (Owner), Shionogi (Owner), Takeda (Owner), Tanabe Seiyaku (Owner)"		Epidural				N2A (Narcotics)	N02A-A (Natural opium alkaloids)	"MH15E, Morphine hydrochlorideextradural"			29/01/2008	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800020071?userId=52029392&bpIds=3004037004&checksum=113bc6ec2c3c31b3e89bdd3d73ebaf19ff13bff8-1617045530450-5ffd376ede7eac545fa5383803d70780badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023252	Research programme: metabotropic glutamate receptor antagonists - Banyu			Yes			Discontinued (Preclinical)	"Anxiety disorders, Pain, Neurological disorders"		Metabotropic glutamate receptor antagonists	"Banyu (Originator), Banyu (Owner)"		unspecified				"N2 (Analgesics), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"N02 (Analgesics), N03A (Antiepileptics), N07X-X (Other nervous system drugs)"				24/01/2008	"Anxiety Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800023252?userId=52029392&bpIds=3004037004&checksum=19ffec8cbd0464400e6dbf8a400f3de7d8797aa2-1617045530451-6535f28073c6368bd39070c70145de73badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009464	L 783003		"3, 4-Dihydrofuran-5-one, 2, 2-dimethyl-3-[(4-methylsulfonyl)phenyl]-4-phenyl-,"				Discontinued (II)	"Migraine, Inflammation"	C19 H18 O4 S	Cyclo-oxygenase 2 inhibitors	"Merck & Co (Originator), Merck & Co (Owner)"		"unspecified, PO"				"M1A3 (Coxibs, plain), N2C (Anti-Migraine Preparations)"	"M01A-H (Coxibs), N02C (Antimigraine Preparations)"				23/01/2008	"Advances in the Treatment of Nausea and Migraine, Inflammation"				no		no							https://adis.springer.com/drugs/800009464?userId=52029392&bpIds=3004037004&checksum=20907dc839ab3553b8de54c81b222b85f5f7b156-1617045530453-a94a04ace56156e41dbbc2de04cae383badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009132	L 775606		"5-(1,2,4-Triazol-4-yl)-3-[[(4-phenethyl)piperazin-1-yl]propyl]-1<EM>H</EM>-indole"				Discontinued (Preclinical)	Migraine	C25 H29 F N6		"Merck Sharp & Dohme (Originator), Merck Sharp & Dohme (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				23/01/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800009132?userId=52029392&bpIds=3004037004&checksum=c363be684eca3e64afbbcd97d070ff00c7099c58-1617045530454-9717246c96c2be2b9ea8dec7403276f4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001138	L 365260	118101-09-0	"Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)-"				Discontinued (II)	"Peptic ulcer, Pain, Anxiety disorders"	C24 H22 N4 O2	Cholecystokinin B receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		PO	biliary	"Active Metabolites (no), Linear Kinetics (yes), Route of Elimination (biliary), protein binding (%) (96 (Adult)), T<sub>_beta</sub> (h) (8 - 12 (Adult)), T<sub>max</sub> (h) (1 - 1.5 (Adult))"		"A2B9 (All other antiulcerants), N2 (Analgesics), N5C (Tranquillisers)"	"A02X (Other Drugs for Acid Related Disorders), N02 (Analgesics), N05B-X (Other anxiolytics)"				23/01/2008	"Anxiety Disorders, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800001138?userId=52029392&bpIds=3004037004&checksum=df643129b0838fc3da6be29ab0a911a46b2cf2f6-1617045530455-8bfd791867970defe334c5b79c332bb8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015959	ARM 434		"<EM>N,N</EM>-Diethyl-4-[1-(8-quinolyl)-1-(1-piperazinyl)methyl]benzamide"				Discontinued (Preclinical)	Pain	C25 H30 N4 O	Opioid delta receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				21/01/2008	Pain				no		no							https://adis.springer.com/drugs/800015959?userId=52029392&bpIds=3004037004&checksum=cae1380581d1f541a252ad43ce91bd6a02d067e6-1617045530456-9618317101560e1165eee0126b8c8788badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006887	SNC 80	156727-74-1	"(+)-4-[(aR)-a((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)- 3-methoxybenzyl]-N,N-diethylbenzamide"				Discontinued (Preclinical)	Pain	C28 H39 N2 O2	Opioid delta receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				21/01/2008	Pain				no		no							https://adis.springer.com/drugs/800006887?userId=52029392&bpIds=3004037004&checksum=42b920fbbaff5e1004e28d0291fad544d913c4ae-1617045530457-d17512e5e6e07e7975027c0c74350e61badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020794	GW 273629		"<EM>S</EM>-[2-[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine"				Discontinued (I)	Migraine	C7 H15 N3 O4 S	Nitric oxide synthase type II inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	"273629, GSK 273629, GW273629"			21/01/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800020794?userId=52029392&bpIds=3004037004&checksum=4825375515e4b78e659a7ee5099657e8f02debc0-1617045530458-2c2f124669e1bb09341c2ea67bd835fbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014971	2-BFI		2-(2-Benzofuranyl)-2-imidazoline				Discontinued (Preclinical)	Pain	C11 H10 N2 O	Imidazoline receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/01/2008	Pain				no		no							https://adis.springer.com/drugs/800014971?userId=52029392&bpIds=3004037004&checksum=f3b3b52e076c243676a059a6c99b48d594b03f35-1617045530459-7711417905c2282d112554549d12c907badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014975	ARM 390		"<EM>N, N</EM>-Diethyl-4-(phenylpiperidine-4-ylidene-methyl)benzamide"				Discontinued (Preclinical)	Pain	C23 H28 N2 O	Opioid delta receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	ARM 100390			21/01/2008	Pain				no		no							https://adis.springer.com/drugs/800014975?userId=52029392&bpIds=3004037004&checksum=e3d70c2e86614fe184dffbcdea23edd084ccefeb-1617045530460-7558b38087c5e7df6068ea4419f21159badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014970	BU 224		"2-[4, 5-Dihydroimidazol-2yl]quinoline hydrochloride"				Discontinued (Preclinical)	Pain	C12 H11 N2 . H Cl	Imidazoline receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/01/2008	Pain				no		no							https://adis.springer.com/drugs/800014970?userId=52029392&bpIds=3004037004&checksum=511e01c0e0758361b09b991e48c3045a344101d5-1617045530461-53b0ba3f504fe27f4df4e7d05452de9abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017221	Radafaxine	192374-14-4	"(2<EM>S</EM>,3<EM>S</EM>)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol"				Discontinued (II)	"Restless legs syndrome, Major depressive disorder, Obesity, Bipolar disorders, Neuropathic pain, Fibromyalgia"	C13 H18 Cl N O2	"Adrenergic receptor antagonists, Dopamine uptake inhibitors"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				"A8A (Antiobesity Preparations, Excluding Dietetics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N4A (Anti-Parkinson Drugs), N6A (Anti-Depressants and Mood Stabilisers)"	"A08 (Antiobesity Preparations, Excl. Diet Products), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N04B-X (Other dopaminergic agents), N06A (Antidepressants)"	"'162, 353162, Bupropion metabolite, GW 353162"			21/01/2008	"Affective Disorders, Obesity, Pain, Parkinson's Disease and Movement Disorders, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800017221?userId=52029392&bpIds=3004037004&checksum=fd3f9c1db3403255ac9dc9a4f48134a8d4bffa8d-1617045530463-a5e2441741e71c52c61d8ef2db884753badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011107	SB 235863		"3-Methoxy-4', 17-dimethyl-6, 7-didehydropyrrolo[2', 3' : 6, 7]morphinan-5'-carboxylic acid 1-(2-methyl)propyl ester"				Discontinued (Preclinical)	Pain	C26 H32 N2 O4	Opioid delta receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	SB 235863A			18/01/2008	Pain				no		no							https://adis.springer.com/drugs/800011107?userId=52029392&bpIds=3004037004&checksum=2974c643d9b720bbdcad445603803b319cc2ec9d-1617045530464-7d530a7d934aebc944391edf8bafa741badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006082	GR 203040	168398-02-5	"(2S, 3S)-N-[2-Methoxy-5-(tetrazol-1-yl)-benzyl]-N-(2-phenyl-piperidin-3-yl)-amine"				Discontinued (Preclinical)	"Migraine, Nausea and vomiting, Pain"	C20 H24 N6 O	Neurokinin 1 antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"A4A (Antiemetics and Antinauseants), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"A04A-D (Other antiemetics), N02B-G (Other analgesics and antipyretics), N02C-X (Other antimigraine preparations)"				17/01/2008	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800006082?userId=52029392&bpIds=3004037004&checksum=46d85ed2e6c73201b418b24037095a1ed1485d5e-1617045530465-b86eba2fed199a3946a191bf63e785ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003930	Nolpitantium besilate	155418-06-7	"1-[2-[3-(3,4-Dichlorophenyl)-1-[2-(3-isopropoxyphenyl)acetyl]piperidin-3(S)-yl]ethyl]-4-phenyl-1-azoniabicyclo[2.2.2]octane benzenesulfonate"				Discontinued (II)	"Inflammation, Ulcerative colitis, Asthma, Pain, Nausea and vomiting, Migraine"	C37 H45 Cl2 N2 O2 . C6 H5 O3 S	Neurokinin 1 antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		"unspecified, PO"				"A4A9 (Other antiemetics and antinauseants), A7E (Intestinal Anti-Inflammatory Agents), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N2C (Anti-Migraine Preparations), R3 (Anti-Asthma and COPD Products), V3 (All Other Therapeutic Products)"	"A04A-D (Other antiemetics), A07E (Intestinal Antiinflammatory Agents), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), N02C-X (Other antimigraine preparations), R03 (Drugs for Obstructive Airway Diseases), V03A (All Other Therapeutic Products)"	SR 140333			17/01/2008	"Advances in the Treatment of Nausea and Migraine, Inflammation, Inflammatory Bowel Disorders, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800003930?userId=52029392&bpIds=3004037004&checksum=d39afe404d460eada4271e094846bc6bc758454b-1617045530467-c6b0a6e0cd07a6692e98f138dcb79236badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003534	GR 65630	113140-33-3	3-(5-Methyl-1H-imidazol-4-yl)-1-(1-methyl-1H-indol- 3-yl)-1-propanone				Discontinued	Nausea and vomiting	C16 H17 N3 O	Serotonin 3 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)	GR 65630A			17/01/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800003534?userId=52029392&bpIds=3004037004&checksum=753d0ef37922957360ec72096d6a5908301fa89d-1617045530468-05595aeba56166e05474a97dee24bcebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008820	Vouacapan		"6_, 7_-Dihydroxy vouacapan-17_-oate"				Discontinued (Preclinical)	Pain		Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner), GlaxoSmithKline (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				17/01/2008	Pain				no		no							https://adis.springer.com/drugs/800008820?userId=52029392&bpIds=3004037004&checksum=d5e688878b04eb3dc2194cfce9df598924a0a05f-1617045530469-0ae00be0ee7a765f112bcb60566532f7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003775	GR 64349	137593-52-3	N2-[2(<EM>S</EM>)-[3(<EM>R</EM>)-(<EM>L</EM>-Lysyl-<EM>L</EM>-asparatyl-<EM>L</EM>-seryl-<EM>L</EM>-phenylalanyl-<EM>L</EM>-valylamino)-2-oxopyrrolidin-1-yl]-4-methylpentanoyl]-<EM>L</EM>-methioninamide				Discontinued	Pain	C42 H68 N10 O11 S	Neurokinin 1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				17/01/2008	Pain				no		no							https://adis.springer.com/drugs/800003775?userId=52029392&bpIds=3004037004&checksum=7e08a16d5a3b1c74c4acfcde24efbbe915a55543-1617045530469-5bd07e0314d354aecce99900e83f8edebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007062	BMS 181885		"3-[3-[4-(5-Methoxy-4-pyrimidyl)-1-piperazinyl]propyl]-5-(1,2-dioxo-4-methyl-3-cyclobuten-3-yl)amino-1<EM>H</EM>-indole"				Discontinued (I)	Migraine		"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				16/01/2008	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800007062?userId=52029392&bpIds=3004037004&checksum=5f856754895bf54bea64a64cc033ee1211fc4bf1-1617045530470-822c03ca211bf0e645710a50c4db9569badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015818	BMS 347070						Discontinued (II/III)	"Osteoarthritis, Pain, Colorectal cancer"		Cyclo-oxygenase 2 inhibitors	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		unspecified				"L1 (Antineoplastics), M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"				16/01/2008	"Cancer, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800015818?userId=52029392&bpIds=3004037004&checksum=f22aa9a505064aa60d9b22b1509d0de0879a5d3c-1617045530471-c068cf0eacd1e37a334a15dab6a9d3f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012918	CGX 1007			Yes			Discontinued (I)	"Epilepsy, Neurodegenerative disorders, Pain"		NR2B N-Methyl-D-Aspartate antagonists	"Salk Institute (Originator), University of Utah (Originator), Salk Institute (Owner), University of Utah (Owner), Cognetix (Market Licensee)"		"Intrathecal, IV"				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N7X (All other CNS drugs)"	"N02B-G (Other analgesics and antipyretics), N03A (Antiepileptics), N07X (Other Nervous System Drugs)"	"Conantokin G, ConG"			14/01/2008	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800012918?userId=52029392&bpIds=3004037004&checksum=167cae6dfb4917c58531863c518ca8925bf5718a-1617045530472-710493299ec85af9b6c993c376c0b9efbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004548	HYAL AT2101			No			Discontinued (Preregistration)	"Pain, Rheumatic disorders, Aphthous ulcer pain"		Cyclooxygenase inhibitors	"SkyePharma Inc (Originator), SkyePharma Inc (Owner), Symbion Health (Market Licensee)"		Topical				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	"Diclofenac + HA topical, Hyaluronic acid + diclofenac, HyanalgeseD, Oralease"			11/12/2007	"Pain, Rheumatic Disease"			Oralease	no		no							https://adis.springer.com/drugs/800004548?userId=52029392&bpIds=3004037004&checksum=6c8a214fb9d180daeee8b3314561e8fd8cf0f99b-1617045530474-a888ddf0f425375de3b6e3dace7855f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002792	KT 2962	129648-96-0	"1-Azulenesulfonic acid, 3-(4-(((4-chlorophenyl)sulfonyl)amino)butyl)-6-(1-methylethyl)-, monosodium salt"				Discontinued (I)	"Asthma, Migraine, Reperfusion injury, Thrombosis, Coronary thrombosis, Cerebrovascular disorders"	C23 H25 Cl N O5 S2 . Na	"Thromboxane A2 receptor antagonists, Free radical scavengers"	"Kotobuki Seiyaku (Originator), Kotobuki Seiyaku (Owner)"		"PO, unspecified"				"B1C (Platelet Aggregation Inhibitors), C1X (All Other Cardiac Preparations), N2C (Anti-Migraine Preparations), R3 (Anti-Asthma and COPD Products)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), C01E-B (Other cardiac preparations), N02C (Antimigraine Preparations), R03 (Drugs for Obstructive Airway Diseases)"	KT2 962			05/12/2007	"Advances in the Treatment of Nausea and Migraine, Ischaemic Heart Disease, Obstructive Airways Disease, Thromboses"				no		no							https://adis.springer.com/drugs/800002792?userId=52029392&bpIds=3004037004&checksum=93b0ca040430e91e8d864b4e550b361084c9876e-1617045530475-0e1dd719bf76694ae0f9e4b75a39358bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008192	BP 294		(<EM>R</EM>)-(_)-2-<EM>N</EM>-1-(1<EM>H</EM>-Imidazol-4-yl)- 2-propyl-iminophenylmethyl-phenol				Discontinued (I)	"Peptic ulcer, Asthma, Pain, Inflammation"	C20 H21 N3 O	Histamine H3 receptor agonists	"Bioprojet (Originator), Bioprojet (Owner), INSERM (Collaborator)"		"unspecified, PO"		"Activity vs parent (&gt;), T<sub>_beta</sub> (h) (1.6 (Active metabolite)), T<sub>max</sub> (h) (1 - 2 (Adult)), T<sub>max</sub> (h) (1.7 (Active metabolite))"		"A2B (Antiulcerants), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), R3 (Anti-Asthma and COPD Products)"	"A02B (Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (GORD)), M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), R03 (Drugs for Obstructive Airway Diseases)"	FUB 94			28/11/2007	"Inflammation, Obstructive Airways Disease, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800008192?userId=52029392&bpIds=3004037004&checksum=baf07963684dc9a43ff25881eeda92b9d4e65a75-1617045530477-2fc64278e3646e86133bd695965bda9dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019174	Research programme: pain therapeutics - TransMolecular						Discontinued (Research)	Pain		Sodium channel modulators	"TransMolecular (Originator), TransMolecular (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				27/11/2007	Pain				no		no							https://adis.springer.com/drugs/800019174?userId=52029392&bpIds=3004037004&checksum=112e4785753bda3ad37ceb200c404615b15ab8c2-1617045530478-2257191a453051b120f5516bbf1e4201badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005394	GP 515	144928-48-3	"1H-Pyrazolo[3,4-d]pyrimidine4-amine, 1-(5-amino-5-deoxy-_-<EM>D</EM>-ribofuranosyl) -3-bromo-"				Discontinued (Preclinical)	"Septic shock, Pain, Inflammation"	C10 H13 Br N6 O3	Adenosine kinase inhibitors	"SICOR (Originator), SICOR (Owner)"		unspecified				"J1K (Aminoglycosides), M1A2 (Anti-rheumatics, non-steroidal combination), N2 (Analgesics)"	"J01G (Aminoglycoside Antibacterials), M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	GP 1515			26/11/2007	"Bacterial Infections, Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800005394?userId=52029392&bpIds=3004037004&checksum=13712c698dcfc10aab6f124b48e1c0b4f3f1fad8-1617045530479-4a42970ceae4c3d89b6182699ff009b1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021804	AMG 517		<EM>N</EM>-[4-[6-[4-(Trifluoromethyl)phenyl]pyrimidin-4-yloxy]benzo[<EM>d</EM>]thiazol-2-yl]acetamide				Discontinued (I)	Pain	C20 H13 F3 N4 O2 S	TRPV cation channel antagonists	"Amgen (Originator), Amgen (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	AMG517			23/11/2007	Pain				no		no							https://adis.springer.com/drugs/800021804?userId=52029392&bpIds=3004037004&checksum=0c8816c4e9f6afedc904b7c0e308b07ea130e5c3-1617045530479-dd18acf50b53775db10e20d753248178badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020106	Interleukin-4 gene therapy - University of Pittsburgh						Discontinued (Preclinical)	Cancer pain		Immunostimulants	"University of Pittsburgh (Originator), University of Pittsburgh (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B (Other Analgesics and Antipyretics)"	S4IL4			20/11/2007	Pain				no		no							https://adis.springer.com/drugs/800020106?userId=52029392&bpIds=3004037004&checksum=3c59868aa13cdffcc79cdd9697c34ae716b10851-1617045530480-cf84ff30e871e21500ebb3d245554217badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006868	LA 351	6537-46-8	"5H-[(1)]Benzopyrano[(2,3-b)]pyridin-5-one"				Discontinued (Preclinical)	Pain	C12 H7 N O2	Undefined mechanism	"Lacer (Originator), Lacer (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				01/11/2007	Pain				no		no							https://adis.springer.com/drugs/800006868?userId=52029392&bpIds=3004037004&checksum=5f215629f96135c81b1967eedead11cac9b6c046-1617045530481-d34b0773c1b1659419466aa4cf5a4bb5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003927	Licofelone	156897-06-2	"[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1<EM>H</EM>-pyrrolizin-5-yl]acetic acid"			"= Diclofenac, = Naproxen"	Discontinued (III)	"Osteoarthritis, Pain, Inflammation, Rheumatoid arthritis, Asthma"	C23 H22 Cl N O2	"5-lipoxygenase inhibitors, Cyclooxygenase inhibitors"	"EuroAlliance (Originator), Merckle (Originator), EuroAlliance (Owner), Merckle (Owner), Alfa Wassermann Inc (Market Licensee), Ascentia Pharma (Market Licensee), Dainippon Sumitomo Pharma (Market Licensee), Lacer (Market Licensee)"		"PO, unspecified"		"T<sub>_beta</sub> (h) (11.1 (Adult)), T<sub>_beta</sub> (h) (8.7 (Elderly)), T<sub>max</sub> (h) (.74 - 4 (Adult))"		"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3C (Non-Steroidal Respiratory Anti-Inflammatories)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"	ML 3000			01/11/2007	"Obstructive Airways Disease, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800003927?userId=52029392&bpIds=3004037004&checksum=793e2674a2903a22d940fda35d40846f75d21b6a-1617045530482-14862af74fd5e77c085d5253b4c7afbcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000985	Mofezolac	78967-07-4	"5-Isoxazoleacetic acid, 3,4-bis-(4-methoxyphenyl)-"			³ Ibuprofen	Marketed	"Postoperative pain, Musculoskeletal disorders, Pain, Rheumatic disorders"	C19 H17 N O5	Cyclooxygenase inhibitors	"Gilead Sciences (Originator), Gilead Sciences (Owner), Mitsubishi Tanabe Pharma Corporation (Market Licensee)"		PO			"Anorexia, Gastrointestinal disorders, Gastrointestinal haemorrhage, Liver disorders, Oedema, Stomatitis, Thrombocytopenia"	"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"	"Disopain, N 22"			01/10/2007	"Pain, Rheumatic Disease"			Disopain	no		no							https://adis.springer.com/drugs/800000985?userId=52029392&bpIds=3004037004&checksum=e598ec833ca003f90d03162d5ff879b21e060e51-1617045530484-7b9edc4cc8e845413b46b1c235d2c147badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009807	Tinoridine	24237-54-5	"Ethyl 2-amino-6-benzyl-4,5,6,7-tetrahydrothieno[2,3-<EM>c</EM>]pyridine-3-carboxylate"				Marketed	"Inflammation, Pain"	C17 H20 N2 O2 S	Cyclooxygenase inhibitors	"Mitsubishi Pharma Corporation (Originator), Mitsubishi Tanabe Pharma Corporation (Owner)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics)"	"Nonflamin, Tienoridine, Tienoridine hydrochloride, Tinoridine hydrochloride, Y 3642"			01/10/2007	"Inflammation, Pain"			"Nonflamin, Nonflamin"	no		no							https://adis.springer.com/drugs/800009807?userId=52029392&bpIds=3004037004&checksum=a8cb11268d93476c7a472612670a8d5e375704b6-1617045530485-318530f6ae5e3d663e9048f38e5f64bdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012973	Research programme: bradykinin B1 receptor antagonists - Fournier Pharma						Discontinued (Preclinical)	"Inflammation, Pain"		Bradykinin B1 receptor antagonists	"Fournier Pharma (Originator), Fournier Pharma (Owner)"		Parenteral				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"LF 200042, LF 521"			24/09/2007	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800012973?userId=52029392&bpIds=3004037004&checksum=115be016c70574376f51bea7c19391a395949b09-1617045530485-278b2e98a3db5158132235dcdf5b6774badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011154	Research programme: AMPA receptor antagonists - Purdue Pharma/Senju			Yes			Discontinued (Preclinical)	"Epilepsy, Schizophrenia, Stroke, Amyotrophic lateral sclerosis, Pain, Eye disorders"		AMPA receptor antagonists	"Purdue Pharma (Originator), Purdue Pharma (Owner), Senju Pharmaceutical (Collaborator)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N5A (Antipsychotics), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"N02B (Other Analgesics and Antipyretics), N03A-X (Other antiepileptics), N05A-X (Other antipsychotics), N07X (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"				03/09/2007	"Epilepsy and Seizure Disorders, Eye Disorders, Neurological Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800011154?userId=52029392&bpIds=3004037004&checksum=af01ad9803112edfb551cf63b32839a07027c106-1617045530486-8f8888663a1b4c22d39ac43804247c56badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011152	Research programme: subtype-selective NMDA receptor antagonists - Purdue Pharma/Senju			Yes			Discontinued (Preclinical)	"Eye disorders, Parkinson's disease, Pain, Neurological disorders, Epilepsy, Cerebral ischaemia"		"NMDA receptor antagonists, Glutamate receptor antagonists"	"Pfizer (Originator), Purdue Pharma (Originator), Pfizer (Owner), Purdue Pharma (Owner), Senju Pharmaceutical (Collaborator)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N7X (All other CNS drugs), S1X (Other Ophthalmologicals)"	"N02B (Other Analgesics and Antipyretics), N03A-X (Other antiepileptics), N04 (Anti-Parkinson Drugs), N07X (Other Nervous System Drugs), S01X (Other Ophthalmologicals)"				03/09/2007	"Epilepsy and Seizure Disorders, Eye Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800011152?userId=52029392&bpIds=3004037004&checksum=10991b66c2cc67d8ef114aeb1d21feaaf9d53b40-1617045530488-6973685a40757ea440bb95d76fe6f5a1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011985	HZ 2		"(1<EM>R</EM>, 2<EM>S</EM>, 4<EM>R</EM>, 5<EM>S</EM>)-3, 7-Dimethyl-9-oxo-2, 4-di(2-pyridinyl)-3, 7-diazabicyclo[3.3.1]nonane-1,5-dicarboxylic acid dimethyl ester"				Discontinued (Preclinical)	Pain	C23 H26 N4 O5	Opioid kappa receptor agonists	"Grunenthal (Originator), Grunenthal (Owner)"		Parenteral				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				31/08/2007	Pain				no		no							https://adis.springer.com/drugs/800011985?userId=52029392&bpIds=3004037004&checksum=632091873289da25bd9c2b1f09ccc96f540f32a7-1617045530488-257a665bd10c55716f123c8d63c7e035badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006102	TAN 67	148545-09-9	"2-Methyl-4a_-(3-hydroxyphenyl)-1,2,3,4,4a,5, 12,12a_-octahydro-quinolino[2,3,3-g]isoquinoline"				Discontinued (Preclinical)	Pain	C23 H24 N2 O	Opioid delta receptor agonists	"Toray (Originator), Toray (Owner), University of Arizona (Collaborator)"		unspecified				N2A (Narcotics)	N02A-X (Other opioids)				31/08/2007	Pain				no		no							https://adis.springer.com/drugs/800006102?userId=52029392&bpIds=3004037004&checksum=14978fa585510a3315d30b40b9cf8e8353a21128-1617045530489-44c6876cee37cb178d6d4312ea4999bebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012903	TAN 684		"(4<EM>R</EM>-(4alpha,4abeta,7beta,7abeta,12b<EM>S</EM>))- <EM>N</EM>-(3-(Cyclopropylmethyl)-4a,9-dihydroxy-4,12-methano- 2,3,4,4a,5,6,7,7a-octahydro-1<EM>H</EM>benzofuro(3,2-e)isoquinolinium methyliodide,7-[(3-furyl)ethenyl(<EM>E</EM>)carbonyl-<EM>N</EM>-methylamino]-,"				Discontinued (Preclinical)	Pain	C29 H35 I N2 O5	Opioid kappa receptor agonists	"Toray (Originator), Toray (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				31/08/2007	Pain				no		no							https://adis.springer.com/drugs/800012903?userId=52029392&bpIds=3004037004&checksum=dee538c79f6d5372c37715b9710d210c073f5cf7-1617045530490-e1739df7afa0cdc48616608e9ea72b83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007788	ADL 21294	34552-83-5	"1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-_,_-diphenyl-, monohydrochloride"				Discontinued (II)	"Ocular pain, Pain, Pruritus, Dental pain"	C29 H33 Cl N2 O2 . H Cl	Opioid mu receptor agonists	"University of California, San Diego (Originator), University of California, San Diego (Owner), Adolor Corporation (Licensee), Kwang Dong Pharmaceutical (Sub-licensee)"		"Ophthalmic, Topical, Intra-articular"				"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2A (Narcotics), S1R (Ophthalmic Non-steroidal Anti-Inflammatories)"	"D04A-X (Other antipruritics), N02A (Opioids), S01B-C (Antiinflammatory agents, non-steroidals)"	"ADL 21294, Loperamide ophthalmic Adolor, Loperamide topical Adolor"			31/08/2007	"Eye Disorders, Pain, Skin Disorders"				no		no		HER2		"CYP3A4, CYP3A5, HER2, Hydrocortisone, Ki67"			https://adis.springer.com/drugs/800007788?userId=52029392&bpIds=3004037004&checksum=00d9162e3c3cb1e61a7f46a3c7cb28a9a4f7295f-1617045530491-468045af2de69a4fc7fe9c352ab2ad7ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022017	Research programme: analgesics - Cenomed BioSciences						No development reported (Preclinical)	Pain		Undefined mechanism	"Cenomed BioSciences LLC (Originator), Cenomed BioSciences LLC (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"CM2359, CM2397"			31/08/2007	Pain				no		no							https://adis.springer.com/drugs/800022017?userId=52029392&bpIds=3004037004&checksum=217a298b57631d9fde84dc677170d6157c27bc84-1617045530492-edf2d922e048116020e996c298c2b309badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015351	Fentanyl transdermal - 3M Drug Delivery Systems/Purdue Pharma	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (I)	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"3M Drug Delivery Systems (Originator), Purdue Pharma (Originator), 3M Drug Delivery Systems (Owner), Purdue Pharma (Owner)"		Transdermal				N2 (Analgesics)	N02A-B03 (Fentanyl)				30/08/2007	"Drug Delivery Systems, Pain"				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800015351?userId=52029392&bpIds=3004037004&checksum=82a64385f000345e765c0c56d5554655382bb029-1617045530493-fda9f5c8e343159a70aac2faade2f8cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005617	SM 21	155156-22-2	2-(4-Chlorophenyoxy)butyric acid endo-8-methyl-8-azabicyclo[3. 2. 1]oct-3-yl ester maleate				Discontinued (Preclinical)	"Dementia, Pain"	C18 H24 Cl N O3 . C4 H4 O4	"Acetylcholine stimulants, Sigma-2 receptor antagonists"	"Sumitomo Pharmaceuticals (Originator), Sumitomo Pharmaceuticals (Owner), Nonindustrial source (Collaborator)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N6D (Nootropics)"	"N02B (Other Analgesics and Antipyretics), N07A-X (Other parasympathomimetics)"	SM21			30/08/2007	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800005617?userId=52029392&bpIds=3004037004&checksum=564582e87ef57551de46293786b761d00e8136b3-1617045530494-533dfe60ef996cf32b501a0cd6171e42badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009655	CO 102862		4-(4-Fluorophenoxy)benzaldehyde semicarbazone	Yes			Discontinued (I)	"Epilepsy, Neuropathic pain"	C14 H12 F N3 O2	Sodium channel antagonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics)"	"N02B (Other Analgesics and Antipyretics), N03A (Antiepileptics)"	V 102862			29/08/2007	"Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009655?userId=52029392&bpIds=3004037004&checksum=ba0ce39c4e31fece3c0d95589e2ae31145e02737-1617045530495-533ea83aabcdf6114544b65989bff60ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012021	Research programme: ion channel blockers - Scion Pharmaceuticals						No development reported (Preclinical)	"Neuropathic pain, Neurological disorders, Atrial fibrillation, Pain"		"Ion channel antagonists, Calcium channel antagonists"	"CeNeS Pharmaceuticals (Originator), CeNeS Pharmaceuticals (Owner), Scion Pharmaceuticals (Licensee)"		unspecified				"C8 (Calcium Antagonists), N2 (Analgesics), N7 (Other CNS Drugs)"	"C08 (Calcium Channel Blockers), N02 (Analgesics), N07 (Other Nervous System Drugs)"	"SPI 860, SXX5, SXX6"			29/08/2007	"Arrhythmias, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800012021?userId=52029392&bpIds=3004037004&checksum=c2e8033c1434959556232713096deac604b9757e-1617045530496-5f152350a6cbc79d57618703885bf8c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005227	NT 3						Discontinued (II)	"Peripheral nervous system diseases, Constipation, Diabetic neuropathies"		Neuron stimulants	"Regeneron Pharmaceuticals (Originator), Takeda (Originator), Regeneron Pharmaceuticals (Owner), Takeda (Owner), Amgen (Market Licensee)"		"unspecified, SC"				"A10X (Other Drugs Used in Diabetes), A3F (Gastroprokinetics), N2 (Analgesics), N7 (Other CNS Drugs)"	"A03F (Propulsives), A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N07X (Other Nervous System Drugs)"	"Neurotrophic factor3, Neurotrophin3, NT3, Recombinant human neurotrophic factor"			22/08/2007	"Diabetes, Digestive System Disorders, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800005227?userId=52029392&bpIds=3004037004&checksum=7bad06f87da2faa60451d0025b67b98bc6d48eea-1617045530497-0ee885f2fb458e4d2606615b1f3a878dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015898	CJC 1008						Discontinued (II)	"Neuralgia, Postoperative pain"		Opioid receptor agonists	"ConjuChem Biotechnologies (Originator), ConjuChem Biotechnologies (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"CCI 1008, DACDynorphin A, DACOpioid"			21/08/2007	Pain				no		no							https://adis.springer.com/drugs/800015898?userId=52029392&bpIds=3004037004&checksum=22a7d658fee25a4e1ceaf09b006b8014d54d048d-1617045530498-250e8d4cd9a796e753aafa13e1cb92c1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012951	MBT		<EM>N</EM>-Methyl-5-<EM>tert</EM>-butyltryptamine	No			Discontinued (Preclinical)	Migraine	C15 H22 N2	Serotonin 1D receptor agonists	"Eli Lilly and Company (Originator), Lundbeck Research USA (Originator), Eli Lilly and Company (Owner), Lundbeck Research USA (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				20/08/2007	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800012951?userId=52029392&bpIds=3004037004&checksum=a0a09931fcb97bb4f2e20476c26d0c6be155e36e-1617045530499-254e2dc55e3c82d8b12091437ca81572badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015058	Research programme: galanin modulators - Synaptic Pharmaceutical						Discontinued (Preclinical)	"Diabetes mellitus, Pain, Obesity, Major depressive disorder, Alzheimer's disease"		"Galanin receptor agonists, Galanin receptor antagonists"	"Lundbeck Research USA (Originator), Lundbeck Research USA (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), A8A (Antiobesity Preparations, Excluding Dietetics), N2 (Analgesics), N6A (Anti-Depressants and Mood Stabilisers), N7D9 (All other anti-Alzheimer products)"	"A08A (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), N02 (Analgesics), N06A (Antidepressants), N07X (Other Nervous System Drugs)"				20/08/2007	"Affective Disorders, Alzheimer's Disease and Cognition Disorders, Diabetes, Obesity, Pain"				no		no							https://adis.springer.com/drugs/800015058?userId=52029392&bpIds=3004037004&checksum=0983fbf2f0200ddd5131ed63df055df539f0356e-1617045530500-12b38212c11ed55e9f17d410c35bd10fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018549	Morphine/lidocaine topical spray - EpiCept						Discontinued (II)	Pain		"Opioid receptor agonists, Sodium channel antagonists"	"Memorial Sloan-Kettering Cancer Center (Originator), Memorial Sloan-Kettering Cancer Center (Owner), EpiCept Corporation (Collaborator)"		Topical				"N1B (Anaesthetics, Local), N2A (Narcotics)"	"N01B-B02 (Lidocaine), N01B-B52 (Lidocaine, combinations), N02A-A01 (Morphine), N02A-A51 (Morphine, combinations)"	"EpiCeptMP/DP, EpiCeptMS Spray, Lidocaine/morphine, LidoPAINMP/DP, MS Spray"			17/08/2007	Pain			LidoPAINMP/DP	no		no							https://adis.springer.com/drugs/800018549?userId=52029392&bpIds=3004037004&checksum=22ea6618615c729a0c566156841f8cc5540227d5-1617045530501-12a130096d83d4ae3c2bcecbf7b79237badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020019	ED 1612						Discontinued (Clinical)	Pain		Opioid receptor agonists	"Sosei R&D (Originator), Sosei R&D (Owner)"		PO				"N2 (Analgesics), N2A (Narcotics)"	"N02 (Analgesics), N02A (Opioids)"	ED1612			17/08/2007	Pain				no		no							https://adis.springer.com/drugs/800020019?userId=52029392&bpIds=3004037004&checksum=7feeb62982271fdf71545bb4d201c6b19d7ae3c1-1617045530501-01240139611491bc6df8ed16213b0261badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005419	L 745337	158205-05-1	"N-[6-(2,4-Difluorophenylthio)-1-oxoindan-5-yl]methanesulfonamide sodium salt"				Discontinued (II)	"Inflammation, Pain"	C16 H12 F2 N Na O3 S2	Cyclo-oxygenase 2 inhibitors	"Merck Frosst (Originator), Merck Frosst (Owner)"		unspecified				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"				16/08/2007	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800005419?userId=52029392&bpIds=3004037004&checksum=30874c8d2fd43c0af9fbe141fb80f76e0ed28960-1617045530502-a327676ed25407bac970a3c6042749afbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006328	CHIR 4531		"[N-(2,2-Diphenylethyl)glycyl]-[N-[3,4- (methylenedioxy)-benzyl]glycyl]-N-[2- (4-hydroxyphenyl)ethyl]glycinamide"				Discontinued (Preclinical)	Pain	C36 H38 N4 O6	Opioid mu receptor agonists	"Chiron Corporation (Originator), Chiron Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				15/08/2007	Pain				no		no							https://adis.springer.com/drugs/800006328?userId=52029392&bpIds=3004037004&checksum=48890f953a7d843afcddb679848be85845c77f96-1617045530503-35d49e02e19e2843bf1d9d8b5a2cf1febadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003789	CDRI 82205		"[D-Ala2,MePhe4,Gly5]-enkephalin isopropylamide"				Discontinued	Pain	C29 H40 N6 O6	Opioid receptor agonists	"Central Drug Research Institute (Originator), Central Drug Research Institute (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	Compound 82/205			15/08/2007	Pain				no		no							https://adis.springer.com/drugs/800003789?userId=52029392&bpIds=3004037004&checksum=a88a1a6ab114e7030c3c2e7f364ac3f4c2704c3f-1617045530504-eed22ebd9a25a661980e842ef88acbc4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019520	DLX 0110						Discontinued (Preclinical)	Pain		Undefined mechanism	"DELEX Therapeutics (Originator), YM BioSciences (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	DLX0110			07/08/2007	Pain				no		no							https://adis.springer.com/drugs/800019520?userId=52029392&bpIds=3004037004&checksum=2274c825c133962bc1b6e2c348ce167350b7afa8-1617045530505-39b47df35637355e5ca210ea649d510cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019940	E 2070						Discontinued (I)	Neuropathic pain		Sodium channel antagonists	"Eisai Co Ltd (Originator), Eisai Co Ltd (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				06/08/2007	Pain				no		no							https://adis.springer.com/drugs/800019940?userId=52029392&bpIds=3004037004&checksum=a1cbcefe16159d01361f4bb1a8df391b5a00af67-1617045530505-3f990b130e2de5a9540d196e459294e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015057	Research programme: pain therapy - Grunenthal/Lundbeck						Discontinued (Preclinical)	Pain		Undefined mechanism	"Grunenthal (Originator), Lundbeck Research USA (Originator), Grunenthal (Owner), Lundbeck Research USA (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				25/07/2007	Pain				no		no							https://adis.springer.com/drugs/800015057?userId=52029392&bpIds=3004037004&checksum=3082e5af3f9541521d4b61e20edbefd03dedf168-1617045530506-0aa783a7b94bfe97e1f5e06209aafe96badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019471	Research programme: sodium channel antagonists - Zenyth Therapeutics						No development reported (Preclinical)	Pain		Sodium channel antagonists	"Zenyth Therapeutics (Originator), Zenyth Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	AM 66			13/07/2007	Pain				no		no							https://adis.springer.com/drugs/800019471?userId=52029392&bpIds=3004037004&checksum=a37f526dce9ab53461f39b57645c5a629b9b854a-1617045530507-6533156941f4da0d5262d83f0118939fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018288	AM 577						No development reported (Preclinical)	Pain		Cannabinoid receptor CB2 agonists	"Zenyth Therapeutics (Originator), Zenyth Therapeutics (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				13/07/2007	Pain				no		no							https://adis.springer.com/drugs/800018288?userId=52029392&bpIds=3004037004&checksum=eaf218cab3abba26c8eb72854b2d6e1166942ee7-1617045530507-f89b507a31592c1adc07cbe0fe5d1d64badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020413	Research programme: migraine prophylactic therapy - Sepracor						Discontinued (Preclinical)	Migraine		Undefined mechanism	"Sepracor (Originator), Sepracor (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	SEP 225382			11/07/2007	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800020413?userId=52029392&bpIds=3004037004&checksum=af48d2c3deddbcb0e21652186562de59b584c099-1617045530508-ceb2eb42f0fee223018f0e27cf5082e2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022575	FP 0153						Discontinued (Preclinical)	"Parkinson's disease, Migraine"		Undefined mechanism	"Faust Pharmaceuticals (Originator), Faust Pharmaceuticals (Owner)"		unspecified				"N2C (Anti-Migraine Preparations), N4A (Anti-Parkinson Drugs)"	"N02C (Antimigraine Preparations), N04 (Anti-Parkinson Drugs)"	FP0153			06/06/2007	"Advances in the Treatment of Nausea and Migraine, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800022575?userId=52029392&bpIds=3004037004&checksum=1004279f9fff832a157718894c676a7188cca574-1617045530509-2408c17ab30e8b65522e708863d3a4b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005379	117m Sn DTPA						Discontinued (II)	"Cancer pain, Bone cancer"		Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner), Bayer Schering Pharma (Market Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"Pentetate 117m Sn, Stanamet, Tin117m DTPA"			05/06/2007	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800005379?userId=52029392&bpIds=3004037004&checksum=e9fe7d112b3ae84ca3701fdf7108d961db3b0b14-1617045530510-230f60f7f00663328ec042f6ff2ecc7fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020146	406275 - GlaxoSmithKline			Yes			No development reported (I)	"Epilepsy, Migraine, Neuropathic pain"		Gap junction modulators	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"N2 (Analgesics), N2C (Anti-Migraine Preparations), N3A (Anti-Epileptics)"	"N02 (Analgesics), N02C (Antimigraine Preparations), N03A (Antiepileptics)"	"362115, 362115A, 406725, 406725A"			21/05/2007	"Advances in the Treatment of Nausea and Migraine, Epilepsy and Seizure Disorders, Pain"				no		no							https://adis.springer.com/drugs/800020146?userId=52029392&bpIds=3004037004&checksum=30f2627b18d65b4a84772671a40c29513cd4b314-1617045530511-d00ddfd8f27f010a4902a8a2978e63a2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020166	644784						No development reported (I)	"Schizophrenia, Pain"		Cyclo-oxygenase 2 inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"N2 (Analgesics), N5A (Antipsychotics)"	"N02 (Analgesics), N05A (Antipsychotics)"	GW 644784			21/05/2007	"Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800020166?userId=52029392&bpIds=3004037004&checksum=d4befd44db2db6bb7058232fcd05b5f67bbc5c59-1617045530512-b8879cbbe8baf05e0aacb3cdc16956aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013496	Clonidine gel - Curatek Pharmaceuticals	4205-90-7	"1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro-"	No			Discontinued (III)	"Diabetic neuropathies, Postherpetic neuralgia"	C9 H9 Cl2 N3	"Alpha 2 adrenergic receptor agonists, Imidazoline I1 receptor agonists, Imidazoline receptor agonists"	"Curatek Pharmaceuticals (Originator), Curatek Pharmaceuticals (Owner)"		Topical				"A10X (Other Drugs Used in Diabetes), N2A (Narcotics)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics)"				04/05/2007	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800013496?userId=52029392&bpIds=3004037004&checksum=44ebece8bd55ecb957faf01d23459b3773fc67b4-1617045530513-995064dbc002fcde345ce46a54dff0c4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017645	ELN 154088						Discontinued (II)	Pain		Undefined mechanism	"Elan Corporation (Originator), Elan Corporation (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				02/05/2007	Pain				no		no							https://adis.springer.com/drugs/800017645?userId=52029392&bpIds=3004037004&checksum=38ae0be7a1db5eecb1a4bc93c04cd4dbbf86079d-1617045530514-2cc15573fe4d27ac47a1d04a06065752badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012220	SVT 2016						Discontinued (I)	"Pain, Osteoarthritis"		Cyclo-oxygenase 2 inhibitors	"SALVAT (Originator), University of Barcelona (Originator), SALVAT (Owner), University of Barcelona (Owner)"		PO				"M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	SVT2016			02/05/2007	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800012220?userId=52029392&bpIds=3004037004&checksum=ed6d2292e731e3a821dd049693f312bd9d4adbcd-1617045530515-0f2e84de9861aaac7ea0d97a0b0ca887badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009270	REN 1654						Discontinued (II)	"Postherpetic neuralgia, Dementia, Sciatica, Inflammatory bowel diseases"		"Free radical scavengers, Tumour necrosis factor inhibitors"	"Renovis (Originator), Renovis (Owner)"		"PO, unspecified"				"A7E (Intestinal Anti-Inflammatory Agents), N2 (Analgesics), N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"A07E (Intestinal Antiinflammatory Agents), N02 (Analgesics), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	"CPI 1189, REN 1189"			01/05/2007	"Alzheimer's Disease and Cognition Disorders, Inflammatory Bowel Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009270?userId=52029392&bpIds=3004037004&checksum=fb716932312ef47f1f25df872d6bd3079a55c77a-1617045530517-87f7d169f2b20c0a87b95df612116cf4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800020484	Research programme: nitrone analgesic therapy - Renovis						Discontinued (Preclinical)	Pain		Undefined mechanism	"Renovis (Originator), Renovis (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				01/05/2007	Pain				no		no							https://adis.springer.com/drugs/800020484?userId=52029392&bpIds=3004037004&checksum=0493d43913b1a32cd0aabcd230f967d02fa7d5ab-1617045530518-2499749d9a58661e1adb556373638216badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009399	Morphine inhalation - Aradigm Corporation	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate"				Discontinued (II)	"Postoperative pain, Cancer pain"	C17 H19 N O3 . 1/2 H2 S O4 . 5/2H2 O	Opioid mu receptor agonists	"Aradigm Corporation (Originator), Aradigm Corporation (Owner), GlaxoSmithKline (Market Licensee)"		Inhalation				N2A (Narcotics)	N02A-A01 (Morphine)				26/04/2007	"Drug Delivery Systems, Pain"				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800009399?userId=52029392&bpIds=3004037004&checksum=a172b37c68d269cc5430706a89e84d14992ee204-1617045530520-28c49cf18cdc78b986e6d9973d924169badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019774	PW 4103						Discontinued (I)	Menstrual migraine		Undefined mechanism	"Penwest Pharmaceuticals (Originator), Penwest Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				25/04/2007	Women's Health				no		no							https://adis.springer.com/drugs/800019774?userId=52029392&bpIds=3004037004&checksum=ec9470946a1980019b1912f473ff2a653a170cd6-1617045530521-3b56c03f74c6b23e0d63cce601d4f5dfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019769	Research programme: pain therapeutics - Penwest Pharmaceuticals						Discontinued (Preclinical)	Pain		Undefined mechanism	"Penwest Pharmaceuticals (Originator), Penwest Pharmaceuticals (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Pain therapeutics research programme Penwest Pharmaceuticals, PW 4102, PW 4104"			25/04/2007	Pain				no		no							https://adis.springer.com/drugs/800019769?userId=52029392&bpIds=3004037004&checksum=8b760be45ea62b4d952041693224be2266be9dbb-1617045530522-d8682669e47d28f9e8c7872d780ced7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022000	Research programme: nerve injury therapeutics - Galapagos/NeuroTargets						No development reported (Preclinical)	"Pain, Spinal cord injuries"		Undefined mechanism	"Galapagos NV (Originator), NeuroTargets (Originator), Galapagos NV (Owner), NeuroTargets (Owner)"		unspecified				"N2 (Analgesics), N7X (All other CNS drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"				13/04/2007	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800022000?userId=52029392&bpIds=3004037004&checksum=e5accb96b2e2de374f209f7a1bb8f63d89e3cf3c-1617045530523-0e4fa763c0db3723a01b1c5a42f471ebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015961	BL 1832						Discontinued (III)	Pain		Undefined mechanism	"Bioglan Pharma [CEASED] (Originator), Winston Laboratories (Originator), Bioglan Pharma [CEASED] (Owner), Winston Laboratories (Owner)"		Topical				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				01/03/2007	Pain				no		no							https://adis.springer.com/drugs/800015961?userId=52029392&bpIds=3004037004&checksum=b16e51f343b68feca7c91b0b688d6ab9d2ace61f-1617045530524-0431e79dfaf70aa9c4aaabb6513b4982badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016444	BL 1834	001668-19-5	"<EM>N, N</EM>-Dimethyl-3-dibenz[b,e]oxepin-11 (6<EM>H</EM>)-ylidene-1-propanamine"				Discontinued (II)	Pain	C19 H21 N O	Undefined mechanism	"Bioglan Pharma [CEASED] (Originator), Bioglan Pharma [CEASED] (Owner)"		Intranasal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				01/03/2007	Pain				no		no							https://adis.springer.com/drugs/800016444?userId=52029392&bpIds=3004037004&checksum=844b19bc98095777aba384c209992136d5b909ab-1617045530525-d6061de6abb4c646032d6c738cefd9a9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006315	PD 142898	146516-50-9	"Benzenebutanoic acid, _-[[3-(1H-indol-3-yl)-2-methyl-2-[[[2-methylcyclohexyl)oxy]carbonyl]amino]-1-oxopropyl]amino]-,[1S-[1_[S<SUP>*</SUP>(R<SUP>*</SUP>)],2_]]"				Discontinued (Preclinical)	"Anxiety disorders, Pain"		"Cholecystokinin A receptor antagonists, Cholecystokinin B receptor antagonists"	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N5C (Tranquillisers)"	"N02B (Other Analgesics and Antipyretics), N05B-X (Other anxiolytics)"				24/01/2007	"Anxiety Disorders, Pain"				no		no							https://adis.springer.com/drugs/800006315?userId=52029392&bpIds=3004037004&checksum=edd610ce4901e123ddf1e7360766b3ee9ba4e307-1617045530527-af0a58d56b60759cf80ddec37a31e329badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800023876	ALGRX 1207			Yes			Discontinued (I)	"Anaesthesia, Neuropathic pain"		Sodium channel antagonists	"Anesiva (Originator), Anesiva (Owner)"		Topical				"N1 (Anaesthetics), N2 (Analgesics)"	"N01 (Anesthetics), N02 (Analgesics)"	"1207, ALGRX1207"			22/01/2007	Pain				no		no							https://adis.springer.com/drugs/800023876?userId=52029392&bpIds=3004037004&checksum=1e9bedabe97ccf4a9ed0a4706d2df9441b8d2fda-1617045530528-6daaf10bbb6703d46f30184e85d05296badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011102	ARR 12495AA		"(±)-1-Methyl-1,2-diphenylethylamine"				Discontinued (Preclinical)	"Pain, Inflammation"	C15 H17 N2	Glutamate receptor antagonists	"AstraZeneca R&D Charnwood (Originator), AstraZeneca R&D Charnwood (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	FPL 12495AA			22/01/2007	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800011102?userId=52029392&bpIds=3004037004&checksum=3ebb6e3807f80e30022c0fa506e61cb7c9721d34-1617045530529-e731b9f8fc71efaea5c0a40c9df5cfd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010189	ARR 17477		<EM>N</EM>-[4-[2-(3-Chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine				Discontinued (Preclinical)	"Amyotrophic lateral sclerosis, Stroke, Pain"	C20 H20 Cl N3 S	Nitric oxide synthase inhibitors	"Astra Arcus USA (Originator), AstraZeneca R&D Charnwood (Originator), Astra Arcus USA (Owner), AstraZeneca R&D Charnwood (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	ARL 17477			22/01/2007	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800010189?userId=52029392&bpIds=3004037004&checksum=b6be6c2b57241079feb937913afdfae86d0cca7b-1617045530531-e3467cfc0361c92846dc1989cafacc5abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005784	CP 135807	151272-90-1	3-[1-Methylpyrrolidin-2(R)-ylmethyl]-5-(3-nitropyridin-2-ylamino)-1H-indole				Discontinued (Preclinical)	Migraine	C19 H21 N5 O2	Serotonin 1D receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				18/01/2007	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800005784?userId=52029392&bpIds=3004037004&checksum=1b4523da1dcd88bd5597ad3f462b22955a2b2dd6-1617045530532-0cbdfff39272da867bf6764b76958fadbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011156	ES 2421		"4-Acetoxy-7, 7', 9, 9'-tetramethoxy-3, 3'-dimethyl-5, 5'-bi(3, 4-dihydro-1<EM>H</EM>-naphtho[2, 3-c]pyran)-10, 10'-diol"				Discontinued (Preclinical)	Pain	C34 H36 O10	Glutamate receptor antagonists	"Kyowa Hakko (Originator), Kyowa Hakko (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				19/12/2006	Pain				no		no							https://adis.springer.com/drugs/800011156?userId=52029392&bpIds=3004037004&checksum=88b3153407813ed6057a9d134e4c7974068915ae-1617045530532-ab98eb0a4fe8c300d176754c086896e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010740	KF 24705		"2-Oxymetyl-11-(4-oxy-4-phenylpiperidin-1-yl)-dibenzo[3, 3-b]oxepine"				Discontinued (Preclinical)	Pain	C26 H27 N O3	Undefined mechanism	"Kyowa Hakko (Originator), Kyowa Hakko (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				19/12/2006	Pain				no		no							https://adis.springer.com/drugs/800010740?userId=52029392&bpIds=3004037004&checksum=81b419af5efdf51864c925e332c6108a28bc0df1-1617045530533-da0acb667a09baed249d971ca3e294f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003533	Dotarizine	84625-59-2	"1-(Diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine"				Discontinued (Preregistration)	"Migraine, Vertigo, Stroke"	C29 H34 N2 O2	"Calcium channel antagonists, Serotonin 1C receptor antagonists, Serotonin 2 receptor antagonists"	"Ferrer (Originator), Ferrer (Owner), Azwell (Market Licensee), Galephar (Market Licensee), Kayaku (Market Licensee), Mylan Laboratories (Market Licensee)"		unspecified				"N2C (Anti-Migraine Preparations), N7 (Other CNS Drugs)"	"N02C-X (Other antimigraine preparations), N07C-A (Antivertigo preparations)"	"Dotaricin, FI 6026"			12/12/2006	"Advances in the Treatment of Nausea and Migraine, Neurological Disorders"				no		no							https://adis.springer.com/drugs/800003533?userId=52029392&bpIds=3004037004&checksum=3ae886d87e3b86084716816dede5fba43c49d45a-1617045530535-a4993524e5f1f223181fb45fd3c72978badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016171	JTC 801		<EM>N</EM>-(4-Amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride				No development reported (II)	Pain	C26 H25 N3 O2 . H Cl	Nociceptin receptor antagonists	"Japan Tobacco (Originator), Japan Tobacco (Owner)"		"Injection, PO"				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				04/12/2006	Pain				no		no							https://adis.springer.com/drugs/800016171?userId=52029392&bpIds=3004037004&checksum=b656fd90a6caf5009ef50518e51ef6645a2085cf-1617045530536-2ee3d235c382e18701d9a0a01df506b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025279	Neurotropin - Argenes/Nippon Zoki			No			Marketed	Neuropathic pain		"Alpha 2 adrenergic receptor agonists, Serotonin 3 receptor agonists"	"Nippon Zoki (Originator), Nippon Zoki (Owner), Argenes (Market Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	"Fibromylagia therapy Argenes/Nippon Zoki, Neurotropin"			27/11/2006	Pain			Neurotropin	no		no							https://adis.springer.com/drugs/800025279?userId=52029392&bpIds=3004037004&checksum=c89eeb226b85c1696fc564893768318891ac9a96-1617045530537-8bce0d0986fb6632ff41bed630e8f03fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016993	NGX 6320						Discontinued (Preclinical)	Neuropathic pain		Undefined mechanism	"NeurogesX (Originator), NeurogesX (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/11/2006	Pain				no		no							https://adis.springer.com/drugs/800016993?userId=52029392&bpIds=3004037004&checksum=5571bdfd2db2dece80cc9dc6e2e6f2bd04478702-1617045530538-a1ba3b88e201bb8e9f926e8bcf1758aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016992	NGX 5020						Discontinued (I)	Pain		Undefined mechanism	"NeurogesX (Originator), NeurogesX (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/11/2006	Pain				no		no							https://adis.springer.com/drugs/800016992?userId=52029392&bpIds=3004037004&checksum=714289c5eb7fcf1aa219ce28c9d46175754ae1e1-1617045530539-b3138bf80ab824d522cabc08442b805ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014528	Research programme: nitrosothiol esters of diclofenac - NitroMed		"[2-(2,6-Dichloroanilino)phenyl]acetic acid, 2-ethyl-2-nitrosothiobutyl ester"				Discontinued (Preclinical)	"Pain, Osteoarthritis"	C20 H22 Cl2 N2 O3 S	Cyclooxygenase inhibitors	"NitroMed (Originator), NitroMed (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	SNitrosodiclofenac			21/11/2006	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800014528?userId=52029392&bpIds=3004037004&checksum=476a5e74eccf90634d7dcc355f2d378753a94261-1617045530540-3fc520c0a0e55f6b6216e094da7c5ee1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017571	Fentanyl inhalation - Aradigm Corporation	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				No development reported (I)	"Cancer pain, Pain"	C22 H28 N2 O	Opioid mu receptor agonists	"Aradigm Corporation (Originator), Aradigm Corporation (Owner)"		Inhalation				N2A (Narcotics)	N02A-B03 (Fentanyl)				20/11/2006	"Drug Delivery Systems, Pain"				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800017571?userId=52029392&bpIds=3004037004&checksum=8dd0e3b383622b98e93632fa534bec0fa6bce84d-1617045530541-8ec00d18776301c4d2de18bf36ed0abbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010668	DPI 3290	182417-73-8	"(+)-3-[1(<EM>R</EM>)-[4-Allyl-2(<EM>S</EM>),5(<EM>R</EM>)-dimethylpiperazin-1-yl]-1-(3-hydroxyphenyl)methyl]-<EM>N</EM>-(3-fluorophenyl)-<EM>N</EM>-methyl-benzamide"				Discontinued (II)	Pain	C30 H34 F N3 O2	"Opioid delta receptor agonists, Opioid mu receptor agonists"	"Enhance Biotech (Originator), Enhance Biotech (Owner), Organon Teknika (Market Licensee)"		"IV, Sublingual"				N2A (Narcotics)	N02A (Opioids)	ORG41793			13/11/2006	Pain				no		no							https://adis.springer.com/drugs/800010668?userId=52029392&bpIds=3004037004&checksum=f86ddfc84cdab362525059307877f3a5596e48ca-1617045530542-c69c36988bfefbbaa17565a6d8b80c92badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013110	RS 132943		"(3<EM>S</EM>)-(4-Bromo-2, 6-dimethylphenoxymethyl)-1-methylpiperidine hydrochloride"	No			Discontinued (Preclinical)	Neuropathic pain	C14 H21 Br N O . H Cl	Sodium channel antagonists	"Roche Palo Alto LLC (Originator), Roche (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				09/11/2006	Pain				no		no							https://adis.springer.com/drugs/800013110?userId=52029392&bpIds=3004037004&checksum=ec7bb5c3f0e7452fe9bfb8bcd28f6ea9cce41613-1617045530543-8d05838c6f54a36991c98660bc99d3c8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022565	Research programme: neuropathic pain therapy - D-Pharm						Discontinued (Preclinical)	Neuropathic pain		Undefined mechanism	"D-Pharm (Originator), D-Pharm (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	DP236			08/11/2006	Pain				no		no							https://adis.springer.com/drugs/800022565?userId=52029392&bpIds=3004037004&checksum=4888d75fe3d6d435f764f151759e7286e1935607-1617045530543-f19b2abeb34d3d38d8562eed6263e5bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006578	RO 158081		"1-[2-(Dimethylamino)-1-(4-chlorophenyl)ethyl]cyclohexan-1,2-diol"				Discontinued (II)	Pain	C16 H24 N Cl O2	Serotonin uptake inhibitors	"Roche (Originator), Roche (Owner)"		unspecified			"Constipation, Dizziness, Headache, Insomnia, Nausea, Palpitations, Skin disorders, Urination disorders, Vision disorders"	N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				08/11/2006	Pain				no		no							https://adis.springer.com/drugs/800006578?userId=52029392&bpIds=3004037004&checksum=305d28b848e2fa2730767161a92926b89509cd54-1617045530544-c42e0d5319536c8145e98b9e7b7dba7ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800025259	Research programme: ketoprofen topical - Novavax	22071-15-4	2-(3-benzoylphenyl)-propionic acid				Discontinued (Preclinical)	Pain	C16 H14 O3	Arachidonic acid inhibitors	"Novavax (Originator), Novavax (Owner)"		Topical				N2 (Analgesics)	N02 (Analgesics)	NX304			08/11/2006	Pain				no		no							https://adis.springer.com/drugs/800025259?userId=52029392&bpIds=3004037004&checksum=678ec66e038e5aeb5b332bfefe5ff00033bd04f2-1617045530545-3f776530c5abcb82c5e5af288d9d1813badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005866	SYM 2081	31137-74-3	"(2S, 4R)-4-Methylglutamic acid"				Discontinued (Preclinical)	Pain	C6 H11 N O4	Glutamate receptor antagonists	"Annovis (Originator), Annovis (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	SYM2081			06/11/2006	Pain				no		no							https://adis.springer.com/drugs/800005866?userId=52029392&bpIds=3004037004&checksum=46331bb02ac0efc0b13941eac76f31ccb6be479e-1617045530546-a4496da114384b7f42ca1b21352e55f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019082	OT 21818						Discontinued (Preclinical)	"Neuropathic pain, Diabetic neuropathies"		Undefined mechanism	"Otsuka Pharmaceutical (Originator), Otsuka Pharmaceutical (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	OT21818			06/10/2006	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800019082?userId=52029392&bpIds=3004037004&checksum=27d47856fef0418b23b96b57b6a08cb4f4c9a752-1617045530546-d9b6627680c24f35dc4d1281c9ece735badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015624	Research programme: muscarinic M4 receptor agonists - Banyu						Discontinued (Preclinical)	Pain		Muscarinic M4 receptor agonists	"Banyu (Originator), Banyu (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Muscarinic M4 receptor agonists research programme Banyu			05/10/2006	Pain				no		no							https://adis.springer.com/drugs/800015624?userId=52029392&bpIds=3004037004&checksum=afe109ec61bf5bc87b8c90d718cba30c819eac76-1617045530547-eb44cd5516979c79b979c163db4eebfbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004621	Neutral endopeptidase	82707-54-8					Discontinued (Preclinical)	"Migraine, Small cell lung cancer, Asthma, Lung cancer, Inflammatory bowel diseases"		Endopeptidase inhibitors	"Genentech (Originator), Genentech (Owner), Celera Group (Market Licensee)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), L1X9 (All other antineoplastics), N2C (Anti-Migraine Preparations), R3 (Anti-Asthma and COPD Products)"	"A07E (Intestinal Antiinflammatory Agents), L01X-X (Other antineoplastic agents), N02C-X (Other antimigraine preparations), R03 (Drugs for Obstructive Airway Diseases)"	"NEP, rNEP"			04/10/2006	"Advances in the Treatment of Nausea and Migraine, Cancer, Inflammatory Bowel Disorders, Obstructive Airways Disease"				no		no							https://adis.springer.com/drugs/800004621?userId=52029392&bpIds=3004037004&checksum=3cc0f15e57f23c0110ea719672362d164e16dafb-1617045530548-ffa2620205c47a1f8470f7efa4840917badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017141	Research programme: glycine transporter 2 inhibitors - Organon						No development reported (Preclinical)	Neuropathic pain		Glycine antagonists	"Organon (Originator), Organon (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"glycine transporter 2 inhibitors research programme Organon, GlyT2 inhibitors research programme Organon"			25/09/2006	Pain				no		no							https://adis.springer.com/drugs/800017141?userId=52029392&bpIds=3004037004&checksum=d5e004a283298bc20a54b0be0786ca6d2ad2e9be-1617045530549-8a4520f69dc5246111c2cb48fa275553badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006349	S-fluoxetine	100568-02-3					Discontinued (II)	Migraine	C17 H18 F3 N O	Serotonin uptake inhibitors	"Sepracor (Originator), Sepracor (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				31/08/2006	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006349?userId=52029392&bpIds=3004037004&checksum=1ed2760176d7223d78ad552ff9089726f42af49c-1617045530550-fe53db77d43e380a3257164f92cd3b83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009246	Research programme: opiate agonists - Alanex/AstraZeneca						Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Alanex Corporation (Originator), Alanex Corporation (Owner), AstraZeneca (Market Licensee)"		PO				N2 (Analgesics)	N02 (Analgesics)	Opiate agonists research programme Alanex/AstraZeneca			23/08/2006	Pain				no		no							https://adis.springer.com/drugs/800009246?userId=52029392&bpIds=3004037004&checksum=6945df527b95ed3b3d05547df47b95cf15c5c425-1617045530550-38dc9baa7aa42626eedc770459a5360cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011770	ADL 100101						Discontinued (II)	"Visceral pain, Pruritus"		Opioid kappa receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		"IV-injection, Topical, Ophthalmic"			Headache	"D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2A (Narcotics)"	"D04A-X (Other antipruritics), N02A (Opioids)"	"ADL 0101, ADL 100101"			22/08/2006	"Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800011770?userId=52029392&bpIds=3004037004&checksum=cfa65263b5928ee440c8cf8db82e7c4634265eca-1617045530551-af83833ceb4d044c629a226f37833739badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800021015	Research programme: pain therapies - Microbia						No development reported (Preclinical)	Pain		Undefined mechanism	"Microbia (Originator), Microbia (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	"Dual action analgesic, Pain therapies research programme Microbia"			03/08/2006	Pain				no		no							https://adis.springer.com/drugs/800021015?userId=52029392&bpIds=3004037004&checksum=51d25dc67333d7280e5aee6da283727f22c16cde-1617045530552-c704e35a1e914e8a8bd7614f3fd23057badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010832	Research programme: cyclo-oxygenase-2 inhibitors - Esteve						No development reported (Preclinical)	"Pain, Cancer, Osteoarthritis"		Cyclo-oxygenase 2 inhibitors	"Esteve (Originator), Esteve (Owner)"		unspecified				"L1 (Antineoplastics), M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	"COX2 inhibitors research programme Esteve, Cyclooxygenase2 inhibitors research programme Esteve, Research programme COX2 inhibitors Esteve"			18/07/2006	"Cancer, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800010832?userId=52029392&bpIds=3004037004&checksum=55e77e895bcf5061dd7897a6a4ddef941f5f4d8e-1617045530553-d7a72c150f66c385addebd4c060c60ffbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013898	Research programme: sodium channel antagonists - NeuroSearch/Pierre Fabre			Yes			Discontinued (Preclinical)	"Pain, Major depressive disorder, Epilepsy, Cerebral ischaemia"		Sodium channel antagonists	"Pierre Fabre (Originator), Pierre Fabre (Owner), NeuroSearch (Market Licensee)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N6A (Anti-Depressants and Mood Stabilisers), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N03A-X (Other antiepileptics), N06A-X (Other antidepressants), N07X (Other Nervous System Drugs)"				13/07/2006	"Affective Disorders, Epilepsy and Seizure Disorders, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800013898?userId=52029392&bpIds=3004037004&checksum=d5bff6602a0bcff99bfc8437f482955a613829cf-1617045530554-83fe7341e5681c77eafde18457989be8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008680	Morphine/dextromethorphan - Endo			No			Discontinued (III)	Cancer pain		"Glutamate receptor antagonists, NMDA receptor antagonists"	"Endo Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	"N02A-A51 (Morphine, combinations)"	"Dextromethorphan/morphine Endo, EN 3231, MorphiDex"			11/07/2006	Pain			MorphiDex	no		no							https://adis.springer.com/drugs/800008680?userId=52029392&bpIds=3004037004&checksum=aee2608025f101a9410c01985c93ee328475b6f0-1617045530554-af675e235026095b4566d0bf8d731383badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009950	ADL 100116						No development reported (I)	Pain		Opioid kappa receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	"ADL 0100016, ADL 100116"			10/07/2006	Pain				no		no							https://adis.springer.com/drugs/800009950?userId=52029392&bpIds=3004037004&checksum=e0908f303e84452bb9487fc2bb948dae5ad43b98-1617045530555-a98ea748f3410f414eb62cde3b15ad39badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018999	Opioid analgesic - Nastech/Controlled Chemicals						No development reported (Preclinical)	Pain		"Opioid receptor agonists, Opioid receptor antagonists"	"Controlled Chemicals (Originator), Nastech Pharmaceutical Company (Originator), Controlled Chemicals (Owner), Nastech Pharmaceutical Company (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	Oxycodone derivatives			06/07/2006	Pain				no		no							https://adis.springer.com/drugs/800018999?userId=52029392&bpIds=3004037004&checksum=e92bba7516a519c8654930c1f6ca67701e0cc090-1617045530556-7acb71c457071e23da38113187209509badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017005	Research programme: cannabinoid receptor agonists - Organix		"4-Morpholinebutanoic acid (6a<EM>R,</EM> 10a<EM>R</EM>)-3-(5-cyano-1,1-dimethylpentyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6<EM>H-</EM>benzo[<EM>c</EM>]-1-benzopyran-1-yl ester hydrochloride"				No development reported (Preclinical)	Pain	C32 H46 N2 O4 . H Cl	Cannabinoid receptor agonists	"Organix (Originator), Organix (Owner), Virginia Commonwealth University (Collaborator)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	O1057			27/06/2006	Pain				no		no							https://adis.springer.com/drugs/800017005?userId=52029392&bpIds=3004037004&checksum=ad139b918ec14600c445505558fb15c7d6a0e256-1617045530557-5f0b3b768a8bcbf5eb304a94eaae0d84badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018327	ENT 103						Discontinued (Preclinical)	Pain		Undefined mechanism	"Entropin (CEASED) (Originator), Entropin (CEASED) (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	Radiolabelled ENT103			07/04/2006	Pain				no		no							https://adis.springer.com/drugs/800018327?userId=52029392&bpIds=3004037004&checksum=0710a4ca364c98bfaf811082c438a5cbdcd70980-1617045530557-6bd6ed5c263eb19d2b8eae9f49603c1cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016835	AZD 4282						Discontinued (I)	Neuropathic pain		NMDA receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				03/04/2006	Pain				no		no							https://adis.springer.com/drugs/800016835?userId=52029392&bpIds=3004037004&checksum=59c5d3d1aed6697a6143c4f4ae314f91a4e03dcd-1617045530558-1e79b50af40c61a0a46af19e44f50812badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013107	AM 336		"H-Cys-Lys-Ser-Lys-Gly-Ala-Lys-Cys-Ser-Lys-Leu-Met-Tyr-Asp-Cys-Cys-Ser-Gly-Ser-Cys-Ser-Gly-Thr-Val-Gly-Arg-Cys-NH2 (1-16),(8-20),(15-27)-tris(disulfide)"				Discontinued (II)	Pain	C107 H179 N35 O36 S7	Calcium channel antagonists	"Zenyth Therapeutics (Originator), Zenyth Therapeutics (Owner)"		Intrathecal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"CVID, Leconotide, omegaconotoxin C VID"			27/03/2006	Pain				no		no							https://adis.springer.com/drugs/800013107?userId=52029392&bpIds=3004037004&checksum=b81f53776a5ccaad9b3111fede3c2646a901fe01-1617045530559-37ba51e6eadae8d081458819e8e303aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002937	Meclinertant	146362-70-1	"2-[1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1<EM>H</EM>-pyrazol-3-ylcarboxamido]adamantane-2-carboxylic acid"				Discontinued (II)	"Colorectal cancer, Small cell lung cancer, Anorexia nervosa, Irritable bowel syndrome, Schizophrenia, Prostate cancer, Pancreatic cancer, Pain, Cancer"	C32 H31 Cl N4 O5	Neurotensin antagonists	"sanofi-aventis (Originator), sanofi-aventis (Owner)"		"unspecified, PO"				"L1 (Antineoplastics), N2A (Narcotics), N5A (Antipsychotics)"	"L01 (Antineoplastic Agents), N02A (Opioids)"	"Reminertant, SR 48692"			28/02/2006	"Affective Disorders, Cancer, Digestive System Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800002937?userId=52029392&bpIds=3004037004&checksum=9cc00ad8f8a49fab6f7c27ca55ec0b5b2b52bc12-1617045530560-afb1ed6e22358f7556865cedaa0a835ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008532	CI 1021	158991-23-2	<EM>N</EM>-[2-(1<EM>H</EM>-Indol-3-yl)-1(<EM>R</EM>)-methyl-1-[1(<EM>S</EM>)-phenylethylcarbamoyl]ethyl]carbamic acid benzofuran-2-ylmethyl ester				No development reported (Clinical)	"Nausea and vomiting, Pain"	C30 H29 N3 O4	Neurokinin 1 antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"A4A (Antiemetics and Antinauseants), N2B (Non-Narcotics and Anti-Pyretics)"	"A04A (Antiemetics and Antinauseants), N02B (Other Analgesics and Antipyretics)"	PD 154075			22/02/2006	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800008532?userId=52029392&bpIds=3004037004&checksum=a71902d8da2ed26c94bac4137fce711c9a082d99-1617045530561-8ef2e7546a481b7180bf45a925458187badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013632	Ultramorph						No development reported (II)	Pain		Opioid mu receptor agonists	"Innovata (Originator), Innovata (Owner)"		Inhalation				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				21/02/2006	Pain				no		no							https://adis.springer.com/drugs/800013632?userId=52029392&bpIds=3004037004&checksum=7225cba2970bd363bc19b9cca423b3795c1a61ba-1617045530562-021410a9bfe84d4f1194957bd9c95419badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004262	WIN 552122		"(<EM>R</EM>)-4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)- 1-(1-naphthalenyl-carbonyl)-6<EM>H</EM>-pyrrolo[3,2,1-ij] quinolin-6-one"				Discontinued (Preclinical)	"Pain, Glaucoma, Neurological disorders, Movement disorders"	C27 H26 N2 O3	"Cannabinoid receptor CB1 agonists, Cannabinoid receptor agonists"	"Sanofi Winthrop (Originator), Sanofi Winthrop (Owner), University of Minnesota (Collaborator)"		"unspecified, Ophthalmic"				"N2 (Analgesics), N4A (Anti-Parkinson Drugs), N7X (All other CNS drugs), S1E2 (Miotics and antiglaucoma preparations, topical)"	"N02 (Analgesics), N04B-X (Other dopaminergic agents), N07X (Other Nervous System Drugs), S01E-X (Other antiglaucoma preparations)"	"WIN 55212, WIN 552122"			20/02/2006	"Eye Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800004262?userId=52029392&bpIds=3004037004&checksum=d310a8e06cd1753b8202f2ad1115eb33ef5b0512-1617045530563-b3282bc72b6b60058ed5b75739f5f73ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001280	Loxiglumide	107097-80-3	"Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)-"				No development reported (II)	"Pancreatic cancer, Biliary pain, Pancreatitis, Non-ulcer dyspepsia, Irritable bowel syndrome"	C21 H30 Cl2 N2 O5	Cholecystokinin A receptor antagonists	"Rottapharm (Originator), Rottapharm (Owner), Kaken Pharmaceutical (Market Licensee)"		"PO, unspecified, IV"	biliary	"Route of Elimination (biliary), T<sub>_beta</sub> (h) (6 (Adult)), T<sub>max</sub> (h) (2.1 (Adult))"	Diarrhoea	"A3F (Gastroprokinetics), A7 (Antidiarrhoeals, Oral Electrolyte Replacers and Intestinal Anti-inflammatories), L1 (Antineoplastics), N2 (Analgesics)"	"A03F-A (Propulsives), A07 (Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents), L01 (Antineoplastic Agents), N02 (Analgesics)"	"CR 1505, Loside, Loxizin"			20/02/2006	"Cancer, Digestive System Disorders, Pain, Peptic Ulcer Disease"			Loxizin	no		no							https://adis.springer.com/drugs/800001280?userId=52029392&bpIds=3004037004&checksum=77620b145c39b88c2c5c28520315f0c1340682bc-1617045530565-66cd552037b5a5f9318e12562fcf5c72badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009714	GPI 5000		2-(Phosphonomethyl)pentanedioic acid	Yes			No development reported (Preclinical)	"Neurodegenerative disorders, Neuropathic pain, Diabetic neuropathies"	C6 H11 O7 P	Glutamate carboxypeptidase II inhibitors	"MGI GP (Originator), MGI GP (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs), N7X (All other CNS drugs)"	"A10X (Other Drugs Used in Diabetes), N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	2PMPA			16/02/2006	"Diabetes, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009714?userId=52029392&bpIds=3004037004&checksum=4d3fbdd9411698439be1513804868bda886d9948-1617045530566-5559b3f5179a50f8d111bd2c294c7311badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016504	GW 493838						Discontinued (II)	"Neuropathic pain, Lipid metabolism disorders"		Adenosine A1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"C10A (Cholesterol and Triglyceride Regulating Preparations), N2B (Non-Narcotics and Anti-Pyretics)"	"C10A (Lipid Modifying Agents, Plain), N02B (Other Analgesics and Antipyretics)"	493838			06/12/2005	"Hyperlipidaemia, Pain"				no		no							https://adis.springer.com/drugs/800016504?userId=52029392&bpIds=3004037004&checksum=f9a025c170cf9c418401e87054529cdd700c91ff-1617045530567-e6ae782381dd6bae512a9c01e137cd28badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018451	ALGRX 2872						Discontinued (Clinical)	Migraine		Serotonin receptor agonists	"AlgoRx Pharmaceuticals (Originator), AlgoRx Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	ALGRX2872			01/11/2005	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800018451?userId=52029392&bpIds=3004037004&checksum=0340ee092ec66cd08279058541ec19e7a4eedd33-1617045530568-28cb8e3e20ba1827328e5c4cc0b59169badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013915	Propranolol - intranasal - Questcor	525-66-6	"2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-,"				Discontinued (II)	Migraine	C16 H21 N O2	Undefined mechanism	"Questcor Pharmaceuticals (Originator), Questcor Pharmaceuticals (Owner)"		Intranasal				"C7A (Beta-Blocking Agents, Plain), N2C (Anti-Migraine Preparations)"	"C07A-A05 (Propranolol), N02C (Antimigraine Preparations)"	Migrastat			17/10/2005	Advances in the Treatment of Nausea and Migraine			Migrastat	no		no		"9-cis-Retinoic acid, C-peptide, CA-125, PSA, Thyroid stimulating hormone, beta, Thyroxine"	"ATP-binding cassette, sub-family B (MDR/TAP), member 7, C-peptide"	"9-cis-Retinoic acid, A1C, Adiponectin, AKT, BNP, C-peptide, CA-125, CD40L, COMT, CTx, CUGBP, Elav-like family member 5, D-dimer, E-selectin, Endothelin 1, GLP-1, HIF, Hydrocortisone, ICAM-1, IL10, IL6, IL8, Ki67, L-selectin, MMP-2, MMP9, Nitric Oxide, Norepinephrine, opioid related nociceptin receptor 1, PAI-1, PINP, PKA, Tissue factor, tPA, VCAM-1, VEGF-A, VEGF-C, Von Willebrand factor"		"(S)-Abscisic acid, adrenoceptor beta 2, surface, aldo-keto reductase family 1 member B, Angiopoietin 2, AT-III, Beta-D-Glucose, BRAF, CRP, CYP2D6, Fibrinogen, FSH, HER2, IFN-gamma, IL2, IL4, immunoglobulin kappa variable 1D-39, Insulin, negative elongation factor complex member C/D, NTx, oxytocin receptor, Thrombin, TPO Auto-antibodies"	https://adis.springer.com/drugs/800013915?userId=52029392&bpIds=3004037004&checksum=f272f617a2879bd7f66be76a49c6def9ed5509bd-1617045530571-7f08e7fe68400398c6e8c305b572cc81badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800022515	Fentanyl topical - Novavax	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (Preclinical)	Pain	C22 H28 N2 O	Opioid mu receptor agonists	"Novavax (Originator), Novavax (Owner)"		Topical				N2B (Non-Narcotics and Anti-Pyretics)	N02A-B (Phenylpiperidine derivatives)	NX300			26/05/2005	Pain				no		no							https://adis.springer.com/drugs/800022515?userId=52029392&bpIds=3004037004&checksum=26e832e8daabf396b4a55207d0c99cbc34ed0b1b-1617045530572-ff7adf108151fbbb9fe14d6f353bf236badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019468	RI 273						Discontinued (Preclinical)	"Amyotrophic lateral sclerosis, Pain"		Protein tyrosine kinase inhibitors	"Rinat Neuroscience (Originator), Rinat Neuroscience (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"	"mAb 2256, RI273"			26/04/2005	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800019468?userId=52029392&bpIds=3004037004&checksum=7c428666e2555a1d6e30e4604f6444d3c104c4be-1617045530572-2d1cc22fdcc833318d0b434c9d897d42badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018187	REN 214						Discontinued (Preclinical)	Pain		Undefined mechanism	"Renovis (Originator), Renovis (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				28/02/2005	Pain				no		no							https://adis.springer.com/drugs/800018187?userId=52029392&bpIds=3004037004&checksum=2afd97233783ba7823cd72fada509b1430733be3-1617045530573-5b9209d3ebd18c49653beb1f8f96d453badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019747	AP 48						Discontinued (III)	Pain		Opioid mu receptor agonists	"ALZA Corporation (Originator), ALZA Corporation (Owner)"		Transdermal				N2 (Analgesics)	N02 (Analgesics)				22/10/2004	Pain				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800019747?userId=52029392&bpIds=3004037004&checksum=83107f49457fa61674a4a303c7133d02e3265472-1617045530575-41ba3b7a957c4d5230abf7b6fe872379badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009200	Rhenium Re 186 etidronate	140709-07-5	"(1-Hydroxyethylidene)bis[phosphonic acid], Rhenium (<SUP>186</SUP>Re) salt"				Discontinued (Preregistration)	"Cancer pain, Cancer metastases"	C2 H8 O7 P2	Undefined mechanism	"Mallinckrodt Medical (Originator), Mallinckrodt Medical (Owner), Memorial Sloan-Kettering Cancer Center (Collaborator), University of Cincinnati (Collaborator)"		Injection			Thrombocytopenia	N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Re 186 HEDP			06/10/2004	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800009200?userId=52029392&bpIds=3004037004&checksum=778b9557de4cf2b9413c7b42f4d83f77da1d30ca-1617045530576-49d0cc75675a577587cacb48b8a066a6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009395	MDL 74721		"(R)-2-(N1,N1-dipropylamino)-8-methylsulfonylmethyl-1,2,3,4-tetrahydronapthalene"				Discontinued (Preclinical)	Migraine	C18 H30 N2 O2 S	Serotonin 1D receptor antagonists	"Aventis (Originator), Aventis (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				15/09/2004	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800009395?userId=52029392&bpIds=3004037004&checksum=84d7f4bca9374be622d68d31f26a3f8b21de4242-1617045530576-d91fd1adc29cc6694ed817db90a452b8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003743	MDL 100250		"N-[[1,2,3,4-Tetrahydro-2-(mercaptomethyl)-2-naphthalenyl]carbonyl]-glycine"				Discontinued	Pain	C14 H17 N O3 S	Neprilysin inhibitors	"Aventis (Originator), Aventis (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				15/09/2004	Pain				no		no							https://adis.springer.com/drugs/800003743?userId=52029392&bpIds=3004037004&checksum=dca7b5fb4a1a32f9471611f47705679c0f4aa8b7-1617045530577-16efa782f427032d5c9174cfce0297a8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009848	Gacyclidine	68134-81-6	"Piperidine, 1-(2-methyl-1-(2-thienyl)cyclohexyl)-, cis-"	Yes			Discontinued (II)	"Brain injuries, Spinal cord injuries, Postoperative pain"	C16 H25 N S	NMDA receptor antagonists	"Ipsen (Originator), Ipsen (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07X (Other Nervous System Drugs)"	GK 11			30/08/2004	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009848?userId=52029392&bpIds=3004037004&checksum=f826f94c16f30d1097e4a99ff8d22be6ad4e39e6-1617045530578-83188b81ca85e1563ad66b2c31824cc3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018186	REN 213						Discontinued (II)	Postoperative pain		Opioid receptor agonists	"Renovis (Originator), Renovis (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				02/08/2004	Pain				no		no							https://adis.springer.com/drugs/800018186?userId=52029392&bpIds=3004037004&checksum=41ff12ef89a5782d924983d522fd8e858951e3f0-1617045530579-f070dc1160c3390ecad39a5770b02e55badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009397	Fentanyl iontophoretic - Fournier	437-38-7	<EM>N</EM>-Phenyl-<EM>N</EM>-[1-(2-phenylethyl)-4-piperidinyl]propanamide				Discontinued (II)	Postoperative pain	C22 H28 N2 O	Opioid receptor agonists	"Groupe Fournier (Originator), Groupe Fournier (Owner)"		Transdermal				N2A (Narcotics)	N02A-B03 (Fentanyl)	TS 36			19/04/2004	"Drug Delivery Systems, Pain"				no		no		"A1AT, acireductone dioxygenase 1, ephrin A5, Norepinephrine"	small proline rich protein 2A	"A1AT, absent in melanoma 2, acireductone dioxygenase 1, ACTH, Adiponectin, ASPA, ATP binding cassette subfamily C member 3, CD3d, CD3e, CD3g, CD4, CD8a, COMT, CRP, CXCL10, ephrin A5, GTP cyclohydrolase 1, HIF, Hydrocortisone, IFN-gamma, IL1 beta, IL10, IL13, IL17, IL4, IL5, IL6, IL8, integrin, alpha M (complement component 3 receptor 3 subunit), MCP1, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor), MIP-1 alpha, MMP-2, Norepinephrine, OPRM1, Prader Willi/Angelman region RNA 5, Procalcitonin, proteasome 26S subunit, non-ATPase 1, small proline rich protein 2A, TGF-beta, TNF-alpha, VEGF-A, VEGF-C, WDFY family member 4, Xanthine oxidase"	VEGF-A	"BNP, CD27 molecule, CD28 molecule, CD45, CXCL12, HLA-DR, HMGB1, IL12A, IL12B, Insulin, interleukin 33, myelin basic protein, PSA, troponin I, cardiac, vasodilator-stimulated phosphoprotein"	https://adis.springer.com/drugs/800009397?userId=52029392&bpIds=3004037004&checksum=41011a2779378422827fd3576bce84b4177c73e9-1617045530580-a202878fc57fdebaa8e7deaeeac7a176badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019089	SRSS 023						Discontinued (Preclinical)	Migraine		Serotonin 1 receptor agonists	"Sirus (Originator), Sirus (Owner)"		Sublingual				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				15/04/2004	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800019089?userId=52029392&bpIds=3004037004&checksum=bf0826860a02c9638cab9b7c482a74c0500e6c4a-1617045530581-5b9387d2e06fd91c5091452e16d38d30badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800018179	SRSC 355						Discontinued (Preclinical)	Neuropathic pain		Undefined mechanism	"Sirus (Originator), Sirus (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	SGX 355			15/04/2004	Pain				no		no							https://adis.springer.com/drugs/800018179?userId=52029392&bpIds=3004037004&checksum=fe286aba84b5485ab8c07a11de4dc60fbc15de30-1617045530582-04d7d5fcb8a8a1965c96445f9bd308cbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800019085	SRSS 016						Discontinued (Preclinical)	Pain		Undefined mechanism	"Sirus (Originator), Sirus (Owner)"		Sublingual				N2 (Analgesics)	N02 (Analgesics)				15/04/2004	Pain				no		no							https://adis.springer.com/drugs/800019085?userId=52029392&bpIds=3004037004&checksum=d2c7df2abb9e8a8b640e8622f3c12b8013a6d55e-1617045530583-93180d527053fe0388a16130ed12d9cbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000658	Nerve growth factor - Genentech	9061-61-4					Discontinued (III)	"Peripheral nervous system diseases, Neuropathic pain, Diabetic neuropathies, Alzheimer's disease, Herpes simplex virus infections"		Neuron stimulants	"Amgen Boulder (Originator), Chiron Corporation (Originator), Genentech (Originator), Amgen Boulder (Owner), Chiron Corporation (Owner), Genentech (Owner), Ceregene (Market Licensee)"		"unspecified, SC"				"A10X (Other Drugs Used in Diabetes), J5B (Antivirals, excluding anti-HIV products), N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs), N7D9 (All other anti-Alzheimer products)"	"A10X (Other Drugs Used in Diabetes), J05 (Antivirals for Systemic Use), N02B (Other Analgesics and Antipyretics), N06D-X (Other anti-dementia drugs), N07X (Other Nervous System Drugs)"	Neuleze			06/04/2004	"Alzheimer's Disease and Cognition Disorders, Diabetes, Neurological Disorders, Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800000658?userId=52029392&bpIds=3004037004&checksum=a4d4aecf6c909ffdb01d2a0f2e19d6095ea9cbbf-1617045530584-040bcf04f707ec3b8952d440b1c1b3d1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017025	Research programme: pain therapy - Nobex						Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Nobex Corporation (Originator), Nobex Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	pain therapy research programme Nobex			31/03/2004	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800017025?userId=52029392&bpIds=3004037004&checksum=bd743618a59a93942b0f0e0d12474defe27f521b-1617045530585-99522c66d6687fb5b9a8086651111189badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001357	U 50488H	83913-06-8	"Benzeneacetamide, 3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-, (1S-trans)-, hydrochloride"				Discontinued (Preclinical)	"Pain, Arrhythmias, Anxiety disorders, Peptic ulcer, Rheumatoid arthritis"	C19 H26 Cl2 N2 O . H Cl	"Opioid kappa receptor agonists, Potassium channel antagonists, Sodium channel antagonists"	"Pharmacia Corporation (Originator), Pharmacia Corporation (Owner), Nonindustrial source (Collaborator)"		unspecified				"A3F (Gastroprokinetics), C1B (Anti-Arrhythmics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), N5C (Tranquillisers)"	"A03F-A (Propulsives), C01 (Cardiac Therapy), M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics), N05B (Anxiolytics)"	U 50488			01/03/2004	"Anxiety Disorders, Arrhythmias, Pain, Peptic Ulcer Disease, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800001357?userId=52029392&bpIds=3004037004&checksum=18e0cccce5908ef9d64785c1c5137636f03bfa82-1617045530586-b7f9cf4777d620a2e159a073565d238dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004025	4-Methylcatechol	452-86-8	4-Methylcatechol				Discontinued (Preclinical)	"Neuropathic pain, Diabetic neuropathies"	C7 H8 O2	Nerve growth factor stimulants	"Unknown (Originator), Unknown (Owner), Nonindustrial source (Collaborator)"		unspecified				"A10X (Other Drugs Used in Diabetes), N2 (Analgesics)"	"A10X (Other Drugs Used in Diabetes), N02 (Analgesics)"				30/01/2004	"Diabetes, Pain"				no		no							https://adis.springer.com/drugs/800004025?userId=52029392&bpIds=3004037004&checksum=318f96fa0074293e8a56391d6c0a19def333b147-1617045530587-b86f08189c9a17762076942921403a89badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016055	Research programme: pain therapy - Penwest/Laboratoires Irex						Discontinued (Preclinical)	Pain		Undefined mechanism	"Laboratoires Irex (Originator), Penwest Pharmaceuticals (Originator), Laboratoires Irex (Owner), Penwest Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Pain therapy research programme Penwest/Laboratoires Irex			23/01/2004	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800016055?userId=52029392&bpIds=3004037004&checksum=9ba4b2eb3670f850461b2ed770baa593a56517a4-1617045530588-cd10d1ee185c311d82d39a77947ca41bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015093	D 6428						Discontinued (I)	Pain		Undefined mechanism	"Celltech Group (Originator), Penwest Pharmaceuticals (Originator), Celltech Group (Owner), Penwest Pharmaceuticals (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				23/01/2004	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800015093?userId=52029392&bpIds=3004037004&checksum=af732f8de3516f13607d67737d5d95d884aeeda4-1617045530589-33715da878ccf74a90bf379f417bced1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800016666	Research programme: pain therapy - Arakis/Penwest						Discontinued (Preclinical)	Pain		Undefined mechanism	"Penwest Pharmaceuticals (Originator), Sosei R&D (Originator), Penwest Pharmaceuticals (Owner), Sosei R&D (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				23/01/2004	"Drug Delivery Systems, Pain"				no		no							https://adis.springer.com/drugs/800016666?userId=52029392&bpIds=3004037004&checksum=b2282c6bf6ec4e681a9549350c6f641cabe3987b-1617045530590-6d9387078e24be314c082a2c61e0727fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006885	SNF 9007	137415-20-4	Asp-Tyr-<EM>d</EM>-Phe-Gly-Trp-[N-Me]-Nle-Asp-PheNH<SUB>2</SUB>				No development reported (Preclinical)	Pain		"Opioid delta receptor antagonists, Opioid mu receptor antagonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-X (Other opioids)				18/12/2003	Pain				no		no							https://adis.springer.com/drugs/800006885?userId=52029392&bpIds=3004037004&checksum=36e349b308531184d7917eb879b7a4b6eec1ff34-1617045530590-adab955290656af6ad5ff01ee4a5a951badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015862	ONO AE1 329						No development reported (Preclinical)	Pain		Prostaglandin E4 agonists	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/12/2003	Pain				no		no							https://adis.springer.com/drugs/800015862?userId=52029392&bpIds=3004037004&checksum=3588718a64289c1dee04d901f5f49a31eb459476-1617045530591-5167e30af63e73041f7ee39412bd725ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009757	R-ketorolac		"5-Benzoyl-2, 3-dihydro-1(R)<EM>H</EM>-pyrrolizine-1-carboxylic acid"				No development reported (Preclinical)	Pain	C15 H13 N O3	Cyclo-oxygenase 2 inhibitors	"Sepracor (Originator), Sepracor (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/12/2003	Pain				no		no							https://adis.springer.com/drugs/800009757?userId=52029392&bpIds=3004037004&checksum=bf7486fdcd55a18e2143efd08a3122524d71f780-1617045530592-d79f8122baedc34ec4e8670db1b4a990badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014972	ONO 2921						No development reported (Preclinical)	Neuropathic pain		Calcium channel antagonists	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/12/2003	Pain				no		no							https://adis.springer.com/drugs/800014972?userId=52029392&bpIds=3004037004&checksum=6d400bde4d4303394eaf14d3f0ea355e0b3993ea-1617045530593-f41839a516251b17335b95ed6eb0f298badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013802	RWJ 314313		4-[2-Chloro-5-[3(<EM>R</EM>)-pyrrolidinyloxy]pyridin-3-yl]benzonitrile				No development reported (Preclinical)	Pain	C16 H14 Cl N3 O	Nicotinic receptor agonists	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				18/12/2003	Pain				no		no							https://adis.springer.com/drugs/800013802?userId=52029392&bpIds=3004037004&checksum=abeb9acd98deeff91edd89808c9ea8c9d9e5b727-1617045530593-1c37df952b11721f25a85d306d6645e6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003107	Avicatonin	103451-84-9	Butyroyl-Ala-Ser-Leu-Ser-Thr-2-aminobutyric acid-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ala-Gly-Thr-Pro-NH2				No development reported (Preclinical)	"Inflammation, Pain, Postmenopausal osteoporosis"	C147 H243 N41 O46	Calcitonin stimulants	"Mitsubishi Chemical (Originator), Mitsubishi Chemical (Owner)"		IM				"H4A (Calcitonins), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"H05B-A (Calcitonin preparations), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics)"	MCI 536			18/12/2003	"Inflammation, Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800003107?userId=52029392&bpIds=3004037004&checksum=eb5ef66d1390db3ce89e4bb6714bb2cb0a6d8be3-1617045530594-9e4b1b6a480e1dea016187bf7b8269eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012992	Colykade						Discontinued (II)	Pain		Cholecystokinin B receptor antagonists	"Merck & Co (Originator), Merck & Co (Owner), ML Laboratories (Market Licensee)"		unspecified				N2A (Narcotics)	N02 (Analgesics)				16/12/2003	Pain				no		no							https://adis.springer.com/drugs/800012992?userId=52029392&bpIds=3004037004&checksum=2641dd830a0eb4bdcfe4df9a9cd7998f2d931fa4-1617045530595-1ce134ec399531f4428227973d402ddabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008400	ALX 0646						Discontinued (I)	Migraine		Serotonin receptor agonists	"NPS Allelix (Originator), NPS Allelix (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	ALX 646			12/12/2003	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800008400?userId=52029392&bpIds=3004037004&checksum=df0baa59253ecfa0a20505d843d14d8ab540df6c-1617045530596-8f71cfe43bfdfc31680c135f97793f0fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011726	Morphine-6-glucuronide - ML Laboratories	70001-26-2	"(5_,6_)-4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-yl _-D-glucopyranosiduronic acid"				No development reported (II)	"Postoperative pain, Cancer pain"	C23 H29 N O9	Opioid mu receptor agonists	"Unknown (Originator), Unknown (Owner), ML Laboratories (Market Licensee)"		"IV, Inhalation"				N2A (Narcotics)	"N02A-A (Natural opium alkaloids), N02A-F (Morphinan derivatives)"	"Isomorph, M6G ML Laboratories"			17/11/2003	Pain				no		no							https://adis.springer.com/drugs/800011726?userId=52029392&bpIds=3004037004&checksum=769b2c758cd9dcaaca216a9792235a458ebfa081-1617045530596-d9f6119dc809983fdc6db9d5869e9c14badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007990	S 18523	174769-78-9	1-[4-(1<EM>H</EM>-Tetrazol-5-yl)butyl]indol-3-ylcarbonyl- [(<EM>R</EM>)-4-hydroxy]-L-proyl-[3-L-(_-naphthyl)-alanine- <EM>N</EM>-benzyl-<EM>N</EM>-methylamide potassium salt				No development reported (Preclinical)	"Pain, Respiratory tract disorders, Inflammation"	C40 H41 K N8 O4	Neurokinin 1 antagonists	"Servier (Originator), Servier (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics), R3 (Anti-Asthma and COPD Products)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics), R03 (Drugs for Obstructive Airway Diseases)"				03/11/2003	"Inflammation, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800007990?userId=52029392&bpIds=3004037004&checksum=ca63b5cdbb139512f2170db0a6ca08c1e1153d9b-1617045530597-f7a105db0896519508458b27bea23007badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010541	SS 20		<EM>endo</EM>-2-[(4-Chlorophenyl)thio]propionic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester				Discontinued (Preclinical)	Pain	C17 H22 N Cl O2 S	Acetylcholinesterase inhibitors	"Fidia Farmaceutici (Originator), Fidia Farmaceutici (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				10/10/2003	Pain				no		no							https://adis.springer.com/drugs/800010541?userId=52029392&bpIds=3004037004&checksum=da776da21ab6a090966925a7bfb2d46498c32146-1617045530598-4f9ce41684719c7ff63edad0297f8455badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010539	ET 142		<EM>endo</EM>-2-(4-Chlorophenoxy)propionic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester				Discontinued (Preclinical)	Pain	C17 H22 N Cl O3	Acetylcholinesterase inhibitors	"Fidia Farmaceutici (Originator), Fidia Farmaceutici (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				10/10/2003	Pain				no		no							https://adis.springer.com/drugs/800010539?userId=52029392&bpIds=3004037004&checksum=985d8d986bc4f7b013db9934d1c4f13ffa0bbd85-1617045530599-b6de87ada6476d5cc13aa64aecfc8443badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006874	FID 072021		3-Atropanyl 2-(4-chlorophenoxy)butyrate				Discontinued (Preclinical)	Pain	C18 H24 N Cl O3	"Acetylcholine inhibitors, Acetylcholine stimulants"	"Nonindustrial source (Originator), Nonindustrial source (Owner), Fidia Farmaceutici (Market Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				10/10/2003	Pain				no		no							https://adis.springer.com/drugs/800006874?userId=52029392&bpIds=3004037004&checksum=9550634d494ac10e7a3768623f3b80f38143fe9b-1617045530600-76dc133e136d000757bc42752c05a4ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009193	SM 32		2-(Phenylthio)butyric acid endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester oxalate				Discontinued (Preclinical)	Pain	C18 H25 N O2 S . C2 H2 O4	Acetylcholine stimulants	"Fidia Farmaceutici (Originator), Fidia Farmaceutici (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				10/10/2003	Pain				no		no							https://adis.springer.com/drugs/800009193?userId=52029392&bpIds=3004037004&checksum=9098f21682e8869529d22802e035b19cc3019fdd-1617045530600-9edd628f3168100f224084601ff8af26badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006836	ReN 1869		"1-[3-(10,11-Dihydro-5<EM>H</EM>-dibenzo[a,d]cyclohepten-5-ylidene)propyl]piperidine-3(<EM>R</EM>)-carboxylic acid"				Discontinued (II)	"Rheumatic disorders, Neuropathic pain"	C24 H27 N O2	Undefined mechanism	"Novo Nordisk (Originator), Novo Nordisk (Owner), ReNeuron (Licensee)"		PO			"Dizziness, Fatigue, Somnolence"	"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	"NN 1869, NNC 051869, NNC 1869"			08/10/2003	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800006836?userId=52029392&bpIds=3004037004&checksum=49b82e6d4020efb60686f2a9c0ea1b39847cd5a9-1617045530602-00f2c90277519d2564b083c76c68e699badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005282	Sameridine	143257-97-0	"4-Piperidinecarboxamide, N-ethyl-1-hexyl-N-methyl-4-phenyl-"				Discontinued (II)	Anaesthesia	C21 H34 N2 O	Opioid mu receptor agonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified		"Cl (L/h) (17 (Adult)), T<sub>_beta</sub> (h) (3 - 4 (Adult)), Vd (L/kg) (3 - 6 (Adult))"	"Dizziness, Headache"	"N1B (Anaesthetics, Local), N2B (Non-Narcotics and Anti-Pyretics)"	"N01B (Anesthetics, Local), N02 (Analgesics)"	LPB 139			08/10/2003	Pain				no		no							https://adis.springer.com/drugs/800005282?userId=52029392&bpIds=3004037004&checksum=299a7be3a84e64b0ff9bb0ae6d9636264dc26d16-1617045530603-0ff16390b32ae66ff61ba99e6f204f19badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001121	Remacemide	128298-28-2	"(±)-2-Amino-N-(1-methyl-1,2-diphenylethyl)acetamide"	Yes			Discontinued (III)	"Huntington's disease, Epilepsy, Stroke, Neurological disorders, Parkinson's disease, Neuropathic pain"	C17 H20 N2 O	"Glutamate receptor antagonists, NMDA receptor antagonists"	"AstraZeneca R&D Charnwood (Originator), AstraZeneca R&D Charnwood (Owner)"		"PO, IV-infusion, unspecified"	hepatic	"Active Metabolites (yes), Linear Kinetics (yes), Route of Elimination (hepatic), Cl (L/h) (72 (Adult)), T<sub>_beta</sub> (h) (3.8 (Adult)), T<sub>max</sub> (h) (1.4 (Adult))"	"CNS disorders, Dizziness, Drowsiness, Eye disorders, Fatigue, Gastrointestinal disorders, Heartburn, Liver disorders"	"N2B (Non-Narcotics and Anti-Pyretics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N03A-X (Other antiepileptics), N04 (Anti-Parkinson Drugs), N07 (Other Nervous System Drugs)"	PR 934423			08/10/2003	"Epilepsy and Seizure Disorders, Neurological Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800001121?userId=52029392&bpIds=3004037004&checksum=13994d248817604049cf1fa3f00cd08c283b3c2d-1617045530604-d61f22acfca90347bdfa9da61719bcd8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014968	ADL 10398						Discontinued (Preclinical)	Pain		Opioid kappa receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	"ADL 010398, ADL 10398"			07/10/2003	Pain				no		no							https://adis.springer.com/drugs/800014968?userId=52029392&bpIds=3004037004&checksum=dade2fbe4896b55e4bd5304eec2c478215f66bd3-1617045530605-13c0e0cbfeb43f16fcee903148490f42badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017184	Research programme: ORL1 antagonists - Adolor						Discontinued (Preclinical)	"Pain, Neuropathic pain"		Opioid receptor antagonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ORL1 antagonists research programme Adolor			07/10/2003	Pain				no		no							https://adis.springer.com/drugs/800017184?userId=52029392&bpIds=3004037004&checksum=d22809bb409a57774639bd896527ca0f13a0e467-1617045530606-a438a9520f69e4c1363cca1a095559cbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007429	CP 122721	145742-28-5	"(+)-(2S,3S)-3-(2-Methoxy-5-trifluoromethoxybenzyl)amino- 2-phenylpiperidine"				No development reported (II)	"Major depressive disorder, Nausea and vomiting, Pain"	C20 H24 N2 F3 O2	Neurokinin 1 antagonists	"Pfizer (Originator), Pfizer (Owner)"		"unspecified, PO"				"A4A (Antiemetics and Antinauseants), N2B (Non-Narcotics and Anti-Pyretics), N6A (Anti-Depressants and Mood Stabilisers)"	"A04A-D (Other antiemetics), N02B (Other Analgesics and Antipyretics), N06A (Antidepressants)"				07/10/2003	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800007429?userId=52029392&bpIds=3004037004&checksum=1f395e4354ccdc505877ee0f8d1f75b15f321390-1617045530607-1ff81e87bc2a373db2570fef755a6a28badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014046	ReN 0189						Discontinued (Preclinical)	"Inflammation, Neuropathic pain"		Undefined mechanism	"Novo Nordisk (Originator), Novo Nordisk (Owner), ReNeuron (Licensee)"		unspecified				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	NNC 470189			30/09/2003	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800014046?userId=52029392&bpIds=3004037004&checksum=97c6ae307a123992a5a483c3fb25daa4afe8ab1b-1617045530608-58f6ab1971239d2fa1c80f043c0b564abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009145	Tilmacoxib	180200-68-4	4-(4-Cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzene-sulfonamide				Discontinued (II)	"Rheumatoid arthritis, Familial adenomatous polyposis, Osteoarthritis, Postoperative pain"	C16 H19 F N2 O3 S	"Cyclo-oxygenase 2 inhibitors, Apoptosis stimulants, Cyclooxygenase inhibitors"	"Japan Tobacco (Originator), Japan Tobacco (Owner), Fujisawa (Market Licensee)"		"PO, unspecified"		"Activity vs parent (&lt;), T<sub>_beta</sub> (h) (40.3 - 75 (Adult)), T<sub>max</sub> (h) (1.5 - 6 (Adult))"		"L1 (Antineoplastics), M1A3 (Coxibs, plain), N2B (Non-Narcotics and Anti-Pyretics)"	"L01 (Antineoplastic Agents), M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	JTE 522			23/09/2003	"Cancer, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800009145?userId=52029392&bpIds=3004037004&checksum=c9aebb081bc1c6bba16caa3e6a59a628ff0d2358-1617045530610-adb13e78ec31c8b14172097f51d7fe64badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009965	Lidocaine/dextromethorphan - Endo/Indevus						Discontinued (Preclinical)	Migraine		"NMDA receptor antagonists, Opioid receptor agonists, Sodium channel antagonists"	"Endo Pharmaceuticals (Originator), Indevus Pharmaceuticals (Originator), Endo Pharmaceuticals (Owner), Indevus Pharmaceuticals (Owner)"		Intranasal				N2C (Anti-Migraine Preparations)	"N01B-B52 (Lidocaine, combinations), N02C-X (Other antimigraine preparations)"	LidodexNS			19/09/2003	Advances in the Treatment of Nausea and Migraine			LidodexNS	no		no							https://adis.springer.com/drugs/800009965?userId=52029392&bpIds=3004037004&checksum=8e90d56cd2580bed7132df10370f16cc18d3c7cd-1617045530611-92515d3d41aab71f669b5287e2eb75eabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010408	SDZ 249482		"Thiourea, <EM>N<SUP>1</SUP></EM>-[1-(3-methoxy-4-propoxy) phenyl]methyl-<EM>N<SUP>2</SUP></EM>-[4-(2, 2-dimethylethyl) phenyl]methyl-,"				Discontinued (Preclinical)	Pain	C23 H32 N2 O2 S	Undefined mechanism	"Novartis (Originator), Novartis (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				27/08/2003	Pain				no		no							https://adis.springer.com/drugs/800010408?userId=52029392&bpIds=3004037004&checksum=9c7278a4576925b142d90b0cab0a80f7dc8a7356-1617045530612-fa1f21724d60523188ebc04654481702badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014454	Butorphanol-intranasal - Nastech						Discontinued (I)	Migraine		Opioid receptor agonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Nastech Pharmaceutical Company (Market Licensee)"		Intranasal				N2C (Anti-Migraine Preparations)	N02A-F (Morphinan derivatives)				05/08/2003	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800014454?userId=52029392&bpIds=3004037004&checksum=b823903196c7db4fa181d6fe04c963cbbcee5905-1617045530613-5ca7f8183c4d0c66de509614af1bb275badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001436	GR 79236	124555-18-6	"<EM>N</EM>-[(1S, trans)-2-hydroxycyclopentyl]adenosine"				Discontinued (II)	"Type 2 diabetes mellitus, Pain, Hyperlipidaemia, Reperfusion injury"	C15 H21 N5 O5	Adenosine A1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), C10 (Lipid-Regulating/Anti-Atheroma Preparations), C1X (All Other Cardiac Preparations), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), C01E-B (Other cardiac preparations), C10A (Lipid Modifying Agents, Plain), N02B (Other Analgesics and Antipyretics)"				03/07/2003	"Diabetes, Hyperlipidaemia, Ischaemic Heart Disease, Pain"				no		no							https://adis.springer.com/drugs/800001436?userId=52029392&bpIds=3004037004&checksum=f9d86c65675ec160ae6f2079088a36c7e9d41cad-1617045530614-009efac2b72133b9ffb6ae9a243318c0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008589	SR 144190		"(+)-(<EM>R</EM>)-<EM>N</EM>-[1-[2-[4-Benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-<EM>N',N'</EM>-dimethylurea"				Discontinued (I)	"Major depressive disorder, Anxiety disorders, Asthma, Inflammatory bowel diseases, Pain"	C33 H38 F2 N4 O3	Neurokinin 2 antagonists	"Sanofi-Synthelabo (Originator), Sanofi-Synthelabo (Owner)"		unspecified				"A7E (Intestinal Anti-Inflammatory Agents), N2B (Non-Narcotics and Anti-Pyretics), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers), R3 (Anti-Asthma and COPD Products)"	"A07E (Intestinal Antiinflammatory Agents), N02B (Other Analgesics and Antipyretics), N05B (Anxiolytics), N06A (Antidepressants), R03 (Drugs for Obstructive Airway Diseases)"				30/06/2003	"Affective Disorders, Anxiety Disorders, Inflammatory Bowel Disorders, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800008589?userId=52029392&bpIds=3004037004&checksum=9cb064405f891f2f1cf76a5e3469950f36c2ffd4-1617045530615-65cfb3184bed9ddcc1cca8ef1a2599c5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015693	S 19014		"5'6'-Dimethylspiro[4,5-dihydro-1<EM>H</EM>-imidazol-4,2'-indane]"				No development reported (Preclinical)	Migraine	C13 H16 N2	Alpha 1 adrenergic receptor agonists	"Servier (Originator), Servier (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				24/06/2003	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800015693?userId=52029392&bpIds=3004037004&checksum=7353920c7b2612c54c7848c80c2fc2ae5919c034-1617045530615-e4b7973b28990648b1ed1d14328d9ccbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013270	Ergotamine inhalation - Sheffield						Discontinued (Clinical)	Migraine		Alpha adrenergic receptor antagonists	"Sheffield Pharmaceuticals (Originator), Sheffield Pharmaceuticals (Owner)"		Inhalation				N2C (Anti-Migraine Preparations)	N02C-A (Ergot alkaloids)	Tempoergotamine			17/06/2003	"Advances in the Treatment of Nausea and Migraine, Drug Delivery Systems"				no		no							https://adis.springer.com/drugs/800013270?userId=52029392&bpIds=3004037004&checksum=6a6452c05a5ba274db9b926ea55d6d51ccf0e076-1617045530616-abda967deffe01b3be7a54dbedfa4efdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014676	Morphine inhalation - Sheffield Pharmaceuticals	6211-15-0	"9<EM>H</EM>-9,9c-Iminoethanophenanthro[4,5-<EM>bcd</EM>]furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-, sulfate (2:1) pentahydrate"				Discontinued (Clinical)	Cancer pain	C17 H19 N O3 . 1/2 H2 S O4 . 5/2 H2 O	Opioid mu receptor agonists	"Sheffield Pharmaceuticals (Originator), Sheffield Pharmaceuticals (Owner)"		Inhalation				N2A (Narcotics)	N02A-A01 (Morphine)				17/06/2003	"Drug Delivery Systems, Pain"				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800014676?userId=52029392&bpIds=3004037004&checksum=427ad1901563d71ea3c1d53cc8da2c6c90d6351c-1617045530617-4b95d464246c2eacd9d11fc38c14cbfabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010407	Aspartame	53906-69-7	3-Amino-<EM>N</EM>-(_-carboxyphenethyl)succinamic acid <EM>N</EM>-methyl ester				No development reported (Clinical)	"Sickle cell anaemia, Pain, Osteoarthritis, Rheumatoid arthritis"	C14 H18 N2 O5	Haemoglobin modulators	"Oklahoma Medical Research Foundation (Originator), Oklahoma Medical Research Foundation (Owner)"		"PO, unspecified"			"Drug hypersensitivity, Gastrointestinal disorders, Neurological disorders, Skin disorders"	"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	"APM, EQUAL, SC 18862"			04/04/2003	"Haematological Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800010407?userId=52029392&bpIds=3004037004&checksum=ac1ac5a17b2cc84f3310d741df69d98373ab1803-1617045530618-bbf08fb0e9b79588fd5f9baeb0d1f460badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000126	Piritrexim	72732-56-0	"2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-<EM>d</EM>]pyrimidine mono(2-hydroxyethanesulfonate)"				No development reported (II)	"Kaposi's sarcoma, Pain, Bladder cancer"	C17 H19 N5 O2 . C2 H6 O4 S	Tetrahydrofolate dehydrogenase inhibitors	"ILEX Oncology Inc (Originator), ILEX Oncology Inc (Owner), MPI Development (Market Licensee)"		"PO, unspecified"			"Anaemia, Diarrhoea, Leucopenia, Mucositis, Nausea, Neutropenia, Skin eruptions, Thrombocytopenia, Vomiting"	"L1B (Antimetabolites), N2B (Non-Narcotics and Anti-Pyretics)"	"L01B (Antimetabolites), N02B (Other Analgesics and Antipyretics)"	"BW 301U, Piritrexim isethionate"			25/03/2003	"Cancer, Pain"				no		no							https://adis.springer.com/drugs/800000126?userId=52029392&bpIds=3004037004&checksum=8d3f8f670400dd6ff3aa5fbed944ffa323f7d7bc-1617045530620-4412a01a433baea9f7fa4c26ad83362cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013338	Research programme: analgesics - CeNeS/Endo						Discontinued (Preclinical)	Pain		Undefined mechanism	"CeNeS Pharmaceuticals (Originator), Endo Pharmaceuticals (Originator), CeNeS Pharmaceuticals (Owner), Endo Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Analgesics research programme CeNeS/Endo			21/03/2003	Pain				no		no							https://adis.springer.com/drugs/800013338?userId=52029392&bpIds=3004037004&checksum=0601111df460ab5d27e5dd2dcc4dd1742eca09e7-1617045530620-c7058bd0dd6b2d08a94d38aa0b30b12bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014952	PD 0204318		"[1-(4-Dimethylaminobenzyl)piperidin-4yl]-[4-(3, 3-dimethylbutyl)phenyl]-(3-methyl-but-2enyl)amine"				No development reported (Preclinical)	Pain	C31 H46 N3	Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				04/03/2003	Pain				no		no							https://adis.springer.com/drugs/800014952?userId=52029392&bpIds=3004037004&checksum=6929872256a07381bf8dc98388469f1a1d93756b-1617045530621-e81ec8d297e1594209b1781aef4cf30dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003313	GR 73632	133156-06-6	N-(5-Amino-1-oxopentyl)-L-phenylalanyl-L-phenylalanyl- L-prolyl-N-methyl-L-leucyl-L-methioninamide				No development reported (Preclinical)	Pain	C33 H46 N6 O5 S	Neurokinin 1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				03/03/2003	Pain				no		no							https://adis.springer.com/drugs/800003313?userId=52029392&bpIds=3004037004&checksum=f4514c9ab92cb6d04f8531ee870dfa50fe1f2cf3-1617045530622-10343b609d451938b4e02b7e260ab6e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007136	R-ketoprofen		"R-(-)-Benzeneacetic acid, 3-benzoyl-_-methyl-"				No development reported (II)	"Neuropathic pain, Tinnitus"	C16 H14 O3	Cyclooxygenase inhibitors	"Sepracor (Originator), Sepracor (Owner)"		"PO, unspecified"	renal	"Linear Kinetics (yes), Route of Elimination (renal), Cl (L/h) (5.76 - 6.12 (Adult)), T<sub>_beta</sub> (h) (2.3 - 2.4 (Adult)), T<sub>max</sub> (h) (.33 - 4 (Adult)), Vd (L/kg) (.28 - .29 (Adult))"		"N2B (Non-Narcotics and Anti-Pyretics), S2D (Other Otologicals)"	"N02 (Analgesics), S02D (Other Otologicals)"				25/02/2003	"Ear, Nose and Throat Disorders, Pain"				no		no							https://adis.springer.com/drugs/800007136?userId=52029392&bpIds=3004037004&checksum=c2e205ed565f6a0f009495829bf59712572a8c17-1617045530623-31b8f9501cd2912b35ebbd611aff20e1badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011742	Nalbuphine N-oxide		"(5_, 6_)-17-(Cyclobutylmethyl)-4, 5-epoxy-morphinan-3, 6, 14-triol <EM>N</EM>-oxide"				Discontinued (Preclinical)	"Migraine, Postoperative pain"	C21 H27 N O5	Opioid receptor agonists	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner), Endo Pharmaceuticals (Collaborator)"		unspecified				"N2A (Narcotics), N2C (Anti-Migraine Preparations)"	"N02A-F (Morphinan derivatives), N02C (Antimigraine Preparations)"	DUP 769			18/02/2003	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800011742?userId=52029392&bpIds=3004037004&checksum=5a0356db3e7192bba9a932918b375763ef604e74-1617045530624-84d725f383d77f03b60bbe6321b54cfbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009543	ZD 6416						Discontinued (II)	Neuropathic pain		Prostaglandin E1 antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				07/02/2003	Pain				no		no							https://adis.springer.com/drugs/800009543?userId=52029392&bpIds=3004037004&checksum=5207546aad4dc383805591a9a24dd3c09c0c4f44-1617045530624-aa55f6adbdc3d7d8b46bb48112bca489badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800017903	ENT 102						Discontinued (Preclinical)	Pain		Undefined mechanism	"Entropin (CEASED) (Originator), Entropin (CEASED) (Owner)"		Injection				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				28/01/2003	Pain				no		no							https://adis.springer.com/drugs/800017903?userId=52029392&bpIds=3004037004&checksum=3cda203cb6a5280371d31d17f222bc3ea78d2ca9-1617045530625-74bfd64414eb538eb56675a4e31b9199badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015654	SAM 1095		Tyrosyl-threonyl-glycyl-phenylalanyl-leucyl-seryl(_-D-glycosyl)amide				No development reported (Preclinical)	Pain	C39 H57 N7 O14	Opioid delta receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				22/01/2003	Pain				no		no							https://adis.springer.com/drugs/800015654?userId=52029392&bpIds=3004037004&checksum=b435601e1fdf767af701d848d55128fa71bff592-1617045530626-7111a77f66fdafa47d58088ca7eff4b8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008901	GV 196771	166974-22-7	"1<EM>H</EM>-Indole-2-carboxylic acid, 4, 6-dichloro-3-[(1-phenyl-2-oxo-pyrrolidinyl-3)]methylenyl-, (<EM>E</EM>),"				Discontinued (II)	Pain	C20 H14 Cl2 N2 O3	Glycine antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/01/2003	Pain				no		no							https://adis.springer.com/drugs/800008901?userId=52029392&bpIds=3004037004&checksum=67f501f9969fbdebc84fdf945f932adc9dfc9105-1617045530627-9a1136983db1021cd3a6236793da9e83badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015392	ESP7		Tyrosyl-prolyl-phenylalanyl-phenylalanyl-glycyl-leucyl-methionine amide	Yes			No development reported (Preclinical)	Pain	C45 H60 N8 O8 S	"Neurokinin 1 receptor agonists, Opioid mu receptor agonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				20/01/2003	Pain				no		no							https://adis.springer.com/drugs/800015392?userId=52029392&bpIds=3004037004&checksum=2960edb02eba5368803d4cea7c73b255b572f76d-1617045530627-346f43f6a72957c3b2a4b73573962129badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011929	CO 106284						Discontinued (Preclinical)	Pain		Nociceptin receptor antagonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)				23/12/2002	Pain				no		no							https://adis.springer.com/drugs/800011929?userId=52029392&bpIds=3004037004&checksum=97fb2ed19b502db8b2177735bef7781a2885de05-1617045530628-56a614bcaba75131a4a34b068be139a9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003616	Licostinel	153504-81-5	"6,7-Dichloro-5-nitroquinoxaline-2,3(1H,4H)-dione"	Yes			Discontinued (I)	"Craniocerebral trauma, Stroke, Neurological disorders, Pain"	C8 H3 Cl2 N3 O4	"Glycine gated NMDA receptor antagonists, NMDA receptor antagonists, Glutamate receptor antagonists"	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		"IV, unspecified"			"Agitation, Dizziness, Headache, Injection site reactions, Nausea, Somnolence, Vomiting"	"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"	ACEA 1021			23/12/2002	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800003616?userId=52029392&bpIds=3004037004&checksum=7516c1939d7fb814cf218faf893539db118ba6ea-1617045530629-7e7fc502eb4ee91e579f4e3bd988ac99badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008398	ALX 0625						Discontinued (Preclinical)	Migraine		Undefined mechanism	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				12/12/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800008398?userId=52029392&bpIds=3004037004&checksum=f3b6bd416a7d6d74e005b55e05c473bdcd415e0b-1617045530630-596f926e310e9f7626d63f96b847c2a4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013628	ALX 0388		"Indole,3-[1-methyl-2(<EM>S</EM>)-pyrrolidin-2yl]methyl-5-(2-tienyl)-,"				Discontinued (Preclinical)	Migraine	C18 H20 N2 S	Serotonin 1B receptor agonists	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				12/12/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013628?userId=52029392&bpIds=3004037004&checksum=ce1115badc4c24153f9f479cb5f900846f531b10-1617045530631-54441db44250e9d65ce793d5299b94eabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014941	ALX 1405						Discontinued (Preclinical)	Pain		Glycine reuptake inhibitors	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				12/12/2002	Pain				no		no							https://adis.springer.com/drugs/800014941?userId=52029392&bpIds=3004037004&checksum=bf3cee0881dcc01dd39f22d8c18f688d3f96adb8-1617045530632-66246a8d63105546bb4c3a969bb7feaebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013352	ALE 0540		"2-(2-Hydroxyethylamino)-5-nitro-2, 3-dihydro-1<EM>H</EM>-benz[de]isoquinoline-1, 3-dione"				Discontinued (Preclinical)	Neuropathic pain	C14 H11 N3 O5	Nerve growth factor receptor antagonists	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				12/12/2002	Pain				no		no							https://adis.springer.com/drugs/800013352?userId=52029392&bpIds=3004037004&checksum=3b37e8c4ad318a950966cf3809e3a974cf174f44-1617045530633-6d6e8753c68fde5fe4cd89b8407ddd01badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014940	ALX 1393						Discontinued (Preclinical)	Pain		Glycine reuptake inhibitors	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				12/12/2002	Pain				no		no							https://adis.springer.com/drugs/800014940?userId=52029392&bpIds=3004037004&checksum=2467b005aa6d17e74744b0fc617f969bf62dfbd0-1617045530634-b88526eb26283312bb56a6c7e40ee7f7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015962	BL 1872						Discontinued (Preclinical)	Pain		Undefined mechanism	"Bioglan Pharma [CEASED] (Originator), Bioglan Pharma [CEASED] (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				03/12/2002	Pain				no		no							https://adis.springer.com/drugs/800015962?userId=52029392&bpIds=3004037004&checksum=9c46f195dff7e8076c5ded29ca749732a83a4220-1617045530635-7bdc171b88116467e1911f15c6a59014badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011319	AA 501						No development reported (Preclinical)	Pain		"Neurokinin 1 receptor agonists, Opioid receptor agonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				28/11/2002	Pain				no		no							https://adis.springer.com/drugs/800011319?userId=52029392&bpIds=3004037004&checksum=6c3adde9487135a02a2cb0e94e27eff64298edcd-1617045530636-ab8da54776fb0bf7aa3aa7708a3ed694badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012917	SPC 1						No development reported (Preclinical)	Pain		Undefined mechanism	"Unknown (Originator), Unknown (Owner), Nonindustrial source (Collaborator)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				28/11/2002	Pain				no		no							https://adis.springer.com/drugs/800012917?userId=52029392&bpIds=3004037004&checksum=7b330f778899874aeae64940660920f8cd1110e6-1617045530637-15f30fe4dd0ebc966db1075267e56400badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015007	DMT-DALDA						No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				12/11/2002	Pain				no		no							https://adis.springer.com/drugs/800015007?userId=52029392&bpIds=3004037004&checksum=5eeaf94d95bfff9728fe42d6101886f86163d9ea-1617045530637-12fd836d6438f9204ccd8a4294475ba7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006877	Davasaicin	174661-97-3	"2-[4-(2-Aminoethoxy)-3-methoxyphenyl]-<EM>N</EM>-[3-[(3, 4-dimethylphenyl)propyl]acetamide hydrochloride"				No development reported (II)	"Pain, Neuralgia, Diabetic neuropathies, Pruritus"	C22 H30 N2 O3 . H Cl	TRPV cation channel agonists	"Korea Research Institute of Chemical Technology (Originator), Korea Research Institute of Chemical Technology (Owner), Dong-A Pharmaceutical (Market Licensee), Stiefel Laboratories (Market Licensee)"		unspecified				"A10X (Other Drugs Used in Diabetes), D4A (Anti-Pruritics, Including Topical Antihistamines, Anaesthetics, etc), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), D04A-B (Anesthetics for topical use), N02B (Other Analgesics and Antipyretics)"	"capsavanil, DA 5018, KR 25018"			08/11/2002	"Diabetes, Pain, Skin Disorders"				no		no							https://adis.springer.com/drugs/800006877?userId=52029392&bpIds=3004037004&checksum=6d2565587258289cff7a54550b36e1b769d4178f-1617045530639-3fb37163ae286c1075dc1560686e9250badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014060	MCL 101		(-)-<EM>N</EM>-(Cyclobutylmethyl)morphinan-3-ol (<EM>S</EM>)-mandelate				No development reported (Preclinical)	"Pain, Opioid-related disorders"	C21 H29 N O . C8 H8 O3	"Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				"N2A (Narcotics), V3 (All Other Therapeutic Products)"	"N02A-A (Natural opium alkaloids), V03A (All Other Therapeutic Products)"				05/11/2002	"Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800014060?userId=52029392&bpIds=3004037004&checksum=39a2199de136e59b1aca5fa485035189bf170d5f-1617045530640-ac6e58ba4a1b54e710482c3cfdb61c44badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010174	Morphine oral - CeNeS	6211-15-0	"(5_, 6_)-4, 5-Epoxy-17-methyl-7, 8-didehydromorphinan-3, 6-diol sulfate (2:1) pentahydrate"				Discontinued (Clinical)	Pain	C17 H19 O3 . 1/2H2 S O4 . 5/2H2 O	Opioid mu receptor agonists	"CeNeS Pharmaceuticals (Originator), CeNeS Pharmaceuticals (Owner)"		PO				N2A (Narcotics)	N02A-A01 (Morphine)	Morphine OSAT			15/10/2002	Pain				no		no		OPRM1	"CYP2D6, UDP glucuronosyltransferase family 2 member B7"	"5-hydroxytryptamine receptor 3B, ACTH, Annexin A5, arrestin, beta 2, BNP, CD3d, CD3e, CD3g, CD4, CD56, CD8a, CKB, CKM, COMT, D-dimer, EH domain containing 2, hyaluronan synthase 3, Hydrocortisone, IL10, IL17, IL6, KRAS, Leptin, LIM homeobox transcription factor 1, beta, MDR1, Morphine-3-glucuronide, natural killer cell triggering receptor, NRAS, OPRM1, Prolactin, purinergic receptor P2Y12, sphingolipid transporter 1 (putative), symplekin, Testosterone, TNF-alpha, troponin I, cardiac, UDP glucuronosyltransferase family 2 member B7, vasodilator-stimulated phosphoprotein"	"ACTH, CD3e, CD4, CD56, CD8a, Hydrocortisone, Prolactin"	"CEA, CRP, Cytokeratin 20, exo/endonuclease G, GM-CSF, HIF, IL1 beta, IL2, IL4, IL5, IL8, Luteinizing hormone, PGE2, Retinoyl b-glucuronide, VEGF-A"	https://adis.springer.com/drugs/800010174?userId=52029392&bpIds=3004037004&checksum=890e3f467bd540d0a0bd7237993da0c5fc4066d8-1617045530642-f56bb579c4d7215b08ca434cca031716badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013399	Tropoxin		"8-Methyl-8-azabicyclo[3,2,1]octan-3-one O-(3,4,5-trime-thoxybenzoyl)oxime"				No development reported (Preclinical)	Migraine	C18 H24 N2 O5	Serotonin 2 receptor antagonists	"Unknown (Originator), Unknown (Owner), Nonindustrial source (Collaborator)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				10/10/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013399?userId=52029392&bpIds=3004037004&checksum=8f7696cbf8602fceb9af4c1ee946a98c27ec6ed2-1617045530643-dd8abbea024e8c9192748e6256cef4e3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012822	Esterom						Discontinued (III)	"Shoulder injuries, Back injuries, Sprains, Pain"		Undefined mechanism	"Entropin (CEASED) (Originator), Entropin (CEASED) (Owner)"		"Topical, unspecified"				"M5X (All Other Musculoskeletal Products), N2 (Analgesics)"	"M09A-X (Other drugs for disorders of the musculo-skeletal system), N02 (Analgesics)"				07/10/2002	"Musculoskeletal Disorders, Pain"				no		no							https://adis.springer.com/drugs/800012822?userId=52029392&bpIds=3004037004&checksum=c8256b347f3f9846772e2b52aff663ab86091572-1617045530645-276a3889d4135c6632846328e1296ce7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010972	NCX 284						Discontinued (Preclinical)	"Pain, Inflammation"		"Cyclooxygenase inhibitors, Nitric oxide donors"	"NicOx (Originator), NicOx (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"	NOdiclofenac			03/10/2002	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800010972?userId=52029392&bpIds=3004037004&checksum=d5ca7bb29f73463e827e02b0fb2e74d34343936b-1617045530646-cbee2142e726aaf4833003817a549de4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007329	HCT 6015		"4'-Nitroxybutyl-[(±)-5-benzoyl-2,3-dihydro-1<EM>H</EM>-pyrrolizine] 1-carboxylate"				Discontinued (Preclinical)	"Pain, Rheumatic disorders"	C19 H20 N2 O6	"Cyclo-oxygenase 2 inhibitors, Nitric oxide donors"	"NicOx (Originator), NicOx (Owner)"		"unspecified, PO"				"M1A3 (Coxibs, plain), N2B2 (Nonprescription-bound non-narcotics and anti-pyretics)"	"M01A-B (Acetic acid derivatives and related substances), M01A-H (Coxibs), N02B (Other Analgesics and Antipyretics)"	"Nitroketorolac, NOketorolac"			03/10/2002	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007329?userId=52029392&bpIds=3004037004&checksum=12138df70e2d8df6379ad1545aff600c7f8a7f13-1617045530647-76cfadf7158f24ffe8ecefb7a99f34f9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010173	Diclofenac rectal - CeNeS	15307-86-5	"Benzeneacetic acid, 2-[(2, 6-dichlorophenyl)amino]-"				Discontinued (I)	Postoperative pain	C14 H11 Cl2 N O2	Cyclooxygenase inhibitors	"CeNeS Pharmaceuticals (Originator), CeNeS Pharmaceuticals (Owner)"		Rectal				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Diclofenac HycoreR			12/09/2002	Pain				no		no							https://adis.springer.com/drugs/800010173?userId=52029392&bpIds=3004037004&checksum=4619f4047898fd3f314c81b9633a64008754410b-1617045530648-facbfd094ccf162cdb0ce4a8d5945837badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011794	RWJ 52353		"6, 7-Dihydrobenzothiophene, 4-(1<EM>H</EM>-imidazol-4-yl)-,"				No development reported (Preclinical)	Pain	C11 H10 N2 S	Alpha 2 adrenergic receptor agonists	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				29/08/2002	Pain				no		no							https://adis.springer.com/drugs/800011794?userId=52029392&bpIds=3004037004&checksum=451e2f2376a2f0bd273f6360ea53389263aa83a8-1617045530649-4bb2debae0f7b4a9a52678cfffa5a65abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011771	CMI 936		"2-exo-[5-(3-Methyl-1, 2, 4-oxadiazolyl)]-[2.2.1]-7azabicycloheptane"				No development reported (Preclinical)	Pain	C9 H13 N3 O	Muscarinic M4 receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				29/08/2002	Pain				no		no							https://adis.springer.com/drugs/800011771?userId=52029392&bpIds=3004037004&checksum=729490df2385053e831c7d5e281076e21c6bc633-1617045530650-a9f23c4f916bc30286cba7ffc0c90288badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009404	CMI 980		3-[2-[5-(4-Fluorophenyl)tetrahydrofuran-2-yl]ethynyl]pyridine				No development reported (Preclinical)	Pain	C17 H14 F N O	Opioid receptor agonists	"Millennium Pharmaceuticals (Originator), Millennium Pharmaceuticals (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				23/08/2002	Pain				no		no							https://adis.springer.com/drugs/800009404?userId=52029392&bpIds=3004037004&checksum=902dc43abd6ec51c7c10c6b3bd105548ae6cd365-1617045530651-de533d52d290edf8c16ea9d825be311bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005335	HP 228	172617-89-9	Acetyl-<EM>l</EM>-norleucyl-<EM>l</EM>-glutaminyl- <EM>l</EM>-histidyl-<EM>d</EM>-phenylalanyl-<EM>l</EM>- arginyl-<EM>d</EM>-tryptophyl-glycinamide dihydrochloride	Yes			Discontinued (II)	"Type 2 diabetes mellitus, Obesity, Postoperative pain, Inflammation, Chemotherapy-induced damage, Asthma"	C47 H65 N15 O9 . 2HCl	"Melanocortin receptor agonists, Immunomodulators, Interleukin 10 stimulants"	"SYGNIS Pharma (Originator), SYGNIS Pharma (Owner), Dura Pharmaceuticals (Collaborator)"		"IV, Parenteral, unspecified, Inhalation"		"T<sub>_beta</sub> (h) (2.02 - 2.63 (Adult)), Vd (L/kg) (.22 - .31 (Adult))"		"A10X (Other Drugs Used in Diabetes), A8A (Antiobesity Preparations, Excluding Dietetics), M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3 (Anti-Asthma and COPD Products), V3D (Detoxifying Agents for Antineoplastic Treatment)"	"A08A (Antiobesity Preparations, Excl. Diet Products), A10X (Other Drugs Used in Diabetes), M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases), V03A-F (Detoxifying agents for antineoplastic treatment)"				13/08/2002	"Diabetes, Drug Withdrawal, Inflammation, Obesity, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800005335?userId=52029392&bpIds=3004037004&checksum=b80127c73dad9f19c39cc8c9d7cd3ddbfb22ca55-1617045530652-c4060106e27db03eb2a3b518a6b6b4e8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013581	BL 1827						Discontinued (I)	"Postoperative pain, Cancer pain"		Opioid receptor agonists	"Bioglan Pharma [CEASED] (Originator), Bioglan Pharma [CEASED] (Owner), CeNeS Pharmaceuticals (Market Licensee)"		Sublingual				N2A (Narcotics)	N02A (Opioids)	"Analgesic sublingual spray Bioglan Pharma/CeNeS Pharmaceuticals, Opioid sublingual aerosol spray"			12/08/2002	Pain				no		no							https://adis.springer.com/drugs/800013581?userId=52029392&bpIds=3004037004&checksum=fe8ba09a91310a256266647cd6625b10458daf56-1617045530653-f21b89603bea25f362937e86fa703f4ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013342	S 18920						No development reported (Preclinical)	Neuropathic pain		Neurokinin 1 antagonists	"Nonindustrial source (Originator), Servier (Originator), Nonindustrial source (Owner), Servier (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				09/08/2002	Pain				no		no							https://adis.springer.com/drugs/800013342?userId=52029392&bpIds=3004037004&checksum=d55ab445d8eddb23670ded698dd87d6497521021-1617045530654-b6555ad5228951cb61c1895bbdae570bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010481	PNU 109291		"1(<EM>S</EM>)-[2-[4-(4-Methoxyphenyl)piperazin-1-yl]ethyl]-<EM>N</EM>-methyl-3,4-dihydro-1<EM>H</EM>-2-benzopyran-6-carboxamide"				No development reported (Preclinical)	Migraine	C24 H31 N3 O3	Serotonin 1D receptor agonists	"Pharmacia Corporation (Originator), Pharmacia Corporation (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				02/08/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800010481?userId=52029392&bpIds=3004037004&checksum=5e4ac4130116a8567319902065210296cc93064c-1617045530656-72fb379314305e84a8e92bfe9f71601dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012778	Deracoxib	169590-41-4	4-[3-(Difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1<EM>H</EM>-pyrazol-1-yl]benzenesulfonamide				No development reported (Preclinical)	"Pain, Inflammation"	C17 H14 F3 N3 O3 S	Cyclo-oxygenase 2 inhibitors	"Pharmacia Corporation (Originator), Pharmacia Corporation (Owner)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"	SC 59046			02/08/2002	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800012778?userId=52029392&bpIds=3004037004&checksum=e851130b339df55e98654238fb5338fb0a5c7a85-1617045530657-3305a7363b09e06be2e09ad336f42073badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012896	LY 306740			No			No development reported (Preclinical)	Pain		Neurokinin 1 antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner), Nonindustrial source (Collaborator)"		unspecified				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)				01/08/2002	Pain				no		no							https://adis.springer.com/drugs/800012896?userId=52029392&bpIds=3004037004&checksum=918cb55fc0424b09b559464da28d794f61ddd715-1617045530658-74fed5220c1d3f66187a4315e35faa98badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010651	LY 344864	186544-26-3	"(<EM>R</EM>)-<EM>N</EM>-[3-(Dimethylamino)-2,3,4,9-tetrahydro-1<EM>H</EM>-carbazol-6-yl]-4-fluorobenzamide"	Yes			No development reported (Preclinical)	Migraine	C21 H22 F N3 O	Serotonin 1F receptor agonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				30/07/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800010651?userId=52029392&bpIds=3004037004&checksum=58be8dd58100738272d1d6b4118b6784d5e40fd1-1617045530659-f290e2100bd06ae3cf875ce3f5577baebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001395	LY 053857	60634-51-7	"6-Methyl-1-(1-methylethyl)ergoline-8-carboxylic acid, 2-hydroxy-1-methylpropylester(Z)-2-butenedioate[1:1]"	Yes			No development reported (II)	"Migraine, Thrombosis, Ischaemic heart disorders"	C23 H32 N2 O3 . C4 H4 O4	Serotonin 2 receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				"B1C (Platelet Aggregation Inhibitors), N2C (Anti-Migraine Preparations)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), N02C-X (Other antimigraine preparations)"	LY 53857			30/07/2002	"Advances in the Treatment of Nausea and Migraine, Ischaemic Heart Disease, Thromboses"				no		no							https://adis.springer.com/drugs/800001395?userId=52029392&bpIds=3004037004&checksum=742b1059784dd23b647ae802c3c80fcd64e29913-1617045530660-c428f8afcc1b76790aee93ea8f9a91e5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011993	PD 173212		"(2<EM>R</EM>)-<EM>O</EM>-Benzyltyrozine <EM>tert</EM>-butyl amide, (2<EM>S</EM>)-<EM>N</EM>-methyl-<EM>N</EM>-leucyl-<EM>N</EM>- (4-<EM>tert</EM>-butylbenzyl-1)-,"				No development reported (Preclinical)	"Stroke, Pain"	C38 H52 N3 O3	Calcium channel antagonists	"Elan Pharmaceuticals (Originator), Pfizer (Originator), Elan Pharmaceuticals (Owner), Pfizer (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"				23/07/2002	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800011993?userId=52029392&bpIds=3004037004&checksum=ca662b2d67392ceab98c7b441df331b6e02d3bab-1617045530661-7bbe3d7eb896f7128221491e688362aabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011895	PD 175069		"4-<EM>O</EM>-benzylphenylalanine amide <EM>tert</EM>-butyl ester, _-[[4-methyl-2(<EM>R</EM>)-[[1-(3-methyl)butyl]methylamino]-1-oxa]pentyl]amino-,"				No development reported (Preclinical)	"Pain, Stroke"	C32 H49 N3 O3	Calcium channel antagonists	"Elan Pharmaceuticals (Originator), Pfizer (Originator), Elan Pharmaceuticals (Owner), Pfizer (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7X (All other CNS drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"				23/07/2002	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800011895?userId=52029392&bpIds=3004037004&checksum=2f3d506b191c594b6ff80e2bcd7c5c4e6ff3f550-1617045530663-479e65ac10d87d2854bba0d20d26b4d9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012586	PD 176078		"2(<EM>R</EM>)-<EM>N</EM>-methylleucine amide, <EM>N</EM>-4, 4-<EM>bis</EM>-(4, 4-fluorophenyl)butyl-,"				No development reported (Preclinical)	Pain	C23 H30 F2 N2 O . H Cl	Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	PD 0176078			23/07/2002	Pain				no		no							https://adis.springer.com/drugs/800012586?userId=52029392&bpIds=3004037004&checksum=80ab7a83ce2323641e8a00363bccf98af7c8c366-1617045530664-0548cded5c79e98dd6a08d32611b2308badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011795	PD 151307		"(2<EM>S</EM>)-<EM>O</EM>-Benzyltyrozine <EM>tert</EM>-butyl ester, (2<EM>R</EM>)-<EM>N</EM>-leucyl-<EM>N</EM>-(hexahydroazepin- 1<EM>H</EM>-1-yl)carbonyl-"				No development reported (Preclinical)	Pain	C33 H47 N3 O5	Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				23/07/2002	Pain				no		no							https://adis.springer.com/drugs/800011795?userId=52029392&bpIds=3004037004&checksum=dde8f501379af70249136d50dce94107d23a9e83-1617045530665-d36562ee251295b59e235636ba06056dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012005	PD 164387		"2,6-Di-<EM>tert</EM>-butyl-4-(5-ethylsulfanyl[1,3,4]-thiadiazol-2-yl)phenol"				No development reported (Preclinical)	"Pain, Inflammation"	C18 H26 N2 O S2	Cyclo-oxygenase 2 inhibitors	"Pfizer (Originator), Pfizer (Owner)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"				23/07/2002	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800012005?userId=52029392&bpIds=3004037004&checksum=a3e0505cfabd4b410127083a002549c0b86ca3cc-1617045530666-74d764aed272d4336b21edcf1e65c76ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800012008	PD 138387		"(<EM>Z</EM>)-5-(3,5-Di-<EM>tert</EM>-butyl-4-hydroxy-benzylidene)-2-(methoxyamino)thiazol-4-one"				No development reported (Preclinical)	"Inflammation, Pain"	C19 H26 N2 O3 S	Cyclo-oxygenase 2 inhibitors	"Pfizer (Originator), Pfizer (Owner)"		PO				"M1A3 (Coxibs, plain), N2 (Analgesics)"	"M01A-H (Coxibs), N02 (Analgesics)"				23/07/2002	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800012008?userId=52029392&bpIds=3004037004&checksum=555faf8a19c6e366197c5a3862d3da7a45c5473a-1617045530667-9629ea3764e7b8de7693cecd8c41a778badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010186	Ezlopitant	147116-64-1	"(2<EM>S</EM>,3<EM>S</EM>)-2-(Diphenylmethyl)-3-[(5-isopropyl-2-methoxybenzyl)amino]quinuclidine"				No development reported (Preclinical)	"Pain, Nausea and vomiting"	C31 H38 N2 O	"Neurokinin 1 antagonists, Substance P inhibitors"	"Pfizer (Originator), Pfizer (Owner)"		unspecified			"Dehydration, Uraemia"	"A4A (Antiemetics and Antinauseants), N2B (Non-Narcotics and Anti-Pyretics), V3 (All Other Therapeutic Products)"	"A04A-D (Other antiemetics), N02B (Other Analgesics and Antipyretics), V03A-F (Detoxifying agents for antineoplastic treatment)"	CJ 11974			19/07/2002	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800010186?userId=52029392&bpIds=3004037004&checksum=a8bc8c565e6f472da1ff3fa35317d60bcd9ebef6-1617045530668-de1fdef4524d8083a40ab6e10a105b59badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004225	Dapitant	153438-49-4	"(3aS,4S,7aS)-4-(2-Methoxyphenyl)-2-[2(R*)-2- (2-methoxyphenyl)propionyl]-7,7-diphenylperhydro- isoindol-4-ol"				No development reported (II)	"Pain, Migraine"	C37 H39 N O4	Neurokinin 1 antagonists	"Aventis (Originator), Aventis (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"N02B-G (Other analgesics and antipyretics), N02C-X (Other antimigraine preparations)"	RPR 100893			08/07/2002	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800004225?userId=52029392&bpIds=3004037004&checksum=4ff96f73f2ff2041b14b7cc45340e70b2cce8f33-1617045530669-305ecd8bdf9a968f829d7b05867cb1cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006325	RP 61127		2-(2-Benzimidazolyl)-10-[1-methyl-2-(1-pyrrolidinyl) ethyl]phenothiazine				No development reported (Preclinical)	Pain	C26 H26 N4 S	Opioid kappa receptor agonists	"Aventis (Originator), Aventis (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				03/07/2002	Pain				no		no							https://adis.springer.com/drugs/800006325?userId=52029392&bpIds=3004037004&checksum=e35e1044a64dac0d01812ca86d5cf9f439564bd2-1617045530670-8e1f1ec128758cfef33661b8a7008adcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008819	RPR 111905		"(+)-(3aS, 4S, 6S, 7aR)-2-[4-Hydroxy-4-(2-methoxyphenyl)-2- [2(S)-(2-methoxyphenyl)propionyl]perhydroisoindol-6-yl] acetonitrile"				No development reported (Preclinical)	"Inflammation, Pain"	C27 H32 N2 O4	Substance P inhibitors	"Aventis (Originator), Aventis (Owner)"		unspecified				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B (Other Analgesics and Antipyretics)"				03/07/2002	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800008819?userId=52029392&bpIds=3004037004&checksum=3165b351b8ea6f25b1b6f60e3100b30c22fe5af8-1617045530671-6463548881bd9b61e4f911156df220d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006907	CP 0494		Hyp<SUP>3</SUP>-Cys<SUP>6</SUP>-<EM>d</EM>-Phe<SUP>7</SUP>-Leu<SUP>8</SUP>-<EM>d</EM>-Arg[BK]-[oxymorphone]				Discontinued (Preclinical)	Pain		"Bradykinin B2 receptor antagonists, Opioid mu receptor agonists"	"Cortech (Originator), Cortech (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				02/07/2002	Pain				no		no							https://adis.springer.com/drugs/800006907?userId=52029392&bpIds=3004037004&checksum=6fc885ef36b1d116062072f2b58c8e9511384f01-1617045530672-494c092cf11bf99b7d6ed9a8a2af57babadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001227	Fananserin	127625-29-0	"2-(3-[4-(4-Fluorophenyl)-piperazinyl] propyl) naphto[1,8-c,d] isothiazole-1,1-dioxide"				No development reported (II)	"Anxiety disorders, Major depressive disorder, Migraine, Sleep disorders, Alcoholism, Eating disorders, Schizophrenia"	C23 H24 F N3 O2 S	"Serotonin 2 receptor antagonists, Dopamine D4 receptor antagonists"	"Aventis (Originator), Aventis (Owner)"		"PO, unspecified"				"N2C (Anti-Migraine Preparations), N5A (Antipsychotics), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers), N7 (Other CNS Drugs)"	"N02C (Antimigraine Preparations), N05A (Antipsychotics), N05B-X (Other anxiolytics), N05C-M (Other hypnotics and sedatives), N06A-X (Other antidepressants), N07X (Other Nervous System Drugs)"	RP 62203			26/06/2002	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Drug Withdrawal, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800001227?userId=52029392&bpIds=3004037004&checksum=7ed253e703aa773474a27c072da05a4fe52b828e-1617045530674-72ea9340ed6e398c4a0c93e03eb60b93badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800014969	ADL 100102						Discontinued (Preclinical)	Pain		Opioid kappa receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)	ADL100102			17/06/2002	Pain				no		no							https://adis.springer.com/drugs/800014969?userId=52029392&bpIds=3004037004&checksum=c63ea8cceda1c01bc9d4816c6e3af587c381171a-1617045530675-eb5b591ce34fa2b0f52efab88c24ec03badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013923	MT 500						Discontinued (I)	Migraine		Serotonin 2B receptor antagonists	"Roche (Originator), Roche (Owner), POZEN (Market Licensee)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				06/06/2002	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013923?userId=52029392&bpIds=3004037004&checksum=35cae835e73fc15a8a8757160c417b311b3b3ab7-1617045530676-716ed44134fcccb9485b88d322bc1b01badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009577	DBO 11		"3-<EM>p</EM>-Nitrocinnamyl-8-propionyl-3, 8-diazabicyclo (3.2.1) octane"				No development reported (Preclinical)	Pain	C24 H23 N3 O3	Opioid mu receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				30/04/2002	Pain				no		no							https://adis.springer.com/drugs/800009577?userId=52029392&bpIds=3004037004&checksum=659ef35308a46d6586326685553d1b393042b2d0-1617045530677-755090595f045f6ac2cbe060b61f5c5ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009071	DBO 83		3-(6-Chloropyridazin-3-yl)-diazabicyclo[3.2.1]octane dihydrochloride monohydrate				No development reported (Preclinical)	"Cognition disorders, Pain"	C10 H13 N4 Cl . 2H Cl . H2 O	Nicotinic receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				"N2A (Narcotics), N7D9 (All other anti-Alzheimer products)"	"N02A (Opioids), N07X (Other Nervous System Drugs)"				30/04/2002	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009071?userId=52029392&bpIds=3004037004&checksum=37f264d2844155fd98cbf097e997352099af407b-1617045530678-9e6df57a524a4a3a214b903e2e73266cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011758	SK 9709		L-Tyrosyl-D-alanyl-L-phenylalanyl-L-leucyl-L-arginyl-_(CH2NH)-L-argininamide				No development reported (Preclinical)	Pain	C39 H63 N13 O6	"Opioid kappa receptor agonists, Opioid mu receptor agonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-A (Natural opium alkaloids)				29/04/2002	Pain				no		no							https://adis.springer.com/drugs/800011758?userId=52029392&bpIds=3004037004&checksum=b3112063195bf7fc6f5ff018fdca7db0e0df9408-1617045530679-a6513c9f68e43382ede1f3a3be9c2309badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011980	Beta-endorphin gene therapy						No development reported (Preclinical)	Neuropathic pain		Opioid receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		Intrathecal				N2 (Analgesics)	N02A (Opioids)				29/04/2002	Pain				no		no							https://adis.springer.com/drugs/800011980?userId=52029392&bpIds=3004037004&checksum=adc8985e7389109cfd081ff0bdf8df56bc4305ae-1617045530680-2e877dbe27ac6ceade54345142ef9141badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011772	CMI 1145		"2-exo-[5-(3-Amino-1, 2, 4-oxadiazolyl)]-[2.2.1]-7azabicycloheptane"				No development reported (Preclinical)	Pain	C8 H12 N4 O	Muscarinic M4 receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				29/04/2002	Pain				no		no							https://adis.springer.com/drugs/800011772?userId=52029392&bpIds=3004037004&checksum=882fb4842a37216bbac20d195493d63454c5199f-1617045530681-fcaf0fc7c3f8e2efa774ad232f64a0ecbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013339	NJA 92		<EM>N</EM>-(1-phenyl-1-pyrazol-3-yl)-<EM>N</EM>-[1-(2-phenyl)ethyl]-4-piperidyl-propionamide				No development reported (Preclinical)	Pain	C25 H30 N4 O	Opioid receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-B (Phenylpiperidine derivatives)				23/04/2002	Pain				no		no							https://adis.springer.com/drugs/800013339?userId=52029392&bpIds=3004037004&checksum=8becbdc63513a70930db0301516392e23af6ef97-1617045530682-a9178461a91a8c435c0c4df7915c2ea7badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003488	Apadoline	135003-30-4	(R)-(+)-10-(Methyl-2-(1-pyrrolidinyl)ethyl)N-propyl-phenothiazine-2-carboxamide				No development reported	Pain	C28 H29 N2 O S	Opioid kappa receptor agonists	"Aventis (Originator), Aventis (Owner)"		unspecified			"Constipation, Diplopia, Dizziness, Drowsiness, Headache, Nausea, Psychomotor agitation"	N2 (Analgesics)	N02 (Analgesics)	"RP 60180, RP 60180A, RPR 60180"			09/10/2001	Pain				no		no							https://adis.springer.com/drugs/800003488?userId=52029392&bpIds=3004037004&checksum=f3f0a295c0a39de4e53febde809fa8faa89ad60b-1617045530683-2cc1205a0620b30b741c4d6e38d1fc27badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001257	CP 96345	132746-60-2	"(2<EM>S-cis</EM>)-2-(Diphenylmethyl)-<EM>N</EM>-[(2-methoxyphenyl)methyl]- 1-azabicyclo[2,2,2]octan-3-amine"				No development reported (I)	"Pain, Rheumatic disorders, Asthma"	C28 H32 N2 O	Neurokinin 1 antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics), R3 (Anti-Asthma and COPD Products)"	"M01 (Antiinflammatory and Antirheumatic Products), N02 (Analgesics), R03 (Drugs for Obstructive Airway Diseases)"				09/10/2001	"Obstructive Airways Disease, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800001257?userId=52029392&bpIds=3004037004&checksum=16c498a24b2dc7b8503a3c5480d0305c69015303-1617045530685-8d4157ff764acd0aefc4d1369c872e3fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005872	GR 82334	129623-01-4	"Physalemin, 9-deglycine-10-[(5S)-6-oxo-L- _-(2-methylpropyl)-1,7-diazaspiro[4.4]nonane- 7-acetic acid]-11-L-tryptophanamide"				No development reported (Preclinical)	Pain	C69 H91 N15 O16	Neurokinin 1 antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				08/10/2001	Pain				no		no							https://adis.springer.com/drugs/800005872?userId=52029392&bpIds=3004037004&checksum=76610cb30a05eaf6c294e066c31b5c9e317b23ee-1617045530686-cc13d95bd92085e2cde8243fa46309cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011990	RWJ 52807		"(3a<EM>R</EM>, 10c<EM>R</EM>)-2-Methyl-1, 2, 3, 3a, 4, 5, 6, 10c-octahydropyrrolo[3,4-c]carbazole"				No development reported (Preclinical)	Pain	C15 H18 N2	"Alpha 1 adrenergic receptor agonists, Alpha 2 adrenergic receptor agonists"	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				05/10/2001	Pain				no		no							https://adis.springer.com/drugs/800011990?userId=52029392&bpIds=3004037004&checksum=9514315f0786bc7ec27e6a799978ab106deaade6-1617045527693-6fd5566570a5bed5a6727e23c10737a0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800015196	Latranal						Discontinued (II)	Neuropathic pain		Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner), Praecis Pharmaceuticals (Licensee)"		Topical				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				01/10/2001	Pain				no		no							https://adis.springer.com/drugs/800015196?userId=52029392&bpIds=3004037004&checksum=825d6285ecb9ef7ca39a40b4c52208ef3360df9e-1617045527694-8b123a9b013c888578f829017a544a3abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005458	RB 101	135949-60-9	"N-(R,S)-2-benzyl-3-[(S)(2-amino-4-methylthio)butyl dithio]-1-oxopropyl-L-phenylalanine benzyl ester"	Yes			No development reported (Preclinical)	"Major depressive disorder, Pain, Substance-related disorders"	C31 H38 N2 O3 S3	Neprilysin inhibitors	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				"N2A (Narcotics), N6A (Anti-Depressants and Mood Stabilisers), V3 (All Other Therapeutic Products)"	"N02A (Opioids), N06A (Antidepressants), V03A (All Other Therapeutic Products)"				28/09/2001	"Affective Disorders, Drug Withdrawal, Pain"				no		no							https://adis.springer.com/drugs/800005458?userId=52029392&bpIds=3004037004&checksum=21019ebb02301c0ace586855a75a0eab920d6417-1617045527695-a189c69d55e6e274b46571e2b4e8c1d8badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010524	SDZ NKT 343		2-Nitrophenylcarbamoyl-(<EM>S</EM>)-prolyl-(<EM>S</EM>)-3-(2-naphthyl)alanyl-<EM>N</EM>-benzyl-<EM>N</EM>-methylamide				No development reported (Preclinical)	"Nausea and vomiting, Pain, Migraine"		Neurokinin 1 antagonists	"Novartis (Originator), Novartis (Owner)"		PO				"A4A9 (Other antiemetics and antinauseants), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"A04A-D (Other antiemetics), N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations)"				07/09/2001	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800010524?userId=52029392&bpIds=3004037004&checksum=afb1151d54985c6643a9d36dc168ad7d7577060a-1617045527696-a5be470757587b62de903469dde6081abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004504	SCH 50971	167610-28-8	"(+)-(3R,4R)-3-(1H-Imidazol-4-yl)-4-methylpyrrolidine"				No development reported (Preclinical)	"Anxiety disorders, Gastrointestinal disorders, Migraine"	C8 H13 N3	Histamine H3 receptor agonists	"Schering-Plough (Originator), Schering-Plough (Owner)"		unspecified				"A3A (Plain Antispasmodics and Anticholinergics), N2C (Anti-Migraine Preparations), N5C (Tranquillisers)"	"A03A (Drugs for Functional Bowel Disorders), N02C (Antimigraine Preparations), N05B-X (Other anxiolytics)"				07/09/2001	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Digestive System Disorders"				no		no							https://adis.springer.com/drugs/800004504?userId=52029392&bpIds=3004037004&checksum=04d058a2585631ccc1ec0536e12d800f4437557e-1617045527697-877072a4159082d668c55468b5f3c48bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000702	CI 988	130404-91-0	"[R-(R*,R*)]-4-[[2-[[3-(1<EM>H</EM>-Indol-3-yl)-2-methyl-1-oxo-2 -[[(tricyclo [3.3.1.1.<SUP>3,7</SUP>] dec-2-yloxy) carbonyl] amino] propyl] amino] -1-phenylethyl] amino] -4-oxobutanoate with1-deoxy-1-(methylamino)-D-glucotil (1:1)"				No development reported (III)	"Anxiety disorders, Pain, Peptic ulcer, Cancer"	C35 H42 N4 O6 . C7 H17 N O5	Cholecystokinin B receptor antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified			"Diarrhoea, Dyspepsia, Flatulence, Nausea"	"A2B9 (All other antiulcerants), L1X9 (All other antineoplastics), N2 (Analgesics), N5C (Tranquillisers)"	"A02X (Other Drugs for Acid Related Disorders), L01X-X (Other antineoplastic agents), N02 (Analgesics), N05B-X (Other anxiolytics)"	PD 134308			27/08/2001	"Anxiety Disorders, Cancer, Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800000702?userId=52029392&bpIds=3004037004&checksum=5553b559cfcc8c64b6eaba13520d65b395041fe1-1617045527698-af23be73f3312c1e2e12739835ceebabbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800011278	Esprolol						Discontinued (II)	"Angina pectoris, Migraine, Anxiety disorders"		Beta-adrenergic receptor antagonists	"Selectus Pharmaceuticals [CEASED] (Originator), Selectus Pharmaceuticals [CEASED] (Owner)"		Sublingual		T<sub>_beta</sub> (h) (.2 (Adult))	Mouth disorders	"C7 (Beta-Blocking Agents), N2C (Anti-Migraine Preparations)"	"C07A (Beta Blocking Agents), N02C-X (Other antimigraine preparations)"				25/06/2001	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Ischaemic Heart Disease"				no		no							https://adis.springer.com/drugs/800011278?userId=52029392&bpIds=3004037004&checksum=d803ea9ad646fe69c6104faed0324ac76a16b69e-1617045527699-af9171b14cf7e39e0cc810d2bb660163badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004033	YM 022	145084-28-2	"Urea, (R)-1-[2, 3-dihydro-1-(o-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(m-tolyl)-,"				Discontinued (II)	"Peptic ulcer, Pain"	C32 N28 N4 O3	Cholecystokinin B receptor antagonists	"Yamanouchi (Originator), Yamanouchi (Owner)"		unspecified				"A2B9 (All other antiulcerants), N2 (Analgesics)"	"A02X (Other Drugs for Acid Related Disorders), N02 (Analgesics)"				20/06/2001	"Pain, Peptic Ulcer Disease"				no		no							https://adis.springer.com/drugs/800004033?userId=52029392&bpIds=3004037004&checksum=930ee2b8b7c30b156d25d25b649e64a11a2d7d6d-1617045527700-063da5f78bc392fe05ff955d51cae651badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009229	SDZ 220581	174575-17-8	(_)-(S)-2-amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propionic acid monoammonium salt				No development reported (Preclinical)	"Neurological disorders, Pain"	C16 H17 Cl N O5 P . N H3	Glutamate receptor antagonists	"Novartis (Originator), Novartis (Owner)"		"unspecified, PO"				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07X (Other Nervous System Drugs)"				13/06/2001	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009229?userId=52029392&bpIds=3004037004&checksum=7f39a0de8d1a95aa5d2ea94d1d09db0c5bcbb7c3-1617045527701-add0dda801cf239ae55f21f7db1149b6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008716	RWJ 50515 035		"(3aS*, 4S*, 7aR*)-4-Hydroxy-2-methyl-4-phenyl-3a, 7a-octahydroisoindole monocyclohexanesulfamic acid (1:1) salt"				No development reported (Preclinical)	Pain	C15 H21 N O . C6 H13 N O3 S	Undefined mechanism	"Johnson & Johnson Pharmaceutical Research & Development (Originator), Johnson & Johnson Pharmaceutical Research & Development (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	RWJ 50515035			12/06/2001	Pain				no		no							https://adis.springer.com/drugs/800008716?userId=52029392&bpIds=3004037004&checksum=c69635eb0319bf5a2a7ad74cb7307ba2270e45b3-1617045527702-65c9af0b581d0ef9d5ed6cdcd6884dd5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006210	L 733060	148700-85-0	"cis-3-[3,5-Bis(trifluoromethyl)benzyloxy]- 2-phenylpiperidine"				No development reported (Preclinical)	"Pain, Migraine, Rheumatoid arthritis"	C20 H19 F6 N O	Neurokinin 1 antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics), N2C (Anti-Migraine Preparations)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics), N02C (Antimigraine Preparations)"				11/06/2001	"Advances in the Treatment of Nausea and Migraine, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800006210?userId=52029392&bpIds=3004037004&checksum=4bfaeaf7425392bc9221849ba8c4721e1dbb17aa-1617045527703-541dc594dca5b1c5ab110d5d311f758bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005855	OHM 3295	117523-53-2	N-[1-(2-Phenylethyl)-4-piperidyl]-N-(3-pyridyl) furan-2-carboxamide				No development reported (Preclinical)	Pain	C23 H25 N3 O2	Immunomodulators	"Baxter International (Originator), Baxter International (Owner)"		unspecified				N2 (Analgesics)	"L03 (Immunostimulants), N02 (Analgesics)"	ANQ 3295			08/06/2001	Pain				no		no							https://adis.springer.com/drugs/800005855?userId=52029392&bpIds=3004037004&checksum=54e45e9bd2d9c6f2121277742347aec35004ef52-1617045527704-1bcd6e585307c0b96b44df4771521006badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007968	Methoclocinnamox	117332-67-9					No development reported (Preclinical)	Pain		"Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Unknown (Originator), Unknown (Owner), Nonindustrial source (Collaborator)"		unspecified				N2A (Narcotics)	N02A (Opioids)				07/06/2001	Pain				no		no							https://adis.springer.com/drugs/800007968?userId=52029392&bpIds=3004037004&checksum=0b335c0c43dfb009c98e8b337b06b715b8ef77a9-1617045527705-cdf30077fbb0b3ac8c27ad8315018bbfbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003544	L 659877	125989-12-0	Cyclo(L-glutaminyl-L-tryptophyl-L-phenylalanylglycyl- L-leucyl-L-methionyl)				No development reported (Preclinical)	Pain	C38 H50 N8 O7 S	Neurokinin 2 antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				07/06/2001	Pain				no		no							https://adis.springer.com/drugs/800003544?userId=52029392&bpIds=3004037004&checksum=3ae2b45862dab32d7dcdad1293c99fe4ab2ef689-1617045527705-00a06166228e2ff6f61ef84156b6ebb3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003413	CP 122638	143321-78-2	N-Methyl-3-[pyrrolidin-2(R)-ylmethyl]-1H-indol-5-yl- methylsulfonamide				Discontinued	Migraine	C15 H21 N3 O2 S	Serotonin 1D receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				05/06/2001	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800003413?userId=52029392&bpIds=3004037004&checksum=9a7783653c1a1af64104f867c8fd8a2243ec26d1-1617045527706-78cb2ab2051558865be29f19d1561ecabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007883	Endo-Adts gene therapy						No development reported (Preclinical)	Pain		Gene transference	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				30/05/2001	Pain				no		no							https://adis.springer.com/drugs/800007883?userId=52029392&bpIds=3004037004&checksum=84b0497ff6772fe74615448f7336aa9efc125da7-1617045527707-2756e8f7ae5750a5027641f51db0c0f2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003817	Filenadol	78168-92-0	"4-Morpholineethanol, _-1,3-benzodioxol-5-yl-_-methyl-, (R*,S*)-(+,-)-"				No development reported	Pain	C14 H19 N O4	Cyclooxygenase inhibitors	"Ferrer (Originator), Ferrer (Owner)"		PO				N2 (Analgesics)	N02B (Other Analgesics and Antipyretics)	"FI 2024, Filantor"			30/05/2001	Pain			Filantor	no		no							https://adis.springer.com/drugs/800003817?userId=52029392&bpIds=3004037004&checksum=04f0c81fbcd3bf4e5f0c43042e8fda650f1cfcaf-1617045527708-7148bd6e304aacece4edec698caa142abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007858	EXP 631	151656-58-5	"4-(3-Thienyl)-_,_,1-trimethyl-4-piperidinemethanol hemifumarate"				No development reported (Preclinical)	"Pain, Mood disorders"	C13 H21 N O S . 1/2 C4 H4 O4	Biogenic monoamine uptake inhibitors	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N6A (Anti-Depressants and Mood Stabilisers)"	"N02B (Other Analgesics and Antipyretics), N06A-F (Monoamine oxidase inhibitors, non-selective)"				30/05/2001	"Affective Disorders, Pain"				no		no							https://adis.springer.com/drugs/800007858?userId=52029392&bpIds=3004037004&checksum=9ac832b48b0c071cc057723bda3626d892bcb0dd-1617045527709-6b93084d3d4f2b3538b01b9269423ee3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009662	S 8115						Discontinued (III)	Cancer pain		Opioid receptor agonists	"Mundipharma International (Originator), Mundipharma International (Owner), Shionogi (Market Licensee)"		unspecified				N2A (Narcotics)	N02A (Opioids)				29/05/2001	Pain				no		no							https://adis.springer.com/drugs/800009662?userId=52029392&bpIds=3004037004&checksum=e99dbdd68ff18a85c1f81244d3f74a4f70424300-1617045527710-8a3c74c867a687f7c6dafa73f9e86603badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007966	KT 90	129200-07-3	(-)-3-Acetyl-6_-acetylthio-N-cyclopropylmethyl-normorphine				No development reported (Preclinical)	Pain	C24 H26 N O5 S	Opioid receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-F (Morphinan derivatives)				26/05/2001	Pain				no		no							https://adis.springer.com/drugs/800007966?userId=52029392&bpIds=3004037004&checksum=846a510824cbcb0208c51fa73a00cd1d65886e72-1617045527710-b6f17ccef16ff7a14ea400fe19cf444ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003093	T 3788	76604-64-3	"Benzeneacetic acid, _-methyl-4-(3-methyl-2-thienyl)-, (R)-"	No			Discontinued (III)	"Pain, Inflammation, Postmenopausal osteoporosis"	C14 H14 O2 S	"Cyclooxygenase inhibitors, Immunomodulators"	"Maruho (Originator), Maruho (Owner), FUJIFILM Toyama Chemical (Collaborator)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), M5B (Bone Calcium Regulators), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E (Propionic acid derivatives), M05B (Drugs Affecting Bone Structure and Mineralization), N02B (Other Analgesics and Antipyretics)"	"M 5010, M 5011, M 5011C, SMTPPA"			25/05/2001	"Musculoskeletal Disorders, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800003093?userId=52029392&bpIds=3004037004&checksum=d63f08ad13f42c451aa6da258595ea1b323f49fd-1617045527711-00fdd915b384db4f6b55076c21f3b818badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009580	DBO 17		"3-Propionyl-8-<EM>p</EM>-nitrocinnamyl-3, 8-diazabicyclo (3.2.1) octane"				No development reported (Preclinical)	Pain	C24 H23 N3 O3	Opioid mu receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				22/05/2001	Pain				no		no							https://adis.springer.com/drugs/800009580?userId=52029392&bpIds=3004037004&checksum=122e41599346a656a359cf716d3830748132bb4f-1617045527712-020deef76484cf478b5d6c36cfc9fe4cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008679	Epiboxidine	188895-96-7	exo-2-(3-Methyl-5-isoxazolyl)-7-azabicylo[2.2.1]heptane				No development reported (Preclinical)	Pain	C10 H14 N2 O	Nicotinic receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				22/05/2001	Pain				no		no							https://adis.springer.com/drugs/800008679?userId=52029392&bpIds=3004037004&checksum=d99abb33e93ad8f0aab4a4b77b1a319b4ca8207f-1617045527713-b7638613b55f1d419f89d17d6e09a270badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008533	FR 172357		"<EM>N,N</EM>-Dimethylbenzamide, 4-[[2,4-dichloro-3-[(3-bromo-2-methyl)imidazo[1,2-a]pyridin-7-yloxymethyl]phenyl]-<EM>N</EM>-methylcarbamoylmethylamino-1-oxo-2(<EM>E</EM>)-propen-3-yl]-, methanesulfonate"				No development reported (Preclinical)	"Inflammation, Pain"	C30 H28 Br Cl2 N5 O4 . C H4 O3 S	Bradykinin B2 receptor antagonists	"Fujisawa (Originator), Fujisawa (Owner)"		"unspecified, PO"				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				22/05/2001	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800008533?userId=52029392&bpIds=3004037004&checksum=73b9bca4bbb77f94e2d4c0483fb42a99cdb4e1af-1617045527714-efd98cc0639b937bc65e5b54bbdf1294badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007531	Homoepibatidine		(2-Chloro-pyridin-5-yl)-8-azabicyclo[3.2.1]octane				No development reported (Preclinical)	Pain	C11 H15 N2 Cl	Nicotinic receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				21/05/2001	Pain				no		no							https://adis.springer.com/drugs/800007531?userId=52029392&bpIds=3004037004&checksum=5174a349980f557379622dc22a4aab0e30940f82-1617045527715-f503c878d2e1aa75e3ab47e7621204bbbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010348	SB 218842	175013-73-7	"<EM>N</EM>-[(3<EM>R</EM>,4<EM>S</EM>)-6-acetyl-3-hydroxy-2,2-dimethyl-4-chromanyl]-3,5-difluorobenzamide"				Discontinued (I)	Migraine	C20 H19 F2 NO4	Undefined mechanism	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	Tidembersat			27/03/2001	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800010348?userId=52029392&bpIds=3004037004&checksum=bcc65eec4eb4b723d7714da7a2f2e0666bde98a2-1617045527716-c54cce27c86e64a556664fe2290603d0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004107	GP 3269		"7-(5-Deoxy-_-<EM>D</EM>-ribofuranosyl-4-(4-fluorophenylamino)-5-phenyl-7<EM>H</EM>-pyrrolo[2,3-<EM>d</EM>]pyrimidine"	Yes			Discontinued (I)	"Parkinson's disease, Epilepsy, Pain"	C23 H21 F N4 O3	Adenosine kinase inhibitors	"SICOR (Originator), SICOR (Owner), Metabasis Therapeutics (Collaborator)"		"unspecified, PO"				"N2 (Analgesics), N3A (Anti-Epileptics), N4A (Anti-Parkinson Drugs)"	"N02 (Analgesics), N03A-X (Other antiepileptics), N04 (Anti-Parkinson Drugs)"	GP 13269			27/02/2001	"Epilepsy and Seizure Disorders, Pain, Parkinson's Disease and Movement Disorders"				no		no							https://adis.springer.com/drugs/800004107?userId=52029392&bpIds=3004037004&checksum=d489fca3c813bf984a986210ce654890c3f203b1-1617045527717-95662695f83ba3b7dd91ca416da2f748badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003345	GR 71251	127493-01-0	"9-Deglycine-10-[(5S)-6-oxo--L_-(2-methylpropyl)1, 7-diazaspiro[4, 4]nonane-7-acetic acid]-11-L-tryptophanamide-substance P"				No development reported	Pain	C74 H105 N19 O18	Neurokinin 1 antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B-G (Other analgesics and antipyretics)				26/02/2001	Pain				no		no							https://adis.springer.com/drugs/800003345?userId=52029392&bpIds=3004037004&checksum=7d550752d07a07d59192d791a40d41d7fd971a60-1617045527718-183ecd358d4ef9cf8c0f8d0fa254606dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008840	Biphalin	83916-01-2	Tyrosyl-<EM>d</EM>-alanyl-glycyl-phenylalanine				No development reported (Preclinical)	Pain	C23 H28 N4 O6	"Opioid delta receptor agonists, Opioid mu receptor agonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				26/02/2001	Pain				no		no							https://adis.springer.com/drugs/800008840?userId=52029392&bpIds=3004037004&checksum=ffb2f9a416fbd8d9d6576de0291d1c2de5f7a292-1617045527718-e740872f3f40802d2fcf0c27030fc52bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003733	GR 94839	133407-20-2	"4-Acetyl-1-(3,4-dichlorophenyl)-acetyl-2- [(3-hydroxy-1-pyrrolidinyl)methyl]-piperazine"				No development reported	Pain		Opioid kappa receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				26/02/2001	Pain				no		no							https://adis.springer.com/drugs/800003733?userId=52029392&bpIds=3004037004&checksum=4c56e111d6958175c8e55923d5094f5e76b425c0-1617045527719-67f332e7b6a7fbdf7aca7fa342b8fa67badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009238	PD 29361		"5, 5'-Methylenebis-(7-piperidinylmethyl-8-quinolinol)"	Yes			No development reported (Preclinical)	"Neurological disorders, Pain"	C31 H36 N4 O2	Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"				26/02/2001	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009238?userId=52029392&bpIds=3004037004&checksum=06d7eda8be2a1bd63ffc714f60fef63473e1e250-1617045527720-4783be2968d0383640473b5c007ad8b0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007477	BMDB		"Benzofuran, 2-(4-bromobenzoyl)-3-methyl- 4,6-dimethoxy-"				No development reported (Preclinical)	Pain	C18 H15 Br O4	Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				26/02/2001	Pain				no		no							https://adis.springer.com/drugs/800007477?userId=52029392&bpIds=3004037004&checksum=2d3b2052eee49874d7e07efa1230a8fa8f6babfd-1617045527721-17aa4c2ac0e08447298c9aee1e32615abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009118	PD 158143		"1,1-Diphenyl-4,4-<EM>bis</EM>[(4-hydroxy-5-axepinomethyl)phenyl]pentane"				No development reported (Preclinical)	"Pain, Stroke"	C43 H54 N2 O2	Calcium channel antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				26/02/2001	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009118?userId=52029392&bpIds=3004037004&checksum=61b41cdc3bf028e0e1cad0110b620726629c5c3e-1617045527722-4e11ce03df2821b3c19babbee891bc33badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009117	PD 157667		"6-(Azepinomethyl)-1, 2, 3, 4-tetrahydro-5-hydroxy-2-(4, 4-diphenylbutyl)isoquinoline"				No development reported (Preclinical)	"Stroke, Pain"	C32 H40 N2 O	"Calcium channel antagonists, Potassium channel antagonists, Sodium channel antagonists"	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"N2 (Analgesics), N7 (Other CNS Drugs)"	"N02 (Analgesics), N07 (Other Nervous System Drugs)"				23/02/2001	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009117?userId=52029392&bpIds=3004037004&checksum=e5ce81a0fbd0361b655dac0f44dec19ce7db4032-1617045527723-97993e05deaa88f19536145e4497e170badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007216	AAL 13	131060-08-7	"Quinoline, 2-[4-(3-chloropropyl) piperazin-1-yl]-"				No development reported (Preclinical)	"Pain, Inflammation"	C16 H20 Cl N3	"Adrenergic receptor antagonists, Serotonin uptake inhibitors"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				02/02/2001	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800007216?userId=52029392&bpIds=3004037004&checksum=357ff54337e8b717180a4334fa1ee1011bf10f0d-1617045527724-33e1f7bd2e5ea52f4580655e9684332ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005877	Dynorphin A	88161-22-2					Discontinued (II)	"Postoperative pain, Cancer pain"		Opioid receptor agonists	"Neurobiological Technologies (Originator), Neurobiological Technologies (Owner)"		IV		"Cl (L/h) (384 (Adult)), T<sub>_beta</sub> (h) (1.02 (Adult)), Vd (L/kg) (.13 (Adult))"	"Flushing, Somnolence"	N2A (Narcotics)	N02A (Opioids)				30/01/2001	Pain				no		no							https://adis.springer.com/drugs/800005877?userId=52029392&bpIds=3004037004&checksum=fa51c4a07c73e4cd842165664ba6a468143968fd-1617045527725-0336dec9ee8deda58428b966bbbeee47badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013921	AIT 297						Discontinued (Preclinical)	Migraine		Undefined mechanism	"Spectrum Pharmaceuticals (Originator), Spectrum Pharmaceuticals (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)				29/12/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800013921?userId=52029392&bpIds=3004037004&checksum=f86b148b1a61905c8de2a77282947ebda1b6e6b4-1617045527725-230f1d713a69b7cade298e64725e54c3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003741	324C91						No development reported	Migraine		Serotonin 1D receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO		bioavailability oral (%) (70 (Adult))		N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/12/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800003741?userId=52029392&bpIds=3004037004&checksum=018df172e1626fd9548ccf628c6120c0bf67176d-1617045527726-9f50be22d88af724b4a7cd3dd3f17361badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001953	FK 888	138449-07-7	<EM>N</EM><SUP>2</SUP>-[(4<EM>R</EM>)-4-hydroxy-1-(1-methyl-1<EM>H</EM>-indol-3-yl)carbonyl-L-prolyl]-<EM>N</EM>-methyl-<EM>N</EM>-phenylmethyl-3-(2-naphthyl)-L-alaninamide				Discontinued (II)	"Bronchitis, Asthma, Migraine"	C36 H36 N4 O4	Neurokinin 1 antagonists	"Fujisawa (Originator), Fujisawa (Owner), Fujisawa (Collaborator)"		Inhalation				"N2C (Anti-Migraine Preparations), R3 (Anti-Asthma and COPD Products), R7 (Other Respiratory System Products)"	"N02C (Antimigraine Preparations), R03 (Drugs for Obstructive Airway Diseases), R07 (Other Respiratory System Products)"				19/10/2000	"Advances in the Treatment of Nausea and Migraine, Obstructive Airways Disease, Respiratory Tract Disorders"				no		no							https://adis.springer.com/drugs/800001953?userId=52029392&bpIds=3004037004&checksum=90faba06ebf0710e09f336434b66bb93f61e3961-1617045527728-5721847023b249d1921e608e1f02da35badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010426	GW 275919						Discontinued (II)	"Inflammation, Pain"		Undefined mechanism	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				05/09/2000	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800010426?userId=52029392&bpIds=3004037004&checksum=a16b355af2e71d1a8333d935f5802abe0c48280c-1617045527729-cd1154220711ae480a4af7b3d7689b85badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000015	Atrinositol	28841-62-5	"D-myo-inositol, 1,2,6-tris(dihydrogen phosphate)"				Discontinued (Clinical)	"Hypertension, Diabetic complications, Thrombosis, Pain, Atherosclerosis, Heart failure"	C6 H15 O15 P3	"Neuropeptide Y receptor antagonists, Neuropeptide inhibitors"	"Perstorp (Originator), Perstorp (Owner)"		unspecified				"A10X (Other Drugs Used in Diabetes), B1C (Platelet Aggregation Inhibitors), C1 (Cardiac Therapy), C10A9 (All other cholesterol/triglyceride regulators), C2A (Antihypertensives (of Non-Herbal Origin) Plain), N2B (Non-Narcotics and Anti-Pyretics)"	"A10X (Other Drugs Used in Diabetes), B01A-C (Platelet aggregation inhibitors excl. heparin), C01 (Cardiac Therapy), C02 (Antihypertensives), C10A-X (Other lipid modifying agents), N02B (Other Analgesics and Antipyretics)"	PP 56			01/08/2000	"Diabetes, Heart Failure, Hyperlipidaemia, Hypertension, Pain, Thromboses"				no		no							https://adis.springer.com/drugs/800000015?userId=52029392&bpIds=3004037004&checksum=0db7077767d8fd31799cd17ae79728463ca3f205-1617045527730-0fcba0d00d5a816c0e87fb0ba61b7d37badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008817	LY 334370	182563-09-3	4-Fluoro-<EM>N</EM>-[3-(1-methyl-4-piperidinyl)-1<EM>H</EM>-indol-5-yl]-benzamide fumarate	Yes			Discontinued (II)	Migraine	C21 H22 F N3 O . C4 H4 O4	Serotonin 1F receptor agonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO		"T<sub>_beta</sub> (h) (15 (Adult)), T<sub>max</sub> (h) (1 - 2 (Adult))"		N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				25/07/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800008817?userId=52029392&bpIds=3004037004&checksum=fee45ca68c24df39b0ad7a77ce19a3a797bc866b-1617045527731-393bd682f8b74c91a5ec3191078c4d36badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006197	Lanepitant	170566-84-4	<EM>N</EM>-[1(<EM>R</EM>)-(1<EM>H</EM>-Indol-3-ylmethyl)-2-[<EM>N</EM>-(2- methoxybenzyl)acetamido]ethyl]-2-[4- (1-piperidinyl)piperidin-1-yl]acetamide	No			No development reported (II)	"Pain, Asthma, Migraine"	C33 H45 N5 O3	Neurokinin 1 antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified				"N2 (Analgesics), N2C (Anti-Migraine Preparations), R3X (All Other Anti-Asthma and COPD Products)"	"N02B (Other Analgesics and Antipyretics), N02C-X (Other antimigraine preparations), R03 (Drugs for Obstructive Airway Diseases)"	LY 303870			10/07/2000	"Advances in the Treatment of Nausea and Migraine, Obstructive Airways Disease, Pain"				no		no							https://adis.springer.com/drugs/800006197?userId=52029392&bpIds=3004037004&checksum=801b115df56cb5a2924c925c3469c650078bf9ec-1617045527732-8201479dd34cff6acbcaada38769e390badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007276	SC 107						Discontinued (Preclinical)	"Musculoskeletal pain, Rheumatic disorders, Pain"		Prostaglandin synthase inhibitors	"Scotia Holdings [CEASED] (Originator), Scotia Holdings [CEASED] (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				04/07/2000	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007276?userId=52029392&bpIds=3004037004&checksum=2e76aecea037800c17c188976228c38f57bf0ddd-1617045527733-24c4eaab3c939e3874261d0f02318a3fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001471	CP 93129	127792-75-0	"3-(1,2,5,6-Tetrahydro-4-pyridyl)-5-pyrrolo[3,2-b] pyridone"				No development reported (Preclinical)	Migraine	C12 H13 N3 O	Serotonin 1B receptor agonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				23/06/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800001471?userId=52029392&bpIds=3004037004&checksum=b5aa70f99b3fa091c0d4eacb5d086d675588231c-1617045527734-2dd01decda5ddf80d59dc4415e342d7dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010000	BL 2401		(±)-3-[2-Benzyl-3-(propionylthio)propionyl]amino-5-methylbenzoic acid				Discontinued (Preclinical)	Pain	C21 H23 N O4 S	Neprilysin inhibitors	"Dainippon Pharmaceutical (Originator), Dainippon Pharmaceutical (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	BL2401			14/06/2000	Pain				no		no							https://adis.springer.com/drugs/800010000?userId=52029392&bpIds=3004037004&checksum=1a65cda12ddabdb2d0e89745becb081ab87152e5-1617045527734-e497a5a9455c07b5af65d5f21f0fe3dcbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003739	Lobuprofen	98207-12-6	2-[4-(m-Chlorophenyl)-1-piperazinyl]ethyl (±)-p-isobutylhydratropate hydrochloride				Discontinued (II)	Pain	C25 H33 Cl N2 O2 . H Cl	Cyclooxygenase inhibitors	"Juste (Originator), Juste (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	ICJ 2280A			06/06/2000	Pain				no		no							https://adis.springer.com/drugs/800003739?userId=52029392&bpIds=3004037004&checksum=7b5da134e88f64724c540eda33e87cc8d0a8eec7-1617045527735-e71076f7a4dcb4eb1afb60d1beee20e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800010652	Donitriptan		4-(4[2-[3-(2Aminoethyl)-1H-indol-5-ylocy]-acetyl]-piperazin-1-yl)-benzonitrile hydrochloride				Discontinued (Preclinical)	Migraine	C23 H25 N5 O2 . H Cl	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Pierre Fabre (Originator), Pierre Fabre (Owner)"		PO				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)	F 11356			22/05/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800010652?userId=52029392&bpIds=3004037004&checksum=73df317c37c7fbf5f1e8b1e4506316a7c7ad3097-1617045527736-90bbff5b2a683ebd0c1a60be46a337eebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800013341	AM 543						Discontinued (Preclinical)	Pain		Calcium channel antagonists	"Zenyth Therapeutics (Originator), Zenyth Therapeutics (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				27/04/2000	Pain				no		no							https://adis.springer.com/drugs/800013341?userId=52029392&bpIds=3004037004&checksum=f80026249777bcc9fcc3dd7f82374abd7a1b213b-1617045527737-fba1b47f4046a1952cfcd0b607fdc5edbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008330	TYR W MIF 1	144450-13-5	"Glycinamide, L-tyrosyl-L-prolyl-L-tryptophyl-"				No development reported (Preclinical)	Pain	C28 H32 N6 O5	"Opioid mu receptor agonists, Opioid mu receptor antagonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				28/03/2000	Pain				no		no							https://adis.springer.com/drugs/800008330?userId=52029392&bpIds=3004037004&checksum=265b3c805b1777351f12bc7123fe5bcf7585b146-1617045527737-a2e16e8924ba5b671ebef2519f296239badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008413	QX 314	21306-56-9	"1-(2',6'-Dimethyl-phenylcarbamoyl-methyl)triethylammonium bromide"				No development reported (Preclinical)	Pain		Opioid receptor agonists	"Research Biochemicals (Originator), Research Biochemicals (Owner)"		SC				N2A (Narcotics)	N02A (Opioids)				28/03/2000	Pain				no		no							https://adis.springer.com/drugs/800008413?userId=52029392&bpIds=3004037004&checksum=5bab74e5e4883746db5384e07e2ebd51759c2d9e-1617045527738-5a6aeb0544c5b9186467564817c45036badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005881	R 84760	157824-23-2	"Thiomorpholine, 4-[(5,6-dichloro-2,3-dihydro-1H-inden-1-yl) carbonyl]-3-(1-pyrrolidinylmethyl)-, monohydrochloride"				No development reported (Preclinical)	Pain	C19 H24 Cl2 N2 O S . H Cl	Opioid kappa receptor agonists	"Sankyo (Originator), Sankyo (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				28/03/2000	Pain				no		no							https://adis.springer.com/drugs/800005881?userId=52029392&bpIds=3004037004&checksum=16b0ef85b458c0006f94eb51198bf494c06d6c92-1617045527739-f5613c46a44ba4f918b14a37574a783dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005787	CP 122288	143321-74-8	N-methyl-3-[1-methylpyrrolidin-2(R)-ylmethyl]-1H-indol-5-ylmethylsulfonamide				Discontinued (II)	Migraine	C16 H23 N3 O2 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Pfizer (Originator), Pfizer (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				22/03/2000	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800005787?userId=52029392&bpIds=3004037004&checksum=d75c98846aa9b2bda1ebac474c821f03fe303b43-1617045527740-f8f2ebf2b2f0271e2964159981a40e6ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008444	LY 316108	162183-61-1	"(5R,6R)-<EM>exo</EM>-6-[4-[(4,4,4-Trifluorobutyl)thio]-1, 2, 5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane"	Yes			No development reported (Preclinical)	"Irritable bowel syndrome, Pain"	C13 H18 N3 F3 S2	Muscarinic receptor agonists	"Eli Lilly and Company (Originator), Novo Nordisk (Originator), Eli Lilly and Company (Owner), Novo Nordisk (Owner)"		PO				"A3A (Plain Antispasmodics and Anticholinergics), N2B (Non-Narcotics and Anti-Pyretics)"	"A03A (Drugs for Functional Bowel Disorders), N02B (Other Analgesics and Antipyretics)"	NNC 112192			09/02/2000	"Digestive System Disorders, Pain"				no		no							https://adis.springer.com/drugs/800008444?userId=52029392&bpIds=3004037004&checksum=0d2d95f67c77f1f8a6e3ed439cf5c76330d05523-1617045527741-86d577165fd8ba7655741c14b94e70ffbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005859	Vedaclidine	141575-50-0	"(+)-3-(4-Butylsulfanyl-1,2,5-thiadiazol-3-yl)-1-azabicyclo[2.2.2]octane"	No			No development reported (II)	Pain	C13 H21 N3 S2	Muscarinic receptor agonists	"Novo Nordisk (Originator), Novo Nordisk (Owner), Eli Lilly and Company (Market Licensee)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	"LY 297802, NNC 101053, NNC 111053"			09/02/2000	Pain				no		no							https://adis.springer.com/drugs/800005859?userId=52029392&bpIds=3004037004&checksum=db054f76d0ce837915987910061102346687d964-1617045527742-d8f34bf4290512fc568c605eeea84515badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007509	L 742694	159706-39-5	"2(S)-((3,5-Bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl- 4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine"				No development reported (Preclinical)	"Pain, Nausea and vomiting"	C22 H20 N4 F6 O3	Neurokinin 1 antagonists	"Merck & Co (Originator), Merck & Co (Owner)"		"PO, unspecified"				"A4A (Antiemetics and Antinauseants), N2B (Non-Narcotics and Anti-Pyretics)"	"A04A-D (Other antiemetics), N02B (Other Analgesics and Antipyretics)"				08/02/2000	"Advances in the Treatment of Nausea and Migraine, Pain"				no		no							https://adis.springer.com/drugs/800007509?userId=52029392&bpIds=3004037004&checksum=be1daeabd7d72b144e530b17b8e4ecaa9ab2980d-1617045527743-c2c2bbf18d15ea6f4280a633b49e124fbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007143	NPS 846			Yes			Discontinued (Preclinical)	"Neurological disorders, Pain"		"Glutamate receptor antagonists, NMDA receptor antagonists"	"NPS Pharmaceuticals (Originator), NPS Pharmaceuticals (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"				06/01/2000	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800007143?userId=52029392&bpIds=3004037004&checksum=561feda8edaed6e4fa5d7cb3bdc6613141901043-1617045527744-cccac513c9f2bf528ab86c774999fe4dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009536	ZD 6804						Discontinued (I)	Pain		Prostaglandin receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				09/12/1999	Pain				no		no							https://adis.springer.com/drugs/800009536?userId=52029392&bpIds=3004037004&checksum=b6d37cc15a5dcb086187c772fdea10c120016515-1617045527745-f01dfa95604434ec7f1dc7c14ca2e295badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006843	ZD 4953						Discontinued (II)	Pain		Prostaglandin receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				09/12/1999	Pain				no		no							https://adis.springer.com/drugs/800006843?userId=52029392&bpIds=3004037004&checksum=f3cacb9a854ed605e05bde42e31818796c7e04ea-1617045527746-e8aeacd610414076e6d30afcc9ad826bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006608	ZD 9379	170142-29-7	"7-Chloro-4-hydroxy-2-(4-methoxy-2-methylphenyl)pyridazino[4,5-b]quinoline-1,10(2H,5H)-dione monosodium salt"	Yes			Discontinued (II)	"Pain, Stroke"	C19 H13 Cl N3 O4 . Na	Glycine antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO				"N2B (Non-Narcotics and Anti-Pyretics), N7 (Other CNS Drugs)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"				09/12/1999	"Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800006608?userId=52029392&bpIds=3004037004&checksum=cc85e1793f1154acb3ffed02cc68bf1746477327-1617045527746-8b245f1bcb208b047bdfd7b922ba49e9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002229	SB 200646A	143797-62-0	1-(1-Methylindol-5-yl)-3-(3-pyridyl)urea hydrochloride				Discontinued (Preclinical)	"Eating disorders, Anxiety disorders, Major depressive disorder, Migraine, Obsessive-compulsive disorders"	C15 H14 N4 O . H Cl	"Serotonin 2B receptor antagonists, Serotonin 2C receptor antagonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"N2C (Anti-Migraine Preparations), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers)"	"N02C (Antimigraine Preparations), N05B-X (Other anxiolytics), N06A (Antidepressants)"	SB 200646			26/11/1999	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders"				no		no							https://adis.springer.com/drugs/800002229?userId=52029392&bpIds=3004037004&checksum=948772c924c382d5e3780ee164b8647d6df3e8d1-1617045527748-93306b102aa038063dab7a2c9dd2c4d4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006271	SB 213698	173398-79-3	"(6a<EM>S</EM>, 6a<EM>R</EM>)-9-Methyl-6a-(3-hydroxyphenyl)-6, 6a, 7, 8, 9, 10, 10a, 11-octahydroquinolino[2, 3-g]isoquinoline"				No development reported (Preclinical)	Pain	C23 H24 N2 O	Opioid delta receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				22/11/1999	Pain				no		no							https://adis.springer.com/drugs/800006271?userId=52029392&bpIds=3004037004&checksum=16361e20d6cdd513fe1ab493706437df122046f1-1617045527749-0ba76d6a6a4f5587a1fd62423d9130e0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008418	SB 219825		"(-)-trans-6, N, N-Triethyl-8a-(3-hydroxyphenyl)-3-methyl-4, 4a, 5, 6, 7,8,8a,9-octahydro-1H-pyrrolo[2,3-g]isoquinoline-2-carboxamide"				Discontinued (Preclinical)	Pain	C25 H35 N3 O2	Opioid delta receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				18/11/1999	Pain				no		no							https://adis.springer.com/drugs/800008418?userId=52029392&bpIds=3004037004&checksum=3df7d86c1b9064012de9127f9d60b47942636c09-1617045527749-9ae2b7732138900d658d363c5556f0f0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007933	SKF 92374	98104-48-4	N<SUP>2</SUP>-Cyano-N<SUP>1</SUP>-[3-(4-imidazolyl)propyl]- N<SUP>3</SUP>-methylguanidine				Discontinued (Preclinical)	Pain	C9 H14 N6	Histamine H2 receptor antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/11/1999	Pain				no		no							https://adis.springer.com/drugs/800007933?userId=52029392&bpIds=3004037004&checksum=7d2eda336b5794ce1eda431909750bbc53524f1f-1617045527750-3a0392d4fa8288a525195ec38a383e2cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800008347	ATBO		2-Amino-5-<EM>tert</EM>-butyl-2-oxazoline				No development reported (Preclinical)	Pain	C6 H11 N2 O	Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				16/09/1999	Pain				no		no							https://adis.springer.com/drugs/800008347?userId=52029392&bpIds=3004037004&checksum=7c650ccf9b56dbb21ed88c40109342e0c2b8f398-1617045527751-622ac0f3bdc95694acea2863aee2ed61badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003531	GR 127607						Discontinued (I)	Migraine		Serotonin 1 receptor agonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				24/08/1999	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800003531?userId=52029392&bpIds=3004037004&checksum=e9503527148944891eae26698ec8787cce8982e5-1617045527752-ecdb47789fadf40f61b416a207fe1b02badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003489	524C79						Discontinued (I)	"HIV infections, Neuralgia, Hepatitis B, Pain"		"RNA-directed DNA polymerase inhibitors, Glutamate antagonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"J5B (Antivirals, excluding anti-HIV products), J5C (HIV antivirals), N2 (Analgesics)"	"J05A (Direct acting antivirals), N02 (Analgesics)"				24/08/1999	"Pain, Viral Infections"				no		no							https://adis.springer.com/drugs/800003489?userId=52029392&bpIds=3004037004&checksum=df18c49007e119ac074a2880d327badbe06dbbe1-1617045527753-bea45cc08c1a08c76b1c76cf4d2df045badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009029	GR 4991W93						Discontinued (II)	Migraine		"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C (Antimigraine Preparations)	4991W93			22/07/1999	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800009029?userId=52029392&bpIds=3004037004&checksum=30705a3f3cd40ffb6e28d079ba1c86150f9d6ee4-1617045527754-7c8fd4ec8c54d143ecbac594f0717af4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007690	ACEA 1328	160954-05-2	"6,7-Dimethyl-5-nitroquinoxaline-2,3(1H, 4H)-dione"				Discontinued (Preclinical)	Pain	C10 H9 N3 O4	Glutamate receptor antagonists	"Purdue Pharma (Originator), Purdue Pharma (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				21/07/1999	Pain				no		no							https://adis.springer.com/drugs/800007690?userId=52029392&bpIds=3004037004&checksum=c9b5f90e1845bd1115c8cb73b1c26c3ead73d3d3-1617045527755-caa6e9498223397eb19b721047bee051badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009546	GR 253035						Discontinued (I)	"Alzheimer's disease, Pain"		Cyclo-oxygenase 2 inhibitors	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				"N2B (Non-Narcotics and Anti-Pyretics), N7D9 (All other anti-Alzheimer products)"	"N02B (Other Analgesics and Antipyretics), N07 (Other Nervous System Drugs)"				20/07/1999	"Alzheimer's Disease and Cognition Disorders, Pain"				no		no							https://adis.springer.com/drugs/800009546?userId=52029392&bpIds=3004037004&checksum=fe5b7a7bf5460602d8cd04e4160ab5d107d04cb3-1617045527756-06f0ede069185f594b105facfb41e0b5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006453	4030W92		"(-)-(<EM>R</EM>)-5-(2, 3-Dichlorophenyl)-6-(fluoromethyl)pyrimidine-2, 4-diamine"				Discontinued (II)	Neuropathic pain	C11 H9 N4 Cl2 F	Sodium channel antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)	GR 403W92			16/07/1999	Pain				no		no							https://adis.springer.com/drugs/800006453?userId=52029392&bpIds=3004037004&checksum=e4af2ff0553f61f1472fb824bc695e2e3190dd1a-1617045527756-8156a0ca2b9bd2abf0338d402e672d2bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009627	ADL 0100032						Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				01/07/1999	Pain				no		no							https://adis.springer.com/drugs/800009627?userId=52029392&bpIds=3004037004&checksum=3fa15ac7fa47226572ba6720ebaddddcab91d23b-1617045527757-f3ee6d6fc6866b1762e5cf3cee01ae92badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009626	ADL 0100024						Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Adolor Corporation (Originator), Adolor Corporation (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				01/07/1999	Pain				no		no							https://adis.springer.com/drugs/800009626?userId=52029392&bpIds=3004037004&checksum=2b8778c7651b69242e1cf9eb201e2fa76ea3fa31-1617045527758-34f7e7b7d1c2b496b5215053cef91332badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000690	ICI 169369	85273-96-7	"N,N-dimethyl-2-[(3-phenyl-2-quinolinyl)thio]- ethanamine hydrochloride"				Discontinued (II)	"Migraine, Psychotic disorders, Anxiety disorders"	C19 H20 N2 S . Cl H	Serotonin 2 receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		PO		T<sub>max</sub> (h) (2.8 - 4.4 (Adult))		"N2C (Anti-Migraine Preparations), N5A (Antipsychotics), N5C (Tranquillisers)"	"N02C-X (Other antimigraine preparations), N05A-X (Other antipsychotics), N05B-X (Other anxiolytics)"				07/04/1999	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800000690?userId=52029392&bpIds=3004037004&checksum=c2c7ca4d0ba483b9cb1dd998310903ba8536092d-1617045527759-40be62e68b2970abf0002117239df816badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006374	FPL 15765		"9-Amino-benzo[5,6-b]indane"				No development reported (Preclinical)	Pain	C13 H17 N	Glutamate receptor antagonists	"AstraZeneca (Originator), AstraZeneca (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				07/04/1999	Pain				no		no							https://adis.springer.com/drugs/800006374?userId=52029392&bpIds=3004037004&checksum=06d6dc2dfc48d54e99456b54ea10b87866be33ff-1617045527760-693f9f9ab388ba8d8b806153749b9eebbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800009729	GW 286103		"5-(2, 3-Dichlorophenyl)-2-[3(<EM>R</EM>), 5(<EM>S</EM>)-dimethylpiperazin-1-yl]pyrimidin-4-amine"				Discontinued (Preclinical)	Pain	C16 H19 Cl2 N5	Sodium channel antagonists	"GlaxoSmithKline (Originator), GlaxoSmithKline (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				15/03/1999	Pain				no		no							https://adis.springer.com/drugs/800009729?userId=52029392&bpIds=3004037004&checksum=f4d21750eba0392674873bf54a5db4580a6abdd7-1617045527761-72af449c681e1e8d52687d76d4f2dd30badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001397	LY 215840	137328-52-0	"Ergoline-8-carboxamide, N-(2-hydroxycyclopentyl)-6-methyl-1-(1-methylethyl)-, [8_(1S,2R)]-"	Yes			No development reported (Clinical)	"Thrombosis, Migraine"	C24 H33 N3 O2	"Serotonin 2A receptor antagonists, Serotonin 7 receptor antagonists"	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		unspecified			"Dizziness, Fatigue, Headache, Nausea"	"B1C (Platelet Aggregation Inhibitors), N2C (Anti-Migraine Preparations)"	"B01A-C (Platelet aggregation inhibitors excl. heparin), N02C-X (Other antimigraine preparations)"				08/12/1998	"Advances in the Treatment of Nausea and Migraine, Thromboses"				no		no							https://adis.springer.com/drugs/800001397?userId=52029392&bpIds=3004037004&checksum=093e90e0ec4175b6bf9107628d11d0e3ba8bb4fe-1617045527763-03490ab4c6399f0a1bbe650d06e8a052badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005885	SNX 239	162995-02-0					No development reported (Preclinical)	Neuralgia		Calcium channel antagonists	"Elan Pharmaceuticals (Originator), Elan Pharmaceuticals (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				11/11/1998	Pain				no		no							https://adis.springer.com/drugs/800005885?userId=52029392&bpIds=3004037004&checksum=e285299c43cc39c27601f31825d4c6447215fe70-1617045527764-bb110824c10a3679d04ad6e852d64457badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006439	L 732138	148451-96-1	"N-Acetyl-L-tryptophan-3,5-bis-trifluoromethyl benzyl ester"				No development reported (Preclinical)	"Pain, Rheumatoid arthritis, Migraine"	C22 F6 H20 N2 O3	"Neurokinin 1 antagonists, Substance P inhibitors"	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				"M1A1 (Anti-rheumatics, non-steroidal plain), N2 (Analgesics), N2C (Anti-Migraine Preparations)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02A (Opioids), N02C-X (Other antimigraine preparations)"				06/10/1998	"Advances in the Treatment of Nausea and Migraine, Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800006439?userId=52029392&bpIds=3004037004&checksum=7b655fd582c9a4068e4af0c2fcd5ae3a3c87c690-1617045527765-4fd253fc245500a22ea9a6eca2dde04cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007028	L 741519	154594-20-4	"1-Methyl-4-[5-(4<EM>H</EM>-1,2,4-triazol-4-yl)-1<EM>H</EM>-indol-3-yl]piperidine"				No development reported (Preclinical)	Migraine	C16 H19 N5	Serotonin 1D receptor agonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800007028?userId=52029392&bpIds=3004037004&checksum=011f43c729167d9eb30f613855f134ed7a4ae65e-1617045527766-e6e847bc1c24f68176bb1eb485a2f379badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006490	VS 460		"3-[3-[<EM>N</EM>-[2-[<EM>N</EM>-(5,6-Dimethoxypyrimidin-4-yl)-<EM>N</EM>-methylamino]ethyl-<EM>N</EM>-methylamino]propyl]-<EM>N</EM>-methyl-1<EM>H</EM>-indol-5-ylmethylsulfonamide"				No development reported (Preclinical)	Migraine	C23 H34 N6 O4 S	Serotonin 1D receptor agonists	"Laboratorios Vita (Originator), Laboratorios Vita (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006490?userId=52029392&bpIds=3004037004&checksum=87ff402888ad57e7a821d2075cbb7546e3b67d98-1617045527767-99e34df9c09e6decc941774344af8740badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007474	VS 462		3-[3-[4-[5-Methoxy-6-(methylamino)pyrimidin-4-yl]piperazin-1-yl]propyl]-<EM>N</EM>-methyl-1<EM>H</EM>-indol-5-ylmethylsulfonamido				No development reported (Preclinical)	Migraine	C23 H33 N7 O3 S	Serotonin 1D receptor agonists	"Laboratorios Vita (Originator), Laboratorios Vita (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800007474?userId=52029392&bpIds=3004037004&checksum=e91951acd937a8540c3b597c26846f6da7a3f655-1617045527768-b8255c04ffd7378258d323dd9dc1672bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006344	L 741604	154594-22-6	"N,N-Dimethyl-N-[2-[5-(4H-1,2,4-triazol-4-yl)-1H-indol-3-yl]ethyl]amine"				No development reported (Preclinical)	Migraine	C14 H17 N5	Serotonin 1D receptor agonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006344?userId=52029392&bpIds=3004037004&checksum=9e11b8a724f8c3d183a99397a6799d316dde19d6-1617045527768-fefb9bf33aa87f0537f358cd1e6518afbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006487	VS 390		"1-(5,6-Dimethoxypyrimidin-4-yl)-4-[3-(5-methoxy-1<EM>H</EM>-indol-3-yl)propyl]piperazine"				No development reported (Preclinical)	Migraine	C22 H29 N5 O3	Serotonin 1D receptor agonists	"Laboratorios Vita (Originator), Laboratorios Vita (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006487?userId=52029392&bpIds=3004037004&checksum=4d5289e8bde4382988dea69f5c4613d561f025f6-1617045527769-4431221b7e22fe3887ce062f87766534badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006489	VS 395	172705-88-3	"3-[3-[4-(5,6-Dimethoxypyrimidin-4-yl)piperazin-1-yl]propyl]-N-methyl-1H-indol-5-ylmethylsulfonamide"				No development reported (Preclinical)	Migraine	C23 H32 N6 O4 S	Serotonin 1D receptor agonists	"Laboratorios Vita (Originator), Laboratorios Vita (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				06/10/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006489?userId=52029392&bpIds=3004037004&checksum=1a7ef454d25736512ae2e9e65c75e857a553a1ad-1617045527770-c2938e23dc5b292a10b5aad9018609abbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003505	PD 144418	154130-99-1	"3-[3-(4-Methylphenyl)isoxazol-5-yl]-1-propyl-1,2,5,6- tetrahydropyridine"	Yes			No development reported (Preclinical)	"Psychotic disorders, Stroke, Epilepsy, Neuromuscular disorders, Pain"	C18 H22 N2 O	Opioid receptor antagonists	"Pfizer (Originator), Pfizer (Owner)"		unspecified				"M5X (All Other Musculoskeletal Products), N2A (Narcotics), N3A (Anti-Epileptics), N5A (Antipsychotics), N7 (Other CNS Drugs)"	"M09A (Other Drugs for Disorders of the Musculo-Skeletal System), N02A-X (Other opioids), N03A-X (Other antiepileptics), N05A-X (Other antipsychotics), N07X (Other Nervous System Drugs)"				30/09/1998	"Epilepsy and Seizure Disorders, Musculoskeletal Disorders, Neurological Disorders, Pain, Psychotic Disorders"				no		no							https://adis.springer.com/drugs/800003505?userId=52029392&bpIds=3004037004&checksum=b16e9534825ef863d67acaca58b3f5e7e1e18fbd-1617045527771-8e471451b3d82d786963ff57ae50aa6cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001500	Enadoline	124378-77-4	"[5R-(5_,7_,8_)]-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl]-4-benzofuranacetamide monohydrochloride"	Yes			Discontinued (II)	"Pain, Neurological disorders, Arrhythmias"	C24 H32 N2 O3 . H Cl	"Opioid kappa receptor agonists, Sodium channel antagonists"	"Pfizer (Originator), Pfizer (Owner)"		"unspecified, IM"			"Anxiety, CNS disorders, Confusion, Dizziness, Drowsiness, Fever, Hallucinations, Headache, Hyperhidrosis, Nausea, Taste disorders, Tinnitus, Vision disorders"	"C1B (Anti-Arrhythmics), N2A (Narcotics)"	"C01B (Antiarrhythmics, Class I and III), N02A-X (Other opioids)"	"CI 977, PD 129290"			29/09/1998	"Arrhythmias, Neurological Disorders, Pain"				no		no							https://adis.springer.com/drugs/800001500?userId=52029392&bpIds=3004037004&checksum=1b6e38c021d8a65347cb6fd2d929ebed042dd754-1617045527772-f11fb949db9f5fe28cbef2850c9d536dbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003295	Deltibant	140661-97-8	Hexamethylene-bis-[succinimido-cys(leu)-phe-gly-hyp-pro-arg]				Discontinued (III)	"Systemic inflammatory response syndrome, Brain injuries, Brain oedema, Shock, Asthma, Cancer pain, Postoperative pain, Stroke, Migraine"	C128 H194 N40 O28 S2	Bradykinin receptor antagonists	"Cortech (Originator), Cortech (Owner)"		unspecified				"J8X (All Other Anti-Infectives), N2 (Analgesics), N2C (Anti-Migraine Preparations), N7 (Other CNS Drugs), R3 (Anti-Asthma and COPD Products)"	"J01X (Other Antibacterials), N02 (Analgesics), N02C (Antimigraine Preparations), N07X (Other Nervous System Drugs), R03 (Drugs for Obstructive Airway Diseases)"	"Bradycor, CP 0127, SB 238592, Septicor"			28/09/1998	"Advances in the Treatment of Nausea and Migraine, Bacterial Infections, Inflammation, Neurological Disorders, Obstructive Airways Disease, Pain, Vascular Disorders"			"Bradycor, Bradycor, Septicor, Septicor"	no		no							https://adis.springer.com/drugs/800003295?userId=52029392&bpIds=3004037004&checksum=3fab07e93bee274b6f1c13e8c27c17d092a5b77a-1617045527774-f11084d0a0936ffb74daabf05571451bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007967	N-CBM TAMO		"14_,14_-[dithiobis[(2-oxo-2,1-ethanediyl)imino] bis[7,8-dihydro-N-(cyclobutylmethyl)-normorphinone]"				No development reported (Preclinical)	Pain	C46 H54 N4 O8 S2	"Opioid kappa receptor agonists, Opioid mu receptor antagonists"	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A-F (Morphinan derivatives)				02/09/1998	Pain				no		no							https://adis.springer.com/drugs/800007967?userId=52029392&bpIds=3004037004&checksum=455fb293e76339692d92aaac5edb2da29fbcb0aa-1617045527775-35e1451977fa4e9404fd83f9fd92186cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007357	MER W8020	157630-13-2					No development reported (Preclinical)	"Rheumatoid arthritis, Pain"		Undefined mechanism	"Mercian (Originator), Mercian (Owner)"		Intraperitoneal				"M1A1 (Anti-rheumatics, non-steroidal plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02B-G (Other analgesics and antipyretics)"				02/09/1998	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007357?userId=52029392&bpIds=3004037004&checksum=719e116f7a18f99510fc62784e5c342ee85f1658-1617045527776-3f65aac10038d18b13d7989296b6fc7cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007731	TAMO		"14_,14_-[Dithio-bis[(2-oxo-2,1-ethanediyl)imino]] bis(7,8-dihydromorphinone)"				No development reported (Preclinical)	Pain		Opioid mu receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				02/09/1998	Pain				no		no							https://adis.springer.com/drugs/800007731?userId=52029392&bpIds=3004037004&checksum=e1083f709bac34ca36e1dccb9ae42d9f31c7d312-1617045527777-afb0ab6c62258bb830ecc094db70ac22badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007732	RWJ 38705	147441-56-3	"(1RS, 2RS)-2-[(Dimethylamino)-methyl]-1-(3-methoxyphenyl)- cyclohexanol N-oxide"				No development reported (Preclinical)	Pain	C16 H25 N O3	Opioid receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	tramadolNoxide			02/09/1998	Pain				no		no							https://adis.springer.com/drugs/800007732?userId=52029392&bpIds=3004037004&checksum=4dd4767267d9cf8bcf115bf62f4b3a03669e25cf-1617045527777-f146cd8f9f0f82382bdbf044c02937c3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007475	S 128134		"3-[2-(4-Phenylpiperazine-1-yl)-ethyl]-2-oxo-2,3-dihydro- oxazolo[4,5-b]pyridine"				No development reported (Preclinical)	Pain	C18 H20 N4 O2	Alpha 2 adrenergic receptor agonists	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				02/09/1998	Pain				no		no							https://adis.springer.com/drugs/800007475?userId=52029392&bpIds=3004037004&checksum=5d3be7eb5047d21c8805b575ed111767ac3dcc61-1617045527778-8140d91aceeaf4f05eba4999b9c1fbb0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006892	UPF 523	168560-79-0	"(±)-1-Aminoindane-1,5-dicarboxylic acid"				No development reported (Preclinical)	Pain	C11 H11 N O4	Glutamate receptor antagonists	"Nonindustrial source (Originator), Novo Nordisk (Originator), Nonindustrial source (Owner), Novo Nordisk (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				02/09/1998	Pain				no		no							https://adis.springer.com/drugs/800006892?userId=52029392&bpIds=3004037004&checksum=fef75eeedaf46b8a3534f809040ff005f254dbc8-1617045527779-eae8a0a95d864b4bc76fea244abdb544badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007977	NPC 18521	168824-73-5	"<EM>d</EM>-Arg-Arg-[1-phenyl-1,3,8-triazaspiro[4,5]-decane-4-one -3-acetyl]-Ser-<EM>d</EM>-tetrahydroisoquinolinyl-octahydroindolinyl-Arg"				No development reported (Preclinical)	"Inflammation, Pain"	C55 H82 N18 O10	Bradykinin B2 receptor antagonists	"Scios (Originator), Scios (Owner), Nonindustrial source (Collaborator)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2B (Non-Narcotics and Anti-Pyretics)"	"M01 (Antiinflammatory and Antirheumatic Products), N02B (Other Analgesics and Antipyretics)"				02/09/1998	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007977?userId=52029392&bpIds=3004037004&checksum=a1ea2e6dfcae9a072e4d7fb3df2c61801d395f69-1617045527780-5ef29a13901dd97d7fddbc3aeb694dc9badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006583	WIN 51708	144177-30-0	"[1R-(1_,3a_,3b_,5a_,15a_,15b_,17a_)]-1-ethynyl -2,3,3a,3b,4,5,5a,6,15,15a,15b,16,17,17a-tetrahydro- 15a,17a-dimethyl-1H-benzimidazo[2,1-b]cyclopenta [5,6]naphtho[1.2-g]quinazolin-1-ol"				No development reported (Preclinical)	Pain		Neurokinin 1 antagonists	"Sanofi Winthrop (Originator), Sanofi Winthrop (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				31/08/1998	Pain				no		no							https://adis.springer.com/drugs/800006583?userId=52029392&bpIds=3004037004&checksum=4764c8b106b136135fff0d4ac253640712d90c5b-1617045527781-56578b0e084eb1799835fe005b30b695badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006460	SPA S 646	115053-54-8	"L-Tyrosine, <EM>N</EM>-(<EM>N</EM>-L-threonyl-L-_-aspartyl)-"				No development reported (Preclinical)	Pain	C17 H23 N3 O8	Undefined mechanism	"Nonindustrial source (Originator), Nonindustrial source (Owner)"		"Rectal, IM"				N2 (Analgesics)	N02 (Analgesics)				31/08/1998	Pain				no		no							https://adis.springer.com/drugs/800006460?userId=52029392&bpIds=3004037004&checksum=4b9620a9f4d5d49aa19678d3b9961bb0a0ea766d-1617045527782-4fb57ac048ecbf6a6b2bf6836fcd0ae3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006639	NPC 18688	174693-30-2	"2-[1'-(D-Arginyl-L-arginyl)-3-cyclohexyl-5-oxospiro[imidazolidin-4,4'-piperidin]-1-yl]-acetyl-L-seryl-D-(1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl-L-(perhydroindol-2-ylcarbonyl)-L-arginine"				No development reported (Preclinical)	Pain	C55 H88 N18 O10	Bradykinin B2 receptor antagonists	"Scios (Originator), Scios (Owner), Nonindustrial source (Collaborator)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				31/08/1998	Pain				no		no							https://adis.springer.com/drugs/800006639?userId=52029392&bpIds=3004037004&checksum=03e6993bd9cf7b8823c5d3be7c5fb8b92c5e0d5c-1617045527783-23cb0b184f17cbc42ab8428a4b3246c2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005632	OHM 3597	131728-61-5	"1H-Isoindole-1,3(2H)-dione, [4-[methyloxycarbonyl- (N-ethylcarbonyl-N-phenyl)amino]-1-(2-ethyl)] piperidinyl-,"				No development reported (Preclinical)	Pain	C26 H28 N3 O4	Opioid mu receptor agonists	"Baxter International (Originator), Baxter International (Owner)"		unspecified				N2A (Narcotics)	N02A-B (Phenylpiperidine derivatives)				16/07/1998	Pain				no		no							https://adis.springer.com/drugs/800005632?userId=52029392&bpIds=3004037004&checksum=886fe0c5b4fa27abaa0076fcbc882d3c91c82e94-1617045527784-2ae925110882562cb3e69e0f2cfee1d5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005870	RU 54808	187112-51-2	"(+)-2-(1,2-bis(1-Oxopropoxy)ethyl)-4-hydroxy- N-(2-thiazolyl)-8-(trifluoromethyl)-3-quinoline carboxamide"				No development reported (Preclinical)	Pain	C22 H20 F3 N3 O6 S	"Cyclooxygenase inhibitors, Lipoxygenase inhibitors"	"Aventis (Originator), Aventis (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				16/07/1998	Pain				no		no							https://adis.springer.com/drugs/800005870?userId=52029392&bpIds=3004037004&checksum=f559c79547d7853dd7cde3499e30aef1b78ce021-1617045527785-04952df16da83279b046520a921415cabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005628	ONO NT 012	163438-84-4	"5(Z)-7-[(1S,2S,3S,5R)-3-(trans-_-styren) sulfonamido-6,6-dimethylbicyclo[3.1.1]hept-2-yl]-5-heptenoic acid"				No development reported (Preclinical)	Pain	C24 H33 N O4 S	"Prostaglandin E1 antagonists, Prostaglandin E3 agonists, Thromboxane A2 receptor antagonists"	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				16/07/1998	Pain				no		no							https://adis.springer.com/drugs/800005628?userId=52029392&bpIds=3004037004&checksum=21ae5076957d2787ad8cc679e32fcfe475604229-1617045527786-8b0876d13e6960721784636325f61256badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007978	Ibuproxam betadex		S-(+)-2-(4-Isobutylphenyl)-propiohydroxamic acid with _-cyclodextrin				Discontinued (Preclinical)	Pain	C13 H19 N O2	Cyclooxygenase inhibitors	"LEK (Originator), LEK (Owner)"		unspecified				"M1A1 (Anti-rheumatics, non-steroidal plain), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-E (Propionic acid derivatives), N02B (Other Analgesics and Antipyretics)"				08/07/1998	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007978?userId=52029392&bpIds=3004037004&checksum=2c78f78f747524be9c6f7ccc6a86efcaa91b8b50-1617045527787-76b9b23fe3294a58940124fe6ba1dde3badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005889	D 1367						Discontinued (I)	Pain		Cyclo-oxygenase 2 inhibitors	"Celltech Group (Originator), Celltech Group (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				18/05/1998	Pain				no		no							https://adis.springer.com/drugs/800005889?userId=52029392&bpIds=3004037004&checksum=a57404494537b25900db7282d7435f5a4ffc9d93-1617045527787-7d6ba23ad813ee1af8687731a29600e4badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005987	SDZ 224015		"<EM>Z</EM>-valyl-alanyl-3(<EM>S</EM>)-3-amino-4-oxo-5-(2,6-dichlorobenzoyl-oxypentanoic acid) ethyl ester"				Discontinued (Preclinical)	"Pain, Inflammation"	C30 H35 Cl2 N3 O9	Caspase 1 inhibitors	"Novartis (Originator), Novartis (Owner)"		PO				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics)"				07/05/1998	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800005987?userId=52029392&bpIds=3004037004&checksum=322b9834c9a66ea8ab5a1e8e6d50211470fe9938-1617045527788-83177b6027f957a48c18391c9499de2cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002898	ALX 1323						Discontinued (Preclinical)	Migraine		Serotonin 1D receptor antagonists	"NPS Allelix (Originator), NPS Allelix (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-X (Other antimigraine preparations)				05/05/1998	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800002898?userId=52029392&bpIds=3004037004&checksum=167d176a3fa56ff4810da365d1f3c4b3015ade45-1617045527789-24b60039a0835aafea15231b5acc8b50badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800007345	Diclofenac digolil						Discontinued (I)	"Inflammation, Pain"		"Arachidonic acid inhibitors, Cyclooxygenase inhibitors"	"FAES Farma (Originator), FAES Farma (Owner)"		Topical				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A-B (Acetic acid derivatives and related substances), N02B (Other Analgesics and Antipyretics)"	F 5402M			07/04/1998	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800007345?userId=52029392&bpIds=3004037004&checksum=4e97ef3061caff375ef3507464f0ad36f27ff47b-1617045527789-77181b2cabf91bd155184f818bf1f3f5badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003222	D 21151	100537-30-2	"Phthalazine, 1-phenoxy-"				Discontinued (Preclinical)	Pain	C14 H10 N2 O	Thromboxane B2 antagonists	"ASTA Medica [CEASED] (Originator), ASTA Medica [CEASED] (Owner)"		PO				N2 (Analgesics)	N02B-G (Other analgesics and antipyretics)				02/12/1997	Pain				no		no							https://adis.springer.com/drugs/800003222?userId=52029392&bpIds=3004037004&checksum=f4ab70ea8be04453db6954ed3e6dc95a2a6b102e-1617045527790-ec7b057ce66158f46ee8bf44d236a62abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002784	MDL 102588	150016-76-5	2-[1-(2-Benzyloxyphenoxy)-4-phenylbutyl]-2-imidazoline				No development reported	"Major depressive disorder, Anxiety disorders, Hypertension, Migraine"	C26 H28 N2 O2	"Alpha 2 adrenergic receptor agonists, Serotonin 1C receptor agonists, Serotonin 2 receptor agonists"	"Aventis (Originator), Aventis (Owner)"		unspecified				"C2 (Antihypertensives), N2C (Anti-Migraine Preparations), N5C (Tranquillisers), N6A (Anti-Depressants and Mood Stabilisers)"	"C02K (Other Antihypertensives), N02C-C (Selective serotonin (5HT1) agonists), N05B-X (Other anxiolytics), N06A (Antidepressants)"				22/09/1997	"Advances in the Treatment of Nausea and Migraine, Affective Disorders, Anxiety Disorders, Hypertension"				no		no							https://adis.springer.com/drugs/800002784?userId=52029392&bpIds=3004037004&checksum=19107c4f8ff380c11930e0fe6f5e28aa505e37e6-1617045527791-417c246aff7d4736199fdc581c4cf097badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800006286	Alniditan	152317-89-0	"(R)-N-(3,4-Dihydro-2H-1-benzopyran-2-ylmethyl)-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine"				Discontinued (III)	Migraine	C17 H26 N4 O	Serotonin 1D receptor agonists	"Janssen L.P. (Originator), Janssen L.P. (Owner)"		SC			"Nausea, Paraesthesia"	N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)	R91274			08/07/1997	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800006286?userId=52029392&bpIds=3004037004&checksum=9d5c2e67f4387355a2f9ef23f4f80dbe243ea3aa-1617045527792-4876c30db25556410dc5fe2dedbb4c97badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002115	Spiradoline	87151-85-7	"(±)-2-(3,4-Dichlorophenyl)-N-methyl-N-[5R,7S,8S)-7- (1-pyrrolidinyl)-1-oxaspiro[4,5]dec-8-yl] acetamide"				Discontinued (III)	"Pain, Parkinson's disease, Arrhythmias"	C22 H30 Cl2 N2 O2	"Opioid kappa receptor agonists, Potassium channel antagonists, Sodium channel antagonists"	"Pharmacia Corporation (Originator), Pharmacia Corporation (Owner)"		unspecified				"C1B (Anti-Arrhythmics), N2A (Narcotics), N4A (Anti-Parkinson Drugs)"	"C01 (Cardiac Therapy), N02A (Opioids), N04 (Anti-Parkinson Drugs)"	U 62066E			01/07/1997	"Arrhythmias, Pain, Parkinson's Disease and Movement Disorders"				no		no				ACTH			https://adis.springer.com/drugs/800002115?userId=52029392&bpIds=3004037004&checksum=32f3e412fb642d1c9f75d0d66fd4aa2a51c88ce8-1617045527793-eb8f454b37bf7a62f9fc48afe306d59ebadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800001969	RP 67580	135911-02-3	"2-[1-Imino-2-(2-methoxy-phenyl)-ethyl]-perhydro-4- oxo-7,7-diphenylisoindole"				Discontinued (Preclinical)	"Inflammation, Pain"	C29 H30 N2 O2	"Neurokinin 1 antagonists, Substance P inhibitors"	"Aventis (Originator), Aventis (Owner)"		unspecified				"M1 (Anti-Inflammatory and Anti-Rheumatic Products), N2 (Analgesics)"	"M01A-X (Other antiinflammatory and antirheumatic agents, non-steroids), N02 (Analgesics)"				03/06/1997	"Inflammation, Pain"				no		no							https://adis.springer.com/drugs/800001969?userId=52029392&bpIds=3004037004&checksum=fe5f0f8bf1021c5fa6c6add307149c18f35db8e9-1617045527794-083d3f6af2c7e26a2899286446576ed2badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002927	Avitriptan	151140-96-4	3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-propyl]-N-methyl-1H-indole-5-methanesulfonamide				Discontinued (III)	Migraine	C22 H30 N6 O3 S	"Serotonin 1B receptor agonists, Serotonin 1D receptor agonists"	"Bristol-Myers Squibb (Originator), Bristol-Myers Squibb (Owner)"		PO		"T<sub>_beta</sub> (h) (4 - 9.5 (Adult)), T<sub>max</sub> (h) (1.25 - 2.75 (Adult))"		N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)	BMS 180048			04/02/1997	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800002927?userId=52029392&bpIds=3004037004&checksum=b54456a2e57d85dbac41ee3da2132497e1693fc9-1617045527795-126ab76dddb601880e5d24ea122710d6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800000706	Sergolexole	108674-86-8	"[trans-(8_)]6-Methyl-1-[1-methylethyl] ergoline-8- carboxylic acid, 4-methoxycyclohexyl ester maleate"	No			Discontinued (II)	"Anxiety disorders, Migraine"	C26 H36 N2 O3 . C4 H4 O4	Serotonin 2 receptor antagonists	"Eli Lilly and Company (Originator), Eli Lilly and Company (Owner)"		PO		Activity vs parent (&lt;)		"N2C (Anti-Migraine Preparations), N5C (Tranquillisers)"	"N02C-X (Other antimigraine preparations), N05B-X (Other anxiolytics)"	LY 281067			04/02/1997	"Advances in the Treatment of Nausea and Migraine, Anxiety Disorders"				no		no							https://adis.springer.com/drugs/800000706?userId=52029392&bpIds=3004037004&checksum=7ed942ab9e0fe9a3fc374713ea17dfa488d86073-1617045527796-439c405b43d428da50e6ce7dfca38077badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002124	MDL 100687		6-[2-(5-Hydroxy-1H-indol-3-yl)ethylamino]-N- [4-(trifluoromethyl)phenyl]hexanamide monohydrochloride				No development reported	Migraine	C23 F3 H26 N3 O2 . H Cl	Serotonin 1D receptor agonists	"Aventis (Originator), Aventis (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				03/02/1997	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800002124?userId=52029392&bpIds=3004037004&checksum=2137ff5f13b8df2327ae4ac8ab4fa5d24f7ebd76-1617045527797-0167d11dacf5b44774b41d100f58aa13badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003061	E 2078	103613-84-9	N-Methyl-tyrosyl-glycyl-glycyl-phenylalanyl-leucyl-arginyl-N-methyl-arginyl-D-leucine N-ethylamide				Discontinued (II)	Pain	C50 H81 N15 O9	Opioid kappa receptor agonists	"Eisai Co Ltd (Originator), Eisai Co Ltd (Owner)"		unspecified		"Cl (L/h) (9.6 - 14.4 (Adult)), T<sub>_beta</sub> (h) (1.2 - 1.8 (Adult))"		N2A (Narcotics)	N02A (Opioids)	66A078			15/07/1996	Pain				no		no							https://adis.springer.com/drugs/800003061?userId=52029392&bpIds=3004037004&checksum=2b7d35e1dea1f430f0f938ed9068b31b6a4861a0-1617045527797-aad2dcdf9fc8dcbcbcab968d025815eabadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003083	ONO 9902		"(4S)-4-[(2S)-2-benzyl-3-[(1RS)-1,3-Dihydro-3-isobenzofuran-1-ylthio]propionylamino]-4-(N-phenylcarbamoyl)-butyric acid"				Discontinued (II)	Cancer pain	C29 H28 N2 O6 S	Neprilysin inhibitors	"Ono Pharmaceutical (Originator), Ono Pharmaceutical (Owner)"		PO				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				16/04/1996	Pain				no		no							https://adis.springer.com/drugs/800003083?userId=52029392&bpIds=3004037004&checksum=477aba5759840f1b4bffd7dbb972918fd52e5a98-1617045527798-11a565a94c67eb2175aabecdbe8b9c7abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003086	Tilnoprofen arbamel	118635-52-2	"N, N-Dimethylcarbamoylmethyl 2-methyl-5H-[1] benzopyrano[2, 3-b]pyridine-_(<EM>R</EM>)-methyl-7-acetate"				Discontinued (III)	"Pain, Rheumatoid arthritis"	C20 H22 N2 O4	Cyclooxygenase inhibitors	"Mitsubishi Pharma Corporation (Originator), Mitsubishi Pharma Corporation (Owner), Japan Tobacco (Collaborator)"		PO				"M1A (Anti-Rheumatics, Non-Steroidal), N2B (Non-Narcotics and Anti-Pyretics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02B (Other Analgesics and Antipyretics)"	Y 23023			11/03/1996	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800003086?userId=52029392&bpIds=3004037004&checksum=4785ee510914f890f6f5a6d2f9a759a6e28f9128-1617045527799-0d1183a472e78724dfb814fd4818567abadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800005879	WIN 64821	150881-27-9	"(2_,2'_,5_,5'_)-2,5:2'5'-Dide(epidithio)- 3,3'-didemethyl 1-19,19'-dideoxy-19,19'-diphenylchaetocin"				Discontinued (Preclinical)	Pain	C40 H36 N6 O4	Neurokinin antagonists	"Sanofi Winthrop (Originator), Sanofi Winthrop (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)				22/12/1995	Pain				no		no							https://adis.springer.com/drugs/800005879?userId=52029392&bpIds=3004037004&checksum=9a575fbf00b46dc07df35dceab4e6228888177ba-1617045527800-bdf6645a4f4328211315e0d2e87a64a0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003457	L 694247	137403-12-4	"2-[5-[3-[4-[(Methylsulfonyl)amino]-benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3yl]ethylamine"				Discontinued (Preclinical)	Migraine	C20 H21 N5 O3 S	Serotonin 1D receptor agonists	"Merck & Co (Originator), Merck & Co (Owner)"		unspecified				N2C (Anti-Migraine Preparations)	N02C-C (Selective serotonin (5HT1) agonists)				08/11/1995	Advances in the Treatment of Nausea and Migraine				no		no							https://adis.springer.com/drugs/800003457?userId=52029392&bpIds=3004037004&checksum=ab4b4bca11c8876ee36a4a97570db08a36991096-1617045527801-4701647bdf2cad5f431fa7b1b3fbbda0badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003434	NE 21610	118090-17-8	N-[[4-(2-aminoethoxy)-2-methoxyphenyl]methyl]-9Z-octadecenamide				Discontinued (II)	Pain	C28 H48 N2 O3	Undefined mechanism	"Procter & Gamble (Originator), Procter & Gamble (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				24/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003434?userId=52029392&bpIds=3004037004&checksum=9b21658bbdfa7de79c2fe41185cc95c99fcc447a-1617045527802-c7a388b01f0a12c474dba40f511b0ac6badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003298	Tonazocine	71461-18-2	"±-1-[(2R*, 6S*, 11S*)-1, 2, 3, 4, 5, 6-Hexahydro-8-hydroxy-3, 6, 11-trimethyl-2,6-methano-3-benzazocin-11-yl]-3-octanone"				No development reported	Pain	C23 H35 NO2	"Opioid delta receptor agonists, Opioid mu receptor antagonists"	"Sanofi Winthrop (Originator), Sanofi Winthrop (Owner)"		"PO, Parenteral"			Drowsiness	N2A (Narcotics)	N02A (Opioids)	WIN 421562			22/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003298?userId=52029392&bpIds=3004037004&checksum=8eaf483b7769212a3e6b70bdcdaefed1bede30b9-1617045527802-6e79b16d29775eaadd664234af06782bbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003819	WIN 521142						No development reported	Pain		Undefined mechanism	"Sanofi Winthrop (Originator), Sanofi Winthrop (Owner)"		PO				N2 (Analgesics)	N02 (Analgesics)				22/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003819?userId=52029392&bpIds=3004037004&checksum=a7fa335cf6dc84bdf8ccabe91735edb285e80952-1617045527803-4effdfc20eb57997ce995cd8c669a02cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003192	Trefentanil	120656-74-8	"1-[2-(4-Ethyl-4, 5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-[N-(2-fluorophenyl) propionamido] piperidine hydrochloride"				Discontinued (II)	Pain	C25 H31 F N6 O2 . HCl	Opioid mu receptor agonists	"Baxter International (Originator), Baxter International (Owner)"		IV-injection		"Cl (L/h) (.029 (Adult)), T<sub>_beta</sub> (h) (2.11 - 2.13 (Adult))"		N2A (Narcotics)	"N01A-H (Opioid anesthetics), N02A (Opioids)"	A 3665			21/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003192?userId=52029392&bpIds=3004037004&checksum=1d37d4e77fa33e622040d6f3e21cad0ae110b7e0-1617045527804-e4d4b56134244ab0b42e492c7af34726badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003687	MEN 10207	126050-12-2	"L-Argininamide, L-alpha-aspartyl-L-tyrosyl-D-tryptophyl-L- valyl-D-tryptophyl-D-tryptophyl-"				Discontinued (Preclinical)	Pain	C57 H68 N14 O10	Neurokinin 2 receptor antagonists	"Menarini (Originator), Menarini (Owner)"		unspecified				N2B (Non-Narcotics and Anti-Pyretics)	N02B (Other Analgesics and Antipyretics)	Neurokinin A (410) try(5)trp(689)arg(10)			21/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003687?userId=52029392&bpIds=3004037004&checksum=35dab18bea025375b33918ad9d34e301a8bad3e3-1617045527805-b7764ee48890b7f84a631265a79dccccbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003754	ANQ 4334		"Propanamide, <EM>N</EM>-[(4-(4-methyl-2-thiazolyl)-1-[(2- (1<EM>H</EM>-pyrazol-1-yl)ethyl)]-4-piperidinyl)]-<EM>N</EM>-phenyl-"				Discontinued (Preclinical)	Pain		Opioid receptor agonists	"Baxter International (Originator), Baxter International (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)	A 4334			14/08/1995	Pain				no		no							https://adis.springer.com/drugs/800003754?userId=52029392&bpIds=3004037004&checksum=9a283a799d6df72bbea269da4985ac59c83bb1d4-1617045527806-e00300480bfd8eadb3675938722c4d23badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003821	D 20450						Discontinued (Preclinical)	Pain		Undefined mechanism	"ASTA Medica [CEASED] (Originator), ASTA Medica [CEASED] (Owner)"		unspecified				N2 (Analgesics)	N02 (Analgesics)				20/07/1995	Pain				no		no							https://adis.springer.com/drugs/800003821?userId=52029392&bpIds=3004037004&checksum=71c68442b4dd7345c2172c048e4f985880c0f0bf-1617045527806-39d51622197811daf096a44d87996c16badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800002366	AHR 10037	78281-73-9	"Benzeneacetamide, 2-amino-3-(4-chlorobenzoyl)-"				Discontinued (Preclinical)	"Pain, Inflammation"	C15 H13 Cl N2 O2	Cyclooxygenase inhibitors	"AH Robins (Originator), AH Robins (Owner)"		unspecified				"M1A (Anti-Rheumatics, Non-Steroidal), N2 (Analgesics)"	"M01A (Antiinflammatory and Antirheumatic Products, Non-steroids), N02 (Analgesics)"				14/07/1995	"Pain, Rheumatic Disease"				no		no							https://adis.springer.com/drugs/800002366?userId=52029392&bpIds=3004037004&checksum=8667df5d74c66cd2c59ba5451117c817ddf6a4cf-1617045527807-55edac1ba4f31e9e446ee0174cc6280cbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800004080	EK 399	98849-86-6	L-Tyrosyl-_-(methylsulfinyl)-D-_-aminobutyrylglycyl-N-ethyl-L-phenylalanine-2-acetilydrazide monoacetate				Discontinued (Preclinical)	Pain	C29 H40 N6 O7 S . C2 H4 O2	Opioid receptor agonists	"Takeda (Originator), Takeda (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				20/01/1995	Pain				no		no							https://adis.springer.com/drugs/800004080?userId=52029392&bpIds=3004037004&checksum=466c3f023fa744a8baf8ec4f2aef13f67b6e3f11-1617045527808-44c4095b591e8e7a273cd9ac3b51c4cdbadf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003731	EMD 60400	142773-98-6	2-Amino-N-[1-phenyl-2-((3S)-1S-3-hydroxypyrrolidine-1-yl)ethyl]-N-methyl-phenyl acetamide				Discontinued (Preclinical)	Pain	C21 H27 N3 O2	Opioid kappa receptor agonists	"Merck KGaA (Originator), Merck KGaA (Owner)"		unspecified				N2A (Narcotics)	N02A (Opioids)				20/01/1995	Pain				no		no							https://adis.springer.com/drugs/800003731?userId=52029392&bpIds=3004037004&checksum=283aeabebb9044675ffd7a8eabecaa28d56930dc-1617045527809-a8dcf9b409c6f4a810883d9a91788642badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4
800003450	PD 117302	111728-01-9	(±)-trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzo(b)-thiophene-4-acetamide				Discontinued (Preclinical)	Pain	C21 H28 N2 S O	"Opioid kappa receptor agonists, Opioid kappa receptor antagonists"	"Pfizer (Originator), Pfizer (Owner)"		PO				N2A (Narcotics)	N02A (Opioids)	PD 1173022			26/08/1994	Pain				no		no							https://adis.springer.com/drugs/800003450?userId=52029392&bpIds=3004037004&checksum=81024b2aa4385442426e020c43d5acdfe9ced1fe-1617045527809-2e592c25fb0843fcd087a0bd598aee50badf3d92bc2778055d3caa554576af18894e69995d1562cf49561bdb11a7312fb28447bacaa6580f4c419dc370db77e4